[
  {
    "page_content": "Comparative analysis through propensity score matching in thyroid cancer: unveiling the impact of multiple malignancies Abstract\nBackground",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:0"
    }
  },
  {
    "page_content": "Background\nThe incidence of thyroid cancer is on the rise worldwide, with childhood exposure to radiation being the sole acknowledged catalyst for its emergence. Nonetheless, numerous other factors that may pose risks are awaiting thorough examination and validation. This retrospective study aims to explore the malignancies linked to thyroid cancer and contrast the survival rates of those afflicted with a solitary tumor versus those with multiple primary neoplasms (MPN).\nMethods",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:1"
    }
  },
  {
    "page_content": "Methods\nThis retrospective study examined data from King Hussein Cancer Center (KHCC), Jordan. Among 563 patients diagnosed with thyroid cancer, 30 patients had thyroid malignancy as part of MPN. For a 1:3 propensity score-matched analysis, 90 patients with only a primary thyroid malignancy were also enrolled.\nResults",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:2"
    }
  },
  {
    "page_content": "Hematologic and breast malignancies were among the most frequent observed cancers alongside thyroid neoplasm. Patients who had MPN were diagnosed at older age, had higher body mass index and presented with higher thyroglobulin antibody levels (p < 0.05 for each). Additionally, MPN patient displayed a stronger family history for cancers (p= 0.002). A median follow-up duration of 135 months unveiled that MPN patients faced a worse 5-year survival compared to their counterparts with a singular",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:3"
    }
  },
  {
    "page_content": "compared to their counterparts with a singular neoplasm (87% vs 100% respectively; p < 0.01). However, no distinction emerged in the 5-year event-free survival between these two groups.",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:4"
    }
  },
  {
    "page_content": "Conclusion",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:5"
    }
  },
  {
    "page_content": "MPN correlates with a significantly altered survival outcome of thyroid cancer patients. The diagnosis of thyroid carcinoma at an older age, accompanied by elevated initial thyroglobulin antibody levels and a notable familial predisposition, may raise concerns about the potential occurrence of synchronous or metachronous tumors. # Introduction Thyroid cancer (TC) constitutes 1% of all cancer cases (1–5). The incidence of TC has been increasing in most populations worldwide (6, 7). This increase",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:6"
    }
  },
  {
    "page_content": "most populations worldwide (6, 7). This increase may be attributed to advancements in clinical practices and/or changes in histological criteria, as well as potential alterations in environmental and hormonal factors (5, 8, 9). While TC is generally more prevalent in females, males have a higher likelihood of having a positive family history of malignancy (10). Treatment options for TC vary depending on the histology and extent of the disease, encompassing surgical intervention, radioactive",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:7"
    }
  },
  {
    "page_content": "encompassing surgical intervention, radioactive iodine therapy, suppressive thyroid hormone therapy, and occasionally, external beam radiotherapy (11). Despite acknowledged ethnic variations, the prognosis for treated TC is favorable, with excellent overall survival (OS) rates (5, 12–14). When considering the histologic subtypes, TC can be divided into five unique classifications: papillary TC (PTC), follicular TC (FTC), medullary TC (MTC), anaplastic TC, and miscellaneous subtypes (15). It is",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:8"
    }
  },
  {
    "page_content": "TC, and miscellaneous subtypes (15). It is worth noting that the majority of TC, around 95%, originates from the follicular epithelium, manifesting in PTC, FTC, and anaplastic variations (16). In numerous surveyed countries, the most prevalent subtype is PTC, accounting for 70% or more of cases (14, 17, 18). The prognosis is highly favorable for PTC and FTC, whereas other histologic subtypes demonstrate a poorer prognosis and limited therapeutic options (19–22). As the early cancer detection",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:9"
    }
  },
  {
    "page_content": "options (19–22). As the early cancer detection becomes more common, individuals who survive this disease are living longer, which may increase the risk of developing multiple primary neoplasms (MPN) (23). A limited number of investigations have been conducted to examine the potential risk of developing a second neoplasm following a diagnosis of TC, including comprehensive studies conducted in Europe and the United States (24–28). These studies have consistently demonstrated a rise in the",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:10"
    }
  },
  {
    "page_content": "have consistently demonstrated a rise in the occurrence of cancers subsequent to TC diagnosis. Additionally, it has been observed that TC can be diagnosed as a second primary neoplasm subsequent to other forms of cancer (25, 29–32). The present study aimed to examine the cancers associated with TC and to compare survival rates between patients with thyroid-only cancers and patients with thyroid cancer as part of MPN. This may help shed light on common etiological factors affecting such a",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:11"
    }
  },
  {
    "page_content": "on common etiological factors affecting such a challenging group of patients. # Materials and methods ## Data collection The medical records of 563 patients diagnosed with TC between September 1998 and December 2021 were retrospectively enrolled. For these patients, demographic data were collected and included age at diagnosis and patient gender. In addition, pathological data included cancer site, cancer type, cancer grade, and cancer stage according to the American Joint Committee on Cancer",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:12"
    }
  },
  {
    "page_content": "to the American Joint Committee on Cancer 8th Edition (AJCC 8th) (33). Moreover, the baseline postoperative levels for serum thyroglobulin and thyroglobulin antibodies were collected (34). Other important details include a history of MPN. The diagnosis of MPN relies on the criteria put forth by Warren et al. in 1933 (35), which require histopathological confirmation. Furthermore, each individual cancer included in MPN must be identifiable as separate from the surrounding normal mucosa (35).",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:13"
    }
  },
  {
    "page_content": "separate from the surrounding normal mucosa (35). Last, the possibility of the second neoplasm being metastatic should be excluded (35). For those patients, another round of pathological analysis was performed for other cancer subtypes in addition to ranking each and every subtype along with labeling the date of diagnosis for each cancer. According to the criteria set forth by the International Association of Cancer Registries and the International Agency for Research on Cancer (IACR/IARC),",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:14"
    }
  },
  {
    "page_content": "Agency for Research on Cancer (IACR/IARC), synchronous MPN are defined as the diagnosis of two or more primary malignancies within a 6-month timeframe (36). In contrast, metachronous MPN pertain to the presence of more than two primary malignancies emerging beyond the 6-month timeframe (36). To refine our investigation, the study cohort was further segmented into two distinct groups. The first group consisted of patients diagnosed with MPN who had TC as a component of their MPN (n = 30). A 1:3",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:15"
    }
  },
  {
    "page_content": "TC as a component of their MPN (n = 30). A 1:3 propensity score matching strategy was utilized to select a comparable group of patients with only TC. This technique sought to identify individuals with similar characteristics, including gender, chronic diseases (namely diabetes mellitus, hypertension, and dyslipidemia), type of thyroid cancer, and stage. By employing this propensity score matching approach, our objective was to mitigate the influence of any factors that could potentially",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:16"
    }
  },
  {
    "page_content": "influence of any factors that could potentially influence the outcomes. As a result, a cohort of 120 patients was obtained for subsequent analysis. In light of the absence of a comprehensive genetic analysis within our examined cohort, a meticulous screening process of patient records was undertaken to eliminate subjects exhibiting indications of syndromic manifestations elucidated by Vânia Nosé (37). These manifestations encompass, among others, Multiple Endocrine Neoplasia Type 2, Cowden",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:17"
    }
  },
  {
    "page_content": "Multiple Endocrine Neoplasia Type 2, Cowden Syndrome, Familial Adenomatous Polyposis, Carney Complex, and Werner Syndrome (37). Notably, there were no instances of patients presenting with the mentioned syndromes in our studied population. ## Ethics consideration This retrospective study received its approval from the Institutional Review Board of King Hussein Cancer Center (KHCC) in Amman, Jordan (Registration number: 22 KHCC 131, 11 August 2022). Written informed consent for this study was",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:18"
    }
  },
  {
    "page_content": "Written informed consent for this study was not needed due to its retrospective nature. ## Statistical analysis The statistical analysis was conducted using Stata software version 17 (College Station, TX, USA). To determine the data distribution, a normality test called Shapiro Wilk was utilized. Normally distributed variables were presented as the mean ± standard deviation (SD). The median and interquartile range (IQR) were expressed for variables that did not have a normal distribution.",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:19"
    }
  },
  {
    "page_content": "that did not have a normal distribution. Normally distributed variables are presented as the mean ± standard deviation (SD). The frequencies of categorical variables were represented by percentages (%). To analyze categorical variables, we used either the chi squared test or Fisher exact test while the nonparametric Mann Whitney U test or t-test were used to analyze continuous variables based on their appropriateness. Kaplan−Meier plots and log-rank tests were utilized to illustrate the",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:20"
    }
  },
  {
    "page_content": "log-rank tests were utilized to illustrate the survival curves. cancer-specific OS and event-free survival (EFS) were calculated. First, we conducted an analysis focused on cancer-specific OS and EFS. In this context, cancer-related OS was defined as the interval from the time of initial diagnosis to the point of death directly attributed to any cancer subtype. Instances of death resulting from unrelated causes were censored. In the same manner, cancer-specific EFS was delineated as the span",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:21"
    }
  },
  {
    "page_content": "cancer-specific EFS was delineated as the span from the time of diagnosis to the advent of advancing, or recurring cancer. Subsequently, an examination of univariate and multivariate Cox proportional hazard analysis was undertaken to investigate the predictive weight of diverse clinicopathologic factors. A significance threshold of less than 0.05 (p < 0.05) was deemed statistically significant. # Results This retrospective study utilized KHCC cohort of TC patients to explore patients who had",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:22"
    }
  },
  {
    "page_content": "cohort of TC patients to explore patients who had MPN. A total of 30 patients were identified with MPN. Those patients were observed to have 68 neoplasms in total. Thirty-one of these were thyroid neoplasms and the remaining 37 were other malignancies. Demographic and clinicopathologic characteristics are shown in Table 1. ## Patients with multiple primary neoplasms ### Incidence Between September 1998 and December 2021, of 563 TC patients, 533 patients (95%) had a single thyroid neoplasm. The",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:23"
    }
  },
  {
    "page_content": "patients (95%) had a single thyroid neoplasm. The remaining 30 patients (5%) were diagnosed with MPN. For patients with MPN, a total of 24 patients had two primary neoplasms. In addition, a total of four patients presented with three neoplasms while only two patients had four neoplasms. ### Temporal presentation The median interval between first and second primary neoplasms was 13 months with an IQR of 2–46 months. Of all 30 patients diagnosed with MPN, only one third (n= 10) had synchronous",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:24"
    }
  },
  {
    "page_content": "with MPN, only one third (n= 10) had synchronous malignancies. The remaining 20 patients had metachronous MPN. TC was the first diagnosed neoplasm in eight patients. However, all remaining patients were diagnosed with TC subsequent to their initial primary neoplasm (",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:25"
    }
  },
  {
    "page_content": "Table 2\n). ### Thyroid cancer subtypes In all 30 patients presented with MPN, a total of 31 TC neoplasms were observed. Approximately, 24 patients had an established diagnosis of PTC as the predominant histopathologic subtype (n= 24). Follicular and hurtle subtypes were found in 2 patients each. In addition, MTC was diagnosed in 3 patients (\nTable 1\n). It is noteworthy that one of our MPN patients had an established diagnosis of both synchronous Hurthle and papillary subtypes (\nTable 2",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:26"
    }
  },
  {
    "page_content": "Table 2\n). ### Coexisting malignancies: by region A total of 37 coexisting malignancies were observed. Notably, hematologic and breast malignancies were among the most common identifiable coexisting malignancies in patients with MPN (n=8 for each). This was followed by head and neck cancers (n=6). Then an equivalent number of patients who had gastrointestinal and genitourinary malignancies were identified (n= 5 for each). Other cancer subtypes followed in predominance (\nTable 3",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:27"
    }
  },
  {
    "page_content": "). ## Propensity score matching As stated before, 1:3 propensity score matching was performed to observe differences in clinical factors and survival outcomes between the two matched subgroups. ### Differences between patients with single and multiple neoplasms When comparing single thyroid neoplasm with MPN, patients who had TC as part of MPN were substantially older; the median age at diagnosis was 54 years vs 41 years for patients with single TC diagnosis (p= 0.04). They also had a higher",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:28"
    }
  },
  {
    "page_content": "TC diagnosis (p= 0.04). They also had a higher body mass index (p= 0.003). In addition, they had a higher baseline thyroglobulin antibody (median value for MPN was 45.5 vs 11 for patients with single TC; p= 0.0003). Finally, a significantly higher percentage of patients had a positive family history of malignancy in patients diagnosed with MPN vs patients with a single TC (50% vs 20%; p= 0.002). Notably, the percentage of smokers, recurrence rates, mortality from TC, elapsed duration since",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:29"
    }
  },
  {
    "page_content": "rates, mortality from TC, elapsed duration since postoperative thyroid markers conduction, and elapsed duration since initial TC diagnosis did not differ significantly when comparing both subgroups (",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:30"
    }
  },
  {
    "page_content": "Table 4\n). ### Impact on survival With regards to cancer-specific OS, patients with MPN had worse OS than those with TC alone. At a median follow-up of 135 months, MPN patients were found to have a poorer 5-year survival than patients with TC alone (p < 0.01). However, the 5-year EFS was not significantly different between these two subcohorts (\nFigure 1\n). Both univariate and multivariable Cox hazard models (\nTable 5",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:31"
    }
  },
  {
    "page_content": "), suggest that the presence of MPN can have a negative effect on OS (p≤ 0.02). # Discussion Our research underscores an important finding regarding patients with MPN, revealing a notably lower survival rate. According to our study, MPN patients were diagnosed at an older age, displayed an elevated body mass index, and presented with increased thyroglobulin antibody levels, along with a more pronounced familial history of cancer. The global rise in TC incidence is a widely recognized trend,",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:32"
    }
  },
  {
    "page_content": "in TC incidence is a widely recognized trend, largely attributed to the progress in clinical procedures, biochemical knowledge, and imaging technologies (38). The evolution of medical guidelines and practices, such as more thorough evaluations of the thyroid gland, has resulted in higher rates of TC detection. Progress in understanding the biochemical aspects of TC, including the identification of new biomarkers and genetic mutations linked to the disease, has also been a significant factor",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:33"
    }
  },
  {
    "page_content": "the disease, has also been a significant factor (39). Additionally, the widespread use of advanced ultrasound technology has facilitated the identification of small thyroid nodules, including thyroid microcarcinomas (38). In our MPN subcohort, imaging played a crucial role in the initial detection and evaluation of TC, underscoring the importance of ongoing clinical monitoring and multidisciplinary care for both cancer survivors and sufferers. However, advancements in therapeutic and diagnostic",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:34"
    }
  },
  {
    "page_content": "advancements in therapeutic and diagnostic techniques have drawbacks, as previous research has linked the occurrence of secondary cancer and MPN to exposure to radiation (40, 41). While radiation therapy is effective in treating various types of cancer, it is also associated with an increased risk of developing additional primary malignancies. The carcinogenic impact of radiation on the thyroid gland primarily stems from the DNA damage caused by ionizing radiation, leading to genetic mutations",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:35"
    }
  },
  {
    "page_content": "ionizing radiation, leading to genetic mutations and chromosomal abnormalities that initiate cancer formation. Additionally, exposure to radiation significantly heightens the likelihood of developing thyroid cancer, with the risk increasing in proportion to the dosage received, even at lower levels (40). With regards to TC treatment, effective management strategies involve a multidisciplinary approach that incorporates surgical, oncological, medical, and radiological assessments (42). Surgical",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:36"
    }
  },
  {
    "page_content": "and radiological assessments (42). Surgical intervention has been found to reduce mortality and event rates in cases of operable TC, even when dealing with microcarcinomas (43). Furthermore, research has indicated that radioactive iodine therapy can significantly enhance survival outcomes for individuals with differentiated TC (44–47). For example, a large study involving 96,557 patients demonstrated that the use of radioactive iodine was linked to improved disease-specific survival in this",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:37"
    }
  },
  {
    "page_content": "to improved disease-specific survival in this population (48). Furthermore, radioactive iodine therapy has been shown to improve rates of recurrence-free survival, by eliminating residual thyroid tissue and microscopic disease (49). This treatment is particularly advantageous for patients with certain risk factors, such as extrathyroidal extension or lymph node involvement, as it reduces the likelihood of cancer recurrence (50). MPN are infrequent, exhibiting a greater occurrence in older",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:38"
    }
  },
  {
    "page_content": "exhibiting a greater occurrence in older patients (51). The occurrence of MPN is predominantly noted in cancer survivors as well as in cancer subtypes that are associated with favorable outcomes. Therefore, the rising prevalence of TC and the favorable survival outcomes have resulted in a higher occurrence of MPN (52). However, MPN in survivors of TC may contribute significantly to mortality rates. This emphasizes the need for vigilant surveillance of MPN occurrence to enhance prognosis. In our",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:39"
    }
  },
  {
    "page_content": "of MPN occurrence to enhance prognosis. In our study population consisting of 563 individuals, we identified 30 patients who developed MPNs, indicating a prevalence of approximately 5% at our institution, which closely aligns with prior findings from Taiwan (26). Lin et al. outlined that TC patients with MPN exhibit a lower female-to-male ratio, an older mean age, and more advanced TNM stages compared to those with only TC (26). These patients also receive higher doses of therapeutic",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:40"
    }
  },
  {
    "page_content": "patients also receive higher doses of therapeutic radioactive iodine and have a higher total mortality rate (26). Notably, hematological malignancies and renal cell carcinoma are prevalent as secondary cancers in these patients, despite not being among the top ten common cancers in the general population of Taiwan, indicating a distinct pattern of secondary malignancies in thyroid cancer patients (26). The possibility of being diagnosed with another neoplasm after surviving a first one is 14%",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:41"
    }
  },
  {
    "page_content": "neoplasm after surviving a first one is 14% higher for people who have previously had cancer compared to the general population (53). This percentage is anticipated to increase due to the growing number of cancer survivors. Consequently, there has been a rise in the occurrence of MPN among individuals who have overcome cancer, accounting for almost one-fifth of all newly diagnosed malignancies in recent studies (54). With regards to MPN incidence, there is a notable variation in the reported",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:42"
    }
  },
  {
    "page_content": "there is a notable variation in the reported incidence shared in current literature ranging from 1–37% (55). The variation observed in these findings can be attributed to the different methodologies used for calculations and the diverse ethnic populations studied. In the United States, the prevalence of primaries has been reported in percentages over time. For example, it was found to be 3.5% in New Mexico in 1977, 5.3% according to a study conducted in 1968, and finally 8% based on data from",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:43"
    }
  },
  {
    "page_content": "in 1968, and finally 8% based on data from 1975–2001 (56–58). Similarly, in Western Europe, the occurrence of MPN varied across studies; it was recorded as 0.7% in a hospital registry in Scotland in 1972, 6.3% based on European cancer registries from 1995 to 1999, and reached up to 11.7% according to an autopsy series from Sweden in 1969 (59–61). The literature also shows variation in the numbers and types of multiple primaries in relation to the total number of cancer patients. For example,",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:44"
    }
  },
  {
    "page_content": "the total number of cancer patients. For example, the incidence of three or more primaries ranged from 0.2% in a cancer center in Jordan (2006–2011) to 2.0% in a cancer center in France (1980–2009) (62–64). Similarly, metachronous primaries accounted for 3% in a recent study from the United States (2005–2012) which is equivalent to our obtained results (55). Currently, there is a lack of a definitive risk factor that has been confirmed for the development of MPN. However, various factors have",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:45"
    }
  },
  {
    "page_content": "development of MPN. However, various factors have been previously investigated. It has been hypothesized that the presence of MPN in cancer survivors may be influenced by increased vigilance or can be a result of previous treatments, and could also be linked to mutual risk factors such as environmental factors, and genetic predisposition (60). In addition, ethnic background is a significant determinant of susceptibility to certain diseases (55). Various societies exhibit varying rates of",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:46"
    }
  },
  {
    "page_content": "(55). Various societies exhibit varying rates of occurrence for specific types of neoplasms (14). For instance, the Japanese population experiences a notable prevalence of gastric cancer, while having a relatively low incidence of prostate cancer (65). Conversely, the Jordanian population demonstrates a considerably higher occurrence of prostate and lung malignancies (66). There is a strong correlation between obesity and the development of cancer in the general population, specifically in",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:47"
    }
  },
  {
    "page_content": "cancer in the general population, specifically in relation to breast cancer, genitourinary cancers, and gastrointestinal cancers (67). Therefore, obesity has been found to significantly increase the likelihood of developing MPN. This connection was observed in the current study, which found that patients with MPN were more likely to be obese than those with a single form of malignancy. In addition, the higher levels of baseline thyroglobulin antibodies in patients with MPN can point to the",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:48"
    }
  },
  {
    "page_content": "antibodies in patients with MPN can point to the possibility of autoimmune thyroid disease. A recent cohort study by Chen et al. concluded that patients with autoimmune thyroid disease are more susceptible to developing various cancers, including breast, colorectal, and head and neck cancers (68). They also found that elderly patients with autoimmune thyroid disease can have an increased risk of developing thyroid and colorectal cancer compared with the general population (68). Therefore,",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:49"
    }
  },
  {
    "page_content": "with the general population (68). Therefore, clinicians must be aware of such associations in the clinical oncology care. Family history is a significant risk factor for the development of MPN. There is a notable presence of familial clustering across almost all cancer sites, and this clustering is primarily observed in close relationships within families spanning multiple generations (69). The majority of hereditary cancers display an excess of multiple primary tumors and an early onset of the",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:50"
    }
  },
  {
    "page_content": "multiple primary tumors and an early onset of the disease (67). This clustering phenomenon may be attributed to abnormal genes or gene variants. Various cancer predisposition genes, including BRCA1, BRCA2, and p16/CDKN2A, have already been identified in high-risk pedigrees (67, 69). Additionally, individuals with hereditary nonpolyposis colorectal cancer who have MPN often exhibit a higher frequency of mismatch repair genes, such as hMSH2 and hMLH1 (70). Moreover, cribriform variants of PTC",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:51"
    }
  },
  {
    "page_content": "hMLH1 (70). Moreover, cribriform variants of PTC were identified as being classically linked with familial adenomatous polyposis (71). Breast cancer and TC are among the most prevalent forms of cancer in women (72). In our study, we found a higher incidence of breast cancer in MPN patients. Breast cancer was found to be the most common secondary cancer in patients with TC, occurring either simultaneously, prior to, or after the TC diagnosis. This bidirectional relationship between thyroid and",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:52"
    }
  },
  {
    "page_content": "bidirectional relationship between thyroid and breast cancer has been previously suggested in a retrospective study, which also found an increased risk of developing a MPN in patients with a history of breast or TC (73). Various factors, such as iodine transport, obesity, sex hormones, thyroid hormones, and cancer treatment, have been potentially implicated in the development of both types of cancer (73, 74). Lei et al. explored the prognosis of breast cancer patients who subsequently developed",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:53"
    }
  },
  {
    "page_content": "breast cancer patients who subsequently developed metachronous TC using information obtained from the Surveillance, Epidemiology, and End Results database (75). The study aimed to compare the prognosis of breast cancer patients who had a second primary thyroid cancer with those who did not, analyzing a wide range of clinicopathological and treatment characteristics, and evaluating the impact of second metachronous TC on breast cancer survival. The population studied included breast cancer",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:54"
    }
  },
  {
    "page_content": "The population studied included breast cancer patients diagnosed between 2000 and 2014, with a subset of these patients developing a second primary TC within this timeframe. The study found that the impact of other malignancies on TC prognosis (and vice versa) can vary depending on the type and timing of the secondary cancer, as well as the specific characteristics of the cancer itself. This study contributes significantly to understanding the complex interplay between primary and secondary",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:55"
    }
  },
  {
    "page_content": "complex interplay between primary and secondary malignancies, highlighting the importance of considering the type, timing, and specific characteristics of secondary cancers in the prognosis of the primary cancer (75). The presentation of hematologic malignancy with a second primary neoplasm is most commonly observed during the follow-up period (76). Breast, lung, and TC are the most frequently occurring secondary tumors (76). Typically, secondary TC in these patients occurs at a later time. It",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:56"
    }
  },
  {
    "page_content": "TC in these patients occurs at a later time. It has been established that radiotherapy administered at the early stages of lymphoma is linked to an increased risk of developing secondary TC (77). Another study demonstrated that prior radiotherapy of the head, neck, and upper diaphragm may also contribute to the development of TC (78). In lymphoma patients, a recent study found that diffuse large B-cell lymphoma was the most commonly observed hematologic malignancy alongside TC in MPN patients",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:57"
    }
  },
  {
    "page_content": "malignancy alongside TC in MPN patients (76). Similar to our findings, PTC was the most coinciding malignancy discovered incidentally (76). Based on our analysis, it was found that patients with MPN exhibited a lower survival rate. This is more in line with previous research findings, as MPN had shown a detrimental and statistically significant impact on the survival of patients with TC (52). Liou et al. found that the overall mortality rate in TC patients with MPN could be 4.4 times higher",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:58"
    }
  },
  {
    "page_content": "in TC patients with MPN could be 4.4 times higher compared to those without MPN (79). Similarly, Lang et al. reported a considerable mortality rate of 43.5% in TC patients with nonsynchronous MPN (80). This study faces several limitations, chiefly due to its retrospective nature, a limited number of patients, and being conducted at a single institution. Moreover, despite attempts to mitigate confounding variables through propensity score matching and the exclusion of genetic conditions, the",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:59"
    }
  },
  {
    "page_content": "and the exclusion of genetic conditions, the retrospective approach may have compromised accurate final selection due to the lack of exhaustive details on genetic testing, thyroid marker assays, and laboratory analyses, among other factors. Despite this, the present study is the first to address this topic using propensity score-matching among MPN patients of Middle-Eastern ethnicity. # Conclusion The onset of MPN can significantly influence the survival outcome of TC patients. The diagnosis of",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:60"
    }
  },
  {
    "page_content": "survival outcome of TC patients. The diagnosis of thyroid carcinoma at an older age, accompanied by elevated initial thyroglobulin antibody levels and a notable familial predisposition, may raise concerns about the potential occurrence of synchronous or metachronous neoplastic manifestations. Further analysis with larger patient cohorts is necessary to confirm the results of this study. # Data availability statement The raw data supporting the conclusions of this article will be made available",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:61"
    }
  },
  {
    "page_content": "of this article will be made available by the authors, without undue reservation. # Ethics statement The studies involving humans were approved by Institutional Review Board of King Hussein Cancer Center (KHCC) in Amman, Jordan (Registration number: 22 KHCC 131, 11 August 2022). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:62"
    }
  },
  {
    "page_content": "in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article. # Author contributions A-AI: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. ASA: Conceptualization, Data curation, Formal Analysis,",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:63"
    }
  },
  {
    "page_content": "Data curation, Formal Analysis, Investigation, Methodology, Software, Writing – original draft, Writing – review & editing. DA-A: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Project administration, Writing – original draft, Writing – review & editing. EL: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Project administration, Software, Supervision, Writing – original draft, Writing – review & editing. AA-O: Conceptualization,",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:64"
    }
  },
  {
    "page_content": "– review & editing. AA-O: Conceptualization, Writing – original draft, Writing – review & editing. MA-M: Conceptualization, Investigation, Writing – original draft, Writing – review & editing. YY: Conceptualization, Data curation, Formal Analysis, Writing – original draft, Writing – review & editing. NA-H: Writing – original draft, Writing – review & editing. IM: Writing – original draft, Writing – review & editing. SS: Writing – review & editing, Methodology, Writing – original draft. GS:",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:65"
    }
  },
  {
    "page_content": "Methodology, Writing – original draft. GS: Conceptualization, Formal Analysis, Methodology, Validation, Writing – original draft, Writing – review & editing.",
    "metadata": {
      "source": "../data/plain/PMC11184125.plain.txt",
      "id": "../data/plain/PMC11184125.plain.txt:66"
    }
  },
  {
    "page_content": "Clinical Factors Associated with Skin Neoplasms in Individuals with Lynch Syndrome in a Longitudinal Observational Cohort Abstract\nBackground:\nLittle is known about patient-specific risk factors for skin neoplasia in individuals with Lynch Syndrome (LS).\nObjective:\nIdentify clinical factors associated with development of skin neoplasms in LS.\nMethods:",
    "metadata": {
      "source": "../data/plain/PMC10238628.plain.txt",
      "id": "../data/plain/PMC10238628.plain.txt:0"
    }
  },
  {
    "page_content": "Methods:\nClinical data were systematically collected on a cohort of LS carriers (confirmed pathogenic germline variants [PGVs] in MLH1, MSH2, MSH6, PMS2, or EPCAM) age ≥18 undergoing clinical genetics care at Dana-Farber Cancer Institute from 1/2000–3/2020. Multivariable logistic regression was performed to evaluate clinical factors associated with skin neoplasia.\nResults:",
    "metadata": {
      "source": "../data/plain/PMC10238628.plain.txt",
      "id": "../data/plain/PMC10238628.plain.txt:1"
    }
  },
  {
    "page_content": "Of 607 LS carriers, 9.2% had LS-associated skin neoplasia and 15.0% had non-LS-associated skin neoplasia. 58.2% (353/607) had documentation of prior dermatologic evaluation. 29.7% (38/128) with skin neoplasms lacked a history of visceral LS-associated malignancy. LS-associated skin neoplasms were significantly associated with male sex, age, race, MLH1 PGVs, MSH2/EPCAM PGVs, and personal history of non-LS skin neoplasms. Non-LS-associated skin neoplasms was significantly associated with age,",
    "metadata": {
      "source": "../data/plain/PMC10238628.plain.txt",
      "id": "../data/plain/PMC10238628.plain.txt:2"
    }
  },
  {
    "page_content": "neoplasms was significantly associated with age, number of first- and second-degree relatives with non-LS-associated skin neoplasms, and personal history of LS-associated skin neoplasms.",
    "metadata": {
      "source": "../data/plain/PMC10238628.plain.txt",
      "id": "../data/plain/PMC10238628.plain.txt:3"
    }
  },
  {
    "page_content": "Limitations:\nSingle-institution observational study; demographic homogeneity.\nConclusions:\nSkin neoplasms are common in individuals with LS. We identified clinical factors associated with LS- and non-LS-associated skin neoplasms. Regular dermatologic surveillance should be considered for all LS carriers.",
    "metadata": {
      "source": "../data/plain/PMC10238628.plain.txt",
      "id": "../data/plain/PMC10238628.plain.txt:4"
    }
  },
  {
    "page_content": "Incidence of myeloid neoplasms in Spain (2002–2013): a population-based study of the Spanish network of cancer registries Abstract",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:0"
    }
  },
  {
    "page_content": "Comprehensive population-based data on myeloid neoplasms (MNs) are limited, mainly because some subtypes were not recognized as hematological cancers prior to the WHO publication in 2001, and others are too rare to allow robust estimates within regional studies. Herein, we provide incidence data of the whole spectrum of MNs in Spain during 2002–2013 using harmonized data from 13 population-based cancer registries. Cases (n = 17,522) were grouped following the HAEMACARE groupings and",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:1"
    }
  },
  {
    "page_content": "grouped following the HAEMACARE groupings and 2013-European standardized incidence rates (ASRE), incidence trends, and estimates for 2021 were calculated. ASRE per 100,000 inhabitants was 5.14 (95% CI: 5.00–5.27) for myeloproliferative neoplasms (MPN), 4.71 (95% CI: 4.59–4.84) for myelodysplastic syndromes (MDS), 3.91 (95% CI: 3.79–4.02) for acute myeloid leukemia, 0.83 (95% CI: 0.78–0.88) for MDS/MPN, 0.35 (95% CI: 0.32–0.39) for acute leukemia of ambiguous lineage, and 0.58 (95% CI:",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:2"
    }
  },
  {
    "page_content": "leukemia of ambiguous lineage, and 0.58 (95% CI: 0.53–0.62) for not-otherwise specified (NOS) cases. This study highlights some useful points for public health authorities, such as the remarkable variability in incidence rates among Spanish provinces, the increasing incidence of MPN, MDS, and MDS/MPN during the period of study, in contrast to a drop in NOS cases, and the number of cases expected in 2021 based on these data (8446 new MNs). # Introduction Hematological malignancies are the fourth",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:3"
    }
  },
  {
    "page_content": "Hematological malignancies are the fourth most frequently diagnosed group of cancers worldwide1, with an annual incidence rate of 39.37 per 100,000 inhabitants in Europe in 2000–20022. They encompass a heterogeneous group of diseases with diverse etiology, presentation, and outcomes. Our understanding of these neoplasms has evolved rapidly during the recent decades, resulting in multiple classification updates. Currently, the World Health Organization (WHO) classification of hematologic",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:4"
    }
  },
  {
    "page_content": "Organization (WHO) classification of hematologic malignancies, first published in 20013 and later updated in 20084 and 20165, is the gold standard for the study of these neoplasms. Such continuous definition refinements, however, have posed significant problems for population-based cancer registries to present complete and accurate data for the full spectrum of hematological neoplasms6, and particularly for myeloid neoplasms (MNs). MNs are a group of clonal disorders characterized by excessive",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:5"
    }
  },
  {
    "page_content": "of clonal disorders characterized by excessive proliferation, impaired self-renewal and/or altered differentiation of hematopoietic stem cells and myeloid progenitor cells. Broadly, MNs are classified into four large categories: acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), and MDS/MPN overlap syndromes. However, MDS and several MPN subtypes were first recognized as malignant disorders—and thus, reportable to cancer registries—in 2000, with",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:6"
    }
  },
  {
    "page_content": "reportable to cancer registries—in 2000, with the publication of the third revision of the International Classification of Disease for Oncology (ICD-O-3)7. Regarding AML, past epidemiological studies were prone to group all leukemias together, at best differencing by age range (i.e. pediatric/adult) and chronicity (i.e. acute/chronic), but ignoring cell lineage differences (i.e. lymphoid/myeloid). This situation changed after correspondence was established between the WHO classifications and",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:7"
    }
  },
  {
    "page_content": "established between the WHO classifications and the ICD-O-3 codes. Since then, several studies using the largest European2,8 and North American9–12 datasets, as well as from hematology-specialized cancer registries13,14 have reported detailed epidemiological data of MNs. Still, and given that most entities are too rare to make power robust estimates within regional studies, population-based data of several clinically meaningful histological subtypes are limited. Particularly in Spain, there are",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:8"
    }
  },
  {
    "page_content": "are limited. Particularly in Spain, there are no available comprehensive nationwide estimates, with only one previous study providing regional data15. The aim of this study was to assess the incidence of MNs subtypes in Spain over the period 2002–2013, and to estimate the number of MNs expected in 2021, using harmonized data from the Spanish Network of Cancer Registries (REDECAN). # Methods REDECAN was created in 2010 in order to develop standards for cancer registration, undertake quality",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:9"
    }
  },
  {
    "page_content": "for cancer registration, undertake quality audits, and promote the use of cancer surveillance data within Spain16,17. Currently, it comprises 15 population-based cancer registries, 14 of them covering the entire population and one of them only children. In particular, 13 population based-cancer registries (i.e. Asturias, Canary Islands, Castellón, Ciudad Real, Cuenca, Euskadi, Girona, Granada, La Rioja, Mallorca, Murcia, Navarra, and Tarragona) contributed to this study (Table 1), covering ∼26%",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:10"
    }
  },
  {
    "page_content": "to this study (Table 1), covering ∼26% of the total Spanish population in January 2013 (12,143,157 out of 47,129,783)18. All incident MNs registered from 2002 to 2013 (or the available period) were included in the analyses. Cases were codified using the ICD-O-37,19, and classified following the HAEMACARE scheme2, a European project aimed to improve standardization of epidemiological information on hematological malignancies (Table 2). In brief, MNs were grouped into six broad categories: MPN,",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:11"
    }
  },
  {
    "page_content": "MNs were grouped into six broad categories: MPN, MDS/MPN, MDS, AML, acute leukemia with ambiguous lineage, and not otherwise specified (NOS). Within AML, the following groupings were considered: AML with recurrent cytogenetic abnormalities, AML with multilineage dysplasia, AML and MDS therapy-related, AML not otherwise categorized (NOC), and AML NOS. In the 2001 WHO classification3, the number of blast cells to define AML decreased from 30 to 20% so that some conditions previously considered",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:12"
    }
  },
  {
    "page_content": "20% so that some conditions previously considered MDS, such as refractory anemia with excess blasts in transformation (9984/3), were included with the AMLs. In line with previous studies20, we grouped these cases as AML with multilineage dysplasia (9895/3) as this cytological property is characteristic of MDS. Likewise, therapy related-MDS (9987/3) were included in the AML therapy related (9920/3) subgroup, and cases of chronic myeloid leukemia NOS (CML NOS) (9863/3) were grouped with CML",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:13"
    }
  },
  {
    "page_content": "NOS (CML NOS) (9863/3) were grouped with CML BCR-ABL positive (9875/3). Finally, in cases of hematological transformation, only the first tumor was considered for incidence21. Crude rate (CR) and age-standardized incidence rate using the 2013 European standard population (ASRE) were calculated using population data provided by the National Statistics Institute (Instituto Nacional de Estadística—INE)18, and expressed per 100,000 person-years. Poisson regression models were used to analyze the",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:14"
    }
  },
  {
    "page_content": "regression models were used to analyze the overall incidence time trends and to estimate the annual percent change (APC). The number of cases in Spain for 2021 was determined by applying to the 2021 Spanish population18 the age-specific rates estimated for the year 2021. The latter were obtained by applying the APC (period 2002–2013) to the last quinquennium of known incidence (i.e. 2009–2013). All analyses were performed using R software (version 3.6.1)22. ## Ethics approval This study is",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:15"
    }
  },
  {
    "page_content": "3.6.1)22. ## Ethics approval This study is based on data from cancer registries gathered in the Spanish network of cancer registries (REDECAN). The public health administration of each autonomous community/province* authorized the collection and use of this data for its analysis without requirement of informed consent and ethical approval, covered by the Spanish general and public health laws 14/1986 and 33/2011. *The authorizing bodies for each autonomous community/province are listed below:",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:16"
    }
  },
  {
    "page_content": "autonomous community/province are listed below: Asturias: Sección de Información Sanitaria. Servicio de Evaluación de la Salud, Calidad y Programas de la Dirección General de Salud Pública. Consejería de Sanidad; Canary Islands: Servicio de Epidemiología y Prevención. Dirección General de Salud Pública. Servicio Canario de la Salud; Castellón: Conselleria de Sanitat. Dirección General de Salud Pública; Ciudad Real: Consejería de Sanidad y Asuntos Sociales de la Junta de Comunidades de",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:17"
    }
  },
  {
    "page_content": "y Asuntos Sociales de la Junta de Comunidades de Castilla-La Mancha; Cuenca: Consejería de Sanidad y Asuntos Sociales. Junta de Comunidades de Castilla la Mancha; Euskadi: Dirección de Planificación, Ordenación y Evaluación Sanitarias. Departamento de Salud. Gobierno Vasco; Girona: Plan Director de Oncología-Instituto Catalán de Oncología; Granada: Consejería de Salud de la Junta de Andalucía, adscrito para su desarrollo a la Escuela Andaluza de Salud Pública (EASP); La Rioja: Servicio de",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:18"
    }
  },
  {
    "page_content": "de Salud Pública (EASP); La Rioja: Servicio de Epidemiología y Prevención Sanitaria de la Consejería de Salud y Servicios Sociales del Gobierno de La Rioja; Mallorca: Dirección General de Salud Pública y Participación; Murcia: Consejería de Salud de Murcia; Navarra: Departamento de Salud del Gobierno de Navarra. Instituto de Salud Pública y Laboral de Navarra; Tarragona: Hospital Universitario Sant Joan de Reus. # Results MNs accounted for 30.81% (n = 17,522) of all hematologic malignancies",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:19"
    }
  },
  {
    "page_content": "(n = 17,522) of all hematologic malignancies (n = 56,777) diagnosed in Spanish population covered by cancer registries between 2002 and 2013. The quality and completeness of each registry, together with the study period and the total cases are detailed in Table 1. Of the total, 96.3% of the cases had microscopic confirmation, 3.6% were NOS cases, and 1.9% were recorded exclusively by death certificate (DCO). In particular, 33.5% of cases were MPN, 29.8% MDS, 25.7% AML, 5.2% MDS/MPN, 2.3% acute",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:20"
    }
  },
  {
    "page_content": "29.8% MDS, 25.7% AML, 5.2% MDS/MPN, 2.3% acute leukemia of ambiguous lineage, and the remaining 3.6% were NOS cases. ## Myeloproliferative neoplasms The CR and ASRE for MPN were 4.68 (95% CI 4.56; 4.80) and 5.14 (95% CI 5.00; 5.27), respectively. The most frequent subtype was essential thrombocythemia (41% of cases, ASRE = 2.10 (95% CI 2.01; 2.18)), followed by chronic myeloid leukemia (23% of cases, ASRE = 1.13 (95% CI 1.06; 1.19)), and polycythemia vera (18%, ASRE = 0.95 (95% CI 0.89; 1.01))",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:21"
    }
  },
  {
    "page_content": "vera (18%, ASRE = 0.95 (95% CI 0.89; 1.01)) (Table 2). Median age (IQR) at diagnosis was 69 (54–78) years, being slightly lower in cases with mastocytosis, 54 (36–66) years. Higher rates in men than in women were reported in almost all subtypes, being particularly higher in primary myelofibrosis (sex ratio = 2.83), while no difference by sex was seen in essential thrombocythemia (sex ratio = 1.02). The incidence of MPN increased across the period in 2002–2013, with an APC of 1.6% (95% CI 0.8;",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:22"
    }
  },
  {
    "page_content": "in 2002–2013, with an APC of 1.6% (95% CI 0.8; 2.4) (Table 3). Moreover, results by specific subtype indicate that this increment in the incidence was namely due to the contribution of essential thrombocythemia (4.6%, 95% CI 3.3; 5.9), primary myelofibrosis (3.5%, 95% CI 0.6; 6.5), and polycythemia vera (2.2%, 95% CI 0.3; 4.1). Conversely, we evidenced a decrease in the incidence of chronic myeloid leukemia (− 2.1%, 95% CI − 3.7; − 0.4) and MPN NOS (− 5.0%, 95% CI − 7.6; − 2.4). ##",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:23"
    }
  },
  {
    "page_content": "and MPN NOS (− 5.0%, 95% CI − 7.6; − 2.4). ## Myelodysplastic/myeloproliferative neoplasms The CR and ASRE for MDS/MPN were 0.73 (95% CI 0.68; 0.77) and 0.83 (95% CI 0.78; 0.88), respectively. By far, the most common subtype was chronic myelomonocytic leukemia (84% of cases), with an ASRE of 0.70 (95% CI 0.65; 0.75) and a marked male predominance (sex ratio = 3.1) (Table 2). The median (IQR) age at diagnosis was 77 (70–83) years. The incidence of MDS/MPN rose markedly throughout 2002–2013, with",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:24"
    }
  },
  {
    "page_content": "MDS/MPN rose markedly throughout 2002–2013, with an APC of 6.9% (95% CI: 4.8; 9.1) (Table 3). ## Myelodysplastic syndromes The CR and ASRE for MDS were 4.16 (95% CI 4.04; 4.27) and 4.71 (95% CI 4.59; 4.84), respectively (Table 2). The most frequent subtype was MDS with excess of blasts (17%, ASRE = 0.82 (95% CI 0.77; 0.88)), closely followed by MDS with multilineage dysplasia (15%, ASRE = 0.70 (95% CI 0.65; 0.75)) and MDS with single lineage dysplasia (14%, ASRE = 0.66 (95% CI: 0.61; 0.71)],",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:25"
    }
  },
  {
    "page_content": "(14%, ASRE = 0.66 (95% CI: 0.61; 0.71)], while 42% of the cases were MDS unclassifiable. Median age (IQR) at diagnosis was 78 (71–83) years, and incidence rates were higher in men, except in MDS associated with isolated del(5q), in which we noted a reverse sex ratio (0.43). There was a positive incidence trend of overall MDS throughout the period (APC = 1.3%, 95% CI 0.4; 2.1), mostly due to MDS with multilineage dysplasia (APC = 19.1%, 95% CI 16.3; 21.9) and MDS associated with isolated del(5q)",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:26"
    }
  },
  {
    "page_content": "21.9) and MDS associated with isolated del(5q) (APC = 13.7%, 95% CI 7.2; 20.6). Conversely, cases of MDS with single lineage dysplasia decreased across the period of study (APC = − 11.9%, − 13.9; − 9.8) (Table 3). ## Acute myeloid leukemia The CR and ASRE for AML were 3.59 (95% CI 3.48; 3.69) and 3.91 (95% CI 3.79; 4.02), respectively (Table 2). Among the 4498 AML cases, 47% were AML NOC, 14% were AML with recurrent cytogenetic abnormalities, 11% were AML with multilineage dysplasia, 3% were",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:27"
    }
  },
  {
    "page_content": "11% were AML with multilineage dysplasia, 3% were therapy-related, and 25% were NOS. Within AML with recurrent cytogenetic abnormalities (n = 608), the most frequent subtype was AML with t(15;17), followed by AML with t(8;21). A male predominance was shared across all subgroups (overall sex ratio = 1.45), with the exception of AML and MDS therapy related (sex ratio = 0.83). The median (IQR) age of AML patients was 68 (50–78) years, being lower in AML with cytogenetic abnormalities (49 (35–67)",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:28"
    }
  },
  {
    "page_content": "in AML with cytogenetic abnormalities (49 (35–67) years). The incidence of overall AML was relatively stable over time, yet there was an increase in the incidence of specified cases in detriment of AML NOS cases (APC = − 5.2%, 95% CI − 6.9; − 3.4) (Table 3). ## Acute myeloid leukemia with ambiguous lineage and NOS cases There were 395 cases of acute myeloid leukemia with ambiguous lineage, 12% of them being biphenotypic acute leukemia. The overall CR and ASRE were 0.32 (95% CI 0.28; 0.35) and",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:29"
    }
  },
  {
    "page_content": "CR and ASRE were 0.32 (95% CI 0.28; 0.35) and 0.35 (95% CI 0.32; 0.39), respectively. Finally, there were 632 NOS cases (3.6% of the overall dataset), with a higher median age than that of the MNs as a whole [81 (73–86) years]. We evidenced a marked negative incidence trend across the period of study, both for acute leukemia of ambiguous lineage (APC = − 9.2. 95% CI − 12.0; − 6.3), and NOS cases (APC = − 14.3%, 95% − 16.5; − 12.1) (Table 3). ## Projections for 2021 Predicted incidence of MNs",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:30"
    }
  },
  {
    "page_content": "Projections for 2021 Predicted incidence of MNs for 2021, overall and by sex, are detailed in Table 4. According to our projections, 8446 new incident cases of MNs will be diagnosed in Spain in 2021, of which 2835 will be MPN, 650 MSD/MPN, 2670 MDS, 2060 AML, and 106 acute leukemia of ambiguous lineage, and 126 NOS cases. # Discussion In line with previous studies, incidence of MNs was markedly higher in men than in women for most subtypes. Notable exceptions included MDS associated with",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:31"
    }
  },
  {
    "page_content": "Notable exceptions included MDS associated with isolated del(5q), AML and MDS therapy related, and essential thrombocythemia, already reported in the literature. Likewise, the incidence of all MNs increased with advancing age, being particularly marked in NOS cases, in which the incidence rose sharply from age 70 years. This might suggest a decline in the quality of the diagnostic workup in the elderly, who are less likely to receive aggressive diagnostic tests due to comorbidity and/or",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:32"
    }
  },
  {
    "page_content": "diagnostic tests due to comorbidity and/or frailty, and may therefore receive a suboptimal treatment for their conditions23. Regarding specific MNs subtypes, lower incidence rates for most entities were reported in our study in comparison to the most recent data provided by the HMRN14. This could be partly explained by the specialized nature of the HMRN (with all diagnoses made and coded by clinical specialists working at a single integrated hematopathology laboratory), and by the lack of",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:33"
    }
  },
  {
    "page_content": "hematopathology laboratory), and by the lack of concordance in the recording of progressions/transformations. In contrast, incidence rates of overall MPN, MDS, and MDS/MPN in our region were markedly higher in comparison to European2,8,13 and US9–11 datasets, most of them covering years before/close to the implementation of the ICD-O-3 and the 2001 WHO classification. As far as MPN are regarded, disparities were mainly attributed to polycythemia vera and essential thrombocythemia, while rates",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:34"
    }
  },
  {
    "page_content": "vera and essential thrombocythemia, while rates of chronic myeloid leukemia (consistently documented since 1970’s with the identification of its causal chromosome transition), primary myelofibrosis, and mastocytosis were similar across studies. Such differences may be linked to the identification of the JAK2 mutation in 200524 and the derived 2008 WHO guidelines for MPN, whose impact is not documented in series covering only previous years. On the other hand, the incidence of AML, which is a",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:35"
    }
  },
  {
    "page_content": "the other hand, the incidence of AML, which is a long-established entity, was more homogeneous across different regions. Indeed, overall rates were consistent with European2,8 and US25 findings, as well as with smaller European series13,26–28, while slightly lower rates were reported in Canada29 and Switzerland30. Karyotypic information was not available for many of our cases, and thus, the proportion of AML with cytogenetic abnormalities (14%) was slightly lower in comparison with more",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:36"
    }
  },
  {
    "page_content": "(14%) was slightly lower in comparison with more specific studies31–33. However, rates of AML with t(15;17)(q22;q12) were still higher compared to the European average, further supporting the hypothesis that such entity might be more prevalent among individuals with Spanish ancestry34. Finally, most of these studies included AML of ambiguous lineage within AML-NOS subgroups, although it is placed as a distinct category from AML since the introduction of the 2008 WHO classification. Further",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:37"
    }
  },
  {
    "page_content": "of the 2008 WHO classification. Further studies are warranted to clarify the epidemiology of these entities owing their clinical relevance. We evidenced increasing incidence trends of MDS/MPN, MDS, and several MPN, previously reported in the literature and mostly linked to refinements in the diagnostic, classification, and registration practices. Within the latter, this was particularly seen in the three most frequent Philladelphia chromosome negative subtypes, and thus, may be linked to the",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:38"
    }
  },
  {
    "page_content": "negative subtypes, and thus, may be linked to the implementation of screening for JAK2 mutation. In the same vein, Girodon et al.35 documented an almost twofold increase in the incidence of essential thrombocythemia after 2005, but not in the remaining MPN subtypes. In agreement with the few European studies examining AML incidence trends13,15, we found a stable incidence of overall AML across the period of study. In contrast, an increasing trend was found in a Dutch pediatric study",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:39"
    }
  },
  {
    "page_content": "trend was found in a Dutch pediatric study (1990–2015)36 and in Canada (1992–2010)29 and US from 2009 to 201025 in the general population, the latter mainly attributed to changes in the registration of transformations in the Surveillance, Epidemiology, and End Results (SEER) program. Finally, NOS cases decreased remarkably across the period of study, which could be attributed both to a more specific clinical diagnosis and/or to an improved codification in Spanish cancer registries. The etiology",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:40"
    }
  },
  {
    "page_content": "in Spanish cancer registries. The etiology of MNs, in line with most hematological malignancies, is still uncertain. Several subtypes have been consistently associated with treatments (i.e. radiation, alkylating agents or topoisomerase II inhibitors)37, while environmental epidemiological studies suggest a potential role of obesity, tobacco exposure, autoimmune disorders, and infections in myelodisplastic38 or myeloproliferative diseases39. However, neither these factors, nor the genetic",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:41"
    }
  },
  {
    "page_content": "However, neither these factors, nor the genetic alterations currently described40, can explain the large variability in the incidence of these neoplasms2. In addition, drawing etiological hypothesis based on geographic heterogeneity in incidence rates is hampered by heterogeneity in accuracy and completeness in the registration of several subtypes. Several medical-claims-based studies have shown an underreporting of MNs41–44, namely MDS and MPN (which are often diagnosed and managed in an",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:42"
    }
  },
  {
    "page_content": "MPN (which are often diagnosed and managed in an outpatient setting, and might be missed by surveillance systems relying on hospital registration), and among the elderly (in which diagnostic evaluation might not be as aggressively sought as in younger individuals). Indeed, we evidenced marked differences in incidence rates across Spanish provinces, with the highest incidence rates of MDS, MPN, and MDS/MPN reported in the Girona cancer registry, which has started several initiatives15,45 to cope",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:43"
    }
  },
  {
    "page_content": "has started several initiatives15,45 to cope with these challenges. Following the example of the French Network of Cancer Registries (FRANCIM)46, training programs to improve the codification and registration of hematological neoplasm have been boosted in the REDECAN during the last few years, which are expected to start to bear fruits in future studies. Since 2008, there have been numerous advances in the identification of genetic biomarkers associated with specific MNs, which led to the",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:44"
    }
  },
  {
    "page_content": "associated with specific MNs, which led to the release of an updated WHO classification in 20165. The impact of these changes will be noticeable within the next years, when they become routinely distinguished in clinical practice and consistently coded in cancer registries. The incorporation of these updates at a cancer registry level will be eased with the release of the ICD-O-3, second revision47, which is recommended for use from 2020. Further studies with contemporary data including these",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:45"
    }
  },
  {
    "page_content": "studies with contemporary data including these classification changes are warranted. The number of expected MNs in 2021 depicts the present cancer burden of these malignancies in Spain. However, these data should be interpreted with caution due to several factors. First, some subtypes are extremely rare, making estimates less robust. Furthermore, the estimates provided herein do not reflect the impact of the new 2016 WHO classification5, nor that of coronavirus disease 2019 (COVID-19)48, as",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:46"
    }
  },
  {
    "page_content": "that of coronavirus disease 2019 (COVID-19)48, as they are based on extrapolations of cancer data collected in previous years. Regarding the latter, although the full extent of the impact of the COVID-19 pandemic remains unknown, delays in cancer diagnosis are expected to cause a short-term decline in cases followed by an increasing incidence of advanced-stage diagnosis49,50. In addition, if, over the period 2002–2013, there had been an increase in the completeness in the registration of MN",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:47"
    }
  },
  {
    "page_content": "in the completeness in the registration of MN cases, with the corresponding positive effect on the APC, this would cause an overestimation in the number of cases predicted for the year 2021. Nonetheless, these results are still interesting for clinicians and public health specialists in evaluating the cost of management and new treatments for these pathologies, and to account for the gap between the expected and the observed cases after the COVID-19 pandemic. Among the strengths of this",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:48"
    }
  },
  {
    "page_content": "COVID-19 pandemic. Among the strengths of this population-based study is the large number of MNs that allowed us to assess and compare incidence rates not only for common but also for relatively rare entities. However, several limitations must be considered when interpreting our results. First, the changing classification and diagnostic criteria (and consequent heterogeneity in disease definitions across countries, clinical centers, and cancer registries) hamper the interpretation of our",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:49"
    }
  },
  {
    "page_content": "registries) hamper the interpretation of our incidence rates and trends, as well as comparisons with previous studies. In addition, we cannot exclude the aforementioned underreporting of cases, particularly documented in MDS and MPN, and among the elderly. In addition, we lacked a centralized pathology and clinical review, which could have decreased the proportion of NOS cases and improved the quality of our data. This is particularly relevant for MDS, due to the poor inter-observed concordance",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:50"
    }
  },
  {
    "page_content": "MDS, due to the poor inter-observed concordance in diagnosis and the numerous non-neoplastic conditions that can mimic such neoplasms51,52. Nevertheless, in spite of the unavoidable biases due to variability and variation in registration quality and coding practices, over 95% of cases had adequate morphology specification. In conclusion, this study presents the first comprehensive population-based analysis of MNs incidence in Spain. It highlights some useful points for public health",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:51"
    }
  },
  {
    "page_content": "highlights some useful points for public health authorities, such as the increasing incidence of several subtypes, the remarkable variability in incidence rates (especially of MDS, MPN, and MDS/MPN) among provinces, and the number of cases expected in 2021 based on these data. The negative trend in the incidence of NOS cases suggests a more specific diagnosis and/or improvements in the registration of these cases across the study period, however, additional efforts should be made to improve the",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:52"
    }
  },
  {
    "page_content": "additional efforts should be made to improve the quality of MNs data in future studies.",
    "metadata": {
      "source": "../data/plain/PMC8748501.plain.txt",
      "id": "../data/plain/PMC8748501.plain.txt:53"
    }
  },
  {
    "page_content": "Gene S-phase kinase associated protein 2 is a novel prognostic marker in human neoplasms Abstract\nBackground\nNeoplasms are a series of diseases affecting human health. Prognostic and tumor status–related markers for various tumors should be identified.\nMethods",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:0"
    }
  },
  {
    "page_content": "Based on 19,515 samples from multiple sources, for the first time, this study provided an overview of gene S-phase kinase associated protein 2 (SKP2) in pan-cancer. Differential SKP2 expression in multiple comparison groups was identified by the Kruskal–Wallis test and Wilcoxon rank-sum test. The prognosis significance of SKP2 in individuals with neoplasm was evaluated through univariate Cox regression analysis and Kaplan-Meier curves. The area under the curve was utilized to detect the",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:1"
    }
  },
  {
    "page_content": "area under the curve was utilized to detect the accuracy of SKP2 in predicting cancer status. Spearman’s rank correlation coefficients were calculated in all correlation analyses. Gene set enrichment analysis was used to identify essential signaling pathways of SKP2 in human neoplasms.",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:2"
    }
  },
  {
    "page_content": "Results",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:3"
    }
  },
  {
    "page_content": "The study disclosed the upregulated SKP2 expression in 15 neoplasms and decreased SKP2 expression in three cancers (p < 0.05). The transcription factor Forkhead Box M1 may contribute to the increased expression levels of SKP2 in certain tumors. Over-expressed SKP2 represented a risk factor for the prognosis of most cancer patients (hazard ratio > 1, p < 0.05). SKP2 expression made it feasible to distinguish neoplasm and control tissues of 21 neoplasms (sensitivity = 0.79, specificity = 0.87,",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:4"
    }
  },
  {
    "page_content": "(sensitivity = 0.79, specificity = 0.87, area under the curve = 0.90), implying its potential in screening a series of neoplasms. Further, the research revealed the close association of SKP2 expression with DNA methyltransferases, mismatch repair genes, microsatellite instability, tumor mutational burden, neoantigen count, and immunity.",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:5"
    }
  },
  {
    "page_content": "Conclusions\nSKP2 plays an essential role in multiple neoplasms and may serve as a marker for treating and identifying these neoplasms.\nSupplementary Information",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:6"
    }
  },
  {
    "page_content": "The online version contains supplementary material available at 10.1186/s12920-023-01561-4. # Introduction Neoplasms are a series of diseases affecting human health and are the important causes of human death worldwide. It was predicted that in 2020 alone, there would be approximately 20 million newly diagnosed neoplasm patients and about 10 million related deaths worldwide. Although the clinical therapeutic effect on certain tumors has been significantly improved, the prognosis of most tumor",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:7"
    }
  },
  {
    "page_content": "improved, the prognosis of most tumor patients is not satisfactory [1–3]. Delay in diagnosis is a fundamental reason for the poor prognosis of tumor patients, and neoplasms are frequently diagnosed at an advanced stage. Efforts should therefore be focused on prognostic and tumor status–related markers for various types of neoplasms. The gene S-phase kinase associated protein 2 (SKP2) is located on chromosome 5p13.2 of human chromosome 5, and its homonymous encoded protein is a member of the",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:8"
    }
  },
  {
    "page_content": "its homonymous encoded protein is a member of the F-box protein family. SKP2 has significant carcinogenic characteristics due to its complex functions, such as participation in cell cycle regulation. The carcinogenic characteristics of SKP2 have been verified in several mouse experiments, which highlights the potential of the gene for targeted therapy. In addition, in various cancers, SKP2 is differentially (mainly highly) expressed in cancer tissues versus control tissues. For example,",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:9"
    }
  },
  {
    "page_content": "tissues versus control tissues. For example, elevated expression of SKP2 and its association with poor prognosis were reported in breast and prostate cancer. Cell experiments have also supported the promotion of SKP2 in cancer progression. Thus, current studies consistently reveal the essential roles of SKP2 in multiple tumors. However, there are no reports focusing on SKP2 in pan-cancer. Moreover, the potential clinical significance of SKP2 (e.g., distinguishing tumor patients from individuals",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:10"
    }
  },
  {
    "page_content": "distinguishing tumor patients from individuals without cancer) and the immune correlation of the gene in a variety of tumors are unclear. The current study comprehensively highlights the expression levels and clinical roles (e.g., prognosis) of SKP2 in a series of neoplasms based on thousands of samples from several sources. Further, the associations of SKP2 expression with DNA methyltransferases (DNMTs), mismatch repair genes (MMRGs), microsatellite instability (MSI), tumor mutational burden",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:11"
    }
  },
  {
    "page_content": "instability (MSI), tumor mutational burden (TMB), neoantigen count, and immunity (e.g., filtration levels of immune cells) were also revealed, which may promote understanding of SKP2 in pan-cancers. # Materials and methods ## Collection and processing of datasets and cohorts An SKP2 mRNA expression dataset of normal organs was downloaded from GTEx, and the dataset included 8,671 human samples. A dataset from CCLE, including 457 specimens of neoplasm cell lines, was obtained from DepMap Portal.",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:12"
    }
  },
  {
    "page_content": "cell lines, was obtained from DepMap Portal. Moreover, a TCGA (The Cancer Genome Atlas) cohort of 33 kinds of neoplasms containing 9,358 neoplasm and 722 control samples was derived from the Xena database. A “TARGET-AML” dataset was also acquired from the Xena database, including 173 LAML (acute myeloid leukemia) patients; among the 173 patients, 169 were with chromosome 5 alternations, including t(3;5)(q25;q34), del5q, and monosomy 5. Given the imbalanced sample size (169 versus 4) for the",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:13"
    }
  },
  {
    "page_content": "the imbalanced sample size (169 versus 4) for the TARGET-AML dataset, the synthetic minority oversampling technique (SMOTE) algorithm of the “DMwR” package was used to synthesize a new dataset (16 versus 8) to validate the results based on the TARGET-AML dataset. The expression value of each gene in the mRNA-related datasets listed above was normalized with log2 (x + 1) conversion. A total of 134 samples (three normal lung samples were used as control groups for both the LUAD and LUSC groups;",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:14"
    }
  },
  {
    "page_content": "control groups for both the LUAD and LUSC groups; Supplementary Material 1) from THPA were included for validating SKP2 expression at protein levels. The inclusion criteria for these specimens were as follows: (1) immunohistochemical staining for SKP2 protein involved both the neoplasm group and the control group rather than a single neoplasm group or control group; (2) both the neoplasm group and the control group contained at least two specimens; and (3) neoplasm tissues and normal tissues",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:15"
    }
  },
  {
    "page_content": "and (3) neoplasm tissues and normal tissues were processed with the same antibody. The criteria for staining scores were: 0, 1, 2, and 3 for negative, weak, moderate, and intense staining levels of SKP2 protein, respectively, while the quantity scores were: 0, 1, 2, and 3 for none, < 25%, 75–25%, and > 75% of stained cells. The total immunohistochemical score represented the SKP2 protein levels for each sample and was evaluated by the staining intensity score and the quantity score. ##",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:16"
    }
  },
  {
    "page_content": "intensity score and the quantity score. ## Collection of clinical information Clinical features, containing age, gender, and AJCC (American Joint Committee on Cancer) stage, were downloaded from the Xena database for the TCGA cohort. The four kinds of prognosis information—OS (overall survival), DSS (disease-specific survival time), DFI (disease-free interval), and PFI (progression-free interval)—were also obtained in the Xena database. ## Extraction of expression data of specific genes",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:17"
    }
  },
  {
    "page_content": "Extraction of expression data of specific genes Transcription factors (TFs) that may upregulate SKP2 expression were predicted from the Cistrome Data Browser, and ChIP-Seq (chromatin immunoprecipitation followed by sequencing) data of certain TFs were also downloaded from this database. The mRNA expression data of TFs were extracted from the TCGA cohort. The expression levels of three DNMTs (DNMT1, etc.), five MMRGs (MLH1, etc.), and 46 immune checkpoints (BTLA, etc.) were also extracted in the",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:18"
    }
  },
  {
    "page_content": "(BTLA, etc.) were also extracted in the TCGA cohort. ## Collection of other data All the MSI, TMB, and immune neoantigen count data for patients in the TCGA cohort were downloaded from SangerBox (3.0). Immune cell infiltration levels and three kinds of scores—stromal score, immune score, and ESTIMATE score—for individuals in the TCGA cohort were downloaded from TIMER and SangerBox (3.0), respectively, and the data were calculated via the corresponding TIMER and ESTIMATE algorithms. A gene set",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:19"
    }
  },
  {
    "page_content": "TIMER and ESTIMATE algorithms. A gene set called “c2.cp.kegg.v7.4.symbols” was downloaded from MSigDB (v7.5.1) for exploring the underlying mechanisms of SKP2 in multiple neoplasms in terms of KEGG (Kyoto Encyclopedia of Genes and Genomes) [18–21] signaling pathways. CRISPR (clustered regularly interspaced short palindromic repeats) data downloaded from DepMap Portal were used to explore whether SKP2 was an essential gene for a series of cancer cells. The gene effect was utilized to evaluate",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:20"
    }
  },
  {
    "page_content": "cells. The gene effect was utilized to evaluate the possibility of SKP2 as an essential cancer gene — the lower the gene effect score, the higher the likelihood that SKP2 was essential for cancer cell lines (zero scores suggesting not essential). The half-maximal inhibitory concentration (IC50) data of 57 drugs approved by the American Food and Drug Administration or verified by clinical trials were obtained from CellMiner. The data were applied to explore the susceptibility of certain drugs",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:21"
    }
  },
  {
    "page_content": "to explore the susceptibility of certain drugs for patients with distinct SKP2 expression levels and to identify potential drugs for treating these individuals. ## Statistical analysis The chi-square test was used to detect the equilibrium of baseline data between comparison groups (e.g., cancer group versus control group). The difference in SKP2 expression in various compared groups was identified via the Kruskal–Wallis test and Wilcoxon rank-sum test. Multiple comparisons were also performed",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:22"
    }
  },
  {
    "page_content": "test. Multiple comparisons were also performed using the false discovery rate method to assess whether there was a significant difference in SKP2 mRNA expression between neoplasms and control groups. The Wilcoxon rank-sum test was used to compare the expression levels of TFs between cancer and control groups, and Spearman’s rank correlation coefficients were utilized to evaluate the relationship between TF expression and SKP2 expression. The prognosis effect of SKP2 for neoplasms patients was",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:23"
    }
  },
  {
    "page_content": "effect of SKP2 for neoplasms patients was assessed by univariate Cox regression analysis and Kaplan-Meier curves. The area under the curve (AUC) was applied to detect the accuracy of SKP2 in predicting cancer status. Spearman’s rank correlation coefficients were calculated in all correlation analyses. Gene set enrichment analysis (GSEA) was applied for searching KEGG pathways based on the clusterProfiler package. Except for the summary receiver operating characteristic curve, which was",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:24"
    }
  },
  {
    "page_content": "operating characteristic curve, which was generated in Stata (v15.0), all other analyses were carried out in R (v4.1.0). A p-value of less than 0.05 suggested statistical significance. # Results ## Differential SKP2 expression in neoplasms Figure 1 shows the overall design of this study. Balanced age and gender distributions were detected among the cancer and control groups for most cancers (p > 0.05; Supplementary Materials 2 and 3). Various organs of humans were detected with distinct SKP2",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:25"
    }
  },
  {
    "page_content": "organs of humans were detected with distinct SKP2 expression levels (p < 0.05); for example, the cervix uteri and heart were observed increasing and decreasing SKP2 expression levels, respectively (Fig. 2A). Similarly, differential SKP2 expression was detected in different cell lines of neoplasms (p < 0.05) (Fig. 2B), and such a phenomenon was also found in tissues of 18 types of 21 investigated neoplasms — high SKP2 expression in 15 neoplasms (bladder urothelial carcinoma [BLCA], etc.) and low",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:26"
    }
  },
  {
    "page_content": "urothelial carcinoma [BLCA], etc.) and low SKP2 expression in three neoplasms — KICH (kidney chromophobe), PRAD (prostate adenocarcinoma), and THCA (thyroid carcinoma) (p < 0.05) (Fig. 2C). Considering the imbalanced age distribution between COAD (colon adenocarcinoma), LIHC (liver hepatocellular carcinoma), and UCEC (uterine corpus endometrial carcinoma) and their control groups (p < 0.05; Supplementary Material 2), adjustment tests were carried out. The results showed that, for both the old",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:27"
    }
  },
  {
    "page_content": "out. The results showed that, for both the old (≥ 65 years old) and the young (< 65 years old), SKP2 expression levels in the COAD, LIHC, and UCEC groups were higher than those in their control groups (p < 0.05; Fig. 2D), consistent with the results without adjustment tests (Fig. 2C). The gender distribution between BLCA and its control was also imbalanced (p < 0.05; Supplementary Material 3), while the further adjustment test supported an increased SKP2 expression level in the BLCA group",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:28"
    }
  },
  {
    "page_content": "increased SKP2 expression level in the BLCA group compared to its control group (p < 0.05; Fig. 2E). Therefore, compared with the control tissues, the mRNA expression of SKP2 in most cancers was significantly different. Fig. 1Overview of the study. DNMT, DNA methyltransferase; MMR, mismatch repair; MSI, microsatellite instability; TMB, tumor mutational burden Fig. 2SKP2 expression in pan-cancer and its correlations with clinical characteristics. SKP2 expression in normal tissues (panel A),",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:29"
    }
  },
  {
    "page_content": "SKP2 expression in normal tissues (panel A), neoplasms cell lines (panel B), and pan-cancer (panels C–E). Panels D–E: Adjustment analysis of SKP2 expression in certain neoplasms. For panels C–E: *p < 0.05, **p < 0.01, ***p < 0.001; p-value is based on the Wilcoxon rank-sum test (multiple comparison test by false discovery rate) In addition to mRNA level, we evaluated the expression of SKP2 in various cancers and their control tissues at the protein level. For CESC (cervical squamous cell",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:30"
    }
  },
  {
    "page_content": "protein level. For CESC (cervical squamous cell carcinoma and endocervical adenocarcinoma), COAD, HNSCC (head and neck squamous cell carcinoma), kidney cancer, LIHC, LUAD (lung adenocarcinoma), LUSC (lung squamous cell carcinoma), STAD (stomach adenocarcinoma), and UCEC, in comparison to normal tissues, the staining intensity of anti-SKP2 antibody was significantly stronger in cancer tissues (Fig. 3A), while the converse trend was investigated in THCA (Fig. 3A). Moreover, increasing SKP2",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:31"
    }
  },
  {
    "page_content": "in THCA (Fig. 3A). Moreover, increasing SKP2 protein levels in CESC, COAD, and STAD were confirmed by statistical analysis (p < 0.05; Fig. 3B), consistent with the results at the mRNA level. Although no significant differences in SKP2 protein levels were found between cancer tissues and control tissues for the other nine neoplasms (e.g., BLCA), the expression of SKP2 at both protein and mRNA levels exhibited the same trends for most of these neoplasms (Supplementary Material 4). According to",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:32"
    }
  },
  {
    "page_content": "(Supplementary Material 4). According to the above results, SKP2 was upregulated in up to 15 cancers discussed in this research. TFs tend to play essential roles in gene expression regulation. TFs that may regulate SKP2 expression in the 15 cancers were investigated, which may contribute to understanding possible mechanisms for the overexpression of SKP2. A total of 200 TFs that may upregulate SKP2 expression were obtained from the Cistrome Data Browser. Among these TFs, FOXM1 (forkhead box M1)",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:33"
    }
  },
  {
    "page_content": "Browser. Among these TFs, FOXM1 (forkhead box M1) is encoded by the gene FOXM1. FOXM1 was highly expressed in the 15 cancers (p < 0.05; Supplementary Material 5A), where elevated SKP2 expression was also detected. Moreover, significantly positive correlations were found between the expression levels of FOXM1 and SKP2 (ρ ≥ 0.3, p < 0.05; Supplementary Material 5B). What is important is that the binding peaks of FOXM1 can be observed upstream of the transcription start site of SKP2 (Supplementary",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:34"
    }
  },
  {
    "page_content": "transcription start site of SKP2 (Supplementary Material 5C). These results indicated that elevated FOXM1 expression might contribute to the high SKP2 expression in the 15 cancers. Notably, the possible mechanisms of SKP2 expression in cancers may be complex. For example, chromosome 5 alternations (SKP2 is located on chromosome 5) are commonly observed in LAML. Compared to the group without chromosome 5 alternations, a trend of downregulation of SKP2 expression levels can be observed in LAML",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:35"
    }
  },
  {
    "page_content": "of SKP2 expression levels can be observed in LAML patients with chromosome 5 alternations, based on the raw data (Supplementary Material 6A). The result was validated via the SMOTE data (p < 0.05, Supplementary Material 6B). This suggests that, except for the regulatory effect of TFs, attention should also be given to other factors that may affect SKP2 expression in specific cancers. Thus, the underlying mechanisms of SKP2 expression in cancers require further investigation. Fig. 3Validation of",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:36"
    }
  },
  {
    "page_content": "further investigation. Fig. 3Validation of SKP2 expression in neoplasms at protein levels. Panel A: Elevated SKP2 protein levels were detected in most neoplasm (except BLCA, PRAD, and THCA) tissues rather than corresponding normal tissues; images are available from v21.0.proteinatlas.org. The three numbers at the lower left of each panel indicate patient identify document, staining level, and quantity, respectively. Panel B: Elevated SKP2 protein levels can be detected in CESC, COAD, and STAD;",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:37"
    }
  },
  {
    "page_content": "levels can be detected in CESC, COAD, and STAD; *p < 0.05; p-value is based on the Wilcoxon rank-sum test ## Clinical characteristics of patients with various SKP2 expression levels Patients with different clinical characteristics may have various prognoses. For example, cancer patients with advanced AJCC stages tend to have poorer prognoses than others. Thus, we analyzed the relationship between SKP2 expression and available clinical characteristics data of patients. The results showed that",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:38"
    }
  },
  {
    "page_content": "data of patients. The results showed that increased SKP2 expression tended to be observed in advanced AJCC stages for certain neoplasms (p < 0.05) (Fig. 4A and Supplementary Material 7). Elevated SKP2 expression was observed in male instead of female patients with HNSCC, LAML, or READ (rectum adenocarcinoma); in contrast, the opposite phenomenon was found in KIRP (kidney renal papillary cell carcinoma) and SARC (sarcoma) (p < 0.05) (Supplementary Material 8). Individuals with cancer of",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:39"
    }
  },
  {
    "page_content": "Material 8). Individuals with cancer of different ages exhibited varying levels of SKP2 expression. For instance, decreasing SKP2 expression was also detected in older patients with BRCA (breast invasive carcinoma) and young patients with PCPG (pheochromocytoma and paraganglioma) (p < 0.05) (Supplementary Material 9). Given that SKP2 expression was associated with at least two clinical characteristics among five neoplasms (BRCA, KIRP, LIHC, LUAD, and READ), covariate analysis was performed for",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:40"
    }
  },
  {
    "page_content": "and READ), covariate analysis was performed for these neoplasms. Consequently, AJCC stage distribution was correlated with age distribution in KIRP (p < 0.05; Supplementary Material 10) and, thus, further adjustment analysis was carried out for this cancer. For patients with this cancer at AJCC stage I, males were observed to have lower SKP2 expression than females (Fig. 4B); this discrepancy was not identified for KIRP at stages II, III, or IV (Supplementary Material 11). For KIRP, a positive",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:41"
    }
  },
  {
    "page_content": "(Supplementary Material 11). For KIRP, a positive association between SKP2 expression and AJCC stage was determined not for females but for males (p < 0.05) (Fig. 4C and Supplementary Material 11). Fig. 4Correlations between SKP2 expression with clinical parameters. For panels A–C, the p-value is based on the Wilcoxon rank-sum test ## Prognosis differences of patients with disparate SKP2 expression levels To directly evaluate the prognostic significance of SKP2 expression in various tumors,",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:42"
    }
  },
  {
    "page_content": "of SKP2 expression in various tumors, univariate Cox regression analyses and Kaplan-Meier curves were performed in this research. The two analysis methods consistently indicated that elevated SKP2 expression represented poor OS and/or DSS for patients with ACC (adrenocortical carcinoma), KICH, KIRP, LGG (brain lower grade glioma), LIHC, MESO (mesothelioma), PRAD, SKCM (skin cutaneous melanoma), or THCA (hazard ratio [HR] > 1, p < 0.05) and favorable OS and DSS for individuals with OV (ovarian",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:43"
    }
  },
  {
    "page_content": "OS and DSS for individuals with OV (ovarian serous cystadenocarcinoma), READ, or THYM (thymoma) (HR < 1, p < 0.05) (Fig. 5A–D). In DFI and PFI, SKP2 expression also played a risk role for patients with ACC and KIRP (HR > 1, p < 0.05) (Fig. 6A–D). Moreover, SKP2 expression was significantly correlated with poor PFI in individuals with KICH, LGG, LIHC, MESO, or UVM (uveal melanoma) (HR > 1, p < 0.05), as well as with considerable PFI in OV patients (HR < 1, p < 0.05) (Fig. 6B and D). ##",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:44"
    }
  },
  {
    "page_content": "patients (HR < 1, p < 0.05) (Fig. 6B and D). ## Difference in cancer status of patients with distinct SKP2 expression levels The prognostic significance of SKP2 expression in various cancers was notable, but it was still unclear whether SKP2 could distinguish cancer samples from control samples, which was analyzed in this study. In 21 kinds of neoplasms investigated in this part, SKP2 well differentiated 15 types of neoplasm (BLCA, etc.) tissues and their normal counterparts (AUC > 0.75)",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:45"
    }
  },
  {
    "page_content": "and their normal counterparts (AUC > 0.75) (Fig. 7A). Particularly, SKP2 expression had a remarkable capacity to differentiate eight cancers from their control tissues; the eight neoplasms were BLCA, CESC, COAD, ESCA (esophageal carcinoma), GBM (glioblastoma multiforme), LUSC, PCPG (pheochromocytoma and paraganglioma), and READ (AUC > 0.90) (Fig. 7A). SKP2 expression made it feasible to discern the neoplasm and control tissues of the 21 cancers (sensitivity = 0.79, specificity = 0.87,",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:46"
    }
  },
  {
    "page_content": "cancers (sensitivity = 0.79, specificity = 0.87, AUC = 0.90) (Fig. 7B), particularly for the 15 cancers listed above (sensitivity = 0.83, specificity = 0.91, AUC = 0.94) (Fig. 7C). Fig. 5Relation of SKP2 expression with overall survival (panels A–B) and disease-specific survival of neoplasm patients (panels C–D) Fig. 6Relation of SKP2 expression with disease-free interval (panels A–B) and progression-free interval of neoplasm patients (panels C–D) Fig. 7Receiver operating characteristic curves",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:47"
    }
  },
  {
    "page_content": "Fig. 7Receiver operating characteristic curves for detecting the ability of SKP2 expression to distinguish neoplasm tissues from their normal tissues. Panel A: Receiver operating characteristic curves. Panels B–C: Summary receiver operating characteristic curves. AUC, area under the curve Fig. 8Spearman coefficient of SKP2 expression with DNA methyltransferase expression (panel A), mismatch repair gene expression (panel B), microsatellite instability (panel C), tumor mutational burden (panel",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:48"
    }
  },
  {
    "page_content": "(panel C), tumor mutational burden (panel D), and immune neoantigen count (panel E). The letter “ρ” is followed by the Spearman correlation coefficient ## SKP2 expression with DNMTs, MMRGs, MSI, and TMB DNMTs, MMRGs, MSI, and TMB are considered prognostic markers and treatment indicators of cancer [25–27]. Exploring the relationship between SKP2 and these indicators may help identify the marker role of SKP2 in neoplasms. A significantly positive correlation between SKP2 expression and the",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:49"
    }
  },
  {
    "page_content": "correlation between SKP2 expression and the expression levels of three DNMTs and five MMRGs was detected in almost all the 33 cancers analyzed (Fig. 8A and B). The close association of SKP2 expression with MSI and TMB was also observed in multiple neoplasms, especially for DLBC (lymphoid neoplasm diffuse large B-cell lymphoma) (ρ = −0.51, p < 0.05) in MSI (Fig. 8C), as well as KICH, LUAD (lung adenocarcinoma), and READ in TMB (ρ > 0.3, p < 0.05) (Fig. 8D). These results suggest that SKP2 may",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:50"
    }
  },
  {
    "page_content": "(Fig. 8D). These results suggest that SKP2 may affect the progression of neoplasms by influencing DNMTs, MMRGs, MSI, and TMB. ## SKP2 expression with immunity Elevated MSI and TMB tend to increase immune neoantigen levels; thus, the relationship between immune neoantigen count and SKP2 expression was investigated. As a result, the positive relevance of immune neoantigen count with SKP2 expression was detected in SARC, TGCT (testicular germ cell tumors), and LUAD (p < 0.05) (Fig. 8E). The immune",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:51"
    }
  },
  {
    "page_content": "and LUAD (p < 0.05) (Fig. 8E). The immune neoantigen can potentially induce an immune response, which involves activating a variety of immune cells. Interestingly, significant correlations (generally positive) between the SKP2 expression and infiltration levels of most of the six immune cells — B cells, CD4 T cells, CD8 T cells, neutrophil cells, macrophage cells, and dendritic cells — were observed in THYM, KICH, and KIRC (kidney renal clear cell carcinoma) (Fig. 9A). Furthermore, SKP2 was",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:52"
    }
  },
  {
    "page_content": "cell carcinoma) (Fig. 9A). Furthermore, SKP2 was also closely related to the immune microenvironment, including immune cells. For instance, for ACC, SKCM, TGCT, and GBM, negative associations between SKP2 expression and immune environment (including stromal, immune, and ESTIMATE scores) were detected (Fig. 9B). Notably, the relationship between SKP2 expression and both immune cell infiltration levels and immune environment scores varied with tumor type (Supplementary Materials 12 and 13),",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:53"
    }
  },
  {
    "page_content": "tumor type (Supplementary Materials 12 and 13), implying the complex mechanisms of SKP2 in neoplasms. Immune checkpoints are known to regulate the growth and proliferation of immune cells negatively. In our study, SKP2 expression was relevant to the expression levels of multiple immune checkpoints. Particularly, the close correlation (ρ > 0.3, p < 0.05) between SKP2 expression and at least 15 immune checkpoints can be detected in DLBC, KIRC, PRAD, and UVM (Supplementary Material 14), which may",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:54"
    }
  },
  {
    "page_content": "and UVM (Supplementary Material 14), which may partly explain the correlations between SKP2 expression and the immune environment. ## SKP2 expression with GSEA SKP2 plays an essential role in multiple neoplasms, and the corresponding mechanisms require investigation. Previous studies have revealed the molecular mechanism of the gene in a single neoplasm, but whether SKP2 had a similar molecular mechanism in a variety of tumors was unknown. Therefore, we attempted to clarify this issue via GSEA.",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:55"
    }
  },
  {
    "page_content": "we attempted to clarify this issue via GSEA. Among the 26 KEGG signaling pathways with a GSEA p-value less than 0.05, the “olfactory transduction” pathway was observed in 11 neoplasms (Supplementary Materials 15 and 16), highlighting the critical role of this pathway in multiple neoplasms. Additionally, SKP2 was found to be associated with specific signaling pathways (e.g., “complement and coagulation cascades,” “cytokine–cytokine receptor interaction,” and “metabolism of xenobiotics by",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:56"
    }
  },
  {
    "page_content": "interaction,” and “metabolism of xenobiotics by cytochrome P450”) in at least two cancers (Supplementary Material 16), which required further experimental investigation. At the same time, it is also necessary to further study the molecular mechanism of SKP2 in specific cancers. For example, SKP2 may play its roles in GBM and SARC through complex mechanisms (at least five signaling pathways) (Supplementary Materials 17 and 18). ## Importance of SKP2 in a variety of cancer cells and exploration",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:57"
    }
  },
  {
    "page_content": "SKP2 in a variety of cancer cells and exploration of potential targeted drugs We further verified the vital role of SKP2 in various tumors through CRISPR data. The CRISPR results demonstrated the essential cancer role of SKP2 in a series of neoplasms, including BLCA, CESC, COAD, ESCA, STAD, LIHC, SKCM, PRAD, SARC, THCA, UCS (uterine carcinosarcoma), and UVM (gene effect < 0) (Fig. 9C). In other words, in these neoplasm cells, those with low SKP2 expression tend to be depleted, suggesting SKP2",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:58"
    }
  },
  {
    "page_content": "expression tend to be depleted, suggesting SKP2 can promote the development of these neoplasms. The above results indicate the importance of SKP2 in multiple neoplasms, and the gene may be a potential marker for the treatment of several cancers. Thus, a drug sensitivity analysis for SKP2 was carried out. Through the analysis results based on CellMiner data, 19 types of 57 drugs approved by the American Food and Drug Administration or verified by clinical trials may benefit cancer patients with",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:59"
    }
  },
  {
    "page_content": "clinical trials may benefit cancer patients with high-SKP2 expression, as cancer cells with upregulated SKP2 expression were susceptible to these drugs based on the results of IC50 (p < 0.05) (Fig. 10). Fig. 9SKP2 expression with the immune microenvironment, and its essential role in some cancer types. Panels A–B: The relevance between SKP2 expression with infiltration levels of immune cells (panel A) and immune-related scores (panel B). Panel C: SPK2 was identified as an essential cancer gene",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:60"
    }
  },
  {
    "page_content": "SPK2 was identified as an essential cancer gene with a gene effect score of less than 0 in most cancers Fig. 10Drug sensitivity of SKP2. Drugs with a p-value of less than 0.01 are shown in this figure. **p < 0.01; ***p < 0.001; p-value is based on the Wilcoxon rank-sum test. IC50, half-maximal inhibitory concentration # Discussion Based on 19,515 samples from several sources, for the first time in an overview of pan-cancer, this study disclosed the overexpression of SKP2 and its risk factor for",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:61"
    }
  },
  {
    "page_content": "overexpression of SKP2 and its risk factor for the prognosis of patients in multiple neoplasms. The increased expression levels of SKP2 in tumors may result from regulation of the TF FOXM1. SKP2 expression made it feasible to distinguish the neoplasm and control tissues of 21 neoplasms, implying its potential in screening a series of neoplasms. Further, the study also investigated the associations between SKP2 expression and several factors including DNMTs, MMRGs, MSI, TMB, neoantigen count,",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:62"
    }
  },
  {
    "page_content": "DNMTs, MMRGs, MSI, TMB, neoantigen count, and immunity, as well as conducted GSEA, and examined drug susceptibility. The study identified the potential of SKP2 as a marker for the treatment and identification of these neoplasms. It also provided clues to understanding the underlying mechanisms of pan-cancer. SKP2 is upregulated in most tumors. Previously, the elevated expression level of SKP2 was identified in a few cancers, such as COAD and oral squamous cell carcinoma. In our study, distinct",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:63"
    }
  },
  {
    "page_content": "squamous cell carcinoma. In our study, distinct SKP2 expression was found in various normal organ and neoplasm cells. Moreover, SKP2 mRNA was found to be highly expressed in 15 tumors — BLCA, CESC, CHOL, COAD, ESCA, GBM, HNSCC, KIRC, LIHC, LUAD, LUSC, PCPG, READ, STAD, and UCEC, and the overexpression status of SKP2 in cancer tissues of CESC, COAD, and STAD was verified at the protein level. By contrast, a low expression of SKP2 mRNA was observed in tissues of KICH, PRAD, and THCA. Taken",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:64"
    }
  },
  {
    "page_content": "in tissues of KICH, PRAD, and THCA. Taken together, the overexpression of SKP2 was identified in most neoplasms. The regulation mechanisms of SKP2 expression in tumors remain unclear. Based on our study, the increased expression levels of SKP2 in tumors may result from regulation of the TF FOXM1, as evidenced by (1) the high expression of both FOXM1 and SKP2 in 15 cancers (CESC, etc.); (2) positive correlations between the expressions of FOXM1 and SKP2 in the 15 tumors; and (3) the presence of",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:65"
    }
  },
  {
    "page_content": "SKP2 in the 15 tumors; and (3) the presence of binding peaks of FOXM1 upstream of the transcription start site of SKP2. However, the possible mechanisms of SKP2 expression in cancers may be complicated. An example is that a downregulation of SKP2 expression levels was identified in LAML patients with chromosome 5 alternations compared to those without chromosome 5 alternations. In addition to this, according to previous studies, amplification of the SKP2 locus was reported in certain cancers,",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:66"
    }
  },
  {
    "page_content": "the SKP2 locus was reported in certain cancers, such as in lung cancer, biliary tract cancer, and glioblastoma [32–34], which may contribute to the upregulation of SKP2 in these cancers at transcriptional levels. However, considering that the number of samples with gene amplification was far smaller than that of samples with high SKP2 expression in certain cancers (e.g., small-cell lung carcinoma), it is possible that high SKP2 expression cannot be attributed solely to gene amplification.",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:67"
    }
  },
  {
    "page_content": "be attributed solely to gene amplification. Indeed, abnormal SKP2 expression was also identified in the absence of SKP2 locus amplification, and regulation at post-transcriptional levels may play a role in this process. Thus, further research is needed to explore the mechanisms of high SKP2 expression in tumors. High expression of SKP2 is related to the poor prognosis of tumors. Bochis et al. revealed that high SKP2 expression predicted higher tumor-node-metastasis stages in patients with COAD",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:68"
    }
  },
  {
    "page_content": "stages in patients with COAD and was related to poor OS and relapse-free survival. Yamada et al. identified that over-expressed SKP2 was a signal of poor prognosis for patients with oral squamous cell carcinoma. They confirmed that downregulation of SKP2 could significantly reduce the migration and invasion ability of oral squamous cell carcinoma cells. In several tumors, such as breast cancer, osteosarcoma, and glioblastoma, overexpression of SKP2 was associated with poor prognosis. Based on",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:69"
    }
  },
  {
    "page_content": "SKP2 was associated with poor prognosis. Based on our pan-cancer study, increased SKP2 was a risk factor for the prognosis (OS, DSS, DFI, and/or PFI) of individuals with one of ten types of cancers — ACC, KICH, KIRP, LGG, LIHC, MESO, PRAD, SKCM, THCA, and UVM — while it predicted a favorable prognosis in READ, THYM, and OV patients. Thus, the risk role of upregulated SKP2 expression is detected in most tumors, demonstrating the clinical value of the gene for prognosis. Based on this finding, a",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:70"
    }
  },
  {
    "page_content": "the gene for prognosis. Based on this finding, a potential practical application example is to detect the expression level of SKP2 in cancer patients by some techniques (e.g., microarray, RNA-sequence or quantitative polymerase chain reaction) in the future, and to predict the prognosis of the patients according to the expression level of SKP2, thereby providing some reference for the clinical management of these patients. A few studies have reported the potential of SKP2 as a prognostic",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:71"
    }
  },
  {
    "page_content": "reported the potential of SKP2 as a prognostic marker, but its identification effect on cancer status has not been investigated. Based on the AUC analysis of the current study, SKP2 is a remarkable molecule to distinguish cancer tissues and normal tissues for various cancers (particularly BLCA, CESC, COAD, ESCA, GBM, LUSC, PCPG, and READ). Such a result suggests that SKP2 is a potential biomarker for predicting cancer status in multiple tumors. This study preliminarily discussed the underlying",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:72"
    }
  },
  {
    "page_content": "This study preliminarily discussed the underlying mechanisms of SKP2 in multiple neoplasms by investigating the correlation of SKP2 with DNMTs, MMRGs, MSI, and TMB. Epigenetic alterations can influence biological processes (e.g., growth and proliferation) of neoplasms. DNMT-mediated DNA methylation and MMRG-led MMR are common epigenetic modifications, enabling DNMTs and MMRGs to impact disease development. For example, DNMT1, DNMT3A, and DNMT3B have been shown to promote LAML, which may be due",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:73"
    }
  },
  {
    "page_content": "have been shown to promote LAML, which may be due to DNMTs silencing certain tumor suppressor genes through hypermethylation of these genes, thereby promoting the progression of LAML. Dysfunction of MMRGs may lead to the loss of control of various biological processes, thereby affecting tumor formation and treatment. In our study, the expression level of SKP2 was significantly positively correlated with the expression levels of three DNMTs and five MMRGs, suggesting that the effect of SKP2 on",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:74"
    }
  },
  {
    "page_content": "five MMRGs, suggesting that the effect of SKP2 on DNMT and MMR may be one of the critical pathways for the gene to promote cancer. Dysfunctions of MMR can cause MSI, and elevated levels of MSI exhibit high TMB. Increased MSI and TMB are associated with elevated neoantigen, thereby stimulating or promoting the body’s immune response; thus, MSI and TMB are considered practical markers for predicting response to immunotherapy [41–43]. SKP2 was not only positively correlated with the MSI and TMB of",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:75"
    }
  },
  {
    "page_content": "positively correlated with the MSI and TMB of some cancers (e.g., COAD, READ, and SARC), but also positively associated with immune neoantigen count. This suggests that SKP2 may also have the potential to predict the immune response to immunotherapy, which requires further investigation. The relationship between SKP2 and the immune microenvironment, including immune cell levels, is very complex in many tumors. On the one hand, SKP2 was positively correlated with six immune cell infiltration",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:76"
    }
  },
  {
    "page_content": "correlated with six immune cell infiltration levels (B cells, CD4 T cells, CD8 T cells, neutrophil cells, macrophage cells, and dendritic cells) in some tumors (especially THYM, KICH, and KIRC), suggesting that SKP2 may act as an immune antigen to activate the immune response, thereby causing an increase in immune cell levels. Such a finding has also been supported in some single cancers. For example, Kim et al. found that upregulated SKP2 was positively correlated with the level of regulatory",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:77"
    }
  },
  {
    "page_content": "correlated with the level of regulatory T cell infiltration. Alvaro et al. reported that Hodgkin lymphoma cells with high SKP2 expression had higher T cell infiltration levels than those with low SKP2 expression. On the other hand, SKP2 was negatively correlated with immune microenvironment scores in some tumors (such as ACC, SKCM, TGCT, and GBM), suggesting that SKP2 may also be involved in significantly negative regulation of the immune microenvironment in these tumors and then affect the",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:78"
    }
  },
  {
    "page_content": "in these tumors and then affect the prognosis of patients. However, previous research has not provided similar reference information. Therefore, the current studies suggest that SKP2 may have two sides in immune regulation for different tumors, but further investigations are necessary. This study also suggested the potential direction of SKP2 in tumor-related research and the drugs targeting this molecule. The protein encoded by cyclin dependent kinase inhibitor 1B (CDKN1B/p27) is a negative",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:79"
    }
  },
  {
    "page_content": "kinase inhibitor 1B (CDKN1B/p27) is a negative regulator of the cell cycle. The complex composed of this protein enables cells to stay in the G1 phase of their cycle and, thus, it has the effect of inhibiting tumors. As a ubiquitin ligase subunit, SKP2 can target to degrade CDKN1B, promote the transformation of cells from the G1 phase to the S phase, and then cause the growth and proliferation of cancer cells; this is considered the typical function of SKP2 [46–48]. It is noteworthy that, based",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:80"
    }
  },
  {
    "page_content": "of SKP2 [46–48]. It is noteworthy that, based on the GSEA focusing on a common potential molecular mechanism in different neoplasms, the olfactory transduction pathway may also be essential for SKP2 to affect cancer progression, as the pathway was observed in up to 11 neoplasms. Indeed, olfactory transduction has been found to be related to the occurrence and development of tumors. For example, a series of olfactory receptors are identified as cancer-driven factors [49–51]. However, whether",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:81"
    }
  },
  {
    "page_content": "cancer-driven factors [49–51]. However, whether SKP2 affects the process of cancer through an olfactory transmission mechanism requires further experimental verification. In other aspects, the CRISPR data from DepMap Portal confirmed the essential cancer role of SKP2 in certain tumors (BLCA, etc.), suggesting that SKP2 promotes cancer in these tumors. Further, the current study revealed a series of drugs that may be suitable for neoplasm patients with high SKP2 expression. This study has",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:82"
    }
  },
  {
    "page_content": "with high SKP2 expression. This study has certain limitations. Due to limited specimens, SKP2 mRNA expression differences in various cancers were not verified at the protein level, and there was an imbalance in sample size between the experimental and control groups in the TARGET-AML dataset. In addition, no body-fluid samples were collected to detect SKP2 screening for pan-cancer. More studies are needed to verify the molecular mechanism of SKP2 in various cancers. Collectively, this study",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:83"
    }
  },
  {
    "page_content": "SKP2 in various cancers. Collectively, this study provided a comprehensive analysis of SKP2 in human neoplasms. SKP2 plays an essential role in multiple neoplasms and may serve as a marker for treating and identifying these neoplasms. # Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1. THPA samples included in this study for exploring SKP2 protein levels Supplementary Material 2. Age distribution differences between cancer",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:84"
    }
  },
  {
    "page_content": "2. Age distribution differences between cancer group and normal group Supplementary Material 3. Gender distribution differences between cancer group and normal group Supplementary Material 4. The SKP2 expression trends at protein levels in multiple neoplasms Supplementary Material 5. The potential association between transcription factor FOXM1 and SKP2 in pan-cancer. Panel A: Expression of FOXM1 was significantly upregulated in 15 human cancer types, as determined by Wilcoxon rank-sum test",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:85"
    }
  },
  {
    "page_content": "types, as determined by Wilcoxon rank-sum test (multiple comparison test by false discovery rate, **p < 0.01, ***p < 0.001). Panel B: The mRNA expression levels of FOXM1 were positively correlated with those of SKP2 in 15 cancer types (Spearman correlation coefficients are indicated as numerical values). Panel C: ChIP-Seq binding peaks of FOXM1 were observed upstream of SKP2 transcriptional start sites Supplementary Material 6. SKP2 expression between LAML patients with chromosome 5",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:86"
    }
  },
  {
    "page_content": "between LAML patients with chromosome 5 alternations and those without chromosome 5 alternations. A: Wilcoxon rank-sum test based on original data. B: Wilcoxon rank-sum test based on SMOTE data Supplementary Material 7. The relationship of SKP2 expression with cancer patients’ AJCC stage Supplementary Material 8. The relationship of SKP2 expression with cancer patients’ gender Supplementary Material 9. The relationship of SKP2 expression with cancer patients’ age Supplementary Material 10.",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:87"
    }
  },
  {
    "page_content": "cancer patients’ age Supplementary Material 10. Identification of covariate between age, gender, and AJCC stage Supplementary Material 11. The relationship of SKP2 expression with KIRP patients’ age and AJCC stage Supplementary Material 12. The associations between SKP2 expression and immune cell infiltration levels Supplementary Material 13. The associations between SKP2 expression and immune environment Supplementary Material 14. The relationship of SKP2 expression with immune checkpoints",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:88"
    }
  },
  {
    "page_content": "of SKP2 expression with immune checkpoints gene expression Supplementary Material 15. KEGG results based on gene set enrichment analysis in this study Supplementary Material 16. A summary of KEGG results based on gene set enrichment analysis in this study Supplementary Material 17. The potential signaling pathways of SKP2 in GBM Supplementary Material 18. The potential signaling pathways of SKP2 in SARC",
    "metadata": {
      "source": "../data/plain/PMC10259050.plain.txt",
      "id": "../data/plain/PMC10259050.plain.txt:89"
    }
  },
  {
    "page_content": "FOXO transcription factor family in cancer and metastasis Abstract",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:0"
    }
  },
  {
    "page_content": "Forkhead box O (FOXO) transcription factors regulate diverse biological processes, affecting development, metabolism, stem cell maintenance and longevity. They have also been increasingly recognised as tumour suppressors through their ability to regulate genes essential for cell proliferation, cell death, senescence, angiogenesis, cell migration and metastasis. Mechanistically, FOXO proteins serve as key connection points to allow diverse proliferative, nutrient and stress signals to converge",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:1"
    }
  },
  {
    "page_content": "nutrient and stress signals to converge and integrate with distinct gene networks to control cell fate, metabolism and cancer development. In consequence, deregulation of FOXO expression and function can promote genetic disorders, metabolic diseases, deregulated ageing and cancer. Metastasis is the process by which cancer cells spread from the primary tumour often via the bloodstream or the lymphatic system and is the major cause of cancer death. The regulation and deregulation of FOXO",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:2"
    }
  },
  {
    "page_content": "death. The regulation and deregulation of FOXO transcription factors occur predominantly at the post-transcriptional and post-translational levels mediated by regulatory non-coding RNAs, their interactions with other protein partners and co-factors and a combination of post-translational modifications (PTMs), including phosphorylation, acetylation, methylation and ubiquitination. This review discusses the role and regulation of FOXO proteins in tumour initiation and progression, with a",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:3"
    }
  },
  {
    "page_content": "in tumour initiation and progression, with a particular emphasis on cancer metastasis. An understanding of how signalling networks integrate with the FOXO transcription factors to modulate their developmental, metabolic and tumour-suppressive functions in normal tissues and in cancer will offer a new perspective on tumorigenesis and metastasis, and open up therapeutic opportunities for malignant diseases. # Introduction Cancer is a leading cause of death worldwide. It is a group of diseases",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:4"
    }
  },
  {
    "page_content": "of death worldwide. It is a group of diseases that can initiate in any tissue or organ when abnormal cells grow uncontrollably and migrate from their original sites to invade other parts of the body. Metastasis is the process by which cancer cells spread from their origins to secondary sites of the body, often via the bloodstream or the lymphatic system. In most cases, metastatic cancer cannot be cured by treatment. Because of this, metastasis is the major cause of cancer mortality and is",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:5"
    }
  },
  {
    "page_content": "is the major cause of cancer mortality and is responsible for over 90% of cancer deaths. Forkhead box (FOX) proteins are a vast group of transcription factors united by an evolutionarily conserved winged-helix DNA binding domain. FOXOs (forkhead box proteins of class O subgroup) are considered to be tumour suppressors by virtue of their established functions in cell cycle arrest, apoptosis, senescence, differentiation, DNA damage repair and scavenging of reactive oxygen species. Besides these",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:6"
    }
  },
  {
    "page_content": "of reactive oxygen species. Besides these cellular processes essential for cancer initiation (tumorigenesis), FOXOs have also emerged as key modulators of metastasis and angiogenesis, two key factors critical for cancer progression and establishment at secondary sites. The FOX winged-helix structure, reminiscent of a butterfly, consists of three N-terminal α-helices, three β-strands and two loops. Through this unique structural feature, the FOX proteins recognise the cis-regulatory sequences in",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:7"
    }
  },
  {
    "page_content": "recognise the cis-regulatory sequences in their target genes to direct gene expression. To date, 19 (A–S) subfamilies and 50 mammalian FOX proteins have been identified and are classified according to their sequence homology within the winged-helix and other functional domains. Despite the FOX proteins possessing highly analogous DNA binding domains, their distinct tissue-specific expression patterns and regulatory mechanisms provide them their dedicated functions. However, in addition to their",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:8"
    }
  },
  {
    "page_content": "functions. However, in addition to their specific roles, evidence suggests that FOX proteins also possess a certain degree of functional redundancy to safeguard organisms against a broad spectrum of developmental and metabolic diseases due to the loss of function of a single-core FOX protein or gene in haploid insufficiency. In consequence, the misregulation, misexpression and/or mutation of FOX genes can lead to human genetic and metabolic diseases, deregulated ageing and cancer. # Normal FOXO",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:9"
    }
  },
  {
    "page_content": "deregulated ageing and cancer. # Normal FOXO function In mammals, the FOXO subfamily consists of four members (FOXO1, FOXO3, FOXO4 and FOXO6). These four FOXO transcription factors bind to their target genes as monomers or heterodimers to control cell fate under distinct conditions. They also interact with co-activator, co-repressors and other protein partners to modulate and to fine-tune their activity. All FOXO proteins have 4 different core functional domains, namely the winged-helix DNA",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:10"
    }
  },
  {
    "page_content": "functional domains, namely the winged-helix DNA binding domain, the nuclear localisation sequence, the nuclear export sequence and the transactivation domain. The FOXO-DNA binding domain recognises and binds to the consensus sequences (5′-GTAAA(C/T)A-3′) in the genome. Furthermore, the consensus flanking sequences also play a critical part in determining the interaction specificity between the target gene and FOX protein. Each of the FOXO proteins is differentially expressed in distinct",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:11"
    }
  },
  {
    "page_content": "proteins is differentially expressed in distinct tissues. For instance, FOXO1 and FOXO4 are highly expressed in adipose tissue and skeletal muscle, respectively. FOXO3 is ubiquitously expressed in multiple tissues, including the brain, kidney and heart, whilst FOXO6 is predominantly expressed during the development and in nervous tissue. Despite their distinct tissue-specific expression patterns, regulatory overlap and functional redundancy among FOXO proteins have been observed. This may",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:12"
    }
  },
  {
    "page_content": "among FOXO proteins have been observed. This may impact the role and regulation of FOXOs in multiple FOXO protein–expressing cells. FOXO genes are conserved throughout evolution from lower organisms to mammals but exist only as a single gene in invertebrates. FOXO is known as dFOXO in the fruit fly Drosophila melanogaster, Daf-16 in the nematode Caenorhabditis elegans and FoxO in Hydra vulgaris. In fact, the first forkhead (FOX) gene was initially identified in fruit flies as a genetic mutation",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:13"
    }
  },
  {
    "page_content": "identified in fruit flies as a genetic mutation to a homeotic gene, leading to the development of an abnormal forked head structure. A later study showed that dFOXO controls Drosophila lifespan and mediates insulin signalling in flies. In C. elegans, Daf-16 is characterised as a downstream target of insulin/insulin-like growth factor 1 (IGF-1) pathway and the expression of Daf-16 is associated with C. elegans ageing and longevity. In Hydra, FoxO is a critical regulator for unlimited lifespan.",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:14"
    }
  },
  {
    "page_content": "is a critical regulator for unlimited lifespan. Whilst direct experimental evidence for a role for FOXO in longevity has not been demonstrated in mammals, studies from these evolutionarily conserved model organisms suggest that FOXO proteins are important for the regulation of development and senescence/ageing. Collectively, these FOXO transcription factors are involved in the regulation of the cell cycle, apoptosis and metabolism. In the experimental model organisms, FOXOs have also been found",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:15"
    }
  },
  {
    "page_content": "model organisms, FOXOs have also been found to control stem cell maintenance and lifespan as well as age-related diseases, such as cancer, ageing and diabetes. Multiple upstream pathways regulate FOXO activity through post-translational modifications and co-factor interactions. The diversity of this upstream regulation and the downstream effects of FOXOs suggest that they function as regulators of tissue homeostasis over time and coordinators of responses to environmental changes, including",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:16"
    }
  },
  {
    "page_content": "of responses to environmental changes, including growth factor deprivation, metabolic stress (e.g. metabolite starvation) and oxidative stress. As transcription factors, the predominant mode of action of FOXO proteins is through binding to FHRE elements located at proximal gene promoter regions and recruiting other components of the transcription apparatus, including other transcription factors, transcriptional co-factors and chromatin regulators to modulate target gene transcription. Compacted",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:17"
    }
  },
  {
    "page_content": "to modulate target gene transcription. Compacted chromatin constitutes a barrier to transcription activators accessing promoters, and studies using a recombinant FOXO1 protein have shown that FOXO proteins can operate as ‘pioneer’ factors, by recognising their cognate sites within the promoter on a nucleosome, opening up chromatin and conferring an active chromatin state for transcription to proceed. This role of FOXO proteins as pioneer factors is further confirmed by later studies showing",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:18"
    }
  },
  {
    "page_content": "is further confirmed by later studies showing that FOXO1, like other forkhead proteins, can open and remodel chromatin and recruit additional regulatory factors to promote transcription via its winged-helix motif. Moreover, recent epigenetic studies have shown that FOXO3 is also recruited to the more distal gene regulatory elements called enhancers. In these cases, FOXO3 and, probably, other FOXOs function by binding to already active enhancers to further promote their ability to drive cell",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:19"
    }
  },
  {
    "page_content": "to further promote their ability to drive cell type–specific gene expression. # Tumour-suppressive roles of FOXOs ## FOXOs and tumorigenesis FOXOs are considered to be tumour suppressors by virtue of their established functions in cell cycle arrest, senescence, apoptosis, differentiation, DNA damage repair and scavenging of reactive oxygen species. Studies using FOXO gene knockout mice have helped to confirm FOXO proteins as genuine tumour suppressors. FOXO (foxo1/3/4−/−) triple-knockout mice",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:20"
    }
  },
  {
    "page_content": "FOXO (foxo1/3/4−/−) triple-knockout mice develop thymic lymphomas and haemangiomas. These triple FOXO1/3/4-deficient animals have been shown to be predisposed to lymphomagenesis through the loss of restriction on cellular proliferation and survival. At the same time, these triple-FOXO1/3/4-deficient animal studies also reveal that the FOXO isoforms have overlapping functions in distinct biological functions in specific tissues, and that FOXO proteins are associated with cancer progression,",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:21"
    }
  },
  {
    "page_content": "proteins are associated with cancer progression, metastasis and angiogenesis. FOXO proteins have been proposed as tumour suppressors primarily because of their established functions in promoting cell cycle arrest and apoptosis as well as preventing the accumulation of damages induced by genotoxic agents and oxidative stress. ## FOXOs and senescence Senescence is an irreversible state of cell cycle arrest and a critical tumour-suppressive barrier to obstruct neoplastic transformation of stem",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:22"
    }
  },
  {
    "page_content": "to obstruct neoplastic transformation of stem cells. It limits the renewal capacity of stem cells and cancer cells. A role for FOXO protein in cellular senescence is confirmed by an in vivo study showing that oncogene-induced senescence also involves the repression of the phosphoinositide 3-kinase (PI3K)-Akt oncogenic signalling pathway and the consequent induction of FOXO activity. In support of this, FOXO3 overexpression or inhibition of the PI3K-Akt signalling axis can induce cells to enter",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:23"
    }
  },
  {
    "page_content": "signalling axis can induce cells to enter senescence through promoting the expression of p27Kip1. In addition, FOXO3 promotes the expression of the retinoblastoma family protein p130 (RB2) to induce senescence in proliferating cells. FOXO3 can also repress the expression of the potent oncogene FOXM1 to limit stem cell renewal to trigger senescence [28–31]. FOXM1 can counteract oxidative stress–induced senescence through enhancing the transcription of the cell self-renewal Bmi-1 gene. Moreover,",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:24"
    }
  },
  {
    "page_content": "of the cell self-renewal Bmi-1 gene. Moreover, inhibition of FOXM1 in cancer cells, such as those of breast, gastric, gallbladder and liver cancer, leads to cellular senescence [33–36]. In agreement, overexpression of the cyclin-dependent kinase (CDK)4/6-targeting microRNA miR-506 can induce senescence in ovarian cancer cells through repressing FOXM1. Likewise, the CDK4/6 inhibitor LEE011 can also induce senescence in neuroblastoma cells through restricting the induction of FOXM1. Collectively,",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:25"
    }
  },
  {
    "page_content": "restricting the induction of FOXM1. Collectively, these findings propose a key tumour-suppressive role for FOXO proteins and downstream targets in cellular senescence in both normal and cancer cells. ## FOXOs and autophagy As tumour suppressors, FOXOs play multiple roles in restricting cancer development and progression. FOXO proteins are involved in the regulation of autophagy which functions to destroy and recycle the cytoplasmic organelles and macromolecules. Autophagy is a",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:26"
    }
  },
  {
    "page_content": "organelles and macromolecules. Autophagy is a tumour-suppressive mechanism in that it can prevent cellular transformation by preventing the accumulation of carcinogenic defective lipids, proteins and organelles. Moreover, it is also a mediator of anticancer chemotherapy–induced cell death. Conversely, autophagy also enables cancer cells to survive under stress conditions, such as nutrient starvation, oxidative stress and chemotherapy. For example, haploinsufficiency of the autophagy genes, such",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:27"
    }
  },
  {
    "page_content": "haploinsufficiency of the autophagy genes, such as LC3, BECN1 and Bif-1, has been shown to drive chromosome instability, increase migration and promote early tumorigenesis [40–43]. One of the first reports of FOXO3 having a role in autophagy comes from a mouse muscle atrophy study showing that FOXO3 activates protein degradation by inducing autophagy in skeletal muscle cells. FOXO proteins are also involved in the regulation of autophagy in order to recycle essential amino acids during nutrient",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:28"
    }
  },
  {
    "page_content": "to recycle essential amino acids during nutrient starvation. FOXO3 has been shown to induce autophagy in a FOXO1-dependent fashion by activating PIK3CA to enhance the PI3K-Akt activity. Specifically, FOXO1 depletion has been found to attenuate FOXO3-induced autophagy in a number of cell lines. Autophagic cell death is enhanced when the acetylated FOXO1 binds to an E1-like autophagy-related protein 7 (Atg7), an essential initiator of autophagy. Despite these findings showing that FOXOs have a",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:29"
    }
  },
  {
    "page_content": "Despite these findings showing that FOXOs have a tumour-suppressive role in the context of autophagy, other reports indicate they have an oncogenic role. For example, studies from neuronal cells reveal that c-Jun N-terminal kinase (JNK) deficiency causes increased autophagy by promoting cell survival through the FOXO1-BNIP3-Beclin-1 pathway. In these JNK-deficient neurons, FOXO1 is activated to promote the expression of BNIP3 which displaces the autophagic effector Beclin-1 from inactive Bcl-XL",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:30"
    }
  },
  {
    "page_content": "autophagic effector Beclin-1 from inactive Bcl-XL complexes to induce autophagy and cell survival. However, under energy stress conditions, p38 mitogen-activated protein kinase (MAPK) has also been shown to induce this FOXO-BNIP3 axis to repress mTORC1 and cell survival. Similarly, the deacetylase SIRT1 has been shown to repress the ability of acetylated FOXO3 to induce BNIP3 expression to promote apoptosis and attenuate autophagy. On the evidence of these findings, the role of FOXO proteins in",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:31"
    }
  },
  {
    "page_content": "of these findings, the role of FOXO proteins in autophagy is likely to be context-dependent and can be a double-edged sword in terms of tumour suppression and malignant transformation. ## FOXOs and metastasis Numerous histopathological studies have demonstrated a connection between low FOXO expression and increased cancer metastasis [51–53]. A critical event that plays multiple roles in metastasis is the epithelial-mesenchymal transition (EMT), which is a biological process by which epithelial",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:32"
    }
  },
  {
    "page_content": "which is a biological process by which epithelial cells undergo changes that allow the development of a more aggressive mesenchymal cellular phenotype with the properties of stem cells. EMT has, in fact, been suggested to be engaged in multiple steps of the metastasis process. A recent study shows that FOXO1 silencing using small interfering ribonucleic acid (siRNA) in hepatocellular carcinoma enhances mesenchymal and reduces epithelial marker expression, as in EMT. The study also reveals that",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:33"
    }
  },
  {
    "page_content": "as in EMT. The study also reveals that EMT induced by zinc finger E-box-binding homeobox 2 (ZEB2) can be suppressed by FOXO1 overexpression. The metastasis suppressor gene nm23-H1 is involved in restricting the progression of a number of human cancers, including non-small cell lung cancer (NSCLC), and has also been shown to be positively regulated by FOXO1 in lung cancer. In addition to FOXO1, FOXO3 is also strongly associated with the metastasis of multiple malignancies, including breast,",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:34"
    }
  },
  {
    "page_content": "of multiple malignancies, including breast, pancreatic and kidney cancers [57–59]. Although overwhelming evidence has pinpointed FOXOs as suppressors of cell migration and metastasis, some literature suggests that FOXOs have an otherwise oncogenic role. Some correlation studies have linked high FOXO expression with poor cancer patient prognosis and enhanced metastasis [60–67]. Specifically, high FOXO1 and FOXO3 expression has been correlated with matrix metalloproteinase (MMP) upregulation and",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:35"
    }
  },
  {
    "page_content": "matrix metalloproteinase (MMP) upregulation and enhanced cancer metastasis. Overexpression of FOXO1 can also promote the podocyte EMT induced by high glucose conditions. Equally, FOXO3 has been demonstrated in many studies to promote cell invasion and migration through inducing the expression of MMPs, including MMP-2, MMP-3, MMP-9 and MMP-13 [69, 71–73]. However, it is also notable that these studies have been centred upon normal endothelial cells. Although FOXO4 has been shown to activate the",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:36"
    }
  },
  {
    "page_content": "Although FOXO4 has been shown to activate the expression of MMP-9 essential for vascular smooth muscle cell migration, it also inhibits gastric cancer cell proliferation and migration. The fact that FOXOs are involved in regulating cell migration is further supported by the observation that FOXO6 regulates Plxna4-mediated neuronal migration during development. However, when overexpressed, FOXO6 has also been shown to inhibit breast cancer cell migration and invasion. These conflicting findings",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:37"
    }
  },
  {
    "page_content": "and invasion. These conflicting findings may reflect the cell type–specific roles of FOXOs in cell migration and metastasis. It is possible that FOXOs have a pro-metastatic function in normal endothelial cells but switch to a tumour-suppressive anti-metastatic role in cancer cells. On the whole, these findings support the hypothesis that FOXO proteins are genuine tumour suppressors but the underlying mechanisms involved in this switch from normal to cancer cells need further elucidation. ##",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:38"
    }
  },
  {
    "page_content": "to cancer cells need further elucidation. ## FOXOs and angiogenesis Angiogenesis is the process whereby new blood vessels are formed. This process facilitates the delivery of oxygen and nutrients to the target tissues and cells. These functions also make angiogenesis essential for the spreading and establishment of tumour metastases. Essentially, angiogenesis facilitates the escape of tumour cells into the bloodstream and the establishment of metastatic colonies at secondary sites. In a manner",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:39"
    }
  },
  {
    "page_content": "colonies at secondary sites. In a manner similar to angiogenesis, lymphangiogenesis also helps to disseminate lymphatic metastases. Insights from human endothelial cell studies and gene knockout mouse models have revealed a clear role for FOXO proteins in regulating the angiogenic activity of endothelial cells and blood vessel formation. Indeed, overexpression of constitutively active FOXO1 or FOXO3, but surprisingly not FOXO4, significantly inhibits endothelial tube formation and migration.",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:40"
    }
  },
  {
    "page_content": "endothelial tube formation and migration. Appropriately, FOXO1 and FOXO3 are, in fact, the most abundant FOXO proteins in mature endothelial cells. Consistent with this, silencing of either FOXO1 or FOXO3 also leads to a significant increase in the migratory and sprout-forming capacity of endothelial cells. In concordance with a key role for FOXOs in angiogenesis, further gene expression profiling analysis also reveals that endogenous FOXO1 and FOXO3 negatively regulate a set of",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:41"
    }
  },
  {
    "page_content": "FOXO1 and FOXO3 negatively regulate a set of angiogenesis-related and vascular remodelling genes, including angiopoietin 2 (Ang2) and eNOS, to repress blood vessel formation and maturation. The role of FOXOs in angiogenesis is further supported by studies in FOXO1/3/4 triple-knockout mice showing that FOXO depletion potentiates angiogenesis in mouse liver in response to simulation by pro-angiogenic growth factors, such as vascular endothelial growth factor (VEGF) and basic fibroblast growth",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:42"
    }
  },
  {
    "page_content": "growth factor (VEGF) and basic fibroblast growth factor (bFGF). Further work using the FOXO1/3/4 knockout mouse system confirms that FOXOs directly regulate the expression of endothelial cell morphogenic and vascular homeostatic mediators, including Sprouty2 and PBX1, which control the process of angiogenesis. FOXO3 has also been reported to repress the expression of the potent angiogenic growth factor VEGF at the promoter level in breast cancer. Similarly, FOXO1 has also been found to regulate",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:43"
    }
  },
  {
    "page_content": "Similarly, FOXO1 has also been found to regulate VEGFA expression and promote angiogenesis. # Deregulation of FOXOs in cancer and metastasis ## FOXO mutation in cancer The human FOXO1 (also known as FKHR; forkhead in rhabdomyosarcoma) was first identified as the fusion partner of paired box protein (PAX) 3/7 in alveolar rhabdomyosarcoma, a paediatric tumour of skeletal muscle. The majority of highly metastatic and aggressive alveolar rhabdomyosarcomas harbour the FOXO1-PAX3/7 protein, resulting",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:44"
    }
  },
  {
    "page_content": "harbour the FOXO1-PAX3/7 protein, resulting from t(2;13)(q35;q14) and t(1;13)(p36;q14) chromosomal translocation, respectively. Both PAX3 and PAX7 are important regulators of myogenesis, and their fusion proteins with FOXO1 carry the FOXO1 transactivation domain which confers a gain-of-function oncogenic PAX3/7 phenotype. These genetic changes are somatic and not inherited in the family. A G protein–coupled receptor (GPCR) Cnr1 has previously been shown to induce PAX3-FOXO1 expression to",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:45"
    }
  },
  {
    "page_content": "been shown to induce PAX3-FOXO1 expression to augment cell invasive capacity in alveolar rhabdomyosarcoma. From the study, the use of Cnr1 antagonist or genetic deletion attenuates migration of alveolar rhabdomyosarcoma to the lungs. In a similar manner to the FOXO1 chromosomal translocation in alveolar rhabdomyosarcoma, FOXO3 (also known as FKHRL1) and FOXO4 (also known as AFX) are translocated to the MLL gene in mixed lineage leukaemia (MLL), an aggressive paediatric blood cancer. MLL is",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:46"
    }
  },
  {
    "page_content": "an aggressive paediatric blood cancer. MLL is characterised by the presence of a MLL-FOXO3/4 fusion protein, resulting from the t(6;11)(q21;q23) and t(X;11)(q13.1;q23) chromosomal translocation, respectively. Importantly, these genetic rearrangements in alveolar rhabdomyosarcoma and MLLs not only create new oncogenic fusion proteins but also cause the loss of FOXO allele from the original chromosome, resulting in FOXO locus haploinsufficiency. Unlike the other FOXOs, FOXO6 has not been shown to",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:47"
    }
  },
  {
    "page_content": "the other FOXOs, FOXO6 has not been shown to be involved in chromosomal translocation. It has also been reported that the FOXO3 is a tumour suppressor gene commonly deleted during early-stage lung adenocarcinoma carcinogenesis. Characterisation of a common chromosomal 6q21 deletion in mature B cell lymphomas and childhood acute lymphoblastic leukaemia has also uncovered FOXO3 as being one of the three tumour suppressor genes frequently deleted in these rare blood cancers. A loss of FOXO1 in a",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:48"
    }
  },
  {
    "page_content": "in these rare blood cancers. A loss of FOXO1 in a chromosomal deletion at 13q14 is associated with tumorigenesis of the benign mammary and vaginal myofibroblastomas. Similarly, deletion of FOXO3 at 6q21 is shown to be linked with a rare highly aggressive lymphoid malignancy, natural killer cell neoplasms. However, despite these examples of translocation and deletion of FOXO genes in alveolar rhabdomyosarcoma, mixed lineage leukaemia, lung adenocarcinoma and natural killer cell neoplasms, FOXO",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:49"
    }
  },
  {
    "page_content": "and natural killer cell neoplasms, FOXO genes are generally rarely mutated in human cancers, suggesting deregulated FOXO expression and function as the predominant mechanism for cancer development and progression. The reason for the lack of FOXO mutations in cancer is unclear. However, it has been shown that a monoallelic 13q14 deletion in mammalian cells can result in a reduction in FOXO1 expression levels and cellular proliferation stress, which can, in turn, cause oxidative stress to",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:50"
    }
  },
  {
    "page_content": "which can, in turn, cause oxidative stress to activate the p38 MAPK to induce cellular senescence via the oestrogen receptor (ER) stress-activating transcription factor 6 (ATF6) axis. This might represent a tumour suppressor loss–induced senescence mechanism to prevent the loss of FOXO genes. ## Regulation of FOXOs by post-translational modifications As mentioned, FOXOs are predominantly deregulated at the post-translational level in most cancers. In response to external stimuli, FOXO proteins",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:51"
    }
  },
  {
    "page_content": "In response to external stimuli, FOXO proteins are rapidly reversible-regulated by multiple layers of post-translational and post-transcriptional modifications including phosphorylation, acetylation, ubiquitination, glycosylation and methylation (Fig. 1). These modifications control FOXO functions through adjusting their turnover (stability), altering their subcellular localisation, changing their DNA binding affinity, controlling their transcriptional activity and regulating their interaction",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:52"
    }
  },
  {
    "page_content": "activity and regulating their interaction with co-factors. For example, these post-translational modifications can induce FOXO conformational changes and introduce new binding motifs for FOXO-binding proteins, which, in turn, regulate the expression, subcellular localisation, DNA binding and transcriptional activity of FOXOs. FOXO proteins are best studied for their regulation via phosphorylation at different conserved serine and threonine amino acid residues predominantly by the insulin and",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:53"
    }
  },
  {
    "page_content": "acid residues predominantly by the insulin and cellular stress pathways.Fig. 1Compilation of post-translational modifications and post-transcriptional controls of FOXO proteins. At the protein level, multiple signalling pathways from different sources converge to regulate FOXO subcellular localisation, activity and stability. At the post-transcriptional level, microRNA regulates FOXO proteins to modulate cell proliferation, invasion and metastasis. Regulation: red, negative; green, positive;",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:54"
    }
  },
  {
    "page_content": "Regulation: red, negative; green, positive; and grey, not known. Amino acids: threonine (Thr), lysine (Lys), serine (Ser) and arginine (Arg) ## FOXOs and Akt-mediated phosphorylation The growth factor–regulated PI3K-Akt (also known as PKB) signalling cascade is one of the most frequently dysregulated pathways in cancer, resulting commonly in an upregulation of Akt and thereby an attenuation of FOXO activity. Consumption of glucose-containing diets increases glucose levels in the blood serum",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:55"
    }
  },
  {
    "page_content": "diets increases glucose levels in the blood serum which supplies different organs as a primary source of energy. In response to high serum glucose levels, pancreatic β-cells synthesise and secrete insulin to lower the elevated blood glucose level by promoting the cellular glucose uptake using insulin-regulated glucose transporter GLUT4 through the PI3K-Akt signalling pathway. Indeed, cancer cells utilise glucose for proliferation and metastasis. Upon induction of the insulin receptors, the",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:56"
    }
  },
  {
    "page_content": "Upon induction of the insulin receptors, the activated Akt suppresses the function and alter the subcellular localisation of FOXO proteins. Specifically, the high nutrient availability triggers insulin signalling pathway to promote Akt-mediated FOXO1 (Thr24, Ser256 and Ser319), FOXO3 (Thr32, Ser253 and Ser315), FOXO4 (Thr28, Ser193 and Ser258) and FOXO6 (Thr26 and Ser184) phosphorylations. Notably, FOXO6 is only phosphorylated at two sites and it is not regulated by nucleo-cytoplasmic",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:57"
    }
  },
  {
    "page_content": "and it is not regulated by nucleo-cytoplasmic shuttling. FOXO1 (Thr24 and Ser256) and FOXO3 (Thr32 and Ser253) phosphorylations serve as docking sites for chaperone protein 14-3-3 on the N-terminus and the DNA binding domain of the FOXO protein. The binding of the 14-3-3 protein is believed to expose the FOXO nuclear export sequence to promote nuclear exclusion. Similarly, the binding of the 14-3-3 to FOXO proteins reduces the access of nuclear importing machinery to nuclear localisation",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:58"
    }
  },
  {
    "page_content": "importing machinery to nuclear localisation sequence (NLS), suggesting that the 14-3-3 interaction prevents FOXO from nuclear translocation. Another study has shown that simultaneous binding of 14-3-3 on these phosphorylated sites also disrupts and affects FOXO DNA binding capability. For FOXO1, the cytoplasmic sequestration is shown to be promoted by the phosphorylation at Ser256 which introduces a negative charge to the basic nuclear localisation signal sequence. In response to growth factor,",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:59"
    }
  },
  {
    "page_content": "signal sequence. In response to growth factor, phosphorylation of FOXO1 by Akt at Ser319 also primes the casein kinase 1 (CK1) to phosphorylate FOXO1 further at Ser322 and Ser325. These CK1 phosphorylation sites directly promote the interaction between FOXO1 and the nuclear export machinery Ran-CRM1 complex. Conversely, the Akt-mediated phosphorylated FOXO1 and FOXO3 nuclear exclusion can be rescued by dephosphorylation mediated by protein phosphatase 2A (PP2A) (Fig. 2).Fig. 2FOXO regulation by",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:60"
    }
  },
  {
    "page_content": "2A (PP2A) (Fig. 2).Fig. 2FOXO regulation by phosphorylation. Signals from various sources induce signalling pathways to regulate FOXO activity. Insulin signalling pathway induces Akt-mediated FOXO inhibition and facilitates 14-3-3 protein binding and nuclear exclusion. Subsequently, the cytoplasmic FOXO is ubiquitinated by SKP2 for protein degradation. This 14-3-3-bound FOXO can be rescued by JNK phosphorylation and PP2A dephosphorylation. Stress-activated p38, JNK and PERK promote FOXO",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:61"
    }
  },
  {
    "page_content": "Stress-activated p38, JNK and PERK promote FOXO transcriptional activity. In parallel, AMP sensor detects low intracellular energy and promotes FOXO via AMPK phosphorylation. However, stress-activated ERK inhibits FOXO activity by promoting MDM2-mediated polyubiquitination High levels of Akt-phosphorylated FOXO proteins are correlated with poor patient overall disease-free survival rate in many cancers. At the molecular level, a study shows that the Akt signalling pathway suppresses cell",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:62"
    }
  },
  {
    "page_content": "that the Akt signalling pathway suppresses cell migration and invasion through FOXO1 to inhibit runt-related transcription factor 2 (RUNX2) transcriptional activity in prostate cancer. FOXO4 has also been identified by a genome-wide RNAi screen to be a suppressor of metastasis through antagonising PI3K/AKT signal pathway and RUNX2-dependent transcription in prostate cancer. Besides RUNX2, its closed relatives RUNX1 and RUNX3 are also linked to FOXO proteins in restricting cancer survival.",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:63"
    }
  },
  {
    "page_content": "to FOXO proteins in restricting cancer survival. However, in these cases, RUNX1 and RUNX3 bind to and cooperate with FOXO proteins to promote cell death in breast and gastric cancers. Moreover, Akt-regulated FOXO4 has been shown to promote anti-metastatic protein ANXA8 in the bile duct cancer, cholangiocarcinoma. FOXO3 can also modulate cell invasion by regulating the expression of MMP-9 in glioblastoma. Through FOXO6, EGFR signalling controls SRY-related HMG-box 2 (SOX2) expression in lung",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:64"
    }
  },
  {
    "page_content": "SRY-related HMG-box 2 (SOX2) expression in lung cancer. Recently, a SOX2 knockdown experiment shows that basal cell carcinoma migration is regulated by Akt signalling pathway. In agreement, another recent study shows that hypoxia-induced breast cancer cell migration is regulated by SOX2 transcription factor. ## Stress signals in FOXO regulation Unlike the nutrient and growth factor–mediated PI3K-Akt signalling cascade, FOXO activity can be enhanced by the stress-activated signalling pathway. In",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:65"
    }
  },
  {
    "page_content": "by the stress-activated signalling pathway. In cancer cells, stress can promote or restrict cancer growth and progression. Reactive oxygen species (ROS) levels are often elevated in cancers by various factors, including enhanced oncogenic activity and increased metabolic function. In mitochondria, ROS is a by-product of oxidative phosphorylation where a large amount of energy is generated. During the process, electron transport chain complex–produced superoxide is reduced into hydrogen peroxide",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:66"
    }
  },
  {
    "page_content": "superoxide is reduced into hydrogen peroxide by Sirtuin-stimulated manganese-dependent superoxide dismutase (MnSOD, also called SOD2). This FOXO-regulated SOD2 modulates cellular antioxidant capacity. A loss of FOXO function increases intracellular ROS, pushing cancer cells to rely on Warburg effect to prevent further cellular damages. However, lower SOD2 expression allows cancer cells to acquire beneficial DNA damages for enhanced proliferation and to obtain drug resistance mutations.",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:67"
    }
  },
  {
    "page_content": "and to obtain drug resistance mutations. Similarly, chemically induced stresses from multiple chemotherapeutic treatments have also been shown to integrate with FOXO activity. Cancer cells control these stresses by inducing JNK to activate FOXO-mediated oxidative stress resistance. Notably, the responses of FOXOs to stress are dependent on the stress intensity in different conditions and contexts. Oxidative stress–activated JNK can also phosphorylate the 14-3-3 protein (Ser184) to enhance FOXO",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:68"
    }
  },
  {
    "page_content": "the 14-3-3 protein (Ser184) to enhance FOXO activity. The phosphorylation releases FOXO proteins from 14-3-3, exposing the nuclear localisation signals to promote nuclear translocation. In parallel, JNK also antagonises Akt activity by phosphorylating FOXO3 at Ser574 for activation. Under oxidative stress, JNK phosphorylates FOXO4 directly at Thr447 and Thr451 to promote FOXO4 nuclear localisation. Similarly, oxidative stress induces mammalian Ste20-like kinase 1 (Mst1) kinase activation in",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:69"
    }
  },
  {
    "page_content": "Ste20-like kinase 1 (Mst1) kinase activation in Hippo signalling pathway to promote FOXO1-mediated apoptosis. During oxidative stress, Mst1 phosphorylates FOXO1 (Ser212) and FOXO3 (Ser207) directly to disrupt the binding of 14-3-3 protein to promote FOXO activity. Recently, FOXO protein activity has been inversely linked to epidermal growth factor receptor 2 (EGFR2, also known as HER2) overexpression. A study shows that HER2 negatively regulates FOXO1 at the transcriptional level. Like the",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:70"
    }
  },
  {
    "page_content": "FOXO1 at the transcriptional level. Like the insulin signalling pathway, this HER2 regulation of FOXO activity is mediated via the PI3K/Akt signalling pathway. Consistently, treatment of cancer cells with EGFR/HER2-tyrosine kinase inhibitors (EGFR/HER2-TKI; e.g. gefitinib and lapatinib) or anti-ErbB-2 monoclonal antibodies (e.g. trastuzumab) induces cell proliferative arrest and/or cell death, and this has been shown to be mediated through the PI3K/Akt/FOXO3 signalling axis [31, 126–132].",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:71"
    }
  },
  {
    "page_content": "the PI3K/Akt/FOXO3 signalling axis [31, 126–132]. Appropriately, an HER2 upregulation induces both Akt and JNK to promote gastric cancer growth and metastasis. These findings suggest that multiple stress signals converge and integrate to regulate FOXO activity and that FOXO proteins are important factors in a pivot balance to determine cell fates (Fig. 3). It is also plausible that an intermediate degree of stress promotes cell metastasis to evade from the source of stress whilst a high level",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:72"
    }
  },
  {
    "page_content": "from the source of stress whilst a high level of stress induces cell death.Fig. 3The balance of signal regulation. FOXO proteins are the point of signal integration from various sources. The intensity of these signals critically determines cell fate. Activated kinases in different pathways can either inhibit or activate FOXO transcriptional activity. A shift in signal intensity towards the inhibition of FOXO proteins allows cancer development and progression Beside the stress-induced JNK, FOXO",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:73"
    }
  },
  {
    "page_content": "progression Beside the stress-induced JNK, FOXO is also regulated by two other major MAPKs: extracellular signal–regulated kinases (ERKs) and the p38 family of stress-activated MAPKs. These signalling pathways (JNK, ERK and p38) modulate the FOXO-regulated intracellular ROS cooperatively. In fact, the outcome of the FOXO activity regulation is predominantly controlled by the duration and magnitude of the multiple MAPK signal integration. Each of the MAPKs (JNK, ERK and p38) is regulated by",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:74"
    }
  },
  {
    "page_content": "of the MAPKs (JNK, ERK and p38) is regulated by mitogen-activated protein kinase phosphatases (MKPs) to control its activity and subcellular localisation, increasing the complexity of FOXO regulation. Indeed, increased MKP expression elevates cancer progression and drug resistance, linking MKPs to FOXO function. Although there is no evidence of a direct link between MKP and FOXO activities in human cancer, a study has demonstrated that insulin-induced MKP3 (also known as dual-specificity",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:75"
    }
  },
  {
    "page_content": "MKP3 (also known as dual-specificity phosphatase 6; DUSP7) interacts and dephosphorylates FOXO1 on Ser256 in a mouse model to promote its nuclear import for gluconeogenic gene transcription. Noteworthy, gluconeogenetic enzymes play a crucial part in the regulation of cancer EMT. A study also shows that ERK directly phosphorylates FOXO1 at Ser246, Ser284, Ser295, Ser326, Ser413, Ser415, Ser429, Ser467 and Ser475 to alter the transcriptional activity of Ets1, a regulator of angiogenesis-related",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:76"
    }
  },
  {
    "page_content": "of Ets1, a regulator of angiogenesis-related genes. However, the functional consequence of the ERK/FOXO1-regulated Ets1 on the induction of angiogenesis and metastasis has yet to be confirmed in cancer cells. In cancer, the ERK and p38 MAPK pathways cooperate to control anoikis, a form of cell death triggered by a loss of extracellular matrix (ECM) attachment. Anoikis resistance, the insensitivity to anoikis-induced cell death, is a prerequisite for EMT and cancer metastasis. Indeed, anoikis",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:77"
    }
  },
  {
    "page_content": "for EMT and cancer metastasis. Indeed, anoikis has been shown to be regulated by FOXO3 activity during breast cancer metastasis. It has also been shown that both ERK and p38 MAPK can activate FOXO1 by phosphorylation. Nine serine residues in FOXO1 are phosphorylated by ERK, whilst five of them (i.e. Ser284, Ser295, Ser326, Ser467 and Ser475) are also phosphorylated by p38 MAPK. Whilst the physiological consequence of the ERK and p38 MAPK-dependent FOXO1 phosphorylation is unclear, p38 MAPK",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:78"
    }
  },
  {
    "page_content": "FOXO1 phosphorylation is unclear, p38 MAPK induction promotes fibroblast cell invasion and anchorage-independent cell growth. In agreement, inhibition of p38 MAPK reduces glioma invasiveness. MKK4 also mediates suppression of metastasis in ovarian cancer via activation of p38 MAPK. Moreover, the upstream regulator of ERK MEK1/2 can directly induce Akt for FOXO1 phosphorylation to promote cell migration. Another study shows that inhibition of both Akt and ERK signalling pathways synergistically",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:79"
    }
  },
  {
    "page_content": "Akt and ERK signalling pathways synergistically induces FOXO transcriptional activity to inhibit angiogenesis. Moreover, UV irradiation induces stress-mediated JNK to suppress both ERK and Akt activities and promotes FOXO3 nuclear translocation, probably for DNA damage repair. Conversely, ERK2 can also promote cell migration and invasion through the Rac1/Cdc42 guanine nucleotide exchange factor (GEF) DOCK10, which induces JNK to activate FOXO1 and promote EMT. Paradoxically, the loss of FOXO1",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:80"
    }
  },
  {
    "page_content": "and promote EMT. Paradoxically, the loss of FOXO1 which is followed by an upregulation of p38 initiates a compensatory mechanism to promote other FOXO protein activities. p38 MAPK has been shown to phosphorylate FOXO3 on Ser7 to mediate nuclear localisation and senescence in response to doxorubicin-induced DNA damages in breast cancer. In a similar manner, the p38 MAPK is also activated by cetuximab to induce cell death and inhibit cell proliferation via FOXO3 in colorectal cancer. During ER",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:81"
    }
  },
  {
    "page_content": "via FOXO3 in colorectal cancer. During ER stress, unfolded protein response (UPR) activates inositol-requiring enzyme 1 (IRE1), protein kinase R (PKR)-like ER kinase (PERK) and ATF6 to promote ER folding capacity and maintain cellular proteostasis for cell survival. Furthermore, PERK has previously been shown to promote FOXO1 activity by direct phosphorylation at Ser298, Ser301 and Ser303, representing another layer of FOXO regulation in cancer. Nevertheless, a recent study has shown that PERK,",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:82"
    }
  },
  {
    "page_content": "Nevertheless, a recent study has shown that PERK, instead of promoting FOXO activity, can inhibit FOXO activity through enhancing Akt activity. Together, these findings suggest that cancer cell metastasis is regulated by FOXO proteins, whose activity is, in turn, modulated by stress-activated signals, including the JNK, ERK and p38 MAPKs. ## FOXO ubiquitination The Akt-phosphorylated FOXOs (e.g. FOXO1 at Ser256) are recognised by the activated F-box protein S-phase kinase-associated protein 2",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:83"
    }
  },
  {
    "page_content": "F-box protein S-phase kinase-associated protein 2 (SKP2) in the SCFSKP2 E3 ligase complex, which targets FOXO proteins for polyubiquitination and degradation. Interestingly, FOXO3 has also been shown to be a negative regulator of SKP2 expression, and this could represent a positive feed-forward loop in the regulation of FOXO expression and activity. Collectively, the Akt-phosphorylated FOXOs are sequestered in the cytoplasm, transcriptionally inactive and targeted by the ubiquitin-proteasome",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:84"
    }
  },
  {
    "page_content": "inactive and targeted by the ubiquitin-proteasome system for degradation. At the molecular level, ERK phosphorylates FOXO1 and FOXO3 (Ser294, Ser344 and Ser425) to recruit the MDM2 E3 ubiquitin ligase for FOXO poly-ubiquitination and proteasomal degradation. Besides poly-ubiquitination, a study suggests that FOXO4 can be mono-ubiquitinated at Lys199 and Lys211 by MDM2 in response to oxidative stress for nuclear translocation. The mono-ubiquitinated FOXO4 can be reversed by ubiquitin-specific",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:85"
    }
  },
  {
    "page_content": "FOXO4 can be reversed by ubiquitin-specific protease 7 (USP7; also known as HAUSP)–mediated de-ubiquitination. However, the mono-ubiquitination on other FOXO proteins has not been demonstrated and the exact mechanism of this modification is still unclear (Fig. 2). As glucose is a source of energy, Akt-mediated FOXO1 ubiquitination is also interconnected with an energy homeostasis regulator, the 5′ adenosine monophosphate–activated protein kinase (AMPK). AMPK is an intracellular energy sensor",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:86"
    }
  },
  {
    "page_content": "(AMPK). AMPK is an intracellular energy sensor which senses the ADP/ATP ratio and regulates cell growth, autophagy and metabolism. A study shows that AMPK-mediated FOXO1 phosphorylation at Ser383 and Thr649 promotes FOXO protein stability, nuclear translocation and transcriptional activity. A recent study also demonstrates that AMPK can phosphorylate FOXO1 at Ser22 to activate FOXO1 by blocking Akt-mediated FOXO sequestration by the 14-3-3 protein in the cytoplasm. Indeed, the hypoxia-induced",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:87"
    }
  },
  {
    "page_content": "in the cytoplasm. Indeed, the hypoxia-induced AMPK has been shown to promote FOXO1 activity. Likewise, FOXO3 is also phosphorylated by AMPK at Thr179, Ser399, Ser413, Ser555, Ser588 and Ser626 for transcriptional activation, but this AMPK-mediated phosphorylation enhances the activity of FOXO3, without altering its subcellular localisation and DNA binding affinity. Indeed, AMPK-induced FOXO3 phosphorylation has been shown to suppress pancreatic cancer growth and metastasis. Of note, in response",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:88"
    }
  },
  {
    "page_content": "growth and metastasis. Of note, in response to growth factor stimulation, IκB kinase (IKK) also exclusively phosphorylates FOXO3 (Ser644) for ubiquitination and degradation as the other FOXO proteins do not have similar amino acid residues. ## FOXO regulation by other kinases and factors Besides the PI3K-Akt and stress-activated MAPK signalling pathways, many other kinases and dependent cascades also contribute to FOXO regulation. For instance, the p21-activated kinase (PAK1, a downstream",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:89"
    }
  },
  {
    "page_content": "the p21-activated kinase (PAK1, a downstream target of PI3K) can bind and phosphorylate FOXO1 directly to prevent its nuclear translocation in breast cancer. Similarly, the transforming growth factor β–activated kinase (TAK1)-Nemo-like kinase (NLK) pathway also mediates FOXO1 phosphorylation in the transactivation domain to drive its nuclear exclusion. The dual-specificity tyrosine-phosphorylated and regulated kinase 1 (DYRK1) phosphorylates FOXO1 (Ser329) to promote its activity in",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:90"
    }
  },
  {
    "page_content": "FOXO1 (Ser329) to promote its activity in unstimulated quiescent mammalian cells. Recently, a study shows that the glucagon-activated PKA also phosphorylates FOXO1 at Ser276 to promote its nuclear relocalisation and stability in liver cancer and limit insulin-induced FOXO nuclear export and their ubiquitination-degradation. During normal cell divisions, CDK/cyclin complexes are the main regulators of the cell cycle checkpoints which can influence cell fates. However, in cancer, these CDK/cyclin",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:91"
    }
  },
  {
    "page_content": "cell fates. However, in cancer, these CDK/cyclin complexes are commonly deregulated, resulting in deregulated and highly proliferative cells. Indeed, CDK1 (also called CDC2) and CDK2 have shown to phosphorylate FOXO1 at Ser249 to alter its subcellular localisation. Paradoxically, FOXO1 has also been found to be activated by CDK1 to induce apoptosis gene activation in post-mitotic neurons but FOXO1 phosphorylation by CDK1 promotes its inhibition in human prostate adenocarcinoma cells. These",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:92"
    }
  },
  {
    "page_content": "in human prostate adenocarcinoma cells. These contrasting findings may reflect the deregulation of normal FOXO1 control and function in cancer cells. On the other hand, CDK2 has been confirmed to inhibit FOXO1 by promoting its nuclear exclusion to suppress FOXO1 transcriptional activity. With respect to cell migration, an activator of CDK1 and CDK2, Cdc25A phosphatase can enhance FOXO1 stability to promote MMP-1-mediated metastasis in breast cancer. Consistent with this finding, the",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:93"
    }
  },
  {
    "page_content": "breast cancer. Consistent with this finding, the FOXO1-derived small peptide FO1-6nl inhibits CDK1/2-mediated FOXO1 phosphorylation and prevents prostate cancer proliferation. In addition, FOXO3 circular RNA (circ-FOXO3) has been reported to form an inhibitory complex with CDK2 and p21Cip1 to restrict cell cycle progression. During cell division, genotoxic stress, induced by cytotoxic chemotherapeutic agents, can revert the FOXO phosphorylation state and induce a senescent and/or apoptotic",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:94"
    }
  },
  {
    "page_content": "state and induce a senescent and/or apoptotic response in cancer cells [64, 126, 127, 129, 151, 155, 177, 180–184]. On the other hand, FOXO3 can also upregulate the expression of DNA damage–inducible 45 (GADD45) of the DNA repair mechanism and has a role in ATM-mediated DNA damage response to prevent cancer from acquiring further mutations. These findings further emphasise the importance of FOXO3 in the prevention of cancer propagation and progression. ## FOXO acetylation Although mammalian",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:95"
    }
  },
  {
    "page_content": "## FOXO acetylation Although mammalian cells have protein kinases in place to regulate FOXO activity, another post-translational modification (PTM) acetylation applies extra layers of control to fine-tune their cellular functions. In general, depending on the sites of modification, acetylation of nuclear proteins usually alters their DNA binding affinity and, hence, their activity. For FOXO proteins, acetylation occurs predominantly at the Wing2 region of the forkhead DNA binding domain, where",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:96"
    }
  },
  {
    "page_content": "region of the forkhead DNA binding domain, where FOXO proteins were used for recognising their DNA consensus sequences on target genes; however, the functional consequence of FOXO acetylation is not clear-cut. An earlier report suggests that acetylation of sites Lys242, Lys245 and Lys262 located within the DNA binding domain of FOXO1 attenuates its transcriptional activity. In support of this, it has been demonstrated that oxidative stress–induced CREB-binding protein (CBP)/p300 acetylates",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:97"
    }
  },
  {
    "page_content": "CREB-binding protein (CBP)/p300 acetylates FOXO1 at Lys245, Lys248 and Lys262 to restrict its DNA binding in cancer. However, another subsequent crystallographic structural analysis suggests that acetylation at equivalent sites (Lys242 and Lys245) in FOXO3 enhances its DNA binding and, therefore, its transcriptional activity. For FOXO1, there is also a controversial link between phosphorylation and acetylation. One study shows that FOXO1 acetylation requires insulin-induced Akt phosphorylation",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:98"
    }
  },
  {
    "page_content": "requires insulin-induced Akt phosphorylation to prime the modification. Yet, another suggests that p300-mediated acetylation can increase sensitivity for the inhibitory FOXO1 phosphorylation at Ser253. Despite the controversy over the exact order in which these modifications occur, these data suggest that acetylation and Akt-mediated phosphorylation cooperate to inhibit FOXO1 activity. Upon acetylation, FOXO1 has also been shown to have a reduced affinity for the genomic compacting protein",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:99"
    }
  },
  {
    "page_content": "affinity for the genomic compacting protein nucleosomes, affecting multiple gene accessibility for other transcription factors. FOXO acetylation is primarily mediated by CBP/p300 and reversed by Sirtuins (SIRTs), which are a group of highly conserved NAD-dependent deacetylases which have many roles in epigenetics and human diseases, including cancer. An earlier study suggests that SIRT2-mediated deacetylation promotes FOXO3 transactivation activity to reduce cellular ROS and induce cell death",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:100"
    }
  },
  {
    "page_content": "to reduce cellular ROS and induce cell death in cancer cells. However, a later study by the same research group has shown that SIRT1 and SIRT2 mediate deacetylation of FOXO3 to promote FOXO3 ubiquitination and degradation in Skp2-dependent manner, implying that acetylation increases FOXO stability and enhances its tumour-suppressive function. The discrepancy between the two studies is likely due to the overlapping and compensatory roles played by SIRT1 and SIRT2 in cancer, whilst inhibition of",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:101"
    }
  },
  {
    "page_content": "SIRT1 and SIRT2 in cancer, whilst inhibition of one leads to the induction of the other. In support of a tumour-suppressive role for FOXO acetylation, a report shows that the acetylation recruits FOXO1 to promyelocytic leukaemia (PML) protein in the nucleus to protect FOXO1 against ubiquitination and to promote its activity in pancreatic beta cells. In agreement, the interaction between FOXO3 and PML has also been observed in breast cancer. In addition, another study shows that four-and-a-half",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:102"
    }
  },
  {
    "page_content": "another study shows that four-and-a-half LIM 2 (FHL2) interacts with FOXO1 to facilitate SIRT1-mediated deacetylation to reduce FOXO1 activity in prostate cancer. SIRT6 also represses FOXO3 acetylation to promote clonal renewal and survival in breast cancer. Similarly, FOXO4 acetylation induces apoptosis of podocytes in diabetes through activating the pro-apoptotic gene Bim (Bcl-2l11). Studies on mitochondrial reprogramming have produced further evidence that SIRTs repress FOXO acetylation to",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:103"
    }
  },
  {
    "page_content": "evidence that SIRTs repress FOXO acetylation to promote cancer progression and metastasis. Elevated ROS in cancer has been shown to lead to mitochondrial reprogramming via the evolutionarily conserved SIRT-FOXO-SOD2 axis to neutralise oxidative stress and promote cancer survival and metastasis. Besides SIRTs, the histone deacetylase HDAC3 has been shown to be specifically recruited by geminin to FOXO3 to facilitate FOXO3 deacetylation and breast cancer metastasis. In spite of this",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:104"
    }
  },
  {
    "page_content": "and breast cancer metastasis. In spite of this tumour-suppressive protective role, geminin is also frequently overexpressed in human cancers. Collectively, the evidence accumulated to date suggests that FOXO acetylation is mediated by EP300/CBP and is reversed by SIRTs in general, promoting the tumour-suppressive function of FOXOs by increasing the transcription of genes important for cell proliferative arrest, senescence and cell death. Besides its tumour-suppressive function, recent evidence",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:105"
    }
  },
  {
    "page_content": "its tumour-suppressive function, recent evidence also reveals that FOXO acetylation is also targeted by anticancer chemotherapeutics to mediate their cytotoxic and cytostatic function. For example, it has been reported that capsaicin treatment induces CBP and represses SIRT1 expression, resulting in an increase in FOXO1 acetylation to limit pancreatic tumour growth. Moreover, SIRT6 can promote paclitaxel and epirubicin resistance in breast cancer. EP300 and SIRT1/6 also co-regulate the",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:106"
    }
  },
  {
    "page_content": "cancer. EP300 and SIRT1/6 also co-regulate the cytotoxic function of the EGFR/HER2 inhibitor lapatinib through modulating FOXO3 acetylation and activity in breast cancer. Similarly, SIRT2-mediated FOXO3 deacetylation has also been implicated in lapatinib response and sensitivity, and that SIRT2 can specifically antagonise the cytotoxicity of lapatinib through mediating FOXO3 deacetylation in both sensitive and resistant nasopharyngeal carcinoma (NPC) cells. The synthetic glucocorticoid",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:107"
    }
  },
  {
    "page_content": "(NPC) cells. The synthetic glucocorticoid dexamethasone also targets FOXO3 phosphorylation on Ser7 and acetylation on Lys242/Lys245 to mediate its cytotoxic function in B acute lymphoblastic leukaemia (B-ALL). These findings also propose that SIRTs can be important biomarkers for metastatic and drug-resistant clones and that targeting the SIRT-FOXO3 axis may provide novel strategies for treating cancer and for overcoming chemoresistance. Indeed, specific as well as pan-SIRT inhibitors have",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:108"
    }
  },
  {
    "page_content": "specific as well as pan-SIRT inhibitors have proved to be effective in tackling cancer and in overcoming cancer drug resistance. ## Other FOXO PTMs Methylation is a post-translational modification which introduces a methyl group to proteins. Protein methylation is predominantly associated with histone methylation which modulates gene expression. However, FOXO proteins are also direct targets of methylation. For instance, the ubiquitously expressed and tissue-specific protein arginine",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:109"
    }
  },
  {
    "page_content": "expressed and tissue-specific protein arginine N-methyltransferase 1 (PRMT1) has been reported to methylate FOXO1 at Arg248 and Arg250 to block the Akt-mediated Ser253 phosphorylation and inhibition. The lysine methyltransferase Set9 has also been demonstrated to methylate FOXO3. This Set9-mediated FOXO3 methylation at Lys270 leads to attenuation of its DNA binding activity and downregulation of transactivation without affecting the Akt-mediated phosphorylation, its protein stability and",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:110"
    }
  },
  {
    "page_content": "phosphorylation, its protein stability and subcellular localisation. On the evidence of these studies, FOXO methylation appears to promote the activity of FOXO proteins. In fact, protein methylation has been shown to have a role in protein-protein interaction, DNA binding affinity, protein stability and subcellular localisation. It is also unclear whether like methylation, other less common post-translational modifications (i.e. glutathionylation, glycosylation, SUMOylation, hydroxylation,",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:111"
    }
  },
  {
    "page_content": "glycosylation, SUMOylation, hydroxylation, neddylation, citrullination, prenylation, palmitoylation, myristoylation and s-nitrosylation) also directly modify FOXO proteins and if they are involved in modulating FOXO activity in cancer. For example, neddylation inactivation by the specific inhibitor MLN4924 can prevent FOXO3 nuclear export, decrease its binding to the ESR1 (oestrogen receptor) gene promoter and improve fulvestrant sensitivity in breast cancer. Nevertheless, in this case, it is",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:112"
    }
  },
  {
    "page_content": "breast cancer. Nevertheless, in this case, it is still unknown whether FOXO3 is directly modified by neddylation and if FOXO3 neddylation has a role in modulating its activity. ## Protein-protein interactions in FOXO regulation Apart from the post-translational modifications, protein-protein interactions also modulate FOXO function and activity. Peroxisome proliferator–activated receptors (PPARs) are a family of ligand-activated nuclear receptor transcription factors that function downstream of",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:113"
    }
  },
  {
    "page_content": "transcription factors that function downstream of ERK to regulate cell metabolism and adipocyte differentiation. In this respect, FOXO1 and PPAR can compete for ERK signals and thereby antagonise the transcriptional activity of one another. In liver carcinoma cells, PPAR can also interfere with the binding of apolipoprotein C III (ApoC-III) to FOXO1, affecting the lipid metabolism and serum triglyceride levels. ApoC-III plays a key role in the regulation of triglyceride metabolism and has been",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:114"
    }
  },
  {
    "page_content": "of triglyceride metabolism and has been suggested to be a predictive marker for NSCLC. Nonetheless, lipid metabolism and lipid-mediated signalling are a key to cancer metastasis, and dysregulated lipid metabolic enzymes are known to be associated with cancer cell invasion and metastasis. In the nucleus, androgen receptor (AR) has been reported to interact with FOXO1. The nuclear receptor AR, which is expressed in a vast range of tissue, responds to the male sex hormone androgen for activation.",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:115"
    }
  },
  {
    "page_content": "to the male sex hormone androgen for activation. Indeed, the development of prostate cancer is intimately associated with androgen. In prostate cancer, elevated AR expression promotes EMT. Likewise, AR promotes haematogenous metastasis and angiogenesis of clear cell renal cell carcinoma (CCRCC). In prostate cancer, an activated nuclear AR binds to and reduces the DNA binding capacity of FOXO1 in an Akt-independent manner, affecting the expression of the proapoptotic genes, such as Fas. Thus, AR",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:116"
    }
  },
  {
    "page_content": "of the proapoptotic genes, such as Fas. Thus, AR binding generally reduces the tumour-suppressive function of FOXO proteins. ER is another hormone-regulated receptor that has a strong link with cancer metastasis. ER is overexpressed in multiple cancers, including breast and ovarian cancers. In breast cancer, ER, encoded by oestrogen receptor alpha gene (ESR1), is commonly deregulated by gene amplification, point mutations and genetic fusion, leading to enhanced cancer invasion and metastasis.",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:117"
    }
  },
  {
    "page_content": "to enhanced cancer invasion and metastasis. The oestrogen-activated ER has been shown to interact with FOXO1 to repress its activity, and it is speculated that this interaction may play a part in the regulation of cancer metastasis. Poly(ADP-ribose) polymerase 1 (PARP1) is a nuclear protein important for the regulation of DNA damage repair, chromatin remodelling, cell death and gene transcription. PARP1 has been shown to promote cell metastasis in melanoma and in prostate and lung cancers",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:118"
    }
  },
  {
    "page_content": "in melanoma and in prostate and lung cancers [229–231]. FOXO1 interacts with PARP1and gets poly(ADP-ribosyl)ated in an Akt-independent manner, resulting in suppression of FOXO1 transcriptional activity and cell proliferation. In cancer cells, PPARγ co-activator 1α (PGC-1α) interacts with FOXO1 and acts as a co-activator in hepatocytes for activation of gluconeogenic genes. The study shows that the interaction is involved in the cellular oxidative stress protection and can be interrupted by",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:119"
    }
  },
  {
    "page_content": "stress protection and can be interrupted by insulin-mediated Akt phosphorylation. Moreover, FOXO1 has been shown to regulate PGC-1α at the transcript level, suggesting a feedback mechanism for oxidative stress regulation. Like PGC-1α, FOXO1 also interacts with C/EBPα to promote the expression of gluconeogenic genes, including phosphoenolpyruvate carboxykinase (PEPCK). The gluconeogenic enzymes are known to affect cancer growth. Recently, gluconeogenesis has also been shown to be upregulated in",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:120"
    }
  },
  {
    "page_content": "has also been shown to be upregulated in brain metastatic breast cancer cells, suggesting that an increase in energy production can promote cancer metastasis via FOXOs. Fanconi anaemia, complementation group D2 (FANCD2) is an important DNA damage response protein, which is activated during DNA replication as well as DNA damage repair. In the rare genetic disease Fanconi anaemia (FA), the loss of FANCD2 activity has been shown to contribute to an accumulation of genetic mutations and therefore",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:121"
    }
  },
  {
    "page_content": "accumulation of genetic mutations and therefore promote leukaemogenesis or tumorigenesis. In cancer cells, FANCD2 also interacts with FOXO3 to regulate antioxidant gene expression in response to oxidative stress. Whilst the interaction between FANCD2 and FOXO3 has not been directly linked to cancer metastasis, FANCD2 overexpression on its own has been shown to be correlated with lymph node metastasis of colon cancer. Elevated FANCD2 expression also increases cancer therapy tolerance and is",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:122"
    }
  },
  {
    "page_content": "also increases cancer therapy tolerance and is associated with an increased risk of metastasis. Indeed, induction of antioxidant gene expression by FANCD2 and FOXO3 can also impact on cancer therapy resistance as radiotherapy and chemotherapeutic drugs can influence cancer treatment outcome through their modulation of ROS. Notably, in parallel to FOXO protein regulation, MYC, which controls at least 15% of the entire genome, is also regulated by the PI3K-Akt pathway. With similar upstream",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:123"
    }
  },
  {
    "page_content": "by the PI3K-Akt pathway. With similar upstream regulation, the oncogenic MYC also competes with FOXO3 for the binding of promoter regions of genes, including p27Kip1. The p27Kip1 is a CDK inhibitor which regulates cell cycle progression, and it is often downregulated in cancer. FOXO proteins also cooperate with other FOX proteins to bind to and drive the transcription of target genes. For example, FOXO1 and FOXA1/A2 have been shown to facilitate one another’s binding and collaborate to open",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:124"
    }
  },
  {
    "page_content": "one another’s binding and collaborate to open chromatin at insulin-regulated genes. Furthermore, FOXO1 also cooperates with FOXA1 to function as pioneer factors to facilitate AR binding in prostate cancer. In other words, FOXOs also work together with other FOX proteins to facilitate the recruitment of other transcriptional elements to promote the transcription of target genes. ## FOXO post-transcriptional regulation by microRNAs MicroRNAs (miRs) are small non-coding RNAs (about 22 nucleotides)",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:125"
    }
  },
  {
    "page_content": "are small non-coding RNAs (about 22 nucleotides) that participate in RNA silencing, and these small RNAs also participate in the regulation of FOXO expression post-transcriptionally through inducing FOXO messenger RNA (mRNA) degradation, translation inhibition and gene silencing (Fig. 1). MicroRNAs, such as miR-107, miR-132, miR-223 and miR-1269, have been shown to negatively regulate FOXO1 expression to promote cell proliferation in a number of cancer cells [252–255]. Likewise, miR-21 promotes",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:126"
    }
  },
  {
    "page_content": "cancer cells [252–255]. Likewise, miR-21 promotes the proliferation of pancreatic ductal adenocarcinoma (PDAC) through repressing FOXO1 expression. Notably, the miR-21 has also been shown to regulate cancer metastasis. Interestingly, miR-21 can also promote growth, metastasis and drug resistance in cancer cells by targeting phosphatase and tensin (PTEN) homologue, an upstream repressor of Akt-PI3K activity and, therefore, an indirect activator of FOXOs. Thus, miRs, like miR-21, regulate not",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:127"
    }
  },
  {
    "page_content": "of FOXOs. Thus, miRs, like miR-21, regulate not only FOXO expression but also their activity at the same time. Wnt/beta-catenin activates miR-183/miR-96/miR-182 expression in hepatocellular carcinoma to promote cancer cell invasion. Meanwhile, a similar group of microRNAs, miR-193, miR-96 and miR-182, also suppress FOXO1 expression in hepatocellular carcinoma, resulting in enhanced cell invasion and metastasis. A similar outcome is also observed with FOXO1, when targeted by miR-135a and",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:128"
    }
  },
  {
    "page_content": "with FOXO1, when targeted by miR-135a and miR-544. In endometrial cancer, miR-9, miR-27a, miR-96, miR-128, miR-153, miR-183 and miR-186 also function cooperatively to suppress FOXO1-regulated cell cycle arrest and cell death. The concerted effort of this group of miRNAs to suppress FOXO1 renders depletion of one miR species having no effects on FOXO1 expression or endometrial cancer cell proliferation and survival. The microRNA miR-29c also represses FOXO1 expression to facilitate breast cancer",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:129"
    }
  },
  {
    "page_content": "FOXO1 expression to facilitate breast cancer cell growth, migration and invasion, whilst miR-135b inhibits FOXO1 expression to promote cell proliferation and invasion in osteosarcoma. In contrast, miR-124 and miR-145 can enhance FOXO1 activity to promote cell cycle arrest and delay cell proliferation, respectively. Interestingly, miR-96 is found to promote colorectal cancer proliferation through targeting both FOXO1 and FOXO3, suggesting that there are common complementary sequences in FOXOs",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:130"
    }
  },
  {
    "page_content": "there are common complementary sequences in FOXOs for miR binding. Similarly, miR-182 suppresses both FOXO1 and FOXO3 expression levels in prostate and skin cancer, respectively, to promote cancer cell migration and invasion. In agreement, a study with anti-miR-182 mimetics in the xenograft mouse model has shown that miR-182 inhibition can restrict ovarian cancer cell invasion and metastasis in vivo. Furthermore, miR-132, miR-223 and miR-27a can induce proliferative arrest and cancer cell death",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:131"
    }
  },
  {
    "page_content": "induce proliferative arrest and cancer cell death through FOXO1 and FOXO3. In Alzheimer disease, miR-132 and miR-212 also control FOXO3-mediated neuronal apoptosis. FOXO3 is also targeted by miR-592 and miR-1307 to promote colorectal cancer metastasis and prostate cancer proliferation, respectively. FOXO4 is targeted by miR-499-5p and miR-1274a for enhanced cell metastasis in colon and gastric cancers, respectively. Similarly, miR-150 restricts the expression of FOXO4 to promote cervical cancer",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:132"
    }
  },
  {
    "page_content": "expression of FOXO4 to promote cervical cancer proliferation and lung cancer cell metastasis. Not only FOXO expression and activity are regulated by miRs; evidence also exists that miRs are also regulated by FOXO proteins. In fact, cross-talks between miR-155-5p and FOXO3 have been shown to modulate cell growth in lung cancer. The miR-155 has also been associated with circular RNA FOXO3 (circ-FOXO3) and FOXO3 in lung cancer migration and invasion. The circ-FOXO3 shares identical sequences with",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:133"
    }
  },
  {
    "page_content": "The circ-FOXO3 shares identical sequences with FOXO3 mRNA and can buffer several miRs from interacting with FOXO3 mRNA. Thus, circ-FOXO3 can upregulate FOXO3 expression by preventing the binding of miR to the FOXO3 mRNA. Furthermore, FOXO3 upregulates miR-622 to suppress hypoxia-inducible factor 1 alpha (HIF-1α) to induce cell invasion and migration in lung cancer. FOXO3 has also been shown to bind and activate miR-34 for β-catenin inhibition which subsequently suppresses cell migration in",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:134"
    }
  },
  {
    "page_content": "which subsequently suppresses cell migration in prostate cancer. Whilst many reports have documented the direct relationships between miR and FOXO expression levels, another microRNA (miR-205) has been shown to antagonise Akt signalling in lung cancer, providing an indirect route to activate FOXO activity. Although miRs have been established to play a key part in regulating FOXO expression and cancer metastasis, how these miRs are regulated themselves remains to be explored. Nonetheless, these",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:135"
    }
  },
  {
    "page_content": "remains to be explored. Nonetheless, these findings suggest that post-transcriptional regulation of FOXO expression is important for the regulation of FOXO activity in the modulation tumorigenesis and metastasis. ## Cross-communication between FOXOs and other FOX proteins In mammals, there are 50 known FOX proteins. Together, they regulate a wide range of biological processes encompassing cell proliferation, survival, differentiation, migration and stress response. These FOX proteins share",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:136"
    }
  },
  {
    "page_content": "and stress response. These FOX proteins share highly homologous DNA binding domains and recognise overlapping gene targets. In consequence, tissue-specific misregulation or misexpression of these FOX genes can lead to a gain of function and result in cancer initiation and progression. Recent evidence also suggests these FOX proteins share several attributes, and intriguingly, one of them common to the majority of FOX proteins is their regulation of cancer metastasis. Apart from having",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:137"
    }
  },
  {
    "page_content": "of cancer metastasis. Apart from having overlapping functions, the expression and activity of FOXOs are also influenced directly and indirectly by their close cousins, such as FOXM1, FOXC1, FOXC2, FOXF1, FOXS1, FOXG1 and FOXK2 (Fig. 4). FOXM1 (also known as HFH-11B, Trident, Win and MPP2) is an oncogenic transcription factor which is known to be overexpressed during early cancer development. It is also a potent regulator of metastasis. To date, many studies have documented that FOXM1 is a key",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:138"
    }
  },
  {
    "page_content": "many studies have documented that FOXM1 is a key regulator of cancer cell proliferation, DNA damage repair, cancer drug resistance, metastasis and invasion. The tumour suppressor FOXO3 can antagonise the oncogenic activity of FOXM1 in a number of ways. Apart from FOXO3 and FOXM1 having opposite effects on chromatin remodelling of common target genes, FOXO3 also competes with FOXM1 for DNA binding at target genes and directly represses FOXM1 expression at the promoter level. These multiple",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:139"
    }
  },
  {
    "page_content": "expression at the promoter level. These multiple levels of control of FOXM1 by FOXO3 emphasise the significance of FOXO3 as a tumour suppressor. FOXO3 and FOXM1 are also intimately associated with chemotherapeutic drug resistance and cancer stem cell properties [30, 289–291]. Furthermore, the FOXO3-FOXM1 axis has been shown to regulate VEGF, an important factor for angiogenesis and metastasis. Indeed, targeting FOXM1 has been shown to significantly inhibit cancer growth and metastasis.",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:140"
    }
  },
  {
    "page_content": "inhibit cancer growth and metastasis. Interestingly, FOXM1 and Aurora kinase A (AURKA) promote the activity and expression of each other in a positive feedback loop. AURKA has also been shown to negatively regulate FOXO1 at the transcriptional level, indicating that FOXM1 can indirectly regulate FOXO expression via AURKA to sustain its expression and activity in cancer cells. Likewise, Akt and FOXM1, both upstream inhibitors of FOXO3, also positively regulate cell migration in a positive",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:141"
    }
  },
  {
    "page_content": "positively regulate cell migration in a positive feedback loop manner to promote tongue squamous cell carcinoma cell migration. FOXC1 (also known as FKHL7) is another forkhead protein closely related to metastasis and FOXO function. High FOXC1 expression has been found to be associated with highly metastatic colon, breast and liver cancers [296–299]. FOXC1 has also been shown to induce MMP-7 expression to promote breast cancer metastasis. Furthermore, overexpression of FOXC1 promotes tumour",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:142"
    }
  },
  {
    "page_content": "overexpression of FOXC1 promotes tumour metastasis and predicts poor prognosis in liver cancer. Conversely, knockdown of FOXC1 reduces the expression of mesenchymal genes, such as vimentin, fibronectin and N-cadherin. Furthermore, FOXC1 knockdown displays lower expression levels of MMP-1, MMP-2, MMP-7 and MMP-9 with reduced mesenchymal characteristics and metastatic capability. In melanoma, FOXC1 has been shown to promote tumorigenesis by activating the MST1R/PI3K/Akt pathway and is associated",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:143"
    }
  },
  {
    "page_content": "the MST1R/PI3K/Akt pathway and is associated with poor prognosis. Thus, FOXC1 can repress FOXO activity through enhancing the PI3K/Akt signalling. Similarly, FOXC2 (also known as MGH1 and FKHL14) has been linked to metastasis in breast cancer, colorectal cancer (CRC) and osteosarcoma [303–306]. FOXC2 has been demonstrated to also upregulate ERK and Akt activities to mediate FOXO3 inhibition. Anoikis can also induce FOXC2 expression to facilitate cancer migration in osteosarcoma. This",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:144"
    }
  },
  {
    "page_content": "facilitate cancer migration in osteosarcoma. This anoikis-induced osteosarcoma cell invasiveness and metastasis to the lung are dependent on the ability of FOXC2 to induce CXCR4, a chemokine receptor responsible for tumour growth, invasion, angiogenesis, metastasis, relapse and therapeutic resistance. High FOXC2 expression is strongly correlated with invasion and metastasis of CRC, whereas downregulation of FOXC2 reduces colon cancer invasiveness and their metastatic potential. In concordance,",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:145"
    }
  },
  {
    "page_content": "and their metastatic potential. In concordance, FOXC2 has been found to be required for EMT and the display of mesenchymal-like properties in breast cancer. FOXF1 (also known as FKHL5) is essential for mesenchymal cell migration. Previously, FOXF1 has been shown to induce p38 MAPK activity, one of the upstream activators of FOXO1 and FOXO3. Similarly, FOXF1 suppresses osteosarcoma cell invasion and migration by decreasing MMP-2 and MMP-9 expression levels. In agreement, FOXF1 can be promoted by",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:146"
    }
  },
  {
    "page_content": "levels. In agreement, FOXF1 can be promoted by the tumour suppressor p53 to induce the expression of E-cadherin (the epithelial cadherin), an epithelial cell marker. Although FOXF1 has not been directly associated with FOXOs, it is plausible that FOXF1 can induce p38 MAPK to activate FOXO activity. On the contrary, FOXF1 has also been found to induce EMT and angiogenesis by activating SNAI1 and VEGFA, respectively, to promote cancer metastasis and angiogenesis in colon cancer. In the tumour",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:147"
    }
  },
  {
    "page_content": "and angiogenesis in colon cancer. In the tumour microenvironment, FOXF1 also stimulates cancer-associated fibroblasts to facilitate lung cancer tumorigenesis and migration. Based on this evidence, it is likely that FOXF1 has different metastatic and angiogenic roles in epithelial and mesenchymal cells. FOXS1 (also known as FKHL18) has been shown to suppress the transcriptional activity of FOXO3 and FOXO4. Although FOXS1 is predominately expressed in the nervous system, overexpression of FOXS1",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:148"
    }
  },
  {
    "page_content": "in the nervous system, overexpression of FOXS1 can inhibit gastric cancer proliferation and metastasis. Microarray analysis of metastasis-associated mRNA also shows that FOXS1 is downregulated in high metastatic lung cancer. The forkhead protein FOXG1 (previously known as BF1) forms a complex with FOXO and SMAD proteins to promote neuronal differentiation. Notably, SMAD3 and SMAD4 also interact with FOXO1 to promote the transcription of p21Cip1, an important negative cell cycle regulator.",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:149"
    }
  },
  {
    "page_content": "an important negative cell cycle regulator. Whilst the FOXG1-FOXO1 complex has not been proved to be directly linked to cell metastasis, suppression of FOXG1 by miR-200b can promote cell proliferation and metastasis in cervical cancer. Furthermore, miR-422a also negatively regulates FOXG1 expression to modulate liver cancer metastasis. FOXK2 has also been found to regulate FOXO3 expression at the transcriptional level to mediate the cytotoxic effects of epirubicin and paclitaxel in breast",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:150"
    }
  },
  {
    "page_content": "effects of epirubicin and paclitaxel in breast cancer. Interestingly, like FOXO3, FOXK2 has been shown to be able to repress breast cancer carcinogenesis.Fig. 4Relationships between FOX proteins. Apart from the conventional signalling pathways, FOXO proteins are also regulated by other FOX proteins which modulate FOXO activity. FOXO proteins are the central axis of many signalling pathways which determine cell fates. Downregulation of FOXO proteins enhances cell proliferation, invasion,",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:151"
    }
  },
  {
    "page_content": "proteins enhances cell proliferation, invasion, metastasis and angiogenesis Although a direct relationship between FOXOs and some of the other FOX proteins has yet to be established, these FOX proteins have already been shown to have a key role in cancer cell metastasis. For instance, FOXQ1 has been shown to modulate EMT in breast, gastric, bladder and cervical cancers [325–328]. FOXQ1 also promotes metastasis by transactivating ZEB2 and VersicanV1 expression in liver cancer. Likewise, FOXQ1",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:152"
    }
  },
  {
    "page_content": "expression in liver cancer. Likewise, FOXQ1 also negatively regulates CDH1, which encodes epithelial cadherin or E-cadherin, to promote oesophageal squamous cell carcinoma metastasis. In colon cancer, FOXQ1 transactivates Twist1 to suppress E-cadherin expression. Notably, loss of FOXF2 expression promotes EMT in breast and liver cancers. In agreement, FOXF2 has shown to negatively regulate FOXC2-mediated cancer and EMT phenotypes. This occurrence of closely linked downstream genes between FOXOs",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:153"
    }
  },
  {
    "page_content": "of closely linked downstream genes between FOXOs and other forkheads also highlights the involvement of tissue-specific misregulation or misexpression of FOX proteins, including FOXOs, during tumorigenesis, in particular in cancer metastasis. # Targeting FOXO in cancer therapy To date, many naturally derived and chemically synthesised compounds have been appraised for their potentials in cancer treatment. Remarkably, many compounds studied with demonstrated therapeutic capacities have been",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:154"
    }
  },
  {
    "page_content": "demonstrated therapeutic capacities have been found to modulate FOXO expression and/or activity. This is due to the involvement of FOXO proteins in the regulation of genes linked to crucial drug action–related cellular processes, including stem cell renewal, DNA repair, cell death, metabolism, cell migration, angiogenesis, cell cycle control and cell division, as mentioned earlier. Therefore, not surprising, the mechanisms of resistance to conventional cytotoxic chemotherapeutics and to",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:155"
    }
  },
  {
    "page_content": "conventional cytotoxic chemotherapeutics and to molecularly targeted therapies are also linked directly to deregulated signalling mediated through the FOXO transcription factors. Many currently used and proven cancer therapeutics, including paclitaxel, doxorubicin, epirubicin, lapatinib, gefitinib, imatinib and cisplatin, have been confirmed to mediate their cytotoxic and cytostatic functions through FOXO. For example, the anti-EGFR/HER small molecule inhibitors lapatinib and gefitinib have",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:156"
    }
  },
  {
    "page_content": "molecule inhibitors lapatinib and gefitinib have been shown to mediate their cytostatic and cytotoxic functions though activating FOXO3 via modulating the PI3K-Akt and p38/JNK/ERK pathways. Similarly, the therapeutic monoclonal antibody trastuzumab (Herceptin) directed against the extracellular domain of mutated HER2 also mediates its antiproliferative effects through FOXO3 and its downstream target survivin (BRC5). Genotoxic agents, including doxorubicin, epirubicin, cisplatin and",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:157"
    }
  },
  {
    "page_content": "including doxorubicin, epirubicin, cisplatin and 5-fluorouracil (5-FU), can also cause DNA damage and oxidative stress via FOXO3. The anthracycline doxorubicin induces FOXO3 activation and nuclear translocation by phosphorylating FOXO3 on Ser7 residue via p38 MAPK. FOXO3 also induces doxorubicin-induced apoptosis through its transcriptional repression of miR-21 which, in turn, modulates the expression of pro-apoptotic factors, Fas-L, Bim and survivin. Another study shows that FOXO3 activation",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:158"
    }
  },
  {
    "page_content": "Another study shows that FOXO3 activation increases expression of TRAIL and cell death in response to doxorubicin in hepatocellular carcinoma (HCC), suggesting that FOXO3 is required for doxorubicin sensitivity. Conversely, FOXO3 inactivation and sequestration in the cytoplasm are closely associated with doxorubicin resistance. Furthermore, SIRT1 has been shown to deacetylate p53 and FOXO3 which contributes to doxorubicin resistance. In a similar manner, another anthracycline epirubicin, which",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:159"
    }
  },
  {
    "page_content": "manner, another anthracycline epirubicin, which is an epimer of doxorubicin, also mediates its anticancer activity through FOXO3. Other studies have verified FOXO3 as a key mediator of cisplatin action. Accordingly, it has been shown that cisplatin treatment causes a decrease in Akt-mediated FOXO3 phosphorylation in colon cancer cells, resulting in its nuclear translocation and activation. Conversely, impaired FOXO3 nuclear accumulation and the consequent failure to induce apoptosis have been",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:160"
    }
  },
  {
    "page_content": "consequent failure to induce apoptosis have been associated with the development of cisplatin resistance. Interestingly, increased FOXO3 activation in cisplatin-resistant colon cancer cells with the small molecule Akt inhibitor, tricirbine/API-2, can override cisplatin resistance by blocking Akt-mediated FOXO3 phosphorylation. Paclitaxel functions by inducing microtubule dysfunction and, eventually, cell death by mitotic catastrophe. Paclitaxel has been shown to induce JNK-MAPK to phosphorylate",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:161"
    }
  },
  {
    "page_content": "been shown to induce JNK-MAPK to phosphorylate and activate FOXO3 directly, as well as derepressing the inhibition of Akt on FOXO3 to induce apoptosis via Bim and other pro-apoptotic molecules. Indeed, FOXO3 phosphorylation by p38/JNK MAPK on Ser7 can promote its nuclear localisation and activation as well as its acetylation by CBP/p300 on Lys-242/245. Compounds such as β-lapachone and 5-fluorouracil have been shown to induce cancer apoptosis through the activation of FOXOs and its target",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:162"
    }
  },
  {
    "page_content": "through the activation of FOXOs and its target FOXM1. Some naturally derived compounds including benzyl isothiocyanate, resveratrol, quercetin, arsenic trioxide and caffeic acid phenethyl ester (CAPE) have been shown to restrain cancer growth through FOXO activation. Naturally derived compounds which can be found in daily diets also have a great potential in preventing cancer progression. Recently, studies with the extracted compounds are intensified to promote the concern for healthier diets.",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:163"
    }
  },
  {
    "page_content": "to promote the concern for healthier diets. For instance, resveratrol in grapes promotes the transcriptional activity of FOXOs through AMPK to reduce ROS in a number of cancers. Benzyl isothiocyanate (BITC) promotes the expression of FOXO-regulated Bim, p27Kip1 and p21Cip1 by reducing the Akt-mediated FOXO phosphorylation in pancreatic tumour. Similarly, pterostilbene in blueberries activates FOXO1 by the suppression of Akt and ERK activity and increases 5-FU chemosensitivity in colon cancer. A",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:164"
    }
  },
  {
    "page_content": "5-FU chemosensitivity in colon cancer. A glutamate receptor antagonist, dizocilpine (also known as MK-801), has been shown to enhance FOXO1 nuclear localisation and promote its tumour suppressor function. The chilli pepper extract capsaicin activates JNK to induce FOXO1 acetylation for Bim-induced apoptosis in pancreatic cancer. Polydatin, a natural precursor of resveratrol, also upregulates FOXO1 through inhibition of Akt and STAT3 signalling pathway to suppress hepatocellular carcinoma cell",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:165"
    }
  },
  {
    "page_content": "pathway to suppress hepatocellular carcinoma cell migration and invasion. Isorhapontigenin, another analogue of resveratrol, also inhibits STAT1 to enhance FOXO1 activity and limits bladder cancer cell invasion. Polyphenol epigallocatechin-3-gallate in green tea can upregulate FOXO3 and suppress breast cancer metastasis. Ergosterol from the mushroom Amauroderma rude also increases FOXO3 expression to inhibit cell migration and invasion. Although some studies have exposed the underlying",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:166"
    }
  },
  {
    "page_content": "Although some studies have exposed the underlying mechanisms of action of some of these compounds, the exact mechanisms for the rest of these naturally derived compounds are not fully understood. Thus far, none of these naturally derived compounds is officially used in the clinic for cancer treatment in consequence. Nevertheless, these findings further support the hypothesis that FOXOs serve as the sensor as well as the mediator of anticancer agents. As FOXO expression and activity are often",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:167"
    }
  },
  {
    "page_content": "agents. As FOXO expression and activity are often adaptively downregulated in malignancies and are further attenuated in drug-resistant cancer, the expression of some of their important downstream transcriptional targets is also diminished as a result. Thus, it is rational to propose that interventions aimed at the downstream targets of FOXO proteins could induce cancer and drug-resistant cell-specific elimination and form the basis for novel anticancer therapies. Indeed, recent research has",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:168"
    }
  },
  {
    "page_content": "anticancer therapies. Indeed, recent research has shown that PERK (PKR-like endoplasmic reticulum kinase, also called eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2A3K)) is regulated by FOXO3 and thus exposed a transformed cell and chemotherapeutic drug–resistant cancer cell vulnerability in PERK. In this case, small molecule PERK inhibitors, which have been generated and tested for neurodegenerative diseases, can be repositioned to target cancer cells. # Conclusion",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:169"
    }
  },
  {
    "page_content": "repositioned to target cancer cells. # Conclusion Collectively, research studies to date have pointed to a key tumour-suppressive role for FOXO transcription factors. This is mediated through the ability of FOXOs to regulate genes essential for cell proliferative arrest, cell death, autophagy, senescence, angiogenesis, cell migration and metastasis. FOXO proteins also integrate diverse proliferative, nutrient and stress signals with distinct gene networks to control cell fate, metabolism and",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:170"
    }
  },
  {
    "page_content": "networks to control cell fate, metabolism and cancer development. Notably, evidence also exists that FOXO proteins can sometimes support cancer progression, angiogenesis, metastasis and drug resistance in a cell type and context–dependent manner. Intriguingly, the mechanisms of action of conventional cytotoxic chemotherapeutics and novel molecularly targeted therapies are also invariably linked to FOXO transcription factors (Fig. 5). Thus, FOXO proteins have been firmly established as not only",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:171"
    }
  },
  {
    "page_content": "proteins have been firmly established as not only important markers for cancer diagnosis and prognosis but also targets for cancer intervention. Whilst the mechanisms underlying their roles and regulations are still being uncovered, accumulated research has also shown that FOXO expression and activity are predominantly regulated at the post-transcriptional and post-translational levels and are adaptively downregulated in cancer cells. Thus, targeting the upstream regulators of FOXOs may provide",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:172"
    }
  },
  {
    "page_content": "the upstream regulators of FOXOs may provide novel strategies of cancer treatment and for overcoming drug resistance. Equally, the FOXO downstream targets, which are adaptively downregulated with FOXOs in cancer, may represent vulnerabilities for cancer intervention strategies.Fig. 5Role of the FOXO transcription factors. FOXOs exhibit tumour-suppressive roles in inhibiting tumorigenesis by promoting cell apoptosis and senescence. However, depending on the cell type and context–dependent",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:173"
    }
  },
  {
    "page_content": "depending on the cell type and context–dependent manner, FOXOs may drive cell autophagy, metastasis and angiogenesis for the cell survival. Notably, FOXOs play a very important role in stress modulation and drug resistance",
    "metadata": {
      "source": "../data/plain/PMC7497309.plain.txt",
      "id": "../data/plain/PMC7497309.plain.txt:174"
    }
  },
  {
    "page_content": "Risk of Second Primary Neoplasms Among Cancer Survivors: A Population‐Based, Cohort Study in Golestan Province, Northern Iran, 2004–2019 ABSTRACT\nBackground\nRecent reports of the Golestan population‐based cancer registry (GPCR) suggested increasing trends in the incidence and survival rates of cancers in Golestan, Northern Iran. We investigated the risk of developing second primary neoplasms (SPNs) among cancer survivors in Golestan.\nMethods",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:0"
    }
  },
  {
    "page_content": "Methods\nThe GPCR cases for whom a first primary cancer was diagnosed between 2004 and 2019 were included as cohort participants. The cohort members were followed by the end of 2020, and the occurrence of a second primary neoplasm (SPN) was considered as the study outcome event. The standardized incidence ratios (SIRs) and the Absolute excess risks (AERs), with corresponding 95% confidence intervals (95% CI) were calculated to evaluate the risk of SPNs.\nResults",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:1"
    }
  },
  {
    "page_content": "Of the total 32,980 cases with first primary cancer, with a median follow‐up of 3.4 years, 772 (2.3%) SPNs were registered. Our findings suggested a significantly higher risk of occurring new neoplasms among cancer survivors, with a SIR of 4.6 (95% CI: 4.3–4.9) and an AER of 41.8 per 10,000 person‐years (95% CI: 37.6–46.0). Rural residents had a higher risk of SPN (SIR = 5.48) than urban dwellers (SIR = 3.99). Patients with first primary cancers of the ovary (SIR = 6.83) and prostate",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:2"
    }
  },
  {
    "page_content": "cancers of the ovary (SIR = 6.83) and prostate (SIR = 6.72) had the highest risk of any SPNs. The highest risk of site‐specific SPNs was observed for the SPNs of the ovary (SIR = 8.11) and NHL (SIR = 7.07).",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:3"
    }
  },
  {
    "page_content": "Conclusions",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:4"
    }
  },
  {
    "page_content": "Our results suggest that cancer patients are at significantly higher risk of getting a new neoplasm than the general population. These findings highlight the need for designing and implementing efficient surveillance programs for cancer survivors. # Introduction Cancer is a significant global health challenge with rising incidence and prevalence. In 2020, there were 19.3 million new cancer cases and 9.9 million cancer‐related deaths reported worldwide. These numbers are projected to increase",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:5"
    }
  },
  {
    "page_content": "These numbers are projected to increase even further in the coming years. In addition, the 2019 Global burden of disease (GBD) study showed the growing burden of cancer in low and middle‐sociodemographic index (SDI) countries including Iran. Iran is witnessing a growing trend in cancer incidence, and it is predicted that the number of cancer cases will have a 42.6% increase from 2016 to 2025. In the Golestan province, a high‐risk area for upper gastrointestinal cancers in Northern Iran, this",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:6"
    }
  },
  {
    "page_content": "gastrointestinal cancers in Northern Iran, this rate is even higher. The Golestan Population‐based Cancer Registry (GPCR) reported that the number of new cancer cases in 2025 is estimated to increase by 61.3% compared with 2016 statistics in this region. These days, thanks to cancer prevention strategies, advances in diagnostic techniques, and high‐quality care for cancer patients, the trend of survival in cancer cases is increasing globally. Recent reports from the GPCR suggested an increase",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:7"
    }
  },
  {
    "page_content": "reports from the GPCR suggested an increase in survival rates of cancer patients among Golestan residents. Cancer survivors have a higher risk of multiple primary cancer (estimated 1.5 to 3.1 times higher) in comparison with the general population. According to the International Agency for Research on Cancer (IARC) protocols, multiple primary cancers are defined as the occurrence of two or more distinct cancers in an individual, which is neither an extension, nor a recurrence, nor metastasis.",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:8"
    }
  },
  {
    "page_content": "an extension, nor a recurrence, nor metastasis. Statistics showed that the risk of multiple primary cancers is higher among patients with better survival chances, for example, breast cancer; this can be related to the cancer treatment late effects or common risk factors to the first primary cancers. Therefore, it is expected that with an increase in the number of new cancer cases in the future (it is predicted to reach 30.2 million new cancer cases by 2040 globally) and the growing trend in",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:9"
    }
  },
  {
    "page_content": "cases by 2040 globally) and the growing trend in survival rate generally, the risk of subsequent primary neoplasms is also likely to increase. Therefore, investigating the risk of developing subsequent primary cancers is crucial for making effective plans for follow‐up in cancer patients. Considering recent reports of increasing trends in the incidence and survival rates of cancers in Golestan province, we conducted this study to investigate the risk of second primary neoplasms (SPNs) among",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:10"
    }
  },
  {
    "page_content": "the risk of second primary neoplasms (SPNs) among cancer survivors in this high‐risk population, between 2004 and 2019. # Materials and Methods ## Source of Data and Definitions Data on cancer patients as well as data on SPN were obtained from the GPCR dataset. The GPCR started its activity as a high‐quality population‐based cancer registry in 2004. It covers the population of Golestan province, with 1.87 million residents in 2016, constituting 2.3% of Iran's total population, located in",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:11"
    }
  },
  {
    "page_content": "2.3% of Iran's total population, located in Northern Iran with an area of about 20,000 km2. The GPCR was accepted as a voting member of the International Association of Cancer Registries (IACR) in 2007, and its data were accepted for publication in volumes X, XI, and XII of the Cancer Incidence in Five Continents (CI‐5) project of the IARC. Based on the indices of data quality, the GPCR is a high‐quality population‐based cancer registry which collects data on cancer patients with acceptable",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:12"
    }
  },
  {
    "page_content": "collects data on cancer patients with acceptable accuracy and completeness across sub‐populations of the Golestan province (e.g., urban and rural populations). The GPCR registered subsequent primary neoplasms (multiple primary cancers) in cancer patients using the IARC “international rules for multiple primary cancers”. According to the IARC rules, multiple primary cancers are defined and registered as occurring two or more primary neoplasms in a person that originate in the primary site or",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:13"
    }
  },
  {
    "page_content": "in a person that originate in the primary site or tissue and are not extension, recurrence, or metastasis. Based on the number of multiple primary cancers in the GPCR dataset, only SPN were included in the present study. In other words, we excluded third primary neoplasms due to the very small sample size in the GPCR dataset. The GPCR considered a passive follow‐up for its registered cases by performing linkage between the GPCR dataset and the Golestan death registry dataset. We obtained",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:14"
    }
  },
  {
    "page_content": "the Golestan death registry dataset. We obtained follow‐up data, including vital status and date of death, from the GPCR dataset. ## Study Cohort and Follow‐Up The GPCR cases for whom a first primary cancer was diagnosed between 2004 and 2019 were included as our cohort participants. Patients with non‐malignant tumors were excluded. We also excluded cases with non‐melanoma skin cancer (NMSC). Based on the availability of follow‐up data in the GPCR dataset, our cohort members were followed until",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:15"
    }
  },
  {
    "page_content": "dataset, our cohort members were followed until the end of 2020. Person‐years at risk were accumulated for each of our cohort participants from the date of diagnosis of the first primary cancer up to the earliest of three events: date of diagnosis of an SPN, date of death, or end of follow‐up (December 31, 2020). ## Explanatory Variables According to the availability of data, we stratified all analyses by sex, residence area, year of diagnosis of first cancer, age at diagnosis of first cancer,",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:16"
    }
  },
  {
    "page_content": "first cancer, age at diagnosis of first cancer, and cancer site. The year of diagnosis of the first cancer was categorized into 3 periods including 2004–2009, 2010–2014, and 2015–2019. Considering age at diagnosis of the first primary cancers, participants were categorized into children (0–14 years), adolescents and young adults (AYA) (15–39 years), and adults (≥ 40 years). The age categorization was made according to the previous studies and based on differences in tumor characteristics and",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:17"
    }
  },
  {
    "page_content": "based on differences in tumor characteristics and behaviors between the selected age groups. For site‐specific analysis, cancer sites were classified based on the International Classification of Disease, tenth revision (ICD‐10). According to the most recent reports of the GPCR, the following 10 most common cancer sites, including breast (female) (C50), stomach (C16), esophagus (C15), colorectum (C18‐C20), lung (C34), leukemia (C91‐C95), brain (C70‐C72), prostate (C61), bladder (C67),",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:18"
    }
  },
  {
    "page_content": "brain (C70‐C72), prostate (C61), bladder (C67), non‐Hodgkin lymphoma (NHL) (C82‐C85, C96), thyroid (C73), liver (C22), ovary (C56), larynx (C32), and pancreas (C25) were considered for site‐specific analysis. ## Statistical Analysis ### Incidence Rates of First Primary Cancer in the General Population The numbers and incidence rates of first primary cancer in the general population of Golestan (2004–2019) were presented across sex, residence area, period of diagnosis, age groups, and cancer",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:19"
    }
  },
  {
    "page_content": "area, period of diagnosis, age groups, and cancer sites. Crude incidence rates in the general population (General incidence rates) were calculated by dividing the number of first primary cancer cases by the corresponding number of the general population of Golestan. Age standardized incidence rates (ASR) of first primary cancer were calculated by the direct standardization method using the World standard population. ### Assessing the Risk of SPN The median and interquartile range (IQR) were",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:20"
    }
  },
  {
    "page_content": "SPN The median and interquartile range (IQR) were calculated for overall follow‐up time and time to SPN. The observed numbers of SPNs among the study cohort were presented by sex, residence area, period of diagnosis, age group, and cancer site. To evaluate the risk of SPN, we calculated the standardized incidence ratios (SIRs) and the Absolute excess risks (AERs). The main aim of the calculation of SIRs is to measure the strength of association between first and second primary cancers. The AERs",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:21"
    }
  },
  {
    "page_content": "first and second primary cancers. The AERs are calculated to measure the absolute increase in risk of a SPN. As a requirement for the calculation of SIRs and AERs, we needed to calculate the expected number of SPNs among the study cohort. The expected number of SPNs was calculated by applying the general incidence rates (incidence rates of first primary cancers in general population of Golestan) to the person‐years at risk among the study cohort stratified by sex, age group, and cancer site.",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:22"
    }
  },
  {
    "page_content": "stratified by sex, age group, and cancer site. SIRs were calculated as the ratio of the observed and the expected number of SPNs. The SIRs were stratified by sex, residence area, period of diagnosis, age group, and cancer site. We also calculated the 95% confidence intervals (95% CIs) for the SIRs assuming a Poisson distribution. AERs were calculated as the observed minus the expected number of SPNs, divided by the person‐years at risk and multiplied by 10,000. The AERs were stratified by sex,",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:23"
    }
  },
  {
    "page_content": "by 10,000. The AERs were stratified by sex, residence area, period of diagnosis, age group, and cancer site. The 95% CIs for AERs were calculated according to the previously described method, assuming a normal distribution. SIRs and AERs were considered to be statistically significant if the 95% CIs did not include 1 and 0, respectively. In the case of fewer than 5 observed SPNs, the SIR and AER were not calculated, because the results were not reliable due to the small number of SPNs.",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:24"
    }
  },
  {
    "page_content": "not reliable due to the small number of SPNs. Statistical analyses were performed using R software (version 4.3.1). ## Ethical Considerations The protocol of this study was reviewed and approved by the ethics committee of the Golestan University of Medical Sciences (ethics code: IR.GOUMS.REC.1400.212). # Results Overall, the study cohort contributed 144,321.8 person‐years of follow‐up between January 1, 2004, and December 31, 2020 (median follow‐up 3.4 years; IQR: 0.9–8.0). Table 2 shows the",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:25"
    }
  },
  {
    "page_content": "3.4 years; IQR: 0.9–8.0). Table 2 shows the person‐years of follow‐up across age groups, sex, residence area, period of diagnosis, and cancer sites. Of the total 772 SPNs, 378 (49.0%), 447 (57.9%), and 643 (83.3%) were diagnosed in men, rural residents, and adults, respectively. The most common sites of SPNs were stomach (n = 89, 11.5%), colorectum (79, 10.2%), breast (79, 10.2%), and esophagus (53, 6.9%). The SIRs and AERs were similar for males (SIR = 4.50, AER = 42.28) and females (4.66,",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:26"
    }
  },
  {
    "page_content": "(SIR = 4.50, AER = 42.28) and females (4.66, 41.38). Our findings suggested higher SIRs and AERs for rural residents (SIR = 5.48, AER = 48.37) than for urban residents (3.99, 37.46). The SIRs (95% CIs) for children, AYA, and adult population were 22.5 (95% CIs: 7.80–37.20), 10.91 (8.96–12.86), and 1.60 (1.48–1.72), and the corresponding AERs (95% CIs) were 19.93 (6.00–33.86), 39.19 (31.13–47.26), and 21.46 (15.81–27.11), respectively. When assessing the risk of any SPN by the site of the first",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:27"
    }
  },
  {
    "page_content": "the risk of any SPN by the site of the first primary cancer, the highest SIRs of any SPN were found for patients with first primary cancer of ovary (SIR = 6.83; 95% CI: 4.30–9.36) and prostate (SIR = 6.72; 95% CI: 4.71–8.73). When assessing the risk of site‐specific SPN (i.e., by the site of the second primary neoplasm) among the whole cohort, the highest SIRs were observed for the SPNs of ovary (SIR = 8.11; 95% CI: 5.21–11.01) and NHL (SIR = 7.07; 4.91–9.23) (Table 2). Table 3 shows the risk",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:28"
    }
  },
  {
    "page_content": "4.91–9.23) (Table 2). Table 3 shows the risk of SPNs by site of first primary cancer and site of SPN among AYA and adult population. Tables S1 and S2 show similar findings by gender for AYA and adult population, respectively. The highest SIRs of any SPN were found for patients with first primary cancer of lung (SIR = 16.67; 95% CI: 2.06–31.28) and ovary (SIR = 2.61; 95% CI: 1.55–3.68) among AYA and adult cancer patients, respectively. When assessing the risk of site‐specific SPN (i.e., by the",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:29"
    }
  },
  {
    "page_content": "the risk of site‐specific SPN (i.e., by the site of the second primary neoplasm) in AYA and adult population, the highest SIRs were observed for the SPNs of NHL (SIR = 23.33; 95% CI: 11.11–35.56) and ovary (SIR = 3.09; 95% CI: 1.88–4.30), respectively. # Discussion Our findings demonstrated a significantly elevated risk of developing a new neoplasm among cancer patients compared to the general population with an SIR of 4.5 and an AER of 41.8 per 10,000 person‐years. This higher risk of new",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:30"
    }
  },
  {
    "page_content": "per 10,000 person‐years. This higher risk of new primary neoplasm was similarly indicated in different studies. In a Canadian study, the SIR and AER among the children and youth (0–19 years) were calculated as 6.5 and 16.5 per 10,000 person‐years, respectively. There are several explanations for the greater risk of new primary neoplasm among cancer survivors, including shared genetic susceptibilities, shared environmental factors, side effects of cancer therapies (e.g., radiotherapy,",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:31"
    }
  },
  {
    "page_content": "effects of cancer therapies (e.g., radiotherapy, chemotherapy), and increased survival rate and life expectancy in cancer patients. Different types of cancers may have similar genetic susceptibilities. A 2023 study in the US reported that breast cancer patients carrying three genes, BRCA1, BRCA2, and ERCC2, were up to 56% more likely to be diagnosed with SPNs. Genetic variants inherited can influence DNA damage repair mechanisms associated with diverse cancer predisposition syndromes, raising",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:32"
    }
  },
  {
    "page_content": "diverse cancer predisposition syndromes, raising the risk of SPNs over time. In addition to genetic factors, many environmental factors (e.g., smoking) are common risk factors for different types of cancers. Continued long‐term exposure to these risk factors in cancer survivors may result in a higher risk of subsequent primary neoplasms. Although cancer therapies can improve prognosis in cancer patients, they may also lead to adverse effects, such as the development of SPNs. Recent research",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:33"
    }
  },
  {
    "page_content": "such as the development of SPNs. Recent research suggested that radiation therapy could significantly elevate the likelihood of developing SPNs among patients with initial lung cancer, breast cancer, nasopharyngeal carcinoma, and prostate cancer. Previous studies reported that external beam radiation therapy, as a common and efficacious treatment for prostate cancer, was linked to a higher risk of developing SPNs of the bladder, lung, and rectum. In addition to their adverse effects, cancer",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:34"
    }
  },
  {
    "page_content": "In addition to their adverse effects, cancer therapies could increase life expectancy and survival, resulting in a higher chance of developing new primary neoplasms among cancer survivors. A study from the US reported that the cumulative incidence of SPNs increased from 7.2% at 5 years to 17.2% after 20‐year survival. The observed significant risk of SPNs in the present study may be explained by the above‐mentioned factors. According to the previous GPCR reports, cancers of the breast, stomach,",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:35"
    }
  },
  {
    "page_content": "GPCR reports, cancers of the breast, stomach, colorectum, prostate, lung, and esophagus were the most common malignancies in the Golestan population. Different reports from Golestan province suggested a very high incidence of upper gastrointestinal cancers and increasing trends in incidence rates of different types of cancers in this high‐risk area, mainly due to an increase in exposure to risk factors during recent decades. The results of the Golestan Cohort Study suggested that Golestan",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:36"
    }
  },
  {
    "page_content": "the Golestan Cohort Study suggested that Golestan residents were exposed to cancer‐related risk factors including drinking hot tea, indoor air pollution, drinking unpiped water, opium consumption, smoking, obesity, and agricultural pesticides, which may be related to different types of cancers. Additionally, similar to other studies, cancer survival in the Golestan province has been on the rise in recent years, primarily due to improvements in healthcare access and therapeutic services. Further",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:37"
    }
  },
  {
    "page_content": "access and therapeutic services. Further investigations are recommended to clarify the factors related to the high risk of SPNs among Golestan cancer patients. Regarding the high risk of developing new neoplasms in cancer patients, designing and implementing effective and efficient surveillance programs for cancer survivors should be considered a priority in healthcare systems, especially in high‐risk populations including Golestan province of Iran. As Golestan province is one of the 31",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:38"
    }
  },
  {
    "page_content": "of Iran. As Golestan province is one of the 31 provinces of Iran that makes up about 2% of Iran's total population, and regarding diverse lifestyle and genetic characteristics across different provinces, similar studies are recommended to investigate the epidemiological features of SPNs in other parts of Iran. Our findings showed a higher risk of SPNs among rural residents compared to urban populations, which is likely attributable to the interplay of socioeconomic disparities, lifestyle",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:39"
    }
  },
  {
    "page_content": "interplay of socioeconomic disparities, lifestyle factors, environmental exposures, and healthcare access issues. Limited access to healthcare resources and financial constraints in rural areas may contribute to delayed diagnosis and treatment of primary cancers, increasing the risk of SPN development. Additionally, rural populations may be more exposed to specific risk factors (e.g., agricultural risk factors, etc.), which are shared risk factors for different types of cancers, resulting in an",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:40"
    }
  },
  {
    "page_content": "for different types of cancers, resulting in an increase in the risk of SPNs. Further research is needed to better understand the underlying factors and develop targeted interventions to address this health disparity. Our findings showed that patients with ovary (SIR = 6.83) and prostate (SIR = 6.72) cancer have a greater chance of developing second primary cancer. Ovary cancer is ranked the eighth most prevalent cancer among women worldwide. Although the incidence rates have been declining in",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:41"
    }
  },
  {
    "page_content": "the incidence rates have been declining in certain regions, such as northern Europe and North America, some studies have shown that individuals diagnosed with ovarian cancer may be at elevated risk for the development of SPNs. A retrospective analysis of SEER data revealed a heightened incidence of SPNs among gynecological cancer survivors, underscoring the necessity for life‐long surveillance. Although current literature lacks specific data on the risk of SPNs in ovarian cancer patients,",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:42"
    }
  },
  {
    "page_content": "on the risk of SPNs in ovarian cancer patients, several factors may contribute to the increased risk of SPNs in this population, including genetic predisposition, common environmental risk factors, and treatment‐related effects. Recent advancements in ovarian cancer treatment have improved patients' survival rates, resulting in an increased risk of SPNs in ovarian cancer patients. Developing a second primary cancer in prostate cancer patients can be accounted for by prostate cancer treatment",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:43"
    }
  },
  {
    "page_content": "can be accounted for by prostate cancer treatment effects, particularly radiotherapy, which increases the risk of a second tumor among prostate cancer survivors. Despite advancements in radiotherapy techniques, the adverse effects of prostate cancer therapies, including second primary cancer among long‐term survivors, remain a concern. Additionally, genetic mutations and family history have been identified as risk factors for SPNs in prostate cancer cases. Prostate cancer is the second most",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:44"
    }
  },
  {
    "page_content": "cancer cases. Prostate cancer is the second most common cancer in men globally. In the Golestan province, Iran, prostate cancer incidence rates have risen from 8.4 per 100,000 in 2004 to 17.6 in 2016, with projections of reaching 25.0 in 2025. Given the high incidence and increasing trends of prostate cancer and the high risk of developing SPN in prostate cancer patients, appropriate surveillance programs should be developed for prostate cancer survivors in Golestan province. Our findings",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:45"
    }
  },
  {
    "page_content": "survivors in Golestan province. Our findings demonstrated that SPNs of the ovary and NHL were the most important second neoplasms among our cancer survivors. The risk of ovary neoplasm is more than 8‐fold higher among cancer survivors than in the general population. Developing ovary cancer as the second primary malignancy among cancer patients can be related to a shared genetic mutation. In other words, some cancer patients, for example, female breast cancer cases after 10 years of breast",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:46"
    }
  },
  {
    "page_content": "breast cancer cases after 10 years of breast cancer diagnosis, may carry a specific germline mutation that is consistent with ovary cancer. Moreover, the common risk factors between breast and ovary cancers, including hormones and dietary factors, can affect the occurrence of the SPN of ovary among cancer patients. We also found a significantly higher risk of NHL among cancer survivors when compared to the general population. Large tumors and their treatment can weaken the immune system, making",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:47"
    }
  },
  {
    "page_content": "treatment can weaken the immune system, making it more susceptible to new cancers. This increased risk is particularly evident for NHL, especially after therapies targeting the bone marrow, a common side effect in lymphohematopoietic malignancies. The main study limitation includes short‐term follow‐up, with a median follow‐up time of 3.4 years, and consequently a small number of SPN across sub‐populations. The GPCR was a relatively newly established cancer registry (started in 2004), and this",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:48"
    }
  },
  {
    "page_content": "cancer registry (started in 2004), and this was the main reason for short‐term follow‐up in the present study. By continuing the GPCR activity in the next years, more comprehensive findings with long‐term follow‐up data and a larger number of SPNs may be presented in future GPCR reports. In conclusion, our findings suggest that cancer patients are at higher risk of getting a new primary cancer when compared to the general population. Designing and implementing comprehensive surveillance",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:49"
    }
  },
  {
    "page_content": "and implementing comprehensive surveillance programs for cancer survivors should be considered in health policy‐making, especially in high‐risk populations including the Golestan province of Iran. Cancer patients with a higher risk of SPNs, including those with ovary and prostate cancers, should be considered a top priority. Further investigations are warranted to clarify the epidemiological aspects and risk factors of SPNs, as well as to design the most effective surveillance programs for",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:50"
    }
  },
  {
    "page_content": "the most effective surveillance programs for cancer survivors. # Author Contributions Susan Hasanpour‐Heidari: data curation (equal), formal analysis (equal), writing – original draft (equal). Shahryar Semnani: investigation (equal), project administration (equal), writing – review and editing (equal). Abdolreza Fazel: investigation (equal), project administration (equal), writing – review and editing (equal). Mohammad Naeimi‐Tabiei: investigation (equal), methodology (equal), writing – review",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:51"
    }
  },
  {
    "page_content": "(equal), methodology (equal), writing – review and editing (equal). Mahshid Mehrjerdian: investigation (equal), methodology (equal), writing – review and editing (equal). SeyedMehdi Sedaghat: methodology (equal), validation (equal), writing – review and editing (equal). Hamideh Sadeghzadeh: methodology (equal), validation (equal), writing – review and editing (equal). Faezeh Salamat: data curation (equal), investigation (equal), writing – review and editing (equal). Nastaran Jafari‐Delouei:",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:52"
    }
  },
  {
    "page_content": "and editing (equal). Nastaran Jafari‐Delouei: data curation (equal), investigation (equal), writing – review and editing (equal). Fatemeh Ghasemi‐Kebria: data curation (equal), investigation (equal), writing – review and editing (equal). Honeyehsadat Mirkarimi: data curation (equal), investigation (equal), writing – review and editing (equal). Nesa Shokouhifar: data curation (equal), investigation (equal), writing – review and editing (equal). Behnoush Abedi‐Ardekani: methodology (equal),",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:53"
    }
  },
  {
    "page_content": "Behnoush Abedi‐Ardekani: methodology (equal), validation (equal), writing – review and editing (equal). Elisabete Weiderpass: supervision (equal), validation (equal), writing – review and editing (equal). Gholamreza Roshandel: conceptualization (equal), formal analysis (equal), writing – original draft (equal). Reza Malekzadeh: conceptualization (equal), supervision (equal), writing – review and editing (equal). # Conflicts of Interest The authors declare no conflicts of interest. # Supporting",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:54"
    }
  },
  {
    "page_content": "declare no conflicts of interest. # Supporting information",
    "metadata": {
      "source": "../data/plain/PMC12090201.plain.txt",
      "id": "../data/plain/PMC12090201.plain.txt:55"
    }
  },
  {
    "page_content": "Effects of the COVID-19 Pandemic on Cancer-Related Patient Encounters Abstract\nPURPOSE\nWhile there are studies under way to characterize the direct effects of the COVID-19 pandemic on the care of patients with cancer, there have been few quantitative reports of the impact that efforts to control the pandemic have had on the normal course of cancer diagnosis and treatment encounters.\nMETHODS",
    "metadata": {
      "source": "../data/plain/PMC7444638.plain.txt",
      "id": "../data/plain/PMC7444638.plain.txt:0"
    }
  },
  {
    "page_content": "We used the TriNetX platform to analyze 20 health care institutions that have relevant, up-to-date encounter data. Using this COVID and Cancer Research Network (CCRN), we compared cancer cohorts identified by querying encounter data pre-COVID (January 2019-April 2019) and current (January 2020-April 2020). Cohorts were generated for all patients with neoplasms (malignant, benign, in situ, and of unspecified behavior), with new incidence neoplasms (first encounter), with exclusively malignant",
    "metadata": {
      "source": "../data/plain/PMC7444638.plain.txt",
      "id": "../data/plain/PMC7444638.plain.txt:1"
    }
  },
  {
    "page_content": "(first encounter), with exclusively malignant neoplasms, and with new incidence malignant neoplasms. Data from a UK institution were similarly analyzed. Additional analyses were performed on patients with selected cancers, as well as on those having had cancer screening.",
    "metadata": {
      "source": "../data/plain/PMC7444638.plain.txt",
      "id": "../data/plain/PMC7444638.plain.txt:2"
    }
  },
  {
    "page_content": "RESULTS",
    "metadata": {
      "source": "../data/plain/PMC7444638.plain.txt",
      "id": "../data/plain/PMC7444638.plain.txt:3"
    }
  },
  {
    "page_content": "Clear trends were identified that suggest a significant decline in all current cohorts explored, with April 2020 displaying the largest decrease in the number of patients with cancer having encounters. Of the cancer types analyzed, lung, colorectal, and hematologic cancer cohorts exhibited smaller decreases in size in April 2020 versus 2019 (−39.1%, −39.9%, −39.1%, respectively) compared with cohort size decreases for breast cancer, prostate cancer, and melanoma (−47.7%, −49.1%, −51.8%,",
    "metadata": {
      "source": "../data/plain/PMC7444638.plain.txt",
      "id": "../data/plain/PMC7444638.plain.txt:4"
    }
  },
  {
    "page_content": "cancer, and melanoma (−47.7%, −49.1%, −51.8%, respectively). In addition, cancer screenings declined drastically, with breast cancer screenings dropping by −89.2% and colorectal cancer screenings by −84.5%.",
    "metadata": {
      "source": "../data/plain/PMC7444638.plain.txt",
      "id": "../data/plain/PMC7444638.plain.txt:5"
    }
  },
  {
    "page_content": "CONCLUSION\nTrends seen in the CCRN clearly suggest a significant decrease in all cancer-related patient encounters as a result of the pandemic. The steep decreases in cancer screening and patients with a new incidence of cancer suggest the possibility of a future increase in patients with later-stage cancer being seen initially as well as an increased demand for cancer screening procedures as delayed tests are rescheduled.",
    "metadata": {
      "source": "../data/plain/PMC7444638.plain.txt",
      "id": "../data/plain/PMC7444638.plain.txt:6"
    }
  },
  {
    "page_content": "Polygenic risk scores, radiation treatment exposures and subsequent cancer risk in childhood cancer survivors Abstract",
    "metadata": {
      "source": "../data/plain/PMC11029534.plain.txt",
      "id": "../data/plain/PMC11029534.plain.txt:0"
    }
  },
  {
    "page_content": "Survivors of childhood cancer are at increased risk for subsequent cancers attributable to late effects of radiotherapy and other treatment exposures, but further understanding of the impact of genetic predisposition on risk is needed. Combining genotype data for 11,220 five-year survivors from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort we found that cancer-specific polygenic risk scores (PRSs) derived from general population GWAS cancer loci identified survivors of",
    "metadata": {
      "source": "../data/plain/PMC11029534.plain.txt",
      "id": "../data/plain/PMC11029534.plain.txt:1"
    }
  },
  {
    "page_content": "GWAS cancer loci identified survivors of European ancestry at increased risk of subsequent basal cell carcinoma (BCC; odds ratio per PRS standard deviation 1.37, 95% CI 1.29–1.46), female breast cancer (1.42, 1.27–1.58), thyroid cancer (1.48, 1.31–1.67), squamous cell carcinoma (1.20, 1.00–1.44), and melanoma (1.60, 1.31–1.96), but the association for colorectal cancer was not significant (1.19, 0.94–1.52). Investigation of joint associations between PRS and radiotherapy found",
    "metadata": {
      "source": "../data/plain/PMC11029534.plain.txt",
      "id": "../data/plain/PMC11029534.plain.txt:2"
    }
  },
  {
    "page_content": "associations between PRS and radiotherapy found more-than-additive increased risks of BCC, breast, and thyroid cancers. For survivors with radiotherapy exposure, the cumulative incidence of subsequent cancer by age 50 years was increased for those with high versus low PRS. These findings suggest a degree of shared genetic etiology for these malignancy types in the general population and survivors that remains evident in the context of strong radiotherapy-related risk.",
    "metadata": {
      "source": "../data/plain/PMC11029534.plain.txt",
      "id": "../data/plain/PMC11029534.plain.txt:3"
    }
  },
  {
    "page_content": "Overview of virus and cancer relationships. Position paper Abstract",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:0"
    }
  },
  {
    "page_content": "The role of certain viruses in the etiology of some tumors is today indisputable, but there is a lack, however, of an overview of the relationship between viruses and cancer with a multidisciplinary approach. For this reason, the Health Sciences Foundation has convened a group of professionals from different areas of knowledge to discuss the relationship between viruses and cancer, and the present document is the result of these deliberations. Although viruses cause only 10-15% of cancers,",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:1"
    }
  },
  {
    "page_content": "Although viruses cause only 10-15% of cancers, advances in oncology research are largely due to the work done during the last century on tumor viruses. The clearest cancer-inducing viruses are: HPV, HBV, HCV, EBV and, depending on the geographical area, HHV-8, HTLV-1 and HIV. HPVs, for example, are considered to be the causative agents of cervical carcinomas and, more recently, of a proportion of other cancers. Among the Herpes viruses, the association with the development of neoplasms is well",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:2"
    }
  },
  {
    "page_content": "with the development of neoplasms is well established for EBV and HHV-8. Viruses can also be therapeutic agents in certain neoplasms and, thus, some oncolytic viruses with selective tropism for tumor cells have been approved for clinical use in humans. It is estimated that the prophylaxis or treatment of viral infections could prevent at least 1.5 million cancer deaths per year. # INTRODUCTION The success in human longevity achieved in recent decades is impressive and could be even greater if",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:3"
    }
  },
  {
    "page_content": "is impressive and could be even greater if the major challenges of neurodegenerative diseases, cardiovascular disease and cancer could be controlled. Of the three challenges above, cancer treatment is perhaps achieving more success than the other two, not only because of better prevention and earlier diagnosis, but also because of increasingly effective and better-tolerated treatment. Viruses offer a first approximation to the aetiological diagnosis in the case of cancer and the role some of",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:4"
    }
  },
  {
    "page_content": "in the case of cancer and the role some of them play in the pathogenesis of certain tumours is today indisputable. Their prevention, such as in the case of HPV and cervical cancer, has radically changed our expectations for the future and allows us to envision the eradication of this tumour. Unfortunately, the virus-cancer relationship is not so clear-cut in many other tumours and when we look for global data on that relationship, we find scattered and inaccurate, irregular literature of a very",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:5"
    }
  },
  {
    "page_content": "and inaccurate, irregular literature of a very uneven nature and quality. For this reason, the Health Sciences Foundation has proposed examining the virus-cancer relationship more generally, in a multidisciplinary forum, aiming to obtain answers to a series of simple questions from experts in different aspects of the problem. This meeting has included oncologists, gastroenterologists, internists, gynaecologists, specialists in infectious diseases and HIV, microbiologists, basic biologists,",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:6"
    }
  },
  {
    "page_content": "and HIV, microbiologists, basic biologists, representatives of patient associations and the media, and specialists in preventive medicine and ethics. A first block of questions was aimed at putting the dimension of the Virus-Cancer relationship, the cancers most clearly caused by viruses, the great historical milestones of this relationship and some aspects of oncogenesis into perspective. In a second block, some potential solutions ranging from vaccines to the treatment of hepatitis C were",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:7"
    }
  },
  {
    "page_content": "vaccines to the treatment of hepatitis C were addressed and the possible role of bacteria and parasites as alternative oncogenic agents was also discussed. We also wanted to understand the importance that cancer patient associations place on this relationship, the understanding that the media has of the problem and the ethical aspects that all this raises. # MATERIAL AND METHODS The members of the Board of Trustees of the Health Sciences Foundation proposed a series of questions on the",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:8"
    }
  },
  {
    "page_content": "Foundation proposed a series of questions on the relationship between viruses and cancer that would answer the main uncertainties of the problem at present. The questions were accepted by a multidisciplinary panel of experts. Each question was reported by one of the experts and subsequently the text and its conclusions were discussed by the working group until conclusions were reached that were accepted by all. We now turn to the questions and their development. The views expressed are not",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:9"
    }
  },
  {
    "page_content": "their development. The views expressed are not intended to set out any particular recommendation or therapeutic indication and represent only the opinion of the group’s speakers and not necessarily that of the institutions in which they work. # QUESTION: WHAT ARE THE MAJOR HISTORICAL MILESTONES IN THE VIRUS AND CANCER RELATIONSHIP? In the early 1970s, most tumours were assumed to be caused by viruses, so much of the research into cancer revolved around tumour viruses. This assumption was",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:10"
    }
  },
  {
    "page_content": "around tumour viruses. This assumption was eventually discarded and today it is estimated that only 10-15% of cancers are caused by viruses. However, research into viruses and cancer, the milestones of which are summarised below, proved decisive in understanding the aetiology of the disease [1-4]. ## Discovery of the avian sarcoma virus In the early 1900s, Peyton Rous, working at the Rockefeller Institute in New York, showed that a type of sarcoma affecting chickens was transmissible through",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:11"
    }
  },
  {
    "page_content": "affecting chickens was transmissible through homogenate filtrates that could only contain viruses. Years later, the causative virus was isolated and named Rous Sarcoma Virus (RSV). This discovery marks the beginning of research into tumour viruses. ## Transformation in cell cultures During the 1960s, Harry Rubin and Howard Temin managed to establish a new experimental model to study tumour viruses at the California Institute of Technology. It consisted of the infection of fibroblasts in culture",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:12"
    }
  },
  {
    "page_content": "of the infection of fibroblasts in culture with the Rous Sarcoma Virus. The infection caused radical changes in the phenotype of the cells, which acquired capacities characteristic of tumour cells, such as: reduced dependence on growth factors, immortality, anchorage-independent growth, motility, invasiveness, loss of contact inhibition, metabolic reprogramming and the ability to form tumours in syngeneic or immunosuppressed mice. These changes were called cellular transformation. The new",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:13"
    }
  },
  {
    "page_content": "were called cellular transformation. The new experimental system ushered in a new era in tumour virus research. ## Discovery of DNA tumour viruses In 1960, at the Rockefeller Institute in New York, Richard Shope identified the virus that causes papillomas in rabbits. Papillomas are benign tumours that rarely progress to squamous cell carcinomas of the skin. Unlike Rous Sarcoma Virus, whose genetic material is RNA, papillomaviruses are made of DNA. There are currently more than 100 human",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:14"
    }
  },
  {
    "page_content": "of DNA. There are currently more than 100 human papillomaviruses (HPV) described. The discovery of HPV was followed by the discovery of more tumour viruses whose genetic material is DNA, including: i) Polyomavirus, which when infecting mice caused tumours of various origins, hence its name, ii) Simian Virus 40 (SV40), which is a lytic virus in some primate cell types and silent in rodent cells and is therefore called non-permissive. In non-permissive cells, SV40 produces cellular",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:15"
    }
  },
  {
    "page_content": "In non-permissive cells, SV40 produces cellular transformation, although at a very low frequency [7-9]. Papillomavirus, polyomavirus, and SV40 are known as papovaviruses. Their DNA is a small circular molecule. Other viruses with oncogenic capabilities include: i) Adenovirus, which infects the airways and can produce tumours when it infects hamster cells, ii) Herpesvirus, which produces different tumours in human cells, iii) Epstein Barr Virus (EBV), which can produce Burkitt’s lymphomas or",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:16"
    }
  },
  {
    "page_content": "(EBV), which can produce Burkitt’s lymphomas or nasopharyngeal carcinomas. Compared to the papovaviruses, the latter three are very large. ## Integration of the virus into the host cell genome Several lines of evidence showed that the tumour viruses had to remain active in the tumour cells to maintain the transformed phenotype. The inactivation of the virus produced a return to the normal cellular state. Different viruses use different mechanisms to keep tumour cells from dividing after",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:17"
    }
  },
  {
    "page_content": "to keep tumour cells from dividing after division. Some, like EBV or HPV, become integrated, becoming a part of the cell genome. Almost all cervical tumours are produced by HPVs, which make up the part of their genome necessary for cell transformation (the E6 and E7 oncogenes). Herpesviruses use two strategies to perpetuate their genome in tumour cells. Some, such as human herpesvirus-6 (HHV-6) integrate into the telomeric regions of the chromosomes, which are transcriptionally silenced, making",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:18"
    }
  },
  {
    "page_content": "which are transcriptionally silenced, making the virus able to remain latent for long periods of time. Others, such as the herpesvirus that produces Kaposi’s sarcoma (HHV-8), replicate episodically, i.e., extrachromosomally, but are able to bind to chromosomes temporarily to ensure replication. While DNA virus integration solved how they could remain in the tumour cells, it created a seemingly unsolvable problem. How did RNA viruses like Rous Sarcoma Virus remain? The solution to this problem",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:19"
    }
  },
  {
    "page_content": "Virus remain? The solution to this problem led to one of the most surprising discoveries in biology: retrotranscription. Howard Temin and David Baltimore showed that RNA viruses copy their genome into double-stranded DNA, which integrates into the host cell’s genome. Retrotranscription violated the dogma proposed by Francis Crick by which the flow of biological information follows the DNA-RNA-Protein direction. In fact, retrotranscription is a mandatory step in the life cycle of retroviruses;as",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:20"
    }
  },
  {
    "page_content": "step in the life cycle of retroviruses;as the RNA viruses that undergo this process are called. In contrast, the integration of DNA viruses is a very rare event (< 1 in 1,000 infections). ## Identifying the first of a long list of oncogenes Rous Sarcoma Virus, like most retroviruses, has a reduced genome (~10 kb). In it are encoded the genes necessary for its retrotranscription and integration, as well as the proteins that form part of its capsid. This simplicity made them very useful tools in",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:21"
    }
  },
  {
    "page_content": "This simplicity made them very useful tools in identifying the elements required for cell transformation. By comparing viral variants capable of replication but not transformation, with variants capable of transformation but not replication, it was concluded that a single gene, called src, was responsible for cell transformation. Characterising the src oncogene, in 1974 Harold Varmus and Michael Bishop, working at the University of California, San Francisco, obtained a totally unexpected result",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:22"
    }
  },
  {
    "page_content": "Francisco, obtained a totally unexpected result [11-13]. They found copies of src in cells that had not been transformed by Rous Sarcoma Virus. Actually, src is a gene present in totally normal cells that was hijacked by the tumour virus Rous Sarcoma Virus. This result was an authentic revolution and led to several conclusions that have revolutionised the way we think about cancer, some of which are detailed below:",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:23"
    }
  },
  {
    "page_content": "The cellular version of src, known as c-src had to play a role in the homeostasis of healthy cells.An ancestral form of the Rous Sarcoma Virus acquired the src after infecting a normal cell. In fact, there is ALV (avian leukosis virus) which is infectious but not tumoral and has the same genes as Rous Sarcoma Virus, except src.The identification of c- and v-src opened the possibility that in the normal genome there were numerous proto-onco-genes that could have been co-opted by other tumour",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:24"
    }
  },
  {
    "page_content": "that could have been co-opted by other tumour retro-viruses.A single oncogene, v-src was sufficiently pleiotropic to modify the 20-30 characteristics that differentiate a normal cell from a tumour cell. The discovery of src initiated a race to identify oncogenes carried by retroviruses, which led to the characterisation of oncogenes involved in the pathogenesis of numerous tumours. These are two examples:",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:25"
    }
  },
  {
    "page_content": "The avian myelomatosis virus, which produces transformation of marrow cells by means of the v-myc oncogene. In this case the original non-tumour virus was also the AVL.The Harvey and Kirsten sarcoma viruses, which led to the identification of the H-Ras and K-Ras oncogenes. Currently the list of oncogenes associated with retroviruses exceeds two dozen. # QUESTION: AT PRESENT, WHAT PROPORTION OF MALIGNANT TUMOURS IN GENERAL HAVE A PROVEN OR PROBABLE CAUSALITY IN A VIRAL INFECTION? It is accepted",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:26"
    }
  },
  {
    "page_content": "CAUSALITY IN A VIRAL INFECTION? It is accepted that one out of six tumours in the world is probably associated with an infection. It is important to highlight that in the series published on this subject, the sources of information and the criteria for detecting infectious agents are heterogeneous and this conditions the reliable approach to the subject. It should be noted that the role of the virus as an aetio-logical agent of tumours is conditioned by its prevalence, by its detection methods",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:27"
    }
  },
  {
    "page_content": "by its prevalence, by its detection methods and by the estimation of the attributable risk in exposed populations. The accuracy of the measurement of exposure is critical as it ensures that the different methods for calculating attributable risk provide results that are compatible with reality. The experience of the “Global burden of cancers attributable to liver flukes” group shows that infections capable of becoming carcinogenic have demonstrated that biomarkers that are sensitive and capable",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:28"
    }
  },
  {
    "page_content": "that biomarkers that are sensitive and capable of distinguishing high-risk from low-risk infections are essential in elucidating the true strength of their role in cancer. An additional aspect that supports the robustness of the contributions is that three main groups of infectious agents and cancer modalities were used for the estimation of tumours attributable to the infection. Firstly, cancer sites where infectious agents are assumed to contribute to almost 100% of all cases (cervical cancer",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:29"
    }
  },
  {
    "page_content": "to almost 100% of all cases (cervical cancer due to high-risk HPV). Secondly, cancer sites attributable to infection whenever the infectious agent is detected in the tumour tissue using sensitive and validated detection methods (oral, oropharyngeal, anal, laryngeal, vulvar, vaginal and penile cancers due to high-risk HPV; nasopharyngeal cancers, Hodgkin’s and non-Hodgkin’s lymphomas due to EBV and - although it is a bacterial infection - gastric MALT lymphoma due to H. pylori). Thirdly, cancer",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:30"
    }
  },
  {
    "page_content": "MALT lymphoma due to H. pylori). Thirdly, cancer cases where infectious agents increase the risk of developing a tumour, but are not responsible for all new cancer cases, even when antibodies to the infectious agent are detected in the serum. The proportion of new cancer cases in France associated with infectious agents is comparable to that of other high-income countries. The estimates of this study are overall slightly higher (4.1%) than those of the specific analyses for the United Kingdom",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:31"
    }
  },
  {
    "page_content": "of the specific analyses for the United Kingdom and Australia in 2010, where gender categorisation showed that 2.5% and 2.4% of all new cancer cases among men were attributable to infectious agents in both countries, respectively, and 3.5% and 3.7% of all new cancer cases among women were also attributable to infectious agents. These differences with previous studies are due, in part, to differences in the risk of infection between areas, as well as differences in what is considered the gold",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:32"
    }
  },
  {
    "page_content": "as differences in what is considered the gold standard for measuring the prevalence of infection in association with specific cancers. There are important global differences, depending on health and sociocultural conditions, in how these infections are responsible for tumour genesis. Thus, in Australia and New Zealand the infectious origin of a cancer is in 3.3% of cases compared to 32.7% in Sub-Saharan Africa. Improving the quality and quantity of knowledge seems essential so as to prioritise",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:33"
    }
  },
  {
    "page_content": "of knowledge seems essential so as to prioritise preventive programmes and reduce the disease burden. # QUESTION: WHICH ARE THE TUMOURS WITH THE MOST CLEARLY DEMONSTRATED VIRAL AETIOLOGY? Infections by certain microorganisms (viruses, bacteria, and parasites) are risk factors for developing certain cancers. According to the latest update of the IARC monograph on biological agents associated with cancer, the following micro-organisms were classified as carcinogenic (group 1) (Table 1). #",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:34"
    }
  },
  {
    "page_content": "classified as carcinogenic (group 1) (Table 1). # QUESTION: IS IT POSSIBLE TO BROADLY UNDERSTAND THE PATHOGENESIS OF VIRUS-MEDIATED ONCOGENESIS? WHAT ARE BRADFORD HILL’S PRINCIPLES OF CAUSALITY? As described above, viruses can transform normal cells into tumour cells by activating oncogenes. In some cases, such as Rous Sarcoma Virus, the virus itself contains the oncogene. In others, such as EBV, the virus causes the proliferation of lymphoid cells that eventually remodel their genome so that",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:35"
    }
  },
  {
    "page_content": "that eventually remodel their genome so that the expression of the c-Myc oncogene becomes aberrantly high. HPVs integrate pieces of their genome randomly into cells. When these pieces include the oncogenes E6 and E7, they transform the cells, as happens in the vast majority of cervical and some oropharyngeal tumours [2-4, 7, 14, 25-31]. In 1965, Sir Austin Bradford Hill listed nine principles that must be demonstrated epidemiologically in order to establish a causal relationship between an",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:36"
    }
  },
  {
    "page_content": "to establish a causal relationship between an event and the observed effect. Bradford Hill’s principles of causality have been used frequently in public health research. None of the principles proves a causal relationship per se; the more principles are fulfilled, the more the notion of a causal relationship is strengthened. Of particular relevance was the application of Bradford Hill principles in the demonstration of the causal relationship between tobacco use and cancer. The following is a",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:37"
    }
  },
  {
    "page_content": "tobacco use and cancer. The following is a list of principles and how they demonstrate the recently proposed cause-and-effect relationship between HPV and oropharyngeal tumours:",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:38"
    }
  },
  {
    "page_content": "The power of the association. While a small association does not mean that there is no causal effect, a larger association makes it more plausible. For example, the risk of oral squamous cell cancer is 2.8 times higher in patients infected with certain strains of HPV.Consistency. If the findings of different observers in different populations are consistent, the probability of causality increases. Different independent studies, conducted in entirely different populations, came to the same",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:39"
    }
  },
  {
    "page_content": "entirely different populations, came to the same conclusion about the relationship between HPV and oral cancers.Specificity. HPV is associated with oropharyngeal cancers, where HPV infections have been identified.Temporality. The effect has to occur after the cause. HPV infections precede the development of oropharyngeal tumours. In fact, the longer the infection has lasted, the greater the risk of cancer.Biological gradient. Greater exposure should generally lead to greater incidence of the",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:40"
    }
  },
  {
    "page_content": "should generally lead to greater incidence of the effect. However, in some cases, the mere presence of the factor can trigger the effect. In the case of HPV infections the gradation is difficult to establish.Plausibility. A mechanism that explains how the cause can generate the possible effect is very useful, although it depends on the state of our knowledge. The fact that HPV contains oncogenes, whose action mechanism is very well characterised, increases the possibilities of a causal",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:41"
    }
  },
  {
    "page_content": "increases the possibilities of a causal relationship.Coherence. Coherence between epidemiological and laboratory findings increases the likelihood of causality. HPV oncogenes can transform cells in the laboratory.Experimental evidence. It’s very much related to the previous point. There is ample experimental evidence of the ability of HPV to direct malignant transformation in various experimental models.Analogy. The effect is seen in analogous situations. Certain oncogenic variants of HPV, such",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:42"
    }
  },
  {
    "page_content": "Certain oncogenic variants of HPV, such as HPV16, have a clear causal relationship with oral cancer, while very low tumourigenic variants are difficult to find in this type of tumour. # QUESTION: HOW COULD THE INVOLVEMENT OF HPV IN GENITAL TUMOURS BE SUMMED UP IN FIGURES? HPV is one of the main causative agents of cancer as it is implicated in 4.5% (640,000 cases) of all new cancer cases worldwide each year (8.6% women; 0.9% men). It is estimated that in 2012 it caused more than half of all",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:43"
    }
  },
  {
    "page_content": "that in 2012 it caused more than half of all cancers attributable to infections in women (570,000 cases). The vast majority of HPV-related neoplasms develop in the anogenital tract (primarily cancer of the cervix and less frequently cancer of the vagina, vulva, and anus). High quality cancer incidence data are essential. Such information is currently only available to a small fraction of the world’s population. The absence of this information may lead to a misinterpretation of the actual",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:44"
    }
  },
  {
    "page_content": "may lead to a misinterpretation of the actual disease burden, as well as to a possible delay or neglect in the implementation of preventive measures or an impossibility to evaluate such measures. # QUESTION: WHAT WOULD BE THE IMPACT OF HPV AS A CAUSAL AGENT OF EXTRAGENITAL TUMOURS? Beyond anogenital locations, HPV is associated with head and neck cancer The term “head and neck cancer” has been widely adopted in recent literature to include lesions at several anatomical sites: the lip, oral",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:45"
    }
  },
  {
    "page_content": "at several anatomical sites: the lip, oral cavity, nose and sinuses, nasopharynx, oropharynx, hypopharynx, and larynx. HPV is predominantly associated with oropharyngeal cancer and within that with tonsil cancer. The classic risk factors for head and neck cancer are tobacco and alcohol use, but recent decades have seen an increase in the proportion of HPV-associated oropharyngeal cancer cases. This increase may be due to changes in sexual behaviour as well as a decrease in the prevalence of",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:46"
    }
  },
  {
    "page_content": "as well as a decrease in the prevalence of smoking. Annually, 24,000 new cases of HPV-associated oropharyngeal cancer are diagnosed in men and 5,500 in women. Globally, the proportion of HPV-associated cases in oropharyngeal cancer is 30% (and of the tonsil about 50%) with a large difference depending on countries-regions, being more than 80% in countries such as the USA or Northern Europe, and less than 10% in countries in Africa or other regions. HPV 16 is the most prevalent type found in",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:47"
    }
  },
  {
    "page_content": "HPV 16 is the most prevalent type found in more than 80% of HPV-positive tumours. It should be noted that HPV-related oropharyngeal cancers differ from unrelated cancers in both epidemiological and clinical and molecular characteristics. Patients with positive HPV16 tumours appear to have better overall and disease-specific survival compared to the negative group. Laryngeal squamous cell papilloma and recurrent respiratory papillomatosis are well established HPV-induced tumours, primarily 6 and",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:48"
    }
  },
  {
    "page_content": "established HPV-induced tumours, primarily 6 and 11. # QUESTION: IS IT POSSIBLE TO MEASURE THE IMPACT OF THE HEPATITIS B AND C VIRUSES ON THE INCIDENCE OF LIVER TUMOURS? Within the natural history of chronic hepatitis of viral origin, the chronic hepatitis-cirrhosis-cancer sequence has been well known for decades. This incontrovertible data allows us to pose different questions of great relevance, such as whether it is possible to know the epidemiological impact of this association. The",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:49"
    }
  },
  {
    "page_content": "epidemiological impact of this association. The question is not simple; unlike the unidirectional and almost linear relationship between other types of viral infection and the development of cancer, the oncogenic capacity of hepatotropic viruses is modulated by different factors, as listed below. i) Cirrhosis is an oncogenic element “per se” A differential and characteristic data of hepatocellular carcinoma is that in more than 85 % of cases it occurs in a liver affected by cirrhosis.",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:50"
    }
  },
  {
    "page_content": "cases it occurs in a liver affected by cirrhosis. Strikingly, it is common to find hepatocellular carcinoma in patients with cirrhosis of non-viral cause (such as alcoholism and particularly metabolic fatty liver disease). This fact, besides having a marked influence on the treatment strategy, indicates that the mechanisms associated with the development of cirrhosis (inflammation, angio-genesis, fibrogenesis, etc.) generate a micro-environment with its own oncogenic potential independent of",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:51"
    }
  },
  {
    "page_content": "with its own oncogenic potential independent of the viral infection itself. ii) Each virus has its own oncogenic potential Regardless of the relatively similar natural history of chronic hepatitis associated with virus B and virus C, both viruses are very different in terms of their own character (DNA or RNA virus), their replicative cycle (with or without integration into the host cell genome) and the different degrees of production of necrosis, oxidative stress, expression of viral proteins",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:52"
    }
  },
  {
    "page_content": "oxidative stress, expression of viral proteins etc. Furthermore, the relationship between the intensity of viral replication and the risk of cancer is clearly different; while it is clear in virus B, it does not exist in the case of virus C. Finally, the possibility of liver cancer in patients without cirrhosis is markedly more frequent in patients with hepatitis B, especially in Asia. iii) There are significant geographical differences The contribution of the different risk factors linked to",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:53"
    }
  },
  {
    "page_content": "of the different risk factors linked to the development of hepatocellular carcinoma has clear geographical differences that are related to the most frequent cause(s) of cirrhosis in each area. Thus, the incidence of hepatocellular carcinoma in Europe is mostly associated with patients with cirrhosis due to virus C, while in Asia this association is with virus B (Table 2). iv) Chronic viral infection is associated with other risk conditions It is well known that the progression of chronic liver",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:54"
    }
  },
  {
    "page_content": "well known that the progression of chronic liver disease is affected by different factors that are often present in patients with viral origin chronic liver disease, such as alcohol consumption, the presence of metabolic syndrome, or tobacco use. It should be noted that they are all well-known co-factors involved in the development of cancer. Therefore, the precise contribution of each of the factors involved (viral and non-viral) in the development of liver neoplasms is difficult to define. In",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:55"
    }
  },
  {
    "page_content": "of liver neoplasms is difficult to define. In any case, there is no doubt that both by direct and indirect mechanisms (through the presence of cirrhosis, as mentioned above) the association between hepatotropic viruses and liver cancer is of unquestionable relevance, being possibly responsible for more than 60% of primary liver tumours. # QUESTION: WHAT HAVE HTLV-I AND HIV MEANT AS DIRECT OR INDIRECT CANCER-CAUSING AGENTS? HTLV-1 and HIV are two viruses first described in the 1980s and directly",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:56"
    }
  },
  {
    "page_content": "viruses first described in the 1980s and directly or indirectly involved in human oncogenesis. Both share the same transmission routes (breast milk, sexual relations, blood products), the integration of their genome into the T cell and a long latency period, more pronounced in the HTLV-1, between infection and disease development. ## Human T lymphotropic virus type 1 (HTLV-1) HTLV-1 infects 10-20 million people worldwide and its main geographical distribution is Japan, the Caribbean, South",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:57"
    }
  },
  {
    "page_content": "distribution is Japan, the Caribbean, South America and sub-Saharian Africa. Only 5% of infected people develop disease and the 2 conditions that it causes are adult T-cell leukaemia-lymphoma (ATL) and HTLV-1-associated myelopathy or tropical spastic paraparesis. People with HTLV-1 positive serology have a 2-5% risk of developing ATL over their lifetime. The risk is greater in males and typically appears 4-5 decades after infection in subjects who acquire it in childhood, with rare occurrence",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:58"
    }
  },
  {
    "page_content": "who acquire it in childhood, with rare occurrence in those who become infected in adulthood. The HTLV-1 genome is composed of a single strand of RNA that is integrated into the cell. It then expresses 2 oncogenic proteins: the transcriptional transactivator protein (Tax) and the HBZ protein. Both proteins, Tax and HBZ, are specifically and directly involved in oncogenesis with Tax being the initiator of tumour genesis and HBZ being in charge of maintenance. ATL is characterised by a clonal",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:59"
    }
  },
  {
    "page_content": "of maintenance. ATL is characterised by a clonal proliferation of CD4+ T cells with the HTLV-1 integrated. These cells, morphologically, have a dentate nucleus with dense chromatin and basophilic (flower-like) cytoplasm. There are 4 clinical forms, the characteristics if which are summarised in Table 3. Treatment is not very effective in any of the stages and, although in aggressive cases there is an initial response with chemotherapy, early relapses with fatal outcomes occur in short periods",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:60"
    }
  },
  {
    "page_content": "with fatal outcomes occur in short periods of time. The combination of AZT with interferon has been used in some patients with variable results. ## Human Immunodeficiency Virus (HIV) The origin of tumour diseases in patients with HIV infection is multifactorial, the most important factors being HIV itself, immunosuppression, co-infection with oncogenic viruses and increased survival due to the use of antiretroviral treatment (ART) (Figure 1). HIV is a necessary but not sufficient condition, as",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:61"
    }
  },
  {
    "page_content": "is a necessary but not sufficient condition, as it is not strictly considered an oncogenic virus. However, fragments of its genome have been found in some patients with NHL, and the tat gene appears to be involved in the growth of Kaposi’s sarcoma cells. For all these reasons, it is considered an essential agent, but not the only one for the development of the tumours that appear in these patients. Immunosuppression and uncontrolled HIV viremia increase the risk of developing neoplasms, such",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:62"
    }
  },
  {
    "page_content": "increase the risk of developing neoplasms, such that an undetectable viral load and CD4+ lymphocytes >500 per mm3 are factors that protect against the development of some tumours, which explains why a decrease in the number of AIDS-defining malignancies (ADM) has been observed with the use of ART. On the other hand, paradoxically, there is an increase in non-AIDS-defining malignancies (NADM) due, in part, to the increased survival of patients as a result of the use of ART, which prolongs life",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:63"
    }
  },
  {
    "page_content": "a result of the use of ART, which prolongs life without completely restoring immune function (Figure 2). All of this conditions a greater exposure to environmental carcinogens (tobacco, ultraviolet light), a greater possibility of superinfection by oncogenic viruses and an increase in the possibilities of genetic mutations appearing in patients with a family history of cancer, giving rise to the appearance of neoplasms that in other times did not develop due to the early mortality of the",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:64"
    }
  },
  {
    "page_content": "did not develop due to the early mortality of the patients (Figure 1). Another important point is that the presence of HIV causes a persistent stimulation of B lymphocytes, which alters anti-tumour immunity, facilitates the expression of oncogenic genes and allows superinfection by viruses with oncogenic capacity, such as EBV, HVH-8, HBV, HCV or HPV. All ADM are associated with viral diseases, as well as the most frequent ones within NADM except for pulmonary carcinoma directly related to",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:65"
    }
  },
  {
    "page_content": "for pulmonary carcinoma directly related to smoking (Figure 2) Table 4 shows the differences and similarities between HTLV-1 and HIV. # QUESTION: WHAT PROPORTION OF HIV PATIENTS WHO DIE DO SO BECAUSE OF AN HIV-ASSOCIATED NEOPLASM? Since the introduction of ART in 1996, mortality among people living with HIV (PLHIV) has decreased significantly (Figure 3) so that in 2016, 498 people died while in the initial years of the epidemic the numbers were much higher, reaching 5,857 deaths in 1995.",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:66"
    }
  },
  {
    "page_content": "were much higher, reaching 5,857 deaths in 1995. However, immune reconstitution is generally not complete, so patients are exposed to the effects of chronic inflammation and persistent immune activation. Both processes favour the appearance of the so-called non-AIDS diseases, whose importance has progressively increased in recent years and which are one of the main causes of morbidity and mortality among PLHIV. This broad group of diseases includes most comorbidities, which in some cases become",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:67"
    }
  },
  {
    "page_content": "most comorbidities, which in some cases become more important than the HIV infection itself. Among other processes, cardiovascular pathology, renal disease, osteoporosis and bone fractures, neurocognitive impairment and tumour pathology stand out. Malignant neoplasms are a major cause of hospitalisation and death in PLHIV as a result of ART use and a decrease in opportunistic infections. Today, cancer can be diagnosed in 25-40% of patients, and while in the pre-ART era only 10% of deaths were",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:68"
    }
  },
  {
    "page_content": "while in the pre-ART era only 10% of deaths were of tumour origin, now up to 30% are. In our environment, according to data from the CORIS cohort, neoplasms were the most frequent cause of death by non-AIDS diseases between 2004 and 2015. In this same study it is important to note that 38.2% of the tumours diagnosed were AIDS-defining malignancies (ADM) and 61.8% were non-AIDS-defining malignancies (NADM) (Table 5). At the EACS Congress, the results obtained from the review of neoplasms",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:69"
    }
  },
  {
    "page_content": "the results obtained from the review of neoplasms diagnosed from 1986 to 2018 in a Spanish centre were communicated. 643 out of 5,411 patients (12%) suffered at least one neoplasm. NADM increased over time with a decrease in the ADM/NADM ratio (Figure 4). 101 patients (15.9%) died due to tumour progression, with higher mortality among NADM 25.3% vs. ADM 10.6% (p<0.001). The highest mortality was seen in tumours of the pancreas (90%), lung (68%) and colon (69%). Another Spanish group analysed",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:70"
    }
  },
  {
    "page_content": "and colon (69%). Another Spanish group analysed the mortality in 157 PLHIV and found that 56 deaths were directly related to AIDS and 13 of them (23.2%) were due to a ADM. In the same series another 86 deaths occurred due to non-AIDS related processes and 14 (16.4%) were as a result of a NADM. Therefore, the overall mortality due to a neoplasm in this series was 17%. In other series outside our scope, the results are similar. Thus, Engels et al found that approximately 10% of deaths in PLHIV",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:71"
    }
  },
  {
    "page_content": "found that approximately 10% of deaths in PLHIV receiving ART during the period 1995 to 2009 were due to a neoplasm with a progressive increase over time. A large proportion of the deaths were due to non-Hodgkin’s lymphomas, lung cancer and hepatocellular carcinoma. As in our environment, it is observed that deaths due to NADM are increasing in importance while there is a decrease in the number of deaths due to AIDS itself. All these studies show a decrease in mortality from AIDS-indicating",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:72"
    }
  },
  {
    "page_content": "show a decrease in mortality from AIDS-indicating diseases and a predominance of deaths from non-AIDS diseases in recent years, with neoplasms being one of the most frequent causes in all the series, even though the patients are on ART and virologically suppressed. In Table 1 we see reflected the importance of death of tumour origin in PLHIV in other series different from those described in the text # QUESTION: WHAT IS THE INVOLVEMENT OF HERPESVIRUS IN THE CAUSALITY OF CANCER? The human herpes",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:73"
    }
  },
  {
    "page_content": "IN THE CAUSALITY OF CANCER? The human herpes virus (HHV) group includes herpes simplex virus (HSV) 1 and 2, varicella zoster virus (VZV), cytomegalovirus (CMV), Epstein Barr Virus (EBV), HHV-6, 7 and 8. In general, they are characterised by producing primary infection at an early age and subsequently establishing latency in different tissues, from which they are able to reactivate, producing clinical manifestations again. In Table 6 we have summarised their most frequent clinical",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:74"
    }
  },
  {
    "page_content": "6 we have summarised their most frequent clinical manifestations, including the tumour processes with which they have been associated. Involvement in tumour processes is well established for EBV and HHV-8, and we will devote most of our review to them [53-55]. The rest of the herpes viruses are not considered to directly cause any type of cancer, although their role as co-factors is discussed. For example, there is some evidence to suggest that HSV-2 may increase the risk of cervical cancer",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:75"
    }
  },
  {
    "page_content": "HSV-2 may increase the risk of cervical cancer after HPV infection and that it may play a role in the tumour genesis of serous ovarian carcinoma and in some prostate tumours. Associations between HHV6 and different tumours have also been sought, but these have not yet been confirmed. We will focus on the involvement of EBV in the development of tumour processes. EBV is the primary agent of infectious mononucleosis. It establishes latency asymptomatically in virtually all adults, in B cells, T",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:76"
    }
  },
  {
    "page_content": "in virtually all adults, in B cells, T cells, epithelial cells and myocytes and usually does not cause a cytopathic effect. However, it shows a clear ability to transform cells and is associated with the development of B-cell lymphomas, T-cell lymphomas, Hodgkin’s lymphomas and nasopharyngeal and other head and neck carcinomas. In transplant recipients, it produces a Post-transplant lymphoproliferative disease (PTLD) that can be very aggressive. Burkitt’s lymphoma (BL), is the most common",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:77"
    }
  },
  {
    "page_content": "Burkitt’s lymphoma (BL), is the most common childhood malignancy in equatorial Africa (8-10 cases/105 annually) and characteristically affects the jaw. The relationship between BL and EBV is practically 100% in endemic cases, 10-80% in sporadic cases and 30-40% in HIV-related cases. The cells usually express EBNA and CD20. It is considered that malaria may also be a co-factor in the production of this tumour, although the mechanism is not clear (immunosuppression of specific T cells, increased",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:78"
    }
  },
  {
    "page_content": "(immunosuppression of specific T cells, increased EBV viral load, or favouring reactivation of the virus in B lymphocytes, among other theories).Nasopharyngeal carcinoma is a rare tumour in most parts of the world, except in southern China, where it is one of the most common cancers. Unlike Burkitt’s lymphoma, EBV is present in all anaplastic nasopharyngeal carcinoma cells, in both high- and low-incidence areas. However, other co-factors are necessary (exposure to environmental carcinogens in",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:79"
    }
  },
  {
    "page_content": "(exposure to environmental carcinogens in food, genetic alterations, etc.), since the seroprevalence of EBV infection is much higher than the incidence of the tumour. Nasopharyngeal carcinoma cells express dormant proteins of EBV, including EBNA-1 and two membrane proteins, LMP-1 and LMP-2, along with the BamHI-A fragment of the EBV genome.HIV+ patients have a lymphoma incidence 60-100 times higher than expected and 70% of them are associated to EBV infection, usually of monoclonal origin. The",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:80"
    }
  },
  {
    "page_content": "EBV infection, usually of monoclonal origin. The profound immuno-suppression of these patients facilitates the failure of EBV control by decreasing specific cytotoxic lymphocytes. Non-Hodgkin’s lymphomas in HIV+ patients often affect the CNS. In B-cell lymphomas, EBV-coded proteins promote cell immortalisation and proliferation by stimulating the NFκB pathway and increasing the expression of anti-apoptotic genes. In HIV+ children, EBV infection has been linked to the development of smooth",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:81"
    }
  },
  {
    "page_content": "has been linked to the development of smooth muscle tumours (leiomyoma and leiomyosarcoma). The non-Hodgkin’s lymphoma most frequently associated with EBV is diffuse large cell.As early as the 1980s it was shown that the EBV genome is found in more than 50% of Hodgkin’s lymphomas, including Reed-Sternberg cells. It is also demonstrated in patients with HL-induced hemophagocytic syndrome. The proportion of HL with EBV is even higher in children under 10. The two most frequent markers in HL are",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:82"
    }
  },
  {
    "page_content": "under 10. The two most frequent markers in HL are EBER-1 and the latent membrane protein (LMP).EBV infection is also associated with T-cell lymphomas, including fulminant forms of T-cell lymphoma after acute EBV infection. In the context of mature T/NK lymphomas, with the possible exception of extranodal NK/T cell lymphoma, the role played by EBV infection is even more complex than in B lymphomas and exceeds the intention of this review. It has been proposed that the type of infected cell, the",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:83"
    }
  },
  {
    "page_content": "been proposed that the type of infected cell, the EBV viral load in plasma, and the degree of viral lymphatic replication have prognostic value in T/NK cell lymphomas.Another lymphoma associated with EBV infection is nasal angiocentric lymphoma, which is endemic in Asia, Central and South America. This tumour affects the nasal septum, palate, gastrointestinal tract and, less frequently, the skin, testicles and peripheral nerves. EBV is detected in virtually all neoplastic cells that are",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:84"
    }
  },
  {
    "page_content": "in virtually all neoplastic cells that are probably derived from NK cells.PTLD is associated in most cases with EBV. The term includes a continuum of abnormalities ranging from benign polyclonal B-cell proliferation to malignant B-cell lymphoma. In these disorders the virus directly induces the transformation of naive or mature memory cells. The frequency of PTLD is related to post-transplant immunosuppression and is more frequent in EBV-negative recipients who develop primary infection, and",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:85"
    }
  },
  {
    "page_content": "recipients who develop primary infection, and therefore in transplanted children. Recovery of T-immunity or administration of specific T-cells (adoptive immunity) will bring the disease back.Other entities related to this virus are hemophagocytic lymphohistiocytosis, lymphomatoid granulomatosis or X-linked lymphoproliferative disease. The treatment of all these tumours does not include the administration of antivirals since the cells are not in the lytic cycle, which is necessary for Acyclovir",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:86"
    }
  },
  {
    "page_content": "the lytic cycle, which is necessary for Acyclovir to be effective. The usefulness of cell therapy with specific cytotoxic T-lymphocytes against EBV and Rituximab is being studied. # QUESTION: WHAT IS THE RELATIONSHIP BETWEEN KAPOSI’S SARCOMA AND HERPES VIRUS? Kaposi’s sarcoma (KS) is an angioproliferative tumour and one of the clearest examples of a tumour that requires infection by a virus and that is also modulated by the patient’s immune status. The pathogenesis of the tumour requires",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:87"
    }
  },
  {
    "page_content": "status. The pathogenesis of the tumour requires infection with human herpesvirus 8 (HHV-8), also called Kaposi’s sarcoma associated herpesvirus (KSHV). It is named after Moritz Kaposi, a Hungarian dermatologist who first described the entity in 1872. Before briefly describing some of the characteristics of the KS, it should be noted that the HHV8 also causes two other tumours: cavity lymphoma or primary effusion lymphoma (PEL) and Castleman’s disease. Cavity lymphoma is a B-cell non-Hodgkin’s",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:88"
    }
  },
  {
    "page_content": "Cavity lymphoma is a B-cell non-Hodgkin’s lymphoma that has a preference for the peritoneal, pleural, and pericardial spaces. Castleman’s disease is also a very rare lymphoproliferative disorder that causes fever, splenomegaly, hepatomegaly, and lymphadenopathy, and can affect both HIV-negative and HIV-positive patients. KS is characterised by vessel proliferation (angiogenesis), accompanied by inflammation and proliferation of spindle cells. HHV-8 infects the cells and the gene products of the",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:89"
    }
  },
  {
    "page_content": "infects the cells and the gene products of the virus influence both the regulation of the cell cycle and the control of apoptosis. The infection induces a disordered proliferation of cells that mostly do not express a lytic cycle, but a latent infection. In addition, the function of the tumour suppressor genes is interrupted and recognition by the host immune system is prevented, thus promoting tumour growth. By performing a PCR in the biopsy, it is possible to amplify viral DNA sequences and",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:90"
    }
  },
  {
    "page_content": "it is possible to amplify viral DNA sequences and also to identify, using immunohistochemistry, latent viral antigen in spindle cells (membrane proteins). Four types of KS are recognised depending on the type of patients affected: 1) Classic or sporadic KS, which corresponds to the form originally described by Kaposi and which is extraordinarily rare (0.03% per year among HIV-positive males over 50 in the Mediterranean area). It usually occurs in males over 50-60 years of age and mainly affects",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:91"
    }
  },
  {
    "page_content": "males over 50-60 years of age and mainly affects people from the Mediterranean area (Sardinia, Sicily, etc.) or with Jewish ancestry; 2) Endemic KS prevalent in sub-Saharan Africa before the AIDS epidemic. It affects children and adults and it is believed that continuous exposure to certain types of soil facilitates the appearance of the disease; 3) iatrogenic KS, associated with the use of immunosuppressants and described mainly in solid organ transplant recipients; 4) finally, AIDS-associated",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:92"
    }
  },
  {
    "page_content": "recipients; 4) finally, AIDS-associated KS (epidemic KS). With better control of the AIDS epidemic, incidence in the US has dropped from rates that reached 47 cases per year per million people. Since then, Kaposi’s sarcoma has become less common, producing about 6 cases per million people each year. The different epidemiological and clinical aspects of these four types are summarised in Table 7. Infection with the HHV8 virus is a necessary condition for the development of KS, but not",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:93"
    }
  },
  {
    "page_content": "condition for the development of KS, but not sufficient, since other cofactors are required for its appearance, such as genetic predisposition (sporadic form), and above all immunosuppression, either iatrogenic (organ transplant) or due to HIV infection. Thus, the prevalence of seropositivity in the population is much higher than that of Kaposi’s sarcoma. The most common clinical presentation of KS, especially in the early stages of the tumour, is skin and mucosal lesions. It is characterised",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:94"
    }
  },
  {
    "page_content": "is skin and mucosal lesions. It is characterised by the appearance of raised violet lesions that mainly affect the lower extremities, the face (especially the nose), the oral mucosa and the genitals. They may be accompanied by significant oedema, reflecting vascular obstruction by lymphadenopathy or the action of cytokines involved in the pathogenesis of the tumour. Oral lesions appear in one-third of patients and mainly affect the gums and palate and may interfere with nutrition and speech. It",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:95"
    }
  },
  {
    "page_content": "and may interfere with nutrition and speech. It is important to remember that KS can also have extracutaneous manifestations, mainly in advanced stages, affecting mainly the gastrointestinal and respiratory tracts. The gastrointestinal system is now less frequently affected. Its diagnosis is difficult in the absence of concomitant skin lesions. Clinical manifestations of gastrointestinal KS include weight loss, abdominal pain, nausea and vomiting, gastrointestinal bleeding, malabsorption,",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:96"
    }
  },
  {
    "page_content": "gastrointestinal bleeding, malabsorption, intestinal obstruction, and diarrhoea. As for lung disease, it can appear with highly variable radiological findings, including nodules, single or multiple, interstitial or alveolar infiltrates, pleural effusion, adenopathy or solitary nodules. The diagnosis is based on the characteristic appearance of the lesions in endoscopy or bronchoscopy and is confirmed by biopsy. The incidence of KS in solid organ transplant recipients is 0-5-1% and represents",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:97"
    }
  },
  {
    "page_content": "transplant recipients is 0-5-1% and represents approximately 6% of post-transplant tumours, excluding skin cancer. This incidence is much higher than that of the general population and is justified by the chronic immunosuppression required by transplant patients. Although KS is mostly described in HIV-positive patients, primary infection after transplantation has been shown to be the most important risk factor in our environment. This primary infection can be acquired through the transplanted",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:98"
    }
  },
  {
    "page_content": "can be acquired through the transplanted organ, or through the administration of blood products or other routes. About half of the KS diagnosed in transplant recipients respond only by reducing immunosuppression, or by switching to Sirolimus (Rapamycin) which has anti-tumour and anti-angiogenic effects. In the patient with HIV infection, KS has been described in all risk groups, although with a higher incidence among homosexual or bisexual men, in relation to a higher seropositivity rate among",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:99"
    }
  },
  {
    "page_content": "in relation to a higher seropositivity rate among these patients (close to 40%). KS rates in some studies reached 18%-50% 10 years after the diagnosis of HIV infection, if the CD4 figure was <200 cells/mm3. However, although the rate of HHV-8 infection has not changed, early and effective antiretroviral treatment has significantly reduced the frequency of this tumour. The standardised incidence rate (SIR) for Kaposi’s sarcoma compared to the general population was 22,100, and declined to 3,640",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:100"
    }
  },
  {
    "page_content": "population was 22,100, and declined to 3,640 with widespread use of antiretroviral treatment. Some HIV+ patients with Kaposi’s sarcoma present with a systemic inflammatory syndrome due to cytokine release (KICS) that is characterised by fever, gastrointestinal, respiratory and neurological manifestations and is associated with an elevated KSHV tumour load. Treatment of KS depends on the extent of the tumour and its location and symptoms. As with solid organ transplant recipients, HIV-positive",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:101"
    }
  },
  {
    "page_content": "solid organ transplant recipients, HIV-positive patients may respond to immune recovery from the initiation of highly active antiretroviral therapy (HAART), although others may also require local or systemic chemotherapy. It has also been observed that KS is less frequent in patients who have received Ganciclovir or Foscarnet, demonstrating the relative sensitivity of the virus to these antivirals. The relative survival over five years is over 75%. # QUESTION: DO MICROORGANISMS OTHER THAN",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:102"
    }
  },
  {
    "page_content": "75%. # QUESTION: DO MICROORGANISMS OTHER THAN VIRUSES HAVE AN ONCOGENIC ROLE? Viruses are certainly the most oncogenic infectious agents. However, there are other non-viral microorganisms that are clearly related. A bacterium: Helicobacter pylori; and three parasites (the so-called “Oriental liver flukes”): Schistosoma haematobium, Clonorchis sinensis and Opisthorchis viverrini,” are classified in Group I of carcinogens by the International Agency for Research on Cancer ## Cancer-related",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:103"
    }
  },
  {
    "page_content": "Agency for Research on Cancer ## Cancer-related bacteria -Helicobacter pylori is a helical bacillus that lives exclusively in the human gastric epithelium. H. pylori infection can cause inflammation of the gastric mucosa that can progress, leading to gastritis, peptic ulcers and mucous-associated lymphoid tissue lymphoma (MALT). Because of its spiral shape, it can literally “screw itself in” to colonize the stomach epithelium, in addition to having the urease that allows it to neutralise its",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:104"
    }
  },
  {
    "page_content": "the urease that allows it to neutralise its acidic environment. The bacteria generates free radicals, injects a cytotoxin known as CagA that alters the structure of the cells lining the stomach and generates locally high levels of molecules signalling inflammation such as TNF-alpha or interleukin 6 that could induce mutation of the epithelial cells of the stomach. Tropheryma whipplei, another bacteria in the digestive tract that causes Whipple’s disease, may be associated in a similar way with",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:105"
    }
  },
  {
    "page_content": "disease, may be associated in a similar way with neoplasms. Salmonella typhi has been linked with hepatobiliary and gall bladder tumours and -Chlamydia pneumoniae and Myco-bacterium tuberculosis have been linked with lung cancer. Chronic Bacterial Osteomyelitis and hidradenitis suppurativa are associated with squamous cell carcinoma of the skin also [70-74]. ## Cancer-related parasites Millions of people in the world, especially those living in the tropics, suffer from some form of parasitic",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:106"
    }
  },
  {
    "page_content": "the tropics, suffer from some form of parasitic disease. The oncogenic role of certain parasites has been known for many decades. Three parasites, trematode helminths, cause urinary or hepatobiliary tumours:",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:107"
    }
  },
  {
    "page_content": "Schistosoma haematobium is very prevalent in sub-Saharan Africa and is a major cause of urinary bladder carcinoma. The disease is acquired after skin contact with fresh water infected with larvae. Adults invade the urinary venous plexuses and the eggs are expelled with the urine after passing through the bladder wall, causing haematuria, fibrosis and calcifications. Granulomas form on the wall of the bladder and evolve into nodules or masses that ulcerate, degenerating into both benign and",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:108"
    }
  },
  {
    "page_content": "that ulcerate, degenerating into both benign and malignant tumours. In addition, bladder lesions may increase the exposure of the epithelium to carcinogenic substances. Schistosoma japonicum may be oncogenic and produce colorectal cancer.Clonorchis sinensis is very prevalent in South East Asia (China, Thailand, Korea, Vietnam, Laos and Cambodia) and Opisthorchis viverrini (also found in Russia), to a lesser extent, causes cholangiocarcinoma. The disease is acquired by eating raw freshwater",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:109"
    }
  },
  {
    "page_content": "The disease is acquired by eating raw freshwater fish. Adults invade the bile ducts and occasionally the gallbladder and pancreatic duct, where they cause cholangitis and cholecystitis and can lead to cirrhosis. In massive and chronic infections, inflammation, scaling, metaplasia and ductal fibrosis can degenerate into cholangio-carcinoma and liver carcinoma, especially in patients exposed to carcinogenic agents such as nitrosamines. Opisthorchis felineus could perhaps be equally",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:110"
    }
  },
  {
    "page_content": "Opisthorchis felineus could perhaps be equally oncogenic.Other parasites may have a putative or indirect oncogenic role. The association between Plasmodium falciparum and the Epstein-Barr virus is not entirely clear in the oncogenesis of Burkitt’s lymphoma in Africa. Toxoplasma gondii has been detected in some patients with intraocular lymphoma. Strongyloides stercoralis may be associated with gastric lymphoma and adenocarcinoma of the colon.A new form of neoplasm associated with a parasite,",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:111"
    }
  },
  {
    "page_content": "new form of neoplasm associated with a parasite, namely Hymenolepis nana, has been reported in 2015 in an immunosuppressed patient: the transformation of the parasite into a tumour that subsequently spreads. It is the first and only known case of a person suffering from cancer originating from a parasite (the cancer cells were not human but parasitic). But, how can a parasite cause cancer? Adult helminths are constantly moving, burrowing and laying eggs that secrete toxic proteins; the host",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:112"
    }
  },
  {
    "page_content": "laying eggs that secrete toxic proteins; the host tries to get rid of them, which induces chronic inflammation that can eventually degenerate into metaplasia. However, some parasites may be protective in tumour genesis, inducing apoptosis phenomena and inhibiting signals of inflammatory regulation and angiogenesis. Certain proteins excreted by Fasciola hepatica, Echinococcus granulosus, Trichinella spiralis, Toxoplasma gondii, and Trypanosoma cruzi are capable of inhibiting tumour cell growth",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:113"
    }
  },
  {
    "page_content": "are capable of inhibiting tumour cell growth in vitro, and may be used as anti-cancer therapy in the future. # QUESTION: COULD THE CONCEPTS OF ONCOGEN AND ONCOPROTEINS BE SUMMARISED? AND THE CONCEPT OF GENOMIC INSTABILITY? Studies on chicken sarcoma in the first decade of the 20th century suggested that the origin of the tumours was viral. For example, pioneering studies by Peyton Rous showed how filtering pulverized chicken sarcoma through a sieve that did not allow cells to pass, only",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:114"
    }
  },
  {
    "page_content": "a sieve that did not allow cells to pass, only viruses, then injecting the extract, transmitted the sarcoma to the recipient chicken. Throughout almost two thirds of the century this viral theory of the origin of cancer was the main driving force behind cancer research and, in fact, a good number of viruses capable of triggering tumour processes were found. As oncologist Ludwik Gross said in 1970, “The viral origin of most malignant tumours has already been documented beyond any reasonable",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:115"
    }
  },
  {
    "page_content": "has already been documented beyond any reasonable doubt. It would be quite difficult to assume a fundamentally different aetiology for human tumours”. However, some observations did not fit with this model. For example, trying to explain the high incidence of tumours among miners, the Japanese pathologist Katsaburo Yamagiwa observed that repeated exposure of the skin to charcoal induced sarcomas in rabbits. This suggested that the carbon must have some chemical agent that induced a change in",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:116"
    }
  },
  {
    "page_content": "have some chemical agent that induced a change in the animal’s skin cells, and made them grow out of control, but how? The answer finally came in the 1980s with the discovery of oncogenes. The concept of oncogenes derives from the presence of genes that are mutated in tumour cells, and which are responsible for transforming them into malignant ones. These genes perform normal functions in the cell such as stimulating growth, increasing survival, or defining identity. However, the presence of",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:117"
    }
  },
  {
    "page_content": "or defining identity. However, the presence of certain mutations in them means that, once translated into protein, they have an altered capacity capable of transforming a normal cell into a malignant one. The genes that, once mutated, give rise to oncogenes are called proto-oncogenes, and the proteins that are generated from these are called oncoproteins. The discovery of the first oncogene was published in 1982 by 3 independent laboratories, those directed by the doctors Robert Weinberg,",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:118"
    }
  },
  {
    "page_content": "those directed by the doctors Robert Weinberg, Michael Wigler and the Spaniard Mariano Barbacid, who managed to sequence transforming oncogenes isolated from bladder cancer cells. The first oncogene discovered was RAS, which we know today is a family of genes whose function is to regulate cell growth in response to growth factors. Many others were later discovered, notable cases such as MYC or cyclin E (CCNE) which, as in the case of SAR, control cell growth. We now know that many of the",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:119"
    }
  },
  {
    "page_content": "control cell growth. We now know that many of the oncogenes are related to genes that control cell growth in such a way that oncogenic mutations promote the uncontrolled proliferation characteristic of tumours. While for several decades it was thought that most oncogenes were related to cell proliferation or their increased survival, tumour genome sequencing studies revealed, not without surprise, that in fact the class of genes most represented among oncogenes are those related to chromatin",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:120"
    }
  },
  {
    "page_content": "among oncogenes are those related to chromatin and epigenetics. Although in many cases we still do not fully understand how these alterations in epigenetic-related genes can trigger tumour processes, the most accepted idea is that these mutations change the identity of cells and generate undifferentiated states. This undifferentiated cell, which has lost its identity, is the one that subsequently -and thanks also to other mutations that promote its growth- gives rise to tumours. As expected,",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:121"
    }
  },
  {
    "page_content": "its growth- gives rise to tumours. As expected, oncogenic mutations are often targets of tumour treatments, and the development of drugs that target all types of oncogenes, including those epigenetic-related genes, is currently a very active field within drug development and new anti-tumour therapies. In addition to the presence of oncogenes, another characteristic present in practically all tumour cells is genomic instability. First described by Teodor Boveri at the beginning of the 20th",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:122"
    }
  },
  {
    "page_content": "by Teodor Boveri at the beginning of the 20th century, genomic instability is defined as the presence of genomes with multiple chromosomal aberrations in tumour cells such as: the gain or loss of entire chromosomes, chromosomal translocations, or the loss or duplication of regions of one or more chromosomes. Genomic instability is caused by failures in DNA replication or in the distribution of chromosomes during mitosis, processes that are often involved in tumour cells. Furthermore, it has",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:123"
    }
  },
  {
    "page_content": "involved in tumour cells. Furthermore, it has recently been discovered that oncogenes are also a source of genomic instability, as they promote abnormal replication that leads to DNA damage. Fortunately, all cells have mechanisms that suppress genomic instability and normal cells keep their genome stable. The fact that genomic instability is a distinctive feature of tumour cells has opened the door to anti-tumour strategies based on selectively killing cells with genomic instability. One known",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:124"
    }
  },
  {
    "page_content": "killing cells with genomic instability. One known example is the poly(ADP)-ribose polymerase (PARP) inhibitors that have been shown to be effective in killing tumour cells with deficiencies in DNA repair in breast, ovarian and prostate tumours. Another alternative that is now being clinically studied, and in which the laboratory of one of us played an important role, is that of ATR kinase inhibitors, which are mainly responsible for the type of genomic instability initiated by oncogenes. #",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:125"
    }
  },
  {
    "page_content": "of genomic instability initiated by oncogenes. # QUESTION: WHAT PROPORTION OF CANCER DEATHS CAUSED BY VIRUSES COULD BE PREVENTED BY EXISTING VACCINES? Cancer mortality series offer an uneven picture between regions of the world, due to the multiplicity of factors involved in their genesis. A global approach estimates that about 1.5 million cancer deaths could be avoided annually if the underlying infections that led to the development of the tumour were prevented or treated. A pioneering",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:126"
    }
  },
  {
    "page_content": "tumour were prevented or treated. A pioneering contribution in this area is that of Catherine de Martel et al who published their analysis of the incidence of 27 types of cancer in 184 countries in Lancet Oncology in 2012, describing the fact that two thirds of these deaths occur in less developed countries. These authors carried out an analysis to estimate the proportion of cancers globally that could be attributed to infections and have calculated, by categorising the planet into eight",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:127"
    }
  },
  {
    "page_content": "calculated, by categorising the planet into eight regions, the population that could be affected by new tumours and which could have been prevented by a specific intervention against exposure. They point out that of the 12.7 million new cancers worldwide in 2008, about 2 million were attributable to infections, and of these, 1.6 million (80%) were in developing countries. Of the 7.5 million deaths that occurred in 2008 attributable to an oncological process, an estimated 1.5 million were due to",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:128"
    }
  },
  {
    "page_content": "process, an estimated 1.5 million were due to potentially preventable and treatable infections. An upwardly weighted estimate of 172 deaths worldwide could be prevented every hour from tumours caused by infectious agents potentially preventable by immunisation. There are significant contrasts between different areas of the planet in how these infections are responsible for oncogenesis. Thus, in Australia and New Zealand the infectious origin of a cancer is identified in 3.3% of cases compared",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:129"
    }
  },
  {
    "page_content": "a cancer is identified in 3.3% of cases compared to 32.7% in Sub-Saharan Africa. In women, cervical cancer accounted for approximately half of the cancer burden related to infection; in men, liver and gastric cancers accounted for more than 80%. About 30% of cases attributable to infections occur in people under 50. In a smaller scope, a Spanish group has been able to describe, in a series of 190,203 cervical smears collected between 2012 and 2014, in women screened for Human Papillomavirus",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:130"
    }
  },
  {
    "page_content": "2014, in women screened for Human Papillomavirus (HPV) in Castilla y León, that its prevalence in foreign women was 23.51%, significantly higher than in Spanish women (9.6%; p <0,001) and that the presence of morphological changes in the foreign women was also higher. The application of preventive public health methods which already exist, such as vaccines (or anti-infective treatments in another conceptual framework), could have a significant effect on the global burden of cancer in the",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:131"
    }
  },
  {
    "page_content": "effect on the global burden of cancer in the future. In the specific field of viral agents, it is worth noting that we already have vaccines with proven effectiveness against HPV and Hepatitis B Virus (HBV). “Increasing vaccine coverage should be a priority for health systems in high-burden countries,” as G Danaei states in an editorial accompanying the aforementioned study. A significant proportion of cancer cases attributable to infections can be prevented through improvements in vaccination",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:132"
    }
  },
  {
    "page_content": "be prevented through improvements in vaccination and screening programmes. Expansion of vaccination (for HBV and HPV), screening and treatment programmes (e.g., for Hepatitis C Virus -HCV-) could greatly reduce mortality due to them. An additional aspect of vaccination programmes is to describe their acceptance by the population, to carry out economic assessment studies that verify their suitability and availability from the perspective of the social funder, and to establish their",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:133"
    }
  },
  {
    "page_content": "of the social funder, and to establish their accessibility. In developed countries, in the context of patients co-infected with the Human Immunodeficiency Virus (HIV), very suggestive lines of work have been established by De Martel and Plummer’s own group. These authors indicate that, although HPV and hepatotropic viruses such as HBV and HCV do not represent a differentiated weight in this category of patients in the USA, they do constitute the Human Herpesrvirus-8 (HHV-8) at the expense of",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:134"
    }
  },
  {
    "page_content": "Human Herpesrvirus-8 (HHV-8) at the expense of its aetiological involvement in Kaposi’s Sarcoma and Epstein-Barr Virus (EBV) due to its causal relationship with lymphoid pathology. There is no doubt that the research applied to vaccines that can be extended to the Herpesviridae family will represent a decisive impulse towards minimising their impact on patients co-infected with HIV. # QUESTION: WHAT IMPACT IN NUMBERS HAS HPV VACCINATION HAD ON REDUCING FEMALE GENITAL CANCER? Vaccines against",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:135"
    }
  },
  {
    "page_content": "REDUCING FEMALE GENITAL CANCER? Vaccines against human papillomavirus (HPV) induce an elevated production of antibodies capable of neutralising the virus and preventing infection of the anogenital tract and, therefore, the possible development of precancerous lesions and cancer. Given the natural history of infection, which requires years or decades from initiation to development of cancer, protection against persistent infection and pre-malignant lesions is considered a surrogate marker of",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:136"
    }
  },
  {
    "page_content": "lesions is considered a surrogate marker of protection against cancer. More than 10 years after the commercialisation of HPV vaccines, many studies provide data on their effectiveness (effectiveness in the general population and in real life) [95-99]. The fact that there is a reduction in the prevalence of vaccine genotypes or a reduction in the rate of pre-malignant lesions in the vaccinated population is certainly indicative of protection against cancer. A recent systematic review and",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:137"
    }
  },
  {
    "page_content": "against cancer. A recent systematic review and meta-analysis assesses the population-level impact of vaccine effectiveness in the real-world setting. Since 2007, a total of 99 countries and territories have initiated vaccination programmes. In 2016, WHO expanded the recommendation in favour of promoting the vaccination of multiple cohorts of girls over single-cohort vaccination. The analysis of 1,702 potential articles allowed the final inclusion of 65 articles carried out in 14 high-income",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:138"
    }
  },
  {
    "page_content": "of 65 articles carried out in 14 high-income countries (23 articles to assess HPV infection, 29 for anogenital warts and 13 for CIN2+ lesions). This meta-analysis of over 60 million individuals and 8 years of post-vaccination follow-up provides compelling evidence of the substantial impact of vaccination programmes on reducing HPV infection, and the diagnosis of anogenital warts and CIN2+ lesions. Specifically, the prevalence of HPV 16 and 18 decreased significantly by 83% (RR 0-17, 95% CI",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:139"
    }
  },
  {
    "page_content": "decreased significantly by 83% (RR 0-17, 95% CI 0•11–0•25) among girls aged 13-19, and 66% (RR 0-34, 95% CI 0•23–0•49) among women aged 20-24. Also, the prevalence of HPV 31, 33 and 45 decreased significantly by 54% (RR 0-46, 95% CI 0•33–0•66) among girls aged 13-19 years. Five to nine years after vaccination, diagnosis of CIN2+ lesions decreased significantly by 51% (RR 0-49, 95% CI 0•42–0•58) among girls aged 15-19 years and by 31% (RR 0•69, 95% CI 0•57–0•84) among women aged 20-24 years.",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:140"
    }
  },
  {
    "page_content": "95% CI 0•57–0•84) among women aged 20-24 years. This meta-analysis demonstrates a stronger and faster direct impact, as well as a herd effect, in countries with high coverage and which included multiple vaccine cohorts. Therefore, these real-world data confirm that both the cause (high-risk HPV infection) and the immediate pre-cancer condition (CIN2+) are decreasing significantly among vaccinated populations and therefore the vaccine is effective in preventing cervical and other HPV-related",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:141"
    }
  },
  {
    "page_content": "in preventing cervical and other HPV-related cancers. Another recent study in the U.S. assessed the type of HPV present in cytology samples from women aged 20-29 years assessed at Kaiser Permanente Northwest in 2007 and in two periods of the vaccine era: 2012-2013 and 2015-2016. The prevalence of vaccine HPV types went from 13.1% in 2007 to 2.9% in 2015-2016. After 9-10 years from the introduction of the vaccine, the prevalence of HPV vaccine types decreased by 78% among 20-24 years old and by",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:142"
    }
  },
  {
    "page_content": "decreased by 78% among 20-24 years old and by 38% among 25-29 years old. This decrease was observed in both vaccinated and unvaccinated women, which is evidence of both direct and herd protection. In the same vein, data from Scotland from nine cohorts of women aged 20 years have been published to evaluate the effectiveness of the bivalent vaccine in preventing precancerous lesions. The analysis confirms an 89% reduction in prevalent CIN3+; an 88% reduction in CIN2+; and a 79% reduction in CIN1",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:143"
    }
  },
  {
    "page_content": "reduction in CIN2+; and a 79% reduction in CIN1 in vaccinated women born in 1995 and 1996 compared to unvaccinated women born in 1988. Unvaccinated women also showed a lower prevalence of CIN3+ lesions, supporting a herd protection effect. Because of this effect, a reduction in HPV 16/18 infections would not only impact women themselves but also the overall network of sexual relationships between men and women. The fact that the vaccination programme reduced all types of CIN3+ lesions, and not",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:144"
    }
  },
  {
    "page_content": "reduced all types of CIN3+ lesions, and not only those related to types 16 and 18 included in the bivalent vaccine, indicates strong cross-protection against other common oncogenic types such as HPV 31/33/45, in accordance with previous clinical trials. Finally, data from registries showing a decrease in cervical cancer are still at a very early stage. Specifically, in Finland, monitoring of cancer registries in vaccinated women in clinical trials and their comparison with unvaccinated cohorts",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:145"
    }
  },
  {
    "page_content": "and their comparison with unvaccinated cohorts (period 2002/2007-2015) confirms that not a single case was diagnosed in the vaccinated cohort versus 10 cases of HPV-related cancer in the unvaccinated cohort (8 cases of cervical cancer, one vulvar cancer and one oropharyngeal cancer). However, in this analysis the vaccinated and unvaccinated cohorts were not comparable, which limits the interpretation of the data. Another study of the annual incidence of invasive cervical cancer in the United",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:146"
    }
  },
  {
    "page_content": "of invasive cervical cancer in the United States compares the four years prior to the introduction of the vaccine (2003–2006) with the vaccine era (2011–2014). There was a significant 29% reduction in average annual incidence rates during the study period (6.0 versus 8.4 per 1,000,000 people, rate ratio = 0.71, 95% CI: 0.64-0.80) among women aged 15 to 24 years, and 13.0% lower among women 25 to 34 years. During these years, vaccine coverage increased to 55.3% in the younger cohorts. Although",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:147"
    }
  },
  {
    "page_content": "to 55.3% in the younger cohorts. Although incidence rates had already declined prior to the introduction of the vaccine, these strongly declining data suggest that it may be partly attributable to the introduction of the HPV vaccine In relation to the impact on non-genital tumours, in the case of both anal and oropharyngeal cancer, more than 80% of HPV-associated cases are caused by HPV16, and more than 90% by at least one of the types 16/18/31/33/45/52/58/6/11. The currently available vaccines",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:148"
    }
  },
  {
    "page_content": "The currently available vaccines would have a very high reduction impact on these two types of cancer. # QUESTION: IN AN IDEAL WORLD IN WHICH HEPATITIS C IS ERADICATED, COULD WE ESTIMATE THE DECREASE IN MORTALITY ATTRIBUTABLE TO LIVER TUMOURS? WHAT WOULD BE THE IMPACT ON TUMOUR MORTALITY IN A WORLD WHERE HEPATITIS B VACCINATION WAS UNIVERSAL? The question posed is an interesting “epidemiology-fiction” exercise of great future importance and of enormous potential value in terms of public health.",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:149"
    }
  },
  {
    "page_content": "potential value in terms of public health. The theoretical substrate of the question is essentially based on the fact that there is no reservoir other than human beings for viruses B and C, which encourages the logical hope that their elimination (by the implantation of universal vacci-nation or by means of antiviral treatment applied to all possible patients) would be capable of clearly attenuating, even until its disappearance, liver diseases associated with chronic viral infection, including",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:150"
    }
  },
  {
    "page_content": "with chronic viral infection, including primary liver cancer. This attractive concept would be particularly true in an ideal scenario of no new patients with hepatitis B due to vaccination, although the risk of cancer would persist in those patients already infected, in whom screening would still be essential However, there are several elements that mitigate the un-doubted potential impact on the incidence of hepatocellular carcinoma. i) In patients with advanced hepatitis C, viral suppression",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:151"
    }
  },
  {
    "page_content": "with advanced hepatitis C, viral suppression does not negate the risk of liver disease progression Different studies have clearly shown that the sustained viral response in patients treated with direct antivirals has a marked effect on the progression of liver disease in patients in the early stages of infection and that it reduces the risk of complications in patients with more advanced disease. However, in patients with significant portal hypertension (over 10 mmHg), i.e. those with more",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:152"
    }
  },
  {
    "page_content": "hypertension (over 10 mmHg), i.e. those with more advanced disease and at risk of developing complications of cirrhosis, antiviral treatment fails to lower portal pressure below the risk threshold in a significant proportion of patients, the higher it is, the greater the degree of deterioration. Therefore, the risk of developing hepatocellular carcinoma (clearly influenced by the presence of cirrhosis with severe portal hypertension) is not eliminated despite the elimination of the virus in",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:153"
    }
  },
  {
    "page_content": "despite the elimination of the virus in patients with advanced disease. Therefore, as long as there are patients treated in whom there is basically advanced fibrosis, the risk of developing hepatocellular carcinoma is not zero. There are no data, however, to quantify the safe threshold of fibrosis below which screening would not be necessary ii) Is antiviral treatment of hepatitis C capable of triggering hepatocellular carcinoma? This is a very controversial issue arising from the observation",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:154"
    }
  },
  {
    "page_content": "controversial issue arising from the observation in a Spanish multicentre study of an increased frequency of hepatocellular carcinoma recurrence and in its severity in patients with hepatocellular carcinoma treated with radical intent and who immediately afterwards received antiviral treatment for hepatitis C. The researchers speculated about the possible impact of the abrupt suppression of the chronic immune response associated with the cure of the C virus infection with a loss of “anti-tumour",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:155"
    }
  },
  {
    "page_content": "the C virus infection with a loss of “anti-tumour surveillance” mediated by immune system cells. Information for and against this hypothesis has emerged since this study. In general, it can be considered that anti-viral treatment does not per se increase the risk of developing hepatocellular carcinoma in patients with cirrhosis with no known tumour. However, delaying the attempt to eradicate the virus in patients recently treated for hepatocellular carcinoma is recommended [103-106]. iii) There",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:156"
    }
  },
  {
    "page_content": "carcinoma is recommended [103-106]. iii) There are other causes of cirrhosis and hepatocellular carcinoma As discussed in previous questions, the presence of cirrhosis per se, regardless of its cause, is a pro-oncogenic factor. This is extremely important in patients who are carriers of fatty metabolic liver disease, which is a real epidemic in the Western world. Strikingly, this disease, whose pathogenic complexity and systemic inflammatory substrate are widely known, has its own pro-oncogenic",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:157"
    }
  },
  {
    "page_content": "are widely known, has its own pro-oncogenic mechanisms. From the epidemiological point of view, it is important to note that patients with hepatocellular carcinoma associated with fatty metabolic liver disease are more frequently observed than in other non-cirrhotic liver aetiologies, are diagnosed in more advanced stages, and are therefore less likely to receive treatment with curative intent. The future impact in terms of increased incidence of hepatocellular carcinoma associated with this",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:158"
    }
  },
  {
    "page_content": "of hepatocellular carcinoma associated with this disease is not known with certainty, but if the forecasts of increased prevalence worldwide are true, a dramatic increase can be expected in the medium term. In fact, recent studies clearly reinforce this trend. Ultimately, the impact of a universal elimination of hepatotropic viruses on the development of liver cancer would be of great importance, although it would not completely eliminate this dreaded disease # QUESTION: IS THERE A PROSPECT FOR",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:159"
    }
  },
  {
    "page_content": "disease # QUESTION: IS THERE A PROSPECT FOR AN EPSTEIN-BARR VIRUS VACCINATION? The relationship between viruses and cancer is clearly underestimated and little known, both at the professional level and at the population level, despite such strong data as the fact that the second carcinogen demonstrated worldwide at present is a virus (HPV) [108-115]. Successful and widespread vaccines have been achieved against HBV and HPV, but a widespread vaccine against EBV remains elusive. EBV, as already",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:160"
    }
  },
  {
    "page_content": "against EBV remains elusive. EBV, as already mentioned, is an oncogenic virus as proven by its association with Burkitt’s lymphoma and its ability to transform B cells in vitro, through the expression of Epstein-Barr nuclear antigens (EBNA) and latent membrane protein (LMP). EBV-infected cells are also capable of withstanding the cellular lysis of acute infection and this also contributes to neoplastic development. The lifelong persistence of EBV in humans is a complex multi-step process that",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:161"
    }
  },
  {
    "page_content": "in humans is a complex multi-step process that begins with infection of the oropharynx, and culminates in the maintenance of EBV in circulating memory B cells. EBV probably uses the normal B-cell differentiation pathway to achieve persistence because it is able to implement various latency and lytic transcription programmes, assuming different antigenic states within infected individuals. However, despite the wide variety of antigens that predominate throughout the EBV life cycle, EBV candidate",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:162"
    }
  },
  {
    "page_content": "throughout the EBV life cycle, EBV candidate vaccines have traditionally focused on only a limited number of EBV antigens. Both therapeutic and prophylactic vaccines have been explored. Therapeutic vaccines aim to enhance and maintain the immune response in patients with EBV-associated disorders and have been studied mainly in nasopharyngeal carcinoma using dendritic cells with specific CD8 epitopes against LMP2 and using the MVA (Modified Vaccinia Ankara) platform including LMP2 and EBNA 1",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:163"
    }
  },
  {
    "page_content": "Ankara) platform including LMP2 and EBNA 1 antigens [118-120]. The data suggests that tumour growth can be controlled by the immune system. These studies have led to trials with different therapeutic vaccines that have been well tolerated and the results of phase I and II trials are encouraging but suggest that they are not in themselves the solution for nasopharyngeal carcinoma (the main carcinoma on which these types of vaccines have been tested) as they have an effect on only a low",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:164"
    }
  },
  {
    "page_content": "been tested) as they have an effect on only a low proportion of patients and on a temporary basis [123-126]. The largest number of studies have focused on prophylactic vaccines. In 1995, a first test was performed with the recombinant attenuated virus itself and did not induce antibodies in sero-positive adults. The experts, faced with these results, decided that vaccination was not an appropriate approach to control this virus Over the past two decades, trials have been based on glycoprotein",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:165"
    }
  },
  {
    "page_content": "decades, trials have been based on glycoprotein 350, which led to a phase II trial with a sample size of 181 people. With a three-dose protocol, antibodies remained for 18 months and the incidence of infectious mononucleosis was reduced by 78% but the vaccine did not reduce the risk of acquiring EBV infection. Work has also been done with a vaccine based on glyco-protein 350 for its pre-kidney transplant application in children that was not very immunogenic. Similar data were obtained to the",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:166"
    }
  },
  {
    "page_content": "immunogenic. Similar data were obtained to the Phase II trial with a vaccine using the toxoid conjugated EBNA3 nuclear antigen designed to elicit specific T-cell responses to EBV, but it also failed to prevent EBV infection. It should be noted that this vaccine is very simple to perform due to the simplicity of the antigen. Antigen-antibody conjugates, or antigen-armed antibodies (AgAbs), which specifically deliver antigenic peptides to antigenic cells, have also been used as vaccine candidates",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:167"
    }
  },
  {
    "page_content": "cells, have also been used as vaccine candidates without conclusive results. EBV antigens have also been introduced in virus-like particles and in self-assembling nanoparticles. These platforms allow monomeric antigens to be similar to EBV, but as they lack DNA they are not infectious. Chimeric viruses are also achieved by the fusion of EBV antigens with the structural proteins of Newcastle disease virus. In these structures, for example, gp350 induces a greater response to vaccination [116,",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:168"
    }
  },
  {
    "page_content": "induces a greater response to vaccination [116, 131-137]. All these studies leave us a long way from achieving an effective vaccine against EBV and its primary diseases and, more importantly, against its ability to induce tumour processes. # QUESTION: WHAT ARE ONCOLYTIC VIRUSES? WHAT ARE THE PROSPECTS FOR TREATMENT WITH THEM? An oncolytic virus is a virus that preferentially infects and kills cancer cells. As the infected cancer cells are destroyed, the oncolysis releases new viral particles",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:169"
    }
  },
  {
    "page_content": "the oncolysis releases new viral particles that help destroy the remaining tumour. The potential of viruses as anti-cancer agents was first discovered in the early 20th century, although coordinated research efforts did not begin until the 1960s. Several viruses, including adenovirus, reovirus, measles virus, HVS, Newcastle disease virus, and others, have been clinically tested as oncolytic agents. Most current oncolytic viruses are designed to be selective against tumour cells, although there",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:170"
    }
  },
  {
    "page_content": "be selective against tumour cells, although there are naturally occurring examples, such as Reovirus and Senecavirus, that have been used in clinical trials. The acquisition of virus selectivity by the tumour cell can be obtained by modifying the proteins of the viral capsid, giving it a high selectivity by the tumour cells. It can also be achieved by modifying the virus genome so that replication only takes place inside the tumour cell. This is achieved either by modifying the transcription in",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:171"
    }
  },
  {
    "page_content": "achieved either by modifying the transcription in the target cell, or by attenuation, which involves introducing deletions in the viral genome to favour its entry into the tumour cells and eliminate its ability to penetrate healthy cells. It is also possible to introduce genes into oncolytic viruses that encode the synthesis of endostatin and angiostatin, natural proteins that inhibit angiogenesis, with the consequent necrosis of the tumour. Oncolytic viruses not only cause direct destruction",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:172"
    }
  },
  {
    "page_content": "viruses not only cause direct destruction of tumour cells, but also stimulate the host’s anti-tumour immune system responses. Most are genetically modified to increase tumour tropism and reduce virulence for non-neoplastic host cells. Thus, they can stimulate a pro-inflammatory environment by improving antigen release/recognition and subsequent immune activation to counteract immune evasion by malignant cells. In fact, oncological tic viruses also aim to take advantage of the tumour’s tolerance",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:173"
    }
  },
  {
    "page_content": "aim to take advantage of the tumour’s tolerance mechanisms, which can facilitate viral infection and the death of cells that are not protected by the immune system. This allows for a theoretical domino effect involving chained viral transfer between the neoplastic cells and increased immune activation. There are currently numerous viral species in different stages of research for immuno-oncological use. Possibly the best studied so far are herpes viruses, of which some strains have been found",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:174"
    }
  },
  {
    "page_content": "viruses, of which some strains have been found to have a tropism for natural tumour cells while others have been designed to improve selectivity [139-143]. Initial scans using herpes have shown promising results in murine glioblastoma. Additional efficacy has been seen in prostate cancer, using a recombinant smallpox-vaccine virus capable of regulating prostate-specific antigen and the expression of three co-stimulating factors involved in the presence of the antigen and activation of T cells.",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:175"
    }
  },
  {
    "page_content": "of the antigen and activation of T cells. In addition, several strains of recombinant vaccine virus have shown promise as antineoplastic agents. One strain has anti-tumour angiogenesis, another has shown efficacy against hepatocellular carcinoma in animal models and the third improves the recognition of tumour cells [146-149]. Other viruses have been or are being explored as possible vehicles of immunomodulation in cancer, such as Newcastle disease virus, coxsackievirus, reovirus, and even the",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:176"
    }
  },
  {
    "page_content": "virus, coxsackievirus, reovirus, and even the measles virus [150-153]. Among those approved for treatment by the FDA is Talimo-gene laherparepvec (OncoVEX GM-CSF), also known as T-vec, from Amgen which successfully completed phase III trials for advanced melanoma in March 2013. In October 2015, the U.S. Food and Drug Administration approved T-vec, under the brand name Imlygic®, for the treatment of melanoma in patients with inoperable tumours, becoming the first approved oncolytic agent in the",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:177"
    }
  },
  {
    "page_content": "the first approved oncolytic agent in the Western world. It is based on the Herpes simplex virus (HSV-1). It has also been tested in a Phase I trial for pancreatic cancer and in a Phase III trial in head and neck cancer along with chemotherapy and radiotherapy with cisplatin. Oncolytic viruses are generally associated therapeutically with other therapeutic strategies such as association with checkpoint inhibitors, Ipilimumab, Pembrolizumab, Atezolizumab, anti-tumour lymphocytes (CAR-T) or",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:178"
    }
  },
  {
    "page_content": "Atezolizumab, anti-tumour lymphocytes (CAR-T) or associations of oncolytic viruses with tumour epitopes: vaccines. Clinical trials with oncolytic viruses in entities as different as colorectal cancer, glioblastoma, tumours with widespread metastases, pancreatic cancer, bladder cancer, ovarian cancer or primary tumours of the peritoneum are underway and represent a hope for the therapeutic future of these malignancies. # QUESTION: WHAT IS THE COST TO HEALTH CARE SYSTEMS OF TUMOURS DUE TO VIRUSES",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:179"
    }
  },
  {
    "page_content": "TO HEALTH CARE SYSTEMS OF TUMOURS DUE TO VIRUSES THAT COULD HAVE BEEN AVOIDED? WHAT ROLE SHOULD HEALTH AUTHORITIES PLAY IN APPROACHING THIS ISSUE? In addition to the human cost of cancer, the financial cost is considerable. Direct costs include treatment expenses as well as the cost of care and rehabilitation. Indirect costs include the loss of economic output due to work lost and premature death. There are also costs that are difficult to quantify such as non-medical costs. The exact global",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:180"
    }
  },
  {
    "page_content": "such as non-medical costs. The exact global cost of cancer is unknown but is expected to increase due to the increase in the number of new cancer cases, as well as the rising cost of cancer therapies The health authorities must act on this issue, fundamentally modifying the prevention of risk factors and implementing preventive strategies. The risk factors for the most immediate intervention are the decrease in genital HPV infections where, among other means, it is possible to intervene with",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:181"
    }
  },
  {
    "page_content": "other means, it is possible to intervene with vaccines and vaccination and the treatment of hepatitis virus infections. # QUESTION: IS THE PRESS AWARE OF THIS ISSUE? WHAT ROLE SHOULD IT PLAY? Over the last ten years, the press and media have reduced the resources, spaces and personnel dedicated to generating, producing and writing health and medical content as a result of the economic crisis that affected them both through the closure of companies and newspaper titles, as well as through",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:182"
    }
  },
  {
    "page_content": "and newspaper titles, as well as through financial adjustments and staff cuts. Training and specialisation levels have also been reduced in the health, sanitation and science sections for the same reasons. Despite the variability of the economic crisis, the media have not recovered lost ground and continue to be immersed in situations of weakness and economic-financial fragility. The impact of new technologies -no longer so new- and the possibilities they have offered for opening up the",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:183"
    }
  },
  {
    "page_content": "they have offered for opening up the publication of content to society, as well as the appearance of new communication channels, have posed a risk for the media and threat of loss or dissolution of their preponderant role as the central and principal reference of information for society, having to compete with platforms such as the internet -in its broadest facet of distribution of all kinds of products-, social networks and so-called citizen journalism. Despite these circumstances, the press",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:184"
    }
  },
  {
    "page_content": "Despite these circumstances, the press and media have placed cancer and everything related to this disease at the forefront of relevance and interest with respect to health and healthcare issues and content, giving it a media prominence above other diseases, with a broad and compact informative approach that considers angles and approaches ranging from health policy, the variety of tumours, the role of patients, research and scientific advances, the work of medical-scientific societies and the",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:185"
    }
  },
  {
    "page_content": "the work of medical-scientific societies and the oncology sector, the activity of health or pharmaceutical centres and companies, the commemoration of World Days, etc. “Journalism loves cancer” would be the quick and easy headline. Having thus explained and exposed the prominence of cancer in the press and media with a broad, diversified and comprehensive scope, it must also be said that viruses, infections, their prognosis, their effects and their medical and social impact as a public health",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:186"
    }
  },
  {
    "page_content": "medical and social impact as a public health issue are also a subject of strong media coverage, such as flu, AIDS and hepatitis. However - and here we have the paradox of two related worlds that are disconnected both in the media and in society -, despite the many studies and evidence that link and concatenate the viruses with cancer, the information, dissemination, knowledge and content provided by the media in their health and cancer information to society hardly connect these two aspects,",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:187"
    }
  },
  {
    "page_content": "to society hardly connect these two aspects, unlike others such as cancer-smoking, or cancer-ageing. The role of vaccines, at a time when the anti-vaccine movements are rearming and advancing, first on social networks and then in society, is also decisive in this issue, and while the big question in the popular imagination continues to be whether a cancer vaccine will ever be discovered, medicine has some that serve to curb certain tumours. Thus, the press and the media neither transmit nor",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:188"
    }
  },
  {
    "page_content": "the press and the media neither transmit nor have great knowledge about the binomial subject of study of this Symposium; they do not dedicate special time, space, resources or contents (informative or educational) to this specific angle of the many news stories they publish about cancer. We suggest, therefore, some measures from the media to report on cancer and viruses Include in the news coverage on cancer - which is widespread and frequent - information related to its relationship with",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:189"
    }
  },
  {
    "page_content": "- information related to its relationship with viruses, either as emergent or underlying information. It is an aspect that matters to society and so the media should not ignore it.Investigate and activate content on the virus / cancer binomial from the editorial planning boards, with reliable and specialised sources.To broaden the sense of disclosure on medicine, diseases, prevention and research, beyond the information resulting from announcements, reports or campaigns; and to emphasise this",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:190"
    }
  },
  {
    "page_content": "reports or campaigns; and to emphasise this treatment of the contents.Combat health and cancer myths and ‘fake news’ with rigorous, clear and accurate verification practices to stop confusion, poor news and information gaps.The press and media are undoubtedly committed to the fight against cancer and include news coverage in their agendas and work strategies, but the relationship between oncological diseases and viruses must have greater incidence, reach, development and presence. # QUESTION:",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:191"
    }
  },
  {
    "page_content": "reach, development and presence. # QUESTION: HOW IS THE VIRUS CANCER RELATIONSHIP EXPERIENCED, FROM THE PERSPECTIVE OF THE SPANISH PATIENTS WITH CANCER GROUP, GEPAC? The Virus and Cancer association is little known by the population and information from cancer patient associations is also partial and deficient in this respect. Therefore, a great deal of educational and informative work remains to be done in this area. This absence often forces one to turn to “Doctor Google” for information,",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:192"
    }
  },
  {
    "page_content": "one to turn to “Doctor Google” for information, which can lead to misinformation, since one does not know which sites are reliable, or does not have sufficient knowledge to fully understand and interpret the data that appear. Probably what resonates most with patients, families and society at large are associations such as HPV, HBV or HIV and cancer. According to the U.S. National Cancer Institute, “Certain infectious germs, including viruses, bacteria and parasites, can cause cancer or",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:193"
    }
  },
  {
    "page_content": "bacteria and parasites, can cause cancer or increase the risk of tumour formation. Also, some infections weaken the immune system, making the body less able to fight other infections that cause cancer. Some viruses, bacteria and parasites also cause chronic inflammation that can lead to cancer [158-160] With no knowledge of these basic facts, it should not be surprising that the social demand and requirement by patients and associations for adequate vaccines, when they exist, is also not of an",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:194"
    }
  },
  {
    "page_content": "vaccines, when they exist, is also not of an appropriate intensity. It is often ignored that protection with a condom is not always sufficient for the prevention of all types of sexually transmitted viruses, in addition to limiting sexual partners. GEPAC wants to highlight the need for sex education for the prevention of STDs, to teach safe sexual practices, care for personal health and our sexual partners. If we are informed, we know all the ways of contagion and we are aware of the importance",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:195"
    }
  },
  {
    "page_content": "of contagion and we are aware of the importance of medical check-ups if we live in dangerous situations; we can reduce the number of people affected by this type of illness. It should be noted that most of the viruses that can pose a cancer risk can be transmitted through certain body fluids or blood. And not only that, this type of virus and thus disease, in addition to the health problems they entail, are linked to psychological repercussions that will depend on the severity of your",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:196"
    }
  },
  {
    "page_content": "that will depend on the severity of your situation, symptoms and treatment received. In addition, it can lead to anxiety, depression, or feelings of guilt or fear of criticism due to the social stigma. Perhaps guilt is the most difficult emotion to handle in a situation where the contraction of a virus seems to be linked to risky sexual practices. For all these reasons, we can conclude that only by educating young people and working with the groups most at risk will we be able to have informed",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:197"
    }
  },
  {
    "page_content": "most at risk will we be able to have informed adults in the future and thus reduce cases of infection. # QUESTION: WHAT ARE THE REFLECTIONS ON THE VIRUS CANCER RELATIONSHIP FROM AN ETHICAL PERSPECTIVE? Classical medical training, the one we received in medical schools, has been and is the victim of a bias that vitiates many of our approaches to issues such as the one raised here, that of the relationship between viruses and cancer. It is a bias that did not exist in classical medicine but has",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:198"
    }
  },
  {
    "page_content": "that did not exist in classical medicine but has become invasive since the early 19th century. The advances in experimental research made it possible from that moment on to describe with great precision the pathognomonic symptoms of some diseases, almost at the same time as their causal agents were found. Think, for example, of the microorganisms that were identified by the dozens in the late 19th century, and which led to the utopia of thinking that each morbid species would be produced by a",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:199"
    }
  },
  {
    "page_content": "that each morbid species would be produced by a specific agent: meningitis by meningococcus, pneumonia by pneumococcus, etc. On the other hand, the advances in experimental pharmacology allowed the identification of the first “specific” drugs that acted against the aetio-logical agents that produced diseases, leaving all other organic structures unharmed. It was the dream of Béchamp’s “atoxyl” and Ehrlich’s “magic bullets”. At the heart of all this was an unconscious presupposition, that of",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:200"
    }
  },
  {
    "page_content": "this was an unconscious presupposition, that of “specificity”. Diseases were species like those in botany and zoology. A catalogue of diseases similar to Linnaeus’s Systema Naturæ, the catalogue of “morbid species”, could therefore be drawn up. Each of them would have a “specific aetiology”, which, for example, microbiology would discover, and “specific therapeutics” would also begin to be found, which by attacking the cause of the disease, would restore the state of health. It was therefore a",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:201"
    }
  },
  {
    "page_content": "restore the state of health. It was therefore a linear process, starting with a specific cause, continuing with the clinical picture of a morbid species and ending with the application of a specific treatment. It was the chain of specificity. The role of medicine was to find the remedies, usually pharmacological, that would act on the specific agent and allow “restitutio ad integrum”. A paradigmatic example of this is pulmonary tuberculosis. The clinical picture of this disease, which was very",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:202"
    }
  },
  {
    "page_content": "clinical picture of this disease, which was very common at the time of the industrial revolution, was described with great precision by the great masters of the anatomical clinical method, including Laënnec. Koch identified the bacillus that caused it, and later, in the mid-20th century, the first specific treatment, streptomycin, was developed. From that moment on, every doctor knew what he had to do: use that antibiotic, and the tuberculosis and TB drugs that came soon after, to kill the Koch",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:203"
    }
  },
  {
    "page_content": "TB drugs that came soon after, to kill the Koch bacillus and thus cure the disease. But the example of tuberculosis is very illustrative of the limitations of this way of understanding the disease. I still remember the debates about tuberculosis from my time as a medical student in the 1960s. Could it be said that TB was caused by Koch’s bacillus? Wasn’t it also true that pauperism, malnutrition, poor hygiene, etc., played a role? What was the cause of the tuberculosis? Was it just one or was",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:204"
    }
  },
  {
    "page_content": "cause of the tuberculosis? Was it just one or was it many? And how to articulate them? I have brought this example to mind because it is very illustrative of the way in which school medicine has understood illness, and because it expresses very well the so-called “chain of specificity”. TB is caused by Koch’s bacillus. If we eradicated it, there would be no pulmonary tuberculosis, even with pauperism, malnutrition, etc. These, on the other hand, are not strictly medical issues, but social ones.",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:205"
    }
  },
  {
    "page_content": "are not strictly medical issues, but social ones. Let us now turn to our problem, that of viruses and cancer. It is clear that cancer is the result of genetic dysregulation. This alteration is produced by various agents, including viruses. If we were able to eliminate these or correct the alterations, they produce in the genome by means of gene editing techniques, some, if not all, of the important types of cancer would disappear. That is the goal of medicine, and that is the aim of the",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:206"
    }
  },
  {
    "page_content": "the goal of medicine, and that is the aim of the research being done today. It is, again, the linear scheme, the chain of specificity. Things are, however, more complex. There is no single causal factor. In fact, this term should disappear from our vocabulary, or at least become a discreet second term. Cause is what necessarily produces an effect, so that even if all the concomitant factors were to disappear, the effect would be produced by it alone. Something impossible to affirm in the",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:207"
    }
  },
  {
    "page_content": "it alone. Something impossible to affirm in the empirical world. What we know are not causes, even if they seem to be, but functional correlations. In fact, all experimental research aims to identify them as precisely as possible. They are correlations, not causes. And among these correlations, there is no doubt that the Koch bacillus plays an important role, but so do immunity and environmental conditions, etc. In fact, not every person infected with Koch’s bacillus develops tuberculosis.",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:208"
    }
  },
  {
    "page_content": "with Koch’s bacillus develops tuberculosis. Rather than establishing a linear relationship between cause, clinical picture and therapy, it is necessary to make use of more complex schemes, of a circular or at least spiral nature. In the genesis of cancer, endogenous factors intervene, such as the genome we have, but also exogenous factors. The fact is that viruses are some of those exogenous factors that infect cells and alter their genetic information. There are many other exogenous factors",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:209"
    }
  },
  {
    "page_content": "There are many other exogenous factors that produce similar results. Think of radiation, for example, or tobacco. These are the factors that can be called direct. But there are many other indirect factors. Thus, tobacco is a direct agent in the case of certain lung cancers but acts as an indirect agent in hepatocellular carcinoma. And along with tobacco and alcohol, place sexual habits in the case of infection by the human papillomavirus, food habits in fatty liver and the increased likelihood",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:210"
    }
  },
  {
    "page_content": "in fatty liver and the increased likelihood of liver cancer, etc. The conclusion of all this already long journey is that life habits are important factors in the genesis of cancer, in some cases indirectly, through viruses, and in others directly. This seems elementary, but it is far from clear, not only in the population, but even among doctors. We believe that what is important is the control of the gene alterations that trigger uncontrolled cell reproduction, and that the other is not a",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:211"
    }
  },
  {
    "page_content": "cell reproduction, and that the other is not a question of medicine. And we lose sight of the fact that rather than being curative, medicine should be preventative. The dizzying increase in its therapeutic capacity is making us forget this primary truth. The primary role of the physician is not cure but prevention; health education is preferable. Otherwise, we arrive at the absurdity that we live and suffer every day. This is the case of the diabetic who eats cakes because this can be fixed by",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:212"
    }
  },
  {
    "page_content": "who eats cakes because this can be fixed by increasing the dose of insulin, or the loss of respect for HIV because we already have effective therapies. Prevention, or rather, health education, is not just about information. That is one of the great mistakes that have become almost universal. Educating is far more difficult and complicated than informing. Education is always about knowing how to manage one’s own life autonomously and prudently. It’s knowing how to make the right decisions. Or to",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:213"
    }
  },
  {
    "page_content": "knowing how to make the right decisions. Or to put it another way, it’s making the choices we have to make. And here’s the ethics. The aim of this discipline is none other than to teach us how to make decisions, the right decisions, so that we do what we have to do. The big question of ethics is always the same: what should I do? And there can only be one answer: among all the possible courses of action in a given situation, only the decision that leads to the optimal course is good or correct,",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:214"
    }
  },
  {
    "page_content": "leads to the optimal course is good or correct, that is, the one which adheres to the values at stake most and injures them least. Only the optimum course is good. Everything else is bad. A good surgeon is the one who performs the best possible operation, and a good judge is the one who passes the best possible sentence, etc. To know how to do this, and do it well, is to be educated. This is not easy, because the human mind is full of dark areas, those that Freud called unconscious, that skew",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:215"
    }
  },
  {
    "page_content": "those that Freud called unconscious, that skew our decisions without us noticing. Good education is the art of managing all these factors properly so that our decisions are the best they can possibly be. This, and no other, is the goal of ethics.",
    "metadata": {
      "source": "../data/plain/PMC8638760.plain.txt",
      "id": "../data/plain/PMC8638760.plain.txt:216"
    }
  },
  {
    "page_content": "Association of Radiotherapy for Rectal Cancer and Second Gynecological Malignant Neoplasms Key Points\nQuestion\nIs radiotherapy for rectal cancer associated with the increasing risk of second gynecological malignant neoplasms and prognosis in women with rectal cancer?\nFindings",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:0"
    }
  },
  {
    "page_content": "Findings\nIn this cohort study of 20 142 patients with rectal cancer, radiotherapy for rectal cancer was associated with an increased risk of second cancer of the uterine corpus and ovarian cancer. Development of cancer of the uterine corpus was associated with a worse prognosis.\nMeaning",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:1"
    }
  },
  {
    "page_content": "Meaning\nResults of this study suggest that special attention is warranted to reduce the risk of second gynecological malignant neoplasms in the treatment and follow-up of patients with rectal cancer after radiotherapy. Abstract\nImportance\nRadiotherapy is a common treatment for rectal cancer, yet the risk of second gynecological malignant neoplasms (SGMNs) in patients with rectal cancer undergoing radiotherapy have not been adequately studied.\nObjective",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:2"
    }
  },
  {
    "page_content": "Objective\nTo investigate the association between radiotherapy and the risk of individual types of SGMN in patients with rectal cancer and assess survival outcomes.\nDesign, Setting, and Participants",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:3"
    }
  },
  {
    "page_content": "Design, Setting, and Participants\nA large population-based cohort study was designed to identify the risk of SGMNs in patients with rectal cancer diagnosed from January 1973 to December 2015. The statistical analysis was conducted from September 2019 to April 2020. The study was based on the 9 cancer registries of Surveillance, Epidemiology, and End Results database. A total of 20 142 female patients with rectal cancer in localized and regional stage were included.\nExposure",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:4"
    }
  },
  {
    "page_content": "Exposure\nReceipt of neoadjuvant radiotherapy for rectal cancer.\nMain Outcomes and Measures",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:5"
    }
  },
  {
    "page_content": "Main Outcomes and Measures\nThe development of an SGMN defined as any type of GMN occurring more than 5 years after the diagnosis of rectal cancer. The cumulative incidence of SGMNs was estimated by Fine-Gray competing risk regression. Poisson regression was used to evaluate the radiotherapy-associated risk for SGMNs in patients undergoing radiotherapy vs patients not undergoing radiotherapy. The Kaplan-Meier method was used to assess the survival outcomes of patients with SGMNs.\nResults",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:6"
    }
  },
  {
    "page_content": "Of 20 142 patients, 16 802 patients (83.4%) were White and the median age was 65 years (interquartile range, 54-74 years). A total of 5310 (34.3%) patients were treated with surgery and radiotherapy, and 14 832 (65.7%) patients were treated with surgery alone. The cumulative incidence of SGMNs during 30 years of follow-up was 4.53% among patients who received radiotherapy and 1.53% among patients who did not. In competing risk regression analysis, undergoing radiotherapy was associated with a",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:7"
    }
  },
  {
    "page_content": "undergoing radiotherapy was associated with a higher risk of developing cancer of the uterine corpus (adjusted hazard ratio, 3.06; 95% CI, 2.14-4.37; P <.001) and ovarian cancer (adjusted hazard ratio, 2.08; 95% CI, 1.22-3.56; P =.007) compared with those who did not receive radiotherapy. The dynamic radiotherapy-associated risks (RR) for cancer of the uterine corpus significantly increased with increasing age at rectal cancer diagnosis (aged 20-49 years: adjusted RR, 0.79; 95% CI, 0.35-1.79;",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:8"
    }
  },
  {
    "page_content": "years: adjusted RR, 0.79; 95% CI, 0.35-1.79; P =.57; aged 50-69 years: adjusted RR, 3.74; 95% CI, 2.63-5.32; P <.001; aged ≥70 years: adjusted RR, 5.13; 95% CI, 2.64-9.97; P <.001) and decreased with increasing latency since rectal cancer diagnosis (60-119 months: adjusted RR, 3.22; 95% CI, 2.12-4.87; P <.001; 120-239 months: adjusted RR, 2.72; 95% CI, 1.75-4.24; P <.001; 240-360 months: adjusted RR, 1.95; 95% CI, 0.67-5.66; P =.22), but the dynamic RR for ovarian cancer increased with",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:9"
    }
  },
  {
    "page_content": "the dynamic RR for ovarian cancer increased with increasing latency since rectal cancer diagnosis (60-119 months: adjusted RR, 0.70; 95% CI, 0.26-1.89; P =.48; 120-239 months: adjusted RR, 2.26; 95% CI, 1.09-4.70; P =.03; 240-360 months: adjusted RR, 11.84; 95% CI, 2.18-64.33; P =.004). The 10-year overall survival among patients with radiotherapy-associated cancer of the uterine corpus was significantly lower than that among matched patients with primary cancer of the uterine corpus (21.5% vs",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:10"
    }
  },
  {
    "page_content": "primary cancer of the uterine corpus (21.5% vs 33.6%; P =.01).",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:11"
    }
  },
  {
    "page_content": "Conclusions and Relevance\nRadiotherapy for rectal cancer was associated with an increased risk of cancer of the uterine corpus and ovarian cancer. Special attention should be paid to reduce radiotherapy-associated SGMNs and improve their prognosis. Abstract",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:12"
    }
  },
  {
    "page_content": "This cohort study assesses the association between radiotherapy and the risk of individual types of second gynecological malignant neoplasms in patients with rectal cancer and estimates survival outcomes for patients with secondary cancers. # Introduction During the last decades, several large randomized trials have demonstrated that neoadjuvant radiotherapy plays a well-established role in the improvement of locoregional control of rectal cancer but is not associated with increased long-term",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:13"
    }
  },
  {
    "page_content": "but is not associated with increased long-term survival.1,2,3 Therefore, the benefits and adverse events of radiotherapy should be carefully balanced when considering all potential effects of radiotherapy. Radiotherapy-associated second primary cancer (SPC) is a rare but notable late complication of cancer therapy.4 Studies assessing the risk of SPC are inconsistent regarding the role of radiotherapy for rectal cancer treatment.5,6,7 Although some studies have demonstrated an increased risk of",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:14"
    }
  },
  {
    "page_content": "studies have demonstrated an increased risk of overall SPCs after radiotherapy for rectal cancer treatment, others have reported no obvious increased risk.8,9,10 Because of the likelihood of pelvic organs receiving a greater radiotherapy dose than organs in nonpelvic areas, it is necessary to understand the risk of SPCs in organs within the irradiated volume.9,11,12 Assessments of the potential risk of radiotherapy-associated SPC for pelvic cancers, including malignant neoplasms of prostate and",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:15"
    }
  },
  {
    "page_content": "including malignant neoplasms of prostate and bladder, have verified the idea of an increased risk of SPCs in patients undergoing pelvic radiotherapy.13,14,15 However, whether the risk of second gynecological malignant neoplasms (SGMNs) is increased after radiotherapy for rectal cancer has not been well addressed. Although previous studies8,9,10,16,17,18,19,20 have investigated the risk of SGMNs among patients with rectal cancer treated with radiotherapy, the current research on this topic is",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:16"
    }
  },
  {
    "page_content": "the current research on this topic is limited and contradictory. Most studies oversimplified the risk estimation by grouping various types of gynecological malignant neoplasms (GMNs) into 1 broad category, without consideration of the great tumor heterogeneity and differences in pathogenesis among SGMN entities.8,9,10,16,17,18,19,20 The understanding of radiotherapy-associated SGMN has prognostic and therapeutic implications but has been rarely studied. Therefore, we performed this study with",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:17"
    }
  },
  {
    "page_content": "studied. Therefore, we performed this study with the aims of investigating radiotherapy and the risk of individual types of SGMN and assessing patient survival outcomes. # Methods ## Database and Participants Female patients diagnosed with rectal cancer as the first primary cancer were identified from 9 registries of the Surveillance, Epidemiology and End Results (SEER) database between January 1, 1973, and December 31, 2015. All primary cancer sites were coded according to the International",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:18"
    }
  },
  {
    "page_content": "sites were coded according to the International Classification of Diseases for Oncology, Third Edition. The patients included were pathologically diagnosed with rectal cancer (C19.9) or rectosigmoid cancer (C20.9). The tumor stage was restricted to the localized and regional stage, and the details of tumor stage are shown in eTable 1 in the Supplement. The exclusion criteria included patients in whom rectal cancer were not their first primary cancer, patients who were aged younger than 20",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:19"
    }
  },
  {
    "page_content": "cancer, patients who were aged younger than 20 years, patients with distant stage, patients who survived less than 5 years after rectal cancer diagnosis, patients who did not undergo surgery, and patients with missing data on radiotherapy, surgery, age, tumor stage, race, survival status or follow-up information. This study has been approved by the Ethics Committee of Cancer Hospital, Chinese Academy of Medical Sciences. The access to and use of SEER data did not require informed patient",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:20"
    }
  },
  {
    "page_content": "use of SEER data did not require informed patient consent. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cohort studies. ## Treatment Interventions for Rectal Cancer Patients with rectal cancer were classified into 2 groups according to initial treatment modality. The radiotherapy group was composed of patients with rectal cancer who received surgery and neoadjuvant external-beam radiotherapy, and the",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:21"
    }
  },
  {
    "page_content": "neoadjuvant external-beam radiotherapy, and the no-radiotherapy group was composed of patients who received surgery alone. We excluded patients who received other types of radiotherapy (ie, brachytherapy, combination therapy). The SEER database collected data only on the initial course of cancer treatment, and the radiotherapy doses were not registered in the SEER database. ## Definition and Follow-up of SGMNs The primary outcome of this study was the development of an SGMN, which was defined",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:22"
    }
  },
  {
    "page_content": "was the development of an SGMN, which was defined as any type of GMN occurring more than 5 years after the treatment of rectal cancer because of at least a 5-year latency period from radiotherapy exposure to solid tumor occurrence.21 The SEER program adheres to the International Classification of Diseases for Oncology, Third Edition guidelines to distinguish SPCs from recurrent disease. To obtain comprehensive estimations for the risk of SGMNs, we first estimated the risk for all types of",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:23"
    }
  },
  {
    "page_content": "we first estimated the risk for all types of combined SGMNs and then separately estimated the risk in different types of female genital organs, including the cervix uteri (C53.0-C53.9), corpus and uterus (C54.0-C54.9, C55.9), ovary (C56.9) and other female genital organs as 1 group (C51.0-C51.9, C52.9, C57.0-C57.9, C58.9). The follow-up for SGMNs began 5 years after rectal cancer diagnosis and ended at the date of diagnosis of any SGMN, all-cause death, or after 30 years of follow-up, whichever",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:24"
    }
  },
  {
    "page_content": "death, or after 30 years of follow-up, whichever occurred first. The cut-off point for follow-up was defined as January 1, 2016 (April 2019 SEER data release). ## Statistical Analysis Fine-Gray competing risk regression analysis was used to assess the cumulative incidence of SGMN development. Experiencing a non-SGMN and dying of all causes were considered competing events by calculating hazard ratios (HRs) and 95% CIs for SGMN occurrence. The multivariable risk model was built by using a",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:25"
    }
  },
  {
    "page_content": "The multivariable risk model was built by using a backward selection procedure with variables with 2-sided P <.05 in univariable analyses, which was considered statistically significant and included in multivariable analyses. χ2 tests were used to compare categorical data, or Fisher exact test when frequencies were below 5. Mann-Whitney test were used for analysis of continuous variables with a normal and nonnormal distribution, respectively. This procedure was performed with R software,",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:26"
    }
  },
  {
    "page_content": "This procedure was performed with R software, version 3.5.3 (R Project for Statistical Computing). The radiotherapy-associated risk (RR) was estimated by using Poisson regression analysis with the relative risk and 95% CIs of SGMN development for patients with rectal cancer who received radiotherapy compared with those who did not receive radiotherapy, and the RRs were calculated with R software version 3.5.3. Then, Poisson regression analysis was used to calculate the standardized incidence",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:27"
    }
  },
  {
    "page_content": "was used to calculate the standardized incidence ratio (SIR) and 95% CIs. The SIR was defined as the ratio of observed incidence SGMNs among rectal cancer survivors to the incidence of GMNs in the US general population. The SIRs were calculated with SEER*Stat 8.3.6. Both RRs and SIRs were adjusted for the age at rectal cancer diagnosis and the calendar year of rectal cancer diagnosis in our analysis. The details of statistical methods are shown in eFigure 2 in the Supplement. To further",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:28"
    }
  },
  {
    "page_content": "shown in eFigure 2 in the Supplement. To further evaluate the dynamic risks and incidence for SGMNs associated with radiotherapy, we calculated the RRs and SIRs stratified by latency time since rectal cancer diagnosis, age at rectal cancer diagnosis, and year of rectal cancer diagnosis. To evaluate the prognosis of SGMNs, the Kaplan-Meier method was used to calculate the 10-year overall survival for SGMNs and only primary GMN, and P values were calculated with the log-rank test. Overall",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:29"
    }
  },
  {
    "page_content": "were calculated with the log-rank test. Overall survival was defined as the time from SGMN diagnosis to death from any cause. The only primary GMN was defined as the patients diagnosed with only GMN and without any other cancers throughout their lifetime. Propensity score matching was used to reduce possible bias for survival comparison. These analyses were performed using R software (version 3.5.3). # Results ## Patient Characteristics A total of 22 589 patients with rectal cancer were",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:30"
    }
  },
  {
    "page_content": "total of 22 589 patients with rectal cancer were identified (eFigure 1 in the Supplement). After excluding the patients with nonmatching data, 20 142 patients remained in final cohort, 16 802 patients (83.4%) were White, and the median age was 65 years (interquartile range, 54-74 years). The median follow-up time was 140 months (interquartile range, 92-212 months). A total of 14 832 patients (65.7%) were in the no-radiotherapy group and 5310 patients (34.3%) were in the radiotherapy group. The",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:31"
    }
  },
  {
    "page_content": "(34.3%) were in the radiotherapy group. The baseline characteristics of patients with rectal cancer by treatment modality are shown in Table 1. After a latency of 5 years, 176 patients (1.2%) in the no-radiotherapy group and 144 patients (2.7%) in the radiotherapy group developed SGMN. The baseline characteristics of patients who developed SGMN are shown in eTable 2 in the Supplement. ## Cumulative Incidences of SGMNs The cumulative incidence of combined SGMNs was 2.16% after rectal cancer",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:32"
    }
  },
  {
    "page_content": "of combined SGMNs was 2.16% after rectal cancer diagnosis; the incidences were 1.53% in patients with no radiotherapy and 4.53% in patients receiving radiotherapy (P <.001) (Figure 1A). In organ-specific analyses, the cumulative incidences of cancer of the uterine corpus, ovarian cancer, and other SGMNs were significantly higher in the radiotherapy group than the no-radiotherapy group, including cancer of the uterine corpus (1.00% vs 2.80%; P <.001), ovarian cancer (0.29% vs 0.98%; P =.007),",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:33"
    }
  },
  {
    "page_content": "ovarian cancer (0.29% vs 0.98%; P =.007), and other SGMNs (0.20% vs 0.62%; P =.007), but no difference was observed for cervical cancer (Figure 1B-E). ## Risk of SGMNs Attributable to Radiotherapy All variables listed in Table 1 were selected for univariable competing risk regression analysis (eTables 3-7 in the Supplement). In multivariable analysis, radiotherapy was associated with a higher risk of developing combined SGMNs (adjusted HR, 2.99; 95% CI, 2.23-4.02; P <.001). In analyses of each",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:34"
    }
  },
  {
    "page_content": "95% CI, 2.23-4.02; P <.001). In analyses of each type of SGMN, increased risks were observed in cancer of the uterine corpus (adjusted HR, 3.06; 95% CI, 2.14-4.37; P <.001) and ovarian cancer (adjusted HR, 2.08; 95% CI, 1.22-3.56; P =.007) but not in cervical cancer or other SGMNs (Table 2). In subgroup analyses, the increased risk of developing cancer of the uterine corpus and ovarian cancer was associated with radiotherapy in most subgroups with HRs greater than 1.00 (eTables 8-12, and",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:35"
    }
  },
  {
    "page_content": "with HRs greater than 1.00 (eTables 8-12, and eFigures 3 and 4 in the Supplement). The RRs were calculated to confirm the risk of SGMNs attributable to radiotherapy. We found that the adjusted RR of additional risk for combined SGMNs was 2.82 (95% CI, 2.24-3.56, P <.001), and increased risk was also observed for cancer of the uterine corpus (adjusted RR, 3.19; 95% CI, 2.39-4.26; P <.001), ovarian cancer (adjusted RR, 2.26; 95% CI, 1.30-3.91; P =.004), and other SGMNs (adjusted RR, 2.72; 95% CI,",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:36"
    }
  },
  {
    "page_content": "and other SGMNs (adjusted RR, 2.72; 95% CI, 1.43-5.16; P =.002) (Table 2). We then found that the SIR for combined SGMNs was 2.32 (95% CI, 1.95-2.73, P <.05) in patients who received radiotherapy, and the SIRs for patients who underwent radiotherapy were significantly higher for cancer of the uterine corpus (SIR, 2.88; 95% CI, 2.33-3.5; P <.05) and other SGMNs (SIR, 2.79; 95% CI, 1.65-4.41; P <.05) (Table 2). ## Dynamic Risk and Incidence Evaluation for SGMNs To assess the risks of SGMNs",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:37"
    }
  },
  {
    "page_content": "Evaluation for SGMNs To assess the risks of SGMNs attributable to radiotherapy, we established 3 dynamic RR plots based on latency period, time of rectal cancer diagnosis, and age at rectal cancer diagnosis (Figure 2; eTables 13-17 in the Supplement). In the dynamic latency-RR plot, an increased risk of cancer of the uterine corpus was observed in the early latency, but this risk presented a downward trend in the late latency (60-119 months: adjusted RR, 3.22; 95% CI, 2.12-4.87; P <.001;",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:38"
    }
  },
  {
    "page_content": "adjusted RR, 3.22; 95% CI, 2.12-4.87; P <.001; 120-239 months: adjusted RR, 2.72; 95% CI, 1.75-4.24; P <.001; 240-360 months: adjusted RR, 1.95; 95% CI, 0.67-5.66; P =.22) (Figure 2A; eTable 14 in the Supplement). In the dynamic age-RR plot, no increased risk of cancer of the uterine corpus was observed in patients aged 20 to 50 years with rectal cancer, but the risk gradually increased and peaked at an age of older than 70 years (20-49 years: adjusted RR, 0.79; 95% CI, 0.35-1.79; P =.57; 50-69",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:39"
    }
  },
  {
    "page_content": "RR, 0.79; 95% CI, 0.35-1.79; P =.57; 50-69 years: adjusted RR, 3.74; 95% CI, 2.63-5.32; P <.001; ≥70 years: adjusted RR, 5.13; 95% CI, 2.64-9.97; P <.001) (Figure 2B; eTable 14 in the Supplement). In the dynamic diagnosis time-RR plot, a slightly increased risk of cancer of the uterine corpus was observed after radiotherapy in the years from 1975 to 1984, and this risk remained elevated up to the years from 2005 to 2015 (1975-1984: adjusted RR, 2.67; 95% CI, 1.48-4.83; P =.001; 1985-1994:",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:40"
    }
  },
  {
    "page_content": "RR, 2.67; 95% CI, 1.48-4.83; P =.001; 1985-1994: adjusted RR, 3.58; 95% CI, 2.21-5.79; P <.001; 1995-2004: adjusted RR, 2.72; 95% CI, 1.62-4.59; P <.001; ≥2005: adjusted RR, 5.00; 95% CI, 1.80-13.92; P =.002) (Figure 2C; eTable 14 in the Supplement). However, we observed 3 opposite risk trends in 3 RR plots of ovarian cancer compared with the trends in cancer of the uterine corpus, such as in the latency-RR plot (60-119 months: adjusted RR, 0.70; 95% CI, 0.26-1.89; P =.48; 120-239 months:",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:41"
    }
  },
  {
    "page_content": "0.70; 95% CI, 0.26-1.89; P =.48; 120-239 months: adjusted RR, 2.26; 95% CI, 1.09-4.70; P =.03; 240-360 months: adjusted RR, 11.84; 95% CI, 2.18-64.33; P =.004; Figure 2D, Supplement Table 15), age-RR plot (20-49 years: adjusted RR, 4.63; 95% CI, 0.40-54.17; P =.22; 50-69 years: adjusted RR, 2.19; 95% CI, 1.13-4.21; P =.02; ≥70 years: adjusted RR, 2.02; 95% CI, 0.67-6.12; P =.21; Figure 2E, Supplement Table 15) and diagnosis time-RR plot (1975-1984: adjusted RR, 5.06; 95% CI, 1.46-17.55; P =.01;",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:42"
    }
  },
  {
    "page_content": "adjusted RR, 5.06; 95% CI, 1.46-17.55; P =.01; 1985-1994: adjusted RR, 3.05; 95% CI, 1.34-6.96; P =.008; 1995-2004: adjusted RR, 1.02; 95% CI, 0.41-2.52; P =.97; ≥2005: adjusted RR, 1.93; 95% CI, 0.12-31.02; P =.64) (Figure 2D-F; eTable 14 and eTable 15 in the Supplement). In addition, we evaluated the dynamic SIRs for patients treated with radiotherapy and patients not treated with radiotherapy. For patients not treated with radiotherapy, no increased incidences of cancer of the uterine corpus",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:43"
    }
  },
  {
    "page_content": "incidences of cancer of the uterine corpus (eFigure 5A-C in the Supplement) were observed compared with the incidence in the US general population in 3 plots. For patients who underwent radiotherapy, the SIRs for cancer of the uterine corpus presented similar findings as the RR plots (eFigure 5A-C in the Supplement). In analyses of SIRs for ovarian cancer, we found that SIRs for ovarian cancer in patients who did not receive radiotherapy were significantly lower than those in the US general",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:44"
    }
  },
  {
    "page_content": "significantly lower than those in the US general population in 3 plots (eFigure 5D-F in the Supplement), but no significant increased incidence of ovarian cancer was observed for patients treated with radiotherapy compared with the US general population (eFigure 5D-F in the Supplement). The details of RRs and SIRs were shown in eTables 18-22 in the Supplement. ## Survival Outcome of SGMNs We compared survival between patients with cancer of the uterine corpus after radiotherapy and no",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:45"
    }
  },
  {
    "page_content": "of the uterine corpus after radiotherapy and no radiotherapy, and the 10-year overall survival of patients who developed cancer of the uterine corpus after radiotherapy was significantly lower than that of patients after no radiotherapy, both before propensity score matching (Figure 3A) and after propensity score matching (Figure 3B). We then used matched only primary cancer of the uterine corpus patients as a control group by using propensity score matching. We observed that the 10-year",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:46"
    }
  },
  {
    "page_content": "score matching. We observed that the 10-year overall survival for patients who developed cancer of the uterine corpus after radiotherapy was significantly lower than that for matched patients with only primary cancer of the uterine corpus (10-year overall survival, 21.5% vs 36.6%; P =.01) (Figure 3C), and no difference was observed between patients without radiotherapy and matched patients with only primary cancer of the uterine corpus (Figure 3D). Information on only primary GMNs and survival",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:47"
    }
  },
  {
    "page_content": "Information on only primary GMNs and survival analyses for combined SGMNs, ovarian cancer, cervical cancer and other SGMNs were shown in eTables 23-27, and eFigures 6-9 in the Supplement. # Discussion This is, to our knowledge, the first large population-based study to present the risk dynamics and prognosis of individual types of SGMN after radiotherapy among patients with rectal cancer. In our study, the key findings are as follows. First, radiotherapy was considered an important risk factor",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:48"
    }
  },
  {
    "page_content": "was considered an important risk factor for the development of cancer of the uterine corpus and ovarian cancer in patients with rectal cancer. Second, the incidence of cancer of the uterine corpus after radiotherapy was higher than that in the US general population. Third, the risks for developing cancer of the uterine corpus after radiotherapy increased with age, increased with diagnosis time, and decreased with latency, but the opposite trends were observed for ovarian cancer. Fourth, cancer",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:49"
    }
  },
  {
    "page_content": "were observed for ovarian cancer. Fourth, cancer of the uterine corpus after radiotherapy presented a poor prognosis. Previous studies8,9,10,16 assessing the risk of SGMNs after radiotherapy treatment for rectal cancer showed conflicting results (eTable 28 in the Supplement); there are several reasons for these variations in results, including the definition of SGMNs, latency period selection, length of follow-up duration, methodology and sample size of the cohort population. Birgisson et al9",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:50"
    }
  },
  {
    "page_content": "size of the cohort population. Birgisson et al9 and Wiltink et al8 found that radiotherapy was not associated with an increased risk of developing SGMNs in patients with rectal cancer. However, only 8 and 10 SGMNs were observed in these 2 studies, which lacked statistical power to support their conclusions. Rombouts et al10 reported that SGMNs (combined malignant neoplasms of the corpus uteri, cervix uteri, ovary, vulva, and vagina) occurred more frequently in patients with rectal cancer who",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:51"
    }
  },
  {
    "page_content": "frequently in patients with rectal cancer who received radiotherapy, but this study did not perform risk analyses for each type of SGMN. In addition, Kendal et al17 found that an increased risk of developing SGMNs, including cancer of the uterine corpus and cervical cancer as 1 group, after radiotherapy treatment, but they did not consider the great heterogeneity among different types of GMNs. To better address this issue, we separately estimated the risk for each type of SGMN in our study. The",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:52"
    }
  },
  {
    "page_content": "the risk for each type of SGMN in our study. The issue of latency cut-off point was determined to be associated with the risk of SPC occurrence after radiotherapy, which may be the main reason for the conflicting results regarding the risk of developing ovarian cancer from different studies.21 Wang et al19 reported that preoperative radiotherapy increased the risk of SPCs in the uterus but not the cervix or ovary after a latency period of more than 1 year. Similarly, Warschkow et al16 performed",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:53"
    }
  },
  {
    "page_content": "1 year. Similarly, Warschkow et al16 performed a cohort study to evaluate the risk for SPCs with a 1-year latency after radiotherapy treatment for rectal cancer and found that an increased risk of SGMNs after rectal cancer involved malignant neoplasms of the endometrium only, not the ovary, cervix, or vulva. In our study, we identified SGMNs that occurred after a 5-year latency because the 5-year latency period from radiotherapy exposure to solid tumor occurrence allowed for a more reasonable",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:54"
    }
  },
  {
    "page_content": "tumor occurrence allowed for a more reasonable conclusion to be drawn.4 To further confirm the latency influence on risk evaluation, we repeatedly analyzed the risk of SGMN using a 1-year cut-off latency, and found that the risk for cancer of the uterine corpus after radiotherapy continued to be increased, but no risk for other types of SGMNs. The statistical methods used for analysis are essential for the interpretation of the results. We used both competing risk regression and Poisson",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:55"
    }
  },
  {
    "page_content": "used both competing risk regression and Poisson regression to assess the risk of SGMNs. Herein, we assessed the increased risks of cancer of the uterine corpus and ovarian cancer after radiotherapy, but other types of SGMNs presented conflicting results according to different statistical method. We compared the incidence of SGMNs in patients who survived rectal cancer to the US general population, which could provide a more comprehensive understanding of the association between radiotherapy and",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:56"
    }
  },
  {
    "page_content": "of the association between radiotherapy and the incidence of SGMNs. In our analyses, we assessed the dynamic risk and incidence of SGMNs. The highest radiotherapy-associated risk for developing ovarian cancer was found after a latency of more than 20 years, but for cancer of the uterine corpus, the highest risk was within 5 to 10 years. This finding suggests that long-term follow-up may be warranted for the detection of ovarian cancer after radiotherapy, but follow-up for cancer of the uterine",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:57"
    }
  },
  {
    "page_content": "but follow-up for cancer of the uterine corpus should be considered in the early latency. An increased risk of cancer of the uterine corpus was observed with increasing age at diagnosis but was significantly decreased for ovarian cancer. This finding showed that both young patients and patients aged 50 years or older with rectal cancer who underwent radiotherapy faced a high risk of cancer of the uterine corpus. The mechanism underlying these opposite results between cancer of the uterine",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:58"
    }
  },
  {
    "page_content": "opposite results between cancer of the uterine corpus and ovarian cancer warrants further study. Despite the improvements in radiotherapy treatment for rectal cancer in recent decades associated with better local control, our findings showed that the risk of cancer of the uterine corpus increased to 2.7-fold from 1975 to 1984 and gradually increased to 5.0-fold after 2005. This finding may be associated with changes in radiotherapy dose and radiotherapy modality over time. During the study",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:59"
    }
  },
  {
    "page_content": "radiotherapy modality over time. During the study period from 1973 to 2015, radiotherapy treatment modality has shifted toward hypofractionation, which may underlie the higher incidence of cancer of the uterine corpus in more recent years. Compared with nonradiotherapy-associated GMNs, the clinical phenotype and prognosis of radiotherapy-associated SGMNs may present great heterogeneity. In our study, we found that patients with radiotherapy-associated cancer of the uterine corpus had worse",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:60"
    }
  },
  {
    "page_content": "cancer of the uterine corpus had worse survival than matched control patients with only primary cancer of the uterine corpus. However, no survival differences between radiotherapy-associated GMNs and only primary GMNs were observed for other types of GMNs. This finding suggests that the occurrence of radiotherapy-associated cancer of the uterine corpus might be due to the induction of other genetic signaling pathways after radiotherapy exposure, which is different from the normal genetic",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:61"
    }
  },
  {
    "page_content": "which is different from the normal genetic pathway of only primary cancer of the uterine corpus development. Owing to the varied genetic phenotype, radiotherapy-associated cancer of the uterine corpus is resistant to conventional treatment and presents worse prognosis. However, no genomic data in the SEER database could be used to interpret the genetic features of cancer of the uterine corpus after radiotherapy exposure. ## Strengths and Limitations The strengths of the present study include a",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:62"
    }
  },
  {
    "page_content": "The strengths of the present study include a long follow-up period to discover potential SGMNs as well as a large observation population with relatively homogenous treatment exposure identified from the SEER database. This study has limitations. First, a lack of randomization of the initial treatment for rectal cancer may be associated with potential biases. However, the occurrence of SGMNs may not only be associated with radiotherapy exposure but may also be affected by other crucial risk",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:63"
    }
  },
  {
    "page_content": "but may also be affected by other crucial risk factors, such as lifestyle, genetic background, environmental factors, and other cancer-related treatments.22 Therefore, it is impossible to balance all factors between the 2 treatment types. Instead, we adjusted all confounding risk factors using a multivariable risk competing model to reduce the potential bias associated with the lack of randomization. Second, we could not determine the associations between modality of radiotherapy, radiotherapy",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:64"
    }
  },
  {
    "page_content": "between modality of radiotherapy, radiotherapy dose, and number of administrations and the risk of SGMNs. Third, the SEER database records only the initial treatment information of rectal cancer, and whether patients with rectal cancer received delayed radiotherapy in subsequent treatment is unknown, which may potentially misclassify the patients in the radiotherapy group into the no-radiotherapy group. However, this limitation is unlikely to affect our main conclusion but reflects only an",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:65"
    }
  },
  {
    "page_content": "affect our main conclusion but reflects only an underestimation of the increased risk attributable to radiotherapy. # Conclusions In this cohort study, several methodologies were used together to assess an increased risk of developing cancer of the uterine corpus and ovarian cancer in female patients with rectal cancer who received radiotherapy, and the risk of SGMN was evaluated from several dimensions, which together could provide a meaningful reference for the treatment and follow-up of",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:66"
    }
  },
  {
    "page_content": "reference for the treatment and follow-up of SGMNs in patients with rectal cancer after radiotherapy.",
    "metadata": {
      "source": "../data/plain/PMC7794669.plain.txt",
      "id": "../data/plain/PMC7794669.plain.txt:67"
    }
  },
  {
    "page_content": "Impact of national cancer policies on cancer survival trends and socioeconomic inequalities in England, 1996-2013: population based study Abstract\nObjective\nTo assess the effectiveness of the NHS Cancer Plan (2000) and subsequent national cancer policy initiatives in improving cancer survival and reducing socioeconomic inequalities in survival in England.\nDesign\nPopulation based cohort study.\nSetting\nEngland.\nPopulation",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:0"
    }
  },
  {
    "page_content": "Setting\nEngland.\nPopulation\nMore than 3.5 million registered patients aged 15-99 with a diagnosis of one of the 24 most common primary, malignant, invasive neoplasms between 1996 and 2013.\nMain outcome measures\nAge standardised net survival estimates by cancer, sex, year, and deprivation group. These estimates were modelled using regression model with splines to explore changes in the cancer survival trends and in the socioeconomic inequalities in survival.\nResults",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:1"
    }
  },
  {
    "page_content": "One year net survival improved steadily from 1996 for 26 of 41 sex-cancer combinations studied, and only from 2001 or 2006 for four cancers. Trends in survival accelerated after 2006 for five cancers. The deprivation gap observed for all 41 sex-cancer combinations among patients with a diagnosis in 1996 persisted until 2013. However, the gap slightly decreased for six cancers among men for which one year survival was more than 65% in 1996, and for cervical and uterine cancers, for which",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:2"
    }
  },
  {
    "page_content": "and for cervical and uterine cancers, for which survival was more than 75% in 1996. The deprivation gap widened notably for brain tumours in men and for lung cancer in women.",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:3"
    }
  },
  {
    "page_content": "Conclusions",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:4"
    }
  },
  {
    "page_content": "Little evidence was found of a direct impact of national cancer strategies on one year survival, and no evidence for a reduction in socioeconomic inequalities in cancer survival. These findings emphasise that socioeconomic inequalities in survival remain a major public health problem for a healthcare system founded on equity. # Introduction Differences in cancer survival between less and more deprived patients have been well documented for most types of cancer and in different geographical",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:5"
    }
  },
  {
    "page_content": "types of cancer and in different geographical settings.1",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:6"
    }
  },
  {
    "page_content": "7 There is evidence for some explanations related to patient, tumour, and healthcare characteristics, but these can only explain part of the differences depending on the cancer type and healthcare system.8",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:7"
    }
  },
  {
    "page_content": "9 Cancer survival in England has been improving steadily since the 1970s,10 but socioeconomic inequalities in survival persist for most cancers,11 despite concerted efforts and investment in the National Health Service. After the Calman-Hine report in 1995,12 the first fully detailed strategy to tackle cancer in England was the NHS Cancer Plan,13 introduced in 2000. It set out the government’s plans for investment and reform, aiming at improving prevention, delivery of care (including",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:8"
    }
  },
  {
    "page_content": "improving prevention, delivery of care (including implementation of multidisciplinary teams), and research. It led to an inflation adjusted increase of 35% in annual expenditure on cancer services between 2001 and 2004. Among the main aims were improving cancer survival to levels comparable with the rest of Europe and reducing socioeconomic inequalities. In 2007, the Cancer Reform Strategy14 focused on consolidation of progress made since publication of the NHS Cancer Plan and set out plans for",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:9"
    }
  },
  {
    "page_content": "of the NHS Cancer Plan and set out plans for cancer services over the ensuing five years. Again, tackling inequalities and promoting equality in access to cancer services in England were central to the strategy, which also led to the foundation of the National Cancer Equality Initiative in 2008, a multidisciplinary initiative dedicated to this purpose.15 In 2008, the National Awareness and Early Diagnosis Initiative (NAEDI) was launched, with the purpose of stimulating action to diagnose cancer",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:10"
    }
  },
  {
    "page_content": "purpose of stimulating action to diagnose cancer earlier and improve cancer outcomes. Some of the key target areas were tackling negative attitudes to cancer and the barriers to seeing a doctor, supporting primary care, and optimising access to diagnostic tests and referral pathways. These initiatives occurred concomitantly with major reorganisation of the NHS and funding pressure on NHS spending (reduction of the health spend as a proportion of the gross domestic product) after publication of",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:11"
    }
  },
  {
    "page_content": "the gross domestic product) after publication of a white paper in 2010.16 We investigated the effectiveness of the NHS Cancer Plan and subsequent strategies in improving one year survival and reducing socioeconomic inequalities in cancer survival, up to 14 years after the introduction of the plan, in the context of major changes in the NHS since 2010. We focused on one year survival because most inequalities in cancer survival in England arise shortly after diagnosis.17 We examined trends in",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:12"
    }
  },
  {
    "page_content": "shortly after diagnosis.17 We examined trends in cancer survival and in the deprivation gap in survival for patients receiving a diagnosis in three predefined calendar periods: 1996-2000 (before the cancer plan), 2001-05 (initialisation period), and 2006-13 (implementation period), with follow-up to 2014. This allowed comparison of trends before and after introduction of the NHS Cancer Plan, including an initialisation period to reflect the latency before such an extensive and wide ranging",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:13"
    }
  },
  {
    "page_content": "latency before such an extensive and wide ranging strategy might take effect. We also analysed the changes in survival patterns without fixing the calendar periods a priori, to examine survival trends after the successive cancer policy initiatives but without imposing assumptions on the calendar periods during which those changes might occur. # Methods ## Data We extracted data from the population based National Cancer Registry database held by the Office for National Statistics (ONS). The",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:14"
    }
  },
  {
    "page_content": "by the Office for National Statistics (ONS). The primary source of cancer registration records is a range of healthcare providers, such as hospitals, pathology laboratories, and other services that provide all the information on the cancer diagnoses in a given year. This information is collected and maintained by the National Cancer Registration and Analysis Service in Public Health England, which actively updates the database for up to nine months after the registration year. The vital status",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:15"
    }
  },
  {
    "page_content": "after the registration year. The vital status of registered patients with cancer (alive, emigrated, dead, not traced) is updated by ONS and the HSCIC (Health and Social Care Information Centre, now known as NHS Digital). The estimated completeness of this dynamic database is 98% at the registration calendar year, but it can reach 100% within five years.18 We included all young people and adults (age 15-99 years) with a diagnosis of one of the 24 most common primary, malignant (ICD-O",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:16"
    }
  },
  {
    "page_content": "of the 24 most common primary, malignant (ICD-O (international classification of diseases for oncology) behaviour code 3), invasive neoplasms between 1996 and 2013, with potential follow-up until the end of 2014. These represent about 91% of all cancers diagnosed in England. Tumour site was coded according to ICD-10 (international classification of diseases, 10th revision),20 whereas morphology and behaviour were coded according to the international classification of diseases for oncology,",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:17"
    }
  },
  {
    "page_content": "classification of diseases for oncology, second edition (ICD-O-2).21 The data owners undertake various cleaning procedures to ensure high quality of the data, but we also apply a standard set of additional checks for cancer survival analysis, aiming to flag or exclude incomplete, ineligible, or incoherent tumour records, as well as second or higher order tumours arising in the same organ as a previous primary cancer.22 Overall, these procedures led to exclusion of less than 5% of patients. The",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:18"
    }
  },
  {
    "page_content": "led to exclusion of less than 5% of patients. The analyses included over 3.5 million patients. ## Deprivation The index of multiple deprivation (IMD 2004)23 is an ecological measure of deprivation, with seven distinct domains and a combined measure, assigned to individuals living within a given Lower-layer Super Output Area (LSOA). LSOAs are administrative geographical areas established to improve reporting of small area statistics in England and Wales. Patients with cancer were assigned to one",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:19"
    }
  },
  {
    "page_content": "Wales. Patients with cancer were assigned to one of 32 482 LSOAs in England (mean population 1500) on the basis of their postcode of residence at diagnosis. For our study we used the income domain score, which measures the proportion of the population with low income in a given LSOA. The five deprivation categories were based on the fifths of the national distribution of scores for the 32 482 LSOAs in England and patients with cancer were assigned to the deprivation category of their LSOA (from",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:20"
    }
  },
  {
    "page_content": "to the deprivation category of their LSOA (from 1 indicating “least deprived,” or affluent, to 5 indicating “most deprived”). ## Net survival estimation We estimated one year net survival for each cancer by sex, year of diagnosis (1996 to 2013), and deprivation category. Patients with a diagnosis between 1996 and 2013 had the potential to be followed up for at least one year, so we used the classic cohort approach. Net survival is the probability of survival if cancer were the only possible",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:21"
    }
  },
  {
    "page_content": "of survival if cancer were the only possible cause of death. It is the only survival measure enabling comparisons between populations (ie, between periods and socioeconomic levels) in which mortality hazard from other causes may differ, because this measure does not depend on these hazards. Estimation of net survival requires the comparison of the overall mortality hazard experienced by the patients with cancer to their expected mortality hazard—that is, hazard from other causes of death. This",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:22"
    }
  },
  {
    "page_content": "is, hazard from other causes of death. This leads to an estimate of the excess mortality hazard (ie, hazard of death due to the cancer of interest), which mathematically is the complement of net survival.24 Because the cause of death is not considered as reliable in population based data, the expected mortality hazard of the patients with cancer is estimated in the general population that the patients come from. We therefore built life tables for the England general population by calendar year,",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:23"
    }
  },
  {
    "page_content": "the England general population by calendar year, sex, age, and deprivation.25",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:24"
    }
  },
  {
    "page_content": "26 In the absence of data on recent deaths in the general population, we used the 2011 mortality rates for 2012 and 2013. We estimated net survival using the consistent non-parametric estimator defined by Pohar-Perme.27 This estimator accounts for the informative censoring due to patient factors such as age—that is, when some groups of patients are more likely to be censored because of death from other causes. The estimator is implemented in Stata 1428 within the stns command.29 ## Age",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:25"
    }
  },
  {
    "page_content": "in Stata 1428 within the stns command.29 ## Age standardisation Survival estimates for all ages combined were age standardised with the International Cancer Survival Standard weights.30 Age standardisation required to estimate survival in 18 450 unique combinations of cancer (20 in men and 21 in women), sex, year of diagnosis (18 years), deprivation (five categories), and age groups (five groups). In 562 of these combinations it was not possible to estimate survival owing to sparse data. In",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:26"
    }
  },
  {
    "page_content": "to estimate survival owing to sparse data. In those cases, we combined the data for adjacent age groups and assigned the pooled survival estimate to both age groups, the corresponding weights for these age groups being also combined. If survival estimates were missing for more than one age group, we report only the unstandardised survival estimate (382 combinations). These issues arose mostly for mesothelioma, thyroid and testicular cancer, Hodgkin lymphoma, and myeloma, which tend to be rare",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:27"
    }
  },
  {
    "page_content": "lymphoma, and myeloma, which tend to be rare in either very young or very old patients. ## Trends in survival, deprivation gap, and trends in deprivation gap We used multivariable linear regression to investigate the survival patterns for each cancer and by sex. The outcome was one year age standardised net survival and the predictors were year of diagnosis (representing the trend) and deprivation. The model also included an interaction between year of diagnosis and deprivation, which defined",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:28"
    }
  },
  {
    "page_content": "year of diagnosis and deprivation, which defined the temporal trend in the deprivation gap: the significance level of this term was set at 0.05. This allowed us to test the statistical significance of the interaction and to decide if there was evidence for a change in the deprivation gap. A continuous linear effect was considered for the effect of deprivation. We tested a series of linear restricted regression splines with constrained knot location for the effect of year and the interaction",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:29"
    }
  },
  {
    "page_content": "for the effect of year and the interaction term. Knots were fixed at the calendar years 2001 and 2006, to align with the three periods we defined in relation to the NHS Cancer Plan. The final number of knots was determined with an algorithm embedded in the mvrs program in STATA.31 Starting with the model of maximum complexity, this closed-test algorithm uses a backward elimination to choose the best fitting spline, while the overall type I error is kept at a predefined level (here 5%). From the",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:30"
    }
  },
  {
    "page_content": "is kept at a predefined level (here 5%). From the regression models applied to the entire dataset for each sex-cancer combination we estimated both survival and the deprivation gap in survival for each year. Survival is the predicted age standardised one year net survival for patients with a diagnosis in each calendar year. The deprivation gap is the absolute difference between the predicted net survival estimates for the most affluent and most deprived groups (fig 1). By convention, a negative",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:31"
    }
  },
  {
    "page_content": "groups (fig 1). By convention, a negative value for the deprivation gap implies that survival was lower in deprived than in affluent patients. We derived 95% confidence intervals from the linear combination of coefficients acquired from the flexible models. ## Relaxed assumptions Our main analysis incorporated the assumption that 2001 and 2006 were starting points for any change in the slope of the trend in survival or in the deprivation gap in survival. We then relaxed this assumption by",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:32"
    }
  },
  {
    "page_content": "in survival. We then relaxed this assumption by including an internal knot for each year in the initial model, again allowing the knots to be selected by the algorithm embedded in the command.31 The deprivation gap was derived from the same final models as described previously. We performed similar analyses using cubic splines to allow for the possibility of non-linear trends. ## Patient involvement This study is part of the Cancer Survival Group’s commitment to describe and explain",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:33"
    }
  },
  {
    "page_content": "Group’s commitment to describe and explain inequalities in cancer survival affecting older patients, patients of low socioeconomic status, and all patients living in England and in the UK, where cancer survival still lags behind survival in other comparably wealthy countries. We repeatedly receive feedback from patients with cancer and advocacy bodies at national and international meetings to the effect that the cancer survival statistics we produce are an invaluable support for their efforts",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:34"
    }
  },
  {
    "page_content": "are an invaluable support for their efforts to lobby for improved care of patients with cancer. We have a longstanding collaboration with the National Cancer Research Institute Consumer Liaison Group—a group of patients’ representatives that is actively involved in our research. We organise regular meetings at which we discuss our research, exchange ideas, and receive valuable feedback. More than 40 members of this group participated in our most recent meeting, on 13 February 2017, at which our",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:35"
    }
  },
  {
    "page_content": "recent meeting, on 13 February 2017, at which our research (including this study) was presented and discussed in plenary session and in small groups. Two patients are also members of the Advisory Panel for the Cancer Survival Programme, of which this study is a component part. We recently received special recognition from Cancer Research UK for the involvement and engagement of patients in the design and delivery of our research. Our international research programme on cancer survival is also",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:36"
    }
  },
  {
    "page_content": "research programme on cancer survival is also officially endorsed by many cancer patient bodies, including the Association of European Cancer Leagues (Brussels, Belgium), the European Institute for Women’s Health (Dublin, Ireland), and the European Cancer Patient Coalition. These agencies have all used our cancer survival estimates to press for improvements in cancer care locally, but also to improve cancer policy nationally. # Results ## Trends in one year net survival One year survival",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:37"
    }
  },
  {
    "page_content": "Trends in one year net survival One year survival improved for 20 of the 21 cancers examined in women and 16 of the 20 cancers examined in men (table 1). The largest improvements were observed for cancers that were of poor or intermediate prognosis in the 1990s (<65% for those with a diagnosis in 1996), such as cancers of the oesophagus, liver (men), lung (women), and kidney, mesothelioma, and myeloma. For these cancers, the average annual absolute increase in one year age standardised net",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:38"
    }
  },
  {
    "page_content": "increase in one year age standardised net survival was often greater than 1% over the whole study period (fig 2). Survival for men diagnosed as having cancer of the larynx or testis, or Hodgkin lymphoma, was already high in the 1990s, and it improved little by 2013. For 26 of the 41 cancer-sex combinations, survival improved steadily from 1996, but with no statistically significant acceleration after 2006, ie, after the predefined implementation period. This was the case for eight of the 20",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:39"
    }
  },
  {
    "page_content": "period. This was the case for eight of the 20 malignancies in men: six cancers of the digestive tract, melanoma, and non-Hodgkin lymphoma; and for 18 of 21 malignancies in women: six cancers of the digestive tract, lung cancer, mesothelioma, melanoma, four gynaecological cancers, brain cancer, thyroid cancer, non-Hodgkin lymphoma, myeloma, and leukaemia. Changes in the survival trend were observed for several cancers. For mesothelioma in men, one year survival changed little during 1996-2000",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:40"
    }
  },
  {
    "page_content": "one year survival changed little during 1996-2000 (mean annual increase 0.2%), but accelerated to 1.3% each year during 2001-13 (table 1). A similar change occurred for brain tumours in men at the same time point (0.2% to 1.1% each year). For thyroid cancer in men, one year survival changed little during the 10 year period 1996-2005, but then increased by 1.1% each year between 2006 and 2013. A similar pattern was seen for Hodgkin lymphoma in women, which increased by 0.5% a year between 2006",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:41"
    }
  },
  {
    "page_content": "which increased by 0.5% a year between 2006 and 2013. The one year survival trends seen during 1996-2005 accelerated from 2006 for lung cancer, myeloma, and leukaemia in men, and for kidney cancer in both sexes. The average annual increases during 1996-2005 were less than 1% a year, but increased up to 2% a year between 2006 and 2013. For kidney cancer, the annual rate of increase in one year survival doubled from 2006, increasing from 0.6% to 1.4% a year in men, and from 0.8% to 1.5% a year in",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:42"
    }
  },
  {
    "page_content": "a year in men, and from 0.8% to 1.5% a year in women. For prostate cancer, the mean annual increase in one year survival was 1.2% during 1996-2000, null during 2001-05, and 0.6% during 2006-13; by 2013, one year survival had reached 92.1%. When we relaxed the assumption that the trend could only change in 2001 or 2006, fitting flexible splines that allow the trend to change from year to year, the results differed little (data not shown). ## Deprivation gap in one year net survival and trends",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:43"
    }
  },
  {
    "page_content": "gap in one year net survival and trends When survival increased, it concerned all deprivation groups for most sex-cancer combinations. Survival nevertheless remained consistently lower among more deprived patients than the less deprived, and the deprivation gap in one year net survival remained unchanged for 13 cancers in men and 17 cancers in women between 1996 and 2013 (fig 3). The survival gap narrowed only in six out of 20 cancers among men and in two out of 21 cancers among women, and",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:44"
    }
  },
  {
    "page_content": "men and in two out of 21 cancers among women, and widened for three cancers. All these changes were linear. The deprivation gaps were more similar between men and women in 2013 than in 1996. In 1996 there was a clear deprivation gradient in one year survival, which was lower among more deprived than less deprived patients, for all cancers and in both sexes (tables 2 and 3). Seventeen years later, in 2013, survival was still lower among the more deprived groups for all cancers, except Hodgkin",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:45"
    }
  },
  {
    "page_content": "deprived groups for all cancers, except Hodgkin lymphoma in men. A narrowing in the deprivation gap was observed for cancers with survival in 1996 near or higher than 65% among men and 75% among women. In 1996, the largest deprivation gap in men was observed for rectal cancer (−9.4%) and non-Hodgkin lymphoma (−8.2%). The deprivation gap narrowed slightly by 1.6% during 1996-2013 for both colon and rectal cancer, and by 1.3% for non-Hodgkin lymphoma. However, the largest reduction was seen for",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:46"
    }
  },
  {
    "page_content": "However, the largest reduction was seen for Hodgkin lymphoma (3.7%) and prostate cancer (3.2%). For melanoma of the skin, the deprivation gap decreased by 3.5% between 1996 and 2013. The deprivation gap for these cancers ranged from −6.2% to −4.6% in 1996. In 2013, the largest deprivation gap was for rectal cancer (−7.8%) and brain cancer (−7.5%). In women, the largest deprivation gap in 1996, as in 2013, was for bladder cancer (−8.6%), mesothelioma (−8.3%), and oesophageal cancer (−8%). A",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:47"
    }
  },
  {
    "page_content": "(−8.3%), and oesophageal cancer (−8%). A reduction was only seen for cervical cancer (from −7.0% in 1996 to −3.5% in 2013) and uterine cancer (from −5.8% to −2.8%, respectively). The deprivation gap in survival widened for brain tumours in men and lung cancer in women, by 5.1% (from −2.4% in 1996 to-7.5% in 2013) and 1.1% (from −3.7% in 1996 to −4.8% in 2013), respectively. The deprivation gap was narrow in 1996 for a few malignancies and remained among the narrowest in 2013: Hodgkin lymphoma",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:48"
    }
  },
  {
    "page_content": "among the narrowest in 2013: Hodgkin lymphoma (−1.9%) and skin melanoma (−1.9%) in women, and thyroid (−2.7%) and testicular cancers (−2.8%) in men. # Discussion A steady improvement in one year net survival was seen between 1996 and 2013 in England for nearly all 41 cancer-sex combinations. In 2013, one year net survival was higher than 80% for 17 cancer-sex combinations, but this encouraging picture is moderated by the 14 poor prognosis combinations with one year survival still below 50%.",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:49"
    }
  },
  {
    "page_content": "with one year survival still below 50%. Acceleration of this overall improvement was rarely observed, offering little evidence for a direct impact of the NHS Cancer Plan (2000) and later policy initiatives on short term cancer survival. Meanwhile, the deprivation gap in one year net survival remained unchanged for most cancers, with a clear, persistent pattern of lower survival among more deprived patients. Reduction of socioeconomic inequalities was seen only among some cancers for which one",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:50"
    }
  },
  {
    "page_content": "was seen only among some cancers for which one year survival was already more than 65% in 1996, especially among men, suggesting a ceiling effect in that survival has reached a maximum among the least deprived patients. The successive national policy initiatives, including the 2000 Cancer Plan for England, aimed to improve cancer survival, with the target of bringing survival to the level of comparably wealthy countries, and to reduce the inequalities in cancer survival. The lack of consistent",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:51"
    }
  },
  {
    "page_content": "in cancer survival. The lack of consistent results between men and women, as well as the lack of general patterns across cancer types, provide little evidence for any strong impact of the national cancer policies on short term cancer survival. The evidence is even weaker for their impact on the socioeconomic inequalities in cancer survival. ## Strengths and weaknesses of this study A major strength of this study is that it is based on virtually all cancer cases registered in England, and the",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:52"
    }
  },
  {
    "page_content": "all cancer cases registered in England, and the quality and completeness of the English cancer registry data are acknowledged to be high.32 The study also updates by seven years our previous evaluations,11",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:53"
    }
  },
  {
    "page_content": "33 with a total of 18 years of incidence data. These extra years of data allowed us to estimate the trends more accurately. Since our previous evaluations new, more flexible methodologies were introduced. The assumption that trends in survival and in deprivation gap should be different in three predefined periods11 was now relaxed and the periods could vary substantially. The initial assumption was that changes would be expected after 2001 or 2006, or both but further analyses were conducted",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:54"
    }
  },
  {
    "page_content": "2006, or both but further analyses were conducted using more flexible models, which enabled the number and location of the knots to vary across all years of diagnosis. The estimates were not all identical, but they did not affect our main conclusions, in particular on the common absence of inflexion points in the trends in survival and in deprivation gap. Short term net survival mostly reflects the speed of patient management (including diagnosis, staging, and first definitive treatment) as",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:55"
    }
  },
  {
    "page_content": "staging, and first definitive treatment) as well as the quality of the surgical treatment and postoperative care. A persistent deficit in short term cancer survival in England (and more generally in the UK) compared with most wealthy countries has been observed for decades.34",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:56"
    }
  },
  {
    "page_content": "35 Meanwhile, the wide socioeconomic inequalities in cancer survival, also seen for decades, are mostly due to higher short term mortality in more deprived patients.4 Although trends in cancer survival have been regularly used to inform governments on the progress towards the aims of their cancer policies,36",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:57"
    }
  },
  {
    "page_content": "37 to our knowledge, little has been specifically published on the evaluation of how cancer policies impact survival and inequalities at national level. Most studies were at subnational level 38 or focused on very specific interventions, such as screening.39 By contrast, our study was designed to evaluate such policies. We acknowledge that changes in the survival trends are decided solely on acceleration in survival, and comparison with countries of similar wealth would put any observed",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:58"
    }
  },
  {
    "page_content": "of similar wealth would put any observed improvements in perspective. This limitation, however, does not apply to our findings on the persistent socioeconomic inequalities in cancer survival. Furthermore, the weak evidence for an acceleration in cancer survival echoes the constant gap in cancer survival between England and some other wealthy countries.40 Our study also may be too early to detect the full impact of the recently implemented cancer initiatives, although it confirms the findings of",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:59"
    }
  },
  {
    "page_content": "initiatives, although it confirms the findings of our earlier studies.11",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:60"
    }
  },
  {
    "page_content": "33 Such studies should be regularly updated. ## Meaning of the study Since the introduction of the NHS Cancer Plan (2000), acceleration in the positive survival trends was witnessed only for a few cancers and mostly among men, who experienced a lower initial increase compared with women (cancer of the lung, brain, and thyroid, mesothelioma, myeloma, and leukaemia). No such acceleration was found among women. For lung cancer, and more specifically non-small cell carcinoma, the proportion of",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:61"
    }
  },
  {
    "page_content": "non-small cell carcinoma, the proportion of patients receiving a surgical treatment was low in England,41 but this proportion increased from around 10% until 200842 to 17% in 2015.43 This improvement may be partly the result of a higher number of specialised surgeons44 and a higher proportion of patients managed in specialised centres, which could reduce the variability in postoperative mortality.45 These changes may have impacted the outcome for mesothelioma, too. The continuous expansion in",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:62"
    }
  },
  {
    "page_content": "mesothelioma, too. The continuous expansion in the availability of diagnostic tools (eg, computed tomography, magnetic resonance imaging, ultrasound machines) in England is likely to have increased the proportion of brain and thyroid tumours diagnosed at an earlier stage.46 Survival pattern for bladder cancer is particular as one year survival decreased slightly between 1996 and 2001, then stabilised. It reflects a change in coding around 2000, under which papillomas were reclassified from",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:63"
    }
  },
  {
    "page_content": "under which papillomas were reclassified from invasive to uncertain (whether benign or malignant), therefore excluded from survival analyses. Omitting these tumours with a good prognosis resulted in a decrease in cancer survival.47 Despite these improvements in survival there was no reduction in the inequalities in survival from lung, brain, or thyroid tumour, or from mesothelioma. Particular efforts were dedicated in England to high incidence cancers with intermediate prognosis (one year",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:64"
    }
  },
  {
    "page_content": "cancers with intermediate prognosis (one year survival between 40% and 65% in 1996) such as colon and rectal cancers, and one could have expected a faster improvement in survival and a reduction of the deprivation gap after the policy initiatives. Survival from these cancers in England remained behind internationally,40",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:65"
    }
  },
  {
    "page_content": "48 and inequalities in survival from these cancers hardly narrowed. Short term survival increased dramatically since 1996 for most other digestive cancers with poor prognosis (one year survival <40% in 1996), but the more deprived patients still experienced lower survival. It is likely that the longstanding deficit in survival and the socioeconomic inequalities in survival in England share the same causal factors, which can be grouped into patient, tumour, and healthcare system factors. The",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:66"
    }
  },
  {
    "page_content": "tumour, and healthcare system factors. The National Awareness and Early Diagnosis Initiative49 and the Be Clear on Cancer Campaign50 aimed specifically to tackle some of the patient related (cancer awareness, barriers) and tumour related (tumour stage) issues. Although cancer awareness varies internationally51 and by deprivation,52 it seems to explain none of the international disparities in cancer survival51 and little of socioeconomic inequalities.53 A lot of effort has also gone into",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:67"
    }
  },
  {
    "page_content": "A lot of effort has also gone into diagnosing cancers at an earlier stage. Patients tend to have a diagnosis of more advanced tumours in England compared with wealthy countries,54",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:68"
    }
  },
  {
    "page_content": "57 and among the more deprived patients compared with the least deprived.9 However, as stage specific survival tends to be lower in England, more advanced stage would explain only part of the international54\n57 and socioeconomic inequalities in cancer survival.58",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:69"
    }
  },
  {
    "page_content": "59 A higher proportion of patients are now receiving a diagnosis through Two Week Wait or GP referral while for some cancers there is a major decrease in emergency presentation.60 Although stage distribution might have slightly moved towards earlier stages, the picture remains patchy and there was no evidence to suggest a narrowing of these gaps in survival. These policy initiatives put a greater emphasis on individual factors than on the observed suboptimal management of patients with cancer.",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:70"
    }
  },
  {
    "page_content": "suboptimal management of patients with cancer. The variations in cancer management (eg, differential route to diagnosis, staging investigation, treatment) are likely to explain some of the low survival observed in England and among more deprived patients, whereas the role of the individual factors in the observed variations in management seems minor. For example, the background consultation rate in primary care of patients with cancer does not differ between routes to cancer diagnosis",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:71"
    }
  },
  {
    "page_content": "not differ between routes to cancer diagnosis (emergency presentation or not).61",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:72"
    }
  },
  {
    "page_content": "62 In contrast, interventions on healthcare system factors might have a large impact on cancer survival, as shown by the recent changes in the management of patients with lung cancer.43 However, such interventions have not influenced the socioeconomic inequalities in cancer survival yet, possibly because they do not directly address the differential interactions between the healthcare system and the patients, which could lead to suboptimal management of subgroups of the population. ##",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:73"
    }
  },
  {
    "page_content": "management of subgroups of the population. ## Conclusion and policy implications Little evidence has been found about the acceleration in cancer survival after the successive national cancer policy initiatives. Survival in the most deprived has been consistently lower and the deprivation gap has shown little change over the years for patients with a diagnosis during 1971-902 and 1986-9963 in England and Wales. This study contributes with more recent data and updates evidence that the",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:74"
    }
  },
  {
    "page_content": "more recent data and updates evidence that the deprivation gap persisted in England even after the introduction of successive national policies, which among other goals targeted social inequalities related to cancer.11 These findings should be taken into consideration by cancer policy makers and inform future initiatives. Shifting the focus from individual factors to healthcare system factors might prove to be beneficial in improving cancer outcomes among the most disadvantaged. Further",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:75"
    }
  },
  {
    "page_content": "outcomes among the most disadvantaged. Further research on these factors can help shed light and improve the efficacy of future cancer policies.",
    "metadata": {
      "source": "../data/plain/PMC5850596.plain.txt",
      "id": "../data/plain/PMC5850596.plain.txt:76"
    }
  },
  {
    "page_content": "Incidence and survival of lymphoid neoplasms in Spain, 2002-2013: A population-based study from the Spanish Network of Cancer Registries (REDECAN) Abstract\nIntroduction\nThe aim of this study was to describe incidence, incidence trends and survival patterns of lymphoid neoplasms (LNs) and its subtypes in Spain in the period 2002-2013 using data from the Spanish Network of Cancer Registries (REDECAN).\nMaterials and Methods",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:0"
    }
  },
  {
    "page_content": "Data were extracted from 13 Spanish population-based cancer registries. LNs incident cases were codified using the International Classification of Diseases for Oncology, third edition (ICD-O-3) and grouped according to the WHO 2008 classification. Age-standardized incidence rates to the 2013 European standard population (ASIRe) were obtained. Poisson regression models were used to analyze trends in incidence rates and estimate the annual percentage change (APC) for each subtype. The number of",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:1"
    }
  },
  {
    "page_content": "change (APC) for each subtype. The number of cases in Spain for 2023 was estimated by applying the estimated age-specific rates for the year 2023 to the 2023 Spanish population. Observed survival (OS) was estimated by the Kaplan-Meier method and net survival (NS) by the Pohar-Perme method. Sex- and age-specific estimates of 5-year NS were calculated, as well as its changes according to two periods of diagnosis (2002-2007 and 2008-2013).",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:2"
    }
  },
  {
    "page_content": "Results\nConclusions",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:3"
    }
  },
  {
    "page_content": "This study presents the first complete and extensive population-based analysis of LNs incidence and survival in Spain. These population-based data provide relevant information to better understand the epidemiology of LNs in Southern Europe and it features some useful points for public health authorities and clinicians. However, additional improvements regarding the registration of these hematological neoplasms can be implemented. # Introduction Hematological neoplasms are a group of diseases in",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:4"
    }
  },
  {
    "page_content": "neoplasms are a group of diseases in which the hematopoietic system, the one in charge of the differentiation and proliferation of erythrocytes, thrombocytes, granulocytes and lymphocytes, is involved. The altered proliferation and/or differentiation of the different lineage precursors drives to a wide group of diseases with diverse etiology, presentation and outcomes, and depending on the lineage we find the first stratification of these neoplasms: myeloid neoplasms, lymphoid neoplasms (LNs)",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:5"
    }
  },
  {
    "page_content": "myeloid neoplasms, lymphoid neoplasms (LNs) and histiocytic/dendritic neoplasms. LNs, which comprise a heterogeneous group of more than 60 histological subtypes, are ranked as the 6th to 7th most common cancer worldwide (1). Broadly, they are grouped into four main categories: Hodgkin lymphoma, precursor lymphoid neoplasms, mature B-cell neoplasms, and mature T- and NK-cell neoplasms. Changes in our understanding of LNs have resulted in the continuous update of classification schemes over the",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:6"
    }
  },
  {
    "page_content": "update of classification schemes over the past 60 years (2). The World Health Organization (WHO) with its first classification of tumors of hematopoietic and lymphoid tissues published in 2001 (3), and subsequently updated in 2008 (4), 2016 (5) and 2022 (6), is currently regarded as the gold standard for the diagnosis and research of LNs. Furthermore, the correspondence established between the WHO classification and the last editions of the International Classification of Diseases for Oncology",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:7"
    }
  },
  {
    "page_content": "Classification of Diseases for Oncology (ICD-O-3) codes (7), has provided international standards for the registration and epidemiological surveillance of these diseases. During the last decades, population-based data of LNs has become more available, with multiple studies from hematology-specialized registries (8, 9) or large European and North American datasets (10–14). Specifically in Spain, however, few regional studies have reported incidence and survival data of LNs (15, 16), while there",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:8"
    }
  },
  {
    "page_content": "and survival data of LNs (15, 16), while there is a lack of subtype-specific data at a nationwide level. Therefore, the aim of this study was to describe incidence and survival patterns of LNs subtypes in Spain over the period 2002-2013, and to estimate the number of LNs expected in 2023, using data from the Spanish Network of Cancer Registries (REDECAN). # Materials and methods ## Study population Study data were extracted from 13 Spanish population-based cancer registries (PBCR) (Asturias,",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:9"
    }
  },
  {
    "page_content": "cancer registries (PBCR) (Asturias, Canary Islands –Tenerife and Gran Canaria–, Castellón, Ciudad Real, Cuenca, Euskadi, Girona, Granada, La Rioja, Mallorca, Murcia, Navarra and Tarragona) which together cover 13 provinces and three islands. These PBCR, associated since 2010 in REDECAN (17), provided all LNs, both in pediatric and adult cases, registered from 2002 to 2013 (or the period available between these years) covering almost 26% of the total Spanish population (12,143,157 out of",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:10"
    }
  },
  {
    "page_content": "the total Spanish population (12,143,157 out of 47,129,783 inhabitants in January 2013) (18). Quality indicators, which were defined based on the standards of the International Agency for Research on Cancer (IARC) (19), are detailed by PBCR in Table S1 of the Supplementary material. Overall, 96.7% of the cases included were microscopically verified, 5.0% were not otherwise specified (NOS) cases and 1.1% were cases notified to the registry solely based on death certificates (DCO). ## Cases and",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:11"
    }
  },
  {
    "page_content": "based on death certificates (DCO). ## Cases and groupings Cases were codified using the ICD-O-3 (7) and grouped according to the WHO 2008 classification (4) (",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:12"
    }
  },
  {
    "page_content": "Table 1",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:13"
    }
  },
  {
    "page_content": "). In brief, LNs were grouped into five broad categories: Hodgkin lymphomas, precursor lymphoid neoplasms, mature B-cell neoplasms, mature T-cell and NK-cell neoplasms and lymphoid neoplasms, NOS. ## Statistical analysis Crude (CR) and age-standardized incidence rates using the 2013 European standard population (ASIRe), were calculated using population data provided by the National Statistics Institute (Instituto Nacional de Estadística—INE) (18) and expressed per 100,000 inhabitant-years.",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:14"
    }
  },
  {
    "page_content": "(18) and expressed per 100,000 inhabitant-years. Poisson regression models were used to analyze trends in incidence rates and estimate the annual percentage change (APC) for each subtype of LN. Specific rates by age for the year 2023 were estimated by applying the APCs for the period 2002–2013. The projection of the number of cases of LNs for 2023 was determined by applying to the Spanish population of 2023 the age-specific rates estimated for that same year, assuming a stable incidence trend",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:15"
    }
  },
  {
    "page_content": "that same year, assuming a stable incidence trend over time. For the survival analysis, cases, excluding DCO cases or those diagnosed by autopsy, were followed up until 31 December 2015. Vital status follow-up was carried out using multiple sources of information, such as regional mortality registries, National Death Index, social security database, hospital and primary care records and population censuses, as needed and available in each registry. Observed survival (OS) was estimated by the",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:16"
    }
  },
  {
    "page_content": "Observed survival (OS) was estimated by the Kaplan-Meier method and net survival (NS) by the Pohar-Perme estimator (20). The 1-, 3- and 5-year OS and NS and their corresponding 95% confidence interval (CI) are presented for all LNs as a whole and for their subtypes. Survival between groups of age, sex and period of diagnosis was compared using a log-rank type test (21). All analyses were performed using R software (version 3.6.1). ## Ethics approval This study has been carried out using",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:17"
    }
  },
  {
    "page_content": "approval This study has been carried out using anonymized data from the participating PBCRs that comprise REDECAN. For their part, the cancer registries comply with the legal regulations in force in Europe and Spain on the Protection of Personal Data. No intervention has been performed in human or animal subjects. Informed consent of the patients is not required for this type of study. # Results ## Incidence Table 1 lists the number of cases, the percentage over the total of LNs, the median",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:18"
    }
  },
  {
    "page_content": "the percentage over the total of LNs, the median age, the CR and the ASIRe with its 95% CI and sex ratio (male/female) of each subgroup and subtype according to the ICD-O-3 codes. Incidence rates (CR and ASIRe) by sex are shown in Table S2 of Supplementary material. Incidence trends of LNs during 2002-2013 are detailed in Table 2. The incidence of the LN pool was relatively stable over time (APC: 0.3; 95% CI: -0.1, 0.6), while the main subgroups, with the exception of mature T-cell and NK-cell",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:19"
    }
  },
  {
    "page_content": "with the exception of mature T-cell and NK-cell neoplasms, showed significant variations. Within Hodgkin lymphoma, there was a marked increase of nodular lymphocyte predominant subtype (APC: 6.9%). Incidence of precursor neoplasms decreased slightly, yet within this subgroup, there was a marked increase of B- and T- subtypes to the detriment of NOS cases. Among B-mature cell neoplasms, we evidenced a positive trend of follicular lymphoma (4.0%), marginal zone lymphoma (2.9%), and diffuse large",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:20"
    }
  },
  {
    "page_content": "marginal zone lymphoma (2.9%), and diffuse large B-cell lymphoma (1.2%), in contrast with the negative trend for chronic lymphocytic leukemia/small lymphocytic lymphoma (-2.2%). Among mature T- and NK-cell neoplasms, there was a positive trend for the subgroup that includes peripheral subtypes other than mycosis fungoides/Sézary syndrome. Finally, the NOS subtype decreased markedly (-5.6%). Table S3 of Supplementary material displays incidence trends stratified by sex, showing no notable",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:21"
    }
  },
  {
    "page_content": "trends stratified by sex, showing no notable differences between sexes. ## Projections for 2023 Predicted incidence rates of LNs subtypes for 2023, overall and by sex, are detailed in Table S4 of Supplementary material ## Survival A total of 38,699 LNs were included in the survival analysis. Table 3 shows a simplified classification of LNs subtypes with its number of cases, 5-year OS and NS with their 95% CI. A more extensive table that also includes 1- and 3 -year OS and NS is available in",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:22"
    }
  },
  {
    "page_content": "includes 1- and 3 -year OS and NS is available in Supplementary material, Table S5. The overall 5-y OS and NS were 56.84% (95% CI: 56.33-57.34) and 62.81% (95% CI: 62.1-63.52), respectively. Within the major categories, Hodgkin lymphoma showed higher 5-y NS (82.6%, 95% CI: 81.25-83.98) compared to non-Hodgkin lymphoma 5-y NS (60.74%, 95% CI: 59.97-61.51), with the rates being higher in mature T-cell and NK-cell neoplasms (64.19%, 95% CI: 61.78-66.7) and mature B-cell neoplasms (62.11%, 95% CI:",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:23"
    }
  },
  {
    "page_content": "and mature B-cell neoplasms (62.11%, 95% CI: 61.25-62.99) than in precursor lymphoid neoplasms (54.33%, 95% CI: 51.75-57.03). Regarding specific lymphoma subtypes, the lowest survival rates were observed in plasma cell myeloma/leukemia (39.21%, 95% CI: 37.87-40.61), B-cell prolymphocytic leukemia (47.27%, 95% CI: 29.5-75.74), peripheral T- cell and NK-cell lymphoma (52.12%, 95% CI: 49.18-55.22) and mantle cell lymphoma (52.42%, 95% CI: 48.64-56.51). By contrast, the highest survival rates were",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:24"
    }
  },
  {
    "page_content": "By contrast, the highest survival rates were estimated for Hodgkin lymphoma nodular lymphocyte predominant (90.25%, 95% CI: 85.79-94.93), hairy cell leukemia (85.89%, 95% CI: 79.87-92.37) and mycosis fungoides/Sézary syndrome (85.76%, 95% CI: 82.02-89.66). Changes in 5-y NS according to sex, age-group and period of diagnosis (i.e. 2002-2007 and 2008-2013) are displayed in Figures 1–3, respectively; specific survival values and p-values for log-rank type test are listed in Tables S6–S8 of",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:25"
    }
  },
  {
    "page_content": "log-rank type test are listed in Tables S6–S8 of Supplementary material. Extended versions of these figures for mature T-cell and NK-cell neoplasms subtypes are displayed in Figures S1–S3 of Supplementary material. Slight but statistically significant differences in 5-y NS between sexes were reported globally (",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:26"
    }
  },
  {
    "page_content": "Figure 1\n), mostly due to changes in mature B-cell [62.67% (95% CI: 61.21-64.17) for women and 61.65% (95% CI: 60.65-62.66) for men; p-value for log-rank type test <0.001] and mature T/NK-cell neoplasms [67.91% (95% CI: 64.18-71.87) for women and 61.73% (95% CI: 58.63-65) for men; p-value for log-rank type test <0.001]. By contrast, marked differences were found across age-groups (\nFigure 2\n) and between both periods of diagnosis (\nFigure 3",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:27"
    }
  },
  {
    "page_content": "). Five-y NS of all LNs decreased gradually across age-groups, being 86.69% (95% CI: 84.41-89.03) in children (<15 years), 81.4% (95% CI: 80.5-82.3) in 15-49 years, 71.4% (95% CI: 70.54-72.27) in 50-69 years, and 46.83% (95% CI: 45.53-48.17) in those aged 70+ years (p-value for log-rank type test <0.001). This pattern was reported for all LNs subgroups. Regarding the period of diagnosis, we reported an increase of LNs global survival in the second period 2008-2013 (5-y NS: 64.17%; 95% IC:",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:28"
    }
  },
  {
    "page_content": "second period 2008-2013 (5-y NS: 64.17%; 95% IC: 63.29-65.07) compared to the period 2002-2007 (5-y NS: 61.57%; 95% CI: 60.56-62.61). This was mostly attributed to an improvement of mature B-cell neoplasms survival (p-value for log-rank type test <0.001), more specifically plasma cell neoplasms (p-value for log-rank type test <0.001) and mantle cell lymphoma (p-value for log-rank type test = 0.005). # Discussion This paper presents population-based incidence and survival of LNs in Spain during",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:29"
    }
  },
  {
    "page_content": "incidence and survival of LNs in Spain during the period 2002-2013. Our study, which includes 39,156 cases diagnosed and registered by the 13 Spanish PBCRs that make up REDECAN, further complements existing European data by providing incidence patterns, projections for 2023 and survival analysis of LNs by subtypes. Incidence rates for the most frequent subtypes are in line with those reported in large European datasets (10), as well as by hematology-specialized registries from the United",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:30"
    }
  },
  {
    "page_content": "hematology-specialized registries from the United Kingdom (Haematological Malignancy Research Network, HMRN) (8). By contrast, we reported lower rates in comparison to France (Côte d’Or) (9), to the United States 2016 projected incidence (14), and to Australia’s data for 1982-2006 (22), presumably due to differences in the study periods and classification. Regarding specific entities, we reported lower rates of marginal zone lymphoma and higher rates of follicular lymphoma when comparing to the",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:31"
    }
  },
  {
    "page_content": "of follicular lymphoma when comparing to the HMRN (8), probably due to differences in classification and different completeness of cancer registries. Similarly, we report higher rates of chronic lymphocytic leukemia/small lymphocytic lymphoma and mycosis fungoides/Sézary syndrome, mainly attributable to a higher registration of indolent subtypes by REDECAN rather than a higher actual incidence in Spain. Our data also show higher rates of mantle cell lymphoma which is related to environmental",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:32"
    }
  },
  {
    "page_content": "cell lymphoma which is related to environmental and genetic risk factors like farm life, atopy, and allergy (23). Incidence of LNs showed a male predominance, with the main exception of follicular lymphoma (sex ratio 0.94), also described in the literature (8, 9). With respect to age at diagnosis, most LNs are diagnosed at advanced ages, with a median age at diagnosis around 67 years. In line with previous studies, cases of precursor lymphoid neoplasms, Hodgkin lymphomas, and Burkitt",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:33"
    }
  },
  {
    "page_content": "neoplasms, Hodgkin lymphomas, and Burkitt lymphoma/leukemia were diagnosed at younger ages. In addition, we evidenced that most NOS cases are diagnosed at advanced ages, with an incidence that increases markedly after 70 years. This suggests a decrease in the quality of diagnoses in older people, since they are less likely to receive aggressive diagnostic tests due to comorbidities and/or frailty (24). The global incidence trend of LN was stable during the study period in accordance with",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:34"
    }
  },
  {
    "page_content": "stable during the study period in accordance with reported results of other Western countries (14, 25), although significant variations were found in specific subtypes. However, the continuous update of the WHO classification of LNs across the period of study hampers the interpretation of these trends. Whilst studies have been shown that computer converted ICD-O-3 historical codes for lymphoma subtypes are generally reliable, and that such agreement is improved when those codes are grouped",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:35"
    }
  },
  {
    "page_content": "is improved when those codes are grouped (26), some changes are hard to overcome. For instance, in 2008 the International Workshop on chronic lymphocytic leukemia changed the definition of the disease, now requiring an absolute B-cell count of 5,000 cells/μL rather than the previous absolute lymphocyte count of 5,000 cells/μL, which caused that many former Rai stage 0 cases now should be considered as a pre-malignant condition (monoclonal B-cell lymphocytosis) (27). This may explain the",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:36"
    }
  },
  {
    "page_content": "B-cell lymphocytosis) (27). This may explain the negative trend in the incidence of chronic lymphocytic leukemia/small lymphocytic lymphoma evidenced in our study. On the other hand, we reported a marked decrease in the incidence of NOS cases across the period of study. This might be attributed to more specific clinical diagnoses and also to improved coding in Spanish PBCRs. These improvements in coding are probably due to the training courses organized by REDECAN and given to registry",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:37"
    }
  },
  {
    "page_content": "organized by REDECAN and given to registry professionals, in particular hematological neoplasm coding courses held during the study period. As expected, 5y-NS was widely different across LNs subtypes, and our results are broadly consistent with those reported by specialized registries in the UK (8), France (9), and in European (HAEMACARE, EUROCARE-5) (11–13) and North American datasets (28). However, the survival estimates that we present are higher than those reported by studies using the",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:38"
    }
  },
  {
    "page_content": "higher than those reported by studies using the HAEMACARE database (11). These differences can be due to the HAEMACARE’s study period (2000–2002), prior to the appearance of new treatment lines and more accurate diagnostic techniques that significantly improved survival, and to the use of the Hakulinen method for estimating survival instead of the Pohar-Perme method (29). By contrast, our results for most subtypes were lower than those presented by the HMRN (8). Overall, survival rates differed",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:39"
    }
  },
  {
    "page_content": "by the HMRN (8). Overall, survival rates differed considerably across age-groups, a well-established prognostic factor for most cancers (30). The poor survival of elderly patients with LN is mainly attributed to the presence of comorbidities or to their frail status, which hampers firstly, seeking for a specific diagnosis, and subsequently, the application of several treatment protocols, such as several chemotherapy regimens or stem-cell transplantation (31–33). On the other hand, we evidenced",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:40"
    }
  },
  {
    "page_content": "(31–33). On the other hand, we evidenced differences in the survival of mature B, T and NK-cell neoplasms between sexes that would be related to the impact of chromosomal and hormonal control of immunity (34), among other factors, and its consequent cancer evolution and response to treatment (35, 36). Finally, NS for all LNs improved significantly during the period of study, which was mostly attributed to a better prognosis of mature B-cell neoplasms, particularly in plasma cell neoplasms and",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:41"
    }
  },
  {
    "page_content": "particularly in plasma cell neoplasms and mantle cell lymphoma. This could be related to changes in treatment patterns, such the introduction of rituximab during 2004-2005 for mantle cell lymphoma, and the application of novel agents (thalidomide, bortezomib, lenalidomide) together with autologous stem cell transplantation in 2009 for multiple myeloma (37, 38). The favorable effect on survival of these therapeutic changes were also reported by European PBCRs (39–41). According to our",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:42"
    }
  },
  {
    "page_content": "by European PBCRs (39–41). According to our projections, we expect 17,926 new cases of LNs in 2023. However, these data take into account neither the changes in the WHO classification (new updates were launched in 2016 and 2022) (5, 6), nor the impact of coronavirus disease 19 (COVID-19). Regarding the latter, according to multiple studies, the COVID-19 pandemic may have caused significant delays in diagnosis and initiation of treatment in many cancer sites. This may lead to a subsequent",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:43"
    }
  },
  {
    "page_content": "many cancer sites. This may lead to a subsequent increase in the number of cases diagnosed in more advanced stages, with implications on survival, quality of life, and economic costs (42–44). Finally, the projections presented here could be underestimated due to the continuous improvement in the capture of hematological neoplasms by PBCRs and the development in recent years of more effective diagnostic tools. However, the methods and strategy used in data analysis provide a reasonably accurate",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:44"
    }
  },
  {
    "page_content": "in data analysis provide a reasonably accurate estimate of the current incidence of LNs in Spain, based on the greatest population coverage currently provided by cancer registries in this country. Some limitations must be considered when interpreting our data. First, changes in the classifications and diagnostic criteria of the subtypes studied hamper the interpretation of our results, as well as comparisons with previous studies. In addition, lack of homogeneity among REDECAN registries, since",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:45"
    }
  },
  {
    "page_content": "of homogeneity among REDECAN registries, since there is no centralized pathology and clinical review, can lead to problems of quality and completeness. For instance, this may have implications in the percentage of NOS cases in all provinces or affect the estimates of subtypes such as chronic lymphocytic leukemia or Waldenström’s macroglobulinemia, which have been shown to be underreported by PBCR. Nonetheless, during the last years, REDECAN has implemented training programs to improve the",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:46"
    }
  },
  {
    "page_content": "has implemented training programs to improve the coding and registering of hematological neoplasms in non-specialized Spanish registries, following the example of the French Network of Cancer Registries (FRANCIM) (45). In addition, some LNs subtypes, such as mature T-cell and NK-cell neoplasms, are exceptionally rare; therefore, our estimates may be less robust for those entities. Finally, lack on information on disease stage at diagnosis and therapeutic patterns makes interpretation of",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:47"
    }
  },
  {
    "page_content": "and therapeutic patterns makes interpretation of survival rates difficult. High-resolution studies collecting such data would provide further evidence on the effectiveness of new treatments, as well as to explain geographic variations across Europe (12). # Conclusions This study presents the most comprehensive population-based analysis of LNs incidence and survival in Spain. It features some useful points for public health authorities and clinicians, such as the evolution of the incidence of",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:48"
    }
  },
  {
    "page_content": "such as the evolution of the incidence of several subtypes, and the expected cases in 2023 based on these data. Survival for all cases as a whole improved along the period of study, although rates are still poor for several subtypes. This study also provides information on the quality of the registries, suggesting, with a negative trend of NOS cases, improvements in the registration and/or a more specific diagnosis, although there is still room for improvement. # Data availability statement The",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:49"
    }
  },
  {
    "page_content": "improvement. # Data availability statement The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation. # REDECAN Working Group REDECAN Working Group: Girona Cancer Registry – Coordination of hematology neoplasms in REDECAN: RM-G, Montse Puigdemont, Anna Vidal Vila, AS, Andrés Castillo-Bonilla; Tarragona Cancer Registry – Data coordination in REDECAN: MC, AA, CP, and JG; Álava Cancer Registry: AL-d-M, Patricia Sancho, María Luisa",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:50"
    }
  },
  {
    "page_content": "Registry: AL-d-M, Patricia Sancho, María Luisa Iruretagoyena; Albacete Cancer Registry: Cristina Ramírez; Asturias Cancer Registry: SM, Virginia Menéndez García, Marta Rodríguez Camblor; Bizkaia Cancer Registry: Visitación de Castro, Marta De La Cruz, Joseba Bidaurrazaga; Castellón Cancer Registry: Consol Sabater Gregori, Isabel Sáez Lloret, Ana Vizcaíno Batllés, Xavier Peñalver Herrero; Ciudad Real Cancer Registry: CD-d-C; Cuenca Cancer Registry: AM, Rosario Jimenez Chillarón; Gipuzkoa Cancer",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:51"
    }
  },
  {
    "page_content": "AM, Rosario Jimenez Chillarón; Gipuzkoa Cancer Registry: AA; Gran Canaria Cancer Registry: MDR, Emilio De Miguel, María Carmen Gabas; Granada Cancer Registry: MJS, Daysi Yoe-Ling Chang-Chan; Miguel Rodríguez Barranco; La Rioja Cancer Registry: María Isabel Palacios, Enrique Ramalle; Mallorca Cancer Registry: Paula Franch, Patricia Ruiz Armengol, Carmen Sánchez Contador; Murcia Cancer Registry: MDC, Antonia Sánchez Gil, Ricardo José Vaamonde; Navarra Cancer Registry: MG, Eva Ardanaz; Tenerife",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:52"
    }
  },
  {
    "page_content": "Cancer Registry: MG, Eva Ardanaz; Tenerife Cancer Registry: MAA, Leonor Olga Velázquez, María Magdalena Ramos Marrero; Castilla y León Cancer Registry: Pilar Gutiérrez, Rufino Álamo, Lorena Estévez; Registro Español de Tumores Infantiles: Adela Cañete, Elena Pardo, Rafael Peris Bonet; Registro de Tumores Infantiles y Adolescentes de la Comunitat Valenciana: Consol Sabater Gregori, Ana Vizcaino Batllés, Fernando Almela Vich. # Author contributions RM-G, MS, and CP contributed to the study",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:53"
    }
  },
  {
    "page_content": "RM-G, MS, and CP contributed to the study conception and design. Data collection was performed by CP, AS, MC, MDR, MAA, IS-L, CD-d-C, AIM-N, LS-d-A, AA-A, AL-d-M, MJS, JP, PF, MDC, MG, JG, SM, and RM-G. Data analysis was performed by AA and AS. The first draft of the manuscript was written by CP. All authors contributed to the article and approved the submitted version. # Funding This work was partially funded by the Josep Carreras Leukaemia Research Institute (Grant No.: FIJC1100). # Conflict",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:54"
    }
  },
  {
    "page_content": "Institute (Grant No.: FIJC1100). # Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. # Publisher’s note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article,",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:55"
    }
  },
  {
    "page_content": "product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.",
    "metadata": {
      "source": "../data/plain/PMC9731832.plain.txt",
      "id": "../data/plain/PMC9731832.plain.txt:56"
    }
  },
  {
    "page_content": "Diagnosis and histopathologic prognostication of canine melanocytic neoplasms: A consensus of the Oncology‐Pathology Working Group Abstract",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:0"
    }
  },
  {
    "page_content": "One of the primary objectives of the Oncology Pathology Working Group (OPWG) is for oncologists and pathologists to collaboratively generate consensus documents to standardize aspects of and provide guidelines for veterinary oncologic pathology. Consensus is established through review of relevant peer‐reviewed literature relative to a subgroup's particular focus. In this article, the authors provide a critical review of the current literature for the diagnosis of, and histopathologic",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:1"
    }
  },
  {
    "page_content": "for the diagnosis of, and histopathologic prognostication for, canine cutaneous and oral/lip melanocytic neoplasms, suggest guidelines for reporting, provide recommendations for clinical interpretation, and discuss future directions. This document represents the opinions of the working group and the authors and does not constitute a formal endorsement by the American College of Veterinary Pathologists, American College of Veterinary Internal Medicine or the Veterinary Cancer Society. #",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:2"
    }
  },
  {
    "page_content": "Medicine or the Veterinary Cancer Society. # INTRODUCTION In 2011, Smedley et al., published “Prognostic Markers for Canine Melanocytic Neoplasms: A Comparative Review of the Literature and Goals for Future Investigation”, a critical review of canine melanocytic neoplasm studies published prior to February 2011, as an initiative of the American College of Veterinary Pathologists' (ACVP) Oncology Committee. The authors based that review on the criteria described in the consensus by Webster et",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:3"
    }
  },
  {
    "page_content": "criteria described in the consensus by Webster et al. “Recommended Guidelines for the Conduct and Evaluation of Prognostic Studies in Veterinary Oncology”. The main goal of the 2011 review was to report which published parameters “had the most statistically supported validity for prognostic use in canine melanocytic neoplasia.” Similarly, as an update of the 2011 review, this current manuscript provides a critical consensus review of canine melanocytic neoplasm diagnostic and prognostic",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:4"
    }
  },
  {
    "page_content": "melanocytic neoplasm diagnostic and prognostic pathology studies that have been published from 2011 to 2021 based on the same guidelines published by Webster et al. This consensus is based on the work of the canine melanoma subgroup as part of the Oncology Pathology Working Group (OPWG), a joint initiative of the Veterinary Cancer Society and the ACVP that was formed from the ACVP Oncology Committee. We provide recommendations for the diagnosis, and histopathologic prognostication, of canine",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:5"
    }
  },
  {
    "page_content": "and histopathologic prognostication, of canine cutaneous and oral/lip melanocytic neoplasms in a diagnostic setting, suggest guidelines for reporting, provide recommendations for clinical interpretation, and discuss future directions. This document represents the opinions of the working group and the authors and does not constitute a formal endorsement by the ACVP or the Veterinary Cancer Society. # METHODS ## Development of the consensus report The canine melanoma subgroup of the OPWG, which",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:6"
    }
  },
  {
    "page_content": "The canine melanoma subgroup of the OPWG, which includes all coauthors of this article, reviewed recent canine melanocytic literature. The canine melanoma subgroup includes 6 board‐certified veterinary oncologists (PJB, CS, CT, CAC, NC, PW) and 7 board‐certified veterinary pathologists (RCS, LB, CB, JG, PR, JD, AP). The chairs (PJB and RCS) initially selected the articles for review, which included the 2011 review paper by Smedley et al. and subsequent diagnostic or prognostic articles from",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:7"
    }
  },
  {
    "page_content": "subsequent diagnostic or prognostic articles from February 2011 to December 2017.,,,,,,,,,,,,,,,, Articles were searched in https://pubmed.ncbi.nlm.nih.gov/ using the phrase “canine melanoma”. The abstracts were then evaluated to determine whether or not the paper addressed any diagnostic or prognostic markers. If it was uncertain, the chairs (PJB and RCS) scanned the articles to determine if any previous or new diagnostic or prognostic parameters were evaluated as a minor portion of the study.",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:8"
    }
  },
  {
    "page_content": "were evaluated as a minor portion of the study. Articles related to treatment or prognostic clinical criteria of canine cutaneous and oral/lip melanocytic tumours were not included in this review but were saved for a subsequent consensus report. The focus of this consensus statement is on the histological features of, and molecular markers for, cutaneous and oral/lip melanocytic neoplasms. Three subgroup members were assigned to each article for critical review, avoiding assignment of articles",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:9"
    }
  },
  {
    "page_content": "critical review, avoiding assignment of articles they authored. Each member used an Excel table template that was the same as the one used by Smedley et al. and was based on the standards outlined by Webster et al. This table provided a summary of the objective/hypothesis, study design, materials and methods, statistical soundness, conclusions by the article's authors, and conclusions of the reviewing subgroup member, in addition to other criteria. The co‐chair (RCS) then combined the reviews",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:10"
    }
  },
  {
    "page_content": "The co‐chair (RCS) then combined the reviews from each author into one review per article in the same Excel table format. To expedite review of an additional 6 articles, including one published in 2012 and 5 published from July 2017 to March 2019,,,,, the co‐chair (RCS) completed the review of these articles and distributed the reviews to the subgroup for comments and discussion. Next, the co‐chair (RCS) summarized and condensed the reviews and drafted the initial consensus report. Additional",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:11"
    }
  },
  {
    "page_content": "drafted the initial consensus report. Additional articles were referenced in the report as needed but were not critically reviewed.,,,,,,,,, The reviews and the consensus report were distributed to all subgroup members for edits, discussion and comments and then submitted to the OPWG Executive Committee for review. The consensus was made available to OPWG membership at large, which approved the report by popular vote, and then it was made available online on the OPWG webpage",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:12"
    }
  },
  {
    "page_content": "it was made available online on the OPWG webpage (http://vetcancersociety.org/vcs-members/vcs-groups/oncology-pathology-working-group/) in August 2020. While preparing the current manuscript, 14 additional articles,,,,,,,,,,,,, were identified that were published from November 2019 to August 2021. Again, to expedite review of these 15 additional articles, the co‐chair (RCS) completed the reviews and distributed them to the subgroup for comments and discussion. All authors agreed on inclusion of",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:13"
    }
  },
  {
    "page_content": "discussion. All authors agreed on inclusion of these references here, but they were not present in the OPWG consensus statement and, therefore, were not voted on by the OPWG membership. ## Review of the literature Since 2011, there have been few published studies that have identified novel diagnostic or prognostic markers for canine melanocytic neoplasms that have enough statistical soundness, and that can easily be used in a diagnostic setting. The conclusions in most of these studies still",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:14"
    }
  },
  {
    "page_content": "The conclusions in most of these studies still require further validation via additional corollary studies. Unfortunately, there have only been rare published prospective prognostic studies for canine melanocytic neoplasms and those particular studies have not yielded established prognostic markers at this point. While not the major goal, some of the new studies do provide further support for the use of the parameters recommended in the 2011 review. The studies that provide the most potentially",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:15"
    }
  },
  {
    "page_content": "The studies that provide the most potentially useful data, support previous recommendations, and have future utility are discussed below. # RESULTS A total of 37 articles were originally selected, of which 24 contained prognostic criteria suitable for the consensus document. A total of 23 additional articles were identified after the consensus document was published online. Of these, 14 contained prognostic criteria that were deemed important to include here. ## Diagnostic markers for",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:16"
    }
  },
  {
    "page_content": "to include here. ## Diagnostic markers for melanocytic neoplasms The first step in prognostication, and to decide the correct therapeutic approach, is to obtain an accurate diagnosis. This should also be the first step when performing and reviewing prognostic studies. If melanocytic origin has not been definitively confirmed for every neoplasm in a study population, the results of that study cannot be interpreted accurately. Diagnosis is based on specific histologic features of cutaneous and",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:17"
    }
  },
  {
    "page_content": "on specific histologic features of cutaneous and mucosal melanocytic tumours. However, when histologic features alone are not confirmatory of melanocytic origin, demonstration of immunohistochemical (IHC) labelling for specific melanocytic markers is needed (Table 1). Melanocytic neoplasms in veterinary species have been shown to label for several different IHC markers, but each marker has different sensitivities and specificities among species, including humans, thereby limiting the use of a",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:18"
    }
  },
  {
    "page_content": "including humans, thereby limiting the use of a single antibody for diagnosing amelanotic melanocytic neoplasms. The most sensitive and specific markers to detect melanocytic neoplasms in veterinary species are still Melan‐A and PNL2,, which are antigens that are found on melanocytes. In dogs, antibodies against tyrosinase‐related proteins 1 and 2 (TRP‐1 and TRP‐2) have also been shown to be highly sensitive and specific. A diagnostic melanoma cocktail that contains antibodies against Melan‐A,",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:19"
    }
  },
  {
    "page_content": "that contains antibodies against Melan‐A, PNL2, TRP‐1 and TRP‐2 has been shown to have 100% specificity and 93.9% sensitivity in detecting canine oral melanocytic neoplasms compared to soft tissue sarcomas in one study, and is commercially available. This cocktail has been shown to have a sensitivity that is greater than the individual sensitivities of each individual antibody and to result in a greater labelling intensity. Thus, this cocktail makes it easier to identify labelling in small",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:20"
    }
  },
  {
    "page_content": "makes it easier to identify labelling in small samples and in tumours that only exhibit a small amount of labelling with the individual markers and it is considered to be the current gold standard for diagnosing canine amelanotic malignant melanomas (MM)., The most common cells to label with melanocytic markers are intraepithelial neoplastic cells, which are the most differentiated of the neoplastic cells, as the growth of the neoplasm begins in the epithelium. Thus, it is extremely important",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:21"
    }
  },
  {
    "page_content": "the epithelium. Thus, it is extremely important for clinicians to submit non‐ulcerated portions of the mass, as well as wide lateral margins that include intact lateral flanking epithelium, in order to increase the likelihood of identifying intraepithelial nests of neoplastic melanocytes and to improve likelihood of complete excision. Small nests can sometimes be difficult to discern with routine histology, but they are easily identified with IHC labelling. IHC for S‐100 and for",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:22"
    }
  },
  {
    "page_content": "with IHC labelling. IHC for S‐100 and for microphthalmia‐associated transcription factor (MITF) have also been explored. These markers showed 81.6% and 89.8% sensitivity respectively, but only showed 20% and 30% specificity, respectively, in differentiating melanocytic tumours from soft tissue sarcomas. Campagne et al. used immunofluorescent labelling for MITF to identify neoplastic and non‐neoplastic melanocytes. In that study, the immunofluorescent method showed 100% sensitivity and 100%",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:23"
    }
  },
  {
    "page_content": "method showed 100% sensitivity and 100% specificity. In contrast, the authors stated that IHC labelling for MITF did not identify tumuoral cells in all of the samples. SOX‐10 is a marker that has been used to diagnose melanocytic neoplasms in humans, but until recently, there had been no published studies of its use in dogs. In humans, it is not specific to melanocytes and has been shown to be consistently expressed in benign Schwann cell tumours of soft tissue and the gastrointestinal tract",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:24"
    }
  },
  {
    "page_content": "of soft tissue and the gastrointestinal tract and to be variably present in malignant peripheral nerve sheath tumours. It has also been shown to label myoepithelial cell origin tumours, granular cell tumours, histiocytes, occasional alveolar rhabdomyosarcomas and some epithelial tumours, including rare squamous cell carcinomas of the head and neck and pulmonary small cell carcinomas.,,, In addition, SOX‐10 can be expressed in entrapped non‐neoplastic Schwann cells or melanocytes in various",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:25"
    }
  },
  {
    "page_content": "Schwann cells or melanocytes in various neoplasms and this has to be considered when diagnosing SOX‐10‐positive tumours. In humans, soft tissue sarcomas are uncommon and often are not a differential for a melanoma. In contrast, soft tissue sarcomas, including peripheral nerve sheath tumours, in dogs are very common and are the primary differential for a spindloid melanoma. The diagnostic melanoma cocktail has the lowest sensitivity in spindloid variants of amelanotic MM. Thus, a recent study",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:26"
    }
  },
  {
    "page_content": "variants of amelanotic MM. Thus, a recent study examined additional IHC markers and gene expression patterns in these tumours to improve the ability to differentiate between oral amelanotic spindloid MMs and oral soft tissue sarcomas. IHC labelling for SOX‐10 was also examined in that study. Tsoi et al. examined 20 oral MMs and 20 soft tissue sarcomas for SOX‐10 immunoexpression and found that all 20 oral MMs and 2 out of 20 soft tissue sarcomas labelled for SOX‐10, resulting in 100%",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:27"
    }
  },
  {
    "page_content": "sarcomas labelled for SOX‐10, resulting in 100% sensitivity but only 90% specificity for that antibody. In addition, the authors examined various gene expression patterns and determined that mRNA levels of TYR, CD34, and CALD1 can be used to differentiate between canine oral spindloid amelanotic MMs and soft tissue sarcomas that are negative for specific melanocytic markers (Melan‐A, PNL2, TRP‐1 and TRP‐2) with 100% specificity and 65%, 95% and 60% sensitivity, respectively. Availability of",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:28"
    }
  },
  {
    "page_content": "60% sensitivity, respectively. Availability of gene expression analysis for canine melanomas in a diagnostic setting would greatly improve a pathologist's ability to more confidently distinguish between these two tumour types. Cytologic +/− immunocytochemical (ICC) examination of potential melanocytic neoplasms should not be forgotten as a potential useful preoperative diagnostic tool. In one study, the authors found that ICC using anti‐Melan‐A, anti‐Vimentin, and anti‐cytokeratin improved the",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:29"
    }
  },
  {
    "page_content": "anti‐Vimentin, and anti‐cytokeratin improved the ability to diagnose canine amelanotic oral melanomas with cytology. The diagnosis reached with ICC matched the histologic diagnosis. The study also showed that ICC for Melan‐A can correctly identify metastatic amelanotic melanoma in regional lymph nodes, especially when they are in low numbers or have a round cell morphology. It still may be difficult to differentiate between metastatic neoplastic melanocytes and draining melanocytes, however. ##",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:30"
    }
  },
  {
    "page_content": "melanocytes and draining melanocytes, however. ## Prognostication of melanocytic neoplasms An accurate prognosis is critical for appropriate recommendations for primary and/or adjunct therapy. Assessment of a combination of highly reliable parameters will provide the most accurate prediction of prognosis. In terms of prognostication of canine melanocytic neoplasms, the recommendations in the review paper by Smedley et al. were judged to still be the most diagnostically and prognostically",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:31"
    }
  },
  {
    "page_content": "be the most diagnostically and prognostically useful, with the addition of assessing tumour thickness for non‐oral cutaneous melanocytic neoplasms. ### Tumour location of cutaneous, oral and lip melanocytic neoplasms Historically, canine oral melanocytic tumours have been regarded as malignant and cutaneous melanocytic tumours have been regarded as benign. While, in general, digital/subungual and lip tumours have been shown to have increased recurrence and metastasis compared to tumours at",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:32"
    }
  },
  {
    "page_content": "recurrence and metastasis compared to tumours at other cutaneous sites., Other studies have shown that this is not always the case and that location alone cannot predict prognosis.,,,, In one study, 92% of oral and 74% of feet & lip melanocytic neoplasms were originally classified as malignant but only 59% of oral and 38% of feet & lip neoplasms showed malignant behaviour, and a subset of cutaneous melanocytic neoplasms showed malignant behaviour that would have been predicted to be benign",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:33"
    }
  },
  {
    "page_content": "that would have been predicted to be benign based on location and current microscopic criteria for prognostication. Recently, a significant correlation between histologic diagnosis of cutaneous melanocytic neoplasms and location was found when the diagnostic criteria described by Smedley et al. were used. Similar to Spangler and Kass, these authors found that cutaneous MMs were more likely to be on the digit compared to melanocytomas. They also found that there were fewer MMs than melanocytomas",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:34"
    }
  },
  {
    "page_content": "that there were fewer MMs than melanocytomas on the abdomen. Overall, the challenge is to identify benign oral/lip melanocytic neoplasms and malignant cutaneous ones. At this time, histologic criteria and Ki67 labelling, by use of commercially available antibodies, are evaluated for this purpose. ### Histological criteria In terms of histologic criteria, nuclear atypia, mitotic count (MC), degree of pigmentation, level of infiltration/invasion, and vascular invasion have been shown to be",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:35"
    }
  },
  {
    "page_content": "and vascular invasion have been shown to be statistically relevant for predicting prognosis of cutaneous and oral melanocytic neoplasms in dogs in studies prior to and after 2011.,,,,,,,,,,, Histologically evaluated ulceration,, and macroscopically assessed tumour thickness, are only predictive of prognosis for cutaneous tumours. While assessment of nuclear atypia can result in significant interobserver variation, this parameter continues to show statistical relevance when correctly applied.",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:36"
    }
  },
  {
    "page_content": "statistical relevance when correctly applied. Only one paper reported a lack of association between nuclear atypia and survival in dogs with oral MMs. Nuclear atypia should be assessed according to the strict criteria outlined by Spangler and Kass. Using those criteria, a threshold value of 20% atypical nuclei for cutaneous melanocytic neoplasms and a threshold of 30% atypical nuclei for canine oral/lip melanocytic neoplasms have shown statistical significance for predicting survival times.,,,",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:37"
    }
  },
  {
    "page_content": "significance for predicting survival times.,,, The most accurate way to determine the percentage of atypical nuclei is to count the number of atypical nuclei among 200 cells. Despite the inter‐ and intraobserver variation of MC, it has still shown statistical relevance in several studies of melanocytic neoplasms at various locations, including cutaneous studies published since 2011, and is more objective than nuclear atypia.,,,,,,,, It should be noted that most veterinary studies incorrectly",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:38"
    }
  },
  {
    "page_content": "be noted that most veterinary studies incorrectly refer to MC as mitotic index. Mitotic index is the number of mitotic figures/total number of cells in a defined area or volume of tumour and this has never been done in veterinary pathology. MC is the number of mitotic figures in a defined square mm area. The area 2.37 mm2 was proposed for animal tumours because this is the area in 10 fields of view with a 40× objective and a 10× ocular that has field number (FN) of 22 engraved in the eyepiece.",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:39"
    }
  },
  {
    "page_content": "field number (FN) of 22 engraved in the eyepiece. An ocular with an FN 22 is the most common ocular manufactured by commercial sources for pathologists. For this consensus statement we have defined the MC as the number of mitoses in 10 fields at 400× magnification/40× objective (which we will refer to as hpf throughout this text) because that is how earlier studies performed the MC. Therefore, these terms and definition will be used throughout this report, regardless of how it is stated in the",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:40"
    }
  },
  {
    "page_content": "report, regardless of how it is stated in the cited reference. The MC threshold for cutaneous melanocytic tumours was established by counting mitoses in 10 random high power fields. However, in order to decrease the rate of underestimation of malignant neoplasms, MC should be determined in the area of highest mitotic activity, similar to how the threshold for oral/lip melanocytic neoplasms was determined. Therefore, first scan the neoplasm at 100× magnification/10× objective to locate areas of",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:41"
    }
  },
  {
    "page_content": "magnification/10× objective to locate areas of potentially high mitotic activity. Locate a field containing one or more mitotic figures, if possible, and begin counting mitoses in that area at 400× magnification/40× objective. Count mitotic figures in 10 consecutive hpf. Avoid areas of ulceration, necrosis, and inflammation when counting mitoses. For heavily pigmented neoplasms bleaching may be needed to better assess the MC. Ideally, MCs should now be reported per 2.37 mm2. For cutaneous",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:42"
    }
  },
  {
    "page_content": "now be reported per 2.37 mm2. For cutaneous neoplasms, an MC of 3 or greater in 10 hpf has been associated with more aggressive behaviour and shorter survival times., Neoplasms with less than 3 mitoses in 10 hpf generally exhibit benign behaviour. One study showed that 50% of dogs with neoplasms with an MC of ≥3 in 10 random hpf were alive for <7 months while 90% of dogs with neoplasms with an MC <3 in 10 random hpf were still alive at 2 years. For oral/lip melanocytic neoplasms, a cut‐off of 4",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:43"
    }
  },
  {
    "page_content": "oral/lip melanocytic neoplasms, a cut‐off of 4 mitoses per 10 hpf is a statistically determined threshold value for MC, with dogs having tumours with ≥4 mitoses showing shorter survival times. A marked difference in survival at 1 year between the two groups created by this cut‐off value has been demonstrated with a sensitivity of 90% and a specificity of 84% in one oral/lip study. For pigmentation, it is difficult to measure objectively with validated cutoff points, but a high degree of",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:44"
    }
  },
  {
    "page_content": "validated cutoff points, but a high degree of pigmentation does suggest a favourable clinical outcome for cutaneous and oral/lip melanocytic neoplasms.,,,, Oral/lip neoplasms with ≥50% of pigmented cells have been shown to have longer survival times., However, outcome is not predictable in oral/lip or cutaneous neoplasms with moderate, low, or no pigmentation.,, Pigmentation should be evaluated but should not be used as a sole predicting factor. In addition, ulceration is another prognostic",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:45"
    }
  },
  {
    "page_content": "In addition, ulceration is another prognostic marker that can be used for cutaneous melanocytic neoplasms. Ulceration of cutaneous melanocytic neoplasms has been associated with significantly shorter survival times and was shown to be an independent prognostic factor in two studies., ### Molecular markers Several molecular markers have been investigated for their potential as prognostic markers for canine melanocytic neoplasms (Table 2). Currently, immunohistochemical evaluation of Ki67, as the",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:46"
    }
  },
  {
    "page_content": "immunohistochemical evaluation of Ki67, as the Ki67 index or Ki67 count, is the only established prognostic molecular marker, and it has been shown to be highly predictive of behaviour for both oral and cutaneous melanocytic tumours in dogs in multiple studies, including four that were published after 2011.,,,,,, Whereas MC only accounts for cells in the M phase of the cell cycle, Ki67 is a nuclear protein that is expressed in all phases of the cell cycle, except the resting phase; therefore,",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:47"
    }
  },
  {
    "page_content": "cell cycle, except the resting phase; therefore, it is a measure of growth fraction. The level of Ki67 expression is much more objective and has been shown to have a similar or higher predictive value as traditional histologic criteria for both cutaneous and oral/lip melanocytic neoplasms., Some neoplasms with histological criteria of malignancy, but a low level of Ki67 expression have longer survival times than expected by histology., It is also much easier to identify the areas with the most",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:48"
    }
  },
  {
    "page_content": "much easier to identify the areas with the most proliferation by looking for red nuclear labelling than it is to identify an area of high mitotic activity when scanning a tumour. Thus, this marker is more objective than MC. Nuclei with weak to strong diffuse labelling and nuclei with only nucleolar labelling are counted while avoiding areas of ulceration and inflammation. For heavily pigmented neoplasms, bleaching the sections after immunohistochemical labelling may be needed to better assess",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:49"
    }
  },
  {
    "page_content": "labelling may be needed to better assess Ki67 labelling. If sections are bleached before immunohistochemistry, Ki67 labelling does not work. In cutaneous melanocytic neoplasms, the Ki67 index is determined as a percentage of positive nuclei in 500 cells. Thus, the number of cells evaluated is standardized. Assistance of a 1 cm2 optical grid reticle is very helpful. The grid reticle simply helps the pathologist keep track of which cells have been counted already. For oral/lip melanocytic",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:50"
    }
  },
  {
    "page_content": "been counted already. For oral/lip melanocytic neoplasms, the Ki67 count is determined as the average number of positively labelled neoplastic cell nuclei per area of a 1 cm2 optical grid reticle at 400x magnification/40x objective (5 grid areas counted) in the highest labelling area. This grid method standardizes the area assessed so that it is the same no matter what microscope is used. It should be noted that previous references refer to this method for oral/lip melanocytic tumours as “Ki67",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:51"
    }
  },
  {
    "page_content": "method for oral/lip melanocytic tumours as “Ki67 index”. However, similar to the incorrect use of the term “mitotic index”, it may be more accurate to refer to this method of evaluating Ki67 labelling for oral/lip melanocytic tumours as “Ki67 count”, as it is not reported as a percentage of cells. A threshold value of 19.5 was statistically determined using a receiver operator characteristic (ROC) curve. Kaplan–Meier survival analysis showed that the survival curves for dogs with a Ki67 count",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:52"
    }
  },
  {
    "page_content": "the survival curves for dogs with a Ki67 count <19.5 and dogs with a Ki67 count ≥19.5 are significantly different based on a one‐year survival period (P <.0001). In cutaneous melanocytic neoplasms, a threshold value of 15% had been previously empirically determined and has been evaluated in regard to survival with Kaplan–Meier survival curves. Statistically significant lower survival rates were reported for dogs with neoplasms with a Ki67 index ≥15% in that study, as well as in a more recent",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:53"
    }
  },
  {
    "page_content": "≥15% in that study, as well as in a more recent study., In one study, none of the behaviourally benign cutaneous melanocytic neoplasms had a Ki67 index greater than or equal to 15%. The percentage of correctly classified neoplasms using the Ki67 index (97%) was higher than that of MC (91%) and histological criteria (93%) in one study. Thus, a threshold of 15% should be used to predict prognosis of cutaneous melanocytic neoplasms.,, Assessment of Ki67 value is especially helpful for melanocytic",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:54"
    }
  },
  {
    "page_content": "Ki67 value is especially helpful for melanocytic neoplasms that exhibit both prognostically favourable and poor histological parameters, or so called “grey zone” cases, but it is never wrong to perform Ki67 immunolabelling for added confidence. ### Newly examined prognostic parameters for canine cutaneous melanocytic neoplasms Recently, tumour thickness has been shown to be a useful prognostic marker for cutaneous melanocytic neoplasms in two studies, although the authors of those studies state",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:55"
    }
  },
  {
    "page_content": "although the authors of those studies state that additional studies with larger case numbers are needed to further support its use as an independent prognostic marker., Nonetheless, the study by Silvestri et al. 2019 provides convincing statistical evidence that a greater tumour thickness is associated with shorter overall survival and disease‐free time and provides an easy method to measure tumour thickness with established cut‐off values that can be used in a diagnostic setting. ROC curve",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:56"
    }
  },
  {
    "page_content": "can be used in a diagnostic setting. ROC curve analysis and Youden Index identified cutoffs of 0.95 and 0.75 cm which were associated with a higher hazard for an unfavourable outcome and to develop recurrence/metastasis, respectively. Kaplan–Meier survival curves and log‐rank tests were used to compare overall survival according to diagnosis. Via univariate analysis, dogs with greater tumour thickness had an approximately 10 times higher hazard of death and a greater than 5 times higher hazard",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:57"
    }
  },
  {
    "page_content": "of death and a greater than 5 times higher hazard to develop recurrence/metastasis than dogs with thinner tumours. The cutoff of 0.95 cm discriminated between favourable and unfavourable (tumour‐related death) clinical outcomes (sensitivity = 100%, specificity = 86%; ROC curve analysis, AUC = 0.886; 95%CI, 0.795–0.977; P =.005). A shorter overall survival time was seen for dogs with tumours that were >0.95 cm thick compared to those with a tumour thickness ≤0.95 cm (P <.001). In this study,",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:58"
    }
  },
  {
    "page_content": "thickness ≤0.95 cm (P <.001). In this study, none of the dogs with a tumour thickness ≤0.95 cm died; thus, the 1‐year estimated survival probability was 100% ± 0%, while it was only 45.0% ± 18.8% for dogs with tumour thickness >0.95 cm. To predict which tumours would be more likely to develop recurrence/metastasis, a thickness cutoff of 0.75 cm was determined (sensitivity = 86%, specificity = 81%; ROC curve analysis, AUC = 0.886; 95% CI, 0.795–0.977; P =.005). Those that were >0.75 cm were",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:59"
    }
  },
  {
    "page_content": "P =.005). Those that were >0.75 cm were associated with a shorter disease‐free time than those that were ≤0.75 (P <.001). Dogs with tumours that were >0.75 cm thick had a 1‐year estimated probability of not developing recurrence/metastasis that was 54.7% ± 15.4%, whereas it was 97.2% ± 2.7% for dogs with tumours that were ≤0.75 cm. One must remember that false positives and false negatives can still occur with these thresholds for individual cases, and the prognostic significance of tumour",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:60"
    }
  },
  {
    "page_content": "cases, and the prognostic significance of tumour thickness was not able to be confirmed with multivariable analysis in this study, nor was it compared to Ki67 index. In addition, the tumour thickness cutoff of 0.45 cm was determined by ROC curve analysis to distinguish cutaneous MMs from melanocytomas as defined by histopathology with a sensitivity of 87% and a specificity of 64%. However, the authors stated that these values are not optimal due to the possibility of false‐positive results. The",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:61"
    }
  },
  {
    "page_content": "to the possibility of false‐positive results. The authors used both an ocular micrometre as well as a standard ruler to measure tumour thickness and found that these two methods had excellent agreement. Thus, it is recommended for routine diagnostics to measure tumour thickness by simply applying a ruler to the surface of a glass slide perpendicularly to the epidermis and measuring the largest thickness of the tumour. This study also examined the usefulness of a modified Clark level measurement",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:62"
    }
  },
  {
    "page_content": "usefulness of a modified Clark level measurement for predicting prognosis; however, this measurement was not associated with clinical outcome or presence of recurrence/metastasis and did not show prognostic significance. Studies that compare tumour thickness to other established parameters, such as Ki67 index, are still needed to further evaluate this parameter and to determine if this parameter adds value to the other parameters., In conjunction with the other described prognostic parameters,",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:63"
    }
  },
  {
    "page_content": "with the other described prognostic parameters, pathologists should begin to report tumour thickness for cutaneous melanocytic neoplasms and use the cut‐offs of 0.95 and 0.75 cm as one means of predicting survival times and risk of recurrence/metastasis, respectively. This will allow for greater data collection regarding this parameter. Tumour symmetry and growth pattern (expansive vs. infiltrative) are two additional parameters that have shown prognostic significance in one study but still",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:64"
    }
  },
  {
    "page_content": "prognostic significance in one study but still require further evaluation with larger case numbers. A few studies have evaluated various molecular markers as potential prognostic markers for cutaneous melanocytic neoplasms and some may hold future promise. However, most have low sample sizes, limited or no follow‐up, or other limitations that prevent them from being used in a diagnostic setting at this time. One such marker that requires further investigation is survivin. In one study, nuclear",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:65"
    }
  },
  {
    "page_content": "investigation is survivin. In one study, nuclear survivin expression was significantly greater in malignant cutaneous melanomas compared to melanocytomas, and increased expression (≥8% of neoplastic cells) was related to the presence of metastasis and death of the animal due to melanoma. In a recent study, survivin gene expression from formalin fixed‐paraffin embedded (FFPE) tumour tissue was assessed in both cutaneous and oral melanocytic tumours, and confirmed a correlation of this marker",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:66"
    }
  },
  {
    "page_content": "and confirmed a correlation of this marker with tumour related death and Ki67 index. In the same study, gene expression from FFPE tissue of another marker, H2AFZ, showed promising results as a new prognostic marker, being correlated with MC, Ki67 index, presence of metastasis, and death due to melanoma. RACK1 is another marker that has been investigated as a potential diagnostic, as well as a potential prognostic, marker. In one study, RACK1 distribution differed between benign and malignant",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:67"
    }
  },
  {
    "page_content": "differed between benign and malignant canine melanocytic neoplasms and a RACK1 homogeneous labelling pattern was highly correlated with other criteria such as classic histologic features of malignancy, Ki‐67 index and MC. However, sample size was very small and included both cutaneous and mucosal neoplasms, and there was a lack of follow‐up data in this study; thus, additional testing is needed before this marker can be used in a diagnostic setting. Even then, evaluation of this marker in a",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:68"
    }
  },
  {
    "page_content": "Even then, evaluation of this marker in a diagnostic setting may prove to be too complicated and it has not been shown to add additional value over Ki67 index and MC. In addition, other neoplasms can also label for RACK 1, so this marker cannot be used as a standalone marker for diagnosis of melanocytic origin. Several papers have been published in recent years on the prognostic significance of tumour infiltrating lymphocytes (TILs) in canine melanocytic neoplasms. Several markers used to",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:69"
    }
  },
  {
    "page_content": "melanocytic neoplasms. Several markers used to identify different TIL subtypes, such as regulatory T cells (Treg) or B cells, have been investigated. FoxP3, IDO and CTLA‐4 expression, markers of Treg, have been shown to hold promise as prognostic markers for canine cutaneous and oral melanocytic neoplasms, but also require further evaluation with larger sample sizes, with comparisons to other established prognostic markers, besides MC, and by separating cutaneous from oral melanomas., Ideally,",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:70"
    }
  },
  {
    "page_content": "cutaneous from oral melanomas., Ideally, this should be done with a prospective study. A high number of CD20+ TILs (B cells) has been shown to be associated with tumour‐related death, presence of metastasis/recurrence, shorter overall and disease‐free survival, increased hazard of death, and of developing recurrence/metastasis. No associations were found related to infiltrating CD3+ TILs (T cells). This study compared the degree of CD20+ TILs with other histologic parameters including MC,",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:71"
    }
  },
  {
    "page_content": "with other histologic parameters including MC, tumour thickness and modified Clark level for cutaneous tumours, nuclear atypia, pigmentation, ulceration, necrosis, and cellular pleomorphism. There was a statistically significant association between the quantity of CD20+ TILs and the MC. Tumour size was significantly lower in tumours that lacked CD20+ TILs compared to those with mild, moderate, or severe infiltrates, in terms of quantity. An association was also seen between the quantity of",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:72"
    }
  },
  {
    "page_content": "association was also seen between the quantity of CD20+ TILs and the percent pigmentation or the cellular pleomorphism. Based on these results, a high quantity of CD20+ TILs appears to be a new potential negative prognostic factor for both oral and cutaneous melanocytic tumours. However, the authors state that they need to be confirmed using larger case numbers and by studying cutaneous and oral melanocytic tumours separately. A few studies have evaluated the role of c‐Kit in canine cutaneous,",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:73"
    }
  },
  {
    "page_content": "evaluated the role of c‐Kit in canine cutaneous, as well as oral, melanocytic neoplasms but no significant association between KIT labelling and survival time has been demonstrated.,,,, Gomes et al. demonstrated decreased expression of KIT protein in cutaneous MMs compared to cutaneous melanocytomas. The decreased number of cells labelled in malignant versus benign tumours may give some insight into the role of c‐Kit in melanocytic tumour progression, but the lack of correlation of either",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:74"
    }
  },
  {
    "page_content": "but the lack of correlation of either labelling extension or intensity with other morphologic grading factors does not suggest this will be an important prognostic marker or diagnostic tool. The Gramer et al. study only included three melanomas and two of the three showed KIT expression. One of these tumours had a missense, or non‐synonymous, mutation, but this was not a prognostic study and the sample size was too small to draw any significant conclusions. Other studies that included canine",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:75"
    }
  },
  {
    "page_content": "conclusions. Other studies that included canine cutaneous melanocytic neoplasms could not demonstrate prognostic utility for the markers they evaluated, may have found promising statistical significance but were too preliminary to make any significant conclusions, were not designed as prognostic studies or only used melanoma cell lines.,,,,,,, These included expression of: S100A4, E‐cadherin/β‐catenin, COX‐1 and COX‐2, P‐glycoprotein 1, and MCAM/CD146.,,,,,,, ### Newly examined prognostic",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:76"
    }
  },
  {
    "page_content": "MCAM/CD146.,,,,,,, ### Newly examined prognostic parameters for canine oral/lip mucosal melanocytic neoplasms There are a few new prognostic markers that have been investigated for canine oral melanocytic neoplasms since 2011 and a few of them show potential usefulness. For example, Iussich et al. provides good statistical support for considering platelet‐derived growth factor receptors (PDGFR)‐α and ‐β as prognostic markers in oral MM of dogs. The purpose of this study was to evaluate the",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:77"
    }
  },
  {
    "page_content": "The purpose of this study was to evaluate the expression of PDGFR‐α and ‐β in stage II and III canine oral MMs and to correlate it with prognosis. The neoplasms in this study were confirmed as melanocytic in origin via IHC labelling for PNL‐2 and pathologists recorded nuclear atypia, MC, pigmentation and Ki67 values for each tumour. This study suggests that PDGFRs may play a role in the pathogenesis of oral canine MM and the co‐expression of both PDGFRs‐α and ‐β should be considered as a",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:78"
    }
  },
  {
    "page_content": "of both PDGFRs‐α and ‐β should be considered as a negative prognostic marker. In addition, despite an unclear methodology for determining the Ki67 value that is not consistent with the published method by Bergin et al. (2011), statistical analysis showed that co‐expression of PDGFRs and Ki67 values were both associated with worse prognosis, further supporting the prognostic importance of Ki67 assessment. PDGFRs were detected not only in tumour tissue but also in the stroma, suggesting a",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:79"
    }
  },
  {
    "page_content": "tissue but also in the stroma, suggesting a potential role in matrix remodelling and tumour invasion. The authors stated that further prospective studies on a greater number of cases are warranted to confirm these findings before they are used in a diagnostic setting. Higher protein expressions of Kynurenine 3‐monooxygenase (KMO), signal transducer and activator of transcription 3 (STAT3), and STAT3/phosphorylated (pSTAT3) have recently been shown to be associated with reduced survival times in",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:80"
    }
  },
  {
    "page_content": "to be associated with reduced survival times in canine melanoma patients in one study by Liu et al. The authors used IHC to evaluate expression of these proteins in 85 cases of canine melanoma that included mostly oral tumours (58 oral, 4 lip, 8 skin, 7 digit, and 8 other sites). KMO expression was more common in oral tumours than tumours at other sites. The authors also found a correlation between high MC (≥4 mitoses per 10hpf) and oral location, metastatic cases, those that were >2 cm, and",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:81"
    }
  },
  {
    "page_content": "metastatic cases, those that were >2 cm, and higher stage. KMO, STAT3 and pSTAT3 expressions were all significantly higher in tumours with an MC ≥4 mitoses per 10 hpf. A combination of MC and KMO had a sensitivity of 74.4%, a specificity of 63%, and a diagnostic accuracy of 68.2%. A combination of MC and STAT3 had a sensitivity of 94.9%, a specificity of 43.5%, and a diagnostic accuracy of 67.1%. Another group demonstrated that somatic focal amplification of chromosome (Canis familiaris [CFA])",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:82"
    }
  },
  {
    "page_content": "of chromosome (Canis familiaris [CFA]) 30, but not CFA10, was significantly associated with an amelanotic phenotype, a high MC, and shorter survival times in a set of 73 canine oral MM. Thus, like KMO, STAT3 and pSTAT3, these parameters may prove to be useful prognostic parameters in the future, but they first should be compared to other established prognostic parameters, such as Ki67 and nuclear atypia, to see if they add value. The presence of TILs and the levels of expression of their",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:83"
    }
  },
  {
    "page_content": "of TILs and the levels of expression of their markers in the tumour tissue has been suggested to have a prognostic significance in oral melanomas as well. The expression of the markers RACK1, FoxP3, and IDO and the quantity of CD20+ TILs have been examined in both cutaneous and oral melanocytic neoplasms and discussed above under cutaneous melanocytic neoplasms. Furthermore, the presence and distribution of TILs, including the frequency of CD8+ T cells, CD4+ T cells, and Treg cells by",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:84"
    }
  },
  {
    "page_content": "of CD8+ T cells, CD4+ T cells, and Treg cells by histopathology and flow cytometry have been investigated in a retrospective study of 50 canine oral MMs, confirming their potential utility as prognostic markers. Higher survival rates were seen in dogs that had higher TIL scores, specific TIL patterns termed “brisk” and “nonbrisk” (compared to those with no TILs), and an increased frequency of CD8+ T lymphocytes infiltrating the tumour. Evaluation of TILs is emerging as a potential",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:85"
    }
  },
  {
    "page_content": "Evaluation of TILs is emerging as a potential prognostication method for canine melanocytic tumours and further evaluation is warranted. Also discussed above under cutaneous melanocytic neoplasms was the role of c‐Kit. Murakami et al. evaluated KIT labelling in canine oral MMs and found no association with overall survival or WHO stage. In addition, no significant mutations were identified in exon 11 of c‐Kit. While this study did have some limitations, such as relatively low sample size, lack",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:86"
    }
  },
  {
    "page_content": "such as relatively low sample size, lack of complete detail regarding diagnosis and follow‐up times, and the inclusion of only MMs, this study concluded that KIT expression does not appear to be a prognostic factor for canine melanoma. Brocca et al. similarly did not find a correlation between KIT protein expression and mutation status, as they did not find any mutations in 14 canine oral melanocytic neoplasms. Another recent study by Smedley et al, completely sequenced the c‐Kit gene in canine",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:87"
    }
  },
  {
    "page_content": "al, completely sequenced the c‐Kit gene in canine oral melanocytic neoplasms. The authors identified nine nonsynonymous mutations that resulted in amino acid changes predicted to affect protein function. These mutations were more common in MMs than in those of low malignant potential but the authors did not find any correlation between mutation status, KIT labelling or histologic features. Both of the above studies concluded that there are no current documented indications, in regards to c‐Kit",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:88"
    }
  },
  {
    "page_content": "documented indications, in regards to c‐Kit mutation status or KIT labelling, to suggest tyrosine kinase inhibitors (TKIs) would be beneficial for these tumours., However, a recent single case report described a dog with a gingival MM that had a novel deletion mutation c.1725_1733del within KIT, which was considered to be an oncogenic driver mutation. Other oral melanocytic neoplasm studies that were reviewed could not demonstrate prognostic utility for the markers that they evaluated, may have",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:89"
    }
  },
  {
    "page_content": "for the markers that they evaluated, may have found promising statistical significance but were too preliminary to make any significant conclusions, were not designed as prognostic studies, or only used melanoma cell lines.,,,,,,,,,,,,, These markers included: a metabolite profile that included citric acid, lactic acid, oleic acid, linoleic acid, palmitoleic acid, octadecenoic acid, and glycerol; E‐cadherin/β‐catenin expression; COX‐1 and COX‐2 expression; P‐glycoprotein 1 expression;",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:90"
    }
  },
  {
    "page_content": "COX‐2 expression; P‐glycoprotein 1 expression; expression of MCAM/CD146; activation of the MAPK and PI3K/AKT pathways; the expression pattern of Cx26 and Cx43; nBAP1 protein expression; E‐cadherin expression; Cyclin D1 index; expression of Galectin‐3; expression of B‐cell lymphoma (BCL) 2 and caspase (CASP) 3; and expression of MAGE‐A.,,,,,,,,,,,,, ## Recommendations for prognostication Tables 3 and 4 can be used as guides for prognostication. For each of the evaluated parameters, a favourable",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:91"
    }
  },
  {
    "page_content": "each of the evaluated parameters, a favourable prognosis relates to expected survival times longer than 1 year and a poor prognosis relates to an expected death due to melanocytic neoplasia within less than 1‐year post‐diagnosis for all melanocytic neoplasms. These predictions are based solely on publications that met our strict criteria for inclusion for each single parameter. These predictions do not take into account stage of disease or treatment strategies. Ideally, using the criteria in",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:92"
    }
  },
  {
    "page_content": "strategies. Ideally, using the criteria in Table 3, a cutaneous melanocytic neoplasm should be categorized as a cutaneous melanocytoma (benign melanocytic tumour) or a cutaneous MM. Typically, a cutaneous melanocytoma is non‐ulcerated, often raised, generally small (<2 cm diameter and ≤0.45 cm thickness), limited to the dermis, heavily pigmented, has very bland appearing nuclei, and has a low MC and very low Ki67 index.,,, In some cases, a cutaneous MM may have several of the same features as a",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:93"
    }
  },
  {
    "page_content": "MM may have several of the same features as a melanocytoma but may have only one or two parameters that suggest malignant behaviour, such as high nuclear atypia, a MC above the threshold value, a tumour thickness >0.95 cm, extension beyond the dermis, or a Ki67 index above the threshold value. Clear‐cut cutaneous MMs are often ulcerated, poorly pigmented, exhibit marked nuclear atypia, have a high MC and a high Ki67 index, are >0.95 cm thick, extend beyond the dermis, and may exhibit vascular",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:94"
    }
  },
  {
    "page_content": "beyond the dermis, and may exhibit vascular invasion.,, Ideally, using the criteria in Table 3, a mucosal lip or oral neoplasm should be able to be categorized as an oral MM or a histologically well‐differentiated melanocytic neoplasm (HWDM), also known as a melanocytic neoplasm of low malignant potential. The term melanocytoma should be avoided for oral and lip mucosal melanocytic neoplasms as the long term (>2 years) behaviour of these neoplasms, if not excised, is still uncertain. Thus, they",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:95"
    }
  },
  {
    "page_content": "if not excised, is still uncertain. Thus, they should be treated as neoplasms of low malignant potential. HWDMs are usually raised, non‐ulcerated, <2 cm diameter, heavily pigmented, lack cellular atypia, do not invade bone, and have rare mitoses, a very low Ki67 index, and abundant collagenous stroma., They also often lack junctional activity and lateral surface epithelial spread which improves the chance of complete excision and likely plays a role in the longer survival time of these tumours.",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:96"
    }
  },
  {
    "page_content": "in the longer survival time of these tumours. A mean survival time of 23.4 months has been reported for HWDMs in one study. These features are in strict contrast to oral MMs which often show junctional activity, lateral epithelial spread, poor pigmentation, bone invasion, and marked nuclear atypia and often have a very high MC and Ki67 index., When there are mixed results, results for each parameter should be reported, but Ki67 index should be used for final interpretation in most cases. In",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:97"
    }
  },
  {
    "page_content": "used for final interpretation in most cases. In cases that are still ambiguous, due to all parameters being at or very near the threshold values, a diagnosis of melanocytic neoplasm should be made and each parameter should be discussed. # DISCUSSION ## Future directions None of the published prognostic studies meet all of the standards defined by the Webster et al. white paper but the recommendations in this consensus are based on the results of the studies that adhere to most of those",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:98"
    }
  },
  {
    "page_content": "of the studies that adhere to most of those standards. The first step in any prognostic study is to ensure an accurate diagnosis of melanocytic origin for each case in the study population. This involves the use of specific histologic criteria and IHC labelling for highly sensitive and specific markers, if those specific histologic criteria are lacking.,, Gene expression may also be used to differentiate between amelanotic spindloid MMs and soft tissue sarcomas in the near future. Once",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:99"
    }
  },
  {
    "page_content": "and soft tissue sarcomas in the near future. Once melanocytic origin is established, neoplasms should be classified based on location as well as established histomorphologic and molecular prognostic parameters. Another major requirement for a sound prognostic study is follow‐up data that includes disease free survival times, progression free survival times, overall survival, cause of death, and post‐mortem results. Collection of follow‐up data is one of the most challenging tasks in veterinary",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:100"
    }
  },
  {
    "page_content": "one of the most challenging tasks in veterinary medical research studies and post‐mortem examination of a significant number of cases is often not possible. However, researchers should always have an initial study design, ideally prospective, that will allow for as much follow‐up data as possible. There are very few published studies that are true prognostic studies of canine melanocytic neoplasms and only one of these evaluated prognostic studies is prospective. While prospective studies are",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:101"
    }
  },
  {
    "page_content": "is prospective. While prospective studies are very challenging studies to conduct in veterinary medicine, ideally an effort should be made to conduct such studies in order to verify the recommendations made by the referenced retrospective studies. Additionally, new potential prognostic markers should be evaluated in conjunction with, and compared to, the current statistically proven prognostic parameters, such as nuclear atypia, MC, and Ki67 index. Much of the recent literature has focused on",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:102"
    }
  },
  {
    "page_content": "Much of the recent literature has focused on the genetic features of canine melanocytic neoplasms, and this field holds promise for better diagnosis, prognostication and prediction of metastasis of these tumours, as well as for identification of potential targets for therapy. In the future, genetic analysis may prove to be the gold standard for diagnosis and prognostication but, at this point, the most accurate diagnostic methods are the immunohistochemical markers Melan‐A, PNL2, TRP‐1 and",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:103"
    }
  },
  {
    "page_content": "markers Melan‐A, PNL2, TRP‐1 and TRP‐2 and the most accurate predictors of prognosis include the histologic features described above and Ki67 index. Clinical parameters for prognostication, other than location (cutaneous versus oral/lip), are not addressed here, but are slated for future evaluation and consensus. It is hoped that a combination of histologic, molecular, and clinical parameters will further improve our ability to prognosticate these neoplasms, in order to better determine",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:104"
    }
  },
  {
    "page_content": "these neoplasms, in order to better determine appropriate therapy for each case. # CONFLICT OF INTEREST Philip J. Bergman is a paid consultant and speaker for Boerhinger Ingelheim Animal Health and also receives a minority royalty stream payment for the Oncept melanoma vaccine.",
    "metadata": {
      "source": "../data/plain/PMC9796073.plain.txt",
      "id": "../data/plain/PMC9796073.plain.txt:105"
    }
  },
  {
    "page_content": "Epidemiology, Pattern, and Survival of Multiple Primary Malignant Neoplasms in Southeast Iran: Results of Kerman Population-Based Cancer Registry 2014-2020 Abstract\nPurpose:\nCancer survivors may experience a subsequent primary cancer that affects their survival and quality of life. This study aimed to investigate the epidemiology of multiple primary malignant neoplasms (MPMNs) in Kerman province, southeast Iran during 2014-2020.\nMaterials and Methods:",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:0"
    }
  },
  {
    "page_content": "In this retrospective cohort study, all patients who had been diagnosed with primary cancers and registered with the Kerman Cancer Registry Program (KPBCR) during 2014-2020 were included. MPMNs were defined as primary malignant tumors arising in different sites and/or were of different histological or morphological origins. If the second malignancy was diagnosed within the first six months from the diagnosis of the first tumor it was considered synchronous, and if after six months it was",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:1"
    }
  },
  {
    "page_content": "synchronous, and if after six months it was defined as metachronous. Logistic regression was used to analyze the relationship between age, sex, and primary cancer site with incidence and survival of secondary in the entire population.",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:2"
    }
  },
  {
    "page_content": "Results:",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:3"
    }
  },
  {
    "page_content": "Of 26,315 patients registered with a primary cancer diagnosis, 492 (1.86%) developed subsequent primary cancers. The most common type of secondary cancer was skin and mucosa (n=131, 26.63%) followed by urogenital (n=115, 23.37%), followed by, gastrointestinal (n=62, 14.45%), and breast neoplasms (n=57, 11.59%). Most patients had metachronous tumors (n=350, 71.13%). The primary cancer site (Skin and mucosa, urogenital, and breast) was significantly associated with developing subsequent cancer",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:4"
    }
  },
  {
    "page_content": "associated with developing subsequent cancer among cancer survivors. The overall 5-year survival of MPMNs cases was over 50%. Older age at diagnosis (HR= 1.02) and having synchronous tumors (HR=1.41) were negatively associated with the survival time of patients with MPMNs. Conclusion: Both patients and physicians should be taught about the importance of prevention and the provision of care and screening services among cancer survivors. Studying the epidemiology, susceptibility, and risk factors",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:5"
    }
  },
  {
    "page_content": "epidemiology, susceptibility, and risk factors of MPMNs among cancer survivors will open windows to a better understanding of this phenomenon and policy making. # Introduction Over the last decades, advances in early diagnosis and treatment of cancer have contributed to considerable improvements in the overall survival and life expectancy rates of patients with malignant cancers in most regions of the world with an overall estimated 5-year survival rate of 66% for cancer patients. Cancer",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:6"
    }
  },
  {
    "page_content": "survival rate of 66% for cancer patients. Cancer survivors may experience a subsequent primary cancer that affects their survival and quality of life. Compared to the general population, it is estimated that cancer survivors have a 14% higher risk of developing subsequent primary cancers. The increased risk is significantly associated with a combination of shared lifestyle, genetic and environmental factors. Additionally, radiotherapy and the late effects of treatments may also result in an",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:7"
    }
  },
  {
    "page_content": "late effects of treatments may also result in an increased risk of developing subsequent cancers. Multiple primary malignant neoplasms (MPMNs) refer to neoplasms with different morphologies arising in one patient and were first introduced by Billroth in 1889 and then described by Warren and Gates in 1932. Since that time, the term “multiple primaries” has been widely used in the cancer literature [7-11]. According to the interval between the first and second primary neoplasm, MPMNs are",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:8"
    }
  },
  {
    "page_content": "the first and second primary neoplasm, MPMNs are classified as synchronous or metachronous, with synchronous defined as neoplasms occurring within six months, and metachronous neoplasms occurring beyond 6 months of the first primary diagnosis. With the accompanying trends of developing subsequent primary cancers, there is increased recognition of the need to prioritize effective screening methods, prevention strategies, and counseling for cancer survivors. While developing subsequent primary",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:9"
    }
  },
  {
    "page_content": "survivors. While developing subsequent primary cancers among cancer survivors may confer higher mortality and reduced quality of life, studying the epidemiologic aspects of this phenomenon seems logical. In this context, identifying the characteristics of cancers that have an elevated risk of occurring together can shed light on key questions about MPMNs pattern in different populations. The aim of the present study was to analyze the epidemiology, pattern and survival of the MPMNs cases from a",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:10"
    }
  },
  {
    "page_content": "pattern and survival of the MPMNs cases from a population-based cancer registry program in Kerman Province, South-East Iran. # Materials and Methods This study was approved by the Research Ethics Committee of Kerman University of Medical Sciences (IR.KMU.AH.REC.1400.178). In this retrospective cohort study, all 26,956 patients who have been diagnosed with malignant primary cancers and registered by the Kerman Cancer Registry Program (KPBCR) during 2014-2020 were included. The KPBCR collects",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:11"
    }
  },
  {
    "page_content": "2014-2020 were included. The KPBCR collects data on malignant cancers in Kerman, the largest and most developed city in the southeast of Iran with a population of 3,166 million in 2016. The cases of MPMNs were defined as primary malignant neoplasms arising in different sites and/or were of different histological or morphological origins. According to International Agency for Research on Cancer(IARC) recommended rules, primary neoplasm is one that originates in a primary site or tissue and is",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:12"
    }
  },
  {
    "page_content": "originates in a primary site or tissue and is not an extension, nor a recurrence, nor a metastasis. In addition, neoplasms with different morphologies should be regarded as MPMNs, even if they are diagnosed simultaneously in the same site. In this study, the first site was defined as the first primary cancer reported during 2014-2020. Cases without histopathological verification were excluded from the analysis. According to the interval between the first and the second primary cancer, MPMNs",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:13"
    }
  },
  {
    "page_content": "the first and the second primary cancer, MPMNs were classified as synchronous or metachronous. Synchronous defined as neoplasms occurred within six month, and metachronous neoplasms occurred beyond 6 months of the first primary diagnosis. For the data analysis, we created a datasheet in Stata 17.0. The demographic and clinical profile of each patient including age at diagnosis, date of diagnosis, topography, morphology and date of last follow up were extracted. We stratified the data by site of",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:14"
    }
  },
  {
    "page_content": "were extracted. We stratified the data by site of the first primary cancer, site of the second primary cancer, sex and age at the first primary and the second primary cancer diagnosis. An expert pathologist was asked to distinguish MPMNs cases from suspected metastatic or recurrent cases. Univariate and multivariate logistic regression models were used to explore the association between clinical characteristics of patients (age at first diagnosis, sex, and site of the primary cancer) and",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:15"
    }
  },
  {
    "page_content": "sex, and site of the primary cancer) and developing a subsequent cancer in the entire population (patients diagnosed with cancer during 2014-2020 in Kerman province). The survival time of different MPMNs subgroups was calculated on February 2023 using the Kaplan-Meier method, and statistical significance was analyzed using Chi square or Fisher’s exact test. The factors associated with the overall survival were identified using univariate and multivariate Cox proportional hazard regression model",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:16"
    }
  },
  {
    "page_content": "Cox proportional hazard regression model analyses. Stata (StataCorp, USA) was used for data analysis. A P value <0.05 was considered as statistically significant. # Results This study used REPCAN (Guideline for REporting Population-based CANcer Registry Data) for analysis and reporting data. Baseline characteristics of patients with MPMNs In total, 26,316 patients were diagnosed with cancer during 2014-2020 in Kerman province, Iran. Over half of patients were male (n=14,022, 53.3%). Of this",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:17"
    }
  },
  {
    "page_content": "of patients were male (n=14,022, 53.3%). Of this population registered by KPBCR during this period, 492 (1.87%) developed subsequent primary cancers (MPMNs). Among these MPMNs patients, 280 cases (56.9%) were men and the ratio of males to females was 1.31: 1. The average age(±standard deviation) at diagnosis for all patients diagnosed with primary cancer was 60.7 (±15.4) years. The average age at diagnosis for all patients with secondary cancers (MPMNs) was 58.5 (±16.7) years. Urogenital",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:18"
    }
  },
  {
    "page_content": "(MPMNs) was 58.5 (±16.7) years. Urogenital (n=4978, 18.91%), gastrointestinal (n=3883, 14.75%) and skin and mucosa cancers (n=3066, 11.65%) were the most common primary cancer site categories among all patients diagnosed with primary cancers. Among patients with MPMNs, the most common primary cancer site was Skin and Mucosa (n=131, 26.63%) urogenital system (n=115, 23.37%) (Table 1). As shown in Table 1, 350 patients (71.14%) were metachronous multiple primary neoplasms (mMPMNs) and 142",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:19"
    }
  },
  {
    "page_content": "multiple primary neoplasms (mMPMNs) and 142 patients (28.86%) were synchronous multiple primary malignant neoplasms (sMPMNs). The interval between the first and second primary tumor in mMPMNs cases ranged from 7 to 81 months with an average of 23.6 (± 17.1) and a median of 22 months. The average age was 55.6 (±14.3) years in patients with sMPMNs, and 58.85 (±16.9) years in those with mMPMNs. Squamous cell carcinoma was the most common pathological type of the primary and secondary cancers",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:20"
    }
  },
  {
    "page_content": "type of the primary and secondary cancers including 8.64% of primary cancers and 19.51% of secondary cancers, adenocarcinoma (13.50% of primary cancers and 13.21% of secondary cancers) and basal cell carcinoma (6.13% of primary cancers and 11.38% of secondary cancers) (Table 1). Logistic regression analysis was used to estimate the association of age, sex, and the primary cancer site with developing a secondary cancer among the entire patients diagnosed with primary cancers in Kerman province",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:21"
    }
  },
  {
    "page_content": "diagnosed with primary cancers in Kerman province during 2014-2020. Bivariate logistics regression model indicated a small but positive association between age at first cancer diagnosis and developing a subsequent cancer (OR=1.01, P=0.01). In other words, the odds of developing a subsequent cancer increases if the age at first cancer diagnosis rises. Patients who primarily diagnosed with skin and mucosa (OR=3.44, P<0.0001) or urogenital (OR=1.88, P<0.0001) cancers were more likely to develop a",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:22"
    }
  },
  {
    "page_content": "P<0.0001) cancers were more likely to develop a subsequent cancer. Findings from the multivariate logistic regression model confirmed the significant association of having skin and mucosa (OR=3.47, P<0.0001) or urogenital (OR=1.88, P<0.0001) cancers with an elevated risk of developing a subsequent cancer among patients in Kerman province (Table 2). Clinical Characteristics The most incident combinations of MPMNs based on their sites are presented in Figure 1. Skin and mucosa-skin and mucosa",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:23"
    }
  },
  {
    "page_content": "in Figure 1. Skin and mucosa-skin and mucosa (n=45, 9.1%) and urogenital-urogenital (n=35, 7.1%) were the most common combinations (Figure 1). Squamous cell carcinoma- Squamous cell carcinoma (n=26, 5.3%) were the most incident morphological pairs occurring in patients. Males and females represented different forms of combinations. The most common multiple pairs in men were skin and mucosa-skin and mucosa (n=39, 13.92%), skin and mucosa – urogenital (n=19, 6.78%), and urogenital – urogenital",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:24"
    }
  },
  {
    "page_content": "(n=19, 6.78%), and urogenital – urogenital (n=19, 6.78%) (Appendix 1, Table A). In women urogenital-breast (n=34, 16.03%) and urogenital-urogenital (n=19, 8.96%) were among the most common multiple pairs (Appendix 1, Table B). Prognosis In this study, 199 out of the 492 (40.44%) patients were still surviving in February 2023, but 293 (59.55%) deceased. The survival time of the patients with MPMNs was calculated as the time from the time of diagnosis of primary cancer to death or end of",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:25"
    }
  },
  {
    "page_content": "of diagnosis of primary cancer to death or end of follow-up (February 2023). Five years survival was 52.4% (47.5%-57%), which was highest for breast cancer (64.5% (95% CI: 50.1% -75.8%)) and lowest for Respiratory system cancer (31.7% (95% CI: 16.2%-48.5%)) based on primary site. Five years survival for patients with sMPMNs was lower than patients with mMPMNs (52.8% vs 53.3%) (Table 3, Figure 2). Further investigation of data showed that according to the bivariate Cox proportional hazard",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:26"
    }
  },
  {
    "page_content": "to the bivariate Cox proportional hazard regression analysis, age at diagnosis had significant effect on the survival time of patients with MPMNs (HR= 1.02). In addition, patients with sMPMNs (HR=1.41) indicated higher risk of death than the entire cancer survivors with MPMNs (Table 4). # Discussion The data from this study indicated a considerable prevalence of MPMNs among cancer survivors in Kerman province, Iran. Most secondary cancers were metachronous tumors, independent of age and sex,",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:27"
    }
  },
  {
    "page_content": "metachronous tumors, independent of age and sex, although higher frequencies of secondary cancers were observed in older patients and in males. The risk of developing a secondary cancer was different according to the primary cancer site. Patients with primary skin and mucosa, urogenital and breast cancer indicated higher rates of developing a secondary cancer than the entire cancer survivors. Moreover, 5-year survival of patients with secondary cancers was significantly reduced in patients with",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:28"
    }
  },
  {
    "page_content": "was significantly reduced in patients with older ages, and synchronous tumors. Our findings indicated that around two out of 100 primary cancer survivor, experience a new secondary cancer. Existing evidence suggested an overall prevalence of 0.7 to 17% [16-18] depending on different regions and databases. The diverse incidence of MPMNs across different countries and geographical regions might be associated with genetic factors, environmental factors, diagnostic methods, longer follow-up",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:29"
    }
  },
  {
    "page_content": "factors, diagnostic methods, longer follow-up duration and inclusion of autopsy series in these studies. Furthermore, factors such as improvement in diagnostic tests, sophisticated treatment which increases survival of cancer survivors, medical surveillance and availability of screening tests affect the prevalence. So, the low prevalence of MPMNs in low and middle-income countries including Iran is likely associated with incomplete coverage of cancer registries in these regions, low",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:30"
    }
  },
  {
    "page_content": "of cancer registries in these regions, low availability of screening tests and low survival rate of cancer survivors. Another explanation for this low prevalence may be that we reported the cases just in the time period of seven years which is relatively short. In the present study, the average age at diagnosis among MPMNs cases was lower than the entire cancer survivors. Although MPMNs may occur at any age, existing evidence suggests that the overall incidence of MPMNs cases in lower ages may",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:31"
    }
  },
  {
    "page_content": "incidence of MPMNs cases in lower ages may be associated with the early onset of breast and female genital cancers in women in developing countries. With the progress in the diagnosis and treatment of breast cancer, the 5-year survival for cancer survivors with primary breast cancer increased markedly with time in most countries, therefore, the number of cancer survivors would increase. Current findings indicated that skin and mucosa was the most common primary cancer site among MPMNs cases in",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:32"
    }
  },
  {
    "page_content": "common primary cancer site among MPMNs cases in Iran. According to the national estimates, skin cancer is among the most common types of cancers in the Iranian population. Sun exposure is the main risk factor of skin cancer. Evidences support the increased risk of subsequent malignant melanoma in patients with primary malignant melanoma. This may be as the result of UV radiation in sun exposed areas. In addition, host susceptibility factors such as genetic, family history of melanoma and",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:33"
    }
  },
  {
    "page_content": "such as genetic, family history of melanoma and history of atypical moles has been associated with the increased risk of second melanoma among melanoma survivors. Therefore, intensive surveillance of skin cancer survivors especially among individuals with positive family history and history of atypical moles is recommended. In addition, existing evidence showed increased risk of secondary primary cancers in different organs in skin cancer survivors. In our study, skin-urogenital pair was a",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:34"
    }
  },
  {
    "page_content": "In our study, skin-urogenital pair was a common pair of MPMNs cases. Both of these cancers are among the most common types of cancers in Kerman. The increased risk of bladder cancer following the skin cancer has been addressed in various studies. Common risk factors of these cancers may justify the finding that indicated that smoking which is a well-known risk factor of bladder cancer, is also an independent risk factor for squamous cell carcinoma of skin.Exposure to arsenic, a chemical that",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:35"
    }
  },
  {
    "page_content": "of skin.Exposure to arsenic, a chemical that widely uses in pesticide production, car batteries and electronic devices, is another common risk factor for these two cancers [33-36]. According to our findings, the overall 5- year survival rates of patients with sMPMNs and mMPMNs in Iran was higher than 50%. Older age at diagnosis, and having sMPMNs were associated with poor prognosis among MPMNs cases in Kerman. Poor prognosis of MPMNs cases in older ages was previously reported in other",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:36"
    }
  },
  {
    "page_content": "in older ages was previously reported in other countries. To our knowledge, this is the first report of patient with secondary malignant neoplasms in Iran and our findings have important implications for public health practice. Nevertheless, our results may be subject to some limitations: First, due to rapidly progressive nature of some cancers such as cancer of lung, occurrence of death in a short period of time preclude the occurrence of second primary cancer (competing risk) may affects our",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:37"
    }
  },
  {
    "page_content": "primary cancer (competing risk) may affects our understanding about the true picture of MPMNs. Second, Due to limited number of MPMNs cases in Kerman and subsequent low precision, we couldn’t calculate the incidence of secondary primary cancer related to specific primary cancer site among MPMNs compared to general population. Third, as the coverage of cancer registry in Iran is not complete, under-estimation of cases is probable. Finally, Due to limited follow-up period, estimation of lifetime",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:38"
    }
  },
  {
    "page_content": "limited follow-up period, estimation of lifetime incidence of MPMNs was not possible. In conclusion, with the advent of early screening and more efficient treatments and consequently increased survival of cancer patients, MPMNs would be an issue within the next years. Patients should be educated well about the importance of prevention, life style modification and necessity of screening tests after the diagnosis of first cancer. Future researches in Iran should focus on risk estimation of second",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:39"
    }
  },
  {
    "page_content": "in Iran should focus on risk estimation of second primary cancer in patients with MPMNs and underlying risk factors and efficacy of preventive interventions in cancer survivors.",
    "metadata": {
      "source": "../data/plain/PMC11480609.plain.txt",
      "id": "../data/plain/PMC11480609.plain.txt:40"
    }
  },
  {
    "page_content": "Is early-onset cancer an emerging global epidemic? Current evidence and future implications Abstract",
    "metadata": {
      "source": "../data/plain/PMC9509459.plain.txt",
      "id": "../data/plain/PMC9509459.plain.txt:0"
    }
  },
  {
    "page_content": "Over the past decades, the incidence of early-onset cancers, often defined as cancers diagnosed in adults <50 years of age, in the breast, colorectum, endometrium, oesophagus, extrahepatic bile duct, gallbladder, head and neck, kidney, liver, bone marrow, pancreas, prostate, stomach, and thyroid has increased in multiple countries. Increased use of screening programmes has contributed to this phenomenon to a certain extent, although a genuine increase in the incidence of early-onset forms of",
    "metadata": {
      "source": "../data/plain/PMC9509459.plain.txt",
      "id": "../data/plain/PMC9509459.plain.txt:1"
    }
  },
  {
    "page_content": "increase in the incidence of early-onset forms of several cancer types also seems to have emerged. Evidence suggests an aetiological role of risk factor exposures in early life and young adulthood. Since the mid-20th century, substantial multigenerational changes in the exposome have occurred (including in diet, lifestyle, obesity, environment and the microbiome), all of which might interact with genomic and/or genetic susceptibilities. However, the effects of individual exposures remain",
    "metadata": {
      "source": "../data/plain/PMC9509459.plain.txt",
      "id": "../data/plain/PMC9509459.plain.txt:2"
    }
  },
  {
    "page_content": "the effects of individual exposures remain largely unknown. To study early-life exposures and their implications for multiple cancer types will require prospective cohort studies with dedicated biobanking and data collection technologies. Raising awareness among both the public and health-care professionals will also be critical. In this Review, we describe changes in the incidence of early-onset cancers globally and suggest measures that will likely reduce the burden of cancers and other",
    "metadata": {
      "source": "../data/plain/PMC9509459.plain.txt",
      "id": "../data/plain/PMC9509459.plain.txt:3"
    }
  },
  {
    "page_content": "likely reduce the burden of cancers and other chronic non-communicable diseases.",
    "metadata": {
      "source": "../data/plain/PMC9509459.plain.txt",
      "id": "../data/plain/PMC9509459.plain.txt:4"
    }
  },
  {
    "page_content": "Germline Pathogenic/ Likely Pathogenic Mutations and Subsequent Neoplasms among Childhood Cancer Survivors – A report from the Children’s Oncology Group ALTE03N1 Study Abstract\nPurpose:",
    "metadata": {
      "source": "../data/plain/PMC12367065.plain.txt",
      "id": "../data/plain/PMC12367065.plain.txt:0"
    }
  },
  {
    "page_content": "Purpose:\nThere is emerging evidence that germline pathogenic/likely pathogenic (P/LP) mutations in cancer predisposition genes (CPGs) increase the risk of subsequent neoplasms (SNs) in childhood cancer survivors. However, clinical application of this observation is hampered by the lack of knowledge regarding sub-populations at risk for SNs who could potentially benefit from genetic screening.\nPatients and Methods:",
    "metadata": {
      "source": "../data/plain/PMC12367065.plain.txt",
      "id": "../data/plain/PMC12367065.plain.txt:1"
    }
  },
  {
    "page_content": "Whole exome sequencing was performed using germline DNA from 499 survivors with SNs (cases) and 625 survivors without (matched controls) in a Children’s Oncology Group study. Using conditional logistic regression, we estimated demographic/clinical/therapeutic characteristics and P/LP mutations associated with SN risk. We then randomly partitioned the case-control dataset using a 60/40 split to create training and test data respectively, and developed a clinical risk classifier. Model",
    "metadata": {
      "source": "../data/plain/PMC12367065.plain.txt",
      "id": "../data/plain/PMC12367065.plain.txt:2"
    }
  },
  {
    "page_content": "and developed a clinical risk classifier. Model performance and its improvement with addition of P/LP mutation status was evaluated on the test data using the area under the receiver operating curve (AUC).",
    "metadata": {
      "source": "../data/plain/PMC12367065.plain.txt",
      "id": "../data/plain/PMC12367065.plain.txt:3"
    }
  },
  {
    "page_content": "Results:",
    "metadata": {
      "source": "../data/plain/PMC12367065.plain.txt",
      "id": "../data/plain/PMC12367065.plain.txt:4"
    }
  },
  {
    "page_content": "We found a 4.26-fold higher odds of SNs among P/LP mutation carriers (95%CI=2.36–7.69). The clinical risk classifier (including sex, primary cancer type and year of diagnosis, exposure to radiation and platinum compounds, and length of follow-up) showed a significant performance improvement with the addition of P/LP mutation status, and P/LP*platinum and P/LP*radiation interactions (AUC increased from 0.79 to 0.82, p=0.014). Using the clinical risk classifier, we classified survivors at",
    "metadata": {
      "source": "../data/plain/PMC12367065.plain.txt",
      "id": "../data/plain/PMC12367065.plain.txt:5"
    }
  },
  {
    "page_content": "risk classifier, we classified survivors at low-risk (22%) and moderate-to-high-risk (78%) of developing SNs. Overall, 86.4% of the survivors with any P/LP mutations, and all TP53 and RB1 mutation carriers were partitioned into the moderate-to-high risk group.",
    "metadata": {
      "source": "../data/plain/PMC12367065.plain.txt",
      "id": "../data/plain/PMC12367065.plain.txt:6"
    }
  },
  {
    "page_content": "Conclusion:\nThese findings provide a risk-based approach for identifying childhood cancer survivors who could be referred for genetic testing, informing surveillance strategies based on refined risk-classification.",
    "metadata": {
      "source": "../data/plain/PMC12367065.plain.txt",
      "id": "../data/plain/PMC12367065.plain.txt:7"
    }
  },
  {
    "page_content": "Incidence, Risk Factors, and Mortality Associated With Second Malignant Neoplasms Among Survivors of Adolescent and Young Adult Cancer Key Points\nQuestion\nWhat are the incidence patterns and risk factors for second malignant neoplasms (SMN) among survivors of adolescent and young adult cancer?\nFindings",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:0"
    }
  },
  {
    "page_content": "Findings\nThis cohort study of 10 574 survivors of adolescent and young adult cancer found that these individuals had a 2.6-fold greater risk of developing SMN compared with individuals with no history of cancer. Risk factors for SMN included demographic factors, stage at diagnosis, and radiation therapy and varied by first cancer type, with survivors of breast cancer, melanoma, and testicular cancer having substantially elevated risk for SMN of the same type.\nMeaning",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:1"
    }
  },
  {
    "page_content": "Meaning\nThis study suggests that SMN risk is elevated in survivors of adolescent and young adult cancer and provides data that may be used to identify individuals at high risk and inform screening for SMN. Abstract\nThis cohort study estimates the incidence, mortality, and associated risk factors for the development of second malignant neoplasms in individuals who survived adolescent and young adult cancers. Abstract\nImportance",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:2"
    }
  },
  {
    "page_content": "Importance\nDetailed data describing the epidemiology of second malignant neoplasms (SMN) are needed for survivors of adolescent and young adult (AYA) cancer to inform the development of age-appropriate survivorship care guidelines.\nObjective\nTo describe the incidence, risk factors, and mortality for SMN in survivors of AYA cancer.\nDesign, Setting, and Participants",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:3"
    }
  },
  {
    "page_content": "Design, Setting, and Participants\nThis retrospective matched cohort study included 10 574 two-year survivors diagnosed with cancer between January 1, 1990, and December 31, 2012, at age 15 to 39 years in an integrated health care delivery system in Southern California. A comparison cohort without a history of cancer was individually matched 13:1 to survivors of AYA cancer by age, sex, and calendar year. Data analysis was completed in July 2018.\nExposures",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:4"
    }
  },
  {
    "page_content": "Exposures\nSecondary malignant neoplasm risk factors of interest included age, stage, and calendar year at first cancer diagnosis; sex; race/ethnicity; radiation therapy; and chemotherapy.\nMain Outcomes and Measures",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:5"
    }
  },
  {
    "page_content": "Main Outcomes and Measures\nDiagnoses of SMN were ascertained using cancer registries from the National Cancer Institute Surveillance, Epidemiology, and End Results Program through December 31, 2014. Poisson regression was used to evaluate the association between cancer survivor status and developing SMN and risk factors for SMN, while risk of all-cause mortality by SMN status was examined in Cox regression.\nResults",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:6"
    }
  },
  {
    "page_content": "A total of 10 574 survivors of AYA cancer (6853 [64.8%] female; median [range] age, 33 [15-39] years; 622 with SMN) and 136 683 participants in the comparison cohort (88 513 [64.8%] female; median [range] age, 33 [15-39] years; 3437 with first cancer) were included. In survivors of AYA cancer, 20-year cumulative incidence of SMN was 12.5%. The incidence rate ratio (IRR) of developing SMN in survivors of AYA cancer was 2.6 (95% CI, 2.4-2.9) compared with the comparison cohort. Survivors of",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:7"
    }
  },
  {
    "page_content": "compared with the comparison cohort. Survivors of breast cancer, melanoma, and testicular cancer had substantially elevated risk for SMN of the same organ (IRR, 5.6 [95% CI, 4.6-6.8], 11.2 [95% CI, 7.3-17.2], and 16.2 [95% CI, 6.8-38.4], respectively). Among survivors of AYA cancer, older age (IRR for age 30-39 years, 1.79 [95% CI, 1.21-2.65]), female sex (IRR, 1.31 [95% CI, 1.09-1.57]), white race/ethnicity (IRR for Asian race, 0.61 [95% CI, 0.43-0.87]), advanced stage at first cancer",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:8"
    }
  },
  {
    "page_content": "CI, 0.43-0.87]), advanced stage at first cancer diagnosis (IRR for stage II, 1.29 [95% CI, 1.11-1.65]), and use of radiotherapy (IRR, 1.50 [95% CI, 1.26-1.79]) were associated with increased risk of SMN. Survivors of AYA cancer who developed SMN had an all-cause mortality rate 7.2 (95% CI, 6.1-8.5) times greater than survivors without SMN.",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:9"
    }
  },
  {
    "page_content": "Conclusions and Relevance",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:10"
    }
  },
  {
    "page_content": "This study suggests that SMN risk is elevated in survivors of AYA cancer and varies across survivor subgroups. Survival following SMN may be significantly compromised. These data may form the basis for identifying individuals at high risk, as well as informing screening for SMN. # Introduction Second malignant neoplasms (SMN) are among the most debilitating late effects in cancer survivors.1,2 In survivors of childhood cancers, SMN is the most common cause of non–relapse-related mortality.3 In",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:11"
    }
  },
  {
    "page_content": "cause of non–relapse-related mortality.3 In an analysis using the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) data, the majority of individuals with 2 primary cancers died of their SMN rather than their initial cancer.4 Therefore, prevention and early detection of SMN are critical for prolonging life for cancer survivors.5,6 Extensive effort has been made to characterize SMN in survivors of childhood cancer.7,8,9,10,11 However, this knowledge may not be",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:12"
    }
  },
  {
    "page_content": "However, this knowledge may not be applicable to survivors of cancers diagnosed later in life. The risk and risk factors for SMN vary across age groups because of differences in primary cancers, treatment exposures, age at exposures, exposure to other etiological factors, and background incidence,12 necessitating age-specific approaches for managing SMN risk among cancer survivors. Adolescents and young adults (AYAs; defined as individuals aged 15-39 years) have been an understudied population",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:13"
    }
  },
  {
    "page_content": "15-39 years) have been an understudied population for cancer survivorship. Several studies have evaluated SMN risk by age groups13,14,15 or in survivors of cancer types that are more common in AYAs.16,17,18,19,20 Most of these studies have examined data from large cancer registries such as SEER and used an external comparison group (eg, the general population) for evaluating the excess risk of SMN. However, using external comparison for causal inference is associated with several known",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:14"
    }
  },
  {
    "page_content": "causal inference is associated with several known limitations,21 including the inability to address potential incomparability between cancer survivors and the general population, such as insurance status and health care access.22 Information on therapeutic agents is also not typically available in these cancer registries. Furthermore, detailed characterization of timing and risk factors for SMN in survivors of AYA cancer remain largely incomplete in the literature. In the current study, we",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:15"
    }
  },
  {
    "page_content": "in the literature. In the current study, we evaluated the development of SMN in survivors of AYA cancer who were members of Kaiser Permanente Southern California (KPSC) using a matched cohort design, providing an internal comparison with similar demographic characteristics, socioeconomic status, and access to health care. We used existing electronic medical records to examine the association between treatment exposures and SMN in survivors of AYA cancer. Our objective was to provide a",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:16"
    }
  },
  {
    "page_content": "of AYA cancer. Our objective was to provide a comprehensive assessment of SMN risk in survivors of AYA cancer using study methods that minimized confounding to inform survivorship care planning for survivors of AYA cancer. # Methods ## Study Setting and Study Population Kaiser Permanente Southern California is an integrated health care organization that provides comprehensive health services to more than 4.4 million racially/ethnically and socioeconomically diverse members (approximately 1% of",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:17"
    }
  },
  {
    "page_content": "diverse members (approximately 1% of the US population) who are broadly representative of residents in Southern California.23,24 Members of KPSC who met the following criteria were included in the cohort of survivors of AYA cancer: (1) diagnosed with invasive cancer at age 15 to 39 years between 1990 and 2012 at KPSC; (2) survived for at least 2 years (index date) after cancer diagnosis; and (3) retained KPSC membership at index date. Among individuals who met the inclusion criteria, those",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:18"
    }
  },
  {
    "page_content": "individuals who met the inclusion criteria, those diagnosed with another primary cancer before the index date were excluded, as we were mainly interested in SMN that occurred after completion of treatment to inform posttreatment surveillance strategies. We identified survivors of AYA cancer using KPSC’s SEER-affiliated cancer registry. Quality of the cancer registry data is assured by the SEER standard and is audited by SEER staff on a regular basis.25 Members of KPSC without a history of",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:19"
    }
  },
  {
    "page_content": "basis.25 Members of KPSC without a history of cancer were included as a reference group (referred to as the comparison cohort in this article) to survivors of AYA cancer. Participants in the comparison cohort were matched 13:1 to each individual cancer survivor by age (yearly), sex, and calendar year of the index date. They were identified from those who were KPSC members in the year of the corresponding cancer diagnosis for a cancer survivor and who survived and remained as a KSPC member 2",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:20"
    }
  },
  {
    "page_content": "and who survived and remained as a KSPC member 2 years after (ie, after the index date). This study was approved, and the requirement of informed consent waived, by KPSC’s institutional review board. This article follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.26 ## Identification of SMN All study participants were followed up from index date to death or end of 2014 (for SMN or first cancer) or end of 2015 (for mortality outcome),",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:21"
    }
  },
  {
    "page_content": "cancer) or end of 2015 (for mortality outcome), whichever came first. Diagnoses of malignant neoplasms, including those made outside of the KPSC system (eg, if a participant terminated KPSC membership during study follow-up), were identified using both KPSC’s cancer registry and the California State Cancer Registry. Both registries are SEER-affiliated and do not capture relapse or metastasis. As a result, a second cancer record for the same participant was considered SMN. For SMN of the same",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:22"
    }
  },
  {
    "page_content": "was considered SMN. For SMN of the same organ or type as the first cancer, SEER used a set of multiple primaries rules to distinguish SMN from recurrence.27,28 These rules differ by cancer types. For solid tumors, the determining factors may involve histology, biology, or clinical presentation, among other factors, while for hematologic cancers, the rules were mainly based on histology. The SEER multiple primaries rules for the most common first cancer types in survivors of AYA cancer are",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:23"
    }
  },
  {
    "page_content": "first cancer types in survivors of AYA cancer are illustrated in eTable 1 in the Supplement. Nonmelanoma skin cancer was not included in this study as it was not consistently captured by the cancer registries. ## Data Collection Covariates of interest included demographic characteristics, cancer characteristics, exposure to chemotherapy and radiation therapy, and death information. All data for this study were collected using KPSC’s electronic health records and cancer registries, except for",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:24"
    }
  },
  {
    "page_content": "health records and cancer registries, except for information on death, which was also collected using outside claims, California State Death Files, and national Social Security death files. Specifically, race/ethnicity information was obtained from KPSC’s membership file and the cancer registry. ## Statistical Analysis The distribution of demographic, cancer, and treatment characteristics and the incidence rate of subsequent cancer were calculated. The crude and the adjusted incidence rate",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:25"
    }
  },
  {
    "page_content": "The crude and the adjusted incidence rate ratios (IRRs) of SMN associated with being a survivor of AYA cancer compared with those in the comparison cohort were estimated using bivariate and multivariable Poisson regression adjusting for age, sex (except for breast, cervix, ovary, and testicular cancer), and race/ethnicity, for the overall study cohort and by patient characteristics, first cancer type, and SMN type. We also calculated IRRs for specific SMN among the most common first cancer",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:26"
    }
  },
  {
    "page_content": "specific SMN among the most common first cancer types in survivors of AYA cancer (ie, breast, lymphoma, melanoma, and testicular cancer). For breast SMN among breast cancer survivors, a sensitivity analysis was performed including only breast second primary malignant neoplasms of different histology or laterality (about 70% of all identified breast SMN) from the first cancer. All testicular second primary malignant neoplasms identified in this study had different laterality from the first",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:27"
    }
  },
  {
    "page_content": "study had different laterality from the first testicular cancer. The cumulative incidence of SMN over the study follow-up period was calculated using nonparametric methods accounting for competing risk and presented graphically for visual inspection, for the study cohort and by selected common first cancer type.29 Differences in cumulative incidence were tested using the Gray test.30 Among survivors of AYA cancer, multivariable Poisson regression was performed to evaluate the association of",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:28"
    }
  },
  {
    "page_content": "was performed to evaluate the association of age, sex, race/ethnicity, first cancer type, TNM stage at diagnosis, and exposure to radiation therapy on risk of SMN, overall and separately with solid vs nonsolid SMN (defined as lymphomas, leukemias, and myelomas). The association of initial cancer type was evaluated in separate analyses restricted to the more prevalent cancer types, ie, breast cancer, lymphoma, testicular cancer, melanoma, and thyroid cancer. The associations of exposures to",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:29"
    }
  },
  {
    "page_content": "thyroid cancer. The associations of exposures to selected chemotherapy agents (alkylating agents, anthracycline, platinum, and epipodophyllotoxins) were evaluated in another analysis restricted to those diagnosed between 2000 and 2012, when chemotherapy data became accessible electronically. Risk factors for SMN were also evaluated separately for the most common first cancer types among survivors of AYA cancer. As sample size allowed, risk factor analyses were also conducted for breast SMN",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:30"
    }
  },
  {
    "page_content": "analyses were also conducted for breast SMN among breast cancer survivors and melanoma SMN among melanoma survivors. For the overall risk factor analyses, sensitivity analyses excluding breast SMN and, separately, melanoma SMN as outcomes were conducted to further understand whether these SMN might be driving the associations observed given that they were the 2 most common SMN types. The increase in all-cause mortality after a diagnosis of SMN in survivors of AYA cancer relative to that after",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:31"
    }
  },
  {
    "page_content": "in survivors of AYA cancer relative to that after the first cancer diagnosis in the comparison cohort was examined in bivariate and multivariable Cox models adjusting for age, sex, and race/ethnicity. Among survivors of AYA cancer, the risk of all-cause mortality associated with having an SMN was evaluated using a time-dependent Cox model to account for the time-varying nature of SMN diagnosis, adjusting for age, sex, race/ethnicity, stage at diagnosis, and cancer type. All analyses in this",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:32"
    }
  },
  {
    "page_content": "diagnosis, and cancer type. All analyses in this study were completed by July 2018 with SAS statistical software version 9.3 (SAS Institute Inc). A 2-sided P value less than.05 was considered statistically significant. # Results A total of 14 753 KPSC members between ages 15 and 39 years were diagnosed with invasive cancer during 1990 to 2012 at KPSC. Of these, 12 994 (88%) survived at least 2 years and were eligible for this study. After applying the exclusion criteria, 10 574 survivors of AYA",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:33"
    }
  },
  {
    "page_content": "the exclusion criteria, 10 574 survivors of AYA cancer (6853 [64.8%] female; median [range] age, 33 [15-39] years; 622 with SMN) were included in the analyses with 136 683 participants (88 513 [64.8%] female; median [range] age, 33 [15-39] years; 3437 with first cancer) in the matched comparison cohort (eFigure 1 in the Supplement). Among survivors of AYA cancer, 7% were aged 15 to 19 years; 24%, 20 to 29 years; and 68%, 30 to 39 years. Approximately 47% were non-Hispanic white. The most common",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:34"
    }
  },
  {
    "page_content": "47% were non-Hispanic white. The most common first cancer diagnosis was breast cancer (17%), followed by thyroid cancer (14%), melanoma (11%), lymphomas (11%), and testicular cancer (9%). One-quarter (25%) of survivors of AYA cancer received external beam radiation therapy. In survivors of AYA cancer diagnosed in 2000 to 2012, exposure to selected chemotherapy agents ranged from 7% for epipodophyllotoxins to 24% for anthracyclines (Table 1). ## Risk of SMN The survivors of AYA cancer and the",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:35"
    }
  },
  {
    "page_content": "Risk of SMN The survivors of AYA cancer and the comparison cohort contributed 93 290 and 1 379 136 person-years of observation, respectively, through December 31, 2014. During the study period, 622 survivors of AYA cancer developed an SMN (6.7 per 1000 person-years). The 10- and 20-year cumulative incidence of SMN from index date was 5.6% and 12.5%, respectively. Of survivors of AYA cancer who developed SMN, the most common SMN types were breast cancer (32%), melanoma (14%), and ovarian cancer",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:36"
    }
  },
  {
    "page_content": "cancer (32%), melanoma (14%), and ovarian cancer (5%). Ninety-three percent of the SMN were solid tumors (Table 2). As a group, gastrointestinal cancers also constituted a substantial proportion (11%) of SMN (eTable 2 in the Supplement). The median (range) follow-up time in survivors of AYA cancer was 7.7 (0-23.0) years from the index date, or 9.7 (2-25) years after initial cancer diagnosis. ## Excess Risk of SMN in Survivors of AYA Cancer Survivors of AYA cancer had a 2.6-fold (95% CI,",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:37"
    }
  },
  {
    "page_content": "Survivors of AYA cancer had a 2.6-fold (95% CI, 2.4-2.9) increased risk of subsequent malignant neoplasm compared with the comparison cohort (Table 2). The IRR was significantly elevated for all demographic subgroups and was greatest for those aged between 15 and 19 years at first cancer diagnosis (adjusted IRR [aIRR], 7.5 [95% CI, 4.8-11.8]). The aIRR for SMN was significantly elevated for all primary cancer types, except for thyroid and cervical cancer. The aIRR for SMN was also significantly",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:38"
    }
  },
  {
    "page_content": "cancer. The aIRR for SMN was also significantly elevated for most SMN cancer types, except for cancer of the cervix, uterus, central nervous system, and thyroid. Risk for SMN was highest for bone SMN (aIRR, 11.4 [95% CI, 4.3-30.7]). The IRR for specific pairs of first and second cancer showed unique SMN patterns across different first cancer types (Table 3). Survivors of breast cancer, melanoma, and testicular cancer had 5.62 (95% CI, 4.63-6.83), 11.22 (95% CI, 7.34-17.16), and 16.17 (95% CI,",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:39"
    }
  },
  {
    "page_content": "11.22 (95% CI, 7.34-17.16), and 16.17 (95% CI, 6.80-38.43) times greater risk of developing another breast cancer, melanoma, and testicular cancer, respectively, compared with the comparison cohort. In the sensitivity analysis, aIRR for developing another breast cancer of different histology or laterality among breast cancer survivors was 4.3 (95% CI, 3.5-5.4). Breast cancer survivors also had elevated risk for subsequent ovarian cancer (aIRR, 5.3 [95% CI, 2.7-10.4]) and melanoma (aIRR, 2.95",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:40"
    }
  },
  {
    "page_content": "5.3 [95% CI, 2.7-10.4]) and melanoma (aIRR, 2.95 [95% CI, 1.45-6.00]). Risk for developing a breast SMN was elevated in lymphoma and melanoma survivors (aIRR, 2.31 [95% CI, 1.18-4.51] and aIRR, 1.80 [95% CI, 1.04-3.12], respectively). Survivors of testicular cancer were also at increased risk of subsequent prostate cancer (aIRR, 2.9 [95% CI, 1.2-7.2]). ## Cumulative Incidence Function of SMN The trajectory of overall SMN cumulative incidence functions varied by first cancer type (eFigure 2 in",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:41"
    }
  },
  {
    "page_content": "varied by first cancer type (eFigure 2 in the Supplement). In breast cancer survivors, cumulative incidence increased steadily over the follow-up period. By contrast, a steeper increase in incidence was observed 18 to 20 years after diagnosis in lymphoma, melanoma, and testis cancer survivors. The Figure shows the cumulative incidence functions by specific pairs of first (breast, melanoma, testis) and second cancer. Increased risk of SMN of the same type as the first cancer, but not for other",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:42"
    }
  },
  {
    "page_content": "same type as the first cancer, but not for other SMN types examined, was apparent immediately after index date (eg, melanoma SMN among melanoma survivors, shown in Figure, C). ## Risk Factors for SMN Among survivors of AYA cancer, older age at diagnosis (IRR for age 30-39 years, 2.09 [95% CI, 1.35-3.25]), female sex (IRR, 1.38 [95% CI, 1.14-1.67]), advanced stage at diagnosis (IRR for stage II, 1.31 [95% CI, 1.07-1.60]), and exposure to radiation therapy (IRR, 1.56 [95% CI, 1.30-1.87]) were",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:43"
    }
  },
  {
    "page_content": "therapy (IRR, 1.56 [95% CI, 1.30-1.87]) were independently associated with greater risk of solid SMN (Table 4). On the other hand, Asian race/ethnicity (IRR compared with non-Hispanic white, 0.60 [95% CI, 0.41-0.86]), and more recent calendar period of diagnosis (IRR for diagnosis in 2003-2014 compared with 1990-2002, 0.81 [95% CI, 0.67-0.97]) were associated with lower risk of solid SMN. For nonsolid SMN, Hispanic race/ethnicity (IRR, 1.99 [95% CI, 1.01-3.95]) advanced stages at diagnosis (IRR",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:44"
    }
  },
  {
    "page_content": "CI, 1.01-3.95]) advanced stages at diagnosis (IRR for stage II, 2.58 [95% CI, 1.04-6.43]; IRR for stage III/IV, 4.41 [95% CI, 1.77-11.00]), and cancers for which TMN stage were not applicable (IRR, 5.17 [95% CI, 2.13-12.56]) were associated with higher risk. In sensitivity analysis excluding breast SMN as an outcome, female sex was no longer associated with increased SMN risk (IRR, 0.77 [95% CI, 0.63-0.94]). In sensitivity analyses excluding melanoma SMN, Asian race/ethnicity was no longer",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:45"
    }
  },
  {
    "page_content": "melanoma SMN, Asian race/ethnicity was no longer associated with reduced risk of solid SMN (IRR, 0.79 [95% CI, 0.55-1.13]). In analyses restricted to the 5 most common first cancer types, survivors of breast cancer (aIRR, 2.80 [95% CI, 1.84-4.26]) and melanoma (aIRR, 2.67 [95% CI, 1.78-4.02]) had the greatest increased risk of solid SMN compared with thyroid cancer. Among those whose first cancer was diagnosed in 2000 to 2012, none of the chemotherapy agents examined were significantly",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:46"
    }
  },
  {
    "page_content": "chemotherapy agents examined were significantly associated with SMN, solid or nonsolid (Table 4). Among breast cancer survivors, Asian individuals had lower risk of developing any SMN (aIRR, 0.50 [95% CI, 0.27-0.93]) or breast SMN, while radiotherapy was associated with increased risk of any SMN (aIRR, 1.52 [95% CI, 1.12-2.05]) or breast SMN (eTable 3 in the Supplement). Among melanoma survivors, advanced stage at diagnosis was associated an almost 3-fold risk of any SMN (aIRR, 2.83 [95% CI,",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:47"
    }
  },
  {
    "page_content": "3-fold risk of any SMN (aIRR, 2.83 [95% CI, 1.40-5.71]) but not melanoma SMN. Among lymphoma survivors, black race and radiation therapy were associated with increased risk of SMN. Demographic characteristics, stage, and radiation therapy (for testicular cancer) were not associated with risk of SMN among testicular and thyroid cancer survivors (eTable 3 in the Supplement). ## Mortality Following SMN The 5-year overall mortality following an SMN diagnosis was 31.9% (128 of 401) for survivors of",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:48"
    }
  },
  {
    "page_content": "diagnosis was 31.9% (128 of 401) for survivors of AYA cancer. Adjusted hazard ratio (aHR) for mortality after developing SMN was 1.90 (95% CI, 1.61-2.24) for survivors of AYA cancer compared with mortality after developing first cancer in the comparison group (eTable 4 in the Supplement). Among survivors of AYA cancer, those with SMN were at 7-fold increased risk of dying compared with survivors who did not develop SMN (aHR, 7.17 [95% CI, 6.06-8.49]). # Discussion We observed a 3-fold SMN risk",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:49"
    }
  },
  {
    "page_content": "# Discussion We observed a 3-fold SMN risk increase in survivors of AYA cancer compared with a demographically matched comparison cohort who did not have a history of cancer at the index date. This risk increase was primarily driven by solid SMN. Increased risk for SMN varied by patient characteristics, first cancer type, and SMN type. Among survivors with primary breast cancer, melanoma, and testicular cancer, a particularly elevated risk for SMN of the same organ was found. Overall, we",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:50"
    }
  },
  {
    "page_content": "for SMN of the same organ was found. Overall, we observed several demographic, clinical, and treatment characteristics to be associated with SMN. Furthermore, risk factors for SMN appeared to differ by first cancer type. These findings have important implications for prevention and early detection strategies for SMN and could inform the development of cancer screening guidelines for survivors of AYA cancer. In general, an SMN risk increase of 4 to 6 times has been reported for childhood cancer",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:51"
    }
  },
  {
    "page_content": "to 6 times has been reported for childhood cancer survivors compared with the general population.8,14,31 However, survivors of AYA cancer bear a greater absolute burden of SMN.14 A few studies have specifically examined relative risk of SMN among survivors of AYA cancer, and all used an external group for comparison.13,14,15,31 Although previous studies have used different methods, a moderately elevated risk of SMN has been consistently reported. For survivors of AYA breast cancer, melanoma,",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:52"
    }
  },
  {
    "page_content": "For survivors of AYA breast cancer, melanoma, and testicular cancer, our data suggest a need for an early detection program for subsequent cancer of the same organ. We used the SEER multiple primary rules established by expert consensus to determine SMN of the same organ in this observational study. While potential misclassification of second primary vs recurrence is possible, a more conservative IRR estimate of developing breast SMN of different histology or laterality among breast cancer",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:53"
    }
  },
  {
    "page_content": "histology or laterality among breast cancer survivors resulted in a similar conclusion, suggesting that the implication of our findings for early surveillance is likely valid. The association observed between breast and ovarian cancer as well as between breast cancer and melanoma is consistent with patterns of a shared genetic predisposition (eg, BRCA1 and/or BRCA2).32,33 Increased risk of prostate cancer among testicular cancer survivors has not been commonly reported and should be further",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:54"
    }
  },
  {
    "page_content": "not been commonly reported and should be further studied accounting for prostate cancer screening practices. In our study, female survivors were at greater risk of SMN compared with male survivors, likely because breast cancer was the most common SMN type in this age group. In fact, in a sensitivity analysis excluding breast SMN, female participants were at decreased risk of SMN. Similarly, lower risk in Asian participants for solid SMN could be partially due to the lower risk of melanoma in",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:55"
    }
  },
  {
    "page_content": "be partially due to the lower risk of melanoma in Asian populations,34 as, in the sensitivity analysis excluding melanoma SMN, Asian individuals were no longer at lower risk of SMN. Recent calendar period was associated with lower risk of solid SMN, which could be due to the longer latency of solid SMN. The potential reason for higher risk of nonsolid SMN in Hispanic participants is unclear. We did not observe an association with SMN risk, solid or nonsolid, for any of the chemotherapy",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:56"
    }
  },
  {
    "page_content": "solid or nonsolid, for any of the chemotherapy categories examined. Although the follow-up time for the chemotherapy analysis was considered limited for evaluating risk of solid tumor SMN, it was reasonable for evaluating nonsolid SMN as most nonsolid malignancies linked to chemotherapy are expected to develop early. We found different risk factors for SMN by first cancer type, suggesting potentially varying pathogenic mechanisms of SMN by first cancer type. Among breast cancer survivors,",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:57"
    }
  },
  {
    "page_content": "first cancer type. Among breast cancer survivors, despite generally increased breast cancer risk associated with advanced age, younger age at initial diagnosis was not associated with lower risk for subsequent SMN or breast SMN, arguing for a strong genetic predisposition for those diagnosed at young age. As expected, radiotherapy is a risk factor that should be considered for SMN surveillance. In melanoma survivors, advanced stage at diagnosis was associated with an almost 3-fold risk of",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:58"
    }
  },
  {
    "page_content": "was associated with an almost 3-fold risk of developing nonmelanoma SMN. Black race and radiation were associated with SMN in lymphoma survivors. The underlying reasons for these observations (except for radiation) are not fully understood. Those with SMN were at 7-fold increased risk of dying compared with survivors who did not develop SMN. A recent study by Keegan and colleagues35 reported worse survival outcomes following SMN compared with those who develop first malignancy of the same type,",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:59"
    }
  },
  {
    "page_content": "who develop first malignancy of the same type, and this difference was more profound in AYAs than in older adults. A study in breast cancer survivors showed that early detection of the second primary breast cancer was linked to improved relative survival by about 30% to 50%,5 supporting implementation of effective screening strategies. The role of traditional cancer risk factors and genetic testing for SMN prevention need to be addressed by future studies.36,37,38 ## Limitations There are",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:60"
    }
  },
  {
    "page_content": "future studies.36,37,38 ## Limitations There are several limitations that should be considered. In addition to those we have described, cancers diagnosed among patients moving out of California would be missed. We were also unable to perform stratified analyses by more first cancer types or by SMN type owing to limited power. Furthermore, we did not examine the association with radiation field or dose-response relationships. The generalizability of our findings to those without insurance should",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:61"
    }
  },
  {
    "page_content": "of our findings to those without insurance should also be confirmed. Despite the limitations, our study has several unique strengths. First, we used an internal comparison group with equal health care access, eliminating the potential concern of confounding due to differential access and insurance coverage in prior registry-based studies in the United States. Second, we characterized the pairwise relationship between specific first and second cancer type among the most common first cancer types",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:62"
    }
  },
  {
    "page_content": "type among the most common first cancer types in AYAs, which has implications for SMN prevention and screening. For example, counseling can be offered for female melanoma survivors about breast cancer risk and prevention. We were also among the first to evaluate the association between exposure to a specific class of chemotherapy agents and SMN risk in AYAs, which could not be done in registry-based studies. # Conclusions This study provided a detailed overview of SMN focusing on survivors of",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:63"
    }
  },
  {
    "page_content": "detailed overview of SMN focusing on survivors of AYA cancers using an internal, individually matched comparison cohort without a history of cancer and characterized in detail the cumulative incidence function and risk factors for SMN among survivors of AYA cancer. Additional studies are needed to characterize SMN risk factors within specific pairs of first and second malignant neoplasm type to inform the development of tailored screening and prevention guidelines. Given the challenge of",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:64"
    }
  },
  {
    "page_content": "and prevention guidelines. Given the challenge of long-term follow-up of survivors of AYA cancer in a traditional cohort setting,39 retrospective analysis of members from integrated health systems with access to information on detailed treatment history, lifestyle, and genetic risk factors via electronic medical records may be one of the most promising approaches to further understand the role of treatment and other cancer risk factors in SMN development, especially when enhanced with linkage",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:65"
    }
  },
  {
    "page_content": "especially when enhanced with linkage with large-scale registries or surveys.",
    "metadata": {
      "source": "../data/plain/PMC6563559.plain.txt",
      "id": "../data/plain/PMC6563559.plain.txt:66"
    }
  },
  {
    "page_content": "Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia Abstract",
    "metadata": {
      "source": "../data/plain/PMC10488320.plain.txt",
      "id": "../data/plain/PMC10488320.plain.txt:0"
    }
  },
  {
    "page_content": "Myeloid neoplasms and acute leukemias derive from the clonal expansion of hematopoietic cells driven by somatic gene mutations. Although assessment of morphology plays a crucial role in the diagnostic evaluation of patients with these malignancies, genomic characterization has become increasingly important for accurate diagnosis, risk assessment, and therapeutic decision making. Conventional cytogenetics, a comprehensive and unbiased method for assessing chromosomal abnormalities, has been the",
    "metadata": {
      "source": "../data/plain/PMC10488320.plain.txt",
      "id": "../data/plain/PMC10488320.plain.txt:1"
    }
  },
  {
    "page_content": "assessing chromosomal abnormalities, has been the mainstay of genomic testing over the past several decades and remains relevant today. However, more recent advances in sequencing technology have increased our ability to detect somatic mutations through the use of targeted gene panels, whole-exome sequencing, whole-genome sequencing, and whole-transcriptome sequencing or RNA sequencing. In patients with myeloid neoplasms, whole-genome sequencing represents a potential replacement for both",
    "metadata": {
      "source": "../data/plain/PMC10488320.plain.txt",
      "id": "../data/plain/PMC10488320.plain.txt:2"
    }
  },
  {
    "page_content": "represents a potential replacement for both conventional cytogenetic and sequencing approaches, providing rapid and accurate comprehensive genomic profiling. DNA sequencing methods are used not only for detecting somatically acquired gene mutations but also for identifying germline gene mutations associated with inherited predisposition to hematologic neoplasms. The 2022 International Consensus Classification of myeloid neoplasms and acute leukemias makes extensive use of genomic data. The aim",
    "metadata": {
      "source": "../data/plain/PMC10488320.plain.txt",
      "id": "../data/plain/PMC10488320.plain.txt:3"
    }
  },
  {
    "page_content": "makes extensive use of genomic data. The aim of this report is to help physicians and laboratorians implement genomic testing for diagnosis, risk stratification, and clinical decision making and illustrates the potential of genomic profiling for enabling personalized medicine in patients with hematologic neoplasms. Abstract",
    "metadata": {
      "source": "../data/plain/PMC10488320.plain.txt",
      "id": "../data/plain/PMC10488320.plain.txt:4"
    }
  },
  {
    "page_content": "Complementing the recently published Blood articles outlining the 2022 International Consensus Classifications for hematological malignancies (Vol. 140, Issue 11), this pair of Special Reports illustrates how molecular pathology can be applied to precision medicine. de Leval and colleagues summarize the potential of DNA sequencing of tumors and cell-free plasma, epigenetic profiling, and single-cell analyses to inform clinical decision-making about diagnosis, prognosis, and treatment for",
    "metadata": {
      "source": "../data/plain/PMC10488320.plain.txt",
      "id": "../data/plain/PMC10488320.plain.txt:5"
    }
  },
  {
    "page_content": "about diagnosis, prognosis, and treatment for patients with lymphoid neoplasms. Similarly, Duncavage and colleagues cover genomic profiling for myeloid neoplasms and the acute leukemias, focusing principally on somatic changes but also with emphasis on the emerging importance of germline gene mutations in certain diseases. Both articles provide up-to-date references for how to apply genomic information to practice.",
    "metadata": {
      "source": "../data/plain/PMC10488320.plain.txt",
      "id": "../data/plain/PMC10488320.plain.txt:6"
    }
  },
  {
    "page_content": "Impacts of socioeconomic and environmental factors on neoplasms incidence rates using machine learning and GIS: a cross-sectional study in Iran Abstract",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:0"
    }
  },
  {
    "page_content": "Neoplasm is an umbrella term used to describe either benign or malignant conditions. The correlations between socioeconomic and environmental factors and the occurrence of new-onset of neoplasms have already been demonstrated in a body of research. Nevertheless, few studies have specifically dealt with the nature of relationship, significance of risk factors, and geographic variation of them, particularly in low- and middle-income communities. This study, thus, set out to (1) analyze",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:1"
    }
  },
  {
    "page_content": "This study, thus, set out to (1) analyze spatiotemporal variations of the age-adjusted incidence rate (AAIR) of neoplasms in Iran throughout five time periods, (2) investigate relationships between a collection of environmental and socioeconomic indicators and the AAIR of neoplasms all over the country, and (3) evaluate geographical alterations in their relative importance. Our cross-sectional study design was based on county-level data from 2010 to 2020. AAIR of neoplasms data was acquired",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:2"
    }
  },
  {
    "page_content": "2010 to 2020. AAIR of neoplasms data was acquired from the Institute for Health Metrics and Evaluation (IHME). HotSpot analyses and Anselin Local Moran's I indices were deployed to precisely identify AAIR of neoplasms high- and low-risk clusters. Multi-scale geographically weight regression (MGWR) analysis was worked out to evaluate the association between each explanatory variable and the AAIR of neoplasms. Utilizing random forests (RF), we also examined the relationships between environmental",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:3"
    }
  },
  {
    "page_content": "examined the relationships between environmental (e.g., UV index and PM2.5 concentration) and socioeconomic (e.g., Gini coefficient and literacy rate) factors and AAIR of neoplasms. AAIR of neoplasms displayed a significant increasing trend over the study period. According to the MGWR, the only factor that significantly varied spatially and was associated with the AAIR of neoplasms in Iran was the UV index. A good accuracy RF model was confirmed for both training and testing data with",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:4"
    }
  },
  {
    "page_content": "confirmed for both training and testing data with correlation coefficients R2 greater than 0.91 and 0.92, respectively. UV index and Gini coefficient ranked the highest variables in the prediction of AAIR of neoplasms, based on the relative influence of each variable. More research using machine learning approaches taking the advantages of considering all possible determinants is required to assess health strategies outcomes and properly formulate policy planning. # Introduction In 2019,",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:5"
    }
  },
  {
    "page_content": "policy planning. # Introduction In 2019, neoplasms—a type of aberrant and excessive tissue growth1—were projected to have disability adjusted life years (DALYs) of 4,239 per 100,000 people globally2. Neoplasia is the term used to describe the process by which tumor forms or is produced3,4. Neoplasms are categorized by ICD-10 (a medical classification list by the World Health Organization [WHO]) into four primary groups, namely benign, malignant, in situ, and neoplasms with unclear or unknown",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:6"
    }
  },
  {
    "page_content": "in situ, and neoplasms with unclear or unknown activity4. Cancers, usually referred to as malignant neoplasms, are the main focus of current studies as they are one of the driving causes of death and major obstacles to raising life expectancy5–7. 482,229 newly diagnosed cancer cases that were registered by the Iranian National Population-Based Cancer Registry between 2014 and 2017 were analyzed in a comprehensive study carried out by Faramarzi and co-authors. To investigate geographical",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:7"
    }
  },
  {
    "page_content": "and co-authors. To investigate geographical patterns throughout Iran, they used a local Moran I analysis along with a purely spatial scanning model. The results indicated that males accounted for about 53% of all cases. The most frequent malignancy in men was stomach cancer. Iran's northern and northwest was found to have a significant incidence of stomach cancer in both sexes. While, the most prevalent cancer in women, breast cancer, was found to be concentrated in the northern areas of the",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:8"
    }
  },
  {
    "page_content": "to be concentrated in the northern areas of the country8. In the South Iranian province of Kerman, a cross-sectional study was carried out by Montazeri et al.9 to examine the spatiotemporal mapping of prostate and breast cancers. high-high clusters of breast cancer were found in the northwest of the province using cluster analysis at the county level; while, high–high clusters related to prostate cancer were found in this region by cluster analysis at the county and district levels. Globally,",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:9"
    }
  },
  {
    "page_content": "at the county and district levels. Globally, the burden of cancer incidence and death is increasing at a rapid pace. This can be attributed to a number of factors, including population increase and aging, as well as shifts in the distribution and frequency of its primary risk factors, many of which are linked to socioeconomic development10,11. The potential impact of environmental exposures on cancer was investigated in a study by Huang et al.12. Based on county-level data, they ran a spatial",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:10"
    }
  },
  {
    "page_content": "Based on county-level data, they ran a spatial autoregressive model to investigate the relationship between the mortality rates of four cancers in women (breast, cervical, ovarian, and uterine cancer) and the Environmental Quality Index (EQI, which included air, water, land, built environment, and sociodemographic domain). They found a correlation between increased breast, ovarian and uterine cancer mortality and lower environmental quality. It is asserted that certain hepatitis strains raise",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:11"
    }
  },
  {
    "page_content": "is asserted that certain hepatitis strains raise the chance of developing some malignancies. Persistent infections caused by Hepatitis B (HBV) and Hepatitis C (HCV) raise the risk of liver cancer, and the chance of contracting both the hepatitis B and C viruses increases the risk of being afflicted with liver cancer20, as well as other types including digestive system cancers21. Furthermore, there is an increased risk of bile duct cancer and some non-Hodgkin lymphomas in individuals infected",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:12"
    }
  },
  {
    "page_content": "non-Hodgkin lymphomas in individuals infected with one or both hepatitis viruses20,22. Cervical cancer, the second largest cause of cancer-related mortality among women, is known to be significantly elevated in cases when sexually transmitted diseases (STDs), such as genital warts, Human Immunodeficiency Virus (HIV) and Syphilis, are present23,24. The risk of developing other cancer types also grows up following being afflicted with STDs25. The primary behavioral drivers of neoplasms, like",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:13"
    }
  },
  {
    "page_content": "The primary behavioral drivers of neoplasms, like smoking and environmental exposures, are significantly impacted by socioeconomic conditions at both the individual and local levels26. It is crucial to analyze the socioeconomic patterns in cancer mortality and incidence in order to assess the health inequalities associated with cancer between the most and least advantaged social groups and to identify regions or population groups that are most at risk of cancer27. In a recent study conducted by",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:14"
    }
  },
  {
    "page_content": "risk of cancer27. In a recent study conducted by Banerjee and Jones (2022), Geographically Weighted Regression (GWR) was utilized to investigate the influence of location on the association between sociodemographic variables and breast cancer. The results revealed that the age-adjusted breast cancer incidence rate per 100,000 were significantly predicted by the Gini coefficient and poverty rate28. Previous research on the relationship between the environment and disease outbreaks is undermined",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:15"
    }
  },
  {
    "page_content": "environment and disease outbreaks is undermined by two methodological flaws. First, the use of traditional linear regression models is somewhat to blame for the inconsistent results29. Such linear models do not take variable interactions, non-linearities, etc. into consideration, since they lack theoretical foundation. Data-driven machine learning techniques have been recently surfaced as approaches to address these shortcomings in environmental health research30. The random forest algorithm is",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:16"
    }
  },
  {
    "page_content": "health research30. The random forest algorithm is an effective ensemble learning technique for both classification and regression issues31. Second, unlike ordinary least squares (OLS), the random forest technique is not dependent on restricted model assumptions.32,33, Third, global regressions models applied in a body of research require the estimated coefficients are spatially stationary- that is; they do not fluctuate throughout space regardless of location. This method is problematic,",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:17"
    }
  },
  {
    "page_content": "of location. This method is problematic, particularly when the study area is extensive34. To address these failures and to investigate the interaction between neoplasms and some driving factors, our study aimed to (1) determine the spatial distribution and spatial clustering patterns of the age-adjusted neoplasms incidence rate in Iran, (2) demonstrate the provinces in which the interaction of high or low values of both dependent and explanatory variables are pronounced using popularity tool,",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:18"
    }
  },
  {
    "page_content": "variables are pronounced using popularity tool, (3) measure the spatial dependence of each explanatory variables as a function of the distance (4) assess the spatial relationships between the AAIR of neoplasms and various socioeconomic, environmental, and public health factors using MGWR and (5) evaluate the relative importance of independent variables on AAIR of neoplasms using Random Based Forest (RF). # Methodology ## Topology of the study area Iran is situated in the northern hemisphere",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:19"
    }
  },
  {
    "page_content": "area Iran is situated in the northern hemisphere above the equator, with its latitudinal location being 32.4279° N. Iran's coordinates are 53.6880° E, which places it in the eastern hemisphere. The country located in West Asia shares boundaries with the Gulf of Oman, the Persian Gulf, and the Caspian Sea (Fig. 1). Geographically speaking, it is mostly found on the Persian Plateau, encompassing 1,648,195 square kilometers (636,000 square miles) which makes it the sixteenth largest country in the",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:20"
    }
  },
  {
    "page_content": "makes it the sixteenth largest country in the world.Figure 1Study area and its location in the region. This map was generated using ArcGIS pro 2.5. (ESRI, Redlands, CA, USA, http://www.esri.com). ## Sources of data Data on the age-adjusted incidence rate of neoplasms per 100,000 population for five years (2010, 2013, 2015, 2017, and 2020) and all 32 provinces were obtained from the Institute for Health Metrics and Evaluation (IHME, https://www.healthdata.org/research-analysis/gbd). Disability",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:21"
    }
  },
  {
    "page_content": "Disability age-adjusted life years (DALYs) for Hepatitis B (HBV), Hepatitis C (HCV), and sexually transmitted diseases (STD) excluding HIV were obtained from the same source. Literacy rate, number of healthcare centers in each province, and Gini coefficients were collected from the Statistical Center of Iran (https://www.amar.org.ir/). Tobacco consumption rate (percentage of people who currently smoke one type of tobacco on a daily basis, %) were obtained from the National Institute of Health",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:22"
    }
  },
  {
    "page_content": "obtained from the National Institute of Health Researches of Iran (http://nihr.tums.ac.ir). Average annual UV index values35, and mean concentrations of ground-monitored PM2.5 (µg/m3)36 were collected from two recently published articles. ## Descriptive and exploratory analyses ### Spatial autocorrelation and Hot Spot analyses For an exploratory spatial study of our response variable (AAIR of neoplasms), we used the Moran's I statistic. Positive spatial autocorrelation is shown by a positive",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:23"
    }
  },
  {
    "page_content": "spatial autocorrelation is shown by a positive Moran's I value; negative spatial autocorrelation is indicated by a negative one, and values close to 0 reflect a spatially random pattern37,38. Four scenarios37 could occur in the local Moran's I index, which evaluates the relationship between points and neighbors; namely (High–High (H–H); indicates positive spatial autocorrelation for both the value of AAIR and its neighbors, High–Low (H–L), Low–High (L–H), and Low–Low (L-L)). Subsequently, an",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:24"
    }
  },
  {
    "page_content": "(L–H), and Low–Low (L-L)). Subsequently, an event's accumulation in very big or very small amounts can be examined using Getis-Ord Gi* index, which also includes markers of hot spots (high-risk areas) and cold spots (low-risk areas). Hot spots are indicated by positive Z-score values, and cold spots are indicated by negative Z-score values39. All the maps exhibited in this study were generated by ArcGIS pro 2.5. ### Semivariogram Semivariograms were used to determine a variable's spatial",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:25"
    }
  },
  {
    "page_content": "were used to determine a variable's spatial coherence. When two specimens are spatially coherent, it indicates that they are dependent on one another up to a predetermined distance. This dependency is thought to be represented by a semivariogram, a mathematical model40. Semovariogaram was calculated based on Eq. (1).1\\documentclass[12pt]{minimal} \\usepackage{amsmath} \\usepackage{wasysym} \\usepackage{amsfonts} \\usepackage{amssymb} \\usepackage{amsbsy} \\usepackage{mathrsfs} \\usepackage{upgreek}",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:26"
    }
  },
  {
    "page_content": "\\usepackage{mathrsfs} \\usepackage{upgreek} \\setlength{\\oddsidemargin}{-69pt} \\begin{document}$$\\gamma \\left(h\\right)=\\frac{1}{2N(h)}\\sum_{i=1}^{N(h)}{[Z({x}_{i}-Z\\left({x}_{i}+h\\right)]}^{2}$$\\end{document}γh=12N(h)∑i=1N(h)[Z(xi-Zxi+h]2where, N (h) is the value of the semivariogram for distance h, Z(xi) denotes the sample value at point xi, and Z(xi + h) is the sample value at point xi + h. The symbol (h) indicates the distance in the designated direction between the position xi and xi + h.",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:27"
    }
  },
  {
    "page_content": "direction between the position xi and xi + h. Range, sill, and nugget are three parameters of a semivariogram, which are defined as follows: Range or impact radius is the length of time that the variogram takes to approach the horizontal line and reach a fixed point. Sill is the variogram's consistent value within the effect's range. Its value is the sum of the variances of all the samples that was utilized to determine the change in facade. Nugget; for h = 0, it is the variogram's value at the",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:28"
    }
  },
  {
    "page_content": "for h = 0, it is the variogram's value at the origin. Its value ought to be zero in theory41. Using the spatial dependence index based on Eq. (2), the optimal correlation is found.2\\documentclass[12pt]{minimal} \\usepackage{amsmath} \\usepackage{wasysym} \\usepackage{amsfonts} \\usepackage{amssymb} \\usepackage{amsbsy} \\usepackage{mathrsfs} \\usepackage{upgreek} \\setlength{\\oddsidemargin}{-69pt} \\begin{document}$$SD=\\frac{nugget}{nugget+partialsill} \\times",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:29"
    }
  },
  {
    "page_content": "\\times 100$$\\end{document}SD=nuggetnugget+partialsill×100 Three scenarios are considered while examining the value of SD: less than 25% indicates strong geographical correlation; between 25 and 75% demonstrate moderate spatial correlation; and more than 75% depicts poor spatial correlation42. ### Multi-scale geographically weighted regression MGWR can be used to investigate correlations between explanatory and dependent variables that differ spatially. It includes both the recently introduced",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:30"
    }
  },
  {
    "page_content": "It includes both the recently introduced Multiscale GWR (MGWR) technique, which relaxes the assumption that all of the processes being modeled run at the same spatial scale, and the previously used Geographically Weighted Regression (GWR) approach to modeling process spatial heterogeneity43. In order to evaluate geographical variation in the relationship between socioeconomic traits, environmental factors, and neoplasm incidence rates, we used MGWR modeling. As opposed to classical regression,",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:31"
    }
  },
  {
    "page_content": "modeling. As opposed to classical regression, this method permits the model parameters to change in different geographic units. We chose the fixed Gaussian spatial kernel in the MGWR model to control for an ideal bandwidth, which is thought to be constant throughout space43. The bandwidth search was conducted using the Golden Section search option, which reduces the range of values for the ideal bandwidth and delivers the lowest score44. For the optimization criterion, we employed the corrected",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:32"
    }
  },
  {
    "page_content": "optimization criterion, we employed the corrected Akaike's Information criterion (AICc), whereby the bandwidth with the lowest AICc is chosen and applied to the analysis. MGWR analysis was conducted in MGWR 2.2 software45. ### Popularity analysis Popularity tool counts the instances of the input raster values at each position and assigns an ordinal ranking to each one, meaning the most, second, and so on are the most popular.46. In other words, this tool finds, cell by cell, the value in an",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:33"
    }
  },
  {
    "page_content": "this tool finds, cell by cell, the value in an argument list that is at a particular degree of popularity. To prepare the maps of bivariate interaction of each two variables (dependent and one independent) and analyze high-high or low-low interaction effects in each province, raster maps of AAIR of neoplasms and each covariate values were first prepared. Thereafter, each raster was categorized to 10 classes and each class was numbered from 1 to 10 to classify values from low to high. Then, the",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:34"
    }
  },
  {
    "page_content": "10 to classify values from low to high. Then, the interactions between each of variables were tested by popularity analysis tool using ArcGIS pro2.5. It is worth nothing that two covariates, namely the number of healthcare centers and literacy rate in each province which assumes to be inversely correlated with AAIR, were conversely ranked. ### Random forest and validation A regression-based method according to ensemble learning is called a random forest (RF)47. Many regression trees that have",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:35"
    }
  },
  {
    "page_content": "forest (RF)47. Many regression trees that have grown to their maximum size without pruning make up the algorithm. The average of the forecasts from each individual tree yields the final predictions. The RF, in contrast to standard regression, does not rely on rigorous statistical assumptions, models complicated correlations, and takes variable interaction into account. A series of trees based on N independent observational data were used to create an RF. Following the construction of each tree,",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:36"
    }
  },
  {
    "page_content": "an RF. Following the construction of each tree, the test data are added and the number of trees corresponding to the input vector and output is defined. Calculating the final outcome involves averaging these outputs. The default value for the number of trees parameters is 100. It has been asserted that increasing the number of trees in the forest model will result in more accurate model prediction48. Accordingly, we increased the number of trees to 500, and 5 randomly sampled variables at each",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:37"
    }
  },
  {
    "page_content": "to 500, and 5 randomly sampled variables at each split were suggested to have high prediction accuracy49. To analyze the performance metrics of RF model for both training and validation data, we used coefficient of determination (R2) and standard error (SE). In order to link prediction with the assignment of relevance to specific predictors, importance measures have been developed to characterize the contribution of explanatory variables to prediction50,51; which was described by Efron52. Here,",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:38"
    }
  },
  {
    "page_content": "which was described by Efron52. Here, we examined the arrangement of variable importance (VIMP), which is widely used as a method to improve the interpretability of Random Forests. Importance was calculated using Gini coefficient, which can be thought of as the number of times a variable is responsible for a split and the impact of that split divided by the number of trees. (https://pro.arcgis.com/en/pro-app/3.1/tool-reference/spatial-statistics/how-forest-works.htm). # Results and discussion",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:39"
    }
  },
  {
    "page_content": "# Results and discussion ## Spatial distribution of the age-adjusted incidence rate of neoplasms ## Spatial distribution of explanatory variables Spatial distribution of independent variables is shown in Supplementary Fig. S1 (Supplementary Information). At the national level, DALYs of STD varied more than three times, from 11.32 in South Khorasan to 32.21 per 100,000 in Kohgiluyeh and Boyer-Ahmad, indicating major differences between provinces. DALYs of HBV and HCV are distributed unevenly",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:40"
    }
  },
  {
    "page_content": "DALYs of HBV and HCV are distributed unevenly across provinces in Iran. There are regional similarities in the HBV and HCV distribution features (Supplementary Fig. S1). The highest values for both HBV and HCV were observed for Golestan, Qazvin, Hamedan, Fars, and Kermanshah. Tobacco consumption rate were prevalent in Qazvin, Fars, Bushehr, and West Azarbaijan. There was a noticeable concentration in the distribution of UV index among the provinces. While the southern parts of the country had",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:41"
    }
  },
  {
    "page_content": "While the southern parts of the country had the highest values of UV index, the west regions including Ilam. Khuzistan, and Kohgiluyeh and Boyer-Ahmad had the most substantial annual mean concentrations of PM2.5. A yearly annual mean concentration of 5 µg/m3 for PM2.5 values is the recommended threshold by WHO56. However, none of the studied areas adhered to this limit and all of them exceeded the suggested threshold, indicating 22–52 times higher than that of recommended by WHO. Except for",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:42"
    }
  },
  {
    "page_content": "than that of recommended by WHO. Except for Bushehr, people with limited literacy rate were concentrated in regions in the west and southwest. The Gini coefficient calculates the deviation from perfect equality in the distribution of income (or, occasionally, consumption expenditure) among people or households in an economy. Gini coefficient was the highest in Sistan and Baluchestan showing income inequality across the population living in this area. Ardabil and Qazvin recorded the lowest",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:43"
    }
  },
  {
    "page_content": "this area. Ardabil and Qazvin recorded the lowest values indicating more equal distribution of wealth in these provinces. There was a remarkable difference in the number of healthcare centers distribution across regions of Iran where the lowest numbers were observed in Alborz, Qom, Markazi, and Fars. ## Assessment of global Moran's I Spatial dependence can be established with particular statistical measures. In this model, the question of whether neoplasms incidence rate in close proximity to",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:44"
    }
  },
  {
    "page_content": "neoplasms incidence rate in close proximity to one another were more similar than those in remote proximity was investigated using spatial autocorrelation. The feature locations and assigned values were used to assess the AAIR spatial autocorrelation results prior to the application of hot spot analysis (Fig. 3). As depicted, the incidence rate of neoplasms in the study area was in the clustering pattern in 2020, according to the geographical autocorrelation (global Moran's I) over the study",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:45"
    }
  },
  {
    "page_content": "autocorrelation (global Moran's I) over the study period. The corresponding p-value was less than 0.1, with a Moran's index of 0.139. Based on these findings, the equivalent Z-score was 1.652, which implies small significant clustering patterns of data and the probability that this clustering pattern due to the product of chance was less than 10%. For other study period years (2010, 2013, 2015, and 2017), however, Z-score ranged from − 1.65 to + 1.65 (includes zero), which indicates that the",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:46"
    }
  },
  {
    "page_content": "(includes zero), which indicates that the random pattern could describe AAIR data for those years and there was no clustering pattern (Supplementary Fig. S2). Olfatifar et al., investigated the patterns of clustering in the incidence rate of breast cancer in Iran between 2004 and 2010. They found that the Moran's index for 2004 was positive and significant, indicating that the cancer incidence pattern was clustered and that the provinces or blocks had values comparable to those of their",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:47"
    }
  },
  {
    "page_content": "or blocks had values comparable to those of their neighbors. However, the index was not significant for the other years of study57.Figure 3Spatial autocorrelation of the age-adjusted incidence rate of neoplasms in 2020. ## Hotspot inspection The benefit of hotspot analysis from the standpoint of disease prevention and control and policy-making is its ability to characterize particular geographic units based on statistically significant differences58. The Getis-Ord Gi* statistic was used to find",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:48"
    }
  },
  {
    "page_content": "The Getis-Ord Gi* statistic was used to find neoplasms hotspots, and the outcomes are shown in Fig. 4. With a 90% confidence level, this figure shows the clustering of high values (hot spots) for Semnan, Kurdistan, Gilan, and Ardabil. As depicted, this high-high clustering suggests that in these areas environs are more likely to see high values of AAIR (H–H). Additionally, with 95% confidence level low values (cold areas) were detected two provinces located in the southern part of the country.",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:49"
    }
  },
  {
    "page_content": "located in the southern part of the country. Hot spot analysis, also known as Getis-Ord GI*, has been used to predict multiple disease outbreaks in the past and is seen to be a useful method for identifying spatial clusters of both high and low values38,59,60. After determining which counties are within the hot areas, precautions should be taken to stop the rising trend to nearby nations, particularly those that are in cold spots61.Figure 4Hotspot map of AAIR of neoplasms in 2020. This map was",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:50"
    }
  },
  {
    "page_content": "map of AAIR of neoplasms in 2020. This map was generated using ArcGIS pro 2.5. (ESRI, Redlands, CA, USA, http://www.esri.com). ## Multiscale geographically weighted regression The summary statistics of the calculated coefficients of the local terms (MGWR model) are shown in Table 1. The mean annual UV index has a statistically significant result (p < 0.05) according to the geographical heterogeneity test, indicating spatial diversity in this variable. With the lowest AIC value (~ 95) and the",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:51"
    }
  },
  {
    "page_content": "With the lowest AIC value (~ 95) and the highest R2 value (0.38) and adjusted R2 of 0.23, the MGWR model accounted for almost 38% of the variation in the incidence rate of neoplasm among Iranian population. It is clear from Table 1 that that except for UV index other variables were not associated with AAIR of neoplasms (p > 0.05). The negative coefficient observed for this variable indicates it’s inversely association with AAIR of neoplasms. In a very recent study conducted by Gregoire et al.,",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:52"
    }
  },
  {
    "page_content": "a very recent study conducted by Gregoire et al., exposure to UV rays was broken down into quintiles and the authors concluded that there was no correlation between UV exposure and the overall risk of breast cancer. Higher UV exposure, however, was inversely linked to a lower incidence of one breast cancer type (without estrogen receptors (ER)62. ## Semivariogram analysis of covariates Semivariogram findings are displayed in Table 2 and Fig. 5. The highest value of nugget, as a key parameter of",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:53"
    }
  },
  {
    "page_content": "highest value of nugget, as a key parameter of the semivariogram, was associated with DALYs of HBV, DALYs of HCV, and the number of healthcare centers, while its lowest value is correlated with literacy rate, and PM2.5. Again, as can be seen, the lowest value of Semivariogram range was meaningfully associated with HBV, HCV, the number of healthcare centers and tobacco consumption rate, while its highest value was correlated with UV index, and PM2.5. The sill's results indeed reveal that its",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:54"
    }
  },
  {
    "page_content": "PM2.5. The sill's results indeed reveal that its lowest value is associated with HBV, HCV, tobacco consumption rate, while its maximum value is related to PM 2.5 and UV index. According to the SD (%) results, PM2.5 and UV index exhibited strong spatial correlation (SD < 25%); while STD, literacy rate and Gini coefficients showed moderate spatial correlation over the entire area of Iran (25% < SD < 75%). Other criteria including HBV, HCV, number of healthcare centers, and tobacco consumption",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:55"
    }
  },
  {
    "page_content": "of healthcare centers, and tobacco consumption rate demonstrated weak spatial correlation (SD > 0.75%).Figure 5Result of semivariogram. (a) DALYs of STD, (b) DALYs of HBV, (c) DALYs of HCV, (d) Number of healthcare centers, (e) Tobacco consumption rate (%), (f) UV index, (g) Annual mean concentration of PM2.5, (h) Literacy rate (%), and (i) Gini coefficient. ## Detecting regions with elevated incidence rate of neoplasms that are located in critical values of explanatory variables It is of",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:56"
    }
  },
  {
    "page_content": "critical values of explanatory variables It is of paramount importance to exhibit in which provinces higher or lower values of each independent variable affect the neoplasms rate. To address this question, on a cell-by-cell basis, the popularity tool in ArcGIS pro 2.5 was used to identify the value in an argument list (covariates) that is at a particular level of popularity (incidence rate of neoplasms). The findings of the examination of each covariate on values of AAIR of neoplasms in each",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:57"
    }
  },
  {
    "page_content": "covariate on values of AAIR of neoplasms in each cell are shown in Supplementary Fig. S3(1)), which depicts the areas where higher incidence rate of neoplasms were observed (based on the DALYs of STD). It is clear that the higher DALYs of sexually transmitted diseases (excluding HIV) in Kohgiluyeh and Boyer-Ahmad and Sistan and Baluchistan have contributed to the shifted values of AAIR of neoplasms. The counties in the south and northwest were mostly affected by DALYs of HBV and HCV",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:58"
    }
  },
  {
    "page_content": "were mostly affected by DALYs of HBV and HCV determinants; the center (Isfahan) was also affected by both covariates (Supplementary Fig. S3(2), (3)). Similar to HBV, HCV was more significant in Bushehr, Alborz, Golestan, Gilan, Ardabil, and west Azerbaijan. Seemingly, the reduced number of healthcare centers has taken part in increased AAIR of neoplasms in Qom and Qazvin (Supplementary Fig. S3(4)), while higher rate of tobacco consumption was found as a significant factor in determining the",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:59"
    }
  },
  {
    "page_content": "found as a significant factor in determining the incidence of neoplasms in Qazvin and Bushehr (Supplementary Fig. S3(5)). AAIR of neoplasms is considerable in the South and moderate in the central parts of the country, but less significant in the north when it comes to underlying UV index (Supplementary Fig. S3(6)). In the meantime, counties in the Southwest have the highest rate of AAIR due to the detrimental effects of PM2.5 (Supplementary Fig. S3(7)). There has been a high concentration of",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:60"
    }
  },
  {
    "page_content": "S3(7)). There has been a high concentration of PM2.5 in the provinces of Khuzestan, Ilam, Kermanshah, Lorestan, Chaharmahal and Bakhtiari, Fars, Bushehr, Tehran, and Isfahan in recent years36, which could be assigned to natural dust storms. Indeed, ineffective ambient air pollution abatement policies at the regional, national and subnational levels in Iran, plus ongoing urbanization and industrialization and associated emissions, as well as unsustainable development have led to annual level of",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:61"
    }
  },
  {
    "page_content": "development have led to annual level of PM2.5 concentration more than WHO AQGs standards63,64. Dust storm events, especially during the spring, have deteriorated the air quality in western and south-western provinces as compared to other regions. Sistan and Baluchistan severely showed higher rate of AAIR due to the low literacy rate of its community followed by Kerman, Hormozgan, Khuzestan, Ilam and East Azerbaijan (Supplementary Fig. S3(8)) similarly, AAIR of neoplasms was also more",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:62"
    }
  },
  {
    "page_content": "S3(8)) similarly, AAIR of neoplasms was also more significant in Sistan and Baluchestan as a result of higher Gini coefficients followed by Tehran and Hamedan (Supplementary Fig. S3(9)). The Gini coefficient calculates how far an economy's income or consumption expenditures are distributed from a perfectly equal distribution among its dwellers or households (https://databank.worldbank.org/metadataglossary/world-developmentindicators/series/SI.POV.GINI). While it has infrequently been applied in",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:63"
    }
  },
  {
    "page_content": "While it has infrequently been applied in epidemiology and medicine, Gini coefficient which considers the absolute relative difference between people, accurately captures the variability in illness risk 65,66. ## Random forest The benefits of the Random Forest technique are flexibility in data types, minimal sensitivity to spatial autocorrelation, and multicollinearity67,68. The significance of determinants described by the percentage, utilized in the RF model was ranked in Fig. 6a. Figure 6b",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:64"
    }
  },
  {
    "page_content": "in the RF model was ranked in Fig. 6a. Figure 6b illustrate the ranges (distribution) of VIMP (including min, max and mean) through these 500 trees. The findings show that UV index, followed by Gini coefficient, literacy rate, annual mean concentration of PM2.5, and the number of healthcare centers were the most driving factors in explaining the prevalence of neoplasms; whereas, tobacco consumption rate played a negligible role. In RF model, a continuous variable is predicted by comparing the",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:65"
    }
  },
  {
    "page_content": "continuous variable is predicted by comparing the observed value of each test feature with the predictions made by the trained model; Hence, we examined the validation of model by R2 and SE for both training and validation of data (Table 3). As depicted, the high correlation coefficient (R2 > 0.9) and low SE for both training and validation procedure imply the accuracy of the model. Additionally, in statistics, the low p value (< 0.05) indicates the suitability of the model. The training and",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:66"
    }
  },
  {
    "page_content": "the suitability of the model. The training and validation share defined as the percentage of overlap between the ranges of training data and the input explanatory variable, as well as the percentage of overlap between ranges of the validation data and the training data were also examined for validation of model (Table 4). The training share column shows the proportion of overlap between the values of all the features in the input training features and the values of the training subset for each",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:67"
    }
  },
  {
    "page_content": "and the values of the training subset for each continuous explanatory variable. It is clear that for all explanatory variables above 95% of the range of values of the input training features are covered by the training dataset which is quite satisfactory. To generate the validation share diagnosis, a comparable calculation was thence carried out (Table 4). The high values of the shared UV index, DALYs (HBV), DALYs (HCV), and Tobacco consumption rate (%) indicate the overlap occurred between the",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:68"
    }
  },
  {
    "page_content": "(%) indicate the overlap occurred between the validation subset for each of these variables. The training subset shows the importance of them in predicting the AAIR of neoplasms in each province.Figure 6(a) VIMP (%) obtained based on RF. The proportion of the overall sum of the Gini coefficients is indicated in the % (x axis of (a)), (b) Max, Min and Mean of each studied VIMP Based on RF through 500 trees. The Gini coefficients for each listed variable are added together in the Importance axis",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:69"
    }
  },
  {
    "page_content": "are added together in the Importance axis (Y in (b)). # Conclusions In Iran, as a middle income country in middle-east, the incidence rate of neoplasms has substantially increased from 2010 to 2020. Small significant clustering patterns of AAIR of neoplasms were noticed in 2020. By using MGWR, we discovered that AAIR of neoplasms was significantly and conversely correlated with UV index values. The SD (%) results obtained from semivariogram analysis, however, revealed that despite DALYs of STD,",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:70"
    }
  },
  {
    "page_content": "however, revealed that despite DALYs of STD, literacy rate, and Gini coefficient had moderate spatial correlation throughout the country, PM2.5 and UV index showed strong spatial association. Weak spatial correlation was shown by other criteria, such as DALYs of HBV, HCV, the number of healthcare centers, and tobacco consumption rate. The provinces that are heavily affected by each explanatory variable were identified using popularity tool. Additionally, the results highlighted the good",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:71"
    }
  },
  {
    "page_content": "Additionally, the results highlighted the good accuracy of RF model in simulating neoplastic regions. Furthermore, UV index and Gini coefficient were the two most influential factors according to our nationwide assessment of the variable importance. ## Limitations Given its limitations, the results of our investigation should be taken into consideration. Notably, our study did not take into account critical environmental elements that may have an impact on incidence rate of neoplasms, such as",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:72"
    }
  },
  {
    "page_content": "an impact on incidence rate of neoplasms, such as Air Quality Index (AQI), Organic and inorganic chemicals (i.e., gasoline, asbestos). Likewise, we were unable to include family history, diet and obesity, and psychological factors which are linked to incidence of cancers, in our analysis, due to the lack of credential data for some provinces. Additionally, we considered the DALYS of HVB and HVC for the risk factors of all neoplasms in Iran owing to the few articles that have established the",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:73"
    }
  },
  {
    "page_content": "to the few articles that have established the relation of infection with one or both hepatitis virus as a risk factor of other type of cancers (including bile duct cancer and lymphoma) in addition to liver cancer. Similarly, it is approved that STD can enhance the risk for developing certain cancers besides cervical cancer. Despite the insignificant and subtle correlation here observed between AAIR of neoplasms and these variables, our finding raise concerns about the importance of these",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:74"
    }
  },
  {
    "page_content": "raise concerns about the importance of these factors on each cancer type and highlight the importance of evaluating the spatial effects of being afflicted with some of these specific infections and developing certain cancers. ## Supplementary Information Supplementary Figures.",
    "metadata": {
      "source": "../data/plain/PMC11078954.plain.txt",
      "id": "../data/plain/PMC11078954.plain.txt:75"
    }
  },
  {
    "page_content": "Genotype and Associated Cancer Risk in Individuals With Telomere Biology Disorders Key Points\nQuestion\nAre there differences in cancer risk between genetically defined subgroups of telomere biology disorders (TBDs) compared with the general population?\nFindings",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:0"
    }
  },
  {
    "page_content": "Findings\nThis cohort study including 230 individuals with TBDs found a 3-fold increased risk of cancer in individuals with TBDs compared with the general population. Individuals with autosomal-recessive or X-linked TBDs had the highest risk of cancer, at approximately 19-fold in those without prior organ transplant.\nMeaning\nThese findings suggest cancer screening in individuals with TBDs could be tailored by genotype. Abstract",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:1"
    }
  },
  {
    "page_content": "This cohort study examines differential cancer risk in individuals with telomere biology disorders by genetic subgroup. Abstract\nImportance\nTelomere biology disorders (TBDs) are inherited cancer-prone bone marrow failure syndromes with differences in morbidity and mortality based on mode of inheritance.\nObjective\nTo quantify cancer risks in TBDs by genetic subgroups.\nDesign, Setting, and Participants",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:2"
    }
  },
  {
    "page_content": "Design, Setting, and Participants\nThis longitudinal cohort study of TBDs assessed cancer occurrences from 2002 through 2022. Participants were individuals with a TBD-associated pathogenic germline variant recruited across institutions by self-referral. Data were collected and analyzed through June 30, 2022.\nExposures\nThe exposure was TBD genotypes, with subgroups defined by inheritance pattern (autosomal-dominant [AD–non-TINF2] vs autosomal-recessive/X-linked [AR/XLR] vs AD-TINF2).",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:3"
    }
  },
  {
    "page_content": "Main Outcomes and Measures\nThe main outcome was cancer; secondary outcomes included death, or organ transplant. Cumulative cancer incidence was determined considering death or transplant as competing events. Observed:expected (O:E) ratios of cancer before and after any organ transplant were calculated using the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program.\nResults",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:4"
    }
  },
  {
    "page_content": "Among 230 individuals with TBD (135 [58.7%] male; median [range] age at last follow-up, 34.6 [1.4-82.2] years) included, the risk of cancer was 3-fold higher than the general population (O:E, 3.35 [95% CI, 2.32-4.68]). The highest risk was observed in individuals with AR/XLR (O:E, 19.16 [95% CI, 9.19-35.24]) with a significantly younger cancer onset than in individuals with AD–non-TINF2 (median [range] age, 36.7 [25.2-53.6] years vs 44.5 [32.2-67.5] years; P =.01). The risk of solid tumors was",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:5"
    }
  },
  {
    "page_content": "years; P =.01). The risk of solid tumors was highest in individuals with AR/XLR (O:E = 23.97 [95% CI, 10.96-45.50]), predominantly head and neck squamous cell carcinomas (O:E, 276.00 [95% CI, 75.20-706.67]). Hematologic malignant neoplasm risk was highest in individuals with AD–non-TINF2 (O:E, 9.41 [95% CI, 4.30-17.86]). Solid tumor cumulative incidence increased to 12% for individuals with AR/XLR by age 45 years and to 13% for individuals with AD–non-TINF2 by age 70 years. The cumulative",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:6"
    }
  },
  {
    "page_content": "with AD–non-TINF2 by age 70 years. The cumulative incidence of hematologic malignant neoplasms leveled off at 2% by age 30 years and 19% by age 70 years in individuals with AR/XLR and AD–non-TINF2, respectively. Individuals with AD-TINF2 showed the highest cumulative incidence for transplant or death (49% by age 15 years). Following transplant, individuals with AR/XLR (O:E, 136.11 [95% CI, 54.72-280.44) or AD-TINF2 (O:E, 81.07 [95% CI, 16.72-236.92]) had the highest cancer risk, predominantly",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:7"
    }
  },
  {
    "page_content": "had the highest cancer risk, predominantly young-onset head and neck squamous cell carcinomas (median [range] age, 32.2 [10.5-35.5] years).",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:8"
    }
  },
  {
    "page_content": "Conclusions and Relevance",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:9"
    }
  },
  {
    "page_content": "This cohort study of individuals with TBDs found an increased cancer risk compared with the general population, with the earliest age at onset for individuals with AR/XLR inheritance. Cancer risks increased after organ transplant across all subgroups. These differences in TBD-associated cancer risks by mode of inheritance suggest cancer screening could be tailored by genotype, but additional research is warranted. # Introduction Telomere biology disorders (TBDs) are a spectrum of cancer-prone",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:10"
    }
  },
  {
    "page_content": "disorders (TBDs) are a spectrum of cancer-prone inherited bone marrow failure syndromes caused by germline pathogenic variants in genes involved in telomere maintenance.1,2,3,4 Dyskeratosis congenita, the prototypic TBD, is defined by the mucocutaneous triad of dysplastic nails, oral leukoplakia, and abnormal skin pigmentation. Individuals with TBDs are at very high risk of bone marrow failure, pulmonary fibrosis, liver disease, and many other multisystem medical problems.1,2,3,4 Some",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:11"
    }
  },
  {
    "page_content": "other multisystem medical problems.1,2,3,4 Some individuals present in early childhood with multiple complications, whereas others develop isolated features later in life.3,5 TBDs are associated with very short telomeres for age and pathogenic/likely pathogenic (P/LP) germline variants in at least 17 different telomere biology genes, including autosomal-dominant (AD; TERC, NAF1, TINF2, RTEL1, NOP10, NHP2, PARN, ZCCHC8, and RPA1), autosomal-recessive (AR; CTC1, STN1, WRAP53, and DCLRE1B), and",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:12"
    }
  },
  {
    "page_content": "(AR; CTC1, STN1, WRAP53, and DCLRE1B), and X-linked recessive (XLR; DKC1) inheritance patterns.1,2,3,4,6 For several genes, both AD and AR inheritance have been reported (ACD, TERT, RTEL1, PARN, NOP10, NHP2, and POT1). Heterozygous variants in TINF2 are primarily de novo, but families with AD inheritance have been reported.1,3 AD inheritance (AD–non-TINF2) is associated with a better overall survival (median overall survival, 64.9 years), while recessive (AR or XLR) and AD-TINF2 genotypes",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:13"
    }
  },
  {
    "page_content": "recessive (AR or XLR) and AD-TINF2 genotypes manifest with more severe clinical phenotypes, leading to significant lower median overall survival (median overall survival, 31.8 and 37.9 years, respectively) compared with AD–non-TINF2.5 Telomeres, nucleoprotein complexes that protect chromosome ends,7,8 shorten with each cell division and on reaching a critically short length, apoptosis or cellular senescence is triggered.9 During carcinogenesis, cells overcome critically short telomeres by",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:14"
    }
  },
  {
    "page_content": "cells overcome critically short telomeres by upregulating telomerase (encoded by TERT) using the alternative lengthening of telomeres pathway or other mechanisms.10 Long telomeres are considered drivers of cancer risk by promoting cancer cell survival and the accumulation of somatic variations.10,11,12 Cancer predisposition with long telomeres (CPLT) is associated with melanoma, thyroid cancer, sarcoma, glioma, and lymphoproliferative neoplasms and caused by rare germline P/LP variants in",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:15"
    }
  },
  {
    "page_content": "and caused by rare germline P/LP variants in components of the shelterin telomere protection complex (POT1, TERF2IP, ACD, TINF2, and TERF1).13,14,15,16,17,18,19 Notably, individuals with CPLT have not been reported to show TBD phenotypes. TBDs are associated with increased risk of certain cancers compared with the general population, which may be due to chromosomal instability caused by short and/or dysfunctional telomeres. The TBD cancer spectrum primarily includes head and neck squamous cell",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:16"
    }
  },
  {
    "page_content": "primarily includes head and neck squamous cell carcinoma (HNSCC), myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML) and is distinct from CPLT.20,21 In 2018, risks, defined as observed-to-expected ratios (O:Es), were reported as highest for HNSCC (O:E, 216), MDS (O:E, 578), and AML (O:E, 74).20 The same analysis observed higher O:Es for solid tumors following hematopoietic cell transplant (HCT) for patients with TBDs compared with those not undergoing HCT. Another study found O:Es",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:17"
    }
  },
  {
    "page_content": "not undergoing HCT. Another study found O:Es of 61 for oral cavity squamous cell carcinoma (SCC), 21 for AML, and 145 for MDS, not considering transplant status.21 Numerous studies have suggested an increased risk of neoplasms following organ transplant in the non-TBD population, but there are limited data on the contribution of organ transplants on cancer risk in TBDs.20,22,23,24,25 Experts recommend annual HNSCC screening, but evidence-based guidelines are lacking.26 Our genotype-phenotype",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:18"
    }
  },
  {
    "page_content": "guidelines are lacking.26 Our genotype-phenotype analyses identified distinct differences in morbidity and mortality between genotype subgroups defined by inheritance patterns.5 We identified an 8-fold increased hazard ratio for cancer in TBDs associated with biallelic or XLR pathogenic germline variants.5 Further studies focusing on cancer risk by genetic TBD subtypes have not yet been published. Given the significant differences in TBD-related morbidity and mortality by mode of inheritance,",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:19"
    }
  },
  {
    "page_content": "morbidity and mortality by mode of inheritance, we sought to specifically quantify cancer types and risk in genetically defined subgroups of TBDs by analyzing 20 years of data collected from 230 patients. # Methods This cohort study was approved by the National Cancer Institute (NCI) institutional review board and registered at ClinicalTrials.gov (identifier: NCT00027274). This study is part of the inherited bone marrow syndromes study, a retrospective and prospective longitudinal cohort study",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:20"
    }
  },
  {
    "page_content": "and prospective longitudinal cohort study opened in January 2002 that continues to accrue participants and is not a cancer screening study. All participants or their legal guardians sign a written informed consent in accordance with Health and Human Services regulation 45 CFR 46. Clinical information, including self-reported race and ethnicity, is obtained through questionnaires completed by participants, provided medical and pathology records, and self or family member report. For this",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:21"
    }
  },
  {
    "page_content": "and self or family member report. For this analysis, we included all individuals with a confirmed pathogenic germline variant in a known TBD-associated gene by genetic testing or family report (eTable 1 and eFigure 1 in Supplement 1) enrolled between January 1, 2002, and June 1, 2022. A total of 138 individuals with TBD (60.0%) were included in our 2018 cancer study,20 and 200 individuals with TBD (87.0%) were included in the 2022 genotype-phenotype analysis.5 Individuals with genotype inferred",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:22"
    }
  },
  {
    "page_content": "analysis.5 Individuals with genotype inferred by mode of inheritance based on family history were included. For the TBD cohort, disease-causing inheritance pattern per gene was considered based on published events (eTable 1 and eTable 2 in Supplement 1).1,3 TBD carriers were defined as individuals with a monoallelic P/LP variant in a TBD-related gene solely associated with AR inheritance (eg, WRAP53 or CTC1) or female carriers of P/LP variants in the XLR gene DKC1 (eTable 1 in Supplement 1).",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:23"
    }
  },
  {
    "page_content": "in the XLR gene DKC1 (eTable 1 in Supplement 1). All variants were annotated using SnpEff,27 ANNOVAR,28 AutoPVS1,29 and ClinVar30 databases (downloaded June 29, 2022) and classified as P/LP using modified American College of Medical Genetics and Genomics and Association for Molecular Pathology criteria31 as previously described.5 P/LP criteria for TERC included (1) location in the pseudoknot region; (2) absence in gnomAD genome; (3) functional data proving disruption of TERC function; (4)",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:24"
    }
  },
  {
    "page_content": "data proving disruption of TERC function; (4) TBD-consistent phenotype segregation within a family; (5) presence in unrelated individuals with a consistent phenotype, including publications; and (6) reported P/LP in ClinVar. Exome sequence data were available in a representative subset (54 individuals affected by TBD and 7 TBD carriers) and used to assess whether P/LP variants in other cancer susceptibility genes were present in the cohort.32,33 There were pathogenic heterozygous variants in",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:25"
    }
  },
  {
    "page_content": "There were pathogenic heterozygous variants in MUTYH (4 families) and FANCA (1 family) not deemed disease causing. ## Statistical Analysis Cancer diagnoses were collected from medical records and participant self-report and reviewed through June 30, 2022. Cancer entities quantified included all solid tumors (including in situ diagnoses), hematologic malignant neoplasms, and nonmelanoma skin cancers. The number of solid tumors and their respective subgroups, hematologic malignant neoplasms",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:26"
    }
  },
  {
    "page_content": "subgroups, hematologic malignant neoplasms (lymphomas, leukemia, and AML), and MDS from the NCI TBD cohort was compared with data from NCI’s Surveillance, Epidemiology, and End Results (SEER) Program.34 We analyzed cancer occurrence before and after transplant (HCT and/or lung transplant and/or liver transplant) separately without distinguishing cancer occurrences by first or second transplant due to low numbers. As MDS is not a standard SEER category, International Classification of Diseases",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:27"
    }
  },
  {
    "page_content": "International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) histology codes were used to create a comparison group, and MDS was analyzed separately from other hematologic malignant neoplasms (eTable 3 in Supplement 1). SeerStat version 8.4.0.1 was used to calculate O:Es using the sum of observed diagnoses in the study cohort divided by the expected number based on incidence data of general population in SEER. We calculated 95% CIs using the exact method. For rate data, the SEER",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:28"
    }
  },
  {
    "page_content": "using the exact method. For rate data, the SEER Research Data, 8 Registries, Nov 2021 Sub (1975-2019) database was used. The data were adjusted for age, race and ethnicity, and year of cancer diagnosis (eTable 3 in Supplement 1). Race categories were Black, White (including unknown), and other (eg, Asian, Native American or Alaska Native, or multiple). We included data on race and ethnicity because these may influence cancer rates and are part of SEER reporting. Each cancer was counted",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:29"
    }
  },
  {
    "page_content": "part of SEER reporting. Each cancer was counted separately in individuals with multiple cancers. R software version 4.3.3 (R Project for Statistical Computing) was used for non-SEER analyses. For comparison of median ages between subgroups, we used unpaired Wilcoxon rank test. Survival analysis was conducted using Kaplan-Meier estimates, using log-rank test for comparisons, and cumulative incidence analysis were conducted with the R cuminc function, using computing gray test for comparisons. As",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:30"
    }
  },
  {
    "page_content": "using computing gray test for comparisons. As TBDs are congenital diseases with a lifetime risk of complications, both survival and cumulative incidence analyses were considered starting at birth, not at time of study enrollment. Cancer-free participants were censored at age at the last follow-up. Competing events considered were death or transplant, solid tumor, or hematologic malignant neoplasms, whichever occurred first. Cohort subgroup comparisons were defined by inheritance pattern (eg,",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:31"
    }
  },
  {
    "page_content": "were defined by inheritance pattern (eg, AD–non-TINF2, AR/XLR, and AD-TINF2 separately) as previously described.5 We computed rate ratios using the R rateratio function. All statistical tests were 2-sided, and P <.05 was deemed significant. In an exploratory analysis, we assessed TBD-associated P/LP germline variant data from 9089 participants in The Cancer Genome Atlas35 (TCGA) (eFigure 2 and eTable 4 in Supplement 1). # Results ## NCI TBD Cohort Characteristics A total of 230 individuals with",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:32"
    }
  },
  {
    "page_content": "Characteristics A total of 230 individuals with TBD (135 [58.7%] male; median [range] age at last follow-up 34.6 [1.4-82.2] years) from 107 unrelated families in the NCI TBD cohort had AD TERT, AD RTEL1, or XLR DKC1 as the predominate genotypes (Table 1; eTable 5 in Supplement 1). Individuals with AD-TINF2, DKC1, or biallelic variants were significantly younger than those with AD–non-TINF2 disease. The median transplant- and cancer-free survival was 45.5 (95% CI, 40.4-52.1) years overall and",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:33"
    }
  },
  {
    "page_content": "was 45.5 (95% CI, 40.4-52.1) years overall and was highest for individuals with AD–non-TINF2, at 59.8 (95% CI, 53.5-65.6) years, whereas it was only 22.7 (95% CI, 17.1-27.5) years for individuals with AR/XLR and 28.2 (95% CI, 5.2-42.5) years for individuals with TINF2 disease (eFigure 3 in Supplement 1). Of 92 deceased individuals across all genotypes, 26 (28.3%) had a prior cancer diagnosis, which was the reported cause of death in 12 of these deaths (46.2%). Death was related to cancer",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:34"
    }
  },
  {
    "page_content": "these deaths (46.2%). Death was related to cancer therapy (chemotherapy or HCT) in an additional 4 deaths. ## Risk of Cancer in TBDs Prior to Transplant Of 230 individuals with TBD, 25 had 34 cancers prior to any transplant (HCT or liver or lung transplant) at a median (range) age of 42.9 (25.2-67.5) years, equating to a 3-fold increased risk compared with the general population (O:E, 3.35 [95% CI, 2.32-4.68]) (Table 2; eTables 6-9 in Supplement 1). Cancers included 5 reported as in situ",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:35"
    }
  },
  {
    "page_content": "1). Cancers included 5 reported as in situ diagnoses (1 cervical cancer, 4 HNSCCs) (eTable 5 in Supplement 1). Three individuals had 2 or more cancers: 1 female patient (AD TERC) had 8 distinct HNSCCs over 22.4 years; 1 male patient (DKC1) was diagnosed with anal SCC and HNSCC, and another male patient (DKC1) developed esophageal cancer followed by rectal cancer. The cancer frequency was similar for individuals with AR/XLR and AD–non-TINF2 TBD (Table 1), but the age at cancer was much younger",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:36"
    }
  },
  {
    "page_content": "(Table 1), but the age at cancer was much younger in individuals with AR/XLR TBD (median [range] age, 36.7 [25.2-53.6] years) vs AD–non-TINF2 (median [range] age, 44.5 [32.2-67.5] years) (P =.004) (Table 2). The O:E was 19.16 (95% CI, 9.19-35.24) for AR TBDs compared with 2.56 (95% CI, 1.62-3.84) for AD–non-TINF2 disease. The risk of solid tumors was highest in individuals with AR/XLR (O:E, 23.97 [95% CI, 10.96-45.50]), whereas O:Es for hematologic malignant neoplasms (including lymphoma) was",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:37"
    }
  },
  {
    "page_content": "malignant neoplasms (including lymphoma) was higher in individuals with AD–non-TINF2 (O:E, 9.41 [95% CI, 4.3-17.86]. There was only 1 individual with TINF2 who had not undergone transplant with a malignant neoplasm; they had a non-Hodgkin lymphoma of the lung. HNSCC was associated with the highest risk in TBDs, with an overall O:E of 54.37 (95% CI, 29.72-91.22) (AD–non-TINF2: O:E, 43.12 [95% CI, 20.68-79.29]; AR/XLR: O:E, 276.00 [95% CI, 75.20-706.67]). Seven individuals (3.0%; 5 male and 2",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:38"
    }
  },
  {
    "page_content": "Seven individuals (3.0%; 5 male and 2 female) were diagnosed with at least 1 HNSCC at a median (range) age of 43.1 (25.2-62.8) years. This risk was most notable for tongue SCC, with an O:E of 158.50 (95% CI, 81.90-276.87) for all TBDs compared with the general population (AD–non-TINF2: O:E, 145.41 [95% CI, 69.73-267.42]; AR/XLR: O:E, 496.66 [95% CI, 60.15-1794.10]). There was a 4-fold increased risk of digestive system cancers, most notable in individuals with AR/XLR, with an 800-fold increased",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:39"
    }
  },
  {
    "page_content": "with AR/XLR, with an 800-fold increased risk of esophagus cancer and 240-fold for anorectal cancer compared with the general population (Table 2). Only 1 patient with HNSCC reported smoking or alcohol use. In 3 individuals with esophageal cancer, 2 reported an extensive smoking history, and data were not available for 1 individual. We evaluated the adverse events of hematologic malignant neoplasms (including lymphomas and leukemias, excluding MDS) solid tumors, and transplant or death (Figure).",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:40"
    }
  },
  {
    "page_content": "solid tumors, and transplant or death (Figure). Hematologic malignant neoplasms (excluding MDS) and solid tumor cumulative incidences were 12% and 13%, respectively, by the age 70 years for all individuals. The cumulative incidence of hematologic malignant neoplasms leveled off at 2% by age 30 years in individuals with AR/XLR and 19% by age 70 years in individuals with AD–non-TINF2. Solid tumor cumulative incidence increased to 12% by age 45 years for individuals with AR/XLR, whereas it was 4%",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:41"
    }
  },
  {
    "page_content": "for individuals with AR/XLR, whereas it was 4% at the same age for individuals with AD–non-TINF2, with a later increase to 13% by age 70 years. Individuals with AD-TINF2 had the highest cumulative incidence for either transplant or death at an early age (49% vs 30% [AR/XLR] and 4% [AD–non-TINF2] by age 15 years). Of note, when considering only unrelated individuals (107 individuals), cumulative incidences remained similar (eFigure 4 in Supplement 1); however, analyses were limited by low",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:42"
    }
  },
  {
    "page_content": "1); however, analyses were limited by low numbers. MDS was considered separately from other malignant neoplasms and evaluated solely before HCT. Two individuals with MDS had previously received a lung transplant (2.0 and 7.6 years prior to MDS). The risk of MDS was more than 500 times increased in individuals with TBDs compared with the general population (O:E, 529.70 [95% CI, 308.57-848.10]). For the subgroup of individuals with AR/XLR, the MDS risk was more than 4000-fold. Nonmelanoma skin",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:43"
    }
  },
  {
    "page_content": "risk was more than 4000-fold. Nonmelanoma skin cancers (basal cell carcinoma or SCC) were reported by 12 individuals before transplant (7 individuals reported multiple, including in situ skin SCC in 2 individuals), and the median (range) age at first skin cancer was 39.5 (27.1-61.1) years (data missing for 1 individual). As nonmelanoma skin cancer is not included in SEER data, their O:Es could not be calculated. ## Increased Cancer Risk Following HCT or Solid Organ Transplant Of 230 individuals",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:44"
    }
  },
  {
    "page_content": "HCT or Solid Organ Transplant Of 230 individuals with TBDs, 74 underwent HCT or lung or liver transplant (Table 1). One individual who underwent lung transplant received a subsequent kidney transplant. The median (range) age was 18.9 (0.9-63.1) years at first transplant and 22.5 (2.2-69.0) years at last contact, resulting in 338.3 posttransplant person-years at risk. Eight individuals who had undergone transplant were diagnosed with 13 distinct cancers (Table 3; eTables 10-13 in Supplement 1).",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:45"
    }
  },
  {
    "page_content": "cancers (Table 3; eTables 10-13 in Supplement 1). There was a 25-fold increased risk of any cancer following transplant for individuals with TBDs compared with the SEER population (OE, 25.08 [95% CI, 13.35-42.89]), mostly solid tumors, specifically HNSCC (O:E, 483.88 [95% CI, 208.91-953.44]). Solid tumor occurrence increased drastically following transplant (rate ratio, 10.88 [95% CI, 5.31-22.33]; counting each solid tumor separately in individuals with multiple occurrences). Following",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:46"
    }
  },
  {
    "page_content": "individuals with multiple occurrences). Following transplant, individuals with AR/XLR had the highest O:E for any cancer (O:E, 136.11 [95% CI, 54.72-280.44]), and the risk was more than 6000-fold for HNSCC, with even higher risks for tongue SCC compared with the general population. Individuals with posttransplant HNSCC were remarkably young at cancer diagnosis (median [range] age, 32.2 [10.5-35.5] years). Of 17 individuals with TINF2, 3 (17.6%) had malignant neoplasms after transplant (2 HNSCC",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:47"
    }
  },
  {
    "page_content": "had malignant neoplasms after transplant (2 HNSCC and 1 urinary bladder cancer). Nonmelanoma skin cancers (basal cell carcinoma or SCC) were reported by 6 individuals (8.1%) after transplant, first occurring at a median (range) of 3.9 (1.8-7.5) years after transplant. Of these, 3 individuals reported several skin cancers, including in situ skin SCCs. Among 44 individuals who died after transplant, the most common causes of death were treatment-related (16 individuals [36.4%]) or pulmonary (12",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:48"
    }
  },
  {
    "page_content": "(16 individuals [36.4%]) or pulmonary (12 individuals [27.3%]) complications, including 1 individual diagnosed with AML 2.8 years after lung transplant who died during leukemia induction therapy. Three individuals (6.8%), all with AD-TINF2, died due to posttransplant malignant neoplasms. ## Cancer in NCI TBD Carriers There were 44 clinically unaffected NCI TBD carriers, including 9 with monoallelic WRAP53, 10 with monoallelic CTC1, and 25 female DKC1 variant carriers (Table 1). None underwent",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:49"
    }
  },
  {
    "page_content": "DKC1 variant carriers (Table 1). None underwent HCT or lung or liver transplant. The median (range) age at last follow-up was 51.6 (7.4-85.3) years, with only 1 individual with postmenopausal breast cancer. The SEER comparison did not reveal increased O:Es (eTable 14 in Supplement 1). ## Exploratory Analysis: TCGA Participants With Germline P/LP TBD-Associated Gene Variants We identified 42 germline variants of interest in 58 of 9089 TCGA participants (0.6%) across all cancer entities,",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:50"
    }
  },
  {
    "page_content": "participants (0.6%) across all cancer entities, including 8 variants present in the NCI’s TBD cohort (4 loss of function and 4 missense affecting either CTC1, RTEL1, TERT, or WRAP53) (eTable 5 and eTable 15 in Supplement 1). Of these, 38 were classified as P/LP. Four variants (TERT p.R1086H, NOP10 p.L3fs, POT1 p.M589fs, WRAP53 p.G350fs) fulfilled several American College of Medical Genetics and Genomics and Association for Molecular Pathology pathogenicity criteria without formally being P/LP",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:51"
    }
  },
  {
    "page_content": "criteria without formally being P/LP and were designated as variant of unknown significance most likely pathogenic. Individuals harboring germline P/LP or VUS-P variants in TBD-associated genes were compared with the total TCGA participants by affected organ or cancer entity category. The cancer spectrum affected most organ systems, and no specific clustering of affected genes or variants among cancer entities was noted (eTable 16 in Supplement 1). # Discussion This cohort study identified",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:52"
    }
  },
  {
    "page_content": "1). # Discussion This cohort study identified important differences in cancer risk in individuals with TBDs that can impact clinical care. The overall excess risk of any cancer for individuals with TBDs prior to transplant was 3.35-fold higher than in the general population after age adjustment. Notably, individuals with AD–non-TINF2 TBDs who had not undergone transplant had a 2.56-fold increased risk of cancer, whereas the risk in individuals with AR/XLR disease was 19.16-fold higher than the",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:53"
    }
  },
  {
    "page_content": "AR/XLR disease was 19.16-fold higher than the general population. The risk of cancer increased substantially after HCT or lung or liver transplant in the entire cohort (O:E, 3.35 prior to transplant vs 25.08 after) and was associated with mode of inheritance. It is important to note that comparisons of pre– vs post–organ transplant outcomes are limited because of the heterogeneity in clinical phenotypes, variability in specific genotypes, and challenges related to adjustment for confounding",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:54"
    }
  },
  {
    "page_content": "challenges related to adjustment for confounding factors, such as indication and survival bias. Age, the most common cancer risk factor in the general population, may be a relatively minor contributor to cancer risk in the TBDs, given that patients receiving transplant were younger at last follow-up than patients having not or not yet been transplanted (median age, 22.5 and 33.8 years, respectively). Additionally, the age at onset for cancer was higher in the individuals who had not yet",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:55"
    }
  },
  {
    "page_content": "was higher in the individuals who had not yet undergone transplantation vs those who had (median age, 42.9 vs 32.7 years). In non-TBD cohorts, malignant neoplasm risk after solid organ transplant increases to 2-fold higher than the general population and by 4- to 12-fold after HCT.36,37,38,39,40,41 It is not known whether transplant and/or immunosuppression affect the natural history of TBD phenotypes, and additional longitudinal studies are required. The most frequent solid malignant neoplasms",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:56"
    }
  },
  {
    "page_content": "The most frequent solid malignant neoplasms in our cohort, HNSCC and esophageal, are associated with smoking and alcohol use in the general population.42 Notably, most individuals with TBD (70%) with these malignant neoplasms did not report smoking or significant alcohol use. This finding is similar to a 2023 study of a clinically defined TBD cohort (median age 50 years, vs 34 years in our cohort) that found a specifically high risk of HNSCC in males with DKC1 P/LP variants.43 In the general",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:57"
    }
  },
  {
    "page_content": "males with DKC1 P/LP variants.43 In the general population, HNSCC is frequently associated with human papillomavirus (HPV) infection, but this does not appear to be the case in individuals with TBDs.44 It was previously suggested that individuals with TBDs have a lower-than-expected number of common cancers, such as lung or colorectal cancer.43 Common adult-onset solid malignant neoplasms (eg, lung, colorectal, or breast) were also not present in our cohort, but given the complexities of TBD",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:58"
    }
  },
  {
    "page_content": "in our cohort, but given the complexities of TBD phenotypes and competing risks of morbidity and mortality (eg, bone marrow failure or pulmonary fibrosis), it is not possible to statistically address the risk (or proposed lack thereof) of other common malignant neoplasms in TBDs at this time. Reassuringly, individuals harboring a heterozygous variant in a predominately AR gene, CTC1 or WRAP53, and including DKC1 (females), were not at increased risk of cancer. Larger, population-based studies",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:59"
    }
  },
  {
    "page_content": "risk of cancer. Larger, population-based studies are warranted to fully understand whether there are clinically significant manifestations in these individuals. We used TCGA germline variant data to explore patterns or types of cancer not yet defined in individuals with germline P/LP TBD gene variants. While there were likely undiagnosed individuals with TBDs in TCGA, hematologic malignant neoplasms and HNSCC were not increased in those individuals. Variable disease penetrance and expressivity",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:60"
    }
  },
  {
    "page_content": "Variable disease penetrance and expressivity are frequent in TBDs.3,45 It is possible that individuals with a potential underlying TBD in TCGA represent a later-onset phenotype, although it is not possible to determine this with TCGA data. The carcinogenic mechanisms in TBDs are not well understood but likely are related to accumulation of DNA damage and dysfunctional telomeres.19,46 Telomere length in the general population is a fine balance, with long telomeres being associated with certain",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:61"
    }
  },
  {
    "page_content": "with long telomeres being associated with certain cancers and short telomeres with cardiovascular and inflammatory diseases.7,19 Individuals with TBDs have very short and dysfunctional telomeres and develop cancer at much younger ages,20 but the specific mechanisms by which cancers in individuals with TBDs maintain telomeres is unknown. ## Strengths and Limitations Strengths of this study include a larger sample size and longer follow-up than prior reports and analyses by mode of inheritance",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:62"
    }
  },
  {
    "page_content": "prior reports and analyses by mode of inheritance and organ transplant status. This allowed us to fine tune to overall cancer risk estimate to 3.35 from our prior estimates of 4.220 and 11.47 This study is limited by its relatively small size (although large for TBDs), predominantly White population, and possible biased ascertainment towards individuals with more medical complications, including cancer, who may be more likely to enroll in a research study. Population-based studies are needed to",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:63"
    }
  },
  {
    "page_content": "study. Population-based studies are needed to determine the impact of social determinants and diverse racial and ethnic background on cancer risk in the context of TBDs. We also acknowledge the lack of data on individuals with more recently discovered or suspected TBD genes (eg, DCLRE1B, RPA1, MDM4, NPM1, TYMS, POLA1)2 and likely over reporting of individuals with MDS, given MDS diagnostic challenges and inability to conduct central pathology review. # Conclusions This cohort study found",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:64"
    }
  },
  {
    "page_content": "review. # Conclusions This cohort study found statistically significant differences in TBD-associated cancer risks based on the mode of inheritance and further refined these risk estimates by organ transplant status. The O:Es resulting from comparison of cancer in individuals with TBDs with SEER population data were refined from prior studies, but caution is warranted in interpretation at the individual-patient level due to ascertainment bias intrinsic to most cohort studies. Future studies of",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:65"
    }
  },
  {
    "page_content": "to most cohort studies. Future studies of population cohorts with linked clinical data and across all age groups, races, and ethnicities may allow for more robust statistical estimates of cancer risk. Based on our data, TBDs due to AR/XLR inheritance or AD-TINF2 variants were associated with highest risk of early-onset HNSCC, esophageal, hematologic, and other cancers. Individuals with AD–non-TINF2 TBDs were also at increased risk compared with the general population, but the risks were not as",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:66"
    }
  },
  {
    "page_content": "the general population, but the risks were not as high as for other TBDs. Cancer risks increased substantially after organ transplant in all groups. This study illustrates the importance of large, long-term rare disease cohorts to refine disease risks and provides a foundation on which to develop evidence-based cancer screening modalities in the TBDs.",
    "metadata": {
      "source": "../data/plain/PMC11635530.plain.txt",
      "id": "../data/plain/PMC11635530.plain.txt:67"
    }
  },
  {
    "page_content": "The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms Abstract",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:0"
    }
  },
  {
    "page_content": "The upcoming 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours is part of an effort to hierarchically catalogue human cancers arising in various organ systems within a single relational database. This paper summarizes the new WHO classification scheme for myeloid and histiocytic/dendritic neoplasms and provides an overview of the principles and rationale underpinning changes from the prior edition. The definition and diagnosis of disease types",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:1"
    }
  },
  {
    "page_content": "The definition and diagnosis of disease types continues to be based on multiple clinicopathologic parameters, but with refinement of diagnostic criteria and emphasis on therapeutically and/or prognostically actionable biomarkers. While a genetic basis for defining diseases is sought where possible, the classification strives to keep practical worldwide applicability in perspective. The result is an enhanced, contemporary, evidence-based classification of myeloid and histiocytic/dendritic",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:2"
    }
  },
  {
    "page_content": "of myeloid and histiocytic/dendritic neoplasms, rooted in molecular biology and an organizational structure that permits future scalability as new discoveries continue to inexorably inform future editions. # Introduction The World Health Organization (WHO) classification of tumours is an evidence-based classification of cancers occurring within various organ systems. It is a standard for diagnosis, research, cancer registries, and public health monitoring worldwide. For the first time since the",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:3"
    }
  },
  {
    "page_content": "worldwide. For the first time since the inception of the classification over 60 years ago, the current series (5th edition) has been developed within a unified relational database framework that encompasses the entirety of human cancers. Tumours of each organ system and across volumes (blue books) are classified hierarchically within this novel framework along taxonomy principles and a set of non-negotiables that include process transparency, bibliographic rigor, and avoidance of bias. The",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:4"
    }
  },
  {
    "page_content": "bibliographic rigor, and avoidance of bias. The development of the 5th edition is overseen by an editorial board that includes standing members—representatives from major medical and scientific organizations around the world—who oversee the entire series, in addition to expert members appointed for their leadership and contemporaneous expertise relevant to a particular volume. The editorial board, in turn, identifies authors through an informed bibliometry process, with an emphasis on broad",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:5"
    }
  },
  {
    "page_content": "bibliometry process, with an emphasis on broad geographic representation and multidisciplinary expertise. By design, multidisciplinary author/editor groups (a total of 420 contributors) shared overlapping coverage of disease categories to ensure conceptual continuity and content harmonization. This approach reflects the ways in which the classification is meant to be implemented, with multidisciplinary input that emphasizes a holistic approach to patient management from diagnosis through",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:6"
    }
  },
  {
    "page_content": "to patient management from diagnosis through disease monitoring. The aim of this paper is to provide an overview of the new edition of the WHO classification for myeloid and histiocytic/dendritic tumours. The last edition of the haematolymphoid classification dates back to 2008 and was revised in 2017. An overview of the lymphoid tumours is provided in a companion manuscript. The classification structure follows a lineage-based framework, flowing broadly from benign to malignant and branching",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:7"
    }
  },
  {
    "page_content": "broadly from benign to malignant and branching down to category, family, type (disease/tumour), and subtype. Where possible, a triad of attributes was systematically applied and included: lineage + dominant clinical attribute + dominant biologic attribute. Lineage attribution rests on immunophenotyping with flow cytometry and/or immunohistochemistry. Dominant clinical attributes are general features of the untreated disease and include descriptors such as acute, chronic, cytopenia(s)",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:8"
    }
  },
  {
    "page_content": "descriptors such as acute, chronic, cytopenia(s) (myelodysplasia) and cytosis(es) (myeloproliferation). Most biologic attributes include gene fusions, rearrangements, and mutations. Fusions are part of the nomenclature of types/subtypes when the identities of both implicated genes are required or often desirable criteria for diagnosis (e.g., PML::RARA). Rearrangements, a broad term that encompasses a range of structural genomic alterations leading to gene fusions, are part of the nomenclature",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:9"
    }
  },
  {
    "page_content": "to gene fusions, are part of the nomenclature of types/subtypes when there are multiple possible fusion partner genes of a biologically dominant gene (e.g., KMT2A). Of note, the use of the term rearrangements is maintained in the classification due to its wide usage across prior editions, although it is recognized that it is more appropriate for genomic modifications in genes consisting of various segments (e.g., immunoglobulin genes and T-cell receptor genes). A deliberate attempt is made to",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:10"
    }
  },
  {
    "page_content": "receptor genes). A deliberate attempt is made to prioritize classifying tumour types based on defining genetic abnormalities where possible. Emerging entities are listed as disease subtypes under a novel rubric of other defined genetic alterations. This is envisioned as a landing spot in the classification to incorporate new/rare entities whose recognition is increasing as high-throughput molecular diagnostic tools become more available. This approach replaces the assignment of provisional",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:11"
    }
  },
  {
    "page_content": "approach replaces the assignment of provisional status to such entities. It is recognized that the diagnosis of such subtypes might not be feasible in all practice settings. A set of decision support guidelines was adopted to aid in determining what subtypes would qualify in this context; they include: (1) having distinct molecular or cytogenetic features driven by established oncogenic mechanisms; (2) not meeting subtype criteria under other tumour types with defining genetic abnormalities;",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:12"
    }
  },
  {
    "page_content": "tumour types with defining genetic abnormalities; (3) having distinct pathologic and clinical features, including - but not limited to - response to therapeutic interventions; and, (4) at least two quality peer-review publications by distinct investigator groups. The application of this classification is predicated on integrating morphologic (cytology and histology), immunophenotypic, molecular and cytogenetic data. This is in line with previous editions, with expanded numbers of disease types",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:13"
    }
  },
  {
    "page_content": "editions, with expanded numbers of disease types and subtypes that are molecularly defined. It is hoped that the genetic underpinnings of the classification will prompt the provision of health resources to ensure that the necessary genetic testing platforms are available to peruse the full potential of the classification. Notwithstanding, the full published classification will include listing of essential diagnostic criteria that have the broadest possible applicability, particularly in limited",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:14"
    }
  },
  {
    "page_content": "possible applicability, particularly in limited resource settings. A further aid to broader applicability is the improved hierarchical structure of the classification, which permits reverting to family (class)-level definitions when detailed molecular genetic analyses may not be feasible; this approach is further elaborated on in the introduction of the blue book. In line with the rest of the WHO 5th edition series, the classification of myeloid and histiocytic/dendritic neoplasms follows the",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:15"
    }
  },
  {
    "page_content": "and histiocytic/dendritic neoplasms follows the Human Genome Organization Gene Nomenclature Committee recommendations, including the new designation of gene fusions using double colon marks (::). # Clonal haematopoiesis Clonal haematopoiesis (CH) refers broadly to the presence of a population of cells derived from a mutated multipotent stem/progenitor cell harbouring a selective growth advantage in the absence of unexplained cytopenias, haematological cancers, or other clonal disorders. The",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:16"
    }
  },
  {
    "page_content": "cancers, or other clonal disorders. The incidence of CH increases with age. Substantial advances in understanding the molecular genetics and public health implications of CH took place since the last classification, including recognition of their association with increased overall mortality, cardiovascular diseases, and myeloid malignancies. More specific emerging associations, such as those characterizing the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic UBA1 mutations)",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:17"
    }
  },
  {
    "page_content": "autoinflammatory, somatic UBA1 mutations) syndrome, represent manifestations of the interplay between inflammation and CH/myeloid neoplasia that are being gradually uncovered. Inclusion of CH in the classification represents a key inaugural effort to define and codify such myeloid precursor lesions. Clonal haematopoiesis of indeterminate potential (CHIP) is defined in the classification as a term referring specifically to CH harbouring somatic mutations of myeloid malignancy-associated genes",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:18"
    }
  },
  {
    "page_content": "mutations of myeloid malignancy-associated genes detected in the blood or bone marrow at a variant allele fraction (VAF) of ≥ 2% (≥4% for X-linked gene mutations in males) in individuals without a diagnosed haematologic disorder or unexplained cytopenia. (Supplemental Data Table S1) The significance of variants detected at lower levels is unclear at present. Clonal cytopenia of undetermined significance (CCUS) is defined as CHIP detected in the presence of one or more persistent cytopenias that",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:19"
    }
  },
  {
    "page_content": "of one or more persistent cytopenias that are otherwise unexplained by haematologic or non-haematologic conditions and that do not meet diagnostic criteria for defined myeloid neoplasms. Cytopenia definitions are harmonized for CCUS, MDS, and MDS/MPN; they include Hb <13 g/dL in males and <12 g/dL in females for anaemia, absolute neutrophil count <1.8 ×109/L for leukopenia, and platelets <150 × 109/L for thrombocytopenia. ## Summary Box: CH is recognized as a category of precursor myeloid",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:20"
    }
  },
  {
    "page_content": "is recognized as a category of precursor myeloid disease state.CHIP and CCUS are formally defined. # Myeloproliferative neoplasms Myeloproliferative neoplasms (MPN) are listed in Table 1. The main types remain largely unchanged from the prior edition. Initial diagnostic evaluation of MPN continues to depend on close correlation between clinical features, molecular diagnostics, and usually morphologic evaluation of a trephine bone marrow biopsy. Most MPN patients are diagnosed in chronic phase",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:21"
    }
  },
  {
    "page_content": "Most MPN patients are diagnosed in chronic phase (CP), which may progress into a blast phase (BP) associated with the accumulation of secondary cytogenetic and/or molecular aberrations. ## Chronic myeloid leukaemia risk factors are refined, and accelerated phase is no longer required Chronic myeloid leukaemia (CML) is defined by the BCR::ABL1 fusion resulting from t(9;22)(q34;q11). The natural history of untreated CML before the introduction of targeted tyrosine kinase inhibitors (TKI) was",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:22"
    }
  },
  {
    "page_content": "of targeted tyrosine kinase inhibitors (TKI) was biphasic or triphasic: an initial indolent CP followed by a blast phase (BP), with or without an intervening accelerated phase (AP). With TKI therapy and careful disease monitoring, the incidence of progression to advanced phase disease has decreased, and the 10-year overall survival rate for CML is 80–90%. The designation of AP has thus become less relevant, where resistance stemming from ABL1 kinase mutations and/or additional cytogenetic",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:23"
    }
  },
  {
    "page_content": "kinase mutations and/or additional cytogenetic abnormalities and the development of BP represent key disease attributes. Accordingly, AP is omitted in the current classification in favour of an emphasis on high risk features associated with CP progression and resistance to TKI. Criteria for BP include: (1) ≥20% myeloid blasts in the blood or bone marrow; or (2) the presence of an extramedullary proliferation of blasts; or (3) the presence of increased lymphoblasts in peripheral blood or bone",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:24"
    }
  },
  {
    "page_content": "lymphoblasts in peripheral blood or bone marrow. The optimal cutoff for lymphoblasts and the significance of low-level B-lymphoblasts remain unclear and require additional studies. ## Minor changes in diagnostic criteria for BCR::ABL1-negative myeloproliferative neoplasms The classification retains an emphasis on distinguishing between polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF) using diagnostic criteria established in previous editions, with minor",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:25"
    }
  },
  {
    "page_content": "established in previous editions, with minor refinements. Distinction between these types is based on integrating peripheral blood findings with molecular data and bone marrow morphologic evaluation findings, as none of these parameters alone provide sufficient diagnostic specificity. Major diagnostic criteria for the diagnosis of PV include elevated haemoglobin concentration and/or haematocrit, accompanied by trilineage hyperplasia (panmyelosis), with pleomorphic mature megakaryocytes in the",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:26"
    }
  },
  {
    "page_content": "with pleomorphic mature megakaryocytes in the bone marrow, and NM_004972:JAK2 p.V617F or JAK2 exon 12 mutations. As the determination of increased red cell mass with 51Cr-labeled red cells has become uncommon in routine clinical practice, it has been removed as a diagnostic criterion. The diagnostic criteria of ET are well-established and have not changed. Primary myelofibrosis (PMF) is characterized by a proliferation of abnormal megakaryocytes and granulocytes in the bone marrow, which is",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:27"
    }
  },
  {
    "page_content": "and granulocytes in the bone marrow, which is associated in fibrotic stages with a polyclonal increase in fibroblasts that drive secondary reticulin and/or collagen marrow fibrosis, osteosclerosis, and extramedullary haematopoiesis. Recognizing prefibrotic PMF remains necessary to separate it not only from ET and PV but also from fibrotic PMF. The importance of serial monitoring of bone marrow fibrosis and spleen size using reproducible and standardized criteria remain pertinent, especially for",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:28"
    }
  },
  {
    "page_content": "criteria remain pertinent, especially for patients receiving JAK1/2 inhibitors. PV and ET progress to AP (10-19% blasts) and BP (≥20% blasts) in a minority of cases, but leukaemic transformation is more frequent in PMF, and leukaemia-free survival is shorter in fibrotic than prefibrotic PMF. While JAK2, CALR, and MPL mutations are considered driver events, mutations in other genes – particularly TET2, ASXL1, and DNMT3A – are found in over half of patients with MPN. Mutations affecting splicing",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:29"
    }
  },
  {
    "page_content": "patients with MPN. Mutations affecting splicing regulators (SRSF2, SF3B1, U2AF1, ZRSR2) and other regulators of chromatin structure, epigenetic functions and cellular signaling (e.g., EZH2, IDH1, IDH2, CBL, KRAS, NRAS, STAG2, TP53) are less common. These additional mutations are more frequent in PMF and advanced disease compared to PV and ET, and some are known to correlate with a poorer prognostic risk (e.g., EZH2, IDH1, IDH2, SRSF2, U2AF1, and ASXL1 mutations in PMF). Chronic neutrophilic",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:30"
    }
  },
  {
    "page_content": "and ASXL1 mutations in PMF). Chronic neutrophilic leukaemia (CNL) is a BCR::ABL1-negative MPN characterized by sustained peripheral blood neutrophilia (white blood cell count (WBC) ≥ 25 × 109/ L, with ≥80% segmented neutrophils and bands), bone marrow hypercellularity due to neutrophilic granulocyte proliferation, and hepatosplenomegaly. CSF3R mutations are common in this disease and detected in >60% of cases. Chronic eosinophilic leukaemia (CEL) is a multi-system disorder characterized by a",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:31"
    }
  },
  {
    "page_content": "is a multi-system disorder characterized by a sustained clonal proliferation of morphologically abnormal eosinophils and eosinophil precursors resulting in persistent hypereosinophilia in blood and bone marrow [19–21]. Several changes to the diagnostic criteria of CEL are introduced: (1) the time interval required to define sustained hypereosinophilia is reduced from 6 months to 4 weeks; (2) addition of requirement for both clonality and abnormal bone marrow morphology (e.g., megakaryocytic or",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:32"
    }
  },
  {
    "page_content": "bone marrow morphology (e.g., megakaryocytic or erythroid dysplasia); and, (3) elimination of increased blasts (≥2% in peripheral blood or 5-19% in bone marrow) as an alternative to clonality. These criteria improve the distinction between CEL and entities such as idiopathic hypereosinophilic syndrome and hypereosinophilia of unknown significance. As the criteria of CEL and its place relative to other disorders with eosinophilia have become well characterized, the qualifier “not otherwise",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:33"
    }
  },
  {
    "page_content": "well characterized, the qualifier “not otherwise specified” is no longer needed and has been omitted from the name. As in prior editions, MPN, not otherwise specified (MPN-NOS) is a designation that should be reserved for cases with clinical, laboratory, morphologic, and molecular features of MPN but lacking diagnostic criteria of any specific MPN type or with features that overlap across distinct MPN types. ## Juvenile myelomonocytic leukaemia is recognized as a myeloproliferative neoplasm of",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:34"
    }
  },
  {
    "page_content": "is recognized as a myeloproliferative neoplasm of early childhood with frequent association with germline pathogenic gene variants Juvenile myelomonocytic leukaemia (JMML) is a haematopoietic stem cell-derived myeloproliferative neoplasm of early childhood. The pathogenetic mechanism in at least 90% of cases involves unchecked activation of the RAS pathway. A diagnosis of JMML can be made by combining clinical, laboratory, and molecular criteria. Updates to diagnostic criteria include: (1)",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:35"
    }
  },
  {
    "page_content": "Updates to diagnostic criteria include: (1) exclusion of KMT2A rearrangements; (2) elimination of monosomy 7 as a cytogenetic criterion; and, (3) emphasizing the significance of diagnostic molecular studies, particularly those aimed at demonstrating RAS pathway activation. The genetic background of JMML plays a major role in risk stratification and therapeutic approaches, with cases initiated by somatic mutations involving PTPN11 and germline pathogenic variants associated with",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:36"
    }
  },
  {
    "page_content": "and germline pathogenic variants associated with neurofibromatosis type 1 being the most aggressive types, while some cases associated with pathogenic germline CBL variants undergoing occasionally spontaneous remission. The inclusion of JMML under MPN reflects its molecular pathogenesis and underscores the virtual absence of stigmata of bona fide myelodysplastic neoplasia in this disease. ### Summary Box: CML phases consolidated into chronic and blast phases, with emphasis on risk features in",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:37"
    }
  },
  {
    "page_content": "blast phases, with emphasis on risk features in chronic phase.Diagnostic criteria of CEL are updated, and the qualifier NOS is omitted.JMML is categorized under myeloproliferative neoplasms. # Mastocytosis Mastocytosis comprises rare heterogeneous neoplasms characterized by an accumulation of abnormal mast cells in various organs or tissues, typically driven by constitutive activation of the KIT receptor. The pathology of mastocytosis is complex, and clinical features span a broad spectrum that",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:38"
    }
  },
  {
    "page_content": "and clinical features span a broad spectrum that may be modulated by the presence of comorbidities. Significant comorbidities include IgE-dependent allergies, vitamin D deficiency, and psychiatric, psychological or mental problems. The classification continues to recognize three disease types: systemic mastocytosis (SM), cutaneous mastocytosis (CM) and mast cell sarcoma (MCS). (Table 2) A somatic point mutation in the KIT gene at codon 816 is detected in >90% of patients with SM. Other rare",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:39"
    }
  },
  {
    "page_content": "detected in >90% of patients with SM. Other rare activating KIT alterations include mutations in the extracellular (e.g., deletion of codon 419 on exon 8 or A502_Y503dup in exon 9), transmembrane (e.g., NM_000222:KIT p.F522C), or juxtamembrane (e.g., NM_000222:KIT p.V560G) domains, detected in <1% of advanced SM cases but enriched in cases of indolent SM. Most patients with advanced SM and NM_000222:KIT p.D816V have additional somatic mutations involving most frequently TET2, SRSF2, ASXL1,",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:40"
    }
  },
  {
    "page_content": "involving most frequently TET2, SRSF2, ASXL1, RUNX1, and JAK2. An associated haematologic (usually myeloid) neoplasm may be detected in these patients. Diagnostic criteria for SM have been modified. Namely, expression of CD30 and the presence of any KIT mutation causing ligand-independent activation have been accepted as minor diagnostic criteria. Basal serum tryptase level >20 ng/ml, which should be adjusted in case of hereditary alpha-tryptasaemia, is a minor SM criterion. In addition, bone",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:41"
    }
  },
  {
    "page_content": "is a minor SM criterion. In addition, bone marrow mastocytosis is now a separate subtype of SM characterized by absence of skin lesions and B-findings and a basal serum tryptase below 125 ng/ml. Classical B-findings (‘burden of disease’) and C-findings (‘cytoreduction-requiring’) have undergone minor refinements. Most notably, NM_000222:KIT p.D816V mutation with VAF ≥ 10% in bone marrow cells or peripheral blood leukocytes qualifies as a B-finding. The classification recognizes",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:42"
    }
  },
  {
    "page_content": "as a B-finding. The classification recognizes well-differentiated systemic mastocytosis (WDSM) as a morphologic pattern that can occur in any SM subtype, characterized by round and well-granulated mast cells usually heavily infiltrating the bone marrow. In most patients with WDSM, KIT codon 816 mutation is not detected, and neoplastic mast cells are usually negative for CD25 and CD2 but positive for CD30. ## Summary Box: Diagnostic criteria for mastocytosis have been refined: CD30 and any KIT",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:43"
    }
  },
  {
    "page_content": "mastocytosis have been refined: CD30 and any KIT mutation are introduced as minor diagnostic criteria.Bone marrow mastocytosis is a new SM subtype.KIT D816V mutation with VAF ≥ 10% qualifies as a B-finding. # Myelodysplastic neoplasms ## New terminology and grouping framework The classification introduces the term myelodysplastic neoplasms (abbreviated MDS) to replace myelodysplastic syndromes, underscoring their neoplastic nature and harmonizing terminology with MPN. These clonal",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:44"
    }
  },
  {
    "page_content": "harmonizing terminology with MPN. These clonal haematopoietic neoplasms are defined by cytopenias and morphologic dysplasia. As indicated above, cytopenia definitions are adopted for consistency across CCUS, MDS, and MDS/MPN. Additionally, the recommended threshold for dysplasia is set at 10% for all lineages. MDS entities are now grouped as those having defining genetic abnormalities and those that are morphologically defined. (Table 3) It is posited that such reorganization enhances",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:45"
    }
  },
  {
    "page_content": "It is posited that such reorganization enhances classification rigor by emphasizing genetically-defined disease types and ceding the prior emphasis on ‘risk-based’ grouping in the classification (based on blast percentage, ring sideroblasts, and number of lineages with dysplasia) in favour of more comprehensive risk-stratification schemes such as the Revised International Prognostic Scoring System for MDS (IPSS-R). An additional modification is a clarified terminology to distinguish between MDS",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:46"
    }
  },
  {
    "page_content": "clarified terminology to distinguish between MDS with low blasts (MDS-LB) and MDS with increased blasts (MDS-IB), while retaining longstanding cutoffs. ## MDS with defining genetic abnormalities Myelodysplastic neoplasms with defining genetic abnormalities are grouped together and include: MDS with low blasts and isolated 5q deletion (MDS-5q), MDS with low blasts and SF3B1 mutation (MDS-SF3B1), and MDS with biallelic TP53 inactivation (MDS-biTP53). The latter supersedes MDS-5q and MDS-SF3B1.",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:47"
    }
  },
  {
    "page_content": "The latter supersedes MDS-5q and MDS-SF3B1. The diagnostic criteria of MDS-5q have not changed. While recognized as factors that may potentially alter the biology and/or prognosis of the disease, the presence of SF3B1 or a TP53 mutation (not multi-hit) does not per se override the diagnosis of MDS-5q. Recent studies have identified MDS-SF3B1 as a distinct disease type that includes over 90% of MDS with ≥5% ring sideroblasts. The term MDS with low blasts and ring sideroblasts is retained as an",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:48"
    }
  },
  {
    "page_content": "blasts and ring sideroblasts is retained as an acceptable alternative to be used for cases with wild-type SF3B1 and ≥15% ring sideroblasts. This permits inclusion of rare MDS cases harbouring driver mutations in other RNA splicing components. Pathogenic TP53 alterations of any type (sequence variations, segmental deletions and copy neutral loss of heterozygosity) are detected in 7-11% of MDS [29–31]. Among these, about two-thirds of patients have multiple TP53 hits (multi-hit), consistent with",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:49"
    }
  },
  {
    "page_content": "multiple TP53 hits (multi-hit), consistent with biallelic TP53 alterations. Biallelic TP53 (biTP53) alterations may consist of multiple mutations or mutation with concurrent deletion of the other allele. This “multi-hit” mutational status results in a neoplastic clone that lacks any residual wild-type p53 protein. Clinical detection of biallelic TP53 alterations is based on sequencing analysis (covering at least exons 4 to 11), often coupled with a technique to detect copy number status,",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:50"
    }
  },
  {
    "page_content": "with a technique to detect copy number status, usually fluorescence in situ hybridization with a probe set specific for the TP53 locus on 17p13.1 and/or array techniques (e.g., comparative genomic hybridization or single nucleotide polymorphism arrays). Loss of genetic material at the TP53 locus may also be inferred by next-generation sequencing. A TP53 VAF ≥ 50% may be regarded as presumptive (not definitive) evidence of copy loss on the trans allele or copy neutral loss of heterozygosity when",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:51"
    }
  },
  {
    "page_content": "or copy neutral loss of heterozygosity when a constitutional TP53 variant can be ruled out. When two or more TP53 mutations are detected, they usually affect both alleles and can be considered a multi-hit status. Over 90% of patients with MDS-biTP53 have complex, mostly very complex (>3), karyotype and thus are regarded as very high risk in IPSS-R. Additional studies are needed to determine whether biTP53 status is per se AML-defining, a point for consideration in future editions.",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:52"
    }
  },
  {
    "page_content": "a point for consideration in future editions. Notwithstanding, published data suggests that MDS-biTP53 may be regarded as AML-equivalent for therapeutic considerations. ## MDS, morphologically defined Hypoplastic MDS (MDS-h) is listed as a distinct MDS type in this edition. Long recognized as having distinctive features, MDS-h is associated with a T-cell mediated immune attack on haematopoietic stem and progenitor cells, along with oligoclonal expansion of CD8 + cytotoxic T-cells overproducing",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:53"
    }
  },
  {
    "page_content": "of CD8 + cytotoxic T-cells overproducing IFNγ and/or TNFα. Several features overlap across the triad of MDS-h, paroxysmal nocturnal haemoglobinuria (PNH) and aplastic anaemia (AA), including an association with CH [34–36]. Many patients with MDS-h have sustainable responses to agents used in patients with AA (i.e., anti-thymocyte globulin, ATG). As such, an emphasis is placed on careful morphologic evaluation, typically requiring trephine biopsy evaluation in addition to evaluation of bone",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:54"
    }
  },
  {
    "page_content": "evaluation in addition to evaluation of bone marrow smears and touch preparations, and detection of mutations and/or clonal cytogenetic abnormalities. Individuals with germline pathogenic variants in GATA2, DDX41, Fanconi anaemia (FA) or telomerase complex genes can have hypoplastic bone marrow and evolve to MDS and/or AML and do not respond to immunosuppressive treatment. As the number of dysplastic lineages is usually dynamic and often represents clinical and phenotypic manifestation of",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:55"
    }
  },
  {
    "page_content": "clinical and phenotypic manifestation of clonal evolution – rather than per se defining a specific MDS type, the distinction between single lineage and multilineage dysplasia is now considered optional. The updated MDS classification scheme and the incorporation of CCUS in the classification obviates the need for “NOS” or “unclassifiable” attributes. Specifically, MDS, unclassifiable, which was present in the prior edition, is removed. ## The boundary between MDS and AML is softened, but the",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:56"
    }
  },
  {
    "page_content": "boundary between MDS and AML is softened, but the 20% blast cutoff to define AML is retained Reassessment of the bone marrow blast percentage defining the boundary of MDS-IB2 and AML has been advocated for several cogent reasons and in view of novel therapeutic approaches that show efficacy in patients currently classified as MDS or AML with 10-30% myeloid blasts [37–39]. Salient practical challenges underpinning arguments for such a reassessment include: (1) any blast-based cutoff is arbitrary",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:57"
    }
  },
  {
    "page_content": "include: (1) any blast-based cutoff is arbitrary and cannot reflect the biologic continuity naturally inherent in myeloid pathogenic mechanisms; (2) blast enumeration is subject to sampling variations/error and subjective evaluation; and, (3) no gold standard for blast enumeration exists, and orthogonal testing platforms can and often do produce discordant results. The pros and cons of merging MDS-IB2 with AML and adopting a 10% cutoff for what would be called MDS/AML were explored in",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:58"
    }
  },
  {
    "page_content": "for what would be called MDS/AML were explored in multidisciplinary expert discussions and at editorial board meetings in the course of producing this classification. Lowering the blast cutoff to define AML was felt to suffer from the same challenges listed above and would merely replace one cutoff with another. Further, an arbitrary cutoff of 10% blasts to define AML (even if qualified as MDS/AML or AML/MDS) carries a risk of overtreatment. Accordingly, a balanced approach was adopted by",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:59"
    }
  },
  {
    "page_content": "Accordingly, a balanced approach was adopted by eliminating blast cutoffs for most AML types with defining genetic alterations but retaining a 20% blast cutoff to delineate MDS from AML. Notwithstanding, there was broad agreement that MDS-IB2 may be regarded as AML-equivalent for therapeutic considerations and from a clinical trial design perspective when appropriate. ## Childhood myelodysplastic neoplasms: Enhanced specificity of disease terminology introduced Childhood MDS is a clonal",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:60"
    }
  },
  {
    "page_content": "terminology introduced Childhood MDS is a clonal haematopoietic stem cell neoplasm arising in children and adolescents (<18 years of age) leading to ineffective haematopoiesis, cytopenia(s), and risk of progression to AML. The annual incidence is 1-2 per million children, with 10-25% presenting with increased blasts. JMML, myeloid proliferations associated with Down syndrome, and MDS post cytotoxic therapy are excluded from this group and belong elsewhere in the classification. The qualifying",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:61"
    }
  },
  {
    "page_content": "elsewhere in the classification. The qualifying term childhood MDS emphasizes that this category of myeloid neoplasms is biologically distinct from that seen in adults, underscoring the need to further elucidate its pathogenesis which remains incompletely understood Childhood MDS with low blasts (cMDS-LB) replaces the former term “refractory cytopenia of childhood (RCC)”. It includes two subtypes: childhood MDS with low blasts, hypocellular; and, childhood MDS with low blasts, not otherwise",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:62"
    }
  },
  {
    "page_content": "and, childhood MDS with low blasts, not otherwise specified (NOS). (Table 4) Exclusion of non-neoplastic causes of cytopenia such as infections, nutritional deficiencies, metabolic diseases, bone marrow failure syndromes (BMFS), and germline pathogenic variants remains an essential diagnostic prerequisite for childhood MDS with low blasts. Approximately 80% of cases show hypocellular bone marrow with features similar to severe aplastic anemia and other BMFS, requiring close morphologic",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:63"
    }
  },
  {
    "page_content": "and other BMFS, requiring close morphologic examination to evaluate the distribution, maturation, and presence of dysplasia in haematopoietic lineages. Some cytogenetic findings such as monosomy 7, 7q deletion, or complex karyotype are associated with an increased risk of progression to AML and typically treated with haematopoietic stem cell transplantation, while cases with normal karyotype or trisomy 8 can have an indolent course. Childhood MDS with increased blasts (cMDS-IB) is defined as",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:64"
    }
  },
  {
    "page_content": "MDS with increased blasts (cMDS-IB) is defined as having ≥5% blasts in the bone marrow or ≥2% blasts in the peripheral blood. The genetic landscape of cMDS-IB and cMDS-LB is similar, and they both differ from MDS arising in adults. Acquired cytogenetic abnormalities and RAS-pathway mutations are more common in cMDS-IB compared to cMDS-LB. ### Summary Box: Myelodysplastic syndromes renamed myelodysplastic neoplasms (abbreviated MDS).MDS genetic types updated to include MDS-5q, MDS-SF3B1 and",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:65"
    }
  },
  {
    "page_content": "types updated to include MDS-5q, MDS-SF3B1 and MDS-biTP53Hypoplastic MDS (MDS-h) is recognized as a distinct disease type.MDS with low blasts (MDS-LB) is a new term that enhances clarity.MDS with increased blasts (MDS-IB) is a new term that enhances clarity.Terminology of childhood MDS types is updated. # Myelodysplastic/myeloproliferative neoplasms This category of myeloid neoplasms is defined by overlapping pathologic and molecular features of MDS and MPN, often manifesting clinically with",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:66"
    }
  },
  {
    "page_content": "of MDS and MPN, often manifesting clinically with various combinations of cytopenias and cytoses. The definition of cytopenias is the same as that for MDS. The classification includes major revisions in the diagnostic criteria of CMML and terminology changes for other MDS/MPN types. (Table 5) ## Chronic myelomonocytic leukaemia diagnostic criteria, subtypes, and blast-based subgrouping criteria reflect diagnostic refinement and emphasize unifying characteristics The prototype and most common",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:67"
    }
  },
  {
    "page_content": "characteristics The prototype and most common MDS/MPN is chronic myelomonocytic leukaemia (CMML), which is characterized by sustained peripheral blood monocytosis and various combinations of somatic mutations involving epigenetic regulation, spliceosome, and signal transduction genes. Diagnostic criteria are revised to include prerequisite and supporting criteria. (Table 6) The first prerequisite criterion is persistent absolute (≥0.5 × 109/ L) and relative (≥10%) peripheral blood monocytosis.",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:68"
    }
  },
  {
    "page_content": "and relative (≥10%) peripheral blood monocytosis. Namely, the cutoff for absolute monocytosis is lowered from 1.0 ×109/L to 0.5 ×109/L to incorporate cases formerly referred to as oligomonocytic CMML [45–47]. To enhance diagnostic accuracy when absolute monocytosis is ≥0.5 ×109/L but <1.0 ×109/L, detection of one of more clonal cytogenetic or molecular abnormality and documentation of dysplasia in at least one lineage are required. Abnormal partitioning of peripheral blood monocyte subsets is",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:69"
    }
  },
  {
    "page_content": "of peripheral blood monocyte subsets is introduced as a new supporting criterion. Additional studies are needed to determine the optimal approach to classifying individuals with unexplained clonal monocytosis who do not fit the new diagnostic criteria of CMML. Two disease subtypes with salient clinical and genetic features are now formally recognized based on WBC: myelodysplastic CMML (MD-CMML) (WBC < 13 × 109/L) and myeloproliferative CMML (MP-CMML) (WBC ≥ 13 × 109/L). MP-CMML is commonly",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:70"
    }
  },
  {
    "page_content": "(MP-CMML) (WBC ≥ 13 × 109/L). MP-CMML is commonly associated with activating RAS pathway mutations and adverse clinical outcomes. The blast-based subgroup of CMML-0 (<2% blasts in blood and <5% blasts in bone marrow) introduced in the previous edition has been eliminated in view of evidence that its addition provides no or limited prognostic significance. ## Atypical chronic myeloid leukaemia is renamed MDS/MPN with neutrophilia, and other terminology updates Diagnostic criteria for other",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:71"
    }
  },
  {
    "page_content": "terminology updates Diagnostic criteria for other MDS/MPN types were largely unchanged. The term MDS/MPN with neutrophilia replaces the term atypical CML. This change underscores the MDS/MPN nature of the disease and avoids potential confusion with CML. MDS/MPN with ring sideroblasts and thrombocytosis is redefined based on SF3B1 mutation and renamed MDS/MPN with SF3B1 mutation and thrombocytosis. The term MDS/MPN with ring sideroblasts and thrombocytosis has been retained as an acceptable term",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:72"
    }
  },
  {
    "page_content": "has been retained as an acceptable term to be used for cases with wild-type SF3B1 and ≥15% ring sideroblasts. MDS/MPN, unclassifiable is now termed MDS/MPN, not otherwise specified; this is in line with an intentional effort to remove the paradoxical qualifier “unclassifiable” from the entire classification. ### Summary Box: CMML diagnostic criteria undergo major revisions, including lowering the cutoff for absolute monocytosis, adopting MD-CMML and MP-CMML subtypes, and eliminating",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:73"
    }
  },
  {
    "page_content": "MD-CMML and MP-CMML subtypes, and eliminating CMML-0.Atypical chronic myeloid leukaemia renamed MDS/MPN with neutrophilia.MDS/MPN with ring sideroblasts and thrombocytosis redefined based on SF3B1 mutation and renamed MDS/MPN with SF3B1 mutation and thrombocytosis. # Acute myeloid leukaemia ## Enhanced grouping framework permitting scalable genetic classification and deemphasizing blast enumeration where relevant The classification of AML is re-envisioned to emphasize major breakthroughs over",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:74"
    }
  },
  {
    "page_content": "to emphasize major breakthroughs over the past few years in how this disease is understood and managed. Foremost is the separation of AML with defining genetic abnormalities from AML defined by differentiation. (Table 7) The latter eliminates the previously confusing use of the term AML NOS, under which types based on differentiation were listed. Another key change, as indicated above, is the elimination of the 20% blast requirement for AML types with defining genetic abnormalities (with the",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:75"
    }
  },
  {
    "page_content": "with defining genetic abnormalities (with the exception of AML with BCR::ABL1 fusion and AML with CEBPA mutation). Removal of the blast cutoff requires correlation between morphologic findings and the molecular genetic studies to ensure that the defining abnormality is driving the disease pathology. This approach was deemed more appropriate than assigning another arbitrary lower bone marrow blast cutoff. A third component of the new structure is the introduction of a section on AML with other",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:76"
    }
  },
  {
    "page_content": "the introduction of a section on AML with other defined genetic alterations, a landing spot for new and/or uncommon AML subtypes that may (or may not) become defined types in future editions of the classification. As such, the overall AML classification structure continues to emphasize integration of clinical, molecular/genetic, and pathologic parameters and emphasis on clinicopathologic judgement. ## AML with defining genetic abnormalities While the classification retains much of the",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:77"
    }
  },
  {
    "page_content": "While the classification retains much of the established diagnostic criteria for AML with PML::RARA, AML with RUNX1::RUNX1T1, and AML with CBF::MYH11, increased recognition of the importance of highly sensitive measurable residual disease (MRD) evaluation techniques, and the impact of concurrent molecular alterations reflect factors that impact patient management and therapeutic decisions in current practice. Namely, prognostic factors have expanded from KIT mutations, which are still relevant,",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:78"
    }
  },
  {
    "page_content": "from KIT mutations, which are still relevant, to include additional cytogenetic features and MRD status post induction. The diagnostic criteria of AML with DEK::NUP214 and AML with RBM15::MRTFA (formerly RBM15::MKL1) have also remained largely unchanged. AML with BCR::ABL1 and AML with CEBPA mutation are the only disease types with a defined genetic abnormality that require at least 20% blasts for diagnosis. The blast cutoff requirement is needed for the former to avoid overlap with CML.",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:79"
    }
  },
  {
    "page_content": "needed for the former to avoid overlap with CML. Distinguishing AML with BCR::ABL1 from initial myeloid blast phase of CML can be challenging, and additional evidence continues to be needed to better characterize this AML type. There is insufficient data to support any change in the blast cutoff criterion for AML with CEBPA mutation. Three AML types with characteristic rearrangements involving KMT2A, MECOM, and NUP98 are recognized. A blast count under 20% is acceptable based on studies",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:80"
    }
  },
  {
    "page_content": "count under 20% is acceptable based on studies demonstrating that patients with <20% blasts (MDS) and any of these rearrangements have clinical features that resemble those with higher blast counts. It is important to note that rearrangements involving these three genes, particularly NUP98, may be cryptic on conventional karyotyping. AML with KMT2A rearrangement is the new term that replaces “AML with t(9;11)(p22;q23); KMT2A-MLLT3”. More than 80 KMT2A fusion partners have been described, with",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:81"
    }
  },
  {
    "page_content": "KMT2A fusion partners have been described, with MLLT3, AFDN, ELL, and MLLT10 being most common. While not required, the identification of the fusion partner is desirable since it could provide prognostic information and may impact disease monitoring. Adult patients often present with high blast counts, usually with monocytic differentiation. In children particularly, AML with KMT2A::MLLT3 and KMT2A::MLLT10 show megakaryoblastic differentiation and/or low blast counts in bone marrow aspirate",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:82"
    }
  },
  {
    "page_content": "and/or low blast counts in bone marrow aspirate smears. AML defined by mutations include AML with NPM1 and AML with CEBPA mutation. AML with NPM1 mutation can be diagnosed irrespective of the blast count, albeit again with emphasis on judicious clinicopathologic correlation. This approach aligns with data showing that cases previously classified as MDS or MDS/MPN with NPM1 progress to AML in a short period of time. Similar data have emerged from patients with CH who acquire NPM1 mutation. The",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:83"
    }
  },
  {
    "page_content": "patients with CH who acquire NPM1 mutation. The definition of AML with CEBPA mutation has changed to include biallelic (biCEBPA) as well as single mutations located in the basic leucine zipper (bZIP) region of the gene (smbZIP-CEBPA). The favourable prognosis associated with smbZIP-CEBPA has been demonstrated in cohorts of children and adults up to 70 years old. RUNX1 mutations in AML overlap with such a broad range of defining molecular features that it was determined to lack enough",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:84"
    }
  },
  {
    "page_content": "features that it was determined to lack enough specificity to define a standalone AML type. Several changes were introduced to the entity formerly designated AML with myelodysplasia-related changes, now called AML, myelodysplasia-related (AML-MR). This AML type is defined as a neoplasm with ≥20% blasts expressing a myeloid immunophenotype and harboring specific cytogenetic and molecular abnormalities associated with MDS, arising de novo or following a known history of MDS or MDS/MPN. Key",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:85"
    }
  },
  {
    "page_content": "following a known history of MDS or MDS/MPN. Key changes include: (1) removal of morphology alone as a diagnostic premise to make a diagnosis of AML-MR; (2) update of defining cytogenetic criteria; and, (3) introduction of a mutation-based definition based on a set of 8 genes – SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, STAG2, > 95% of which are present specifically in AML arising post MDS or MDS/MPN. The presence of one or more cytogenetic or molecular abnormalities listed in Table 8",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:86"
    }
  },
  {
    "page_content": "or molecular abnormalities listed in Table 8 and/or history of MDS or MDS/MPN are required for diagnosing AML-MR. AML with other defined genetic alterations represents a landing spot for new, often rare, emerging entities whose recognition is desirable to determine whether they might constitute distinct types in future editions. At present, subtypes under this heading include AML with rare genetic fusions. ## AML defined by differentiation This AML family includes cases that lack defining",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:87"
    }
  },
  {
    "page_content": "This AML family includes cases that lack defining genetic abnormalities. (Table 9) It is anticipated that the number of such cases will diminish as discoveries provide novel genetic contexts for their classification. Notwithstanding, categorizing AML cases lacking defining genetic abnormalities based on differentiation offers a longstanding classification paradigm with practical, prognostic, and perhaps therapeutic implications. The classification includes an updated comprehensive framework of",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:88"
    }
  },
  {
    "page_content": "includes an updated comprehensive framework of differentiation markers and criteria, harmonized with those of mixed-phenotype acute leukaemia (MPAL) and early T-precursor lymphoblastic leukaemia/lymphoma (ETP-ALL) (see section below on acute leukaemia of ambiguous lineage). Indeed, the recent identification of BCL11B rearrangements in MPAL T/Myeloid, ETP-ALL, acute leukaemia of ambiguous lineage (ALAL) and a subset of AML with minimal differentiation suggests a biologic continuum across these",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:89"
    }
  },
  {
    "page_content": "suggests a biologic continuum across these entities, a finding with likely implications on future editions of the classification [58–61]. Acute erythroid leukaemia (AEL) (previously pure erythroid leukaemia, an acceptable related term in this edition) is a distinct AML type characterized by neoplastic proliferation of erythroid cells with features of maturation arrest and high prevalence of biallelic TP53 alterations. Diagnostic criteria include erythroid predominance, usually ≥80% of bone",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:90"
    }
  },
  {
    "page_content": "erythroid predominance, usually ≥80% of bone marrow elements, of which ≥30% are proerythroblasts (or pronormoblasts). The occurrence of AEL cases in which nucleated erythroid cells constitute less than 80% of bone marrow cellularity is recognized; such cases share the same clinicopathologic features of other AEL. The central role that biallelic TP53 mutations play in this aggressive AML type is underscored. The diagnosis of AEL supersedes AML-MR. De novo AEL and cases that arise following MDS",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:91"
    }
  },
  {
    "page_content": "De novo AEL and cases that arise following MDS or MDS/MPN share distinctive morphologic features, with prominent proerythroblast proliferation. Proerythroblast have been shown to play an important role in treatment resistance and poor prognosis in AML patients. Several molecular drivers can give rise to acute megakaryoblastic leukaemia (AMKL), which arises within three clinical groups: children with Down syndrome, children without Down syndrome, and adults. Immunophenotyping and detection of",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:92"
    }
  },
  {
    "page_content": "and adults. Immunophenotyping and detection of markers of megakaryocytic differentiation are required to make a diagnosis of AMKL and detect the newly described “RAM immunophenotype”, which correlates with CBFA2T3::GLIS2, a subtype of AML with other defined genetic alterations. ## Myeloid sarcoma Myeloid sarcoma represents a unique tissue-based manifestation of AML or transformed MDS, MDS/MPN, or MPN. Cases of de novo myeloid sarcoma should be investigated comprehensively, including cytogenetic",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:93"
    }
  },
  {
    "page_content": "comprehensively, including cytogenetic and molecular studies, for appropriate classification and planning therapy. Molecular alterations in myeloid sarcoma and concurrent bone marrow disease are concordant in ~70% of patients, suggesting that myeloid sarcoma may be derived from a common haematopoietic stem cell or precursor. Relevant gene mutations are detected in a subset of patients with morphologically normal-appearing bone marrow, suggesting low-level clonal myeloid disease or CH in the",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:94"
    }
  },
  {
    "page_content": "low-level clonal myeloid disease or CH in the bone marrow. ### Summary Box: AML is arranged into two families: AML with defining genetic abnormalities and AML defined by differentiation. AML, NOS is no longer applicable.Most AML with defining genetic abnormalities may be diagnosed with <20% blasts.AML-MR replaces the former term AML “with myelodysplasia-related changes”, and its diagnostic criteria are updated. AML transformation of MDS and MDS/MPN continues to be defined under AML-MR in view",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:95"
    }
  },
  {
    "page_content": "continues to be defined under AML-MR in view of the broader unifying biologic features.AML with rare fusions are incorporated as subtypes under AML with other defined genetic alterations.AML with somatic RUNX1 mutation is not recognized as a distinct disease type due to lack of sufficient unifying characteristics. # Secondary myeloid neoplasms ## A newly segregated category encompassing diseases that arise in the setting of certain known predisposing factors Myeloid neoplasms that arise",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:96"
    }
  },
  {
    "page_content": "predisposing factors Myeloid neoplasms that arise secondary to exposure to cytotoxic therapy or germline predisposition are grouped in this category. AML transformation of MPN is retained in the MPN category, while AML transformation of MDS and MDS/MPN is kept under AML-MR (see above). The framework of this disease category was redesigned with an eye towards two important areas: (1) providing a scalable structure for incorporating novel discoveries in the area of germline predisposition to",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:97"
    }
  },
  {
    "page_content": "in the area of germline predisposition to myeloid neoplasia; (2) recognizing the dual importance of cataloguing myeloid neoplasms that arise following exposure to cytotoxic therapies for clinical purposes as well as population health purposes. The latter factor is gaining increased recognition as cancer survival is prolonged and the incidence of late complications of therapy such as secondary myeloid neoplasia increases. An overarching principle in this context is the requirement to consider",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:98"
    }
  },
  {
    "page_content": "in this context is the requirement to consider “post cytotoxic therapy” and “associated with germline [gene] variant” as disease attributes that should be added as qualifiers to relevant myeloid disease types whose criteria are fulfilled as defined elsewhere in the classification, e.g. AML with KMT2A rearrangement post cytotoxic therapy or MDS with low blasts associated with germline RUNX1 variant. ## Myeloid neoplasms post cytotoxic therapy: introduction of more precise terminology and novel",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:99"
    }
  },
  {
    "page_content": "of more precise terminology and novel associations with new cytotoxic drug classes As in previous editions, this category includes AML, MDS, and MDS/MPN arising in patients exposed to cytotoxic (DNA-damaging) therapy for an unrelated condition. The terminology and definitions of this disease category have been modified slightly to reflect an improved understanding of the risk that CH plays as a risk factor for myeloid neoplasia related particularly to the expansion of pre-existing clones",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:100"
    }
  },
  {
    "page_content": "to the expansion of pre-existing clones secondary to selection pressures of cytotoxic therapy agents in an altered marrow environment. Thus, the diagnosis of myeloid neoplasms post cytotoxic therapy (MN-pCT) entails fulfilment of criteria for a myeloid neoplasm in addition to a documented history of chemotherapy treatment or large-field radiation therapy for an unrelated neoplasm. This would exclude CCUS, which by definition lacks sufficient support for morphologic dysplasia. Cases with a ‘de",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:101"
    }
  },
  {
    "page_content": "for morphologic dysplasia. Cases with a ‘de novo molecular signature’ such as NPM1 mutation and core-binding factor leukaemias should still be assigned to this category since the “post cytotoxic therapy” designation is based on the medical history, and the indication of the most specific diagnosis in the pathology report is recommended when possible. Exposure to PARP1 inhibitors is added as a qualifying criterion for MN-pCT, and methotrexate has been excluded. It is recommended that",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:102"
    }
  },
  {
    "page_content": "has been excluded. It is recommended that specification of the type of myeloid neoplasm is made when possible, with the appendix “post cytotoxic therapy” appended, e.g. CMML post cytotoxic therapy. The majority of AML-pCT and MDS-pCT are associated with TP53 mutations. The outcomes of such patients are generally worse with biallelic (multi-hit) TP53 alterations, manifesting as ≥2 TP53 mutations, or with concomitant 17p/TP53 deletion or copy neutral LOH. Less frequent mutations involve genes",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:103"
    }
  },
  {
    "page_content": "LOH. Less frequent mutations involve genes such as PPM1D and DNA-damage response genes that may require additional work-up for germline predisposition. ## Myeloid neoplasms associated with germline predisposition: A novel scalable model is introduced Myeloid neoplasms associated with germline predisposition include AML, MDS, MPN, and MDS/MPN that arise in individuals with genetic conditions associated with increased risk of myeloid malignancies. Myeloid neoplasms arising in individuals with",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:104"
    }
  },
  {
    "page_content": "Myeloid neoplasms arising in individuals with Fanconi anemia, Down syndrome, and RASopathies are discussed in separate dedicated sections. These diseases are now classified using a formulaic approach that couples the myeloid disease phenotype with the predisposing germline genotype, e.g., AML with germline pathogenic variants in RUNX1. The clinical manifestations of these diseases are grouped into three subtypes under which most germline predisposition conditions can be assigned. (Table 10)",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:105"
    }
  },
  {
    "page_content": "conditions can be assigned. (Table 10) Genetic counseling and evaluation of family history is an expected component of the diagnostic evaluation of index patients. Myeloid proliferations associated with Down syndrome, typically associated with somatic exon 2 or 3 GATA1 mutation, continue to encompass two clonal conditions that arise in children with constitutional trisomy 21: transient abnormal myelopoiesis (TAM), which is confined to the first 6 months of life and myeloid leukaemia of Down",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:106"
    }
  },
  {
    "page_content": "6 months of life and myeloid leukaemia of Down syndrome (ML-DS). ### Summary Box: Myeloid neoplasms (MDS, MDS/MPN, and AML) post cytotoxic therapy (MN-pCT) require full diagnostic work up; the term replaces therapy-related.Exposure to PARP1 inhibitors is added as a qualifying criterion for MN-pCT.The diagnostic framework for myeloid neoplasm associated with germline predisposition is restructured along a scalable model that can accommodate future refinement and discoveries. # Myeloid/lymphoid",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:107"
    }
  },
  {
    "page_content": "refinement and discoveries. # Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (MLN-TK) are myeloid or lymphoid neoplasms driven by rearrangements involving genes encoding specific tyrosine kinases leading to fusion products in which the kinase domain is constitutively activated leading to cell signaling dysregulation that promotes proliferation and survival. (Table 11) These",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:108"
    }
  },
  {
    "page_content": "proliferation and survival. (Table 11) These BCR::ABL1-negative diseases have long been recognized in view of their distinctive clinicopathologic features and sensitivity to TKI. They encompass a broad range of histologic types, including MPN, MDS, MDS/MPN, AML, and MPAL, as well as B- or T- lymphoblastic leukaemia/lymphoma (ALL). Extramedullary disease is common. While eosinophilia is a common and salient feature, it may be absent in some cases. From a diagnostic hierarchy standpoint, the",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:109"
    }
  },
  {
    "page_content": "From a diagnostic hierarchy standpoint, the diagnosis of MLN-TK supersedes other myeloid and lymphoid types, as well as SM. In some instances, defining genetic abnormalities of MLN-TK are acquired during course of a myeloid neoplasm such as MDS or MDS/MPN or at the time of MPN BP transformation. MLN-TK must be excluded before a diagnosis of CEL is rendered. The majority of MLN-TK cases associated with PDGFRA rearrangements have cytogenetically cryptic deletion of 4q12 resulting in",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:110"
    }
  },
  {
    "page_content": "cryptic deletion of 4q12 resulting in FIP1L1::PDGFRA, but PDGFRA fusions involving other partners are also identified. Cases with PDGFRB rearrangement result most commonly from t(5;12)(q32;p13.2) leading to ETV6::PDGFRB; however, more than 30 other partners have been identified. Cases with FGFR1 rearrangement may manifest as chronic myeloid neoplasms or blast-phase disease of B-cell, T-cell, myeloid or mixed-phenotype origin, typically with associated eosinophilia. The characteristic",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:111"
    }
  },
  {
    "page_content": "with associated eosinophilia. The characteristic cytogenetic feature is an aberration of chromosome 8p11. Detection of JAK2 rearrangements leading to fusion products with genes other than PCM1 have been recognized, supporting MLN-TK with JAK2 rearrangement as a distinct type. Cases with FLT3 fusion genes are particularly rare and result from rearrangements involving chromosome 13q12.2. They manifest as myeloid sarcoma with MPN features in the bone marrow or T-ALL with associated eosinophilia,",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:112"
    }
  },
  {
    "page_content": "marrow or T-ALL with associated eosinophilia, but disease features and phenotypic presentation may be variable and diverse. MLN-TK with ETV6::ABL1 should be separated from B-ALL with ETV6::ABL1. The natural history of MLN-TK with PDGFRA or PDGFRB has been dramatically altered by TKI therapy, particularly imatinib. In contrast, patients with FGFR1, JAK2 and FLT3 fusions and ETV6::ABL1 have more variable sensitivity to available newer generation TKIs; in most cases, long-term disease-free",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:113"
    }
  },
  {
    "page_content": "TKIs; in most cases, long-term disease-free survival may only be achievable with allogeneic haematopoietic stem cell transplantation. Other less common defined genetic alterations involving tyrosine kinase genes have also been discovered, and these are listed as MLN-TK subtypes under MLN-TK with other defined tyrosine kinase fusions until further data is accrued. ## Summary Box: Family renamed myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (MLN-TK).Recognition of",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:114"
    }
  },
  {
    "page_content": "kinase gene fusions (MLN-TK).Recognition of novel types with JAK2 rearrangements, FLT3 rearrangements, and ETV6::ABL1 fusion.New scalable genetic framework introduced under MLN-TK with other defined tyrosine kinase fusions. # Acute leukaemias of mixed or ambiguous lineage Acute leukemia of ambiguous lineage (ALAL) and mixed-phenotype acute leukaemia (MPAL) are grouped under a single category in view of their overlapping clinical and immunophenotypic features, which in recent studies have been",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:115"
    }
  },
  {
    "page_content": "features, which in recent studies have been shown to also share common molecular pathogenic mechanisms. Here too, a framework for a molecular classification is laid by separating ALAL/MPAL with defining genetic abnormalities from those that are defined based on immunophenotyping only. (Table 12) Two new subtypes of ALAL with defining genetic alterations are added. The first subtype is MPAL with ZNF384 rearrangement, which commonly has a B/myeloid immunophenotype and is identified in ~50% of",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:116"
    }
  },
  {
    "page_content": "immunophenotype and is identified in ~50% of pediatric B/myeloid MPAL with fusion partners including TCF3, EP300, TAF15, and CREBBP. ZNF384-rearranged B/myeloid MPAL and B-ALL have similar transcriptional profile, suggesting a biological continuum. The other subtype is ALAL with BCL11B rearrangement, which has a more heterogenous immunophenotype - identified in acute undifferentiated leukaemia (AUL) and ~20-30% of T/myeloid MPAL. BCL11B rearrangement is also identified in AML with minimal",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:117"
    }
  },
  {
    "page_content": "is also identified in AML with minimal differentiation or without maturation and ~20-30% of ETP-ALL. [59–61, 80] These different types of acute leukaemias with stem cell, myeloid, and T-ALL features having BCL11B rearrangement in common suggests a biological continuum. Other genomic findings such as PHF6 mutations and PICALM::MLLT10 fusions are also enriched in MPAL, but more studies are needed. The assignment of lineage by immunophenotyping is dependent on the strength of association between",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:118"
    }
  },
  {
    "page_content": "dependent on the strength of association between each antigen and the lineage being assessed. As a general principle, the closer the expression of an antigen is to either the intensity and/or pattern of expression seen on the most similar normal population, the more likely it reflects commitment to that lineage. For instance, variable myeloperoxidase expression with an intensity and pattern similar to that seen in early myeloid maturation is more strongly associated with myeloid lineage than",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:119"
    }
  },
  {
    "page_content": "strongly associated with myeloid lineage than uniform dim myeloperoxidase expression. In addition, demonstration of a coordinated pattern of expression of multiple antigens from the same lineage further improves the specificity of those antigens for lineage assignment, e.g. combined expression of CD19, CD22, and CD10 is more strongly associated with B lineage than each antigen individually. Given these principles, the immunophenotypic criteria to be used for lineage assignment in cases where a",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:120"
    }
  },
  {
    "page_content": "be used for lineage assignment in cases where a single lineage is not evident are revised. (Table 13) Assessment of myeloperoxidase expression by cytochemistry and/or flow cytometry immunophenotyping plays a key role intersecting AML with minimal differentiation, T/myeloid MPAL, and ETP-ALL. Various groups have proposed flow cytometry thresholds for positive myeloperoxidase expression in acute leukaemia, ranging from 3 to 28% of blasts [81–83]. The 3% cutoff for myeloperoxidase, historically",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:121"
    }
  },
  {
    "page_content": "The 3% cutoff for myeloperoxidase, historically used for cytochemistry, was determined to have high sensitivity but poor specificity for general lineage assignment in acute leukaemia by flow cytometry. A threshold of >10% for myeloperoxidase positivity seems to improve specificity, but no consensus cutoff has been established. ## Summary Box: Acute leukaemias of mixed or ambiguous lineage are arranged into two families: ALAL with defining genetic abnormalities and ALAL, immunophenotypically",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:122"
    }
  },
  {
    "page_content": "abnormalities and ALAL, immunophenotypically defined.Novel genetic findings are listed as subtypes under ALAL with other defined genetic alterations as additional data accrues.Lineage assignment criteria for MPAL are refined to emphasize principles of intensity and pattern. # Histiocytic/dendritic cell neoplasms These neoplasms are positioned in the classification after myeloid neoplasms in recognition of their derivation from common myeloid progenitors that give rise to cells of the",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:123"
    }
  },
  {
    "page_content": "progenitors that give rise to cells of the monocytic/histiocytic/dendritic lineages. (Table 14) Key changes in the current edition of the classification include: (1) inclusion of clonal plasmacytoid dendritic cell (pDC) diseases in this category; (2) moving follicular dendritic cell sarcoma and fibroblastic reticular cell tumor to a separate category; and, (3) addition of Rosai-Dorfman disease (RDD) and ALK-positive histiocytosis as disease types. Indeed, neoplasms that arise from lymphoid",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:124"
    }
  },
  {
    "page_content": "types. Indeed, neoplasms that arise from lymphoid stromal cells such as follicular dendritic cell sarcoma and fibroblastic reticular cell tumor are now appropriately classified under the new chapter of “stroma-derived neoplasms of lymphoid tissues” as detailed in the companion manuscript. ## Plasmacytoid dendritic cell neoplasms: recognition of clonal proliferations detected in association with myeloid neoplasms and refinement/update of the diagnostic criteria for blastic plasmacytoid dendritic",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:125"
    }
  },
  {
    "page_content": "criteria for blastic plasmacytoid dendritic cell neoplasm Mature plasmacytoid dendritic cell proliferation (MPDCP) associated with myeloid neoplasm reflects recent data showing that these represent clonal proliferation of pDCs with low grade morphology identified in the context of a defined myeloid neoplasm. Clonal MPDCP cells accumulate in the bone marrow of patients with myeloproliferative CMML harbouring activating RAS pathway mutations. Patients with AML can have clonally expanded pDCs",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:126"
    }
  },
  {
    "page_content": "Patients with AML can have clonally expanded pDCs (pDC-AML), which share the same mutational landscape as CD34+ blasts, and frequently arise in association with RUNX1 mutations. It is unknown whether the pathogenetic mechanisms leading to MPDCP in association with MDS or MDS/MPN and with AML are the same. The framework for diagnosing blastic plasmacytoid dendritic cell neoplasm remains largely the same, with emphasis on immunophenotypic diagnostic criteria. (Table 15) ## Dendritic and",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:127"
    }
  },
  {
    "page_content": "diagnostic criteria. (Table 15) ## Dendritic and histiocytic neoplasms: Rosai-Dorfman disease and ALK-positive histiocytosis are new entities in the classification Much has been learned about the molecular genetics of histiocytoses/histiocytic neoplasms in recent years. These neoplasms, in particular Langerhans cell histiocytosis/sarcoma, Erdheim-Chester disease, juvenile xanthogranuloma, RDD and histiocytic sarcoma, commonly show mutations in genes of the MAPK pathway, such as BRAF, ARAF,",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:128"
    }
  },
  {
    "page_content": "in genes of the MAPK pathway, such as BRAF, ARAF, MAP2K1, NRAS and KRAS, albeit with highly variable frequencies, indicating a unifying genetic landscape for diverse histiocytoses and histiocytic neoplasms. ALK-positive histiocytosis furthermore converges on the MAPK pathway, which is one of the signaling pathways mediating ALK activation. Insights on genetic alterations have significant treatment implications, because of availability of highly effective therapy targeting components of the",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:129"
    }
  },
  {
    "page_content": "effective therapy targeting components of the activated signaling pathway, such as BRAF and MEK inhibitors [88–92]. For RDD, the distinctive clinicopathologic features with accumulation of characteristic S100-positive large histiocytes showing emperipolesis, coupled with frequent gain-of-function mutations in genes of the MAPK pathway indicating a neoplastic process, provides a rationale for this inclusion and offers opportunities for targeted therapy [92–95]. ALK-positive histiocytosis, which",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:130"
    }
  },
  {
    "page_content": "[92–95]. ALK-positive histiocytosis, which shows a broad clinicopathologic spectrum unified by the presence of ALK gene translocation (most commonly KIF5B::ALK) and remarkable response to ALK-inhibitor therapy, has been better characterized in recent studies. The multisystem systemic form that typically occurs in infants, with involvement of liver, spleen and/or bone marrow, runs a protracted course but often resolves slowly, either spontaneously or with chemotherapy. Other multisystem and",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:131"
    }
  },
  {
    "page_content": "or with chemotherapy. Other multisystem and single-system cases occur in any age group, with involvement of two or more organs or one organ alone, respectively, most commonly central/peripheral nervous system and skin; the disease has a favourable outcome with systemic and/or surgical therapy. The histiocytes in ALK-positive histiocytosis can assume variable appearances including large oval cells, foamy cells and spindle cells, some with multinucleation (including Touton giant cells) or",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:132"
    }
  },
  {
    "page_content": "multinucleation (including Touton giant cells) or emperipolesis. That is, morphology is not entirely diagnostic, and overlaps extensively with that of juvenile xanthogranuloma and rarely RDD. Thus, it is recommended that ALK immunostaining be performed for histiocytic proliferations not conforming to defined entities, to screen for possible ALK-positive histiocytosis. In most circumstances, classification of a dendritic cell/macrophage neoplasm as Langerhans cell histiocytosis/sarcoma,",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:133"
    }
  },
  {
    "page_content": "as Langerhans cell histiocytosis/sarcoma, indeterminate dendritic cell tumor, interdigitating dendritic cell sarcoma or histiocytic sarcoma is straightforward. Nonetheless, there are rare cases that show overlap or hybrid features, defying precise classification. Among histiocytic neoplasms, a subset of cases occurs in association with or follow a preceding lymphoma/leukaemia, most commonly follicular lymphoma, chronic lymphocytic leukaemia and T- or B-ALL. Since these histiocytic neoplasms",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:134"
    }
  },
  {
    "page_content": "T- or B-ALL. Since these histiocytic neoplasms usually exhibit the same clonal markers and/or hallmark genetic changes as the associated lymphoma/leukaemia, a “transdifferentiation” mechanism has been proposed to explain the phenomenon [99–101]. Furthermore, the histiocytic neoplasm and associated lymphoma/leukaemia often show additional genetic alterations exclusive to each component, suggesting that divergent differentiation or transdifferentiation occurs from a common lymphoid progenitor",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:135"
    }
  },
  {
    "page_content": "occurs from a common lymphoid progenitor clone. Histiocytoses are also sometimes associated with myeloproliferative neoplasms, sharing mutations with CD34+ myeloid progenitors, and with CH. ### Summary Box: Histiocytic/dendritic cell neoplasms are regrouped and positioned to follow myeloid neoplasms in the classification scheme in view of their close ontogenic derivation.Mature pDC proliferation is redefined with an emphasis on recent data demonstrating shared clonality with underlying myeloid",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:136"
    }
  },
  {
    "page_content": "shared clonality with underlying myeloid neoplasms. This framework is bound to evolve in future editions.Diagnostic criteria of BPDCN are refined.ALK-positive histiocytosis is introduced as a new entity. # Genetic tumor syndromes with predisposition to myeloid neoplasia Fanconi anaemia is a heterogeneous disorder caused by germline variants in the BRCA-Fanconi DNA repair pathway (≥21 genes) resulting in chromosomal breakage and hypersensitivity to crosslinking agents used for diagnosis.",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:137"
    }
  },
  {
    "page_content": "to crosslinking agents used for diagnosis. Clinical features include congenital anomalies, bone marrow failure, and cancer predisposition. The new classification distinguishes 5 haematologic categories depending on blast percentage, cytopenia and chromosomal abnormalities. Dysgranulopoiesis and dysmegakaryopoiesis are histologic indicators of progression. Allogenic haematopoietic stem cell transplantation is efficacious. The term RASopathies encompasses a diverse group of complex, multi-system",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:138"
    }
  },
  {
    "page_content": "a diverse group of complex, multi-system disorders associated with variants in genes involved in the RAS mitogen-activating protein kinase (MAPK) pathway. Myeloid neoplasms in RASopathies involve MAPK hyperactivation, leading to myeloid cell proliferation. Genomic analysis of NF1, NRAS, KRAS, PTPN11, and CBL from myeloid neoplasms of patients suspected of having a RASopathy is important and aids in the diagnosis of JMML in the majority of cases. Diagnostic criteria include pathogenic variants",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:139"
    }
  },
  {
    "page_content": "Diagnostic criteria include pathogenic variants in genes associated with the RAS pathway and/or classic phenotype suggestive of a RASopathy. # Disclaimer The content of this article represents the personal views of the authors and does not represent the views of the authors’ employers and associated institutions. This work is intended to provide a preview and summary of content whose copyright belongs solely to the International Agency for Research on Cancer/World Health Organization. Any or",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:140"
    }
  },
  {
    "page_content": "on Cancer/World Health Organization. Any or all portions of the material in this work may appear in future International Agency for Research on Cancer/World Health Organization publications. # Supplementary information Table S1",
    "metadata": {
      "source": "../data/plain/PMC9252913.plain.txt",
      "id": "../data/plain/PMC9252913.plain.txt:141"
    }
  },
  {
    "page_content": "Tumor-Infiltrating Lymphocytes and Neutrophils and Their Location in Canine Mammary Neoplasms with a Solid Arrangement: A Prognostic Factor? Simple Summary",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:0"
    }
  },
  {
    "page_content": "Mammary neoplasms are the most common tumors in female dogs, and mammary neoplasms with a solid arrangement encompass histological types with high proliferative activity that commonly lead to metastasis. In human breast tumors, in addition to the histological type, the characterization of the inflammatory infiltrate and its location are considered prognostic and predictive factors. In veterinary medicine, little is still known about the influence of inflammation on cancer progression and its",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:1"
    }
  },
  {
    "page_content": "of inflammation on cancer progression and its relationship with histological types. In the present study, we observed that neoplasms with a solid arrangement presenting with a high density of lymphocytes and neutrophils, especially in the intratumoral area, are associated with shorter survival time, and that the density of intratumoral B lymphocytes is proportional to the presence of lymph node metastasis. Therefore, tumor inflammation should be considered as a factor influencing the",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:2"
    }
  },
  {
    "page_content": "should be considered as a factor influencing the progression of mammary neoplasms in female dogs. Abstract",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:3"
    }
  },
  {
    "page_content": "In canine mammary neoplasms, greater inflammation is associated with higher histological grade, lymphatic invasion, and metastases. This retrospective study assessed the density of peri- and intratumoral tumor-infiltrating lymphocytes (TILs), tumor-associated neutrophils (TANs), and CD3+ and CD79+ lymphocytes in canine mammary neoplasms with a solid arrangement, and associated such data with histological types, immunophenotype, prognostic factors, cyclooxygenase-2 (Cox-2) expression and overall",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:4"
    }
  },
  {
    "page_content": "cyclooxygenase-2 (Cox-2) expression and overall and cancer-specific survival. Sixty-one neoplasms with a solid arrangement were classified as malignant myoepitheliomas (6/9.8%), solid papillary carcinomas (8/13.1%), carcinomas with a solid pattern (9/14.8%), basaloid carcinomas (BC) (19/31.1%), and malignant adenomyoepitheliomas (19/31.1%). Intra- and peritumoral TILs, TANs, and TCD3+ and BCD79+ lymphocytes were counted, and based on the resulting median, the neoplasms were divided into low or",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:5"
    }
  },
  {
    "page_content": "median, the neoplasms were divided into low or high cell infiltration. BCs had the lowest density of intratumoral TILs (p = 0.02), and luminal B neoplasms showed a significantly higher density of intratumoral TCD3+ than luminal A cases. Neoplasms with a higher density of peritumoral CD3+ and CD79+ had significantly greater proliferative activity. High infiltration of intratumoral BCD79+ lymphocytes was related to nodal metastasis (p = 0.03). Intratumoral TILs and TCD3+ were associated with",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:6"
    }
  },
  {
    "page_content": "Intratumoral TILs and TCD3+ were associated with shorter survival time. Therefore, intratumoral lymphocyte infiltration is possibly an important feature in the progression of cancer and influences the survival in bitches with solid arrangement neoplasms. # 1. Introduction The characterization of tumor microenvironment through the evaluation of infiltrating leukocytes is already established for some types of neoplasms in the human species, such as colorectal carcinomas, oral and cutaneous",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:7"
    }
  },
  {
    "page_content": "such as colorectal carcinomas, oral and cutaneous squamous cell tumors, renal, head and neck, hepatocellular, pancreatic tumors, and mammary and urothelial bladder cell tumors. The presence of tumor-infiltrating lymphocytes (TILs) and their subtypes is associated with morphological (histological grade, size, pleomorphism, and mitotic count) and immunophenotypic characteristics of breast tumors. Thus, TILs are considered prognostic and predictive factors in women’s breast cancers. In women, TILs",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:8"
    }
  },
  {
    "page_content": "factors in women’s breast cancers. In women, TILs tend to be present in a greater proportion in neoplasms without the expression of hormone receptors and show an overexpression of HER-2 and a higher percentage of Ki-67. Also, greater inflammation in triple-negative neoplasms (TN) and tumors with HER-2 overexpression, especially in the intratumoral area, is associated with a better response to chemotherapy treatment. In female dogs, the highest intensity of TILs is observed in higher histologic",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:9"
    }
  },
  {
    "page_content": "of TILs is observed in higher histologic grade neoplasms, with lymphatic invasion and shorter survival time, a characteristic that is considered an independent prognostic factor. In addition, the highest percentage of B cells (CD79+) was seen in carcinoma in mixed tumors with metastasis to lymph nodes when compared to carcinoma in mixed tumors without metastasis to lymph nodes. However, little is known about the influence of inflammation and the relationship of inflammation and immunophenotypes",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:10"
    }
  },
  {
    "page_content": "relationship of inflammation and immunophenotypes in mammary neoplasms in female dogs. No relationship was found between TIL and molecular subtypes in one study, but in another, the peritumoral inflammation was shown as an independent prognostic factor for bitches with triple-negative tumors. Few studies approach tumor-associated neutrophils (TANs) in women breast cancer, and most of those studies are conducted in vitro and in animal models. Similarly to lymphocytes, neutrophils may be",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:11"
    }
  },
  {
    "page_content": "Similarly to lymphocytes, neutrophils may be associated with a longer or shorter survival time, depending on the type of cytokine or receptors present in the microenvironment,. Estrogen receptor-positive neoplasms, in advanced stages, show an increase in the amount of TGF-ß in the microenvironment, favoring the chemotaxis and polarization of N2 neutrophils, which favor neoplastic dissemination and pre-metastatic niche formation. In the few studies involving women, the increase in the average",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:12"
    }
  },
  {
    "page_content": "involving women, the increase in the average amount of neutrophils is associated with TN- and HER-2-positive tumors, and a high density of TANs is associated with shorter disease-free time. In bitches, the amount of neutrophils was higher in carcinoma in mixed tumors and tubular carcinomas compared to solid carcinomas and benign mixed tumors. Although the quantification of TILs in H&E slides is an important parameter and is associated with prognostic and predictive factors in breast cancer in",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:13"
    }
  },
  {
    "page_content": "and predictive factors in breast cancer in women, it is not enough to identify lymphocyte subtypes, which are fundamental for understanding the immune response to cancer. In the present study, we quantified tumor-infiltrating lymphocytes (TILs) and tumor-associated neutrophils (TANs) in the peri- and intratumoral areas, on H&E slides, and on slides with immunohistochemistry for CD3+ and CD79+ lymphocytes. Afterwards, we dichotomized high- and low-density inflammations to associate them with the",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:14"
    }
  },
  {
    "page_content": "inflammations to associate them with the histological types of neoplasms with a solid arrangement, immunophenotypes, prognostic factors (tumor size, regional lymph node metastasis, Ki-67 index, and mitotic count), Cox-2 immunostaining, and overall and specific survival time for bitches. # 2. Material and Methods ## 2.1. Selection and Classification of Samples and Clinical Follow-Up The criteria for sample selection, classification of neoplasms, and clinical follow-up of the animals were based",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:15"
    }
  },
  {
    "page_content": "and clinical follow-up of the animals were based on previous study, which included 65 samples. However, four samples were entirely used up in the first part of the research, and in the present article, 61 of these samples were used. The sixty-one canine mammary neoplasms with a solid arrangement, diagnosed between 2011 and 2022, were selected from the collections of the Comparative Pathology Laboratory at the Institute of Biological Sciences of the Federal University of Minas Gerais (UFMG), the",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:16"
    }
  },
  {
    "page_content": "Federal University of Minas Gerais (UFMG), the Pathology Laboratory of Vila Velha University (UVV), the Celulavet Laboratory, and the Center for Research in Mammary Oncology at the Federal University of Bahia (UFBA). Only samples from female dogs previously diagnosed with neoplasms classified as solid carcinoma or basaloid carcinoma, for which presented macroscopic description information of location and size of neoplasms was available and evaluation of regional lymph nodes was performed, were",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:17"
    }
  },
  {
    "page_content": "of regional lymph nodes was performed, were included. Female dogs presenting with other histological types of more aggressive mammary-origin neoplasms associated with shorter survival times, non-mammary malignant neoplasms, and those that had been treated prior to surgery were excluded from the study. From these criteria, histological slides stained by hematoxylin and eosin (H&E) were re-evaluated by two veterinary pathologists (GDC—board-certified by the Brazilian Association of Veterinary",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:18"
    }
  },
  {
    "page_content": "by the Brazilian Association of Veterinary Pathology, MCF—residency in Veterinary Pathology and Ph.D. in Pathology) and reclassified into carcinomas with a solid pattern (CSP), basaloid carcinomas (BC), solid papillary carcinomas (SPC), malignant adenomyoepitheliomas (MAME), and malignant myoepitheliomas (MME) based on morphological and phenotypic patterns (Figure S1). Neuroendocrine carcinomas were not evaluated in the present study due to the small number of samples. MAME may present benign",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:19"
    }
  },
  {
    "page_content": "small number of samples. MAME may present benign epithelial areas, making it difficult to assess its epithelial invasion area, and MM is composed of more than 90% myoepithelial tissue. Therefore, as these histological types do not fit the standardization of histological grading used for invasive carcinomas, grading was not evaluated in this study. In all 61 cases, the regional lymph nodes were also evaluated for the detection of metastasis. Information on neoplasm size was provided by the",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:20"
    }
  },
  {
    "page_content": "Information on neoplasm size was provided by the laboratory where the samples came from, and tumor size was stratified into T1 (< 3 cm), T2 (between 3 and 5 cm), and T3 (> 5 cm), following the TNM system. For neoplasms larger than T2, more than one histological slide was evaluated; the slide containing the best sample of approximately 2.0 cm with less necrosis and fixation and crushing artifacts was selected. As utilized in the grading system by Elston and Ellis, mitotic counting was performed",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:21"
    }
  },
  {
    "page_content": "Elston and Ellis, mitotic counting was performed in 10 fields (2.37 mm2) at the tumor periphery in continuous fields. As information on distant metastasis assessment was incomplete, the complete staging was not performed in the present study. The time in days from the date of surgery until the death of the dog from any cause and from neoplasia-related cause was calculated for overall survival and specific survival, respectively. Cause of death related to neoplasia means spontaneous death or",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:22"
    }
  },
  {
    "page_content": "related to neoplasia means spontaneous death or euthanasia due to local progression or systemic deterioration in animals with metastatic disease. The follow-up was carried out for a period of at least one year. Information was obtained from the responsible tutor and/or the veterinary clinician. ## 2.2. Immunohistochemistry Four-micrometer-thick sections were obtained from the paraffin blocks and placed on gelatinized slides, submitted to deparaffinization, dehydration in alcohol and xylol, and",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:23"
    }
  },
  {
    "page_content": "dehydration in alcohol and xylol, and manual staining for the markers following previously validated protocols. The antigenic recovery was performed in moist heat, within citrate pH 6.0. Novolink® kit solution (Leica) was used as the secondary antibody and detection system. Evaluations were performed under an Olympus BX-40 microscope coupled with a Spot Insight Color digital camera and with the aid of SPOT capture software version 3.4.5. In order to establish the immunophenotype of the",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:24"
    }
  },
  {
    "page_content": "In order to establish the immunophenotype of the neoplasms, immunohistochemistry was performed for estrogen (ER, ready-to-use, clone Ep1, Dako®) and progesterone (PR, 1:50, clone hpra2, Thermo Fisher®) receptors, cell proliferation factor Ki-67 (1:50, clone mib 1, Dako®), and epidermal growth factor 2 (HER-2, 1:200, clone c erb 2, Thermo Fisher®) in all selected samples. Immunolabeling for cyclooxygenase 2 (Cox-2, ready-to-use, clone Sp21, Invitrogen®) was also performed on 59 samples. The",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:25"
    }
  },
  {
    "page_content": "was also performed on 59 samples. The antibodies are well standardized for the technique used in the laboratory routine, and the antigenic specificity has already been tested, as shown in previous publications. Due to wear of the paraffin block during the study, two cases lacked enough material for this analysis. For the evaluation of ER and PR labeling, a scoring system considering the number of cells with positive nuclear labeling (negative: <1%, +: 1–25% of labeled cells; ++: 26–50% of",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:26"
    }
  },
  {
    "page_content": "<1%, +: 1–25% of labeled cells; ++: 26–50% of labeled cells, + ++: 51–75%; + +++: >75% of labeled cells) was adopted (Figures S2 and S3). Ki-67 was determined by the percentage of cells with nuclear staining in a count of 500 cells through photomicrographs made in a 40× (0.096 mm2) objective hot spot analyzed with Image J® imaging system, and the cutoff point ≥20% of labeled cells was used for classification as high and low proliferation (Figure S4). HER-2 expression followed the guidelines of",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:27"
    }
  },
  {
    "page_content": "S4). HER-2 expression followed the guidelines of membrane marking score, considering scores 0, 1+, and 2+ as negative and 3+ as positive (Figure S5). Then, the neoplasms were categorized into luminal A (ER and/or PR positive, HER2 negative, and Ki-67 <20%); luminal B HER2 negative (ER and/or PR positive, HER2 negative, and Ki-67 ≥20%), luminal B HER2 positive (ER and/or PR positive, HER2 positive, and any Ki-67), HER2 overexpressed (ER and PR negative, and HER2 positive), and triple negative",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:28"
    }
  },
  {
    "page_content": "negative, and HER2 positive), and triple negative (TN) (ER, PR, and HER2 negative). Normal mammary gland was used as positive control, while a buffer solution was used as negative control instead of the primary antibody. The Cox-2 assessment was based on a semi-quantitative evaluation of labeled tumor cells in the cytoplasm. Percentage of labeled tumor cells throughout the evaluated fragment (0= absent, 1= less than 10% of cells labeled, 2= 10 to 30% of cells labeled, 3= 31 to 60% of cells",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:29"
    }
  },
  {
    "page_content": "10 to 30% of cells labeled, 3= 31 to 60% of cells labeled, 4= more than 61% of cells labeled) and intensity score (0= absent, 1= weak (+) labeling, 2= moderate (++) labeling, and 3= strong (+ ++) labeling) were defined. The final score is established by multiplying the distribution by intensity (Figure S6). Anti-CD3 (1:200, Dako®, A052) antibodies were used for the identification of T cells, while anti-CD79 antibodies were used (1:400, Biolegend®, HM47) for the identification of B cells. Normal",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:30"
    }
  },
  {
    "page_content": "HM47) for the identification of B cells. Normal dog lymph nodes were used as positive and negative controls. A buffer solution was used for negative control instead of the primary antibody. The negative control was prepared following the same technique described in the determination of immunophenotypes. ## 2.3. Characterization of the Infiltrate in Histological Slides and Immunohistochemistry Images of eight hot spots at 600× (60× objective and 10× ocular) were captured from the H&E slides and",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:31"
    }
  },
  {
    "page_content": "10× ocular) were captured from the H&E slides and contained a fragment of each neoplasm for quantification of TILs and TANs in the peri- and intratumoral areas, separately. The 600× magnification (0.087 mm2) provides better definition of the cell types. Hot spot stands for the field of the fragment that presents a higher concentration of inflammatory cells. For the quantification of T and B cells labeled for CD3+ and CD79+, images of eight hot spots were captured at 400× (0.196 mm2), following",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:32"
    }
  },
  {
    "page_content": "were captured at 400× (0.196 mm2), following the same capture methodology made on the H&E slides. Photomicrographs were taken by a Spot Insight Color digital camera adapted on the Olympus BX-40 microscope with the aid of SPOT capture software version 3.4.5. The identification of inflammatory cells (neutrophils and lymphocytes) on the histological slides was based on the morphological aspect of each cell. In the slides submitted to immunolabeling, lymphocytes were positive when the label was",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:33"
    }
  },
  {
    "page_content": "lymphocytes were positive when the label was identified in the cytoplasm in a diffuse or granular way (nuclear labeling was not considered). Inflammatory cells (lymphocytes, their subtypes, and neutrophils) were counted separately in the peritumoral area (in the capsule or connective tissue around the neoplasm) and intratumoral area (in the stroma between the neoplastic lobes and in direct contact with the tumor cells) in the eight photographed hot spots of each sample. Finally, the number of",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:34"
    }
  },
  {
    "page_content": "hot spots of each sample. Finally, the number of each type of inflammatory cell, in the respective areas, was summed separately for each neoplasm, and the cutoff point to characterize how high and low density of inflammatory infiltrate was based on the median value of each cell in the study population. From the total number of cells, neutrophil/lymphocyte (N/L) and CD79+/CD3+ lymphocyte ratios were calculated, and the median also served as a cutoff point to separate the samples with high and",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:35"
    }
  },
  {
    "page_content": "point to separate the samples with high and low expression of inflammatory cells. All procedures performed in the present study followed the ethical principles for the use of animals in experimentation. The project was approved by the ethics committee on the use of animals (CEUA-UFMG, no. 11/2017). ## 2.4. Statistics GraphPad Prism software version 8.2 was used for the statistical analysis. Continuous variables (mitotic count and Ki-67 expression) had their normality verified by the",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:36"
    }
  },
  {
    "page_content": "expression) had their normality verified by the Kolmogorov–Smirnov’s test, and the association with the density of inflammatory infiltrate was made by the Mann–Whitney test. For comparison of inflammatory cell infiltrate between different areas on the same tumor, the Wilcoxon test was chosen. Fisher’s exact test was used to analyze the association between qualitative variables (histological types, immunophenotypes, tumor size, presence of lymph node metastasis, and Cox-2 expression) and",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:37"
    }
  },
  {
    "page_content": "lymph node metastasis, and Cox-2 expression) and intensity of inflammation. In all cases, p < 0.05 was considered significant. The analysis of overall and specific survival was made by Kaplan–Meier curves and the long-rank test provided the comparison between curves. For the analysis of survival in relation to inflammatory density, the density of each cell type (high and low) was compared between peritumoral and intratumoral areas. Survival was also associated with N/L and CD3+/CD79+ lymphocyte",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:38"
    }
  },
  {
    "page_content": "associated with N/L and CD3+/CD79+ lymphocyte ratios. The Cox regression model was performed in Jamovi version 2.3.28 for univariate and multivariate analysis, considering variables whose significance was previously established in the survival test by Kaplan–Meier. # 3. Results Sixty-one neoplasms with a solid arrangement were analyzed: six (9.8%) malignant myoepitheliomas, eight (13.1%) solid papillary carcinomas, nine (14.8%) carcinomas with a solid pattern, nineteen (31.1%) basaloid",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:39"
    }
  },
  {
    "page_content": "with a solid pattern, nineteen (31.1%) basaloid carcinomas, and nineteen (31.1%) malignant adenomyoepitheliomas. As for immunophenotypes, 13 neoplasms (21.3%) were luminal A, 42 (68.9%) were luminal B HER-2 negative, and 6 (9.8%) were luminal B HER-2 positive. None of the neoplasms were TN or HER-2 overexpressed. The ages of the animals in the study ranged from 3 to 19 years old, with a mean age of 11 years old (standard deviation 3.3). The majority were mixed-breed animals (18/61, 29.5%),",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:40"
    }
  },
  {
    "page_content": "majority were mixed-breed animals (18/61, 29.5%), followed by poodles (16/61, 26.23%), Yorkshire terriers (4/61, 6.56%), and German shepherds and Shih tzus with the same amount (3/61, 4.92%). Other breeds in smaller numbers included dachshunds, French bulldogs, Akitas, Maltese, Rottweilers, and Beagles. In the quantitative analysis on HE slides, the total number of lymphocytes was significantly higher than that of neutrophils (p = 0.003). Most neoplasms, 44/61 (72.1%), presented a greater",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:41"
    }
  },
  {
    "page_content": "neoplasms, 44/61 (72.1%), presented a greater number of lymphocytes in the peritumoral area than in the intratumoral area (p = 0.0001). This was also observed for neutrophils, with infiltration in the peritumoral area being greater than in the intratumoral area in 45/61 samples (73.8%) (p = 0.02). In the count of lymphocyte subtypes after immunostaining for CD3+ and CD79+, 57 of 61 (93.4%) neoplastic samples showed greater infiltration of total TCD3+ cells when compared to BCD79+ cells, which",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:42"
    }
  },
  {
    "page_content": "TCD3+ cells when compared to BCD79+ cells, which was higher in only 4/61(6.6%) samples (p = 0.0001). Regarding the location of the infiltrate of TCD3+ cells, 37/61 (60.7%) neoplasms presented a higher amount of those cells in the intratumoral area compared to the peritumoral area, but no significant difference was seen (p = 0.20). Meanwhile, BCD79+ cells were in significantly higher number in the peritumoral area in 47/61 (77.3%) neoplasms than in the intratumoral area (p = 0.02). Median and",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:43"
    }
  },
  {
    "page_content": "in the intratumoral area (p = 0.02). Median and standard deviation values of each cell type are shown in Table 1. Table 2 and Table 3 contain the morphological and immunophenotypic characteristics of the infiltrate in each subtype of neoplasms. ## 3.1. Association Between Inflammatory Infiltrate in Relation to Subtypes and Immunophenotypes of Solid Neoplasms In the evaluation of TILs, most CSP (6/66.7%), SPC (6/75%), MME (4/66.7%), and MAME (12/63.2%) neoplasms showed a significantly higher",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:44"
    }
  },
  {
    "page_content": "neoplasms showed a significantly higher density of TILs in the intratumoral area when compared to BC tumors, among which only 4/21.1% neoplasms presented a high density of TILs (p = 0.02). In the peritumoral area, no difference in the density of the lymphocyte infiltrate was observed between histological types (Figure 1A,B). The density of TANs, TCD3+, and BCD79+ cells in the peri- and intratumoral areas showed no significant differences between histological types (Table 1 and Table 2). Figure",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:45"
    }
  },
  {
    "page_content": "histological types (Table 1 and Table 2). Figure 2 shows the intensity of cellular infiltration between basaloid carcinoma and carcinoma with a solid pattern. Neoplasms with luminal B immunophenotypes (HER-2 negative or positive) showed higher density of intratumoral TCD3+ lymphocytes when compared to luminal A neoplasms (p = 0.04). Only three out of thirteen (23.1%) luminal A neoplasms presented a high infiltration of intratumoral TCD3+ lymphocytes, while luminal B HER-2 negative or HER-2",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:46"
    }
  },
  {
    "page_content": "while luminal B HER-2 negative or HER-2 positive presented a higher percentage of neoplasms with a high density of this cell type, which were 23/42 (54.8%) and 5/6 (83.3%), respectively. The density of the infiltration of CD79+ cells (Figure 3), as TILs and TANs, and their respective locations showed no significant association with immunophenotypes. ## 3.2. Association Between Proliferative Rate, Presence of Lymph Node Metastases, and Inflammatory Infiltrate Twenty-one female dogs (34.4%) had",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:47"
    }
  },
  {
    "page_content": "Infiltrate Twenty-one female dogs (34.4%) had lymph node metastases. Of these, 16 (76.2%) had a high density of intratumoral BCD79+ lymphocyte infiltrate (p = 0.03). On the other hand, the density of this peritumoral cell was not associated with the presence of metastasis (p = 0.59) (Figure 4). The density of TANs in the peritumoral area was not statistically significantly associated with lymph node metastases (p = 0.05), even though 15 (71.9%) of the 21 neoplasms that metastasized to lymph",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:48"
    }
  },
  {
    "page_content": "of the 21 neoplasms that metastasized to lymph nodes exhibited a TAN density above the median in the peritumoral area. For TILs and TCD3+ cells, no significant difference was observed between the density and the site of inflammation and lymph node status. Neoplasms with a high density of intratumoral TILs had a higher mitotic count with a median of 20 mitotic figures (2.37 mm2), while neoplasms with a low density of TILs had a median of 14 mitotic figures (p = 0.03). However, the density of",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:49"
    }
  },
  {
    "page_content": "figures (p = 0.03). However, the density of peritumoral TILs was not significantly related to the mitotic count (p = 0.05). A high density of peritumoral TCD3+ and BCD79+ cells was also associated with a higher mitotic count. Neoplasms with a high infiltration of peritumoral TCD3+ and BCD79+ lymphocytes presented a median of 21 mitotic figures, while those with low infiltration presented 13 mitotic figures (p = 0.006) for both cell types. Regarding intratumoral infiltration of CD3+ and CD79+,",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:50"
    }
  },
  {
    "page_content": "intratumoral infiltration of CD3+ and CD79+, only intratumoral CD79 lymphocyte infiltration was significantly associated with mitotic count (p = 0.02). Neoplasms with a high density of those cells had a median of 19 mitotic figures, and those with low infiltration had 12 mitotic figures (p = 0.02). The intensities of peri- (p = 0.9) and intratumoral (p = 0.7) TANs were not associated with mitotic counting. When evaluating the density of inflammation with Ki-67 immunostaining, we observed that",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:51"
    }
  },
  {
    "page_content": "with Ki-67 immunostaining, we observed that neoplasms with high TILs (p = 0.02) and a high infiltration of TCD3+ (p = 0.007) and BCD79+ cells (p = 0.02) in the peritumoral area were associated with a higher percentage of immunostaining (Figure 5). Neoplasms with a high density of TILs and TCD3+ and BCD79+ cells had the same median of Ki-67 labeling (34%), and neoplasms with a low intensity of those cells had a median of 26%, 25%, and 26% of immunostaining, respectively. The remaining locations",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:52"
    }
  },
  {
    "page_content": "respectively. The remaining locations of TILs and CD3+ and CD79+ cells, as well as TANs, were not associated with the percentage of Ki-67 labeling. ## 3.3. Association Between Tumor Size and Cox-2 Immunostaining with Inflammatory Infiltrate The results are detailed in Table 1 and Table 2. Among the neoplasms evaluated (n = 61), 25 (41%) were classified as T1, 12 (19.7%) as T2, and 24 (39.3%) as T3. No association of tumor size with the density of TILs, TANs, TCD3+, and BCD79+ was observed. Of",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:53"
    }
  },
  {
    "page_content": "of TILs, TANs, TCD3+, and BCD79+ was observed. Of the 59 neoplasms evaluated for Cox-2, only 17 (28.8%) presented positive immunostaining; 16 presented scores up to three, and 1 presented a score of six. No statistical difference was seen between peri- and intratumoral inflammations and Cox-2 positivity. ## 3.4. Association Between Inflammatory Infiltrate and Survival Time Information on overall survival was available for 47/61 (77%) female dogs, of which 35 (74%) died and 12 (26%) were alive",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:54"
    }
  },
  {
    "page_content": "of which 35 (74%) died and 12 (26%) were alive at the end of the study. Of the 35 dogs that died, 22 (63%) died from causes related to the mammary tumor. The median overall survival was 365 days (95% CI, 283 to 630 days), and the specific survival was 670 days (95% CI, with a minimum of 365). Female dogs who had neoplasms with a high density of intratumoral TANs had shorter median overall survival time than those with a low infiltration of such cells (p = 0.04, HR = 2.07, CI: 1.02–4.21), which",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:55"
    }
  },
  {
    "page_content": "cells (p = 0.04, HR = 2.07, CI: 1.02–4.21), which were 210 and 425 days of survival, respectively. On the other hand, infiltration with peritumoral TANs (p = 0.2) had no influence on survival. Also, overall survival was not associated with TILs in the peri- (p = 0.14) and intratumoral (p = 0.10) areas, the infiltration of peri- (p = 0.48) and intratumoral (p = 0.05) TCD3+ cells, and the infiltration of peri- (p = 0.17) and intratumoral (p = 0.11) BCD79+ cells (Table 4). In the specific survival",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:56"
    }
  },
  {
    "page_content": "BCD79+ cells (Table 4). In the specific survival evaluation, 50% of female dogs presenting neoplasms with a high density of intratumoral TILs had died in 395 days, and 64% of those with a low density of TILs were still alive after 1000 days (p = 0.02, HR = 2.57, CI:1.11–5.97). That was also similar to what was observed in the evaluation of TCD3+ cells, where patients with high intratumoral density showed a median survival time of 365 days, and 61% of those with low intratumoral density were",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:57"
    }
  },
  {
    "page_content": "61% of those with low intratumoral density were still alive after 1000 days (p = 0.01, HR = 2.85, CI:1.23–5.63). The density of peritumoral TILs (p = 0.53) and TCD3+ (p = 0.50), peri- (p = 0.11) and intratumoral (p = 0.06) BCD79+ cells, and peri- (p = 0.48) and intratumoral TANs (p = 0.28) was not associated with dog survival (Figure 6; Table 4). The N/L and CD3+/CD79 cell ratios were also unrelated to the overall (p = 0.54; p = 0.53) and specific (p = 0.81, p = 0.57) survival time of female",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:58"
    }
  },
  {
    "page_content": "(p = 0.81, p = 0.57) survival time of female dogs. In the specific survival analysis by Cox regression, the univariate analysis showed that a high density of intratumoral TILs increases the risk of death related to the neoplasm. The high presence of TILs is associated with a risk ratio of 2.76 times (p = 0.03, confidence interval, CI, 95% = 1.08–7.07), and the high infiltration of intratumoral TCD3+ cells increased the risk of death related to the neoplasm by three times (p = 0.02,",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:59"
    }
  },
  {
    "page_content": "related to the neoplasm by three times (p = 0.02, CI:1.19–7.8). Female dogs with metastases to regional lymph nodes also had a risk of death 6.5 (CI: 2.61–16.4) times higher. In the multivariate analysis, the only variable that remained associated with the risk of death was the presence of metastasis in lymph nodes, which was responsible for a three-fold increase in the risk of death from the disease (p < 0.001) (Table 5). # 4. Discussion In canine neoplasms with a solid arrangement, the",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:60"
    }
  },
  {
    "page_content": "In canine neoplasms with a solid arrangement, the characteristics of tumor-infiltrating inflammatory cells were associated with survival time, univariate analysis, and some prognostic factors. The increase in the inflammatory infiltrate of lymphocytes and their subtypes was associated with some poor prognostic factors, such as higher mitotic count, Ki-67 expression, and a higher frequency of metastasis to lymph nodes. Female dogs presenting neoplasms with a solid arrangement with a high density",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:61"
    }
  },
  {
    "page_content": "with a solid arrangement with a high density of intratumoral TILs and TCD3+ cells had significantly lower specific survival time when compared to female dogs presenting neoplasms with a low density of intratumoral TILs and CD3+ cells. This is in agreement with what is reported in women who also have luminal neoplasms, leading to an association of a high number of TILs with shorter survival time. This is believed to be related to the type of lymphocytes present since mammary neoplasms with",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:62"
    }
  },
  {
    "page_content": "lymphocytes present since mammary neoplasms with luminal immunophenotype have a lower percentage of TCD8+ cells when compared to TN neoplasms. TCD8+ cells are involved with the anti-tumor response mechanism, leading to neoplastic cell lysis. In contrast, other types of T cells that favor cancer progression and shorten survival may be present, such as regulatory T cells (such as Foxp3) and CD4 helper 2 cells. A limitation of this study was not identifying T lymphocyte subtypes, such as CD4+ and",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:63"
    }
  },
  {
    "page_content": "T lymphocyte subtypes, such as CD4+ and CD8+, or Foxp3. However, we suggest the presence of a predominant immunosuppression and tolerance response in the tumor microenvironment. The neoplasms with a solid arrangement evaluated were MME (9.8%), SPC (13.1%), CSP (14.8%), BC (31.1%), and MAME (31.1%). We had few neoplasms diagnosed as MME and SPC, which may be a limitation regarding the representativeness of the various histological types of these neoplasms. However, some of them are infrequent,",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:64"
    }
  },
  {
    "page_content": "neoplasms. However, some of them are infrequent, as seen in a study reclassifying 72 cases of solid carcinomas in female dogs, where MME represented only 15% of these neoplasms. There was a significant statistical predominance of lymphocytes in relation to neutrophils in all samples, corroborating other studies that evaluated the inflammatory infiltrate in several histological types of mammary neoplasms in female dogs. Lymphocytes are the most studied cells in the tumor microenvironment of",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:65"
    }
  },
  {
    "page_content": "studied cells in the tumor microenvironment of several canine neoplasms, such as oral and cutaneous melanomas, urothelial bladder cell carcinoma, and mammary cancer. However, few authors specify the areas where this inflammation is located. In canine mammary neoplasms with a solid arrangement, the stroma is often scarce among neoplastic nests, making it difficult to assess stromal lymphocytic inflammation as it is studied in women. Therefore, we evaluated peritumoral and intratumoral",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:66"
    }
  },
  {
    "page_content": "we evaluated peritumoral and intratumoral inflammation, as was already performed in other studies in veterinary medicine. In women’s breast cancer, the evaluation of TILs focusses on the stromal area between neoplastic nests, and the percentage of the area occupied by the inflammation is used in prognostic and predictive analysis. In histology, we identified that most of the evaluated neoplasms show a greater amount of infiltration of TILs in the peritumoral area (72.1%) in relation to the",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:67"
    }
  },
  {
    "page_content": "the peritumoral area (72.1%) in relation to the intratumoral area (p = 0.0001). In the evaluation of lymphocyte subtypes, the majority of neoplasms (93.4%) showed a significantly higher amount of T lymphocytes than B lymphocytes (p = 0.0001), similar to what has already been described in women, cats, and female dogs. There was no statistical difference in the amount of TCD3 lymphocytes between the peri- and intratumoral areas in the samples, but CD79 B lymphocytes predominated in the",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:68"
    }
  },
  {
    "page_content": "but CD79 B lymphocytes predominated in the peritumoral area (p = 0.02). Similar to what is seen in breast cancer in women, TCD3+ cells show reasonable homogeneity in samples and may be around and inside the nests of tumor cells, while the CD20+ cell, a marker used for B cells in women, is seen in less quantity and often forming peritumoral aggregates. The formation of peritumoral lymphoid aggregates, which consist predominantly of B cells, is reported in in situ and invasive ductal carcinoma of",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:69"
    }
  },
  {
    "page_content": "in in situ and invasive ductal carcinoma of women, indicating a host’s humoral immune response secondary to the neoplastic cell proliferation. BCs are characterized by compact cell nest formations with cells presenting more hyperchromatic nuclei, especially in the periphery, where cells are organized into palisades. This may cause greater difficulty in the visualization of lymphocytes within the tumor nests and may have influenced the lower intensity of intratumoral TILs we found in this",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:70"
    }
  },
  {
    "page_content": "intensity of intratumoral TILs we found in this histological type compared to the others (p = 0.02). Thus, we may infer that the histological and growth patterns of the neoplasm can interfere with the quantification of TILs, as described in women’s neoplasms. As for immunophenotypes, only luminal A, luminal B HER-2 negative, and luminal B HER-2 positive immunophenotypes were diagnosed. In this study, neoplasms with luminal B HER-2 positive and negative immunophenotypes presented significantly",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:71"
    }
  },
  {
    "page_content": "negative immunophenotypes presented significantly higher density of intratumoral TCD3+ lymphocyte infiltration when compared to those of luminal A immunophenotype (p = 0.04). The mammary cancer immunophenotype is known to influence the amount and composition of inflammatory infiltrate in the tumor microenvironment. Canine luminal A neoplasms may present less activation of genes that produce proteins associated with immune mechanism and inflammatory stimulus than B immunophenotype neoplasms. In",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:72"
    }
  },
  {
    "page_content": "stimulus than B immunophenotype neoplasms. In women, luminal A mammary neoplasms have also been described as presenting a lower presence of TILs than luminal B HER-2 negative neoplasms. Similarly, TN- and HER-2-overexpressed neoplasms also incite greater chemotaxis, both of lymphocytes and neutrophils, due to greater genomic instability. During the inflammatory process, several growth factors and cytokines that activate transcription factors are produced, such as NF-kB and STAT-3, which favor",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:73"
    }
  },
  {
    "page_content": "produced, such as NF-kB and STAT-3, which favor cell proliferation. This is in agreement with what we observed, i.e., the high intensity of intra- and peritumoral lymphocyte inflammation was observed in neoplasms with a higher mitotic count and/or higher immunostaining of Ki-67. In the present study, a high mitotic count was associated with a high density of intratumoral TILs (p = 0.03) and CD79+cells (p = 0.02). In addition, both the mitotic count and Ki-67 immunostaining were proportionally",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:74"
    }
  },
  {
    "page_content": "and Ki-67 immunostaining were proportionally related to the density of peritumoral CD3+ and C79+ cells. As cells proliferate, they can expose new antigens and induce a greater inflammatory response, primarily by cells of the innate immune system, such as TCD8 + and NK lymphocytes. Metastasis to regional lymph nodes was significantly associated with a high density of intratumoral lymphocytes. This finding corroborates other studies of canine mammary tumors, describing a higher percentage of",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:75"
    }
  },
  {
    "page_content": "mammary tumors, describing a higher percentage of BCD79+ cells infiltrating carcinoma in mixed tumors of animals presenting metastasis to lymph nodes and greater peritumoral lymphatic invasion in several types of mammary carcinomas when compared to tumors with a low infiltration of such cells. In canine melanoma, lymph node metastasis is also related to a moderate amount of intratumoral B cells in the primary neoplasm. In both women and in experimental mouse models, an increased infiltration of",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:76"
    }
  },
  {
    "page_content": "mouse models, an increased infiltration of B cells was detected in the microenvironment of neoplasms that metastasized to lymph nodes, and many of those lymphocytes were regulatory B cells, responsible for producing cytokines that reduce the anti-tumor function of T cells via the secretion of IL-10. In experimental models, such an increase in tumor B cells is associated with the appearance of stromal cells in the lymph node and an increase of transcription genes related to important signaling",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:77"
    }
  },
  {
    "page_content": "genes related to important signaling pathways in pre-metastatic nests in lymph nodes. Even though CD79+ B lymphocytes were associated with lymph node metastasis in the female dogs of the present study, the high infiltration of those did not influence the overall and specific survival time. However, we observed that the presence of lymph node metastasis increased the risk of death due to the neoplasm by six and three times in univariate and multivariate analysis, respectively, which makes it an",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:78"
    }
  },
  {
    "page_content": "analysis, respectively, which makes it an independent prognostic factor. Metastasis to lymph nodes was also a factor that increased the risk of cancer-related death in female dogs in other studies. Although we did not observe a significant association of neutrophils with the presence of metastasis to lymph nodes, 71,4% of the neoplasms that metastasized had a high density of peritumoral TANs (p = 0.05). In addition, intratumoral neutrophil infiltration generated an important difference in the",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:79"
    }
  },
  {
    "page_content": "generated an important difference in the overall survival time of female dogs; those with low intratumoral density had a median survival time of 425 days, while those with a high density of neutrophil infiltrate had a median survival time of 210 days (p = 0.04). In human medicine, few breast cancer articles make this association. One of them describes shorter survival time in patients with a high density of neutrophil infiltrate but without specifying the location. To date, no other study",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:80"
    }
  },
  {
    "page_content": "specifying the location. To date, no other study associating tumor neutrophil infiltration with the survival of female dogs with mammary neoplasms is known. Some studies associate a larger tumor size with a greater presence of TILs in women’s luminal neoplasms, but we did not observe a significant association of this variable with TILs, T cells (CD3+), B cells (CD79+), and neutrophils. A higher Cox-2 score was associated with higher tumor inflammatory infiltrate in mammary neoplasms and canine",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:81"
    }
  },
  {
    "page_content": "infiltrate in mammary neoplasms and canine melanoma. However, that finding was not observed in the present study. This may have occurred because we had only 28.8% of neoplasms marked for Cox-2, and most of them presented low scores. Cyclooxygenase is probably not an important factor for inflammatory stimulation in neoplasms with a solid arrangement; however, further studies should be conducted to confirm this hypothesis. The blood neutrophil/lymphocyte ratio has been performed in patients with",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:82"
    }
  },
  {
    "page_content": "ratio has been performed in patients with mammary carcinomas and is indicated as a prognostic factor in studies of cats. In female dogs, a blood ratio >5 N/L before surgery is associated with worse prognosis. Here, we used the cell count in the tumor microenvironment to associate the ratio of N/L and CD79+/CD3+ with survival, but it was not significant. In a study of mammary neoplasms in female dogs, the animals presenting neoplasms with greater lymphocyte infiltration (>600 lymphocytes/8",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:83"
    }
  },
  {
    "page_content": "lymphocyte infiltration (>600 lymphocytes/8 fields) had lower survival time, which was confirmed by the multivariate Cox regression analysis. In the univariate analysis, we observed that the high density of intratumoral TILs and intratumoral T lymphocytes increased the risk of death from the neoplasm by 2.7 and 3 times, respectively, but this was not confirmed by the multivariate analysis. We believe that by identifying the type of inflammatory cells present in these canine mammary tumors and",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:84"
    }
  },
  {
    "page_content": "cells present in these canine mammary tumors and understanding their influence on neoplastic progression, new therapeutic measures targeting immune system modulation can be researched and implemented. Furthermore, it will be possible to correlate the density and location of TILs with the response to chemotherapy, as described in women, where a higher quantity of TILs has been associated with a better response to chemotherapy. # 5. Conclusions In our study, we observed that neoplasms with a",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:85"
    }
  },
  {
    "page_content": "In our study, we observed that neoplasms with a solid arrangement show a greater predominance of lymphocytes than neutrophils and mainly TCD3+ cells. TCD3+ cells predominated in the intratumoral area, while BCD79+ cells predominated in the peritumoral area. The infiltration of lymphocytes and their location in canine mammary neoplasms, evaluated here, are associated with some prognostic factors in female dogs. Nodal metastasis was associated with a high infiltration of intratumoral CD79+ cells,",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:86"
    }
  },
  {
    "page_content": "a high infiltration of intratumoral CD79+ cells, and shorter survival time was associated with a high density of TILs and intratumoral T CD3+ cells. Thus, lymphocyte infiltration, especially the intratumoral infiltration, may be an important feature in cancer progression, inciting a pro-tumor and regulatory response of the anti-tumor response and influencing the survival of female dogs with mammary neoplasms with a solid arrangement. However, in this study, it was not an independent prognostic",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:87"
    }
  },
  {
    "page_content": "this study, it was not an independent prognostic factor. We know that in the laboratory routine, the quantitative evaluation of inflammatory cells in the tumor microenvironment is difficult to carry out. However, the analysis of the intensity of peri- and intratumoral inflammation from a cutoff point can be performed in hematoxylin and eosin stains and associated with morphological characteristics to gather possible prognostic information.",
    "metadata": {
      "source": "../data/plain/PMC11762997.plain.txt",
      "id": "../data/plain/PMC11762997.plain.txt:88"
    }
  },
  {
    "page_content": "Genetic Risk for Subsequent Neoplasms Among Long-Term Survivors of Childhood Cancer Abstract\nPurpose\nChildhood cancer survivors are at increased risk of subsequent neoplasms (SNs), but the germline genetic contribution is largely unknown. We assessed the contribution of pathogenic/likely pathogenic (P/LP) mutations in cancer predisposition genes to their SN risk.\nPatients and Methods",
    "metadata": {
      "source": "../data/plain/PMC6036620.plain.txt",
      "id": "../data/plain/PMC6036620.plain.txt:0"
    }
  },
  {
    "page_content": "Whole-genome sequencing (30-fold) was performed on samples from childhood cancer survivors who were ≥ 5 years since initial cancer diagnosis and participants in the St Jude Lifetime Cohort Study, a retrospective hospital-based study with prospective clinical follow-up. Germline mutations in 60 genes known to be associated with autosomal dominant cancer predisposition syndromes with moderate to high penetrance were classified by their pathogenicity according to the American College of Medical",
    "metadata": {
      "source": "../data/plain/PMC6036620.plain.txt",
      "id": "../data/plain/PMC6036620.plain.txt:1"
    }
  },
  {
    "page_content": "according to the American College of Medical Genetics and Genomics guidelines. Relative rates (RRs) and 95% CIs of SN occurrence by mutation status were estimated using multivariable piecewise exponential regression stratified by radiation exposure.",
    "metadata": {
      "source": "../data/plain/PMC6036620.plain.txt",
      "id": "../data/plain/PMC6036620.plain.txt:2"
    }
  },
  {
    "page_content": "Results",
    "metadata": {
      "source": "../data/plain/PMC6036620.plain.txt",
      "id": "../data/plain/PMC6036620.plain.txt:3"
    }
  },
  {
    "page_content": "Participants were 3,006 survivors (53% male; median age, 35.8 years [range, 7.1 to 69.8 years]; 56% received radiotherapy), 1,120 SNs were diagnosed among 439 survivors (14.6%), and 175 P/LP mutations were identified in 5.8% (95% CI, 5.0% to 6.7%) of survivors. Mutations were associated with significantly increased rates of breast cancer (RR, 13.9; 95% CI, 6.0 to 32.2) and sarcoma (RR, 10.6; 95% CI, 4.3 to 26.3) among irradiated survivors and with increased rates of developing any SN (RR, 4.7;",
    "metadata": {
      "source": "../data/plain/PMC6036620.plain.txt",
      "id": "../data/plain/PMC6036620.plain.txt:4"
    }
  },
  {
    "page_content": "increased rates of developing any SN (RR, 4.7; 95% CI, 2.4 to 9.3), breast cancer (RR, 7.7; 95% CI, 2.4 to 24.4), nonmelanoma skin cancer (RR, 11.0; 95% CI, 2.9 to 41.4), and two or more histologically distinct SNs (RR, 18.6; 95% CI, 3.5 to 99.3) among nonirradiated survivors.",
    "metadata": {
      "source": "../data/plain/PMC6036620.plain.txt",
      "id": "../data/plain/PMC6036620.plain.txt:5"
    }
  },
  {
    "page_content": "Conclusion\nThe findings support referral of all survivors for genetic counseling for potential clinical genetic testing, which should be prioritized for nonirradiated survivors with any SN and for those with breast cancer or sarcoma in the field of prior irradiation.",
    "metadata": {
      "source": "../data/plain/PMC6036620.plain.txt",
      "id": "../data/plain/PMC6036620.plain.txt:6"
    }
  },
  {
    "page_content": "Productivity losses from short-term work absence due to neoplasms in Poland Abstract",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:0"
    }
  },
  {
    "page_content": "Previous evidence on productivity losses from neoplasms focuses mostly on the economic burden from mortality, covers single cancer diagnoses and neglects non-malignant neoplasms. This study aims to broaden this perspective by analysing losses resulting from work absence and all neoplasm diagnoses. The analysis applies the human capital method and social insurance data to estimate productivity losses attributable to neoplasm-related short-term work absence in Poland in the period 2012–2022. The",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:1"
    }
  },
  {
    "page_content": "absence in Poland in the period 2012–2022. The productivity losses due to work absence attributable to all neoplasms in Poland were €583 million in 2012 (0.143% of gross domestic product) and they increased to €969 million in 2022 (0.164%). Around 60% of the losses were associated with cancers while the remaining part of the burden was due to non-malignant neoplasms. The neoplasms that led to the highest losses were benign neoplasms, breast cancer, colorectum cancer and prostate cancer. The",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:2"
    }
  },
  {
    "page_content": "colorectum cancer and prostate cancer. The cancer sites characterised by the greatest losses per absence episode were brain cancer, lung cancer and oesophageal cancer. For most of the neoplasms, we observed increasing losses in an 11-year period analysed. Investing in effective public health policies that tackle neoplasms has the potential to reduce both the health burden and economic losses resulting from these diseases. # Introduction Cancer is a major health concern worldwide and the burden",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:3"
    }
  },
  {
    "page_content": "a major health concern worldwide and the burden of this disease incidence and mortality is growing rapidly1. This translates to severe economic consequences in terms of healthcare spending aimed at cancer treatment (direct costs)2 and productivity losses resulting from the inability to work of those affected (indirect costs)3. The former category of direct costs is conceptually intuitive as it encompasses expenditures associated with producing and delivering health services aimed at disease",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:4"
    }
  },
  {
    "page_content": "and delivering health services aimed at disease treatment. On the other hand, indirect costs are a more abstract concept because they do not result in financial flows per se, they rather illustrate potential losses that society bears due to the sick’s inability to perform economic activities4. Numerous studies have scrutinised productivity losses from cancer and these either focused on specific cancer diseases5–8 or analysed a range of cancer diagnoses together9–12. For the latter category of",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:5"
    }
  },
  {
    "page_content": "together9–12. For the latter category of studies, most investigated a single category of indirect costs—usually mortality losses9–14. The focus on the consequences of cancer deaths is not surprising because mortality constitutes a key health-related burden of neoplasms. Yet, cancer morbidity also yields a significant economic burden. A systematic review of breast cancer indirect costs research3 lists several studies finding that morbidity losses exceed mortality losses, e.g.8,15,16. The",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:6"
    }
  },
  {
    "page_content": "losses exceed mortality losses, e.g.8,15,16. The economic analysis of Poland’s cancer absenteeism for 2009 shows that sick leave absence constituted ~ 19% of the total indirect costs17. This study aims to shed more light on the economic magnitude of the morbidity burden resulting from neoplasms. This is to be done by analysing time trends in sick leave absence and resulting productivity losses due to all neoplasms (both malignant and non-malignant) in Poland in 11 years of 2012–2022 based on",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:7"
    }
  },
  {
    "page_content": "in Poland in 11 years of 2012–2022 based on social insurance data. The contributions of this research are as follows. To begin with, a decade-long analysis provides a comprehensive picture of losses evolution over time; this approach is crucial to understanding the dynamics of losses because we experience a growing incidence of cancer and this plausibly translates to an increasing economic burden. Secondly, this study uses work absence data on every malignant-related diagnosis as defined by the",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:8"
    }
  },
  {
    "page_content": "malignant-related diagnosis as defined by the International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). Until now, the economic studies of neoplasm burden, either focused on single cancers5,6 or on aggregated groups of diseases classified by cancer site11 or did not account for non-malignant neoplasms9,10. Using a complete list of neoplasm diagnoses (ICD-10 codes: C00-D48), this study aims to provide a more comprehensive picture of the economic",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:9"
    }
  },
  {
    "page_content": "a more comprehensive picture of the economic burden of neoplasms. Clearly, absenteeism is only one indirect cost category and this approach does not assess the burden of disease due to presenteeism or mortality; yet, it provides additional insight into the topic. Thirdly, the study additionally uses data aggregated by the cancer site and this allows us to compare sick leave absence losses with mortality losses in a single country (Poland). This was feasible because I used the same",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:10"
    }
  },
  {
    "page_content": "This was feasible because I used the same classification of cancers by site as reported previously in Ortega-Ortega et al.11. With this comparison, we could test whether in Poland the cancers that lead to high mortality losses are the ones that also account for the greatest work absence losses. This complements the picture of neoplasm-related losses in Poland and formulates the direction of future research in other countries' settings. Finally, social insurance data (which is a basis for",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:11"
    }
  },
  {
    "page_content": "social insurance data (which is a basis for empirical analysis here) in Poland is published with a short time lag and this allows for an up-to-date investigation. With this advantage over other epidemiological data which is made available with much longer lags (e.g. mortality), I was able to analyse the impact of the three years of the COVID-19 pandemic on both absence and productivity losses. # Material and methods The study used the human capital method (HCM), societal perspective and social",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:12"
    }
  },
  {
    "page_content": "method (HCM), societal perspective and social insurance data to estimate productivity losses (indirect costs) attributable to neoplasm-related short-term work absence in Poland in an 11-year period of 2012–2022. Using HCM in a morbidity-based analysis, such as in this study, means that indirect costs are estimated as the value of lost productive time due to acute illness and/or short- and long-term disabilities3,18,19. In other words, the output that is not produced because of a sick person’s",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:13"
    }
  },
  {
    "page_content": "that is not produced because of a sick person’s work absence is considered to be an economic loss and the sum of a potential output unproduced by all the sick approximates the social loss resulting from a disease. The scope of this study encompasses short-term (sick leave) absence solely; long-lasting (> 180 days) and permanent inability to work are not accounted for here. Short-term absence is identified based on the number and duration of sickness leave certificates issued by physicians to",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:14"
    }
  },
  {
    "page_content": "leave certificates issued by physicians to the sick insured. This data is routinely reported to the Social Insurance Institution (SII) which provides social allowances to above 90% of the insured population in Poland (excluding farmers, uniformed services and justice services employees). Short-term absence, as defined here, does not account for absence episodes lasting above 180 days; these are subject to rehabilitation and disability benefits and are not analysed here. The study investigated",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:15"
    }
  },
  {
    "page_content": "and are not analysed here. The study investigated the indirect costs of sick leave absence resulting from all neoplasm diseases as defined by the ICD-10 classification. For each of the 88 cancer (malignant) ICD-10 codes (C00-C97) and 48 non-malignant neoplasm ICD-10 codes (D00-D48), I obtained the number of absence days and certificates from the SII’s online database20. The single ICD-10 codes were also grouped. For malignant neoplasms, I used the following classification of 23 cancer sites as",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:16"
    }
  },
  {
    "page_content": "following classification of 23 cancer sites as used by Ortega-Ortega et al. (2021)11: oral cavity and pharynx (ICD-10: C00-C14), oesophagus (C15), stomach (C16), colorectum (C18-C21), liver (C22), gallbladder (C23-C24), pancreas (C25), larynx (C32), lung (C33-C34), melanoma skin (C43), breast (C50), cervix uteri (C53), corpus uteri (C54), ovary (C56), prostate (C61), kidney (C64-C65), bladder (C67), brain and central nervous system (C70-C72), thyroid (C73), Hodgkin lymphoma (C81), non-Hodgkin",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:17"
    }
  },
  {
    "page_content": "(C73), Hodgkin lymphoma (C81), non-Hodgkin lymphoma (C82-C85, C96), multiple myeloma (C88-C90), and leukaemia (C91-C95). The above groups accounted for 91.5% of all cancer-related absence days throughout the period analysed. For non-malignant neoplasms, three groups were distinguished, namely: in situ neoplasms (D00-D09), benign neoplasms (D10-D36), and neoplasms of uncertain or unknown behaviour (D37-D48). An indirect cost of a neoplasm-related absence day was calculated as the average daily",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:18"
    }
  },
  {
    "page_content": "absence day was calculated as the average daily productivity of a working person. To obtain this, the following socioeconomic measures were used: gross domestic product, number of working days per year, full-time and part-time working population, and age-group-specific average remuneration. For a specific year, the total economy’s GDP was divided by the working population and the number of average working days (accounting for statutory paid holidays). To reflect that productivity changes with",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:19"
    }
  },
  {
    "page_content": "To reflect that productivity changes with age, I adjusted the average per worker GDP with age differences in remuneration. Additionally, because marginal productivity is preferred over average productivity in indirect costs estimation18, per worker GDP was adjusted for decreasing marginal productivity by applying a 0.65 coefficient21–23. This adjustment is required as production output depends not only on human capital but also on other inputs such as capital or natural resources. To reflect",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:20"
    }
  },
  {
    "page_content": "such as capital or natural resources. To reflect this, marginal productivity was proxied by a 0.65 coefficient which reflects the output elasticity of labour in the Cobb–Douglas production function as used in the European context24. For a particular neoplasm or group of neoplasms, a product of absence days and adjusted per worker daily GDP yields a productivity loss. All the monetary measures are expressed in real terms using 2020 as a base year and deflated using a consumer price index and",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:21"
    }
  },
  {
    "page_content": "and deflated using a consumer price index and using Euro (€) currency calculated with the average yearly exchange rates for the whole period (2012–2022)—4.33 PLN per €. No discounting was used as no losses span to future years. The model parameters and their values for selected years are tabulated in Table 1. # Results ## Neoplasm-related short-term work absence characteristics Table 2 presents the data on absence characteristics for 23 malignant neoplasm groups classified by cancer site and",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:22"
    }
  },
  {
    "page_content": "neoplasm groups classified by cancer site and three non-malignant neoplasm groups; the data refers to the first year (2012), the middle year (2017) and the last year (2022) of the period analysed. More detailed data disaggregated by 88 cancer ICD-10 codes (C00-C97) and 48 non-malignant neoplasm ICD-10 codes (D00-D48) and for each year of the 2012–2022 are shown in Supplementary Table 1 and Supplementary Table 2. There were over 7.2 million work absence days related to all neoplasms combined in",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:23"
    }
  },
  {
    "page_content": "absence days related to all neoplasms combined in 2012 in Poland and this number increased to 8.6–8.7 million in 2017 and 2022. Of this number, approx. 60% of workdays lost were associated with malignant neoplasms (C00-C97) and this share was stable across the period, with a slight increase to ~ 64% in 2020, the first COVID-19 pandemic year. Cancer-related (neoplasm-related) absence constituted 2.1–2.2% (3.2–3.7%) of all-cause absence days which ranged from 207 million (2012) to 256 million",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:24"
    }
  },
  {
    "page_content": "ranged from 207 million (2012) to 256 million (2020) across the period. Considering work absence by neoplasm type and site, the highest number of workdays lost was attributed to benign neoplasms (D10-D36) with 2.2–2.3 million days lost throughout the period in most of the years. Breast cancer was the most prevalent cause of absence among site-specific cancers and a notable (39%) increase of days lost was observed for the period analysed for this disease. The other malignant neoplasms",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:25"
    }
  },
  {
    "page_content": "for this disease. The other malignant neoplasms characterised by the high work absence were colorectum cancer, lung cancer, and prostate cancer. There were two benign neoplasms which resulted in a high number of absence days and these were leiomyoma of uterus (D25) and benign neoplasm of ovary (D27). The former diagnosis resulted in more absence days than breast cancer in 2012 (963 thousand vs. 942 thousand) but in the following years this number declined and in 2022 it was the second most",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:26"
    }
  },
  {
    "page_content": "declined and in 2022 it was the second most often reason for sick leave absence in Poland. Considering the benign neoplasm of ovary, its magnitude in terms of work days lost was similar to that of lung cancer (see Supplementary Table 1 for details). An average length of absence (ALOA) episode was notably higher in all cancer (20.7 days in 2022) and all neoplasm (18 days) groups than for all the diseases combined (11 days). From 2012 to 2022, the ALOA episode declined by 3.4 days in all cancers",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:27"
    }
  },
  {
    "page_content": "ALOA episode declined by 3.4 days in all cancers (-14.1%), 3.3 days in all neoplasms (-15.5%) and 1.5 days in all-cause absence (-11.9%). The declining pattern of absence duration was evident in almost all analysed disease groups; the highest ALOA decline was identified for melanoma skin cancer (-29.3%); leukaemia (-23.2%); breast cancer (-18.9%) and stomach cancer (-18.7%). The only analysed group with an increased ALOA in the period were in situ neoplasms (+ 4.7%). The effect of the COVID-19",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:28"
    }
  },
  {
    "page_content": "neoplasms (+ 4.7%). The effect of the COVID-19 pandemic on the number of absence days resulting from neoplasms is briefly shown in Supplementary Table 3. For all-cause absence, we observe a 7.2% increase in absence days between 2019 (the pre-pandemic year) and 2020 (the first pandemic year). However, for all neoplasms combined the corresponding number declined by 7%, but for all malignant neoplasms combined, it remained almost unchanged (+ 0.3%). The following pandemic years, 2021 and 2022,",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:29"
    }
  },
  {
    "page_content": "The following pandemic years, 2021 and 2022, resulted in a declining number of all-cause absence days as compared to 2020 (~ 6–7% decrease) and this declining trend was similar in all cancers combined in 2021 and 2022 but in all neoplasms combined only in 2021. Considering particular neoplasm groups, the first pandemic year (2020) resulted in a notable growth in absence days from leukaemia (22.4%), non-Hodgkin lymphoma (19.3%) and Hodgkin lymphoma (10.3%), and it was followed by a decline in",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:30"
    }
  },
  {
    "page_content": "(10.3%), and it was followed by a decline in the two following years in all three diseases. On the other hand, benign neoplasms and lung cancer were at the top of those groups of neoplasms characterised by the greatest decline of absence days in 2020, with a drop of 22.7% and 11.6%, respectively. Generally, no clear picture arises from the analysis of absence days changes during the pandemic period for particular groups of neoplasms and a detailed analysis of this sub-topic is beyond the scope",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:31"
    }
  },
  {
    "page_content": "analysis of this sub-topic is beyond the scope of this paper. ## Productivity losses from neoplasm-related short-term work absence Ten conditions resulting in the highest economically burdening short-term work absence in 2012 were leiomyoma of uterus (ICD-10 code: D25), breast cancer (C50), lung cancer (C34), benign neoplasm of ovary (D27), colon cancer (C18), ovarian cancer (C56), prostate cancer (C61), neoplasm of uncertain or unknown behaviour of other and unspecified sites (D48), rectal",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:32"
    }
  },
  {
    "page_content": "of other and unspecified sites (D48), rectal cancer (C20) and neoplasm of uncertain or unknown behaviour of middle ear and respiratory and intrathoracic organs (D38). In 2022, the losses from ovarian cancer and rectal cancer became relatively lower and, as a result, thyroid cancer (C73) and neoplasm of uncertain or unknown behaviour of oral cavity and digestive organs (D37) were identified in the top ten economically burdening neoplasm diagnoses (Fig. 1). For each of the years analysed, absence",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:33"
    }
  },
  {
    "page_content": "(Fig. 1). For each of the years analysed, absence from the ten most prevalent sick leave malignant diagnoses generated more than half of the all-malignant losses. Additionally, the indirect costs of breast cancer absence solely was as much as 15% of losses from all the diseases analysed here.Figure 1Ten neoplasm diagnoses of highest productivity losses in Poland 2012–2022. Notes: C18—colon cancer; C20—rectal cancer; C34—bronchus and lung cancer; C50—breast cancer; C56—ovarian cancer;",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:34"
    }
  },
  {
    "page_content": "cancer; C50—breast cancer; C56—ovarian cancer; C61—prostate cancer; C73—thyroid cancer; D25—leiomyoma of uterus; D27—benign neoplasm of ovary; D37—neoplasm of uncertain or unknown behaviour of oral cavity and digestive organs; D38—neoplasm of uncertain or unknown behaviour of middle ear and respiratory and intrathoracic organs; D48—neoplasm of uncertain or unknown behaviour of other and unspecified sites. The detailed estimates for all individual ICD-10 codes and for each year of the period",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:35"
    }
  },
  {
    "page_content": "ICD-10 codes and for each year of the period analysed are presented in Supplementary Table 4 and Supplementary Table 5. Sick leave work absence related to all neoplasms combined generated productivity losses from 0.143% GDP in 2012 to 0.170% GDP in 2019; this share declined sharply in the COVID-19 pandemic period of 2020–2021 (0.155–0.158%) and increased subsequently to 0.164% in 2022. For malignant neoplasms solely, the respective share was more stable; it increased from 0.086% of GDP in 2012",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:36"
    }
  },
  {
    "page_content": "stable; it increased from 0.086% of GDP in 2012 to 0.100% throughout the 2017–2020 period and declined only in 2021, the second year of the pandemic (0.094%) (Fig. 2).Figure 2Time trends in relative measures of productivity losses associated with neoplasm-related work absence in Poland 2012–2022. The time-trend analysis of the indirect costs shows that the productivity losses from in situ neoplasms and prostate cancer were more than triple in 2022 compared to 2012. For neoplasms of uncertain or",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:37"
    }
  },
  {
    "page_content": "compared to 2012. For neoplasms of uncertain or unknown behaviour and thyroid cancer, the respective cost more than doubled throughout the period. Generally, for all but one (larynx cancer) analysed groups of malignant diseases the real losses in 2022 were higher than in 2012 (Fig. 3).Figure 3Percentage change of productivity losses associated with neoplasm-related work absence in Poland 2012–2022. # Discussion ## General absence trends This study analysed productivity losses (indirect costs)",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:38"
    }
  },
  {
    "page_content": "analysed productivity losses (indirect costs) resulting from neoplasms-related sick leave absence in Poland in a decade-long period of 2012–2022. The analysis of social insurance data shows that, throughout the period, the number of absence days increased by 20.2% for all neoplasms (7.2 million to 8.7 million) and 19.2% for all cancer diagnoses (4.3 million to 5.2 million). These growths are higher than in all-cause absence (15.3%) and this shows the growing magnitude of neoplasms’ work absence",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:39"
    }
  },
  {
    "page_content": "the growing magnitude of neoplasms’ work absence burden relative to other diseases. For some commonly diagnosed malignant neoplasms like prostate, breast and colorectum cancer, these increases are even higher and they exceed 25%. The growing number of neoplasm-related work absenteeism may result from various factors. Epidemiological and demographic trends make neoplasms a more common disease26–28 and this is reflected in the growing absence in terms of episodes and workdays lost. Additionally,",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:40"
    }
  },
  {
    "page_content": "of episodes and workdays lost. Additionally, resultant of increasing labour shortages in Poland, there are incentives to continue employment after reaching retirement age and the effective labour market exit age in Poland keeps increasing (2010–2020 change: 59.6 to 62.2 years in males and 57.8 to 60.1 years in females29). Consequently, a higher number of senior people work and, because they more often develop cancer than the young, we observe an upward absence trend. This tendency can also",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:41"
    }
  },
  {
    "page_content": "an upward absence trend. This tendency can also result from other labour market factors like increasing employment in the economy (2012–2022 change: 15.6 to 16.7 million) or a dynamic decrease in unemployment rates (2012–2022 change: 13.4% to 5.2%). The latter factor might translate to higher absence rates because when unemployment is low, employees’ decision to take sick leave is less affected by the fear of job loss30,31 and absence rates rise. Interestingly, in contrast to sick leave absence",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:42"
    }
  },
  {
    "page_content": "Interestingly, in contrast to sick leave absence and the incidence of cancer in Poland (the latter not discussed here; for details see26–28), the time trend of neoplasm-related long-term inability to work exhibits a declining tendency. The number of disability pensions granted by the SII for all neoplasms (all cancers) patients was 30.3 thousand (28.1 thousand) in 2013 and it declined to 23.7 thousand (21.8 thousand) in 2022. Also, in four of five cancer diagnoses characterised by most",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:43"
    }
  },
  {
    "page_content": "of five cancer diagnoses characterised by most disability pensions issued, a clear downward trend was apparent throughout the period (see Supplementary Fig. 1). Growing sick leave absence accompanied by decreasing disability rates might suggest that oncological treatment becomes more effective in limiting disability. Possibly, nowadays some of those cancer patients who would not be able to continue to work a decade ago, are now capable of ongoing employment owing to more effective treatment and",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:44"
    }
  },
  {
    "page_content": "employment owing to more effective treatment and their health deterioration results only in absence, not disability32. ## General productivity losses findings and comparison to previous studies The findings show that short-term absence due to cancer and non-malignant neoplasms resulted in considerable losses for the economy and the resulting indirect costs (in real terms) increased by 66.1% in the period analysed for all neoplasms (2012–2022 change: €583 to €969 million). Again, the dynamics of",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:45"
    }
  },
  {
    "page_content": "€583 to €969 million). Again, the dynamics of this burden were higher than in all-cause absence (58.6%). The neoplasm-related absence losses were equivalent to 0.143% of GDP in 2012 and this share raised to 0.164% of GDP ten years later. Present results are in line with previous estimates from Poland; sick leave indirect costs from all neoplasms were €570 million in 201325 (€593 million in this study) and €504 million in 200917 (the year not analysed here). Some minor estimate differences arise",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:46"
    }
  },
  {
    "page_content": "here). Some minor estimate differences arise from methodological choices, e.g. both previous studies used gross value added as a productivity measure while I used adjusted GDP as explained above. This study used the classification of cancers by site as applied in the research on productivity losses from cancer mortality in Europe11. This approach intended to test whether the cancers that lead to high mortality losses are the ones that also account for the greatest work absence losses. Although",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:47"
    }
  },
  {
    "page_content": "for the greatest work absence losses. Although the European study11 does not provide country-specific estimates by cancer site, I obtained data on Poland's losses for 23 cancer sites from the corresponding author (Dr Ortega-Ortega) of the article, who estimated and kindly agreed to share these for comparison. For this comparison, only paid productivity losses from the study11 were used because my estimates refer to formal economy losses and do not account for the burden due to informal",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:48"
    }
  },
  {
    "page_content": "and do not account for the burden due to informal activities referred to as ‘unpaid’ losses by Ortega-Ortega et al.11. There is a quite strong correlation (+ 0.494) between the total productivity losses from mortality and total productivity losses from sickness absence when analysing 23 cancer sites (data for 2018 was used in both loss categories). Therefore, a number of cancers that are ranked high in mortality losses also generate substantial absence losses, and other neoplasms are relatively",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:49"
    }
  },
  {
    "page_content": "losses, and other neoplasms are relatively low-burdening in terms of both absence losses and mortality losses. This is true for, e.g., breast cancer (ranking 3rd in mortality and 1st in absence losses), colorectum cancer (2nd in both mortality and absence), lung cancer (1st and 3rd, respectively) and multiple myeloma (20th and 19th) or Hodgkin Lymphoma (21st and 20th). On the other hand, some cancers that generate large absence losses (prostate—ranked 4th, thyroid—5th, bladder—7th) were ranked",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:50"
    }
  },
  {
    "page_content": "4th, thyroid—5th, bladder—7th) were ranked much lower in the mortality costs hierarchy (ranks 19, 23, 17, respectively). Considering the per death / per absence episode comparison of Poland’s productivity losses generated by cancer, there is a lower and negative correlation between the two categories (-0.234). Therefore, cancers generating high absence losses like lung, oesophagus, and larynx (ranking 2nd to 4th, respectively) are ranked low in mortality losses (21st, 10th, and 14th,",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:51"
    }
  },
  {
    "page_content": "low in mortality losses (21st, 10th, and 14th, respectively). On the other hand, Hodgkin lymphoma, which is by far the most burdening in terms of mortality losses ranks 20th in the absence losses and similar patterns apply to non-Hodgkin lymphoma, leukaemia, and melanoma skin (see Supplementary Table 6). Altogether, the comparison of absence losses with mortality losses by cancer sites in Poland shows that some cancers generate relatively large losses in one of the loss categories and modest",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:52"
    }
  },
  {
    "page_content": "losses in one of the loss categories and modest economic burden in the other. Therefore, drawing policy conclusions on losses from a single indirect cost category (e.g. absenteeism) might be insufficient because the magnitude of losses resulting from a particular cancer might be different once other cost categories (e.g. mortality) are accounted for. To give a broader perspective, all-neoplasm productivity losses from sick leave absence are lower than the same cost category in cardiovascular",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:53"
    }
  },
  {
    "page_content": "than the same cost category in cardiovascular diseases in Poland which generated an average burden of €911 million in 2015–201721 (here: €741 million, on average, for the respective years). Importantly, the burden of short-term work absence associated with neoplasms is relatively low as compared to other groups of conditions. This study analysed neoplasms solely; however, the previous study using 2013 data from Poland25 shows that diseases of the respiratory system or musculoskeletal system",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:54"
    }
  },
  {
    "page_content": "the respiratory system or musculoskeletal system (mental disorders) generated indirect costs of absence four (two) times higher than neoplasms. This clearly shows the differences between neoplasms and the three above-mentioned groups of diseases in terms of their economic burden. Particularly, cancer generates relatively modest productivity losses in terms of sick leave absence, it rather leads to higher losses resulting from premature mortality and long-term inability to work as shown in a",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:55"
    }
  },
  {
    "page_content": "and long-term inability to work as shown in a study of breast, cervix uteri and ovary cancer in Poland33. In contrast, mental disorders or musculoskeletal diseases are characterized by low mortality but higher rates of morbidity leading to greater work absence as compared to neoplasms. Considering spending on cancer treatment in Poland, the public expenditure on neoplasms was around €2.8 billion in 202234 and these direct costs were almost triple the productivity losses resulting from",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:56"
    }
  },
  {
    "page_content": "triple the productivity losses resulting from short-term absence estimated here. ## Neoplasm site-specific absence and productivity losses An important contribution of this study is the analysis of losses from site-specific cancers and single neoplasm diagnoses. A cancer site generating the heaviest economic toll was breast; breast cancer resulted in indirect costs of €146 million in 2022 and it was almost double the respective cost 10 years earlier. The magnitude and rising trend of this",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:57"
    }
  },
  {
    "page_content": "earlier. The magnitude and rising trend of this cancer cost results from the fact that breast cancer is the most common malignant neoplasm in Poland and its incidence is on a steadily rising trend. Moreover, a recent analysis shows that the average annual increase in this cancer incidence in Poland is the highest in the group of ten countries of the region27. This unfavourable tendency might be associated with low breast cancer screening; the 2019 figures show that 26.1% of women aged 45–64 in",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:58"
    }
  },
  {
    "page_content": "figures show that 26.1% of women aged 45–64 in Poland had never undertaken breast examinations by X-ray. Importantly, this share increased by 3.6 percentage points from the time of the previous survey (2014) and was 8.8 percentage points higher than the European Union average value35. The other important cancers in terms of absence losses were malignant neoplasms of colorectum (€63 million in 2022; 74.5% increase in 2012–2022 period), lung (€36 million; 1.7% increase), prostate (€50 million;",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:59"
    }
  },
  {
    "page_content": "million; 1.7% increase), prostate (€50 million; 240% increase), and thyroid (€22 million; 126% increase). For colorectal cancer, again, we observe low adherence to preventive programmes; as much as 80% of the Polish population aged 50–74 in 2019 had never participated in colorectal cancer screening, whilst the respective share for neighbouring countries (39.7% in Slovakia and 33.6% in Czechia) or the EU average (48.7%) was notably lower36. Considering lung cancer, there was hardly any increase",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:60"
    }
  },
  {
    "page_content": "lung cancer, there was hardly any increase in the real indirect costs of sickness absence and this relatively favourable situation arises from the incidence trend in this disease. Particularly, resulting from declining tobacco consumption among men in Poland, we observe a dynamically diminishing incidence of lung cancer, and this trend offsets the increasing incidence in women27. Prostate cancer absence losses are characterised by the greatest dynamics among all cancer sites in the period",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:61"
    }
  },
  {
    "page_content": "dynamics among all cancer sites in the period analysed and this reflects adverse epidemiological trends of incidence; Poland had the largest increase of this cancer cases across 10 analysed countries in the 1990–2019 period27. This study analysed not only the indirect costs of malignant neoplasms but also of benign neoplasms. The results show that the cost of short-term absence from benign neoplasms constitutes a large proportion of all-neoplasm losses. Particularly, the absence from leiomyoma",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:62"
    }
  },
  {
    "page_content": "losses. Particularly, the absence from leiomyoma of uterus (D25) resulted in productivity losses of €103.5 million in 2022, almost nine times higher than respective losses due to cervix uteri (C53). Similarly, benign neoplasm of ovary (D27) led to an economic cost of €40.0 million in 2022 which was almost double the burden of ovarian cancer (C56). This shows that for ovarian and uterus neoplasms, economic losses associated with sickness absence are concentrated in non-malignant cases.",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:63"
    }
  },
  {
    "page_content": "absence are concentrated in non-malignant cases. Therefore, to provide a broad picture of neoplasm-related economic losses, non-malignant diagnoses should be accounted for. ## COVID-19 pandemic, sickness absence and productivity losses The COVID-19 pandemic resulted in serious disruptions in health systems' capabilities to provide timely and effective health services37. The pandemic restrictions were associated with a widespread detrimental impact on cancer care in terms of delayed diagnoses,",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:64"
    }
  },
  {
    "page_content": "on cancer care in terms of delayed diagnoses, reduced service delivery, restricted access to medications, and missed cycles of therapies among others38,39. Consequently, around 20% decrease in the number of cancer diagnoses was observed in Poland in 2020, and this drop was even deeper in the April–May period when the most restrictive anti-SARS-CoV-2 policies were in place (e.g. 26% decline in colorectal cancer diagnoses)40. This under-diagnosis of neoplasms has significantly changed the trend",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:65"
    }
  },
  {
    "page_content": "of neoplasms has significantly changed the trend of disease detection and delayed effects of these disturbances will likely be observed in the coming years41. Accounting for the above trends, one would expect declining rates of neoplasm-related absence in the pandemic years. Interestingly, in the first pandemic year (2020) hardly any change in the number of absence days was observed for all malignant neoplasms combined (+ 0.3% compared to 2019) but a substantial decline in all neoplasms",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:66"
    }
  },
  {
    "page_content": "2019) but a substantial decline in all neoplasms (-7.0%). For benign neoplasms, the respective change was as much as -22.7%. The above figures suggest that physicians were able to sustain the capability to issue sickness absence certificates during the pandemic inception but only for malignant neoplasm patients. Possibly, the health system was focused on more severe malignant neoplasms and there was less room for delivering the same service scope for benign neoplasm patients. Interestingly,",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:67"
    }
  },
  {
    "page_content": "for benign neoplasm patients. Interestingly, there was a considerable increase in the number of absence days resulting from hematologic cancers, i.e. lymphoma (both Hodgkin and non-Hodgkin) and leukaemia in 2020. Some evidence suggests that SARS-CoV-2 might induce hematologic malignancies and their remission42,43; however, after a large increase of absence cases in 2020 in these diseases, we observe a decreasing trend in the two following years of the pandemic. On the other hand, the deepest",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:68"
    }
  },
  {
    "page_content": "of the pandemic. On the other hand, the deepest drop in absence cases in 2020 among malignant neoplasms was observed in lung cancer (-11.6%) and it was followed by two years of continuous decline. This tendency reflects a general time trend of diminishing incidence of lung cancer among men. The impact of the pandemic on cancer-related losses associated with sickness absence is reflected in a 7.4% decline in indirect costs of all neoplasms in 2020, but no changes were identified in the",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:69"
    }
  },
  {
    "page_content": "in 2020, but no changes were identified in the respective category of all malignant neoplasms combined. Clearly, the patterns of productivity losses reflect the tendencies observed in absence days; however, they are additionally strengthened by economic fluctuations, particularly the real GDP decline in 2020. ## Study limitations The following limitations of the analysis should be acknowledged. Firstly, the study only accounts for one category of neoplasm-related productivity losses, namely,",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:70"
    }
  },
  {
    "page_content": "of neoplasm-related productivity losses, namely, short-term work absence. With this approach, only a fragmented picture of the indirect costs of disease arises as no categories of inability to work, mortality or presenteeism were under scrutiny here. However, the above categories, particularly mortality losses, have been investigated in previous studies and my aim here was to provide a detailed (all neoplasm diagnoses as classified in ICD-10), dynamic (a decade-long) investigation with a",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:71"
    }
  },
  {
    "page_content": "dynamic (a decade-long) investigation with a thorough focus on work absence solely. Secondly, the choice of the human capital method as a basis for losses estimation is sometimes criticized in favour of the friction cost method (FCM)18,19. Yet, this study only accounts for short-term absenteeism; therefore, the HCM seems to be a more reasonable choice than FCM because a replacement of an employee who is absent only temporarily is unlikely22. Thirdly, only absence cases registered in the social",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:72"
    }
  },
  {
    "page_content": "only absence cases registered in the social insurance system were accounted for here and, because unrecorded episodes (e.g. using holiday instead of formal absence) are not included, this fact underestimates the real burden. The magnitude of this underestimation is difficult to assess. Fourthly, the analysis used average values of labour and economic model inputs and this might bias the results; e.g. neoplasm patients’ wages might deviate from average market values. Unfortunately, the direction",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:73"
    }
  },
  {
    "page_content": "market values. Unfortunately, the direction and magnitude of this deviation are not evaluable. On the other hand, the use of average values provides a more generalized and representative understanding of the phenomenon and can help smooth out the impact of outliers and variations of individual data. Finally, the research only accounts for productivity losses in the formal sector as no data on unpaid costs borne due to cancer were evaluated here. This is because no data is obtainable on these",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:74"
    }
  },
  {
    "page_content": "This is because no data is obtainable on these diseases’ impact on daily informal activities. Unpaid productivity losses can be evaluated with more certainty for mortality losses as it is clear that a prematurely deceased person will not perform any activities11; yet, such an approach is not appropriate for short-term absence losses. # Conclusion This study analysed decade-long trends in incidence and productivity losses associated with all neoplasm diagnoses in Poland. It found that both",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:75"
    }
  },
  {
    "page_content": "neoplasm diagnoses in Poland. It found that both absence and related economic losses increased steadily over time. Consequently, investing in effective public health policies that tackle neoplasms have the potential to reduce not only the health burden but also economic losses. This is particularly important due to the predicted population ageing and the resulting decline of labour supply in the country. ## Supplementary Information Supplementary Information 1.Supplementary Information 2.",
    "metadata": {
      "source": "../data/plain/PMC10853257.plain.txt",
      "id": "../data/plain/PMC10853257.plain.txt:76"
    }
  },
  {
    "page_content": "Pathogenic Germline Mutations in DNA Repair Genes in Combination With Cancer Treatment Exposures and Risk of Subsequent Neoplasms Among Long-Term Survivors of Childhood Cancer Abstract\nPURPOSE\nTo investigate cancer treatment plus pathogenic germline mutations (PGMs) in DNA repair genes (DRGs) for identification of childhood cancer survivors at increased risk of subsequent neoplasms (SNs).\nMETHODS",
    "metadata": {
      "source": "../data/plain/PMC7430217.plain.txt",
      "id": "../data/plain/PMC7430217.plain.txt:0"
    }
  },
  {
    "page_content": "METHODS\nWhole-genome sequencing was performed on blood-derived DNA from survivors in the St Jude Lifetime Cohort. PGMs were evaluated in 127 genes from 6 major DNA repair pathways. Cumulative doses of chemotherapy and body region–specific radiotherapy (RT) were abstracted from medical records. Relative rates (RRs) and 95% CIs of SNs by mutation status were estimated using multivariable piecewise exponential models.\nRESULTS",
    "metadata": {
      "source": "../data/plain/PMC7430217.plain.txt",
      "id": "../data/plain/PMC7430217.plain.txt:1"
    }
  },
  {
    "page_content": "Of 4,402 survivors, 495 (11.2%) developed 1,269 SNs. We identified 538 PGMs in 98 DRGs (POLG, MUTYH, ERCC2, and BRCA2, among others) in 508 (11.5%) survivors. Mutations in homologous recombination (HR) genes were significantly associated with an increased rate of subsequent female breast cancer (RR, 3.7; 95% CI, 1.8 to 7.7), especially among survivors with chest RT ≥ 20 Gy (RR, 4.4; 95% CI, 1.6 to 12.4), or with a cumulative dose of anthracyclines in the second or third tertile (RR, 4.4; 95%",
    "metadata": {
      "source": "../data/plain/PMC7430217.plain.txt",
      "id": "../data/plain/PMC7430217.plain.txt:2"
    }
  },
  {
    "page_content": "in the second or third tertile (RR, 4.4; 95% CI, 1.7 to 11.4). Mutations in HR genes were also associated with an increased rate of subsequent sarcoma among those who received alkylating agent doses in the third tertile (RR, 14.9; 95% CI, 4.0 to 38.0). Mutations in nucleotide excision repair genes were associated with subsequent thyroid cancer for those treated with neck RT ≥ 30 Gy (RR, 12.9; 95% CI, 1.6 to 46.6) with marginal statistical significance.",
    "metadata": {
      "source": "../data/plain/PMC7430217.plain.txt",
      "id": "../data/plain/PMC7430217.plain.txt:3"
    }
  },
  {
    "page_content": "CONCLUSION\nOur study provides novel insights regarding the contribution of genetics, in combination with known treatment-related risks, for the development of SNs. These findings have the potential to facilitate identification of high-risk survivors who may benefit from genetic counseling and/or testing of DRGs, which may further inform personalized cancer surveillance and prevention strategies.",
    "metadata": {
      "source": "../data/plain/PMC7430217.plain.txt",
      "id": "../data/plain/PMC7430217.plain.txt:4"
    }
  },
  {
    "page_content": "Genetic Drivers in Sebaceous Neoplasms: A Review of Germline and Somatic Mutations and Their Role in Treatment and Management Strategies Simple Summary",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:0"
    }
  },
  {
    "page_content": "Approximately 30% of individuals with a sebaceous neoplasm are identified to have a germline mutation. The aim of our review is to identify germline and somatic mutations in sebaceous neoplasms and the steps for workup to determine those at the highest risk for a germline mutation. Early detection of a germline mutation is important for cancer treatment and screening and has medical implications for the family members of affected patients. Personal and family history are key components in risk",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:1"
    }
  },
  {
    "page_content": "and family history are key components in risk assessments and should be included in the evaluation of all individuals diagnosed with sebaceous neoplasm. Genetic counseling is a valuable resource for those at risk for a germline mutation to determine appropriate testing strategies and to guide referrals to specialists for management if a mutation is identified. Abstract",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:2"
    }
  },
  {
    "page_content": "Background: The efficacy of germline testing in colorectal cancer has been proven; however, germline testing in individuals with sebaceous neoplasms is less well defined. This review aims to summarize the literature on sebaceous neoplasms to date, describing the somatic tumor profiles, tumor screening methods, and personal and family history that are suspicious of a germline mutation. Sebaceous neoplasms can be attributed to a variety of etiologies, including UV exposure, immunodeficiency,",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:3"
    }
  },
  {
    "page_content": "including UV exposure, immunodeficiency, germline mutations, or multifactorial influences associated with aging. Sebaceous tumors with abnormal microsatellite instability and mismatch repair deficiency are indicative of a germline mutation in 20–50% of cases, which is similar to rates found in colorectal tumors. Personal and familial history can also be suggestive of a germline etiology in these patients and should be assessed routinely, as approximately 30% of individuals with sebaceous",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:4"
    }
  },
  {
    "page_content": "approximately 30% of individuals with sebaceous neoplasms carry a germline mutation. We outline a strategy for the identification of individuals at risk for germline mutations, recommendations for the management of mutation carriers, and treatment options for individuals with sebaceous neoplasms. Conclusions: Sebaceous tumors are most often sporadic; however, evaluations of a germline etiology are prudent to effectively identify those at risk of additional malignancies as well as at-risk family",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:5"
    }
  },
  {
    "page_content": "additional malignancies as well as at-risk family members. Referral to genetic counseling and germline genetic testing for individuals at risk can significantly impact cancer treatment and screening in patients and their families. # 1. Introduction The term sebaceous neoplasms refers to a group of tumors with sebaceous differentiation, which includes sebaceous hyperplasia, sebaceomas, sebaceous adenomas, and sebaceous carcinomas. These tumors can be divided into two subcategories: periocular",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:6"
    }
  },
  {
    "page_content": "can be divided into two subcategories: periocular and extraocular. These tumors, although most often sporadic, can be associated with inherited cancer conditions, notably Muir–Torre syndrome (MTS), a subtype of Lynch syndrome involving sebaceous carcinomas. They have also been reported in individuals with MUTYH-associated polyposis (MAP), a genetic cancer predisposition syndrome that results in numerous colorectal polyps due to biallelic pathogenic variants in MUTYH. In this review, we aim to",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:7"
    }
  },
  {
    "page_content": "variants in MUTYH. In this review, we aim to describe sebaceous neoplasms and their associations with hereditary cancer syndromes, as well as the stratification and strength of these associations based on genes, tumor location, age of onset, and pathologic and familial features that may raise suspicion of these conditions. # 2. Dermatologic Findings Associated with Muir–Torre Syndrome ## 2.1. Types of Sebaceous Neoplasms ### 2.1.1. Sebaceous Hyperplasia Sebaceous hyperplasia consists of benign",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:8"
    }
  },
  {
    "page_content": "Sebaceous hyperplasia consists of benign skin lesions that occur when sebaceous glands in the skin collect an excess amount of sebum, forming small bumps on the skin at the base of hair follicles. About 1% of the population develops sebaceous hyperplasia in their lifetime, and it occurs more frequently in infants, the elderly, individuals who are immunosuppressed, and individuals with genetic predisposition to these neoplasms. They commonly appear on the face and chest and typically match the",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:9"
    }
  },
  {
    "page_content": "on the face and chest and typically match the color of the surrounding skin or are yellow or brown. ### 2.1.2. Sebaceoma Sebaceomas are benign cutaneous findings commonly found on the head and neck area of middle-aged to elderly individuals, with a median age of onset of about 70 years of age. They mostly occur as solitary nodules or papules whose coloring may be yellow or match the color of the surrounding skin. Sebaceomas share many similarities with sebaceous adenomas, such as location,",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:10"
    }
  },
  {
    "page_content": "with sebaceous adenomas, such as location, appearance, and age of onset, leading to challenges in differentiation. Sebaceomas are also commonly mistaken for basal cell carcinoma or trichoblastoma, given their partial sebaceous and at least 50% basaloid germ cell population. ### 2.1.3. Sebaceous Adenoma Sebaceous adenomas, compared to sebaceous hyperplasia, tend to be larger and often appear in clusters. Similarly to sebaceomas, they are benign neoplasms whose coloring may be yellow or match the",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:11"
    }
  },
  {
    "page_content": "whose coloring may be yellow or match the color of the surrounding skin. They are typically located on the head and neck region, particularly the nose and cheeks. Middle-aged to elderly adults are more susceptible to these types of tumors. These benign tumors can be difficult to differentiate from other sebaceous neoplasms, particularly when the samples are small or the lesions are more superficial. Sebaceous adenomas are differentiated from sebaceomas in that the adenomas have a basaloid",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:12"
    }
  },
  {
    "page_content": "sebaceomas in that the adenomas have a basaloid germinative cell population of less than 50%. ### 2.1.4. Sebaceous Carcinoma Sebaceous carcinoma is a rare skin cancer that arises from the sebaceous gland. The overall incidence in the United States between 2000 and 2016 was 2.4 cases per million. Another study found the incidence varies by race, with 0.5 cases per million in the Black population, one case per million in the Asian and Pacific Islander population, and two cases per million in the",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:13"
    }
  },
  {
    "page_content": "population, and two cases per million in the White population. In the United States, sebaceous carcinomas most commonly appear between the ages of 60 and 79, regardless of sex assigned at birth. However, multiple studies have reported a higher incidence of sebaceous carcinoma, specifically of the eyelid, in individuals assigned female at birth compared to individuals assigned male at birth. The diagnosis of sebaceous carcinomas can be challenging, but various pathologic features can aid in the",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:14"
    }
  },
  {
    "page_content": "but various pathologic features can aid in the exclusion of benign pathologies, such as sebaceomas and sebaceous adenomas. Tumors that display a more infiltrative growth pattern, atypical mitoses, highly variable nuclei, and necrotic cell death are more likely to be sebaceous carcinomas. Poorly differentiated sebaceous carcinomas can also be challenging to distinguish between basaloid squamous cell carcinomas, basal cell carcinomas, or Merkel cell carcinomas. Sebaceous carcinomas are typically",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:15"
    }
  },
  {
    "page_content": "carcinomas. Sebaceous carcinomas are typically categorized as periocular or extraocular. Although 70–80% of sebaceous carcinomas occur on the head or neck, they can occur anywhere in the body where sebaceous glands are present. The 5-year survival rate ranges between 70 and 97%, and the 10-year survival rate is approximately 79%. One study found that periocular sebaceous carcinomas had a more favorable 5-year survival rate at 75% compared to extraocular occurrences at 68%. Factors that can",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:16"
    }
  },
  {
    "page_content": "extraocular occurrences at 68%. Factors that can increase the risk of sebaceous carcinomas include immunosuppression, ultraviolet (UV) exposure, radiation exposure, and MTS. Periocular tumors arise on the eyelid skin, which is the most common location for sebaceous carcinomas. Ocular tumors confined to the conjunctiva are extremely rare. The upper eyelid is two to three times more frequently affected than the lower eyelid due to the high number of meibomian glands in this region. Women of Asian",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:17"
    }
  },
  {
    "page_content": "meibomian glands in this region. Women of Asian descent have been shown to be at greater risk for these neoplasms compared to other sebaceous neoplasms. On the eyelid, they can present as a firm, round, enlarging nodule with inflammation and thickening of the eyelid. The diagnosis of periocular sebaceous carcinomas can be delayed due to their similar appearance to chalazion, conjunctivitis, blepharitis, or other inflammatory conditions of the eye. Local spread is common and can involve the",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:18"
    }
  },
  {
    "page_content": "eye. Local spread is common and can involve the conjunctiva and cornea; advanced disease may even involve the orbit and adjacent structures. Superficial biopsy should be performed for periocular tumors with dermatoscopic findings, including polymorphous atypical vessels, an underlying yellow background, and ulceration, which are consistent with sebaceous carcinomas. Extraocular sebaceous carcinomas account for only 25% of all sebaceous carcinomas. Extraocular tumors arise outside of the ocular",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:19"
    }
  },
  {
    "page_content": "Extraocular tumors arise outside of the ocular region, most commonly in the head and neck, but they can occur in the trunk and extremities. They present as a red-yellow nodule or papule, often with ulceration. Extraocular tumors with suspicion of sebaceous carcinoma, as previously described for periocular tumors, should prompt thorough dermatoscopic evaluation and a deep biopsy, including the dermis. - Periocular - b.Extraocular ## 2.2. Additional Skin Tumors Associated with MTS ###",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:20"
    }
  },
  {
    "page_content": "Additional Skin Tumors Associated with MTS ### Keratoacanthoma Keratoacanthomas are benign, rapidly growing, dome-shaped skin tumors that begin in a hair follicle. They often occur on areas of the body that receive sun exposure, particularly the head, neck, arms, legs, and back of the hands. Clinically, they are almost indistinguishable when compared to squamous cell carcinomas and subsequently are often treated similarly. Keratoacanthomas are twice as likely to occur in males as opposed to",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:21"
    }
  },
  {
    "page_content": "twice as likely to occur in males as opposed to females and are more common in individuals 60 years of age or older. Factors that can increase risk include immunocompromised status, hereditary cancer predisposition, such as MTS, UV radiation, exposure to carcinogenic chemicals, viral exposure, such as human papillomavirus (HPV), and trauma or surgery to the location. # 3. Sporadic Etiologies and Molecular Profiles of Sebaceous Neoplasms The molecular profile of sebaceous carcinomas has not been",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:22"
    }
  },
  {
    "page_content": "profile of sebaceous carcinomas has not been well defined, as limited studies have explored somatic genetic testing in these tumors. Tetzlaff et al. performed whole exome next-generation sequencing on 27 sebaceous carcinomas (23 periocular and 4 extraocular) from 20 patients. The most common genes with somatic mutations identified in the periocular tumors were TP53 (n = 9), RB1 (n = 6), PIK3CA (n = 2), PTEN (n = 2), ERBB2 (n = 2), and NF1 (n = 2). Common mutations within the extraocular tumors",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:23"
    }
  },
  {
    "page_content": "Common mutations within the extraocular tumors were not easily defined due to the high tumor mutation burden attributed to microsatellite instability in three of the four tumors, but some of the genes with mutations identified in these tumors include the following: ALK, BTK, FGFR2, PTEN, PDGFRB, MET, TSC1, ERBB2, PIK3R2, CHEK2, ABL2, HRAS, NF1, and ABL1. Although the sample size of extraocular tumors was small in this study, Kruskal–Wallis testing identified a significant difference between the",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:24"
    }
  },
  {
    "page_content": "identified a significant difference between the number of mutations in extraocular compared to ocular sebaceous carcinomas (p = 0.036), with more mutations detected in the extraocular lesions. A separate study in Korea examined 29 sebaceous carcinomas (20 periocular, 9 extraocular) and found similar results to Tetzlaff et al., where the most common genes with mutations in periocular tumors were TP53 (n = 13) and RB1 (n = 3). The most common mutation in extraocular tumors was NOTCH1 (n = 5),",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:25"
    }
  },
  {
    "page_content": "in extraocular tumors was NOTCH1 (n = 5), which was significantly enriched compared to periocular tumors (p = 0.001). Additional studies have investigated the somatic profiles of tumors in the setting of risk factors suspected to increase the risk of sebaceous carcinomas. Three categories of somatic profiles emerged: tumors associated with UV radiation, immunosuppression, and multifactorial influences. In the United States, 73% of sebaceous carcinoma cases occur on the head and neck, areas that",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:26"
    }
  },
  {
    "page_content": "cases occur on the head and neck, areas that are often exposed to the sun. In addition, 85% of these cases occur in White individuals, who have the increased risk factor of less photoprotective melanin pigment in their skin compared to other racial groups. When ambient UV radiation exposure was assessed via geographic location, there was an increased risk for sebaceous carcinoma both with and without MTS. These data support UV radiation as a potential etiology for sebaceous carcinomas. The",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:27"
    }
  },
  {
    "page_content": "potential etiology for sebaceous carcinomas. The somatic profile of these UV-related tumors differs from that of their mismatch repair counterparts. Sebaceous neoplasms associated with UV radiation have a higher tumor mutational burden, are more likely to be poorly differentiated and infiltrative, and have frequent TP53, NOTCH1/2, FAT3, RREB1, and KMT2D mutations, a profile resembling that of cutaneous squamous cell and basal cell carcinomas. Immunosuppression has also been noted as a risk",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:28"
    }
  },
  {
    "page_content": "Immunosuppression has also been noted as a risk factor for sebaceous carcinomas. Lanoy et al. found that the risk of sebaceous carcinomas was 8-fold higher in individuals with acquired immunodeficiency syndrome. Similarly, individuals who are receiving immunosuppressive therapy for solid organ transplants have an estimated 25- to 34-fold increased risk compared to the general population. Tumors in individuals with immunosuppression are less likely to have common driver mutations, as shown in a",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:29"
    }
  },
  {
    "page_content": "to have common driver mutations, as shown in a study of a group of 29 patients, in which 31% (n = 9/29) lacked mutations in TP53, RB1, or NOTCH1/2. In four of these nine tumors (44%), the patients were HPV-positive, and the age of onset tended to be younger and without local recurrence. Lastly, there is a population of sebaceous neoplasms that have a low mutation burden, unlike those associated with UV radiation, that are likely attributed to multifactorial influences, such as aging. Cutaneous",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:30"
    }
  },
  {
    "page_content": "influences, such as aging. Cutaneous sebaceous carcinomas with a low mutational burden often occur on the head and neck, as is typical, but lack recurrent characteristic mutation profiles on somatic testing. Ocular sebaceous carcinomas with this low mutational burden often have ZNF750 mutations, with some patients also having TP53 or RB1 driver somatic mutations, and other patients having an increased risk of developing these tumors due to immune deficiency. Overall, in addition to mismatch",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:31"
    }
  },
  {
    "page_content": "deficiency. Overall, in addition to mismatch repair deficiency driving the formation and development of sebaceous neoplasms, which is described in greater detail within successive sections, there are alternative risk factors, including exposure to UV radiation, immunosuppression, and multifactorial influences in sporadic cases that should be considered when assessing the etiology of a sebaceous neoplasm. These alternative factors may aid in determining an etiology for a patient’s personal",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:32"
    }
  },
  {
    "page_content": "determining an etiology for a patient’s personal and/or family history of sebaceous neoplasias in the absence of an identifiable germline variant. # 4. Mismatch Repair Deficiency and Microsatellite Instability in Sebaceous Neoplasms ## 4.1. MMR Deficiency Mismatch repair (MMR) proteins associated with Lynch syndrome include MLH1, MSH2, MSH6, and PMS2—all of which are essential components in DNA repair. The MMR proteins interact as heterodimers that detect and repair mismatches in DNA, such as",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:33"
    }
  },
  {
    "page_content": "that detect and repair mismatches in DNA, such as inaccurately paired bases and DNA abnormalities caused by insertions or deletions. The pairings of heterodimers are as follows: MLH1 binds with PMS2, and MSH2 binds with MSH6. MLH1 and MSH2 are key proteins within the heterodimer that can bind with other proteins to perform DNA mismatch repair. However, PMS2 and MSH6 proteins only dimerize with MLH1 and MSH2, respectively. Therefore, the absence of MLH1 or MSH2 expression will also cause absent",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:34"
    }
  },
  {
    "page_content": "of MLH1 or MSH2 expression will also cause absent protein expression of the corresponding dimerized protein. This is an essential concept in interpreting MMR protein expression and the likelihood of a Lynch syndrome mutation. The expression of MMR proteins in a tumor is detected using immunohistochemistry (IHC) staining. Abnormal MMR protein function within a tumor, referred to as mismatch repair deficiency (dMMR), may lead to tumor microsatellite instability (MSI) due to the cell’s inability",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:35"
    }
  },
  {
    "page_content": "instability (MSI) due to the cell’s inability to perform DNA mismatch repair. ## 4.2. MSI Microsatellites are repetitive DNA sequences, typically made up of one to six base pairs, which may repeat up to 100 times throughout the genetic code. Highly repetitive sequences are prone to strand slippage during DNA replication, resulting in errors. Tumors with dMMR typically result in MSI due to the cell’s inability to repair errors. MSI in a tumor is detected using a methodology combining polymerase",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:36"
    }
  },
  {
    "page_content": "detected using a methodology combining polymerase chain reaction with fluorescent primers and capillary electrophoresis. The standard approach to MSI testing utilizes a panel of microsatellite markers on the National Cancer Institute (NCI) microsatellite panel (two mononucleotide—BAT25/26; three dinucleotide markers—D2S123, D5S346, and D17S250) and compares these markers with a paired normal sample to identify high microsatellite instability (MSI-H) within the tumor. The presence of instability",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:37"
    }
  },
  {
    "page_content": "within the tumor. The presence of instability in at least two markers is considered MSI-H, instability in one marker is considered low microsatellite instability (MSI-L), and stability in all markers would indicate microsatellite stability (MSS). Additional testing may be necessary to exclude MSI-L tumors, especially in the setting of only aberrant dinucleotide repeat mutations. ## 4.3. Tumor Screening with MMR-IHC and MSI Universal tumor screening with MMR-IHC and MSI is recommended for all",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:38"
    }
  },
  {
    "page_content": "with MMR-IHC and MSI is recommended for all colorectal tumors at the time of diagnosis. This is due to the relatively high rates of germline Lynch syndrome mutations in individuals with dMMR staining (25–67%); however, a common alternative etiology for dMMR involving MLH1 and PMS2 is sporadic MLH1 promoter methylation. There is notably a lower sensitivity and specificity for Lynch syndrome in individuals with dMMR by MMR-IHC in extraocular sebaceous carcinomas (81–85% sensitivity and 48%",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:39"
    }
  },
  {
    "page_content": "sebaceous carcinomas (81–85% sensitivity and 48% specificity) versus in colonic tumors (92–94% sensitivity and 88–100% specificity). Limited studies have explored MMR-IHC and MSI testing sensitivity in sebaceous carcinomas, and there are debates regarding the use of these screenings in sebaceous carcinomas, as their clinical relevance is not well defined. Historically, studies have explored tumor screening with MSI and MMR-IHC in individuals with sebaceous and internal tumors concerning MTS.",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:40"
    }
  },
  {
    "page_content": "sebaceous and internal tumors concerning MTS. Machin et al. examined tumor samples from six patients with internal Lynch-associated tumors and cutaneous tumors and found that all ten cutaneous (eight sebaceous adenomas, one sebaceous carcinoma, and one keratoacanthoma) and all eleven internal Lynch-associated tumors exhibited MSI. dMMR on MMR-IHC was concordant for all tumors in this study, with the majority exhibiting loss of MSH2 protein expression (n = 5). This result is suggestive of a",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:41"
    }
  },
  {
    "page_content": "(n = 5). This result is suggestive of a germline etiology for these tumors. Entius et al. compared MSI in tumors from 13 patients with MTS and 8 patients with sporadic sebaceous carcinoma. MSI was detected in 69% (n = 9/13) of the patients with MTS, while none of the sporadic sebaceous carcinoma tumors exhibited MSI (p = 0.002). MMR-IHC for MLH1 and MSH2 was concordant in 89% (n = 8/9) of tumors with MSI: four had loss of MLH1 and four had loss of MSH2. These studies demonstrate the potential",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:42"
    }
  },
  {
    "page_content": "of MSH2. These studies demonstrate the potential use of testing individuals for germline pathogenic variants in the setting of a sebaceous carcinoma with MSI. More recent studies focused on identifying dMMR in an unselected population of sebaceous neoplasms. Notably, very few of these studies explored MSI status in these tumors (Table 1). Cook et al. identified that 32% of sebaceous carcinomas in their cohort had dMMR, which was lower than rates quoted in other studies exploring dMMR status in",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:43"
    }
  },
  {
    "page_content": "quoted in other studies exploring dMMR status in sebaceous neoplasms (49–66%) (Table 1). The lower rate quoted by Cook et al. may be attributed to their focus on only sebaceous carcinomas instead of sebaceous neoplasms in general, as well as the inclusion of periocular tumors, which are typically MMR-proficient. Studies have consistently shown that extraocular sebaceous neoplasias are more likely to be dMMR. Jessup et al. and Cook et al. performed the largest studies analyzing dMMR status and",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:44"
    }
  },
  {
    "page_content": "the largest studies analyzing dMMR status and stratified groups by tumor location. Jessup et al. found that tumor location was significantly (p < 0.0001) associated with IHC status: 95% (n = 59/62) of non-head and neck tumors were dMMR compared to 55% (n = 84/154) of head and neck tumors. However, the authors noted that the sensitivity of tumor location to determine deficiency or proficiency of MMR was low. Cook et al. similarly found that most sebaceous carcinomas with dMMR were at sites other",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:45"
    }
  },
  {
    "page_content": "carcinomas with dMMR were at sites other than the head and neck (65%), although the rates were much lower compared to Jessup et al. This study also investigated extraocular sebaceous carcinomas and found that dMMR tumors were most often located on the trunk (45%; n = 29/64) compared with MMR-proficient tumors (6%; n = 6/100). Although these studies have shown that dMMR is significantly associated with tumor location, solely relying on location to determine which tumors are potentially dMMR",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:46"
    }
  },
  {
    "page_content": "to determine which tumors are potentially dMMR would miss many dMMR tumors, thus potentially decreasing their chances of identifying a germline variant in this population if one were to screen by location. These studies also examined age of onset as a criterion for MMR-IHC testing. Jessup et al. found a similar median age of tumor onset in individuals with dMMR status compared to those with MMR-proficient status in their sebaceous tumors, with the median ages at diagnosis being 68 and 66,",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:47"
    }
  },
  {
    "page_content": "the median ages at diagnosis being 68 and 66, respectively. Cook et al. found that the median age of tumor onset was slightly younger in individuals whose tumors were dMMR versus MMR-proficient, with the median ages at diagnosis being 67 and 78, respectively; notably, this difference was not statistically significant. This variance in median age can likely be attributed to tumor location and pathologies evaluated in each study (Table 1). These studies indicate that utilizing age for tumor",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:48"
    }
  },
  {
    "page_content": "studies indicate that utilizing age for tumor diagnosis, as well as tumor location, as an alternative for screening with MMR-IHC would likely miss a significant number of tumors suggestive of MTS. Sebaceous neoplasms with dMMR most often demonstrated loss of MSH2/MSH6 on MMR-IHC across all studies (60–74%), with loss of MLH1/PMS2 (19–23%) as the second most common finding (Table 1). Jessup et al. postulated that the highest frequency of MSH2/MSH6 deficiency may reflect the fact that MSH2 is the",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:49"
    }
  },
  {
    "page_content": "deficiency may reflect the fact that MSH2 is the most common germline mutation in MTS, although germline mutation status was not confirmed in their cohort. Cook et al. and Everett et al. found that, of those who underwent MMR-IHC and germline testing, most pathogenic variants were detected in MSH2 (Table 2). Schon et al. evaluated germline mutation status in their cohort; however, due to the small sample size, only two pathogenic variants were identified, making it challenging to identify",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:50"
    }
  },
  {
    "page_content": "identified, making it challenging to identify significant trends (Table 2). MLH1 promoter methylation was not explored but would be reasonable to consider in future studies, given the known high prevalence of this finding in sporadic colorectal tumors with MLH1/PMS2 deficiency. Germline testing was not performed for large portions of the cohorts for these studies; therefore, it is hard to conclusively state the use of MMR-IHC in deciding whether one should undergo germline testing. However,",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:51"
    }
  },
  {
    "page_content": "one should undergo germline testing. However, when dMMR is identified in a sebaceous neoplasm, this should prompt consideration for an associated pathogenic germline variant. Although MMR-IHC has been explored in an unselected population of individuals with sebaceous neoplasias, a few studies have investigated MSI in sebaceous tumors outside of the context of MTS. Kruse et al. examined 58 paraffin-embedded sebaceous gland tumors from 58 patients from Germany and Italy. Of these tumors, 25 were",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:52"
    }
  },
  {
    "page_content": "from Germany and Italy. Of these tumors, 25 were sebaceous gland neoplasms and 32 were sebaceous gland hyperplasias. An MSI assessment revealed that 60% (n = 15/25) of sebaceous gland neoplasms and 3% (n = 1/32) of sebaceous gland hyperplasias were MSI-H. A subsequent study showed that in a population suspicious of MTS due to having a personal history of a sebaceous neoplasm and at least one additional malignancy, or a personal history of a sebaceous neoplasm with a family history suspicious of",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:53"
    }
  },
  {
    "page_content": "neoplasm with a family history suspicious of Lynch syndrome, 65% (n = 24/37) of patients with MSI-H tumors were identified with a pathogenic variant consistent with a diagnosis of MTS. Although MSI testing is typically considered in the context of a hereditary condition, such as Lynch syndrome, other etiologies for MSI in sebaceous neoplasms are important to consider. A small study investigated MSI in apparently sporadic sebaceous carcinomas and found a higher rate of MSI in immunosuppressed",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:54"
    }
  },
  {
    "page_content": "found a higher rate of MSI in immunosuppressed renal transplant recipients (60%, n = 3/5) compared to immunocompetent individuals (0%, n = 0/3). Given the relatively small sample size, the authors were unable to establish significant conclusions but postulated that chronic exposure to immunosuppressive drugs, such as azathioprine, could induce MSI due to the preferential selection of cells with dMMR as a mechanism to avoid cytotoxicity. MSI is not routinely used as a stand-alone screening",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:55"
    }
  },
  {
    "page_content": "is not routinely used as a stand-alone screening method for sebaceous neoplasms; however, if MSI is utilized for screening sebaceous neoplasms, it would be important to consider factors such as immunosuppression and dMMR when considering the etiology of MSI-H status. MSI testing and MMR-IHC status have been well documented to have high concordance in colorectal tumors. In the limited studies available, MSI-H and dMMR of sebaceous neoplasms appear to have high concordance as well. IHC screening",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:56"
    }
  },
  {
    "page_content": "to have high concordance as well. IHC screening in sebaceous neoplasias is primarily performed in the context of evaluating for a hereditary predisposition but may find increasing use in consideration with systemic therapy for advanced disease. The yield of MSI and IHC screening in sebaceous carcinomas for germline mutations is challenging to determine due to the relatively small number of individuals who undergo MSI and dMMR tumor screening and germline genetic testing. As a result, although",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:57"
    }
  },
  {
    "page_content": "germline genetic testing. As a result, although it may have use for certain patients, such as those with metastatic disease, universal screening for sebaceous neoplasms via MSI and dMMR for the purposes of determining good candidates for germline testing may be difficult to justify in practice. # 5. Hereditary Cancer Predisposition Syndromes Associated with Sebaceous Neoplasms Although most sebaceous neoplasms are sporadic in origin, it is known that they occur at higher frequencies in",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:58"
    }
  },
  {
    "page_content": "is known that they occur at higher frequencies in individuals with certain risk factors, including genetic predisposition. MTS has long been associated with sebaceous neoplasms and tumors of the gastrointestinal and genitourinary systems and is caused by mutations in DNA MMR genes, which lead to MSI. MTS was initially described separately by Muir and Torre in 1967, who characterized the classical features of the syndrome as the presence of a cutaneous sebaceous neoplasm(s) with one or more",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:59"
    }
  },
  {
    "page_content": "cutaneous sebaceous neoplasm(s) with one or more visceral neoplasms, of which colonic neoplasias are the most common in the absence of other causative factors. MTS is an uncommon variant of Lynch syndrome, having an estimated prevalence of about 1 in 500,000 versus 1 in 279 individuals, respectively. The proportion of patients with MTS has been estimated to be between about 5% and 9% of all Lynch syndrome patients and has a male-to-female predominance with a ratio of three males for every two",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:60"
    }
  },
  {
    "page_content": "with a ratio of three males for every two females diagnosed. Patients with this syndrome generally present between 53 and 61 years of age, with the earliest reported case at 23 years and the oldest at 89 years. Although Lynch syndrome is associated with five genes affecting MMR—MLH1, MSH2, MSH6, PMS2, and EPCAM—to this point, MTS has been primarily associated with three of these genes: MLH1, MSH2, and MSH6. The majority of patients with MTS are due to pathogenic variants in the MSH2 gene",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:61"
    }
  },
  {
    "page_content": "are due to pathogenic variants in the MSH2 gene (88–93%), while MLH1 is the next most common (7–11%). Pathogenic variants in MSH6 and PMS2 are the least common germline causes of MTS, with primarily single-case reports of patients and their families reported in the literature. Elevated risks of sebaceous tumors and keratoacanthomas have not been reported for individuals with EPCAM deletions to date. At least 50% of patients diagnosed with MTS present with an internal malignant disease before",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:62"
    }
  },
  {
    "page_content": "present with an internal malignant disease before skin lesions develop, of which colorectal cancer (CRC) is the most common. It is critical to identify these patients as early as possible to aid in proactive decision-making and facilitate education for their family members who may benefit from testing. Currently, no consensus on the clinical diagnostic criteria for MTS has been published. However, personal medical history, including the presence of a cutaneous sebaceous neoplasm with one or",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:63"
    }
  },
  {
    "page_content": "of a cutaneous sebaceous neoplasm with one or more visceral neoplasms, in addition to other personal and familial factors, can be suggestive of MTS. As previously discussed, dMMR and MSI can be indicative of Lynch syndrome. Pathogenic variants in a Lynch syndrome-associated gene identified on somatic testing can also be suggestive of a germline mutation. In patients with dMMR colorectal tumors, there is an approximate 20–30% yield for germline testing for mutations associated with Lynch",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:64"
    }
  },
  {
    "page_content": "testing for mutations associated with Lynch syndrome, which is consistent with the reported yield of germline testing for patients with sebaceous neoplasms with dMMR (20–50%) (Table 2). Given the similar yield for identifying a germline Lynch syndrome mutation in patients with dMMR in sebaceous carcinomas and CRC, it is reasonable to evaluate for germline testing in the presence of abnormal MMR-IHC testing. With regards to MSI, one study looked at 1066 patients with newly diagnosed colonic",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:65"
    }
  },
  {
    "page_content": "at 1066 patients with newly diagnosed colonic adenocarcinoma. Of these, 135 tumors (12.7%) were MSI-H, and 23 (17%) had a germline deleterious mutation. MSI testing of sebaceous neoplasms in specific patients may have a high germline yield. Mangold et al. demonstrated that in a selected patient population, the yield for germline testing in individuals who had MSI-H tumors was about 65%. Based on this result, it is important to assess individuals for signs and symptoms of MTS, for which a",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:66"
    }
  },
  {
    "page_content": "for signs and symptoms of MTS, for which a referral to a genetics specialist, such as a genetic counselor, may be invaluable. In addition to somatic testing that may be suggestive of a germline mutation, family history can aid in determining the level of suspicion for MTS. Although sebaceous neoplasms can occur in isolation for individuals with MTS, they are often seen in combination with other cancers, affecting both the patient and their family members. As a result, a genetics consult in",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:67"
    }
  },
  {
    "page_content": "members. As a result, a genetics consult in which family history is assessed and evaluated is invaluable. It has been estimated that sebaceous neoplasms precede the internal neoplasms or are concurrent with them in 41% of individuals with MTS. Of the internal neoplasms, the risk is highest for colonic and endometrial cancers, with gastric, ovarian, pancreatic, urothelial, brain (typically glioblastoma), biliary tract, and small intestinal cancers also being associated with Lynch syndrome.",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:68"
    }
  },
  {
    "page_content": "also being associated with Lynch syndrome. Features that raise suspicion of a germline variant within a family include the following:Lynch syndrome-associated cancer diagnosed <age 50;Synchronous or metachronous Lynch syndrome-associated cancers;Multiple relatives on the same side of the family with Lynch syndrome-associated cancers. If a patient’s personal and/or family history is suspicious, identification of a germline pathogenic variant can impact the cancer treatment and the proactive",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:69"
    }
  },
  {
    "page_content": "can impact the cancer treatment and the proactive management recommendations for individuals and their families. It is important to note that a family history suspicious for a hereditary cancer condition is an indication for referral to genetics services, regardless of the somatic testing results. ## Alternative Genetic Etiologies for MTS Phenotype Although MSI can be indicative of an increased risk for MTS, it is estimated that approximately 35% of tumors in patients with this syndrome do not",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:70"
    }
  },
  {
    "page_content": "of tumors in patients with this syndrome do not show instability. In this case, the assumption is that the syndrome is not driven by errors within MMR proteins, as previously discussed, but rather an alternative mechanism. Multiple case reports have identified MTS patients with tumors that show MSS and biallelic inactivation of MUTYH, and their authors suggest MAP as an alternative etiology for MTS, separate from a variant of Lynch syndrome. The function of MUTYH is in base excision repair, in",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:71"
    }
  },
  {
    "page_content": "function of MUTYH is in base excision repair, in which it removes adenine bases from the DNA backbone at sites where adenine is inappropriately paired. Biallelic inactivation of MUTYH in the germline due to an associated pathogenic variant causes MAP. MAP is a hereditary cancer predisposition syndrome associated with a significantly increased risk of colorectal polyps (typically between ten to a few hundred), with an average age of presentation of approximately 50 years old. Unlike Lynch",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:72"
    }
  },
  {
    "page_content": "of approximately 50 years old. Unlike Lynch syndrome, which is inherited in an autosomal dominant manner, MAP is inherited in an autosomal recessive manner and does not display the familial patterns often seen in Lynch syndrome. When compared to MTS associated with dMMR, MTS tumors that are driven by biallelic MUTYH inactivation are often lower in penetrance and present at older ages than their MMR counterparts. # 6. Recommendations and Management for Sebaceous Neoplasms ## 6.1. Somatic Testing",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:73"
    }
  },
  {
    "page_content": "for Sebaceous Neoplasms ## 6.1. Somatic Testing of Sebaceous Neoplasms and Germline Testing After Sebaceous Neoplasm Diagnosis As dMMR has been shown to be a good Lynch syndrome predictor across a broad spectrum of tumor types, it is tempting to perform MMR-IHC on all sebaceous neoplasms to identify individuals at high risk for Lynch syndrome. However, due to a high false-positive rate of MMR-IHC (56%) in sebaceous neoplasms, this is unlikely to be effective as a single method for identifying",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:74"
    }
  },
  {
    "page_content": "be effective as a single method for identifying those with Lynch syndrome. Of note, MMR-IHC may be beneficial for reasons other than identifying Lynch syndrome, including assessing for potential response to immunotherapy in advanced diseases. The sensitivity and specificity of MMR-IHC on sebaceous neoplasms for Lynch syndrome are lower than those of CRC and endometrial cancer, and, therefore, MMR-IHC is less likely to accurately determine if an individual is at high risk to have Lynch syndrome.",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:75"
    }
  },
  {
    "page_content": "is at high risk to have Lynch syndrome. The correlation between sebaceous neoplasms with dMMR and a germline Lynch syndrome mutation was highest when patients had either a personal history of CRC and/or a family history of two or more relatives with CRC. Therefore, additional Lynch syndrome features are a better predictor of Lynch syndrome diagnosis than MMR deficiency of a sebaceous neoplasm, and MMR-IHC on all sebaceous neoplasms may not be necessary. Although several tools are available to",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:76"
    }
  },
  {
    "page_content": "Although several tools are available to identify individuals with CRC at high risk for Lynch syndrome, only one such tool exists to address this question in individuals with sebaceous neoplasms. The Mayo Muir–Torre syndrome risk scoring system provides a score based on the age at diagnosis of a sebaceous neoplasm, the total number of sebaceous neoplasms, personal history of a Lynch syndrome-associated cancer, and family history of any Lynch syndrome-associated cancer. The creators of the",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:77"
    }
  },
  {
    "page_content": "syndrome-associated cancer. The creators of the scoring system found that individuals with a score of 3 or higher were more likely to have MTS, individuals with a score of 2 had an intermediate likelihood, and no individual with a score of 1 or less had MTS. Overall, any individual with a sebaceous neoplasm should be screened for Lynch syndrome, including an assessment for additional Lynch syndrome features, such as personal and family history of Lynch syndrome-related cancers (Figure 1). If",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:78"
    }
  },
  {
    "page_content": "of Lynch syndrome-related cancers (Figure 1). If additional Lynch syndrome features are present that meet a score of 2 or higher on the Mayo scoring tool, referral to genetics for germline testing is indicated (Table A1). Prior to germline testing, if an individual had CRC or endometrial cancer, performing MMR-IHC on these tumors may provide additional insight into the possibility of Lynch syndrome. This is because the specificity of MMR-IHC on CRC and endometrial cancer is much higher than",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:79"
    }
  },
  {
    "page_content": "on CRC and endometrial cancer is much higher than that on sebaceous neoplasms. MMR-IHC on sebaceous neoplasms should not be used in isolation for the identification of candidates for germline testing. The Mayo scoring system indicates the importance of using the Lynch syndrome features of the personal and family history in addition to the personal history of sebaceous neoplasms to guide referrals to genetics for germline testing rather than MMR-IHC on sebaceous neoplasms. Germline genetic",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:80"
    }
  },
  {
    "page_content": "MMR-IHC on sebaceous neoplasms. Germline genetic testing needs to include the Lynch syndrome-associated genes (MLH1, MSH2, MSH6, PMS2, EPCAM), as well as MUTYH. Germline multi-gene panels, including these genes, are currently commercially available. Identifying patients with Lynch syndrome or MAP can lead to increased cancer screening and potential chemopreventive options for the individual, as well as their relatives. ## 6.2. Lynch Syndrome and MAP Management Multiple resources review",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:81"
    }
  },
  {
    "page_content": "and MAP Management Multiple resources review guidelines for the screening and treatment of the many cancers associated with Lynch syndrome. The National Comprehensive Cancer Network (NCCN) guidelines are most often referenced for cancer screening recommendations in individuals with Lynch syndrome and MAP. The latest NCCN guidelines can be accessed here [https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1544, accessed on 27 December 2024]. Cancer risk estimates and associated",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:82"
    }
  },
  {
    "page_content": "2024]. Cancer risk estimates and associated screenings vary by Lynch syndrome-associated genes and are updated regularly. High-quality colonoscopy, typically recommended to be performed every 1–2 years, is the preferred colon screening method for all individuals with Lynch syndrome and MAP. The age at which to start screening varies by the genes affected, as well as family history, but may be initiated as early as age 20. Screening for gynecologic cancers, such as ovarian and endometrial",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:83"
    }
  },
  {
    "page_content": "cancers, such as ovarian and endometrial cancers, remains controversial; transvaginal ultrasound and CA-125 have been found to have poor sensitivity and specificity but can be performed for women who have not undergone prophylactic hysterectomy/salpingo-oophorectomy. In addition, regular endometrial biopsy in asymptomatic women can be considered but has not been shown to be more effective than monitoring for abnormal bleeding suggestive of endometrial cancer. Gastric and small bowel cancer",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:84"
    }
  },
  {
    "page_content": "cancer. Gastric and small bowel cancer screening is performed using high-quality esophagogastroduodenoscopy (EGD), usually performed every 3–5 years in adults. Limited data support pancreatic cancer screening in Lynch syndrome. Pancreatic cancer screening can be considered for individuals with at least one first- or second-degree relative with exocrine pancreatic cancer on the same side of the family as Lynch syndrome. Screening can start at age 50 or 10 years younger than the earliest exocrine",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:85"
    }
  },
  {
    "page_content": "50 or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever comes first. The NCCN recommends pancreatic cancer screening to be performed in experienced high-volume centers, as there are uncertainties about the potential benefits of pancreatic cancer screening. Screening for other Lynch syndrome-associated cancers, such as those of the urinary tract, brain, or biliary tract, can be considered based on family history and personal risk factors as well.",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:86"
    }
  },
  {
    "page_content": "family history and personal risk factors as well. Colon cancer screening for MAP includes high-quality colonoscopy every 1–2 years starting at age 25–30. If the polyp burden cannot be managed endoscopically, colectomy is recommended to reduce the colon cancer risk. Baseline EGD is recommended to begin at age 30–35. Cancer screening recommendations for both MAP and Lynch syndrome are updated regularly, so involvement of a genetics professional in managing these disorders is highly recommended. #",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:87"
    }
  },
  {
    "page_content": "managing these disorders is highly recommended. # 7. Treatment of Sebaceous Carcinomas According to a large survey from the National Cancer Database, over 95% (n = 1320/1388) of patients with sebaceous carcinomas are diagnosed with localized disease without nodal or distant metastases. Surgical resection, whether by wide local excision or Mohs, remains the mainstay of treatment for most sebaceous carcinomas. Sentinel lymph node biopsy may be performed but is controversial due to concerns about",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:88"
    }
  },
  {
    "page_content": "but is controversial due to concerns about low yield and false-negative results in the head and neck. In addition, radiation and topical therapies have been used anecdotally in those with locally advanced disease. For patients with locally advanced or metastatic disease, systemic therapy has been used in the neoadjuvant or palliative setting. 5-Fluorouracil/cisplatin, 5-fluorouracil/carboplatin, mitomycin-C, and cetuximab in combination with radiation have been explored in this area. However,",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:89"
    }
  },
  {
    "page_content": "have been explored in this area. However, with the advent of immunotherapy and the discovery that dMMR tumors are more responsive to immunotherapy, checkpoint inhibitors have started to be used with good results. In 2018, Domingo-Musibay et al. reported a nearly complete response to pembrolizumab for a patient with a widely metastatic sebaceous carcinoma. Although this tumor was MSS, it had high expression of PDL-1. Subsequent case reports have confirmed the efficacy of pembrolizumab, either",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:90"
    }
  },
  {
    "page_content": "confirmed the efficacy of pembrolizumab, either alone or in combination with carboplatin, in the metastatic setting. Of interest, one of these carcinomas was responsive to immunotherapy, despite being MSS and having a PDL-1 expression of <1%. Based on these results, immunotherapy for those with advanced sebaceous carcinomas may be effective for those with tumors that are MSI, have a high expression of PDL-1, or have a high mutational burden. These tests are recommended for all patients with",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:91"
    }
  },
  {
    "page_content": "These tests are recommended for all patients with metastatic disease. In addition, neoadjuvant use of immunotherapy is now being explored in order to prevent exenteration and allow for less extensive surgery for those with locally advanced disease. # 8. Conclusions/Future Directions Current knowledge regarding somatic and germline changes in sebaceous neoplasms has provided valuable information regarding the etiology of many of these tumors. In turn, these insights are starting to guide",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:92"
    }
  },
  {
    "page_content": "In turn, these insights are starting to guide decisions regarding systemic therapy in patients with advanced disease, as well as aiding in the identification of patients and families at risk of internal malignancies associated with hereditary cancer conditions, such as Lynch syndrome. However, the use of somatic testing, such as MMR-IHC or MSI, as sole assessments for hereditary risk is suboptimal, and reviews of the personal and family histories of cancer and colon polyps are critical for all",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:93"
    }
  },
  {
    "page_content": "of cancer and colon polyps are critical for all patients with sebaceous neoplasms. In addition, questions remain about the interactions between somatic profiles, such as those associated with UV radiation and immunosuppression, and germline mutations in this setting. As these pathways become better understood, they have the potential to provide further guidance for the treatment and management of individuals with Lynch syndrome and MUYTH-associated polyposis, as well as those with sporadic",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:94"
    }
  },
  {
    "page_content": "polyposis, as well as those with sporadic sebaceous neoplasms.",
    "metadata": {
      "source": "../data/plain/PMC11852771.plain.txt",
      "id": "../data/plain/PMC11852771.plain.txt:95"
    }
  },
  {
    "page_content": "Neoplasms in Domestic Ruminants and Swine: A Systematic Literature Review Abstract\nSimple Summary",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:0"
    }
  },
  {
    "page_content": "Given the scarcity of information and the lack of comprehensive studies on neoplasms in domestic ruminants, i.e., cattle, sheep, and goats, and domestic pigs, the aim of the present study was to systematically review the scientific literature to verify the occurrence, type, organ system, and organs most affected by neoplasms in domestic cattle, sheep, goats, and pigs. Based on the results, the bovine species was the most affected by the neoplasm and also the most studied in relation to small",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:1"
    }
  },
  {
    "page_content": "and also the most studied in relation to small ruminants and pigs. In all species, the most affected organ system was the integumentary system, and the most frequent neoplasms were squamous cell carcinomas for cattle, goats, and sheep, while melanoma was the most frequent for pigs. Few studies were carried out in slaughterhouses, and those found to be in the majority referred to cattle and pigs, none of them mentioned goats and sheep. No studies were found that measured the economic losses",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:2"
    }
  },
  {
    "page_content": "were found that measured the economic losses associated with the condemnation of carcasses of the studied species. The results reinforce the need to carry out studies on farms and slaughterhouses, which would provide more information such as the total number of animals and the origin of the samples.",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:3"
    }
  },
  {
    "page_content": "Abstract",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:4"
    }
  },
  {
    "page_content": "Background: Due to the limited information and lack of studies on neoplasms in domestic ruminants, i.e., cattle, sheep, and goats, and domestic swine, the objective of the present study was to systematically review the scientific literature to verify the occurrence, type, organ system, and organs most affected by neoplasms in these animals. Methods: The recommendations of the PRISMA methodology were followed for the elaboration of this study. The research consisted of a systematic review of",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:5"
    }
  },
  {
    "page_content": "The research consisted of a systematic review of neoplasms in domestic cattle, sheep, goats, and swine. Results: The number of neoplasms found was 1873. The most affected organ system was the integumentary system with 35.0%, followed in descending order by the alimentary system with 16.90%, the hematopoietic system with 13.50%, the special senses (i.e., eyes and ears) with 10.51%, the female and male genital systems with 7.31%, the urinary system with 4.38%, the liver and biliary system with",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:6"
    }
  },
  {
    "page_content": "with 4.38%, the liver and biliary system with 3.152%, the endocrine glands with 3.91%, the respiratory system with 2.67%, the nervous system with 2.35%, bones and joints with 0.43%, muscles and tendons with 0.37%, the cardiovascular system with 0.21%, and the pancreas with 0.16%. Of the animals with neoplasms studied, cattle were affected in 69.80% of cases, goats in 10.52%, sheep in 10.46%, and swine in 9.18%. In all species, the most frequent neoplasms were squamous cell carcinomas in",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:7"
    }
  },
  {
    "page_content": "neoplasms were squamous cell carcinomas in ruminants, while melanoma was the most frequent in swine. Few studies carried out in slaughterhouses were found, and the existing ones referred to cattle and swine. No data were found on economic losses with carcass condemnation. Conclusions: In view of the above, it is necessary to carry out extensive and detailed studies that provide knowledge about the impact of neoplasms on the production and condemnation of carcasses in domestic cattle, sheep,",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:8"
    }
  },
  {
    "page_content": "of carcasses in domestic cattle, sheep, goats, and swine and the respective risk factors. # 1. Introduction Increased meat production is required due to rising global population and demand for animal protein in food. According to the Food and Agriculture Organization of the United Nations, in the last year the production of meat from ruminants and pigs in the world reached 352.7 million tons. Given the importance of these species as a source of animal protein and the increase in their",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:9"
    }
  },
  {
    "page_content": "of animal protein and the increase in their consumption, associated with the rise in herds and production, the diagnosis of neoplasms has increased. Slaughterhouses for ruminants and swine are important sources of disease detection in food-producing animals, and through retrospective and prospective studies in these places, pathologists contribute to the knowledge of a specific disease or diseases of an entire organ system. Among the lesions detected in the post-mortem examination and,",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:10"
    }
  },
  {
    "page_content": "detected in the post-mortem examination and, eventually, in the ante-mortem are neoplasms. These may have their origin in inherited genetic alterations that will be present in all cells within the organism or in somatic alterations that accumulate in individual cells and tissues of the body over time and may have their origin in chemical, physical (radiation), or infectious causes. As an example of an infectious cause, lymphosarcomas, which are the most frequently found neoplasms in data",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:11"
    }
  },
  {
    "page_content": "are the most frequently found neoplasms in data collection from laboratories and slaughterhouses, are second only to squamous cell carcinoma (SCC). Given the limited information and the lack of comprehensive studies on neoplasms in ruminants and swine, the objective of the present study was to systematically review the scientific literature to verify the occurrence, type, organ system, and organs most affected by neoplasms in ruminants and swine. The review was carried out through the selection",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:12"
    }
  },
  {
    "page_content": "The review was carried out through the selection of articles, case reports, retrospective works, and experimental reproductions published in English, Portuguese, and Spanish in Lilacs, PubMed, SciELO, Science Direct/Elvesier, and Google Scholar databases. # 2. Materials and Methods The recommendations of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) methodology were followed for the preparation of this study. The research consisted of a systematic review of",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:13"
    }
  },
  {
    "page_content": "The research consisted of a systematic review of neoplasms in ruminants and swine. ## 2.1. Inclusion and Exclusion Criteria As inclusion criteria, full articles and short communications published between 2002 and 2021 in indexed journals with relevant information related to the topic of neoplasms in ruminants and swine were considered eligible. As exclusion criteria, conference proceedings, book chapters, and technical manuals were not considered. Works that were inaccessible were also",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:14"
    }
  },
  {
    "page_content": "Works that were inaccessible were also discarded. In view of these criteria, papers were read in full, and after reading, studies lacking relevant data were excluded. ## 2.2. Sources of Information and Search Strategy Articles and case reports were consulted in the electronic databases PubMed (National Library of Medicine, National Institutes of Health, Bethesda, MD, USA), SciELO (Scientific Electronic Library Online), Science Direct/Elsevier, and Google Scholar, published in English,",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:15"
    }
  },
  {
    "page_content": "and Google Scholar, published in English, Portuguese, or Spanish between 1 January 2002 and 31 December 2021. In the search, the descriptors used were “neoplasm OR tumor* OR tumors” and “bovine OR caprine* OR cattle* OR goat* OR ovine OR pig OR pigs OR ruminant OR sheep OR swine”. Filters were used to locate the words only described in the title of the article in English, Portuguese, or Spanish. ## 2.3. Selection of Studies and Data Extraction Two researchers independently performed a selection",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:16"
    }
  },
  {
    "page_content": "researchers independently performed a selection of studies by analyzing the title and abstract and then reading the full text. Complete evaluations of articles and case reports were performed. There were no divergent cases between the two researchers. Information considered relevant and important for the review was collected and described, such as the type of neoplasm, in which organ/system it is located, the country where the work was performed, and the sample origin (slaughterhouse,",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:17"
    }
  },
  {
    "page_content": "performed, and the sample origin (slaughterhouse, laboratory, or farm). ## 2.4. Data Analysis Relevant information and results from eligible articles included in this review were analyzed and described using a descriptive analysis. ## 2.5. Characterization and Classification of Ruminant and Swine Neoplasms The neoplasms of ruminants and swine described in the studies eligible for this review were entered according to the organ system affected, as described by Maxie and Miller. The",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:18"
    }
  },
  {
    "page_content": "affected, as described by Maxie and Miller. The classification used for the neoplasms described in the included studies followed the classification of the World Health Organization (WHO) for domestic animals. # 3. Results Through this search procedure, 392 studies were identified that addressed neoplasms in ruminants and swine. The 392 studies were obtained from the following electronic databases: PubMed = 128; SciELO = 52; Science Direct/Elsevier =183; and Google Scholar = 29. Inclusion",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:19"
    }
  },
  {
    "page_content": "=183; and Google Scholar = 29. Inclusion criteria led to the selection of 70 publications that were read in full (Figure 1). In the evaluation of the studies, the following aspects were considered: neoplasms in cattle, sheep, goats, and swine, diagnosed from slaughterhouses or farms; retrospective studies carried out in pathological anatomy laboratories or in official databases; or case reports, which contained the following elements: the occurrence and classification of each type of neoplasm",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:20"
    }
  },
  {
    "page_content": "and classification of each type of neoplasm by species; the organs most affected; and the main diagnostic methods in ruminants and swine. As for the studies surveyed, 36 were full papers and 34 were case reports. Regarding the number of studies per species, 60 studies reported neoplasms in ruminants (25 in cattle, 18 in goats, and 16 in sheep) and 20 in swine. When the articles and case reports were added up, a total of 79 studies were obtained, as some reported this set of conditions in more",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:21"
    }
  },
  {
    "page_content": "as some reported this set of conditions in more than one species. Considering the origin of cases of neoplasms in ruminants and pigs, only 35.7% (25/70) of studies bring this information to light. Regarding sampling, only 17.0% (12/70) of studies contained this type of information. Of the 12 studies with sampling, five were in cattle, three in goats, four in sheep, two in pigs, and two in goats and sheep together. Of the 1873 neoplasms reviewed, 66.6% (1248/1873) are epithelial, 32.1%",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:22"
    }
  },
  {
    "page_content": "reviewed, 66.6% (1248/1873) are epithelial, 32.1% (602/1873) mesenchymal, and 1.2% (23/1873) are embryonic neoplasms. A summary of the distribution of the number of studies, correlated with the country where they were carried out and the species studied, can be seen in Table 1. Most of the studies reviewed did not report the origin of the cases of neoplasms according to species (Table 2). From the 70 studies, it was possible to extract a total of 1873 cases of spontaneous neoplasms reported in",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:23"
    }
  },
  {
    "page_content": "1873 cases of spontaneous neoplasms reported in ruminants and swine. Of the neoplasms identified in this review, 1308 were reported in cattle, 197 in goats, 196 in sheep, and 172 in swine. For the classification into epithelial, mesenchymal, and embryonic neoplasms, the results are described in Table 3. The distribution of neoplasm cases by species and organ system can be seen in Table 4, Table 5, Table 6 and Table 7. Based on the searched literature, 1873 neoplasms were found. The organ system",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:24"
    }
  },
  {
    "page_content": "1873 neoplasms were found. The organ system that was described with the highest number of neoplasms was the integumentary system with 35.0% (655/1873), then in decreasing order were: the alimentary system with 16.90% (316/1873), the hematopoietic system with 13.50% (253/1873), the special senses sensory system with 10.51% (197/1873), the male and female genital systems with 7.31% (137/1873), the urinary system with 4.384% (80/1873), the hepatic and biliary systems with 3.152% (59/1873),",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:25"
    }
  },
  {
    "page_content": "and biliary systems with 3.152% (59/1873), endocrine glands with 3.091% (58/1873), the respiratory system with 2. 67% (50/1873), the nervous system with 2.354% (44/1873), bones and joints with 0.43% (8/1873), muscles and tendons with 0.374% (7/1873), the cardiovascular system with 0.21% (4/1873), and the pancreas with 0.16% (3/1873). Of the 1873 neoplasms surveyed, 1308 were diagnosed in cattle, which represents 69.80% (1308/1873) of the cases, goats with 10.52% (197/1873), sheep with 10.46%",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:26"
    }
  },
  {
    "page_content": "goats with 10.52% (197/1873), sheep with 10.46% (196/1873), and pigs with 9.18% (172/1873). As observed in Table 2, the bovine species was the most studied, with the highest number of articles and case reports found in the researched databases and the one most affected by neoplasms in the 70 studies reviewed. The results extracted from the reviewed studies indicate that the organ/system most affected by neoplasms in cattle was the integumentary, with 28.80% (376/1308) of the neoplasms diagnosed",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:27"
    }
  },
  {
    "page_content": "with 28.80% (376/1308) of the neoplasms diagnosed in this species. Papillomas/fibropapillomas were the most frequent neoplasms in the integumentary system of cattle, with 54.5% (216/376) of cases, followed by squamous cell carcinomas with 25.8% (97/376). The other neoplasms, as well as the other organ systems affected by neoplasms, are detailed in Table 5. Among the reviewed studies, 18 contained information on neoplasms in goats, which totaled 197 neoplasms, representing 10.5% (197/1873) and",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:28"
    }
  },
  {
    "page_content": "197 neoplasms, representing 10.5% (197/1873) and being the second most affected species. In this species, the most frequently diagnosed neoplasm was SCC (61/197, 31.0%). However, the most affected organ system was the integumentary (95/197, 48.2%). The distribution of the other types of neoplasms and the organ systems affected are described in Table 6. Sixteen studies on neoplasms in sheep were included in this review, and 196 neoplasms were described. The most commonly diagnosed neoplasm in",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:29"
    }
  },
  {
    "page_content": "The most commonly diagnosed neoplasm in this species was SCC (119/196, 60.7%), and the tegumentary system was the most affected (116/196, 59.2%). The other results for other types of neoplasms and the affected organ systems are shown in Table 7. Twenty studies on neoplasms in swine were included in the review. Of the 20 studies reviewed, 172 neoplasms were identified, representing 9.18%. Of the neoplasms found in swine, melanoma was the most diagnosed (34/172, 18.9%), and the integumentary",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:30"
    }
  },
  {
    "page_content": "diagnosed (34/172, 18.9%), and the integumentary system was the most affected (68/172, 39.5%). The other neoplasms found, along with the affected organ systems, are presented in Table 7. # 4. Discussion Neoplasms in production animals increase economic losses, but surveys on their occurrence are scarce. According to the articles and reports reviewed for this review, in the first 20 years of this century, neoplasms in domestic ruminants and in pigs were studied and diagnosed with greater",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:31"
    }
  },
  {
    "page_content": "in pigs were studied and diagnosed with greater frequency worldwide. From the 70 studies reviewed, it was possible to extract a total of 1873 cases of spontaneous neoplasms reported in ruminants and swine. Of the neoplasms identified in this review, 1308 were reported in cattle, 197 in goats, 196 in sheep, and 170 in pigs. Among domestic ruminants and pigs, the most affected organ system was the integumentary (cattle = 28.74% (376/1308), goats = 47.74% (95/199), sheep = 59.20% (116/196); swine",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:32"
    }
  },
  {
    "page_content": "47.74% (95/199), sheep = 59.20% (116/196); swine = 40.00% (68/170). The most diagnosed neoplasm was SCC in ruminates and melanoma in swine. ## 4.1. Cattle The bovine species presented the highest number of neoplasms in the studies reviewed. This species has the highest number of diagnoses of neoplasia, probably due to the large herds distributed around the world associated with increased production in other countries and the greater consumption of beef in the world. The organ system most",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:33"
    }
  },
  {
    "page_content": "of beef in the world. The organ system most affected, according to the studies reviewed, by neoplasms in cattle was the integumentary system; the same was observed in a previous study carried out with neoplasms in production animals. However, the most commonly diagnosed neoplasms were papillomas/fibropapillomas, with 54.45% (216/376) of the cases. This trendfor papillomas was also observed in a study conducted in Egypt, but they did not identify which of the papillomaviruses were involved. In",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:34"
    }
  },
  {
    "page_content": "which of the papillomaviruses were involved. In the literature, 13 types of bovine papillomavirus (BPV 1-13) are described for IS; the types involved are (BPV–1; BPV–2; BPV–3; BPV–5; BPV–8; and BPV–11). Bovine papillomatosis (papillomas/fibropapillomas) is a herd problem as it is easily transmitted by animal-animal contact and by fomite. Most affected animals recover on their own, but in some cases, the papillomas can persist for up to 6 months or longer, resulting in loss of production and",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:35"
    }
  },
  {
    "page_content": "or longer, resulting in loss of production and weight loss. Squamous cell carcinoma was the second most commonly diagnosed neoplasm in IS, with 19.76% (97/491). Similar results were previously described by several authors. It is also important to note that for the bovine species, independently of the organ system, SCC was the most commonly diagnosed neoplasm. The second organ system with the highest number of neoplasms diagnosed according to the current review was the alimentary system, with",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:36"
    }
  },
  {
    "page_content": "current review was the alimentary system, with 18.80% (246/1308). Squamous cell carcinoma with 81.82% (216/264) and papilloma/fibropapilloma with 11.00% (29/264) were the most frequent neoplasms, respectively. Similar results were found in a survey on the frequency of tumors in cattle from samples from slaughterhouses. According to the studies reviewed, the hematopoietic system was the third most affected organ system, with 15.14% (1988/1308) of diagnosed neoplasms, and lymphoma and/or",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:37"
    }
  },
  {
    "page_content": "of diagnosed neoplasms, and lymphoma and/or lymphosarcoma were the most common neoplasms in cattle. Among the hematopoietic neoplasms, lymphoma and/or lymphosarcoma were the most frequent neoplasms in surveys of neoplastic lesions in cattle slaughtered in slaughterhouses. Lymphoma constitutes one of the main bovine tumors, and it is associated with relevant economic losses in the production chain of this species. Lymphoma was also the most frequently found neoplasm in cattle slaughtered in",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:38"
    }
  },
  {
    "page_content": "found neoplasm in cattle slaughtered in Canada and Brazil. Lymphoma is an enzootic neoplastic disease of lymphocytes that affects adult animals of various ages, but predominantly between 4 and 8 years. Although lymphoma is more commonly diagnosed in dairy cattle, this tumor also causes losses in the beef industry, being responsible for the condemnation of organs or carcasses. Ocular SCC is the most frequent neoplasm in cattle worldwide, being responsible for large economic losses due to the",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:39"
    }
  },
  {
    "page_content": "responsible for large economic losses due to the reduction in reproductive life or the condemnation of carcasses in slaughterhouses. With 13.15% (172/1308) of the neoplasms extracted from the studies reviewed, the special senses (i.e., eyes and ears) were the fourth most affected organ system. According to this review, the most frequent neoplasm was ocular SSC. In a study on neoplasms carried out in Egypt, ocular SSC was also the most frequent. According to this review, the other organ systems",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:40"
    }
  },
  {
    "page_content": "According to this review, the other organ systems were less affected by neoplasia in cattle. Among these organ systems, the female and male genital systems account for 7.00% (92/1308) of the observed neoplasms. According to Lucena et al., the female and male genital systems were also the sixth organ system most affected by neoplasms. In this review, the most frequent neoplasms were SSC, papilloma/fibropapilloma, and adenocarcinoma. These findings coincide with the results of a study conducted",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:41"
    }
  },
  {
    "page_content": "coincide with the results of a study conducted in Germany. The US, with 4.97% (65/1308) of the observed neoplasms, showed transitional cell carcinoma as the most frequent neoplasm. These results corroborate a retrospective study that investigated 586 neoplasms in cattle, where transitional cell carcinoma and renal carcinoma were the most frequent. Endocrine glands were responsible for 3.98% (52/1308) of the neoplasms reported in the reviewed studies, with pheochromocytoma being the most",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:42"
    }
  },
  {
    "page_content": "studies, with pheochromocytoma being the most frequent neoplasm. Pheochromocytoma was the third most common neoplasm in samples of slaughtered cattle. The world literature points to a low incidence of adrenal gland tumors in slaughtered cattle, and incidence may vary according to the geographic region, and even epigenetic factors may be involved. The nervous system, with 2.90% (38/1308), had the most frequent neoplasm, the shwannoma, and the same was reported by. The respiratory system, with",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:43"
    }
  },
  {
    "page_content": "was reported by. The respiratory system, with 2.40% (31/1308), had lung adenocarcinoma as the most observed neoplasm; this neoplasm was also observed in samples of slaughtered cattle. Liver and biliary systems were reported to be affected in 1.84% (24/1308) of the neoplasms presented in the reviewed studies, with hepatic adenocarcinoma being the most observed. Hepatocellular carcinoma was also reported in a study with slaughterhouse samples. The other systems, such as bones and joints, muscles",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:44"
    }
  },
  {
    "page_content": "other systems, such as bones and joints, muscles and tendons, the pancreas, and the cardiovascular system, represented less than 0.50% of the neoplasms contained in the reviewed studies. Studies referring to neoplasms in these systems are of low frequency or considered rare. ## 4.2. Goats The goat species had the second highest number of neoplasms according to the studies reviewed, with 10.5% (197/1873), but no studies were found in slaughterhouses. The most affected organ system was the",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:45"
    }
  },
  {
    "page_content": "The most affected organ system was the integumentary system with 48.22% (95/197), and the most frequent neoplasms were SCC with 40% (38/95) and melanoma with 25.26% (24/95). In the literature, existing studies show that the frequency of SCC in goats changes according to the region studied. Data on the occurrence of SCC in goat farms in northern Brazil revealed a frequency of 3.08%, however, the total herd was 747 goats. In the United States of America (USA), in a study carried out in a",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:46"
    }
  },
  {
    "page_content": "of America (USA), in a study carried out in a pathological anatomy laboratory, when examining 100 neoplasms in goats, 10% (10/100) were SCC. In Saudi Arabia, in a study on cutaneous neoplasms in goats, the frequency of SCC was 15%; however, the total number of animals was 15. Skin and adnexal neoplasms are common in animals living in tropical countries, in particular SCC, due to chronic exposure of animals to ultraviolet radiation associated with fair skin. Studies reporting cutaneous melanoma",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:47"
    }
  },
  {
    "page_content": "fair skin. Studies reporting cutaneous melanoma in goats are few, and, when available, they have a low number of diagnoses. Although melanocytic cutaneous neoplasms in small ruminants are rare, it is suggested that Angora is susceptible to melanoma. Of the studies reviewed, most were case reports and/or retrospective studies associated with other species. Another aspect that draws attention is that most melanocytic lesions and/or neoplasms can metastasize to other organs such as the liver,",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:48"
    }
  },
  {
    "page_content": "metastasize to other organs such as the liver, lung, kidney, sternum, and mandible. The male and female genital systems were the second most affected organ systems in goats, with 13.71% (27/197) of the neoplasms identified in the reviewed studies. The most frequent neoplasms were SCC and adenocarcinomas located in the uterus and cervix, with 29.63% (8/27) each. According to the present review, SCC was described on the vulva of goats with depigmented skin in Brazil and in Saudi Arabia. In a USA",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:49"
    }
  },
  {
    "page_content": "skin in Brazil and in Saudi Arabia. In a USA study, among female and male genital system neoplasms, adenocarcinomas represented 11.11% (3/27) of diagnosed neoplasms. Other neoplasms that affected the female and male genital systems with low frequency were metastatic seminoma in a Parda Alpina goat and thecoma in an 8-year-old non-breed goat. Female and male genital system neoplasms in small ruminants are rarely reported due to the early slaughter of these animals. With 12.20% (24/197) of the",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:50"
    }
  },
  {
    "page_content": "of these animals. With 12.20% (24/197) of the reported cases, the hematopoietic system was the third organ system with more diagnoses of neoplasms, with lymphoma (15/197, 7.61%) and thymoma (9/15, 60%) being the most frequent neoplasms. Lymphomas and thymona in this species were reported in studies in the USA. Pakistan and Brazil reported isolated cases of lymphoma in goats. The muscles and tendons, endocrine glands, nervous system, and liver and biliary system accounted for 2.03% (4/197) of",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:51"
    }
  },
  {
    "page_content": "and biliary system accounted for 2.03% (4/197) of the neoplasms raised in each. Rhabdomyosarcoma was the most frequent neoplasm in muscles and tendons, with 75% (3/4). However, this neoplasm is considered less common or rare, and the first description was made by Hogendoorn et al.. According to the studies analyzed, three cases of rhabdomyosarcoma were found in goats. In endocrine glands, pheochromocytoma was the most frequent neoplasm with 75% (3/4) of diagnoses, being a neoplasm considered",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:52"
    }
  },
  {
    "page_content": "(3/4) of diagnoses, being a neoplasm considered uncommon in this species and more common in cattle and dogs. The most frequent neoplasm of the nervous system was lymphoma 50% (2/4). Lymphoma was the most frequent neoplasm in goat liver and biliary tissues, with 1.52% (3/197). Hepatic lymphoma usually arises from metastases of multicentric lymphomas. In the reviewed studies on neoplasms, pancreatic neoplasms were not observed, whereas in bones and joints, only one osteosarcoma was observed. Bone",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:53"
    }
  },
  {
    "page_content": "joints, only one osteosarcoma was observed. Bone neoplasms such as osteosarcoma in goats are rare, reflecting the few reports available in the literature. ## 4.3. Sheep Sheep were the third most affected species by neoplasms with 10.46% (196/1873), according to the studies consulted for this review. However, as with goats, no studies were found in slaughterhouses. The integumentary system was the most affected system and presented 59.19% (116/196) of the neoplasms observed in the studies",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:54"
    }
  },
  {
    "page_content": "of the neoplasms observed in the studies included in the present review. Squamous cell carcinoma is the most frequent neoplasm, with 57.65% (113/196) of the integumentary system. Squamous cell carcinoma is relatively uncommon in sheep. The low occurrence of this type of tumor in sheep is probably due to the fact that these animals are slaughtered before they reach middle age, which reduces their probability of developing neoplasms. Squamous cell carcinoma has been reported in different regions",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:55"
    }
  },
  {
    "page_content": "carcinoma has been reported in different regions of the world, such as Saudi Arabia, Uruguay, Brazil, Egypt, and Argentina. With 26.02% (51/196), the alimentary system was the second most affected system by neoplasms in sheep. However, for this system, the only neoplasm observed was intestinal adenocarcinoma, according to the reviewed studies. The high occurrence of this type of neoplasm in sheep in New Zealand and Australia may be associated with the consumption of P. aquilinum. The cases of",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:56"
    }
  },
  {
    "page_content": "the consumption of P. aquilinum. The cases of intestinal adenocarcinoma in sheep included in this review were all described in New Zealand, with the exception of one incidental case diagnosed in Spain. The respiratory system was the third most affected organ system, with 5.10% (10/196) of the latent neoplasms in the reviewed articles. The lung was the organ most affected by neoplasms, with lung adenocarcinoma being the most frequent neoplasm, accounting for 90% (9/10) of neoplasms observed in",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:57"
    }
  },
  {
    "page_content": "for 90% (9/10) of neoplasms observed in the sheep respiratory system. Ovine pulmonary adenocarcinoma is associated with a contagious disease, common in sheep but rarely affecting goats, that is caused by a beta-retrovirus known as Jaagsiekte sheep retrovirus (JSRV). Ovine pumonary adenocarcinoma is reported worldwide with the exception of Oceania. According to the reviewed studies, the special senses had the fourth highest number of neoplasms at 4.08% (8/196), with SCC being the most common",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:58"
    }
  },
  {
    "page_content": "at 4.08% (8/196), with SCC being the most common neoplasm at 75% (6/8). SCC is one of the most commonly diagnosed cutaneous neoplasms in sheep, although the special senses are not the most affected anatomical site. Studies of risk factors for SCC in the semi-arid region of Brazil, by Carvalho et al. and Macêdo et al., suggested that in sheep, the skin of the head is the anatomical site most affected by SCC. However, SCC can affect other parts of the body, preferably hairless and depigmented",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:59"
    }
  },
  {
    "page_content": "of the body, preferably hairless and depigmented areas, such as the eyelids, ears, snout, vulva, and perineum. The most frequent tumors were those of the female and male genital systems and the liver and biliary systems, with 75% (3/4) each, respectively. The most frequent neoplasms were uterine adenocarcinomas and cholangiocarcinomas, with 1.02% (2/3) each, respectively. Uterine adenocarcinoma in ruminants is considered uncommon, being more commonly diagnosed in cattle and goats and rarely in",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:60"
    }
  },
  {
    "page_content": "diagnosed in cattle and goats and rarely in sheep. Cholangiocarcinoma in sheep is an incidental neoplasm, and it is rarely diagnosed. The hematopoietic and nervous systems were affected by 1.02% (2/196) of the malignancies observed in the reviewed studies, respectively. In the hematopoietic system, 100% of the neoplasms identified in the reviewed studies were lymphomas. In sheep, lymphomas can be of idiopathic origin or due to infection with the bovine leukemia virus. In the nervous system, the",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:61"
    }
  },
  {
    "page_content": "bovine leukemia virus. In the nervous system, the neoplasms found were an adenocarcinoma and a medulloblastoma. Adenocarcinoma likely arose from metastasis from another tissue or organ. The cardiovascular system, with 0.51% (1/196), was affected only by one hemangioma, which is rarely reported for this species. ## 4.4. Pigs Of the studies included in the present review, 172 neoplasms were observed in swine, representing 9.18% (172/1873) of the neoplasms observed in the studies included in the",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:62"
    }
  },
  {
    "page_content": "neoplasms observed in the studies included in the present review. In this species, the most affected organ system was the integumentary system with 39.50% (68/172), with melanoma and melanocytoma being the most frequent neoplasms with 19.77% (34/172) and 16.86% (29/172), respectively. According to Bundza and Felmate, melanocytic lesions are found in pigs slaughtered for consumption, and it is necessary to distinguish whether they are melanosis or melanocytic neoplasms and whether they are",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:63"
    }
  },
  {
    "page_content": "or melanocytic neoplasms and whether they are benign or malignant in order to make an adequate sanitary decision about the carcass and the respective viscera. Data on the occurrence of these lesions in production animals are rare. In a study carried out in Portuguese slaughterhouses, frequencies of 4.81% were found for melanocytomas and 21.15% for melanomas. In Brazil, Brum et al., when studying 37 swine neoplasms, found a frequency of 21.70% for melanomas. Studies available in the literature",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:64"
    }
  },
  {
    "page_content": "melanomas. Studies available in the literature suggest that melanomas are congenital or that they appear in the first weeks of the pig’s life. Melanocytic lesions in pigs spontaneously regress without relapse in approximately 85–90% of cases; it is suggested that this regression mechanism is a cell-mediated immune response. However, some animals may end up dying as the disease progresses. The hematopoietic system was the second most affected with 16.90% (29/172) of neoplasms in pigs, and the",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:65"
    }
  },
  {
    "page_content": "16.90% (29/172) of neoplasms in pigs, and the most frequent neoplasm with 86.20% (25/29) was lymphoma/lymphosarcoma. The third system with the highest number of neoplasms was liver and biliary, which represented 16.30% (28/172) of cases according to the articles included in this review. Hepatocellular carcinoma was the most common neoplasm, accounting for 85.71% (24/28) of all liver and biliary system neoplasms. Primary pig liver neoplasms accounted for 8.20% in a study carried out with samples",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:66"
    }
  },
  {
    "page_content": "for 8.20% in a study carried out with samples from slaughterhouses. There are descriptions in which hepatocellular carcinoma presents as single tumors or diffuse masses through the liver parenchyma; this second presentation predominates in the descriptions in pigs. The urinary system was the fourth most affected system, with 9.88% of neoplasms in swine. The most frequent neoplasm was nephroblastoma, accounting for 94.12% (16/172) of neoplasms within the USA. In a study carried out in Brazil,",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:67"
    }
  },
  {
    "page_content": "within the USA. In a study carried out in Brazil, the frequency of nephroblastoma was 29.70%. Nephroblastoma is a common neoplasm in swine, found most often at slaughter, and it is the main primary renal neoplasm of the species; however, it varies depending on the region. Reports found in the literature indicate that in the United States the incidence is estimated to be 20 nephroblastomas per 100,000 pigs, but in Russia it is 0.35 tumors per 100,000 pigs. The male and female genital systems",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:68"
    }
  },
  {
    "page_content": "100,000 pigs. The male and female genital systems were affected by 8.72% (15/172) of neoplasms in swine. Leiomyoma was the most frequent neoplasm, accounting for 80.00% (12/15) of female and male genital system neoplasms. The prevalence of uterine leiomyomas in pigs is very low and may vary according to the age of the population studied. The potbellied pig seems to have a high incidence of uterine leiomyomas due to the longevity of the species; the opposite occurs with the pig that goes to",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:69"
    }
  },
  {
    "page_content": "the opposite occurs with the pig that goes to slaughter very young. The alimentary system was the sixth most affected system, with 5.20% (9/172) of the neoplasms observed in swine. Lymphoma/lymphosarcoma was the most frequent neoplasm, with 44.44% (4/9) of AS. However, one study observed a frequency of 29.70% of lymphoma/lymphosarcoma in pig samples from slaughterhouses. According to Charles, lymphoma/lymphosarcoma is commonly found in pigs during slaughter. However, a study carried out at a",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:70"
    }
  },
  {
    "page_content": "slaughter. However, a study carried out at a slaughterhouse in the province of Ontario in Canada between 1996 and 2003 indicates that 0.02 to 0.10 carcasses per 10,000 pigs that were slaughtered were condemned due to the fact that they were found to have lymphosarcoma. According to the studies reviewed, the endocrine glands were affected by 1.16% (2/172) of the neoplasms, with pheochromocytoma being the only one observed. Pheochromocytomas are the most common neoplasms arising in the adrenal",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:71"
    }
  },
  {
    "page_content": "the most common neoplasms arising in the adrenal medulla of animals, and they develop most frequently in cattle and dogs, rarely in other domestic animals, and are extremely rare in swine. In a survey carried out in slaughterhouses of 3.7 million pigs in the UK, only a 2.5-year-old female was diagnosed with pheochromocytoma, which shows a low incidence in pigs probably due to the fact that many animals are slaughtered before reaching maturity. The nervous system, respiratory system,",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:72"
    }
  },
  {
    "page_content": "maturity. The nervous system, respiratory system, cardiovascular system, and bones and joints were affected by 0.58% (1/172), according to the studies included in this review. In the nervous system, the neoplasm observed was neuroblastoma, which belongs to the group called peripheral nerve sheath tumors. Neurofibromas are composed of a mixture of Schwann cells, perineural cells, and fibroblasts. In domestic animals, neurofibromas have been described predominantly in dogs and cattle and rarely",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:73"
    }
  },
  {
    "page_content": "predominantly in dogs and cattle and rarely in other species. Lymphomas/lymphosarcomas have been observed only in the respiratory and cardiovascular systems; however, the appearance of this type of neoplasm is associated with metastasis. In slaughter pigs, the incidence of lymphoma/lymphosarcoma varies according to aspects such as the region of study and the age of the animals. A granulocytic sarcoma, a neoplasm rarely reported in the literature, has been described in bones and joints, but also",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:74"
    }
  },
  {
    "page_content": "has been described in bones and joints, but also in the liver, kidneys, and mesenteric lymph nodes. # 5. Conclusions Based on the results of this review, we can conclude that the bovine species was the most affected by neoplasia and also the most studied in relation to small ruminants and swine. In all species, the most affected organ system was the integumentary, and the most frequent neoplasms were the SCC in cattle, goats, and sheep, and melanoma in swine. It was also observed that there",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:75"
    }
  },
  {
    "page_content": "in swine. It was also observed that there were a few studies carried out in slaughterhouses, and those that were found referred to cattle and swine; none of them mentioned goats and sheep. No studies were found that measured the economic losses associated with carcass condemnation of the species studied. In view of the above, it is necessary to carry out studies in farms and slaughterhouses that provide more information, such as the total number of animals and the origin of the samples. Broad",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:76"
    }
  },
  {
    "page_content": "of animals and the origin of the samples. Broad and detailed studies will provide knowledge about the impact of neoplasms on production and carcass condemnation in ruminants and swine and the respective risk factors.",
    "metadata": {
      "source": "../data/plain/PMC9967503.plain.txt",
      "id": "../data/plain/PMC9967503.plain.txt:77"
    }
  },
  {
    "page_content": "Risk of subsequent primary lymphoma in a cohort of 69,460 five‐year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study Abstract\nBackground",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:0"
    }
  },
  {
    "page_content": "Background\nSurvivors of Hodgkin lymphoma (HL) are at risk of developing non‐Hodgkin lymphoma (NHL) after treatment; however, the risks of developing subsequent primary lymphomas (SPLs), including HL and NHL, after different types of childhood cancer are unknown. The authors quantified the risk of SPLs using the largest cohort of childhood cancer survivors worldwide.\nMethods",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:1"
    }
  },
  {
    "page_content": "Methods\nThe Pan‐European Network for Care of Survivors After Childhood and Adolescent Cancer (PanCare) Survivor Care and Follow‐Up Studies (PanCareSurFup) cohort includes 69,460 five‐year survivors of childhood cancer, diagnosed during 1940 through 2008, from 12 European countries. Risks of SPLs were quantified by standardized incidence ratios (SIRs) and relative risks (RRs) using multivariable Poisson regression.\nResults",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:2"
    }
  },
  {
    "page_content": "Overall, 140 SPLs, including 104 NHLs and 36 HLs, were identified. Survivors were at 60% increased risk of an SPL compared with the general population (SIR, 1.6; 95% confidence interval [CI], 1.4–1.9). Survivors were twice as likely to develop NHL (SIR, 2.3; 95% CI, 1.9–2.8), with the greatest risks among survivors of HL (SIR, 7.1; 95% CI, 5.1–10.0), Wilms tumor (SIR, 3.1; 95% CI, 1.7–5.7), leukemia (SIR, 2.8; 95% CI, 1.8–4.4), and bone sarcoma (SIR, 2.7; 95% CI, 1.4–5.4). Treatment with",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:3"
    }
  },
  {
    "page_content": "(SIR, 2.7; 95% CI, 1.4–5.4). Treatment with chemotherapy for any cancer doubled the RR of NHL (RR, 2.1; 95% CI, 1.2–3.9), but treatment with radiotherapy did not (RR, 1.2; 95% CI, 0.7–2.0). Survivors were at similar risk of developing a subsequent HL as the general population (SIR, 1.1; 95% CI, 0.8–1.5).",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:4"
    }
  },
  {
    "page_content": "Conclusions\nIn addition to HL, the authors show here for the first time that survivors of Wilms tumor, leukemia, and bone sarcoma are at risk of NHL. Survivors and health care professionals should be aware of the risk of NHL in these survivors and in any survivors treated with chemotherapy. Abstract",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:5"
    }
  },
  {
    "page_content": "Using data from 69,460 five‐year survivors of childhood cancer across Europe, the authors investigated the risks of subsequent primary lymphoma within the largest cohort reported to date. Novel findings include the identification of an increased risk of non‐Hodgkin lymphoma among survivors of Wilms tumor, leukemia, and bone sarcoma and in any survivors treated with chemotherapy. # INTRODUCTION Approximately 35,000 children and adolescents are diagnosed with cancer in Europe each year. Since the",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:6"
    }
  },
  {
    "page_content": "with cancer in Europe each year. Since the 1970s, 5‐year survival rates have improved dramatically and now reach 80% in most European countries, mostly because of combined chemotherapy modalities and improvements in the delivery of radiotherapy.,, There are currently over 500,000 childhood cancer survivors in Europe, and this number continues to increase. The risk of premature morbidity and mortality for childhood cancer survivors compared with the general population is well documented, with",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:7"
    }
  },
  {
    "page_content": "the general population is well documented, with many health risks arising 20–30 years after a childhood cancer diagnosis. Approximately 60% of childhood cancer survivors develop at least one chronic health condition during their lifetime, and more than one in four develop severe or life‐threatening diseases., A serious long‐term consequence of treatment of childhood cancer is the increased risk of developing subsequent primary neoplasms, which is in the range of three to five times greater that",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:8"
    }
  },
  {
    "page_content": "in the range of three to five times greater that of the general population.,,, Existing evidence suggests that survivors are at increased risk of several types of subsequent primary neoplasms, particularly central nervous system tumors; nonmelanoma skin cancer; and digestive, breast, bone, and genitourinary cancers. Limited numbers of studies have shown that the overall risk of subsequent primary lymphoma (SPL) is also increased,,,; however, to our knowledge, few previous large‐scale studies",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:9"
    }
  },
  {
    "page_content": "our knowledge, few previous large‐scale studies have comprehensively investigated the risk of developing SPLs among childhood cancer survivors—with the largest previous study to date including 45 SPLs. Studies of survivors of Hodgkin lymphoma (HL) have found an increased risk of non‐Hodgkin lymphoma (NHL) but mostly included HL survivors who were diagnosed in adulthood.,,,,,,,,, To date, no large‐scale study has characterized the risks of SPLs and of specific SPLs by type of childhood cancer,",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:10"
    }
  },
  {
    "page_content": "and of specific SPLs by type of childhood cancer, sex, age at diagnosis, decade of diagnosis, attained age, and treatment factors. Identification of those survivors at highest risk of an SPL would be important for informing survivors and health care professionals of who is at risk, potentially detecting SPLs early, and may give clues about potential biologic mechanisms. The principal aim of this largest ever cohort study was to quantify the risk of developing an SPL, further subdivided into HL",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:11"
    }
  },
  {
    "page_content": "of developing an SPL, further subdivided into HL and NHL, among 69,460 survivors of childhood cancer within Europe and compare this risk with that in the general population, including three times the number of SPLs compared with the largest previous study to date. Secondary aims included investigating variations in risk, which may be associated with certain demographic and oncologic factors, and assessing the level of risk sustained in the long term (beyond age 40 years). # MATERIALS AND",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:12"
    }
  },
  {
    "page_content": "long term (beyond age 40 years). # MATERIALS AND METHODS ## PanCare Childhood and Adolescent Cancer Survivor Care and Follow‐Up Studies The Pan‐European Network for Care of Survivors after Childhood and Adolescent Cancer (PanCare) is a network of health care professionals, researchers, childhood cancer survivors, and their families that aims to improve both the care and the quality of life for survivors of childhood cancer. Funded by the seventh Framework Program of the European Union, a",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:13"
    }
  },
  {
    "page_content": "Framework Program of the European Union, a consortium among several institutions of PanCare members established the largest ever collaborative, comprehensive study for childhood cancer survivors: The PanCare Childhood and Adolescent Cancer Survivor Care and Follow‐Up Studies (PanCareSurFup). The overall objectives of PanCareSurFup are to investigate long‐term health risks for childhood cancer survivors, establish clinical guidelines for their follow‐up care, and disseminate research results.,,",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:14"
    }
  },
  {
    "page_content": "care, and disseminate research results.,, The PanCareSurFup cohort comprises data from 5‐year survivors of childhood cancer (diagnosed at ages birth to 20 years between 1940 and 2008) across 12 European countries: France, Italy, Hungary, the Netherlands, Denmark, Sweden, Norway, Finland, Iceland, Slovenia, Switzerland, and the United Kingdom (see Table S1). Data were sourced from both population‐based cancer registries and major treatment centers. Ethical approval and consent for data",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:15"
    }
  },
  {
    "page_content": "centers. Ethical approval and consent for data collection were obtained from the ethical and legal bodies in each of the respective countries contributing to PanCareSurFup. Ethical approval was not obtained specifically for this study because it involved pooling of nonidentifiable data. ## Childhood cancer classification Because of various practices across different countries in terms of childhood cancer registration, the cancer site and the type of childhood cancer were coded using a range of",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:16"
    }
  },
  {
    "page_content": "of childhood cancer were coded using a range of classification systems. To standardize this across the pooled cohort, all childhood tumor classification codes were converted into codes from the third revision of the International Classification of Diseases for Oncology using the Cancer Registry Tools Program., These were then categorised into childhood cancers subgroups according to the International Classification of Childhood Cancer, third edition. Individuals were excluded from the pooled",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:17"
    }
  },
  {
    "page_content": "Individuals were excluded from the pooled cohort if: (1) they had a primary diagnosis of myelodysplastic syndrome, Langerhans cell histiocytosis, or chronic myeloproliferative or lymphoproliferative disorders; (2) tumor coding was nonmalignant, except for intracranial and bladder tumors; and (3) tumor codes were not classifiable according to the third revision of the International Classification of Childhood Cancer. ## Identification of subsequent primary lymphomas SPLs were ascertained using",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:18"
    }
  },
  {
    "page_content": "primary lymphomas SPLs were ascertained using various methods, primarily through population‐based cancer registries and follow‐up clinics and validated through pathology reports or other means of clinical diagnosis. The SPLs were classified by site according to the International Classification of Diseases using the revision appropriate to the year of diagnosis (see Table S2). For inclusion as an SPL, the subsequent lymphoma had to have a different morphology classification than the original",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:19"
    }
  },
  {
    "page_content": "morphology classification than the original childhood cancer, as defined by the International Classification of Diseases for Oncology, third edition classification. In addition, we excluded subsequent NHLs diagnosed after a primary NHL in childhood (N = 8) and subsequent HLs after a primary HL (N = 1), regardless of any difference in morphology. Also, all NHL survivors were excluded from analyses relating to subsequent NHLs, and all HL survivors were excluded from analyses relating to",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:20"
    }
  },
  {
    "page_content": "survivors were excluded from analyses relating to subsequent HLs. ## Statistical analysis Individuals entered the cohort at 5‐year survival from childhood cancer diagnosis and remained at risk of an SPL until the first occurrence of loss to follow‐up, death, or study exit date. Standardized incidence ratios (SIRs) were calculated as the ratio of the observed to expected numbers of lymphomas. Expected rates were calculated by accruing person‐years at risk stratified by age, country, sex, and",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:21"
    }
  },
  {
    "page_content": "at risk stratified by age, country, sex, and calendar year, and multiplying by the equivalent lymphoma incidence rates for the general population. General population incidence rates (also stratified by age, country, sex, and calendar year) were obtained from the Cancer Incidence in Five Continents project. Site‐specific incidence rates do not exist for Hungary, hence these were estimated using Slovakian incidence rates because it is their neighboring country with similar demographic",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:22"
    }
  },
  {
    "page_content": "neighboring country with similar demographic characteristics. Absolute excess risks (AERs) were calculated as the observed minus the expected number of lymphomas, divided by person‐years at risk, and multiplied by 100,000. This can be interpreted as the number of excess lymphomas observed beyond those expected per 100,000 person‐years. Multivariable Poisson regression models were fitted to estimate the relative risk (RR) of all SPLs and subsequent primary NHLs and HLs while adjusting for the",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:23"
    }
  },
  {
    "page_content": "primary NHLs and HLs while adjusting for the effect of potentially confounding factors: sex, childhood cancer diagnosis, country, decade of childhood diagnosis, age at childhood diagnosis, and attained age. RRs can be interpreted as the ratio of SIRs, adjusted for potential confounders. Likelihood‐ratio tests were applied to generate p values for linear trend for ordinal factors of interest or heterogeneity for nominal variables. Because of a relatively small number of observations in",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:24"
    }
  },
  {
    "page_content": "of a relatively small number of observations in subsequent primary HLs, AERs could not be calculated. SIRs, AERs, and RRs were calculated for the treatment factors radiotherapy (yes/no) and chemotherapy (yes/no) for those countries where <30% of treatment data were missing. Therefore, the Nordic countries and an Italian population‐based cohort were completely excluded from analyses involving treatment variables regardless of whether treatment data were available to avoid potential bias. By",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:25"
    }
  },
  {
    "page_content": "data were available to avoid potential bias. By using this approach, for 10.5% of survivors, the radiotherapy data were missing; and, for 12.4% of survivors, the chemotherapy data were missing. In all, information on radiotherapy was available for 90 SPLs, and information on chemotherapy was available for 88 SPLs. To assess the probability of developing an SPL with increasing attained age, the cumulative incidence accounting for the competing risk of death was estimated for types of childhood",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:26"
    }
  },
  {
    "page_content": "of death was estimated for types of childhood cancer with ≥20 observed SPLs. All statistical analyses were conducted in Stata software (Stata Corporation). All analyses were based on complete case analysis (i.e., list‐wise deletion). A two‐sided p value <.05 was considered statistically significant. # RESULTS ## Cohort characteristics Among 69,460 five‐year survivors of childhood cancer, in total, 1,264,624 person‐years were accrued, with loss to follow‐up not exceeding 6% in any country (see",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:27"
    }
  },
  {
    "page_content": "to follow‐up not exceeding 6% in any country (see Table S1). Over the follow‐up period, 140 SPLs were observed in survivors across an age range from 5 to 88 years. From the 140 SPLs, 104 (74.2%) were classified as NHL, and 36 (25.7%) were classified as HL. Most of the SPLs occurred in males (66.4%) and in those surviving HL (n = 33) and leukemia (n = 31; Table 1). ## Overall risk of any subsequent primary lymphoma Overall, childhood cancer survivors were 60% more likely to develop an SPL",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:28"
    }
  },
  {
    "page_content": "survivors were 60% more likely to develop an SPL compared with the expected rates from the general population (SIR, 1.6; 95% CI, 1.4–1.9), with four additional cases of lymphoma observed per 100,000 person‐years (AER, 4.3; 95% CI, 2.8–6.6; Table 2). In particular, HL survivors (SIR, 4.1; 95% CI, 2.9–5.8), but also Wilms tumor (SIR, 2.2; 95% CI, 1.3–3.8), leukemia (SIR, 2.1; 95% CI, 1.5–3.0), and bone sarcoma (SIR, 2.1; 95% CI, 1.1–3.9) survivors, were at increased risk of developing an SPL.",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:29"
    }
  },
  {
    "page_content": "were at increased risk of developing an SPL. Overall, the SIR decreased with increasing attained age (p for trend <.001), but the risk was no longer significantly increased beyond age 50 years (SIR, 1.3; 95% CI, 0.8–2.1). There was a significant increase in SPL risk among those who had received chemotherapy for any childhood cancer compared with those who had not (RR, 1.8; 95% CI, 1.1–2.9; Table 2), independent of whether or not survivors also had received radiotherapy. The cumulative incidence",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:30"
    }
  },
  {
    "page_content": "received radiotherapy. The cumulative incidence of developing an SPL by age 65 years was highest after HL, with a probability of developing an SPL of 1.6% (95% CI, 0.7%–3.1%), whereas only 0.6% was expected based on general population rates (Figure 1). ## Risk of subsequent primary non‐Hodgkin lymphoma Overall, childhood cancer survivors were 2.3 times more likely to develop NHL than the general population (SIR, 2.3; 95% CI, 1.9–2.8), with five additional cases of NHL observed per 100,000",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:31"
    }
  },
  {
    "page_content": "five additional cases of NHL observed per 100,000 person‐years (AER, 4.9; 95% CI, 3.5–6.9; Table 3). Male and female childhood cancer survivors were at similar risk when adjusted for confounding factors (p for heterogeneity =.91). Survivors of HL and Wilms tumor were at greatest risk of developing NHL (SIR, 7.1 [95% CI, 5.1–10.0] and 3.1 [95% CI, 1.7–5.7], respectively), but the risk also was great for survivors of leukemia (SIR, 2.8; 95% CI, 1.8–4.4) and bone sarcoma (SIR, 2.7; 95% CI,",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:32"
    }
  },
  {
    "page_content": "CI, 1.8–4.4) and bone sarcoma (SIR, 2.7; 95% CI, 1.4–5.4). More recent decades of childhood cancer diagnosis showed an increase in the SIRs of developing NHL (p for trend <.001), but this effect was not apparent after adjustment for confounders (p for trend =.64), particularly attained age. Increasing attained age and follow‐up time demonstrated a decreasing trend in the SIRs of developing NHL (Table 3; p for trend <.001). There was a significantly increased risk of developing NHL among",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:33"
    }
  },
  {
    "page_content": "increased risk of developing NHL among survivors who had received chemotherapy for any childhood cancer (RR, 2.1; 95% CI, 1.2–3.9). However, the RR was not significantly increased for survivors who had received radiotherapy for any childhood cancer (RR, 1.2; 95% CI, 0.7–2.0). The cumulative incidence of developing NHL after HL was 1.6% (95% CI, 0.7%–3.1%) by age 65 years (Figure 1; all SPLs after HL were NHLs). ## Risk of subsequent primary Hodgkin lymphoma Overall, childhood cancer survivors",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:34"
    }
  },
  {
    "page_content": "lymphoma Overall, childhood cancer survivors were no more likely to develop HL compared with the general population (SIR, 1.1; 95% CI, 0.8–1.5; Table 4). A childhood cancer diagnosis of NHL conferred an increased risk of developing HL relative to the general population (SIR, 2.4; 95% CI, 1.0–5.9). This was not observed following other types of childhood cancer. The SIR for HL did not vary by decade of diagnosis (p for trend =.21), age at diagnosis (p =.97), or with attained age (p for",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:35"
    }
  },
  {
    "page_content": "diagnosis (p =.97), or with attained age (p for trend =.24), although multivariable analyses suggested that the RRs were lower in those diagnosed in more recent decades (p for trend =.03). # DISCUSSION ## Main findings To our knowledge, this is by far the largest cohort study analyzing the risk of SPLs in childhood cancer survivors and, for the first time within a large‐scale study, the risks of NHL and HL individually. Novel findings include that childhood cancer survivors are 2.3 times more",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:36"
    }
  },
  {
    "page_content": "childhood cancer survivors are 2.3 times more likely to develop NHL than the general population, with survivors of HL, Wilms tumor, leukemia, and bone sarcoma at greatest risk. Conversely, the risk of HL among childhood cancer survivors is not increased, except in survivors of NHL. This study has further found that childhood cancer survivors who have received chemotherapy are almost twice as likely to develop a subsequent primary NHL than survivors treated without chemotherapy. This increase in",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:37"
    }
  },
  {
    "page_content": "treated without chemotherapy. This increase in risk, however, does not extend to survivors who received radiotherapy for any childhood cancer. ## Previous studies When evaluating the overall risk of childhood cancer survivors developing SPLs, the SIR of 1.6 for total lymphoma found in this analysis was consistent with the results of the North American Childhood Cancer Survivor Study conducted in a cohort of 14,359 childhood cancer survivors (SIR, 1.6; 95% CI, 1.2–2.1). In that North American",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:38"
    }
  },
  {
    "page_content": "1.6; 95% CI, 1.2–2.1). In that North American study, the SIR beyond age 40 years was still increased 2.6‐fold (95% CI, 1.5–5.6); however, in our data, the risk was not increased beyond age 50 years (SIR, 1.3; 95% CI, 0.8–2.1), although overlapping confidence intervals suggest that these SIRs are not necessarily inconsistent. There have been suggestions that, for the generality of survivors, historic treatment regimens across North America may have been more aggressive than across Europe, which",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:39"
    }
  },
  {
    "page_content": "been more aggressive than across Europe, which may translate into a higher risk of long‐term complications of treatment, including subsequent primary malignancies. Other studies documenting the risk of developing SPLs derived their data from European cohorts (Nordic countries and the Netherlands, respectively), which also contributed to the current PanCareSurFup cohort. Consistent with our findings, the Nordic study reported a moderately increased risk for bone marrow and lymphatic system",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:40"
    }
  },
  {
    "page_content": "risk for bone marrow and lymphatic system malignancies, although this includes a wider range of diagnoses and thus is less valid to interpret for SPL alone (SIR, 2.6; 95% CI, 2.2–3.2). A Dutch study among 6165 childhood cancer survivors quoted a slightly higher, but not inconsistent, risk of NHL (SIR, 3.9; 95% CI, 2.0–7.0). Furthermore, the Dutch study observed only six cases of HL and, as a result, reported a lower and insignificant risk of HL (SIR, 1.9; 95% CI, 0.7–4.1), which supports our",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:41"
    }
  },
  {
    "page_content": "(SIR, 1.9; 95% CI, 0.7–4.1), which supports our finding that childhood cancer survivors are no more likely to develop HL than the general population. Although very few studies have investigated the risk of NHL among the generality of childhood cancer survivors, several studies have reported increased risks of NHL after (mostly) adult HL, with a wide range in SIRs from 3.0 to 32.0, which is not inconsistent with the SIR of 7.1 found in the current analysis.,,,,,,, Postulated risks factors",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:42"
    }
  },
  {
    "page_content": "current analysis.,,,,,,, Postulated risks factors include immunodeficiency, because Zarate‐Osorno et al. concluded that the types of NHL diagnosed among patients with HL were clinically, histologically, and immunophenotypically similar to that found in immunosuppressed patients. Here, we found that survivors who received chemotherapy were at the highest risk. Whether any specific chemotherapeutic agent or whether chemotherapy‐induced immunosuppression may be implicated in the development of",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:43"
    }
  },
  {
    "page_content": "may be implicated in the development of NHL, however, is not clear. Swerdlow et al found increased risks of NHL among HL survivors after various different chemotherapy regimens, suggesting that not one specific chemotherapy agent is implicated. We also found increased risks of NHL among survivors of Wilms tumor, leukemia, and bone sarcoma who likely have received different chemotherapy regimens. Exposure to prolonged chemotherapy has been shown to be immunosuppressive and thus may create an",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:44"
    }
  },
  {
    "page_content": "to be immunosuppressive and thus may create an environment in which latent oncogenic viruses, such as Epstein–Barr virus, that have been associated with NHL development may be reactivated., Among (bilateral) Wilms tumor survivors, the increased risk may to some extent also be related to immunosuppressive therapy for a kidney transplant, which could cause posttransplantation lymphoproliferative disorders, including NHL, although typically this occurs in the first few years after kidney",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:45"
    }
  },
  {
    "page_content": "this occurs in the first few years after kidney transplantation, with a potential second peak 7–10 years later. However, in our data, all Wilms tumor survivors who developed NHL had unilateral Wilms tumor; and, for 9 of 10 Wilms tumor survivors who developed NHL, this occurred at least 13 years after the original Wilms tumor diagnosis (range, 6–53 years), suggesting that this is probably an unlikely explanation. Similarly, stem cell transplantation among leukemia survivors may have increased",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:46"
    }
  },
  {
    "page_content": "among leukemia survivors may have increased the risk of posttransplantation lymphoproliferative disorders, including NHL; but, in our cohort, only one leukemia survivor with NHL had undergone stem cell transplantation. Further studies evaluating detailed treatment factors and the role of specific chemotherapy exposures in relation to immunosuppression and Epstein–Barr virus infection status are warranted. In the current study, there was no indication of any significant difference in the risk of",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:47"
    }
  },
  {
    "page_content": "of any significant difference in the risk of SPL between those who received radiotherapy only during childhood and those who did not. This is consistent with research conducted in individuals who were exposed to radiation after the atomic bomb, in whom no increased risk was observed either. ## Clinical implications Current guidelines from the Children's Oncology Group for the long‐term surveillance of childhood cancer survivors do not include details of an increased SPL risk. Although we do not",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:48"
    }
  },
  {
    "page_content": "of an increased SPL risk. Although we do not advocate surveillance of survivors because the absolute risks are small, survivors of HL, Wilms tumor, leukemia, and bone sarcoma should be encouraged to seek clinical advice from a medical professional if potentially relevant symptoms of NHL develop, including swellings, fever, and night sweats. Previous studies identified HL survivors to be at risk of NHL, but here we found that survivors of Wilms tumor, leukemia, and bone sarcoma are also at risk;",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:49"
    }
  },
  {
    "page_content": "leukemia, and bone sarcoma are also at risk; it would be important for health care professionals responsible for the long‐term follow‐up of these survivors to be aware of the increased risk. Finally, it may be worth emphasizing to survivors that treatment with radiotherapy does not seem to suggest an increased risk of SPLs. ## Study limitations One of the potential limitations of this study is the lack of detailed data concerning childhood treatment variables, such as cumulative doses of",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:50"
    }
  },
  {
    "page_content": "treatment variables, such as cumulative doses of radiotherapy (including radiotherapy field) and chemotherapy. To fully assess the effect of treatment modalities on SPL risk, it would be beneficial to perform further analysis in the form of a nested case–control study in which detailed treatment information would be collected so that the risk of developing an SPL by cumulative doses of both radiation and chemotherapy agents can be calculated. Another potential limitation of the study is the",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:51"
    }
  },
  {
    "page_content": "Another potential limitation of the study is the relatively small number of subsequent primary HLs observed, meaning that some components of the study may lack statistical power for further detailed analyses. That said, with more than three times the number of SPLs compared with the next largest study, this study is the largest cohort of childhood cancer survivors with subsequent HLs to date and hence provides the most accurate estimates of these risks. Furthermore, it is feasible that, in some",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:52"
    }
  },
  {
    "page_content": "risks. Furthermore, it is feasible that, in some instances, the first primary lymphoma was misdiagnosed as HL instead of NHL. In such cases, the subsequent primary NHL would not have been a true subsequent primary and thus resulted in an overestimate of the risk of developing NHL after HL. Although we cannot investigate the extent to which such misclassification has occurred, in a German study among adult patients with HL (aged 19–71 years), misclassification of the first primary lymphoma as HL",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:53"
    }
  },
  {
    "page_content": "of the first primary lymphoma as HL instead of NHL occurred only for 2.1% of patients, suggesting that the extent to which potential misclassification might affect our results is likely minimal. Also, we observed increased risks of NHL in survivors of Wilms tumor, leukemia, and bone sarcoma, suggesting that there is a critical role of treatment or immunodeficiency in the development of NHL after childhood cancer, and the increase cannot be caused only by misclassification of the first primary",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:54"
    }
  },
  {
    "page_content": "only by misclassification of the first primary cancer. Another potential limitation relates to heterogeneity in subtypes of subsequent primary NHL, with each subtype potentially having a different etiology. An investigation of treatment‐related risk factors for subtypes of NHL is simply not feasible within this large‐scale cohort study and would require a case–control study. # CONCLUSION In conclusion, in this largest cohort study to date, we demonstrate that the risk of developing NHL was",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:55"
    }
  },
  {
    "page_content": "demonstrate that the risk of developing NHL was increased particularly among those surviving HL, Wilms tumor, leukemia, and bone sarcoma and those who were treated with chemotherapy for any cancer. Only NHL survivors were at increased risk of HL. Although, for most childhood cancer survivors, the absolute risk of developing an SPL is low, health care professionals should be aware of the increased risk of developing NHL among survivors of HL, Wilms tumor, leukemia and bone sarcoma and in any",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:56"
    }
  },
  {
    "page_content": "Wilms tumor, leukemia and bone sarcoma and in any survivors treated with chemotherapy. Survivors should be encouraged to seek clinical advice from a medical professional if potentially relevant symptoms of NHL develop, including swellings, fever, and night sweats. # AUTHOR CONTRIBUTIONS Statistical analysis: Isabelle M. Dudley, Raoul C. Reulen, Michael M. Hawkins, David L. Winter, and Ceren Sunguc; initial drafting of the article: Isabelle M. Dudley, Raoul C. Reulen, and Michael M. Hawkins;",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:57"
    }
  },
  {
    "page_content": "Dudley, Raoul C. Reulen, and Michael M. Hawkins; study design and concept: Raoul C. Reulen, Michael M. Hawkins, Leontien C. Kremer, Florent de Vathaire, Lars Hjorth, Roderick Skinner, Riccardo Haupt, and Jop C. Teepen; data provider lead: Jeanette F. Winther, Lars Hjorth, Thorgerdur Gudmundsdottir, Maria Winther Gunnes, Päivi M. Lähteenmäki, Lorna Zadravec Zaletel, Riccardo Haupt, Monica Terenziani, Florent de Vathaire, Leontien C. Kremer, Claudia E. Kuehni, Zsuzsanna Jakab, and Stanislaw",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:58"
    }
  },
  {
    "page_content": "Claudia E. Kuehni, Zsuzsanna Jakab, and Stanislaw Garwicz; data curation: Raoul C. Reulen, David L. Winter, Desiree Grabow, Melanie Kaiser, and Peter Kaatsch; interpretation of data and critically revising of the article: all authors; all authors contributed to final review and editing. # CONFLICTS OF INTEREST Zsuzsanna Jakab reports personal fees from Semmelweis Egyetem outside the submitted work. Lars Hjorth reports personal fees from Bayer and F. Hoffmann‐La Roche outside the submitted work.",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:59"
    }
  },
  {
    "page_content": "F. Hoffmann‐La Roche outside the submitted work. The remaining authors made no disclosures. # Supporting information",
    "metadata": {
      "source": "../data/plain/PMC10099796.plain.txt",
      "id": "../data/plain/PMC10099796.plain.txt:60"
    }
  },
  {
    "page_content": "Relative risk of second malignant neoplasms highest among young adult cancer patients – a population-based registry study in Finland Abstract\nBackground and purpose\nThe objective of this study was to explore the incidence of second malignant neoplasms (SMNs) among adult cancer patients in Finland diagnosed with their first primary cancer (FPC) in 1992–2021.\nMaterial and methods",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:0"
    }
  },
  {
    "page_content": "Material and methods\nThe study used data from the population-based Finnish Cancer Registry (FCR). Risk estimates were calculated using the standardised incidence ratio (SIR), the ratio of observed second cancers compared to the expected numbers assuming the same cancer incidence as the corresponding sex-age-calendar year -split of the general population.\nResults",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:1"
    }
  },
  {
    "page_content": "A total of 573,379 FPCs were diagnosed during 1992–2021. During the follow-up, 60,464 SMNs were diagnosed. Male cancer patients had neither a decreased nor an increased risk (SIR 1.00 [95% CI, 0.99–1.01]) and female patients had an 8% increased risk (SIR 1.08 [95% CI, 1.06–1.09]) of developing any SMN compared to a FPC in the general population. The highest SIR of any SMN was observed in patients aged 20–39 -years at FPC diagnosis, and the SIR decreased by increasing age at diagnosis. Patients",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:2"
    }
  },
  {
    "page_content": "by increasing age at diagnosis. Patients with lymphoid and haematopoietic tissue neoplasms, cancers of the mouth and pharynx, endocrine glands, respiratory and intrathoracic organs, skin, and urinary organs had the highest SIRs, while patients with cancers of the male genital organs and the female breast had the lowest SIRs.",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:3"
    }
  },
  {
    "page_content": "Interpretation",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:4"
    }
  },
  {
    "page_content": "Elevated SIRs were observed in cancer patients diagnosed at an early age and for FPCs known to be in large part attributable to lifestyle factors, which highlights the importance of monitoring and encouraging lifestyle changes. # Introduction Several SMN risk factors have been identified. Both chemotherapy and radiotherapy are associated with the development of secondary malignancies. Genetic predisposition, hormonal influence, and lifestyle and environmental factors also play a part [5–7].",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:5"
    }
  },
  {
    "page_content": "and environmental factors also play a part [5–7]. Smoking, excess body weight and alcohol consumption are all strongly associated with cancer pathogenesis. Positive associations have also been observed between aforementioned lifestyle factors and the increased risk of several different SMNs [8–12]. In Finland, smoking has been decreasing in men since the 1970s; in women it started to decrease more recently. The proportion of individuals consuming alcohol or having excess body weight has",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:6"
    }
  },
  {
    "page_content": "alcohol or having excess body weight has increased since the 1980s. Although modern cancer treatments are increasingly targeted, a higher exposure to known lifestyle risk factors, coupled with improving survival rates, is likely to increase the overall incidence of SMNs in Finland [8–14]. While the cost per new cancer patient decreased between 2009 and 2014, the overall costs will increase along with the number of cancer patients. Information about the risk of developing SMNs will thus be of",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:7"
    }
  },
  {
    "page_content": "about the risk of developing SMNs will thus be of significance when planning future care and preventative measures. The previous comprehensive registry-based study on the risk of developing SMNs in Finland was based on data from 1953 to 1991. Many other European studies cover a similar time period or end before 2010 [18–23]. Prominent risk factors, treatments, and survivorship care have changed over time, thus an update is warranted [13–15]. The objective of this population-based study is to",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:8"
    }
  },
  {
    "page_content": "objective of this population-based study is to explore and describe the incidence of SMNs among adult cancer patients in Finland diagnosed with their first primary cancer (FPC) between 1992 and 2021. The focus will be on the diagnostic age and calendar period of the FPC diagnosis, as well as on the follow-up. # Material and methods This study uses data from the nationwide Finnish Cancer Registry (FCR), which maintains information on all cancer cases diagnosed in Finland since 1953. Hospitals,",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:9"
    }
  },
  {
    "page_content": "cases diagnosed in Finland since 1953. Hospitals, physicians, and laboratories have been obliged to report cancer cases to the FCR since 1961. FCR data includes details on the diagnosis and the tumour, such as the date and method of diagnosis, as well as the topography, morphology and spreading of the tumour. Information on cancer deaths is updated annually from Statistics Finland. The FCR follows the coding rules of the International Agency for Research on Cancer (IARC, 2004) for multiple",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:10"
    }
  },
  {
    "page_content": "for Research on Cancer (IARC, 2004) for multiple cancers with modifications. This means multiple primaries in the same organ are mostly excluded, however, with the national Finnish exception of haematological and lymphatic cancers. Both malignant and benign neoplasms of the brain and the central nervous system are registered. Cancers with unclear growth tendencies and in situ- tumours of the bladder and the urinary system are included as well. In addition, certain other benign tumours are also",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:11"
    }
  },
  {
    "page_content": "addition, certain other benign tumours are also registered, but not reported in routine cancer statistics. In this study, the cancer type classification followed the 10th edition of the World Health Organization’s (WHO) International Classification of Diseases with the following entities included: C00–96, D0.9.0–1, D32–33, D41–43, D45–47, D76. Cancer primary sites were combined into 16 larger site groups, which will be referred to as primary sites (Table 1, Figures 1 and 2). To avoid",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:12"
    }
  },
  {
    "page_content": "sites (Table 1, Figures 1 and 2). To avoid synchronous cancers to be included as second malignancies, the follow-up started 6 months after the date of diagnosis of the FPC. FPCs were included until 2021, excluding the last 6 months of the year, and the follow-up ended on 31 December 2021 at the latest. The follow-up time was considered short when it was up to 5 years, and long if more than 5 years had elapsed since the FPC diagnosis. The diagnostic time of the FPC was divided into three",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:13"
    }
  },
  {
    "page_content": "diagnostic time of the FPC was divided into three periods, 1992–2001, 2002–2011, and 2012–2021. We estimated the risk of developing SMNs using standardised incidence ratios (SIR). We split the general population by sex and 5-year intervals by age and calendar period and calculated the incidence rate for a FPC in given strata. This incidence rate multiplied by person-years in the same age-sex-period-strata gave the expected number of cancer cases for the cancer patient cohort. We then calculated",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:14"
    }
  },
  {
    "page_content": "for the cancer patient cohort. We then calculated the SIR (observed divided by expected number of cases) and confidence intervals (CI) assuming cancer cases are Poisson–distributed. The patient cohort was followed until SMN diagnosis or until the end of the follow-up due to censoring, thus excluding third or a higher number of malignancies. Similarly, for reference rates we followed the general population only until the FPC diagnosis or censoring. Censoring was either due to death unrelated to",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:15"
    }
  },
  {
    "page_content": "Censoring was either due to death unrelated to cancer, emigration from Finland or end of year 2021, whichever was earliest. We chose SIR for estimating the relative risk of SMNs in the cancer prevalent population compared to the general population to evaluate the importance and magnitude of SMNs in the cancer prevalent population, and also to be able to better compare the results with earlier findings in the field, as SIR is frequently used for this purpose. For comparison with other studies in",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:16"
    }
  },
  {
    "page_content": "purpose. For comparison with other studies in the literature, we also made analyses without restricting the follow-up after the diagnosis of the FPC in the general population, as this seemed to be a commonly used method. Only statistically significant findings are referred to as increased or decreased. All statistical analyses were performed using R version 4.0.2 and R package popEpi 0.4.9. # Results The overall risk of developing any SMN after any FPC was neither decreased nor increased among",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:17"
    }
  },
  {
    "page_content": "any FPC was neither decreased nor increased among men (SIR, 1.00 [95% CI, 0.99–1.01]) and increased by 8% among women (SIR, 1.08 [1.06–1.09]) (Table 1, Figures 1 and 2). In women, the SIRs were generally increased among patients aged 20–39-, 40–59- and 60–79 -years over all diagnostic periods and follow-up intervals (Tables 2 and 3). In men, the SIRs were increased among those aged 20–39- and 40–59 -years, and generally decreased among those aged 60–79- and 80 and over (Tables 2 and 3).",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:18"
    }
  },
  {
    "page_content": "aged 60–79- and 80 and over (Tables 2 and 3). Age-specifically, the SIRs were generally lower in women than men among those aged 20–39- and 40–59 -years, while generally being higher in women than men among those aged 60–79- and 80 and over (Tables 1, 2 and 3, Figures 1 and 2). When stratifying the analyses into short (0.5–5 years) and long (over 5 years) follow-up intervals, SIRs among those aged 20–39- and 40–59 -years tended to decrease with a longer follow-up time (Table 3). SIRs decreased",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:19"
    }
  },
  {
    "page_content": "a longer follow-up time (Table 3). SIRs decreased by diagnostic age at FPC among men and women, in men from SIR 2.28 (2.06–2.52) among those aged 20–39 -years to 0.90 (0.87–0.92) among those aged 80 and over, and in women from SIR 1.61 (1.50–1.73) to 1.04 (1.00–1.07), respectively (Table 1, Figures 1 and 2). The decrease was seen over both short and long follow-up intervals (Table 3) and over all studied calendar periods (Table 2). When stratifying the analyses by the FPC site groups, many of",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:20"
    }
  },
  {
    "page_content": "the analyses by the FPC site groups, many of the SIRs for any SMN were increased (Table 1, Figures 1 and 2). The highest SIRs were observed for FPCs of the lymphoid and haematopoietic tissue (SIR 1.73 [1.68–1.79] in men and 1.79 [1.73–1.86] in women), the mouth and pharynx (SIR 1.64 [1.55–1.73] and SIR 1.69 [1.56–1.83]), the endocrine glands (SIR 1.48 [1.32–1.65] and SIR 1.25 [1.17–1.34]), the respiratory and intrathoracic organs (SIR 1.29 [1.22–1.35] and SIR 1.27 [1.16–1.39]), the skin (SIR",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:21"
    }
  },
  {
    "page_content": "and SIR 1.27 [1.16–1.39]), the skin (SIR 1.23 [1.19–1.27] and SIR 1.29 [1.24–1.34]), and the urinary organs (SIR 1.26 [1.22–1.30] and SIR 1.25 [1.19–1.32]), in addition to the breast in males (SIR 1.47 [1.18–1.81]) (Table 1, Figures 1 and 2). However, the largest number of SMNs was observed in cancer cases of the male genital organs and the female breast even if the respective SIRs were low (SIR 0.74 [0.73–0.75] and SIR 0.86 [0.84–0.88]) (Table 1, Figures 1 and 2). In men, the SIR decreased by",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:22"
    }
  },
  {
    "page_content": "1, Figures 1 and 2). In men, the SIR decreased by age at first diagnosis for FPCs of the digestive organs, lymphoid and haematopoietic tissue, the male genital organs, and the respiratory and intrathoracic organs (Supplement 1). It is of note that the SIR for the male genital organs changed from increased in men aged 20–39-years (SIR 2.07 [1.60–2.64]) to decreased in 40–59-years and older (SIR 0.88 [0.84–0.93], 0.73 [0.71–0.74] and 0.72 [0.68–0.75], respectively). In women, the SIR decreased by",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:23"
    }
  },
  {
    "page_content": "respectively). In women, the SIR decreased by age at first diagnosis for FPCs of the breast, the digestive organs, lymphoid and haematopoietic tissue, the skin, the urinary organs, and the brain, meninges and central nervous system (Supplement 1). In the supplementary analysis, where the follow-up was extended beyond the FPC in the general population, we observed a 19% increased risk of developing any SMN among men (SIR 1.19 [1.18–1.20]) and 22% among women (SIR 1.22 [1.21–1.24]) (Supplement",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:24"
    }
  },
  {
    "page_content": "among women (SIR 1.22 [1.21–1.24]) (Supplement 2). # Discussion We found male cancer patients to have neither an increased nor a decreased SMN risk (SIR 1.00) and females cancer patients to have an 8% increased risk (SIR 1.08) compared to a FPC in the general population. The highest risk of any SMN was in those aged 20–39-years at FPC diagnosis, and the risk decreased by increasing age at FPC diagnosis. The risk of any SMN was highest for patients with a FPC of the lymphoid and haematopoietic",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:25"
    }
  },
  {
    "page_content": "with a FPC of the lymphoid and haematopoietic tissue, mouth and pharynx, endocrine glands, respiratory and intrathoracic organs, skin, and urinary organs, in addition to the male breast. By contrast, the risk of any SMN was lowest for cancers of the male genital organs and the female breast, with reduced risk estimates from ages 40 and over. We found higher overall SIRs in women than in men, matching earlier findings from Finland (1.00 in men and 1.25 in women). Previous studies in Sweden (SIR",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:26"
    }
  },
  {
    "page_content": "1.25 in women). Previous studies in Sweden (SIR 1.3 vs 1.6), Austria (SIR 0.90 vs 1.00), Italy (SIR 0.78 vs 0.96), and the US (SIR 1.01 vs 1.10) have yielded similar results [19–21, 27]. Studies conducted in Switzerland (SIR 1.18 vs 1.20) and France (SIR 1.38 vs 1.32), however, found no statistically significant difference in SIRs between the sexes due to overlapping confidence intervals. Explanations could include women being more susceptible to SMNs after radiotherapy and exposed to radiation",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:27"
    }
  },
  {
    "page_content": "SMNs after radiotherapy and exposed to radiation at younger ages than men due to the incidence of breast and thyroid cancer. Furthermore, hormonal drugs such as tamoxifen used to treat breast cancer increase the risk of endometrial cancer. In contrast, lifestyle and environmental factors associated with the development of SMNs are more commonly linked to men than women. Indeed, SMNs after FPCs associated with smoking, alcohol consumption and obesity skewed the results heavily towards men (Table",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:28"
    }
  },
  {
    "page_content": "skewed the results heavily towards men (Table 1, Figures 1 and 2) [6–14]. The difference in overall SIRs between men and women is also likely caused by the SIR for the male genital organs being lower than that for female breast cancer, as these two groups constituted the highest number of FPCs overall (Table 1). Both of these SIRs being decreased likely also explains the observed disparity between the relatively low overall SIR and high site-specific SIRs (Table 1, Figures 1 and 2). Using the",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:29"
    }
  },
  {
    "page_content": "SIRs (Table 1, Figures 1 and 2). Using the IARC’s rules for reporting multiple primaries excludes cancers of the same histological group arising in a pair of organs, thereby possibly decreasing the number of second breast tumours and reducing the SIR. The low SIR after the male genital organs is likely due to prostate cancer making up the majority of cases in men aged 40 and over. Increasing age is one of the most important risk factors associated with prostate cancer, and as we reported the",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:30"
    }
  },
  {
    "page_content": "with prostate cancer, and as we reported the risk by the specific first primary site, these individuals would have no previous cancer history. Moreover, prostate cancer is commonly diagnosed in its latent phase, making some conditions less aggressive and the treatment conservative [28–30]. This could imply less common treatment related risk factors in many of the patients, and therefore a lower likelihood of developing an SMN. It is of note that studies from the US and Austria have presented",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:31"
    }
  },
  {
    "page_content": "studies from the US and Austria have presented separate SIRs both including and excluding prostate cancer, with the SIR excluding prostate cancer increasing from 1.01 to 1.11 in the US and 0.90 to 1.10 in Austria. This suggests that male genital organs could have affected our overall results as well. All FPC sites with the highest SIRs for SMNs have been previously connected to smoking, alcohol consumption and excess body weight, with smoking being especially prevalent (Table 1, Figures 1 and",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:32"
    }
  },
  {
    "page_content": "especially prevalent (Table 1, Figures 1 and 2) [6–12]. Risk factors for FPC sites are also risk factors for SMNs, which relates to the risk of cancer due to habits such as smoking and other long-term lifestyle-related factors with long-lasting effects. Certain treatments have been associated with an increased risk of SMNs as well, with radiotherapy emphasised in long-term outcomes and the risk of solid malignancy, and chemotherapy emphasised in short-term outcomes, as well as the risk of",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:33"
    }
  },
  {
    "page_content": "in short-term outcomes, as well as the risk of lymphoid and haematological malignancies specifically [4–6]. The primary sites with the highest SIRs were mostly in line with earlier findings, as was the low SIR after a FPC of the male genital organs [17–23, 27]. The fluctuations in site-specific risk estimations between studies were most likely affected by how sites were grouped together, where high SIR sites combined with low SIR sites could lead to less emphasised results. In the case of",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:34"
    }
  },
  {
    "page_content": "lead to less emphasised results. In the case of breast cancer, our results differed from many others, with the risk of SMNs usually being increased instead of decreased [17, 19, 21–23, 26]. A previous study including patients from multiple Nordic population-based registries also reported an increased risk of SMNs after breast cancer (SIR 1.15 [95% CI, 1.14–1.17]). Only an Austrian study found the risk of SMNs after breast cancer to be decreased, as did we. Similarly to us, Austria followed the",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:35"
    }
  },
  {
    "page_content": "as did we. Similarly to us, Austria followed the IARC rules excluding bilateral breast cancers (except if different histological group), but so did most previous studies. Thus, this alone does not explain the differences in results. Similarly to the earlier Finnish findings, the SIR was highest in patients aged 20–39 -years and the risk declined by age. This is known to be at least partly caused by an increased susceptibility to radiotherapy. Furthermore, familial aggregation is more often",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:36"
    }
  },
  {
    "page_content": "Furthermore, familial aggregation is more often associated with early onset cancers. The SIR was also found to decrease by age at FPC diagnosis in Switzerland, Austria, Italy and France [18–22]. In our case, the primary sites with the highest SIRs for SMNs among 20–39 -years were lymphoid and haematopoietic tissue in both sexes, in addition to the endocrine glands, digestive organs, male genital organs, and mouth and pharynx in men, as well as skin, soft tissues, and the brain, meninges and",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:37"
    }
  },
  {
    "page_content": "skin, soft tissues, and the brain, meninges and central nervous system in women, which are common cancers in adolescents and young adults (Supplement 1). The distribution of different cancer types, grouped together as one FPC site, varies between age groups, like that of the male genital organs. Among men aged 40 and over, prostate cancer makes up the majority of cases, decreasing the SIR, whereas in 20–39 -year-olds testicle cancer is the major primary site, increasing the SIR. Direct",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:38"
    }
  },
  {
    "page_content": "major primary site, increasing the SIR. Direct comparisons between studies are difficult to make due to methodological differences. For example, in the earlier Finnish study the follow-up of the general population did not end at FPC diagnosis and therefore resulted in lower expected numbers with higher SIRs than the present analyses. This method seemed to be the more commonly used alternative, as we could only find mentions of restricting follow-up to the general population in a Danish study",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:39"
    }
  },
  {
    "page_content": "to the general population in a Danish study from 2012 [18–23, 27]. This does, however, not account for the lower SIRs in Austria’s and Italy’s results. Further complicating comparisons, we evaluated the risk of any SMN by FPC site, whereas, for example, the earlier Finnish study reported SIRs for specific SMNs after any FPC. Many previously mentioned studies calculated risks for both selected specific FPCs and specific SMNs [18–23, 27]. Denmark used hazard ratios for comparing risk between",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:40"
    }
  },
  {
    "page_content": "used hazard ratios for comparing risk between cancer patients and a matched sample of the general population. More recently, cumulative incidence has been used for risk estimations as well, comparing the risk within a cohort of cancer patients. In this case, we preferred using SIR, because we wanted to compare the risk between cancer patients and the general population instead. Although overall second malignancy risk estimations may vary, the common trends point toward similar results. Both",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:41"
    }
  },
  {
    "page_content": "common trends point toward similar results. Both primary and secondary cancer sites associated with smoking, alcohol use and obesity generally score the highest risk estimates, while cancers of the male genitals, specifically prostate cancer, seem to result in some of the lowest risk estimates. The present study used data from the FCR, which is legally based and registers all incident cancers since 1953 in Finland. The FCR follows WHO guidelines for coding, including those for multiple primary",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:42"
    }
  },
  {
    "page_content": "for coding, including those for multiple primary malignancies. The national coverage of cancer cases is high and the losses in follow-up practically none. The overall completeness of the cancer registry is 96% for solid tumours and 86% for non-solid tumours. Yet, while it generally provides accurate and near complete national cancer data on solid malignancies, it has some weaknesses in the case of tumours not histologically verified, such as haematological malignancies. Death certificates with",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:43"
    }
  },
  {
    "page_content": "malignancies. Death certificates with cancer mentioned, information on deaths and migration are transferred to the registry regularly, which increases the coverage and completes the follow-up. The high coverage and valid coding combined with the homogeneity of the Finnish population, make results generalisable to predominantly Caucasian populations and in terms of lifestyle and other environmental factors, to areas with a very high human development index. The median latency for case",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:44"
    }
  },
  {
    "page_content": "development index. The median latency for case verification is 18 months among European cancer registries, which stands true for the FCR as well. There is also a 3–6-month delay before data is published. Details such as treatment information are of low accuracy compared to the clinical records. Our study also lacks information on risk factors, such as smoking history, alcohol consumption or BMI. Among adult cancer patients in Finland, the overall risk of developing a SMN was slightly increased",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:45"
    }
  },
  {
    "page_content": "risk of developing a SMN was slightly increased among women and neither increased nor decreased among men compared to developing a FPC in the general population. However, the risk was materially increased in patients diagnosed at young ages and for primary cancers known to be in large part attributable to lifestyle factors such as smoking, alcohol consumption, and obesity. These risk groups highlight the importance of continued monitoring, choice of treatment and encouraging of lifestyle",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:46"
    }
  },
  {
    "page_content": "choice of treatment and encouraging of lifestyle changes among long-term cancer patients. # Author contributions NM, JP, SH, and JM developed the concept and study design. HK drafted the first version of the manuscript with support from SH and NM. AN and JM conducted the statistical analyses with supervision from JP. All authors contributed to interpretation of the results, critically reviewed the manuscript, and approved the final manuscript before submission. # Supplementary Material",
    "metadata": {
      "source": "../data/plain/PMC11332513.plain.txt",
      "id": "../data/plain/PMC11332513.plain.txt:47"
    }
  },
  {
    "page_content": "Germline risk factors for second malignant neoplasms after treatment for pediatric hematologic malignancies Abstract",
    "metadata": {
      "source": "../data/plain/PMC9820434.plain.txt",
      "id": "../data/plain/PMC9820434.plain.txt:0"
    }
  },
  {
    "page_content": "Survivors of childhood hematologic malignancies are at a substantially higher risk of developing subsequent neoplasms (SNs) when compared with the general population. SNs commonly observed in this population include basal cell carcinoma, brain tumors, thyroid cancer, breast cancer, bone tumors, and sarcoma. Radiation is the primary therapeutic exposure associated with the development of these SNs. There is emerging evidence of an association between chemotherapeutic exposures (alkylating",
    "metadata": {
      "source": "../data/plain/PMC9820434.plain.txt",
      "id": "../data/plain/PMC9820434.plain.txt:1"
    }
  },
  {
    "page_content": "between chemotherapeutic exposures (alkylating agents/anthracyclines) and the development of SNs. Despite a strong dose-dependent association between therapeutic exposures and SN risk, there is significant interindividual variability in the risk for SNs for any given dose of therapeutic exposure. This interindividual variability in risk suggests the role of genetic susceptibility. This article describes the clinical and molecular epidemiology of SNs commonly observed in survivors of childhood",
    "metadata": {
      "source": "../data/plain/PMC9820434.plain.txt",
      "id": "../data/plain/PMC9820434.plain.txt:2"
    }
  },
  {
    "page_content": "SNs commonly observed in survivors of childhood hematologic malignancies and also highlights some of the work focusing on the development of risk prediction models to facilitate targeted interventions.",
    "metadata": {
      "source": "../data/plain/PMC9820434.plain.txt",
      "id": "../data/plain/PMC9820434.plain.txt:3"
    }
  },
  {
    "page_content": "Glycemic Index, Glycemic Load and Cancer Risk: An Updated Meta-Analysis Abstract",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:0"
    }
  },
  {
    "page_content": "Diets high in glycemic index (GI) and glycemic load (GL) have been related to an increased risk of selected cancers, but additional quantification is required. We updated a systematic review and meta-analysis published in 2015 to May 2019 to provide quantitative information on GI/GL and cancer risk. Relative risks (RR) and the corresponding 95 % confidence intervals (CI) for the highest versus the lowest categories of GI and GL were extracted from selected studies and pooled using",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:1"
    }
  },
  {
    "page_content": "extracted from selected studies and pooled using random-effects models. Twenty reports (>22,000 cancer cases) have become available after January 2015, and 15 were added to the meta-analyses by cancer sites, which considered a total of 88 investigations. The five additional reports were reviewed, but not included in the meta-analyses, since data were inadequate to be pooled. For hormone-related cancers, summary RRs for the highest versus lowest GI and GL intakes were moderately increased. They",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:2"
    }
  },
  {
    "page_content": "GI and GL intakes were moderately increased. They ranged from 1.04 (breast) to 1.12 (endometrium) for GI and from 1.03 (prostate) to 1.22 (ovary) for GL, of borderline significance. High GI was associated with small increased risks of colorectal (summary RR for GI: 1.20, 95% CI, 1.07–1.34—GL: 1.09, 95% CI, 0.97–1.22, 19 studies), bladder (GI: 1.25, 95% CI, 1.11–1.41—GL: 1.10, 95% CI, 0.85–1.42, four studies) and kidney cancers (GI: 1.16, 95% CI, 1.02–1.32—GL: 1.14, 95% CI, 0.81–1.60, five",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:3"
    }
  },
  {
    "page_content": "CI, 1.02–1.32—GL: 1.14, 95% CI, 0.81–1.60, five studies). GL was not significantly related to those cancer sites. Stomach, prostate and lung cancers were not associated with GI and GL. The present analysis, based on an updated comprehensive evaluation of the epidemiological literature, indicates moderate unfavorable effects of high versus low GI on colorectal, and possibly bladder and kidney cancers, and a possible moderate positive association between GL and endometrial cancer. # 1.",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:4"
    }
  },
  {
    "page_content": "between GL and endometrial cancer. # 1. Introduction The glycemic index (GI) is an index of carbohydrate foods which indicates how quickly the food causes an increase in blood glucose levels. High GI foods have fast-release carbohydrates and higher blood glucose concentrations, leading to increased insulin secretion. Low GI foods are digested, absorbed and metabolized more slowly, thus, resulting in a more gradual rise in blood glucose. The glycemic load (GL) is the product of GI and the total",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:5"
    }
  },
  {
    "page_content": "load (GL) is the product of GI and the total available carbohydrate content in a given amount of food. It reflects both the quality (i.e., GI) and the quantity of carbohydrates. Postprandial glycaemia, and consequently dietary GI and GL have been related to diabetes, coronary heart disease (CHD) and obesity. A possible role in the development of selected cancers has been also suggested, but the evidence is yet weak. Long-term consumption of a high GI/GL diet results in chronically high blood",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:6"
    }
  },
  {
    "page_content": "high GI/GL diet results in chronically high blood glucose, and hence, to chronically elevated insulin concentration. Insulin increases bioactive IGF-1, which promote cancer development by inhibiting apoptosis and stimulating cell proliferation. In addition, hyperglycemia, insulin resistance, diabetes and obesity, which are linked to glucose metabolism, may affect the risk of cancer. In 2015, we systematically reviewed data from 75 epidemiological reports addressing the association between",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:7"
    }
  },
  {
    "page_content": "reports addressing the association between dietary GI and GL and the risk of cancer, for over 147,000 cancer cases. Seventy-two studies were included in the meta-analyses by cancer sites. The summary relative risks (RR) of hormone-related cancers for the highest versus the lowest study-specific category ranged from 1.05 (95% confidence interval, CI, 0.99–1.11, breast cancer) to 1.13 (95% CI, 0.98–1.32, endometrial cancer) for GI, and from 1.04 (95% CI, 0.91–1.18, prostate cancer) to 1.19 (95%",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:8"
    }
  },
  {
    "page_content": "(95% CI, 0.91–1.18, prostate cancer) to 1.19 (95% CI, 0.85–1.68, ovarian cancer) for GL. A significantly increased colorectal cancer risk emerged for high GI (summary RR = 1.16, 95% CI, 1.07–1.25). Other summary RRs were not significantly above unity. After that review, 20 reports have been published, accounting for 23 distinct original studies and almost 22,000 additional cancer cases. These included the EPIC-Italy cohort investigating multiple cancer sites, the Framingham Offspring cohort on",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:9"
    }
  },
  {
    "page_content": "cancer sites, the Framingham Offspring cohort on adiposity-related cancers, a pooled analysis of two studies on esophageal and gastric cardia adenocarcinoma, three studies on colorectal cancer, one combined analysis of two North European cohorts on cancer of the biliary tract, two studies on lung cancer (including a combined analysis of two Asian cohorts ), one on melanoma, four on breast cancer (including the update to 2011 of the Nurses’ Health Study II (NHSII) ), two on endometrial cancer,",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:10"
    }
  },
  {
    "page_content": "Study II (NHSII) ), two on endometrial cancer, one on ovarian cancer, one on bladder cancer, one on kidney cancer, and one on thyroid cancer. A few meta-analyses have recently reported on GI/GL and a single cancer, but no study has provided an updated comprehensive quantification of the association of GI/GL with a wide range of cancer types in a single report. Given the new original data, we updated our systematic review and meta-analysis to derive a more precise estimation of the associations.",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:11"
    }
  },
  {
    "page_content": "a more precise estimation of the associations. Specifically, we reviewed the most recent (up to May 2019) epidemiological data on the association between dietary GI and GL and cancer risk, updated summary RRs for stomach, colorectal, pancreatic, breast, endometrial, ovarian and prostate cancers and addressed issues of heterogeneity and complexities of interpretation. Moreover, we calculated meta-analytic estimates for kidney, and for the first time, lung and bladder neoplasms. # 2. Materials",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:12"
    }
  },
  {
    "page_content": "time, lung and bladder neoplasms. # 2. Materials and Methods ## 2.1. Search Strategy and Selection Criteria We conducted a systematic review and a series of meta-analyses on dietary GI and dietary GL and cancer risk following recognized reporting guidelines. We included relevant studies selected in our prior systematic review and meta-analysis on GI/GL intake and cancer risk (search up to January 2015 ), and updated the search using the same search strategy through May 2019. Briefly, the",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:13"
    }
  },
  {
    "page_content": "search strategy through May 2019. Briefly, the following string was used in Medline/Pubmed, with no language or other restriction: “((cancer) OR (neoplasm) OR (carcinoma)) AND ((glycemic index) OR (glycemic load) OR (glycaemic index) OR (glycaemic load))”. The electronic search was supplemented by hand searching of references of the selected publications and previous reviews. We selected original cohort or case-control studies that assessed the association between dietary GI and/or GL intake",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:14"
    }
  },
  {
    "page_content": "association between dietary GI and/or GL intake and the incidence of or mortality from a specific cancer (Table 1). Studies analyzing cancer overall were excluded. To be included in the quantitative meta-analyses, studies had to report the estimates of the RRs (i.e., odds ratios, ORs, or RRs, or hazard ratios, HRs) and the corresponding 95% CI for categories of GI/GL intake, or information needed for their calculation; studies providing only the RR for the increment of one unit of GI/GL were",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:15"
    }
  },
  {
    "page_content": "RR for the increment of one unit of GI/GL were reviewed, but not considered in the meta-analyses. We conducted meta-analyses for cancer sites investigated in at least four studies. Two reviewers independently identified eligible studies by screening titles, abstract, and when appropriate, full-texts of articles. Any discrepancy was discussed and resolved by consensus. If there were multiple publications from the same study population, we used data from the longest follow-up (for cohorts) or the",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:16"
    }
  },
  {
    "page_content": "from the longest follow-up (for cohorts) or the larger database (for case-control studies). From each selected publication, we extracted details on study design, country, sex of the participants, tumor site, number of enrolled subjects (cases and controls or cohort size), period of enrolment (for case-control studies) or follow-up (for cohort studies), methods for dietary assessment (type, number of food items, and whether it had been validated), reference food for GI/GL (white bread or",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:17"
    }
  },
  {
    "page_content": "reference food for GI/GL (white bread or glucose), comparison levels of GI and/or GL, RR estimates (i.e., odds ratios/hazard ratios/RRs) for the comparison between the highest versus the lowest category of GI/GL intake, and confounding factors for which adjustment was made. When RR estimates from models with different covariates were provided, we extracted the RRs adjusted for the largest number of confounding factors. ## 2.2. Statistical Analysis We conducted quantitative meta-analyses of GI",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:18"
    }
  },
  {
    "page_content": "We conducted quantitative meta-analyses of GI and GL intake in association with the risk of cancer. In the current analysis, we considered cancer sites investigated in at least four studies and for which new epidemiological data have become available after the previous review, i.e., breast, endometrium, ovary and prostate among hormone-related cancers, stomach, colorectum and pancreas among digestive tract cancers, and lung, bladder and kidney among other cancer sites. Although new data on",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:19"
    }
  },
  {
    "page_content": "among other cancer sites. Although new data on liver cancer have been made available from the EPIC-Italy cohort, we did not update the meta-analysis on liver cancer as that data partially overlapped with those reported in 2013 by Fedirko et al., which analyzed the overall EPIC cohort. We derived summary estimates of the RR by combining study-specific ORs or RRs or HRs for the highest versus the lowest category of GI and GL intake using random-effects models, which account for the heterogeneity",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:20"
    }
  },
  {
    "page_content": "models, which account for the heterogeneity among the RR estimates. Heterogeneity was evaluated through the χ2 test and quantified through and the I2 statistic. We updated subgroup analyses for breast cancer according to menopausal status and body mass index (BMI) (<25 kg/m2 and BMI ≥ 25 kg/m2). One study showing the RR of breast cancer according to GI and GL among women with BMI ≥ 30 kg/m2 was excluded from the subgroup analysis. Publication bias was assessed through funnel plots and Egger",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:21"
    }
  },
  {
    "page_content": "bias was assessed through funnel plots and Egger tests. All the statistical analyses were performed using the STATA software (version 14; StataCorp, College Station, TX, USA). # 3. Results Of the 203 newly identified publications in the Medline literature (from January 2015 to May 2019), 20 were selected as original studies providing results on the association between GI and/or GL and the risk of a specific cancer (Table 1) (for a detailed description of studies on GI/GL and cancer risk",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:22"
    }
  },
  {
    "page_content": "description of studies on GI/GL and cancer risk published before January 2015, refer to Table 1—Supporting information of our previous work ). Eleven reports provided results from case-control studies (including one report of a pooled analysis of two case-control studies ) and nine from cohort studies (including a combined analysis of two cohorts in Shanghai, a combined analysis of two Swedish cohorts, and a prospective analysis based on data from the PREvención con DIeta MEDiterránea (PREDIMED",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:23"
    }
  },
  {
    "page_content": "the PREvención con DIeta MEDiterránea (PREDIMED trial) ). Two reports gave results on a number of cancer sites; the remaining reports were focused on a single cancer type. These reports included a minimum of 32 to a maximum of 5112 cases. Eight reports were based on studies conducted in North America, three in Central/South America, six in Europe, and three in Asia. All studies except one provided results for both GI and GL. Validated FFQs were used in all studies to evaluate dietary habits.",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:24"
    }
  },
  {
    "page_content": "used in all studies to evaluate dietary habits. Most studies used glucose as reference food for GI/GL calculation. GI/GL were categorized in quartiles in 11 reports, in quintiles in five reports and in tertiles in three reports; one study used GI/GL as a continuous variable. Fifteen of the 20 newly identified reports provided data that could be added to our meta-analyses on GI/GL and cancer risk. One publication on breast cancer providing only the RRs for the increment of one unit of GI/GL, and",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:25"
    }
  },
  {
    "page_content": "RRs for the increment of one unit of GI/GL, and four publications on cancers sites for which less than four studies were available (i.e., esophagus and gastric cardia, biliary tract, melanoma, thyroid ), were not considered in the quantitative meta-analyses. In the meta-analyses on breast cancer, the 2015 paper by Farvid et al. with updated results of the NHSII cohort replaced the 2003 paper by Cho et al., which was based on a shorter follow-up and a quarter of the cases. Similarly, in the",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:26"
    }
  },
  {
    "page_content": "and a quarter of the cases. Similarly, in the meta-analyses on colorectal cancer, updated results from the EPIC-Italy cohort replaced data from an earlier publication on the same cohort. Updated data from the EPIC-Italy cohort did not contribute to the meta-analyses on breast and endometrial cancers as the analyses already included larger amounts of data from the overall EPIC cohort. In addition, we retrieved one publication on ovarian cancer not previously identified. ## 3.1. Results of the",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:27"
    }
  },
  {
    "page_content": "not previously identified. ## 3.1. Results of the Individual Studies ### 3.1.1. Multiple Cancer Sites The EPIC-Italy cohort provided results for 21 different cancer types. In a median follow-up of about 15 years, 5112 incident cancers occurred (including 441 colon, 102 rectal, 117 pancreatic, 307 lung, 1362 breast, 203 endometrial, 135 ovarian, 481 prostate, 251 bladder and 136 kidney cancers). For most cancer sites, no association was found for either dietary GI or GL. High GI was associated",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:28"
    }
  },
  {
    "page_content": "either dietary GI or GL. High GI was associated with an increased risk of colon (HR for the fifth versus first quintile: 1.48, 95% CI, 1.09–2.01) and bladder cancer (HR: 1.51, 95% CI, 1.01–2.25), and high GL with an increased risk of colon (HR: 1.80, 95% CI, 1.18-2.74) and diabetes-related cancers (HR: 1.23, 95% CI, 1.03–1.48), but a decreased risk of rectal cancer (HR: 0.42, 95% CI, 0.18–0.98). The Framingham Offspring cohort found no association between GI, GL and adiposity-related cancers,",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:29"
    }
  },
  {
    "page_content": "between GI, GL and adiposity-related cancers, based on a total of 656 incident cancers of the gastrointestinal tract, reticuloendothelial system (blood, bone and spleen), female reproductive tracts, genitourinary organs and the thyroid gland. In analyses by cancer type, no significant associations were found for breast, colorectal, and prostate cancers. The HRs for the third versus first tertile were 0.90 (95% CI, 0.59–1.37) for GI and 0.54 (95% CI, 0.26–1.09) for GL for breast cancer (124",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:30"
    }
  },
  {
    "page_content": "(95% CI, 0.26–1.09) for GL for breast cancer (124 cases), 1.51 (95% CI, 0.81–2.84) for GI and 1.21 (95% CI, 0.43–3.40) for GL for colorectal cancer (68 cases), and 0.74 (95% CI, 0.48–1.12) for GI and 0.76 (95% CI, 0.40–1.43) for GL for prostate cancer (157 cases). ### 3.1.2. Hormone-Related Cancers As for breast cancer, the update of the NHSII, which included 12 additional years of follow-up and almost four times the number of cases compared to the 2003 report, found a null association between",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:31"
    }
  },
  {
    "page_content": "the 2003 report, found a null association between GI and GL and breast cancer risk, with HRs for the fifth versus the first quintile of 1.03 (95% CI, 0.91–1.16) for GI and 0.94 (95% CI, 0.83–1.06) for GL, based on 2833 invasive cases. Similar null results were observed in pre- (HR for GI: 1.05, HR for GL: 0.93) and post-menopause (HR for GI: 1.08, HR for GL: 0.95), as well as among normo- (HR for GI: 1.04, HR for GL: 0.94) and over-weight women (HR for GI: 1.12, HR for GL: 1.19, not",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:32"
    }
  },
  {
    "page_content": "women (HR for GI: 1.12, HR for GL: 1.19, not significant). In a secondary analysis within the framework of the PREDIMED trial, based on 32 incident cases, dietary GI and GL were not related to breast cancer among postmenopausal women at high risk of cardiovascular diseases (HR for the third versus the first tertile 1.02, 95% CI, 0.42–2.46 for GI and 1.00, 95% CI, 0.44–2.30 for GL). No association with breast cancer was also reported in a Mexican population-based case-control study including",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:33"
    }
  },
  {
    "page_content": "population-based case-control study including 1000 women with breast cancer, the ORs for the fourth versus the first quartile being 0.90 (95% CI, 0.68–1.2) for GI and 1.1 (95% CI, 0.82–1.1) for GL. In that study, a null association was also observed in subgroups defined by menopausal status and BMI. A further Mexican case-control study, including 509 cases matched 1:1 by age with 509 population controls, found a positive association between GI and breast cancer overall (OR for 1 unit increase",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:34"
    }
  },
  {
    "page_content": "and breast cancer overall (OR for 1 unit increase 1.15, 95% CI, 1.09–1.23) and luminal A, HER2+ and TN molecular subtypes; no association emerged for GL regardless of the subtype. Two studies investigating GI/GL in relation to endometrial cancer found both an absence of association. The HRs were 0.98 (95% CI, 0.74–1.29) for GI and 0.83 (95% CI, 0.62–1.11) for GL for the fourth versus first quartile in the US Cancer Prevention Study II (CPS-II) Nutrition Cohort, which included 425 incident cases",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:35"
    }
  },
  {
    "page_content": "Cohort, which included 425 incident cases occurred during a median follow-up of about 14 years. In addition, a Canadian case-control study with over 500 cases and 980 population controls found an OR of 0.87 (95% CI, 0.52–1.49) for the fourth versus the first quartile of dietary GL, with no effect modification by BMI. As for ovarian cancer, a case-control study among African-Americans in the USA enrolling about 400 cases and 600 population controls found no association with GI (OR for the fourth",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:36"
    }
  },
  {
    "page_content": "found no association with GI (OR for the fourth versus the first quartile 1.03, 95% CI, 0.84–1.18), but a suggestion of a positive association with GL. The ORs were 1.18 (95% CI, 1.04–1.33) per 10 units of GL/1000 kcal in the continuous analysis and 1.35 (95% CI, 0.93–1.97) for the highest versus the lowest quartile of GL when the variable was considered in categories; in the latter analysis, however, a clear dose-risk relationship did not emerge (ORs for subsequent quartiles: 1.16, 1.57",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:37"
    }
  },
  {
    "page_content": "emerge (ORs for subsequent quartiles: 1.16, 1.57 [significant], 1.35, p for trend = 0.05). ### 3.1.3. Cancers of the Digestive Tract Two case-control and one cohort study on colorectal cancer have become available after the previous meta-analysis. The Japan Public Health Center-based prospective Study (JPHC Study) provided, for the first time, data on GI/GL and colorectal cancer risk in a Japanese population. Based on 1468 incident cases from a population of over 73,000 subjects followed for",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:38"
    }
  },
  {
    "page_content": "a population of over 73,000 subjects followed for 12.5 years on average, the JPHC study found overall non-significant results for GI, as well as GL; the HRs of colorectal cancer for the fourth versus the first quartile were 0.92 (95% CI, 0.73–1.14) in men and 0.97 (95% CI, 0.73–1.30) in women for GI, and 0.79 (95% CI, 0.58-1.08) in men and 0.82 (95% CI, 0.55–1.24) in women for GL. However, a non-significantly reduced risk of (proximal) colon cancer for high GL consumption was observed in men",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:39"
    }
  },
  {
    "page_content": "for high GL consumption was observed in men (HRs for proximal colon cancer: 0.62, 95% CI, 0.36–1.08) and a non-significantly reduced risk of rectal cancer for high GI (HRs 0.58, 95% CI, 0.33–1.03) and GL (HR: 0.52, 95% CI, 0.24–1.14) was found in women. A Chinese case-control study, including 1944 cases and 2027 community-derived or hospital controls, reported a positive association between GI and colorectal (OR for the fourth versus first quartile: 3.10, 95% CI, 2.51–3.85), as well as colon",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:40"
    }
  },
  {
    "page_content": "3.10, 95% CI, 2.51–3.85), as well as colon (1172 cases) and rectal cancer (772 cases), similar in men and women. High GL was not associated with colorectal (OR for the fourth versus first quartile: 1.14, 95% CI, 0.94–1.35), colon or rectal cancer. However, an increased risk of colorectal cancer for the highest versus lowest quartile of GL was found in women only (OR 1.42, 95% CI, 1.04–1.95). A case-control study from Argentina and based on 161 cases of colorectal cancer and 331 population-based",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:41"
    }
  },
  {
    "page_content": "of colorectal cancer and 331 population-based controls showed significant positive associations with GI and GL in women only (OR for the third versus first tertile 2.12, 95% CI, 1.38–3.27 for GI, OR: 1.98, 95% CI, 1.24–3.18 for GL). ### 3.1.4. Other Neoplasms A pooled analysis of two US population-based case-control studies (i.e., the US Multi-Center Study and the Los Angeles Multi-Ethnic Study), including overall 500 esophageal adenocarcinomas, 529 gastric cardia adenocarcinomas and 2027",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:42"
    }
  },
  {
    "page_content": "529 gastric cardia adenocarcinomas and 2027 controls, reported an increased risk of esophageal adenocarcinoma for the fifth versus the first quintile of GI intake (OR 1.58, 95% CI, 1.13–2.21), in the absence, however, of a clear dose-risk relationship (p for trend 0.32). Such positive association was evident only among subjects with BMI ≥ 25 kg/m2. No relation emerged between GI and esophageal adenocarcinoma (OR for the fifth versus the first quintile: 1.21, 95% CI, 0.88–1.67), as well as",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:43"
    }
  },
  {
    "page_content": "quintile: 1.21, 95% CI, 0.88–1.67), as well as between GL intake and esophageal (OR: 0.81, 95% CI, 0.51–1.29) and gastric cardia adenocarcinoma (OR: 0.86, 95% CI, 0.55–1.35). Dietary GI and GL were positively related to the risk of biliary tract cancer in the combined analysis of the Swedish Mammography Cohort and cohort of Swedish Men, which included 140 extrahepatic and 23 intrahepatic cancer cases developed from a population of over 76,000 individuals during a mean follow-up of 13.3 years.",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:44"
    }
  },
  {
    "page_content": "during a mean follow-up of 13.3 years. The HRs for the fourth versus first quartile of dietary GI was 2.12 (95% CI, 1.25–3.58) for extrahepatic and 1.47 (95% CI, 0.54–3.97) for intrahepatic biliary tract cancer; the corresponding values for GL were, respectively, 1.63 (95% CI, 1.01–2.63) and 3.46 (95% CI, 1.22–9.84). Two reports gave results on GI/GL and lung cancer. Data from the Shanghai Women’s and Men’s Health Studies, including 649 incident lung cancers among women and 663 among men",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:45"
    }
  },
  {
    "page_content": "lung cancers among women and 663 among men developed during an average follow-up of about 15 years, indicated no association of GI or GL with lung cancer. The HRs for the fourth versus the first quartile of GI was 1.16 (95% CI, 0.92–1.47) in women and 0.83 (95% CI, 0.67–1.03) in men; the corresponding figures for GL were 1.09 (95% CI, 0.86-1.37) in women and 0.85 (95% CI, 0.68–1.05) in men. Null findings were also found in strata of BMI, smoking, family history of cancer and menopausal status",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:46"
    }
  },
  {
    "page_content": "family history of cancer and menopausal status (in women). In a population-based case-control study from USA based on 1905 incident cases and 2413 controls a significant positive association with lung cancer risk was found for GI (OR for the fifth versus the first quintile 1.49, 95% CI, 1.21–1.83, p for trend < 0.001), but not for GL (OR 1.16, 95% CI, 0.94–1.42). The positive association with GI was more evident among never smokers (OR fifth quintile 2.25, 95% CI, 1.42–3.57) and for the",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:47"
    }
  },
  {
    "page_content": "quintile 2.25, 95% CI, 1.42–3.57) and for the squamous cell carcinoma histologic subtype (OR 1.30, 95% CI, 1.02–1.67). An Italian population-based case-control study including 380 cases of melanoma and 719 age- and sex-matched controls reported a positive association with GL among women (OR 2.38; 95% CI 1.25, 4.52 for the highest versus the lowest quintile, p for trend = 0.070), but not among men (OR 0.86, 95% CI, 0.47–1.57), and a lack of relation with GI in either sex. A positive association",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:48"
    }
  },
  {
    "page_content": "with GI in either sex. A positive association between GL and bladder cancer risk was found in a case-control study from Italy, including 578 cases and 608 hospital-controls. The risk of bladder cancer was significantly increased from the second quartile onwards, and subjects in the fourth quartile had an approximately doubled risk of bladder cancer compared to those in the first one (OR 1.96, 95% CI, 1.16–3.31). No association emerged with GI. One case-control study from USA investigated renal",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:49"
    }
  },
  {
    "page_content": "case-control study from USA investigated renal cell carcinoma and found a positive association for GI and an absence of association for GL. Based on a total of 854 cases and 1255 population-based controls, the ORs for the fourth versus the first quartile were 1.32 (95% CI, 0.99–1.74; p for trend = 0.026) for GI and 1.15 (95% CI, 0.88–1.51) for GL. An analysis based on 556 well-differentiated thyroid cancers within the EPIC cohort found overall no association with GI (HR for the fourth versus",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:50"
    }
  },
  {
    "page_content": "no association with GI (HR for the fourth versus first quartile: 0.94, 95% CI, 0.73–1.20) and GL (HR: 0.95, 95% CI, 0.74–1.24). In stratified analysis, a significant positive relation among overweight (HR: 1.54, 95% CI, 1.05–2.28, p for trend = 0.014) and an inverse one among normoweight subjects (HR: 0.64, 95% CI, 0.46–0.89, p for trend = 0.003) emerged with GI. ## 3.2. Update of the Summary Estimates Overall, 88 reports were included in the meta-analyses on GI/GL and cancer risk (see",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:51"
    }
  },
  {
    "page_content": "the meta-analyses on GI/GL and cancer risk (see Supplementary Materials for complete bibliography references). Summary RRs of hormone-related cancers, digestive-tract cancers and other neoplasms for the highest versus the lowest category of GI (Panel A) and GL (Panel B) intake are presented, respectively, in Figure 1, Figure 2 and Figure 3. There was no evidence of publication bias according to the Egger’s tests for all cancer sites considered (data not shown). ### 3.2.1. Hormone-Related",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:52"
    }
  },
  {
    "page_content": "(data not shown). ### 3.2.1. Hormone-Related Cancers ### 3.2.2. Digestive-Tract Cancers There was a positive significant association between high GI intake and colorectal cancer risk. No other significant associations were detected (Figure 2). Summary RRs were 1.09 (95% CI, 0.79-1.52) for GI (seven studies, 3152 cases—Panel A) and 1.04 (95% CI, 0.80–1.35) for GL (seven studies, 3152 cases–Panel B) for stomach cancer, 1.20 (95% CI, 1.07–1.34) for GI (19 studies, 26,456 cases) and 1.09 (95% CI,",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:53"
    }
  },
  {
    "page_content": "GI (19 studies, 26,456 cases) and 1.09 (95% CI, 0.97–1.22) for GL (19 studies, 25,778 cases) for colorectal cancer, 1.09 (95% CI, 0.98–1.21) for GI (11 studies, 3855 cases) and 0.99 (95% CI, 0.84–1.17) for GL (12 studies, 4289 cases) for pancreatic cancer. Significant heterogeneity across studies was detected in all the meta-analyses, except for that on GI and pancreatic cancer. In a sensitivity analysis, the summary RR of colorectal cancer according to high GI remained statistically",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:54"
    }
  },
  {
    "page_content": "according to high GI remained statistically significant with the exclusion of each study in turn. ### 3.2.3. Other Neoplasms There was no association between high GI or GL intake and lung cancer risk, the summary RRs being 1.11 (95% CI, 0.98–1.26) for GI (six studies, 13,385 cases) and 0.96 (95% CI, 0.87–1.06) for GL (five studies, 12,922 cases) (Figure 3). A significant positive association was found between high GI and bladder cancer, with a summary RR of 1.25 (95% CI, 1.11–1.41; four",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:55"
    }
  },
  {
    "page_content": "a summary RR of 1.25 (95% CI, 1.11–1.41; four studies, 3339 cases); the corresponding summary RR for GL was 1.10 (95% CI, 0.85–1.41; four studies, 3339 cases). Summary RRs for kidney cancer were 1.16 (95% CI, 1.02–1.32) for GI (five studies, 4281 cases) and 1.14 (95% CI, 0.80–1.60) for GL (five studies, 4281 cases). Heterogeneity across studies was low-to-moderate in most of the meta-analyses (I2 ranging from 0 to 40.5), except for those on GI and lung cancer (I2 = 68.2%) and GL and kidney",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:56"
    }
  },
  {
    "page_content": "GI and lung cancer (I2 = 68.2%) and GL and kidney cancer (I2 = 78.6%). In sensitivity analyses, the positive association between high GI and bladder cancer remained significant when any study was removed from the meta-analysis, while the summary RR of kidney cancer for high GI was no longer significant with the exclusion of each study in turn, except that by George et al.. ### 3.2.4. Subgroup Analyses for Breast Cancer In subgroup analyses by menopausal status, the summary RRs of breast cancer",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:57"
    }
  },
  {
    "page_content": "status, the summary RRs of breast cancer for the highest versus the lowest category of GI were 1.08 (95% CI, 0.96–1.21, 13 studies, p for heterogeneity = 0.043, I2= 44.2%) for premenopausal breast cancer and 1.04 (95% CI, 0.96–1.12, 17 studies p for heterogeneity = 0.020, I2= 45.9%) for postmenopausal breast cancer (p for heterogeneity between strata = 0.595) (Figure 4). The corresponding figures for GL were 1.16 (95% CI, 1.00–1.34, 13 studies, p for heterogeneity = 0.002, I2 = 62.1%) for",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:58"
    }
  },
  {
    "page_content": "p for heterogeneity = 0.002, I2 = 62.1%) for premenopausal breast cancer and 1.05 (95% CI, 0.95–1.16, 17 studies, p for heterogeneity < 0.001, I2 = 62.4%) for postmenopausal breast cancer (p for heterogeneity between strata = 0.27). Summary RRs of breast cancer in strata of BMI indicated a null association with GI and GL among normo-weight as well as overweight women. As for GI, the RRs for the highest versus lowest intake were 1.13 (95% CI, 0.97–1.32, six studies, p for heterogeneity = 0.132,",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:59"
    }
  },
  {
    "page_content": "six studies, p for heterogeneity = 0.132, I2 = 35.8%) for BMI < 25 kg/m2 and 0.97 (95% CI, 0.95–1.16, six studies, p for heterogeneity = 0.586, I2 = 0%) for BMI ≥ 25 kg/m2 (p for heterogeneity between strata = 0.103). Values for GL were 1.12 (95% CI, 0.94–1.34, seven studies, p for heterogeneity = 0.003, I2 = 64.3%) for BMI < 25 kg/m2 and 0.99 (95% CI, 0.86–1.14, seven studies, p for heterogeneity = 0.159, I2 = 31.2%) for BMI ≥ 25 kg/m2 (p for heterogeneity between strata = 0.286). # 4.",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:60"
    }
  },
  {
    "page_content": "for heterogeneity between strata = 0.286). # 4. Discussion The present work, based on 88 reports, represents the most updated comprehensive quantification of the relation of GI and GL intake with cancer risk. It updates and expands a previous analysis published in 2015, and provides meta-analytic results for kidney, and for the first time, lung and bladder cancers. The present results largely confirm those of the previous meta-analysis; summary RRs are similar to those previously reported, but,",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:61"
    }
  },
  {
    "page_content": "are similar to those previously reported, but, in general, they are more precise, providing more confidence in the results. We found significant, but small, unfavorable effects of high versus low GI diets for colorectal, and possibly bladder and kidney cancers, and a possible modest positive association between high GL and endometrial cancer. Most of the summary RRs were weakly and non-significantly (or at most marginally significantly) increased, indicating no major role of GI/GL intake in the",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:62"
    }
  },
  {
    "page_content": "indicating no major role of GI/GL intake in the etiology of most cancer types. Possible biological mechanisms to explain the modest associations observed include the impact of GI and GL on blood glucose, HbA1c, and hence, insulin and IGF-1. These may also impact on body weight. Although body weight was allowed for in most of the analyses considered, residual confounding may be present. However, GI and GL are correlated with other aspects of carbohydrate quality, such as cereal fibers.",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:63"
    }
  },
  {
    "page_content": "of carbohydrate quality, such as cereal fibers. Confounding by these factors may also partly explain the observed associations. Our findings are broadly similar to other meta-analyses addressing the role of dietary GI, dietary GL and cancer risk. In particular, no associations with stomach, prostate, and pancreatic cancers were reported by others. A meta-analysis on kidney cancer based on the same study sample yielded essentially identical results, i.e., a positive, but weak, significant",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:64"
    }
  },
  {
    "page_content": "results, i.e., a positive, but weak, significant association with high GI and no association with GL. Although the absence of appreciable heterogeneity among studies supports the robustness of findings on GI and kidney cancer, the still limited number of studies and the null association with GL need to be considered in the interpretation of findings. In addition, the exclusion from the GI-kidney cancer meta-analysis of each study in turn—with the exception of the study by George et al. —gave",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:65"
    }
  },
  {
    "page_content": "the exception of the study by George et al. —gave non-significant summary RR estimates. According to the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR), high dietary GL (but not GI) is probably a cause of endometrial cancer, while evidence on other cancer sites, including colorectal, pancreatic, liver and breast cancers, is inconclusive. The conclusion on endometrial cancer was based on a dose-response meta-analysis based on six cohort studies published up to",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:66"
    }
  },
  {
    "page_content": "based on six cohort studies published up to 2012, which estimated a significant 15% increased risk per 50 units/day of GL. The summary RR of endometrial cancer for high versus low GL was 1.17 (95% CI, 1.00–1.37) in our previous meta-analysis based on 11 studies, and 1.12 (95% CI, 0.97–1.56) in the current update, after the inclusion of two additional studies. Although only marginally significant, such 12% increased risk was not in contrast with the WCRF result, thought the different methods of",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:67"
    }
  },
  {
    "page_content": "the WCRF result, thought the different methods of analyses (i.e., dose-response versus extreme quantile), inclusion criteria (e.g., only cohort versus both cohort and case-control studies) and search updates do not allow a direct comparison. A positive association between high GL (but not GI) and the risk of endometrial cancer was reported in other previous meta-analyses, while a recent high profile publication by Reynold et al, which provided systematic reviews and meta-analyses of prospective",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:68"
    }
  },
  {
    "page_content": "reviews and meta-analyses of prospective studies on the relationship between the most widely studied indicators of carbohydrate quality and incidence of, and mortality from, a wide range of non-communicable diseases, did not find any relation with GI and GL, both in dose-response and extreme quantile analyses. In that report, high GI was associated with a marginally significant 10% increased risk of colorectal cancer (summary RR 1.10, 95% CI, 0.99–1.22), and each 10 units/day of GI to a 5%",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:69"
    }
  },
  {
    "page_content": "0.99–1.22), and each 10 units/day of GI to a 5% increased risk of borderline significance (summary RR 1.05, 95% CI, 1.00–1.10), while no association was reported for GL. Excess risks of colorectal cancer less than 10% for high versus low GI were found in previous meta-analyses of prospective studies. The excess risk was slightly higher (15–20%) —but essentially comparable—in meta-analyses based on both cohort and case-control studies, including the present one. We found a modest nonsignificant",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:70"
    }
  },
  {
    "page_content": "the present one. We found a modest nonsignificant association of GI/GL and breast cancer. Other meta-analyses generally showed no or small (<10%) increased risks for the highest versus the lowest GI or GL. In the meta-analyses by Reynolds et al, summary RRs of breast cancer were 1.05 (95% CI, 1.01–1.10) for high versus low GI (but 1.01, 95% CI, 0.98–1.03 for a 10 unit/day increase) and 1.00 (95% CI, 0.95–1.06) for high versus low GL. In another meta-analysis updated to 2015, the association",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:71"
    }
  },
  {
    "page_content": "meta-analysis updated to 2015, the association with GI—but not with GL—was slightly stronger in postmenopausal than premenopausal women, but the difference was not significant; in addition, BMI did not influence the association between GI, GL and breast cancer. This is in line with the current results, showing comparable estimates of the GI/GL-breast cancer association in pre- and post-menopausal women, as well as in normo-weight and overweight women. No meta-analysis has previously",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:72"
    }
  },
  {
    "page_content": "overweight women. No meta-analysis has previously systematically addressed the association of GI/GL with ovarian, lung or bladder cancers. In our study, GI and GL did not significantly influence the risk of lung and ovarian cancer. We found a significant 25% increased risk of bladder cancer for high versus low GI intake, and the association remained significant when excluding each study in turn; no relation was observed for GL. Conditions related to chronic hyperinsulinemia and hyperglycemia,",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:73"
    }
  },
  {
    "page_content": "to chronic hyperinsulinemia and hyperglycemia, such as diabetes and the metabolic syndrome, have been associated with bladder cancer. Urinary tract infections influence the risk of bladder cancer and may be associated with a diet promoting a large increase in blood glucose. In addition, insulin can increase the expression of epidermal growth factors and protein kinase, and induced bladder cancer cell proliferation in in vitro studies. Part of the different associations of dietary GI and dietary",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:74"
    }
  },
  {
    "page_content": "different associations of dietary GI and dietary GL on selected cancer types may be explained by differences in the underlying dietary patterns. Some studies indeed suggested that while the overall GL of a diet is mostly associated with high-carbohydrate foods, and hence, closely correlates to total carbohydrate intake, GI is associated not to only to high consumption of high-carbohydrate foods, but also to low consumption of some low-carbohydrate foods (and the related nutrients), including",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:75"
    }
  },
  {
    "page_content": "foods (and the related nutrients), including fruit, dairy, vegetables, and legumes. Thus, dietary GI, unlike GL, may reflect more dimensions of diet than just carbohydrates. This could partly explain at least the positive association of GI with colorectal cancer—a cancer potentially related to various aspects of diet—in the absence of any relation with GL. In any case, in 2015, a scientific consensus statement by international experts on carbohydrate research recognized that the GI is a valid",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:76"
    }
  },
  {
    "page_content": "research recognized that the GI is a valid and reproducible measure to express the glycemic response of foods. The heterogeneity in studies’ results observed in most meta-analyses may be due to several reasons, including the dietary habits of the studied populations (i.e., low carbohydrate diets, which include high animal proteins and fats [e.g., for North American populations] versus high carbohydrate diets [e.g., for populations from southern Europe] ), the number and type of carbohydrate",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:77"
    }
  },
  {
    "page_content": "Europe] ), the number and type of carbohydrate items in the FFQs and GI values attributed to FFQ items, with the consequent different ranges of GI/GL (particularly GL) in various studies. Moreover, studies used different methods of GI/GL categorization in the analyses (e.g., tertiles, quartiles, quintiles); therefore, there is heterogeneity in the highest and lowest absolute levels of GI/GL. The study design and the selection of the adjustment factors may also contribute to the observed",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:78"
    }
  },
  {
    "page_content": "factors may also contribute to the observed heterogeneity. In epidemiologic studies, high dietary GI and GL were consistently associated with greater risks of diabetes and CHD. When restricting our analyses on colorectal and breast cancers to large, well-recognized cohorts which reported on GI/GL and such other health outcomes (i.e., the Swedish Mammography Cohort and cohort of Swedish Men, the Shanghai Women’s and Men’s studies, the Health Professional Follow-up Study, the NHSI and NHSII, the",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:79"
    }
  },
  {
    "page_content": "Follow-up Study, the NHSI and NHSII, the EPIC cohort, the Women’ Health Study and the Women’s Health Initiative), results were essentially unchanged, while heterogeneity decreased for the GI-breast cancer (I2 = 0%, p = 0.883), GI-colorectal cancer (I2 = 9.7%, p = 0.353) and GL-breast cancer (I2 = 6%, p = 0.384) meta-analyses, but not appreciably for the meta-analysis on GL and colorectal cancer (I2 = 71.2%, p = 0.001). Most studies adjusted for the most relevant confounders, i.e., BMI/physical",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:80"
    }
  },
  {
    "page_content": "the most relevant confounders, i.e., BMI/physical activity, energy intake, tobacco and social class, but some residual confounding is still possible. GI/GL are positively associated with diabetes, and diabetes increases the risk of colorectal, pancreatic, endometrial and perhaps breast cancer (and possibly decreases the risk of prostate cancer). In addition, diabetic patients are often advised to change their diet to lower carbohydrate intake, and this could underestimate any positive",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:81"
    }
  },
  {
    "page_content": "intake, and this could underestimate any positive association. Therefore, careful consideration of subjects’ diabetes condition is necessary when examining the relation of GI and GL with diabetes-related neoplasms. In most studies on colorectal, endometrial and prostate cancer, authors either: (1) excluded diabetics from the analyses; (2) gave RRs adjusted for diabetes; (3) reported that adjustment for diabetes or restricting the analyses to non-diabetic subjects did not influence the results;",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:82"
    }
  },
  {
    "page_content": "subjects did not influence the results; or (4) reported that the observed association was independent from diabetes. However, excluding women with diabetes slightly strengthened the association between GI and colorectal cancer risk in the Swedish Mammography Cohort, and higher GL was positively associated with endometrial cancer among nondiabetic women only in the Iowa Women’s Health Study. Major strengths of the present study are the consideration of many studies and cancer cases, which",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:83"
    }
  },
  {
    "page_content": "of many studies and cancer cases, which provided statistical power to detect moderate associations for most cancer sites, the use of a rigorous and systematic methodology for identifying and pooling evidence from previous studies, and the ability to examine GI and GL in association with several types of cancer from cohort and case-control studies in a single report. # 5. Conclusions The present analysis provides the most comprehensive and updated quantification of the relation between GI, GL",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:84"
    }
  },
  {
    "page_content": "quantification of the relation between GI, GL and cancer risk. It indicates moderate unfavorable effects of high versus low GI on colorectal, and possibly, bladder and kidney cancers, and a possible modest positive association between GL and endometrial cancer. Such small excess risks may, however, be relevant at the population level, due to the high incidence of selected cancers, namely colorectal and breast cancer.",
    "metadata": {
      "source": "../data/plain/PMC6835610.plain.txt",
      "id": "../data/plain/PMC6835610.plain.txt:85"
    }
  },
  {
    "page_content": "Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study Abstract\nBackground\nSurvivors of childhood cancer are at risk of subsequent primary malignant neoplasms (SPNs), but the risk for rarer types of SPNs, such as oral cancer, is uncertain. Previous studies included few oral SPNs, hence large-scale cohorts are required to identify groups at risks.\nMethods",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:0"
    }
  },
  {
    "page_content": "Methods\nThe PanCareSurFup cohort includes 69,460 5-year survivors of childhood cancer across Europe. Risks of oral SPNs were defined by standardised incidence ratios (SIRs), absolute excess risks and cumulative incidence.\nResults",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:1"
    }
  },
  {
    "page_content": "One hundred and forty-five oral SPNs (64 salivary gland, 38 tongue, 20 pharynx, 2 lip, and 21 other) were ascertained among 143 survivors. Survivors were at 5-fold risk of an oral SPN (95% CI: 4.4–5.6). Survivors of leukaemia were at greatest risk (SIR = 19.2; 95% CI: 14.6–25.2) followed by bone sarcoma (SIR = 6.4, 95% CI: 3.7–11.0), Hodgkin lymphoma (SIR = 6.2, 95% CI: 3.9–9.9) and soft-tissue sarcoma (SIR = 5.0, 95% CI: 3.0–8.5). Survivors treated with radiotherapy were at 33-fold risk of",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:2"
    }
  },
  {
    "page_content": "treated with radiotherapy were at 33-fold risk of salivary gland SPNs (95% CI: 25.3–44.5), particularly Hodgkin lymphoma (SIR = 66.2, 95% CI: 43.6–100.5) and leukaemia (SIR = 50.5, 95% CI: 36.1–70.7) survivors. Survivors treated with chemotherapy had a substantially increased risk of a tongue SPN (SIR = 15.9, 95% CI: 10.6–23.7).",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:3"
    }
  },
  {
    "page_content": "Conclusions",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:4"
    }
  },
  {
    "page_content": "Previous radiotherapy increases the risk of salivary gland SPNs considerably, while chemotherapy increases the risk of tongue SPNs substantially. Awareness of these risks among both health-care professionals and survivors could play a crucial role in detecting oral SPNs early. # Introduction Five-year survival rates after treatment for childhood cancer have increased over the last few decades and are now over 80% in Europe. Half a million people in Europe alone have a history of childhood",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:5"
    }
  },
  {
    "page_content": "in Europe alone have a history of childhood cancer and up to two-thirds of childhood cancer survivors develop at least one long-term complication following treatment. Developing a subsequent primary malignant neoplasm (SPN) is one of the most severe long-term health complications following childhood cancer [5–9]. Previous studies investigating the long-term risk of SPNs found that survivors of childhood cancer are at 5 to 10-fold risk of developing an SPN compared to the general population,",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:6"
    }
  },
  {
    "page_content": "an SPN compared to the general population, particularly breast, genitourinary and digestive cancer. However, the magnitude of the risk for rarer types of SPNs, such as oral cancer, is unclear. Previous studies suggested that head and neck radiation, human papillomavirus (HPV) and haematopoietic stem cell transplantation (HSCT) increase the risk of oral cancer [10–13], but most, if not all, studies included few oral SPNs, with the largest study to date including only 27 oral SPNs. In addition,",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:7"
    }
  },
  {
    "page_content": "to date including only 27 oral SPNs. In addition, few studies investigated subtypes of oral SPNs such as salivary gland or tongue SPNs. Although oral SPNs are rare among childhood cancer survivors, it is likely to have a severe adverse impact on survivors’ health-related quality of life. It is therefore crucial to identify groups at the highest risk of developing oral SPNs among survivors. The principal objective of this large-scale Pan-European cohort study was to investigate the risks of",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:8"
    }
  },
  {
    "page_content": "cohort study was to investigate the risks of developing oral SPNs, including SPNs of the salivary glands and the tongue, among 69,460 5-year survivors of childhood and adolescent cancer. # Methods ## PanCare Childhood and Adolescent Cancer Survivor Care and Follow-up Studies The PanCare Childhood and Adolescent Cancer Survivor Care and Follow-up Studies (PanCareSurFup) is a study across 12 European countries that set up the largest cohort of childhood and adolescent cancer survivors to date. A",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:9"
    }
  },
  {
    "page_content": "and adolescent cancer survivors to date. A principal aim was to investigate the risks of SPNs among five-year survivors of childhood and adolescent cancer. The cohort consisted of 69,460 individuals diagnosed with cancer between 1940 and 2008 age 0–20 years and who survived at least 5 years. Thirteen institutions from 12 different European countries contributed data (Supplementary Table S.1). Data collection methodology and country-specific differences of cohort characteristics are described",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:10"
    }
  },
  {
    "page_content": "of cohort characteristics are described elsewhere. ## Childhood cancer classification Classification systems for the primary site and morphology of childhood cancers varied by country, but to ensure compatibility all site and morphology codes for each tumour were converted into the 3rd revision of the International Classification of Diseases for Oncology (ICD-O-3) using the International Association of Cancer Registries (IACR) Check and Conversion Program. ICD-O-3 codes were then classified",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:11"
    }
  },
  {
    "page_content": "Program. ICD-O-3 codes were then classified into subcategories of childhood cancer by applying the International Classification of Childhood Cancer third edition. Further details can be found elsewhere. ## SPN ascertainment For each SPN, the histology had to be different from the original childhood cancer to count as an SPN. Validation of each SPN was through pathology reports. Oral SPNs (lip, tongue, salivary glands, oral cavity, and pharynx) were defined according to the ICD version relevant",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:12"
    }
  },
  {
    "page_content": "defined according to the ICD version relevant to the year of the SPN diagnosis (Supplementary Table S.2). ## Statistical analysis Time-at-risk commenced at 5 years after the date of childhood cancer diagnosis and ended at the first occurrence of: loss-to-follow up, death, or study exit date. The study exit date differed for each sub-cohort (Supplementary Table S.1). Individuals who were lost-to-follow up were censored at the last known date alive and oral cancer free. Multiple oral SPNs per",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:13"
    }
  },
  {
    "page_content": "and oral cancer free. Multiple oral SPNs per survivor were allowed in calculations where comparisons were made with the general population. Standardised incidence ratios (SIRs) were calculated as the observed number of oral SPNs over the expected number. Expected numbers were estimated by accumulating person-years at risk within country, sex, age (5-year bands), and calendar year (1-year bands) specific strata in the survivor cohort and then multiplying the person-years within each stratum by",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:14"
    }
  },
  {
    "page_content": "the person-years within each stratum by the corresponding stratum specific oral cancer incidence rate from the general population. General population incidence rates were obtained through the open-source Cancer Incidence in Five Continents and the European Cancer Observatory. Absolute excess risks (AERs) were calculated as the difference of the observed and expected number of oral cancers, divided by the total number of person-years at risk and multiplied by 100,000. To evaluate the",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:15"
    }
  },
  {
    "page_content": "risk and multiplied by 100,000. To evaluate the simultaneous effect of the factors; sex, childhood cancer diagnosis, decade of childhood diagnosis, age at childhood diagnosis, attained age, follow-up time, chemotherapy, and radiotherapy, multivariable Poisson regression models were used to calculate adjusted relative risks (RRs). Models including attained age did not include follow-up time (and vice versa) due to collinearity. The RRs can here be interpreted as the ratio of SIRs adjusted for",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:16"
    }
  },
  {
    "page_content": "be interpreted as the ratio of SIRs adjusted for relevant covariates. The Nordic countries and Italian population-based cohorts were excluded from analyses involving radiotherapy and chemotherapy variables as no treatment data were available for the Nordic Countries and <70% for the Italian population-based cohort. Likelihood ratio tests were used to calculate p values for heterogeneity and linear trend where applicable. The cumulative incidence of developing an oral SPN as a function of",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:17"
    }
  },
  {
    "page_content": "of developing an oral SPN as a function of attained age was calculated accounting for death as a competing risk. For all analyses, a p value < 0.05 was considered statistically significant. Stata software version 17.0 was used for all analyses. # Results ## Cohort characteristics In total, 69,460 childhood cancer survivors were followed up for 1,264,634 person-years with 145 oral SPNs ascertained among 143 survivors. The earliest oral SPN occurred at 5 years and latest at 52 years after",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:18"
    }
  },
  {
    "page_content": "occurred at 5 years and latest at 52 years after childhood cancer diagnosis. The mean and median age of an oral SPN was 34 and 32 years, respectively. The most common types of oral SPNs were malignancies of the salivary gland (n = 64) and tongue (n = 38) (Table 1). Oral SPNs occurred most frequently among survivors of leukaemia (n = 52; acute lymphoblastic = 47; acute myeloid = 3; other = 2), Hodgkin lymphoma (n = 18), soft-tissue sarcoma (n = 14) and bone sarcoma (n = 13) (Table 2). ## Risk of",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:19"
    }
  },
  {
    "page_content": "and bone sarcoma (n = 13) (Table 2). ## Risk of subsequent primary oral cancer Overall, survivors were five times more likely than expected to develop an oral SPN (SIR = 5.0, 95% CI: 4.4–5.6) with 9 additional cases per 100,000 person-years (AER = 9.2, 95% CI: 7.9–10.6) (Table 2). Leukaemia survivors were at greatest risk with a 19.2-fold SIR (95% CI: 14.6–25.2). Although to a much lesser extent, survivors of bone sarcoma (SIR = 6.4, 95% CI: 3.7–11.0), Hodgkin lymphoma (SIR = 6.2, 95% CI:",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:20"
    }
  },
  {
    "page_content": "3.7–11.0), Hodgkin lymphoma (SIR = 6.2, 95% CI: 3.9–9.9) and soft-tissue sarcoma (SIR = 5.0, 95% CI: 3.0–8.5) were also at high risk relative to the general population. Regarding attained age, the highest SIR was observed among those aged 20–29 years (SIR = 18, 95% CI: 13.5–24.0) and decreased thereafter with increasing attained age, however, the SIR was still elevated after age 40–49 years (SIR = 3.9, 95% CI: 2.8–5.3). Similarly, the SIRs also decreased with increasing time since 5-year",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:21"
    }
  },
  {
    "page_content": "also decreased with increasing time since 5-year survival (ptrend < 0.001). In contrast, the AERs increased with increasing attained age (ptrend < 0.001) and time since 5-year survival (ptrend < 0.001) due to an increase in the background incidence rate with increasing attained age and time since 5-year survival leading to higher expected numbers. By age 30 years, the cumulative incidence of developing an oral SPN was 0.14% (95% CI: 0.11–0.18%) for all survivors combined (Fig. 1a). By age 50",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:22"
    }
  },
  {
    "page_content": "for all survivors combined (Fig. 1a). By age 50 years, it was 0.45% (95% CI: 0.37–0.55%) and reached 0.78% (95% CI: 0.58–1.03%) by age 65 years (expected = 0.46%). By age 45 years, the cumulative incidence among leukaemia survivors was highest of all survivors reaching 0.74% while the expected incidence was only 0.06% (Fig. 1b), followed Hodgkin lymphoma survivors with a cumulative incidence of 0.28%.Fig. 1The cumulative incidence of developing a subsequent primary oral cancer as a function of",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:23"
    }
  },
  {
    "page_content": "a subsequent primary oral cancer as a function of attained age illustrated in all childhood cancer survivors (a) and in survivors of different types of childhood cancer (b). Specific analyses for leukaemia survivors suggested that those diagnosed between 1990-2008 had a 53-fold risk of an oral SPN (SIR = 52.7, 95% CI: 31.8–87.4) (Table 3); however, multivariable analyses suggested that this was largely due to confounding, particularly by attained age, as there was no trend in RRs by decade of",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:24"
    }
  },
  {
    "page_content": "age, as there was no trend in RRs by decade of diagnosis in multivariable analyses. Survivors aged <30 years experienced the greatest SIRs at over 30-fold expected; however, the SIR was still increased 5.3-fold beyond age 40 years (95% CI: 2.4–11.8). The AER among leukaemia survivors increased significantly with attained age, reaching 37 beyond age 40 years (AER = 36.9, 95% CI: 13.7–98.9). ## Risk of salivary gland cancer The most common oral SPN was that of the salivary glands with 44% of all",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:25"
    }
  },
  {
    "page_content": "was that of the salivary glands with 44% of all SPNs (N = 64) (Table 4). The overall SIR of developing a salivary gland SPN was 17.2 (95% CI: 14.4–20.4). SIRs were greatest among survivors of leukaemia (SIR = 40.1, 95% CI: 26.4–60.9) and Hodgkin lymphoma (SIR = 35.9, 95% CI: 20.4–63.2). Compared to the general population, survivors treated with radiotherapy were at 33-fold increased risk (SIR = 33.5, 95% CI: 25.3–44.5), particularly survivors of Hodgkin lymphoma (SIR = 66.2, 95% CI:",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:26"
    }
  },
  {
    "page_content": "of Hodgkin lymphoma (SIR = 66.2, 95% CI: 43.6–100.5), leukaemia (SIR = 50.5, 95% CI: 36.1–70.7) and CNS tumour (16.3, 95% CI: 8.7–30.2). In multivariable analyses, treatment with radiotherapy increased the RR of a salivary gland SPN 4.9-fold (95% CI: 1.9–12.7) compared to treatment without radiotherapy. Treatment with chemotherapy did not seem to increase the RR of developing a salivary gland SPN (RR = 1.0, 95% CI: 0.4–2.3). The SIRs declined with increasing attained age and time since 5-year",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:27"
    }
  },
  {
    "page_content": "increasing attained age and time since 5-year survival but remained elevated beyond 30 years from 5-year survival (SIR = 6.2, 95% CI: 3.0–13.1). ## Risk of tongue cancer In all, 26% of all SPNs were located in the tongue (N = 38) with all but one type being squamous cell carcinoma (1 spindle cell carcinoma). The risk of developing a tongue SPN was 5.9-fold greater than expected (95% CI: 4.7–7.4) (Table 5). Leukaemia survivors were at greatest risk of developing tongue SPNs (SIR = 25.7, 95% CI:",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:28"
    }
  },
  {
    "page_content": "of developing tongue SPNs (SIR = 25.7, 95% CI: 16.0–41.4), followed by bone sarcoma survivors (SIR = 14.3, 95% CI: 6.4–31.7). Treatment with radiotherapy did not seem to increase the risk (RR = 1.0, 95% CI: 0.4–2.4), but previous treatment with chemotherapy did substantially (SIR = 15.9, 95% CI: 10.6–23.7; RR = 5.6, 95% CI: 1.0–31.2). # Discussion ## Main findings This cohort study with almost 70,000 childhood cancer survivors is the largest study to date to investigate the risk of oral SPNs",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:29"
    }
  },
  {
    "page_content": "to date to investigate the risk of oral SPNs among childhood cancer survivors. Our findings show that childhood cancer survivors are at 5-fold risk of developing oral SPNs compared to general population and that even after age 40 years the risk remains 4-fold higher than expected. Exposure to previous radiotherapy increases the risk of salivary glands SPN substantially, particularly among leukaemia and Hodgkin lymphoma survivors. A novel finding includes the identification of a substantially",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:30"
    }
  },
  {
    "page_content": "includes the identification of a substantially increased risk of tongue SPNs following exposure to chemotherapy. ## Risk of salivary gland malignancies Previous studies have shown that exposure to radiation, particularly during childhood, plays a role in the development of salivary gland tumours with evidence mostly stemming from the atomic bomb survivor study. The most recent publication from the atomic-bomb survivor study suggested a strong radiation dose-response for salivary gland tumours,",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:31"
    }
  },
  {
    "page_content": "dose-response for salivary gland tumours, but no evidence of a radiation effect for other oral cancer types. Most previous studies included few salivary gland malignancies, i.e., 50 cases among atomic bomb studies, and fewer among most studies investigating the risk of salivary gland malignant neoplasms following therapeutic radiation for paediatric malignancies or other conditions. Within the North-American Childhood Cancer Survivor Study (CCSS) 23 salivary SPNs were reported with an SIR of 39",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:32"
    }
  },
  {
    "page_content": "23 salivary SPNs were reported with an SIR of 39 (95% CI: 25.4–57.8). When comparing the SIR in our study with that of the CCSS using the same childhood cancer diagnosis period, the SIR of a salivary gland SPN was 22-fold (95% CI: 14.1–34.7), which is somewhat lower but not inconsistent. The CCSS study suggested that the risk is elevated for the first two decades after childhood cancer treatment, but here we found that the risk is elevated at least for three decades and well beyond age 50",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:33"
    }
  },
  {
    "page_content": "at least for three decades and well beyond age 50 years. The risk was especially high among leukaemia and Hodgkin lymphoma survivors, likely because the salivary glands were within the radiation fields of prophylactic or therapeutic cranial irradiation, total body irradiation (TBI), or the neck and Waldeyer’s ring, or due to potential radiation scatter from other irradiated sites. ## Risk of tongue malignancies To our knowledge, risks of tongue carcinomas in childhood cancer survivors have not",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:34"
    }
  },
  {
    "page_content": "carcinomas in childhood cancer survivors have not been reported before, except for the mentioning of three cases in the CCSS and in a case report in a patient of AML. We report here, for the first time, that survivors of childhood cancer, mostly leukaemia and bone sarcoma survivors, are at substantial risk of developing squamous cell carcinoma of the tongue following exposure to chemotherapy. Three-quarters of the tongue SPNs occurred under age 40 years which is unusual as in the general",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:35"
    }
  },
  {
    "page_content": "age 40 years which is unusual as in the general population squamous cell carcinoma of the tongue generally occurs at much older ages and is typically caused by chronic smoking and/or alcohol exposure. There are number of possible explanations for the increased risk following chemotherapy. Those who received HSCT are more likely to have been treated with aggressive chemotherapy followed by prolonged immunosuppression and may also be more prone to develop chronic graft-versus-host disease. It may",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:36"
    }
  },
  {
    "page_content": "develop chronic graft-versus-host disease. It may also be that chemotherapy may impair the ability of the immune system to target mutagenic cells and fight infections such as HPV—a well-known cause of squamous cell carcinoma of the tongue. In terms of chemotherapy in general, another factor that might promote the development of squamous cell carcinoma of the tongue is chronic inflammation due to cancer treatment. To our knowledge, only a small number of previous studies reported squamous cell",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:37"
    }
  },
  {
    "page_content": "number of previous studies reported squamous cell carcinomas of the tongue in recipients of HSCT, mostly for leukaemia, but the total number of subsequent tongue malignancies reported in the literature was small. Lastly, a genetic predisposition—such as TP53 mutations—may be implicated in developing of tongue cancer. There is a possibility that the association we observed between being treated with chemotherapy and risk of tongue cancer is not causative but due to underlying cancer genetic",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:38"
    }
  },
  {
    "page_content": "causative but due to underlying cancer genetic predisposition in those survivors treated with chemotherapy, such as bone and soft-tissue sarcoma patients. Fanconi anaemia may also increase the risk of a tongue SPN, mainly among acute myeloid leukaemia (AML) survivors, but only three tongue SPNs were among AML survivors suggesting this is an unlikely explanation. A case–control study may be able to address the risks related with specific treatments, life-style factors, and genetic factors. ##",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:39"
    }
  },
  {
    "page_content": "life-style factors, and genetic factors. ## Clinical implications Although the absolute risk of developing oral cancer is low for childhood cancer survivors, survivors treated with direct radiotherapy to the head and neck or radiotherapy involving potential radiation scatter to the head and neck areas are at risk of developing salivary gland SPNs. Those treated with chemotherapy are at risk of developing tongue SPNs. It has been recommended that survivors discuss their cancer history with their",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:40"
    }
  },
  {
    "page_content": "survivors discuss their cancer history with their dentists and visit a dentist at least yearly and preferable every 6 months. It would be important for health professionals, including dentists, dental hygienists, and otorhinolaryngologists, responsible for the care of such survivors to be aware of the treatment patients received historically and the associated risks so that any oral cancers can be detected early. ## Study limitations A potential limitation of our study may include the lack of",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:41"
    }
  },
  {
    "page_content": "limitation of our study may include the lack of detailed treatment information such as type and cumulative dose of chemotherapy agents, and cumulative radiation doses and radiation fields. Collecting such detailed treatment information on nearly 70,000 individuals, with a substantial proportion of survivors treated several decades ago, within this Pan-European cohort would be practically not feasible. Another potential limitation of the study is that we were unable to control for potential",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:42"
    }
  },
  {
    "page_content": "is that we were unable to control for potential confounding factors such as smoking and alcohol intake and thus some of the observed effects may be attributable to smoking and drinking. However, survivors of childhood cancer are generally less likely to smoke and drink than the general population; hence, if there were to be potential confounding by such lifestyle factors this would inflate the already substantial risks. Moreover, previous studies have suggested that the effect of smoking and",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:43"
    }
  },
  {
    "page_content": "have suggested that the effect of smoking and alcohol on the association between radiation exposure and subsequent oral cancer risk is minimal. # Conclusions Although the absolute risk of developing an oral SPN is low, survivors are at 5-fold increased risk of developing oral SPNs compared to the general population. Exposure to previous radiotherapy increases the risk of salivary gland SPNs substantially, whilst exposure to chemotherapy increases the risk of tongue SPNs substantially.",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:44"
    }
  },
  {
    "page_content": "increases the risk of tongue SPNs substantially. Communication between general practitioners, oncologists, and dentists and increased awareness of the risk among both health care professionals and survivors may play a crucial role in identifying and treating oral SPNs early. # Supplementary information Supplementary Tables",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:45"
    }
  },
  {
    "page_content": "Checklist_AJ",
    "metadata": {
      "source": "../data/plain/PMC9814398.plain.txt",
      "id": "../data/plain/PMC9814398.plain.txt:46"
    }
  },
  {
    "page_content": "Breast cancer and neoplasms of the thyroid gland: a bidirectional two-sample Mendelian randomization study Abstract\nBackground\nWith the rising incidence of breast cancer (BC) and neoplasms of the thyroid gland, a potential link between the two has drawn increasing attention. However, the causal relationship remains unclear due to various confounding factors. This study aims to investigate the causality between BC and thyroid tumors using Mendelian Randomization (MR) analysis.\nMethods",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:0"
    }
  },
  {
    "page_content": "We conducted a bidirectional two-sample MR analysis, utilizing breast cancer-associated single nucleotide polymorphisms (SNPs) from the Breast Cancer Association Consortium (BCAC) and thyroid tumor-related SNPs from the FinnGen (https://www.finngen.fi/) database. First, we performed univariable MR (UVMR) to assess the causal relationship between BC and both malignant and benign thyroid tumors, followed by reverse causality analysis. To account for potential confounders, we applied multivariable",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:1"
    }
  },
  {
    "page_content": "potential confounders, we applied multivariable MR (MVMR). The inverse-variance weighted (IVW) method was primarily used, with secondary analyses performed using the weighted median and MR-Egger regression approaches.",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:2"
    }
  },
  {
    "page_content": "Results\nUVMR analysis revealed a significant positive causal relationship between BC and malignant thyroid tumors (odds ratio [OR] and 95% confidence interval [CI]: 1.291, 1.143–1.458, P = 3.90×10-5). No causal relationship was found between BC and benign thyroid tumors. The MVMR analysis, adjusting for confounding factors such as smoking, drinking, and body mass index (BMI), confirmed the robustness of the results.\nConclusion",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:3"
    }
  },
  {
    "page_content": "This study provides genetic evidence supporting a causal relationship between BC and malignant thyroid tumors. These findings highlight the importance of thyroid cancer screening in BC patients. However, further MR studies or randomized controlled trials (RCTs) are necessary to assess small effects accurately. # Introduction BC is the most common malignancy among women and one of the leading cancers globally (1). Its incidence has steadily increased over the past 40 years, with a 0.5% annual",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:4"
    }
  },
  {
    "page_content": "over the past 40 years, with a 0.5% annual rise from 2010 to 2019 (2). BC is classified into several subtypes, including Luminal A, Luminal B, HER2-positive, and triple-negative breast cancer (TNBC) via immunohistochemical method (3). Currently, despite advances in treatment, 20-30% of BC patients develop metastasis, often leading to poor outcomes (4). Treatment for early-stage BC may involve breast-conserving surgery (BCS) or mastectomy, often followed by breast reconstruction. Radiotherapy is",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:5"
    }
  },
  {
    "page_content": "by breast reconstruction. Radiotherapy is commonly used after BCS, while drug therapies include chemotherapy for high recurrence risk, endocrine therapy for hormone receptor-positive cases, and HER2-targeted therapy for HER2-positive patients (5). Immune checkpoint inhibitors (ICIs) show limited efficacy as monotherapy but improve outcomes when combined with chemotherapy, particularly in metastatic TNBC. Also, biomarkers like PD-L1 expression aid in predicting treatment response (6). However,",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:6"
    }
  },
  {
    "page_content": "in predicting treatment response (6). However, these treatments may also bring about some issues. Radiotherapy can lead to thyroid disorders, including hypothyroidism, thyroiditis, and thyroid cancer (7). Nowadays, advances in radiotherapy and dose reduction strategies can mitigate these risks, and regular thyroid function monitoring is advised. Compared to radiotherapy, chemotherapy may reduce thyroid nodules incidence by affecting TSH levels (8). However, ICIs can cause thyroid dysfunction,",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:7"
    }
  },
  {
    "page_content": "(8). However, ICIs can cause thyroid dysfunction, including nodules and neoplasms of the thyroid gland (9). Neoplasms of the thyroid gland, classified by the WHO as thyroid adenomas, low-risk tumors, and thyroid carcinomas, are increasing in incidence (10). Thyroid carcinoma accounts for 1% of all newly diagnosed cancers annually, with risk factors like obesity contributing to its rising incidence (11, 12). While rare, BC can metastasize to the thyroid, usually indicating advanced disease and",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:8"
    }
  },
  {
    "page_content": "thyroid, usually indicating advanced disease and poor prognosis. For instance, Ramírez Stieben et al. reported a BC patient with thyroid metastasis confirmed via fine-needle aspiration biopsy (FNAB) and immunohistochemistry (13). Similarly, Zhou et al. identified eight BC patients with thyroid metastasis, mostly asymptomatic, and responsive to chemotherapy (14). These cases suggest that in patients with thyroid nodules, BC metastasis should be considered. Since there have been clinical reports",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:9"
    }
  },
  {
    "page_content": "Since there have been clinical reports of an association between BC and thyroid neoplasms, several studies have suggested a potential link between BC and thyroid carcinoma, with shared genetic mutations being a key factor. Mutations in PTEN, associated with Cowden syndrome, increase the risk of both BC and thyroid neoplasms (15, 16). Inflammatory pathways like STAT3 may also contribute, as evidenced by elevated STAT3 activity in both BC and thyroid carcinoma patients (17, 18). Premalignant",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:10"
    }
  },
  {
    "page_content": "thyroid carcinoma patients (17, 18). Premalignant thyroid lesions, particularly nodules, are common in BC patients, increasing their risk of developing thyroid cancer (8, 19). Evidence from population studies also suggests a potential link. For example, Shi et al. found a higher incidence of thyroid nodules and dysfunction in BC patients, which may elevate the risk of malignant transformation (8). Also, a retrospective study identified shared genetic risk factors between BC and thyroid",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:11"
    }
  },
  {
    "page_content": "genetic risk factors between BC and thyroid malignancies (20). Although this retrospective study is limited in establishing the temporal sequence between exposure and outcome, making it difficult to determine causality, it suggests that we can analyze the causal relationship from a genetic perspective. However, other studies have not found significant evidence supporting this association (21). While large-scale epidemiological studies or RCTs specifically addressing the BC-thyroid neoplasms",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:12"
    }
  },
  {
    "page_content": "specifically addressing the BC-thyroid neoplasms relationship are limited (22, 23), so there is an urgent need for a “naturally occurring RCT” to objectively and rigorously investigate this association. MR is a robust method for assessing causal relationships and is generally more reliable than traditional multivariable regression due to its ability to mitigate confounding and reverse causation, often referred to as a “naturally occurring RCT” (24–28). Liu et al. utilized MR to investigate the",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:13"
    }
  },
  {
    "page_content": "Liu et al. utilized MR to investigate the causal link between BC and malignant thyroid tumors, finding a significant impact of BC on thyroid carcinoma development (29). However, this study did not address benign thyroid neoplasms and the causal relationship was not strengthened by accounting for some common confounding factors by a MVMR analysis. Due to shared molecular and genetic characteristics, MR is a valuable tool for investigating the causal relationship between BC and neoplasms of the",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:14"
    }
  },
  {
    "page_content": "relationship between BC and neoplasms of the thyroid gland from the perspective of susceptibility genes, providing valuable and deeper insights into the causal mechanisms underlying these associations. Our research extends UVMR and MVMR analyses to evaluate overall BC, which included Luminal A, Luminal B, HER2-positive, and TNBC, in relation to both malignant and benign thyroid neoplasms, enhancing the understanding of the genetic underpinnings of these diseases. In this “naturally occurring",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:15"
    }
  },
  {
    "page_content": "of these diseases. In this “naturally occurring RCT”, we employed the OR to evaluate the relative likelihood of developing neoplasms of the thyroid gland in individuals with BC compared to those without BC, quantifying the increased risk associated with the presence of BC. These findings offer important implications for future research and clinical practice, emphasizing the need for continued investigation into the genetic links between BC and thyroid neoplasms. # Materials and methods ## Study",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:16"
    }
  },
  {
    "page_content": "neoplasms. # Materials and methods ## Study design We performed a bidirectional two-sample MR analysis using instrumental variables (IVs). This analysis employed UVMR to evaluate the causal relationship between overall BC and various types of thyroid gland tumors, including both malignant and benign neoplasms. Initially, we used BC as the exposure and thyroid gland tumors as the outcome to investigate the forward association between these diseases. Subsequently, we assessed the reverse causal",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:17"
    }
  },
  {
    "page_content": "Subsequently, we assessed the reverse causal relationship by treating different types of thyroid neoplasms (both malignant and benign) as exposures and BC as the outcome, to determine the causal effects in the opposite direction (",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:18"
    }
  },
  {
    "page_content": "Figure 1B\n). To enhance our understanding and address potential confounders, we conducted a supplementary analysis using MVMR (\nFigure 2",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:19"
    }
  },
  {
    "page_content": "). This approach aimed to isolate the independent effects of BC and thyroid neoplasms while mitigating the impact of common confounding variables, thereby strengthening the results obtained from the UVMR analysis (30). ## Data sources ### Breast cancer In 2020, Zhang et al. conducted a study on identifying BC susceptibility loci using genome-wide association study (GWAS) methods (31). This research drew from multiple datasets, primarily involving European women from over 20 countries, utilizing",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:20"
    }
  },
  {
    "page_content": "European women from over 20 countries, utilizing data from the iCOGS and OncoArray platforms in 82 BCAC studies. These BCAC studies included large-scale population-based case-control studies, hospital-based case-control studies, and population-based cohort studies, all of which collected detailed information on clinical and pathological characteristics. The BC dataset represented overall BC, which encompassed all subtypes mentioned above, and included 133,384 individuals diagnosed with BC and",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:21"
    }
  },
  {
    "page_content": "133,384 individuals diagnosed with BC and 113,789 control individuals without BC (",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:22"
    }
  },
  {
    "page_content": "Supplementary Table S1\n). ### Neoplasms of the thyroid gland We selected data on malignant and benign thyroid gland neoplasms from the FinnGen dataset. The malignant neoplasms of the thyroid gland dataset included 989 cases and 174,006 controls of European ancestry, with data on 16.4 million SNPs, excluding cases of other cancers. Similarly, the benign thyroid neoplasm dataset comprised 455 cases and 218,337 controls of European ancestry, also with data on 16.4 million SNPs. (",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:23"
    }
  },
  {
    "page_content": "Supplementary Table S1\n). ### Smoking and drinking Liu et al. investigated the genetic factors influencing cigarette and alcohol consumption in the European population (32). This meta-analysis illuminated the complex interactions of these factors. The study encompassed a large cohort of 1.2 million Europeans, providing a comprehensive and insightful analysis (\nSupplementary Table S1",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:24"
    }
  },
  {
    "page_content": "). ### BMI In 2019, a meta-analysis was conducted to explore the relationship between adiposity and genetic factors. Pulit et al. aimed to investigate the genetic factors associated with BMI and to identify novel loci that contribute to the distribution of adipose tissue in vivo (33). The study utilized BMI data from the UK Biobank (UKBB) dataset (https://www.ukbiobank.ac.uk/), a comprehensive repository of health-related information. This dataset, known for its extensively imputed genotype",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:25"
    }
  },
  {
    "page_content": "known for its extensively imputed genotype data, has become a valuable resource for genetic research (",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:26"
    }
  },
  {
    "page_content": "Supplementary Table S1\n). ## Instrument selection In MR studies, IVs must meet three key requirements: (1) they should be strongly correlated with the exposure (correlation assumption); (2) they should not be the cause or consequence of confounding factors related to the exposures and outcomes (independence assumption); and (3) they should only affect outcomes through the exposure (exclusion restriction assumption) (34) (\nFigure 1A",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:27"
    }
  },
  {
    "page_content": "). We identified SNPs that exhibited a strong correlation with the exposure variable following the selection criteria: P < 5×10-8. To eliminate linkage disequilibrium (LD), we applied a strict cutoff of R2 < 0.001 and a 10,000 kb window criterion. To fulfill assumption (1), SNPs that exhibited a strong association with the outcome variable were excluded. Subsequently, we harmonized the effects of SNPs on both exposure and outcome, ensuring that β values were annotated with the same allele.",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:28"
    }
  },
  {
    "page_content": "β values were annotated with the same allele. After these procedures, the remaining SNPs were deemed suitable for MR analysis. A significant issue in MR studies is weak instrument bias. Weak IVs refer to genetic variations with lower explanatory power of the exposure, indicating that while the IVs affect the exposure, the strength of this association is not very high. The F statistic is an effective estimator for evaluating weak IV effects. When F is greater than 10, it indicates a relatively",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:29"
    }
  },
  {
    "page_content": "F is greater than 10, it indicates a relatively low risk of weak instrument bias in MR analysis (35). The calculation formula for the F statistic is: where N represents the number of samples exposed in GWAS, and k stands for the number of IVs. R² represents the degree of exposure explained by the IVs and is the coefficient of determination of the regression equation (36). R² was evaluated from the correlation between the effect allele frequency (EAF) and the SNP-exposure association (β) (37),",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:30"
    }
  },
  {
    "page_content": "(EAF) and the SNP-exposure association (β) (37), calculated using the following formula: ## Statistical analyses ### Forward UVMR and sensitivity analysis Our primary assessment of the causal effect between overall BC and neoplasms of the thyroid gland is derived from the results of the inverse-variance-weighted (IVW) method. The IVW approach provides the most accurate estimates when no horizontal pleiotropy exists among the SNPs (38). To further enhance the robustness of our findings, we",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:31"
    }
  },
  {
    "page_content": "enhance the robustness of our findings, we employed secondary analyses, including the weighted median and MR-Egger regression methods, to corroborate the IVW results. The weighted median method is particularly robust in the presence of heterogeneity, as it excludes up to 50% of invalid IVs from the analysis (38). MR-Egger regression, on the other hand, is adept at detecting and accounting for horizontal pleiotropy, providing reliable estimates even when pleiotropy is present (39). We",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:32"
    }
  },
  {
    "page_content": "even when pleiotropy is present (39). We subsequently conducted sensitivity analyses to evaluate the heterogeneity of genetic variants, the validity of the selected IVs, potential horizontal pleiotropy, and the impact of outliers on our results. The intercept from the MR-Egger regression was used to assess bias and horizontal pleiotropy caused by invalid IVs (39). Additionally, heterogeneity among the SNPs was indicated by a P-value < 0.05 from Cochran’s Q test (40). To further validate the",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:33"
    }
  },
  {
    "page_content": "Cochran’s Q test (40). To further validate the robustness of our findings, we performed a leave-one-out (LOO) analysis. This approach involved sequentially removing individual SNPs from the MR analysis and reanalyzing the data to assess their influence on the overall results (39). In this study, we set the type I error rate at 0.05 and calculated statistical power based on sample size, the R² of the IVs, effect size, and the variance of both the exposure and outcome variables (",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:34"
    }
  },
  {
    "page_content": "Figure 1B",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:35"
    }
  },
  {
    "page_content": "). ### Assessment of the directionality of the causality The observed forward causal relationship may be subject to bias from various factors. In addition to confounding, reverse causality could also contribute to bias. To address these potential sources of bias, we performed both reverse MR analysis and MVMR analysis to rule out any confounding effects and further validate the integrity of our findings. ### Reverse UVMR and sensitivity analysis We conducted a reverse MR analysis to investigate",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:36"
    }
  },
  {
    "page_content": "We conducted a reverse MR analysis to investigate the potential reverse causal relationship between neoplasms of the thyroid gland (exposure) and overall BC (outcome). Using the same criteria for IV selection, we applied three MR methods including IVW, weighted median, and MR-Egger, to explore the potential causal link between the two conditions. After conducting the analysis, we used Cochran’s Q test (P < 0.05) to assess heterogeneity. The MR-Egger intercept was employed to examine horizontal",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:37"
    }
  },
  {
    "page_content": "intercept was employed to examine horizontal pleiotropy and bias caused by invalid IVs. Finally, we performed a LOO analysis to confirm the robustness of our findings (",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:38"
    }
  },
  {
    "page_content": "Figure 1B",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:39"
    }
  },
  {
    "page_content": "). ### Confounding analysis and MVMR Despite conducting multiple sensitivity analyses to assess horizontal pleiotropy in the UVMR results, it is important to remain cautious about the potential association of SNPs with confounding factors. MVMR is an extension of the MR method that allows for the inclusion of SNPs associations with multiple phenotypes within a single analysis, enabling the estimation of the direct effect of each phenotype on the outcome (41). To account for potential",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:40"
    }
  },
  {
    "page_content": "on the outcome (41). To account for potential confounding factors and mitigate the impact of horizontal pleiotropy, we conducted a MVMR analysis as an additional approach. Previous studies have suggested that factors such as smoking, alcohol consumption and BMI may influence the risk of both overall BC and malignant neoplasms of the thyroid gland (42). Therefore, we included variables as smoking status, alcohol consumption, and BMI in our analysis to determine whether they affect the causal",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:41"
    }
  },
  {
    "page_content": "to determine whether they affect the causal relationship between BC and malignant neoplasms of the thyroid gland. This approach aimed to enhance the robustness and credibility of the results obtained from the UVMR analysis (",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:42"
    }
  },
  {
    "page_content": "Figure 2",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:43"
    }
  },
  {
    "page_content": "). All the analyses in this study were conducted using the RStudio (Build 524) and R (Version 4.3.2) software packages which employ R packages such as “TwosampleMR”, “MRInstruments” and “MVMR”. Since we used available summary data from the public database, there was no need for ethical approval. ## Assessment of MR study quality ### Instrument strength To ensure that the IVs are sufficiently strong, the F-statistic should exceed 10. This threshold indicates that the IVs have a robust",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:44"
    }
  },
  {
    "page_content": "threshold indicates that the IVs have a robust association with the exposure variable. ### Correlation with exposure The P-value for the SNP-exposure association should be highly significant, typically less than 5×10-8, to ensure a strong correlation between the SNPs and the exposure variable. When the threshold of P = 5×10-8 fails to identify sufficient relevant SNPs or results in an excessively small number of SNPs, the threshold may be relaxed to P = 5×10-6. ### LD threshold To minimize LD,",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:45"
    }
  },
  {
    "page_content": "to P = 5×10-6. ### LD threshold To minimize LD, SNPs should be independent of one another with an R² value less than 0.001. This criterion ensures that the SNPs are not in high LD, thereby reducing potential bias in the analysis. ### Interpretation of UVMR and MVMR analyses In this study, OR was employed to assess whether exposure to BC is associated with an increased likelihood of neoplasms of the thyroid gland. OR quantifies the relative odds of an event occurring in an exposed group compared",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:46"
    }
  },
  {
    "page_content": "an event occurring in an exposed group compared to a non-exposed group, offering a measure of the association’s strength and direction between an exposure and an outcome. The strength of the causality between the exposure and the outcome was evaluated using the association strength criteria proposed by Monson in 1980 (",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:47"
    }
  },
  {
    "page_content": "Supplementary Table S2",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:48"
    }
  },
  {
    "page_content": "). A weak odds ratio refers to an odds ratio that is close to 1. Specifically, OR value close to 1 (0.9~1.0, 1.0~1.1) indicates nearly no association between exposure and outcome (43), an OR value ranging from 1.2 to 1.5 signifies a weak correlation (44), an OR value ranging from 1.5 to 3.0 refers to a moderate association (45), whereas an OR approaching 0 or positive infinity suggests an extremely strong association. A weak OR refers to values that are close to 1. For instance, in a MR study",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:49"
    }
  },
  {
    "page_content": "that are close to 1. For instance, in a MR study conducted by Zhu et al., which investigated the causal relationship between polyunsaturated fatty acids and Parkinson’s disease, the OR for arachidonic acid in relation to Parkinson’s disease was found to be 1.05. This value is notably close to 1, and the authors therefore categorized it as a weak OR (46). However, due to the large sample sizes typically employed in MR studies, it is entirely possible to observe a statistically significant",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:50"
    }
  },
  {
    "page_content": "possible to observe a statistically significant P-value while obtaining a weak OR due to a small effect size between a risk factor and a disease that truly existed (45). In assessing the causal relationship between the exposure and outcome, the primary analysis is conducted using the IVW method. A significance level of P < 0.05 in the IVW analysis provides initial evidence of a causal association. The robustness of this causal relationship is further supported if both the weighted median and",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:51"
    }
  },
  {
    "page_content": "further supported if both the weighted median and MR-Egger methods also yield P-values less than 0.05 and produce consistent OR values with those obtained from the IVW analysis. In general, a causal relationship can only be considered robust when the ORs obtained from the IVW, MR-Egger, and weighted median methods are consistent, and the corresponding P-values are statistically significant across all methods. Normally, the MR-Egger intercept P-value and Cochran’s Q test P-value being less than",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:52"
    }
  },
  {
    "page_content": "and Cochran’s Q test P-value being less than 0.05 suggest that there is potential significant horizontal pleiotropy between SNPs. However, such a situation may hold under certain conditions. P < 0.05, suggesting heterogeneity among SNPs, the primary results from the IVW and weighted median methods, along with the LOO analysis, remain consistent. This suggests that the horizontal pleiotropy is likely distributed across the SNPs rather than unduly affecting the overall causal estimate. Therefore,",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:53"
    }
  },
  {
    "page_content": "affecting the overall causal estimate. Therefore, the selection of SNPs is considered reliable, and the causal relationship determined by the UVMR remains robust. To further strengthen and validate the UVMR findings, we conducted a MVMR analysis. This additional analysis aims to confirm the robustness of the causal relationship and address potential issues of horizontal pleiotropy. If, after adjusting for confounding factors in the MVMR analysis, the P-value for the causal relationship between",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:54"
    }
  },
  {
    "page_content": "the P-value for the causal relationship between overall BC and malignant neoplasms of the thyroid gland remains less than 0.05, this indicates that the causal association is not affected by confounding factors, consistent with the results from the UVMR. In this study, all data analyses were performed through three independent repetitions and validated by experts from three different institutions: a statistician with 14 years of experience, another statistician with 16 years of experience, and",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:55"
    }
  },
  {
    "page_content": "statistician with 16 years of experience, and an epidemiologist with 33 years of expertise. This thorough validation process ensured the robustness and accuracy of the results. Additionally, all experts involved had no conflicts of interest. # Results ## UVMR Based on the IV selection criteria, we identified 224 SNPs associated with BC (",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:56"
    }
  },
  {
    "page_content": "Supplementary Table S3\n), 11 SNPs linked to malignant thyroid neoplasms (\nSupplementary Table S4\n), and 4 SNPs related to benign thyroid neoplasms (\nSupplementary Table S5",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:57"
    }
  },
  {
    "page_content": "). All selected IVs demonstrated an F-statistic well above 10, indicating that instrument bias is unlikely among the chosen IVs. ### The forward MR analysis #### The causal effect of overall BC on malignant neoplasms of the thyroid gland As shown in Table 1, the IVW method provides preliminary evidence of a positive, causal relationship between overall BC and malignant neoplasms of the thyroid gland from a genetic correlation perspective (OR and 95% CI: 1.291, 1.143-1.458, P = 3.90×10-5).",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:58"
    }
  },
  {
    "page_content": "and 95% CI: 1.291, 1.143-1.458, P = 3.90×10-5). Similarly, results from the MR-Egger (OR and 95% CI: 1.617, 1.258-2.079, P = 2.40×10-4) and weighted median (OR and 95% CI: 1.175, 1.005-1.374, P = 4.30×10-2) methods align with those of the IVW method, further confirming the causal relationship between these two conditions. The results from the IVW method indicate that the risk of developing malignant neoplasms of the thyroid gland in individuals with overall BC is about 1.3 times higher compared",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:59"
    }
  },
  {
    "page_content": "overall BC is about 1.3 times higher compared to those without overall BC. According to Monson’s criteria for assessing the strength of association, the causal relationship between overall BC and malignant neoplasms of the thyroid gland is evident (P < 0.05). Although Table 2 shows evidence of horizontal pleiotropy and heterogeneity among SNPs in the MR-Egger regression and Cochran’s Q test (P < 5×10-2), the LOO analysis demonstrates that the causal effect estimates remain largely consistent",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:60"
    }
  },
  {
    "page_content": "causal effect estimates remain largely consistent when each IV is sequentially removed (",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:61"
    }
  },
  {
    "page_content": "Supplementary Table S6",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:62"
    }
  },
  {
    "page_content": "). This indicates that the selected IVs are robust and the results are reliable. #### The causal effect of overall BC on benign neoplasms of the thyroid gland As shown in Table 1, the IVW method does not support a causal relationship between overall BC and benign neoplasms of the thyroid gland (OR and 95% CI: 1.052, 0.924-1.199, P = 0.44). Similarly, neither the MR-Egger method nor the weighted median method suggests a causal association between these two diseases (P > 5×10-2). The analysis",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:63"
    }
  },
  {
    "page_content": "these two diseases (P > 5×10-2). The analysis presented in Table 2 demonstrates that the P-value of the MR-Egger regression intercept and the P-value for Cochran’s Q test are both greater than 0.05, indicating the absence of horizontal pleiotropy and heterogeneity among SNPs. Furthermore, the LOO analysis, which sequentially removes each SNP, shows no significant changes in the results (",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:64"
    }
  },
  {
    "page_content": "Supplementary Table S7\n), further validating the reliability of the findings. Thus, there is no causal association between overall BC and benign neoplasms of the thyroid gland. ### The reverse MR analysis #### The causal effect of malignant neoplasms of the thyroid gland on overall BC The results from the MR-Egger method suggest a potential causal relationship between malignant neoplasms of the thyroid gland and overall BC (OR and 95% CI: 2.004, 1.543-2.602, P = 1.20×10-3) (\nTable 1",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:65"
    }
  },
  {
    "page_content": "). However, the IVW method, which is considered the most robust, and the weighted median method, do not indicate such a causal relationship (P > 5×10-2), demonstrating that there is no causal effect of malignant neoplasms of the thyroid gland on overall BC. The analysis presented in Table 2, which includes MR-Egger regression and Cochran’s Q test, reveals significant horizontal pleiotropy and heterogeneity among SNPs (P < 5×10-2). However, the LOO analysis shown in Supplementary Table S8",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:66"
    }
  },
  {
    "page_content": "the LOO analysis shown in Supplementary Table S8 indicates that removing individual SNPs does not lead to significant changes in the results. This suggests that the observed pleiotropy and heterogeneity are distributed across the SNPs, and the selection of IVs remains reasonable and robust. #### The causal effect of benign neoplasms of the thyroid gland on overall BC The IVW analysis presented in Table 1 indicates a very slight negative, or, no causal relationship between benign neoplasms of",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:67"
    }
  },
  {
    "page_content": "causal relationship between benign neoplasms of the thyroid gland and overall BC from the perspective of genetic susceptibility (OR and 95% CI: 0.985, 0.976-0.994, P = 1.30×10-3). However, this finding is not supported by the MR-Egger or weighted median methods (P > 0.05), suggesting that the causal association between benign neoplasms of the thyroid gland and overall BC may not be reliable. This statistically significant OR value of only IVW method which is close to 1, may be attributed to the",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:68"
    }
  },
  {
    "page_content": "which is close to 1, may be attributed to the limited number of SNPs associated with neoplasms of the thyroid gland, which is only four (",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:69"
    }
  },
  {
    "page_content": "Supplementary Table S5",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:70"
    }
  },
  {
    "page_content": "). Insufficient number of SNPs can lead to unstable OR values (47). To increase the number of SNPs identified, we could consider relaxing the selection criteria by adjusting the significance threshold from P < 5×10-8 to P < 5×10-5. This adjustment would facilitate the identification of additional SNPs, but it would also increase the risk of false positives (48). Results in Table 2 show that MR-Egger regression and Cochran’s Q test did not detect significant horizontal pleiotropy or",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:71"
    }
  },
  {
    "page_content": "not detect significant horizontal pleiotropy or heterogeneity among SNPs. The LOO analysis also did not identify any SNPs significantly affecting the results, further confirming the robustness and validity of the findings (",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:72"
    }
  },
  {
    "page_content": "Supplementary Table S9\n). ## MVMR In the MVMR analysis, we accounted for several potential confounders, including smoking status, drinking status, and BMI, to further investigate the independent effect of overall BC on malignant neoplasms of the thyroid gland. ### Adjusting for smoking status In Model 1 (\nFigure 3",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:73"
    }
  },
  {
    "page_content": "), we adjusted for smoking (SMK) as a potential confounder to examine the relationship between overall BC and malignant neoplasms of the thyroid gland. The results indicated that, even after accounting for smoking, there remains a significant positive association between overall BC and malignant neoplasms of the thyroid gland (OR and 95% CI: 1.34, 1.19-1.50, P = 1.13×10-6). This suggests that overall BC may be an independent risk factor for malignant neoplasms of the thyroid gland, with its",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:74"
    }
  },
  {
    "page_content": "neoplasms of the thyroid gland, with its effect not being significantly influenced by smoking behavior and individuals with overall BC have a 1.34-fold increased risk of developing malignant neoplasms of the thyroid gland compared to those without overall BC. This finding underscores the importance of overall BC as an exposure of malignant neoplasms of the thyroid gland and also suggests that smoking may not be a major explanatory factor for the association between these two cancers. ###",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:75"
    }
  },
  {
    "page_content": "the association between these two cancers. ### Adjusting for drinking status In Model 2 (",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:76"
    }
  },
  {
    "page_content": "Figure 3",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:77"
    }
  },
  {
    "page_content": "), we further examined the impact of drinking status (DRK) as a potential confounder on the relationship between overall BC and malignant neoplasms of the thyroid gland. The results demonstrated that even after accounting for drinking status, the significant positive association between overall BC and malignant neoplasms of the thyroid gland persisted (OR and 95% CI: 1.34, 1.18-1.51, P = 6.12×10-6). This finding is consistent with the results from Model 1, reinforcing the hypothesis that",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:78"
    }
  },
  {
    "page_content": "from Model 1, reinforcing the hypothesis that overall BC is an independent risk factor for malignant neoplasms of the thyroid gland, revealing that the presence of overall BC is associated with a 34% increased risk of developing malignant neoplasms of the thyroid gland. This finding suggests that while drinking might influence the risk of malignant neoplasms of the thyroid gland, it does not explain the strong association between these two diseases. ### Adjusting for BMI In Model 3 (",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:79"
    }
  },
  {
    "page_content": "Figure 3",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:80"
    }
  },
  {
    "page_content": "), we adjusted for BMI, an important potential confounder, to assess its impact on the relationship between overall BC and malignant neoplasms of the thyroid gland. The results revealed that, even after accounting for BMI, the positive association between overall BC and malignant neoplasms of the thyroid gland remained significant (OR and 95% CI: 1.22, 1.06-1.41, P = 4.79×10-3), which indicates that the risk of developing malignant neoplasms of the thyroid gland is 1.22 times higher in",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:81"
    }
  },
  {
    "page_content": "of the thyroid gland is 1.22 times higher in individuals with overall BC compared to those without overall BC. Although this association is somewhat weaker than in the previous two models, it remains statistically significant and the OR value is greater than 1.2, further supporting the hypothesis that overall BC is an independent risk factor for malignant neoplasms of the thyroid gland. # Discussion Our study aims to elucidate the causal relationship between overall BC and thyroid gland",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:82"
    }
  },
  {
    "page_content": "relationship between overall BC and thyroid gland neoplasms, with a particular focus on malignant thyroid neoplasms. Previous research has indicated a potential association between these two conditions. However, their analysis overlooked benign thyroid lesions, and consequently, the robustness of the findings is somewhat compromised. The motivation for this research stems from the clinical observation that BC and thyroid malignancies often co-occur, prompting questions about underlying shared",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:83"
    }
  },
  {
    "page_content": "prompting questions about underlying shared mechanisms. Additionally, this study is inspired by previous research highlighting genetic commonalities between these two diseases, which suggests that shared genetic factors might play a role in their co-occurrence. For example, in BC research, Tracy et al. identified that the upregulation of mitotically associated long noncoding RNA (MANCR) is associated with lower patient survival rates (49). Similarly, Lu et al. found the same pattern in thyroid",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:84"
    }
  },
  {
    "page_content": "Lu et al. found the same pattern in thyroid cancer patients, suggesting that elevated MANCR expression may be a shared pathogenic factor between breast and thyroid cancers (50). By integrating these observations and inspirations, our research aims to further investigate and elucidate the causal relationship between BC and thyroid malignancies through the lens of genetic susceptibility. By leveraging genetic data and MR techniques, our study seeks to provide a clearer understanding of these",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:85"
    }
  },
  {
    "page_content": "seeks to provide a clearer understanding of these associations and address gaps in current knowledge. In this study, we employed MR to explore the causal relationship between BC and thyroid gland neoplasms. Our findings offer compelling evidence that BC is causally associated with malignant thyroid gland tumors, while no such relationship was observed for benign thyroid tumors. The reverse causal analyses, examining whether thyroid gland neoplasms could influence BC, also yielded no significant",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:86"
    }
  },
  {
    "page_content": "could influence BC, also yielded no significant evidence of an effect. These results were further validated through MVMR analyses, which accounted for potential confounding factors and controlled for horizontal pleiotropy, thereby eliminating any potential influence that might not affect the causal relationship. This confirmed that the observed causal association between overall BC and malignant neoplasms of the thyroid gland aligns with our initial UVMR findings, indicating a robust and",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:87"
    }
  },
  {
    "page_content": "initial UVMR findings, indicating a robust and reliable relationship. Our study’s findings align with the observations of Joseph et al., who conducted a meta-analysis revealing the risk of developing thyroid carcinoma after BC increases by 17% (51). This highlights the clinical relevance of investigating the relationship between BC and thyroid neoplasms. Building on the genetic similarities between BC and thyroid neoplasms, we further explored their broader biological connections, discussing",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:88"
    }
  },
  {
    "page_content": "their broader biological connections, discussing the potential biological mechanisms. Previous research by Piek et al. identified common triggers such as estrogen signaling and environmental factors, which may underpin the observed association between these tumors (23). The role of estrogen and progesterone in both BC and thyroid carcinoma suggests a potential shared mechanism. Transcriptional cross-talk between thyroid hormones and sex hormones plays a significant role in cancer development",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:89"
    }
  },
  {
    "page_content": "plays a significant role in cancer development and response to treatment (52). Breast tissue is the main target of estrogen and progesterone and is sensitive to these two hormones (53). Both types of neoplasms of the thyroid gland are highly sensitive to circulating estrogen, similar to breast tissue (54). Estrogen’s impact on thyroid carcinoma, which has been linked to increased risk in females, may help explain the higher incidence rates observed (55). Moreover, the concept of premalignant",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:90"
    }
  },
  {
    "page_content": "(55). Moreover, the concept of premalignant lesions, as discussed by Shi et al., provides insight into the potential pathway through which BC patients might develop secondary thyroid cancer. Although chemotherapy can reduce the incidence of thyroid nodules by affecting the hypothalamic-pituitary-thyroid axis, timely intervention remains crucial for preventing thyroid cancer (8). This underscores the importance of proactive management in BC patients to mitigate the risk of secondary",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:91"
    }
  },
  {
    "page_content": "in BC patients to mitigate the risk of secondary malignancies. BC patients should actively engage in treatment, initiating therapy as soon as the condition is detected. Despite these insights, our study has several limitations. Firstly, the generalizability of our findings is limited by the use of data exclusively from European populations. This constraint means that our results may not fully reflect the experiences of other demographic groups, potentially affecting their applicability to",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:92"
    }
  },
  {
    "page_content": "potentially affecting their applicability to non-European populations. Future research should aim to include more diverse populations to enhance the generalizability of the findings. Secondly, BC is a heterogeneous disease with multiple subtypes. Our analysis focused on overall BC data, leaving the causal relationships between specific BC subtypes and thyroid gland neoplasms unexplored. Investigating these subtype-specific associations is crucial for a more comprehensive understanding of the",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:93"
    }
  },
  {
    "page_content": "for a more comprehensive understanding of the link between BC and thyroid neoplasms. Additionally, while we have made efforts to ensure rigorous data collection, the possibility of misclassification and detection bias cannot be entirely excluded. Misclassification may occur if patients are inaccurately categorized, while detection bias might arise from varying likelihoods of detecting conditions across different groups. Despite using high-quality databases, any inherent misclassification or",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:94"
    }
  },
  {
    "page_content": "databases, any inherent misclassification or detection bias within these sources could influence our results. Addressing these issues in future studies could improve the accuracy and reliability of the findings. In our MR analysis, we accounted for several common confounding factors. However, there remains uncertainty about the influence of other potential confounders that were not considered. This limitation underscores the need for more extensive research to identify and address additional",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:95"
    }
  },
  {
    "page_content": "research to identify and address additional confounding variables that might affect the observed relationship between BC and thyroid malignancies. Moreover, MR analysis relies on three critical assumptions: the correlation assumption, the independence assumption, and the exclusion restriction assumption. For our results to be credible, these assumptions must be met and we have made efforts to adhere to these assumptions. For readers to accept the validity of these results, they must acknowledge",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:96"
    }
  },
  {
    "page_content": "validity of these results, they must acknowledge the three core assumptions underlying MR. It is also important to acknowledge that the SNPs we selected may exhibit potential horizontal pleiotropy. While this does not appear to affect our overall results, it remains a factor that should be considered when interpreting our findings. In addition, according to Monson’s criteria, there are weak ORs or no associations (0.9~1.0, 1.0~1.1) in our study, although it does not affect the results. Several",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:97"
    }
  },
  {
    "page_content": "although it does not affect the results. Several factors could contribute to this situation, and the limitation mentioned above that not all potential confounders could be fully accounted for and adjusted is one reason. Moreover, the slight heterogeneity among SNPs is also a contributing factor to the weak OR. Meanwhile, the insufficient number of SNPs of benign neoplasms of the thyroid gland can also lead to unreliable OR results (44, 45). The sample size may also contribute to the weak OR.",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:98"
    }
  },
  {
    "page_content": "sample size may also contribute to the weak OR. However, it is possible for a large sample size to yield statistically significant P-values due to genuinely small effects. As highlighted by Zhu et al. in their research, the complex molecular mechanisms underlying diseases may result in weak OR values for causal relationships, even though a risk association between the conditions does indeed exist (43), which means the causal relationship under investigation itself exhibits a weak effect (45).",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:99"
    }
  },
  {
    "page_content": "investigation itself exhibits a weak effect (45). This also reflects one of the inherent limitations of MR methods. While MR techniques offer valuable insights into causal relationships, they do not elucidate the underlying mechanisms driving cancer development. The mechanism of occurrence between these two diseases needs further exploration. From the perspective of genetic susceptibility, we have utilized MR to reveal the causal relationship between overall BC and neoplasms of the thyroid",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:100"
    }
  },
  {
    "page_content": "between overall BC and neoplasms of the thyroid gland. Moving forward, we plan to investigate the nature of shared susceptibility genes between these conditions. This next step will involve elucidating the mechanisms at the genetic and protein molecular levels, and further expanding our understanding to cellular and tissue levels to comprehensively uncover how these mechanisms influence cancer development and progression.",
    "metadata": {
      "source": "../data/plain/PMC11513776.plain.txt",
      "id": "../data/plain/PMC11513776.plain.txt:101"
    }
  },
  {
    "page_content": "Burden of digestive system neoplasms in middle-aged and elderly adults: Temporal trends and geographic disparities (1990–2021) Abstract\nObjective",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:0"
    }
  },
  {
    "page_content": "Objective\nThis study aims to comprehensively analyze the temporal trends and geographic disparities in the burden of seven digestive system neoplasms—esophageal cancer, stomach cancer, colon and rectum cancer, liver cancer, gallbladder and biliary tract cancer, pancreatic cancer, and benign and in situ intestinal neoplasms—among middle-aged and elderly populations from 1990 to 2021, and to project future trends through 2035.\nMethods",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:1"
    }
  },
  {
    "page_content": "This study utilized data from the Global Burden of Disease (GBD) 2021 database to analyze the burden of seven digestive system neoplasms among middle-aged and elderly adults across 204 countries and territories from 1990 to 2021. Estimates of incidence, mortality, and disability-adjusted life years (DALYs) were extracted and stratified by year, sex, age group, region, and Socio-Demographic Index (SDI). Trends were evaluated using estimated annual percentage change (EAPC), and risk factors were",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:2"
    }
  },
  {
    "page_content": "percentage change (EAPC), and risk factors were analyzed using the GBD comparative risk assessment framework.",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:3"
    }
  },
  {
    "page_content": "Results",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:4"
    }
  },
  {
    "page_content": "In 2021, colon and rectum cancer dominated the global burden of digestive system neoplasms. Trends from 1990 to 2021 revealed a clear split: the incidence of colon and rectum cancer (EAPC = 0.26, 95% CI 0.19 to 0.33), liver cancer (EAPC = 0.25, 95% CI 0.82 to 1.38), pancreatic cancer (EAPC = 0.55, 95% CI 0.53 to 0.57), and benign intestinal neoplasms (EAPC = 1.1, 95% CI 0.82 to 1.38) rose globally, while esophageal (EAPC = −0.92, 95% CI −1.06 to −0.79), stomach (EAPC = −1.63, 95% CI −1.71 to",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:5"
    }
  },
  {
    "page_content": "to −0.79), stomach (EAPC = −1.63, 95% CI −1.71 to −1.55), and gallbladder/biliary tract cancers (EAPC = −0.28, 95% CI −0.31 to −0.25) declined. Regional hotspots for burden were East Asia and High-income Asia Pacific. Males generally faced higher burdens, except for gallbladder and biliary tract cancer. Key risk factors included smoking, alcohol consumption, dietary patterns, and metabolic factors such as high BMI and elevated fasting plasma glucose.",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:6"
    }
  },
  {
    "page_content": "Conclusions",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:7"
    }
  },
  {
    "page_content": "The burden of digestive system neoplasms remains substantial in middle-aged and elderly adults, with significant regional differences. With the growing aging population, efforts should prioritize high-risk populations and invest in healthcare infrastructure in middle- and low-SDI regions to control established cancers. Additionally, implementing robust global prevention policies, such as expanding disease screening, raising public health awareness, and managing metabolic disorders, is essential",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:8"
    }
  },
  {
    "page_content": "and managing metabolic disorders, is essential to mitigate the rising tide of digestive system neoplasms. # 1. Introduction Digestive system neoplasms, encompassing esophageal cancer, stomach cancer, colorectal cancer, liver cancer, gallbladder and biliary tract cancer, pancreatic cancer, as well as benign and in situ intestinal neoplasms, are among the most pressing health concerns globally. Digestive cancers account for approximately 26% of the global cancer incidence and 35% of",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:9"
    }
  },
  {
    "page_content": "26% of the global cancer incidence and 35% of cancer-related deaths each year, posing significant challenges to public health. These neoplasms not only substantially reduce patients’ quality of life, shorten their life expectancy, but also impose considerable economic burdens on patients, their families, and healthcare systems. Geographic disparities in the incidence, mortality, and burden of digestive system neoplasms are particularly pronounced. In 2020, the incidence of gastrointestinal",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:10"
    }
  },
  {
    "page_content": "In 2020, the incidence of gastrointestinal cancers in East Asia accounted for 48.4% of the global total, underscoring the region’s disproportionately high burden of these diseases, with particularly high rates of stomach, liver, esophageal, and gallbladder cancers compared to other regions. Contributing factors include distinct dietary patterns, lifestyle behaviors, and the higher prevalence of infectious etiologies in this region. On the contrary, high-income regions such as North America have",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:11"
    }
  },
  {
    "page_content": "high-income regions such as North America have reported increasing incidences of colorectal and pancreatic cancers, which are largely associated with lifestyle factors including obesity and metabolic disorders. At the sex level, men bear a disproportionately higher burden of digestive system neoplasms. Worldwide, distinct male-to-female incidence ratios are observed across specific subtypes of esophageal and gastric cancers, with males significantly outnumbering females in all subtypes, and the",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:12"
    }
  },
  {
    "page_content": "outnumbering females in all subtypes, and the highest ratio observed for esophageal adenocarcinoma (EAC) at 6.7:1. For colorectal cancer, the incidence of colon cancer is approximately 41.2 per 100,000 person-years in men, compared to 32.4 in women, while rectal cancer incidence is 22.8 versus 12.6, respectively. Epidemiological studies consistently demonstrate that the incidence and mortality of digestive system neoplasms increase with age. For example, the incidence of colorectal cancer is",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:13"
    }
  },
  {
    "page_content": "example, the incidence of colorectal cancer is concentrated in the age group of 50–69 years globally. Similarly, pancreatic cancer incidence rates are relatively higher in individuals aged over 65 years, with an upward trend observed, and the average age at diagnosis ranges from 60 to 65 years. And between 2000 and 2019, 81.82% of gastric cancer cases occurred in individuals aged 55 years or older. Additionally, gastrointestinal cancers are often diagnosed at an advanced stages in elderly",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:14"
    }
  },
  {
    "page_content": "often diagnosed at an advanced stages in elderly patients due to misinterpretation of symptoms. Furthermore, the fact that these elderly patients often suffer from multiple chronic comorbidities, such as hypertension and diabetes, which further exacerbates the difficulties in diagnosis and treatment. Although previous studies have systematically analyzed the global burden of digestive system neoplasms, research focusing specifically on middle-aged and elderly populations remains limited and has",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:15"
    }
  },
  {
    "page_content": "and elderly populations remains limited and has paid insufficient attention to benign and in situ intestinal neoplasms. Additionally, elderly patients are underrepresented in clinical trials, meaning that existing treatment strategies may not fully meet their special needs. As the global population continues to age, the prevalence and burden of these diseases are expected to escalate further. This study, using data from the Global Burden of Disease (GBD) 2021 database and advanced statistical",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:16"
    }
  },
  {
    "page_content": "(GBD) 2021 database and advanced statistical methods, seeks to enhance the understanding of this field by focusing on the burden of seven digestive system neoplasms in middle-aged and elderly adults, exploring temporal trends and geographic disparities. By doing so, our study aims to provide tailored insights to inform targeted public health interventions and enhance healthcare strategies for aging populations. # 2. Materials and methods ## 2.1 Data sources The study utilizes the Global Burden",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:17"
    }
  },
  {
    "page_content": "Data sources The study utilizes the Global Burden of Disease (GBD) 2021 data retrieved from the GBD Results Tool (https://vizhub.healthdata.org/gbd-results), which encompassed 371 diseases and injuries and 88 risk factors across 204 countries and regions. The dataset provided estimates of incidence, mortality, and disability-adjusted life years (DALYs) across times, sex, age group, and SDI. Our study includes all countries and regions from the GBD database for the period 1990–2021, focusing on",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:18"
    }
  },
  {
    "page_content": "database for the period 1990–2021, focusing on individuals aged 55 and older, both male and female, diagnosed with digestive system neoplasms. These neoplasms include esophageal cancer, stomach cancer, colon and rectum cancer, liver cancer, gallbladder and biliary tract cancer, pancreatic cancer, and benign and in situ intestinal neoplasms. This systematic characterization of disparities in the burden of digestive neoplasms across regions and populations provides evidence-based insights to",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:19"
    }
  },
  {
    "page_content": "populations provides evidence-based insights to inform precision prevention strategies and healthcare prioritization. This study quantifies the disease burden of digestive system cancers, including digestive tract cancers (esophageal cancer, stomach cancer, and colon and rectum cancer) and digestive support system cancers (liver cancer, gallbladder and biliary tract cancer, and pancreatic cancer), along with benign and in situ intestinal neoplasms, using indicators like incidence, mortality,",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:20"
    }
  },
  {
    "page_content": "using indicators like incidence, mortality, and DALYs. Notably, DALYs are calculated as the sum of two components: years of life lost (YLLs) and years lived with disability (YLDs), with detailed definitions available in the S1 Table. Benign and in situ intestinal neoplasms are analyzed separately from malignant cancers due to their chronic, non-lethal nature and minimal impact on patients’ quality of life. Therefore, their associated DALYs and deaths are reported as 0 in the GBD study. In GBD",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:21"
    }
  },
  {
    "page_content": "deaths are reported as 0 in the GBD study. In GBD 2021, the definitions of seven digestive system neoplasms are mapped to both the International Classification of Diseases (ICD)-10 and ICD-9 codes. The specific ICD codes corresponding to each disease are provided in the S2 Table. The Socio-Demographic Index (SDI) serves as a comprehensive indicator of a country’s overall development status, incorporating multiple socio-economic parameters such as income per capita, average years of education,",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:22"
    }
  },
  {
    "page_content": "as income per capita, average years of education, and fertility rates in younger females. The SDI scale ranges from 0 to 1, with higher values indicating higher levels of socio-economic development. To classify countries according to their development levels, SDI values are divided into five categories based on quartiles: Low SDI (0–0.454743), Low-middle SDI (0.454743–0.607679), Middle SDI (0.607679–0.689504), High-middle SDI (0.689504–0.805129), and High SDI (0.805129–1). ## 2.2 Attributable",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:23"
    }
  },
  {
    "page_content": "and High SDI (0.805129–1). ## 2.2 Attributable risk factors The comparative risk assessment framework employed in the GBD Study is designed to estimate the burden attributable to various risk factors, which are categorized into a four-level hierarchical structure. This study specifically focused on analyzing the most granular risk levels, namely levels 2 and 3, for each risk factor associated with digestive system neoplasms. In GBD 2021, the process of estimating risk factor burden involved a",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:24"
    }
  },
  {
    "page_content": "of estimating risk factor burden involved a series of interconnected methodological steps. First, the relative risk (RR) for health outcomes was calculated based on exposure to specific risk factors. Next, exposure data were gathered and analyzed using Bayesian statistical methods to assess the distribution of risk factors. Theoretical Minimum Risk Exposure Levels (TMRELs) were then established based on the available epidemiological evidence, aiming to identify optimal exposure thresholds.",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:25"
    }
  },
  {
    "page_content": "aiming to identify optimal exposure thresholds. Subsequently, population-attributable fractions (PAFs) were computed for each risk-outcome pair to quantify potential health improvements if exposure were reduced to the TMREL. Age-specific exposure values (SEVs) were also calculated to reflect exposure prevalence, with adjustments made for age-related risk factors. To refine these estimates, mediation factors were applied to account for indirect relationships between risk factors and outcomes.",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:26"
    }
  },
  {
    "page_content": "relationships between risk factors and outcomes. Finally, attributable burden was estimated by multiplying PAFs with the disease burden, measured in DALYs. These results were stratified by SDI quintiles and presented as counts, age-standardized rates, and rankings. In our study, esophageal cancer is found to be associated with high alcohol use, smoking, chewing tobacco, and a diet low in vegetables in individuals aged 55 and older. High alcohol use is defined as alcohol consumption exceeding",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:27"
    }
  },
  {
    "page_content": "use is defined as alcohol consumption exceeding the TMREL, with in GBD 2021 is estimated based on region, age, sex, and year to tailor estimates to specific populations. Alcohol exposure was measured in grams of pure alcohol consumed per day. Smoking and chewing tobacco are defined as the current use of any smoked tobacco product or the use of chewing tobacco, including local products like betel quid with tobacco, in the past 30 days or according to the closest survey definition, regardless of",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:28"
    }
  },
  {
    "page_content": "to the closest survey definition, regardless of frequency. A diet low in vegetables is defined as consuming fewer than 306–372 g/day of vegetables. Stomach cancer is linked to a diet high in sodium and smoking. High sodium intake is defined by 24-hour urinary sodium excretion levels of 1–5 g/day. Turning to colon and rectum cancer, a broader range of risk factors are identified. This included diet low in whole grains, high alcohol use, high fasting plasma glucose (FPG), smoking, diet high in",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:29"
    }
  },
  {
    "page_content": "plasma glucose (FPG), smoking, diet high in red meat, diet low in calcium, diet low in fiber, diet low in milk, low physical activity, diet high in processed meat, and high body-mass index (BMI). For example, low whole grain consumption is defined as average daily consumption of fewer than 160–210 grams, while high BMI is defined as greater than 23 kg/m² for individuals aged 55 and above. Moreover, high FPG is categorized as levels above 4.88–5.30 mmol/L, and low physical activity is quantified",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:30"
    }
  },
  {
    "page_content": "mmol/L, and low physical activity is quantified as less than 3600–4400 MET-minutes per week. High red meat and processed meat consumption are defined as daily consumption of up to 200 grams of unprocessed red meat or any amount of processed meat. Other dietary factors, including low calcium, fiber, and milk intake, were similarly defined based on GBD 2021 thresholds (S3 Table). For liver cancer, the risk factors included smoking, high alcohol use, high FPG, drug use, and high BMI. Drug use is",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:31"
    }
  },
  {
    "page_content": "high FPG, drug use, and high BMI. Drug use is defined as the current use of illicit drugs, including opioids, amphetamines, and cocaine. Gallbladder and biliary tract cancer and pancreatic cancer are found to be influenced by high BMI, and pancreatic cancer is also associated with high FPG and smoking. ## 2.3 Statistical analysis This study evaluated the disease burden of digestive system neoplasms among middle-aged and elderly adults, stratified by age group, sex, year, and geographical",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:32"
    }
  },
  {
    "page_content": "by age group, sex, year, and geographical location. Temporal trends were quantified using estimated annual percentage change (EAPC) with 95% confidence intervals (CIs). Trend interpretation followed three criteria: (1) Increasing if both the EAPC and its lower CI bound exceeded 0; (2) Decreasing if both the EAPC and its upper CI bound were below 0; (3) Stable if the CI included 0. Additionally, we examined the relationship between disease-related DALY rates and SDI for each region. To",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:33"
    }
  },
  {
    "page_content": "DALY rates and SDI for each region. To disentangle age, period, and cohort effects on epidemiological patterns, we employed the Bayesian Age-Period-Cohort (BAPC) model. This model incorporates random walk priors to smooth temporal variations while accounting for population structural changes. The model was implemented via integrated nested Laplace approximation (INLA), a computationally efficient Bayesian framework that treats parameters as random variables with specified prior distributions.",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:34"
    }
  },
  {
    "page_content": "variables with specified prior distributions. Compared to other methods, the BAPC model exhibits superior robustness in handling sparse data and projecting age-standardized trends. Data analysis and visualization were conducted using R software (version 4.4.1), with the following packages employed for data manipulation, statistical analysis, and visualization: “tidyverse”, “dplyr”, “ggplot2”, “ggmap”, “sf”, “BAPC”, and “INLA”. # 3. Results ## 3.1 Digestive system neoplasms in middle-aged and",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:35"
    }
  },
  {
    "page_content": "3.1 Digestive system neoplasms in middle-aged and elderly adults: Global trends In terms of mortality in 2021, esophageal cancer accounted for roughly 468 thousand people (95%UI 412–525), stomach cancer for 817 thousand people (95%UI 698–926), and colon and rectum cancer for 908 thousand people (95%UI 821–976) (Table 1). Notably, all three digestive tract cancers demonstrated declining mortality trends from 1990 to 2021, with stomach cancer (EAPC = −2.05, 95% CI −2.15 to −1.95) showing the most",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:36"
    }
  },
  {
    "page_content": "95% CI −2.15 to −1.95) showing the most pronounced decrease (Table 1). Pancreatic cancer had the highest mortality rate in 2021 at 30.49 per 100,000 (95%UI 27.53 to 32.81) compared to the other two types of digestive support system cancers (Table 1). Over the course of 32 years, pancreatic cancer (EAPC = 0.44, 95% CI 0.42 to 0.46) showed upward mortality trends, whereas liver cancer (EAPC = 0.06, 95% CI −0.07 to 0.19) mortality remained relatively stable, and a decreasing trend was observed for",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:37"
    }
  },
  {
    "page_content": "stable, and a decreasing trend was observed for gallbladder and biliary tract cancer (EAPC = −0.77, 95% CI −0.81 to −0.73)(Table 1). In 2021, colon and rectum cancer accounted for the highest number of DALYs among digestive system neoplasms globally, at about 18.18 million people (95%UI 16.71 to 19.43) (Table 1). From 1990 to 2021, the DALY rate for esophageal cancer (EAPC = −1.5, 95% CI −1.63 to −1.37) showed a declining trend, as did stomach cancer (EAPC = −2.37, 95% CI −2.46 to −2.29) and",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:38"
    }
  },
  {
    "page_content": "cancer (EAPC = −2.37, 95% CI −2.46 to −2.29) and colon and rectum cancer (EAPC = −0.74, 95% CI −0.79 to −0.69)(Table 1). Among digestive support system cancers, pancreatic cancer had the highest DALY rate in 2021, at 608.52 (561.17 to 652.62) (Table 1). Furthermore, from 1990 to 2021, pancreatic cancer (EAPC = 0.22, 95% CI 0.2 to 0.24) experienced an increase in DALYs, while liver cancer (EAPC = −0.26, 95% CI −0.37 to −0.15) and gallbladder and biliary tract cancer (EAPC = −1.01, 95% CI −1.05",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:39"
    }
  },
  {
    "page_content": "biliary tract cancer (EAPC = −1.01, 95% CI −1.05 to −0.96) showed decreasing trends (Table 1). ## 3.2 Digestive system neoplasms in middle-aged and elderly adults: Regional level From 1990 to 2021, the burden of esophageal cancer decreased in most GBD regions, especially in Central Asia, while Western Sub-Saharan Africa showed significant rises for incidence, mortality, and DALY rates (Figs 1[incidence], S1[death] and S2[DALY]). Notably, stomach cancer demonstrated decreasing trends in the",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:40"
    }
  },
  {
    "page_content": "cancer demonstrated decreasing trends in the rates of incidence, mortality and DALY across all GBD regions, particularly pronounced in Eastern Europe (Figs 1, S1 and S2). Colon and rectum cancer saw an increase in incidence and death rates in most regions, especially in Central Latin America. However, the DALY rates have decreased in more than half of the regions, with the largest reductions observed in Australasia (Figs 1, S1 and S2). From 1990 to 2021, there was a remarkable rise in rates of",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:41"
    }
  },
  {
    "page_content": "to 2021, there was a remarkable rise in rates of incidence and mortality for liver cancer across numerous regions, particularly pronounced in Southern Latin America, and Australasia. Conversely, a decline was observed for DALY rate in over half of regions, with the most significant reductions occurring in High income Asia Pacific (Figs 1, S1 and S2). The incidence, mortality, and DALY rates for gallbladder and biliary tract cancer have declined over time in most regions, particularly in Central",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:42"
    }
  },
  {
    "page_content": "time in most regions, particularly in Central Latin America (Figs 1, S1 and S2). Pancreatic cancer demonstrated increasing trends at all rates across the vast majority of regions, with Western Sub to Saharan Africa experiencing the most significant increases in pancreatic cancer burden (Figs 1, S1 and S2). ## 3.3 Digestive system neoplasms in middle-aged and elderly adults: National trends ## 3.4 Digestive system neoplasms in middle-aged and elderly adults: Age and sex patterns In 2021,",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:43"
    }
  },
  {
    "page_content": "and elderly adults: Age and sex patterns In 2021, esophageal cancer showed a significant sex gap in the cases of incidence, deaths, and DALYs started from the 55–79 years. Globally, males had significantly higher incidence, mortality, and DALY rates than females. The highest incidence, mortality, and DALYs of stomach cancer were concentrated in individuals aged between 65–74 years, with males exhibiting higher rates across all age groups above 55. In colon and rectum cancer, females had higher",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:44"
    }
  },
  {
    "page_content": "In colon and rectum cancer, females had higher numbers of cases, deaths, and DALYs than males over the age of 85. For males, the incidence and deaths in males were predominantly observed in the 70–74 age group, while the DALYs were concentrated in the 65–69 age group. The highest rates of incidence, mortality and DALY were recorded in the 85–89 and 90–94 age groups for males. Additionally, in both stomach cancer and colon and rectum cancer, these rates increased progressively with age in",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:45"
    }
  },
  {
    "page_content": "these rates increased progressively with age in females (Figs 3[incidence], S5[death] and S6[DALY]). In 2021, liver cancer incidence, deaths, and DALYs are most concentrated in the 65–69 age group, although the DALYs for males declines with age. Males’ rates of incidence, mortality, and DALYs peaked in the 85–89, 90–94, and 65–69 age groups, respectively, while females’ corresponding maxima were in the 85–89, ≥ 95, and 90–94 age groups. Females constituted the primary demographic affected by",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:46"
    }
  },
  {
    "page_content": "constituted the primary demographic affected by gallbladder and biliary tract cancer with higher incidence, deaths and DALYs compared to males. While the incidence, mortality, and DALY rates for females increased with advancing age, males had the highest rates in the 90–94 age group. The incidence and mortality of pancreatic cancer for both males and females were concentrated in the 70–74 age group, whereas the DALY numbers were primarily in the 65–69 age group. The peak incidence of pancreatic",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:47"
    }
  },
  {
    "page_content": "65–69 age group. The peak incidence of pancreatic cancer occurred in the 90–94 age group. Males had the highest mortality and DALY rates in the 90–94 and 85–89 age groups, while females experienced a steady increase in these rates with age (Figs 3, S5 and S6). ## 3.5 Burden of digestive system neoplasms in middle-aged and elderly adults by SDI The results of the global, regional, and national trends, as well as the age and sex patterns of benign and in situ intestinal neoplasms, are detailed in",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:48"
    }
  },
  {
    "page_content": "and in situ intestinal neoplasms, are detailed in S1 File. ## 3.6 Risk factors of digestive system neoplasms in middle-aged and elderly adults Previous research has explored the association between risk factors and digestive system neoplasms, with consistent and region-specific findings. A pooled analysis of data from 10 case–control studies on EAC revealed that smoking doubled the risk of this malignancy. Consistent with this, our results identified smoking as the leading global risk factor",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:49"
    }
  },
  {
    "page_content": "smoking as the leading global risk factor for esophageal cancer, with particularly high proportional contributions in East Asia and High-income North America. Notably, in South Asia, chewing tobacco emerged as a significant risk factor for esophageal cancer. For gastric cancer, a 2020 meta-analysis encompassing 232 studies found that current smoking increased the odds of developing gastric cancer by 61%. Our study further confirmed that smoking and a high-sodium diet were the most critical",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:50"
    }
  },
  {
    "page_content": "and a high-sodium diet were the most critical global risk factors for gastric cancer, with more pronounced impacts observed in East Asia and High-income North America. In the case of colon and rectum cancer, dietary factors were particularly prominent. Low intake of whole grains, milk, and calcium, coupled with high red meat consumption, were major global contributors to the disease burden. Additionally, BMI and FPG exerted substantial impacts, especially in High-income North America and",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:51"
    }
  },
  {
    "page_content": "especially in High-income North America and Central Latin America. Liver cancer showed a strong association with alcohol use, with the highest proportional contribution observed in Central Europe. For gallbladder and biliary tract cancer, high BMI was the most influential factor across regions, with North Africa and the Middle East experiencing the highest burdens. A meta-analysis of 14 cohort studies confirmed that overweight individuals had a 1.10-fold higher relative risk of gallbladder",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:52"
    }
  },
  {
    "page_content": "a 1.10-fold higher relative risk of gallbladder cancer (95% CI: 1.02–1.18), and obesity was associated with a 1.69-fold increased risk (95% CI: 1.54–1.86), showing a dose-response relationship. For pancreatic cancer, high fasting plasma glucose, smoking, and high BMI emerged as three key risk factors worldwide. Interestingly, high BMI appeared to act as a protective factor in some regions. Specifically, in South Asia, Southeast Asia, and High-income Asia Pacific, the attributable DALYs were",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:53"
    }
  },
  {
    "page_content": "Asia Pacific, the attributable DALYs were −9.20 × 10 ⁻ ⁴(95% UI: −9.88 × 10 ⁻ ³ to 1.31 × 10 ⁻ ²), −1.51 × 10 ⁻ ³ (95% UI: −1.14 × 10 ⁻ ² to 1.45 × 10 ⁻ ²), and −8.83 × 10 ⁻ ³ (95% UI: −2.02 × 10 ⁻ ² to 7.38 × 10 ⁻ ³), respectively. However, since the uncertainty intervals crossed zero, the significance of this protective effect remains questionable (Fig 5). ## 3.7 Predictions of digestive system neoplasms in middle-aged and elderly adults from 2020 to 2035 We projected global age-standardized",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:54"
    }
  },
  {
    "page_content": "2020 to 2035 We projected global age-standardized incidence rate (ASIR), age-standardized death rate (ASDR) and age-standardized DALY rate for digestive system neoplasms in middle-aged and elderly adults from 2020 to 2035 by using the BAPC model. From 2020 to 2035, ASIR of most digestive system neoplasms are projected to decline (S7 Fig). However, esophageal cancer stands out with a continued upward trend in ASIR during the prediction period, in contrast to the other neoplasms. Benign and in",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:55"
    }
  },
  {
    "page_content": "in contrast to the other neoplasms. Benign and in situ intestinal neoplasms demonstrated the most pronounced decrease in ASIR, reversing the rapid growth seen in previous decades. ASDR for all six major digestive system cancers demonstrated consistent declines (S8 Fig). Among these, stomach cancer and colon and rectum cancer exhibited the most substantial mortality decreases. Similarly, the age-standardized DALY rates showed declining trends across all digestive system neoplasms, while",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:56"
    }
  },
  {
    "page_content": "across all digestive system neoplasms, while esophageal and liver cancers displayed slower declines in disease burden (Fig 6). # 4. Discussion This study comprehensively analyzes the global burden and temporal trends of seven major digestive system neoplasms among middle-aged and elderly populations from 1990 to 2021. The findings highlight distinct patterns in disease distribution, risk factor impacts, and evolving trends, with critical implications for public health strategies. In 2021, the",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:57"
    }
  },
  {
    "page_content": "for public health strategies. In 2021, the majority of cases, deaths, and DALYs associated with these cancers were concentrated in individuals aged 65–74, with incidence rates generally increasing with age. This age-related trend may be partially linked to immunosenescence, long-term cumulative exposure to risk factors, and the accumulation of chronic inflammation. Males consistently exhibited higher incidence, mortality, and DALY burdens for most digestive system neoplasms, particularly",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:58"
    }
  },
  {
    "page_content": "for most digestive system neoplasms, particularly esophageal, stomach, and liver cancers. This disparity was likely associated with the higher prevalence of high-risk behaviors among males, such as tobacco use, alcohol consumption, unhealthy dietary patterns, and insufficient physical activity. Moreover, higher concentrations of sex hormone-binding globulin (SHBG) and testosterone have been linked to increased gastric and liver cancer risks in men. In contrast, females exhibited higher rates of",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:59"
    }
  },
  {
    "page_content": "In contrast, females exhibited higher rates of gallbladder and biliary tract cancers, which may partly be attributed to the higher occurrence of gallstones, a recognized risk factor for gallbladder cancer. Furthermore, some studies suggest that reproductive and menstrual factors may be linked to gallbladder cancer, highlighting the potential role of female hormones in its etiology. However, the findings remain inconsistent, necessitating further research to clarify the specific mechanisms",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:60"
    }
  },
  {
    "page_content": "research to clarify the specific mechanisms underlying their role. These sex-specific disparities in digestive system cancers necessitate sex-responsive prevention and intervention strategies. For males, public health policies should prioritize primary prevention, such as intensifying tobacco and alcohol control measures and encouraging regular physical activity. For females, more proactive screening and monitoring of gallbladder and biliary tract diseases are essential, particularly for",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:61"
    }
  },
  {
    "page_content": "tract diseases are essential, particularly for individuals with gallstones or relevant reproductive histories. Such tailored approaches are crucial to improving the precision and effectiveness of efforts to control digestive system neoplasms. Tobacco use, alcohol consumption, dietary patterns, and elevated FPG are major global risk factors for digestive system neoplasms, with their impact and distribution varying significantly across different SDI levels. Smoking, a leading risk factor for",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:62"
    }
  },
  {
    "page_content": "SDI levels. Smoking, a leading risk factor for esophageal cancer, exerts carcinogenic effects through mechanisms such as inducing genetic mutations in esophageal cells, promoting chronic inflammation-mediated epithelial remodeling, and hurting the immune system. In East Asia, persistently high male smoking rates likely sustain the region’s elevated esophageal cancer burden despite global declines. In addition, the use of betel nut-tobacco mixtures remained prevalent in certain South Asian",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:63"
    }
  },
  {
    "page_content": "remained prevalent in certain South Asian countries, resulting in persistent direct contact between carcinogens the esophageal mucosa. These compounds may synergistically increase the risk of esophageal cancer through mechanisms such as hypermethylation of tumor suppressor gene promoters like p16 and genetic mutations in genes such as p53. Additionally, our results indicate that lifestyle factors, particularly a high-sodium diet, contribute significantly to the burden of stomach cancer in",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:64"
    }
  },
  {
    "page_content": "significantly to the burden of stomach cancer in middle-aged and elderly populations, especially in East Asian countries. Reducing the intake of high-salt foods has been proposed as one strategy to address the stomach cancer issue in high-risk Asian countries. Dietary factors play a central role in colorectal cancer (CRC), particularly a low intake of whole grains and a high intake of red and processed meats. This has been confirmed by the National Institutes of Health and American Association",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:65"
    }
  },
  {
    "page_content": "Institutes of Health and American Association of Retired Persons (NIH-AARP) Diet and Health Study, which found that whole grain consumption, but not dietary fiber from other sources, is inversely associated with CRC risk. Additionally, a high intake of red and processed meats has been shown to increase CRC risk through mechanisms such as gut microbiota imbalance and oxidative stress. Therefore, promoting healthy diets rich in whole grains, low in processed foods, and implementing stronger",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:66"
    }
  },
  {
    "page_content": "low in processed foods, and implementing stronger regulations on processed meat products could play a crucial role in reducing the burden of colorectal cancer. As the elderly population experiences a rising incidence of obesity, high BMI has become a key contributor to the growing burden of gallbladder and biliary tract cancers. Health promotion initiatives, including educational campaigns and community empowerment, are crucial for changing lifestyle and dietary habits to prevent obesity.",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:67"
    }
  },
  {
    "page_content": "lifestyle and dietary habits to prevent obesity. Elevated FPG and smoking are recognized as major risk factors for pancreatic cancer, but their interactive effects remain unclear. A large nationwide cohort study in Korea, involving over 9 million adults, found that current smokers with diabetes or prediabetes had a synergistically increased risk of pancreatic cancer (HR = 2.72) compared to never-smokers with normoglycemia. In contrast, a 10-year prospective cohort study of 446,407 Korean men",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:68"
    }
  },
  {
    "page_content": "prospective cohort study of 446,407 Korean men confirmed that smoking and elevated fasting glucose act as independent risk factors for pancreatic cancer. From 1990 to 2021, the global burden of esophageal cancer, stomach cancer, gallbladder cancer, and biliary tract cancer exhibited a declining trend. This positive change resulted from the combined effects of global public health interventions, risk factor control, and improvements in medical care. In particular, the eradication of Helicobacter",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:69"
    }
  },
  {
    "page_content": "In particular, the eradication of Helicobacter pylori infection and the implementation of early endoscopic screening played crucial roles in reducing the burden of stomach and esophageal cancers. Conversely, the global burden of pancreatic cancer rose steadily, with both incidence and mortality increasing, largely driven by population aging. Moreover, due to the lack of effective early screening methods and the disease’s high fatality rate, both direct medical costs and indirect economic losses",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:70"
    }
  },
  {
    "page_content": "direct medical costs and indirect economic losses associated with pancreatic cancer steadily increased. It was suggested that preventive strategies should prioritize primary prevention, focus on modifiable risk factors, such as reducing smoking and controlling obesity and diabetes, to mitigate the burden of disease. For colon and rectum cancer, screening plays a dual role in driving the paradox of rising incidence and falling mortality. On one hand, the widespread adoption of fecal occult blood",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:71"
    }
  },
  {
    "page_content": "the widespread adoption of fecal occult blood testing (FOBT) and colonoscopy in Western countries has significantly enhanced the detection of early lesions. On the other hand, screening directly reduces mortality. Colonoscopy allows for the removal of precancerous polyps lower the risk of post-procedure colorectal cancer by blocking the disease at precancerous or early stages. Additionally, optimized 5-fluorouracil-based adjuvant chemotherapy further improves outcomes in advanced cases.",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:72"
    }
  },
  {
    "page_content": "further improves outcomes in advanced cases. Regarding liver cancer, the decline in mortality from virus-related hepatocellular carcinoma was largely attributed to hepatitis B vaccination programs, antiviral therapies, and improvements in chronic liver disease management. However, with the rising prevalence of metabolic-associated fatty liver disease, the overall incidence of liver cancer continued to increase. It was also noteworthy that the incidence of benign and in situ intestinal neoplasms",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:73"
    }
  },
  {
    "page_content": "of benign and in situ intestinal neoplasms rose sharply, predominantly in high-SDI countries. This trend reflected expanded screening coverage and increased public health awareness, leading to earlier detection of asymptomatic lesions. For example, in the Netherlands’ nationwide colon and rectum cancer screening program, numerous inflammatory polyps and early-stage tumors were detected. High-SDI countries have made significant strides in reducing mortality from digestive system neoplasms,",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:74"
    }
  },
  {
    "page_content": "mortality from digestive system neoplasms, driven by comprehensive cancer screening, early diagnosis, and well-developed treatment systems. In contrast, middle and low-SDI countries face persistent challenges due to limited screening coverage, inadequate chronic disease management, and constrained healthcare resources, leading to higher rates of late-stage diagnoses and sustained disease burden. To alleviate the global burden of digestive system neoplasms in Middle-Aged and Elderly Adults,",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:75"
    }
  },
  {
    "page_content": "neoplasms in Middle-Aged and Elderly Adults, targeted policy and practical measures should be prioritized. First, cost-effective, population-based screening programs, such as FOBT for colorectal cancer or endoscopic screening for gastric cancer, should be tailored to local contexts, with an emphasis on expanding coverage for high-risk middle-aged and elderly populations in resource-limited settings. Second, primary prevention must be strengthened through public health policies promoting",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:76"
    }
  },
  {
    "page_content": "through public health policies promoting physical activity, scaling up tobacco cessation programs, and regulating harmful products like sugar-sweetened beverages to address metabolic risk factors such as obesity and hyperglycemia. Third, healthcare capacity in low and middle-SDI regions must be strengthened by investing in diagnostic and treatment infrastructure, training healthcare professionals, and utilizing telemedicine to ensure timely access to care for elderly populations. Finally,",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:77"
    }
  },
  {
    "page_content": "access to care for elderly populations. Finally, collaboration between academia, healthcare providers, and industry should be fostered to accelerate advances in early detection and precision medicine, exemplified by initiatives like the U.S. “Cancer Moonshot”. By integrating these strategies, global efforts can address the burden of digestive system neoplasms in middle-aged and elderly populations, while also tackling the underlying metabolic drivers, leading to more equitable health outcomes.",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:78"
    }
  },
  {
    "page_content": "leading to more equitable health outcomes. This study, based on data from the GBD Study 2021, systematically assesses the global burden of digestive system neoplasms among middle-aged and elderly populations. Nevertheless, several limitations warrant consideration. First, in certain low- and middle-income countries, the limited availability of high-quality epidemiological data may compromise model-based estimates due to data gaps and diagnostic biases. Second, the GBD applies standardized",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:79"
    }
  },
  {
    "page_content": "biases. Second, the GBD applies standardized disease definitions, which may not fully capture histological diversity or borderline cases, potentially leading to an underestimation of the true disease burden. Furthermore, the attribution of risk factors relies on literature reviews and theoretical minimum risk exposure levels, which may not encompass all relevant exposures or adequately reflect long-term, population-specific variations. Third, this study does not account for subnational",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:80"
    }
  },
  {
    "page_content": "this study does not account for subnational heterogeneity, thereby limiting the generalizability of the findings to regional policy planning Future research should prioritize the integration of real-world data and longitudinal cohort studies to better characterize disease heterogeneity and population-specific features, ultimately informing the development of more targeted and effective prevention strategies. # 5. Conclusions In conclusion, digestive system neoplasms remain a major global public",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:81"
    }
  },
  {
    "page_content": "system neoplasms remain a major global public health issue among middle-aged and elderly populations, with clear temporal trends and regional disparities observed between 1990 and 2021. Despite significant progress in early screening and treatment, the mortality rates for colorectal cancer, liver cancer, and pancreatic cancer have declined, while the incidence of these cancers, along with pancreatic cancer and benign tumors, continues to rise. This trend is primarily attributed to changes in",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:82"
    }
  },
  {
    "page_content": "This trend is primarily attributed to changes in lifestyle and the increasing prevalence of metabolic risk factors. In contrast, the burden of esophageal cancer, gastric cancer, and gallbladder/biliary tract cancer has decreased, reflecting the effectiveness of public health interventions. With the aging global population, the burden of digestive system neoplasms is likely to increase further. Therefore, it is essential to strengthen early screening, health education, and risk factor",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:83"
    }
  },
  {
    "page_content": "screening, health education, and risk factor management, as well as promote advances in precision medicine, particularly in low- and middle-SDI regions. Enhancing public health infrastructure and healthcare access is critical to mitigating this growing health burden. # Supporting information",
    "metadata": {
      "source": "../data/plain/PMC12370137.plain.txt",
      "id": "../data/plain/PMC12370137.plain.txt:84"
    }
  },
  {
    "page_content": "Tumor-Agnostic Therapy—The Final Step Forward in the Cure for Human Neoplasms? Abstract",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:0"
    }
  },
  {
    "page_content": "Cancer accounted for 10 million deaths in 2020, nearly one in every six deaths annually. Despite advancements, the contemporary clinical management of human neoplasms faces a number of challenges. Surgical removal of tumor tissues is often not possible technically, while radiation and chemotherapy pose the risk of damaging healthy cells, tissues, and organs, presenting complex clinical challenges. These require a paradigm shift in developing new therapeutic modalities moving towards a more",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:1"
    }
  },
  {
    "page_content": "new therapeutic modalities moving towards a more personalized and targeted approach. The tumor-agnostic philosophy, one of these new modalities, focuses on characteristic molecular signatures of transformed cells independently of their traditional histopathological classification. These include commonly occurring DNA aberrations in cancer cells, shared metabolic features of their homeostasis or immune evasion measures of the tumor tissues. The first dedicated, FDA-approved tumor-agnostic",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:2"
    }
  },
  {
    "page_content": "The first dedicated, FDA-approved tumor-agnostic agent’s profound progression-free survival of 78% in mismatch repair-deficient colorectal cancer paved the way for the accelerated FDA approvals of novel tumor-agnostic therapeutic compounds. Here, we review the historical background, current status, and future perspectives of this new era of clinical oncology. # 1. Introduction Cancer is among the leading causes of mortality in developed countries due to the high rate of morbidity and limited",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:3"
    }
  },
  {
    "page_content": "due to the high rate of morbidity and limited efficiency of contemporary therapeutic modalities. Indeed, lung cancer, for instance, accounts for an estimated 350 fatalities daily, making it the leading cause of cancer-related mortality across both sexes in 2022. From 2001 to 2017, an increase from 19% to 31% in 3-year survival outcome was observed. During this period, the median survival increased from 8 to 13 months. Despite conventional chemotherapy being the primary treatment for",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:4"
    }
  },
  {
    "page_content": "chemotherapy being the primary treatment for non-small-cell lung cancer, the success rate was less than 5%. Over the course of several decades, cancer management has predominantly relied on scrutinizing tumor tissue at the cellular and supracellular levels. This has led to a site-specific approach in managing tumors, where guidelines are tailored, primarily, on the basis of their location within the human body. Accordingly, cancer research, clinical trials, and the development of anticancer",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:5"
    }
  },
  {
    "page_content": "trials, and the development of anticancer drugs have, so far, hinged on histopathological classifications rather than addressing genetic alterations, highlighting the inherent limitations of these treatment regimes. Moreover, the lack of specificity of conventional therapies has been associated with adverse side effects and toxicity, while they may become ineffective over time as cancer cells develop drug resistance. The limitations of conventional approaches urged a paradigm shift in",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:6"
    }
  },
  {
    "page_content": "conventional approaches urged a paradigm shift in developing new anticancer therapies that considers the unique molecular characteristics of cancer cells. Accordingly, the landscape of cancer treatment has undergone a remarkable transformation with the rapid evolution of clinical genomic testing and simultaneous strides in precision cancer therapies. This has given rise to genomically targeted therapies and immune-boosting agents that represent a groundbreaking shift in cancer therapeutics.",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:7"
    }
  },
  {
    "page_content": "a groundbreaking shift in cancer therapeutics. Indeed, the repertoire of targeted therapies, designed to address specific molecular alterations, has witnessed an exponential surge in recent years. The introduction of immunotherapy has propelled cancer treatment to a new dimension by harnessing the body’s own defenses to combat the disease. Consequently, we find ourselves moving beyond the era of site-specific cancer management, witnessing the emergence of tissue-agnostic biomarkers spanning",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:8"
    }
  },
  {
    "page_content": "emergence of tissue-agnostic biomarkers spanning diverse cancer histologies. This shift has been primarily fueled by actionable alterations identified through next-generation sequencing and the development of drugs capable of precisely targeting these alterations. While initially considered speculative, recent years have provided compelling evidence supporting the efficacy of biomarker-driven, tissue-agnostic therapeutics. Regulatory approvals have played a crucial role in validating this",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:9"
    }
  },
  {
    "page_content": "have played a crucial role in validating this paradigm shift. # 2. Tumor-Agnostic Philosophy ## 2.1. Advances in Understanding the Molecular Events of Tumor Development Advancements in the preparation of histological samples and staining techniques for biological materials enabled researchers to offer a more intricate understanding of tumor structures. In the early 1800s, several scholars observed that neoplastic tumors consisted of cells with irregular shapes. This insight was initially",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:10"
    }
  },
  {
    "page_content": "with irregular shapes. This insight was initially articulated by Schleiden and Müller in 1838, and later corroborated by Schwann in 1839. They identified distinctive characteristics of neoplastic tumors, such as an increased rate of cell division, abnormal mitotic activity, enlarged cell nuclei, and a loss of cellular differentiation. Moreover, they noted additional tumor features like the surrounding stroma, blood vessels, and areas of necrosis, particularly within the cores of tumors. By the",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:11"
    }
  },
  {
    "page_content": "particularly within the cores of tumors. By the late 1800s, an increasing number of researchers leaned towards Virchow’s theory, that the root cause of the disease lay in cellular abnormalities (Figure 1). During the 1970s, it became evident that the cells composing tumor masses display remarkable heterogeneity. They exhibit variations, such as differing resistance to drugs or sensitivity to signals prompting programmed cell death. Furthermore, over time, these cells become increasingly",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:12"
    }
  },
  {
    "page_content": "over time, these cells become increasingly aggressive and acquire new capabilities, such as the ability to metastasize. While the “disease of genes” model of cancer recognized the role of mutations in initiating the disease, it failed to provide a comprehensive explanation for this progression. Consequently, it was inferred that there must exist a mechanism facilitating the emergence and accumulation of successive alterations. The concept that viruses contribute to cancer development traces",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:13"
    }
  },
  {
    "page_content": "viruses contribute to cancer development traces back to the research published by Peyton Rous in 1911. Rous identified a filterable agent, termed Rous sarcoma virus (RSV), in cell extracts from a chicken tumor capable of inducing tumors in healthy chickens. This groundbreaking discovery of a retrovirus laid the foundation for tumor virology, highlighting that certain cancers may have an infectious origin. In the 1960s and 1970s, the first tumor viruses affecting humans were identified. The",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:14"
    }
  },
  {
    "page_content": "viruses affecting humans were identified. The Epstein–Barr virus (EBV), also known as human herpes virus 4 (HHV-4), was first visualized in cells cultured from Burkitt’s lymphoma using electron microscopy, marking the inception of human tumor virology. Subsequent immunofluorescence assays revealed heightened immune responses to EBV antigens in individuals with Burkitt’s lymphoma or nasopharyngeal carcinoma, and biopsy samples from these cancers exhibited the presence of EBV DNA. By the 1960s,",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:15"
    }
  },
  {
    "page_content": "exhibited the presence of EBV DNA. By the 1960s, it became evident that cancer development is closely linked to genetic errors, which are passed on to descendant cells during subsequent divisions. This led to a shift in the interpretation of carcinogenesis from a cellular level to a molecular one, focusing on genetic abnormalities rather than cellular dysfunction. The 1980s witnessed a surge in research focused on genes implicated in carcinogenesis. It became apparent that several genes",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:16"
    }
  },
  {
    "page_content": "It became apparent that several genes identified in oncoviruses shared identical sequences with their cellular counterparts (e.g., SRC, initially discovered in avian DNA), eventually leading to the identification of cellular oncogenes. In the early 1980s, orthologs of viral RAS oncogenes with point mutations were identified in DNA fragments from human cancer cells, marking a significant milestone in molecular oncology research. This was followed by the discovery of cellular counterparts of",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:17"
    }
  },
  {
    "page_content": "by the discovery of cellular counterparts of further viral oncogenes, tumor drivers initially identified in retroviruses, including MYC, RAF, ERBB1 (encoding Epidermal growth factor receptor [EGFR]), AKT, and SIS (encoding subunit B of the platelet-derived growth factor [PDGF]). Subsequent research revealed their key involvement in growth signaling pathways. Research into chromosome abnormalities in cancer cells has revealed a striking finding: tumor cells may harbor an extensive array of",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:18"
    }
  },
  {
    "page_content": "tumor cells may harbor an extensive array of mutations, possibly numbering in the thousands. This substantial quantity prompted Loeb et al. to formulate the “mutator phenotype hypothesis,” suggesting that the conventional mutation rate in healthy cells falls short of explaining the abundance of mutations observed in cancer cells. Consequently, mutations occurring in genes governing DNA synthesis fidelity or DNA repair (caretaker genes), as well as those encoding proteins involved in cell cycle",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:19"
    }
  },
  {
    "page_content": "as those encoding proteins involved in cell cycle regulation or apoptosis (gatekeeper genes), could significantly elevate the baseline mutation rate, potentially elucidating the multiple mutations found in tumor cells. The considerable surge in cancer risk as individuals age coincides with a shift from hematopoietic tumors, which tend to occur earlier in life, to epithelial carcinomas. Genes implicated in the process of carcinogenesis are typically divided into three main categories:",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:20"
    }
  },
  {
    "page_content": "are typically divided into three main categories: proto-oncogenes, tumor suppressor genes, and mutator genes. Proto-oncogenes are responsible for encoding proteins that stimulate cell division. When these genes undergo mutations, the resulting proteins can be overactivated, leading to uncontrolled cell proliferation. Conversely, tumor suppressor genes produce proteins that physiologically inhibit cell division and promote cell survival. Mutator genes, on the other hand, are responsible for",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:21"
    }
  },
  {
    "page_content": "genes, on the other hand, are responsible for maintaining genome integrity, so upon their loss-of-function mutations, they induce chromosomal instability, which can result in mutations in proto-oncogenes and tumor suppressor genes. Additionally, mutator genes can lead to other mutations that confer a selective advantage for certain tumor cell clones to survive in their environment. Current understanding suggests that the initiation of carcinogenesis typically requires gain-of-function mutations",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:22"
    }
  },
  {
    "page_content": "typically requires gain-of-function mutations of proto-oncogenes and loss-of-function mutations of the tumor suppressor ones. Mutations in genes encoding proteins involved in apoptosis, DNA damage detection, and repair also play significant roles in oncogenesis. Cancer cells undergo a process of clonal selection, wherein the initial cells carry a variety of mutations, leading to diversity among their offspring. While most genomic alterations have either neutral or detrimental effects on the",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:23"
    }
  },
  {
    "page_content": "have either neutral or detrimental effects on the cell phenotype, a select few confer a survival advantage. These advantageous clones proliferate and eventually dominate the tumor’s growth. As tumor progression ensues, features that enhance cellular survival accumulate, such as genome instability, which increases the likelihood of additional mutations. Through clonal evolution, the most adapt clones emerge from the heterogeneous population of cancer cells to thrive within the tumor environment.",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:24"
    }
  },
  {
    "page_content": "cells to thrive within the tumor environment. It is believed that cancer usually arises from multiple mutations in tumor-driver genes, with the accumulation of mutations being more critical than their specific sequence of appearance. ## 2.2. Comparative Studies on the Molecular/Genetic Landscape of Individual Tumors Advancements in our understanding of the carcinogenesis along with the development of high-throughput genomics inevitably led to the call for comprehensive investigations of the",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:25"
    }
  },
  {
    "page_content": "the call for comprehensive investigations of the genetic landscapes of diverse neoplasms for mapping their molecular constellations. Indeed, The Cancer Genome Atlas (TCGA) has conducted several pan-cancer genome studies, aiming to comprehensively analyze thousands of cancer genomes across multiple cancer types. These studies have led to the extraction of 21 characteristic mutations from 30 types of cancers, providing a comprehensive landscape and dictionary of mutational signatures in major",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:26"
    }
  },
  {
    "page_content": "and dictionary of mutational signatures in major cancers. Another systematic analysis of 3281 tumors from 12 cancer types to investigate the underlying mechanisms of cancer initiation and progression identified 127 significantly mutated genes involved in diverse cellular processes, including TP53, PTEN, APC, KRAS, and RB. Identified genes were broadly classified into 20 categories, such as transcription factors/regulators, histone modifiers, transcription regulators, metabolic pathway elements,",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:27"
    }
  },
  {
    "page_content": "regulators, metabolic pathway elements, and genome integrity maintenance mediators. TP53 emerged as the most frequently mutated gene in the pan-cancer cohort (42% of samples), with mutations being particularly prevalent in serous ovarian (95%) and serous endometrial carcinomas (89%). PIK3CA followed as the second most commonly mutated gene, observed frequently across most cancer types except ovarian serous carcinoma (OV), kidney renal clear cell carcinoma (KIRC), lung adenocarcinoma (LUAD), and",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:28"
    }
  },
  {
    "page_content": "carcinoma (KIRC), lung adenocarcinoma (LUAD), and acute myeloid leukemia (AML). Mutations in PIK3CA were notably enriched in luminal subtype tumors, notably in uterine corpus endometrial carcinoma (UCEC) (52%) and breast adenocarcinoma (BRCA) (33.6%). Interestingly, tumors lacking PIK3CA mutations often harbored mutations in PIK3R1, with significant occurrences in UCEC (31%) and glioblastoma multiforme (GBM) (11%). Chromatin remodeling genes displayed mutations across many cancer types, with",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:29"
    }
  },
  {
    "page_content": "mutations across many cancer types, with histone-lysine N-methyltransferase genes (MLL2, MLL3, and MLL4) clustering notably in bladder, lung, and endometrial cancers. Additionally, mutations in ARID1A were frequent in bladder urothelial carcinoma (BLCA), UCEC, LUAD, and lung squamous cell carcinoma (LUSC), while ARID5B mutations were prevalent in UCEC (10%). Mutually exclusive KRAS and NRAS mutations were identified, with recurrent activating mutations observed commonly in colon and rectal",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:30"
    }
  },
  {
    "page_content": "mutations observed commonly in colon and rectal carcinoma (COAD/READ) (30%, 5%, and 5% for KRAS (Gly 12), KRAS (Gly 13), and NRAS (Gln 61), respectively). Further intriguing insights have been uncovered by another large-scale survey (MSK-IMPACT) using prospective sequencing on tumors from over 10,000 cancer patients representing a diverse spectrum of solid tumor types. The findings revealed that certain genes, previously deemed significant in TCGA studies, exhibited even higher mutation",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:31"
    }
  },
  {
    "page_content": "in TCGA studies, exhibited even higher mutation frequencies within the MSK-IMPACT dataset. Particularly notable was TP53, which displayed significantly elevated mutation rates across four tumor types (prostate cancer, kidney chromophobe carcinoma, glioblastoma, and gastric cancer) compared to TCGA. In prostate cancer alone, TP53 mutations were over four times more prevalent in MSK-IMPACT (29%) than in TCGA (7%), consistent with prior observations linking TP53 mutations to more aggressive",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:32"
    }
  },
  {
    "page_content": "linking TP53 mutations to more aggressive disease. TP53 emerged as the most frequently altered gene in the MSK-IMPACT dataset, affecting 41% of patients. Its mutations were notably prevalent in high-grade serous ovarian cancer (98%), esophageal adenocarcinoma (89%), and small-cell lung cancer (85%), often leading to functional inactivation through truncation or splicing disruption. Across 43 of the 62 primary tumor types studied, TP53 alterations were present in over 10% of cases. Following",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:33"
    }
  },
  {
    "page_content": "were present in over 10% of cases. Following TP53, KRAS ranked as the second most frequently altered gene (15% of patients), with mutations predominantly observed in pancreatic adenocarcinoma (90%) and colon adenocarcinoma (44%). The G12 codon of KRAS stood out as the most frequently altered among the sequenced tumors, accounting for 80% of all KRAS mutations and 12% of individuals sequenced. Other commonly mutated loci included PIK3CAH1047, PIK3CAE545, and BRAFV600, each occurring in over 20",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:34"
    }
  },
  {
    "page_content": "and BRAFV600, each occurring in over 20 principal tumor types, indicating positive selection for these variants across diverse cancer lineages. While some genes, like TP53 and PIK3CA, displayed consistent mutation rates across multiple tumor types, others such as VHL, APC, and IDH1 showed high mutation rates limited to only a few types of neoplasms. Certain gene fusions were also uniquely associated with particular cancer lineages, such as TMPRSS2-ERG in prostate cancer, EWSR1-FLI1 in Ewing",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:35"
    }
  },
  {
    "page_content": "in prostate cancer, EWSR1-FLI1 in Ewing sarcoma, and DNAJB1-PRKACA in fibrolamellar hepatocellular carcinoma. However, excluding tumors with unusually high mutation rates, 97% of genes in the 410-gene panel showed mutations in at least five major tumor types, highlighting the potential benefits of comprehensive mutation profiling regardless of cancer lineage. In addition to targeting the coding sequences of cancer-associated genes, MSK-IMPACT also captured the promoter region of TERT. Mutations",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:36"
    }
  },
  {
    "page_content": "captured the promoter region of TERT. Mutations occurring at two frequently recurring sites in the TERT promoter have been observed to generate new consensus binding sites for ETS family transcription factors. This leads to increased telomerase expression and decreased cell death. TERT promoter mutations were most commonly found in bladder cancer (70%), glioma (67%), thyroid cancer (60%), and melanoma (49%), particularly cutaneous melanoma. The researchers consistently noted a trend towards",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:37"
    }
  },
  {
    "page_content": "researchers consistently noted a trend towards shorter survival among individuals with altered TERT promoters. ## 2.3. Advances in Molecular Characterization of Patient Tumors Advances in our understanding of the genetic mechanisms of tumor formation by large-scale genomic surveys for cancer-driver mutations, like TCGA and the International Cancer Genome Consortium (ICGC), paved the way for growing demands for high-throughput diagnostic tools for screening characterized molecular hallmarks of",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:38"
    }
  },
  {
    "page_content": "screening characterized molecular hallmarks of cancer in patient samples. This fueled the implementation of novel technologies like next-generation sequencing (NGS) in the clinical practice of tumor diagnostics (Figure 2). NGS allows for the sequencing of longer DNA sections faster than that of the current canonical sequencing technologies for a fraction of the cost. Using short segments of DNA or RNA, NGS uses libraries of these fragments tagged by adapter sequences that allows for efficient",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:39"
    }
  },
  {
    "page_content": "by adapter sequences that allows for efficient bidirectional amplification of all nucleotide fragments using standard primers generating both forward and reverse amplicons. The process known as bridge amplification results in parallel amplification of each fragment of the sample. Sequencing is accomplished using the amplified fragments as template strands and polymerases that incorporate fluorescently labeled nucleotides to the growing strand. Fluorescently labeled nucleotides emit their",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:40"
    }
  },
  {
    "page_content": "Fluorescently labeled nucleotides emit their characteristic signals upon incorporation. Their emission wavelengths and intensity are recorded to determine what nucleotide has been added to the growing strand. Synthesis takes place simultaneously along millions of templates in a common platform, and the emitted signal pattern is continuously recorded. This leads to the read of hundreds to thousands of fragment clusters at the same time, making the technology much more efficient than previous",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:41"
    }
  },
  {
    "page_content": "the technology much more efficient than previous sequencing methods. Sequence information of the fragments finally lines up to reference genome sequences by dedicated algorithms to create the final sequence of the nucleotide sample tested (Figure 2). NGS not only allows for broad mutation detection with faster speeds, allowing for early detection of neoplasms, but requires less patient sample material compared to other detection options. The high-throughput nature of the NGS technology combined",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:42"
    }
  },
  {
    "page_content": "nature of the NGS technology combined with the comprehensive catalog of cancer-driver genetic alterations allowed the innovation of NGS-based diagnostic panels that provide concise and affordable screening for cancer biomarkers in everyday clinical practice. Indeed, over the past few years, several NGS-based cancer biomarker screening kits have been developed and introduced successfully to the hospital laboratory repertoire. One of the first FDA-approved functional screening panels (MSK-IMPACT)",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:43"
    }
  },
  {
    "page_content": "functional screening panels (MSK-IMPACT) utilizing hybridization capture technology and next-generation sequencing was developed by the Memorial Sloan Kettering Cancer Center. This innovative panel has the power of not only screening for pathognomonic mutations within protein-coding regions but also detects copy number alterations, selected promoter mutations, and structural rearrangements across 410 onco- and tumor suppressor genes. Without being limited to a given cancer type, the MSK-IMPACT",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:44"
    }
  },
  {
    "page_content": "limited to a given cancer type, the MSK-IMPACT panel has been successfully used in clinical settings for both aiding in patient’s enrollment to clinical trials and defining targeted drug therapies. Since then, oncopanels have been developed further with different specifics and have become widely used in the current clinical practice (Table 1). Although NGS tends to be the most common approach to biomarker identification, it does not provide information on the biomarker status of target cells at",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:45"
    }
  },
  {
    "page_content": "on the biomarker status of target cells at the protein level. New advances in immunohistochemistry (IHC) can be used as another biomarker screening tool. Large-scale immunohistochemistry screening on tissue microarrays and tissue slice arrays has been proposed as a lower-cost and more efficient option with the aim to complement targeted therapy efforts. Programmed death ligand 1 (PD-L1) binds to programmed death receptor 1 (PD-1) on lymphocytes, causing the lymphocytes to be inactivated. Some",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:46"
    }
  },
  {
    "page_content": "causing the lymphocytes to be inactivated. Some cancer cells have been seen to have an increase in PD-L1, resulting in host immune cells to be rendered inactive against cancer cells. PD-L1 immunohistochemistry assays are now in use to identify PD-L1-positive cancers. Currently, there are four main stains being worked on, 22C3, 28-8, SP142, and SP263, which differ in the antibodies used (Table 2). PD1 IHC has been of keen interest in triple-negative breast cancer and lung cancer. It has been",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:47"
    }
  },
  {
    "page_content": "breast cancer and lung cancer. It has been made very evident that the use of biomarkers is of great importance when it comes to early diagnosis and treatment options; therefore, there is a continuous need to make the discovery and identification of such biomarkers more efficient. In the detection of colorectal cancer (CRC), there is a very large influx of patient samples needed to be tested due to all individuals aged 50–75 in North America needing to be screened. Due to the large volume, more",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:48"
    }
  },
  {
    "page_content": "to be screened. Due to the large volume, more efficient and more cost-effective methods are advantageous. Currently, the common form of diagnosing CRC is through fecal occult blood testing, which tends to have a high false positive and false negative rate, or colonoscopies, which are quite invasive. High-throughput proteomic platforms allow for the screening of protein biomarkers. In high-throughput proteomic platforms, antibody mixtures are used to identify antigens on the protein that has",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:49"
    }
  },
  {
    "page_content": "used to identify antigens on the protein that has been extracted from the biopsy. This method can be used in the detection of CRC via the use of aptamer-based screening. Stool is used as the sample and the results are verified using ELISA. An emerging technique for the detection of biomarkers is electrical biosensors. Electrical biosensors allow you to identify a protein biomarker using molecular imprinting polymers (MIPs), which allow you to create a synthetic receptor for the biomarker you",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:50"
    }
  },
  {
    "page_content": "create a synthetic receptor for the biomarker you are looking for. The formation of these synthetic receptors has been shown to have more rapid and accurate identification of biomarkers. Electrical biosensors have been showing fast and accurate readings at low detection levels, making them a very useful potential product in everyday care. Electrical biosensors have already been used for both detecting well-known cancer biomarkers such as CEA and searching for new biomarkers like STEAP1, opening",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:51"
    }
  },
  {
    "page_content": "searching for new biomarkers like STEAP1, opening new frontiers in cancer diagnosis and management. This technology can be very useful in the investigation of tumor-agnostic targets as well as opening the door to new targets through the ability to create a synthetic receptor, as natural receptors such as enzymes and antibodies can be high in cost as well as requiring strict conditions to function. ## 2.4. Common Molecular Characteristics of Histopathologically Diverse Tumors Using rapidly",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:52"
    }
  },
  {
    "page_content": "Histopathologically Diverse Tumors Using rapidly evolving contemporary high-throughput technologies, the tumor-agnostic approach became a clinical reality over recent years. By screening for characterized common tumor drivers, they provide information in continuously increasing details of the genetic constellation of individual tumors. These data shed light on biomarkers frequently occur in tumors that, formerly, were characterized as unrelated. Cell surface receptors are prominent examples of",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:53"
    }
  },
  {
    "page_content": "Cell surface receptors are prominent examples of such tumor-agnostic markers (Figure 3). Indeed, neurotrophic tyrosine kinase receptors (NTRKs), for instance, have been found in several adult and pediatric malignances, including infantile fibrosarcoma, congenital mesoblastic nephroma, and papillary thyroid cancer [Table 1]. In non-transformed tissues, NTRKs are involved in neuronal growth, differentiation, and survival. In transformed cells, however, NTRK encoding genes are often found to be",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:54"
    }
  },
  {
    "page_content": "NTRK encoding genes are often found to be fused with other genes, leading to their own constitutive upregulation and the consequent activation of their downstream effectors, including elements of the phospholipase Cγ, mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3 phosphate kinase signaling pathways. The latter ones are particularly common targets for mutated cell surface receptors even beyond NTRKs. Anaplastic lymphoma kinase (ALK), a tyrosine kinase receptor mainly",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:55"
    }
  },
  {
    "page_content": "kinase (ALK), a tyrosine kinase receptor mainly expressed in the brain, testis, and small intestines, also signals through the MAPK and PI3K pathways, regulating cell survival and proliferation. ALK also seems to be prone to chromosomal rearrangements, resulting in fusion genes with recurring fusion partners like the nucleophosmin 1 gene (NPM1) or EMAP like 4 gene (EML4). NPM1 produces chaperone proteins as wells as proteins that protect tumor suppressor protein ARF from being degraded by",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:56"
    }
  },
  {
    "page_content": "suppressor protein ARF from being degraded by sequestering ARK into the nucleolus, while EML4 is suspected to produce proteins involved in microtubule formation. In these chimeras with its 5′ region being lost, the 3′ end of ALK usually remains intact, preserving its kinase and allowing ALK to be active without a ligand present, giving rise to constitutively active ALK activities. As a tumor-agnostic target, ALK rearrangements have been found in NSCLC, anaplastic large cell lymphoma, and breast",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:57"
    }
  },
  {
    "page_content": "NSCLC, anaplastic large cell lymphoma, and breast cancer, among others. Another receptor tyrosine kinase, ERBB2, also known as HER2, has also emerged as a powerful tumor-agnostic molecular signature. Although traditionally it has been known for its assignment with breast cancer, ERBB2 overexpression, usually due to in-frame insertions and amplifications, has been identified in CRC and NSCLC alike. ERBB2 is a member of the epidermal growth factor receptor family, primarily signaling through the",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:58"
    }
  },
  {
    "page_content": "receptor family, primarily signaling through the MAPK cascade and phosphatidylinositol pathways, orchestrating the expression of genes involved in the regulation of cell cycle progression and survival. Besides ERBB2, the RET receptor tyrosine kinase plays a similar role among the cell surface cohort of tumor-agnostic biomarkers. RET plays a central role in early human development, but in adult tissues, its functions are unclear. RET fusions with other genes, commonly KIF5B, cause RET receptor",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:59"
    }
  },
  {
    "page_content": "other genes, commonly KIF5B, cause RET receptor tyrosine kinase to be constitutively active and have been frequently detected in NSCLC and papillary thyroid neoplasms. In accordance with the tumor-agnostic philosophy, however, mutated RET variants were also found in neoplasms of breast tissue, widening the diagnostic and treatment repertoire for HER2-negative and -positive breast cancers which are resistant to current traditional treatment. Abnormal signaling from cell surface receptors",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:60"
    }
  },
  {
    "page_content": "Abnormal signaling from cell surface receptors eventually converges on conserved signaling pathways, like the MAPK one, that play central roles in the regulation of the cell cycle. Thus, it is not surprising that rate-limiting elements of these signal transduction machineries are also commonly found to be mutated in histologically diverse neoplasms and, therefore, could serve as tumor-agnostic biomarkers. One of these proven candidates is KRAS, which produces a protein of the RAS family. KRAS",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:61"
    }
  },
  {
    "page_content": "which produces a protein of the RAS family. KRAS undergoes a conformational change when bound to GTP that allows its interaction with GTPase-activating proteins (GAPs), resulting in its endogenous GTPase activity being amplified. Several solid tumors, including NSCLC and colorectal cancers, are associated with KRAS mutations, of which the most common one is G12C missense mutations. G12C produces a KRAS that is more favorably bound to GTP, rendering KRAS constitutively active. Constitutive",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:62"
    }
  },
  {
    "page_content": "KRAS constitutively active. Constitutive activation of KRAS will result in the upregulation of downstream components of the MAPK pathway, leading to the dysregulation of the cell cycle. BRAF, a serine/threonine protein kinase that functions as a proximal effector of the MAPK pathway downstream of RAS, is also commonly mutated in histologically unrelated human tumors, making BRAF another tumor-agnostic target. Indeed, although mutated BRAF has, traditionally, been associated with melanoma, it",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:63"
    }
  },
  {
    "page_content": "traditionally, been associated with melanoma, it has also been identified in gliomas, NSCLC, colorectal tumors, head and neck neoplasms, and hepatocellular carcinomas. BRAF’s most common cancer-causing missense mutation, V600E, renders BRAF to be constitutively active as a monomer, leading to abnormal firing of the critical intracellular machinery that governs cell cycle progression. Tumor suppressor genes also play a central role in the regulation of cell division, so it is not surprising that",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:64"
    }
  },
  {
    "page_content": "of cell division, so it is not surprising that their mutations are seen in almost all human neoplasms. Indeed, TP53, which encodes for p53, a protein involved in cell cycle arrest and apoptosis, is one of the most commonly mutated genes in human neoplasms, predicting it to be an ideal tumor-agnostic target. However, extensive research on TP53 revealed more than 1000 diverse mutations, some of which are dominant negative ones that make the mutant variant interfere with wildtype p53, while other",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:65"
    }
  },
  {
    "page_content": "variant interfere with wildtype p53, while other mutations are rather loss-of-function ones. The extensive variety of mutations plays into the difficulty in using TP53 as a direct tumor-agnostic target. The cell cycle regulator retinoblastoma protein (Rb), which blocks cell cycle progression via E2F, is also commonly mutated in diverse human tumors from the originally associated pediatric retinoblastoma to breast cancer or osteosarcoma. E2F is a regulatory transcription factor that mediates",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:66"
    }
  },
  {
    "page_content": "a regulatory transcription factor that mediates cell cycle progression by controlling the expression of genes like cyclins. Upon the CDK4/6-mediated phosphorylation of Rb, E2F is released, and the cell prepares for cell division by entering the S phase. Mutated RB fails to block E2F, allowing cells to progress through the cell cycle. Interestingly, Rb, similar to TP53, also shows a high degree of mutational mosaicism, at least in part, due to the considerable quantity of CpG islands within the",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:67"
    }
  },
  {
    "page_content": "considerable quantity of CpG islands within the gene, making its direct pharmacological targeting particularly challenging. Thus, current research is moving towards marking additional elements of the p53 and Rb pathways, like the negative p53 regulator MDM2 or the CDK4/6 that inhibits Rb, for potential use as tumor-agnostic biomarkers. To prevent the accumulation of mutations in genes including the proto-onco- and tumor suppressor ones, maintenance of the genome integrity is critical. Thus,",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:68"
    }
  },
  {
    "page_content": "of the genome integrity is critical. Thus, mutations of the mutator genes, including both caretaker genes, which are involved in DNA repair and genome stability, and gatekeeper genes, which are involved in apoptosis, are also widespread in transformed cells, making them potential tumor-agnostic targets. Indeed, germline and acquired mutations in the emblematic member of the caretaker genes, breast cancer gene 1 and 2 (BRCA1/2), are ordinarily associated with breast cancer but have been",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:69"
    }
  },
  {
    "page_content": "associated with breast cancer but have been documented in ovarian and prostate cancers as well. The mutational pattern of BRCA1/2, however, poses challenges. Hereditary BRCA1/2 mutations vary amongst ethnic groups studied, and there is no singular mutation associated with acquired BRCA1/2. In the Japanese population, L63X and Q934X of BRCA1 are the most common mutations, while in the Ashkenazi Jewish population, 5382insC or 185delAG in BRCA1 and 6174delT in BRCA2 are the most prevalent. BRCA1/2",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:70"
    }
  },
  {
    "page_content": "6174delT in BRCA2 are the most prevalent. BRCA1/2 encodes for proteins involved in the repair of DNA double-strand breaks. Thus, BRCA1/2 mutations, along with mutations in other mutator genes like ATM and CHEK2, have been exploited as tumor-agnostic markers, but in a unique application. ATM produces a protein kinase that, when activated, allows for the downstream signals of DNA repair activity to begin, including the activation of BRCA1/2 and CHEK2. CHEK2 produces a protein which is rapidly",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:71"
    }
  },
  {
    "page_content": "CHEK2. CHEK2 produces a protein which is rapidly phosphorylated upon DNA damage and prevents the cell from entering mitosis. CHEK2 is also responsible for the activation of BRCA1 and BRCA2. Inhibition of the poly(adenosine diphosphate [ADP]–ribose) polymerases (PARPs), which are involved in single-strand break repairs, in neoplasms with BRCA1/2, ATM and CHEK2 mutations causes single- and double-strand breaks at the replication forks which will, eventually, lead to the disassembly of the",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:72"
    }
  },
  {
    "page_content": "will, eventually, lead to the disassembly of the replication fork and, consequently, cell cycle arrest. ## 2.5. Molecular Signatures of the Tumor Microenvironment for Tumor-Agnostic Targets Besides the intracellular ones, breakthrough discoveries in tumor immunology shed light on molecular signatures that can serve as tumor-agnostic targets at supracellular levels as well. Indeed, with the rapidly growing attention to the role of the immune system in the development of neoplasms, molecules that",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:73"
    }
  },
  {
    "page_content": "in the development of neoplasms, molecules that are critical in the interaction between the immunocompetent cells and the tumor microenvironment emerged as primary targets for contemporary tumor-agnostic treatment regimes. The tumor microenvironment (TME) is the complex and dynamic cellular environment where a tumor develops. It includes various immune cells such as T and B lymphocytes, tumor-associated macrophages, dendritic cells, natural killer cells, neutrophils, and myeloid-derived",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:74"
    }
  },
  {
    "page_content": "killer cells, neutrophils, and myeloid-derived suppressor cells; stromal cells like cancer-associated fibroblasts, pericytes, and mesenchymal stromal cells; the extracellular matrix; and secreted molecules such as growth factors, cytokines, chemokines, and extracellular vesicles. Additionally, it encompasses the blood and lymphatic vascular networks. These elements are interconnected and interact with the heterogeneous cancer cells. The TME significantly contributes to the acquisition and",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:75"
    }
  },
  {
    "page_content": "significantly contributes to the acquisition and maintenance of cancer hallmarks, such as sustaining proliferative signaling, evading cell death, promoting angiogenesis, enabling invasion and metastasis, triggering tumor-promoting inflammation, and avoiding immune destruction. Due to the pivotal role of the TME in tumor progression and its influence on the effectiveness of cancer treatments, strategies to target the TME have greatly expanded in recent years. These approaches mainly focus on",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:76"
    }
  },
  {
    "page_content": "in recent years. These approaches mainly focus on targeting TAMs, DCs, T cells, tumor vasculature, extracellular matrix, and cancer-associated fibroblasts. Within the TME, tumor-associated macrophages (TAMs) can quickly respond to local stimuli such as cytokines or therapeutic interventions, adopting a range of phenotypes from proinflammatory to anti-inflammatory states. This plasticity is influenced by factors such as the stage of the disease, the affected tissue, and the host microbiota,",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:77"
    }
  },
  {
    "page_content": "the affected tissue, and the host microbiota, collectively determining whether TAMs inhibit or promote tumorigenesis. Targeting macrophages in therapy offers dual benefits: it can block TAMs from directly aiding cancer cell survival and can enhance the cross-presentation to CD8+ T cells, thereby increasing their antitumor efficacy. There are a number of putative biomarkers to pharmacologically control TAM activities including CSF1 and chemokine receptors, costimulatory molecules like CD40, or",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:78"
    }
  },
  {
    "page_content": "receptors, costimulatory molecules like CD40, or elements of intracellular pathways like PI3K that all affect the antitumor phenotypes. Three key characteristics of dendritic cells (DCs) are essential for eliciting a robust and sustained antitumor response: effective migration between lymphoid and non-lymphoid tissues, cross-presentation of tumor-associated antigens (TAAs) to CD8+ cytotoxic T lymphocytes to initiate strong effector responses against the tumor, and the release of chemokines and",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:79"
    }
  },
  {
    "page_content": "the tumor, and the release of chemokines and cytokines to regulate the overall immune response and T-cell homing. This makes DCs promising targets for cancer immunotherapy. Higher densities of DCs, particularly classic dendritic cells, within the TME are associated with improved prognosis in ovarian carcinoma, lung cancers, and breast cancers. However, the TME can disrupt DC functions through various mechanisms. These include reduced production of chemoattractants (e.g., CCL4 and CCL5), which",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:80"
    }
  },
  {
    "page_content": "of chemoattractants (e.g., CCL4 and CCL5), which hampers DC recruitment to the tumor site, and decreased levels of survival signals like FMS-like tyrosine kinase 3 ligand (FLT3L), crucial for DC differentiation and viability. These disruptions result in insufficient T-cell activation and may induce T-cell tolerance to TAAs. Current cancer immunotherapies targeting T cells involve two main strategies: enhancing the antitumor activity of T cells by inhibiting immune checkpoints and boosting",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:81"
    }
  },
  {
    "page_content": "by inhibiting immune checkpoints and boosting adaptive immunity through the adoptive transfer of genetically engineered T cells, such as those with chimeric antigen receptors (CARs) or modified T-cell receptors. Several negative regulators, or checkpoint molecules, control T-cell activation to prevent immune system overactivity. The prototype of them is the pair of cytotoxic T lymphocytes programmed death receptor 1 (PD-1) and its ligand (PD-L1) (Figure 4). Unlike the canonical tumor-driver",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:82"
    }
  },
  {
    "page_content": "(Figure 4). Unlike the canonical tumor-driver biomarkers, neither PD-1 nor PD-L1 are mutated in the context of PD-L1-positive neoplasms. Still, distinct cancer types harboring apparently unrelated tumor-driver mutations have been demonstrated to be positive for PD-L1 expression, making the PD-1/PD-L1 axis an excellent tumor-agnostic target. Elevated expression of PD-L1 of cancer cells paralyzes tumor-infiltrating lymphocytes through engaging their PD-1 receptor, resulting in suppression of both",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:83"
    }
  },
  {
    "page_content": "PD-1 receptor, resulting in suppression of both the innate and adaptive antitumor immunity. PD-L1 positivity has been documented in a wide range of neoplasms including head and neck cancers, NSCLC, and thyroid, tongue, and pancreatic cancers. In many of these neoplasms, elevated PD-L1 expression is thought to be associated with the repression of miR-197, suggesting that the blockade of a transcriptional regulatory mechanism plays a part in the induction of PD-L1-encoding CD274 in certain",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:84"
    }
  },
  {
    "page_content": "the induction of PD-L1-encoding CD274 in certain transformed cells. BRAF mutation-positive colorectal cancers have also been shown to have increased PD-L1 expression, suggesting that the MAPK pathway is involved in the regulation of CD274 expression in the intestinal epithelium. Colorectal cancers, similar to endometrial and gastric tumors, frequently show accumulation of mutations in MLH1, MSH2, MSH6 or PMS2, genes that encode elements of mismatch repair, typically resulting in a high degree",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:85"
    }
  },
  {
    "page_content": "repair, typically resulting in a high degree of microsatellite instability. Since these neoplasms have characteristic increases in the number of tumor-infiltrating lymphocytes, their PD-L1 status has fundamental importance in the tumor-agnostic design of their therapeutic approach. In addition to PD-1/PDL-1, cytotoxic T-lymphocyte antigen-4 (CTLA-4) is another immune checkpoint effector that has recently emerged as a tumor-agnostic biomarker. Physiologically, ligation of CTLA-4 by its ligand",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:86"
    }
  },
  {
    "page_content": "Physiologically, ligation of CTLA-4 by its ligand B7, expressed on antigen-presenting cells, triggers an inhibitory response of T-lymphocyte activity. Thus, pharmacological targeting of the CTLA-4/B7 complex is believed to deliberate T-cell activity from cancer-mediated paralysis and serve as a potential tumor-agnostic target. An alternative coreceptor that also participates in T-cell activation is lymphocyte activation gene-3 (LAG-3). LAG-3, a member of the immunoglobulin superfamily, is",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:87"
    }
  },
  {
    "page_content": "a member of the immunoglobulin superfamily, is expressed on the surface of immune cells and actively suppresses T-cell proliferation and effector T-cell function. LAG-3 is structurally and functionally similar to CD4, which ligates with various binding partners, including major histocompatibility complex class II. LAG-3 ligation greatly inhibits CD8+ T cells due to their higher LAG-3 expression. Although LAG-3 is often co-expressed with PD-1 on tumor-infiltrating lymphocytes, they are distinct",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:88"
    }
  },
  {
    "page_content": "tumor-infiltrating lymphocytes, they are distinct immune checkpoint inhibitors that can be regulated and expressed independently. Consequently, LAG-3 is often upregulated in various neoplasms, including melanoma, to mediate T-cell exhaustion. Besides PD-1, CTLA4, and LAG3, other immune checkpoint molecules like TIM3 and TIGIT have also been identified as potential tumor-agnostic targets for T-cell-mediated cancer immunotherapy. Compared to healthy tissues, tumor vasculature is often irregular",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:89"
    }
  },
  {
    "page_content": "tissues, tumor vasculature is often irregular and dysfunctional, exhibiting heterogeneous vascular permeability. This results from several morphological and functional changes, including high endothelial cell (EC) proliferation rates, reduced cellular tight junctions, abnormal pericyte coverage, and increased extracellular matrix (ECM) deposition. These vascular abnormalities can lead to inefficient oxygen delivery, creating a hypoxic environment within the tumor, which is associated with",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:90"
    }
  },
  {
    "page_content": "within the tumor, which is associated with increased cancer aggressiveness. Additionally, the dysfunctional vessels can selectively block the infiltration of specific immune cells, such as cytotoxic T lymphocytes, and significantly hinder the delivery and distribution of therapeutic agents. Consequently, targeting tumor vasculature has become a major focus in the study of the TME. Efforts have mainly concentrated on depleting vasculature using antiangiogenic therapies and enhancing drug and",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:91"
    }
  },
  {
    "page_content": "antiangiogenic therapies and enhancing drug and immune cell delivery through vessel normalization. The extracellular matrix (ECM) is a complex network of proteins and macromolecules, such as collagens, glycoproteins, elastin, fibronectins, and proteoglycans, which cells secrete into the space between them. ECM composition varies greatly among different organs, and in comparison to healthy tissues, tumor ECM is characterized by increased density, coverage, and stiffness. Within the tumor",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:92"
    }
  },
  {
    "page_content": "coverage, and stiffness. Within the tumor microenvironment, multiple cell types contribute to ECM production. Beyond providing structural support, the ECM plays a crucial role in regulating the behavior of both cancer cells and other cells within the TME. For example, heightened stiffness of the surrounding tissue can trigger the epithelial-to-mesenchymal transition in cancer cells, a process associated with increased tumor invasiveness, stemness, and metastasis. Moreover, the abnormal",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:93"
    }
  },
  {
    "page_content": "stemness, and metastasis. Moreover, the abnormal accumulation of ECM interferes with therapeutic effectiveness by physically impeding the penetration of drugs and activating signaling pathways like integrin and focal adhesion kinase, which promote cell survival and resistance to chemotherapy. Furthermore, specific patterns of ECM-related gene expression have been linked to poor patient prognosis and resistance to therapy across various cancer types. In pediatric osteosarcoma, elevated",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:94"
    }
  },
  {
    "page_content": "cancer types. In pediatric osteosarcoma, elevated expression of ECM remodeling genes like desmoplakin or SPARCL1 contributes to chemotherapy resistance, while in breast cancer, high levels of genes like TWIST are associated with a worse outcome. Many research efforts have focused on strategies to degrade ECM components, such as using collagenases or hyaluronidases to improve drug distribution. Alternatively, given the dynamic nature of ECM remodeling by enzymes produced within the TME, an",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:95"
    }
  },
  {
    "page_content": "remodeling by enzymes produced within the TME, an unconventional therapeutic approach involves directly targeting the synthesis of ECM components. This could be achieved by inhibiting key signaling pathways like TGFβ or HIF1α, which promote ECM production, or by targeting the modifying enzymes necessary for ECM component synthesis, secretion, and maturation. Cancer-associated fibroblasts (CAFs) are pivotal in shaping the tumor microenvironment by producing ECM molecules. These fibroblasts",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:96"
    }
  },
  {
    "page_content": "by producing ECM molecules. These fibroblasts facilitate tumor growth through several mechanisms. Not only do they deposit ECM, but they also produce matrix remodeling enzymes that promote tumor invasion, metastasis, and resistance to therapies. Furthermore, CAFs secrete various cytokines, exosomes, and growth factors, such as leukemia inhibitory factor (LIF) and growth differentiation factor 15 (GDF15), which further drive tumor growth and invasion. The influence of CAFs extends beyond tumor",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:97"
    }
  },
  {
    "page_content": "The influence of CAFs extends beyond tumor cells to other TME components, including the vasculature and immune cells. For instance, CAF-derived VEGF stimulates angiogenesis, while cytokines like IL6, CXCL9, and TGFβ modulate T-cell responses. This complex interaction network highlights the crucial role of CAFs in cancer progression and the dynamic nature of the TME. Developments in our understanding of cellular transformation and the revolution in molecular biology-based diagnostic technologies",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:98"
    }
  },
  {
    "page_content": "molecular biology-based diagnostic technologies led to the current paradigm shift in clinical oncology from the former histopathological classification of human neoplasms to the molecular aberration-focused approach we now know as the tumor-agnostic philosophy. # 3. Tumor-Agnostic Treatment Philosophy in Current Clinical Oncology The identification of key tumor-driver mutations led to the concept of novel anticancer strategies on the basis of targeting common biomarkers of human neoplasms.",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:99"
    }
  },
  {
    "page_content": "targeting common biomarkers of human neoplasms. Regulatory approvals underpinned this paradigm shift, with the FDA greenlighting new therapies tailored for tissue-agnostic indications. ## 3.1. Tumor-Agnostic Applications in Contemporary Clinical Practice ### Immunotherapies Pembrolizumab, the first FDA-approved tumor-agnostic medicine, is a humanized monoclonal antibody that directly binds to PD-1 of T lymphocytes, interfering with the ligation of PD-L1 and preventing the tumor cell-mediated",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:100"
    }
  },
  {
    "page_content": "of PD-L1 and preventing the tumor cell-mediated inhibition of PD-L1+ lymphocytes. In clinical trials, its use showed impressive results, with an objective response rate (ORR) of 40%, a disease control rate (DCR) of 90%, and progression-free survival of 78% in mismatch repair-deficient colorectal cancer patients. In endometrial, small bowel, and gastric cancers, as well as in cholangiocarcinoma patients, the same measures showed 67%, 71%, and 71% for progression-free survival (PFS), ORR, and",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:101"
    }
  },
  {
    "page_content": "71% for progression-free survival (PFS), ORR, and DCR, respectively. Thus, it is not surprising that it was granted accelerated approval by the United States Food and Drug Administration (FDA) for patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) positive tumors in 2017. The approval was based on combined data from five single-arm trials, involving a total of 149 patients diagnosed with MSI-H/dMMR cancers, with the majority (90",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:102"
    }
  },
  {
    "page_content": "with MSI-H/dMMR cancers, with the majority (90 patients) having colorectal cancer. Pembrolizumab exhibited manageable adverse reactions, and recent findings from the phase II KEYNOTE-158 study confirmed its robust and durable antitumor efficacy. A complete response was observed in a wide range of tumor types, including small intestine, gastric, ovarian, endometrial, and cholangiocarcinomas. The response was durable, with a 47.5-month median duration of the clinical response. Following the",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:103"
    }
  },
  {
    "page_content": "duration of the clinical response. Following the approval in 2017, continuous evaluation of pembrolizumab has also revealed its efficiency in treating solid tumors with high metastatic tumor mutational burden (TMB-H). High TMB is defined as the occurrence of more than 10 somatic mutations per megabase and is seen in various histologically unrelated human neoplasms. Based on the rationale that these tumors might be treated more efficiently using immune checkpoint inhibitors than targeting their",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:104"
    }
  },
  {
    "page_content": "immune checkpoint inhibitors than targeting their complex and likely dynamic mutational pattern, pembrolizumab was granted a second accelerated approval by the FDA for patients with TMB-H-positive, unresectable, or metastatic solid tumors in 2020. The rapid and successful implementation of pembrolizumab in practical oncology has led to the development of additional monoclonal antibodies targeting biomarkers involved in the evasion of antitumor immune responses (Table 3). One of these candidates",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:105"
    }
  },
  {
    "page_content": "responses (Table 3). One of these candidates is PD-L1 itself, and humanized monoclonal anti-PD-L1 antibodies, e.g., atezolizumab, have already been developed to block PD-L1’s engagement with inhibitory T-cell proliferation regulators PD-1 and B7, thus preventing T-cell depletion and increasing T-cell-mediated immunity against neoplasms. Atezolizumab has already received FDA approval as the first-line treatment for patients with metastatic non-small-cell lung cancer if they express high levels",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:106"
    }
  },
  {
    "page_content": "lung cancer if they express high levels of PD-L1 or have PD-L1-stained tumor-infiltrating immune cells covering more than 10% of the tumor area and do not possess genomic mutations or rearrangements in epidermal growth factor receptor (EGFR) or ALK. Drug efficacy was evaluated in the IMpower110 clinical trial that compared platinum-based chemotherapy to atezolizumab and documented an impressive improvement in overall survival (OS), with a median OS of 20.2 months compared to the 12.1-month OS",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:107"
    }
  },
  {
    "page_content": "OS of 20.2 months compared to the 12.1-month OS of patients receiving chemotherapy only. In addition to PD-1/PDL-1, antibody-mediated targeting of cytotoxic T-lymphocyte antigen-4 (CTLA-4) has also been developed. Targeted by the human monoclonal antibody ipilimumab, the antibody-mediated ligation of CTLA-4 blocks its interaction with its ligand B7, expressed on antigen-presenting cells, and the blockade of this interaction is believed to facilitate cytotoxic T-lymphocyte activity. On that",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:108"
    }
  },
  {
    "page_content": "cytotoxic T-lymphocyte activity. On that basis, in 2020, the FDA approved ipilimumab as the first-line treatment for patients with non-small-cell lung cancers in combination with nivolumab (another PD-1 inhibitor) if immunohistochemistry confirms PD-L1 expression ≥1% and tumor panel investigations show no presence of EGFR or ALK mutations. Drug efficacy was observed through the CHECKMATE-227 trial, with an overall response rate of 36%. The trial also showed 23% of the patients surviving at",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:109"
    }
  },
  {
    "page_content": "also showed 23% of the patients surviving at least 5 years, which is remarkably significant considering the poor prognosis associated with non-small-cell lung cancers, where the 5-year survival rate is merely 7%. Since CTLA-4 and PD-1 inhibitors act on immune checkpoint regulators in a complementary manner, it is not surprising that their use in combination frequently provokes immune-related adverse reactions. Although the majority of these side effects are mild to moderate and can be well",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:110"
    }
  },
  {
    "page_content": "side effects are mild to moderate and can be well managed with supportive treatments without discontinuing nivolumab and ipilimumab, there have been reports of fatalities due to autoimmune myocarditis, colitis, and myasthenia gravis associated with the use of them as well. The clinical management of these severe side effects is particularly challenging due to the observation that their onset can occur even after drug clearance. To address these challenges, a recent modeling study, based on",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:111"
    }
  },
  {
    "page_content": "challenges, a recent modeling study, based on multiomics investigations, found a close correlation between the number of InDel and point mutations of cancer cells, the amount of tumor-infiltrating lymphocytes, and the risk of immune-related adverse events, highlighting the importance of mutational evaluations of neoplasms before indicating combinatorial immune checkpoint therapies. This modeling also suggests that upon the elevated predicted risk of immune-related adverse events, a reduction in",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:112"
    }
  },
  {
    "page_content": "of immune-related adverse events, a reduction in the dosage of immune checkpoint inhibitors circumvents the unfolding of their severe side effects. The use of bispecific recombinant monoclonal antibodies, like tebotelimab, might be a solution to reduce the severe side effects of combinatorial immune checkpoint inhibitor therapies. Tebotelimab targets both PD-1 and LAG-3 either simultaneously or independently. Its bivalent design ensures individual blocking of PD-1 and LAG-3 from their",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:113"
    }
  },
  {
    "page_content": "individual blocking of PD-1 and LAG-3 from their respective ligands, irrespective of their co-expression. Binding to either PD-1 or LAG-3 promotes cell adherence, thereby increasing the local antibody concentration. Since tumor cells often compensate for the initial pharmacological blockade by inducing secondary checkpoint mediators, the bispecific nature of tebotelimab allows for the effective inhibition of the secondary checkpoint mediator on the same cell. Tebotelimab induces greater T-cell",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:114"
    }
  },
  {
    "page_content": "the same cell. Tebotelimab induces greater T-cell activity and IFN-γ production than monophasic PD-1 or LAG-3 therapies alone or in combination, while exhibiting better tolerance. The potential benefit of dual inhibition of PD-1 and LAG-3 treatments in patients resistant to PD-1 inhibitors, however, is yet to be investigated. Another plausible way to address the challenges that the use of immune checkpoint inhibitors might pose is the use of these medicines in combination with other agents that",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:115"
    }
  },
  {
    "page_content": "medicines in combination with other agents that exploit distinct mechanisms of action (Table 4). Indeed, besides the rapid development of immune checkpoint-targeting medicines, direct tumor drivers have also served as subjects for targeted drug developments. This class of tumor-agnostic agents typically includes small-molecule pharmacological inhibitors that show a high degree of specificity to their dedicated tumor driver targets, so they can complement immune checkpoint-targeting monoclonal",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:116"
    }
  },
  {
    "page_content": "complement immune checkpoint-targeting monoclonal antibodies in combinatorial treatments. Indeed, a recent randomized phase III trial investigating the efficacy of the combination of PD-1, CTLA-4, and BRAF/MEK inhibitors dabrafenib and trametinib in melanoma patients showed significant clinical benefits. Dabrafenib and trametinib have been developed to selectively inhibit mutated BRAF and mitogen-activated protein kinase 1 and 2 (MEK1 and MEK2) through competitive ATP-binding site inhibition",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:117"
    }
  },
  {
    "page_content": "through competitive ATP-binding site inhibition and allosteric blockade, respectively. BRAF mutations have high prevalence in melanomas, papillary thyroid cancers, and non-small-cell lung cancers, although it was also detected in gliomas and gastric cancers. Interestingly, BRAF inhibitors alone, paradoxically, activate the MAPK pathway, fueling the fear of secondary neoplasms. In combination, however, dabrafenib and trametinib effectively block the MAPK pathway and suppress the proliferation of",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:118"
    }
  },
  {
    "page_content": "MAPK pathway and suppress the proliferation of BRAF V600E cells. Accordingly, dabrafenib and trametinib has been approved for use in combination for patients with anaplastic thyroid cancer (ATC) harboring the V600E BRAF mutation, when no other satisfactory treatments are available. Competitive ATP-binding inhibitors selective for mutated kinases have now been developed for various cytoplasmic and receptor kinases and have already found their way into everyday clinical practice. Larotrectinib,",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:119"
    }
  },
  {
    "page_content": "into everyday clinical practice. Larotrectinib, for instance, a highly selective NTRK inhibitor, has already been approved for patients with solid tumors harboring chimeric NTRK genes without a known acquired resistance mutation. Clinical data suggest that Larotrectinib can pass the blood–brain barrier, an important aspect considering the prevalence of NTRK mutations among neoplasms. Indeed, chimeric mutant NTRKs were found in a variety of adult and pediatric neoplasms including infantile",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:120"
    }
  },
  {
    "page_content": "adult and pediatric neoplasms including infantile fibrosarcoma, pediatric papillary thyroid carcinoma, and NSCLC, of which the latter ones can form metastases within the CNS. Unfortunately, Larotrectinib is believed to have high affinity to P-Glycoprotein (P-GP), a well-characterized ABC transporter that is key to the efflux of the blood–brain barrier, suggesting a lower maximum concentration of the agent achievable within the CNS. Other competitive ATP-binding NTRK inhibitors, like",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:121"
    }
  },
  {
    "page_content": "competitive ATP-binding NTRK inhibitors, like entrectinib, however, have weaker P-GP affinities, allowing higher brain-to-plasma concentration ratios. Indeed, clinical data showed a complete response in patients with brain metastases of NTRK-positive lung cancer as well as significant disease reduction in NTRK-positive glioneuronal tumors following entrectinib exposure, highlighting its effectiveness against both primary and metastatic brain neoplasms. Entrectinib, in addition, has inhibitory",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:122"
    }
  },
  {
    "page_content": "Entrectinib, in addition, has inhibitory effects on both ALK and the receptor tyrosine kinase ROS proto-oncogene 1 (ROS1), extending its therapeutic applications beyond NTRK-mutated tumors. Indeed, in clinical trials, efficacy has been documented in both NTRK-mutated and mutated ROS1-harboring neoplasms. Recently, another highly selective ATP-competitive inhibitor for RET, selpercatinib, has been approved by the FDA for treating tumors positive for mutant RET alleles. Positive responses to",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:123"
    }
  },
  {
    "page_content": "for mutant RET alleles. Positive responses to selpercatinib have been reported in various tumors including pancreatic adenocarcinoma, salivary, colorectal, ovarian, breast, and small intestine cancers, soft-tissue sarcomas, bronchial carcinoids, and cholangiocarcinomas alike. Further details on the FDA-approved tumor-agnostic drugs are provided in Table 3. ## 3.2. Future Perspectives Besides the tyrosine kinase and immune checkpoint receptors, significant efforts have been made in developing",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:124"
    }
  },
  {
    "page_content": "significant efforts have been made in developing agents targeting receptors belonging to other functional receptor classes. CD137 (also known as 4-1BB or tumor necrosis factor receptor superfamily member 9), for instance, is a costimulatory molecule transiently expressed on the surface of various leukocytes, including activated T cells and natural killer (NK) cells. Activation of CD137 depends on its ligation with CD137L, a trimer expressed on antigen-presenting cells. This interaction induces",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:125"
    }
  },
  {
    "page_content": "cells. This interaction induces downstream pathways that are crucial for antitumor responses. Upon CD137 activation, CD8+ cytotoxic T cells receive potent signals promoting their proliferation, cytolytic effector functions, and survival, while CD137 ligation in NK cells fosters cytokine release and cytolytic functions. Clinically, CD137 ligation seems to be particularly promising since data suggest that CD137L binding can restore the antitumor capacity of exhausted CD137+ CD8+ T cells, making",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:126"
    }
  },
  {
    "page_content": "capacity of exhausted CD137+ CD8+ T cells, making CD137 a potential target for tumor-agnostic immunotherapy. Unlike the first developed anti-CD137 IgG4 monoclonal antibody urelumab and the IgG2 monoclonal antibody utomilumab, which have severe hepatotoxicity and weaker agonistic functions, respectively, the novel human recombinant IgG4 monoclonal antibody, HuB6, demonstrated effective antitumor activity without systemic toxicity in distinct animal tumor models. HuB6 has similar affinity for",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:127"
    }
  },
  {
    "page_content": "tumor models. HuB6 has similar affinity for human 4-1BB to that of utomilumab but binds to a unique epitope within CD137 and shows greater agonistic activity. Despite being IgG4 recombinants, like urelumab, HuB6 exhibits higher safety profiles in vivo, which can be attributed to variations in epitope binding. Urelumab attaches to an epitope that orients its Fc domain for easy ligation with FcγR, potentially enhancing antibody-dependent cell-mediated cytotoxicity and complement-dependent",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:128"
    }
  },
  {
    "page_content": "cytotoxicity and complement-dependent cytotoxicity. However, stronger immune cell activation, especially in non-tumor tissues, can trigger autoimmune responses leading to severe hepatotoxicity. In contrast, utomilumab binds to an epitope closer to the cell surface, positioning the antibody parallel to the membrane, thereby hindering its interaction with FcγR, potentially leading to its limited agonistic function. HuB6, on the other hand, presents with moderate interaction with FcγR, ranging",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:129"
    }
  },
  {
    "page_content": "with moderate interaction with FcγR, ranging between urelumab and utomilumab. This moderate binding provides sufficient affinity to induce downstream signaling and immune activation without overstimulating the immune system. Furthermore, IgG4 generally elicits a greater interaction with immune cells via FcγR interaction than IgG2, which may enhance the agonistic activity of HuB6 despite its similar affinity for human 4-1BB to utomilumab. In addition to being an efficacious monotherapy, HuB6",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:130"
    }
  },
  {
    "page_content": "to being an efficacious monotherapy, HuB6 also exerted an enhanced antitumor effect in combination with other immunotherapies, such as anti-PD-1, indicating broader clinical applications. This promising antitumor efficacy has led to HuB6’s approval for clinical trials investigating various malignant types in addition to colorectal cancer. Understanding the correlation between the targeted epitopes and the clinical efficacy of monoclonal antibodies, like in the case of targeting CD137, is",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:131"
    }
  },
  {
    "page_content": "like in the case of targeting CD137, is critical to improve the clinical outcome of these novel tumor-agnostic methodologies. Human epidermal growth factor receptor 2 (HER2), for instance, has been heavily studied as a target for monoclonal antibodies, since its overexpression is not only found in breast and gastric neoplasms, but it might be present in non-small-cell lung cancer and colorectal cancer as well. In addition, HER2 mutations have been associated with a more aggressive tumor",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:132"
    }
  },
  {
    "page_content": "have been associated with a more aggressive tumor progression in younger populations. As part of these efforts, a bispecific monoclonal antibody, Zenocutuzumab, has also been recently developed for treating cancers with mutated HER2. Zenocutuzumab is a humanized immunoglobin that contains two distinct Fab arms targeting both HER2 and HER3, employing the so-called dock and block mechanism. The HER2-targeting arm initially binds to HER2 which, usually, is expressed more abundantly on the cell",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:133"
    }
  },
  {
    "page_content": "usually, is expressed more abundantly on the cell surface. This not only increases the local concentration of the antibody but also positions the HER3-targeting arm to block neuregulin 1 (NGRI) from binding to HER3. NRG1 primarily binds to HER2 and HER3, leading to heterodimer formations and subsequent stimulation of oncogenic signaling. Mutated NGR1 has been associated with numerous malignancies including lung, breast, ovarian, prostate, and pancreas. Thus, the Zenocutuzumab-mediated blockade",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:134"
    }
  },
  {
    "page_content": "Thus, the Zenocutuzumab-mediated blockade of NGR1 ligation prevents the conformational change of HER3 required for heterotrimerization with HER2 and NGR1, consequently inhibiting downstream tumor-inducing signaling. So far, Zenocutuzumab has been tested in three patients suffering from NRG1 fusion-positive cancers. Two of the patients with pancreatic cancer experienced tumor regression and continued the therapy for 19 and 11 months, respectively. The third patient with driver-negative",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:135"
    }
  },
  {
    "page_content": "The third patient with driver-negative non-small-cell lung cancer experienced a partial response. The drug is overall well tolerated among the patients, with diarrhea being the most reported adverse drug reaction. As of April 2024, a global, multicenter phase I/II clinical trial is pending to evaluate the efficacy of Zenocutuzumab further. Parallel HER2-directed antibodies are also being developed to serve as delivery vehicles for various anticancer compounds. Indeed, as of 2024, the FDA",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:136"
    }
  },
  {
    "page_content": "anticancer compounds. Indeed, as of 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive tumors, even if already pretreated or with no alternative treatment options available. Trastuzumab deruxtecan is an antibody–drug conjugate consisting of a humanized anti-HER2 antibody linked with a potent cytotoxic drug via a cleavable, peptide-based linker. Once the drug binds to HER2-expressing tumor cells, the linker is",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:137"
    }
  },
  {
    "page_content": "to HER2-expressing tumor cells, the linker is cleaved, releasing the cytotoxic drug. The peptide-based linker is thought to be selectively cleaved by lysosomal enzymes, which are upregulated in the tumor microenvironment. This drug inhibits topoisomerase I through the stabilization of DNA–topoisomerase complexes, resulting in double-strand breaks and subsequent destruction of neoplasms. It is believed that the localized effect of the drug limits systemic toxicity in normal cells. With our",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:138"
    }
  },
  {
    "page_content": "systemic toxicity in normal cells. With our expanding knowledge of the molecular constellation of human neoplasms, new concepts continuously emerge for the development of novel therapeutic modalities. In addition to directly leveraging our immune surveillance against neoplasms, emerging therapeutic treatments focus on interfering with additional aspects of the cellular physiology, like apoptosis. One of these candidate targets is myeloid cell leukemia-a (MCL1), a member of the BCL2 family that",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:139"
    }
  },
  {
    "page_content": "(MCL1), a member of the BCL2 family that regulates intrinsic apoptotic pathways via a series of signaling cascades or through mitochondrial apoptogenic factors. Given the pivotal role of the BCL2 family, it is not surprising that its disruption would contribute to tumorigenesis and drug resistance. Indeed, MCL1 is often upregulated in various solid tumors, particularly in melanomas where its increased expression correlates with poor response to cancer therapies due to upregulation of",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:140"
    }
  },
  {
    "page_content": "to cancer therapies due to upregulation of Myeloid-derived suppressor cells (MDSCs). An increased number of MDSCs are believed to contribute to the immune evasion of tumor cells by altering the tumor microenvironment through the secretion of immunosuppressive agents such as interleukin-10, VEGF, and reactive oxygen species and increased expression of cell surface receptors that suppress T-cell activity. On this basis, recent investigations into BH3 mimetics, a new class of drug consisting of",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:141"
    }
  },
  {
    "page_content": "BH3 mimetics, a new class of drug consisting of small-molecule inhibitors that selectively inhibits anti-apoptotic members through mimicking the action of pro-apoptotic family members, have shed light on potential therapeutic use of targeting apoptosis regulators like MCL1. Indeed, S64315, an MCL1 inhibitor, has gained attention for its hypothesized ability to decrease MDSC frequency through impeding MCL1 expression. Studies have shown that S64315 monotherapy reduces MDSC frequency in mouse",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:142"
    }
  },
  {
    "page_content": "monotherapy reduces MDSC frequency in mouse models, leading to improved CD8+ T-cell function. Moreover, S64315 demonstrated greater efficacy in combination therapy with anti-PD-1, effectively inhibiting melanoma growth and enhancing T-cell activity. However, further research is needed to delineate optimal treatment strategies using MCL1 inhibitors, since their current generation shows dose-dependent cardiac toxicity due to high expression levels of MCL1 in cardiomyocytes. Focusing on the TME,",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:143"
    }
  },
  {
    "page_content": "of MCL1 in cardiomyocytes. Focusing on the TME, many macrophage-targeted therapies are currently in clinical trials for various tumor types. Inhibition of the CSF1 receptor is believed to deplete TAMs and/or modify their functions within the TME, while a pharmacological blockade of CC-motif chemokine ligand 2 (CCL2) or CC-chemokine receptor 2 (CCR2) might prevent TAM recruitment into the TME. CD47/SIRPα complex antagonists are also in the test phase to enhance the TAM-mediated phagocytosis of",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:144"
    }
  },
  {
    "page_content": "phase to enhance the TAM-mediated phagocytosis of cancer cells as well as inhibitors of PI3Kγ and TREM2 proteins to reprogram TAMs toward antitumor phenotypes. Pharmacological intervention of TAM physiology is predicted to affect TME on an intercellular level as well. Indeed, administration of costimulatory molecules, like CD40, is expected to enhance reactivity of the immune system via T-cell activation. To further support T-cell reactivity against tumor cells, strategies to manipulate DCs are",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:145"
    }
  },
  {
    "page_content": "tumor cells, strategies to manipulate DCs are also in the development pipeline, including the use of FLT3L to promote DC expansion and survival in vivo or the modulation of DC activity with GM-CSF. To expand the DC population, the use of DC vaccines to enhance antitumor immunity is also under investigation. Targeting cancer-associated fibroblasts as part of a strategy for tumor-agnostic anticancer therapy is also the focus of current studies. One promising approach involves inhibiting",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:146"
    }
  },
  {
    "page_content": "One promising approach involves inhibiting fibroblast activation protein (FAP), given that FAP-expressing CAFs are linked to immunosuppression in various preclinical models and human samples. Additionally, since CAF activation and function are regulated by signaling pathways such as Hedgehog, NFκB, CXCR4, FGFR, and TGFβ, specific inhibitors targeting these pathways are currently being evaluated in clinical trials. Alternative strategies to depleting CAFs include reprogramming or normalizing",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:147"
    }
  },
  {
    "page_content": "CAFs include reprogramming or normalizing them using vitamin D or vitamin A. For example, treating pancreatic cancer preclinical models with a vitamin D analog has been shown to revert CAFs to their quiescent stellate cell state, thereby enhancing antitumor efficacy. Moreover, recent studies have highlighted that targeting a specific subset of CAFs expressing CD10 and GPR77 can increase chemotherapy sensitivity in breast cancer models. These diverse approaches underscore the potential of",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:148"
    }
  },
  {
    "page_content": "diverse approaches underscore the potential of CAF-targeted therapies in improving cancer treatment outcomes. # 4. Discussion In recent years, there has been a striking rejuvenation in cancer treatment, characterized by a profound shift in therapeutic strategies from targeting specific tumors or molecular traits to concentrating on specific molecules irrespective of tumor origin. Throughout this transformative period, the trajectory of cancer treatment was intimately intertwined with the",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:149"
    }
  },
  {
    "page_content": "treatment was intimately intertwined with the relentless progress of diagnostic technologies, from the inception of microscopy in pathology to the cutting-edge tools of modern molecular biology. The journey into the realm of precision oncology began in the late 1980s when the discovery of human epidermal growth factor-2 (HER2) overexpression or amplification in breast cancer emerged as a pivotal breakthrough. Initially identified through immunohistochemistry (IHC) and subsequently confirmed by",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:150"
    }
  },
  {
    "page_content": "(IHC) and subsequently confirmed by in situ hybridization (ISH) techniques, this revelation paved the way for the development of trastuzumab, a humanized antibody targeting HER2. Its groundbreaking approval by the Food and Drug Administration (FDA) in 1998 marked a significant milestone in cancer treatment. Following this achievement, strides were made in the development of targeted therapies. Noteworthy examples include imatinib, which inhibits the BCR/ABL tyrosine kinase in chronic myeloid",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:151"
    }
  },
  {
    "page_content": "the BCR/ABL tyrosine kinase in chronic myeloid leukemia (CML), and gefitinib, targeting the epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC). A pivotal advancement in reshaping cancer treatment paradigms came with the landmark achievement of the first human genome sequencing in 2001. Yet it was the subsequent emergence of NGS techniques around the same period that truly revolutionized the field, enabling rapid, cost-effective, and extensive parallel sequencing of",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:152"
    }
  },
  {
    "page_content": "and extensive parallel sequencing of DNA and RNA. The widespread integration of modern molecular biology methodologies has provided deeper insights into the intricate molecular landscape of cancer, uncovering a myriad of mutations, some driving selective growth advantages while others remain bystanders. This vast pool of molecular data has undeniably enriched the field of oncology. However, it has also introduced complexities, as distinguishing between driver and non-driver mutations is not",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:153"
    }
  },
  {
    "page_content": "between driver and non-driver mutations is not always straightforward, and not all driver mutations are amenable to targeted therapies. Nevertheless, in certain cancer types, the identification of molecular subgroups based on specific driver mutations has led to the development of tailored targeted therapies, resulting in significant prognostic improvements. The advent of immunotherapy has introduced a formidable new weapon against cancer as well. In select cases, immunotherapy has demonstrated",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:154"
    }
  },
  {
    "page_content": "In select cases, immunotherapy has demonstrated remarkable and enduring responses, highlighting its potential to engage the immune system and evoke robust tumor responses, including through interactions involving amino acid residues. The expansive growth of precision oncology and immune oncology has ushered in two distinct currents in cancer research: combination therapies and molecular-specific/tumor-agnostic treatments. Recognizing that most cancers arise from a complex interplay of molecular",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:155"
    }
  },
  {
    "page_content": "arise from a complex interplay of molecular irregularities, investigators have delved into combination therapies, such as pairing chemotherapy with targeted agents, chemotherapy with immunotherapy, or various combinations of immunotherapy agents. The objective is to heighten treatment efficacy and circumvent potential resistance mechanisms, yielding promising outcomes across diverse cancer types. However, while combination therapies have demonstrated notable advantages, their success may not",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:156"
    }
  },
  {
    "page_content": "notable advantages, their success may not solely stem from synergistic drug interactions. Instead, it could be attributed to a broader treatment spectrum, encompassing different patient subgroups that are responsive to various therapeutic approaches. This approach, however, may entail a “loss of precision”, potentially leading to overtreatment among certain patient subsets. On the contrary, molecular-specific/tumor-agnostic therapies have emerged primarily in response to two specific clinical",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:157"
    }
  },
  {
    "page_content": "primarily in response to two specific clinical dilemmas. Firstly, they address cases where a tumor exhibits a molecular abnormality for which a targeted therapy exists but is typically used for other tumor types. Secondly, they cater to instances where rare mutations/abnormalities with potential treatment options are identified across various tumor types, including those considered rare or ultra-rare. However, both scenarios often involve small sample sizes, making the traditional approach of",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:158"
    }
  },
  {
    "page_content": "sample sizes, making the traditional approach of single-histology trials impractical. Consequently, there has been a rise in off-label use of molecularly targeted agents, resulting in numerous promising case reports. Yet these reports are inherently biased, as negative outcomes from individual cases tend to be underreported. To address these challenges, master protocols have been devised, particularly histology-agnostic/aberration-specific basket and “n-of-1” trials encompassing multiple",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:159"
    }
  },
  {
    "page_content": "basket and “n-of-1” trials encompassing multiple subgroups or studies involving patients with similar or diverse diseases to assess the efficacy of one or more therapies. These protocols have gained considerable traction and have been embraced by regulatory authorities in recent years. They offer a pathway to overcome the limitations posed by small sample sizes, facilitating more rigorous evaluation of novel therapies. Basket trials epitomize a master protocol approach, scrutinizing the",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:160"
    }
  },
  {
    "page_content": "a master protocol approach, scrutinizing the effectiveness of a solitary drug across patients afflicted with diverse diseases but united by a shared molecular anomaly, operating through parallel sub-studies. Rooted in the traditional phase I dose escalation design, these trials pioneer inclusive enrollment, disregarding tissue type, to establish a recommended dosage—a strategy historically employed to pave the way for subsequent phase studies targeting specific histologies. Embracing the notion",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:161"
    }
  },
  {
    "page_content": "specific histologies. Embracing the notion that biomarkers can prognosticate the response to targeted therapy regardless of tumor histology is pivotal for the advancement of tissue-agnostic treatments. Basket trials not only enable the examination of drugs within molecularly defined subgroups but also validate the predictive prowess of biomarkers. Furthermore, they unravel contextual nuances, recognizing histology as a crucial variable: the disease-specific milieu surrounding a targetable",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:162"
    }
  },
  {
    "page_content": "disease-specific milieu surrounding a targetable mutation may influence drug efficacy. Variations in tumor types can redefine the significance of molecular anomalies owing to diverse oncogenic pathways and resistance mechanisms. Moreover, histology-specific factors, such as tumor microenvironments, intricately shape drug delivery and immunosurveillance. Despite their significance, basket trials encounter notable challenges. Their rarity often translates into small sample sizes, undermining the",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:163"
    }
  },
  {
    "page_content": "into small sample sizes, undermining the robustness of conclusions drawn. Subgroups may suffer from scant participant numbers, further complicating result reliability. Predominantly conducted as phase I/II trials, they primarily focus on activity and safety, sidelining efficacy assessments. While randomized controlled trials remain indispensable for drug approval, in the case of exceedingly rare conditions or drugs demonstrating promising early efficacy, a randomized approach may prove",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:164"
    }
  },
  {
    "page_content": "early efficacy, a randomized approach may prove impractical or dispensable for registration. Basket trials offer substantial value in exploring rare cancers or mutations characterized by a single, low-complexity driver mutation. Conversely, common cancers exhibit a multifaceted molecular landscape, governed by numerous genomic, transcriptomic, and proteomic alterations, intricately shaping therapeutic responses. The “n-of-1” trial design, a recent addition to oncology research, aims to delve",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:165"
    }
  },
  {
    "page_content": "addition to oncology research, aims to delve into personalized, molecular-driven treatment strategies tailored to each patient. In this innovative approach, patients are administered a bespoke combination therapy that aligns with their unique molecular profile, necessitating the involvement of an expert tumor molecular board to accurately interpret individual patient data. As personalized precision strategies become increasingly intricate in the evolving landscape of oncology, it becomes",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:166"
    }
  },
  {
    "page_content": "in the evolving landscape of oncology, it becomes imperative to integrate real-world data, expansive registries, and comprehensive observational trials. This integration is vital for elevating the standard of evidence required for future approvals in the field. # 5. Glossary ELISAs—enzyme-linked immunosorbent assays—are an immunologic assay used to detect antibodies, antigens, and proteins. In sandwich ELISA, the plate is first coated with the capture antibody and then the sample is added to",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:167"
    }
  },
  {
    "page_content": "capture antibody and then the sample is added to the plate, and any antigen in the sample will then bind to the capture antibody. A detection antibody is then added which is labeled with an enzyme that will convert to a color for detection. There are other types of ELISA, including competitive, indirect, and direct, which differ in the methods of detection. Objective/Overall response rates—the proportion of patients in the trial who responded to the agent being measured. Disease control",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:168"
    }
  },
  {
    "page_content": "to the agent being measured. Disease control rates—the percentage of patients whose disease has remained stable or has decreased over a period. Duration of response—the length of time during which a tumor responds to the treatment without further growth or progression. Progression-free survival—the length of time during which a person lives without disease progression, such as tumor growth or metastasis. Median duration of the response—the length of time from initial treatment until half of the",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:169"
    }
  },
  {
    "page_content": "of time from initial treatment until half of the patients that responded have experienced disease progression or death. Disease control rate—the percentage of patients with advance disease whose treatment has led to complete response (disappearance of all signs of neoplasm), partial response, (significant decrease in tumor size), or disease stabilization (no significant increase in tumor size). Overall survival—the length of time from the start of a treatment regimen until clinical endpoint",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:170"
    }
  },
  {
    "page_content": "of a treatment regimen until clinical endpoint (i.e., death, disease progression) compared to those in a control group.",
    "metadata": {
      "source": "../data/plain/PMC11201516.plain.txt",
      "id": "../data/plain/PMC11201516.plain.txt:171"
    }
  },
  {
    "page_content": "Artificial intelligence in cancer imaging: Clinical challenges and applications Abstract",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:0"
    }
  },
  {
    "page_content": "Judgement, as one of the core tenets of medicine, relies upon the integration of multilayered data with nuanced decision making. Cancer offers a unique context for medical decisions given not only its variegated forms with evolution of disease but also the need to take into account the individual condition of patients, their ability to receive treatment, and their responses to treatment. Challenges remain in the accurate detection, characterization, and monitoring of cancers despite improved",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:1"
    }
  },
  {
    "page_content": "and monitoring of cancers despite improved technologies. Radiographic assessment of disease most commonly relies upon visual evaluations, the interpretations of which may be augmented by advanced computational analyses. In particular, artificial intelligence (AI) promises to make great strides in the qualitative interpretation of cancer imaging by expert clinicians, including volumetric delineation of tumors over time, extrapolation of the tumor genotype and biological course from its",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:2"
    }
  },
  {
    "page_content": "the tumor genotype and biological course from its radiographic phenotype, prediction of clinical outcome, and assessment of the impact of disease and treatment on adjacent organs. AI may automate processes in the initial interpretation of images and shift the clinical workflow of radiographic detection, management decisions on whether or not to administer an intervention, and subsequent observation to a yet to be envisioned paradigm. Here, the authors review the current state of AI as applied",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:3"
    }
  },
  {
    "page_content": "authors review the current state of AI as applied to medical imaging of cancer and describe advances in 4 tumor types (lung, brain, breast, and prostate) to illustrate how common clinical problems are being addressed. Although most studies evaluating AI applications in oncology to date have not been vigorously validated for reproducibility and generalizability, the results do highlight increasingly concerted efforts in pushing AI technology to clinical use and to impact future directions in",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:4"
    }
  },
  {
    "page_content": "clinical use and to impact future directions in cancer care. # Introduction Cancer, as a self‐sustaining and adaptive process that interacts dynamically with its microenvironment, continues to thwart patients, researchers, and clinicians despite significant progress in understanding its biological underpinnings. Given this complexity, dilemmas arise at every stage of cancer management, including reliable early detection; accurate distinction of preneoplastic and neoplastic lesions;",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:5"
    }
  },
  {
    "page_content": "of preneoplastic and neoplastic lesions; determination of infiltrative tumor margins during surgical treatment; tracking of tumor evolution and potential acquired resistance to treatments over time; and prediction of tumor aggressiveness, metastasis pattern, and recurrence. Technological advances in medical imaging and minimally invasive biomarkers hold promise in addressing such challenges across the spectrum of cancer detection, treatment, and monitoring. However, the interpretation of the",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:6"
    }
  },
  {
    "page_content": "monitoring. However, the interpretation of the large volume of data that is generated by these advancements presents a barrage of new potential challenges. As we learn more about the disease itself, we are learning more about the power of tools that are already available to us, which may be used in unprecedented ways. When a neoplastic lesion is initially detected, it needs to be distinguished from nonneoplastic mimickers and classified based on its predicted clinical course and biological",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:7"
    }
  },
  {
    "page_content": "on its predicted clinical course and biological aggressiveness to optimize the type and intensity of treatment. The widespread availability of computed tomography (CT) and magnetic resonance imaging (MRI) have fueled the incidental detection of lesions within the body with unclear clinical significance, which then initiates a cascade of observation, further testing, or empiric intervention. With treatment, which includes cytoreduction through surgery, elicitation of direct and indirect",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:8"
    }
  },
  {
    "page_content": "surgery, elicitation of direct and indirect mechanisms of tumor kill through radiation, and pharmacotherapies, cancers may adapt to the stressors imposed, evolve, and recur. With the radiographic appearance of a lesion that increases in size after treatment, distinction has to be made between neoplasm or tissue response to injury. On recurrence, neoplastic lesions have been shown to harbor new molecular aberrations distinct from the primary tumor, which may confer resistance to medical or",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:9"
    }
  },
  {
    "page_content": "tumor, which may confer resistance to medical or radiation therapies. This is compounded by the innate intratumoral heterogeneity of cancers at the time of initial diagnosis, which is increasingly demonstrated by research but difficult to capture in routine clinical pathological sampling and profiling. The demand for noninvasive imaging, as the most common method to track response to treatment and to suggest critical information about tumors themselves, has never been greater. Traditional",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:10"
    }
  },
  {
    "page_content": "themselves, has never been greater. Traditional radiographic imaging evaluation of tumor relies upon largely qualitative features, such as tumor density, pattern of enhancement, intratumoral cellular and acellular composition (including the presence of blood, necrosis, and mineralization), regularity of tumor margins, anatomic relationship to the surrounding tissues, and impact on these structures. Size‐based and shape‐based measures of the tumor can be quantified in 1‐, 2‐, 3‐dimensional",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:11"
    }
  },
  {
    "page_content": "tumor can be quantified in 1‐, 2‐, 3‐dimensional analyses. These qualitative phenotypic descriptions are collectively termed “semantic” features. In comparison, a rapidly evolving field called radiomics is enabling digital decoding of radiographic images into quantitative features, including descriptors of shape, size, and textural patterns.1 Recent advances in artificial intelligence (AI) methodologies have made great strides in automatically quantifying radiographic patterns in medical",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:12"
    }
  },
  {
    "page_content": "quantifying radiographic patterns in medical imaging data. Deep learning, a subset of AI, is an especially promising method that automatically learns feature representations from sample images and has been shown to match and even surpass human performance in task‐specific applications.2, 3 Despite requiring large data sets for training, deep learning has demonstrated relative robustness against noise in ground truth labels,4 among others. The automated capabilities of AI offer the potential to",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:13"
    }
  },
  {
    "page_content": "capabilities of AI offer the potential to enhance the qualitative expertise of clinicians, including precise volumetric delineation of tumor size over time, parallel tracking of multiple lesions, translation of intratumoral phenotypic nuances to genotype implications, and outcome prediction through cross‐referencing individual tumors to databases of potentially limitless comparable cases. Furthermore, deep learning approaches promise greater generalizability across diseases and imaging",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:14"
    }
  },
  {
    "page_content": "generalizability across diseases and imaging modalities,5 robustness to noise,6 and reduction of errors—eventually leading to earlier interventions and significant improvements in diagnosis and clinical care. Although these studies remain largely in the preclinical research domain, the continued development of such automatic radiographic “radiomic” biomarkers may highlight clinically actionable changes in tumors and drive a paradigm shift in the discrimination of cancer over time. At the dawn",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:15"
    }
  },
  {
    "page_content": "discrimination of cancer over time. At the dawn of this exciting technological transformation, we review the current evidence and future directions for AI approaches as applied to medical imaging in 4 common cancer types: lung, brain, breast, and prostate cancer. We describe clinical problems and limitations in cancer detection and treatment, how current methods are attempting to address these, and how AI can affect future directions. # AI Applications in Cancer Imaging The desire to improve",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:16"
    }
  },
  {
    "page_content": "in Cancer Imaging The desire to improve the efficacy and efficiency of clinical care continues to drive multiple innovations into practice, including AI. With the ever increasing demand for health care services and the large volumes of data generated daily from parallel streams, the optimization and streamlining of clinical workflows have become increasingly critical. AI excels at recognizing complex patterns in images and thus offers the opportunity to transform image interpretation from a",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:17"
    }
  },
  {
    "page_content": "to transform image interpretation from a purely qualitative and subjective task to one that is quantifiable and effortlessly reproducible. In addition, AI may quantify information from images that is not detectable by humans and thereby complement clinical decision making. AI also can enable the aggregation of multiple data streams into powerful integrated diagnostic systems spanning radiographic images, genomics, pathology, electronic health records, and social networks. Within cancer imaging,",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:18"
    }
  },
  {
    "page_content": "and social networks. Within cancer imaging, AI finds great utility in performing 3 main clinical tasks: detection, characterization, and monitoring of tumors (Fig. 1). Detection refers to the localization of objects of interest in radiographs, collectively known as computer‐aided detection (CADe). AI‐based detection tools can be used to reduce observational oversights and serve as an initial screen against errors of omission.7 Formulated within a pattern‐recognition context, regions with",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:19"
    }
  },
  {
    "page_content": "a pattern‐recognition context, regions with suspicious imaging characteristics are highlighted and presented to the reader. CADe has been used as an auxiliary aide to identify missed cancers in low‐dose CT screening,8 detect brain metastases in MRIs to improve radiology interpretation time while maintaining high detection sensitivity,9 locate microcalcification clusters in screening mammography as an indicator of early breast carcinoma,10 and more generally has improved radiologist sensitivity",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:20"
    }
  },
  {
    "page_content": "generally has improved radiologist sensitivity for detecting abnormalities.11 Characterization broadly captures the segmentation, diagnosis, and staging of tumors. It also can extend to include prognostication based on a given ailment as well as outcome prediction based on specific treatment modalities. Segmentation defines the extent of an abnormality. This can range from basic 2‐dimensional (2D) measurements of the maximal in‐plane tumor diameter to more involved volumetric segmentations in",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:21"
    }
  },
  {
    "page_content": "to more involved volumetric segmentations in which the entire tumor and possible surrounding tissues are assessed. Such information can be used in subsequent diagnostic tasks as well as dosage administration calculations during radiation planning. In current clinical practice, tumors are typically manually defined, with associated limitations including interrater bias,12 inconsistent reproducibility even among experts,13, 14 and consumption of time and labor. Although manually traced",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:22"
    }
  },
  {
    "page_content": "of time and labor. Although manually traced segmentation frequently is used as the basis for judging the accuracy of automated segmentation algorithms, it has the potential to neglect subclinical disease and restrict the region of analysis to human bias. AI has the potential to increase the efficiency, reproducibility, and quality of tumor measurements dramatically with automated segmentation. Finally, with the rapid expansion of computing speed and the increased efficiency of AI algorithms, it",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:23"
    }
  },
  {
    "page_content": "and the increased efficiency of AI algorithms, it is likely that future analysis of cancer lesions will not require a separate segmentation step, and whole‐body imaging data could be evaluated directly by AI algorithm. A whole‐body approach also can allow an analysis of organ structures that may be pathological but are not apparent to human vision. On radiologic data, the subsequent diagnosis of suspicious lesions as either benign or malignant ultimately results in a visual interpretation by",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:24"
    }
  },
  {
    "page_content": "ultimately results in a visual interpretation by radiologists. Clinically, human experience and expertise are applied to solving such problems using subjective, qualitative features. By comparison, computer‐aided diagnosis (CADx) systems use the systematic processing of quantitative tumor features, allowing for more reproducible descriptors. CADx systems have been used to diagnose lung nodules in thin‐section CT15 as well as prostate lesions in multiparametric MRI,16 in which inconsistencies in",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:25"
    }
  },
  {
    "page_content": "MRI,16 in which inconsistencies in interpretation among human readers have been observed.17, 18 Characterization also includes staging, in which tumors are classified into predefined groups based on differences in their cancer’s appearance and spread that are informative for the expected clinical course and treatment strategies. The most widely used cancer staging system is the TNM classification,19, 20 with other schemes applied for specific organs such as the central nervous system (CNS).",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:26"
    }
  },
  {
    "page_content": "organs such as the central nervous system (CNS). Recent studies have extended systems to perform staging by assessing tumor extent and multifocality in breast MRI,21 whereas others have developed automated lesion volume measurement tools in contrast‐enhanced magnetic resonance mammography (MRM).22 An additional level of characterization interrogates the biological characterization of tumors. The emerging field of “imaging genomics” correlates radiographic imaging features with biological data,",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:27"
    }
  },
  {
    "page_content": "imaging features with biological data, including somatic mutations, gene expression, chromosome copy number, or other molecular signatures. The maturity of genomics analyses, from a data standpoint, provides synergistic opportunities for AI‐based imaging efforts.23 Finally, AI can play increasing roles in monitoring changes in a tumor over time, either in natural history or in response to treatment. Traditional temporal monitoring of tumors often has been limited to predefined metrics including",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:28"
    }
  },
  {
    "page_content": "has been limited to predefined metrics including tumor longest diameter measured through the established Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization (WHO) criteria for estimating tumor burden and determining treatment response. In addition to being criticized as oversimplifying the complex tumor geometry captured through sophisticated imaging instruments,24 the generalizability and efficacy of such criteria have been questioned, as in the case of osseous",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:29"
    }
  },
  {
    "page_content": "have been questioned, as in the case of osseous lesions, for which chemotherapy—which has proven to improve survival—does not result in radiographic responses as measured by RECIST.25 AI‐based monitoring, however, is able to capture a large number of discriminative features across images over time that go beyond those measured by human readers. Although the seemingly disparate constituents of computer‐aided monitoring are active areas of research (computer‐aided registration of temporal images,",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:30"
    }
  },
  {
    "page_content": "(computer‐aided registration of temporal images, segmentation, and diagnosis), the field is still in its infancy, with applications yet to surface. In addition to imaging, other minimally invasive biomarkers also are being developed for cancer diagnosis and longitudinal tracking of disease. Most notably, liquid biopsies, or the analysis of circulating tumor DNA (ctDNA) released from tumor cells, provide a window into the current and dynamic state of a cancer26 and allows the tracking of disease",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:31"
    }
  },
  {
    "page_content": "of a cancer26 and allows the tracking of disease progression or regression and monitoring for the emergence of targetable or resistance‐associated cancer mutations in near real‐time.27, 28, 29 Thus, it is conceivable that liquid biopsies, combined with radiomics profiling, may significantly improve cancer treatment through the noninvasive characterization of cancer biology for a more accurate assessment of prognosis and real‐time disease monitoring for the purposes of precision medicine. Within",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:32"
    }
  },
  {
    "page_content": "for the purposes of precision medicine. Within the clinic, the aforementioned AI interventions are expected to augment their respective current standard‐of‐care counterparts (Fig. 2). In addition to supporting clinicians with assistive information, multiple efforts also have demonstrated the utility of AI in the clinical decision‐making phases of the workflow.30 With AI‐based integrated diagnostics, combining molecular and pathological information with image‐based findings will add rich layers",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:33"
    }
  },
  {
    "page_content": "with image‐based findings will add rich layers of intelligence to the findings, eventually leading to more informed decision making. # Lung Cancer Imaging Lung cancer is a leading cause of cancer‐related death among men and women globally.31 Despite improvements in survival over the last several decades for most cancer types, lung cancer is falling behind, mainly because the cancer is often well advanced, with limited treatment options by the time it is detected.32 The finding that the majority",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:34"
    }
  },
  {
    "page_content": "it is detected.32 The finding that the majority of patients who are diagnosed with lung cancer will die from their disease can be attributed to the late stage at diagnosis. Medical imaging and AI are expected to play an important role in improving the early detection and characterization of lung cancer by differentiating benign from malignant nodules. Because early stages are often curable, this could drastically improve patient outcomes, minimize overtreatment, and even save lives.",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:35"
    }
  },
  {
    "page_content": "minimize overtreatment, and even save lives. Furthermore, AI also can enhance lung cancer staging and characterization for treatment selection, as well as monitoring treatment response (Table 1).1, 33, 34, 35, 36, 37, 38, 39, 40, 41 ## Clinical Applications of AI in Lung Cancer Screening Until recently, a method to detect early‐stage lung cancer has been elusive even among high‐risk populations. The National Lung Screening Trial (NLST) demonstrated that screening with low‐dose CT (LDCT) was",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:36"
    }
  },
  {
    "page_content": "that screening with low‐dose CT (LDCT) was associated with a significant 20% reduction in overall mortality among high‐risk current and former smokers.32 Lung cancers identified at an early stage, whether by LDCT screening or incidentally, are more amenable to surgical cure and improved survival outcomes compared with lung cancers that are detected upon presentation with clinical symptoms, which are more frequently at a later stage of disease.42 Although the emergence of immune checkpoint",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:37"
    }
  },
  {
    "page_content": "Although the emergence of immune checkpoint inhibitors and targeted therapies have demonstrated durable long‐term survival in subsets of patients, not all patients benefit from such treatment modalities; thus, early detection has the benefit of improving patient survival and may limit the need for extensive treatment. On the basis of these NSLT findings, annual LDCT is now recommended for high‐risk individuals and is second only to primary prevention (smoking cessation) for mitigating lung",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:38"
    }
  },
  {
    "page_content": "(smoking cessation) for mitigating lung cancer mortality, especially for those who have quit smoking but remain at risk. Although the NLST demonstrated a clear benefit for reducing all‐cause mortality, many limitations are associated with the early detection of lung cancer that could be enhanced with advanced computational analyses.32, 43, 44, 45, 46 In the sections below, we describe current problems and limitations in lung cancer screening, how conventional methods are attempting to overcome",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:39"
    }
  },
  {
    "page_content": "conventional methods are attempting to overcome these limitations, and how AI can improve these areas. Lung cancer screening frequently identifies large numbers of indeterminate pulmonary nodules, of which only a fraction are diagnosed as cancer (Fig. 3). In the NLST, 96.4% of the pulmonary nodules identified in LDCT screens were not cancerous. Currently, there are no established approaches to classify whether these nodules are cancerous or benign. Another potential harm of lung cancer",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:40"
    }
  },
  {
    "page_content": "or benign. Another potential harm of lung cancer screening is the overdiagnosis of slow‐growing, indolent cancers, which may pose no threat if left untreated. As such, it is imperative that overdiagnosis needs to be recognized, identified, and significantly reduced.32 Next, if a nodule is detected, clinical guidelines provide for the evaluation and follow‐up of nodules47 but do not offer decision tools for diagnostic discrimination and to predict risk and the probability of future cancer",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:41"
    }
  },
  {
    "page_content": "predict risk and the probability of future cancer development. Although conventional biostatistics and machine‐learning approaches have been used to address many of the limitations in lung cancer screening, AI has the potential to supplant such approaches to identify biomarkers that reduce imaging false‐positive results and more accurately differentiate between benign and cancerous nodules. This can lead to a more quantitative prediction of lung cancer risk and incidence, leading to robust,",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:42"
    }
  },
  {
    "page_content": "cancer risk and incidence, leading to robust, better defined clinical decision guidelines. The majority of indeterminate pulmonary nodules are incidentally detected (ie, they are not encountered during screening but in routine cross‐sectional imaging for other diagnostic indications, such as CT angiography),48 and pose a dilemma to patients and their providers. Annually, more than 1.5 million Americans are diagnosed with an incidentally detected nodule49; whereas most of these nodules are",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:43"
    }
  },
  {
    "page_content": "nodule49; whereas most of these nodules are benign granulomas, up to 12% may be malignant.50 The Fleischner Society51 and the American College of Radiology Lung CT Screening Reporting and Data System (Lung‐RADS)52 provide recommendations for the follow‐up and management of these incidentally detected nodules, which usually require follow‐up imaging between 3 and 13 months to confirm growth before intervening with more invasive diagnostics (eg, biopsy). These systems are “semantic,” in that they",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:44"
    }
  },
  {
    "page_content": "These systems are “semantic,” in that they describe features that are commonly used in the radiology lexicon to describe regions of interest by human experts. Because they are scored manually, there is high potential for large inter‐reader variability.53 In a recent study, a model incorporating 4 quantitatively scored semantic features (short‐axis diameter, contour, concavity, and texture) conferred an accuracy of 74.3% to distinguish malignant from benign nodules in the lung cancer screening",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:45"
    }
  },
  {
    "page_content": "from benign nodules in the lung cancer screening setting.34 A separate study was conducted to identify semantic features from small pulmonary nodules (less than 6 mm) to predict lung cancer incidence in the lung cancer screening setting and the revealed final model yielded an area under the curve of the receiver operating characteristic of 0.930 based on total emphysema score, attachment to vessel, nodule location, border definition, and concavity.54 Although there was an imbalance between",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:46"
    }
  },
  {
    "page_content": "Although there was an imbalance between malignant and benign nodules in the aforementioned analyses, these studies provide compelling evidence for the utility of semantic features in lung cancer screening. As with nodules detected in the lung cancer screening setting, the standard of care for incidental pulmonary nodules lacks accurate decision tools for predicting malignancy versus benign disease and indolent versus aggressive behavior. Thus, the appropriate management of incidental pulmonary",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:47"
    }
  },
  {
    "page_content": "appropriate management of incidental pulmonary nodules is dictated by the probability of cancer and the potential aggressiveness of its behavior. Prediction of the nature of a nodule may justify diametrically opposing strategies, such as biopsy versus observation. Erroneous prediction carries significant consequences, including a risk of premature mortality from delayed intervention on the one hand and morbidity and mortality resulting from invasive testing on the other. Lung cancer screening",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:48"
    }
  },
  {
    "page_content": "testing on the other. Lung cancer screening also detects cancers that exhibit a wide spectrum of behaviors: some are clinically indolent, and others are aggressive, mandating prompt treatment. One study estimated that greater than 18% of all lung cancers detected by LDCT in the NLST seem to be indolent.43 In 2017, the Arnold Foundation supported a $1 million prize for the automated lung cancer detection and diagnosis challenge. In this challenge, thousands of annotated CT images from The Cancer",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:49"
    }
  },
  {
    "page_content": "thousands of annotated CT images from The Cancer Imaging Archive at the National Cancer Institute (NCI) were provided to the community to train and validate their models. All of the top teams used convolutional neural networks (CNNs) to automatically both detect and diagnose lesions, and the winners had to make their network model publicly available.55 The winning team reported a high performance (log loss = 0.399; in which a perfect model would have a log loss of 0). Although this is",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:50"
    }
  },
  {
    "page_content": "would have a log loss of 0). Although this is encouraging, it is notable that the winning networks require more detailed evaluation of their performance in clinical settings. Furthermore, there was a significant bias, with a 50% cancer prevalence in this challenge, which was higher than the 4% prevalence in a screening population with indeterminate nodules. Although this challenge identified promising methods, it is likely that significant fine tuning will be required before they can have any",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:51"
    }
  },
  {
    "page_content": "tuning will be required before they can have any clinical use. Although the incidence of lung cancer is declining in the United States and most Western nations,56 lung cancer will remain a major public health burden for decades to come. Even after smoking cessation, former smokers remain at increased risk, especially compared with lifetime never smokers, of developing lung cancer. Therefore, improvements in lung cancer screening will remain relevant and important to improve patient outcomes of",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:52"
    }
  },
  {
    "page_content": "and important to improve patient outcomes of this disease. As lung cancer imaging research has evolved from conventional biostatics, to machine learning, to deep learning, we contend that AI could emerge next to develop clinically adoptable approaches, precisely identify those at risk, improve risk prediction of future cancer incidence, discriminate malignant from nonmalignant nodules, and distinguish indolent tumors versus biologically aggressive cancers. ## Characterizing Lung Cancers Using",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:53"
    }
  },
  {
    "page_content": "cancers. ## Characterizing Lung Cancers Using Imaging Lung cancers exhibit a wide spectrum of behaviors, with some that are clinically indolent and others that are aggressive, mandating prompt treatment. Although there are prognostic factors associated with better survival (such as female sex, tumors harboring an epidermal growth factor receptor [EGFR] mutation, early‐stage disease, no regional lymph node involvement, and a good performance status)57 as well as factors associated with poor",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:54"
    }
  },
  {
    "page_content": "status)57 as well as factors associated with poor survival (eg, poor pulmonary function, the presence of cardiovascular disease, male sex, current smoking status, advanced age, and late‐stage tumor),58, 59, 60, 61, 62 these factors have limited clinical utility to address the heterogeneous, dynamic nature of cancer as a “moving target.“ Specifically, a tumor lesion is constantly evolving and diversifying, modifying its phenotype and genomic composition and, through metastatic spread, even its",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:55"
    }
  },
  {
    "page_content": "and, through metastatic spread, even its location. This is even truer when subjected to the selection pressure of therapeutic intervention, in which cancer evolution rapidly explores and exploits resistance mechanisms, potentially even aided by the mutagenic nature of systemic cytotoxic chemotherapy, leaving the treating oncologist chasing a constantly changing disease.63, 64, 65 Image‐based biomarkers, conversely, can noninvasively and longitudinally capture the radiographic phenotype and",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:56"
    }
  },
  {
    "page_content": "capture the radiographic phenotype and characterize the underlying pathophysiology of a tumor. Because of the ease of clinical implementation, size‐based measures, such as the longest diameter of a tumor (eg, RECIST and WHO), are widely used for staging and response assessment. However, sized‐based features and stage of disease have limitations, as these metrics are associated with marked variability in outcomes and response. As such, research efforts to identify semantic features and automatic",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:57"
    }
  },
  {
    "page_content": "to identify semantic features and automatic radiomic features to predict the outcomes of patients with lung cancer have been successful.1, 40, 66, 67, 68 For instance, the CANARY tool (Computer Aided Nodule Assessment and Risk Yield)37 offers semantic‐based risk stratification to identify a potentially vulnerable subset of lung adenocarcinomas that harbor a more aggressive course. Preliminary work has indicated that AI can quantify radiographic characteristics about the tumor phenotype",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:58"
    }
  },
  {
    "page_content": "characteristics about the tumor phenotype automatically and that this information is significantly prognostic in several cancer types, including lung cancer (P < 3.53 × 10−6)69; in addition, it is associated with distant metastasis in lung adenocarcinoma (P = 1.79 × 10−17),40 tumor histologic subtypes (P = 2.3 × 10‐7),68 and underlying biological patterns, including somatic mutations39 and gene expression profiles.38 ## Assessing Intratumor Heterogeneity Through Medical Imaging Medical imaging",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:59"
    }
  },
  {
    "page_content": "Through Medical Imaging Medical imaging also can play an important role in quantifying the intratumor characteristics of lung cancer. Sequencing studies in which multiple, independent samples from the same tumor have been analyzed have demonstrated that intratumor heterogeneity (ITH) is a common feature in solid tumor cancers.70 A tumor consists of billions of independent cancer cells. Low levels of DNA damage or changes in epigenetic regulation are introduced at each cell division, causing",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:60"
    }
  },
  {
    "page_content": "are introduced at each cell division, causing slight changes to the cancer cell genome that increase over time. When a change induces a selective advantage in a particular microenvironment, clonal expansion can give rise to a cancer subclone, with all the cancer cells sharing a single, recent, common ancestor. Genomic ITH, defined as the coexistence of independent cancer subclones within the same tumor, is associated with a poor prognosis in non–small cell lung cancer (NSCLC) and clear cell",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:61"
    }
  },
  {
    "page_content": "non–small cell lung cancer (NSCLC) and clear cell renal cancer.63, 70, 71, 72, 73 However, tumor subclones may be spatially separated and can carry significantly different mutation loads, ranging from highly homogeneous to greater than 8000 heterogeneous mutations differing between individual regions in the same tumor.63, 65 ITH analysis has indicated that, although targetable somatic alterations may appear to be clonal in a single tumor biopsy, they may be entirely absent in additional",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:62"
    }
  },
  {
    "page_content": "biopsy, they may be entirely absent in additional biopsies from different regions of the same tumor.62, 73, 74 This evidence that phenotypic diversification exists within tumors has ramifications for the application of precision medicine techniques based on the molecular characterization of tissue from single‐region biopsies. Because the targets identified in single‐tumor biopsies may be subclonal, therapies against them would be effective only against a subset of the cancer cells, leaving",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:63"
    }
  },
  {
    "page_content": "against a subset of the cancer cells, leaving cancer subclones without the target unharmed (Fig. 4). Different strategies have been proposed to quantify ITH in the clinical setting, including multiregion sequencing of the primary tumor, analysis of circulating tumor DNA, and use of medical imaging data.26, 70, 75 Unfortunately, although multiregion sequencing provides improved measures of the extent of ITH compared with single‐sample analysis,76, 77 it requires a high‐quality tumor specimen of",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:64"
    }
  },
  {
    "page_content": "77 it requires a high‐quality tumor specimen of sufficient size and remains subject to potential sampling bias, with the potential to miss important cancer subclones because of incomplete sampling of the tumor in its entirety. Medical imaging can play an important role in quantifying the intratumor characteristics of lung cancer and improve the ability to capture and quantify ITH. Furthermore, because evolutionary fitness is contextual and depends on the particular microenvironment, it is",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:65"
    }
  },
  {
    "page_content": "depends on the particular microenvironment, it is likely that these environments can be identified by imaging.78 Similar to most tumor‐based biomarkers, there are many limitations, in that they can be subjective to sampling bias because of the heterogeneous nature of tumors and the requirement of tumor specimens for biomarker testing, and the assays often can be timely, expensive, and require large amounts of tissue or tissue analytes.79 In contrast, image‐based features, guided by AI, are",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:66"
    }
  },
  {
    "page_content": "contrast, image‐based features, guided by AI, are available in real time from standard‐of‐care images, do not require timely (and often expensive) laboratory assay testing, are not subject to sampling bias and artifact, and, of course, are noninvasive. And image‐based features represent the phenotype of the entire tumor in 3 dimensions (3D), and not just the portion that was subjected to biomarker testing (ie, from a biopsy).79 ## AI for Assessing Response to Targeted Therapies and",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:67"
    }
  },
  {
    "page_content": "for Assessing Response to Targeted Therapies and Immunotherapies The success of quantitative imaging endpoints based on the RECIST criteria paved the way for the development of AI in oncology, because the widespread adoption of these endpoints as early indicators of survival in clinical trials generated large data sets of CT images with clinical metadata. Retrospective analysis of these clinical trial data sets has been invaluable in meeting the need of AI for big data to enable training and",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:68"
    }
  },
  {
    "page_content": "need of AI for big data to enable training and validating AI algorithms, which otherwise might have been prohibited by the expense and effort necessary to generate these data sets from scratch. In part because of the success of RECIST, quantitative CT analysis is now the workhorse of contemporary oncology,80 creating immediate translational potential for AI predictive models. The strengths of AI are well suited to overcome the challenge posed by the current generation of targeted and",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:69"
    }
  },
  {
    "page_content": "posed by the current generation of targeted and immunotherapies, which can produce a clear clinical benefit that is poorly captured by endpoints based on RECIST. These endpoints rely on the assumption that a successful response to therapy will be reflected by tumor shrinkage and, in particular, the measurement of response based on tumor diameter assumes that tumors are spherical and undergo uniform spatial change after treatment. Targeted therapies and immunotherapies lead to novel patterns of",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:70"
    }
  },
  {
    "page_content": "and immunotherapies lead to novel patterns of response that confound current RECIST‐based endpoints and may contribute to the high failure rate of clinical trials and the cost of drug development. Thus, the ability of AI to quantify the biological processes associated with response other than size answers an urgent need in the field. Currently, response prediction for targeted and immunotherapies is based on biomarkers for immunogenic tumor microenvironment (eg, programmed cell death ligand 1",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:71"
    }
  },
  {
    "page_content": "(eg, programmed cell death ligand 1 [PD‐L1] expression) and mutational status (eg, EGFR). These are acquired via biopsy, which is invasive, difficult to perform longitudinally, and limited to a single region of a tumor. The predictive value of PD‐L1 expression also may be limited. For example, in the KEYNOTE‐189 clinical trial, immunotherapy with pembrolizumab in combination with standard chemotherapy produced a survival benefit in all patients regardless of PD‐L1 expression, even among those",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:72"
    }
  },
  {
    "page_content": "regardless of PD‐L1 expression, even among those with a PD‐L1 tumor proportion score less than 1%, which should indicate a small chance of benefit.81 A growing body of evidence suggests that AI could assess response to immunotherapy through recognition of radiomic biomarkers associated with response. Imaging phenotype was associated with overall survival (OS) in patients with NSCLC after second‐line treatment with anti‐PD1 (nivolumab). In this study, OS was predicted significantly (P =.005) by",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:73"
    }
  },
  {
    "page_content": "OS was predicted significantly (P =.005) by 2 radiomics features at baseline: region dissimilarity (hazard ratio [HR], 0.11; 95% confidence interval [95% CI], 0.03‐0.46 [P =.002]) and entropy (HR, 0.20; 95% CI, 0.06‐0.67 [P =.009]), which indicate a more heterogeneous primary lung tumor with irregular patterns of intensities on contrast‐enhanced CT. Another lung cancer study demonstrated that the prognosis of OS was improved by adding genomic and radiomic information to a clinical model,",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:74"
    }
  },
  {
    "page_content": "and radiomic information to a clinical model, leading to an increase from a 95% CI of 0.65 (Noether P =.001) to a 95% CI of 0.73 (P = 2 × 10−9), and that the inclusion of radiomic data resulted in a significant increase in performance (P =.01).38 These findings indicate that radiomic and genomic biomarkers are complementary, creating a potential role for AI to elucidate predictive associations between their combined data. Although machine learning has been deployed to genetically classify lung",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:75"
    }
  },
  {
    "page_content": "has been deployed to genetically classify lung cancer based on the identification of patterns in microarray gene expression,82 its use to detect radiomic‐genomic correlations predictive of outcome remains understudied.38 AI analysis of quantitative imaging data also may improve the assessment of response to targeted therapy. A decrease in fluorodeoxyglucose uptake by NSCLC tumors treated with bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), identified more",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:76"
    }
  },
  {
    "page_content": "endothelial growth factor (VEGF), identified more patients who responded to treatment than conventional CT criteria (73% vs 18%); in that study, neither positron emission tomography (PET) nor CT was associated with OS (PET, P =.833; CT, P =.557).83 Currently, predicting response to targeted therapy is driven largely by biopsy to assay the status of the mutation being targeted. AI predictive models could supplement this by identifying imaging phenotypes that are associated with mutational",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:77"
    }
  },
  {
    "page_content": "phenotypes that are associated with mutational status. This approach has the advantage of being able to characterize the mutational status of all tumors repeatedly and noninvasively, not merely at the site of the biopsy, which can avoid the lack of predictive power associated with intratumoral heterogeneity and the emergence of distinct acquired resistance mechanisms in separate metastases within the same patient. Support for this approach comes from a quantitative imaging study of patients",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:78"
    }
  },
  {
    "page_content": "from a quantitative imaging study of patients with NSCLC who were treated with gefitinib. Those results indicated that EGFR mutation status could be significantly predicted by the radiomic feature Laws‐Energy (area under the curve [AUC] = 0.67; P =.03).84 Biomarkers must be objectively and reproducibly measurable to serve as criteria for response assessment. AI affords high objectivity through its ability to characterize complex patterns within tumor images without the interobserver variability",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:79"
    }
  },
  {
    "page_content": "images without the interobserver variability associated with visual assessment by human experts. Understanding the measurement error of radiomic features is important to establish the reproducibility of AI predictive models based on them. Different tumor segmentation algorithms introduce variance known to affect the calculation of radiomic features and thus perhaps the performance of AI techniques, which require semiautomatic segmentation.85 Imaging settings, including CT scanners, slice",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:80"
    }
  },
  {
    "page_content": "Imaging settings, including CT scanners, slice thickness, and reconstruction kernels, also affect the calculation of radiomic features.86, 87 Variation in these settings exists within clinical practice and clinical trials and may affect the power and reproducibility of biomarkers developed by AI. The training and validation of CNNs may reduce this effect by selecting predictive features that are reproducible and discarding those that vary between image sets, but this needs to be proven. There",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:81"
    }
  },
  {
    "page_content": "image sets, but this needs to be proven. There is also a tension between the rapid pace of development in the AI field and the need for clinical trial endpoints to maintain historical consistency and achieve validation in large data warehouses before criteria are updated (eg, from RECIST 1.0 to 1.1). Continued progress in the size and appropriateness of public domain cancer data sets is necessary to meet the latter requirement. # CNS Tumor Imaging CNS tumors span a broad spectrum of",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:82"
    }
  },
  {
    "page_content": "Tumor Imaging CNS tumors span a broad spectrum of pathologies, and perhaps are more diverse than tumors of any other organ system in the body. Among tumors arising from or seeding in brain parenchyma, metastases from systemic cancers and gliomas predominate. In addition, a multiplicity of tumors arising from non‐neural tissues that abut the brain are commonly encountered and must be considered within CNS tumors, including meningiomas, pituitary tumors, schwannomas, and lesions of the skull.",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:83"
    }
  },
  {
    "page_content": "tumors, schwannomas, and lesions of the skull. This variegated diorama of diagnoses poses unique demands on clinicians for the accurate assessment of imaging. Three main challenges currently exist during the evaluation of radiologic studies for CNS tumors: 1) accurate diagnosis of the type and extent of disease is tantamount to clinical decision making; 2) reliable tracking of neoplastic disease over time, especially after treatment with its associated effects on surrounding neural tissue,",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:84"
    }
  },
  {
    "page_content": "associated effects on surrounding neural tissue, which may acquire signal characteristics difficult to distinguish from tumor; and 3) the ability to extract genotype signatures from the phenotypic manifestation of tumors on imaging, as the impact of molecular taxonomy becomes increasingly appreciated in influencing tumor behavior and clinical outcome. The traditional paradigm for patients with tumors entails initial radiologic diagnosis of a mass lesion, a decision to treat or observe based on",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:85"
    }
  },
  {
    "page_content": "lesion, a decision to treat or observe based on clinical factors and surgeon or patient preference, a definitive histopathologic diagnosis only after obtaining tissue, molecular genotyping in centers with such resources, and the determination of clinical outcome only after the passage of time (Fig. 2). Accurate extrapolation of pathologic and genomic data from imaging data alone, similar to what is being developed in the field of imaging genomics, would disrupt this classic paradigm to improve",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:86"
    }
  },
  {
    "page_content": "would disrupt this classic paradigm to improve the guidance of patients using more informed data upfront. Imaging genomics also may shed light on reasons for treatment success and failure across a patient population and in multi‐institutional clinical trials across heterogeneous populations. Furthermore, in locations around the globe with scarce access to expert neuroradiologists, limited encounters with rare CNS tumors, or a lack of molecular profiling, computational analysis of imaging",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:87"
    }
  },
  {
    "page_content": "profiling, computational analysis of imaging through shared network algorithms offers a potentially valuable resource to improve care to all patients with brain tumors. ## Diagnostic Dilemmas in CNS Imaging plays an important role in the initial diagnosis of brain tumors and is a routine part of both initial and subsequent evaluation. The complex imaging features of brain tumors, as well as the frequent genetic heterogeneity within tumor types and the invasive nature of the procedures needed to",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:88"
    }
  },
  {
    "page_content": "the invasive nature of the procedures needed to obtain a tissue diagnosis, give rise to diagnostic dilemmas in this field (Table 2).88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103 In the setting of gliomas, the most common malignant primary brain tumors in adults, cross‐sectional imaging techniques such as CT and MRI provide high‐resolution spatial information as well as tissue contrast, allowing radiologists to characterize different glioma subtypes and grades. AI can",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:89"
    }
  },
  {
    "page_content": "different glioma subtypes and grades. AI can improve the utility of current standard diagnostic imaging techniques by refining the preoperative classification of gliomas beyond what human experts can provide. For example, AI has been applied in the research setting to preoperative MRI to distinguish between low‐grade and high‐grade tumors as well as individual WHO grades by training machine‐learning classifiers using image texture features obtained from spatially coregistered, multimodal MRIs",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:90"
    }
  },
  {
    "page_content": "from spatially coregistered, multimodal MRIs (Table 2).88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103 Furthermore, clinically relevant molecular subtypes of gliomas, such as the presence of an isocitrate dehydrogenase (IDH) mutation, can be identified using machine‐learning methods, including deep CNNs trained on conventional MR images.94, 95, 96 Subtype classification problems are not unique to adult gliomas, however. Conceptually similar work has been done on other brain",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:91"
    }
  },
  {
    "page_content": "similar work has been done on other brain tumors, in which it has been demonstrated that classification algorithms trained on radiomics features extracted from conventional MRI can generate predictive models for pituitary adenoma subtypes91 and pediatric brain tumors (Table 2).88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103 Diagnostic ambiguity also can arise when distinguishing between different tumor types. One key clinical dilemma is when differentiating between primary",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:92"
    }
  },
  {
    "page_content": "dilemma is when differentiating between primary CNS lymphoma and glioblastoma, which can have similar imaging phenotypes. Radiomics models, using image‐based texture features, have been shown to enhance the differences between glioblastoma and primary CNS lymphoma.92, 104 Interestingly, a similar diagnostic dilemma often arises when evaluating histopathology slides of these same 2 disease processes; as CNNs are being applied increasingly to histopathology image classifications in research",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:93"
    }
  },
  {
    "page_content": "histopathology image classifications in research studies across the globe,105 we expect robust predictive models to emerge that address this problem as well. To date, most research applications of AI in brain tumors have focused on addressing challenges in distinguishing between histopathologic and molecular subtypes of brain tumors.89, 92, 96 To accomplish this, AI algorithms are trained using preselected patient populations with the specific tumor subtypes. This approach makes it challenging",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:94"
    }
  },
  {
    "page_content": "subtypes. This approach makes it challenging to integrate diagnostic models into the clinical workflow, because the model’s diagnostic accuracy can be consistent only when the testing population resembles that of the training data. With sufficient training data based on more general patient populations, it is likely that the diagnostic capability of AI will expand to include accuracy differentiation among multiple tumor types as well as nontumor mimickers. ## Tumor Detection and Delineation",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:95"
    }
  },
  {
    "page_content": "mimickers. ## Tumor Detection and Delineation Synergistic with accurate diagnostic differentiation between tumor subtypes is the ability of computational algorithms to automatically detect the presence and extent of the tumor itself. On MRI, which is the most common modality of delineating CNS neoplasms, tumors may manifest with variable levels of contrast enhancement or none at all; may be associated with peritumoral edema or hemorrhage; and may blur in margins from adjacent bone, blood",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:96"
    }
  },
  {
    "page_content": "and may blur in margins from adjacent bone, blood vessels, fat, or surgical packing materials. Furthermore, neural response to treatment, also known as pseudoprogression, contributes an additional layer of complexity in discerning tumor from nontumor, as detailed below. Although these features challenge the automatic detection of CNS tumors, the need to develop robust volumetric algorithms for the analysis of tumor and its adjacent microenvironment remains vital. An escalating cascade of",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:97"
    }
  },
  {
    "page_content": "remains vital. An escalating cascade of studies and methodologies for the semiautomatic and automatic detection of CNS tumors has been published in recent years, largely applied to conventional MR imaging, but also to PET and ultrasound images.106, 107, 108, 109, 110, 111, 112, 113 Although they are used most frequently in the exploratory and research setting, semiautomatic algorithms have been applied to treatment planning for stereotactic radiosurgery,111 quantitating the volume of residual",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:98"
    }
  },
  {
    "page_content": "quantitating the volume of residual tumor after surgery,113 and tracking tumor growth over time.109 One can envision the benefits of a robust, automatic tumor‐detection algorithm in the assessment of patients who have numerous intracranial lesions, such as within the setting of CNS metastases, and their differential growth rate or response to treatment over time. Likewise, in skull‐base lesions, which often are irregularly shaped and extend across intracranial and extracranial compartments,",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:99"
    }
  },
  {
    "page_content": "intracranial and extracranial compartments, automatic volumetric reconstruction may detect sensitive changes in growth that are missed by the casual observer. The near universal accessibility of computational tools for image analysis and the sharing of open‐source code by several researchers promises to accelerate the pace of advancement in this field.114 In addition, publicly available imaging databases offer powerful resources for hypothesis testing and validation, including the Multimodal",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:100"
    }
  },
  {
    "page_content": "testing and validation, including the Multimodal Brain Tumor Image Segmentation challenge (BRaTS) data from the Medical Image Computing & Computer Assisted Intervention (MICCAI) group, The Cancer Imaging Archive, and the Ivy Glioblastoma Atlas Project.115 Ultimately, the fruit of such efforts hopefully will develop tools that minimize interobserver variability in tracking tumors across time and treatments and extract deeper layers of data beyond radiographic phenotype from routine imaging for",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:101"
    }
  },
  {
    "page_content": "radiographic phenotype from routine imaging for CNS tumors. ## Monitoring Response to Treatment In 20% to 30% of patients with glioblastoma who receive standard, upfront radiation with adjuvant temozolomide, enlargement of contrast‐enhancing lesion(s) that stabilize or resolve without changes in treatment are observed and termed pseudoprogression.116 Similarly, approximately 25% of CNS metastases develop necrosis within the irradiated field, manifesting as enlarging enhancement that mimics",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:102"
    }
  },
  {
    "page_content": "manifesting as enlarging enhancement that mimics recurrent tumor after stereotactic radiosurgery of brain metastasis.116, 117 Although many conventional or advanced imaging techniques have been investigated to distinguish true tumor from treatment‐related changes, it remains challenging to spatially characterize heterogeneous tissues that often contain both viable tumor and treatment‐related changes. Combining multiple imaging features using machine‐learning approaches can improve the ability",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:103"
    }
  },
  {
    "page_content": "approaches can improve the ability to construct an accurate tissue classifier that can account for the heterogeneity of treated tumors. Texture features extracted from conventional MRI have been identified to distinguish radionecrosis from recurrent brain tumors.97, 98 Perfusion‐weighted and susceptibility weighted MRI sequences also can be combined to differentiate recurrence from radionecrosis in patients with high‐grade glioma.99 Texture analysis also has been applied to amino acid PET",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:104"
    }
  },
  {
    "page_content": "analysis also has been applied to amino acid PET imaging to diagnose pseudoprogression.100 To provide a more direct historical correlation of tumor and necrotic tissues, voxel‐based evaluation of MRI coregistered to sites of stereotactic biopsy has resulted in a parametric model that correlates with cell counts of the biopsied specimens.118 Overall, most of this research is in the phase of moving from pilot data to validation in clinical trials. Only upon more rigorous proof of the clinical",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:105"
    }
  },
  {
    "page_content": "Only upon more rigorous proof of the clinical utility of such technology can regulatory approval and commercialization be achieved followed by dissemination into widespread clinical use. ## Biologic Characterization of CNS Tumors: Prospects and Promise A molecular taxonomy is being defined for the most common CNS tumors with the wide availability and decreasing cost of next‐generation sequencing. Furthermore, it has been observed that molecular signatures confer prognostic implications beyond",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:106"
    }
  },
  {
    "page_content": "signatures confer prognostic implications beyond standard histopathologic classifications, including for adult and pediatric gliomas, meningiomas, pituitary tumors, craniopharyngiomas, medulloblastomas, and ependymomas. These molecular imprints increasingly guide the frequency of surveillance imaging for a tumor, patient consultation for clinical outcome and recurrence risk, and decisions on the type of treatment to administer (eg, radiation or observation).119, 120, 121 However, such",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:107"
    }
  },
  {
    "page_content": "or observation).119, 120, 121 However, such information is largely determined only from tissue sampling of the tumor after an intervention. In addition, as with systemic cancers, brain tumors harbor incredible molecular heterogeneity within an individual tumor and on recurrence using multifocal sampling and single‐cell sequencing strategies. Such heterogeneity likely contributes to the limited effectiveness of current pharmacotherapeutics against brain tumors and the perceived acquired",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:108"
    }
  },
  {
    "page_content": "against brain tumors and the perceived acquired resistance after a period of apparent disease control. Therefore, a noninvasive method of tracking tumor genotype over time that can capture the entire landscape of tumor heterogeneity offers appeal. Radiomic analysis of CNS tumor imaging has the potential to characterize the phenotype of the entire tumor, rather than a core of the tumor, as is frequently sampled for molecular analysis, and provides a noninvasive window into the internal growth",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:109"
    }
  },
  {
    "page_content": "a noninvasive window into the internal growth pattern of the tumor. Previous works have reported significant connections between imaging features, molecular pathways, and clinical outcomes across brain tumors. The behavior of gliomas is significantly associated with their molecular alterations, especially alterations in IDH1/IDH2, EGFR, O6‐methylguanine‐DNA methyltransferase (MGMT), and chromosomes 1p and 19q. The WHO recognized the significance of molecular stratification in gliomas in its",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:110"
    }
  },
  {
    "page_content": "of molecular stratification in gliomas in its 2016 update on the classification of gliomas.122 Machine‐learning algorithms trained on preoperative MR images have been able to distinguish each of these features with 80% to 95% sensitivity and specificity, including the prediction of glioblastoma subtypes and survival,123",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:111"
    }
  },
  {
    "page_content": "IDH mutation status in high‐grade and low‐grade gliomas,95, 96 the presence of chromosome 1p and 19q loss in low‐grade gliomas,95, 124 MGMT methylation status,93 EGFR amplification status,125 and the presence of EGFR receptor variant III126 as well as EGFR extracellular domain mutations (Fig. 5).96, 127 Moreover, unsupervised deep learning methods are showing promise in discerning molecular subgroups in glioblastoma with differential prognoses.128 In meningioma, benign variants (grade I) most",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:112"
    }
  },
  {
    "page_content": "In meningioma, benign variants (grade I) most commonly carry a mutation in one of several putative oncogenic drivers, whereas high‐grade variants (grade II‐III tumors) harbor a variable number of chromosomal alterations. Radiomic analysis of preoperative MRIs from patients with meningioma revealed the ability of computer‐extracted imaging features to strongly associate with meningioma grade89 and also with certain genomic features (W.L.B. and H.J.W.L.A. et al, unpublished data). In addition,",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:113"
    }
  },
  {
    "page_content": "H.J.W.L.A. et al, unpublished data). In addition, quantitative radiomic features could discern subtleties, such as the number of atypical features associated with grade I meningiomas, beyond the capacity of qualitative radiologist‐rated imaging features.89 Similar radiomic analyses are developing for pituitary tumors,91 craniopharyngiomas, chordomas, and other CNS tumors. Beyond single‐tumor subtype analysis, future efforts need to improve the accuracy and sensitivity such that such methods can",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:114"
    }
  },
  {
    "page_content": "and sensitivity such that such methods can be applied to the clinical setting with confidence, derive more nuanced molecular signatures beyond that of a single or dual marker, and accommodate the artifacts associated with recurrent and post‐treatment disease states to allow for truly longitudinal application of radiomics throughout the course of patients who have CNS tumors. ## Clinical Trial Applications Predictive biomarkers can have important roles in clinical trials because of their ability",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:115"
    }
  },
  {
    "page_content": "roles in clinical trials because of their ability to select patients who are more likely to respond to treatment and thereby improve the chance of detecting clinical benefit and lowering the risk of drug toxicity from ineffective therapies. The best known predictive biomarkers for the treatment of glioblastoma is MGMT promoter status, in which methylated tumor subtypes have shown greater response to alkylating agents.129, 130 Recently, the antiangiogenic treatment of newly diagnosed",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:116"
    }
  },
  {
    "page_content": "the antiangiogenic treatment of newly diagnosed glioblastoma was evaluated in 2 phase 3 clinical trials in which bevacizumab, an antibody targeting VEGF, did not result in improved OS when added to the standard treatment.131, 132 Currently, there is no clinically useful molecular marker predictive of treatment response for antiangiogenic therapy. Imaging‐based biomarkers of treatment response prediction for newly diagnosed, recurrent glioblastoma have been investigated using both conventional",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:117"
    }
  },
  {
    "page_content": "have been investigated using both conventional and advanced modalities. Radiomic imaging predictors of response based on conventional imaging features have been identified using a retrospective, single‐center data set of patients with recurrent glioblastoma who received bevacizumab treatment. In a retrospective evaluation of single‐institution and multi‐institutional, single‐arm data sets, radiomic models were constructed using conventional and diffusion MRI features to differentiate long‐term",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:118"
    }
  },
  {
    "page_content": "diffusion MRI features to differentiate long‐term from short‐term survivors.101, 102 Unsupervised clusters of radiomic features based on nonparametric parameters of preoperative perfusion MRI were first extracted independently from 2 data sets of patients with glioblastoma, and the feature clusters subsequently were combined and evaluated for their association with patient survival outcome.103 The radiomic cluster that was associated with poor survival (HR, >3.0) was associated with mutations",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:119"
    }
  },
  {
    "page_content": "survival (HR, >3.0) was associated with mutations in the angiogenesis and hypoxia pathways. These preliminary investigations were based on patients receiving therapy without the availability of a control treatment arm and thus only establish the prognostic values of these imaging markers. There are several advantages of using clinical trial data, both retrospectively and prospectively, to screen and validate radiomic biomarkers. Because these patient populations are relatively uniform",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:120"
    }
  },
  {
    "page_content": "these patient populations are relatively uniform (including treatment regimen type, dose, and duration as well as imaging assessment timing and frequency during the pretreatment and on‐treatment periods), the predictive accuracy for patient outcome will likely improve. The predictive models constructed in this setting can be applied more readily to future prospective trials that use similar protocols. Recent efforts to standardize imaging acquisition protocols for brain tumor trials also should",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:121"
    }
  },
  {
    "page_content": "protocols for brain tumor trials also should increase the generalizability of radiomic models to different clinical trials and to actual clinical implementation.133 # Breast Cancer Imaging Breast cancer is the most commonly diagnosed cancer and the second most common cause of cancer death in US women.31 The 5‐year survival rates for breast cancer have improved tremendously since the 1980s, likely because of the significant uptake of mammographic screening as well as improvements in breast",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:122"
    }
  },
  {
    "page_content": "screening as well as improvements in breast cancer treatment. Breast cancer is a heterogeneous disease, and tumors vary with respect to etiology, prognosis, and response to therapy. The presence of the estrogen receptor (ER) is important for responses to specific treatments (eg, tamoxifen for patients with ER‐positive disease) and prognosis (poorer outcomes for those with ER‐negative disease) and may define etiologic subtypes. Triple‐negative breast cancers are ER‐negative, progesterone",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:123"
    }
  },
  {
    "page_content": "breast cancers are ER‐negative, progesterone receptor (PR)–negative, and human epidermal growth factor receptor 2 (HER2)–negative. They do not present with the typical signs of malignancy on standard mammography,134 are more likely to be detected as interval and high‐grade tumors, and have a poor 5‐year survival rate. Advances in both imaging and computers have synergistically led to a rapid rise in the potential use of AI in various tasks in breast imaging, such as risk assessment, detection,",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:124"
    }
  },
  {
    "page_content": "imaging, such as risk assessment, detection, diagnosis, prognosis, and response to therapy (Table 3).135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150 ## Breast Cancer Screening: Breast Imaging Reporting and Data System Analog to Digital CADe and CADx in breast cancer imaging have been under development for decades.151, 152, 153 CADe systems specifically for screening mammography interpretation have been in routine clinical use since the late 1990s.153, 154 The",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:125"
    }
  },
  {
    "page_content": "clinical use since the late 1990s.153, 154 The detection of cancer by radiologists is limited by the presence of structure noise (camouflaging normal anatomic background), incomplete visual search patterns, fatigue, distractions, the assessment of subtle and/or complex disease states, vast amounts of image data, and the physical quality of the breast image itself. In computer‐aided detection, the computer aims to locate suspect lesions, leaving the classification to the radiologist. Although",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:126"
    }
  },
  {
    "page_content": "the classification to the radiologist. Although CADe continues to be developed for screening mammography, investigators also have sought to automate the detection of breast lesions on 3D ultrasound, breast MRI, and breast tomosynthesis images by incorporating predefined algorithms as well as novel deep learning methods.155, 156, 157, 158 The motivation for computerized detection on 3D breast images arose with the arrival of 3D ultrasound and MRI for use as adjunct imaging for screening women",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:127"
    }
  },
  {
    "page_content": "for use as adjunct imaging for screening women with dense breast tissue.150 CNNs have been used in medical image analysis since the early 1990s for the detection of microcalcifications in digitized mammograms135 as well as for distinguishing between biopsy‐proven masses and normal tissue on mammograms.159 More recently, deep learning methods have allowed for the computer‐aided detection of breast lesions in breast MRI, ultrasound, and mammography.155, 156, 157, 158 ## Breast Cancer Risk",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:128"
    }
  },
  {
    "page_content": "156, 157, 158 ## Breast Cancer Risk Assessment: Density and Parenchyma Computer vision techniques have been developed to extract the density and characteristics of the parenchyma patterns on breast images to yield quantitative biomarkers for use in breast cancer risk prediction and, ultimately, in personalized screening regimes. Both area‐based and volumetric‐based assessments of density are used to estimate mammographic density, because increased density serves as a breast cancer risk factor",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:129"
    }
  },
  {
    "page_content": "density serves as a breast cancer risk factor as well as provides a masking effect that obscures lesions.160, 161, 162 Breast density refers to the amount of fibroglandular tissue in the breast relative to the amount of fatty tissue. In full‐field digital mammography (FFDM), these tissue types are distinguishable, because fibroglandular tissue attenuates x‐rays much more than fat tissue. Because FFDMs are 2D projections of the breast, 3D percentage density values are estimated. In addition to",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:130"
    }
  },
  {
    "page_content": "density values are estimated. In addition to breast density, there is also evidence that the variability in parenchymal patterns (eg, characterizing the spatial distribution of dense tissue) also is related to breast cancer risk. By using radiomic texture analysis, investigators have characterized the spatial distribution of the gray‐scale levels within regions on FFDM when a skewness measure was incorporated into the analysis of mammograms to describe the density variation.160 Others have used",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:131"
    }
  },
  {
    "page_content": "the density variation.160 Others have used texture analysis and deep learning to discriminate BRCA1/BRCA2 gene mutation carriers (or women with breast cancer in the contralateral breast) from women at low risk of breast cancer and, using almost 500 cases, found that women at high risk of breast cancer have dense breasts with parenchymal patterns that are coarse and low in contrast (AUC, approximately 0.82).149, 163, 164 Further efforts have applied texture analysis to breast tomosynthesis",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:132"
    }
  },
  {
    "page_content": "applied texture analysis to breast tomosynthesis images to characterize the parenchyma pattern for ultimate use in breast cancer risk estimation, with preliminary results indicating that texture features correlated better with breast density on breast tomosynthesis (P =.003 in regression analysis) than on digital mammograms.165 In addition, the characterization of breast parenchymal patterns has also been extended to breast parenchymal enhancement (BPE) on dynamic contrast‐enhanced",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:133"
    }
  },
  {
    "page_content": "enhancement (BPE) on dynamic contrast‐enhanced (DCE)‐MRI.163, 164, 166 In a limited data set of 50 BRCA1/BRCA2 carriers, quantitative measures of BPE were associated with the presence of breast cancer, and relative changes in BPE percentages were predictive of breast cancer development after risk‐reducing salpingo‐oophorectomy (P <.05).167 Deep learning methods are increasingly being evaluated to assess breast density as well as parenchymal characterization, an example of which includes the",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:134"
    }
  },
  {
    "page_content": "an example of which includes the performance assessment of transfer learning in the distinction between women at normal risk of breast cancer and those at high risk based on their BRCA1/BRCA2 status.149 ## AI to Improve Breast Cancer Diagnosis Since the 1980s, various investigators have been developing machine learning techniques for CADx in the task of distinguishing between malignant and benign breast lesions.168 These AI methods for CADx involve the automatic characterization of a tumor,",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:135"
    }
  },
  {
    "page_content": "the automatic characterization of a tumor, which is indicated initially by either a radiologist or a computer. The computer characterizes the suspicious region or lesion and/or estimates its probability of disease, leaving patient management to the physician. With the application of AI methods to breast image data, characteristics of tumor size, shape, morphology, texture, and kinetics can be quantitatively obtained. For example, use of the dynamic assessment of contrast uptake on breast MRI",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:136"
    }
  },
  {
    "page_content": "assessment of contrast uptake on breast MRI allows investigators to quantify cancers in terms of heterogeneity, yielding phenotypes of spatial features and dynamic characteristics.141, 169 For example, entropy is a mathematical descriptor of randomness and provides information on how heterogeneous the pattern is within the tumor, thus describing the heterogeneous pattern of the vascular system uptake (ie, contrast uptake) within tumors imaged on contrast‐enhanced breast MRI. Such analyses",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:137"
    }
  },
  {
    "page_content": "on contrast‐enhanced breast MRI. Such analyses potentially could reflect the heterogeneous nature of angiogenesis and treatment susceptibility, as shown by the NCI’s The Cancer Genome Atlas (TCGA) Breast Cancer Phenotype Group.170 With CADx, both predefined and deep‐learned algorithms have been evaluated. It is interesting to note that investigators have shown that the use of either human‐engineered or deep learning features perform well in the classification of breast lesions in the task of",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:138"
    }
  },
  {
    "page_content": "classification of breast lesions in the task of distinguishing between malignant and benign lesions and that the “fusion” of the 2 methods can yield a statistically significant improvement in performance.145, 146 Across all 3 breast‐imaging modalities (690 DCE‐MRI cases, 245 FFDM cases, and 1125 ultrasound cases), the “fusion” classifier performed best, indicating the potential for the complimentary use of both engineered and deep learning tumor features in diagnostic breast cancer workup",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:139"
    }
  },
  {
    "page_content": "tumor features in diagnostic breast cancer workup (DCE‐MRI: AUC = 0.89 [standard error = 0.01]; FFDM: AUC = 0.86 [standard error = 0.01]; and ultrasound: AUC = 0.90 [standard error = 0.01]).146 Other investigators have used transfer learning with CNNs pretrained on 2282 digitized screen‐films and FFDMs for use in characterizing tumors on 324 breast tomosynthesis volumes, which demonstrated the ability to transfer knowledge of the imaged patterns between the imaging modalities.171 ## Predictive",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:140"
    }
  },
  {
    "page_content": "between the imaging modalities.171 ## Predictive Image‐Based Biomarkers Beyond CADe and CADx,2 other AI applications in breast imaging include assessing molecular subtypes, prognosis, and therapeutic response by yielding predictive image‐based phenotypes of breast cancer for precision medicine. A major area of interest within breast cancer research is the attempt to understand relationships between the macroscopic appearance of the tumor and its environment. These relationships can be extracted",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:141"
    }
  },
  {
    "page_content": "environment. These relationships can be extracted from clinical breast images and the biologic indicators of risk, prognosis, or treatment response. Such an effective development of biomarkers benefits from the integration of information from multiple patient examinations (ie, clinical, molecular, imaging, and genomic data; ie, the other “‐omics” that often are obtained during diagnostic workup and subsequent biopsies). In one collaborative effort through the NCI’s TCGA Breast Phenotype Group,",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:142"
    }
  },
  {
    "page_content": "through the NCI’s TCGA Breast Phenotype Group, multidisciplinary investigators phenotypically characterized 84 solid breast tumors to gain image‐based information on the underlying molecular characteristics and gene expression profiles (Fig. 6).170, 172 Statistically significant associations were observed between enhancement texture (entropy) and molecular subtypes (normal‐like, luminal A, luminal B, HER2‐enriched, basal‐like), even after controlling for tumor size (P =.04 for lesions ≤2 cm;",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:143"
    }
  },
  {
    "page_content": "for tumor size (P =.04 for lesions ≤2 cm; P =.02 for lesions from 42 to ≤5 cm). MRI‐genomic associations also were unveiled, furthering the understanding of genetic mechanisms that regulate the development of tumor phenotypes.146, 170 With regard to predicting a patient’s response to a particular therapeutic treatment, for example, the semimanual delineation of functional tumor volume from breast MRI (141 women: 40 with a recurrence and 101 without) was identified as a predictor of",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:144"
    }
  },
  {
    "page_content": "and 101 without) was identified as a predictor of recurrence‐free survival in patients receiving neoadjuvant therapy in the American College of Radiology Imaging Network (ACRIN) study 6657,173 with demonstrated potential for automation.174 # Prostate Cancer Imaging Prostate cancer is the most frequently diagnosed, noncutaneous male malignancy and the second leading cause of cancer‐related mortality among men in the United States.31 Statistics of prostate cancer frequency, morbidity, and",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:145"
    }
  },
  {
    "page_content": "of prostate cancer frequency, morbidity, and mortality can be examined in many different ways. It is a very common cancer, as it is a “tumor of aging,” but it has a very low disease‐specific mortality, all of which reinforce its characterization as a complex public health concern that impacts a large population. Although prostate cancer is a serious disease, most men diagnosed with prostate cancer do not die of it.175 The 5‐year survival rate for patients with prostate cancer ranges from",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:146"
    }
  },
  {
    "page_content": "for patients with prostate cancer ranges from approximately 30% in patients with metastatic disease to 100% in patients with localized disease. The key clinical problems in prostate cancer diagnosis today include: 1) overdiagnosis and overtreatment resulting from an inability to predict the aggressiveness and risk of a given cancer; and 2) inadequate targeted biopsy sampling, leading to misdiagnosis and to disease progression in men with seemingly low‐risk prostate cancer. In a",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:147"
    }
  },
  {
    "page_content": "men with seemingly low‐risk prostate cancer. In a meta‐analysis,176 the reported rate of overdiagnosis of nonclinically significant prostate cancer was as high as 67%, leading to unnecessary treatment and associated morbidity. Because of this range of clinical behavior, it is necessary to differentiate men who have clinically significant tumors (those with a biopsy Gleason score 7 and/or pathologic volume 0.5 mL)177 as candidates for therapy from those who have clinically insignificant tumors",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:148"
    }
  },
  {
    "page_content": "those who have clinically insignificant tumors and can safely undergo active surveillance. It has been noted that potential survival benefits from aggressively treating early‐stage prostate cancer are undermined by harm from the unnecessary treatment of indolent disease. The biological heterogeneity of prostate cancer leads to different clinical outcomes, ranging from indolent to highly aggressive tumors with high morbidity and mortality, and differences in therapy planning, therapy response,",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:149"
    }
  },
  {
    "page_content": "in therapy planning, therapy response, and prognosis of patients. This is reflected by the incorporation of genomic profiling in the National Comprehensive Cancer Network guidelines, including Decipher (GenomeDx Biosciences, San Diego, California), Oncotype DX Prostate (Genomic Health Inc, Redwood City, California), Prolaris (Myriad Genetics Inc, Salt Lake City, Utah), and others. In parallel with molecular characterization, AI also has the potential to empower clinicians in the detection,",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:150"
    }
  },
  {
    "page_content": "potential to empower clinicians in the detection, localization, characterization, staging, and monitoring of prostate cancer. There are no widespread multicenter trials as yet, and therefore much of the initial work is limited to single‐center, single‐algorithm analyses and on small data sets. However, some groups, such as the National Institutes of Health and MICCAI, are developing infrastructure to allow larger, well annotated data sets to become available for AI development. Computational",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:151"
    }
  },
  {
    "page_content": "available for AI development. Computational methods mostly based on supervised machine learning have been successfully applied to imaging modalities such as MRI and ultrasound to detect suspicious lesions and differentiate clinically significant cancers from the rest. The recent application of deep learning in prostate cancer screening and aggressive cancer diagnosis has produced promising results. Multiparametric magnetic resonance imaging (mpMRI) provides the required soft‐tissue contrast for",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:152"
    }
  },
  {
    "page_content": "provides the required soft‐tissue contrast for the detection and localization of suspicious clinically significant prostate lesions and gives information regarding tissue anatomy, function, and characteristics. Importantly, it has superior capabilities to detect the so‐called “clinically significant” disease—one with a Gleason pattern of 4 or higher (Gleason score ≥7) and/or a tumor volume >0.5 cm3. Recent years have seen a growth in the volume of mpMRI examination of prostate cancer because of",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:153"
    }
  },
  {
    "page_content": "mpMRI examination of prostate cancer because of its ability to detect these lesions and allow targeted biopsy sampling. A large population study from the United Kingdom suggested that the use of mpMRI as a triage before primary biopsy can reduce the number of unnecessary biopsies by one‐quarter and can decrease overdiagnosis of clinically insignificant disease.178 This was further validated in data sets that were smaller than would be considered optimal. In the multinational PRECISION study of",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:154"
    }
  },
  {
    "page_content": "optimal. In the multinational PRECISION study of 500 patients,179 men randomized to undergo mpMRI before biopsy experienced a significant increase in the detection of clinically significant disease over the current standard of care, which uses a 10‐core to 12‐core transrectal ultrasound‐guided biopsy (38% vs 26%). The growing trend toward mpMRI has introduced a demand for experienced radiologists to interpret the exploding volumes of oncological prostate MRIs. Furthermore, reading challenging",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:155"
    }
  },
  {
    "page_content": "prostate MRIs. Furthermore, reading challenging cases and reducing the high rate of interobserver disagreements on findings is a remaining challenge for prostate MRI. In 2015, the European Society of Urogenital Radiology, the American College of Radiology, and the AdmeTech Foundation published the second version of the Prostate Imaging Reporting and Data System (PI‐RADS). This provides guidelines for radiologists in reading and interpreting the prostate mpMRI, which aim to increase the",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:156"
    }
  },
  {
    "page_content": "the prostate mpMRI, which aim to increase the consistency of the interpretation and communication of mpMRI findings. Over the past 10 years, AI models have been developed as CADe and CADx systems to detect, localize, and characterize prostate tumors.180 In conjunction with PI‐RADS, accurate CAD systems can increase the interrater reliability and improve the diagnostic accuracy of mpMRI reading and interpretation.181 In preliminary analyses, it has been shown that the addition of a CADx system",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:157"
    }
  },
  {
    "page_content": "has been shown that the addition of a CADx system can improve the performance of radiologists in prostate cancer interpretation.182, 183 Preliminary work in mpMRI CADx systems focused primarily on classic, supervised machine learning methodologies, including combinations of feature extractors and shallow classifiers. In this category of AI systems, feature engineering plays a central role in the overall performance of the CAD system. Combinations of CADe and CADx systems have been reported that",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:158"
    }
  },
  {
    "page_content": "of CADe and CADx systems have been reported that use intensity, anatomic, pharmacokinetic (pharmacokinetic modeling), texture, and blobness features.184 Pharmacokinetics are the detailed metrics that can be extracted from a time‐signal analysis of intravenous contrast passing through a given volume of tissue. They include parameters such as wash‐in and wash‐out. Texture features also are signal‐based and depend heavily on the imaging technique. Others have use intensity features calculated from",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:159"
    }
  },
  {
    "page_content": "have use intensity features calculated from mpMRI sequences, including T2‐weighted MRI, the apparent diffusion coefficient, high b‐values, diffusion‐weighted MRI, and T2 estimation by proton density mapping,184 or they have only used features extracted from pharmacokinetic analysis and diffusion tensor imaging parameter maps.185 Similar image‐based features were included in CAD systems,186, 187, 188, 189 and many of these systems use support vector machines for classification.185, 187, 190,",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:160"
    }
  },
  {
    "page_content": "vector machines for classification.185, 187, 190, 191, 192 In the past years, deep learning networks, and particularly CNNs, have been revolutionizing investigative research into prostate cancer detection and diagnosis. These methods use different modality types, CNN architectures, and learning procedures to train deep networks for prostate cancer classification and have achieved state‐of‐the‐art performance. Some investigators use CNNs to classify MRI findings with an auto‐windowing mechanism",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:161"
    }
  },
  {
    "page_content": "MRI findings with an auto‐windowing mechanism to overcome the high dynamic range of MR images and normalization,193 whereas others use different combinations of mpMRI images by stacking each modality as a 2D channel of RGB images and use them as training examples.194, 195 Furthermore, 3D CNNs can be designed that use specific MRI‐based parameters such as apparent diffusion coefficient, high b‐value, and volume transfer constant (Ktrans) modalities.196 Deep learning systems have been applied to",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:162"
    }
  },
  {
    "page_content": "Deep learning systems have been applied to localize and classify prostate lesions at the same time.197 Both de novo training194, 196, 197 and transfer learning of pretrained models195 have been successful for training CNNs for prostate cancer diagnosis in MRI. The explicit addition of anatomically aware features to the last layers of CNNs has been used successfully to boost their performance.193, 196 In addition to MRI, AI techniques have achieved promising results by incorporating ultrasound",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:163"
    }
  },
  {
    "page_content": "promising results by incorporating ultrasound data, specifically radiofrequency, for prostate cancer classification. Here again, both classic machine learning approaches198, 199 and deep learning200 have been used to train classifiers to grade prostate cancer in temporal ultrasound data. The results of the ongoing research into the use of AI for the detection and characterization of prostate cancer are promising and demonstrate ongoing improvement. The recent body of research in prostate cancer",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:164"
    }
  },
  {
    "page_content": "The recent body of research in prostate cancer image analysis reveals a transition from feature engineering and classic machine learning methods toward deep learning and the use of large training sets. Unlike lung and breast cancers, clinical routines in prostate cancer have not yet adopted regulated CAD systems. However, the recently achieved results of deep learning techniques on midsize data sets, such as the PROSTATEx benchmark, are promising. It is now evident that there has been a rapid",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:165"
    }
  },
  {
    "page_content": "It is now evident that there has been a rapid growth in prostate MR examination volumes worldwide and increasing demand for accurate interpretations. Accurate CAD systems will improve the diagnostic accuracy of prostate MRI readings, which will result in better care for individual patients, because fewer patients with benign and indolent tumors (false‐positives) will need to undergo invasive biopsy and/or radical prostatectomy procedures, which can lower their quality of life. Conversely, early",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:166"
    }
  },
  {
    "page_content": "lower their quality of life. Conversely, early detection of prostate cancer improves the prognosis of patients who have clinically significant prostate cancer (Gleason pattern 4). Computer‐assisted detection and diagnosis systems for prostate cancer help clinicians by potentially reducing the chances of either missing or overdiagnosing suspicious targets on diagnostic MRIs, although this merits additional validation in trials before routine clinical incorporation. # Challenges and Future",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:167"
    }
  },
  {
    "page_content": "clinical incorporation. # Challenges and Future Directions Despite the reported successes of AI within cancer imaging, several limitations and hurdles must be overcome before widespread clinical adoption. With the increasing demand for CT201 and MR202 imaging, care providers are constantly generating large amounts of data. Standards, including the Picture Archiving and Communication System (PACS) and the Digital Imaging and Communications in Medicine (DICOM), have ensured that these data are",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:168"
    }
  },
  {
    "page_content": "(DICOM), have ensured that these data are organized for easy access and retrieval. However, such data are rarely curated in terms of labeling, annotations, segmentations, quality assurance, or fitness for the problem at hand. The curation of medical data represents a major obstacle in developing automated clinical solutions, because it requires trained professionals, making the process expensive in both time and cost. These issues are exacerbated by data‐hungry methods, including deep neural",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:169"
    }
  },
  {
    "page_content": "by data‐hungry methods, including deep neural networks. Unsupervised203 and self‐supervised204 methods do not require explicit labeling and hence promise to alleviate some of these issues, whereas synthetic data205 can potentially enable a faster route toward curation, address the inevitable class imbalance, and mitigate patient privacy concerns. Standardized benchmarking is of particular importance in the medical domain, especially given the multitude of imaging modalities and anatomic sites,",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:170"
    }
  },
  {
    "page_content": "of imaging modalities and anatomic sites, as well as acquisition standards and hardware. The research community has yet to reach a consensus on specific data sets that can be used for comparing and contrasting efforts in terms of performance, generalizability, and reproducibility, although the volume of medical data being made public is an encouraging move forward.206 Furthermore, access to available data sets should be improved to promote intellectual collaboration. Institutional,",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:171"
    }
  },
  {
    "page_content": "intellectual collaboration. Institutional, professional, and government groups should be encouraged to share validated data to support the development of AI algorithms, which requires overcoming certain fundamental technical, legal, and perhaps ethical concerns.207 For example, the National Institutes of Health recently shared chest x‐ray and CT repositories to help AI scientists.208 Such efforts bear expansion to a much wider audience across disease states. Another limitation includes the",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:172"
    }
  },
  {
    "page_content": "disease states. Another limitation includes the interpretability of AI and the ability to interrogate such methods for reasons behind a specific outcome, as well as the anticipation of failures. Although the current state of research has prioritized performance gains over explainability and transparency, the interpretability of AI is an active area of research.209 The benefits of trust and transparency in AI systems will differ based on their performance, allowing for the identification of",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:173"
    }
  },
  {
    "page_content": "performance, allowing for the identification of failures when AI is subhuman and, consequently, transforming superhuman AI into a learning resource. From a legal standpoint, policy makers have taken note: discussions around improving AI accountability through explanations have recently been debated in the EU General Data Protection Regulation210 and continue to surface in sensitive applications for which an explanation is currently required under the law, or is anticipated to be required in the",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:174"
    }
  },
  {
    "page_content": "the law, or is anticipated to be required in the near future. From an ethical perspective, a question poses itself: What would a Hippocratic Oath for clinically deployed AI systems be, and how would it be enforced? Although data curation and modeling practices are biased in nature, because they take into account specific patient cohorts, a conscious effort must be put into understanding exactly who will be the ultimate beneficiaries and stakeholders of such technology. Algorithms can be",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:175"
    }
  },
  {
    "page_content": "of such technology. Algorithms can be unethical by design211 and might exacerbate the already existing tension between providing care and turning profits. In addition, a safeguard against “learned helplessness” must be used as a means to curb high reliance on automation and the ultimate abandonment of common sense. Finally, automated systems also might challenge the dynamics of responsibility within the doctor‐patient relationship, as well as the expectation of confidentiality.212 In terms of",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:176"
    }
  },
  {
    "page_content": "expectation of confidentiality.212 In terms of regulatory aspects, the US Food and Drug Administration has been regulating automated clinical decision‐making systems since the 1990s.213 With the advent of new prediction techniques, including deep learning, predictive models seeking approval must be further scrutinized in terms of the ground truth data used in training them, their intended use cases, and their generalizability and robustness against edge cases, as well as their life‐long",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:177"
    }
  },
  {
    "page_content": "against edge cases, as well as their life‐long learning aspects, as they are continuously updated with more learning and more data. It is likely that AI application software will need to meet rigorous testing that is mandated for new submissions for regulatory approval, including quality control and risk assessment. Because cloud computing and virtualization are being used increasingly to process medical data, health care information technology is gradually becoming part of the “big data”",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:178"
    }
  },
  {
    "page_content": "is gradually becoming part of the “big data” revolution.214 This offers a fertile environment for incorporating state‐of‐the‐art AI systems that often are distributed. Nevertheless, it raises data security and privacy concerns, because maintaining Health Insurance Portability and Accountability Act compliance is essential. Current cyber security research starts to offer solutions, including cryptonets, in which homomorphic encryption allows neural networks to run training and inference on",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:179"
    }
  },
  {
    "page_content": "neural networks to run training and inference on encrypted data.215 Today’s diagnostic paradigm in medicine focuses on the detection of visually recognizable findings that suggest discrete pathologies in images. However, the focus of such detection of singular disease processes may miss concurrent conditions in an individual as a whole. Imaging methods, from simple x‐rays to advanced, cross‐sectional imaging methods such as MRI or CT, provide the opportunity to assess cancer in the context of",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:180"
    }
  },
  {
    "page_content": "opportunity to assess cancer in the context of its surrounding organ system. With the integration of AI, complex assessments of biological networks may have a profound impact on the assessment of response and prognosis and treatment planning. In addition to the finding of a neoplasm, imaging may detect changes in the adjacent or distant organs beyond the tumor that alter patient susceptibility to systemic morbidities, which ultimately can contribute to mortality. This may occur as a byproduct",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:181"
    }
  },
  {
    "page_content": "to mortality. This may occur as a byproduct of disease progression itself or as a byproduct of treatment, such as radiation or chemotherapy. For example, in patients undergoing treatment for thoracic or breast cancer, chemotherapy may lead to myocardial damage, whereas radiation therapy promotes advanced coronary atherosclerosis; patients who survive cancer also experience a high rate of cardiovascular events. Collectively, these cardiotoxicities may confer a signal on routine imaging during",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:182"
    }
  },
  {
    "page_content": "may confer a signal on routine imaging during the monitoring of cancer and be detected in earlier stages of development with comprehensive analytical systems that capture the diorama of disease processes. Initial concepts to apply AI to this clinical scenario stemmed from the finding that thoracic cancers and cardiovascular pathology are adjacent to each other and may be detected simultaneously (ie, coronary calcification or pericardial fat on chest CT). The development of automated, AI‐based",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:183"
    }
  },
  {
    "page_content": "chest CT). The development of automated, AI‐based detection and quantification algorithms therefore would enable the assessment of cardiometabolic markers without the need for additional imaging. In this manner, the role of AI can be extended to screening by simultaneously evaluating additional risks from the same data source. Because health care ultimately aims to prevent disease, the generation of accurate risk models is essential in guiding actionable risk‐modification strategies. Although",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:184"
    }
  },
  {
    "page_content": "actionable risk‐modification strategies. Although AI can detect incidental findings that may be clinically beneficial, these findings also may be clinically irreverent and, if not carefully framed in the correct clinical context, may increase patient stress, health care costs, and undesired side effects from treatment. It is likely that, during the early phase of AI, when human experts will continue to play key roles in gatekeeping AI’s output, the majority of incidental findings detected by AI",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:185"
    }
  },
  {
    "page_content": "majority of incidental findings detected by AI will still be evaluated by humans to discern whether or not they are clinically significant in the same manner as when humans detected incidental findings. Over time, as AI systems mature, these incidental findings may become part of standard data evaluation and reporting, the same way primary lesions are evaluated and reported in the patient’s clinical context. In addition, imaging is not an isolated measure of disease. Increasingly, it is",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:186"
    }
  },
  {
    "page_content": "isolated measure of disease. Increasingly, it is appreciated that the molecular signatures of cancers, including noninvasive blood biomarkers of tumor, socioeconomic status, and even social networks, have an impact on the outcome of patients with cancer. Sources of data also are rapidly expanding beyond direct medical testing and include input from wearables, mobile phones, social media, unstructured electronic health records, and other components of the digital age. AI is well suited to",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:187"
    }
  },
  {
    "page_content": "of the digital age. AI is well suited to integrate parallel streams of information—biological, demographic, and social—over time to improve predictive models for patient outcome. As the power and potential of AI are increasingly proven, multiple directions remain for AI to transition into routine clinical practice. For imaging analysis, the accuracy and predictive power of AI methodologies need significant improvement and a demonstration of comparable efficacy, or better, than human experts in",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:188"
    }
  },
  {
    "page_content": "efficacy, or better, than human experts in controlled studies if they are to be poised to supplant clinician workflows. This shows initial promise in several disease conditions but requires additional proof of clinical utility in prospective trials and education of physicians, technologists, and physicists to incorporate into widespread use.216, 217 Although there likely will always be a “black box” for human experts in viewing AI‐generated results, data visualization tools are increasingly",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:189"
    }
  },
  {
    "page_content": "data visualization tools are increasingly available to allow some degree of visual understanding of how algorithms make decisions.127 The curation of comprehensive data sets and outcomes that incorporate both disease‐related and unrelated elements also will help train and expand AI systems to account for risks beyond cancer itself. In global settings with limited access to expert clinicians or exposure to uncommon pathologies, AI may offer a repertoire of “expert” experiences in disease",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:190"
    }
  },
  {
    "page_content": "a repertoire of “expert” experiences in disease interpretation. Conversely, strategies that predict outcomes without a ground truth provided by human experts may disrupt the traditional workflow familiar to clinicians and patients today.218 Furthermore, the increased incorporation of AI in monitoring health resources and outcomes likely will improve efficiency and reduce cost. As with any new innovative technology, the possibilities for development reside beyond current imagination.",
    "metadata": {
      "source": "../data/plain/PMC6403009.plain.txt",
      "id": "../data/plain/PMC6403009.plain.txt:191"
    }
  },
  {
    "page_content": "Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms Abstract\nSimple Summary",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:0"
    }
  },
  {
    "page_content": "MPN blood cancers are characterized by elevated blood cell counts. Chronic inflammation drives MPNs, which after 10–30 years, may lead to bone marrow failure due to replacement of bone marrow by connective tissue. Chronic inflammation also impacts other organs causing impaired vision, osteoporosis, fractures, heart failure and decreased lung and kidney function. MPNs are also associated with an increased risk of other cancers. Novel, noninvasive technologies are needed to improve the early",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:1"
    }
  },
  {
    "page_content": "technologies are needed to improve the early detection of fibrosis development and MPN progression and to monitor the efficacy of treatment. Herein, we review current knowledge and focus on novel technologies for the measurement of circulating connective tissue biomarkers in MPNs. Future research directions are provided, suggesting studies on single markers or combinations before and during treatment with old and new agents, both targeting the diseased bone marrow cells and the inflammatory",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:2"
    }
  },
  {
    "page_content": "diseased bone marrow cells and the inflammatory processes that drive the progressive fibrosis, which if left untreated, may ultimately lead to bone marrow failure or leukemic transformation.",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:3"
    }
  },
  {
    "page_content": "Abstract",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:4"
    }
  },
  {
    "page_content": "Philadelphia chromosome-negative chronic myeloproliferative neoplasms (MPNs) arise due to acquired somatic driver mutations in stem cells and develop over 10–30 years from the earliest cancer stages (essential thrombocythemia, polycythemia vera) towards the advanced myelofibrosis stage with bone marrow failure. The JAK2V617F mutation is the most prevalent driver mutation. Chronic inflammation is considered to be a major pathogenetic player, both as a trigger of MPN development and as a driver",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:5"
    }
  },
  {
    "page_content": "as a trigger of MPN development and as a driver of disease progression. Chronic inflammation in MPNs is characterized by persistent connective tissue remodeling, which leads to organ dysfunction and ultimately, organ failure, due to excessive accumulation of extracellular matrix (ECM). Considering that MPNs are acquired clonal stem cell diseases developing in an inflammatory microenvironment in which the hematopoietic cell populations are progressively replaced by stromal proliferation—“a wound",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:6"
    }
  },
  {
    "page_content": "replaced by stromal proliferation—“a wound that never heals”—we herein aim to provide a comprehensive review of previous promising research in the field of circulating ECM fragments in the diagnosis, treatment and monitoring of MPNs. We address the rationales and highlight new perspectives for the use of circulating ECM protein fragments as biologically plausible, noninvasive disease markers in the management of MPNs. # 1. Introduction The classic chronic Philadelphia-negative",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:7"
    }
  },
  {
    "page_content": "The classic chronic Philadelphia-negative myeloproliferative neoplasms (MPNs) encompass essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF). They arise due to acquired somatic mutations in the pluripotent stem cell, which subsequently give rise to clonal expansion and clonal evolution over decades (10–30 years) in a biological continuum from the early cancer stage ET to the advanced myelofibrosis stage and ultimately leukemic transformation. The somatic",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:8"
    }
  },
  {
    "page_content": "ultimately leukemic transformation. The somatic “driver” mutations include JAK2V617F, CALR and MPL, which drive the malignant clone throughout the transitions. Among these mutations, the most prevalent is the JAK2V617F mutation, which occurs in virtually all patients with PV (95–98%), and in approximately 50–60% of patients with ET or PMF. Additional non-driver mutations are recorded in > 50% of patients with MPNs and are considered to be implicated in clonal evolution with myelofibrotic and",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:9"
    }
  },
  {
    "page_content": "in clonal evolution with myelofibrotic and leukemic transformation. In the majority of JAK2V617F-negative ET and PMF patients, CALR or MPL mutations are detectable, leaving approximately 10% of patients with MPNs carrying none of the three driver mutations, the so-called “triple-negative” MPNs. MPNs arise from clonal hematopoiesis of indeterminate potential (CHIP), which is an inevitable consequence of normal aging and is defined as the presence of a clonal mutation in a driver gene, occurring",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:10"
    }
  },
  {
    "page_content": "of a clonal mutation in a driver gene, occurring with a variant burden of ≥2% but without any clinical evidence of hematologic cancer. Individuals harboring CHIP have an approximately 10-fold increased risk of developing hematologic cancer, including MPNs. Furthermore, similar to patients with MPNs, individuals with CHIP have an increased risk of cardiovascular diseases, including coronary artery disease and stroke. In recent years, the concept of chronic inflammation as a trigger and driver of",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:11"
    }
  },
  {
    "page_content": "chronic inflammation as a trigger and driver of MPNs has been increasingly recognized. Indeed, it has been proposed that MPNs are “A Human Inflammation Model“ and “A Human Inflammation Model of Cancer Development“. In this regard, chronic inflammation may also trigger and drive the development of accelerated (premature) atherosclerosis in MPNs, as evidenced by a heavy burden of coronary artery and aortic valve calcifications and the well-established increased risk of second cancers in MPNs. The",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:12"
    }
  },
  {
    "page_content": "increased risk of second cancers in MPNs. The importance of immune deregulation with increasing T-cell exhaustion and tumor immune evasion consequent to defective tumor immune surveillance has been repeatedly underscored as one of the major mechanisms, contributing not only to MPN development and disease progression but also to the development of second cancers and their poorer survival as compared to the same cancers in the background population. Highly intriguing, other inflammation-mediated",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:13"
    }
  },
  {
    "page_content": "Highly intriguing, other inflammation-mediated comorbidities are also prevalent in MPNs, including much earlier development of drusen and age-related macular degeneration, increased risk of fractures, likely mediated by the chronic inflammatory state, chronic inflammatory bowel diseases (ulcerative colitis, Crohn’s disease), and chronic kidney disease. Accordingly, patients with MPNs are not only at a constantly increased risk of major thrombosis in, e.g., the brain, heart, lungs, legs and",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:14"
    }
  },
  {
    "page_content": "in, e.g., the brain, heart, lungs, legs and abdominal arteries and veins but also at an increased risk of being burdened by inflammation-mediated multimorbidities, including an increased risk of second cancers. Therefore, both prevention, diagnosis and treatment of MPNs require close interdisciplinary collaboration between experts within several disciplines, including hematology, oncology, cardiology, neurology, gastroenterology, nephrology, rheumatology, ophthalmology and molecular biology. As",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:15"
    }
  },
  {
    "page_content": "ophthalmology and molecular biology. As mentioned above, the MPNs arise from CHIP and evolve over decades from the earliest disease stage ET to the “metastatic” advanced myelofibrosis stage with a multitude of comorbidities. During this evolution, mutated CD34+ stem cells egress from the “inflamed” bone marrow niches into the systemic blood compartment to seed in the spleen, liver and elsewhere (“metastasis”). Since bone marrow failure due to chronic inflammation and progressive accumulation of",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:16"
    }
  },
  {
    "page_content": "inflammation and progressive accumulation of fibrous tissue in the bone marrow is the terminal outcome, there is an urgent unmet need to identify biomarkers to monitor the inflammation-mediated fibrotic disease progression and for the selection of individualized therapies based on knowledge about specific disease pathways as adjuncts to conventional means such as blood cell counts, JAK2V617F mutational load over time and bone marrow biopsies. Previous studies on the potential of circulating",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:17"
    }
  },
  {
    "page_content": "Previous studies on the potential of circulating extracellular matrix (ECM) fragments released to the circulation consequent to the altered MPN-related connective tissue turnover as markers of current early bone marrow inflammation and late fibrogenesis, respectively, have demonstrated highly pertinent associations between circulating levels of several ECM proteins and disease activity and drug responses in MPNs, particularly regarding the procollagen III-N-terminal propeptide, type IV",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:18"
    }
  },
  {
    "page_content": "procollagen III-N-terminal propeptide, type IV collagen, laminin and hyaluronan. Within recent years, the research field on ECM and circulating ECM fragments has expanded immensely in several diseases, not least within cardiovascular diseases and cancer. Importantly, novel technologies have been introduced that detect neoepitopes, referred to as protein fingerprints. These neoepitopes are exposed on the ECM degradation product, generated by, e.g., matrix metalloproteinase (MMP) activity during",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:19"
    }
  },
  {
    "page_content": "matrix metalloproteinase (MMP) activity during altered ECM remodelling in cancer and inflammation-mediated diseases. Measuring specific neo-epitopes on ECM fragments rather than total protein can provide hitherto unprecedented information about fibrogenesis and fibrosis, collagen formation, MMP-mediated collagen degradation and collagen cross-linking in particular (Figure 1). These ECM fragments are released into the circulation and can be measured with highly sensitive and specific",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:20"
    }
  },
  {
    "page_content": "be measured with highly sensitive and specific immunoassays providing a noninvasive biomarker tool. Based upon experimental and clinical studies, we herein address the rationales and perspectives for measuring circulating ECM fragments in MPNs, aiming to achieve an integrated neoepitope signature for disease activity in terms of myeloproliferation, inflammation, fibrosis and angiogenesis. Also, it is a goal within reach to provide additional proof of concept on circulating ECM fragments as",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:21"
    }
  },
  {
    "page_content": "proof of concept on circulating ECM fragments as biomarkers of disease activity in MPNs, thereby contributing to elucidating the role of somatic mutations in blood cells as links between chronic inflammation, vascular diseases, and organ fibrosis in the MPNs. Before addressing the rationales and perspectives of the assessment of circulating ECM fragments as novel tools to monitor disease activity and response to treatment in MPNs, we will briefly review the normal bone marrow stroma, the",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:22"
    }
  },
  {
    "page_content": "briefly review the normal bone marrow stroma, the connective tissue response to injury, including stroma generation in normal wound healing and tumors, and how the bone marrow stroma is altered in MPNs and its impact upon bone marrow function and progression of MPNs towards bone marrow failure and ultimately leukemic transformation.",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:23"
    }
  },
  {
    "page_content": "Figure 1Circulating type III collagen fragments with specific neo-epitopes can be measured with the neo-epitope technology. Cells such as fibroblasts and reticular cells synthesize type III collagen. The type III pro-collagen is released into the extracellular space with subsequent proteolytic removal of the N-terminal propeptide and the C-terminal propeptide leading to collagen fibril formation and intrapeptide and interpeptide cross-linking with enzymes such as lysyl oxidase (LOX).",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:24"
    }
  },
  {
    "page_content": "with enzymes such as lysyl oxidase (LOX). Immune-mediated proteolysis with, e.g., metalloproteinases (MMPs) of the mature type III collagen results in the release of collagen fragments with specific neo-epitopes into the circulation. The neo-epitope technology is based on monoclonal antibodies, which enables the assessment of these specific neo-epitopes in serum or plasma. The biomarker PRO-C3 measures the C-terminal of the N-terminal propeptide, reflecting the true type III collagen formation,",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:25"
    }
  },
  {
    "page_content": "reflecting the true type III collagen formation, while PIIINP measures an internal epitope on the N-terminal propeptide. C3M measures MMP-degraded type III collagen reflecting fibrolysis, while CTX-3 measures cross-linked and MMP-degraded type III collagen. # 2. The Normal Bone Marrow Stroma The ECM of connective tissue is a highly important constituent of the normal bone marrow compartment and a prerequisite for normal bone marrow function. Connective tissue is composed of cells, fibers and",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:26"
    }
  },
  {
    "page_content": "tissue is composed of cells, fibers and amorphous ground substance, which consists mainly of proteoglycans and hyaluronan with collagens as the principal structural component in the ECM (Figure 2). Fibronectin and laminin are major non-collagenous extracellular glycoproteins that are important for cell adhesion and growth. There are 28 different types of collagen, and each collagen is composed of three polypeptide alfa-chains, which form a triple helical structure. The central helical portion",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:27"
    }
  },
  {
    "page_content": "helical structure. The central helical portion comprises the large majority of the molecule. Fibrillar interstitial collagens comprise types I, II, III, V, XI, XXIV and XXVII. Collagen type I is the most abundant protein in the body and is found in, e.g., the skin, bone, and tendons. Collagen type II is found in hyaline cartilage and the vitreous body. Collagen type III codistributes in normal bone marrow with reticular fibers and also in other tissues such as the skin, blood vessels, synovium,",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:28"
    }
  },
  {
    "page_content": "such as the skin, blood vessels, synovium, spleen and lymph nodes. Importantly, this collagen type occurs early at sites of injury. Type V, XI, XXIV and XXVII collagen are less abundantly expressed and may serve unique functions by binding to the other fibrillar collagens and supporting fibrillization. Collagen type IV is a major constituent of basement membranes, a specialized ECM compartment in proximity to the epithelia and blood vessel compartments.",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:29"
    }
  },
  {
    "page_content": "Figure 2Stroma of healthy bone marrow, myelofibrosis, healthy solid tissue and tumor fibrosis. The stroma of healthy bone marrow and healthy solid tissues are similar. These tissues are composed of fibroblasts, immune cells, fibers and amorphous ground substance, which consists mainly of proteoglycans, hyaluronan and collagens. The stroma in myelofibrosis and cancer are characterized by excessive inflammation and deposition of collagen fibers such as type I and type III collagen, as well as new",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:30"
    }
  },
  {
    "page_content": "as type I and type III collagen, as well as new blood vessel formation. In myelofibrosis, megakaryocytes are abundant in the bone marrow. Stroma generation in tumors and in bone marrow in myelofibrosis appear to follow an identical sequential pattern with oedema, angiogenesis and fibrosis. # 3. The Connective Tissue Response to Injury ## 3.1. Stroma Generation in Normal Wound Healing and Tumors The connective tissue response to injury is characterized by distinctive alterations in the",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:31"
    }
  },
  {
    "page_content": "characterized by distinctive alterations in the composition of the ECM. This injury–repair process—oedema–angiogenesis–fibrosis—is qualitatively similar in all organs and tissues and independent of the type of injury. Accordingly, the repair processes during normal wound healing and those seen during tumor stroma generation are, in many respects, quite similar. The differences between normal wound healing and the generation of tumor stroma are principally related to the initiating mechanisms",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:32"
    }
  },
  {
    "page_content": "principally related to the initiating mechanisms and/or lack of completion mechanisms. Both processes are initially characterized by extravasation of plasma proteins, which in wound healing is triggered by local tissue injury with damage to blood vessels, but in tumor stroma generation mediated by the release of a vascular permeability factor (VPF), which markedly enhances the permeability of blood vessels. While normal vascular permeability is restored within a few days in healing wounds, the",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:33"
    }
  },
  {
    "page_content": "restored within a few days in healing wounds, the secretion of VPF from tumor cells implies persistent hyperpermeability of blood vessels with continuous leakage of plasma proteins, e.g., fibrinogen and fibronectin. In this regard, the importance of increased vascular permeability for stroma formation in tumors, healing wounds, and chronic inflammation has most recently been outlined, thereby reconciling vascular endothelial growth factor (VEGF) with VPF. In normal wound healing, platelets are",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:34"
    }
  },
  {
    "page_content": "with VPF. In normal wound healing, platelets are extremely important in the generation of a provisional fibrin–fibronectin matrix by releasing clotting factors and factors, which are mitogens and chemoattractants for connective tissue cells such as fibroblasts. By contrast, platelets do not participate in the generation of the fibrin–fibronectin matrix in tumors, whereas tumor cells are able to secrete several factors with virtually identical functions as those released from platelets,",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:35"
    }
  },
  {
    "page_content": "functions as those released from platelets, including platelet-derived growth factors (PDGFs), VEGF, transforming growth factor beta (TGF-beta), and fibroblast growth factor 2 (FGF-2). The inflammatory oedema of wound healing is also generated due to the accumulation of strongly hydrophilic hyaluronan, a high-molecular-weight polysaccharide consisting of alternating glucosamine and glucuronic acid subunits. Thereafter, the provisional matrix of fibrin and fibronectin is degraded by invading",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:36"
    }
  },
  {
    "page_content": "of fibrin and fibronectin is degraded by invading inflammatory cells, followed by the growth of new capillaries—angiogenesis—with the deposition of basement membrane material, such as collagen type IV and laminin. In this cellular, oedematous and vascular environment, fibroblasts synthesize interstitial collagens with the deposition of type III collagen at the earliest stage and type I collagen in the later phase of fibrogenesis, where the tissue is composed largely of dense collagen and only",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:37"
    }
  },
  {
    "page_content": "is composed largely of dense collagen and only scattered fibroblasts and blood vessels. The continuous extravasation of fibrinogen and fibronectin from blood vessels adjacent to tumors implies that the healing process is constantly triggered since the signal of this process—the fibrin–fibronectin matrix—undergoes continuous remodeling. Accordingly, tumors have been conceived as wounds that never heal because the stimulus for the healing process persists. This also holds true for MPNs. In this",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:38"
    }
  },
  {
    "page_content": "persists. This also holds true for MPNs. In this regard, the MPNs constitute a unique model to study ECM metabolism in cancer since they represent the wounding phases at the earliest cancer stage—ET—presenting with “organ dysfunction” only towards the metastatic myelofibrosis stage of “collagenization” with fibrosis and subsequent bone marrow failure. ## 3.2. Bone Marrow Stroma Generation in Primary Myelofibrosis (PMF) As alluded to above, stroma generation in the bone marrow in PMF and related",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:39"
    }
  },
  {
    "page_content": "generation in the bone marrow in PMF and related neoplasms has many similarities with those recorded during wound healing and tumor stroma generation. Thus, in the early hypercellular phase of PMF, the bone marrow stroma shows signs of inflammation with oedema and infiltration with lymphocytes, plasma cells and mast cells. Furthermore, bone marrow stroma is characterized by excess capillary formation. Myeloproliferation is characterized by a predominance of large dysplastic megakaryocytes,",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:40"
    }
  },
  {
    "page_content": "predominance of large dysplastic megakaryocytes, often located in clusters close to the increased network of fine reticular fibers, which are composed largely of type III collagen (Figure 2). As MPN diseases progress, hematopoietic tissue, except for megakaryocytes, is gradually replaced by dense Van-Giesson-positive collagen fibers (mainly type I collagen) with or without osteomyelosclerosis. However, even at this stage of the disease, there is also an increased deposition of type III collagen",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:41"
    }
  },
  {
    "page_content": "also an increased deposition of type III collagen fibers, which conceivably reflects a continuous stimulus of repair processes. As compared to the early stage of bone marrow fibrosis, the growth of capillaries is even more intense in the advanced stage. In particular, osteomyelosclerosis is accompanied by a marked increase in the number of capillaries, together with the development of continuous sheets of basement membrane material beneath the endothelial cells. Despite stroma generation in",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:42"
    }
  },
  {
    "page_content": "endothelial cells. Despite stroma generation in wound healing, tumors and bone marrow in myelofibrosis appear to exhibit an identical sequential pattern with oedema, angiogenesis and fibrosis, the stroma changes in PMF more closely resemble those seen during tumor stroma generation, where angiogenesis persists. As previously mentioned, the stimulus for capillary growth in PMF is considered to be very similar to that observed in tumor stroma generation, implying that the increased vascular",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:43"
    }
  },
  {
    "page_content": "generation, implying that the increased vascular permeability with extravasation of plasma proteins accounts for the continuous deposition of a fibrin–fibronectin containing matrix, which evokes capillary growth. The increased vascular permeability could be due to altered basement membrane architecture as well as to the liberation of histamin from mast cells, which are always increased in number in PMF. The findings of fibrin deposits and large amounts of fibronectin, mainly having a",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:44"
    }
  },
  {
    "page_content": "and large amounts of fibronectin, mainly having a perivascular distribution, in bone marrow in PMF, may support the concept of a continuous generation of a fibrin–fibronectin matrix in PMF. Furthermore, angiogenesis and endothelial proliferation are elicited by the release of angiogenic growth factors from rapidly proliferating or necrotic megakaryocytes. Indeed, the clustering of megakaryocytes close to sinusoids and their intrasinusoidal localization support the concept of regulatory",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:45"
    }
  },
  {
    "page_content": "localization support the concept of regulatory interactions between megakaryocytes and endothelial cells. In this regard, megakaryocytes are key regulators of the hematopoietic stem cell niche, which is also markedly influenced and regulated by inflammation. Considering the role of chronic inflammation for disease progression in MPNs, sustained chronic inflammation in the stem cell niche may have detrimental effects, leading to hematopoietic stem cell damage and ultimately promoting bone marrow",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:46"
    }
  },
  {
    "page_content": "cell damage and ultimately promoting bone marrow fibrosis and leukemic transformation. Importantly, in a murine model of MPN, JAK2V617F mutant megakaryocytes not only contributed to hematopoietic stem cell/progenitor cell expansion but also to hematopoietic aging. # 4. Histological Studies on Bone Marrow Stroma in MPNs Histologically, two stages of myelofibrosis have broadly been distinguished, “reticulin fibrosis” and “collagen fibrosis”, with the deposition of silver stainable (=reticulin)",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:47"
    }
  },
  {
    "page_content": "the deposition of silver stainable (=reticulin) fibers in the early hypercellular disease phase and the accumulation of a mature collagen type I rich matrix in the advanced disease phase. However, the silver impregnation technique is not specific to any particular matrix protein. Thus, although reticulin fibers are composed of type III procollagen (pN-collagen) and type III collagen, previous studies showed that other connective tissue constituents are also argyrophilic, e.g., type I, IV and V",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:48"
    }
  },
  {
    "page_content": "are also argyrophilic, e.g., type I, IV and V collagen, fibronectin and proteoglycans. Furthermore, in regard to deposition and accumulation of connective tissue in the bone marrow, earlier studies of bone marrow from myelofibrosis patients principally described three stages of myelofibrosis, suggesting that bone marrow fibrosis progresses from an early stage with only slightly increased fiber network (stage 1) to an advanced stage with pronounced hematopoietic hypocellularity and dense",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:49"
    }
  },
  {
    "page_content": "hematopoietic hypocellularity and dense myelofibrosis together with osteomyelosclerosis (stage 3). Using the new well-defined WHO criteria, in the earliest stage of PMF—early prefibrotic myelofibrosis—the reticular fiber network in the bone marrow is normal or only focally slightly increased. Importantly, however, the WHO criteria for the discrimination of ET from prefibrotic PMF have been questioned and not been shown to be reproducible in all studies, leading to a higher proportion of",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:50"
    }
  },
  {
    "page_content": "in all studies, leading to a higher proportion of non-classifiable MPNs. Indeed, this discordance calls for other means to differentiate ET from early prefibrotic myelofibrosis. In this context, the measurement of circulating ECM fragments may be useful and needs to be investigated. Although PMF may evolve from a stage of hypercellularity with minimal fibrosis to an advanced stage with myeloid atrophy and myelofibrosis, this evolution has not been convincingly proven via sequential bone marrow",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:51"
    }
  },
  {
    "page_content": "convincingly proven via sequential bone marrow biopsies during the course of the disease. A few studies have attempted systematically to follow the evolution of bone marrow fibrosis, and highly different results were obtained. Hasselbalch and Lisse found a constant bone marrow pattern or regression of bone marrow fibrosis to be the most common. This was also recorded in other series, even though progressive myelofibrosis was recorded in some studies. Lennert et al. quantified the number of",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:52"
    }
  },
  {
    "page_content": "studies. Lennert et al. quantified the number of argyrophilic fibers in bone marrows from patients with various MPNs, including PMF. Although detailed data were not presented, they stated that MPNs progressed from a low to a high fiber content. Furthermore, they observed the fiber content to be higher in patients who had both fibrosis and osteomyelosclerosis. Using digital image processing, no correlation was found in these earlier studies between bone marrow fiber content and the duration of",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:53"
    }
  },
  {
    "page_content": "bone marrow fiber content and the duration of the disease from the time of onset of symptoms. These discordant results have been attributed to several factors, including different criteria for diagnosis. Thus, some studies enrolled patients without classical features of PMF at first biopsy, i.e., increased the amount of reticular fibers in the bone marrow, leucoerythroblastic anemia and splenomegaly. Today, such patients are classified as early prefibrotic myelofibrosis, which are characterized",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:54"
    }
  },
  {
    "page_content": "myelofibrosis, which are characterized by no or minimal “reticulin fibrosis”, no or minor anemia and in most patients, a normal or only slightly enlarged spleen. The distinction between ET and early prefibrotic myelofibrosis has prognostic implications since patients with prefibrotic MF have a poorer prognosis as compared to ET but a much better prognosis than classical PMF patients with anemia, large spenomegaly and dense bone marrow fibrosis. Despite the fact that the disease entity of early",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:55"
    }
  },
  {
    "page_content": "Despite the fact that the disease entity of early prefibrotic myelofibrosis has been included in the international WHO criteria since 2016, and today is used worldwide, concerns have been raised in regard to its relevance as a separate MPN subgroup, taking into account the rather low reproducibility of the assessment of bone marrow features, which define early prefibrotic MF, even amongst trained haematopathologists. For obvious reasons, the patchy nature of the bone marrow lesions in the early",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:56"
    }
  },
  {
    "page_content": "nature of the bone marrow lesions in the early MPN stages, even within the same bone marrow biopsy specimen, may be challenging in terms of a precise “general“ description of the bone marrow in MPNs. Therefore, novel tools to assess the stroma changes in MPNs are needed, such as serial measurements of circulating, stage-specific ECM protein fragments, which will be addressed below. Although progressive myelofibrosis was recorded in most patients with so-called “early myelofibrosis “ in the",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:57"
    }
  },
  {
    "page_content": "with so-called “early myelofibrosis “ in the previous studies, no progression of myelofibrosis was demonstrated in patients who at diagnosis fulfilled the criteria for classical primary myelofibrosis. As alluded to above, Wolf and Neiman also emphasized that the absence of detectable progressive myelofibrosis might be related to the patchy nature of the stromal proliferation with a striking variability in the amount of reticulin and haematopoietic cellularity within a given biopsy and most",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:58"
    }
  },
  {
    "page_content": "cellularity within a given biopsy and most likely also in various parts of the skeleton. Furthermore, reversal of myelofibrosis has been shown to occur in some patients, either spontaneously, following splenic irradiation, splenectomy, bone marrow transplantation, chemotherapy, monotherapy with pegylated interferon-alpha, combination therapy with ruxolitinib and pegylated interferon-alpha2, or immunosuppressive therapy, including monotherapy with ruxolitinib. Finally, resolution of bone marrow",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:59"
    }
  },
  {
    "page_content": "ruxolitinib. Finally, resolution of bone marrow fibrosis has been observed in patients who enter leukemic transformation. # 5. Biochemical and Immunohistochemical Studies of Bone Marrow The total amount of collagen (hydroxyproline) in bone marrow is increased in PMF. In the early phase of the disease, soluble collagen with reducible cross-links appears to prevail, whereas insoluble, stably cross-linked collagen is abundant in advanced disease. In addition, the content of glycosaminoglycans is",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:60"
    }
  },
  {
    "page_content": "In addition, the content of glycosaminoglycans is decreased, particularly in patients with advanced disease. In most patients, urinary hydroxyproline excretion is normal. Immunohistochemical studies have shown normal bone marrow stroma to be composed of interstitial collagen types I and III (III > I) together with basement membrane collagen (type IV) and type V collagen. Collagen types I and III are scattered throughout the bone marrow, whereas type IV collagen is localized discontinuously",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:61"
    }
  },
  {
    "page_content": "type IV collagen is localized discontinuously beneath the lining of sinusoids.. In addition to type IV collagen, normal bone marrow basement membrane matrix is composed of non-collagenous glycoproteins, including laminin and fibronectin. Laminin and type IV collagen have been shown to be closely co-distributed in normal bone marrow. As mentioned above, in PMF, there is an increased deposition of both interstitial matrix collagens and basement membrane collagens in the bone marrow, together with",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:62"
    }
  },
  {
    "page_content": "collagens in the bone marrow, together with increased numbers of sinuses and capillaries. The interstitial reticulin network in PMF has been shown to be composed mainly of type III collagen and, in many patients, also mature type I collagen fibers. In addition, fibronectin contributes to the reticulin matrix. The type III collagen fibers have been demonstrated by the application of antibodies against type III procollagen (pN collagen), indicating that the propeptide is partly retained on the",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:63"
    }
  },
  {
    "page_content": "that the propeptide is partly retained on the collagen fibers in the bone marrow.) Particularly increased collagen content, including both newly deposited type III procollagen (pN collagen) and mature collagen fibers, was found in patients with osteomyelosclerosis, which was also associated with the most pronounced neovascularization. The demonstration of partially processed type III procollagen containing its aminoterminal propeptide (= pN collagen) in normal and fibrotic bone marrow is in",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:64"
    }
  },
  {
    "page_content": "in normal and fibrotic bone marrow is in accordance with studies of other tissues, e.g., skin, in which co-distribution has been demonstrated between type III collagen and type III pN collagen fibrils. Besides fibroblast and endothelial proliferation, another important change in bone marrow in PMF includes the formation of continuous sheets of basement membranes beneath endothelial cells. This process appears to be very similar to the “capillarization” of liver sinusoids during the development",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:65"
    }
  },
  {
    "page_content": "of liver sinusoids during the development of liver cirrhosis. Despite being discovered for the first time approximately 30 years ago, the pathophysiological implications of altered basement membrane structure in myelofibrosis are, at present, largely unknown. Conceivably, the changes might eventually interfere with the migration of hematopoietic cells from the bone marrow compartment across the marrow-blood barrier into the circulation, allowing stem cells and other immature progenitor cells to",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:66"
    }
  },
  {
    "page_content": "stem cells and other immature progenitor cells to enter the circulation prematurely. # 6. Studies of Extracellular Matrix Metabolism As previously described, the connective tissue responds uniformly to injuries of any kind by distinctive sequential changes in the ECM expression, including oedema formation, angiogenesis and finally, fibrosis, with the deposition of type III collagen in the early phase, mainly as fine fibers, and type I collagen as coarse fibers in the later phase of the lesion",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:67"
    }
  },
  {
    "page_content": "as coarse fibers in the later phase of the lesion (Figure 2). This injury–repair process is qualitatively similar in all organs and is accompanied by the release of various matrix components into the circulation during the synthesis and breakdown of connective tissue constituents at the site of injury. About 30 years ago, radioimmunoassays for the measurement of these connective tissue components in circulation were developed. Since then, these methodologies have been extensively elaborated and",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:68"
    }
  },
  {
    "page_content": "have been extensively elaborated and are today being used to monitor collagen metabolism in various inflammatory and fibrosing disorders, including cancers at the time of diagnosis, during treatment to monitor disease activity and response to treatment and in prognostification as well. In the following, we summarize MPN studies on circulating ECM-associated proteins such as collagen metabolites, matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) (Table 1). ##",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:69"
    }
  },
  {
    "page_content": "of metalloproteinases (TIMPs) (Table 1). ## 6.1. The Aminoterminal Propeptide of Type III Procollagen (PIIINP) All fibrillar collagens (e.g., types I and III) are synthesized as procollagens, which contain additional propeptide extensions at both ends. Prior to collagen fiber formation, the procollagens are converted to collagens. During this process, the propeptide regions of the procollagen molecules are cleaved off in the extracellular space and released into the circulation. Since the",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:70"
    }
  },
  {
    "page_content": "and released into the circulation. Since the propeptides are released in equimolar amounts to the collagen molecules formed, the measurement of circulating levels of these propeptides is thought to reflect collagen synthesis (Figure 1). Willumsen et al. summarized this process recently for neo-epitop specific type III collagen propeptides (PRO-C3) measured in serum in a fraction of patients with various solid tumors, highlighting the prognostic value in the context of overall survival (see",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:71"
    }
  },
  {
    "page_content": "value in the context of overall survival (see below Future Research Directions). In previous studies of PIIINP in patients with PMF and related neoplasms, the highest serum levels were found in patients with PMF, in those PV patients transforming into a myelofibrotic stage of the disease, and in patients with chronic myelogenous leukemia (CML) associated with bone marrow fibrosis. Although these studies suggested serum PIIINP as a useful noninvasive means to monitor the accumulation of",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:72"
    }
  },
  {
    "page_content": "noninvasive means to monitor the accumulation of interstitial type III collagen in the bone marrow, several factors should be considered when interpreting serum PIIINP levels. First, the radioimmunoassay for the aminoterminal propeptide of type III procollagen (RIA-gnost, Hoechst, FRG), used in the seminal studies on circulating PIIINP in MPNs, did not exclusively detect the authentic propeptide released during the conversion of procollagen to collagen but measured at least three molecular",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:73"
    }
  },
  {
    "page_content": "to collagen but measured at least three molecular weight variants of the antigens. The main antigen in normal serum is smaller than the authentic aminopropeptide liberated during the conversion of type III pN collagen to type III collagen. These lower molecular weight peptides were shown to probably represent degradation products of the propeptide, including those related to the degradation of newly synthesized type III procollagen or degradation of that portion of the propeptide retained in",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:74"
    }
  },
  {
    "page_content": "of that portion of the propeptide retained in situ in the bone marrow. However, in rheumatic diseases, the local degradation of pN-collagen in inflamed tissue has not been considered to contribute significantly to elevated serum aminopropeptide levels. Owing to the heterogeneity of the antigens related to the aminoterminal propeptide of type III procollagen, a next-generation equilibrium RIA for the N-terminal propeptide of human type III procollagen (Farmos Diagnostica, Oulu, Finland) was",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:75"
    }
  },
  {
    "page_content": "(Farmos Diagnostica, Oulu, Finland) was additionally applied in a series of patients with PMF and related neoplasms. This assay system did not detect the smaller antigen variants, but only antigen forms equal to or larger than the authentic propeptide. A highly significant correlation was found between the two assay systems, which both discriminated between patients with stable and active disease, the highest propeptide levels being recorded in patients with a syndrome of acute myelofibrosis",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:76"
    }
  },
  {
    "page_content": "patients with a syndrome of acute myelofibrosis and those with accelerated disease. Furthermore, serum propeptide levels correlated significantly with conventional markers of disease activity (leukocyte count and plasma lactic dehydrogenase), which was also observed in longitudinal studies, where a close co-variation between serum PIIINP and these parameters was recorded. Analysis of the antigen profile of PIIINP by means of gel filtration in patients with different disease activity showed",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:77"
    }
  },
  {
    "page_content": "patients with different disease activity showed smaller antigen variants to prevail in patients with stable disease, whereas the intact propeptide dominated in patients with acute or transforming disease. This observation indicated that elevated circulating PIIINP levels primarily reflect de novo synthesis of type III collagen and not increased degradation of the propeptide. Vellenga et al. also found that the antigenicity related to PIIINP was heterogeneous, with at least two main peaks having",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:78"
    }
  },
  {
    "page_content": "with at least two main peaks having molecular weights equal to and smaller than the authentic propeptide. Cytotoxic treatment was accompanied by decreasing serum propeptide levels. Taken together, these early observations indicated type III collagen metabolism to be closely linked to clonal myeloproliferation. Recently, Willumsen et al. introduced an assay that specifically measures propeptide containing the neo-epitope cleavage site generating the true propeptide (PRO-C3) and, therefore,",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:79"
    }
  },
  {
    "page_content": "the true propeptide (PRO-C3) and, therefore, measures the true formation of type III collagen (see Future Research Directions). Second, while an assay for serum PIIINP mainly measures de novo synthesis of type III procollagen at the time of investigation, the degree of bone marrow fibrosis as assessed by a bone marrow biopsy provides evidence about the preceding net collagen deposition. This accumulation may be due to both an increased collagen synthesis and/or impaired degradation of bone",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:80"
    }
  },
  {
    "page_content": "synthesis and/or impaired degradation of bone marrow collagen. Thus, the observed relationship between increasing degrees of bone marrow fibrosis and increasing serum propeptide levels rather reflects an enhanced myeloproliferative activity and hence ongoing stimulation of bone marrow fibroblasts. Third, circulating type III procollagen-related antigens can be derived from sources other than the bone marrow, including both the spleen and liver, due to myeloid metaplasia and fibroplasia in these",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:81"
    }
  },
  {
    "page_content": "to myeloid metaplasia and fibroplasia in these organs. Thus, raised serum PIIINP may theoretically also reflect impaired propeptide metabolism in patients with massive myeloid metaplasia in the liver since serum PIIINP is increased in certain liver diseases and the liver is a main site of PIIINP uptake and degradation. Accordingly, extramedullary clonal myeloproliferation may contribute to the increased serum concentration of PIIINP in patients with massive myeloid metaplasia of the liver.",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:82"
    }
  },
  {
    "page_content": "with massive myeloid metaplasia of the liver. Concerning the relationship between the serum levels of PIIINP and disease activity or disease progression and the degree of bone marrow fibrosis in PMF and related neoplasms, it is important to realize that serum PIIINP is a marker of current organ fibrogenesis (disease activity), whereas fibrosis in the light microscope reflects the amount of previously deposited collagen (disease stage). This concept is substantiated by studies of liver patients,",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:83"
    }
  },
  {
    "page_content": "is substantiated by studies of liver patients, showing equally raised serum values in patients with fatty liver and inactive cirrhosis and no relationship between serum PIIINP and the severity of liver fibrosis. However, a relationship was found between serum PIIINP and ultrastructural, but not light microscopic fibrosis, which might indicate that raised serum PIIINP levels reflect early collagen formation in the liver. ## 6.2. Biomarkers of Type I Collagen Metabolism Circulating",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:84"
    }
  },
  {
    "page_content": "of Type I Collagen Metabolism Circulating carboxyterminal telopeptide of type I collagen (ICTP) in MPNs as a biomarker of type I collagen degradation has been found to be significantly elevated in patients with MPNs as a group compared with healthy controls. However, subgroup analysis displayed only significantly elevated ICTP levels in patients with PV and MF. Of note, in this study, a significant correlation between the biomarker of collagen synthesis—PIIINP—and ICTP was recorded, reflecting",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:85"
    }
  },
  {
    "page_content": "ICTP was recorded, reflecting that the aberrant collagen metabolism in MPNs is characterized by both enhanced collagen synthesis and degradation, the integrated signature of “a wound that never heals“ due to persistent release in the bone marrow of several growth factors (e.g., TGF-beta, FGF, and VEGF) from the malignant hyperproliferating myeloid cells in the bone marrow. Importantly, we found normal levels of biomarkers of type I collagen synthesis–carboxyterminal peptide of type I collagen",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:86"
    }
  },
  {
    "page_content": "peptide of type I collagen (S-PICP) and aminoterminal propeptide of type I collagen (S-PINP), respectively, indicating that in MPNs, collagen I metabolism is disrupted in favour of enhanced collagen I catabolism. This also highlights the importance of not just measuring any type I collagen fragment, but preferentially, a specific fragment, or neo-epitope, that may provide further and reliable information on disease activity/anabolism versus collagen degradation. In contrast, collagen III",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:87"
    }
  },
  {
    "page_content": "collagen degradation. In contrast, collagen III formation is increased consequent to sustained repair processes in the bone marrow microenvironment as reflected in the circulation by elevated PIIINP levels and in the bone marrow as increased reticulin fibrosis, being most prominent in patients with PV and MF. The catabolism of type III collagen, as can be measured using fx MMP-degraded type III collagen (C3M), remains to be explored thoroughly in MPNs, but has shown promising results in various",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:88"
    }
  },
  {
    "page_content": "MPNs, but has shown promising results in various solid tumors (see Future Research Directions). As alluded to below, the trigger event behind this phenotype shift in collagen homeostasis with significant positive correlations between plasma soluble urokinase plasminogen receptor (suPAR), and PIIINP, hyaluronan and ICTP levels might be an increased production of matrix-degrading enzymes in the bone marrow. Notably, biomarkers of remodelling (PIIINP, ICTP, hyaluronan) in the bone marrow (and",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:89"
    }
  },
  {
    "page_content": "ICTP, hyaluronan) in the bone marrow (and elsewhere) correlated significantly with circulating suPAR, reflecting the activity of the urokinase-type plasminogen activator (uPA) system, which plays an important role in matrix degradation and remodelling. In contrast, another family of extracellular proteolytic enzymes, the matrix metalloproteinases (MMPs), herein 2 and 9) and tissue inhibitors of metalloproteinases (TIMPs), which are also important catalyzers of matrix degradation and remodeling",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:90"
    }
  },
  {
    "page_content": "catalyzers of matrix degradation and remodeling (please, see below) were not correlated with circulating biomarkers of collagen metabolism. ## 6.3. Basement Membrane Proteins The fibrotic process in PMF involves the proliferation of both fibroblasts and endothelial cells. Endothelial proliferation is accompanied by a marked increase in basement membrane matrix components (type IV collagen and laminin), which are deposited as continuous sheets beneath the endothelial cells in the bone marrow.",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:91"
    }
  },
  {
    "page_content": "beneath the endothelial cells in the bone marrow. The increase in basement membrane structures in myelofibrosis is also reflected in the circulation, where the concentration of both type IV collagen and laminin is increased in a proportion of patients with PMF and related diseases. Increased serum levels of type IV-collagen-related antigens have also been found in patients with alcoholic liver disease, where they reflect type IV collagen metabolism, including the formation of basement membranes",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:92"
    }
  },
  {
    "page_content": "including the formation of basement membranes beneath the endothelial cells (capillarization of the sinusoids) during the development of liver cirrhosis. This process appears to occur concomitantly with the deposition of collagen in the space of Disse (collagenization), which is also evidenced by a positive correlation between the serum concentration of 7S collagen antigen and PIIINP. Hasselbalch et al. found a similar relationship between the serum concentration of these connective tissue",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:93"
    }
  },
  {
    "page_content": "serum concentration of these connective tissue metabolites in PMF, which may actually reflect that the development of bone marrow fibrosis follows a pattern similar to the development of liver fibrosis, being associated with a parallel deposition of interstitial collagen type III and basement membrane material (type IV collagen). Laminin is a non-collagenous glycoprotein, which, like fibronectin, easily adheres to cell surfaces. Plasma fibronectin has been found to be inversely related to",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:94"
    }
  },
  {
    "page_content": "has been found to be inversely related to spleen size, the lowest levels being recorded in patients with huge spleens. A similar relationship has been shown between serum laminin and spleen size, which may explain that serum laminin values were within the normal range in patients with large spleens despite evidence of active disease. However, normal serum laminin levels have also been recorded in patients with active rheumatoid arthritis, but spleen size was not evaluated in this patient group.",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:95"
    }
  },
  {
    "page_content": "size was not evaluated in this patient group. In conclusion, interstitial collagen and basement membrane metabolism in PMF are closely interrelated, which may reflect a shared stimulus for fibroblast and endothelial proliferation. ## 6.4. Hyaluronan Hyaluronan (hyaluronic acid) is a highly hydrophilic glycosaminoglycan and a main component of the ECM amorphous ground substance, being particularly prevalent in soft connective tissues. Elevated serum hyaluronan (HYA) levels have been found in",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:96"
    }
  },
  {
    "page_content": "serum hyaluronan (HYA) levels have been found in various inflammatory connective tissue diseases, including rheumatoid arthritis and scleroderma. Certain liver diseases are also associated with elevated serum HYA. Hyaluronan has been shown to be synthesized by fibroblasts upon various stimuli, including platelet-derived growth factor, which is also assumed to be involved in the pathogenesis of bone marrow fibrosis in PMF. Raised serum HYA concentrations have been reported in a proportion of",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:97"
    }
  },
  {
    "page_content": "have been reported in a proportion of patients with PMF. Serum HYA concentrations in patients with acute disease were significantly higher than those recorded in patients with chronic disease. Furthermore, serum HYA correlated significantly with serum PIIINP and with the leucocyte count, a close co-variation being found between serum HYA, serum PIIINP and the leucocyte count with parallel changes in patients, transforming into an accelerating disease phase and in those receiving intensive",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:98"
    }
  },
  {
    "page_content": "disease phase and in those receiving intensive chemotherapy. Several explanations may be offered for the relatively modest changes in serum HYA in patients with MPNs. The metabolism of HYA may be altered in patients with splenomegaly, implying a rapid turnover of HYA. Normally, HYA is rapidly cleared from the circulation by the liver endothelial cells, but some circulating HYA is also taken up by the spleen and other lymphoid organs. Thus, the possibility exists that splenic uptake of HYA is",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:99"
    }
  },
  {
    "page_content": "possibility exists that splenic uptake of HYA is enhanced in patients with splenomegaly, explaining the virtually normal serum HYA concentrations in patients with large spleens, despite evidence of connective tissue activation as reflected in elevated serum PIIINP concentrations. The origin of excess HYA in some myelofibrosis patients remains to be clarified. Since both fibroblasts and endothelial cells have the capacity to synthesize HYA, raised HYA levels in the circulation may reflect the",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:100"
    }
  },
  {
    "page_content": "HYA levels in the circulation may reflect the stromal cell reaction to clonal myeloproliferation. Alternatively, excess HYA may be a marker of the malignant clone itself, having the potential for HYA synthesis and production. Thus, a heterogeneous group of glycosaminoglycans has been identified in human neutrophil granules and in Auer rods of leukemic myeloblasts. In addition, proteoglycan synthesis has been demonstrated in hematopoetic progenitor cells. Platelet-derived growth factor (PDGF) is",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:101"
    }
  },
  {
    "page_content": "cells. Platelet-derived growth factor (PDGF) is implicated in the pathogenesis of PMF. Since PDGF and other growth factors are able to stimulate HYA production, it is intriguing to consider the possibility that excess HYA in the circulation in PMF is caused by the intramedullary release of growth factors from the megakaryocyte cell lineage with the ensuing stimulation of HYA production from bone marrow fibroblasts and endothelial cells. Finally, impaired metabolism of HYA owing to myeloid",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:102"
    }
  },
  {
    "page_content": "impaired metabolism of HYA owing to myeloid metaplasia in the liver might contribute to elevated HYA levels in this patient group. The temporal relationship between the above connective tissue components, which are similar to those observed in inflammatory connective diseases, lends support to the concept that repair processes are taking place in the bone marrow in response to clonal myeloproliferation. Thus, the co-variation of serum HYA and serum PIIINP conceivably reflects a common",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:103"
    }
  },
  {
    "page_content": "and serum PIIINP conceivably reflects a common underlying mechanism of connective tissue activation in PMF and related diseases. However, considering the relatively small changes in serum HYA, the clinical utility of single determinations of serum HYA is limited. ## 6.5. Fibronectin As mentioned above, fibronectin is an important connective tissue constituent, which is excessively deposited in the bone marrow in PMF, mainly with a perivascular distribution which supports that the elevated",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:104"
    }
  },
  {
    "page_content": "distribution which supports that the elevated levels in peripheral blood originate from the bone marrow compartment. Low levels of circulating fibronectin levels in patients with myelofibrosis have been associated with large spleens or binding to circulating immune complexes. Alternative splicing of the FN gene results in the generation of protein variants that contain the additional isoforms—extra domain A of FN (EDA) and extra domain B of FN (EDB); FN (EDA) and FN (EDB) are associated with",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:105"
    }
  },
  {
    "page_content": "(EDB); FN (EDA) and FN (EDB) are associated with tissue remodeling, fibroblast differentiation, inflammation, and tumor progression. Highly intriguingly, EDA-FN has been shown to sustain megakaryocyte proliferation and induces a proinflammatory phenotype in bone marrow cell niches. Based upon these observations circulating plasma levels of EDA-FN have been measured in patients with primary myelofibrosis in whom the highest levels of plasma EDA-FN were recorded in patients with a homozygous",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:106"
    }
  },
  {
    "page_content": "were recorded in patients with a homozygous JAK2V617F genotype. Furthermore, increased EDA-FN levels are associated with anemia, increased high-sensitivity C-reactive protein and bone marrow fibrosis. Since elevated plasma EDA-FN at diagnosis was also found to be a predictor of large splenomegaly (over 10 cm from the left costal margin), it was concluded that plasma EDA-FN might be a new marker of disease progression and a novel target for the treatment of splenomegaly. ## 6.6.",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:107"
    }
  },
  {
    "page_content": "target for the treatment of splenomegaly. ## 6.6. Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinases (TIMPs) The abnormal accumulation of ECM in any organ is determined by the balance between matrix anabolic processes and the activity of matrix-degrading enzymes (e.g., MMPs, cathepsins) and their inhibitors (e.g., TIMPs and alpha-2 macroglobulin). These processes can be studied by measuring the plasma concentrations of MMP family members (e.g., MMP-1, MMP-2, MMP-3, MMP-9) and",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:108"
    }
  },
  {
    "page_content": "members (e.g., MMP-1, MMP-2, MMP-3, MMP-9) and tissue inhibitors of MMPs (TIMPs) (e.g., TIMP-1). If the normally delicate balance in tissue modelling or remodelling after tissue injury of any kind is disturbed in favour of a profibrotic state, this imbalance may be reflected by increased circulating levels of anabolic matrix metabolites and/or decreased MMPs and/or increased levels of TIMPs. Studies on plasma levels of MMPs and TIMPs in MPNs have shown decreased levels of several MMPs and",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:109"
    }
  },
  {
    "page_content": "have shown decreased levels of several MMPs and increased TIMPs, in particular in patients with MF, in whom the TIMP-1/MMP-9 ratio was found to be significantly higher as well. Furthermore, whole-blood gene expression profiling studies have shown several MMPs and TIMP3 to be deregulated in MPNs with the significant upregulation of MMP1, MMP7, MMP8, MMP9, MMP11, MMP12, MMP14 and TIMP3. # 7. Reasons to Revisit Blood-Based Extracellular Matrix Biomarkers in Patients with Myeloproliferative",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:110"
    }
  },
  {
    "page_content": "Biomarkers in Patients with Myeloproliferative Neoplasms There are several rationales for reconsidering circulating ECM fragments as biomarkers in patients with MPNs. First, today MPNs are widely recognized as chronic inflammatory neoplasms, which have been described as “A Human Inflammation Model “and“ A Human Inflammation Model for Cancer Development”. As acquired stem cell neoplasms, driven by inflammatory somatic mutations, they have also been conceived as “wounds in the bone marrow, that",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:111"
    }
  },
  {
    "page_content": "conceived as “wounds in the bone marrow, that never heal” implying that the medullary stroma undergoes persistent repair and regeneration in response to clonal expansion, ultimately leading to bone marrow fibrosis and eventually leukemic transformation. Second, MPNs develop in a biological continuum spanning decades from the earliest cancer stages—ET and PV—to the advanced myelofibrotic stage, which is characterized by dense collagenization of the bone marrow consequent to a persistent release",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:112"
    }
  },
  {
    "page_content": "bone marrow consequent to a persistent release of growth factors (e.g., PDGF, TGFbeta, VEGF) from rapidly proliferating and dysplastic megakaryocytes. As such, MPNs constitute a unique model to study circulating ECM biomarkers in different stages of chronic MPN blood cancers, in which chronic inflammation is a major driving force. Third, MPNs are associated with increased cardiovascular disease burden, including hypertension, risk of stroke and myocardial infarction, ischemic heart failure, and",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:113"
    }
  },
  {
    "page_content": "infarction, ischemic heart failure, and aneurysms. Patients with MPNs likely develop atherosclerosis earlier due to a chronic systemic inflammatory response similar to premature atherosclerosis development in other inflammatory diseases, such as type II diabetes mellitus, rheumatoid arthritis, psoriasis, and inflammatory bowel diseases, Crohns’ disease and ulcerative colitis. It is intriguing to speculate if heart failure, in particular heart failure with preserved ejection fraction (HFpEF) is",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:114"
    }
  },
  {
    "page_content": "with preserved ejection fraction (HFpEF) is under-recognized in MPNs, considering that HFpEF has been reported in patients with other chronic inflammatory diseases, such as hypertension and type II diabetes mellitus. This is even more pertinent, considering that circulating ECM biomarkers have shown promise as predictive markers of cardiac fibrosis in HFpEF (please see below Future Research Directions). Fourth, MPNs are associated with an increased risk of age-related macular degeneration",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:115"
    }
  },
  {
    "page_content": "risk of age-related macular degeneration (AMD), which develops much earlier than in the background population. AMD is characterized by pronounced neovascularization, which may impact levels of circulating ECM biomarkers of increased basement membrane turnover, in view that the retina has the highest blood perfusion rate of all organs. Fifth, MPNs are associated with an increased risk of fractures, which likely is due to inflammation-mediated osteopenia. Circulating ECM markers, reflecting bone",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:116"
    }
  },
  {
    "page_content": "Circulating ECM markers, reflecting bone resorption (e.g., CTX-I (C-terminal telopeptide of type-1 collagen), and MMP-3 (matrix metalloproteinase-3)) may emerge as complementary tools to the conventional dual X-ray absorptiometry (DEXA) scans of the skeleton for detection of osteopenia in patients with MPNs. Sixth, MPNs are associated with an increased risk of chronic kidney failure, which is considered to develop as a consequence of a chronic inflammatory state with ensuing renal impairment.",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:117"
    }
  },
  {
    "page_content": "inflammatory state with ensuing renal impairment. It is intriguing to consider if “MPN-glomerulopathy“ actually develops due to fibrogenesis in the kidneys as a consequence of the intramedullary release of growth factors—mitogenic for fibroblasts and endothelial proliferation (e.g., PDGF, TGGbeta, and VEGF). In this context, elevated circulating ECM biomarkers may come up as an integrated signature of chronic multiorgan inflammation and multiorgan fibrosis, including fibrosis in the kidneys.",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:118"
    }
  },
  {
    "page_content": "fibrosis, including fibrosis in the kidneys. Seventh, MPNs are associated with an increased risk of second cancers, including lung cancer and urinary tract cancers. Circulating ECM biomarkers have been shown to be elevated in a large number of solid tumors. Accordingly, by serial measurements of ECM markers development of a second cancer may be detected earlier than presently in patients in whom the MPN appears to be well-controlled and in whom ECM marker levels accordingly are expected to be",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:119"
    }
  },
  {
    "page_content": "ECM marker levels accordingly are expected to be within the normal range. Eighth, immunomodulating treatment with pegylated interferon-alpha2 (IFN) is highly efficacious in patients in the early MPN stages—ET and PV—and early hyperproliferative myelofibrosis but it is of no or minor benefit in patients with advanced myelofibrosis, in whom TGF-beta and VEGF are abundantly expressed in the bone marrow. However, in a preclinical study, a TGF-β1/β3 protein trap molecule (AVID200) has been shown to",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:120"
    }
  },
  {
    "page_content": "protein trap molecule (AVID200) has been shown to have favourable impacts on both hematopoiesis and bone marrow fibrosis in myelofibrosis. Studies in patients with solid tumors have shown that excessive TGF-beta signaling and a collagen-rich peritumoral stroma (desmoplasia) may interfere unfavourably with the interaction between T cells and tumor cells, thereby contributing to resistance mechanisms via immune exclusion. Levels of circulating ECM biomarkers have been shown to be correlated with",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:121"
    }
  },
  {
    "page_content": "biomarkers have been shown to be correlated with clinical outcomes after PD-1/CTLA-4 inhibition in patients with metastatic melanoma. Similarly, ECM biomarkers may be not only useful in predicting response to IFN-alpha2 in MPNs but also in predicting response to PD-1 inhibition in myelofibrosis patients and in response to vaccination as well. Thus, most recent vaccination studies in MPNs have failed in terms of impacting biomarkers of disease activity (leukocyte and platelet counts, CALR and",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:122"
    }
  },
  {
    "page_content": "activity (leukocyte and platelet counts, CALR and JAK2V617F allelic burdens), although strong immune responses were recorded in a proportion of the patients. It is intriguing to consider if the T-cells are trapped in the fibrosing stroma in patients with myelofibrosis or if the malignant cells are partially protected by the surrounding fibrous stroma against attacks by the immune system (e.g., cytotoxic T-cells, and NK cells). If so, measurements of elevated circulating ECM fragments, both in",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:123"
    }
  },
  {
    "page_content": "of elevated circulating ECM fragments, both in terms of individual ECM fragments, but perhaps also a particular ECM protein signature, might provide new insights into the mechanisms behind the efficacy or lack of efficacy of immune therapy in MPNs, including immune escape mechanisms. Ninth, in theory, circulating ECM biomarkers may turn out to become valuable future diagnostic tools to differentiate genuine ET from prefibrotic myelofibrosis, to monitor the transition of prefibrotic MF into",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:124"
    }
  },
  {
    "page_content": "to monitor the transition of prefibrotic MF into classic MF (post-ET MF), PV transition towards myelofibrosis (post-PV myelofibrosis), and ultimately, leukemic transformation. All these stages are characterized by distinct patterns of several inflammatory biomarkers, including C-Reactive Protein (CRP), which are conceivably associated with the profiles of single or clusters of circulating ECM components. Tenth, in the new era of MPNs with minimal residual disease (“operational cure “) as a",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:125"
    }
  },
  {
    "page_content": "residual disease (“operational cure “) as a novel treatment goal, implying normal blood cell counts, low-burden JAK2V617F (below 1–5%) and a normal bone marrow without fibrosis after long-term treatment with stem-cell-targeting therapy with IFN monotherapy or in combination with JAK1-2 therapy (COMBI), circulating ECM biomarkers may be useful in monitoring early bone marrow stroma changes to increased clonal expansion otherwise remaining undetected by peripheral blood cell counts and",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:126"
    }
  },
  {
    "page_content": "undetected by peripheral blood cell counts and accordingly missing an opportunity for the early reinstitution of IFN to halt clonal expansion. Eleventh, ultimately, circulating ECM biomarkers may assist in predicting overall survival in MPNs by providing an integrated signature of the final outcome of chronic systemic inflammation, e.g., multiorgan failure due to fibrosis in the heart, lungs, kidneys and bone marrow. Twelfth, most previous studies on circulating ECM fragments in the context of",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:127"
    }
  },
  {
    "page_content": "on circulating ECM fragments in the context of MPNs have focused on major collagens such as collagen type I, III and IV. In recent years, circulating neo-epitope biomarkers have emerged to also quantify the minor and less-well-understood collagens in serum and for which an association with tumor fibrosis and poor prognosis has been indicated, for example, fragments from type XI and XXII collagen measured in serum from patients with pancreatic cancer (a very stroma rich solid tumor type). Such",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:128"
    }
  },
  {
    "page_content": "(a very stroma rich solid tumor type). Such tools may aid in our understanding of bone marrow fibrogenesis as well. # 8. Perspectives and Future Research Directions Although previous studies have shown that the serum concentrations of PIIINP, laminin and HYA to co-variate with conventional markers of disease activity, reflecting the close association between fibrogenesis in the bone marrow and hyperactive myeloproliferation, only serum PIIINP seemed to be useful in clinical settings. Since the",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:129"
    }
  },
  {
    "page_content": "to be useful in clinical settings. Since the early studies on serum PIIINP in MPNs, measurement of this type III collagen protein using neo-epitope technology such as PRO-C3 has emerged as a reliable indicator of fibrogenetic activity and prognosis across a range of solid tumors. In addition, other sensitive and reproducible assays have been developed, opening avenues for studies of several novel biomarkers of ECM origin in MPNs. Considering that chronic inflammation has been identified as an",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:130"
    }
  },
  {
    "page_content": "chronic inflammation has been identified as an important triggering mediator for clonal expansion from the CHIP stage towards overt MPN development but also has a great impact on disease progression in the MPN disease spectrum, it seems timely to rethink possibilities and perspectives in the area of circulating ECM marker research. By obtaining further insights into the ECM metabolism in MPNs, there are several perspectives present in such studies, including the introduction of circulating",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:131"
    }
  },
  {
    "page_content": "including the introduction of circulating ECM-derived peptides as serological markers singly or as patterns to distinguish between, e.g., genuine ET and prefibrotic myelofibrosis and to follow the impact of different potentially disease-modifying treatment modalities, such as IFN and JAK 1-2 inhibitors, both as monotherapies and in combination, since both agents have been shown to induce regression of bone marrow fibrosis in MPNs. Additionally, future research should include the measurement of",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:132"
    }
  },
  {
    "page_content": "future research should include the measurement of circulating ECM biomarkers in clinical trials by using novel agents that directly target the fibrotic process in the bone marrow. ## 8.1. Zinpentraxin alfa Zinpentraxin alfa is a recombinant human form of pentraxin 2(PTX-2) and seems to be particularly promising. PTX-2 is a regulator of the inflammatory response to tissue injury and fibrosis. PTX-2 binds to damaged cells and facilitates their safe removal in a nonimmunogenic manner. By binding",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:133"
    }
  },
  {
    "page_content": "removal in a nonimmunogenic manner. By binding to Fcγ receptors and dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), PTX-2 facilitates immunoregulatory and phagocytic polarization of monocytes, thereby inhibiting their differentiation into fibroblast-like, collagen-producing cells, named fibrocytes. Highly intriguing in this context, low PTX-2 levels have been reported in patients with myelofibrosis. Zinpentraxin alfa has shown anti-fibrotic and",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:134"
    }
  },
  {
    "page_content": "Zinpentraxin alfa has shown anti-fibrotic and anti-inflammatory activity in preclinical models of fibrosing disorders, including prevention of bone marrow fibrosis by inhibiting bone-marrow-derived fibrocytic differentiation in vitro, reverting bone marrow fibrosis in animals, and also improving survival in a mouse model. Importantly, zinpentraxin alfa has already demonstrated clinical activity and a well-tolerated safety profile in a phase-II trial in patients with pulmonary fibrosis.",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:135"
    }
  },
  {
    "page_content": "trial in patients with pulmonary fibrosis. Preliminary data from a safety and efficacy study of zinpentraxin alfa in patients with myelofibrosis are promising. ## 8.2. Colchicine Circulating ECM markers may also be considered as indicators of treatment response in clinical trials on inexpensive old drugs, such as colchicine, statins, N-acetylcysteine (NAC) and metformin, which all have been shown to have the potential to reduce inflammation and organ fibrosis. Thus, colchicine is an established",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:136"
    }
  },
  {
    "page_content": "fibrosis. Thus, colchicine is an established anti-inflammatory drug, which attenuates the NLRP3 inflammasome and also inhibits collagen synthesis. The anti-inflammatory potential of colchicine has most recently been studied in patients with chronic coronary artery disease, displaying remarkable activity in terms of reducing cardiovascular events and lowering a large number of inflammatory proteins, including CRP, IL1beta, and IL-6. Colchicine preferably accumulates in neutrophils, interfering",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:137"
    }
  },
  {
    "page_content": "accumulates in neutrophils, interfering with neutrophil adhesion, mobilization, and recruitment and inhibiting neutrophil chemotaxis and superoxide production. Accordingly, several circulating neutrophil granule components are strongly reduced during treatment with colchicine, including myeloblastin, carcinoembryonic antigen-related cell adhesion molecule 8, azurocidin, myeloperoxidase as well as circulating urokinase plasminogen activator surface receptor. Therefore, theoretically, colchicine",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:138"
    }
  },
  {
    "page_content": "receptor. Therefore, theoretically, colchicine may benefit patients with MPNs, which are characterized by the in vivo activation of circulating leukocytes and platelets, with a constant release of all the above neutrophil constituents, and hence, elevated circulating levels. Of note, as previously alluded to, a significant association between plasma suPAR, serum PIIINP, serum hyaluronan and the serum concentration of the carboxyterminal telopeptide of type I collagen (S-ICTP) has been",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:139"
    }
  },
  {
    "page_content": "telopeptide of type I collagen (S-ICTP) has been demonstrated, suggesting that enzymes of the uPA system participate in bone marrow remodelling in MPN. YKL-40 (chitinase-3 like protein-1 (CHI3L1)-another biomarker of chronic inflammation, tissue remodelling, fibrosis and of disease burden in chronic inflammatory diseases and cancer, has also been demonstrated to be significantly elevated in patients with MPNs, the highest plasma levels being recorded in patients with myelofibrosis. Whole-blood",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:140"
    }
  },
  {
    "page_content": "in patients with myelofibrosis. Whole-blood gene expression studies in MPNs have demonstrated a marked upregulation of several of the genes encoding the above proteins, including oxidative stress genes and thromboinflammatory genes. Amongst the latter is peptidyl arginine deiminase 4 (PAD4), which induces neutrophil extracellular trap formation (NETOsis) and protein citrullination. In this regard, elevated circulating NETs have recently been reported in MPNs with significantly lower levels",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:141"
    }
  },
  {
    "page_content": "reported in MPNs with significantly lower levels during treatment with IFN, which also suppresses upregulated thromboinflammatory genes, oxidative stress genes and favourably impacts deregulated atherosclerosis and ECM genes in MPNs as well. Importantly, colchicine also potently reduces NETosis activity and oxidative stress. Since NETs promote the differentiation and function of fibroblasts, the reduction in NETosis activity by colchicine may indirectly also impair fibrogenesis. Other",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:142"
    }
  },
  {
    "page_content": "may indirectly also impair fibrogenesis. Other mechanisms for inhibition of fibrogenesis by colchicine include interference with type III procollagen synthesis and increasing collagenase production. Adding to this, colchicine suppresses the release of fibroblast growth factors from alveolar macrophages in vitro, including fibronectin and alveolar-macrophage-derived growth factor. In the context of inducing regression of fibrosis in fibrosing disorders, such as idiopathic pulmonary fibrosis,",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:143"
    }
  },
  {
    "page_content": "disorders, such as idiopathic pulmonary fibrosis, clinical studies on the efficacy of colchicine have yielded discordant results, probably due to suboptimal study designs (e.g., retrospective studies; combination with other agents) but perhaps also because colchicine was initiated at an advanced stage of the fibrotic process. To summarize, based on the above colchicine effects, we anticipate that colchicine should be conceived as a plausible modifier of not only the chronic inflammatory state",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:144"
    }
  },
  {
    "page_content": "of not only the chronic inflammatory state and blood clot formation in MPNs, but may also favourably impact the resolution of bone marrow fibrosis. ## 8.3. N-Acetylcysteine (NAC) The MPNs have been added to the list of “High Oxidative Stress“-diseases since JAK2V617F mutation generates ROS and also enhances oxidative stress via the impairment of mitochondrial antioxidative defence. Taking into account that N-acetylcysteine (NAC) is a highly potent scavenger of ROS, NAC treatment has been",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:145"
    }
  },
  {
    "page_content": "potent scavenger of ROS, NAC treatment has been proposed for the treatment of MPNs not least also because NAC reduces thrombosis in a JAK2V617F knock-in mouse model and also reduces NET formation in neutrophils from patients with MPNs as well as controls. Indeed, NAC may also favourably influence the deposition of collagen in the bone marrow, considering that NAC has shown efficacy in a subset of patients with idiopathic pulmonary fibrosis although not being reproduced in a later study.",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:146"
    }
  },
  {
    "page_content": "although not being reproduced in a later study. However, the beneficial potential of NAC in the treatment of idiopathic pulmonary fibrosis is still being pursued, the arguments and rationales being that a subset of patients with a particular genotype (TOLLIP rs3750920 TT), present in about 25% of patients with idiopathic pulmonary fibrosis, may actually gain benefits, since these patients seemed to benefit from NAC in a later subgroup analysis of the original cohort. Intriguingly, an",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:147"
    }
  },
  {
    "page_content": "analysis of the original cohort. Intriguingly, an association between pulmonary fibrosis and myelofibrosis has been repeatedly described in the literature. Although this association may be explained via the seeding and sequestration of megakaryocytes and other hematopoietic progenitors in the pulmonary microcirculation with ensuing release of growth factors mitogenic for fibroblast- and endothelial proliferation in the lungs, it is pertinent to consider, if some patients with MPN myelofibrosis",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:148"
    }
  },
  {
    "page_content": "consider, if some patients with MPN myelofibrosis and some patients with idiopathic pulmonary fibrosis may actually have some distinctive genotypes in common, which are associated with organ fibrosis. If so, the first step toward personalized medicine for patients with idiopathic pulmonary fibrosis may pave the path for similar initiatives in patients with myelofibrosis and associated neoplasms and also in autoimmune diseases like rheumatoid arthritis, in which pulmonary inflammation has,",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:149"
    }
  },
  {
    "page_content": "arthritis, in which pulmonary inflammation has, within recent years, been recognized as a long-term clinically silent feature. In this scenario, linking genetics to measurements of ECM markers may turn out as a novel approach for personalized precision medicine, which hopefully may improve the selection of the right patients for the right anti-inflammatory and anti-fibrosing treatments. In addition, such combinations of diagnostic tools may also provide new insights into the disease mechanisms",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:150"
    }
  },
  {
    "page_content": "provide new insights into the disease mechanisms underlying pulmonary dysfunction in MPNs, considering that pulmonary mortality most recently has been shown to be a leading cause of death in patients with MPNs. In this regard, it is worth speculating whether undiagnosed pulmonary fibrosis is a significant cause of pulmonary morbidity and mortality in a subset of patients. Concomitant studies of pulmonary function, imaging, inflammatory cytokines and circulating lung-derived ECM fragments are",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:151"
    }
  },
  {
    "page_content": "and circulating lung-derived ECM fragments are conceptually useful tools for studying pulmonary dysfunction and failure upon the clinical course and prognosis in MPNs. ## 8.4. Statins and Metformin Similar to colchicine and NAC, statins possess potent anti-inflammatory and anti-thrombotic capabilities, and it has been argued that statins may impair clonal expansion and evolution in MPN, thereby potentially impeding disease progression and likely also the development of other cancers in MPNs.",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:152"
    }
  },
  {
    "page_content": "also the development of other cancers in MPNs. Indeed, this assumption is supported by the Danish Statin Study on the impact of statins on cancer-associated mortality, which has shown a 15% reduction in cancer-associated mortality in statin users. Furthermore, a most recent Danish register study has shown that statin treatment protects against the development of MPNs. Several reviews in recent years have also underscored the potential of metformin as an anti-cancer agent. In the context of",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:153"
    }
  },
  {
    "page_content": "as an anti-cancer agent. In the context of tumor fibrosis as a barrier for effective tumor eradication by the immune system, it is highly interesting, that metformin seems to induce the depletion of collagen, thereby increasing the efficacy of chemotherapy in pancreatic cancer by degrading the tumor fibrosis barrier, which protects tumor cells from being attacked by effector immune cells. For all the above reasons, clinical trials of the old, inexpensive drugs—colchicine, statins, NAC and",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:154"
    }
  },
  {
    "page_content": "inexpensive drugs—colchicine, statins, NAC and metformin—in patients with newly diagnosed MPNs seem to be pertinent and timely. Such protocols should optimally include concurrent monitoring using conventional biomarkers of chronic inflammation (CRP, Neutrophil-Lymphocyte Ratio), circulating levels of inflammatory cytokines, gene expression profiling studies, and ECM marker patterns to describe in detail the associations between chronic inflammation, tissue remodelling and fibrosis development",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:155"
    }
  },
  {
    "page_content": "tissue remodelling and fibrosis development in MPNs. Of note, as addressed above, most recent studies have shown that both statins and metformin treatment protect against the development of MPNs, highlighting that these agents are potential disease-modifiers as well, likely due to suppression of the chronic inflammatory drive and ultimately, thereby also the development of bone marrow fibrosis. Therefore, studies on circulating ECM protein fragments are of particular interest in individuals",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:156"
    }
  },
  {
    "page_content": "are of particular interest in individuals harboring the driver mutations, JAK2V617F and CALR, in the CHIP stage before the development of MPNs. In this regard, the Danish GESUS (General Suburban Study) cohort of 613 JAK2V617F and 35 CALR-positive CHIP-citizens are ideal cohorts to study consecutively the dynamics of ECM proteins in a large, well-characterized cohort with a shortened life span compared to an age- and gender-matched CHIP-negative cohort. The decreased survival has been shown to",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:157"
    }
  },
  {
    "page_content": "cohort. The decreased survival has been shown to be due to an increased risk of cardiovascular diseases and cancer (unpublished data). Measurements of circulating ECM fragments in this CHIP-cohort are expected to provide important information on the value of ECM fragments as predictors of cardiovascular diseases, development of MPNs, other cancers and other inflammation-mediated diseases, which are likely driven by somatic acquired inflammatory mutations, such as JAK2V617F and CALR. In such",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:158"
    }
  },
  {
    "page_content": "mutations, such as JAK2V617F and CALR. In such studies, the impact of various treatments (e.g., statins, bisphosphonates, NAC and metformin) should also be explored, assuming that a favourable treatment response translates into lower levels of, e.g., serum PIIINP in individuals being treated with these agents as compared to those not being treated. Our recent findings in the GESUS cohort, that statins reduce systemic markers of inflammation and that individuals carrying the inflammatory and",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:159"
    }
  },
  {
    "page_content": "that individuals carrying the inflammatory and thrombogenic JAK2V617F mutation are exposed to increased oxidative stress and DNA damage, potentially implying an increased risk of cardiovascular diseases and development of not only MPN but also other cancers, emphasize the need for studies on new frontline disease markers to elucidate their value as biomarkers for early detection of among others cardiovascular diseases and cancer. Future research on ECM protein metabolism in MPNs should focus on",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:160"
    }
  },
  {
    "page_content": "on ECM protein metabolism in MPNs should focus on the value of circulating ECM fragments as tools to obtain an integrated signature of the impact of clonal myeloproliferation not only on bone marrow stroma changes in terms of fibrogenesis and angiogenesis but also systemically in other organs such as the heart, lungs and kidneys. However, it should be underscored that at this time, it is not possible to determine exactly the tissue origin of single markers or marker profiles, which is a key",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:161"
    }
  },
  {
    "page_content": "single markers or marker profiles, which is a key research issue to be resolved. It is hoped that the presently outlined studies, in conjunction with others, may contribute to defining the potential and future role of ECM markers in the management of the inflammatory and fibrosing processes that determine the transition from multiorgan dysfunction to multiorgan failure in MPNs. As a class example, the ECM biomarker PRO-C6 (endotrophin) is a collagen VI formation-derived peptide, which most",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:162"
    }
  },
  {
    "page_content": "collagen VI formation-derived peptide, which most recently has been published as a potential next-generation biomarker in patients with heart failure with preserved ejection (HFpEF). This biomarker measures type VI collagen formation, which is upregulated, when fibroblasts are activated, giving rise to organ fibrosis. Endotrophin is a proinflammatory and profibrotic mediator, which is thought to contribute to HFpEF and tentatively also in MPN disease progression and development of",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:163"
    }
  },
  {
    "page_content": "in MPN disease progression and development of myelofibrosis. Since HFpEF is prevalent among patients with chronic inflammatory diseases, such as hypertension and type II diabetes, it is intriguing to speculate if HFpEF is similarly prevalent in MPNs, and contributing to the increased cardiovascular disease burden. Concurrent echocardiographic studies and measurements of PRO-C6 are needed to explore the prevalence of HFpEF in MPNs and the potential of PRO-C6 as a novel biomarker for the",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:164"
    }
  },
  {
    "page_content": "potential of PRO-C6 as a novel biomarker for the assessment of individual patient risk and prognosis, but also as a novel tool in therapeutic decision making. In the context of the comorbidity–inflammation paradigm and MPNs as “A Human Inflammation Model “, MPNs and inflammation-mediated comorbidities may reinforce systemic inflammation and, accordingly the development of myocardial fibrosis and HFpEF. This concept is supported by the progressive increase in plasma level of CRP with rising",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:165"
    }
  },
  {
    "page_content": "increase in plasma level of CRP with rising numbers of comorbidities in HFpEF patients. Similarly, recent studies have underscored the important role of chronic inflammation, assessed using serial measurements of CRP and NLR, for the development of MPNs with elevated levels of NLR several years before the diagnosis of MPNs and with a temporal increase in the number of comorbidities. Neutrophil extracellular traps (NETs) have been shown to be induced by the potently inflammatory and thrombogenic",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:166"
    }
  },
  {
    "page_content": "by the potently inflammatory and thrombogenic JAK2V617F mutation, and most recently, a Danish study has reported that elevated NET levels decrease during treatment with pegylated interferon-alpha2 (IFN). Of note, NETs may promote fibroblast activation and fibrosis. Considering that IFN decreases NETs, this effect may also facilitate a reduction in bone marrow fibrosis. Furthermore, IFN has been shown to alleviate angina pectoris in a patient with ischemic heart disease and also favourably",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:167"
    }
  },
  {
    "page_content": "with ischemic heart disease and also favourably impacts deregulated atherosclerosis genes. Accordingly, future research should engage in studies that concurrently investigate the deregulation of inflammation, NETosis, oxidative stress, antioxidative stress and atherosclerosis genes using whole-blood gene expression profiling in concert with serial measurements of circulating ECM biomarkers and levels of NETs in patients with MPNs and +/− HFpEF before and during treatment with IFN. Such studies",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:168"
    }
  },
  {
    "page_content": "and during treatment with IFN. Such studies will likely yield important new insights into common pathogenetic mechanisms in the development of myocardial fibrosis, its occurrence in patients with MPNs and the potential capability of IFN to revert myocardial fibrosis and bone marrow fibrosis. As previously mentioned, incremental bone marrow fibrosis grade is today considered to herald a poor prognosis. However, in some earlier studies, advanced bone marrow fibrosis per se did not appear to have",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:169"
    }
  },
  {
    "page_content": "marrow fibrosis per se did not appear to have a negative influence upon survival. On the contrary, among patients with classic PMF, those with diffuse collagenization of the bone marrow together with osteosclerosis actually fared better than those without osteomyelosclerosis. This observation has not been pursued in other studies but may be of considerable interest since it may reflect that repair processes in the bone marrow in response to clonal, myeloproliferation may actually impair clonal",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:170"
    }
  },
  {
    "page_content": "myeloproliferation may actually impair clonal expansion and thus postpone the acceleration of the disease. Indeed, this early observation aligns with recent findings, supporting that both type III collagen and type VI collagen may have dual roles by being both pro- or anti-tumorigenic. Thus, previous studies showed that a decrease in type III collagen in the tumor stroma may actually increase the aggressiveness of proliferative breast tumors, contrasting upregulated COL3A1 expression, which has",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:171"
    }
  },
  {
    "page_content": "upregulated COL3A1 expression, which has been shown to associate with increased survival in breast cancer patients, suggesting that type III collagen can limit metastasis. Aligning these studies, most recently, tumor-derived type III collagen has been shown to be required in order to maintain tumor dormancy while disruption of type III collagen reactivates tumor cell proliferation. Similarly, type VI collagen types VI-α1 and 2 chains can be anti-tumorigenic by inhibiting both proliferation,",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:172"
    }
  },
  {
    "page_content": "by inhibiting both proliferation, migration and invasion of bladder cancer cells. An association between the attenuation of collagen synthesis in cancer-associated fibroblasts and an increase in tumor growth and spread has also been shown in several mouse studies. Importantly, however, the resolution of tumor fibrosis is also considered to render the cancer cells more accessible to tumor killing by the immune system and targeted therapeutic intervention, including, e.g., with IFN or novel",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:173"
    }
  },
  {
    "page_content": "intervention, including, e.g., with IFN or novel immunomodulating agents. Taken together, the progressive accrual of fibrotic tissue in the bone marrow in MPNs may actually not always be deleterious but rather exert a defence against clonal expansion and myeloproliferation, which, when eventually overwhelmed with the expansion and evolution of the malignant clone and ensuing accelerating myeloproliferation, is the ultimate outcome of balancing between the efforts, attempting to build up a",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:174"
    }
  },
  {
    "page_content": "between the efforts, attempting to build up a barrier (fibrosis, osteosclerosis) against myeloproliferation and egress of immature progenitors from the bone marrow (metastasis) and resolution of fibrosis to facilitate the killing of malignant cells by the immune system. Thus, bone marrow fibroblasts and collagens in MPNs may have dual effects, which should be studied in further detail. In 2023 and ahead, we have the advantage of exploring all these aspects more thoroughly via the concurrent",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:175"
    }
  },
  {
    "page_content": "these aspects more thoroughly via the concurrent measurement of circulating ECM fragments and studies of the bone marrow architecture, using a new technology, which much more precisely and comprehensively assesses bone marrow stroma changes, including fibrosis and angiogenesis, together with a description of cellular morphology with particular focus on the megakaryocyte lineage. By using a machine learning approach, this novel technology allows much better quantification of reticulin fibrosis,",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:176"
    }
  },
  {
    "page_content": "much better quantification of reticulin fibrosis, thereby improving the early detection and monitoring of bone marrow fibrosis (Continuous Indexing of Fibrosis (CIF)) and thereby also improving MPN subtyping. Indeed, in combination with analysis of megakaryocyte morphology, CIF accurately discriminates between ET and pre-fibrotic myelofibrosis and also holds promise in the identification of MPN patients at risk of disease progression. Concurrent studies of the associations between megakaryocyte",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:177"
    }
  },
  {
    "page_content": "studies of the associations between megakaryocyte morphology, CIF and ECM metabolites are expected to further refine disease classification and to improve the distinction between the MPN-subtypes, including the distinction between prefibrotic MF and genuine ET, further strengthening the evidence that prefibrotic MF is aligned along the biological MPN- continuum subtypes. Furthermore, such studies are foreseen to provide highly important insights into the earliest changes in bone marrow stroma",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:178"
    }
  },
  {
    "page_content": "into the earliest changes in bone marrow stroma by studies of JAK2V617F and CALR positive individuals with CHIP. Thereby, we may also obtain novel information on the microenvironmental factors, which are influential for clonal expansion and evolution, both at the earliest stage in the CHIP phase and across the MPN disease spectrum from the early cancer phase to advanced myelofibrosis. This information on the determinant factors for remodeling of the bone marrow in the earliest stage of MPN",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:179"
    }
  },
  {
    "page_content": "of the bone marrow in the earliest stage of MPN development—the CHIP stage—may ultimatively be translated into novel therapies, targeting the chronic inflammatory state to prevent development of CHIP into MPNs and hopefully to prevent disease progression in the MPN-biological continuum as well. In regard to monitoring the efficacy of novel agents, targeting not only the chronic inflammation, driving bone marrow fibrosis development, but also directly the ECM and the fibrotic process CIF in",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:180"
    }
  },
  {
    "page_content": "directly the ECM and the fibrotic process CIF in combination with measurement of circulating ECM peptides, may be extremely important tools, for example in future studies of the role of inhibitors of lysyl oxidase (LOX), taking into account the LOX connection between megakaryocyte pathology and development of bone marrow fibrosis. The importance of LOX was initially attributed to its role for the cross-linking of collagen or elastin and consequently in enhancing fibrosis. This cross-linking",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:181"
    }
  },
  {
    "page_content": "in enhancing fibrosis. This cross-linking contributes to the accumulation of ECM by promoting intrapeptide and interpeptide chain crosslinking. Importantly, LOX is also involved in proliferation of megakaryocytes and deposition of collagen fibers by oxidizing the PDGF receptor-β, amplifying its mitogenic potential and accordingly stimulating megakaryocyte expansion by PDGF-BB. Therefore, LOX has been suggested as a new potential therapeutic target for myelofibrosis based upon several",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:182"
    }
  },
  {
    "page_content": "target for myelofibrosis based upon several experimental and clinical studies, not only in myelofibrosis and related myeloid neoplasms but in other fibrosing diseases as well. In addition to being first reported elevated in a mouse model of MPN, LOX has also been found elevated in patients with MPNs. In MPN patients LOX levels may increase because of increased TGF-beta levels and signaling, since TGF-beta stimulates LOX expression. Importantly, in addition to facilitating collagen crosslinking,",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:183"
    }
  },
  {
    "page_content": "addition to facilitating collagen crosslinking, LOX is also implicated in the development of thrombosis. Thus, elevated LOX augments platelet adhesion to collagen and platelet activation. Accordingly, considering the heavy CVD burden in MPN and the potential of LOX to amplify receptor affinity for PDGF LOX might also have a role in the pathogenesis and progression of CVD in MPN. Since inhibition of LOX may reduce bone marrow fibrosis and thrombosis in mice with experimental MPN and arterial",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:184"
    }
  },
  {
    "page_content": "in mice with experimental MPN and arterial thrombosis clinical LOX-inhibitor trials are currently investigating or being planned with the issue to explore, whether LOX-inhibitors, either as monotherapy or in combination with, e.g., pegylated interferon-alpha2, JAK1-2 inhibitors or DNA-hypometylating agents may also reduce bone marrow fibrosis and thrombosis risk in patients with MPNs. In this regard concurrent studies on the associations between megakaryocyte morphology, CIF and ECM metabolites",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:185"
    }
  },
  {
    "page_content": "megakaryocyte morphology, CIF and ECM metabolites during treatment with LOX-inhibitors might unravel important novel aspects on the role of LOX and the impact of LOX-inhibition for development of bone marrow fibrosis in MPNs. Theoretically, the optimal target for tumor killing is the cancer stem cell, which in myelofibrosis is the mutated bone marrow stem cell. As previously addressed, IFN-alpha2 is widely used in the treatment of MPNs and is able to induce minimal residual disease with normal",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:186"
    }
  },
  {
    "page_content": "to induce minimal residual disease with normal bone marrow architecture in a subset of patients after long-term treatment (approximately 5 years). In concert with the normalization of elevated blood cell counts, a reduction in the potently inflammatory and thrombogen JAK2V617F mutation, lowering of myeloid-derived suppressor cells (MDSCs), boosting of immune cells, and downregulation of tumor antigens, IFN-alpha2 also favourably regulates several deregulated immune and inflammation genes,",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:187"
    }
  },
  {
    "page_content": "deregulated immune and inflammation genes, including the upregulation of HLA genes on tumor cells, thereby making them more accessible to killing by the immune system. In addition, IFN-alpha2 has also demonstrated a potent stem-cell-targeting potential by reactivating dormant JAK2V617F-positive stem cells and put them in cycle to be killed directly by IFN-alpha2 and IFN-activated immune cells (e.g., dendritic cells, NK-cells, T-cells). Interferon-beta (IFN-beta) has similar beneficial",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:188"
    }
  },
  {
    "page_content": "Interferon-beta (IFN-beta) has similar beneficial anti-cancer effects but is likely much stronger than IFN-alpha2, making it a potential alternative to IFN-alpha in the treatment of MPNs and possibly also in the treatment of other cancers as well in combination with novel immunotherapies. Remarkably, IFN-beta has been shown to suppress cancer stem cell properties in triple-negative breast cancer. Combination therapy with IFN-alpha2 and the potent anti-inflammatory drug ruxolitinib (JAK1-2",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:189"
    }
  },
  {
    "page_content": "potent anti-inflammatory drug ruxolitinib (JAK1-2 inhibitor) has very strong synergistic effects with much faster normalization of peripheral blood cell count and a reduction in the JAK2V617F allelic burden in patients with MPNs. Highly intriguing, normal bone marrow architecture with resolution of bone marrow fibrosis is achievable with this combination therapy, even within 12 or 24 months of therapy. Similar combination therapies with cancer-stem cell targeting therapy (IFN-alpha2 or",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:190"
    }
  },
  {
    "page_content": "cancer-stem cell targeting therapy (IFN-alpha2 or IFN-beta) together with a potent anti-inflammatory (e.g., JAK1-2 inhibitor, colchicine) and potentially tumor-fibrosis resolving therapy (e.g., colchicine, metformin, angiotensin II receptor blocker (losartan)) may favourably influence the impact of novel immunomodulating agents, such as immune-check inhibitors and inhibitors of TGF-beta signaling, in the treatment of cancer, e.g., pancreatic cancer and myelofibrosis (Table 2). In this context,",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:191"
    }
  },
  {
    "page_content": "and myelofibrosis (Table 2). In this context, studies of circulating ECM fragments before and during the above mono- or combination therapies are pertinent to study in-depth ECM protein metabolism and correlations to clinical, biochemical and molecular variables in order to discover novel treatment targets and novel predictive biomarkers for treatment response and prognosis. Such studies are also foreseen to add novel information on the role of the extracellular matrix and its composition for",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:192"
    }
  },
  {
    "page_content": "the extracellular matrix and its composition for the efficacy of the above therapies, considering that collagen density has been shown to regulate the activity of tumor-infiltrating T cells and modulates the immunosuppressive effects of macrophages. These studies should also address the role of the various collagen fragments for T-cell suppression and T-cell exhaustion in myelofibrosis, considering that these fragments have been shown to mediate T-cell suppression in other cancers. Table 3",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:193"
    }
  },
  {
    "page_content": "T-cell suppression in other cancers. Table 3 summarizes key research questions to be addressed in future studies of circulating ECM fragments as biomarkers of clonal expansion and evolution in the CHIP-JAK2V617F stage and in the biological MPN disease spectrum from the early cancer stages, ET and PV, to the advanced myelofibrosis stage. # 9. Conclusions MPNs are associated with an evolving chronic inflammatory state, concurrent immunoderegulation and fibrosis, which are often associated with",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:194"
    }
  },
  {
    "page_content": "and fibrosis, which are often associated with gradually emerging chronic inflammation-related comorbidities. Within the last decade, novel sensitive and reproducible assay technologies for quantification of circulating ECM metabolites have been introduced for early detection and follow-up in fibrosing conditions, e.g., myelofibrosis and allied conditions including cancer-related desmoplasia. At the same time, there have been considerable gains in the knowledge about pathogenetic pathways in the",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:195"
    }
  },
  {
    "page_content": "the knowledge about pathogenetic pathways in the MPNs, and their natural history has been elucidated in more detail and classification criteria have been refined. It therefore seems pertinent to take advantage of the current state-of-the-art clinical and laboratory opportunities by resuming previous research efforts to identify candidate ECM markers or marker patterns, aiming at early detection and prognostication of MPN and related comorbidities in large, clinically well-characterized study",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:196"
    }
  },
  {
    "page_content": "in large, clinically well-characterized study populations. Combined with innovative novel advanced artificial intelligence approaches, demonstrating the potential of extracting quantitative data from routinely prepared bone marrow biopsies much more reliably and precisely than conventional histopathology, thereby improving the assessment and classification of MPN patients, such studies are foreseen to offer new insights into the pathobiology of MPNs and how to interrupt the vicious,",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:197"
    }
  },
  {
    "page_content": "of MPNs and how to interrupt the vicious, inflammatory self-perpetuating circle, that otherwise will evolve into bone marrow failure and development of inflammation-mediated multimorbidities. In the context of MPNs sharing with type II diabetes mellitus (DM) so many inflammation-mediated comorbidities, and both diseases being heavily burdened by multimorbidities and multiorgan failure in the advanced disease phases, endotrophin may be one of the promising markers to investigate in MPNs,",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:198"
    }
  },
  {
    "page_content": "of the promising markers to investigate in MPNs, considering its excellent performance as a marker of complications in type 2 DM.",
    "metadata": {
      "source": "../data/plain/PMC10486581.plain.txt",
      "id": "../data/plain/PMC10486581.plain.txt:199"
    }
  },
  {
    "page_content": "Disease heterogeneity and personalized prognosis in myeloproliferative neoplasms Abstract\nBackground\nMyeloproliferative neoplasms (MPN), comprising polycythemia vera, essential thrombocythemia and myelofibrosis, are chronic hematological malignancies with variable progression rates. Genomic characterization of MPN patients offers the potential for personalised diagnosis, risk stratification and management.\nMethods",
    "metadata": {
      "source": "../data/plain/PMC7030948.plain.txt",
      "id": "../data/plain/PMC7030948.plain.txt:0"
    }
  },
  {
    "page_content": "Methods\nWe sequenced coding exons from 69 myeloid cancer genes in 2035 MPN patients, comprehensively annotating driver mutations and copy number changes. We developed a genomic classification for MPNs and multistage prognostic models for predicting individual patient outcomes. Classification and prognostic models were validated on an external cohort.\nResults",
    "metadata": {
      "source": "../data/plain/PMC7030948.plain.txt",
      "id": "../data/plain/PMC7030948.plain.txt:1"
    }
  },
  {
    "page_content": "33 genes carried driver mutations in >4 patients, with JAK2, CALR or MPL mutations being the sole abnormality in 45% patients. The number of driver mutations increased with age and advanced disease. Driver mutations, germline polymorphisms and demographic variables independently predicted whether patients were diagnosed with essential thrombocythemia versus polycythemia vera, and chronic phase disease versus myelofibrosis. We defined 8 genomic subgroups, exhibiting distinct clinical phenotypes,",
    "metadata": {
      "source": "../data/plain/PMC7030948.plain.txt",
      "id": "../data/plain/PMC7030948.plain.txt:2"
    }
  },
  {
    "page_content": "exhibiting distinct clinical phenotypes, including diagnostic blood counts, risk of leukemic transformation and event-free survival. Integrating 63 clinical and genomic variables, we created prognostic models capable of generating personally-tailored predictions of clinical outcomes in chronic phase MPN or myelofibrosis. Predicted and observed outcomes correlated well using internal cross-validation and an independent external cohort. Even within individual categories of existing prognostic",
    "metadata": {
      "source": "../data/plain/PMC7030948.plain.txt",
      "id": "../data/plain/PMC7030948.plain.txt:3"
    }
  },
  {
    "page_content": "individual categories of existing prognostic schemas, our models substantially improved predictive accuracy.",
    "metadata": {
      "source": "../data/plain/PMC7030948.plain.txt",
      "id": "../data/plain/PMC7030948.plain.txt:4"
    }
  },
  {
    "page_content": "Conclusions\nComprehensive genomic characterization identifies distinct genetic subgroups and provides an MPN classification based on causal biological mechanisms. Integration of genomic data with clinical parameters enables personalised predictions of patient outcome and will support management of MPN patients.",
    "metadata": {
      "source": "../data/plain/PMC7030948.plain.txt",
      "id": "../data/plain/PMC7030948.plain.txt:5"
    }
  },
  {
    "page_content": "Risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer (Teenage and Young Adult Cancer Survivor Study): a population-based, cohort study Summary\nBackground\nFew studies have investigated the risks of subsequent primary neoplasms after adolescent and young adult (AYA) cancer. We investigated the risks of specific subsequent primary neoplasms after each of 16 types of AYA cancer.\nMethods",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:0"
    }
  },
  {
    "page_content": "The Teenage and Young Adult Cancer Survivor Study is a population-based cohort of 200 945 survivors of cancer diagnosed when aged 15–39 years in England and Wales from Jan 1, 1971, to Dec 31, 2006. The cohort was established using cancer registrations from the Office for National Statistics and the Welsh Cancer registry. Follow-up was from 5-year survival until the first occurrence of death, emigration, or study end date (Dec 31, 2012). In this analysis, we focus on the risk of specific",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:1"
    }
  },
  {
    "page_content": "this analysis, we focus on the risk of specific subsequent primary neoplasms after 16 types of AYA cancer: breast; cervical; testicular; Hodgkin lymphoma (female); Hodgkin lymphoma (male); melanoma; CNS (intracranial); colorectal; non-Hodgkin lymphoma; thyroid; soft-tissue sarcoma; ovarian; bladder; other female genital; leukaemia; and head and neck cancer. We report absolute excess risks (AERs; per 10 000 person-years) and cumulative incidence of specific types of subsequent primary neoplasm",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:2"
    }
  },
  {
    "page_content": "of specific types of subsequent primary neoplasm after each type of AYA cancer.",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:3"
    }
  },
  {
    "page_content": "Findings",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:4"
    }
  },
  {
    "page_content": "During the 2 631 326 person-years of follow-up (median follow-up 16·8 years, IQR 10·5–25·2), 12 321 subsequent primary neoplasms were diagnosed in 11 565 survivors, most frequently among survivors of breast cancer, cervical cancer, testicular cancer, and Hodgkin lymphoma. AERs of any subsequent primary neoplasms were 19·5 per 10 000 person-years (95% CI 17·4–21·5) in survivors of breast cancer, 10·2 (8·0–12·4) in survivors of cervical cancer, 18·9 (16·6–21·1) in survivors of testicular cancer,",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:5"
    }
  },
  {
    "page_content": "(16·6–21·1) in survivors of testicular cancer, 55·7 (50·4–61·1) in female survivors of Hodgkin lymphoma, and 29·9 (26·3–33·6) in male survivors of Hodgkin lymphoma. The cumulative incidence of all subsequent primary neoplasms 35 years after diagnosis was 11·9% (95% CI 11·3–12·6) in survivors of breast cancer, 15·8% (14·8–16·7) in survivors of cervical cancer, 20·2% (18·9–21·5) in survivors of testicular cancer, 26·6% (24·7–28·6) in female survivors of Hodgkin lymphoma, and 16·5% (15·2–18·0) in",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:6"
    }
  },
  {
    "page_content": "of Hodgkin lymphoma, and 16·5% (15·2–18·0) in male survivors of Hodgkin lymphoma. In patients who had survived at least 30 years from diagnosis of cervical cancer, testicular cancer, Hodgkin lymphoma in women, breast cancer, and Hodgkin lymphoma in men, we identified a small number of specific subsequent primary neoplasms that account for 82%, 61%, 58%, 45%, and 41% of the total excess number of neoplasms, respectively. Lung cancer accounted for a notable proportion of the excess number of",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:7"
    }
  },
  {
    "page_content": "for a notable proportion of the excess number of neoplasms across all AYA groups investigated.",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:8"
    }
  },
  {
    "page_content": "Interpretation",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:9"
    }
  },
  {
    "page_content": "Our finding that a small number of specific subsequent primary neoplasms account for a large percentage of the total excess number of neoplasms in long-term survivors of cervical, breast, and testicular cancer, and Hodgkin lymphoma provides an evidence base to inform priorities for clinical long-term follow-up. The prominence of lung cancer after each of these AYA cancers indicates the need for further work aimed at preventing and reducing the burden of this cancer in future survivors of AYA",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:10"
    }
  },
  {
    "page_content": "burden of this cancer in future survivors of AYA cancer.",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:11"
    }
  },
  {
    "page_content": "Funding",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:12"
    }
  },
  {
    "page_content": "Cancer Research UK, National Institute for Health Research, Academy of Medical Sciences, and Children with Cancer UK. # Introduction 5-year relative survival after adolescent and young adult (AYA) cancer is 82% in Europe.1 Survivors are at increased risk of developing subsequent primary neoplasms, estimated to be between 1·5 and 3·1 times higher than that expected from the general population.2, 3 Previous large-scale studies of survivors of AYA cancers mostly concentrated on the risk of",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:13"
    }
  },
  {
    "page_content": "of AYA cancers mostly concentrated on the risk of subsequent primary neoplasms after common cancers such as lymphomas, testicular cancer, and breast cancer.4, 5, 6, 7, 8, 9, 10, 11, 12, 13 Only one study comprehensively investigated the risks of developing any subsequent primary neoplasm after each type of AYA cancer.3 The main finding from the study was that survivors of AYA cancer had a higher absolute risk of developing a subsequent primary neoplasm than did survivors of childhood or adult",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:14"
    }
  },
  {
    "page_content": "neoplasm than did survivors of childhood or adult cancer. Survivors of primary breast cancer and primary Hodgkin lymphoma had the highest absolute excess risk (54·4 and 48·6 per 10 000 person-years, respectively). However, the study did not investigate the risks of specific subsequent primary neoplasms after each specific type of AYA cancer. Research in contextEvidence before this studyThe risks of subsequent primary neoplasms in survivors of adolescent and young adult (AYA) cancers are largely",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:15"
    }
  },
  {
    "page_content": "and young adult (AYA) cancers are largely unknown. We searched PubMed without any language or date restrictions using the keywords “teenage and young adult cancer OR adolescent and young adult cancer” and “survivor OR long-term” and “second cancer OR subsequent cancer” on Feb 16, 2016, for articles describing subsequent primary neoplasms in this population. A more focused search using each specific AYA cancer as keywords (eg, “Hodgkin lymphoma”) in place of “teenage and young adult cancer OR",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:16"
    }
  },
  {
    "page_content": "in place of “teenage and young adult cancer OR adolescent and young adult cancer” was also done. Additionally, we examined the bibliographies of selected references. Subsequent searches were done on Dec 31, 2016, and July 15, 2018. Most previous publications included the more common AYA cancers, but were not restricted to AYA cancer survivors. We identified only one study that investigated the risk of subsequent primary neoplasms after the entire spectrum of AYA cancers diagnosed at 15–39 years",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:17"
    }
  },
  {
    "page_content": "spectrum of AYA cancers diagnosed at 15–39 years of age.Added value of this studyTo our knowledge, this is the largest study to investigate the risks of subsequent primary neoplasm after each specific AYA cancer and the first to provide excess risks of specific types of subsequent primary neoplasm after each of 16 types of AYA cancer. Unlike previous studies, which focused on the multiplicative risk, we concentrated on the absolute excess risk—ie, the excess number of subsequent primary",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:18"
    }
  },
  {
    "page_content": "risk—ie, the excess number of subsequent primary neoplasms beyond those expected from the general population, which is directly interpretable in terms of adverse health impact on survivors. Our study shows that the excess number of subsequent primary neoplasms increased with increasing years from diagnosis for all AYA cancers investigated in detail. Additionally, we identified a small number of specific subsequent primary neoplasms that account for a substantial proportion of the total excess",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:19"
    }
  },
  {
    "page_content": "for a substantial proportion of the total excess number of neoplasms in survivors of breast cancer, cervical cancer, testicular cancer, and Hodgkin lymphoma.Implications of all the available evidenceOur findings advance previous knowledge on the risks of subsequent neoplasms after AYA cancer and provide an evidence base for identifying priorities for clinical follow-up of survivors of AYA cancer. Because lung cancer accounted for a notable proportion of the excess number of neoplasms across all",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:20"
    }
  },
  {
    "page_content": "of the excess number of neoplasms across all AYA groups investigated, there is need for work aimed at reducing this burden among future survivors. Evidence from previous studies of childhood cancer survivors suggests that the principal factors determining risks of subsequent primary neoplasms relate to aspects of treatments received for the original cancer.14, 15, 16 Treatment of AYA cancer varies greatly by cancer type and therefore, in the absence of detailed treatment information, it is",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:21"
    }
  },
  {
    "page_content": "absence of detailed treatment information, it is essential to stratify risks by specific types of AYA cancer; such risk stratification provides an evidence base for clinical follow-up. The aims of this large-scale population-based study were to calculate risks of all and specific subsequent primary neoplasms after each type of AYA cancer and to explore variation in these risks in relation to years from diagnosis, age at diagnosis, decade of diagnosis, and sex. # Methods ## Study design and",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:22"
    }
  },
  {
    "page_content": "diagnosis, and sex. # Methods ## Study design and participants The Teenage and Young Adult Cancer Survivor Study (TYACSS) was established using cancer registrations relating to neoplasms diagnosed between Jan 1, 1971, and Dec 31, 2006, in individuals aged 15–39 years inclusive, which were obtained from the Office for National Statistics for English cancer registrations, and the Welsh Cancer Intelligence and Surveillance Unit, Public Health Wales, for Welsh cancer registrations. Both",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:23"
    }
  },
  {
    "page_content": "Wales, for Welsh cancer registrations. Both tumour-related (eg, tumour site, morphology, date of diagnosis) and patient-related (eg, sex, date of birth, National Health Service [NHS] number, and unique patient identifier) information were obtained. The cancer registrations were checked for any errors, such as missing data in essential variables (including sex, date of birth, date of diagnosis, tumour site, and tumour histology) and incorrect chronology of events (birth, cancer, death). Cancer",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:24"
    }
  },
  {
    "page_content": "of events (birth, cancer, death). Cancer registrations were excluded if the neoplasm was not malignant (apart from intracranial, intraspinal, and bladder neoplasms where any behaviour was allowed), the histological type was not in the International Classification of Diseases for Oncology classification, the histological type was a non-melanoma skin cancer (these are underascertained by cancer registries), or if they were duplicate registrations. Individuals who had not survived 5 years from",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:25"
    }
  },
  {
    "page_content": "Individuals who had not survived 5 years from their first neoplasm were excluded. We also excluded individuals who had a previous childhood cancer included in the British Childhood Cancer Survivor Study.17 If an individual had multiple neoplasms diagnosed as an AYA cancer, then the first was regarded as the index cancer for the cohort. The process to create the cohort is described in the appendix (p 2). The resulting cohort of 200 945 5-year survivors of AYA cancer was linked to the national",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:26"
    }
  },
  {
    "page_content": "of AYA cancer was linked to the national cancer and death registers via NHS Digital. This enabled ascertainment of all cancers and deaths for patients in the TYACSS cohort up to and including Dec 31, 2012. Ethical approval was provided by the National Research Ethics Service and permission to process information without individual consent by the National Information Governance Board for Health and Social Care. ## Procedures Information on cancer diagnosis, sex, age at cancer diagnosis, decade",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:27"
    }
  },
  {
    "page_content": "diagnosis, sex, age at cancer diagnosis, decade of cancer diagnosis, and years since diagnosis were derived from the cancer registration information. Treatment information was not available because our sole source of data was national cancer registration. First primary neoplasms were grouped according to the internationally acknowledged classification scheme for tumours diagnosed in adolescence and young adulthood.18 Carcinomas and germ cell tumours were further subdivided by anatomical site",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:28"
    }
  },
  {
    "page_content": "were further subdivided by anatomical site because of the implications of radiotherapy site for the risk of subsequent primary neoplasm (appendix pp 3–5). We aimed to produce risk estimates after each specific first primary neoplasm; therefore, survivors of cancers categorised as “other” cancers were not included (appendix pp 2, 6). We focused on the risk of specific subsequent primary neoplasms after 16 types of AYA cancer: breast; cervical; testicular; Hodgkin lymphoma (female); Hodgkin",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:29"
    }
  },
  {
    "page_content": "testicular; Hodgkin lymphoma (female); Hodgkin lymphoma (male); melanoma; CNS (intracranial); colorectal; non-Hodgkin lymphoma; thyroid; soft-tissue sarcoma; ovarian; bladder; other female genital; leukaemia; and head and neck cancer. Age at diagnosis was categorised using 5-year age bands, which divided the total period equally (15–39 years). Decade of diagnosis was divided into 1971–79, 1980–89, and 1990–2006, in order to broadly describe differences in treatment given in these periods (early",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:30"
    }
  },
  {
    "page_content": "in treatment given in these periods (early chemotherapy, chemotherapy, and modern treatment era). Years since diagnosis were classified using 10-year bands following diagnosis. Individual patient record linkage to national cancer registries enabled data to be obtained indicating when an individual in the cohort had a subsequent cancer registration. Subsequent cancer registrations were classified as a subsequent primary neoplasm according to the International Association of Cancer Registries",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:31"
    }
  },
  {
    "page_content": "International Association of Cancer Registries (IACR) and International Agency for Research on Cancer (IARC) rules for determining multiple primary tumours using the IACR/IARC Tools software. To reduce the likelihood of a local spread of the original AYA cancer being classified as a subsequent primary neoplasm, potential subsequent primary neoplasms occurring in anatomical sites close to the first primary neoplasm were excluded (appendix pp 7–8). Additionally, we excluded any cancer in a",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:32"
    }
  },
  {
    "page_content": "7–8). Additionally, we excluded any cancer in a contralateral paired organ. Consequently, reported risk estimates are inevitably conservative. ## Statistical analysis Individuals were followed from 5-year survival until the first occurrence of death, emigration, or study end date (Dec 31, 2012). Standardised incidence ratios (SIRs) were calculated as observed over expected numbers of neoplasms. Absolute excess risks (AERs) were calculated as the observed minus expected number of neoplasms,",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:33"
    }
  },
  {
    "page_content": "the observed minus expected number of neoplasms, divided by the person-years at risk and multiplied by 10 000. The expected number of neoplasms was derived by multiplying the number of person-years accrued, stratified by sex, attained age (5-year bands), and calendar year (1-year bands) by the corresponding cancer rate in the general population of England and Wales,19 and summing appropriately. For AYA cancers with 200 or more observed subsequent primary neoplasms, SIRs are reported by specific",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:34"
    }
  },
  {
    "page_content": "primary neoplasms, SIRs are reported by specific type of subsequent primary neoplasm. We restrict attention to first primary neoplasm/subsequent primary neoplasm combinations with at least 100 subsequent primary neoplasms and a statistically significant SIR. We also identify those first primary neoplasm/subsequent primary neoplasm combinations with between 25 and 99 subsequent primary neoplasms and a statistically significant SIR of at least 5. We considered SIRs to be statistically significant",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:35"
    }
  },
  {
    "page_content": "considered SIRs to be statistically significant at the 5% level (two-tailed test) if the 95% CI did not include 1. We considered AERs to be statistically significant at the 5% level (two-tailed test) if the 95% CI did not include 0. AERs were stratified by years from diagnosis, age at diagnosis, decade of diagnosis, and sex where there were at least 100 subsequent primary neoplasms. To explore the simultaneous effect of these explanatory factors, multivariable Poisson regression incorporating",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:36"
    }
  },
  {
    "page_content": "multivariable Poisson regression incorporating the expected number of events was used to derive relative excess risks (RERs).20 RERs can be interpreted as the ratio of AERs adjusted for other potential explanatory factors included within the statistical model. The key assumption of Poisson regression (mean=variance) was met, and there was no evidence of overdispersion. AERs by an explanatory factor are reported if both the univariable and multivariable tests for linear trend in the AERs were",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:37"
    }
  },
  {
    "page_content": "tests for linear trend in the AERs were each significant and the difference in the AERs between the lowest and highest level of the risk factor was at least nine excess subsequent primary neoplasms. A likelihood ratio test was used to test for linear trend in a factor by comparing the log-likelihood of a model including the variable of interest with the log-likelihood of a model without the variable of interest. Resulting p values are presented. Two-sided p values <0·05 were considered",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:38"
    }
  },
  {
    "page_content": "Two-sided p values <0·05 were considered statistically significant. In deciding the percentage of the total AER attributable to specific subsequent primary neoplasms in relation to years from diagnosis, we ignored negative values for the AER and focused only on the positive values. Thus, the total AER (for the purposes of calculating percentages) after each specific first primary neoplasm is the sum of the positive values for the contributing subsequent primary neoplasms. Cumulative incidence",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:39"
    }
  },
  {
    "page_content": "primary neoplasms. Cumulative incidence was calculated treating death as a competing risk. Multiple subsequent primary neoplasms within an individual were allowed for and counted in all analyses involving observed and expected numbers of subsequent primary neoplasms. This approach avoided bias because the expected numbers (based on cancer registrations in the general population) count all subsequent primary neoplasms. Analyses were done with Stata version 14.1. We did sensitivity analyses in",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:40"
    }
  },
  {
    "page_content": "version 14.1. We did sensitivity analyses in which subsequent leukaemia was included among survivors of AYA Hodgkin lymphoma, leukaemia, and non-Hodgkin lymphoma, and subsequent sarcoma was included among survivors of soft-tissue sarcoma and bone tumours. ## Role of the funding source The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. CJB, RCR, DLW, and MMH had access to the raw data. The corresponding author had",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:41"
    }
  },
  {
    "page_content": "to the raw data. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. # Results The TYACSS cohort comprises 200 945 5-year survivors of cancer diagnosed when aged 15–39 years, between Jan 1, 1971, and Dec 31, 2006, in England and Wales. Cohort characteristics are shown in table 1. 3118 individuals with “other” cancers were excluded from the analysis (appendix pp 2, 6). During the 2 631 326 person-years of",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:42"
    }
  },
  {
    "page_content": "pp 2, 6). During the 2 631 326 person-years of follow-up (median follow-up 16·8 years, IQR 10·5–25·2), 12 321 subsequent primary neoplasms were diagnosed in 11 565 (6%) of the 197 827 survivors included in the analysis. Subsequent primary neoplasms were most frequently seen in survivors of breast cancer (1877 [15%] of 12 321 subsequent primary neoplasms), cervical cancer (1675 [14%]), Hodgkin lymphoma (1606 [13%]), and testicular cancer (1435 [12%]; table 1). Median follow-up was 14·3 years",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:43"
    }
  },
  {
    "page_content": "[12%]; table 1). Median follow-up was 14·3 years (IQR 9·1–22·3) in survivors of breast cancer, 20·2 years (12·8–27·2) in survivors of cervical cancer, 17·7 years (11·7–25·3) in survivors of testicular cancer, 19·3 years (12·3–27·0) in female survivors of Hodgkin lymphoma, and 19·6 years (12·1–27·5) in male survivors of Hodgkin lymphoma. Investigation of all first primary neoplasm/subsequent primary neoplasm combinations with at least 100 subsequent primary neoplasms showed that neither age at",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:44"
    }
  },
  {
    "page_content": "primary neoplasms showed that neither age at diagnosis nor decade of diagnosis was systematically associated with AERs, apart from age at diagnosis for breast cancer after female Hodgkin lymphoma and decade of diagnosis for lung cancer after male Hodgkin lymphoma (appendix p 9). Consequently, in this report we consider only variation of AERs with years from diagnosis and sex. Female survivors of breast cancer had an excess risk of developing any subsequent primary neoplasm corresponding to 20",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:45"
    }
  },
  {
    "page_content": "subsequent primary neoplasm corresponding to 20 excess subsequent primary neoplasms per 10 000 person-years (SIR 1·8, 95% CI 1·7–1·8; AER 19·5 per 10 000 person-years, 95% CI 17·4–21·5; table 2). SIRs for subsequent primary cancers of ovarian, lung, corpus uteri, other genital, melanoma, and colorectal sites were statistically significantly increased (table 3). The total AER of developing any subsequent primary neoplasm increased statistically significantly with time from breast cancer",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:46"
    }
  },
  {
    "page_content": "significantly with time from breast cancer diagnosis to an AER of 25·6 per 10 000 person-years (95% CI 10·4–40·8) subsequent to 30 years from diagnosis (p<0·0001; table 4). Similarly, the AER for developing lung cancer after breast cancer increased statistically significantly with years from diagnosis (p<0·0001; table 4). In patients who had survived at least 30 years, the AER for lung cancer (13·1 per 10 000 person-years, 95% CI 5·1–21·0) accounted for 45% of the total number of excess",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:47"
    }
  },
  {
    "page_content": "accounted for 45% of the total number of excess neoplasms (total AER 28·9 per 10 000 person-years when negative AERs are excluded). The cumulative incidence of lung subsequent primary neoplasms at 35 years from diagnosis was 2·9% (95% CI 2·5–3·2), whereas an incidence of 2·0% was expected (figure, table 5).FigureObserved (solid) and expected (dashed) cumulative incidence of specific subsequent primary neoplasms in survivors of adolescent and young adult cancer*Cumulative incidence exceeds",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:48"
    }
  },
  {
    "page_content": "young adult cancer*Cumulative incidence exceeds scale; please refer to table 5 for cumulative incidence up to 35 years from diagnosis. Survivors of cervical cancer had an excess risk of developing any subsequent primary neoplasm corresponding to ten excess subsequent primary neoplasms per 10 000 person-years (SIR 1·3, 95% CI 1·2–1·3; AER 10·2 per 10 000 person-years, 95% CI 8·0–12·4; table 2). SIRs for subsequent primary neoplasms of bladder, lung, and colorectal sites were statistically",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:49"
    }
  },
  {
    "page_content": "lung, and colorectal sites were statistically significantly increased. We noted a statistically significant reduction in the SIR related to breast cancer (SIR 0·8, 95% CI 0·7–0·8; table 3). The total AER of developing any subsequent primary neoplasm increased with time from cervical cancer diagnosis to an AER of 32·3 per 10 000 person-years (95% CI 15·4–49·1) subsequent to 30 years from diagnosis (p<0·0001), as did the AER for developing lung, colorectal, and bladder cancer (each p<0·0001;",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:50"
    }
  },
  {
    "page_content": "colorectal, and bladder cancer (each p<0·0001; table 4). In patients who had survived at least 30 years, the AERs for lung cancer (17·2 per 10 000 person-years, 95% CI 8·8–25·6), colorectal cancer (10·7, 3·5–17·9), and bladder cancer (10·1, 4·5–15·7) accounted for 37%, 23%, and 22% of the total number of excess neoplasms, respectively (total AER 46·5 per 10 000 person-years when negative AERs are excluded). The cumulative incidences of subsequent lung, colorectal, and bladder neoplasms at 35",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:51"
    }
  },
  {
    "page_content": "lung, colorectal, and bladder neoplasms at 35 years from diagnosis were 3·6% (95% CI 3·2–4·2), 2·6% (2·2–3·0), and 1·3% (1·0–1·6), whereas incidences of 1·6%, 1·4%, and 0·4% were expected, respectively (figure, table 5). Survivors of testicular cancer had an excess risk of developing any subsequent primary neoplasm corresponding to 19 excess subsequent primary neoplasms per 10 000 person-years (SIR 1·8, 95% CI 1·7–1·9; AER 18·9 per 10 000 person-years, 95% CI 16·6–21·1; table 2). SIRs for",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:52"
    }
  },
  {
    "page_content": "95% CI 16·6–21·1; table 2). SIRs for subsequent primary neoplasms of bladder, colorectal, lung, and prostate sites were statistically significantly increased (table 3). The total AER of developing any subsequent primary neoplasm increased with time from testicular cancer diagnosis to an AER of 127·0 per 10 000 person-years (95% CI 100·0–154·0) subsequent to 30 years from diagnosis (p<0·0001), as did the AER for developing bladder, colorectal, lung, and prostate cancer (each p<0·0001; table 4).",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:53"
    }
  },
  {
    "page_content": "and prostate cancer (each p<0·0001; table 4). In patients who had survived at least 30 years, the AERs for prostate cancer (25·3 per 10 000 person-years, 95% CI 12·1–38·6), bladder cancer (22·8, 13·0–32·7), colorectal cancer (19·6, 9·2–29·9), and lung cancer (9·5, 0·1–18·8) accounted for 20%, 18%, 15%, and 8% of the total number of excess neoplasms, respectively. The cumulative incidences of subsequent primary neoplasms at 35 years from diagnosis were 3·7% (95% CI 3·1–4·4) for prostate, 2·9%",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:54"
    }
  },
  {
    "page_content": "were 3·7% (95% CI 3·1–4·4) for prostate, 2·9% (95% CI 2·4–3·6) for bladder, 3·0% (2·5–3·6) for colorectal, and 2·7% (2·2–3·2) for lung, whereas incidences of 2·9%, 1·1%, 1·8%, and 2·0% were expected, respectively (figure, table 5). Female survivors of Hodgkin lymphoma had an excess risk of developing any subsequent primary neoplasm corresponding to 56 excess subsequent primary neoplasms per 10 000 person-years (SIR 3·1, 95% CI 2·9–3·3; AER 55·7 per 10 000 person-years, 95% CI 50·4–61·1; table",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:55"
    }
  },
  {
    "page_content": "per 10 000 person-years, 95% CI 50·4–61·1; table 2). SIRs for subsequent primary cancers of breast and lung sites were statistically significantly increased (table 3). The total AER of developing any subsequent primary neoplasm increased with time from Hodgkin lymphoma diagnosis to an AER of 168·6 per 10 000 person-years (95% CI 129·5–207·8) subsequent to 30 years from diagnosis (p<0·0001), as did the AER for developing breast and lung cancer (each p<0·0001; table 4). In patients who had",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:56"
    }
  },
  {
    "page_content": "(each p<0·0001; table 4). In patients who had survived at least 30 years, the AERs for breast cancer (71·8 per 10 000 person-years, 95% CI 46·4–97·2) and lung cancer (26·0, 11·2–40·8) accounted for 43% and 15% of the total number of excess neoplasms, respectively. The cumulative incidences of breast and lung neoplasms at 35 years from diagnosis were 14·4% (95% CI 12·9–15·9) and 3·8% (3·0–4·8), whereas incidences of 4·9% and 0·9% were expected, respectively (figure, table 5). Male survivors of",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:57"
    }
  },
  {
    "page_content": "respectively (figure, table 5). Male survivors of Hodgkin lymphoma had an excess risk of developing any subsequent primary neoplasm corresponding to 30 excess subsequent primary neoplasms per 10 000 person-years (SIR 2·6, 95% CI 2·4–2·8; AER 29·9 per 10 000 person-years, 95% CI 26·3–33·6; table 2). The SIR for a subsequent primary lung cancer was statistically significantly increased (table 3). The total AER of developing any subsequent primary neoplasm increased with time from Hodgkin lymphoma",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:58"
    }
  },
  {
    "page_content": "increased with time from Hodgkin lymphoma diagnosis to an AER of 121·9 per 10 000 person-years (95% CI 91·3–152·4) subsequent to 30 years from diagnosis (p<0·0001), as did the AER for developing lung cancer (p<0·0001; table 4). In patients who had survived at least 30 years, the AER for lung cancer (50·2 per 10 000 person-years, 95% CI 33·0–67·3) accounted for 41% of the total number of excess neoplasms. The cumulative incidence of lung neoplasms in male survivors of Hodgkin lymphoma was 5·1%",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:59"
    }
  },
  {
    "page_content": "in male survivors of Hodgkin lymphoma was 5·1% (95% CI 4·3–6·0) at 35 years from diagnosis, whereas an incidence of 1·4% was expected (figure, table 5). Female survivors of thyroid cancer had an excess risk of developing any subsequent primary neoplasm corresponding to 13 excess subsequent primary neoplasms per 10 000 person-years (SIR 1·4, 95% CI 1·2–1·5; AER 13·1 per 10 000 person-years, 95% CI 8·4–17·8; table 2). The SIR for a subsequent primary breast cancer was statistically significantly",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:60"
    }
  },
  {
    "page_content": "breast cancer was statistically significantly increased (table 3). The total AER of developing any subsequent primary neoplasm increased with time from thyroid cancer diagnosis to an AER of 21·9 per 10 000 person-years (95% CI −10·9 to 54·7) subsequent to 30 years from diagnosis, (p=0·03; table 4). The cumulative incidence of all subsequent primary neoplasms in female survivors of thyroid cancer was 18·2% (95% CI 16·1–20·5) at 35 years from diagnosis (table 5), whereas an incidence of 13·6% was",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:61"
    }
  },
  {
    "page_content": "(table 5), whereas an incidence of 13·6% was expected. The cumulative incidence of breast cancer was 8·2% (6·7–9·8) at 35 years from diagnosis, whereas an incidence of 6·0% was expected (figure; table 5). Survivors of ovarian cancer had an excess risk of developing any subsequent primary neoplasm corresponding to 12 excess subsequent primary neoplasms per 10 000 person-years (SIR 1·4, 95% CI 1·2–1·5; AER 12·3 per 10 000 person-years, 95% CI 7·5–17·1; table 2). A statistically significant",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:62"
    }
  },
  {
    "page_content": "7·5–17·1; table 2). A statistically significant reduction was found in the SIR for the development of a subsequent primary breast cancer (0·8, 95% CI 0·6–0·9; table 3). The cumulative incidence of all subsequent primary neoplasms was 13·9% (95% CI 12·2–15·7) at 35 years from diagnosis (table 2), whereas an incidence of 12·3% was expected. Both male and female survivors of CNS tumours had an excess risk of developing any subsequent primary neoplasm corresponding to 15 and 11 excess neoplasms,",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:63"
    }
  },
  {
    "page_content": "corresponding to 15 and 11 excess neoplasms, respectively (male survivors: SIR 1·7 [95% CI 1·5–1·9]; AER 14·8 per 10 000 person-years [95% CI 10·7–19·0]; female survivors: SIR 1·3 [1·2–1·5]; AER 11·1 [7·0–15·2]). A statistically significant reduction in the SIR for the development of a subsequent primary breast cancer was found (SIR 0·7, 95% CI 0·6–0·8; table 3). The cumulative incidence of all subsequent primary neoplasms was 11·9% (95% CI 10·6–13·3) in female survivors of CNS tumours and",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:64"
    }
  },
  {
    "page_content": "10·6–13·3) in female survivors of CNS tumours and 10·0% (8·7–11·4) in male survivors of CNS tumours at 35 years from diagnosis (table 2), whereas an incidence of 9·4% was expected. Sensitivity analyses showed that inclusion of leukaemia after AYA Hodgkin lymphoma, non-Hodgkin lymphoma, and leukaemia had little effect on the SIRs and AERs (appendix p 10). Inclusion of sarcomas after AYA soft-tissue sarcoma and bone tumour increased the AERs, but there was substantial overlap in confidence",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:65"
    }
  },
  {
    "page_content": "but there was substantial overlap in confidence intervals (appendix p 10). # Discussion We show that the excess number of subsequent primary neoplasms observed increases with increased period of follow-up from diagnosis after each AYA cancer investigated. In patients who had survived at least 30 years from diagnosis of cervical cancer, testicular cancer, Hodgkin lymphoma in women, breast cancer, and Hodgkin lymphoma in men, we identified just a small number of specific subsequent primary",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:66"
    }
  },
  {
    "page_content": "a small number of specific subsequent primary neoplasms that account for 82%, 61%, 58%, 45%, and 41% of the total excess number of neoplasms, respectively. To our knowledge, our study is the first to report excess risks of specific types of subsequent primary neoplasms after each of 16 types of AYA cancer. One study has previously addressed the risk of all subsequent primary neoplasms combined after each AYA cancer,3 but no study has previously considered specific subsequent primary neoplasms.",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:67"
    }
  },
  {
    "page_content": "considered specific subsequent primary neoplasms. In our study, the burden of the excess number of neoplasms beyond 30 years from diagnosis accounted for by lung cancer was substantial and apparent across all AYA cancers investigated (breast, cervical, testicular, and Hodgkin lymphoma in males and females). It is well known that smoking is carcinogenic and the main risk factor for developing lung cancer. Additionally, smoking increases the risk of developing subsequent primary neoplasms,",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:68"
    }
  },
  {
    "page_content": "risk of developing subsequent primary neoplasms, particularly oral or pharyngeal, oesophageal, stomach, lung, and haematological malignancies.21 Kaul and colleagues22 reported that 33% of survivors of AYA cancer were current smokers compared with 22% in a non-cancer comparison group matched on age, sex, and other factors. This finding confirmed earlier work that AYA cancer survivors smoke in excess.23 Young female survivors have a higher risk of being a current smoker compared with young male",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:69"
    }
  },
  {
    "page_content": "being a current smoker compared with young male survivors, and this difference is largely accounted for by cervical cancer.24 Consistent with our findings, Underwood and colleagues25 reported that survivors of cervical cancer have a two-fold increased risk of developing smoking-related cancers compared with the general population. Studies have shown that smoking is a risk factor for developing lung cancer in survivors of breast cancer26 and Hodgkin lymphoma,27 and that this risk is further",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:70"
    }
  },
  {
    "page_content": "Hodgkin lymphoma,27 and that this risk is further enhanced in patients who have been treated with radiotherapy (for breast cancer and Hodgkin lymphoma) and chemotherapy (for Hodgkin lymphoma). We observed a decrease in the number of excess lung cancers in male survivors of Hodgkin lymphoma with more recent diagnosis. Although this decrease could be caused by a number of factors, it might be related to a change in smoking habits in more recent decades (ie, a reduction in male smokers). The",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:71"
    }
  },
  {
    "page_content": "decades (ie, a reduction in male smokers). The evidence presented in our study, along with previous literature on smoking in cancer survivors, clearly suggests that clinical follow-up of survivors of AYA cancer, particularly survivors of breast cancer, cervical cancer, and Hodgkin lymphoma, should focus on subsequent lung cancer and provision of smoking cessation advice. Generally, it is difficult to compare risks of subsequent primary neoplasms between survivors of AYA and childhood cancer",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:72"
    }
  },
  {
    "page_content": "between survivors of AYA and childhood cancer because there are so many important confounding influences. However, lung cancer as a subsequent primary neoplasm is an exception to this general rule in that from our population-based national cohort of survivors of childhood cancer in Britain, we reported that in survivors aged 40 years and older, lung cancer was associated with an AER of only 2·9 per 10 000 person-years (95% CI 0·4–5·5), which accounted for just 9% of the total AER.28 By",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:73"
    }
  },
  {
    "page_content": "accounted for just 9% of the total AER.28 By contrast, in the present analysis, the AER for lung cancer after at least 30 years from diagnosis of AYA cancer was substantially higher and accounted for a much greater proportion of the total AER. Notably, by contrast with survivors of AYA cancer, the odds ratio for being a current regular smoker among survivors of childhood cancer in Britain was 0·51 compared with the general population of Britain.29 In female survivors of breast cancer, the SIRs",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:74"
    }
  },
  {
    "page_content": "In female survivors of breast cancer, the SIRs reported in our study were broadly consistent with those reported in previous literature.5, 6, 7 The increased risk of ovarian cancer could relate to shared hormonal and genetic (eg, BRCA1 and BRCA2 mutations) risk factors.30 The increased risk of uterine cancers might relate to partial oestrogen agonists used to treat the breast cancer—a previous large case-control study found that risk of uterine cancer increases with duration of tamoxifen",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:75"
    }
  },
  {
    "page_content": "cancer increases with duration of tamoxifen treatment.31 Of the six anatomical sites at which an excess of subsequent primary neoplasms was observed, only the lungs would be directly exposed if external-beam radiotherapy was used to treat the breast cancer. A previous large case-control study showed a dose-response relation between radiotherapy and risk of lung cancer in breast cancer survivors diagnosed at any age (not AYA-specific).26 Existing literature suggests that chest radiotherapy and",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:76"
    }
  },
  {
    "page_content": "literature suggests that chest radiotherapy and smoking are both likely contributors to the substantial number of excess neoplasms accounted for by lung cancer. The bladder and bowel would be directly exposed if external-beam radiotherapy was used to treat cervical cancer. A large case-control study showed a dose-response relation between radiotherapy and the risk of both bladder and rectal cancers in cervical cancer survivors.32 Existing literature suggests that pelvic irradiation and smoking",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:77"
    }
  },
  {
    "page_content": "suggests that pelvic irradiation and smoking are likely contributors to the number of excess neoplasms accounted for by lung, colorectal, and bladder cancer. Clinical follow-up of survivors of AYA cervical cancer, particularly where pelvic irradiation is used, should focus on lung, bowel, and bladder cancers. Treatment for testicular cancer can involve irradiating the para-aortic lymph nodes, which might explain the excess of subsequent primary neoplasms seen in abdominal sites (prostate,",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:78"
    }
  },
  {
    "page_content": "neoplasms seen in abdominal sites (prostate, bladder, and colorectal). The excess of subsequent primary neoplasms observed in the abdomen is consistent with international studies of testicular cancer survivors.8 The excess of lung subsequent primary neoplasms might be caused by radiotherapy to the lungs, since previous studies have reported an increased risk of lung cancer in survivors of testicular cancer who were given chest radiotherapy.8 Clinical follow-up of survivors of AYA testicular",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:79"
    }
  },
  {
    "page_content": "Clinical follow-up of survivors of AYA testicular cancer should focus on prostate, bladder, colorectal, and lung cancers. The lungs would be directly exposed if external-beam radiotherapy was used to treat Hodgkin lymphoma; previous studies of Hodgkin lymphoma survivors have provided evidence of a dose-dependent increase in lung cancer risk with radiotherapy with or without chemotherapy.27 Our findings are consistent with previous large-scale studies of female survivors of Hodgkin lymphoma, for",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:80"
    }
  },
  {
    "page_content": "of female survivors of Hodgkin lymphoma, for which a substantial amount of literature already exists, and by contrast with other AYA cancers considered here, we have little to add.9, 10, 11 Our findings support the decrease in lung cancer risk with more recent calendar period of diagnosis that was reported in a Dutch study of Hodgkin lymphoma survivors.9 This decrease might be due to a latency effect, where more recently diagnosed survivors simply have not had enough time to develop a lung",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:81"
    }
  },
  {
    "page_content": "simply have not had enough time to develop a lung subsequent primary neoplasm, or it might be caused by changes in treatment for Hodgkin lymphoma during recent decades, including withholding radiotherapy or improvements in the delivery of radiotherapy resulting in less damage to healthy tissue than in previous decades.33 However, because a decrease in lung cancer risk was not seen after Hodgkin lymphoma in women, it is possible that the decrease in lung cancer in men is caused by other",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:82"
    }
  },
  {
    "page_content": "decrease in lung cancer in men is caused by other environmental influences, such as changes in smoking habits. Previous studies have reported an increase in the number of excess lung cancers with increasing years from diagnosis;9, 10 however, to our knowledge, our study is the first to report the number of excess lung cancers in male and female survivors separately. Existing literature suggests that treatment (radiotherapy and chemotherapy), in addition to smoking, could contribute to the",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:83"
    }
  },
  {
    "page_content": "in addition to smoking, could contribute to the number of excess neoplasms accounted for by lung cancer.9 Clinical follow-up of male survivors of AYA Hodgkin lymphoma should focus on lung cancer and provision of smoking cessation advice. Younger age at radiation exposure is a risk factor for the development of breast cancer in many populations exposed to radiation, including atomic bomb survivors, patients with tuberculosis monitored with x-rays, and children with benign disorders treated with",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:84"
    }
  },
  {
    "page_content": "and children with benign disorders treated with radiotherapy.34 Thus, the effect of age at diagnosis (closely related to age at radiotherapy) of Hodgkin lymphoma on the risk of breast cancer in our cohort is not surprising. Knowledge of late effects of cancer treatment has resulted in lower radiation exposures for treatments of good prognosis cancers in recent years;35 however, the multivariable regression showed that the risk of developing a subsequent primary neoplasm did not vary with decade",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:85"
    }
  },
  {
    "page_content": "primary neoplasm did not vary with decade of diagnosis of AYA cancer apart from lung cancer after Hodgkin lymphoma in males. Therefore, currently there is little evidence of a detectable impact. Until recently, no internationally agreed clinical guidelines existed regarding surveillance for specific types of neoplasm after AYA cancer, but this is now being addressed by the International Late Effects of Childhood Cancer Guideline Harmonization Group.36 So far, two such guidelines have been",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:86"
    }
  },
  {
    "page_content": "Group.36 So far, two such guidelines have been published.37, 38 There are also guidelines in development relating to second primary CNS tumours and second primary bowel cancers. Strengths of our cohort study relate to its large scale and population-based design, with the inclusion of all 5-year survivors of AYA cancer in England and Wales. The study design minimises selection bias and the results are generalisable to the English and Welsh population. Our study had much greater statistical power",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:87"
    }
  },
  {
    "page_content": "Our study had much greater statistical power than the only comparable previous study by Lee and colleagues,3 because we report almost double the number of subsequent primary neoplasms and an additional million person-years of follow-up. Most previous studies investigating the risk of subsequent primary neoplasms with years from diagnosis have mainly focused on the SIR, a measure of multiplicative risk that relates to an unspecified baseline risk and is therefore difficult to interpret. We",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:88"
    }
  },
  {
    "page_content": "risk and is therefore difficult to interpret. We concentrated on the AER, which is the excess number of subsequent primary neoplasms beyond those expected from the general population, and so is directly interpretable in terms of adverse health impact on survivors. To our knowledge, our study is the first to report AERs by years from diagnosis for each specific AYA cancer. A limitation of using cancer registration data is the absence of detailed treatment information. Treatment for AYA cancer",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:89"
    }
  },
  {
    "page_content": "treatment information. Treatment for AYA cancer varies greatly by cancer type; therefore, in the absence of treatment data, we chose to determine risks in relation to specific cancer types. However, inevitably there is variation in the intensity of treatment given for a specific type of cancer, depending on the stage at diagnosis and whether the disease recurs or relapses after initial treatment. Crude treatment information is inherent in cohort studies based on cancer registry data; however,",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:90"
    }
  },
  {
    "page_content": "studies based on cancer registry data; however, we are planning to conduct case-control studies with detailed treatment dosimetry, questionnaires for lifestyle and other relevant factors, and saliva collection for genotypic factors. A potential limitation of our study is that our results might not be generalisable to populations outside of England and Wales. Another limitation is the possibility that recurrence or metastases of the AYA cancer could have been mistaken for a subsequent primary",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:91"
    }
  },
  {
    "page_content": "could have been mistaken for a subsequent primary neoplasm. However, we used the IACR/IARC rules to define multiple primary cancers and further excluded any additional neoplasms close to the AYA cancer site. By using these criteria, we excluded any contralateral subsequent primary neoplasms such as breast, kidney, ovarian, lung, or testicular subsequent primary neoplasms. Thus, our estimate of the risk of specific subsequent primary neoplasms after specific AYA cancers is probably conservative,",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:92"
    }
  },
  {
    "page_content": "specific AYA cancers is probably conservative, and although many of the estimates we report are substantial, they are likely to be an underestimate of the true risk. In conclusion, our data show that the excess number of subsequent primary neoplasms observed increases with increased period of follow-up from diagnosis after each AYA cancer investigated. In patients who had survived at least 30 years from diagnosis of cervical cancer, testicular cancer, Hodgkin lymphoma, and breast cancer, we",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:93"
    }
  },
  {
    "page_content": "cancer, Hodgkin lymphoma, and breast cancer, we identified just a small number of specific subsequent primary neoplasms that account for high proportions of the total excess number of neoplasms. A notable finding was the excess number of neoplasms accounted for by lung cancer across all AYA groups investigated in detail, in addition to subsequent primary neoplasms occurring in potentially irradiated sites. Our findings provide an evidence base for clinical follow-up relating specifically to the",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:94"
    }
  },
  {
    "page_content": "clinical follow-up relating specifically to the AYA population.",
    "metadata": {
      "source": "../data/plain/PMC6494975.plain.txt",
      "id": "../data/plain/PMC6494975.plain.txt:95"
    }
  },
  {
    "page_content": "Secondary neoplasms in survivors of pediatric acute lymphoblastic leukemia and lymphoblastic lymphoma: a single-center, retrospective study Abstract\nBackground",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:0"
    }
  },
  {
    "page_content": "Acute lymphoblastic leukemia (ALL)-based therapeutic regimens have markedly improved the survival of children with ALL and lymphoblastic lymphoma (LBL). However, survivors are at risk of secondary neoplasms. Few studies on such secondary neoplasms have been conducted outside of Europe and the United States. The aim of this study was to evaluate the incidence of, risk factors for, and outcomes of secondary neoplasms in long-term survivors of ALL and LBL at a tertiary pediatric oncology center in",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:1"
    }
  },
  {
    "page_content": "LBL at a tertiary pediatric oncology center in Mie prefecture, Japan.",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:2"
    }
  },
  {
    "page_content": "Procedure\nWe retrospectively reviewed 188 patients with ALL and LBL who were treated with an ALL-based therapeutic regimen at Mie University Hospital from January 1, 1977 to December 31, 2022 and followed up.\nResults",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:3"
    }
  },
  {
    "page_content": "Ten patients developed secondary neoplasms, with 10-year and 20-year cumulative incidences of 2.9% [standard error (SE) = 1.5%] and 5.5% (SE = 2.3%), respectively. The median interval between the primary-cancer diagnosis and secondary-neoplasm diagnosis was 18.5 years (range: 7.8–41.7 years). All 10 secondary neoplasms were central nervous system (CNS) tumors (6 meningiomas and 4 high-grade gliomas). Radiotherapy (p = 0.007) and CNS involvement in the primary cancer (p < 0.001) increased the",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:4"
    }
  },
  {
    "page_content": "in the primary cancer (p < 0.001) increased the risk of secondary neoplasms among long-term survivors. Gliomas occurred significantly earlier than meningiomas (p = 0.047), and three patients died of secondary neoplasms (all gliomas).",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:5"
    }
  },
  {
    "page_content": "Conclusions",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:6"
    }
  },
  {
    "page_content": "As secondary gliomas occurred earlier than meningiomas and are associated with poor outcomes, physicians should take great pains to minimize their risk to improve long-term survival and quality of life. # Introduction Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, accounting for approximately 20%–30% of pediatric cancers (1). The 5-year survival of children with ALL improved from <35% in the early 1970s to 90% in 2010 (2, 3). Lymphoblastic lymphoma (LBL), the second",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:7"
    }
  },
  {
    "page_content": "(2, 3). Lymphoblastic lymphoma (LBL), the second most common type of non-Hodgkin lymphoma in children, is usually treated with an ALL-based therapeutic regimen because ALL and LBL are on the same disease spectrum (4, 5). The event-free and overall survival rates of children with LBL now exceed 80% (6, 7). The number of long-term survivors of childhood ALL and LBL has risen; however, many survivors experience premature mortality and excess morbidity in the form of secondary neoplasms, chronic",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:8"
    }
  },
  {
    "page_content": "in the form of secondary neoplasms, chronic health conditions, neurocognitive impairment, and a self-reported poor health status because of cancer treatment (2). Secondary neoplasms are considered the most fatal and life-threatening late effects among long-term survivors of childhood ALL and LBL, and several studies have reported the incidence of, type of, risk factors for, and outcomes of secondary neoplasms (8–12). Reported risk factors for secondary-neoplasm development are",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:9"
    }
  },
  {
    "page_content": "factors for secondary-neoplasm development are cancer-predisposing conditions, cranial radiotherapy (CRT), the treatment regimen, female sex, younger age at primary cancer diagnosis, initial characteristics of the primary cancer, radiation dose, and allogeneic hematopoietic stem-cell transplantation (allo-HCT) (8, 10, 11, 13–17). Interestingly, Moser et al. reported that an ALL-based therapeutic regimen was a significant risk factor for secondary neoplasms in long-term survivors of LBL (10).",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:10"
    }
  },
  {
    "page_content": "neoplasms in long-term survivors of LBL (10). ALL-based therapeutic regimens consist of a four-drug induction, central nervous system (CNS) prophylaxis, consolidation therapy, and maintenance therapy for up to 2 years (18). Although recent ALL-based, intrathecal, systemic chemotherapeutic regimens have eliminated prophylactic CRT without jeopardizing leukemia control in the CNS (19), CRT is still administered as a therapeutic approach for ALL and LBL with CNS involvement. CRT may also be",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:11"
    }
  },
  {
    "page_content": "ALL and LBL with CNS involvement. CRT may also be administered as a part of total body irradiation (TBI) within the conditioning regimen of children selected to undergo allo-HCT. The observation that an ALL-based therapeutic regimen is a risk factor for secondary neoplasms in LBL prompted us to analyze the development of secondary neoplasms in patients who received ALL-based therapeutic regimens in our hospital. Furthermore, the majority of studies on secondary neoplasms have been conducted in",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:12"
    }
  },
  {
    "page_content": "on secondary neoplasms have been conducted in Europe and the United States, and the cumulative incidence of secondary neoplasms has varied from less than 1% to 10% or more (8–13, 15, 16). Therefore, we aimed to retrospectively evaluate the cumulative incidence, clinical features, and outcomes of secondary neoplasms in long-term survivors of ALL and LBL who were treated with an ALL-based therapeutic regimen and followed up at our hospital in Japan. # Methods ## Patients Mie University Hospital",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:13"
    }
  },
  {
    "page_content": "# Methods ## Patients Mie University Hospital is a tertiary referral center for pediatric oncology in Mie Prefecture, Japan. Patients with primary ALL or primary LBL treated with an ALL-based therapeutic regimen from January 1, 1977 to December 31, 2022 and still being followed up at Mie University Hospital were eligible for the study. Study participants were selected from among these survivors according to the following inclusion criteria: (a) age ≤18 years at the time of primary cancer",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:14"
    }
  },
  {
    "page_content": "(a) age ≤18 years at the time of primary cancer diagnosis, (b) ≥1 year of follow-up at Mie University Hospital after the end of treatment, and (c) availability of outcome information. Patients lost to follow-up were excluded from the study. The study protocol was approved by the institutional ethics committee (identifier: H2023-228 and H2020-129). The study was performed in accordance with the principles of the Declaration of Helsinki. ## Follow-up and data collection We obtained detailed",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:15"
    }
  },
  {
    "page_content": "and data collection We obtained detailed information on sex, age at diagnosis of the primary cancers, and treatment for primary cancers, including cumulative radiation doses and cumulative doses of anticancer agents. For alkylating agents, the conversion factor for the cyclophosphamide-equivalent dose was 1:4 (i.e., 1 mg cyclophosphamide equals 4 mg ifosfamide). For anthracyclines, the conversion factors for the doxorubicin-equivalent dose were 1:0.5 (i.e., 1 mg doxorubicin equals 0.5 mg",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:16"
    }
  },
  {
    "page_content": "were 1:0.5 (i.e., 1 mg doxorubicin equals 0.5 mg daunorubicin) and 1:10 (i.e., 1 mg doxorubicin equals 10 mg mitoxantrone). Patients were followed up at least annually in the outpatient clinic at our hospital. A secondary neoplasm was defined as a histologically or radiologically distinct neoplasm that developed after diagnosis of the primary cancer, for which it was possible to rule out metastasis or recurrence of the primary cancer. We collected the following data regarding secondary-neoplasm",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:17"
    }
  },
  {
    "page_content": "the following data regarding secondary-neoplasm diagnosis: date of diagnosis; histological or radiological reports, including cytogenetic findings; site of secondary neoplasm; interval to secondary neoplasm; and outcomes. The time at risk for a secondary neoplasm was computed from the date of primary-cancer diagnosis to the date of secondary-neoplasm diagnosis, death, or last contact, whichever came first. The end of the follow-up period was December 31, 2023. ## Statistical analysis The",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:18"
    }
  },
  {
    "page_content": "December 31, 2023. ## Statistical analysis The cumulative incidence of secondary neoplasms over time was calculated using competing-risk methods, with death regarded as a competing event. In the regression model, we evaluated sex, age at primary-cancer diagnosis, CNS involvement, allo-HCT, radiotherapy, and chemotherapy. Age at primary-cancer diagnosis was analyzed as a categorical variable according to quartiles (<5 years, ≥5 years and <10 years, ≥10 years and <15 years, and ≥15 years).",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:19"
    }
  },
  {
    "page_content": "years, ≥10 years and <15 years, and ≥15 years). Primary ALL and LBL were classified into three (precursor B-ALL, T-ALL, and Philadelphia-positive ALL) and two (T-LBL and B-LBL) categories, respectively. Survival analysis was conducted using the Kaplan–Meier method (log-rank method for comparison). Data were analyzed using the BellCurve for Excel software (Social Survey Research Information Co., Ltd. Tokyo, Japan). Statistical significance was set at p < 0.05. # Results ## Patient",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:20"
    }
  },
  {
    "page_content": "was set at p < 0.05. # Results ## Patient characteristics A total of 188 survivors participated in the study and their characteristics are summarized in Table 1. Of 188 patients, 171 were diagnosed with ALL and 17 with LBL. The median age at primary-cancer diagnosis was 5.5 (range, 0.2–18.5) years. The median duration of follow-up from the end of treatment for primary cancer was 14.6 (range, 1.0–43.8; mean, 15.5) years. The duration of follow-up was <5 years for 37 patients, ≥5 but <10 years",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:21"
    }
  },
  {
    "page_content": "was <5 years for 37 patients, ≥5 but <10 years for 31 patients, ≥10 but <15 years for 30 patients, ≥15 but <20 years for 30 patients, and ≥20 years for 60 patients. Twenty-seven patients underwent allo-HCT, and 63 received radiotherapy, either CRT or TBI. Of the 188 patients, 10 developed secondary neoplasms (Table 1). The cumulative incidence of secondary neoplasms at 10 and 20 years was 2.9% [standard error (SE) = 1.5%] and 5.5% (SE = 2.3%), respectively (Figure 1A). The primary-cancer",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:22"
    }
  },
  {
    "page_content": "respectively (Figure 1A). The primary-cancer diagnoses for the 10 patients with secondary neoplasms were B-cell precursor ALL (n = 7), T-cell LBL (n = 2), and T-cell ALL (n = 1). The median age at diagnosis of primary cancer was 4.5 (range, 2.9–14.3) years for patients who subsequently developed a secondary neoplasm, and the median age at diagnosis of the secondary neoplasm was 27.1 (range, 12.2–46.1) years (Table 2). The median time from primary-cancer diagnosis to secondary-neoplasm diagnosis",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:23"
    }
  },
  {
    "page_content": "diagnosis to secondary-neoplasm diagnosis was 18.5 (range, 7.8–41.7 years) years. No patient was diagnosed with secondary neoplasms within 5 years of the primary-cancer diagnosis. The analyzed group did not include patients with known cancer-predisposing conditions. ## Risk factors for secondary neoplasms The cumulative incidence of secondary neoplasms at 20 years was 14.4% (SE = 9.5%) among patients with LBL and 4.6% (SE = 2.4%) among patients with ALL (p = 0.45) (Table 1). Secondary neoplasms",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:24"
    }
  },
  {
    "page_content": "ALL (p = 0.45) (Table 1). Secondary neoplasms had a higher cumulative incidence at 20 years among patients with CNS involvement than those among patients without CNS involvement (25.0%, SE = 21.7% vs. 4.9%, SE = 2.3%, p < 0.001). No statistically significant differences in the cumulative incidence of secondary neoplasms were observed with respect to sex, age at primary diagnosis, or allo-HCT status. However, the cumulative incidence of secondary neoplasms was significantly higher among patients",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:25"
    }
  },
  {
    "page_content": "neoplasms was significantly higher among patients treated with radiotherapy (12.0% at 20 years, SE = 4.6%) than that among patients treated without radiotherapy (0% at 20 years, p = 0.007) (Table 1, Figure 1B). Interestingly, all secondary neoplasms were CNS tumors, either meningiomas (n = 6; World Health Organization grade I) or high-grade gliomas (n = 4; World Health Organization grade III) (Table 2). The median time to the occurrence of secondary neoplasms from the primary-cancer diagnosis",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:26"
    }
  },
  {
    "page_content": "neoplasms from the primary-cancer diagnosis was 11.1 (range, 7.8–15.1) years for gliomas and 28.0 (range, 9.2–41.7) years for meningiomas. Secondary gliomas occurred 7.0–14.0 years after radiotherapy, and three of the four patients were diagnosed before the age of 20 years (Table 2, Figures 2A,B). Conversely, secondary meningiomas tended to appear later, with five of six cases diagnosed ≥20 years after radiotherapy, and the numbers of secondary-meningioma diagnoses did not seem to decrease",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:27"
    }
  },
  {
    "page_content": "diagnoses did not seem to decrease thereafter. The median radiation dose was 18.0 (range, 12.0–24.0) Gy among patients who developed secondary neoplasms, 13.5 (range, 12.0–24.0) Gy for gliomas and 21.0 (range, 15.0–24.0) Gy for meningiomas. No radiation dose–response relationship was observed in our study. Of the 10 patients with secondary CNS neoplasms, six were evaluated using brain magnetic resonance imaging owing to acute or chronic symptoms (convulsions, hemiplegia, or slight discomfort in",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:28"
    }
  },
  {
    "page_content": "(convulsions, hemiplegia, or slight discomfort in the eyes). The four asymptomatic patients were discovered to have secondary CNS neoplasms, all meningiomas, upon routine brain magnetic resonance imaging performed because of a history of radiotherapy. In addition to radiotherapy, exposure to ALL-based therapeutic regimens, including anticancer agents, may result in secondary neoplasms. Therefore, we examined whether exposure to anticancer agents increases the risk of secondary neoplasms owing",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:29"
    }
  },
  {
    "page_content": "increases the risk of secondary neoplasms owing to radiotherapy. Higher cumulative doses of anticancer agents were not associated with a higher incidence of secondary neoplasms among patients who received radiotherapy (Table 3). ## Outcome after secondary neoplasms The 10-year survival rate was 49.4% (SE = 22.8%) for patients with secondary neoplasms (Figure 3A). The median follow-up period after the secondary-neoplasm diagnosis was 5.0 (range, 2.3–10.3) years for the seven patients who were",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:30"
    }
  },
  {
    "page_content": "2.3–10.3) years for the seven patients who were alive at their latest follow-up. All patients with secondary meningiomas survived throughout the follow-up period. Three of the four patients with high-grade gliomas died as a result of the glioma at 1.9, 3.1, and 6.0 years, respectively, after the secondary-neoplasm diagnosis (Figure 3B), and the 3-year probability of survival among the four patients was 37.5% (SE = 28.6%). # Discussion In our study, radiotherapy and CNS involvement in the",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:31"
    }
  },
  {
    "page_content": "study, radiotherapy and CNS involvement in the primary cancer were significant risk factors for secondary neoplasms. However, we did not detect a significant relationship between female sex, younger age at the primary-cancer diagnosis, initial characteristics of the primary cancer, radiation dose, or allo-HCT and the cumulative incidence of secondary neoplasms, in contrast with previous studies (8, 10, 11, 13, 15–17). The 10- and 20-year cumulative incidences of secondary neoplasms were 2.9%",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:32"
    }
  },
  {
    "page_content": "incidences of secondary neoplasms were 2.9% (SE = 1.5%) and 5.5% (SE = 2.3%), respectively, among 188 long-term survivors of ALL and LBL. The risk of secondary neoplasms continued to increase over time and did not plateau, which is consistent with observations in previous reports (8–12). Previous investigations demonstrated clear associations between secondary neoplasms and prior radiotherapy (9, 20–22). Our results are in agreement with those, considering that all patients who developed",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:33"
    }
  },
  {
    "page_content": "considering that all patients who developed secondary neoplasms in our study had received prior CRT or TBI, whereas none of the patients who did not receive radiotherapy developed secondary neoplasms. Interestingly, the secondary neoplasms observed in our study were all CNS tumors, consisting of meningiomas (n = 6) and high-grade gliomas (n = 4), and no secondary neoplasms developed outside the irradiated field. The secondary neoplasms occurred 7.8–41.7 years from the primary-cancer diagnosis,",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:34"
    }
  },
  {
    "page_content": "7.8–41.7 years from the primary-cancer diagnosis, and the median time to development of a secondary glioma was much shorter than that to development of a secondary meningioma (11.0 vs. 28.0 years, p = 0.047). The radiation-related increase in the incidence of glioma was apparent 5–10 years after radiotherapy, but largely disappeared after 15 years. In contrast, the cumulative incidence of meningioma continued to increase over time and did not plateau. This timing difference may be related to",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:35"
    }
  },
  {
    "page_content": "plateau. This timing difference may be related to the age-specific background incidence rates and non-therapeutic exposures, such as tobacco, alcohol, and diet, related to meningiomas. The decrease in the relative risk of glioma over time is consistent with observations in a previous report of survivors of childhood cancer (23), in contrast with the results for atomic-bomb survivors (24) and patients irradiated for tinea capitis (25). Although the mechanisms underlying the early onset of glioma",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:36"
    }
  },
  {
    "page_content": "mechanisms underlying the early onset of glioma are largely unknown, cancer-predisposing conditions may exist. A detailed family history of cancer predisposition could not be obtained in this study, and further genetic investigations could not easily be performed because of the retrospective nature of our study. In a previous study, radiation dose–response relationships were observed for both gliomas and meningiomas (23). For doses in excess of 30 Gy, the relative risks were of the order of 20",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:37"
    }
  },
  {
    "page_content": "30 Gy, the relative risks were of the order of 20 for glioma and 50–100 for meningioma. Possibly owing to the small number of cases, no radiation dose-response relationship was observed in our study. Of 27 patients undergoing allo-HCT, 19 underwent TBI as a part of conditioning regimen and 2 of whom developed secondary gliomas. Further prospective studies are warranted to address this issue. In our study, CNS involvement in the primary cancer was also a risk factor for the development of",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:38"
    }
  },
  {
    "page_content": "was also a risk factor for the development of secondary CNS neoplasms. The cumulative incidence of secondary neoplasms at 20 years in patients with CNS involvement is 25% (SE = 21.7%). The large SE reflects the small sample size, nevertheless, this incidence is noteworthy. Patients with CNS involvement typically receive a higher radiation dose than those without. However, in our study, the irradiation doses for the two patients with CNS involvement who developed secondary CNS neoplasms were 12",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:39"
    }
  },
  {
    "page_content": "who developed secondary CNS neoplasms were 12 and 18 Gy, respectively, and no difference in irradiation dose was observed compared with those with CNS involvement who did not develop secondary CNS neoplasms. Alteration of the microenvironment caused by blast-cell infiltration into the CNS may alter factors such as cytokines, nutrients, and oxygen supplied by the microenvironment, making it suitable for the development of secondary CNS neoplasms. In our cohort, a relatively large number of",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:40"
    }
  },
  {
    "page_content": "In our cohort, a relatively large number of patients, 63 of 188 (33.5%), underwent radiotherapy. At Mie University Hospital, prophylactic cranial irradiation was performed for high-risk patients with ALL and LBL until 2000, and prophylactic cranial irradiation was discontinued for primary ALL and LBL in 2001. Of the 63 patients treated with radiation therapy, 41 were treated before 2000, including 3 patients who received TBI as part of the allo-HCT conditioning regimen and 38 patients who",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:41"
    }
  },
  {
    "page_content": "allo-HCT conditioning regimen and 38 patients who received either prophylactic or therapeutic radiation. Twenty-two patients received radiotherapy after 2001, 16 for TBI, 3 for CNS involvement, and 3 for prophylactic cranial irradiation for relapsed ALL. Prophylactic cranial irradiation for relapsed cases was discontinued in 2015. Several chemotherapeutic agents, especially alkylating agents and topoisomerase-II inhibitors, have been hypothesized to increase the risk of secondary neoplasms",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:42"
    }
  },
  {
    "page_content": "to increase the risk of secondary neoplasms (12). Solid tumors are reportedly associated with cyclophosphamide exposure, and myeloid malignancy is reportedly associated with topoisomerase II inhibitors and higher starting doses of methotrexate and mercaptopurine (12). Cyclophosphamide was also associated with a threefold increased risk of secondary neoplasms in patients with ALL (14). Moreover, in another study, 11q23/MLL rearrangements were observed in one third of patients with",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:43"
    }
  },
  {
    "page_content": "were observed in one third of patients with treatment-related myeloid neoplasia with an aberrant karyotype and previous exposure to epipodophyllotoxins, which are topoisomerase II inhibitors (12). Therefore, we analyzed the relationship between chemotherapeutic agents (in addition to radiotherapy) and the incidence of secondary neoplasms. However, we did not observe a significant relationship between the cumulative dose of chemotherapeutic agents, such as alkylating agents, topoisomerase-II",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:44"
    }
  },
  {
    "page_content": "such as alkylating agents, topoisomerase-II inhibitors (VP-16), and anthracyclines, and the incidence of secondary neoplasms. At least one annual follow-up visit is offered to long-term childhood cancer survivors at our hospital. The long-term follow-up rate was relatively high in our cohort (approximately 80%), and those with secondary neoplasms were all treated and followed up at our hospital. This provided an accurate estimation of the risk of secondary neoplasms and enabled a detailed",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:45"
    }
  },
  {
    "page_content": "of secondary neoplasms and enabled a detailed evaluation of the effect of treatment on secondary neoplasms. However, our results should be interpreted in the context of several limitations. First, because the data were based on a single center, the number of patients who developed secondary neoplasms was small, and the generalizability of the results are limited. Second, although the follow-up rate was relatively high, the number of patients with secondary neoplasms might have been",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:46"
    }
  },
  {
    "page_content": "patients with secondary neoplasms might have been underestimated and the result might have been skewed because of loss to follow-up and death due to any cause, including unreported secondary neoplasms. The information on how many patients were excluded from the study owing to a loss to follow up/death is important. However, the list of patients treated for ALL or LBL prior to 2000 has been lost. The 188 patients who were treated and still being followed up at Mie University Hospital were",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:47"
    }
  },
  {
    "page_content": "being followed up at Mie University Hospital were eligible for this study. Although the number of patients treated from 1977 to 2022 at Mie University Hospital is higher than 188, the exact number is unfortunately unknown. Third, radiation techniques have progressed since the 1970s, with the development of stereotactic radiotherapy, intensity-modulated radiotherapy, and particle-beam therapy. Therefore, discussing the radiotherapy-related risk of secondary neoplasms over the long study period",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:48"
    }
  },
  {
    "page_content": "of secondary neoplasms over the long study period is difficult. In conclusion, our analysis confirmed radiotherapy and CNS involvement in the primary cancer as risk factors for secondary neoplasms. The risk of secondary neoplasms after successful treatment of childhood ALL and LBL was similar with that in previous studies. The development of secondary glioma plateaued by 15 years after irradiation, whereas the incidence of secondary meningioma increased after 10 years. As secondary gliomas are",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:49"
    }
  },
  {
    "page_content": "after 10 years. As secondary gliomas are associated with poor outcomes, physicians should take great pains to minimize their risk to improve long-term survival and quality of life.",
    "metadata": {
      "source": "../data/plain/PMC11810969.plain.txt",
      "id": "../data/plain/PMC11810969.plain.txt:50"
    }
  },
  {
    "page_content": "Radiation-response in primary fibroblasts of long-term survivors of childhood cancer with and without second primary neoplasms: the KiKme study Abstract\nBackground",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:0"
    }
  },
  {
    "page_content": "The etiology and most risk factors for a sporadic first primary neoplasm in childhood or subsequent second primary neoplasms are still unknown. One established causal factor for therapy-associated second primary neoplasms is the exposure to ionizing radiation during radiation therapy as a mainstay of cancer treatment. Second primary neoplasms occur in 8% of all cancer survivors within 30 years after the first diagnosis in Germany, but the underlying factors for intrinsic susceptibilities have",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:1"
    }
  },
  {
    "page_content": "factors for intrinsic susceptibilities have not yet been clarified. Thus, the purpose of this nested case–control study was the investigation and comparison of gene expression and affected pathways in primary fibroblasts of childhood cancer survivors with a first primary neoplasm only or with at least one subsequent second primary neoplasm, and controls without neoplasms after exposure to a low and a high dose of ionizing radiation.",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:2"
    }
  },
  {
    "page_content": "Methods",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:3"
    }
  },
  {
    "page_content": "Primary fibroblasts were obtained from skin biopsies from 52 adult donors with a first primary neoplasm in childhood (N1), 52 with at least one additional primary neoplasm (N2+), as well as 52 without cancer (N0) from the KiKme study. Cultured fibroblasts were exposed to a high [2 Gray (Gy)] and a low dose (0.05 Gy) of X-rays. Messenger ribonucleic acid was extracted 4 h after exposure and Illumina-sequenced. Differentially expressed genes (DEGs) were computed using limma for R, selected at a",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:4"
    }
  },
  {
    "page_content": "were computed using limma for R, selected at a false discovery rate level of 0.05, and further analyzed for pathway enrichment (right-tailed Fisher’s Exact Test) and (in-) activation (z ≥|2|) using Ingenuity Pathway Analysis.",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:5"
    }
  },
  {
    "page_content": "Results",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:6"
    }
  },
  {
    "page_content": "After 0.05 Gy, least DEGs were found in N0 (n = 236), compared to N1 (n = 653) and N2+ (n = 694). The top DEGs with regard to the adjusted p-value were upregulated in fibroblasts across all donor groups (SESN1, MDM2, CDKN1A, TIGAR, BTG2, BLOC1S2, PPM1D, PHLDB3, FBXO22, AEN, TRIAP1, and POLH). Here, we observed activation of p53 Signaling in N0 and to a lesser extent in N1, but not in N2+. Only in N0, DNA (excision-) repair (involved genes: CDKN1A, PPM1D, and DDB2) was predicted to be a",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:7"
    }
  },
  {
    "page_content": "CDKN1A, PPM1D, and DDB2) was predicted to be a downstream function, while molecular networks in N2+ were associated with cancer, as well as injury and abnormalities (among others, downregulation of MSH6, CCNE2, and CHUK). After 2 Gy, the number of DEGs was similar in fibroblasts of all donor groups and genes with the highest absolute log2 fold-change were upregulated throughout (CDKN1A, TIGAR, HSPA4L, MDM2, BLOC1SD2, PPM1D, SESN1, BTG2, FBXO22, PCNA, and TRIAP1). Here, the p53 Signaling-Pathway",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:8"
    }
  },
  {
    "page_content": "and TRIAP1). Here, the p53 Signaling-Pathway was activated in fibroblasts of all donor groups. The Mitotic Roles of Polo Like Kinase-Pathway was inactivated in N1 and N2+. Molecular Mechanisms of Cancer were affected in fibroblasts of all donor groups. P53 was predicted to be an upstream regulator in fibroblasts of all donor groups and E2F1 in N1 and N2+. Results of the downstream analysis were senescence in N0 and N2+, transformation of cells in N0, and no significant effects in N1. Seven",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:9"
    }
  },
  {
    "page_content": "in N0, and no significant effects in N1. Seven genes were differentially expressed in reaction to 2 Gy dependent on the donor group (LINC00601, COBLL1, SESN2, BIN3, TNFRSF10A, EEF1AKNMT, and BTG2).",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:10"
    }
  },
  {
    "page_content": "Conclusion\nOur results show dose-dependent differences in the radiation response between N1/N2+ and N0. While mechanisms against genotoxic stress were activated to the same extent after a high dose in all groups, the radiation response was impaired after a low dose in N1/N2+, suggesting an increased risk for adverse effects including carcinogenesis, particularly in N2+.\nSupplementary Information",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:11"
    }
  },
  {
    "page_content": "The online version contains supplementary material available at 10.1186/s10020-022-00520-6. # Introduction Malignant neoplasms or any neoplasm in the central nervous system occurring in children and adolescents before the age of 20 years are defined as childhood cancer (IARC 2016). Despite extensive research on this topic, risk factors for sporadic childhood cancer remain largely unknown (Thun et al. 2017). Inherited genetic predispositions only account for 10% of childhood cancer cases",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:12"
    }
  },
  {
    "page_content": "only account for 10% of childhood cancer cases (Saletta et al. 2015). Such predispositions can affect pathways that are needed for radiation-response in the course of treatment for the first primary neoplasm (Saletta et al. 2015; Vogelstein et al. 2004). Genotoxic cancer therapies using cytostatic drugs and ionizing radiation (IR) in high doses [HDIR, ≥ 2 Gray (Gy)] during radiation therapy are established risk factors for the development of second primary neoplasms later in life (Spector et",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:13"
    }
  },
  {
    "page_content": "primary neoplasms later in life (Spector et al. 2015; Tukenova et al. 2011; Scholz-Kreisel et al. 2018; Travis et al. 2012; Ron et al. 1988; Inskip et al. 2016; Meadows et al. 1980; Tucker et al. 1991). Young age at exposure is an additional and important risk factor for iatrogenic second primary neoplasms (Hodgson et al. 2017). Of all survivors of a first primary neoplasm occurring before the age of 15 years in Germany, 8% develop a second primary neoplasm within 30 years of the first",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:14"
    }
  },
  {
    "page_content": "primary neoplasm within 30 years of the first diagnosis (Scholz-Kreisel et al. 2018). Since the incidence and survival rates of childhood cancer are increasing worldwide, the number of second primary neoplasms is expected to increase as well (Scholz-Kreisel et al. 2018; Kutanzi et al. 2016; Kaatsch et al. 2017). Contrary to the established cancer risk associated with exposure to HDIR, the carcinogenic potential of low doses of IR (LDIR, < 0.1 Gy) is still being discussed and controversial",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:15"
    }
  },
  {
    "page_content": "is still being discussed and controversial (Inskip et al. 2016; Spycher et al. 2015; Cardarelli et al. 2018; Sutou 2018; Ji et al. 2019; Luckey 1982; Graupner et al. 2017; Ma et al. 2013; Velegzhaninov et al. 2015). In children, studies suggest elevated leukemia risk in association with diagnostic applications of LDIR, such as computed tomography (Berrington de Gonzalez et al. 2016; Little et al. 2018). Despite the potential risk not being fully understood, LDIR are increasingly used in medical",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:16"
    }
  },
  {
    "page_content": "understood, LDIR are increasingly used in medical diagnostics (Smith-Bindman et al. 2008; Linet et al. 2012). In Germany, diagnostic applications account for about 41% of total radiation deposited in organs per person and year (1.6 of 3.9 millisievert) (Claudia Hachenberger et al. 2016). Also, in radiation therapy, the unwanted but inevitable exposure to LDIR outside the primary radiation beam is regarded as an additional risk factor for second primary neoplasms besides the impact of HDIR",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:17"
    }
  },
  {
    "page_content": "primary neoplasms besides the impact of HDIR deposited within the tumor volume (Diallo et al. 2009). Irrespective its dosage, exposure to IR causes a variety of cellular responses primarily based on the potent induction of deoxyribonucleic acid (DNA) damage (Nikitaki et al. 2016). On the cellular level, radiation-induced DNA damage activates complex signaling cascades of DNA repair, cell cycle regulation, apoptosis, senescence, and immunogenic responses (Mavragani et al. 2016). The induction of",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:18"
    }
  },
  {
    "page_content": "(Mavragani et al. 2016). The induction of these signaling pathways is dose-dependent (Graupner et al. 2017; Velegzhaninov et al. 2015; Ghandhi et al. 2015; Tilton et al. 2016; Helm et al. 2020), whereby signaling pathways for the inactivation of cells by apoptosis or premature senescence predominate after HDIR (Sokolov et al. 2015; Ding et al. 2005). Such mechanisms of radiation-response can be measured by changes in gene expression (Wahba et al. 2016) and ribonucleic acid (RNA)-sequencing has",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:19"
    }
  },
  {
    "page_content": "2016) and ribonucleic acid (RNA)-sequencing has shown to be a potent and precise method for transcriptome analysis, replacing probe-based tools such as microarrays (Kukurba et al. 2015). Studies that examined the molecular response to IR via transcriptome analysis have been conducted using vastly different cell types, irradiation doses, time points of extraction of messenger RNA (mRNA), and sequencing-methods depending on their research intent (Sokolov et al. 2015; Ding et al. 2005; Ray et al.",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:20"
    }
  },
  {
    "page_content": "et al. 2015; Ding et al. 2005; Ray et al. 2012; Yunis et al. 2012; Warters et al. 2009; Stecca et al. 1998). In a previous work, we have reported the downregulation of Cell cycle checkpoint control protein RAD9A (RAD9A and Cyclin Dependent Kinase Inhibitor 1A (﻿CDKN1A) in non-irradiated (Victor et al. 2013a) and irradiated [1 Gy, (Weis et al. 2011)] fibroblasts of former childhood cancer patients with at least one second primary neoplasm (N2+), compared to former childhood cancer patients with",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:21"
    }
  },
  {
    "page_content": "compared to former childhood cancer patients with a first primary neoplasm only (N1). Both of these genes are associated with the cellular response and repair of radiation-induced DNA damages. These findings indicate a compromised radiation-response in N2+ that might be associated with an increased risk to their second primary malignancies. Additionally, we hypothesize that former childhood cancer patients show differences in the transcriptional radiation-response in their skin fibroblasts",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:22"
    }
  },
  {
    "page_content": "radiation-response in their skin fibroblasts compared to those of cancer-free controls (N0). To date, changes in gene expression induced by IR have not been examined and results have not been compared between N1 and N2+ using next-generation sequencing and subsequent pathway analysis. The present study aimed to unravel molecular mechanisms of susceptibilities to sporadic cancer in early childhood and therapy-associated second primary neoplasms related to the genotoxic radiation-response. For",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:23"
    }
  },
  {
    "page_content": "related to the genotoxic radiation-response. For this purpose, we explored gene expression profiles using Illumina-based next-generation sequencing and Ingenuity Pathway Analysis (IPA) in N1 (n = 52), N2+ (n = 52), and N0 (n = 52) after exposure to a low and a high dose of IR. # Design, participants, and methods ## Study design and participants The KiKme study is a nested case–control study with emphasis on the interplay between hereditary dispositions, cellular reaction to IR, risk for",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:24"
    }
  },
  {
    "page_content": "dispositions, cellular reaction to IR, risk for sporadic childhood cancer, as well as therapy-related second primary neoplasms. From 2013 to 2019, 591 participants were included in the study. The study population, data collection, and strategies for recruitment were described elsewhere (Marron et al. 2021). For the experiments in this project, primary skin fibroblasts, obtained from skin biopsies of 156 participants from the KiKme-study, were used (Table 1). Former childhood cancer patients",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:25"
    }
  },
  {
    "page_content": "used (Table 1). Former childhood cancer patients registered in the German Childhood Cancer Registry (Scholz-Kreisel et al. 2018) provided the basis for the recruitment of cancer patients (52 with at least one second primary neoplasm and 52 with first primary neoplasms only). Participants had to be at least 18 years old and diagnosed with one first primary neoplasm in childhood. The first primary neoplasm had to be one of the three most common childhood cancers, including leukemia, lymphoma, or",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:26"
    }
  },
  {
    "page_content": "cancers, including leukemia, lymphoma, or a tumor of the central nervous system. The second primary neoplasm had to occur at an anatomic site potentially exposed during radiation therapy, such as thyroid carcinoma, breast cancer, skin carcinoma, malignant melanoma, leukemia, or ependymomas and choroid plexus tumors (Dracham et al. 2018). In addition, 52 cancer-free controls were recruited from patients undergoing an elective surgery unrelated to cancer at the Department of Orthopedic Surgery at",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:27"
    }
  },
  {
    "page_content": "cancer at the Department of Orthopedic Surgery at the University Medical Center Mainz. One long-term childhood cancer survivor with at least one second primary neoplasm, one without a second primary neoplasm, and one cancer-free control were matched according to age at sampling, as well as sex, and then processed as triplets. The long-term cancer survivors of a triplet were also matched according to the tumor entity as well as the age at and year of diagnosis of the first primary neoplasm. ##",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:28"
    }
  },
  {
    "page_content": "of diagnosis of the first primary neoplasm. ## Samples and experiments The acquisition of biosamples, the establishment of primary fibroblasts, radiation experiments, RNA extraction and processing, as well as the analysis for differentially expressed genes (DEGs) have been described in depth elsewhere (Marron et al. 2021; Brackmann et al. 2020). In summary, fibroblasts were obtained via skin biopsies from former childhood cancer patients as a 3 mm punch biopsy from the inside of the cubital",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:29"
    }
  },
  {
    "page_content": "3 mm punch biopsy from the inside of the cubital region. Samples from cancer-free controls were taken from the scar region of the surgery. Primary fibroblasts were expanded from biopsies for 14–15 days and cryopreserved. For radiation experiments, cells were thawed, cultured, and synchronized in G1 by confluency. An overview of the experimental workflow is provided as Fig. 1. Cells were exposed at room temperature to a dose of 2 Gy with 140 kilovolt X-rays at a dose rate of 3.62 Gy per minute",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:30"
    }
  },
  {
    "page_content": "X-rays at a dose rate of 3.62 Gy per minute or to 0.05 Gy with 50 kilovolt X-rays at a dose rate of 0.34 Gy per minute using the D3150 X-ray Therapy System (Gulmay Medical Ltd, Byfleet, UK). This was achieved by reducing voltage to 50 kilovolt and a source-to-target distance of 30 cm. Thus, exposure times were 0.55 and 0.15 min for HDIR and LDIR, respectively. Sham-irradiated cells were kept at the same conditions in the radiation device control room. Cells from matched triplets were cultivated",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:31"
    }
  },
  {
    "page_content": "room. Cells from matched triplets were cultivated and treated simultaneously to prevent batch effects within groups. mRNA was extracted four hours after radiation exposure. In previous work, we showed the highest number of DEGs in fibroblasts at this time point during an overall observational period of 15 min to 24 h postexposure to IR (Brackmann et al. 2020). For mRNA-sequencing (RNA-Seq), libraries were processed on a HiSeq2500 instrument (Illumina, San Diego, California, USA) set to",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:32"
    }
  },
  {
    "page_content": "(Illumina, San Diego, California, USA) set to high-output mode. Single-end reads with a length of 50 base pairs were generated using TruSeq Single Read Cluster Kit v3 (Illumina, San Diego, California, USA) and TruSeq SBS Kit v3 (Illumina, San Diego, California, USA). Base calling was performed by Real-Time Analysis (Version 1.8.4) and the resulting data were converted into FASTQ format using bcl2fastq (Version 1.8.4, Illumina, San Diego, California, USA).Fig. 1Experimental workflow. Primary",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:33"
    }
  },
  {
    "page_content": "USA).Fig. 1Experimental workflow. Primary fibroblasts of all donors were processed as matched triplets consisting of a donor with a first primary neoplasm only, a donor with a second primary neoplasm and a cancer-free control. The triplets were exposed to a low dose of ionizing radiation (LDIR, 0.05 Gray), a high dose of ionizing radiation (HDIR, 2 Gray), or were sham-irradiated (0 Gray). mRNA was extracted 4 h after exposure, Illumina-sequenced, and processed for the investigation of",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:34"
    }
  },
  {
    "page_content": "and processed for the investigation of differentially expressed genes for each donor with regard to the regulation/level in sham-irradiated cells (dashed arrows). Differentially expressed genes as a result of groupwise-expression models were further subjected to Ingenuity Pathway Analysis and resulting gene-sets of the intra-group comparisons were analyzed for over-representation using the Gene Ontology via ConsensusPathDB ## Processing of RNA-Seq data To detect DEGs and conduct pathway",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:35"
    }
  },
  {
    "page_content": "RNA-Seq data To detect DEGs and conduct pathway analysis, RNA-Seq data were processed (Marron et al. 2021). First, Trimmomatic was employed to clean adapter sequences from the raw reads (Bolger et al. 2014). Here, a quality of less than 3 was defined as the threshold to remove bases. The reads with an average quality less than 15 over 4 bases were trimmed. Processed reads were aligned to the human reference genome (GRCh38) using STAR [STAR_2.6.0c, Dobin et al. 2013]. The number of aligned reads",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:36"
    }
  },
  {
    "page_content": "et al. 2013]. The number of aligned reads per gene (seen as equal to the expression per gene), was quantified using FeatureCounts (Liao et al. 2014). Data were then normalized using the voom method (Law et al. 2014). ## Analysis of differential gene expression DEGs dependent on radiation dose were detected using linear models implemented in the limma package (Ritchie et al. 2015), accounting for the individual donor as block variable, as well as the factors donor group and radiation dose. The",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:37"
    }
  },
  {
    "page_content": "the factors donor group and radiation dose. The differential gene expression after irradiation was computed by comparing measurements of fibroblasts of each participant with measurements after sham-irradiation (e.g., counts of transcripts in cells of each individual after 0 Gy versus counts after 2 Gy; Additional files 1, 2). Differential expression was detected using three different models: (1) crude model, (2) considering age and sex (model 1), and (3) considering age, sex, age at and year of",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:38"
    }
  },
  {
    "page_content": "and (3) considering age, sex, age at and year of diagnosis of the first neoplasm, and tumor type (model 2). The latter was used in analysis with N1 and N2+ data only. P-values were computed for the interaction between the effect of radiation and donor group, as well as the effect of radiation alone. Genes with a p-value adjusted at a false discovery rate [FDR, Benjamini–Hochberg procedure (Benjamini et al. 1995)] below 0.05 were flagged as significant for further analyses. Since multiple",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:39"
    }
  },
  {
    "page_content": "significant for further analyses. Since multiple pair-wise comparisons were calculated, p-values from the separate analysis for each donor group have to be regarded as explorative. ## Quantitative real-time reverse-transcriptase polymerase chain reaction (qRT-PCR) Total RNAs were prepared from treated and untreated fibroblast cultures using the Nucleo Spin RNA Plus Kit from Macherey–Nagel (Düren, Germany). 2 µg of the RNA samples were reversely transcribed into complementary DNA using the",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:40"
    }
  },
  {
    "page_content": "transcribed into complementary DNA using the SuperScript IV First-Strand random hexamer Synthesis System (Invitrogen, Waltham, United States). Exon-spanning forward and reverse primers were designed with Primer-BLAST (Ye et al. 2012) or purchased from Qiagen (Hilden, Germany), depending on the availability of primers at Qiagen (Additional file 3a). Transcripts of the TATA-Box Binding Protein gene were used as endogenous reference gene control. Each 10 µl reaction volume contained 25 ng",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:41"
    }
  },
  {
    "page_content": "Each 10 µl reaction volume contained 25 ng complementary DNA or DNA template in 5 µl Sybr-Green Master Mix (Biozym), 2 µl ribonuclease-free PCR graded water (MN), and 1 µl each of forward and reverse primer (10 µM). All reactions were performed in triplicate and two stages, with one cycle of 95 °C for 10 min (first stage) and 45 cycles of 94 °C for 10 s, 10 s at the primer-specific melting temperature, and 72 °C for 10 s (second stage) using the LightCycler 480II Roche. Amplification qualities",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:42"
    }
  },
  {
    "page_content": "LightCycler 480II Roche. Amplification qualities were assayed using melting curves and agarose gel analysis. The qRT-PCR amplification efficiency was calculated using the LinReg program (Ruijter et al. 2009) and the cycle threshold values were corrected using the mean amplification efficiency. Relative quantification was carried out with the comparative cycle threshold method using the endogenous control gene and the control at 0 Gy for calibration. ## Ingenuity pathway and gene ontology",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:43"
    }
  },
  {
    "page_content": "## Ingenuity pathway and gene ontology analysis Pathway analyses were conducted via IPA [Content Version 57662101, QIAGEN Inc., 2020, (Krämer et al. 2014)]. As input, lists of DEGs and the corresponding gene-wise p-values (adjusted with the FDR procedure), as well as the log2 fold-change (LFC) retrieved from the analysis of differential expression were used. The cutoff for the FDR was set to 0.05. The settings for IPA were selected as experimentally observed data in human fibroblasts and",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:44"
    }
  },
  {
    "page_content": "observed data in human fibroblasts and commercial fibroblast cell lines (Additional file 4). In IPA, Fisher’s Exact Test is employed to compute the significance of the overlap of a list of DEGs and a gene list, representing a pathway. Negative logarithms (-log) of the resulting p-values are reported by IPA and a value of at least 1.3 (≙ p-value = 0.05) after Benjamini–Hochberg correction was regarded as significant here. Such pathways were marked as affected. (In-) activation z-score threshold",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:45"
    }
  },
  {
    "page_content": "as affected. (In-) activation z-score threshold was set to z ≥|2| (Krämer et al. 2014). The z-score indicates pathway activation or inactivation by comparing given expressional directions of pathway components with information from the data set entered for analysis. If z ≥|2|, a pathway was marked as modulated. Moreover, pathways with a negative z-score ≤ −2 were marked as inactivated, pathways with a z-score ≥ 2 were marked as activated. The ratio, calculated as the number of DEGs (k) per",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:46"
    }
  },
  {
    "page_content": "ratio, calculated as the number of DEGs (k) per number of postulated genes in the pathway in IPA database (K), was documented as well. For some pathways, z-score calculation was not possible [z = Not a number (NaN)]. This was either because of insufficient data in the IPA database (lack of information on “expected direction of differential expression”) or the information provided by our data was not sufficient. For these pathways, either activity prediction is not useful due to its circular or",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:47"
    }
  },
  {
    "page_content": "prediction is not useful due to its circular or multi-cellular nature, or data are not sufficient for proper calculation of the z-score. The complete output from the IPA analyses can be found in Additional file 5. For all experiments, molecular networks from IPA were extracted. For the sake of legibility, only networks with a network score > 10 were included into the main body of this work, as all data sets showed only 1–2 networks with a score of this magnitude, with the next networks per",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:48"
    }
  },
  {
    "page_content": "of this magnitude, with the next networks per donor group and dose combination reaching scores in the range of 1–6. The full list can be found in Additional file 5d. IPA was also employed to predict upstream regulators. These are transcription factors that are likely to have induced the DEGs and the direction of differential expression. Again, Fisher’s Exact Test was used to calculate a p-value for the significance of overlap of DEGs and genes, known to be regulated by a specific transcription",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:49"
    }
  },
  {
    "page_content": "known to be regulated by a specific transcription factor. As described above, a z-score for the prediction of the activation state was calculated where applicable by IPA. This method was also applied for the prediction of downstream functions and diseases (Additional file 5c). As with pathway analyses, results from upstream and downstream analyses were adjusted using the Benjamini–Hochberg procedure to adjust for FDR. All results of the pathway analyses for model 1 are displayed in heat maps in",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:50"
    }
  },
  {
    "page_content": "for model 1 are displayed in heat maps in Additional file 6. A comparison of differential expression values of genes per donor group and treatment in the analyzed pathways was also plotted as heat maps (Additional file 7). In all analyzed pathways, the molecule activity prediction of IPA was used (Additional file 8). Moreover, genes found in the IPA network analysis were displayed in a heat map, as well (Additional file 9). To account for even small effects in the interaction of radiation and",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:51"
    }
  },
  {
    "page_content": "small effects in the interaction of radiation and donor group, results of the interaction analysis were filtered for the top 50 genes per donor group comparison with regard to the p-value irrespective of the significance threshold. These gene sets were then analyzed for over-representation using the ConsensusPathDB [Additional file 5e, (Kamburov et al. 2012)] against the gene background provided in Additional file 5f. The resulting Gene Ontology (GO) terms were then summarized as well as",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:52"
    }
  },
  {
    "page_content": "(GO) terms were then summarized as well as displayed in tree maps using REVIGO (Supek et al. 2011) with an allowed semantic similarity of 0.9 and organism set to Homo sapiens (Additional file 10a and b). Moreover, we filtered the genes per comparison for those within the 0.01% lowest p-values of each respective data set, a p-value < 0.15, or LFC >|0.75|. For additional sensitivity analyses, DEGs and subsequent IPA analyses were also computed for data (1) stratified by sex and adjusted for age",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:53"
    }
  },
  {
    "page_content": "data (1) stratified by sex and adjusted for age (Additional file 11) and (2) after exclusion of self-reported non-Caucasian participants (n = 1) prior to computing DEGs using model 1 (Additional file 12). In addition to that, we repeated the IPA analyses using only genes showing absolute changes larger than 20% compared to the expression levels after 0 Gy (Additional file 13). # Results ## Study participants Primary fibroblasts of 156 donors were analyzed (52 N0, 52 N1, and 52 N2+; Table 1).",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:54"
    }
  },
  {
    "page_content": "analyzed (52 N0, 52 N1, and 52 N2+; Table 1). The median age of participants was 32.0 and 32.5 years at sampling for long-term survivors of childhood cancer with at least one second primary neoplasm and without, respectively (interquartile range (IQR): 28.0–38.2 years) and 33.0 years (IQR: 27.8–38.0 years) for cancer-free controls. In each donor group, 27 (51.92%) of the participants were female. For long-term childhood cancer survivors, the median age at diagnosis for the first primary",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:55"
    }
  },
  {
    "page_content": "the median age at diagnosis for the first primary neoplasm was 8.0 years (IQRsecond primary neoplasm: 4.0–11.2 years, IQRfirst primary neoplasm: 3.8–12.0 years). The median age at diagnosis for the second primary neoplasm was 23.0 years (IQR: 17.0–30.0 years). ## Differential gene expression after exposure to LDIR In fibroblasts of all donor groups and for all adjustment models (crude model/model 1/model 2), more genes were down- than upregulated after exposure to LDIR (Fig. 2a). The total",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:56"
    }
  },
  {
    "page_content": "after exposure to LDIR (Fig. 2a). The total number of DEGs was about three times higher in both, N2+ (model 1: 694) and N1 (model 1: 653), compared to N0 (model 1: 236). A detailed list of DEGs after LDIR is provided in Additional file 1a. The amount of DEGs was similar across adjusted models for each group of donors. Less than half of all DEGs were upregulated across all three groups in all adjustment models in reaction to LDIR (Fig. 2a). N0 showed the highest fraction of upregulated genes",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:57"
    }
  },
  {
    "page_content": "showed the highest fraction of upregulated genes (44.07%, model 1), albeit the lowest amount (n = 104, model 1) of total upregulated genes, followed by N2+ (40.63%, model 1), and N1 (37.67%, model 1) after LDIR. Compared to female N1 and N2+ and male N0, male N1 and N2+ showed a larger number of DEGs after LDIR (Additional file 11a). These were mostly centered at the p-value threshold of significance. The top genes with regard to the p-value in the main analysis were differentially expressed in",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:58"
    }
  },
  {
    "page_content": "main analysis were differentially expressed in all groups nevertheless (Additional file 11b). The removal of self-reported non-Caucasian participants did not change the results of the differential expression analysis after LDIR (Additional file 12a). Moreover, upregulated genes after LDIR showed higher peaks concerning the -log(p-value) in the volcano plots (Fig. 2b). Only upregulated genes showed a p-value < 10–10 across donor groups after LDIR. The top 10 genes with regard to p-value after",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:59"
    }
  },
  {
    "page_content": "The top 10 genes with regard to p-value after LDIR are shown stratified by donor group and LFC-direction in Fig. 2c. All of the highest-ranking upregulated genes were present in all groups after LDIR. Across these top-ranking genes that were downregulated, mutS homolog 6 (MSH6), Disabled homolog 2 (DAB2), Peroxisome proliferator-activated receptor gamma coactivator-related protein 1 (PPRC1), Nucleoporin 153 (NUP153), Serum response factor (SRF), 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:60"
    }
  },
  {
    "page_content": "3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), and TBC1 Domain Family Member 10A (TBC1D10A) were observed to be only downregulated in N1 and N2+. Cyclin E2 (CCNE2) was only downregulated in N2+. Nevertheless, qPCR conducted on MSH6 for a subsample (n = 6 per group) did not confirm differential expression after LDIR (Additional file 3b). In a previous work within the collective of the KiKme study [n = 2 per group, (Brackmann et al. 2020)], we showed that across groups Mouse double",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:61"
    }
  },
  {
    "page_content": "2020)], we showed that across groups Mouse double minute 2 (MDM2) is upregulated after LDIR (Additional file 3c).Fig. 2Summarized results on differential gene expression after 0.05 Gray. Differentially expressed genes in irradiated compared to sham-irradiated fibroblasts from donors with a first primary neoplasm only (N1), donors with at least one second primary neoplasm (N2+), and cancer-free controls (N0) 4 h after exposure to 0.05 Gray (false discovery rate adjusted p-value < 0.05). The data",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:62"
    }
  },
  {
    "page_content": "discovery rate adjusted p-value < 0.05). The data are presented for the crude model, model 1 (considering age at sampling and sex), and model 2 [considering age at sampling, sex, age at and year of diagnosis of the first neoplasm, and tumor type (not applicable for N0 data)]. In total, 14,756 genes were detected in the samples. Shown are A the proportion of up- and downregulated genes stratified by dose, group, and model, B volcano plots for the results of model 1, and C top 10 genes with",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:63"
    }
  },
  {
    "page_content": "the results of model 1, and C top 10 genes with regard to p-value, stratified by direction of log2 fold-change Analysis for interactions of the effect of radiation dose and donor group was used to identify genes showing a differential reaction to radiation exposure between donor groups. Only one gene showed a differential reaction after exposure to LDIR: Comparing N2+ and N0, Calmodulin binding transcription activator 2 (CAMTA2) was upregulated with a borderline significant p-value [LFC: 0.101,",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:64"
    }
  },
  {
    "page_content": "a borderline significant p-value [LFC: 0.101, p-value = 0.056 (crude model)] after LDIR (Table 2). All genes that were differentially expressed after LDIR in more than one donor group showed the same direction of differential expression (Additional files 1b and 2b). Comparing fibroblasts of cancer survivors with N0, member RAS oncogene family (RAB41), CAMTA2, POZ/BTB and AT hook containing zinc finger 1 (PATZ1), receptor interacting serine/threonine kinase 1 (RIPK1), speedy/RINGO cell cycle",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:65"
    }
  },
  {
    "page_content": "kinase 1 (RIPK1), speedy/RINGO cell cycle regulator family member E3 (SPDYE3), and zinc finger protein 226 (ZNF226) were of interest based on the extended criteria after LDIR (Table 2, Fig. 3a). Comparing N1 with N2+, nine genes of interest were observed after LDIR: ADNP antisense RNA 1 (ADNP-AS1), ALG9 alpha-1,2-mannosyltransferase (ALG9), clustered mitochondria homolog pseudogene 3 (CLUHP3), deleted in lymphocytic leukemia 2 (DLEU2), uncharacterized LOC101927630, myosin VIIB (MYO7B),",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:66"
    }
  },
  {
    "page_content": "LOC101927630, myosin VIIB (MYO7B), transcription factor CP2 (TFCP2), Transforming growth factor beta-induced anti-apoptotic factor 1 (TIAF1), and long intergenic non-protein coding RNA 2257 (LINC02257). Due to multiple occurrences of identical p-values, filtering for the top 50 genes with regard to the p-value per donor group comparison for the use in GO enrichment analysis resulted in more than 50 genes in two instances (n = 82 for N1/N2+ vs. N0 and n = 55 for N1 vs. N0). All of these were",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:67"
    }
  },
  {
    "page_content": "N0 and n = 55 for N1 vs. N0). All of these were used in the GO analyses.Fig. 3Summarized results on interaction effects. Results of analysis for differentially expressed genes in irradiated compared to sham-irradiated fibroblasts from donors with a first primary neoplasm only (N1), donors with at least one second primary neoplasm (N2+), and cancer-free controls (N0) 4 h after exposure to A 0.05 Gray and B 2 Gray including the interaction of group status and radiation dose. The data are",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:68"
    }
  },
  {
    "page_content": "of group status and radiation dose. The data are presented for model 1 (considering age at sampling and sex). The highlighted genes were selected based on the data structure of each comparison, to highlight top-ranking genes: if their p-value was among the top 0.01% of that data set, p-value < 0.15, and/or log2 fold-change> |0.75|. Dashed horizontal lines indicate the significance threshold of the adjusted p-value < 0.05 ## Functional analysis of DEGs after exposure to LDIR The",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:69"
    }
  },
  {
    "page_content": "analysis of DEGs after exposure to LDIR The over-representation analysis resulted in distinct GO terms for all comparisons of interactions between radiation dose and donor group and can be found in Additional files 5e and 10b. Noteworthy, N2+ compared to N0 showed a large cluster of seven GO terms subsumed under the term tRNA methylation. Comparing N1/N2+ with N0, stem cell differentiation and xenobiotic transport (including ion transport) were the largest clusters of GO terms (three terms",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:70"
    }
  },
  {
    "page_content": "the largest clusters of GO terms (three terms each). Data of DEGs per donor group, radiation dose, and adjustment model were used for upstream analyses in IPA (Fig. 4, Additional file 5b). We observed Tumor protein p53 (p53) as a common predicted upstream regulator in fibroblasts of all donor groups after LDIR (Additional file 5a). N2+ and N0 showed E2F",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:71"
    }
  },
  {
    "page_content": "Transcription Factor 1 (E2F1) to be an additional upstream regulator after LDIR, which was not significant after correction for false discovery.Fig. 4Results of Ingenuity Pathway Analysis. Overview of affected (false discovery rate adjusted at p-value < 0.05) and (in-) activated pathways (|z|≥ 2), predicted upstream effectors, downstream biofunctions and diseases, and observed molecular networks after irradiation with a low (0.05 Gray) or a high dose (2 Gray) ordered by p-value. For molecular",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:72"
    }
  },
  {
    "page_content": "dose (2 Gray) ordered by p-value. For molecular networks, the network score instead of a p-value and no z-score was calculated by Ingenuity Pathway Analysis and is given inside the tiles. For each combination of dose, model, and donor group, the top functions of the network with a score > 10 is presented, except for N2+ after 2 Gray, where two networks had a score above 10 in all models. On the right-hand side, the functions associated with the networks are shown. *p-value < 0.05,",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:73"
    }
  },
  {
    "page_content": "with the networks are shown. *p-value < 0.05, **p-value < 0.01, ***p-value < 0.001. Model 1: considering age at sampling and sex, model 2: considering age at sampling, sex, age at and year of diagnosis of the first neoplasm, and tumor type (not used with data from N0), N0 = fibroblasts of cancer-free controls, N1 = fibroblasts of childhood-cancer survivors, N2+ = fibroblasts of childhood-cancer survivors with at least one second primary neoplasm Correspondingly, pathway analysis showed that p53",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:74"
    }
  },
  {
    "page_content": "Correspondingly, pathway analysis showed that p53 Signaling was affected and activated after LDIR, however only in N0 (crude model and model 1) and N1 (crude model and model 2), but not in N2+ (Fig. 4, Additional file 5b). Here, Proliferating cell nuclear antigen (PCNA) and Tumor Protein P53 Inducible Nuclear Protein 1 (TP53INP1) were not differentially expressed in N2+, P53-Induced Death Domain Protein 1 (PIDD1), and B-cell lymphoma 2 (BCL2) only in N0 (Additional file 7b). Using only DEGs",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:75"
    }
  },
  {
    "page_content": "only in N0 (Additional file 7b). Using only DEGs with an LFC higher than |0.25|, p53 Signaling was not activated in any donor group and only affected in all donor groups and models but N1, model 1 (Additional file 13). In this analysis, Cyclins and Cell Cycle Regulation and Estrogen-mediated S-phase Entry were inactivated in all models of N2+. In the sensitivity analysis Molecular Mechanisms of Cancer were only affected in N2+ after LDIR. Downstream functions in reaction to LDIR for N0 were",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:76"
    }
  },
  {
    "page_content": "functions in reaction to LDIR for N0 were predicted by IPA as well (Fig. 4, Additional file 5c). These were Cell viability of fibroblast cell lines [CDKN1A, DNA Polymerase Eta (POLH), and Breast Cancer Gene 2, DNA repair associated (BRCA2)], Nucleation of fibroblast cell lines (CDKN1A and BRCA2), Excision repair of DNA [CDKN1A and DNA damage-binding protein 2 (DDB2)], and Repair of DNA (CDKN1A, PPM1D, and DDB2). Except the latter, all of these were only present in data of the crude model,",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:77"
    }
  },
  {
    "page_content": "were only present in data of the crude model, whereas Repair of DNA was also found in model 1. In each donor group and adjustment model, one network with a score over 10 was identified by IPA in the data from the LDIR treatment (Fig. 4, Additional files 5d and 9). The annotated functions of the network in N0 were Cell Cycle, Cell Death and Survival, and DNA Replication, Recombination, and Repair in the crude model and model 1. For N1, annotations in the crude model and model 2 were Cell Cycle,",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:78"
    }
  },
  {
    "page_content": "in the crude model and model 2 were Cell Cycle, Cell Death and Survival, and Gene Expression after LDIR. In model 1, the network included Cell Cycle, Cellular Development, and DNA Replication, Recombination, and Repair after LDIR. For N2+, top diseases and functions were Cancer, Cell Death and Survival, and Organismal Injury and Abnormalities for all models. Together, we observed a trend towards the activation of cell cycle control and DNA repair in N0 and cell death- and cancer-associated",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:79"
    }
  },
  {
    "page_content": "in N0 and cell death- and cancer-associated signaling pathways in N2+ following LDIR. ## Differential gene expression after exposure to HDIR As in treatment with LDIR, there were more downregulated than upregulated DEGs in fibroblasts of all donor groups after exposure to HDIR (Fig. 5a, Additional file 1a). The total number of DEGs was slightly higher in N2+ and N1 compared to N0 in all adjustment models and the number of DEGs per group differed only slightly between adjustment models after",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:80"
    }
  },
  {
    "page_content": "only slightly between adjustment models after HDIR. As with reaction to LDIR, upregulated genes after HDIR showed lower p-values compared to downregulated genes (Fig. 5b, model 1 only). In detail, only upregulated genes showed a p-value in the range of 10–75 to 10–275 in all donor groups. All of the highest-ranking up- and downregulated genes were found in all groups after HDIR (Fig. 5c, model 1 only). Here, qRT-PCR conducted for PCNA for a subsample (n = 6 per group) did confirm differential",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:81"
    }
  },
  {
    "page_content": "(n = 6 per group) did confirm differential expression after HDIR for N1 (Additional file 3b). Also, the upregulation of CDKN1A and MDM2 across all groups in the present study has been previously confirmed by us using qRT-PCR [(Brackmann et al. 2020), Additional file 3c]. Neither stratifying for sex, nor the prior removal of self-reported non-Caucasian participants did change the results of the differential expression main analysis for exposure to HDIR. Contrary to the reaction to LDIR, several",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:82"
    }
  },
  {
    "page_content": "HDIR. Contrary to the reaction to LDIR, several genes were differentially expressed when comparing the response to HDIR between donor groups (Table 2, Fig. 3b, Additional file 1b). Bridging integrator 3 (BIN3), cordon-bleu WH2 repeat protein like 1 (COBLL1), eukaryotic translation elongation factor 1 alpha lysine and N-terminal methyltransferase (EEF1AKNMT), long intergenic non-protein coding RNA 601 (LINC00601), sestrin 2 (SESN2), and Tumor necrosis factor receptor superfamily member 10a",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:83"
    }
  },
  {
    "page_content": "necrosis factor receptor superfamily member 10a (TNFRSF10A) were differentially expressed comparing fibroblasts of both cancer groups to N0 after HDIR (model 1). Additionally, BTG Anti-Proliferation Factor 2 (BTG2) was differentially expressed comparing N1 to N0 (model 1). As with the gene expression after LDIR, the general direction of the gene expression after HDIR in genes that were commonly differentially expressed in more than one donor group, was identical (Additional files 1b and 2b).",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:84"
    }
  },
  {
    "page_content": "was identical (Additional files 1b and 2b). The additional filtering for non-significant genes with a p-value smaller than 0.15, the 0.01% lowest p-values of the respective data, or with an LFC larger than |0.75|, found five genes of interest for the comparison of cancer survivor groups after HDIR: ADAM metallopeptidase with thrombospondin type 1 motif 17 (ADAMTS17), dual oxidase maturation factor 1 (DUOXA1), hyaluronan synthase 13 (HAS3), the uncharacterized locus LOC100505622, and zinc finger",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:85"
    }
  },
  {
    "page_content": "locus LOC100505622, and zinc finger protein 2 (ZNF2) (Table 2, Fig. 3b).Fig. 5Summarized results on differential gene expression after 2 Gray. Differentially expressed genes in irradiated compared to sham-irradiated fibroblasts from donors with a first primary neoplasm only (N1), donors with at least one second primary neoplasm (N2+), and cancer-free controls (N0) 4 h after exposure to 2 Gray (false discovery rate adjusted p-value < 0.05). The data are presented for the crude model, model 1",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:86"
    }
  },
  {
    "page_content": "data are presented for the crude model, model 1 (considering age at sampling and sex), and model 2 [considering age at sampling, sex, age at and year of diagnosis of the first neoplasm, and tumor type (not applicable for N0 data)]. In total, 14,756 genes were detected in the samples. Shown are A the proportion of up- and downregulated genes stratified by dose, group, and model, B volcano plots for the results of model 1, and C top 10 genes with regard to p-value, stratified by direction of log2",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:87"
    }
  },
  {
    "page_content": "to p-value, stratified by direction of log2 fold-change ## Functional analysis of DEGs after exposure to HDIR Comparing reaction to HDIR between donor groups, analysis for GO term enrichment resulted in several group-specific differences (Additional files 5e and 10b﻿). Comparing the reaction of N0 to N1 and N2+, the largest GO term clusters were regulation of signal transduction and DNA damage response signal transduction by p53 class mediator after HDIR. Comparing N0 and N1, the largest",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:88"
    }
  },
  {
    "page_content": "after HDIR. Comparing N0 and N1, the largest cluster (8 terms) was signal transduction in response to DNA damage and comparing N0 with N2+ the largest cluster (2 terms) was DNA methylation. The comparison between the cancer groups (N1 and N2+) resulted in two GO terms (transporter complex and cation channel complex). Fibroblasts of all donor groups had p53 as a predicted upstream regulator in reaction to HDIR (Fig. 4, Additional file 5a) in the main analysis. Moreover, E2F1 was predicted to be",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:89"
    }
  },
  {
    "page_content": "main analysis. Moreover, E2F1 was predicted to be an upstream regulator in all adjustment models of N1 and N2+ after HDIR. In the sensitivity analysis using an LFC threshold of |0.25|, p53 was predicted to be an active upstream regulator with a z-score > 2 for all models of N0 and N1, but not N2+ (Additional file 13). Additionally, MYB Proto-Oncogene Like 2 (MYBL2), Lin-9 homolog (LIN9), Chromobox homolog 7 (CBX7), and H2.0 Like Homeobox (HLX) were inactivated, Bromodomain Containing 7 (BRD7)",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:90"
    }
  },
  {
    "page_content": "were inactivated, Bromodomain Containing 7 (BRD7) was an activated upstream regulator for all donor groups and all models after HDIR, based on the IPA prediction. Only in all models of N2+ Jun Proto-Oncogene (JUN) was an active upstream regulator. In the pathway analysis of the main analysis, p53 Signaling was found to be affected after HDIR. Contrary to LDIR, it was affected in all groups and models. Moreover, it was activated in all groups and models except N2+ (crude model) after HDIR. The",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:91"
    }
  },
  {
    "page_content": "models except N2+ (crude model) after HDIR. The Mitotic Role of Polo-Like Kinase pathway was inactivated in all donor groups, but not affected in any model for N0. Here, STE20-like serine/threonine-protein kinase (SLK) and Checkpoint kinase 2 (CHEK2) were only downregulated in all models of N1 and N2+ (Additional file 7a). In the sensitivity analysis, p53 Signaling was activated in both models for N0 and affected in all models of N1 and N2+ (Additional file 13). Here, the Mitotic Role of",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:92"
    }
  },
  {
    "page_content": "file 13). Here, the Mitotic Role of Polo-Like Kinase pathway was inactivated in all models of all groups. Moreover, only in the sensitivity analysis, Cyclins and Cell Cycle Regulation, Kinetochore Metaphase Signaling Pathway, and Estrogen-mediated S-phase entry were inactivated in all models of all donor groups after HDIR. In the main analysis, there were five pathways where z-score calculation was not possible by IPA that were affected in at least one group. The Molecular Mechanisms of Cancer",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:93"
    }
  },
  {
    "page_content": "one group. The Molecular Mechanisms of Cancer pathway was affected in all donor groups and models. Chronic Myeloid Leukemia Signaling was affected in N2+ (crude model and model 1), Hereditary Breast Cancer Signaling in all models of N0 and N2+, Prostate Cancer Signaling in all models for N1, and DNA Double-Strand Break Repair by Homologous Recombination in N2+ (crude model and model 1) after HDIR. In the analysis for downstream diseases and bio functions (Fig. 4, Additional file 5c), senescence",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:94"
    }
  },
  {
    "page_content": "(Fig. 4, Additional file 5c), senescence (senescence of cells and senescence of fibroblast cell lines) showed a trend toward activation, interphase [(N0: interphase and interphase of fibroblasts (both, crude model and model 1), N2+: interphase (all models) and interphase of fibroblasts (crude model)] toward inactivation after HDIR. In N0, transformation (cell transformation and transformation of fibroblast cell lines) showed a trend toward inactivation. Synthesis of DNA was found in N2+ (all",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:95"
    }
  },
  {
    "page_content": "Synthesis of DNA was found in N2+ (all models) with a trend toward inactivation in N0 and N2+ after HDIR. Repair of DNA was found to be a downstream function in N0 and N1, though not significant. Following HDIR, associated functions for the network in N0 across all adjustments were Cellular Development, Cellular Growth and Proliferation, and Connective Tissue Development and Function (Fig. 4, Additional files 5d and 9). In N1, networks for both adjustment models showed associated functions to",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:96"
    }
  },
  {
    "page_content": "adjustment models showed associated functions to be Cell Cycle, Cell Death and Survival and Cellular Development after HDIR. In N2+, we observed two networks for model 1 and model 2. For both adjustment models, associated functions for the first respective network were Cellular Development, Embryonic Development, and Organismal Development in N2+. The second network in N2+ differed and was Cell Cycle, Cell Death and Survival, and Cellular Development for model 1 and Cell Cycle, Cellular",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:97"
    }
  },
  {
    "page_content": "Development for model 1 and Cell Cycle, Cellular Development, and DNA Replication, Recombination, and Repair for model 2. # Discussion In the present nested case–control study we examined and compared the gene expression and associated pathways in primary skin fibroblasts of childhood cancer survivors without or with a subsequent second primary neoplasm and of cancer-free controls after exposure to different doses of IR. Our results revealed alterations in the response to a low and a high dose",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:98"
    }
  },
  {
    "page_content": "in the response to a low and a high dose of IR in fibroblasts of former childhood cancer patients compared to cancer-free controls. The IPA-analysis of upstream regulators, molecular networks, and predicted downstream-effects supported these findings and indicate impaired protection and higher vulnerability to the genotoxic impact of IR in former childhood cancer patients. In particular, compromised DNA repair and cell cycle-regulation may foster the development of therapy-associated second",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:99"
    }
  },
  {
    "page_content": "the development of therapy-associated second primary neoplasm already after exposure to low doses of radiation. ## Exposure to LDIR P53 Signaling is the most prominent pathway activated by genotoxic stress, e.g., shown after irradiation of whole blood with a variety of doses and dose rates (Ghandhi et al. 2015). Furthermore, the predicted downstream activities are in line with previous findings on the response to LDIR (Ding et al. 2005). In our data, activity prediction in N0 and N1 was",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:100"
    }
  },
  {
    "page_content": "In our data, activity prediction in N0 and N1 was similar: cell cycle progression, apoptosis, and DNA repair were increased with cell survival being inactivated.﻿ This pathway not being affected in any model for N2+ and being only weakly affected in N1 is an important finding for the personalized risk assessment of the application of LDIR in diagnostics. Results from pathway analysis were further supported by the corresponding molecular networks and their attributed functions and diseases,",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:101"
    }
  },
  {
    "page_content": "and their attributed functions and diseases, where N0 and N1 had DNA Repair as associated function, while only N2+ included Cancer. After LDIR, a key molecule among others (PGR, PCNA, TP53INP1 IL15, HSPA8, SOD1, CHUK, IRF1, CDC6, CCNE2) in the network of N0 was DDB2, with important functions for (excision-) repair and cell fate decision (Sugasawa et al. 2019; Stoyanova et al. 2009). Additionally, the downstream functions Excision Repair and Repair of DNA were only found for N0. This implies,",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:102"
    }
  },
  {
    "page_content": "of DNA were only found for N0. This implies, that if an insufficient or no apoptotic response occurs, induced genomic mutations may be transmitted to following generations carrying a potential carcinogenic risk by inducing resistance and increased DNA damage tolerance. Multiple exposures to LDIR could then amplify this effect (Martin et al. 2010). We additionally hypothesize that the high difference in number of DEGs following LDIR between N0 and N1/N2+ may implicate an undirected reaction in",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:103"
    }
  },
  {
    "page_content": "N1/N2+ may implicate an undirected reaction in N1 and N2+, including expression of genes without necessity for radiation-response, while N0 react in a more precise manner. Interestingly, after stratifying by sex, this was found only in male N1 and N2+, whereas the number of DEGs in female N1 and N2+ was similar to those in male and female N0 after LDIR. Sex-specific differences in radiation-response have been proposed before (Alsbeih et al. 2016). Nevertheless, further research is needed to",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:104"
    }
  },
  {
    "page_content": "Nevertheless, further research is needed to elaborate on such differences in fibroblasts of childhood cancer survivors after LDIR. ## Exposure to HDIR After HDIR, our most important finding was that p53 Signaling was affected and activated in all models of N1 and N0 but not activated in the crude model or N2+. When we applied a 20% LFC-threshold, only N0 showed activation of this pathway. The inactivation of the Mitotic Roles of Polo-Like Kinase pathway after HDIR in N1 and N2+ was in line with",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:105"
    }
  },
  {
    "page_content": "pathway after HDIR in N1 and N2+ was in line with a radiation-induced G1 arrest as Polo-like kinases are, amongst others, responsible for G1/S-transition (Zitouni et al. 2014). A notable difference to N0 was the upregulation of Heat shock protein 90-α (Hsp90α) after HDIR in N2+ and N1 donors that has been previously described in various pathological conditions (Zuehlke et al. 2015) and stabilization of the Polo-like kinase 1. Future efforts are needed to investigate this signal in detail in",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:106"
    }
  },
  {
    "page_content": "needed to investigate this signal in detail in order to validate our findings. Molecular Mechanisms of Cancer was affected in all donor groups after HDIR and cell survival was inactivated via the radiation-triggered activation of the nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cells (NF-kB), a well-documented mechanism (Pordanjani et al. 2016). In N1 and N0, cell cycle progression was inactivated and apoptosis was activated after HDIR. Remarkably, we observed an inverse response",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:107"
    }
  },
  {
    "page_content": "HDIR. Remarkably, we observed an inverse response to HDIR in N2+ that was mediated by the up-regulation of RAC-alpha serine/threonine-protein kinase 1 (AKT1). The different isoforms of the proto-oncogene AKT promote radiation resistance by fostering DNA repair, survival, and proliferation (Sahlberg et al. 2014; Hollander et al. 2011). Here, activation of cell cycle progression and inactivation of apoptosis may lead to accumulation of DNA-damage that is subsequently carried on in further",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:108"
    }
  },
  {
    "page_content": "that is subsequently carried on in further cellular generations. ## Comparison of the reactions to LDIR and HDIR In reaction to LDIR, a limited subset of genes has been found to be consistently upregulated by other studies, like CDKN1A (Sokolov et al. 2015), which is activated in a p53-dependent manner and plays a pivotal role in cell cycle arrest (Sokolov et al. 2015; Maier et al. 2016). Kabacik et al. (2011) proposed a set of genes to be positively associated with the radiation response after",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:109"
    }
  },
  {
    "page_content": "associated with the radiation response after 2, 4, and 24 h, following HDIR (2 and 4 Gy) in cultured lymphocytes and peripheral whole blood, among them PCNA, Sestrin 1 (SESN1), Growth arrest and DNA-damage-inducible protein GADD45 alpha (GADD45A), CDKN1A, Cyclin G1 (CCNG1), Ferredoxin Reductase (FDXR), BCL2 Binding Component 3 (BBC3), and MDM2. The results for the upregulation of these genes after LDIR or HDIR were confirmed in the present work for all donor groups. Comparing the prediction of",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:110"
    }
  },
  {
    "page_content": "for all donor groups. Comparing the prediction of pathway-specific downstream activity of p53 Signaling, results were similar between LDIR and HDIR: After both treatments, activation of apoptosis and downregulation of cell survival was inferred. However, Cell Cycle Progression was activated after LDIR and inactivated after HDIR, which may be rooted in the cellular effort to rather repair than induce apoptosis after the lower genotoxic insult that LDIR entails compared to HDIR. ## Interactions",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:111"
    }
  },
  {
    "page_content": "LDIR entails compared to HDIR. ## Interactions between radiation dose and donor groups CAMTA2, the only gene with a borderline significant p-value when comparing group-specific differential expression in reaction to LDIR (comparing N2+ and N0, crude model) has been shown to be involved in cancer (Luan et al. 2019), stress reaction across species (Mollet et al. 2016), and cardiac hypertrophy (Song et al. 2006). The genes differentially expressed after HDIR (N2+ /N1 vs. N0 and N1 vs. N0) were",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:112"
    }
  },
  {
    "page_content": "after HDIR (N2+ /N1 vs. N0 and N1 vs. N0) were associated to regulation of apoptosis [TNFRSF10A, (Pan et al. 1997)], survival in chronic lymphocytic leukemia [COBLL1, (Plešingerová et al. 2018; Plesingerova et al. 2017)], prevention of accumulation of reactive oxygen species [SESN2, (Wang, et al. 2019)], cell growth/proliferation, heat shock response, and tumorigenesis [EEF1A1 (also known as METTL13), which is methylated by EEF1AKNMT (Vera et al. 2014; Liu et al. 2019)]. ## Strengths and",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:113"
    }
  },
  {
    "page_content": "et al. 2014; Liu et al. 2019)]. ## Strengths and limitations To the best of our knowledge, this is the first study that examined the genome-wide transcriptome response to IR in primary fibroblasts of a large group of former childhood cancer patients compared to cancer-free controls. Moreover, the participants were carefully matched for sex, age at sampling, as well as age at and type of first cancer diagnosis to account for the largest sources of variation. In addition, cases were matched by",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:114"
    }
  },
  {
    "page_content": "of variation. In addition, cases were matched by year of diagnosis to account for differences in treatment. Following our previous work, we used fibroblasts from skin biopsies, that were collected from a large, well-defined pool of cell donors [n = 156, (Marron et al. 2021)]. Unlike other studies, we chose to not use commercial cell lines (Velegzhaninov et al. 2015; Ding et al. 2005; Mezentsev et al. 2011; Hou et al. 2015; Ghandhi et al. 2008; Jen et al. 2005). Although commercial cell lines",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:115"
    }
  },
  {
    "page_content": "Jen et al. 2005). Although commercial cell lines may be well researched, they do not adequately depict intrinsic individual biological variability. Therein also lies a limitation, as this unknown variation might have influenced our results. Our study controlled for this with the aforementioned careful matching of subjects, accounting for variation in the R software package limma, and adjustment of differential expression for factors that introduce most variation, such as age and sex. Despite",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:116"
    }
  },
  {
    "page_content": "most variation, such as age and sex. Despite other cell types being more accessible, such as lymphocytes via venipuncture, we chose fibroblasts to perform our radiation experiments on, because survival and cultivation of lymphocytes without immortalization by Epstein-Barr virus transformation is very limited (Neitzel 1986). Additionally, untransformed fibroblasts keep an intact cell cycle that may provide a more complete analysis of gene expression, even in confluency. Moreover, as some of our",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:117"
    }
  },
  {
    "page_content": "even in confluency. Moreover, as some of our participating long-term childhood cancer survivors have received bone marrow transplants, blood samples would have contained foreign blood cells of the bone marrow donors (Victor et al. 2013b). This would have precluded analysis of germline mutations, which was our main aim. Finally, pathways were analyzed using IPA. This steadily updated and curated database allows the analysis of complex RNA-sequencing data. It gives insight beyond expression of",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:118"
    }
  },
  {
    "page_content": "data. It gives insight beyond expression of single genomic features by incorporating measurements and inferring further information from the transcriptional patterns provided. Moreover, we conducted sensitivity analyses, such as the exclusion of self-reported non-Caucasian participants, which did not change the results of this study after LDIR or HDIR. This came unsurprisingly, as to date there is no data that reports on disparities in radiation-response based on ethnicity. Despite the",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:119"
    }
  },
  {
    "page_content": "based on ethnicity. Despite the strengths mentioned, important issues for radiation carcinogenesis such as systemic or non-targeted radiation effects like the bystander effect or genomic instability (Mavragani et al. 2016) were not addressed in our work. We aimed to provide initial results for future studies by using primary cells and performing radiation experiments in vitro. It was essential to examine basic cellular events before accounting for highly complex intercellular or systemic",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:120"
    }
  },
  {
    "page_content": "for highly complex intercellular or systemic effects. As this is an important factor for radiation-related adverse effects and carcinogenesis, we aim to address these important issues in future works for tissues, cellular networks, and different cell types, with particular regard for an involvement of the immune response/system (Mavragani et al. 2016; El-Saghire et al. 2013). As the design of the study allowed only the inclusion of long-term cancer survivors, aggressive tumor entities with high",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:121"
    }
  },
  {
    "page_content": "survivors, aggressive tumor entities with high mortality rates could not be taken into account. However, most cancers share constitutive characteristics, such as autonomous and unlimited proliferation, evasion of cell death, or invasion of normal tissues (Spector et al. 2015). This work investigated the impact of two different radiation doses at a single time point post-exposure. A low and a high dose were chosen to simulate clinically relevant exposure during radiologic examinations or",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:122"
    }
  },
  {
    "page_content": "exposure during radiologic examinations or radiation therapy, respectively (Pearce et al. 2012; Seidlitz et al. 2017). Even though gene expression patterns after LDIR show a dynamic transient response within 24 h post-radiation (Albrecht et al. 2012; Berglund et al. 2008), we (Brackmann et al. 2020) and others (Yunis et al. 2012; Chaudhry et al. 2012) observed the highest amount of DEGSs at 3–4 h after irradiation compared to sham-irradiated cells and we hence chose this time point of analysis",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:123"
    }
  },
  {
    "page_content": "and we hence chose this time point of analysis for our investigations. Although dose rate effects at the transcriptome level are known for radiation exposures, such studies usually compare acute and very protracted irradiations. The latter is usually performed at dose rates of a few mGy per minute for several hours until the desired cumulative dose is reached. In the present study, however, both exposure scenarios with very short irradiation times represent acute exposures. Thus, the difference",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:124"
    }
  },
  {
    "page_content": "represent acute exposures. Thus, the difference in absolute dose is expected to dominate the impact on the transcriptome, but the influence of varying dose rates between HDIR and LDIR cannot be ruled out. In irradiation experiments with human lymphocytes, different dose rates (1.03 Gy/min vs. 3.1 Gy/min) had no effect on activation of p53 signaling at the same cumulative doses (Ghandhi et al. 2015). # Conclusion In this study, we report alterations in the radiation-response in primary",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:125"
    }
  },
  {
    "page_content": "alterations in the radiation-response in primary fibroblasts of former childhood cancer patients compared to cancer-free donors that were most pronounced in reaction to a low dose of IR in long-term survivors which developed a subsequent second primary neoplasm. Mechanisms directed against genotoxic stress were activated to the same extent after a high dose in all donor groups. However, the radiation response was impaired after a low dose in fibroblast of childhood cancer survivors. This",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:126"
    }
  },
  {
    "page_content": "in fibroblast of childhood cancer survivors. This suggests an increased risk for adverse effects by accumulation of DNA-damage following genotoxic insult that may subsequently lead to carcinogenesis, particularly in fibroblasts of donors with at least one second primary neoplasm. This work provides the foundation for further projects and facilitates guided validatory works on the proposed differences in molecular mechanisms coping with IR. # Supplementary Information Additional file 1. All",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:127"
    }
  },
  {
    "page_content": "Supplementary Information Additional file 1. All results of the differential gene expression analyses. AF1a. Complete list of differentially expressed genes. Model 1 considers age at sampling and sex; model 2 considers age at sampling, sex, age at and year of first diagnosis, and tumor type (not used with data from cancer-free controls). Abbreviations: Gy = Gray, N0 = fibroblasts of cancer-free controls, N1 = fibroblasts of childhood-cancer survivors, N2+ = fibroblasts of childhood-cancer",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:128"
    }
  },
  {
    "page_content": "survivors, N2+ = fibroblasts of childhood-cancer survivors with at least one second primary neoplasm, FDR = p-value adjusted for false discovery rate. AF1b. Differential expression computed with the interaction of radiation and donor group. The comparison-column refers to the donor groups that were compared in the analysis for interactions of the effect of radiation dose and donor group to identify genes showing a differential reaction to radiation exposure between donor groups. Abbreviations:",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:129"
    }
  },
  {
    "page_content": "exposure between donor groups. Abbreviations: Gy = Gray, N0 = fibroblasts of cancer-free controls, N1 = fibroblasts of childhood-cancer survivors, N2+ = fibroblasts of childhood-cancer survivors with at least one second primary neoplasm, FDR = p-value adjusted for false discovery rate.Additional file 2. Comparisons of FDR and LFC across donor groups. Comparison of differential expression (DE) and its direction between donor groups.Additional file 3. Primer for and results of qRT-PCR. AF3a.",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:130"
    }
  },
  {
    "page_content": "file 3. Primer for and results of qRT-PCR. AF3a. Constructed and purchased primer sequences for the qPCR. AF3b. Log10 relative expression measured in quantitative polymerase reverse transcriptase chain reaction (qRT-PCR) for selected genes compared to TATA-Box Binding Protein (TBP), stratified by group (each n = 6, three replicates per individuals) and radiation dose. Significance stars imply the p-value thresholds of two-sided t-tests after adjustment for false discovery rate (*",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:131"
    }
  },
  {
    "page_content": "after adjustment for false discovery rate (* p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001). N0 = fibroblasts of cancer-free controls, N1 = fibroblasts of childhood-cancer survivors, N2+ = fibroblasts of childhood-cancer survivors with at least one second primary neoplasm. AF3c. Log10-relative expression measured in quantitative polymerase reverse transcriptase chain reaction (qRT-PCR) for mouse double minute 2 (MDM2) and Cyclin Dependent Kinase Inhibitor 1A (CDKN1A) compared to",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:132"
    }
  },
  {
    "page_content": "Kinase Inhibitor 1A (CDKN1A) compared to TATA-Box Binding Protein (TBP). Data adapted from Brackmann et al. 2020, coloured by group (each n = 2, three replicates per individual) and stratified by radiation dose. Significance stars imply the p-value thresholds of two-sided t-tests (* p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001). N0 = fibroblasts of cancer-free controls, N1 = fibroblasts of childhood-cancer survivors, N2+ = fibroblasts of childhood-cancer survivors with at least one",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:133"
    }
  },
  {
    "page_content": "of childhood-cancer survivors with at least one second primary neoplasm.Additional file 4. IPA settings.Additional file 5. All results of IPA and GO analyses. AF5a. Complete list of predicted upstream regulators. Model 1 considers age at sampling and sex; model 2 considers age at sampling, sex, age at and year of first diagnosis, and tumor type (not used with data from cancer-free controls). Abbreviations: Gy = Gray, N0 = fibroblasts of cancer-free controls, N1 = fibroblasts of childhood-cancer",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:134"
    }
  },
  {
    "page_content": "controls, N1 = fibroblasts of childhood-cancer survivors, N2+ = fibroblasts of childhood-cancer survivors with at least one second primary neoplasm, FDR = p-value adjusted for false discovery rate. AF5b. Complete list of all affected pathways. Model 1 considers age at sampling and sex; model 2 considers age at sampling, sex, age at and year of first diagnosis, and tumor type (not used with data from cancer-free controls). Abbreviations: Gy = Gray, N0 = fibroblasts of cancer-free controls,",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:135"
    }
  },
  {
    "page_content": "N0 = fibroblasts of cancer-free controls, N1 = fibroblasts of childhood-cancer survivors, N2+ = fibroblasts of childhood-cancer survivors with at least one second primary neoplasm, FDR = p-value adjusted for false discovery rate. AF5c. Complete list of all predicted downstream diseases and biofunctions. Model 1 considers age at sampling and sex; model 2 considers age at sampling, sex, age at and year of first diagnosis, and tumor type (not used with data from cancer-free controls).",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:136"
    }
  },
  {
    "page_content": "(not used with data from cancer-free controls). Abbreviations: Gy = Gray, N0 = fibroblasts of cancer-free controls, N1 = fibroblasts of childhood-cancer survivors, N2+ = fibroblasts of childhood-cancer survivors with at least one second primary neoplasm, FDR = p-value adjusted for false discovery rate. rate. AF5d. Complete list of all molecular networks. Model 1 considers age at sampling and sex; model 2 considers age at sampling, sex, age at and year of first diagnosis, and tumor type (not",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:137"
    }
  },
  {
    "page_content": "and year of first diagnosis, and tumor type (not used with data from cancer-free controls). Abbreviations: Gy = Gray, N0 = fibroblasts of cancer-free controls, N1 = fibroblasts of childhood-cancer survivors, N2+ = fibroblasts of childhood-cancer survivors with at least one second primary neoplasm. AF5e. Complete list of Gene Ontology (GO) terms for the top 50 genes (with regard to the p-value) from the gene expression models comparing the reaction to treatment based on phenotype, considering",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:138"
    }
  },
  {
    "page_content": "to treatment based on phenotype, considering age at sampling and sex (model 1). Abbreviations: Gy = Gray, N0 = fibroblasts of cancer-free controls, N1 = fibroblasts of childhood-cancer survivors, N2+ = fibroblasts of childhood-cancer survivors with at least one second primary neoplasm, FDR = p-value adjusted for false discovery rate. AF5f. List of genes used as background for the Gene Ontology over-representation analysis.Additional file 6. All enriched pathways after 2 Gray. Heat map showing",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:139"
    }
  },
  {
    "page_content": "enriched pathways after 2 Gray. Heat map showing all pathways that were significantly enriched in one of the three donor groups (false discovery rate adjusted p-value < 0.05) in the differential gene expression data after exposure to 2 Gray. Model 1 considers age at sampling and sex, model 2 additionally considers age at and year of diagnosis of the first neoplasm, and tumor type. N0 = fibroblasts of cancer-free controls, N1 = fibroblasts of childhood-cancer survivors, N2+ = fibroblasts of",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:140"
    }
  },
  {
    "page_content": "childhood-cancer survivors, N2+ = fibroblasts of childhood-cancer survivors with at least one second primary neoplasm, * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001.Additional file 7. Heat maps for differentially expressed genes in affected/modulated pathways.Additional file 8. Molecule activity prediction using Ingenuity Pathway Analysis.Additional file 9. Heat map of genes in relevant molecular networks. Heat map showing all genes and their respective log2 fold-change that were",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:141"
    }
  },
  {
    "page_content": "and their respective log2 fold-change that were associated with molecular networks with a network score > 10 in any of the three donor groups in the differential gene expression data after exposure to 0.05 or 2 Gray. Model 1 considers age at sampling and sex; model 2 considers age at sampling, sex, age at and year of first diagnosis, and tumor type (not used with data from cancer-free controls). Tiles with black frames show genes that were part of the top networks for that dose/group/model",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:142"
    }
  },
  {
    "page_content": "of the top networks for that dose/group/model combination. N0 = fibroblasts of cancer-free controls, N1 = fibroblasts of childhood-cancer survivors, N2+ = fibroblasts of childhood-cancer survivors with at least one second primary neoplasm.Additional file 10. Results of GO over-representation analyses in gene expression models with interaction terms for donor group. AF10a. Heat maps displaying p-value and log2 fold-change of the top 5 genes per radiation dose, the direction of log2 fold-change",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:143"
    }
  },
  {
    "page_content": "radiation dose, the direction of log2 fold-change per group-wise comparison for expression models including group-dose interaction (with regard to p-value). Log2 fold-change values can be found inside the tiles. Only the results for model 1 (considering age at sampling and sex) are displayed. N0 = fibroblasts of cancer-free controls, N1 = fibroblasts of donors with a first primary neoplasm, N2+ = fibroblasts of donors with at least one second primary neoplasm. * p-value < 0.05, **",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:144"
    }
  },
  {
    "page_content": "one second primary neoplasm. * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001 (adjusted for false discovery rate). AF10b. Tree maps displaying clustered top gene ontology terms for the top 50 genes (with regard to p-value) for expression models including group-dose interaction (with regard to p-value) for each group-wise comparison. Only the results for model 1 (considering age and sex) are displayed. N0 = fibroblasts of cancer-free controls, N1 = fibroblasts of donors with a first",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:145"
    }
  },
  {
    "page_content": "controls, N1 = fibroblasts of donors with a first primary neoplasm, N2+ = fibroblasts of donors with at least one second primary neoplasm.Additional file 11. Results of differential gene expression and pathway analyses stratified by sex. AF11a. Bar charts showing the number and proportion of up- and downregulated genes stratified by dose, donor group, and sex. Differentially expressed genes were computed comparing irradiated to sham-irradiated fibroblasts after exposure to 0.05 and 2 Gray",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:146"
    }
  },
  {
    "page_content": "fibroblasts after exposure to 0.05 and 2 Gray (false discovery rate adjusted p-value < 0.05), considering age at sampling. N0 = fibroblasts of cancer-free controls, N1 = fibroblasts of childhood-cancer survivors, N2+ = fibroblasts of childhood-cancer survivors with at least one second primary neoplasm; * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001. AF11b. Upper Half: Volcano plots showing differential expression after 0.05 Gray stratified by donor group and sex, considering age at",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:147"
    }
  },
  {
    "page_content": "by donor group and sex, considering age at sampling. Lower Half: Heat map showing top five ranking genes with regard to p-value per group considering age at sampling. N0 = fibroblasts of cancer-free controls, N1 = fibroblasts of childhood-cancer survivors, N2+ = fibroblasts of childhood-cancer survivors with at least one second primary neoplasm; * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001. N.S. = not significant (p-value > 0.05). AF11c. Upper Half: Volcano plots showing",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:148"
    }
  },
  {
    "page_content": "AF11c. Upper Half: Volcano plots showing differential expression after 2 Gray stratified by donor group and sex, considering age at sampling. Lower Half: Heat map showing top five ranking genes with regard to p-value per group considering age at sampling. N0 = fibroblasts of cancer-free controls, N1 = fibroblasts of childhood-cancer survivors, N2+ = fibroblasts of childhood-cancer survivors with at least one second primary neoplasm; * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001.",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:149"
    }
  },
  {
    "page_content": "** p-value < 0.01, *** p-value < 0.001. N.S. = not significant (p-value > 0.05). AF11d. Overview of affected (false discovery rate adjusted p-value < 0.05) and (in-) activated pathways (|z|≥ 2), predicted upstream effectors, downstream biofunctions and diseases, and observed molecular networks after irradiation with a low (0.05 Gray) or a high dose (2 Gray) ordered by p-value, stratified by sex and considering age at sampling. For molecular networks, the network score instead of a p-value and",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:150"
    }
  },
  {
    "page_content": "the network score instead of a p-value and no z-score was calculated by Ingenuity Pathway Analysis. N0 = fibroblasts of cancer-free controls, N1 = fibroblasts of childhood-cancer survivors, N2+ = fibroblasts of childhood-cancer survivors with at least one second primary neoplasm; *p-value < 0.05, ** p-value < 0.01, ***p-value < 0.001. AF11e. Heat map showing all pathways from Ingenuity Pathway Analysis that were significantly enriched in one of the three donor groups (false discovery rate",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:151"
    }
  },
  {
    "page_content": "of the three donor groups (false discovery rate adjusted p-value < 0.05) using results from the differential gene expression data stratified by sex and considering age at sampling after exposure to 2 Gray. N0 = fibroblasts of cancer-free controls, N1 = fibroblasts of childhood-cancer survivors, N2+ = fibroblasts of childhood-cancer survivors with at least one second primary neoplasm; * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001.Additional file 12. Results of differential gene",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:152"
    }
  },
  {
    "page_content": "file 12. Results of differential gene expression and pathway analyses after exclusion of self-reported non-Caucasian donors. AF12a. Bar charts showing the proportion of up- and downregulated genes stratified by dose, and donor group after exclusion of self-reported non-Caucasian participants. Differentially expressed genes in irradiated compared to sham-irradiated fibroblasts from N0 = fibroblasts of cancer-free controls, N1 = fibroblasts of childhood-cancer survivors, N2+ = fibroblasts of",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:153"
    }
  },
  {
    "page_content": "childhood-cancer survivors, N2+ = fibroblasts of childhood-cancer survivors with at least one second primary neoplasm. Model 1 considers age at sampling and sex; model 2 considers age at sampling, sex, as well as age at and year of diagnosis of the first neoplasm, and tumor type. AF12b. Overview of affected (false discovery rate adjusted p-value < 0.05) and (in-) activated pathways (|z|≥ 2), predicted upstream effectors, downstream biofunctions and diseases, and observed molecular networks",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:154"
    }
  },
  {
    "page_content": "and diseases, and observed molecular networks after irradiation with a low (0.05 Gray) or a high dose (2 Gray) ordered by p-value, after exclusion of self-reported non-Caucasian participants. For molecular networks, the network score instead of a p-value and no z-score was calculated by Ingenuity Pathway Analysis. Model 1 considers age at sampling and sex. N0 = fibroblasts of cancer-free controls, N1 = fibroblasts of childhood-cancer survivors, N2+ = fibroblasts of childhood-cancer survivors",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:155"
    }
  },
  {
    "page_content": "N2+ = fibroblasts of childhood-cancer survivors with at least one second primary neoplasm; * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001. AF12c. Heat map showing all pathways from Ingenuity Pathway Analysis that were significantly enriched in one of the three donor groups (false discovery rate adjusted p-value < 0.05) in the differential gene expression data after exclusion of self-reported non-Caucasian participants after exposure to 2 Gray. Model 1 considers age at sampling and",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:156"
    }
  },
  {
    "page_content": "to 2 Gray. Model 1 considers age at sampling and sex. N0 = fibroblasts of cancer-free controls, N1 = fibroblasts of childhood-cancer survivors, N2+ = fibroblasts of childhood-cancer survivors with at least one second primary neoplasm; * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001.Additional file 13. Results of pathway analysis after exclusion of genes with less than 20% up- or downregulation.Overview of affected (false discovery rate adjusted at p-value < 0.05) and (in-) activated",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:157"
    }
  },
  {
    "page_content": "adjusted at p-value < 0.05) and (in-) activated pathways (|z| ≥ 2), predicted upstream effectors, downstream biofunctions and diseases after irradiation with a low (0.05 Gray) or a high dose (2 Gray) ordered by p-value.* p--value < 0.05, ** p--value < 0.01, *** p--value < 0.001. Model 1: considering age at sampling and sex, model 2: considering age at sampling, sex, age at and year of diagnosis of the first neoplasm, and tumor type (not used with data from N0), N0 = fibroblasts of cancer-free",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:158"
    }
  },
  {
    "page_content": "data from N0), N0 = fibroblasts of cancer-free controls, N1 = fibroblasts of childhood-cancer survivors, N2+ = fibroblasts of childhood-cancer survivors with at least one second primary neoplasm.",
    "metadata": {
      "source": "../data/plain/PMC9450413.plain.txt",
      "id": "../data/plain/PMC9450413.plain.txt:159"
    }
  },
  {
    "page_content": "Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms Abstract",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:0"
    }
  },
  {
    "page_content": "Interferons (IFNs) are key initiators and effectors of the immune response against malignant cells and also directly inhibit tumor growth. IFNα is highly effective in the treatment of myeloproliferative neoplasms (MPNs), but the mechanisms of action are unclear and it remains unknown why some patients respond to IFNα and others do not. Here, we identify and characterize a pathway involving PKCδ-dependent phosphorylation of ULK1 on serine residues 341 and 495, required for subsequent activation",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:1"
    }
  },
  {
    "page_content": "341 and 495, required for subsequent activation of p38 MAPK. We show that this pathway is essential for IFN-suppressive effects on primary malignant erythroid precursors from MPN patients, and that increased levels of ULK1 and p38 MAPK correlate with clinical response to IFNα therapy in these patients. We also demonstrate that IFNα treatment induces cleavage/activation of the ULK1-interacting ROCK1/2 proteins in vitro and in vivo, triggering a negative feedback loop that suppresses IFN",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:2"
    }
  },
  {
    "page_content": "a negative feedback loop that suppresses IFN responses. Overexpression of ROCK1/2 is seen in MPN patients and their genetic or pharmacological inhibition enhances IFN-anti-neoplastic responses in malignant erythroid precursors from MPN patients. These findings suggest the clinical potential of pharmacological inhibition of ROCK1/2 in combination with IFN-therapy for the treatment of MPNs. Abstract",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:3"
    }
  },
  {
    "page_content": "Interferon alpha (IFNalpha) therapy is showing promising results to treat myeloproliferative neoplasms (MPNs). Here, the authors show that IFNalpha response requires ULK1 phosphorylation to induce p38-MAPK signalling but it is counteracted by ROCK1-2 activation suggesting combination therapy of IFNalpha-ROCK1-2 inhibition may improve MPNs treatment. # Introduction Type I interferons (IFNs) are critical frontline effectors of the immune defense against pathogens and cancer1,2. Additionally, IFNs",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:4"
    }
  },
  {
    "page_content": "pathogens and cancer1,2. Additionally, IFNs act directly on tumor cells blocking their growth, survival, migration, and other pro-tumorigenic events3. Type I IFNs exert their effects by binding to the Type I IFN receptor (IFNAR) and subsequently activating multiple signaling pathways that lead to the expression of IFN-stimulated genes (ISGs), whose protein products drive several distinct biological functions4–6. Extensive clinical studies using different formulations of IFN-alpha (IFNα) have",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:5"
    }
  },
  {
    "page_content": "different formulations of IFN-alpha (IFNα) have demonstrated anti-tumor activity against several malignancies. IFNα treatment is especially effective in Philadelphia chromosome negative myeloproliferative neoplasms (MPNs), and has been approved by the U.S. Food and Drug Administration for the treatment of hairy cell leukemia, AIDS-related Kaposi’s sarcoma, and chronic myelogenous leukemia (CML)3,7. MPNs are clonal hematopoietic stem cell (HSC) disorders characterized by an increased risk of",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:6"
    }
  },
  {
    "page_content": "disorders characterized by an increased risk of bleeding, thrombosis, bone marrow fibrosis and, in some cases, transformation to acute myeloid leukemia (AML)8,9. There are three types of MPNs: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). In 95% of MPN patients, somatic mutations in one of three genes: JAK2, CALR, or MPL occur in a single HSC, giving rise to malignant stem cells with constitutively active MPL-JAK-STAT signaling8. JAK2V617F is the most",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:7"
    }
  },
  {
    "page_content": "MPL-JAK-STAT signaling8. JAK2V617F is the most common mutation and occurs in ~95% of PV patients and 50–60% of ET and PMF patients10–13. JAK2 inhibitors are approved for the treatment of MPNs, however, overall they have a modest effect and rarely achieve complete molecular or pathologic remission14. In contrast, in recent clinical studies, pegylated IFNα (PEG-IFN) was shown to induce durable hematological and molecular responses in MPN patients, and in some cases complete remission7,15–19. The",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:8"
    }
  },
  {
    "page_content": "and in some cases complete remission7,15–19. The mechanism(s) of action of IFN in MPNs are unclear and the reason for molecular relapses, which have been reported in some patients20, are unknown. We have previously demonstrated that Unc-51-like kinase 1 (ULK1) is required for IFN-induced anti-clonogenic effects against malignant erythroid progenitor cells from MPN patients and that ULK1 is required for IFN-mediated activation of p38 MAPK and expression of specific ISGs21. In the present study,",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:9"
    }
  },
  {
    "page_content": "of specific ISGs21. In the present study, we identify protein kinase C-delta (PKCδ) as an upstream regulator of the ULK1-p38 MAPK cascade. We also identify ROCK1/2 as interactor proteins of ULK1 and negative feedback regulators of IFNα-induced anti-neoplastic effects in primary MPN cells. Additionally, we provide evidence that increased expression of elements of the pathway correlate with clinical response to IFNα therapy in MPN patients, underscoring the importance of this signaling circuit in",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:10"
    }
  },
  {
    "page_content": "the importance of this signaling circuit in the IFN-system. # Results ## Type I IFN treatment activates a PKCδ-ULK1-p38 MAPK signaling cascade At the outset, we sought out the IFN-regulated signals controlling engagement of ULK1. There are putative PKCδ phosphorylation sites in ULK122 and, identified from our previous work, PKCδ activity is essential for type I IFN-induced phosphorylation of p38 MAPK and the subsequent transcription of ISGs23,24. This prompted us to investigate if PKCδ and ULK1",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:11"
    }
  },
  {
    "page_content": "This prompted us to investigate if PKCδ and ULK1 interact during activation of IFNAR in JAK2V617F-positive cells. In co-immunoprecipitation assays using two JAK2V617F-expressing leukemia cell lines, we found ULK1 associated with PKCδ, both before and after IFNα-treatment (Fig. 1a, b). This constitutive interaction between PKCδ and ULK1, however, was not JAK2V617F-dependent, as it was also detected in JAK2V617F-negative leukemia lines (Fig. 1c, d). These results raised the possibility that IFN",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:12"
    }
  },
  {
    "page_content": "d). These results raised the possibility that IFN could stimulate PKCδ-induced phosphorylation of ULK1. Thus, to determine whether ULK1 is a substrate for PKCδ associated with type I IFN signaling, in vitro kinase assays were conducted on anti-PKCδ immunoprecipitates, using inactive GST-ULK1 as an exogenous substrate. Our results revealed that PKCδ phosphorylates ULK1 in a type I IFN-dependent manner (Fig. 1e).Fig. 1PKCδ binds to and directly phosphorylates ULK1 on serine residues 341 and",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:13"
    }
  },
  {
    "page_content": "phosphorylates ULK1 on serine residues 341 and 495.a–d Immunoblots for the indicated proteins in total cell lysates (input) or immunoprecipitates (IP) with anti-ULK1 or RIgG (negative control) antibodies from (a) HEL, (b) SET-2, (c) KT-1, and (d) U937 cells, left untreated or treated with IFNα or IFNβ (104 IU/mL) for 10 min, as indicated. Blots are representative of two independent experiments for each cell line. RIgG, normal Rabbit Immunoglobulin G. IP samples and corresponding total cell",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:14"
    }
  },
  {
    "page_content": "G. IP samples and corresponding total cell lysates (input) were resolved and blotted from the same gel as shown in Supplementary Information (uncropped blots). e KT-1 cells were starved overnight and then treated with IFNβ (104 IU/mL) for 10 or 30 min, as indicated. After cell lysis, equal amounts of protein were immunoprecipitated (IP) with either PKCδ antibody or control normal rabbit immunoglobulin G (RIgG), as indicated. In vitro kinase assays to assess PKCδ activity were subsequently",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:15"
    }
  },
  {
    "page_content": "assays to assess PKCδ activity were subsequently performed on the immunoprecipitates, using GST-ULK1 recombinant inactive protein as an exogenous substrate. (Top panel) Autoradiography film demonstrating PKCδ-induced phosphorylation of ULK1 after IFNβ treatment. (Bottom panels) Immunoblots demonstrating total GST-ULK1 protein and total immunoprecipitated PKCδ expression used in each condition for the in vitro kinase assay. Note: a lane between ULK1 and RIgG immunoprecipitates was loaded with 1x",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:16"
    }
  },
  {
    "page_content": "and RIgG immunoprecipitates was loaded with 1x loading dye for best separation between the wells. Kinase assay shown is representative of three independent experiments. *unspecific band. f cDNA expression plasmids encoding the indicated myc-ULK1 derivatives were used for transfections and recombinant proteins were immunoprecipitated (c-Myc-IP) from HEK293T cells, inactivated, and subjected to in vitro kinase assays using GST-PKCδ recombinant protein as kinase. (Top panel) Autoradiography film",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:17"
    }
  },
  {
    "page_content": "as kinase. (Top panel) Autoradiography film demonstrating PKCδ-induced phosphorylation of myc-ULK1s and autophosphorylation of GST-PKCδ, as indicated. (Bottom panel) Coomassie Blue staining depicts loading/molecular weight (MW) of myc-ULK1 constructs. EV, myc-tagged empty vector. Kinase assay shown is representative of two independent experiments. Source data are provided as a Source Data file. As previous studies using liquid chromatography (LC) and tandem mass spectrometry (MS/MS) have",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:18"
    }
  },
  {
    "page_content": "(LC) and tandem mass spectrometry (MS/MS) have identified Ser341, Ser467 and Ser495 as the putative PKCδ phosphorylation sites in ULK122, we next generated single serine-to-alanine (S/A) ULK1 mutants (S341A, S467A and S495A) and a triple (SSS/AAA) ULK1 mutant (S341/467/495 A). ULK1 WT and Ser-to-Ala ULK1 mutants were overexpressed in HEK293T cells, immunoprecipitated from cell lysates, inactivated, and used as substrates for purified active GST-PKCδ in the presence of 32P-ATP in kinase assays",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:19"
    }
  },
  {
    "page_content": "in the presence of 32P-ATP in kinase assays (Fig. 1f). While replacement of Ser467 by Ala did not result in an obvious alteration of phosphorylation, mutation of Ser341 to Ala (S341A) and Ser495 to Ala (S495A) reduced phosphorylation of ULK1 by PKCδ (Fig. 1f). Additionally, this reduction was more evident for the triple mutant (SSS/AAA) ULK1 (Fig. 1f). These results suggest that PKCδ directly phosphorylates ULK1 on both Ser341 and Ser495 residues (Fig. 1f), which prompted us to generate two",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:20"
    }
  },
  {
    "page_content": "(Fig. 1f), which prompted us to generate two phospho-specific ULK1 antibodies, one recognizing ULK1 phosphorylated on Ser341 and the other recognizing ULK1 phosphorylated on Ser495. We confirmed the specificity of the antibodies using Ulk1/2−/− mouse embryonic fibroblasts (MEFs) transfected with myc-tagged empty vector, ULK1 WT, ULK1 S341A and ULK1 S495A mutants (Supplementary Fig. 1a, b). The p-Ser341ULK1 antibody gave a strong signal in the Ulk1/2−/− cells transfected with both ULK1 WT and",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:21"
    }
  },
  {
    "page_content": "Ulk1/2−/− cells transfected with both ULK1 WT and ULK1 S495A mutant, but not in cells transfected with empty vector or the ULK1 S341A mutant. Likewise, the p-Ser495ULK1 antibody gave a strong signal in the Ulk1/2−/− cells transfected with both ULK1 WT and ULK1 S341A mutant, but not in the cells transfected with empty vector or ULK1 S495A mutant, confirming the specificity of these antibodies (Supplementary Fig. 1a, b). Next, using Ulk1/2+/+ MEFs, we provide evidence that phosphorylation of ULK1",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:22"
    }
  },
  {
    "page_content": "we provide evidence that phosphorylation of ULK1 on both Ser341 and Ser495 is induced by IFNα treatment (Supplementary Fig. 2). Moreover, using siRNA-mediated knockdown of PKCδ in U937 cells, we show that PKCδ expression is required for IFNα-mediated phosphorylation of ULK1 on Ser341 and Ser495, but not on Ser757, an AKT/mTOR phosphorylation site21 (Fig. 2a–c). As ULK1 is required for IFN-mediated activation of p38 MAPK, leading to transcription of ISGs21, we next sought to determine whether",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:23"
    }
  },
  {
    "page_content": "of ISGs21, we next sought to determine whether phosphorylation of ULK1 on Ser341 and Ser495 residues is essential for IFN-induced activation of p38 MAPK. To this end, we overexpressed myc-tagged empty vector, ULK1 WT, ULK1 S341A and ULK1 S495A in Ulk1/2−/− MEFs. These cells were then treated with IFNα and the phosphorylation of p38 MAPK was assessed. ULK1 WT, but not the ULK1 S/A mutants, could rescue IFNα-induced activation of p38 MAPK (Fig. 2d). Additionally, we overexpressed myc-tagged empty",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:24"
    }
  },
  {
    "page_content": "Additionally, we overexpressed myc-tagged empty vector, ULK1 WT, ULK1 S341A and ULK1 S495A in ULK1 KO KT-1 cells. ULK1 protein expression or its absence was confirmed by anti-ULK1 immunoblotting (Supplementary Fig. 3 and Fig. 2e). The different transfected cells were then either left untreated or were treated with IFNα for 6 h and the mRNA expression of ISGs was evaluated by qRT-PCR analysis. In contrast with ULK1 S341A and ULK1 S495A, expression of the ULK1 WT substantially increased the",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:25"
    }
  },
  {
    "page_content": "of the ULK1 WT substantially increased the IFNα-induced expression of IFIT1, OAS1 and IFIT3 compared to empty vector-transfected ULK1 KO KT-1 cells (Fig. 2f–h). Moreover, siRNA-mediated targeted inhibition of PKCδ expression reversed the suppressive effects of IFNα on primitive malignant erythroid precursors (Fig. 3a). Thus, as previously shown for ULK121 and p38 MAPK25, PKCδ engagement by activation of IFNAR is essential for the suppressive effects of IFNα on primary malignant PV progenitors,",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:26"
    }
  },
  {
    "page_content": "of IFNα on primary malignant PV progenitors, in vitro. Taken together these results provide evidence of previously unknown signaling events, in which activation of IFNAR controls PKCδ-mediated ULK1 phosphorylation on Ser341 and Ser495 and that ULK1 phosphorylation at these sites is required for downstream activation of p38 MAPK and transcription of ISGs.Fig. 2Type I IFN-induced PKCδ-dependent phosphorylation of ULK1 on serine residues 341 and 495 is required for ULK1-mediated activation of p38",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:27"
    }
  },
  {
    "page_content": "is required for ULK1-mediated activation of p38 MAPK and consequent expression of ISGs.a U937 cells were transfected with either control siRNA or PKCδ siRNA. 24 h later, cells were starved overnight (cultured in RPMI medium without FBS) and then were either left untreated or were treated with IFNα (104 IU/mL) for 10 or 30 min, as indicated. Immunoblotting analysis was performed for the indicated proteins. Blots are representative of three independent experiments. *unspecific band. b, c Bands",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:28"
    }
  },
  {
    "page_content": "experiments. *unspecific band. b, c Bands for the indicated proteins were scanned and quantified for untreated and 10 min IFNα-treated samples by densitometry, using ImageJ software. Quantified data are means ± SEM of pULK1/GAPDH from three independent experiments. Adjusted p-values are reported by two-way ANOVA followed by Tukey’s multiple comparisons test to assess the differences in ULK1 phosphorylation on Ser341 and Ser495 with treatment (untreated vs. IFNα), siRNA (Ctrl siRNA vs. PKCδ",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:29"
    }
  },
  {
    "page_content": "(untreated vs. IFNα), siRNA (Ctrl siRNA vs. PKCδ siRNA) and their interaction as predictors. arb. units, arbitrary units. d Immunoblotting analysis of p-p38 MAPK in lysates from Ulk1/2−/− MEFs transfected with myc-tagged empty vector (EV), ULK1 WT, ULK1S341A or ULK1S495A plasmids treated with IFNα (104 IU/mL) for 10 min, as indicated. Blots are representative of three independent experiments. e–h",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:30"
    }
  },
  {
    "page_content": "ULK1 KO KT-1 cells were transfected with myc-tagged empty vector (EV), ULK1 WT, ULK1S341A or ULK1S495A plasmids. e Immunoblotting analysis of ULK1 in lysates from ULK1 KO KT-1 transfected cells, as indicated. Blots are representative of three independent experiments. f–h qRT-PCR analysis of (f) IFIT1, (g) OAS1, and (h) IFIT3 in ULK1 KO KT-1 transfected cells treated for 6 h with IFNα (5000 IU/mL). Shown is mRNA expression fold change over respective untreated ULK1 KO KT-1 transfected cells.",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:31"
    }
  },
  {
    "page_content": "untreated ULK1 KO KT-1 transfected cells. Data are means ± SEM from three independent experiments. Adjusted p-values are reported by one-way ANOVA followed by Tukey’s multiple comparisons test. See also Supplementary Figs. 1–3. Source data are provided as a Source Data file.Fig. 3Correlation between PKCδ, ULK1 and p38 MAPK expression and responsiveness to IFN treatment in primary MPN cells.a Peripheral blood mononuclear cells from patients with PV were transfected with either control siRNA",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:32"
    }
  },
  {
    "page_content": "PV were transfected with either control siRNA (Ctrl siRNA) or PKCδ siRNA, and the effects of IFNα treatment (103 IU/mL) on malignant erythroid (BFU-E) colony formation were assessed by clonogenic assays in methylcellulose. Data are expressed as percent colony formation relative to control siRNA-transfected untreated cells (Ctrl siRNA) and represent means ± SEM of three independent experiments, using cells from three different individual patients with PV. In the graph, data for the same",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:33"
    }
  },
  {
    "page_content": "patients with PV. In the graph, data for the same individual patient is represented by the same symbol for each experimental condition. Statistical analyses were performed using a linear mixed effects model, with % colony formation relative to the control group as the outcome, treatment (the three remaining groups) as the fixed effect, and subject as a random effect to account for within-subject correlation between multiple conditions. Kenward-Roger degrees of freedom adjustment was used, which",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:34"
    }
  },
  {
    "page_content": "degrees of freedom adjustment was used, which improves performance when sample size is small. Pairwise group comparison tests were adjusted for multiple comparisons using Tukey’s method. Statistical significant p-values (two-sided) are reported. b Correlation between PKCδ (PRKCD), ULK1, or p38 MAPK (MAPK14) baseline mRNA expression and clinical response of PV or ET patients to PEG-IFNα treatment (clinical trial #NCT01259817)7 based on a simplified, two-group criteria: R, responders (n = 9); NR,",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:35"
    }
  },
  {
    "page_content": "two-group criteria: R, responders (n = 9); NR, non-responders (n = 9). The clinical characteristics of each patient are provided in Supplementary Table 1. 18S gene expression was used as a reference gene. Data are expressed as ΔCt value for each gene, respectively (means ± SEM are shown). Statistical analyses were performed using linear mixed effects models77, with Ct as the outcome variable, and target (18S or one of PKCδ, ULK1 or MAPK14 genes), responder status (yes vs. no), and their",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:36"
    }
  },
  {
    "page_content": "genes), responder status (yes vs. no), and their interaction as fixed effects, and subject as the random effect to account for the correlation between within-subject replicates. Kenward-Roger degrees of freedom adjustment, which improves performance when sample size is small, was used. p-values (two-sided) are reported. Source data are provided as a Source Data file. To investigate whether constitutive levels of elements of this pathway may therefore discern responsiveness to IFN treatment, we",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:37"
    }
  },
  {
    "page_content": "discern responsiveness to IFN treatment, we examined mRNA expression levels of PKCδ, ULK1 and p38 MAPK in peripheral blood or bone marrow mononuclear cells from patients enrolled in the Myeloproliferative Disorders Research Consortium (MPD-RC)-111 study who received PEG-IFN-α2a (Pegasys) (clinical trial #NCT01259817)7 (Supplementary Table 1). Patients expressing higher pre-treatment mRNA levels of ULK1 and p38 MAPK were more likely to respond to PEG-IFN-α2a therapy (Fig. 3b), from which we",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:38"
    }
  },
  {
    "page_content": "to PEG-IFN-α2a therapy (Fig. 3b), from which we infer a key role for this pathway in the anti-neoplastic effects of IFN in vivo. Future prospective clinical studies will be required to fully validate these findings and examine the potential of ULK1 and p38 MAPK as biomarkers of IFN-responsiveness. ## ROCK1 and ROCK2 are overexpressed in MPN patients and interact with ULK1 Next, to identify binding partners of ULK1 in cells of MPN origin, we performed nano-LC MS/MS analysis of endogenous",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:39"
    }
  },
  {
    "page_content": "we performed nano-LC MS/MS analysis of endogenous protein-ULK1 complexes isolated from untreated and IFNα-treated JAK2V617F-expressing HEL cells. The data indicate that ULK1 potentially interacts with 40 proteins in untreated cells, and with 38 proteins after IFNα treatment, 33 of which are identical in untreated and treated cells and 5 exclusively interact with ULK1 following IFN treatment (Supplementary Fig. 4, ProteomeXchange identifier PXD021748.). Among these five, is ROCK1 (Supplementary",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:40"
    }
  },
  {
    "page_content": "Among these five, is ROCK1 (Supplementary Fig. 4), a protein involved in promoting survival of some malignant hematopoietic cells26,27. We provide evidence that expression of both ROCK1 and, its related isoform, ROCK228, is increased in peripheral blood neutrophils from ET, PMF, and PV patients compared to age-matched healthy donors (Fig. 4a, b). Moreover, we used the DepMap Portal (https://depmap.org/portal/) to assess the relative protein expression of ROCK1 and ROCK2 in leukemia and other",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:41"
    }
  },
  {
    "page_content": "of ROCK1 and ROCK2 in leukemia and other types of cancer cell lines (Supplementary Fig. 5). Interestingly, ROCK1 expression is higher in leukemia and lymphoma cell lines, compared to other types of cancer cell lines, whereas ROCK2 expression is the highest in colon cancer cells (Supplementary Fig. 5). Using co-immunoprecipitation followed by immunoblotting analyses, we found that ULK1 interacts preferentially with the cleaved/active forms of both ROCK1 and ROCK2 proteins28 in",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:42"
    }
  },
  {
    "page_content": "forms of both ROCK1 and ROCK2 proteins28 in JAK2V617F-expressing cells (Fig. 4c, d).Fig. 4ROCK1 and ROCK2 interact with ULK1 in JAK2V617F-positive cells and are overexpressed in MPN patients.a, b Scatter dot plots of ROCK1 and ROCK2 expression in healthy individuals (normal, n = 11) and patients with ET (n = 47), MF (n = 18) and PV (n = 28). Data extracted from GSE5464672. Shown are means ± SEM of Log2 mRNA expression. Statistical analyses were performed using one-way ANOVA followed by",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:43"
    }
  },
  {
    "page_content": "were performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. Adjusted p-values are reported. c, d Immunoblots for the indicated proteins in total cell lysates (input) or in anti-ULK1 or RIgG (negative control) antibody immunoprecipitates (IP) from JAK2V617F-positive HEL cells left untreated or treated with IFNα (104 IU/mL) for 10 min, as indicated. Blots are representative of three independent experiments. RIgG, normal Rabbit Immunoglobulin G. IP samples and corresponding",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:44"
    }
  },
  {
    "page_content": "Immunoglobulin G. IP samples and corresponding total cell lysates (input) were resolved and blotted from the same gel as shown in Supplementary Information (uncropped blots). See also Supplementary Figs. 4 and 5. Source data are provided as a Source Data file. Caspases mediate cleavage and subsequent activation of ROCK1/228 and type I IFNs promote apoptosis through activation of caspases29, prompting us to examine whether IFNα treatment could induce cleavage/activation of ROCK1/2, in vivo. For",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:45"
    }
  },
  {
    "page_content": "cleavage/activation of ROCK1/2, in vivo. For these studies, we used a conditional Jak2V617F knock-in (KI) MPN mouse model30 (Fig. 5a). As expected, 5 weeks after transplantation of Jak2V617F KI bone marrow cells collected from Jak2V617F/+VavCre+ CD45.2 donor mice, a robust PV-like MPN phenotype developed in CD45.1 recipient mice (Supplementary Fig. 6a–f). Murine PEG-IFNα treatment was then initiated once a week for 4 weeks (Fig. 5a). As seen in previous MPN mouse model studies using IFNα31–33,",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:46"
    }
  },
  {
    "page_content": "previous MPN mouse model studies using IFNα31–33, PEG-IFNα treatment significantly reduced hematocrit (HCT) and red blood cell (RBC) levels in these mice (Supplementary Fig. 6g–j). Notably, PEG-IFNα treatment increased the cleavage of both ROCK1 and ROCK2 proteins in bone marrow mononuclear cells isolated from CD45.1 recipient mice (Fig. 5b–e). Additionally, we provide evidence that IFNα treatment induces activation/cleavage of caspase 3, PARP and ROCK proteins in both JAK2V617F-positive HEL",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:47"
    }
  },
  {
    "page_content": "and ROCK proteins in both JAK2V617F-positive HEL cells and in JAK2V617F-negative U937 and KT-1 cells, in vitro, and these effects are repressed by co-treatment with a pan-caspase inhibitor, Z-VAD-FMK (Fig. 5f–h). In further studies, to determine whether PEG-IFNα treatment induces activation/cleavage of caspase 3 and activation of ROCK proteins in both Jak2+/+ (wild-type) and Jak2V617F/+ hematopoietic cells in vivo, we transplanted CD45.1 recipient mice with either Jak2+/+ or Jak2V617F/+ KI bone",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:48"
    }
  },
  {
    "page_content": "mice with either Jak2+/+ or Jak2V617F/+ KI bone marrow cells collected from Jak2+/+VavCre- and Jak2V617F/+VavCre+ CD45.2 donor mice, respectively (Fig. 6a). Three weeks after transplantation, engraftment of Jak2+/+ and Jak2V617F/+ CD45.2+ cells in CD45.1 recipient mice was confirmed (Supplementary Fig. 7a) and a PV-like MPN phenotype developed in Jak2V617F/+, but not in Jak2+/+, recipient mice (Supplementary Fig. 7b–e). Murine PEG-IFNα treatment was then initiated once a week for 4 weeks",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:49"
    }
  },
  {
    "page_content": "was then initiated once a week for 4 weeks (Fig. 6a). At week 3, 24 h post-IFNα treatment we collected peripheral blood and isolated mononuclear cells from the recipient mice (Fig. 6a, p-MYPT1 in peripheral blood mononuclear cells (PBMCs)). In both Jak2+/+ and Jak2V617F/+ recipient mice, PEG-IFNα treatment increased phosphorylation of the ROCK1/2 downstream target myosin phosphatase target subunit 1 (MYPT1)28, compared to vehicle-control-treated mice (Fig. 6b), consistent with an IFNα-induced",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:50"
    }
  },
  {
    "page_content": "mice (Fig. 6b), consistent with an IFNα-induced increase in ROCK1/2 kinase activity. Importantly, IFNα-induced phosphorylation of p-MYPT1 was greater in Jak2V617F/+ compared to Jak2+/+ recipient mice (p = 0.0382). Additionally, PEG-IFNα treatment decreased hematocrit and red blood cell levels in Jak2V617F/+, but not in Jak2+/+, recipient mice (Fig. 6c, d and Supplementary Fig. 7f, g), consistent with earlier reports that IFNα treatment targets JAK2V617F-mutant over non-malignant hematopoietic",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:51"
    }
  },
  {
    "page_content": "JAK2V617F-mutant over non-malignant hematopoietic cells32. Twenty-four hours after the fourth dose of PEG-IFNα, mononuclear bone marrow cells from recipient mice were isolated and we evaluated cleavage/activation of caspase 3 by immunoblotting and phosphorylation of MYPT1 by flow cytometry analyses. The data show that PEG-IFNα treatment induces cleavage of caspase 3 (Fig. 6e) and phosphorylation of MYPT1 (Fig. 6f, g) in both Jak2+/+ and Jak2V617F/+ bone marrow cells. These results were",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:52"
    }
  },
  {
    "page_content": "Jak2V617F/+ bone marrow cells. These results were consistent with the analyses performed using bone marrow cells isolated from PEG-IFNα-treated wild-type C57BL/6 J mice (Supplementary Fig. 8). Together these results suggest that IFNα treatment induces caspase-dependent ROCK1/2 activation in normal and malignant hematopoietic cells, suggesting a potential role for ROCK1/2 in regulation of IFN-mediated biological responses.Fig. 5IFNα treatment induces cleavage/activation of ROCK1 and ROCK2 in a",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:53"
    }
  },
  {
    "page_content": "cleavage/activation of ROCK1 and ROCK2 in a mouse model of MPN and in hematopoietic malignant cells in vitro.a–e CD45.1 mice were transplanted with Jak2V617F KI bone marrow cells isolated from JAK2V617F/+VavCre+ CD45.2 donor mice. Five weeks after transplantation and confirmation of engraftment (see Supplementary Fig. 6a–f), CD45.1 recipient mice were treated with murine PEG-IFNα once a week (600 ng/mouse, subcutaneous injection) for 4 weeks or vehicle (PBS). a Schematic illustration of the MPN",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:54"
    }
  },
  {
    "page_content": "(PBS). a Schematic illustration of the MPN mouse model and treatment regimen performed before phenotypic analyses. b, c Western blot analysis of ROCK1 and ROCK2 in mononuclear bone marrow cells isolated 4 weeks after initiation of vehicle-control treatment (n = 5 for ROCK1, n = 4 for ROCK2) or PEG-IFNα treatment (n = 5 for ROCK1 and ROCK2) of CD45.1 recipient mice. d, e Bands for cleaved-ROCK1, cleaved-ROCK2 and respective GAPDH shown in b and c were quantified by densitometry using ImageJ",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:55"
    }
  },
  {
    "page_content": "c were quantified by densitometry using ImageJ software. Quantified data are means ± SEM of cleaved ROCK/GAPDH and each data point represents data for one individual mouse. Two-sample two-tailed t-test was performed to calculate differences in cleaved ROCK1/2 between the two treatment groups. p-values are reported. arb. units, arbitrary units. See also Supplementary Fig. 6g–j. f–h Immunoblotting analysis of the indicated proteins in lysates from (f) HEL, (g) U937, and (h) KT-1 cells either left",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:56"
    }
  },
  {
    "page_content": "(f) HEL, (g) U937, and (h) KT-1 cells either left untreated or treated with IFNα (1000 IU/mL) and/or the caspase inhibitor (CASPi) Z-VAD-FMK (20 μM) for 24 or 48 h, as indicated. Blots are representative of two independent experiments for each cell line. Source data are provided as a Source Data file.Fig. 6PEG-IFNα treatment induces cleavage/activation of caspase 3 and phosphorylation of ROCK1/2 downstream target MYPT1 in Jak2+/+ and Jak2V617F/+ hematopoietic cells in vivo.a–g CD45.1 mice were",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:57"
    }
  },
  {
    "page_content": "hematopoietic cells in vivo.a–g CD45.1 mice were transplanted with either Jak2+/+ or Jak2V617F/+ KI bone marrow cells isolated from Jak2+/+VavCre- CD45.2 donor mice or Jak2V617F/+VavCre+ CD45.2 donor mice, respectively. Three weeks after transplantation and confirmation of engraftment (see Supplementary Fig. 7a–e), CD45.1 recipient mice were either treated with murine PEG-IFNα once a week (600 ng/mouse, subcutaneous injection) for 4 weeks or vehicle (PBS). a Schematic illustration of the in",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:58"
    }
  },
  {
    "page_content": "vehicle (PBS). a Schematic illustration of the in vivo models and treatment regimen performed before phenotypic analyses. Gy: gray units of ionizing radiation dose. b Scatter dot plots show median fluorescence of phosphorylated MYPT1 (p-MYPT1 A647) in Jak2+/+ (purple) or Jak2V617F/+ (orange) peripheral blood mononuclear cells (PBMCs) collected 24 h after the third dose of PEG-IFNα (triangles: Jak2+/+ IFNα n = 5 and Jak2VF/+ IFNα n = 5) or vehicle (circles: Jak2+/+ CTRL n = 5 and Jak2VF/+ CTRL",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:59"
    }
  },
  {
    "page_content": "(circles: Jak2+/+ CTRL n = 5 and Jak2VF/+ CTRL n = 5). Data were assessed by flow cytometry and the gating strategy used is shown in Supplementary Fig. 7h. c, d Scatter dot plots show (c) hematocrit (HCT) and (d) red blood cell (RBC) counts of recipients from vehicle-control (Jak2+/+ CTRL n = 5 and Jak2VF/+ CTRL n = 5) and PEG-IFNα (Jak2+/+ IFNα n = 5 and Jak2VF/+ IFNα n = 5) groups after four doses of PBS (vehicle-control) or PEG-IFNα treatment. Data shown are means ± SEM. e Immunoblotting",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:60"
    }
  },
  {
    "page_content": "Data shown are means ± SEM. e Immunoblotting analysis of caspase 3 in lysates from bone marrow mononuclear cells (BMMCs) isolated from CD45.1 recipient mice 24 h after the fourth dose of PEG-IFNα (Jak2+/+ IFNα n = 5 and Jak2VF/+ IFNα n = 5) or vehicle (Jak2+/+ CTRL n = 5 and Jak2VF/+ CTRL n = 5), as indicated. f, g Scatter dot plots show median fluorescence of phosphorylated MYPT1 (p-MYPT1 A647) in Jak2+/+ or Jak2V617F/+ (f) CD71 negative (CD71-) and (g) CD71-positive (CD71+) BMMCs isolated",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:61"
    }
  },
  {
    "page_content": "and (g) CD71-positive (CD71+) BMMCs isolated from CD45.1 recipient mice 24 h after the fourth dose of PEG-IFNα (Jak2+/+ IFNα n = 5 and Jak2VF/+ IFNα n = 5) or vehicle (Jak2+/+ CTRL n = 5 and Jak2VF/+ CTRL n = 5). Data were assessed by flow cytometry and the gating strategy used is shown in Supplementary Fig. 7i. b–d, f, and g We used a two-way ANOVA to analyze the differences in b, f, and g p-MYPT1 median fluorescence, c percentage of HCT and d RBC counts with treatment (CTRL vs. IFNα),",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:62"
    }
  },
  {
    "page_content": "and d RBC counts with treatment (CTRL vs. IFNα), mutation (Jak2+/+ vs. Jak2VF/+) and their interaction as predictors. b The increase of MYPT1 phosphorylation induced by IFNα in Jak2+/+ PBMCs was smaller than in Jak2VF/+ PBMCs (p = 0.0382, interaction term). c The decrease of HCT percentage induced by IFNα in Jak2+/+ recipient mice was smaller than in Jak2VF/+ recipient mice (p = 0.0025, interaction term). d The decrease of RBC levels induced by IFNα in Jak2+/+ recipient mice was smaller than in",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:63"
    }
  },
  {
    "page_content": "in Jak2+/+ recipient mice was smaller than in Jak2VF/+ recipient mice (p = 0.0001, interaction term). f, g The difference in the increase of MYPT1 phosphorylation induced by IFNα in Jak2+/+ vs. Jak2VF/+ BM cells is not statistically significant (p > 0.05). Model-based pairwise comparisons were performed, and p-values were adjusted for multiple comparisons using Tukey’s method. p-values are reported. b–g Each data point or lane number represents data from an individual mouse. Results are",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:64"
    }
  },
  {
    "page_content": "data from an individual mouse. Results are representative of two independent in vivo studies. Source data are provided as a Source Data file. ## Inhibition of ROCK1/2 enhances IFNα-dependent anti-MPN responses First, we sought to determine whether ROCK1/2 expression is required for transcription of ISGs. siRNA-mediated knockdown of ROCK1/2 (Supplementary Fig. 9a, b) did not enhance or inhibit IFNα-induced transcription of ISGs in JAK2V617F-positive HEL cells (Supplementary Fig. 9c–f). To",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:65"
    }
  },
  {
    "page_content": "HEL cells (Supplementary Fig. 9c–f). To determine the effects of ROCK1/2 activation on IFN anti-neoplastic responses, we evaluated the effects of genetic or drug-targeted inhibition of ROCK1/2 in JAK2V617F-positive cells, alone or in combination with IFNα. siRNA-mediated inhibition of ROCK1/2 expression (Fig. 7a) in combination with IFNα treatment significantly decreased cellular viability of SET-2 cells, compared to either ROCK1/2 knockdown or IFNα treatment alone (Fig. 7b). Similar effects",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:66"
    }
  },
  {
    "page_content": "IFNα treatment alone (Fig. 7b). Similar effects were observed in SET-2 (Fig. 7c, left panel) and HEL (Fig. 7c, middle and right panel) cells treated with the ROCK1/2 inhibitors GSK429286A or Fasudil in combination with IFNα treatment, compared to treatment with either inhibitor alone. Moreover, GSK429286A in combination with IFNα treatment significantly reduced the clonogenic capacity of HEL cells, compared to either inhibitor alone (Fig. 7d). Importantly, siRNA-mediated knockdown of ROCK1/2",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:67"
    }
  },
  {
    "page_content": "Importantly, siRNA-mediated knockdown of ROCK1/2 expression or drug-targeted inhibition of ROCK1/2 activity with Fasudil enhanced the suppressive effects of IFNα on primitive malignant erythroid precursors from PV patients who responded poorly to IFN treatment (Fig. 7e, f).Fig. 7Inhibition of ROCK1 and ROCK2 enhances IFNα-induced anti-neoplastic responses in MPN cells.a Immunoblotting analysis of ROCK1 and ROCK2 in lysates from control (Ctrl) siRNA or ROCK1 and ROCK2 (ROCK1/2) siRNA-transfected",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:68"
    }
  },
  {
    "page_content": "or ROCK1 and ROCK2 (ROCK1/2) siRNA-transfected JAK2V617F-positive SET-2 cells. b Proliferation and cell viability of control (Ctrl) siRNA or ROCK1 and ROCK2 (ROCK1/2) siRNA-transfected JAK2V617F-positive SET-2 cells either left untreated, or treated with IFNα was measured using a WST assay. Data are expressed as percent cell viability relative to Ctrl siRNA-transfected untreated cells (Ctrl siRNA), and represent means ± SEM of five independent experiments. Each symbol on the graphs represents",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:69"
    }
  },
  {
    "page_content": "experiments. Each symbol on the graphs represents an independent biological replicate. c Proliferation of JAK2V617F-positive (left panel) SET-2 or (middle and right panels) HEL cells treated with ROCK1/2 inhibitor (GSK429286A or Fasudil) and/or IFNα vs. DMSO-vehicle control (Ctrl) was measured using a WST assay. Each symbol on the graphs represents an independent biological replicate. Data are expressed as percent cell viability relative to Ctrl-treated cells and represent means ± SEM of four,",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:70"
    }
  },
  {
    "page_content": "cells and represent means ± SEM of four, five and three independent experiments, as indicated. d Clonogenic capability of JAK2V617F-positive HEL cells treated with the ROCK1/2 inhibitor GSK429286A and/or IFNα vs. DMSO-vehicle control (Ctrl). Each symbol on the graphs represents an independent biological replicate. Data are expressed as percent colony formation relative to Ctrl-treated cells and represent means ± SEM of three independent experiments. e Clonogenic capability of Ctrl siRNA or",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:71"
    }
  },
  {
    "page_content": "e Clonogenic capability of Ctrl siRNA or ROCK1/2 siRNA-transfected peripheral blood mononuclear cells from patients with PV, either left untreated or treated with IFNα. Data are expressed as percent colony formation relative to control siRNA-transfected untreated cells (Ctrl siRNA) and represent means ± SEM of four independent experiments, using cells from four different patients with PV. f Clonogenic capability of peripheral blood mononuclear cells from patients with PV treated with the",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:72"
    }
  },
  {
    "page_content": "cells from patients with PV treated with the ROCK1/2 inhibitor Fasudil and/or IFNα vs. DMSO-vehicle control (Ctrl). Data are expressed as percent colony formation relative to Ctrl-treated cells and represent means ± SEM of four independent experiments, as indicated, using cells from four different patients with PV. e, f Each data point on the graphs represents an independent biological replicate and data for an individual patient is represented by the same symbol for each experimental",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:73"
    }
  },
  {
    "page_content": "by the same symbol for each experimental condition. b–d Data were normalized to the control group (Ctrl siRNA or Ctrl) and statistical analyses comparing the other three groups were performed using one-way ANOVA followed by Tukey’s multiple comparisons test. Adjusted p-values are reported. e, f Data were analyzed using linear mixed effects models, with % colony formation relative to the control group as the outcome, treatment (the three remaining groups) as the fixed effect, and subject as a",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:74"
    }
  },
  {
    "page_content": "groups) as the fixed effect, and subject as a random effect to account for within-subject correlation between multiple conditions. Kenward-Roger degrees of freedom adjustment was used, which improves performance when sample size is small. Pairwise group comparison tests were adjusted for multiple comparisons using Tukey’s method. p-values are reported. Source data are provided as a Source Data file. Next, we examined the effects of targeting ROCK1/2 on the inhibitory effects of IFNα in our MPN",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:75"
    }
  },
  {
    "page_content": "on the inhibitory effects of IFNα in our MPN mouse model. Five weeks after transplantation of CD45.1 recipient mice with Jak2V617F KI bone marrow cells (Supplementary Fig. 10a–e), we treated mice for 4 weeks with the ROCK inhibitor Fasudil34 four times per week, with or without PEG-IFNα treatment given once a week (Fig. 8a). Mice tolerated single agent and combination drug treatments well, as monitored by body weight (Supplementary Fig. 10f). At week 3 after initiation of treatment, we",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:76"
    }
  },
  {
    "page_content": "At week 3 after initiation of treatment, we collected peripheral blood and isolated mononuclear cells from the recipient mice 26 h post-IFNα treatment and 2 h post-Fasudil treatment or its vehicles (Fig. 8a, p-MYPT1). PEG-IFNα treatment increased phosphorylation of MYPT1 compared to vehicle-control and Fasudil only treated mice (Fig. 8b), and co-treatment with Fasudil and PEG-IFNα inhibited this increase in peripheral blood mononuclear cells (Fig. 8b). Four weeks post-treatment, further",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:77"
    }
  },
  {
    "page_content": "(Fig. 8b). Four weeks post-treatment, further decreases in hematocrit (HCT) and hemoglobin (HB) were noticeable in the IFNα + Fasudil-treated mice, compared to mice that were treated with vehicle or either drug alone (Fig. 8c, d). Red blood cell counts were significantly decreased in both IFNα- and IFNα + Fasudil-treated mice compared to vehicle- and Fasudil-treated mice (Supplementary Fig. 10g). By contrast, no significant differences were observed in platelet levels among the four treatment",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:78"
    }
  },
  {
    "page_content": "in platelet levels among the four treatment groups (Supplementary Fig. 10h). Additionally, the reductions in spleen weight, percentage of bone marrow and spleen Ter119highCD71high basophilic erythroblasts (R2), and bone marrow myeloid progenitors, granulocyte-monocyte progenitors (GMPs), and megakaryocyte-erythroid progenitors (MEPs) between vehicle-treated and IFNα + Fasudil-treated mice are greater than between vehicle-treated and IFNα-treated mice (Fig. 8e–j). No significant differences were",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:79"
    }
  },
  {
    "page_content": "mice (Fig. 8e–j). No significant differences were observed between IFNα and IFNα + Fasudil-treated mice for bone marrow and spleen Ter119medCD71high proerythroblasts (R1), Ter119highCD71med polychromatophilic erythroblasts and Ter119highCD71low orthochromatophilic erythroblasts (R3 + R4) and for bone marrow hematopoietic stem cells (Lin-Sca+Kit+, LSK) and common myeloid progenitors (CMP) (Supplementary Fig. 11). Taken together with the in vitro findings, these results suggest that IFNα",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:80"
    }
  },
  {
    "page_content": "vitro findings, these results suggest that IFNα treatment activates ROCK1/2 proteins in a negative feedback regulatory manner, triggering mechanisms that suppress its anti-neoplastic effects in MPNs (Fig. 9), and inhibition of activated ROCK1/2 proteins enhances the anti-neoplastic effects of IFNα in MPNs.Fig. 8The ROCK1/2 inhibitor, Fasudil, blocks PEG-IFNα induced ROCK1/2 activation and enhances PEG-IFNα effects in a MPN mouse model.a–j CD45.1 mice were transplanted with Jak2V617F/+ KI bone",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:81"
    }
  },
  {
    "page_content": "mice were transplanted with Jak2V617F/+ KI bone marrow cells isolated from Jak2V617F/+VavCre+ CD45.2 donor mice. Five weeks after transplantation and confirmation of engraftment (see Supplementary Fig. 10a–e), CD45.1 recipient mice were treated with vehicles (PBS, CTRL), or PEG-IFNα (IFNα, 600 ng/mouse, subcutaneous injection) once a week, and/or Fasudil (FAS, 25 mg/kg, intraperitoneal injection) four times per week for 4 weeks. a Schematic illustration of the MPN mouse model, treatment regimen",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:82"
    }
  },
  {
    "page_content": "of the MPN mouse model, treatment regimen per week, and analyses performed. Gy: gray units of ionizing radiation dose. b Scatter dot plots show median fluorescence of phosphorylated MYPT1 (p-MYPT1 A647) in peripheral blood mononuclear cells collected 26 h after the third dose of PEG-IFNα and 2 h after the eleventh dose of Fasudil and/or respective vehicles (CTRL, n = 3; FAS, n = 4; IFNα, n = 4; FAS + IFNα, n = 4). Data were assessed by flow cytometry and the gating strategy used is shown in",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:83"
    }
  },
  {
    "page_content": "and the gating strategy used is shown in Supplementary Fig. 7h. Results are representative of two independent experiments. c–j Scatter dot plots show effects of Fasudil (FAS) and/or PEG-IFNα (IFNα) treatments on (c) hematocrit (HCT) percentage and (d) hemoglobin (HB) levels in peripheral blood, (e) spleen weight (images are representative of spleen size per treatment group), f–g percentage of Ter119highCD71high basophilic erythroblasts (R2) in f bone marrow (BM) and g spleen, and on the h–j",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:84"
    }
  },
  {
    "page_content": "f bone marrow (BM) and g spleen, and on the h–j percentage of bone marrow h myeloid progenitors, i granulocyte-monocyte progenitors (GMP) and j megakaryocyte-erythroid progenitors (MEP). c–j Data shown are means ± SEM pooled from four independent studies (CTRL n = 15, FAS n = 17, IFNα n = 15, FAS + IFNα n = 18); each independent study performed using 3–6 mice per treatment group. The flow cytometry gating strategy used is shown in Supplementary Figs. S11a and S11f. b–j Statistical analyses were",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:85"
    }
  },
  {
    "page_content": "and S11f. b–j Statistical analyses were performed using one-way ANOVA followed by Tukey’s multiple comparisons test. Adjusted p-values are reported. See also Supplementary Figs. 10 and 11. Source data are provided as a Source Data file.Fig. 9Schematic illustration of the proposed signaling feedback circuit activated by type I IFNs and regulation of IFN-mediated anti-neoplastic responses.Type I IFNs bind their transmembrane receptor (IFNAR) activating AKT/mTORC1-dependent phosphorylation of ULK1",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:86"
    }
  },
  {
    "page_content": "AKT/mTORC1-dependent phosphorylation of ULK1 on Ser757, which inhibits ULK1 engagement into autophagy-related pathways21. In parallel, IFN-mediated downstream activation of PKCδ kinase activity induces ULK1 phosphorylation on Ser341 and Ser495, required for downstream phosphorylation of p38 MAPK and transcription of ISGs, which inhibit proliferation and survival of MPN cells. Engagement of IFNAR also induces activation of caspases leading to apoptosis of MPN cells. However, caspase activation",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:87"
    }
  },
  {
    "page_content": "of MPN cells. However, caspase activation mediates cleavage/activation of ROCK1/2 proteins, found to bind ULK1, that drive pro-survival mechanisms in MPN cells, negatively regulating IFN anti-neoplastic effects. # Discussion Over the past 4 decades, accumulating evidence has revealed that type I IFNs exert important anti-tumor effects and have a critical role in immune surveillance against the development of malignancies3,6. A precise understanding of the mechanisms of action of type I IFNs on",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:88"
    }
  },
  {
    "page_content": "of the mechanisms of action of type I IFNs on both tumor and immune cells is critical, as this will provide the means to identify, in advance, patients who will respond to IFN treatment and thereby predict clinical responses. Moreover, this knowledge will lead to new therapeutic approaches and the development of combination treatments to enhance the action(s) of IFNs and/or overcome resistance mechanisms. It is well established that activation of IFNAR initiates signaling events mediated via",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:89"
    }
  },
  {
    "page_content": "of IFNAR initiates signaling events mediated via the classical JAK/STAT pathway and many other “non-classical” pathways6,35. It is the concerted actions of these signaling pathways and their effectors that drive the biological outcomes of IFN treatment and, at the same time, control excessive responses35. We now identify PKCδ as a key initiator of the p38 MAPK pathway and demonstrate that PKCδ binds to and directly phosphorylates ULK1 on serine residues 341 and 495. We establish that",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:90"
    }
  },
  {
    "page_content": "on serine residues 341 and 495. We establish that phosphorylation of ULK1 on these sites is required for downstream engagement of p38 MAPK and transcription of ISGs. Activation of PKCδ is critical for the generation of IFN responses, as we provide evidence that PKCδ knockdown reverses the IFNα-mediated anti-clonogenic effects in PV patient primary cells. Using MPN patient samples collected prior to initiation of PEG-IFNα therapy, we observed that higher baseline expression levels of the",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:91"
    }
  },
  {
    "page_content": "that higher baseline expression levels of the downstream effectors of PKCδ, namely ULK1 and p38 MAPK, predict a better response to IFNα treatment. These findings suggest that ULK1 and p38 MAPK could potentially be used as part of a pool of biomarkers to predict response to IFNα-based therapies for MPN patients, but future large prospective clinical studies will be required to definitively address this. In previous studies, PKCδ has been characterized as both a tumor-promoting and a",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:92"
    }
  },
  {
    "page_content": "characterized as both a tumor-promoting and a tumor-suppressing kinase, dependent on the stimulus and cell-type context36–39. PKCδ promotes cellular apoptosis through both p38 MAPK-dependent and -independent mechanisms, induces cell cycle arrest and inhibits tumor growth and progression39. By contrast, PKCδ enhances the migration, invasion, and metastasis of some tumor cells40–43. Similarly, ULK1 has been shown to have opposing roles in cancer, again depending on the cellular context and",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:93"
    }
  },
  {
    "page_content": "again depending on the cellular context and stimulus44. In response to stress, such as starvation, ULK1 is phosphorylated on Ser555 by AMPK to induce autophagy45, shown to play tumor-promoting and tumor-suppressing functions in a context-dependent manner46. Additionally, other stimuli, such as IFNs, induce ULK1 engagement in autophagy-independent signaling events, controlling several biological functions21,44,47–51. Phosphorylation of ULK1 on Ser757 (autophagy-inhibitory site) is associated",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:94"
    }
  },
  {
    "page_content": "Ser757 (autophagy-inhibitory site) is associated with shorter overall survival in non-small cell lung cancer patients52. In breast cancer patients, low levels of ULK1 correlate with lymph node metastasis and poor survival53. Hypoxia-induced expression of the kinase-dead ULK1 mutant increases lung metastasis in a breast cancer xenograft mouse model54 and, in another study, ULK1 was shown to phosphorylate Exo70 to inhibit breast cancer metastasis55. In contrast, a kinase-dead ULK1 mutant",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:95"
    }
  },
  {
    "page_content": "In contrast, a kinase-dead ULK1 mutant suppressed growth and metastasis and increased survival in a neuroblastoma xenograft mouse model56. We now report that activation of a PKCδ-ULK1-p38 MAPK signaling pathway is required for IFNα-induced anti-neoplastic effects in MPN patients. Interestingly, in a recent study, the atypical PKC λ/ι isoform was found to directly phosphorylate ULK2, inhibiting its activity and promoting its degradation57. Inactivation/loss of PKCλ/ι was found to induce ULK2",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:96"
    }
  },
  {
    "page_content": "of PKCλ/ι was found to induce ULK2 activity, which directly activates the TBK1-STING-IRF3 pathway, leading to IFN production and anti-tumor responses57. In another study, the PKCδ isozyme, PKCα, was shown to induce phosphorylation of ULK1 on Ser423, reducing autolysosome formation and promoting ULK1 degradation58. Additional studies are required to interrogate the potential role of PKCδ-induced phosphorylation of ULK1 on Ser341 and Ser495 in the regulation of autophagy and IFN production.",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:97"
    }
  },
  {
    "page_content": "the regulation of autophagy and IFN production. Beyond defining the mechanism by which the ULK1/p38 MAPK pathway is engaged in PV cells, our studies have identified an important feedback mechanism that negatively regulates IFN-responses, that may be a therapeutic target. This involves ROCK1/2, shown to interact with ULK1. Importantly, we provide evidence that IFNα treatment induces cleavage/activation of ROCK1/2 in vitro and in vivo in both JAK2+/+ and JAK2V617F/+ hematopoietic cells. Since",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:98"
    }
  },
  {
    "page_content": "and JAK2V617F/+ hematopoietic cells. Since IFNα treatment does not affect hematocrit, hemoglobin, red blood cells and platelet levels in Jak2+/+ recipient mice, our results suggest that IFN-mediated activation of ROCK1/2 could represent a feedback mechanism to control the IFN effects on normal hematopoiesis. In contrast, we found that both ROCK isoforms are overexpressed in peripheral blood cells from MPN patients, compared to healthy individuals and genetic or pharmacological inhibition of",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:99"
    }
  },
  {
    "page_content": "and genetic or pharmacological inhibition of ROCK1/2 enhanced IFNα-induced anti-neoplastic effects in primary MPN cells and in a MPN model in vivo. Our findings support a role for the IFN-mediated activation of ROCK1/2 as pro-tumorigenic in MPN cells. In other studies, ROCK1/2 have been shown to regulate actomyosin contractility and cytoskeleton assembly, important features for tumor progression, migration and invasion59–62. ROCK1 and ROCK2 have also been shown to have redundant roles in cell",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:100"
    }
  },
  {
    "page_content": "also been shown to have redundant roles in cell cycle progression and have been implicated in tumorigenesis63. Genetic deletion of not one, but both ROCK isoforms, blocked tumor formation in mouse models of non-small cell lung cancer and melanoma63. Recently, engagement of ROCK-myosin II signaling was identified as a mechanism of resistance to MAPK inhibitors in melanoma64. Furthermore, the ROCK inhibitor, Fasudil, has been shown to decrease disease burden in myeloproliferative disease (MPD)",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:101"
    }
  },
  {
    "page_content": "burden in myeloproliferative disease (MPD) mouse models27,65 and combination of imatinib with either Fasudil or the ROCK inhibitor Y-27632 showed synergistic inhibition of CD34+ chronic myeloid progenitor cell growth66. To date, the ROCK inhibitors Fasudil and Ripasudil are approved in Japan for the treatment of cerebral vasospasm and glaucoma, respectively, and several ROCK inhibitors are being tested clinically for the treatment of different diseases, including cancer34. Viewed altogether,",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:102"
    }
  },
  {
    "page_content": "diseases, including cancer34. Viewed altogether, our data identify an important IFNα-regulated negative feedback mechanism that leads to caspase-dependent cleavage/activation of ROCK1/2, which interacts with ULK1, and negatively regulates IFNα anti-neoplastic responses. These findings support future studies to evaluate the clinical potential of combinations of ROCK inhibitors with PEG-IFNα and/or the JAK inhibitor ruxolitinib33 for the treatment of MPN patients. # Methods ## Patient-derived",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:103"
    }
  },
  {
    "page_content": "of MPN patients. # Methods ## Patient-derived samples Studies were approved by the Institutional Review Board of Northwestern University in accordance to the Declaration of Helsinki protocol. Peripheral blood (PB) was collected from patients with Polycythemia Vera (PV) after their informed consent and PBMCs were isolated following Histopaque density gradient separation (Sigma). PB and bone marrow (BM) MCs from patients with PV or ET were also obtained from the New York Blood Center bank,",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:104"
    }
  },
  {
    "page_content": "obtained from the New York Blood Center bank, including samples collected at baseline from clinical trial # NCT01259817 after patients’ informed consent. For the study correlating expression of genes of interest with clinical outcomes to IFN treatment, primary samples collected before treatment from 18 patients (9 responders and 9 non-responders) were randomly selected with the assistance of the MPN-RC Biostatistics Core C and provided by the MPN-RC Tissue Bank Core B for our analysis. MPN",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:105"
    }
  },
  {
    "page_content": "MPN-RC Tissue Bank Core B for our analysis. MPN patients had been enrolled in the MPD-RC-111 study, which included patients with polycythemia vera (PV) and essential thrombocythemia (ET) that were refractory or intolerant to hydroxyurea therapy (clinical trial #NCT01259817), after providing informed consent. Fifteen patients were diagnosed as having PV while 3 patients had ET (9 males, 9 females, between ages 36-84 years). The clinical characteristics of each patient are provided in",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:106"
    }
  },
  {
    "page_content": "characteristics of each patient are provided in Supplementary Table 1. Responses were assessed after 12 months of treatment7 according to criteria established by the European LeukemiaNET. Follow-up information on responses was available after 24 months for some of the patients at the time of the qRT-PCR analysis. There were 9 responders and 9 non-responders analyzed. One patient had a partial response after 12 months, but was classified as a non-responder after 24 months of IFN treatment and",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:107"
    }
  },
  {
    "page_content": "after 24 months of IFN treatment and was therefore included as a non-responder in Fig. 3b. A more detailed description of participants enrolled in the clinical trial #NCT01259817 and criteria for assessment of clinical response have been previously described7. The criteria for enrollment of patients in clinical trial #NCT01259817 have been previously described7. Samples for banking and for the in vitro colony studies were obtained from MPN patients seen for evaluation, follow-up, and/or",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:108"
    }
  },
  {
    "page_content": "patients seen for evaluation, follow-up, and/or treatment in the clinics of the respective institutions, after informed consent was obtained. PBMCs and bone marrow mononuclear cells (BMMCs) were used to perform qRT-PCR analyses and PBMCs were used to perform hematopoietic cell progenitor assays. ## Animals Mice were housed in a pathogen-free barrier facility at Northwestern University. The light cycle is 14:10, lights are on at 5 a.m., off at 7 p.m.. The room temperature is 72° Fahrenheit",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:109"
    }
  },
  {
    "page_content": "at 7 p.m.. The room temperature is 72° Fahrenheit (F) +/– 2° (70–74 °F, 21.1–23.3° celsius) and room humidity ranges 30–70% (average is 50%). The animals are housed in ventilated animal holding racks with building supplied HEPA filter air directly to the ventilated racks. Supply air is provided via separate plenums from the exhausted cage air. Cage change cycle is cage bottoms changed out every 14 days unless excessively soiled and complete change out every 4 weeks. The animals are provided",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:110"
    }
  },
  {
    "page_content": "out every 4 weeks. The animals are provided reverse osmosis water through an automatic watering system directly to the cage. Racks are flushed daily and checked daily to verify water availability. All animal studies were approved by the Northwestern University Institutional Animal Care and Use Committee (Protocol # IS00012751) and conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals. Both female and male (6–12-week-old) Jak2V617F/+ conditional knock-in (KI)",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:111"
    }
  },
  {
    "page_content": "Jak2V617F/+ conditional knock-in (KI) mice (CD45.2)30 (provided by B. L. Ebert and A. Mullally, Harvard Medical School) and Vav-Cre+ (CD45.2) (B6.Cg-Commd10Tg(Vav1-icre)A2Kio/J) (The Jackson Laboratory Stock, Stock No: 008610) mice were used for breeding to generate Jak2+/+VavCre- and Jak2V617F/+VavCre+ donor mice. In all, 10–11-week-old female and male CD45.1 (B6.SJL-PtprcaPepcb/BoyJ) mice (The Jackson Laboratory, Stock No. 002014) were used as recipients and 6–10-week-old female and male",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:112"
    }
  },
  {
    "page_content": "as recipients and 6–10-week-old female and male Jak2+/+VavCre- and Jak2V617F/+VavCre+ donor mice were used as donors for the transplant studies. Once engraftment and a PV-like phenotype (for the Jak2V617F/+VavCre+ recipients) was confirmed in recipient mice, these were randomized into treatment groups by hematocrit and/or hemoglobin levels. In all, 9–10-week-old female C57BL/6J mice (The Jackson Laboratory, Stock No: 000664) were used for the studies to assess the effects of IFNα treatment in",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:113"
    }
  },
  {
    "page_content": "to assess the effects of IFNα treatment in wild-type mice in vivo. These mice were randomized into treatment groups by body weight. ## Cells and cell culture HEL (TIB-180; ATCC), KT-167 (RRID:CVCL_D200) and U937 (CRL-1593.2; ATCC) cells were grown in RPMI 1640 medium (Gibco) supplemented with 10% fetal bovine serum (FBS) and antibiotics. SET-2 cells (ACC-608; DSMZ) were grown in RPMI 1640 medium (Gibco) supplemented with 20% FBS and antibiotics. HEK293T cells (CRL-3216; ATCC) and the",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:114"
    }
  },
  {
    "page_content": "HEK293T cells (CRL-3216; ATCC) and the immortalized Ulk1/2+/+ and Ulk1/2−/− MEFs68 provided by C. B. Thompson (Memorial Sloan-Kettering Cancer Center) were grown in DMEM medium (Gibco) supplemented with 10% FBS and antibiotics. All cell lines were frozen at low passage in liquid nitrogen and were kept in culture for no longer than ten-fifteen passages. All cells were cultured at 37 °C and 5% CO2. All cells were tested for mycoplasma contamination using a MycoAlert PLUS mycoplasma detection kit,",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:115"
    }
  },
  {
    "page_content": "using a MycoAlert PLUS mycoplasma detection kit, following the manufacturer’s instructions (Lonza). Cell lines were tested by STR analyses and matched to the ATCC or DSMZ database every 6 months to 1 year. ## Generation of ULK1 KO KT-1 cells using CRISPR-Cas9 technology ULK1 KO KT-1 cells were generated using Edit-R Lentiviral hEF1α-Blast-Cas9 Nuclease Plasmid DNA and Edit-R Human ULK1 Lentiviral sgRNA (no. CAS10138 and no. VSGH10142-246477203, GE Healthcare Dharmacon), as previously",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:116"
    }
  },
  {
    "page_content": "GE Healthcare Dharmacon), as previously described48. Lack of ULK1 protein in ULK1 KO KT-1 cells was confirmed by immunobloting analysis. ## Plasmids, transfections, and cell treatments The pRK5/myc-hULK1 plasmid (a gift from Do-Hyung Kim; Addgene plasmid #31961; http://n2t.net/addgene:31961; RRID:Addgene_31961)69 was used to generate the single serine-to-alanine ULK1 mutants (S341A, S467A, and S495A) and a triple ULK1 mutant (S341/467/495A) plasmids, using site-directed mutagenesis, by",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:117"
    }
  },
  {
    "page_content": "plasmids, using site-directed mutagenesis, by BioInnovatise, Inc. Mutations were confirmed by DNA sequencing analyses using the following primer: 5’cgagaagaacaagacgttgg3’ and BLASTN program (https://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&BLAST_SPEC=GeoBlast&PAGE_TYPE=BlastSearch). The pRK5 empty vector (EV) was made by digestion of pRK5/myc-hULK1 plasmid with SalI and NotI restriction enzymes to release ULK1 gene, followed by fill-in and ligation reactions by BioInnovatise, Inc. The EV",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:118"
    }
  },
  {
    "page_content": "ligation reactions by BioInnovatise, Inc. The EV was sequenced using the SP6 primer: 5’gatttaggtgacactatag3’. HEK293T cells were transfected with plasmid using Lipofectamine 2000 transfection reagent (Invitrogen), according to the manufacturer’s protocol and then used for immunoprecipitation of myc-tagged proteins. Ulk1/2−/− MEFs were transfected with plasmid using TurboFect Transfection Reagent (Thermo Fisher Scientific), according to the manufacturer’s protocol. The next day, Ulk1/2−/− cells",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:119"
    }
  },
  {
    "page_content": "protocol. The next day, Ulk1/2−/− cells were either left untreated or were treated with mouse IFNα (10 × 103 IU/mL) for 10 min, as indicated. Cell pellets were collected, lysed in phospho-lysis buffer [50 mM Hepes (pH 7.3), 150 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA (pH 8.0), 100 μM sodium fluoride, 10 μM sodium pyrophosphate, 0.5% Triton X-100, and 10% glycerol] supplemented with protease and phosphatase inhibitors, and processed for immunoblotting analyses. To assess the requirement of PKCδ for",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:120"
    }
  },
  {
    "page_content": "analyses. To assess the requirement of PKCδ for IFNα-induced phosphorylation of ULK1 on Ser341 and Ser495, U937 cells were transfected with control (ON-TARGETplus Non-targeting Control Pool, # D-001810-10-05; Dharmacon) or PKCδ (ON-TARGETplus Human PRKCD siRNA SMARTpool, # L-003524-00-0005; Dharmacon) siRNAs using Amaxa Biosystems Nucleofector Kit C and program W-001 (Lonza), as per the manufacturer’s instructions (1 × 106 cells/transfection reaction). The next day, transfected cells were",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:121"
    }
  },
  {
    "page_content": "reaction). The next day, transfected cells were starved overnight (cultured in 0% FBS RPMI medium) and then were either left untreated or were treated with IFNα (104 IU/mL) for 10 or 30 min, as indicated. Cell pellets were collected, lysed in phospho-lysis buffer supplemented with protease and phosphatase inhibitors, and processed for immunoblotting analyses. For the experiments to evaluate the role of ULK1 phosphorylation on Ser341 and Ser495 on transcription of ISGs, ULK1 KO KT-1 cells were",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:122"
    }
  },
  {
    "page_content": "on transcription of ISGs, ULK1 KO KT-1 cells were transfected with myc-tagged EV, ULK1 WT, ULK1 S341A, or ULK1 S495A plasmids using Amaxa Biosystems Nucleofector Kit V and program X-001 (Lonza), as per the manufacturer’s instructions (3 × 106 cells/transfection reaction). Transfection efficiency was assessed by immunoblotting analysis. The next day, cells were either left untreated or were treated with IFNα (5000 IU/mL) for 6 h and total RNA was isolated using the RNeasy Mini Kit (QIAGEN), as",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:123"
    }
  },
  {
    "page_content": "isolated using the RNeasy Mini Kit (QIAGEN), as per the manufacturer’s instructions. For the experiments to assess whether ROCK1/2 regulate transcription of ISGs, HEL cells were transfected with either control (ON-TARGETplus Non-targeting Control Pool, # D-001810-10-05; Dharmacon) or ROCK1 (ON-TARGETplus Human ROCK1 siRNA SMARTPool, # L-003536-00-0005; Dharmacon) and ROCK2 (ON-TARGETplus Human ROCK2 siRNA SMARTPool, # L-004610-00-0005; Dharmacon) siRNAs, using Amaxa Biosystems Nucleofector Kit",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:124"
    }
  },
  {
    "page_content": "siRNAs, using Amaxa Biosystems Nucleofector Kit V and program X-005 (Lonza), as per the manufacturer’s instructions (4 × 106 cells/transfection reaction). The next day, cells were either left untreated or were treated with IFNα (1000 IU/mL) for 24 h and total RNA was isolated using the RNeasy Mini Kit (QIAGEN), as per the manufacturer’s instructions. For the experiments to determine whether IFNα-induced cleavage of ROCK1/2 is caspase-dependent, HEL, U937 and KT-1 cells were either left",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:125"
    }
  },
  {
    "page_content": "HEL, U937 and KT-1 cells were either left untreated or treated with IFNα (1000 IU/mL) and/or the caspase inhibitor (CASPi) Z-VAD-FMK (20 μM; Selleckchem Cat No. S7023) for 24 or 48 h, as indicated. Cell pellets were collected, lysed in phospho-lysis buffer supplemented with protease and phosphatase inhibitors, and processed for immunoblotting analyses. ## Co-immunoprecipitation of endogenous protein-ULK1 complexes To study the physical interaction between ULK1 and PKCδ, HEL, SET-2, KT-1, or",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:126"
    }
  },
  {
    "page_content": "between ULK1 and PKCδ, HEL, SET-2, KT-1, or U937 cells were either left untreated or were treated with human IFNα (Infergen) or IFNβ (Biogen) (104 IU/mL) for 10 min, as indicated. To study the physical interaction between ULK1 and ROCK1 or ROCK2, HEL cells were either left untreated or were treated with human IFNα (104 IU/mL) for 10 min. After treatment, cell pellets were lysed in NP-40 buffer [20 mM Hepes (pH 7.4), 180 mM KCl, 0.2 mM EGTA, 10% glycerol, and 0.1% NP-40] supplemented with",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:127"
    }
  },
  {
    "page_content": "10% glycerol, and 0.1% NP-40] supplemented with protease and phosphatase inhibitors. For immunoprecipitation (IP) of endogenous protein-ULK1 complexes, 500 μg of protein (total cell lysates) from each sample were incubated overnight at 4 °C with rotation with ULK1 (D8H5) rabbit monoclonal antibody (2.1 μg/mg protein; #8054, Cell Signaling Technology), followed by incubation for 1 h at 4 °C with rotation with protein G Sepharose 4 Fast Flow beads (GE Healthcare). As control, the same procedure",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:128"
    }
  },
  {
    "page_content": "(GE Healthcare). As control, the same procedure was followed using rabbit (DA1E) monoclonal antibody IgG XP Isotype control (2.1 μg/mg protein; #3900, Cell Signaling Technology) instead of ULK1 antibody. After IP, the beads were washed three times with NP-40 buffer without glycerol. Protein-ULK1 complexes were eluted from the beads by incubation with Lane Marker Reducing Sample Buffer (Pierce) at 95 °C for 10 min. Eluates were resolved by SDS-PAGE and processed for immunoblotting analyses. ##",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:129"
    }
  },
  {
    "page_content": "and processed for immunoblotting analyses. ## Immunoprecipitations and in vitro kinase assays To determine whether PKCδ could directly phosphorylate ULK1, KT-1 cells were starved overnight and then left untreated or were treated with human IFNβ (104 IU/mL) for 10 and 30 min, as indicated, then lysed in phospho-lysis buffer [50 mM Hepes (pH 7.3), 150 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA (pH 8.0), 100 μM sodium fluoride, 10 μM sodium pyrophosphate, 0.5% Triton X-100, and 10% glycerol] supplemented",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:130"
    }
  },
  {
    "page_content": "0.5% Triton X-100, and 10% glycerol] supplemented with protease and phosphatase inhibitors. 500 μg of protein (total cell lysates) from each sample were used for IP of PKCδ using PKCδ (D10E2) rabbit monoclonal antibody (0.6 μg/mg protein; #9616, Cell Signaling Technology), followed by incubation with protein G Sepharose 4 Fast Flow beads (GE Healthcare Life Sciences). As a control, the same procedure was followed, but using rabbit monoclonal antibody (DA1E) IgG XP Isotype control (0.6 μg/mg",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:131"
    }
  },
  {
    "page_content": "antibody (DA1E) IgG XP Isotype control (0.6 μg/mg protein; #3900, Cell Signaling Technology), instead of PKCδ antibody. The beads were washed three times with phospho-lysis buffer [50 mM Hepes (pH 7.3), 150 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA (pH 8.0), 100 μM sodium fluoride, 10 μM sodium pyrophosphate, 0.1% Triton X-100], and twice with kinase buffer [25 mM Tris-HCl (pH 7.4), 0.5 mM EDTA, 5 mM MgCl2, 1 mM DTT, 700 μg/mL of phosphatidylserine), prior to the kinase reaction. In vitro kinase",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:132"
    }
  },
  {
    "page_content": "prior to the kinase reaction. In vitro kinase reactions to detect PKCδ kinase activity were performed for 30 min with rotation at room temperature in kinase buffer supplemented with 20 μM of ATP (#V915A; Promega) and 10 μCi of γ-32P ATP (#BLU502Z250UC, PerkinElmer Life Science) per reaction. ULK1 recombinant human protein (1.3 μg/reaction; #PV6430, Life Technologies) was heat inactivated at 65 °C for 20 min in a sonicating bath and then used as an exogenous substrate in the kinase reactions.",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:133"
    }
  },
  {
    "page_content": "an exogenous substrate in the kinase reactions. Kinase reactions were stopped by incubation with Lane Marker Reducing Sample Buffer (Pierce) at 95 °C for 10 min. Samples were then resolved by SDS-PAGE, transferred to an Immobilon-P PVDF membrane (Millipore), and processed for autoradiography and subsequent immunoblotting analyses. To determine the specific PKCδ phosphorylation sites in ULK1, myc-tagged empty vector, ULK1 WT, and S/A ULK1 mutant plasmids were transfected into HEK293T cells and,",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:134"
    }
  },
  {
    "page_content": "plasmids were transfected into HEK293T cells and, 24 h later, cell pellets were collected and lysed in NP-40 buffer supplemented with protease and phosphatase inhibitors. For IP of myc-tagged proteins, 5 mg of protein (total cell lysates) from each transfection were incubated with 200 μL of c-Myc antibody (9E10) conjugated to agarose beads (500 μg/mL, 25% agarose; #sc-40 AC; Santa Cruz Biotechnology) for 3 h at 4 °C with rotation. The beads were then washed twice with phospho-lysis buffer,",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:135"
    }
  },
  {
    "page_content": "were then washed twice with phospho-lysis buffer, twice with NP-40 buffer without glycerol and twice with kinase dilution buffer III (#K23-09; SignalChem). After the last wash, samples were resuspended in kinase dilution buffer III and 10 μL aliquots were stored at –80 °C. The immunoprecipitated myc-tagged proteins were heat inactivated at 65 °C for 20 min in a sonicating bath and then used as substrates for active recombinant full-length human PKCδ protein (50 ng/reaction; #P64-10G-10;",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:136"
    }
  },
  {
    "page_content": "human PKCδ protein (50 ng/reaction; #P64-10G-10; SignalChem) in the presence of γ-32P ATP in kinase assays, following the manufacturer’s instructions (SignalChem). Kinase reactions were stopped by incubation with Lane Marker Reducing Sample Buffer (Pierce) at 95 °C for 10 min and samples were then resolved by SDS-PAGE. The gel was stained with Coomassie blue (SimplyBlue SafeStain; Thermo Fisher Scientific) and then dried overnight and processed for autoradiography. ## Generation and validation",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:137"
    }
  },
  {
    "page_content": "for autoradiography. ## Generation and validation of phospho-specific ULK1 antibodies The rabbit polyclonal p-Ser341ULK1 antibody was generated against the peptide sequence C-AGFLHS(pS)RDSGGS-amide and the rabbit polyclonal p-Ser495ULK1 antibody was generated against the peptide sequence C-VLARKM(pS)LGGGRP-amide and then purified by affinity purification (90% purity peptide) by Pierce/Thermo Fisher Scientific. To confirm the antibodies’ specificity (p-Ser341ULK1 antibody used at 1:1000 and",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:138"
    }
  },
  {
    "page_content": "(p-Ser341ULK1 antibody used at 1:1000 and p-Ser495ULK1 antibody used at 1:500) myc-tagged empty vector, ULK1 WT, and S/A ULK1 mutant plasmids were transfected into Ulk1/2−/− MEFs using TurboFect Transfection Reagent (Thermo Fisher Scientific) according to the manufacturer’s protocol and, 24 h later, cells were treated with IFNα (104 IU/mL) for 10 min and then lysed in phospho-lysis buffer supplemented with protease and phosphatase inhibitors, and processed for immunoblotting analyses. ##",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:139"
    }
  },
  {
    "page_content": "and processed for immunoblotting analyses. ## Immunoblotting analyses Equal amounts of total-cell lysates were mixed with Lane Marker Reducing Sample Buffer (Pierce), boiled at 95 °C for 5 min, resolved by SDS-PAGE, and then transferred to an Immobilon-P PVDF membrane (Millipore) using the Trans-Blot Turbo transfer system (Bio-Rad). For immunoblotting analyses, the membranes were probed with primary antibodies, followed by horseradish peroxidase–conjugated secondary antibodies, and antibody",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:140"
    }
  },
  {
    "page_content": "secondary antibodies, and antibody binding was detected by enhanced chemiluminescence using an Amersham ECL prime Western blotting detection reagent (GE Healthcare Life Sciences). The commercially available antibodies used for western blotting are rabbit monoclonal anti-ULK1 (D8H5; 1:1000; # 8054), rabbit monoclonal anti-PKC-delta (D10E2; 1:1000; # 9616), rabbit polyclonal anti-GST (1:1000; # 2622), rabbit monoclonal anti-Phospho-p38 MAPK (Thr180/Tyr182) (3D7; 1:1000; # 9215), rabbit monoclonal",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:141"
    }
  },
  {
    "page_content": "(3D7; 1:1000; # 9215), rabbit monoclonal anti-p38 MAPK (D13E1) XP (1:1000; # 8690), rabbit monoclonal anti-ROCK1(C8F7) (1:1000; # 4035), rabbit monoclonal anti-ROCK2 (D1B1) (1:1000; # 9029), rabbit monoclonal anti-phospho-ULK1 (Ser757) (D7O6U) (1:1000; # 14202), rabbit polyclonal anti-caspase 3 (1:1000; # 9662), and rabbit polyclonal anti-PARP (1:1000; # 9542) from Cell Signaling Technology, rabbit polyclonal anti-PKC Delta (1:1000, # 14188-1-AP) from Proteintech and the mouse monoclonal",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:142"
    }
  },
  {
    "page_content": "from Proteintech and the mouse monoclonal anti-GAPDH clone 6C5 (1:20,000; # MAB374) from EMD Millipore. Bands corresponding to proteins of interest were scanned and quantified by densitometry using ImageJ software. ## Mass spectrometry To identify proteins that interact with endogenous ULK1, HEL cells were either left untreated or treated with human IFNα (104 IU/mL) for 10 min, then lysed in NP-40 buffer [20 mM Hepes (pH 7.4), 180 mM KCl, 0.2 mM EGTA, and 0.1% NP-40] supplemented with protease",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:143"
    }
  },
  {
    "page_content": "EGTA, and 0.1% NP-40] supplemented with protease and phosphatase inhibitors. Three milligrams of protein (total cell lysates) from untreated and IFNα-treated samples was used for immunoprecipitation of endogenous protein-ULK1 complexes using ULK1 (D8H5) rabbit monoclonal antibody. As control, the same procedure was followed for IFNα-treated lysates, but using rabbit (DA1E) monoclonal antibody immunoglobulin G (IgG) XP isotype control instead of the ULK1 antibody. After incubation overnight with",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:144"
    }
  },
  {
    "page_content": "ULK1 antibody. After incubation overnight with rotation at 4 °C, samples were incubated for 1 h at 4 °C with rotation with protein G Sepharose 4 Fast Flow beads (50 μL/sample; #17-0618-01; GE Healthcare Life Sciences) and then washed three times with NP-40 buffer and twice with wash buffer [20 mM Hepes (pH 7.4), 180 mM KCl, and 0.2 mM EGTA]. Protein-ULK1 complexes were eluted from the beads by incubation with Lane Marker Reducing Sample Buffer (Pierce) at 95 °C for 10 min, and proteomic",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:145"
    }
  },
  {
    "page_content": "(Pierce) at 95 °C for 10 min, and proteomic analyses were performed in the Northwestern Proteomics Core Facility (Northwestern University, Chicago). IP-eluted proteins were initially separated using SDS-PAGE and the gel then cut into 10 equivalent height bands before standard in-gel digestion70. Resulting peptides were extracted from the gel pieces and desalted using solid-phase extraction on a Pierce C18 Spin column, before elution in 40 μL of 80% acetonitrile in 0.2% formic acid. After",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:146"
    }
  },
  {
    "page_content": "of 80% acetonitrile in 0.2% formic acid. After lyophilization, peptides were reconstituted with 0.1% formic acid in water and injected onto a trap column (150 μm; inner diameter [ID] by 3 cm) coupled with a nanobore analytical column (75 μm; ID by 15 cm; both ReproSil-Pur C18-aQ, 3 μm. Samples were separated using a linear gradient of solvent A (95% water, 5% acetonitrile, and 0.1% formic acid) and solvent B (5% water, 95% acetonitrile, and 0.1% formic acid) over 60 min. nLC-MS/MS data were",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:147"
    }
  },
  {
    "page_content": "formic acid) over 60 min. nLC-MS/MS data were obtained on a Velos Orbitrap (Thermo Fisher Scientific) mass spectrometer. Data were searched using Mascot 2.5 (Matrix Science, http://www.matrixscience.com/index.html) against the human SwissProt database (https://www.uniprot.org/uniprot/?query=reviewed:yes) to identify the proteins processed by nLC-MS/MS, and results were reported at 1% false-discovery rate in Scaffold 4 (Proteome Software). Proteins identified by nLC-MS/MS analysis in the control",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:148"
    }
  },
  {
    "page_content": "identified by nLC-MS/MS analysis in the control group (rabbit IgG) were excluded from our data analysis. ## DepMap data analysis Proteomic data for ROCK1 (Q13464) and ROCK2 (O75116) proteins were downloaded from the public DepMap portal (https://depmap.org/portal/) for a total of 375 cell lines and the data were graphed according to primary disease. ## Cellular viability assays In the experiments to assess the effects of silencing ROCK1/2 on IFNα-induced anti-proliferative responses, SET-2",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:149"
    }
  },
  {
    "page_content": "IFNα-induced anti-proliferative responses, SET-2 cells were transfected with either control (ON-TARGETplus Non-targeting Control Pool, # D-001810-10-05; Dharmacon) or ROCK1 (ON-TARGETplus Human ROCK1 siRNA SMARTPool, # L-003536-00-0005; Dharmacon) and ROCK2 (ON-TARGETplus Human ROCK2 siRNA SMARTPool, # L-004610-00-0005; Dharmacon) siRNAs using Amaxa Biosystems Nucleofector Kit V and program X-013 (Lonza) as per the manufacturer’s instructions. 24 h later, control siRNA or ROCK1/2",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:150"
    }
  },
  {
    "page_content": "24 h later, control siRNA or ROCK1/2 siRNA-transfected cells (knockdown efficiency was confirmed by immunoblotting analyses) were seeded (10,000 cells/well) in quadruplicate in individual wells of 96-well plates in the absence or presence of human IFNα (100 IU/mL), for 5 days. In the experiments to assess the effects of drug-targeted inhibition of ROCK1/2 on IFNα-induced anti-proliferative responses, SET-2 cells were seeded (10,000 cells/well) in quadruplicate in wells of 96-well plates and",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:151"
    }
  },
  {
    "page_content": "in quadruplicate in wells of 96-well plates and treated with vehicle-control (DMSO), GSK429286A (20 μM; #73182; StemCell Technologies), and/or human IFNα (100 IU/mL) for 5 days. In parallel experiments, HEL cells were seeded (1500 cells/well) in quadruplicate in wells of 96-well plates and treated with vehicle-control (DMSO), GSK429286A (30 μM) or Fasudil (30 μM; #73662; StemCell Technologies) and/or human IFNα (1000 IU/mL) for 5 days. Cell viability and proliferation were quantified using Cell",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:152"
    }
  },
  {
    "page_content": "and proliferation were quantified using Cell Proliferation Reagent WST-1 (Hoffman-La Roche Inc./Sigma), according to the manufacturer’s protocol and the absorbance was measured using the Epoch microplate spectrophotometer and Gen5 software (BioTek). ## Hematopoietic cell progenitor assays In the experiments to assess the role of PKCδ or ROCK1/2 on IFNα-mediated anti-clonogenic effects, primary PBMCs from PV patients were transfected with control or PKCδ (ON-TARGETplus Human PRKCD siRNA",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:153"
    }
  },
  {
    "page_content": "control or PKCδ (ON-TARGETplus Human PRKCD siRNA SMARTPool, # L-003524-00-0005, Dharmacon), or ROCK1 and ROCK2 siRNAs using TransIT-TKO Transfection Reagent (Mirus), as per the manufacturer’s instructions, as indicated. Hematopoietic progenitor colony formation for human erythroid precursors (burst-forming unit erythroid [BFU-E]) was then determined in clonogenic assays in MethoCult H4434 Classic medium (Stemcell Technologies) in the absence or presence of human IFNα (1000 IU/mL). In the",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:154"
    }
  },
  {
    "page_content": "or presence of human IFNα (1000 IU/mL). In the experiments to assess the effects of drug-targeted inhibition of ROCK1/2 on IFNα-mediated anti-clonogenic effects, HEL cells were seeded in MethoCult H4534 Classic medium (Stemcell Technologies) and treated with vehicle-control (DMSO), GSK429286A (5 μM), and/or human IFNα (100 IU/mL). In parallel, primary PBMCs from PV patients were seeded in MethoCult H4434 Classic medium (Stemcell Technologies) and treated with vehicle-control (PBS), Fasudil",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:155"
    }
  },
  {
    "page_content": "and treated with vehicle-control (PBS), Fasudil (30 μM), and/or human IFNα (1000 IU/mL). Hematopoietic colony formations were scored as in previous studies21,71. Percent (%) of colony formation was calculated by dividing each colony count by the average colony count in the control group, and multiplying by 100%. ## Quantitative RT-PCR Total RNA was isolated from bone marrow or PBMCs banked at the New York Blood Center and that were harvested before starting PEG-IFNα treatment from MPN patients",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:156"
    }
  },
  {
    "page_content": "starting PEG-IFNα treatment from MPN patients enrolled in the Myeloproliferative Disorders Research Consortium (MPD-RC)-111 study (clinical trial #NCT01259817)7 using the RNeasy Mini Kit (QIAGEN) as per the manufacturer’s instructions. Two micrograms of total cellular mRNA were reverse-transcribed into cDNA using the Omniscript RT kit (QIAGEN) and oligo(dT)12–18 primers (Life Technologies). Quantitative RT-PCR was carried out using a Bio-Rad CFX96 Real Time System (Bio-Rad), using commercially",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:157"
    }
  },
  {
    "page_content": "Real Time System (Bio-Rad), using commercially available fluorescein amidite (FAM)–labeled primer/probe sets (Thermo Fisher Scientific) to determine human PRKCD (PKCδ) (Hs00178914_m1), ULK1 (Hs00177504_m1) and MAPK14 (p38 MAPK) (Hs01051152_m1) mRNA expression. Human 18S (Hs99999901_s1) expression was used as a reference gene and to calculate delta Ct (ΔCt) for each gene in each patient. Results were then matched to response status to PEG-IFNα therapy for each patient and statistical analyses",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:158"
    }
  },
  {
    "page_content": "therapy for each patient and statistical analyses were performed as indicated in the respective figure legend. For the qRT-PCR studies using transfected ULK1 KO KT-1 cells and transfected HEL cells, two micrograms of total cellular mRNA were reverse-transcribed into cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative RT-PCR was carried out using a Bio-Rad CFX96 Real Time System (Bio-Rad) using commercially available fluorescein amidite (FAM)–labeled",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:159"
    }
  },
  {
    "page_content": "available fluorescein amidite (FAM)–labeled primer/probe sets (Thermo Fisher Scientific) to determine human ROCK1 (Hs01127701_m1), ROCK2 (Hs00178154_m1), IFIT1 (Hs00356631_g1), OAS1 (Hs00973635_m1), IFIT3 (Hs01922752_s1), IRF7 (Hs01014809_g1) and IFI6 (Hs00242571_m1). Human GAPDH (Hs03929097_g1) expression was used for normalization and to calculate delta Ct (ΔCt) for each gene for each experimental condition. The mRNA expression was calculated using the ΔΔCt method, and the data were plotted",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:160"
    }
  },
  {
    "page_content": "using the ΔΔCt method, and the data were plotted as the increase in fold change compared with untreated samples. Ct values were collected using the Bio-Rad CFX Maestro software. ## Gene expression analyses in MPN patients Levels of ROCK1 (ID: 213044_at) and ROCK2 (ID: 211504_x_at) mRNA expression in peripheral blood neutrophils isolated from healthy individuals and patients with ET, MF, and PV were extracted from the GSE54646 dataset72 accessible at NCBI GEO database, and Log2 of gene",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:161"
    }
  },
  {
    "page_content": "accessible at NCBI GEO database, and Log2 of gene expression was calculated for each gene. ## Mice bone marrow transplantation and treatment Jak2V617F conditional knock-in (KI) mice (CD45.2)30 were provided by B. L. Ebert and A. Mullally (Harvard Medical School). Vav-Cre+ (CD45.2) (B6.Cg-Commd10Tg(Vav1-icre)A2Kio/J) (Stock No: 008610) and wild-type CD45.1 (B6.SJL-PtprcaPepcb/BoyJ) (Stock No. 002014) mice were obtained from Jackson Laboratory. Jak2V617F/+ KI mice were crossed with Vav-Cre+ mice",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:162"
    }
  },
  {
    "page_content": "KI mice were crossed with Vav-Cre+ mice to produce Jak2V617F/+VavCre+ and Jak2+/+VavCre- female and male donor mice. Jak2V617F/+VavCre+ mice express Jak2V617F under the control of the hematopoietic-specific Vav promoter73. For genotyping, tail-tips were collected at weaning, digested, then recovered DNA was amplified using the following primers: Vav-Cre F: 5’-AGA TGC CAG GAC ATC AGG AAC CTG-3’, Vav-Cre R: 5’-ATC AGC CAC ACC AGA CAC AGA GAT C-3’ and JAK2-F: 5’-CGT GCA TAG TGT CTG TGG AAG TC-3’,",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:163"
    }
  },
  {
    "page_content": "and JAK2-F: 5’-CGT GCA TAG TGT CTG TGG AAG TC-3’, JAK2-R: 5’-CGT GGA GAG TCT GTA AGG CTC AA-3’. CD45.1 recipient female and male mice were subjected to 11 gray (Gy) units of ionizing radiation. One week prior to and 2-weeks following irradiation, mice were fed bactrim-supplemented water. Two to 3 h after irradiation, mice were injected intravenously with 2 × 106 bone marrow Jak2V617F/+VavCre+ or Jak2+/+VavCre- cells, post red blood cell lysis, into the tail vein or retro-orbitally. Peripheral",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:164"
    }
  },
  {
    "page_content": "into the tail vein or retro-orbitally. Peripheral blood (PB) was collected and hematocrit, hemoglobin levels, and chimerism (engraftment) were measured 3 or 5 weeks after transplantation. Mice were randomized into treatment groups by hematocrit and/or hemoglobin levels. To test the effects of IFNα treatment on ROCK1/2 activation, recipient mice (Fig. 5a [10–11-week-old female mice vehicle-control group: n = 5 and IFNα groupː n = 6] and Fig. 6a [10–11-week-old female mice vehicle-control group:",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:165"
    }
  },
  {
    "page_content": "female mice vehicle-control group: n = 5 and IFNα groupː n = 5, study was repeated with 10–11-week-old male mice vehicle-control group: n = 5 and IFNα groupː n = 5]) or C57BL/6J mice (Supplementary Fig. 8a [9–10-week-old female mice vehicle-control group: n = 10 and IFNα groupː n = 10]) were treated once a week for 4 weeks with murine ropeginterferon-α (PEG-IFN-α; PharmaEssentia; 600 ng in 500 μL PBS, subcutaneous injection) or with vehicle (PBS). To test the effects of drug-targeted inhibition",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:166"
    }
  },
  {
    "page_content": "To test the effects of drug-targeted inhibition of ROCK1/2 in combination with IFNα treatment in vivo (Fig. 8a), recipient mice were treated for 4 weeks with Fasudil (FAS; # 10010559; Cayman Chemical; 25 mg/kg, intraperitoneal injection) four times per week or vehicle (PBS), and/or with PEG-IFNα (600 ng in 500 μL PBS, subcutaneous injection) once a week or vehicle (PBS), and analyzed 3 days after the last injection. We used 3–6 mice (10–11 week old) per treatment group as the number of",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:167"
    }
  },
  {
    "page_content": "week old) per treatment group as the number of recipient mice that we are able to transplant is dependent on the number of the same sex and age of Jak2VF/+VavCre+ donor mice that we can generate by breeding. We combined the data from four independent studies in the same plot for the different parameters studied (Fig. 8 and Supplementary Figs. 10 and 11 CTRL: n = 8 females and n = 7 males; FAS: n = 10 females and n = 7 males; IFNα: n = 8 females and n = 7 males; FAS + IFNα: n = 10 females and",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:168"
    }
  },
  {
    "page_content": "and n = 7 males; FAS + IFNα: n = 10 females and n = 8 males). ## Blood count analysis and isolation of BM cells for immunoblotting Peripheral blood (PB) was collected in EDTA-coated tubes (VWR) and hematocrit, hemoglobin, red blood cells and platelets levels were analyzed on the Hemavet (Model 950, Drew scientific) and data collected using the Hemavet 950 software. BM cells were flushed, homogenized through a 70 µm cell strainer (Fisher Scientific/Falcon, Cat # 352350) and red blood cells",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:169"
    }
  },
  {
    "page_content": "Cat # 352350) and red blood cells (RBCs) were lysed with 1x RBC lysis buffer (eBioscience 10x RBC Lysis Buffer, Thermo Fisher Scientific/invitrogen, Cat # 00-4300-54) prior to total protein isolation, using phospho-lysis buffer for immunoblotting analyses. ## Flow cytometry analysis To determine the efficiency of engraftment of CD45.2+ bone marrow cells, PB was collected in EDTA-coated tubes, red blood cells were lysed using 1x RBC lysis buffer, then cells were stained in FACS buffer (PBS, 0.5%",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:170"
    }
  },
  {
    "page_content": "then cells were stained in FACS buffer (PBS, 0.5% BSA, 1 mM EDTA) using the antibodies: PerCP-Cy5.5 mouse anti-mouse CD45.2 (Clone 104; BD Pharmigen) (1:200; # 561096) and V450 mouse anti-mouse CD45.1 (Clone A20; BD Horizon) (1:200; # 560520) from BD Biosciences. Unstained and single color controls were used for each experiment. Percentage of engraftment was defined as the proportion of Jak2+/VF cells as a percentage of total mononuclear cells in peripheral blood. Calculation:",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:171"
    }
  },
  {
    "page_content": "cells in peripheral blood. Calculation: (%Jak2+/VF)/(%Jak2+/VF + %WT) × 100. Population frequencies were calculated as a percentage of the respective donor CD45 expressing cells (WT-CD45.1; Jak2+/VF-CD45.2). To assess the effects of PEG-IFNα and/or Fasudil treatments on phosphorylation of MYPT1 in PBMCs, PB was collected in EDTA-coated tubes and red blood cells were lysed using 1x RBC lysis buffer. PBMCs were then fixed, permeabilized and stained using the BD Cytofix/Cytoperm",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:172"
    }
  },
  {
    "page_content": "and stained using the BD Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (# BD 554714) and the mouse monoclonal anti-p-MYPT1 (F-11) Alexa Fluor 647 (1:50; Santa Cruz Biotechnology # sc-377531 AF647) or normal mouse IgG1 Alexa Fluor 647 (negative control, 1:50; Santa Cruz Biotechnology # sc-24636) antibodies, according to the manufacturer’s instructions. Unstained and negative controls were used for each experiment. To assess the effects of PEG-IFNα treatment on phosphorylation of MYPT1",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:173"
    }
  },
  {
    "page_content": "of PEG-IFNα treatment on phosphorylation of MYPT1 in BMMCs, BM cells were flushed, homogenized through a 70 µm cell strainer, and red blood cells were lysed using 1x RBC lysis buffer. BMMCs were then fixed, permeabilized and stained using the BD Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (# BD 554714) and the PE/Cyanine7 anti-mouse CD71 (1:200; BioLegend # 113812), the mouse monoclonal anti-p-MYPT1 (F-11) Alexa Fluor 647 (1:50; Santa Cruz Biotechnology # sc-377531 AF647) or the",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:174"
    }
  },
  {
    "page_content": "Cruz Biotechnology # sc-377531 AF647) or the normal mouse IgG1 Alexa Fluor 647 (negative control, 1:50; Santa Cruz Biotechnology # sc-24636) antibodies, according to the manufacturer’s instructions. Unstained, single color and negative controls were used for each experiment. To assess the effects of PEG-IFNα and/or Fasudil treatments on erythroid development, BM cells were flushed and homogenized through a 70 µm cell strainer, and spleens were harvested, weighed and then mechanically",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:175"
    }
  },
  {
    "page_content": "were harvested, weighed and then mechanically dissociated and homogenized through a 70 µm cell strainer. BM and spleen cells were then stained in FACS buffer using the antibodies: APC anti-mouse TER-119/Erythroid Cells (1:200; BioLegend # 116212) and PE/Cyanine7 anti-mouse CD71 (1:200; BioLegend # 113812). Unstained and single color controls were used for each experiment. To assess the effects of PEG-IFNα and/or Fasudil treatments on myeloid progenitor cells, BM cells were flushed and",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:176"
    }
  },
  {
    "page_content": "progenitor cells, BM cells were flushed and homogenized through a 70 µm cell strainer, red blood cells were lysed with 1x RBC lysis buffer and BM mononuclear cells were then stained in FACS buffer using V450 Mouse Lineage Antibody Cocktail (1:20; BD Biosciences # 561301), Ly-6A/E (Sca-1) Monoclonal Antibody (D7), PE-Cyanine7, eBioscience (1:100; Invitrogen/Thermo Fisher Scientific # 25-5981-82), APC Rat Anti-Mouse CD117 (c-kit) antibody (1:100; BD Biosciences # 553356), PE Rat anti-Mouse CD34",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:177"
    }
  },
  {
    "page_content": "BD Biosciences # 553356), PE Rat anti-Mouse CD34 antibody (1:40; BD Biosciences # 551387), and PerCP-Cy5.5 Rat Anti-Mouse CD16/CD32 antibody (1:200; BD Biosciences # 560540). Unstained and single color controls were used for each experiment. All samples were analyzed by flow cytometry using a BD LSRII flow cytometer, the data acquired using BD FACSDiva, and analyzed using FlowJo software v10.6 (Treestar, CA). ## Quantification and statistical analysis All statistical analyses were performed",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:178"
    }
  },
  {
    "page_content": "analysis All statistical analyses were performed with GraphPad Prism 8, except for qRT-PCR and colony formation assays using PV patient-derived samples for which R package lme4 version 1.1.26 (https://cran.r-project.org/web/packages/lme4/index.html) was used74,75. Unless otherwise indicated in the figure legend, plots shown are representative of at least three independent biological replicates or from samples collected from at least three different patients or three different mice. Sample size",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:179"
    }
  },
  {
    "page_content": "patients or three different mice. Sample size for each experimental group/condition is reported in the respective figure legend. For mouse experiments, each data point represents data for one individual mouse. Statistically significant differences were determined using two-sample two-tailed t-test when comparing a normally distributed outcome between two groups. When comparing more than two groups, significance was determined using one-way ANOVA with Tukey’s post-hoc test for multiple",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:180"
    }
  },
  {
    "page_content": "ANOVA with Tukey’s post-hoc test for multiple comparisons correction or with Dunnett’s for multiple comparisons to a single control group. Two-way ANOVA was used to compare groups in experiments with two independent variables (factors) with Tukey’s post-hoc test for multiple comparisons correction. For the experiments using MPN-patient-derived primary cells, differences between experimental conditions were analyzed using linear mixed effects models with patient as a random effect to account for",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:181"
    }
  },
  {
    "page_content": "with patient as a random effect to account for the within-subject correlation between multiple conditions. Kenward-Roger degrees of freedom adjustment was used, and pairwise group comparison tests were adjusted for multiple comparisons using Tukey’s method. The statistical analysis performed for each dataset is included in the figure legends. Differences were considered statistically significant when p-values were less than 0.05. ## Reporting summary Further information on research design is",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:182"
    }
  },
  {
    "page_content": "summary Further information on research design is available in the Nature Research Reporting Summary linked to this article. # Supplementary information Supplementary Information",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:183"
    }
  },
  {
    "page_content": "Reporting summary",
    "metadata": {
      "source": "../data/plain/PMC8975834.plain.txt",
      "id": "../data/plain/PMC8975834.plain.txt:184"
    }
  },
  {
    "page_content": "An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin Abstract",
    "metadata": {
      "source": "../data/plain/PMC7700753.plain.txt",
      "id": "../data/plain/PMC7700753.plain.txt:0"
    }
  },
  {
    "page_content": "Immunohistochemistry represents an indispensable complement to an epidemiology and morphology-driven approach to tumor diagnosis and site of origin assignment. This review reflects the state of my current practice, based on 15-years’ experience in Pathology and a deep-dive into the literature, always striving to be better equipped to answer the age old questions, “What is it, and where is it from?” The tables and figures in this manuscript are the ones I “pull up on the computer” when I’m",
    "metadata": {
      "source": "../data/plain/PMC7700753.plain.txt",
      "id": "../data/plain/PMC7700753.plain.txt:1"
    }
  },
  {
    "page_content": "are the ones I “pull up on the computer” when I’m teaching at the microscope and turn to myself when I’m (frequently) stuck. This field is so exciting because I firmly believe that, through the application of next-generation immunohistochemistry, we can provide better answers than ever before. Specific topics covered in this review include 1. broad tumor classification and associated screening markers; 2. the role of cancer epidemiology in determining pretest probability; 3. broad-spectrum",
    "metadata": {
      "source": "../data/plain/PMC7700753.plain.txt",
      "id": "../data/plain/PMC7700753.plain.txt:2"
    }
  },
  {
    "page_content": "pretest probability; 3. broad-spectrum epithelial markers; 4. non-canonical expression of broad tumor class screening markers; 5. a morphologic pattern-based approach to poorly to undifferentiated malignant neoplasms; 6. a morphologic and immunohistochemical approach to define 4 main carcinoma types; 7. CK7/CK20 coordinate expression; 8. added value of semiquantitative immunohistochemical stain assessment; algorithmic immunohistochemical approaches to 9. “garden variety” adenocarcinomas",
    "metadata": {
      "source": "../data/plain/PMC7700753.plain.txt",
      "id": "../data/plain/PMC7700753.plain.txt:3"
    }
  },
  {
    "page_content": "approaches to 9. “garden variety” adenocarcinomas presenting in the liver, 10. large polygonal cell adenocarcinomas, 11. the distinction of primary surface ovarian epithelial tumors with mucinous features from metastasis, 12. tumors presenting at alternative anatomic sites, 13. squamous cell carcinoma vs. urothelial carcinoma, and neuroendocrine neoplasms, including 14. the distinction of pheochromocytoma/paraganglioma from well-differentiated neuroendocrine tumor, site of origin assignment in",
    "metadata": {
      "source": "../data/plain/PMC7700753.plain.txt",
      "id": "../data/plain/PMC7700753.plain.txt:4"
    }
  },
  {
    "page_content": "tumor, site of origin assignment in 15. well-differentiated neuroendocrine tumor and 16. poorly differentiated neuroendocrine carcinoma, and 17. the distinction of well-differentiated neuroendocrine tumor G3 from poorly differentiated neuroendocrine carcinoma; it concludes with 18. a discussion of diagnostic considerations in the broad-spectrum keratin/CD45/S-100-“triple-negative” neoplasm.",
    "metadata": {
      "source": "../data/plain/PMC7700753.plain.txt",
      "id": "../data/plain/PMC7700753.plain.txt:5"
    }
  },
  {
    "page_content": "Subsequent malignant neoplasms in the Childhood Cancer Survivor Study: Occurrence of cancer types where human papillomavirus is an established etiologic risk factor Abstract\nBackground:\nHuman papillomavirus-associated subsequent malignant neoplasms (SMNHPV) in childhood cancer survivors are poorly understood.\nMethods:",
    "metadata": {
      "source": "../data/plain/PMC8738100.plain.txt",
      "id": "../data/plain/PMC8738100.plain.txt:0"
    }
  },
  {
    "page_content": "Methods:\nSMNHPV cumulative risk was assessed among 24,363 Childhood Cancer Survivor Study participants. Standardized incidence ratios (SIRs) and absolute excess risk (AER) were calculated using age-, sex- and calendar year rates from the Surveillance, Epidemiology and End Results (SEER) program. Poisson regression models identified SMNHPV risk factors, evaluating relative SIRs (rSIR) and 95% Confidence Intervals (95% CI).\nResults:",
    "metadata": {
      "source": "../data/plain/PMC8738100.plain.txt",
      "id": "../data/plain/PMC8738100.plain.txt:1"
    }
  },
  {
    "page_content": "46 survivors developed an SMNHPV (median age of 31 years [range: 10-56], median time from primary cancer of 21 years [range: 9-35]). SMNHPV locations included oropharynx (N=44), anorectum (N=6), uterine cervix (N=2), vulva (N=2). Thirty-year cumulative incidence was 0.3% (95% CI: 0.2%-0.4%) and SIR was nearly three-fold the general population (SIR=2.86, 95% CI 2.05-4.00). Female survivors were not at increased risk of cervical or vulvar cancers compared to the general population. All survivors",
    "metadata": {
      "source": "../data/plain/PMC8738100.plain.txt",
      "id": "../data/plain/PMC8738100.plain.txt:2"
    }
  },
  {
    "page_content": "compared to the general population. All survivors had an elevated risk of oropharyngeal (Males SIR=4.06, 95% CI 2.37-6.97; Females SIR=8.44, 95% CI 4.88-14.61) and anorectal (Males SIR=13.56, 95% CI 5.09-36.13; Females SIR=9.15, 95% CI 2.29-36.61) SMNHPV. Males (vs. females, rSIR=1.99, CI 1.00-3.94), head/neck/pelvic RT dose >3000 cGy (vs none, rSIR=2.35, CI 1.11-4.97), and cisplatin-equivalent dose >400 mg/m2 (vs none, rSIR=4.51, CI: 1.78-11.43) were associated with increased SMNHPV SIRs in",
    "metadata": {
      "source": "../data/plain/PMC8738100.plain.txt",
      "id": "../data/plain/PMC8738100.plain.txt:3"
    }
  },
  {
    "page_content": "were associated with increased SMNHPV SIRs in multivariable analysis.",
    "metadata": {
      "source": "../data/plain/PMC8738100.plain.txt",
      "id": "../data/plain/PMC8738100.plain.txt:4"
    }
  },
  {
    "page_content": "Conclusion:\nChildhood cancer survivors are at increased risk for SMN in locations susceptible to HPV-associated malignancies. Further research examining HPV in the etiology of SMN and the promotion of HPV vaccination and surveillance guidelines for SMNHPV in cancer survivors is warranted. Precis\nChildhood cancer survivors are at increased risk for secondary malignant neoplasms in locations associated with HPV infection.",
    "metadata": {
      "source": "../data/plain/PMC8738100.plain.txt",
      "id": "../data/plain/PMC8738100.plain.txt:5"
    }
  },
  {
    "page_content": "International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data Abstract",
    "metadata": {
      "source": "../data/plain/PMC9479031.plain.txt",
      "id": "../data/plain/PMC9479031.plain.txt:0"
    }
  },
  {
    "page_content": "We present the new International Consensus Classification (ICC) of myeloid and lymphoid neoplasms, introduced by a Perspective by Sehn and Cazzola. This classification better integrates genomic information to allow therapy to be more easily tailored to targeted agents. In the Perspective, the authors propose that the ICC be adapted to an interactive web-based portal to allow more nimble modification to reflect new discoveries and improve diagnostic, prognostic, and predictive information.",
    "metadata": {
      "source": "../data/plain/PMC9479031.plain.txt",
      "id": "../data/plain/PMC9479031.plain.txt:1"
    }
  },
  {
    "page_content": "prognostic, and predictive information. Abstract",
    "metadata": {
      "source": "../data/plain/PMC9479031.plain.txt",
      "id": "../data/plain/PMC9479031.plain.txt:2"
    }
  },
  {
    "page_content": "The classification of myeloid neoplasms and acute leukemias was last updated in 2016 within a collaboration between the World Health Organization (WHO), the Society for Hematopathology, and the European Association for Haematopathology. This collaboration was primarily based on input from a clinical advisory committees (CACs) composed of pathologists, hematologists, oncologists, geneticists, and bioinformaticians from around the world. The recent advances in our understanding of the biology of",
    "metadata": {
      "source": "../data/plain/PMC9479031.plain.txt",
      "id": "../data/plain/PMC9479031.plain.txt:3"
    }
  },
  {
    "page_content": "advances in our understanding of the biology of hematologic malignancies, the experience with the use of the 2016 WHO classification in clinical practice, and the results of clinical trials have indicated the need for further revising and updating the classification. As a continuation of this CAC-based process, the authors, a group with expertise in the clinical, pathologic, and genetic aspects of these disorders, developed the International Consensus Classification (ICC) of myeloid neoplasms",
    "metadata": {
      "source": "../data/plain/PMC9479031.plain.txt",
      "id": "../data/plain/PMC9479031.plain.txt:4"
    }
  },
  {
    "page_content": "Classification (ICC) of myeloid neoplasms and acute leukemias. Using a multiparameter approach, the main objective of the consensus process was the definition of real disease entities, including the introduction of new entities and refined criteria for existing diagnostic categories, based on accumulated data. The ICC is aimed at facilitating diagnosis and prognostication of these neoplasms, improving treatment of affected patients, and allowing the design of innovative clinical trials.",
    "metadata": {
      "source": "../data/plain/PMC9479031.plain.txt",
      "id": "../data/plain/PMC9479031.plain.txt:5"
    }
  },
  {
    "page_content": "Incidence of lymphoid neoplasms among atomic bomb survivors by histological subtype, 1950 to 1994 Key Points\nA pathology review of 553 lymphoid neoplasm cases among atomic bomb survivors provides WHO classification subtype distribution.Significant radiation dose response observed for precursor lymphoid neoplasms but not for mature lymphoid neoplasms or HL. Abstract",
    "metadata": {
      "source": "../data/plain/PMC8759532.plain.txt",
      "id": "../data/plain/PMC8759532.plain.txt:0"
    }
  },
  {
    "page_content": "Epidemiological data have provided limited and inconsistent evidence on the relationship between radiation exposure and lymphoid neoplasms. We classified 553 lymphoid neoplasm cases diagnosed between 1950 and 1994 in the Life Span Study cohort of atomic bomb survivors into World Health Organization subtypes. Mature B-cell neoplasms represented 58%, mature T-cell and natural killer (NK)-cell neoplasms 20%, precursor cell neoplasms 5%, and Hodgkin lymphoma (HL) 3%, with the remaining 15%",
    "metadata": {
      "source": "../data/plain/PMC8759532.plain.txt",
      "id": "../data/plain/PMC8759532.plain.txt:1"
    }
  },
  {
    "page_content": "Hodgkin lymphoma (HL) 3%, with the remaining 15% classified as non-Hodgkin lymphoid (NHL) neoplasms or lymphoid neoplasms not otherwise specified. We used Poisson regression methods to assess the relationship between radiation exposure and the more common subtypes. As in earlier reports, a significant dose response for NHL neoplasms as a group was seen for males but not females. However, subtype analyses showed that radiation dose was strongly associated with increased precursor cell neoplasms",
    "metadata": {
      "source": "../data/plain/PMC8759532.plain.txt",
      "id": "../data/plain/PMC8759532.plain.txt:2"
    }
  },
  {
    "page_content": "with increased precursor cell neoplasms rates, with an estimated excess relative risk per Gy of 16 (95% Confidence interval: 7.0, >533) at age 50. The current data based primarily of tissue-based diagnoses suggest that the association between radiation dose and lymphoid neoplasms as a group is largely driven by the radiation effect on precursor cell neoplasms while presenting no evidence of a radiation dose response for major categories of mature cell neoplasms, either B- or T-/NK-cell, or more",
    "metadata": {
      "source": "../data/plain/PMC8759532.plain.txt",
      "id": "../data/plain/PMC8759532.plain.txt:3"
    }
  },
  {
    "page_content": "cell neoplasms, either B- or T-/NK-cell, or more specific disease entities (diffuse large B-cell lymphoma, plasma cell myeloma, adult T-cell leukemia/lymphoma) or HL.",
    "metadata": {
      "source": "../data/plain/PMC8759532.plain.txt",
      "id": "../data/plain/PMC8759532.plain.txt:4"
    }
  },
  {
    "page_content": "Genetic and epigenetic bases of long-term adverse effects of childhood cancer therapy Abstract",
    "metadata": {
      "source": "../data/plain/PMC11924961.plain.txt",
      "id": "../data/plain/PMC11924961.plain.txt:0"
    }
  },
  {
    "page_content": "Over the past decade, genome-scale molecular profiling of large childhood cancer survivorship cohorts has led to unprecedented advances in our understanding of the genetic and epigenetic bases of therapy-related adverse health outcomes in this vulnerable population. To facilitate the integration of knowledge generated from these studies into formulating next-generation precision care for survivors of childhood cancer, we summarize key findings of genetic and epigenetic association studies of",
    "metadata": {
      "source": "../data/plain/PMC11924961.plain.txt",
      "id": "../data/plain/PMC11924961.plain.txt:1"
    }
  },
  {
    "page_content": "of genetic and epigenetic association studies of long-term therapy-related adverse effects including subsequent neoplasms and cardiomyopathies among others. We also discuss therapy-related genotoxicities including clonal haematopoiesis and DNA methylation, which may underlie accelerated molecular ageing. Finally, we highlight enhanced risk prediction models for survivors of childhood cancer that incorporate both genetic factors and treatment exposures, aiming to achieve enhanced accuracy in",
    "metadata": {
      "source": "../data/plain/PMC11924961.plain.txt",
      "id": "../data/plain/PMC11924961.plain.txt:2"
    }
  },
  {
    "page_content": "exposures, aiming to achieve enhanced accuracy in predicting risks for this population. These new insights will hopefully inspire future studies that harness both expanding omics resources and evolving data science methodology to accelerate the translation of precision medicine for survivors of childhood cancer.",
    "metadata": {
      "source": "../data/plain/PMC11924961.plain.txt",
      "id": "../data/plain/PMC11924961.plain.txt:3"
    }
  },
  {
    "page_content": "Impact of Perioperative Immunonutrition on Postoperative Outcomes in Patients with Upper Gastrointestinal Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Abstract",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:0"
    }
  },
  {
    "page_content": "There is no consensus on the efficacy of perioperative immunonutrition in patients with upper gastrointestinal (GI) cancer surgery. We clarified the impact of perioperative immunonutrition on postoperative outcomes in patients with upper GI cancers. We searched MEDLINE (PubMed), MEDLINE (OVID), EMBASE, Cochrane Central Register of Controlled Trials, Web of Science Core Selection, and Emcare from 1981–2022 using search terms related to immunonutrition and upper GI cancer. We included randomized",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:1"
    }
  },
  {
    "page_content": "and upper GI cancer. We included randomized controlled trials. Intervention was defined as immunonutritional therapy, including arginine, n-3 omega fatty acids, or glutamine during the perioperative period. The control was defined as standard nutritional therapy. The primary outcomes were infectious complications, defined as events with a Clavien–Dindo classification grade ≥ II that occurred within 30 days after surgery. After screening, 23 studies were included in the qualitative synthesis and",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:2"
    }
  },
  {
    "page_content": "were included in the qualitative synthesis and in the quantitative synthesis. The meta-analysis showed that immunonutrition reduced infectious complications (relative risk ratio: 0.72; 95% confidence interval: 0.57–0.92; certainty of evidence: Moderate) compared with standard nutritional therapy. In conclusion, nutritional intervention with perioperative immunonutrition in patients with upper GI cancers significantly reduced infectious complications. The effect of immunonutrition for upper GI",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:3"
    }
  },
  {
    "page_content": "The effect of immunonutrition for upper GI cancers in reducing the risk of infectious complications was about 30%. # 1. Introduction For cancer patients, surgical resection is the main treatment, and one of the risk factors for problems after surgery is preoperative malnutrition. Patients with gastrointestinal cancers often have worsened nutritional status, which ranges from 20–70%. The immune system and tissue repair are impacted by malnutrition. Furthermore, the surgical invasion-induced",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:4"
    }
  },
  {
    "page_content": "Furthermore, the surgical invasion-induced catabolic processes result in the loss of vital nutrients, which might induce immune response dysregulation and increase the risk of infectious complications. To decrease infection and total postoperative complications, nutritional interventions are necessary to reduce preoperative malnutrition. There is no consensus on the efficacy of perioperative immunonutrition in patients with upper GI cancer after surgery. An immunonutrition therapy using either",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:5"
    }
  },
  {
    "page_content": "surgery. An immunonutrition therapy using either arginine, n-3 omega fatty acids, or glutamine has been developed and used clinically to reduce infectious complications and postoperative length of stay. A postoperative inflammatory response is modulated by immunonutrition, which reduces immunosuppression caused by inflammatory cytokines. While standard nutritional therapy is used for malnutrition, immunonutrition is used not only for malnutrition but also to reduce invasion or restore immunity.",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:6"
    }
  },
  {
    "page_content": "but also to reduce invasion or restore immunity. However, its efficacy and optimal timing are clinically unresolved, especially in upper GI cancer surgeries. Therefore, we planned a systematic review and meta-analysis of perioperative immunonutrition in patients with upper GI cancers. This study aimed to clarify the effectiveness of perioperative immunonutrition in patients undergoing elective surgery for upper GI cancer. We also investigated whether the recommendations for patients who are",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:7"
    }
  },
  {
    "page_content": "whether the recommendations for patients who are malnourished differed from those who are not malnourished. We hypothesized that perioperative immunonutrition reduces infectious complications in patients with and without malnourishment. # 2. Materials and Methods We conducted a systematic review of the relevant literature in accordance with the Cochrane Handbook, Preferred Reporting Items for Systematic Reviews and Meta-Analysis 2020 guidelines (PRISMA-2020), and the Minds Manual for Guideline",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:8"
    }
  },
  {
    "page_content": "(PRISMA-2020), and the Minds Manual for Guideline Development 2020. The protocol was published in PROSPERO (CRD42023471825). ## 2.1. Eligibility Criteria and Study Selection We included randomized controlled trials (RCTs) of patients aged over 18 years who underwent elective upper GI cancer surgery with perioperative immunonutrition. Intervention was defined as perioperative immunonutritional therapy, including arginine, n-3 omega fatty acids, or glutamine was given preoperatively,",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:9"
    }
  },
  {
    "page_content": "acids, or glutamine was given preoperatively, postoperatively, or both. The control was defined as standard oral or intravenous nutritional therapy without immunonutrition. The intervention and control groups received the same amount of nutrition. We excluded studies in which more than 25% of patients had benign disease or cancer at other sites, review articles, case reports, crossover trials, and cluster-, quasi-, and non-randomized trials. ## 2.2. Search Strategy Appendix A provides the",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:10"
    }
  },
  {
    "page_content": "## 2.2. Search Strategy Appendix A provides the search formulae. We searched MEDLINE (PubMed), MEDLINE (OVID), Embase (OVID), Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science Core Selection, and Emcare (OVID). The period covered by the RCT was 2000–2022. ## 2.3. Study Selection and Data Collection Two independent reviewers screened the titles and abstracts, assessing their eligibility based on the full texts. The same reviewers performed independent data extraction from",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:11"
    }
  },
  {
    "page_content": "performed independent data extraction from the included studies using a standardized data collection form. Reviewer disagreements were resolved through discussion or with a mediating third reviewer. The original authors were contacted for missing data. ## 2.4. Risk-of-Bias Assessment Two of the three researchers carried out risk-of-bias (ROB) assessments using the Cochrane Collaboration ROB tool, which has five domains: randomization, deviation from intervention, missing data, measurement of",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:12"
    }
  },
  {
    "page_content": "from intervention, missing data, measurement of outcome, and selective reporting. The ratings “high risk”, “some concerns”, and “low risk” were assigned to each domain and overall. The resolution of the disagreement was decided by a third person. ## 2.5. Outcomes The primary outcomes were the total postoperative and infectious complications. The secondary outcomes were severe complications, anastomotic leakage, postoperative pneumonia, postoperative mortality, nutritional intervention adverse",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:13"
    }
  },
  {
    "page_content": "mortality, nutritional intervention adverse events, and postoperative hospitalization. Postoperative complications were defined as events with a Clavien–Dindo (CD) classification grade of ≥II that occurred within 30 days after surgery. Severe complications were defined as those with a CD grade of ≥III. ## 2.6. Synthesis of Results We pooled the relative risk ratios (RRs) and 95% confidence intervals (CIs) for postoperative complications, postoperative mortality, and nutritional intervention",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:14"
    }
  },
  {
    "page_content": "mortality, and nutritional intervention adverse events, and the mean differences (MDs) and 95% CIs for postoperative hospitalization in patients with upper GI cancer. An intention-to-treat analysis was performed for dichotomous data where possible. We used Review Manager software 5.4.2 and performed meta-analyses with a random-effects model, assuming that the true effect would be low owing to many unmeasured or unknown factors and individual differences between studies in accordance with the",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:15"
    }
  },
  {
    "page_content": "between studies in accordance with the Cochrane Handbook. Statistical heterogeneity was evaluated by visually inspecting forest plots and calculating the I2 statistic (I2 values of 0–40% may not be important; 30–60% may represent moderate heterogeneity; 50–90% may represent substantial heterogeneity; 75–100%, considerable heterogeneity). When there was substantial heterogeneity (I2 > 50%), we assessed the reason. To elucidate the influence of effect modifiers, subgroup analyses according to",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:16"
    }
  },
  {
    "page_content": "effect modifiers, subgroup analyses according to malnutrition status (with or without malnutrition), intervention timing (preoperative, postoperative, or perioperative), cancer site (esophageal or gastric), and difference in ingredient (arginine absent or arginine present) were performed when sufficient data were available. We also performed a sensitivity analysis for the frequency of malnourishment (>50% or >75%). In one of these analyses, studies using imputed statistics were excluded, while",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:17"
    }
  },
  {
    "page_content": "using imputed statistics were excluded, while the other included only participants who completed the study with complete data. Potential publication bias was assessed by visual inspection of the funnel plots for outcomes in more than 10 studies. ## 2.7. Certainty Assessment Based on the Cochrane Handbook, we summarized the findings for total postoperative complications, infectious complications, severe complications, anastomotic leakage, postoperative pneumonia, postoperative mortality,",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:18"
    }
  },
  {
    "page_content": "postoperative pneumonia, postoperative mortality, nutritional intervention adverse events, and postoperative hospitalization. The summary included grading of certainty of evidence (COE) according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. We started with “high” COE. If there were any serious concerns in any domain, we lowered the grade from “high” COE. The effect estimates displayed in the Summary of Findings table were created using RRs and MD.",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:19"
    }
  },
  {
    "page_content": "of Findings table were created using RRs and MD. To determine the inconsistency domain of the GRADE ratings, we examined the consistency of the RR and MD. # 3. Results ## 3.1. Study Selection The PRISMA flowchart is shown in Figure 1. A total of 391 records were searched on 16 October 2023. After screening, 23 studies (2249 patients) were included in the qualitative synthesis and in the quantitative synthesis. No unpublished data or ongoing studies were identified. The reasons for exclusion",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:20"
    }
  },
  {
    "page_content": "were identified. The reasons for exclusion were incorrect population (n = 40), incorrect control (n = 4), protocol without results (n = 1), insufficient outcome data (n = 9), duplicate records (n = 2), and other reasons (n = 16). ## 3.2. Study and Patient Characteristics Table 1 summarizes the characteristics of the 23 studies included in the quantitative synthesis. Of these studies, 10 were for esophageal cancer, 7 were for gastric cancer, and 6 were for mixed upper GI. Regarding the",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:21"
    }
  },
  {
    "page_content": "and 6 were for mixed upper GI. Regarding the nutritional intervention timing, 5 studies were conducted preoperatively, 8 were postoperatively, and 10 were preoperatively and postoperatively. We did not find any literature that included only patients with malnutrition. Table 1 summarizes the findings using the GRADE approach. ## 3.3. Risk of Bias Figure 2 summarizes the ROB in the included studies. Regarding postoperative complications, there was a low ROB for incomplete outcome data and",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:22"
    }
  },
  {
    "page_content": "was a low ROB for incomplete outcome data and selective reporting and a low ROB or “some concerns” for random sequence generation and allocation concealment. The ROB for the participant and personnel blinding and outcome assessment were low”, some concerns” or high. ## 3.4. Meta-Analysis Results Table 2 shows a summary of the findings of this study. The results of the meta-analysis are shown in Figure 3. Nine studies reported total postoperative complications. Immunonutrition does not reduce",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:23"
    }
  },
  {
    "page_content": "complications. Immunonutrition does not reduce total postoperative complications compared to standard nutritional therapy (RR: 0.94, 95% CI: 0.76–1.16, I2 = 47%, n = 9, COE: moderate; Figure 3a). Eighteen studies reported infectious complications. Immunonutrition reduces infectious complications compared to standard nutritional therapy (RR: 0.72, 95% CI: 0.57–0.92, I2 = 50%, n = 18, COE: moderate, Figure 3b). Four studies reported severe complications. Immunonutrition is unlikely to reduce",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:24"
    }
  },
  {
    "page_content": "Immunonutrition is unlikely to reduce severe complications compared to standard nutritional therapy (RR: 1.06, 95% CI: 0.67–1.67, I2 = 0%, n = 4; COE: moderate; Figure 3c). Seventeen studies reported anastomotic leakage. Immunonutrition probably reduces anastomotic leakage compared to standard nutritional therapy (RR: 0.72, 95% CI: 0.51–1.03, I2 = 0%, n = 17, COE: moderate, Figure 3d). Twenty-one studies reported postoperative pneumonia. Immunonutrition is unlikely to reduce postoperative",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:25"
    }
  },
  {
    "page_content": "is unlikely to reduce postoperative pneumonia compared to standard nutritional therapy (RR: 1.00, 95% CI: 0.79–1.25, I2 = 0%, n = 21, COE: moderate; Figure 3e). Sixteen studies reported mortality rates. Immunonutrition is unlikely to reduce mortality compared to standard nutritional therapy (RR: 0.79, 95% CI: 0.44–1.42, I2 = 0%, n = 16, COE: moderate; Figure 3f). Nineteen studies reported postoperative hospital stays. Immunonutrition reduces postoperative hospital stay compared to standard",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:26"
    }
  },
  {
    "page_content": "postoperative hospital stay compared to standard nutritional therapy (MD: −1.45, 95% CI: −2.43, −0.46, I2 = 57%, n = 19; COE: high, Figure 3g). Six studies reported nutritional intervention adverse events. Immunonutrition is unlikely to increase nutritional intervention adverse events compared to standard nutritional therapy (RR: 0.82, 95% CI: 0.63–1.06, I2 = 0%, n = 6, COE: moderate, Figure 3h). ## 3.5. Subgroup Analyses We performed subgroup analyses according to intervention timing",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:27"
    }
  },
  {
    "page_content": "analyses according to intervention timing (preoperative, postoperative, or perioperative), cancer site (esophageal or gastric), and difference in ingredient (arginine absent or arginine present). Subgroup and sensitivity analysis for malnutrition were not performed because of the paucity of studies that included patients with malnourishment. ### 3.5.1. Subgroup Analyses According to Intervention Timing The results of the subgroup analyses according to intervention timing are shown in Figure 4.",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:28"
    }
  },
  {
    "page_content": "to intervention timing are shown in Figure 4. In the subgroup analysis, total postoperative complications were reduced for postoperative administration compared to preoperative plus postoperative administration (p = 0.05, Figure 4a). The subgroup analyses showed no efficacy differences between the groups according to the intervention timing for infectious complications (p = 0.42, Figure 4b), anastomotic leakage (p = 0.65, Figure 4c), postoperative pneumonia (p = 0.66, Figure 4d), and mortality",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:29"
    }
  },
  {
    "page_content": "pneumonia (p = 0.66, Figure 4d), and mortality (p = 0.81, Figure 4e). Postoperative hospital stay was shorter with postoperative administration compared to preoperative or preoperative plus postoperative administration (p < 0.001, Figure 4f). The subgroup analysis for adverse events showed no efficacy difference between the groups (p = 0.89, Figure 4g). The subgroup analysis for severe complications was not performed due to the small number of studies. ### 3.5.2. Subgroup Analyses According to",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:30"
    }
  },
  {
    "page_content": "### 3.5.2. Subgroup Analyses According to Cancer Site The results of the subgroup analyses according to cancer site are shown in Figure 5. The subgroup analyses showed no efficacy differences between the groups according to the cancer site for total postoperative complications (p = 0.33, Figure 5a), infectious complications (p = 0.17, Figure 5b), anastomotic leakage (p = 0.39, Figure 5c), postoperative pneumonia (p = 0.68, Figure 5d), and mortality (p = 0.48, Figure 5e). Postoperative hospital",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:31"
    }
  },
  {
    "page_content": "(p = 0.48, Figure 5e). Postoperative hospital stay was shorter in the gastric cancer group than in the esophageal cancer group (p < 0.001, Figure 5f). The subgroup analysis for adverse events showed no efficacy difference between the groups (p = 0.16, Figure 5g). The subgroup analysis for severe complications was not performed due to the small number of studies. ### 3.5.3. Subgroup Analyses for Ingredient Difference The results of the subgroup analyses according to ingredient differences are",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:32"
    }
  },
  {
    "page_content": "analyses according to ingredient differences are shown in Figure 6. The subgroup analyses showed no efficacy differences between the groups according to the ingredient difference for total postoperative complications (p = 0.73, Figure 6a), infectious complications (p = 0.70, Figure 6b), severe complications (p = 0.88, Figure 6c), anastomotic leakage (p = 0.88, Figure 6d), postoperative pneumonia (p = 0.88, Figure 6e), mortality (p = 0.81, Figure 6f), and postoperative hospital stay (p = 0.49,",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:33"
    }
  },
  {
    "page_content": "6f), and postoperative hospital stay (p = 0.49, Figure 6g). The subgroup analysis for adverse events was not performed due to the small number of studies. ### 3.5.4. Subgroup Analyses for Total Duration The results of the subgroup analyses according to total duration are shown in Figure 7. The subgroup analyses showed no efficacy differences between the groups according to the total duration for total postoperative complications (p = 0.23, Figure 7a), infectious complications (p = 0.43, Figure",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:34"
    }
  },
  {
    "page_content": "7a), infectious complications (p = 0.43, Figure 7b), anastomotic leakage (p = 0.91, Figure 7c), postoperative pneumonia (p = 0.09, Figure 7d), and mortality (p = 0.31, Figure 7e). Postoperative hospital stay was shorter in the <10 days group than in the ≥10 days group (p < 0.001, Figure 7f). The subgroup analysis for adverse events showed no efficacy difference between the groups (p = 0.13, Figure 7g). The subgroup analysis for severe complications was not performed due to the small number of",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:35"
    }
  },
  {
    "page_content": "was not performed due to the small number of studies. ### 3.5.5. Subgroup Analyses for Malnutrition The results of the subgroup analyses according to malnutrition are shown in Figure 8. The subgroup analyses showed no efficacy differences between the groups according to the malnutrition for infectious complications (p = 0.51, Figure 8a), anastomotic leakage (p = 0.94, Figure 8b), postoperative pneumonia (p = 0.09, Figure 8c), and mortality (p = 0.94, Figure 8d). Postoperative hospital stay was",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:36"
    }
  },
  {
    "page_content": "0.94, Figure 8d). Postoperative hospital stay was shorter in the malnutrition group than in the no-malnutrition group (p < 0.001, Figure 8e). The subgroup analyses for total complications, severe complications, and adverse events were not performed due to the small number of studies. ## 3.6. Funnel Plots The funnel plots are shown in Figure 9. Funnel plots were visualized as symmetrical, indicating minimal publication bias in the reporting of infectious complications (Figure 9a), anastomotic",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:37"
    }
  },
  {
    "page_content": "infectious complications (Figure 9a), anastomotic leakage (Figure 9b), postoperative pneumonia (Figure 9c), mortality (Figure 9d), and postoperative hospital stay (Figure 9e). For total postoperative complications, severe complications, and adverse events, funnel plots were not prepared because there were fewer than 10 references, as per the Cochrane Handbook. # 4. Discussion The results of the present systematic review and meta-analysis of 23 studies and 2249 patients revealed that",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:38"
    }
  },
  {
    "page_content": "of 23 studies and 2249 patients revealed that immunonutrition probably reduces infectious complications in patients with upper GI cancers after surgery. In addition, immunonutrition probably reduces the rates of anastomotic leakage and the postoperative hospital stay. However, immunonutrition is unlikely to reduce the rate of total complications, severe complications, postoperative pneumonia, and postoperative mortality. Compared to standard nutrition, immunonutrition is unlikely to increase",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:39"
    }
  },
  {
    "page_content": "immunonutrition is unlikely to increase nutritional intervention adverse events. In a subgroup analysis, postoperative administration decreased the total number of postoperative complications and shortened the length of hospital stay. The subgroup analyses showed no efficacy differences between the groups according to the ingredient difference. We did not perform sensitivity analysis because of the paucity of studies that included patients with malnutrition. This study shows that compared to",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:40"
    }
  },
  {
    "page_content": "malnutrition. This study shows that compared to standard nutritional therapy, nutritional intervention with immunonutrition can reduce postoperative complications, especially infectious complications, without increasing nutrition-related adverse events. There was no consensus on the impact of immunonutrition on postoperative outcomes in patients with upper GI cancers because different results have been reported; however, this may be due to the different numbers of studies included in the",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:41"
    }
  },
  {
    "page_content": "the different numbers of studies included in the meta-analysis. A summary of the results of previous meta-analyses is presented in Table 3. Mingliang et al. and Zhuo et al. reported that immunonutrition does not reduce infectious complications for esophageal cancer. On the other hand, Tian et al. reported a decrease in infectious complications (odds ratio: 0.48, 95% CI: 0.20–0.98). The difference between them is the number of RCTs included in the meta-analysis; the former may have been",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:42"
    }
  },
  {
    "page_content": "in the meta-analysis; the former may have been underpowered. Also, Song et al. reported a reduction in infectious complications in patients with gastric cancer (OR: 0.56, 95% CI: 0.36–0.86). This study has the strength of summarizing a much larger number of studies compared to previous reports and showing a possible reduction in infectious complications. Subgroup analysis by the timing of immunonutrition administration showed the differences in total postoperative complications and",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:43"
    }
  },
  {
    "page_content": "in total postoperative complications and postoperative hospital stay for postoperative administration. Tian et al. reported that postoperative administration in patients with esophageal cancer is associated with lower rates of infectious complications and postoperative pneumonia. Osland et al. reported that perioperative and postoperative dosing in patients with GI cancer can reduce postoperative complications. Similarly, this present SR showed that postoperative administration may have been",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:44"
    }
  },
  {
    "page_content": "that postoperative administration may have been effective in patients with upper GI cancers. The mechanisms by which immunonutrition improves postoperative outcomes include improved nutritional status for malnutrition and resistance to infection by modulating immune function. High levels of postoperative inflammation from invasive surgery cause immunodeficiency, although immunonutrition has the opposite consequence of excessive inflammation suppression. According to one study, preoperative",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:45"
    }
  },
  {
    "page_content": "suppression. According to one study, preoperative immunonutrition decreased inflammatory cytokines following pancreaticoduodenectomy, which may be responsible for the decrease in postoperative complications. Ates et al. reported that postoperative administration of immunonutrition resulted in lower postoperative CRP. These results suggest that pre- and postoperative administration may reduce inflammation. Additionally, it functions as an immunostimulation against inflammation following surgical",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:46"
    }
  },
  {
    "page_content": "against inflammation following surgical invasion, which decreases immunity to infection and induces immunosuppression. The former should be used preoperatively as modulating and the latter postoperatively as stimulating. In this study, subgroup analysis showed that immunonutrition with arginine was not effective in preventing postoperative complications and reducing hospital stays. This may mean that immune-enhancing nutrients are not effective in patients with upper GI cancer. These may have",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:47"
    }
  },
  {
    "page_content": "in patients with upper GI cancer. These may have different results depending on the degree of surgical invasiveness and the extent of resection. We performed subgroup analysis with a cutoff value of >50% malnutrition, but there was no difference in postoperative complications between patients with and without malnutrition, and only postoperative hospital stay was significantly different. There were no RCTs in which all patients were malnourished. Riso et al. compared postoperative outcomes in",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:48"
    }
  },
  {
    "page_content": "Riso et al. compared postoperative outcomes in patients with malnutrition in head and neck cancer and reported no severe complications in the immunonutrition group. In this subgroup analysis, the reason for the absence of significant differences in postoperative complications was due to the small number of RCTs that included malnutrition. Immunomodulation by administration of immunonutrition may be necessary in patients with malnutrition because of the possibility of immune impairment, but this",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:49"
    }
  },
  {
    "page_content": "of the possibility of immune impairment, but this was not evident in this study. Further studies on patients with malnutrition are required. This study had several limitations. First, there are few RCTs in patients with malnutrition. Further studies are required in patients with malnutrition. Second, the mechanism by which immunonutrition may improve postoperative outcomes in upper GI cancers remains unclear. One hypothesis is that it suppresses postoperative inflammation. However, further",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:50"
    }
  },
  {
    "page_content": "postoperative inflammation. However, further studies are required. Third, the optimal immunonutritional dose remains unknown. Further RCTs with different dosage designs are required. Despite these limitations, the meta-analysis includes large numbers of RCTs, which addresses the problem of previous meta-analyses that were unable to show statistical differences despite clinical differences owing to the small number of RCTs. Our findings have several significant clinical implications. # 5.",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:51"
    }
  },
  {
    "page_content": "several significant clinical implications. # 5. Conclusions Nutritional intervention with perioperative immunonutrition in patients with upper GI cancer significantly reduced infectious complications without increasing nutritional intervention adverse events. The effect of immunonutrition for upper GI cancers in reducing the risk of infectious complications was about 30%. Further studies with different dosage designs are required in patients with malnutrition.",
    "metadata": {
      "source": "../data/plain/PMC10933766.plain.txt",
      "id": "../data/plain/PMC10933766.plain.txt:52"
    }
  },
  {
    "page_content": "Cancer Prevalence across Vertebrates Abstract\nAnalysis of 16,049 animal necropsies from 292 vertebrate species shows that cancer prevalence increases with body mass and somatic mutation rates, but decreases with gestation time. Abstract",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:0"
    }
  },
  {
    "page_content": "Cancer is pervasive across multicellular species, but what explains the differences in cancer prevalence across species? Using 16,049 necropsy records for 292 species spanning three clades of tetrapods (amphibians, sauropsids, and mammals), we found that neoplasia and malignancy prevalence increases with adult mass (contrary to Peto’s paradox) and somatic mutation rate but decreases with gestation time. The relationship between adult mass and malignancy prevalence was only apparent when we",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:1"
    }
  },
  {
    "page_content": "malignancy prevalence was only apparent when we controlled for gestation time. Evolution of cancer susceptibility appears to have undergone sudden shifts followed by stabilizing selection. Outliers for neoplasia prevalence include the common porpoise (<1.3%), the Rodrigues fruit bat (<1.6%), the black-footed penguin (<0.4%), ferrets (63%), and opossums (35%). Discovering why some species have particularly high or low levels of cancer may lead to a better understanding of cancer syndromes and",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:2"
    }
  },
  {
    "page_content": "to a better understanding of cancer syndromes and novel strategies for the management and prevention of cancer.",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:3"
    }
  },
  {
    "page_content": "Significance: Evolution has discovered mechanisms for suppressing cancer in a wide variety of species. By analyzing veterinary necropsy records, we can identify species with exceptionally high or low cancer prevalence. Discovering the mechanisms of cancer susceptibility and resistance may help improve cancer prevention and explain cancer syndromes.",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:4"
    }
  },
  {
    "page_content": "See related commentary by Metzger, p. 14 # Introduction Cancer is a ubiquitous problem for multicellular species (1) and a leading cause of death in humans (2). Every multicellular body is a cooperative cellular system, with cells suppressing replication (3), dividing labor (4), sharing resources (5), regulating cell death (6) and taking care of the extracellular environment (1). However, cooperative systems are susceptible to cheaters, which emerge as cancers in multicellular organisms (7).",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:5"
    }
  },
  {
    "page_content": "emerge as cancers in multicellular organisms (7). Because cancer cells can outcompete normal cells with respect to replication, survival, resource use, and other cellular behaviors, natural selection within the body can favor cancer cells via somatic evolution. Cancer has been a strong selective pressure on multicellular organisms and mechanisms for cancer suppression likely co-evolved along with the evolution of multicellularity (8, 9). Despite this persistent selective pressure of cancer,",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:6"
    }
  },
  {
    "page_content": "this persistent selective pressure of cancer, species vary in their investment in cancer defenses across the tree of life. Sir Richard Peto predicted in 1977 that the risk of cancer should scale with the number of cells in an organism and the length of its lifespan (10, 11). This prediction is based on the fact that tumors evolve from single cells, partially due to the accumulation of somatic mutations over time (10). His observation that cancer risk does not appear to increase with increases",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:7"
    }
  },
  {
    "page_content": "risk does not appear to increase with increases in body mass and longevity across species (10), a phenomenon known as “Peto’s paradox,” launched the field of comparative oncology (12). Early work in comparative oncology found that birds, and to a lesser extent reptiles, develop fewer neoplasms than mammals (13–15). While single case studies have been reported (16), it has been difficult to estimate true neoplasia prevalence in these taxa. In 2015, we published neoplasia prevalence estimates in",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:8"
    }
  },
  {
    "page_content": "we published neoplasia prevalence estimates in 37 mammal species and reported support for Peto’s paradox, that is, bigger, longer lived species do not get more cancer (17). Follow up studies have supported Peto’s paradox and demonstrated the ubiquity of cancer across mammals (18, 19). A recent study of 131 species of mammals with at least five necropsies per species, found no relationship between body mass and neoplasia prevalence, though they did observe an increase in both neoplasia and",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:9"
    }
  },
  {
    "page_content": "did observe an increase in both neoplasia and malignancy prevalence in 25 species of amphibians and 71 species of squamates (bioRxiv 2022.07.12.499088). Our study of 110,148 animals across 191 species of mammals found no relationship between body mass and death due to cancer (18). Other studies have applied the same logic of Peto’s paradox to the study of cancer rates in different human organs. Organs with more stem cells and more cell divisions should get more cancer than organs with fewer",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:10"
    }
  },
  {
    "page_content": "should get more cancer than organs with fewer cell divisions (20–23). The extensive variation in cancer risk across vertebrates provides a unique opportunity to identify species with exceptional cancer resistance that can lead to new discoveries of cancer resistance mechanisms outside the traditional human and murine studies. Additionally, the discovery of cancer vulnerable species could lead to new insights into cancer syndromes as well as provide spontaneous “natural” animal models of disease",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:11"
    }
  },
  {
    "page_content": "spontaneous “natural” animal models of disease that can help us gain a better understanding of various types of cancer and their treatments. Here we present a large, curated database of tetrapod veterinary necropsy records, including 16,049 individual animals across 292 species of animals, encompassing reptiles, birds, amphibians, and mammals. Because necropsies typically are recorded as having “neoplasia,” which includes both benign and malignant tumors, we developed a terminology dictionary",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:12"
    }
  },
  {
    "page_content": "tumors, we developed a terminology dictionary to distinguish benign from malignant neoplasms in the necropsy reports. We calculate and analyze both neoplasia prevalence as well as malignancy (cancer) prevalence. Only a subset of benign neoplasms evolve into cancers over a lifetime, so neoplasia prevalence is always greater than or equal to malignancy prevalence. We also tested for age bias in the animals that died with neoplasms or cancers. To test for general mechanisms of cancer suppression,",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:13"
    }
  },
  {
    "page_content": "for general mechanisms of cancer suppression, we tested for an association with DNA damage response or somatic mutation rate and neoplasia. We think of the cancer prevalence in a species as the interaction of the species’ susceptibility to cancer with its environmental exposures. The cancer prevalence of a species is an aspect of its phenotype, with clear fitness relevance. We investigated how that phenotype evolved across the tree of life. Traditional models of phenotype evolution include a",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:14"
    }
  },
  {
    "page_content": "models of phenotype evolution include a model of neutral evolution [Brownian motion (24, 25)], early diversification followed by neutral evolution [Early Burst (26)], and periods of rapid change on particular branches followed by stabilizing selection around new “optimal” phenotypes [The Ornstein–Uhlenbeck model (27–29)]. We tested these three models to determine that best fit the neoplasm prevalence and malignancy prevalence phenotypes across the tree of life. # Results ## Variation in Cancer",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:15"
    }
  },
  {
    "page_content": "tree of life. # Results ## Variation in Cancer Prevalence across Clades We found evidence of neoplastic disease in necropsies across all analyzed taxonomic clades (Fig. 1A–D). For all vertebrates, the median prevalence of neoplasia at death was 4.89% (range = 0%–62.86%) and median malignancy prevalence was 3.20% (range = 0%–40.95%). Mammals had the most neoplasia at death with a median of 12% (range = 0%–63%) and median malignancy prevalence of 7% (range = 0%–41%). Sauropsids, which includes",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:16"
    }
  },
  {
    "page_content": "7% (range = 0%–41%). Sauropsids, which includes Aves and Squamata, followed with a median neoplasia prevalence of 4% (range = 0%–39%) and median malignancy prevalence of 1.6% (range = 0%–35%). Lastly, amphibians had a median neoplasia prevalence of 1.2% (range = 0%–46%) and median malignancy prevalence of 0% (range = 0%–33%; Fig. 2A and B). The ranking of prevalence by clade is consistent with previous studies (13, 15). In Fig. 2, we have shown Aves and Squamata separately, but because reptiles",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:17"
    }
  },
  {
    "page_content": "and Squamata separately, but because reptiles are not a monophyletic clade, we have grouped reptiles with birds in the Sauropsida clade for the purposes of further analyses. Despite a lower mean prevalence for both benign and malignant tumors, sauropsids and amphibians show a wide range of neoplastic disease burden across species. There is a small but highly statistically significant correlation between the prevalence of benign neoplasms and the prevalence of malignant neoplasms across species",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:18"
    }
  },
  {
    "page_content": "prevalence of malignant neoplasms across species (r = 0.34; P < 0.0001; Supplementary Fig. S1). Supplementary Tables S1 and S2 list the species with the highest and lowest neoplasia and malignancy prevalences, as well as the proportion of neoplasms that are malignant. Among the vertebrates with the highest prevalence of neoplasia, 63% of ferrets (Mustela putorius) died with a neoplasm (45% of which was lymphoma), 56% of opossums (Didelphis marsupialis) died with a neoplasm (46% of which was in",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:19"
    }
  },
  {
    "page_content": "died with a neoplasm (46% of which was in the lung), and 45% of four-toed hedgehogs (Atelerix albiventris) died with a neoplasm (42% of which was in the alimentary tract; Supplementary Table S3). ## Life History Analyses of Neoplasia and Malignancy Prevalence Evolutionary life history theory provides a framework for understanding the tradeoffs governing species’ survival and reproduction (30, 31). Life history theory can be used to explain how species level traits shape organismal cancer risk",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:20"
    }
  },
  {
    "page_content": "species level traits shape organismal cancer risk based on trade-offs between investment in somatic maintenance (e.g., cancer suppression) and reproduction or growth. Several smaller studies have shown that specific life history traits, such as litter size, can help explain some of the variation in neoplasia prevalence in animals managed under human care (19). In this study, we tested for the relationship between 14 life history traits and two dependent variables: (i) neoplasia prevalence and",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:21"
    }
  },
  {
    "page_content": "dependent variables: (i) neoplasia prevalence and (ii) malignancy prevalence (Supplementary Figs. S2–S39). We implemented both univariate and multivariate models. To control for phylogenetic relatedness, we used a phylogenetic regression model (pglsSEyPagel, available on GitHub). Because each species had a different number of necropsies, ranging from 20 to 477, we weighted species data points by the number of necropsies in our dataset. In our univariate analyses, we found a significant positive",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:22"
    }
  },
  {
    "page_content": "analyses, we found a significant positive relationship between body mass and neoplasia prevalence [2.1% neoplasia per Log10(g), P = 0.007] across all vertebrates but no significant relationship between body mass and malignancy prevalence (0.65% malignancy per Log10g, P = 0.287; Fig. 3A and B). These results are in contrast to three of the four previous studies (bioRxiv 2022.07.12.499088; refs. 17–19) published on body mass and cancer prevalence in animals. We also found a significant positive",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:23"
    }
  },
  {
    "page_content": "in animals. We also found a significant positive relationship between neoplasia prevalence and maximum longevity (0.01% neoplasia per Log10 months, P = 0.02; 0.005% malignancy per Log10 months, P = 0.276; Fig. 3C and D). Lastly, we found animals with longer gestation times also get fewer malignancies (N = 151 species, −5.3% neoplasia per Log10 months, P = 0.1, −5.65% malignancies per Log10 months, P = 0.02; Fig. 3E and F). Given that the life history traits, such as adult body mass, maximum",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:24"
    }
  },
  {
    "page_content": "history traits, such as adult body mass, maximum longevity, and gestation time are all positively correlated (Supplementary Fig. S40), we implemented multivariate models that control for multiple life history factors. These multivariate models contained all significant predictors of neoplasia or malignancy prevalence (adult mass, maximum longevity, and gestation time). We found that both adult body mass (2.9% neoplasia per Log10g, P = 0.01) and gestation time (−18.6% neoplasia per Log10 month P",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:25"
    }
  },
  {
    "page_content": "time (−18.6% neoplasia per Log10 month P = 0.0001) provide independent information for estimating neoplasia prevalence but not longevity (P = 0.12; Supplementary Fig. S41). Because gestation time and body mass are correlated (r = 0.71; Supplementary Fig. S40) but have the opposite relationship to neoplasia and malignancy prevalence, we tested a two-variable model and found that when controlling for adult mass [3.8% neoplasia per Log10(g), P = 0.0006], gestation time had a significant negative",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:26"
    }
  },
  {
    "page_content": "gestation time had a significant negative relationship with neoplasia prevalence [−15.8% neoplasia per Log10 months, P = 0.0002; R2 = 0.20] and vice versa. When controlling for gestation time, adult body mass had a significant positive relationship with malignancy prevalence [1.9% malignancies per Log10(g), P = 0.02], and when controlling for adult mass, gestation time also predicts malignancy prevalence (−12% malignancies per Log10 months of gestation, P = 0.0002).Body mass and gestation time",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:27"
    }
  },
  {
    "page_content": "P = 0.0002).Body mass and gestation time were still statistically significant predictors (adjusted P < 0.05) of neoplasia and malignancy prevalence after a 5% false discovery rate correction for multiple testing (Supplementary Fig. S41). We validated our results by implementing phylogenetic binomial regressions (bioRxiv 2022.07.12.499088) on records that include the age of the animal (N = 3,022 mammals). All the above statistically significant relationships remain significant at P < 0.05 level",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:28"
    }
  },
  {
    "page_content": "remain significant at P < 0.05 level using binomial regressions (Supplementary Table S4). In addition, binomial regressions reveal a significant positive relationship in mammals between body mass and neoplasia [OR = 9.5% neoplasia per Log10(g), P = 0.012 but P = 0.06 with PGLS], as well as malignancy prevalence [OR = 1.5% malignancy per Log10(g), P = 0.015 but P = 0.458 with PGLS; Supplementary Figs. S16 and S17]. Within mammals the relationship between longevity and neoplasia prevalence (OR =",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:29"
    }
  },
  {
    "page_content": "between longevity and neoplasia prevalence (OR = −0.50 neoplasia per Log10 month lifespan, P = 0.14) or malignancy prevalence (OR = 0.21 malignancy per Log10 month lifespan, P = 0.57) were not statistically significant. Within mammals, analyses of adult body mass and gestation time together showed the same relationships as all vertebrates [OR = −18% neoplasia and −15% malignancy per Log10 months of gestation, P = 0.036 and P < 10−10; 3.4% neoplasia and 2.6% malignancy per Log10(g) of adult body",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:30"
    }
  },
  {
    "page_content": "and 2.6% malignancy per Log10(g) of adult body mass, P = 0.017 and 0.0066, respectively, with PGLS; Supplementary Figs. S38 and S39]. The positive relationship between body mass and neoplasia/malignancy prevalence were even stronger with binomial regressions [OR = 14% neoplasia and 14% malignancy per Log10(g) adult body mass, P = 0.002 and P = 0.0035]. Similarly, the binomial regression revealed gestation time had a significant negative relationship with neoplasia/malignancy prevalence (OR =",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:31"
    }
  },
  {
    "page_content": "with neoplasia/malignancy prevalence (OR = −44% neoplasia and −48% malignancy per Log10 months of gestation, P = 0.0009 and 0.001). Overall, we found no evidence of a relationship between litter or clutch size and neoplasia prevalence (Supplementary Figs. S2 and S3). However, when we restrict the analysis to mammals, litter size is positively associated with both neoplasia and malignancy prevalence (neoplasia: P = 0.02, R2 = 0.07; malignancy: P = 0.03, R2 = 0.11; Supplementary Figs. S19 and",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:32"
    }
  },
  {
    "page_content": "P = 0.03, R2 = 0.11; Supplementary Figs. S19 and S20), supporting our earlier analysis of 37 mammals from the San Diego Zoo (19). In birds, larger clutch size is also associated with higher neoplasia and malignancy prevalence (32). We also found that time to sexual maturity, growth rate, and basal metabolic rates (which were only available for mammals) were not significant predictors of neoplasia or malignancy prevalence (Supplementary Figs. S7–S10, S13, S14, S23, and S24). In addition to",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:33"
    }
  },
  {
    "page_content": "S7–S10, S13, S14, S23, and S24). In addition to calculating the prevalence of neoplasms and malignancies, we also calculated the proportion of neoplasms that were malignant, which for some neoplasms is a measure of the likelihood that a benign neoplasm transforms into a malignant one. We found no statistically significant relationships between any of those life history factors and the proportion of neoplasms that were malignant (Supplementary Figs. S42–S53). ## DNA Damage Response and Somatic",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:34"
    }
  },
  {
    "page_content": "S42–S53). ## DNA Damage Response and Somatic Mutation Rates DNA damage response is an important anticancer mechanism. Accurate repair of damaged DNA or clearance of damaged cells through apoptosis ensures that mutations capable of driving tumorigenesis do not persist or accumulate. For example, we previously reported that increased apoptosis in response to DNA damage in elephant cells was associated with low cancer mortality (17). To determine if DNA damage response is a general mechanism of",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:35"
    }
  },
  {
    "page_content": "if DNA damage response is a general mechanism of cancer defense across species, we measured the ability of primary fibroblasts from 15 species to respond to DNA damage (Fig. 4A; Supplementary Figs. S54–S68). DNA damage response was assessed by measuring cell cycle arrest, which halts cell division until damage is repaired, and apoptosis, which kills cells that cannot be repaired. (17, 33). We hypothesized that animals with less neoplasia and malignancy would respond more robustly to DNA damage.",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:36"
    }
  },
  {
    "page_content": "would respond more robustly to DNA damage. Cell cycle arrest in response to increasing doses of ionizing radiation and apoptosis in response to increasing doses of a chemotherapeutic drug (doxorubicin) was measured over time. We observed variability in DNA damage response across the species that we tested and this variability was not associated with neoplasia or malignancy (Fig. 4A; Supplementary Figs S54–S68), although cell cycle arrest in response to 10 Gy radiation trended toward an",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:37"
    }
  },
  {
    "page_content": "in response to 10 Gy radiation trended toward an association with neoplasia prevalence (Fig. 4A). Perhaps the most important role of DNA damage response is the suppression of somatic mutation accumulation, because mutations drive tumor formation and cancer progression (22, 34, 35). Therefore, we hypothesized that lower somatic mutation rates across species would correlate with lower cancer prevalence. We obtained previously reported somatic mutation rates from nine species in our dataset and",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:38"
    }
  },
  {
    "page_content": "rates from nine species in our dataset and tested for a correlation with neoplasia prevalence (36). Mutation rates had been estimated based on dividing the number of mutations detected in DNA sequencing of single colonic crypts by the age of the animal (36). We discovered a positive association between somatic mutation rates and neoplasia prevalence and that species with fewer somatic mutations also developed less neoplasia (Fig. 4B; PGLS P = 0.0059). We also observed a similar trend for",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:39"
    }
  },
  {
    "page_content": "P = 0.0059). We also observed a similar trend for somatic mutation rates and malignancy prevalence but it was not statistically significant (Supplementary Fig. S69, PGLS P = 0.087). ## Age at Death with Cancer in Animals Age is the single biggest risk factor for the development of cancer in humans (37). Most mechanisms of somatic maintenance, including immune cell surveillance, DNA damage response, and telomere shortening, decrease in efficacy as we age (38–42). To test if observed neoplasms in",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:40"
    }
  },
  {
    "page_content": "we age (38–42). To test if observed neoplasms in animals under human care may be due to the animals living beyond their natural lifespans, we plotted the age of the animals with neoplasia at death, compared to the animals that died without neoplasms, scaled by their average lifespan (Fig. 5A–F). The vast majority of animal deaths with neoplasia diagnoses occur before the average lifespan in most animals. Only amphibians seem to be developing more neoplasms as they live past their normal",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:41"
    }
  },
  {
    "page_content": "more neoplasms as they live past their normal lifespan under human care (Fig. 5C). The distribution of tumor diagnoses across lifespan in these three clades also demonstrates that cancer is not limited to a disease solely of extended lifespan, and in sauropsids, neoplasia is not particularly a disease of old age (Fig. 5B). ## Evolution of Cancer Suppression and Susceptibility Comparative phylogenetics provides a wealth of computational tools to model species’ trait evolution across a phylogeny",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:42"
    }
  },
  {
    "page_content": "model species’ trait evolution across a phylogeny (24). To explore how cancer susceptibility evolved across the tree of life (Fig. 6A–C), we fit three of the most common phenotype evolution models (Ornstein–Uhlenbeck, Brownian Motion, and Early Burst) to neoplasia prevalence as a continuous trait. We found that a model of stabilizing selection on neoplasia prevalence (Ornstein–Uhlenbeck) fits the distribution of neoplasia prevalence the best (Supplementary Table S5). Malignancy prevalence",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:43"
    }
  },
  {
    "page_content": "(Supplementary Table S5). Malignancy prevalence evolution is also best explained by the Ornstein–Uhlenbeck model of sudden shifts followed by stasis in the phenotype. # Discussion We estimated cancer prevalence across a wide range of tetrapod species that includes mammals, amphibians, reptiles, and birds. Importantly and contrary to previous studies, our analyses highlight limitations to Peto’s paradox, by showing that large animals do tend to get somewhat more neoplasms and malignancies when",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:44"
    }
  },
  {
    "page_content": "get somewhat more neoplasms and malignancies when compared with smaller animals. The observation that larger animals tend to get more cancer was only apparent when we used a binomial regression or controlled for the fact that animals with longer gestation times tend to get both fewer neoplasms and fewer cancers. Previous studies, including ours, likely missed this relationship because it has a small effect; most previous studies involved fewer species and they did not control for gestation time",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:45"
    }
  },
  {
    "page_content": "and they did not control for gestation time (bioRxiv 2022.07.12.499088; refs. 18, 19). Large animals only get slightly more cancer than small animals. Whether or not they get as much cancer as one would expect from their body size and longevity depends on the model one uses to predict cancer prevalence as a function of body mass (43–45). A previous study on 191 mammal species found that longer gestation lengths protect against cancer mortality (46). Our findings also show that longer gestation",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:46"
    }
  },
  {
    "page_content": "Our findings also show that longer gestation periods predict neoplasia and cancer prevalence across animals, with species that have longer gestation periods exhibiting lower rates of malignancy. There are multiple hypotheses to explain the link between gestation length and cancer risk. First, from a life history perspective, animals with longer gestation lengths may be “growing slow” to invest more resources toward somatic maintenance during fetal development, including cell cycle regulation",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:47"
    }
  },
  {
    "page_content": "development, including cell cycle regulation and differentiation, thereby reducing their vulnerability to cancer. Notably, some of the species reported to get very little cancer, such as Cetacea (e.g., dolphins and whales) and Chiroptera (e.g., bats), are also exceptions to the typical relationship between gestation length and body size (bioRxiv 2023.10.22.563491). This uncoupling of life history traits could help explain the observed link between cancer risk and gestation length in our study.",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:48"
    }
  },
  {
    "page_content": "cancer risk and gestation length in our study. Additionally, this “slow growth” during fetal development may also prevent “jackpot” somatic mutations in gestation, which expand to large clones through the process of development and can significantly contribute to the risk of progressing to cancer later in life (47, 48). Another consideration is that species with longer gestation lengths may have reduced genomic conflict. Additionally, mammals with long gestations typically have singleton births",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:49"
    }
  },
  {
    "page_content": "long gestations typically have singleton births (bioRxiv 2023.10.22.563491). Long gestation periods with one offspring allow for more effective maternal–fetal communication and regulation, reducing conflicts between maternal and paternal alleles that can lead to cellular dysregulation and cancer (49). Lastly, it may be the case that hormonal exposures during pregnancy help protect against cancer in the mothers, as we see for some forms of cancer in humans (50, 51). This last hypothesis could be",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:50"
    }
  },
  {
    "page_content": "in humans (50, 51). This last hypothesis could be tested by examining the relationship between gestation time and cancer in females versus males, across species. Cancer prevalence across species varies greatly. Here we have used a large collection of species, and expanded our analyses beyond mammals (17–19), to test for patterns in cancer prevalence. We only include species with at least 20 necropsies (median 35), compared with 10 individuals per species in our original study (17), and weighted",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:51"
    }
  },
  {
    "page_content": "species in our original study (17), and weighted species more in our regression analyses if their cancer prevalence estimate is more accurate because it is based on more necropsies. In a similar study by Bulls and colleagues, they also found a positive relationship between body size with both neoplasia and malignancy prevalence in amphibians and squamates when restricting their data to species with at least five necropsies (bioRxiv 2022.07.12.499088). Further, a reanalysis of cancer mortality",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:52"
    }
  },
  {
    "page_content": "Further, a reanalysis of cancer mortality data from Vincze and colleagues (18) across 189 species found that larger animals were more likely to die due to cancer than smaller mammals [3% cancer mortality per Log10(g), P < 0.001]. Using a binomial regression, both our data and from Bulls and colleagues found a negative relationship between neoplasia and longevity, but this relationship is nonsignificant in our dataset (bioRxiv 2022.07.12.499088). The fact that neoplasia prevalence seems to",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:53"
    }
  },
  {
    "page_content": "The fact that neoplasia prevalence seems to evolve by sudden shifts followed by stabilizing selection (the Ornstein–Uhlenbeck model of phenotypic evolution) is consistent with life history theory predictions that investment in somatic maintenance should be under selection in specific ecological conditions (30), rather than drifting neutrally consistent with random Brownian motion. We hypothesize from these results that changes in cancer suppression may be due to large–if rare–changes in genomic",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:54"
    }
  },
  {
    "page_content": "may be due to large–if rare–changes in genomic architecture and/or their ecology that changes the tradeoffs with cancer suppression. These apparent changes in the investment in –cancer suppression may help pinpoint the mechanisms of cancer suppression adaptations in those lineages. Some of the variation in cancer prevalence may be noise, due to estimating cancer prevalence from tens of individuals. However, much of that variation comes from the vast diversity of species across amphibians,",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:55"
    }
  },
  {
    "page_content": "the vast diversity of species across amphibians, reptiles, birds, and mammals. We have explained only a small portion (∼20%) of the variation in species vulnerability and suppression of cancer. There is clearly more to be discovered. Peto’s paradox is based on the expectation that large, long-lived animals should get more cancer because they have more cells that divide for a longer amount of time, increasing the likelihood that cancer will arise (10, 12). Comparative oncology studies have used",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:56"
    }
  },
  {
    "page_content": "(10, 12). Comparative oncology studies have used body mass as a proxy for the number of cells in an animal (bioRxiv 2022.07.12.499088; refs. 18, 19, 44). This is reasonable because cell sizes vary little across animals, with the exception of adipocytes (52, 53). Future studies might benefit from more rigorous measures and modeling of cell numbers (as well as turnover rates and stem cell numbers) across species. Although adult body mass is positively correlated with both neoplasia and malignancy",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:57"
    }
  },
  {
    "page_content": "correlated with both neoplasia and malignancy prevalence, partially resolving Peto’s paradox, the effect size is larger for neoplasia (2.1% neoplasia per Log10g) than for malignancies (1.9% malignancies per Log10g), when controlling for gestation time. Without controlling for gestation time, the association between adult body mass and malignancy prevalence is not strong enough to be statistically significant. To be precise, Peto’s paradox only relates to cancers, not benign neoplasms, so the",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:58"
    }
  },
  {
    "page_content": "relates to cancers, not benign neoplasms, so the stronger relationship between body mass and neoplasia prevalence does not resolve the paradox. There may be several explanations for the stronger association of body mass with neoplasia prevalence than malignancy prevalence. The simplest is that malignancies are less common than neoplasms, which include both benign and malignant neoplasms. This reduces the statistical power and the expected size of the effects. However, the blunted relationship",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:59"
    }
  },
  {
    "page_content": "of the effects. However, the blunted relationship between body mass and malignancy prevalence may also be due to natural selection acting to evolve mechanisms to suppress malignant transformation. Cancer suppression mechanisms are likely under stronger selection among these larger and longer lived organisms because it was critical to suppress cancer for longer in order for these organisms to successfully reproduce. Thus, we might expect a relatively constant cancer rate across species with more",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:60"
    }
  },
  {
    "page_content": "constant cancer rate across species with more cancer suppression mechanisms in large, long-lived organisms (7, 17, 54–58) and fewer in small, short-lived organisms. Further, there are at least four transitions in neoplastic progression that natural selection might alter to increase the survivability of cancer in a species: (i) initiation of a neoplasm, (ii) transformation of that neoplasm into malignancy (i.e., invasion through the basement membrane), (iii) metastasis, and (iv) death caused by",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:61"
    }
  },
  {
    "page_content": "(iii) metastasis, and (iv) death caused by the cancer. Our data relate to the first two transitions. Specifically, we quantify the prevalence of neoplasms in a species, the prevalence of malignant neoplasms, and the proportion of neoplasms detected that are malignant. However, the selective pressure of cancer is ultimately due to its effects on mortality and so quantifying the prevalence of cancer as a cause of death is also important for evolutionary studies of comparative oncology (18). The",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:62"
    }
  },
  {
    "page_content": "studies of comparative oncology (18). The discrepancy between our earlier analysis of a different data set of 191 mammal species, which found no relationship between body mass and cancer mortality, and our current results may be attributed to at least three differences: (i) here we analyze cancer prevalence, not cancer mortality, (ii) our current results are based on all vertebrates, not just mammals, and (iii) in our previous analyses, we separately analyzed the chance that a species had",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:63"
    }
  },
  {
    "page_content": "separately analyzed the chance that a species had non-zero cancer mortality and then tested for a relationship between log body mass and cancer mortality in species with non-zero cancer mortality, so that the species with very low cancer mortality (zero in that sample) were excluded from the second analysis. To test for general mechanisms of cancer defense across species, we included cross-species functional assays highlighted in Fig. 4A. Our results demonstrate variation in the fibroblast",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:64"
    }
  },
  {
    "page_content": "results demonstrate variation in the fibroblast response to radiation and chemotherapy induced DNA damage. Here we provide the first test of association between DNA damage response and cancer prevalence across species. While response to DNA damage was not a significant predictor of neoplasia or malignancy prevalence after 4 or 10 grays radiation, the trend follows our hypothesis that sensitivity to DNA damage may be one mechanism of cancer suppression (17). As we continue to accumulate DNA",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:65"
    }
  },
  {
    "page_content": "(17). As we continue to accumulate DNA damage response data across more species and more individuals from each species, future studies may reveal a clear relationship. On the other hand, the variation in DNA damage response may suggest that different species evolved unique mechanisms of cancer suppression and, in some cases, they do not require enhanced DNA damage response. For example, some species may rely more on enhanced mechanisms of immune surveillance, thereby eliminating a relationship",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:66"
    }
  },
  {
    "page_content": "surveillance, thereby eliminating a relationship between DNA damage response measurements and neoplasia or malignancy prevalence. However, related to DNA damage response, we did find a connection between somatic mutation rates (36) and neoplasia prevalence (Fig. 4B). This result is consistent with the known importance of somatic mutations in carcinogenesis (21–23, 35, 59–61). Even with only nine species in our analysis, a strong relationship between somatic mutation rate and neoplasia",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:67"
    }
  },
  {
    "page_content": "between somatic mutation rate and neoplasia prevalence was apparent. This relationship should be validated with the addition of both more somatic mutation rate data and more cancer prevalence data. Furthermore, future research should determine what mechanisms evolved in some species to suppress the accumulation of somatic mutations. Potential mechanisms include prevention of DNA damage, accurate repair of DNA damage, death of damaged cells, or use of high fidelity DNA polymerases (17, 62–64).",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:68"
    }
  },
  {
    "page_content": "use of high fidelity DNA polymerases (17, 62–64). ## Insights from Comparative Oncology for Human Cancers Species with a high prevalence of particular cancers may help to generate targeted studies to elucidate the biological basis of those cancers, help draw informative parallels to particular cancer syndromes in humans, and serve as more realistic models for studying those cancers (65). For instance, 46% of the malignant tumors diagnosed in the opossum (Didelphis marsupialis) were lung",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:69"
    }
  },
  {
    "page_content": "in the opossum (Didelphis marsupialis) were lung adenocarcinomas (Supplemental Table S7), which is a leading cause of human cancer mortality in the United States (66). Forty-five percent of the cancers in four-toed hedgehogs (Atelerix albiventris) were gastrointestinal cancers, mostly oral squamous cell carcinomas (67). They may hold insights for oral cancer. Forty-two percent of cancers in ferrets (Mustela putorius) were lymphomas, which may make them a good animal model for that disease.",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:70"
    }
  },
  {
    "page_content": "make them a good animal model for that disease. These spontaneous cancers may be more similar to human cancers compared to those that develop in genetically engineered mouse models, though that remains to be tested. There is an exciting opportunity to discover cancer suppression mechanisms in species with few to no observed neoplasms and in species that seem to prevent benign neoplasms from progressing to malignancy (Fig. 1). For example, the paucity of neoplasms in dolphins and porpoises may",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:71"
    }
  },
  {
    "page_content": "of neoplasms in dolphins and porpoises may result from having large, long-lived cetacean ancestors that were under strong selection to suppress cancer (54). Our earlier analysis of cancer gene evolution in cetaceans found evidence of positive selection in a large number of tumor suppressor genes and proto-oncogenes (54). We previously found that animals that live longer than would be expected for their body size, like bats, tend to have more copies of tumor suppressor genes (68). In support of",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:72"
    }
  },
  {
    "page_content": "of tumor suppressor genes (68). In support of these observations, we found nine bats, with an average lifespan of 16 years, have low neoplasia prevalence. We had hoped to discover species that are able to prevent malignant transformation by finding species that get a fair number of benign neoplasms but few to no malignant neoplasms. The common paradigm in understanding the evolution of cancer suppression emphasizes the importance of protecting against tumor initiation. However, mechanisms that",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:73"
    }
  },
  {
    "page_content": "tumor initiation. However, mechanisms that suppress malignant transformation could be similarly important in maintaining an organism’s fitness. Unfortunately, only a few species in our data set fit that description. The species with the lowest proportion of malignant to benign neoplasms was the common squirrel monkey (Saimiri sciureus), with only 12% of their tumors being malignant. ## Challenges for Comparative Oncology There are a number of potential sources of bias in comparative oncology",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:74"
    }
  },
  {
    "page_content": "potential sources of bias in comparative oncology data. Similar to humans, there are likely both intrinsic genetic predispositions and extrinsic environmental exposures that play a role in cancer initiation and development in animals in our study. The diverse range of species in our data poses challenges in generalizing explanations for cancer trends. Understanding the etiology for the cancer-prone species is a major next step and can help reduce some of these biases. Some species could live",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:75"
    }
  },
  {
    "page_content": "some of these biases. Some species could live longer in zoological institutions, thereby unmasking a vulnerability to cancer at an age that they would be unlikely to attain in the wild. For example, an extended lifespan in managed care may be an explanation for the high prevalence in some species, especially for short-lived species that tend to benefit more from living in zoos (69). For two species that had some of the highest reported neoplasms in our study, Virginia opossums and domestic",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:76"
    }
  },
  {
    "page_content": "in our study, Virginia opossums and domestic hedgehogs, the etiology of their cancers is unknown (70, 71). However, if extended lifespan were the only factor, we would not expect to see such a high prevalence of the same diagnoses (e.g., squamous cell carcinoma of the oral cavity in hedgehogs and pulmonary adenocarcinoma in opossums), suggesting there could be other components such as a genetic predisposition, viruses, or submission bias. Further, we would expect the effects of extended",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:77"
    }
  },
  {
    "page_content": "Further, we would expect the effects of extended lifespan to only impact a small subset of animals with high predation in the wild. Supporting our conclusions, Fig. 5 shows that the neoplasms were diagnosed prior to average lifespan in most cases, suggesting that extended lifespan due to managed care is not a large factor in these data. In fact, one unexpected finding was that neoplasms appear in birds and reptiles at relatively young ages, although some birds such as chickens are known to be",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:78"
    }
  },
  {
    "page_content": "some birds such as chickens are known to be prone to virally induced cancers when they are young (72). In our data, sauropsids and amphibians, but not mammals, sometimes substantially out-live their estimated lifespans (Fig. 5A–F). These results may be due to differences in how lifespans have been estimated for mammals versus non-mammals. We hypothesized the highest cancer rates in our dataset might be due to a particular viral etiology or environmental mismatch, especially if it is a single",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:79"
    }
  },
  {
    "page_content": "mismatch, especially if it is a single specific cancer type. Our data comes from species living in artificial conditions of managed populations, sometimes called an evolutionary mismatch (73). These animals were generally protected from predators, provided with veterinary care, had different diets and exercise from their wild counterparts, many lived in an urban environment, and interacted with different species and microbes than a free-ranging animal. Novel conditions could contribute to",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:80"
    }
  },
  {
    "page_content": "animal. Novel conditions could contribute to cancer risk for some species that would normally not be exposed to such conditions in the wild. However, when we excluded species with the highest neoplasia or malignancy prevalences, the statistical significance of our results did not change (Supplementary Fig. S70). It is striking to us that four of the species with the lowest prevalence of neoplasms in our data set, the gray squirrel, the common dormouse, the striped grass mouse, and the common",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:81"
    }
  },
  {
    "page_content": "dormouse, the striped grass mouse, and the common field vole are all from wild, urban populations. These necropsies come from the London Zoo that has a policy of performing a necropsy on any animal they recover that dies on its grounds, not just the animals under its care. This is a hint that cancer may well be less common in the wild, although this observation may be dependent on the species and their wildlife habitat (74). Infections or exposures to viruses can explain the high cancer",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:82"
    }
  },
  {
    "page_content": "exposures to viruses can explain the high cancer prevalence among certain species. For example, lymphoma in koalas has been linked to viral infections (75). In our study, lymphomas were common in ferrets, however an infectious etiology was not documented. There is some speculation that retroviruses are linked to lymphoma in ferrets (76). However, infections are often identified or suspected by veterinarians during physical examinations and postmortem analyses. Histopathology would identify",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:83"
    }
  },
  {
    "page_content": "analyses. Histopathology would identify lesions that are suggestive of viral origin and infections would be confirmed through PCR analyses, so it is unlikely that infections alone are driving these high rates of cancer in ferrets. We cannot completely dismiss the possibility of a genetic predisposition contributing to the high prevalence of cancer in these cases. Future research should focus on species with both a high cancer incidence and a significant proportion of cases stemming from a",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:84"
    }
  },
  {
    "page_content": "a significant proportion of cases stemming from a single diagnosis to investigate potential genetic predispositions. To reduce potential sampling bias, we restricted our data to Association of Zoos and Aquariums (AZA)–accredited institutions, which are encouraged to necropsy all animals that pass away under their care. However, if the “gross” cause of death was obvious for an animal, an institution may not have submitted the animal’s samples for histopathology and would not be included in our",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:85"
    }
  },
  {
    "page_content": "histopathology and would not be included in our data collection. Similarly, if a particular type of neoplasia is difficult to detect in a necropsy (including some leukemias and intracerebral tumors) or was only present at a microscopic level, it may have been undercounted. Ninety-four percent of our necropsies were evaluated by a single pathology laboratory, limiting the potential for bias in diagnosis due to using different laboratories. If cancers regularly regress prior to death, we would",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:86"
    }
  },
  {
    "page_content": "regularly regress prior to death, we would underestimate cancer prevalence in those species. However, cancer regression without treatment is exceedingly rare in veterinary experience and has only been consistently reported in a few species: melanoma in pigs (77) and benign histiocytoma in dogs (78, 79). The functional assays also had some limitations. Currently, the most available cell type from animals is fibroblasts, and as more cell lines become available in the future, it will be important",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:87"
    }
  },
  {
    "page_content": "available in the future, it will be important to test DNA damage response in other cell types. Additionally, with more sample availability in the future, important biological factors can be controlled for, like age and sex. The data analyzed here represent the first attempts to determine if mechanisms of cancer suppression are shared across species, and our data suggests that suppression of somatic mutations may be a common defense mechanism. ## The Future of Comparative Oncology In the future,",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:88"
    }
  },
  {
    "page_content": "The Future of Comparative Oncology In the future, it will be important to collect additional data to validate our discoveries of species with particularly low and high cancer prevalence, such as those highlighted in Fig. 1. Several life history traits, such as basal metabolic rate (BMR), may explain cancer risk but with BMR measured in only a few species, we lacked statistical power to detect a relationship with neoplasia or malignancy prevalence. Here we have dramatically expanded the amount",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:89"
    }
  },
  {
    "page_content": "Here we have dramatically expanded the amount of data on cancer prevalence in non-human animals, but the accumulation of data must continue if we are to match the robustness seen in human cancer epidemiology. In particular, much could be learned from analyzing the age-incidence curves of cancer (18, 80) but that would require significantly more individuals for each species. There is a large gap in comparative oncology data on wild animals. Gathering data from free-ranging populations is",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:90"
    }
  },
  {
    "page_content": "Gathering data from free-ranging populations is challenging, as it is difficult to detect cancer due to the animals decomposing or being eaten before they can be necropsied. Additionally, accurate age estimates are much more difficult to obtain in wild populations compared to those managed by humans. However, wild animal populations would greatly enhance the field of comparative oncology by validating species that have low cancer prevalence and testing for evolutionary mismatches for animals in",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:91"
    }
  },
  {
    "page_content": "for evolutionary mismatches for animals in captivity. ## Conclusion Cancer is a problem of multicellularity (1). While we found a relationship between both body mass and gestation time with cancer prevalence, we are just beginning to discover patterns of cancer susceptibility and cancer defenses across species. It is likely species evolved a variety of mechanisms to suppress cancer. The discovery of particular species with extremely low neoplasia prevalence provides opportunities to elucidate",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:92"
    }
  },
  {
    "page_content": "prevalence provides opportunities to elucidate cancer suppression mechanisms that are compatible with life and reproductive success. Investigation of species with extreme vulnerability to a particular cancer may also help us understand those cancers as well as human syndromes that predispose to those cancers. We hope to learn from nature how to better prevent cancer in both humans and non-human animals. # Methods ## Analysis of Veterinary Necropsy Records We collected necropsy records with",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:93"
    }
  },
  {
    "page_content": "Records We collected necropsy records with permission from 99 zoological institutions, aquariums, and other facilities that house animals under managed care. Gross necropsies had all been conducted by veterinarians who specialize in nondomestic species and neoplasia was identified histologically by board-certified veterinary pathologists. Ninety-four percent of the histopathology from the necropsies in our dataset was evaluated by a single pathology laboratory, the others were evaluated by just",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:94"
    }
  },
  {
    "page_content": "laboratory, the others were evaluated by just two other pathology laboratories. Cases where suspect neoplasms were not examined histologically were excluded from the dataset. We used a terminology dictionary (Supplementary Table S6) to distinguish benign from malignant neoplasms based on the diagnoses in the necropsy reports. We excluded neonatal records to reduce bias from high levels of neonate and infant mortality that is common in many species. Because only common names were recorded for",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:95"
    }
  },
  {
    "page_content": "Because only common names were recorded for most records, we developed a tool, kestrel, to translate common names into scientific names which is available at https://pkg.go.dev/github.com/icwells/kestrel. All of the institutions that provided prior approval for the use of their data in these analyses are AZA accredited. AZA accreditation encourages the institution to perform a necropsy on all animals that die under their care to determine cause of death and to monitor morbidity and mortality of",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:96"
    }
  },
  {
    "page_content": "death and to monitor morbidity and mortality of each species. Furthermore, each institution had Institutional Animal Care and Use Committee approval with the Exotic Species Cancer Research Alliance and the Arizona Cancer and Evolution Center for the use of their deceased animal’s records of animals with neoplasia for use in this study. Previous analyses included both necropsies for animals diagnosed with neoplasia and animals that were still alive (18). In this study, we restricted our analyses",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:97"
    }
  },
  {
    "page_content": "(18). In this study, we restricted our analyses to only necropsies—for both cancer and non-cancer diagnosed animals—because alive animals may have undetected cancer or might be eventually diagnosed with cancer, thus skewing estimates in cancer prevalence. ## Comparative Phylogenetic Methods in Comparative Oncology Interspecies comparisons must account for the shared ancestry and the constraint of natural selection on species’ traits before a determinant of any correlations can be made. For the",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:98"
    }
  },
  {
    "page_content": "of any correlations can be made. For the life history models of neoplasia and malignancy prevalence, the R programming packages (RRID:SCR_001905) “phytools” (81), “ape” (82), and “caper” (83) were all used for phylogenetic comparisons and the handling of phylogenetic data. To accomplish this, we wrote the function pglsSEyPagel which is built upon phytool’s pglsSEy (phylogenetic generalized least squares for uncertainty in Y). pglsSEyPagel expands upon the pglsSEy function by adding the estimate",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:99"
    }
  },
  {
    "page_content": "upon the pglsSEy function by adding the estimate of Pagel’s lambda (84) to the regression, rather than assuming it is fixed at 1 (i.e., Brownian motion). Because malignancy and neoplasia prevalences are constrained to the unit interval and many are close to zero, we transformed the prevalence with the standard arcsine-square root but that did not change the statistical significance for any of our analyses. We have reported the untransformed regressions for ease of interpretation (Supplementary",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:100"
    }
  },
  {
    "page_content": "for ease of interpretation (Supplementary Fig. S71). Compar.gee is another method from the “ape” package that utilizes phylogenetic input but uses a Generalized Estimating Equation to carry out binomial regressions (bioRxiv 2022.07.12.499088) that take into account the sample size for each species. The P values for malignancy and neoplasia prevalence varied minimally when univariate tests for body mass, longevity, and gestation length were conducted. We did see larger coefficients with the",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:101"
    }
  },
  {
    "page_content": "We did see larger coefficients with the results from this model (see Supplementary Table S4). In order to validate our pglsSEyPagel findings, we carried out a bootstrap analysis. For each species, we randomly selected half of its individual records to be aggregated at the species level. Each re-sample would then be regressed using pglsSEyPagel, testing for the relationship between malignancy prevalence or neoplasia prevalence and the chosen life history variable. This iterative process was",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:102"
    }
  },
  {
    "page_content": "life history variable. This iterative process was repeated 100 times each for body mass, longevity, and gestation length. Additionally, we controlled our pglsSEyPagel results by individual age for those which age records available, instead of depending upon longevity records from life history databases. Values did change but conclusions remained the same (see Supplementary Table S7). ## Testing for Relationships with Life History Factors We extracted data for maximum lifespan, adult body mass,",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:103"
    }
  },
  {
    "page_content": "data for maximum lifespan, adult body mass, basal metabolic rate, gestation length, litter size, time to sexual maturity, and growth rate from PanTHERIA, AnAge, and Amniote (85–87). We used a weighted phylogenetic regression to control for non-independence of phenotypes (e.g., neoplasia prevalence) in closely related species. We report the phylogenetic signal, lambda, for each analysis, along with the P value and R2. Due to the nature of the PGLS model, R2 is not a standard output. To report",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:104"
    }
  },
  {
    "page_content": "model, R2 is not a standard output. To report the fit of the model, we employed a pseudo R2 approach using the “rr2” R package. The function “R2” from the package can utilize phylogenetic relationships within the R2 calculation. A single phylogenetic tree encompassing the three clades was collected from timetree.org. We pruned the tree to the 292 species in our data set using the setdiff and keep.tip/drop.tip functions in the APE R package. Estimates for neoplasia and malignancy prevalence are",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:105"
    }
  },
  {
    "page_content": "for neoplasia and malignancy prevalence are more accurate in species with more necropsies. To address the differences in number of necropsies and to limit the noise from prevalence estimates based on few individuals, we weighted the species data points by the square-root of the number of necropsies records we have. Our R code for all analyses and figures included in this manuscript is freely available at https://github.com/zacharycompton/cancerAcrossVertebrates.git or at",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:106"
    }
  },
  {
    "page_content": "or at https://codeocean.com/capsule/7079513/tree/v1. The key files are species-cancer-prevalence-data.csv along with the data-description-min20.txt file that provides the documentation for the meaning of each column in the data file. In addition, we only analyzed species for which we had at least 20 necropsy results [previous studies had used 10 (17) or 20 (18, 19) for the lower bound number of individuals]. The main pglsSEyPagel analyses were done with all species together, including mammals,",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:107"
    }
  },
  {
    "page_content": "with all species together, including mammals, sauropsids, and amphibians. In the analyses of litter size and gestation time, we also tested for a relationship with neoplasia prevalence in mammals alone. We carried out a total of 28 pglsSEyPagel analyses. To control for multiple testing, we used a false discovery rate of 5%. ## DNA Damage Response Assays Established, primary cells from mammals were obtained from San Diego Zoo Wildlife Alliance Frozen Zoo [capybara, Linnaeus’s (also called",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:108"
    }
  },
  {
    "page_content": "Frozen Zoo [capybara, Linnaeus’s (also called Linne’s) two-toed sloth, red-necked wallaby, rock hyrax, Rodrigues fruit bat, six-banded armadillo, southern white rhinoceros, and Virginia opossum] or generated at Huntsman Cancer Institute from tissues collected from four-toed hedgehog (also known as African pygmy hedgehog), ferret, domestic rabbit, leopard, Asian elephant, and Cape hunting dog. Brown rat (Cell Applications) fibroblasts were obtained from the indicated commercial source.",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:109"
    }
  },
  {
    "page_content": "obtained from the indicated commercial source. Experiments were performed on cells passaged 20 or fewer times from initial establishment. San Diego Zoo Wildlife Alliance Frozen Zoo karyotypes all established primary cells to confirm species source. Experiments were initiated within 3 months of obtaining or generating cells and completed within 1 to 5 years. Cells routinely tested negative for mycoplasma as measured by MycoAlert Mycoplasma Detection Kit (Lonza). In order to include more species",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:110"
    }
  },
  {
    "page_content": "Kit (Lonza). In order to include more species in our analysis of DNA damage response, we included species with a minimum of 10 necropsies. Detailed information on primary donor demographics, passage numbers, and dates obtained can be found in Supplementary Table S8. Cells were seeded in 96-well plates at 2,000 cells per well in cell growth media and allowed to adhere overnight. The following day, doxorubicin was added at one of four concentrations [0 µmol/L (DMSO vehicle control), 0.11 µmol/L,",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:111"
    }
  },
  {
    "page_content": "[0 µmol/L (DMSO vehicle control), 0.11 µmol/L, 0.33 µmol/L, and 1 µmol/L]. Each condition was tested in triplicate in three separate experiments. Cell proliferation and apoptosis were measured by real-time fluorescence microscopy (IncuCyte, Sartorius) at 2-hour intervals for 3 days. Apoptosis was measured using a fluorescent cell death marker, Annexin V dye (Sartorius). Images were processed and analyzed using IncuCyte software. The number of dead or dying cells was identified by counting",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:112"
    }
  },
  {
    "page_content": "of dead or dying cells was identified by counting Annexin V positive cells. In addition, cell count overtime was calculated using IncuCyte cell-by-cell software. To measure response to radiation-induced DNA damage, cells were irradiated with one of four doses: 0, 0.4, 2, and 10 Gy. Radiation dose was delivered using an RS-2000 X-Ray Irradiator (Radsource). Cells were then seeded in 96-well plates in cell growth media containing Annexin V dye (Sartorius). Cells were imaged by real-time",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:113"
    }
  },
  {
    "page_content": "V dye (Sartorius). Cells were imaged by real-time fluorescence microscopy (IncuCyte, Sartorius) at 2-hour intervals for 5 days. We estimated cell cycle arrest by normalizing the cell count of irradiated cells to untreated cells by dividing the area under the curve (AUC) of cell count over time for treated cells by the AUC of cell count over time for the untreated cells. We converted that number into a percentage that represents the percent of cell proliferation relative to untreated cells. We",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:114"
    }
  },
  {
    "page_content": "proliferation relative to untreated cells. We then tested if this normalized amount of cell growth was predictive of neoplasia prevalence using the phylogenetically controlled pglsSEyPagel regression (Fig. 4A). ## Somatic Mutation Rates Cagan and colleagues (36) published somatic mutation rates (single base substitution per genome per year) for 16 species based on sequencing 208 individual colonic crypts from 56 animals from the London Zoo. They divided the number of somatic mutations, detected",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:115"
    }
  },
  {
    "page_content": "divided the number of somatic mutations, detected by whole-genome sequencing, by age (in years) of the individual at the time that the tissue was taken, to estimate the mutation rate per year. Nine of those species are in our dataset, allowing us to use a pgls regression to test for an association between mean somatic mutation rates and neoplasia prevalence. ## Data Availability All data and code are available at zacharycompton/cancerAcrossVertebrates (gEithub.com) and",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:116"
    }
  },
  {
    "page_content": "(gEithub.com) and https://codeocean.com/capsule/7079513/tree/v1, with the exception of the ages of individual animals and the locations of their tumors, which are restricted due to privacy agreements with the contributing zoos. Access to that data may be granted with permissions of the zoos. # Supplementary Material",
    "metadata": {
      "source": "../data/plain/PMC11726020.plain.txt",
      "id": "../data/plain/PMC11726020.plain.txt:117"
    }
  },
  {
    "page_content": "Genotyping of Transcriptomes links somatic mutations and cell identity Abstract",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:0"
    }
  },
  {
    "page_content": "Defining the transcriptomic identity of malignant cells is challenging in the absence of surface markers that distinguish cancer clones from one another or from admixed non-neoplastic cells. To address this challenge, we developed Genotyping of Transcriptomes (GoT), integrating genotyping with high-throughput droplet-based single-cell RNA-seq. We applied GoT to study how somatic mutations corrupt the complex process of human hematopoiesis, profiling 38,290 CD34+ cells from patients with",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:1"
    }
  },
  {
    "page_content": "profiling 38,290 CD34+ cells from patients with CALR-mutated myeloproliferative neoplasms (MPN). High-resolution mapping of malignant vs. normal hematopoietic progenitors revealed increasing CALR-mutation fitness advantage with myeloid differentiation. We identified the unfolded protein response as a predominant outcome of CALR mutations, with significant cell identity dependency, as well as NF-κB pathway upregulation specifically in uncommitted stem cells. We further extended the GoT toolkit",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:2"
    }
  },
  {
    "page_content": "stem cells. We further extended the GoT toolkit to genotype multiple targets and loci distant from transcript ends. Collectively, these findings revealed that the transcriptional output of MPN somatic mutations is dependent on the native cell identity. # RESULTS ## Genotyping of Transcriptomes (GoT) couples targeted cDNA genotyping with single-cell whole transcriptomes to reveal that CALR mutant progenitor cells are comingled with wildtype cells throughout differentiation To link genotypes to",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:3"
    }
  },
  {
    "page_content": "throughout differentiation To link genotypes to single-cell RNA-seq (scRNA-seq) in high-throughput droplet-based platforms, we modified the 10x Genomics platform (Pleasanton, CA) to amplify the targeted transcript and locus of interest (Methods, Fig. 1a, Extended Data Fig. 1b,c). We then interrogated amplicon reads for mutational status, and linked the genotype to single-cell gene expression profiles via shared cell barcodes (Extended Data Fig. 2a,b). We tested the ability of GoT to co-map",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:4"
    }
  },
  {
    "page_content": "2a,b). We tested the ability of GoT to co-map single-cell genotypes and transcriptomes with a species-mixing experiment, wherein mouse cells with a mutant CALR transgene were mixed with human cells with a wildtype CALR transgene (Fig. 1b)12. Consistent with precision genotyping, the vast majority of cells with mouse transcripts showed mutant CALR, whereas cells with human transcripts showed wildtype CALR (96.7% of cells matching the expected species; Fig. 1b, Extended Data Fig. 2c–g). While",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:5"
    }
  },
  {
    "page_content": "species; Fig. 1b, Extended Data Fig. 2c–g). While CALR mutations have been demonstrated to activate MPL resulting in megakaryocytic proliferation7,12–16, how the mutations perturb early hematopoietic stem progenitor cell (HSPC) differentiation is largely unknown. We therefore applied GoT to CD34+ bone marrow cells from five patients with CALR-mutated essential thrombocythemia (ET), not treated with disease-modifying therapy at the time of biopsy (Supplementary Table 1). CALR genotyping data",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:6"
    }
  },
  {
    "page_content": "(Supplementary Table 1). CALR genotyping data were available for 16,614 of 18,722 cells (88.7%), compared to only 1.4% by interrogation of CALR in the conventional 10x Genomics data (Fig. 1c, Extended Data Fig. 3a–d). To interrogate the cellular identities of these progenitors, we performed clustering agnostic to the genotyping information, based on the transcriptome information alone (Fig. 1d, Extended Data Fig. 4a–c)17,18. Genotype projection onto progenitor maps demonstrated that mutated",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:7"
    }
  },
  {
    "page_content": "onto progenitor maps demonstrated that mutated cells involved all CD34+ stem and progenitor clusters, consistent with previous bulk PCR analysis of CALR in FACS-sorted CD34+ subsets6 (Fig. 1e, see Extended Data Fig. 4d,e for validation with an alternative clustering framework19). Notably, mutated cells did not form novel independent clusters, confirming that scRNA-seq alone cannot distinguish mutant from wildtype cells, and demonstrating that CALR mutations in ET impact the entire hematopoietic",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:8"
    }
  },
  {
    "page_content": "mutations in ET impact the entire hematopoietic differentiation hierarchy. ## The fitness impact of CALR mutations increases with myeloid differentiation, associated with increased proliferation in mutant progenitors While mutant cells were observed across all progenitor clusters, their frequencies varied between clusters. CALR mutated cell frequency was higher in committed myeloid progenitors (Fig. 1f), especially MkPs which are closely associated with the disease phenotype of elevated",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:9"
    }
  },
  {
    "page_content": "associated with the disease phenotype of elevated platelets, compared to uncommitted HSPC clusters across samples (P-value <10−10, linear mixed model, Fig. 1g, Extended Data Fig. 5a). Consistently, pseudo-temporal ordering (pseudotime) analysis20,21 showed that CALR mutated cells were enriched in cells with later pseudotime points compared to wildtype cells (Fig. 1h,i, P-value <10−10, linear mixed model, Extended Data Fig. 5b,c). We orthogonally validated this finding via bulk gDNA droplet",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:10"
    }
  },
  {
    "page_content": "validated this finding via bulk gDNA droplet digital PCR, showing a lower CALR variant allele frequency (VAF) in CD34+CD38− HSPCs compared to CD34+CD38+ progenitors (P-value = 0.02, Wilcoxon rank-sum test, Fig. 1j). Thus, while CALR mutations arise in uncommitted HSCs and, therefore, propagate to populate the entire differentiation tree, the impact of CALR mutations on fitness increases with myeloid differentiation (Extended Data Fig. 5d,e). GoT uniquely enables direct transcriptional program",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:11"
    }
  },
  {
    "page_content": "uniquely enables direct transcriptional program comparison between mutant and wildtype cells, not only within the same sample, but also within the same progenitor cluster. For example, CALR-mutated progenitors displayed increased expression of genes upregulated in progenitors from JAK2-mutated ET22, most significantly in MkP clusters (combined P-value <10−10, Fisher’s method, Fig. 2a,b), as JAK2 and CALR mutations partially converge through activation of similar downstream pathways23. We",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:12"
    }
  },
  {
    "page_content": "activation of similar downstream pathways23. We therefore reasoned that progenitor subtype-specific comparison of cell-cycle gene expression (Supplementary Table 2)24 in mutant vs. wildtype cells may reveal whether the lower fitness impact of CALR mutations in HSPCs compared with MkPs stems from differences in cell proliferation. Indeed, while mutant HSPCs exhibited only a modest increase in cell cycle gene expression compared to wildtype (P-value = 0.015, Wilcoxon rank-sum test, mean fold",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:13"
    }
  },
  {
    "page_content": "= 0.015, Wilcoxon rank-sum test, mean fold change 1.2, 95% confidence interval, 1.1–1.4), mutant MkPs demonstrated a robust increase in cell cycle expression vs. their wildtype counterparts (P-value = 4.4 × 10−4, Wilcoxon rank-sum test, fold change 1.8 [1.4–2.8]; Fig. 2c, Extended Data Fig. 6a). Notably, the degree of cell cycle gene expression increase in mutant MkPs correlated with the patients’ platelet counts (Fig. 2d), suggesting that interrogation of the early progenitor cells may",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:14"
    }
  },
  {
    "page_content": "interrogation of the early progenitor cells may correlate with clinical phenotypes and inform our understanding of patient-to-patient variability despite shared mutated genotypes. Cell-to-cell variation exists even within progenitor clusters. For example, MkPs represent a heterogeneous population composed of less differentiated cells with higher expression of HSC genes25 (HSChiMkPlo), and more committed MkP cells displaying high expression of MkP-related genes26 (HSCloMkPhi; Fig. 2e,",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:15"
    }
  },
  {
    "page_content": "of MkP-related genes26 (HSCloMkPhi; Fig. 2e, Supplementary Table 2). Even within the MkP cluster, HSCloMkPhi cells showed increased cell cycle gene expression, and a higher mutant cell frequency compared to HSChiMkPlo cells (P-value = 0.01, Fisher’s exact test). Similarly, mutant cells within the platelet-primed HSPCs (MkPhiTGFβlo) had higher cell cycle gene expression than wildtype MkPhiTGFβlo HSPCs, whereas mutant and wildtype HSPCs in a more quiescent state (MkPloTGFβhi) showed no cell cycle",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:16"
    }
  },
  {
    "page_content": "state (MkPloTGFβhi) showed no cell cycle difference (Fig. 2f). These findings further emphasize that the impact of CALR mutation is dependent on cell state, and imparts a greater proliferative advantage in more differentiated cells. These data also reveal that CALR mutations skew differentiation toward myeloid progenitors, including megakaryocytic priming, early in hematopoiesis (Extended Data Fig. 6b). ## De novo differential expression analysis reveals cell identity dependent upregulation of",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:17"
    }
  },
  {
    "page_content": "reveals cell identity dependent upregulation of the unfolded protein response in CALR-mutant cells GoT data further offer a unique opportunity for de novo differential gene expression discovery, by examining wildtype vs. mutant cells within the same progenitor subset. Crucially, the wildtype cells serve as an ideal comparison set, as they share all potential environmental and patient-specific variables as the mutated cells. We identified 198 genes to be differentially expressed between mutant",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:18"
    }
  },
  {
    "page_content": "to be differentially expressed between mutant and wildtype MkPs (FDR adjusted P-value < 0.1; Fig. 3a, Supplementary Table 3). Mutated MkPs upregulated HSPA5 that encodes BiP, a key player in protein quality control that modulates the activities of the three transmembrane transducers of the unfolded protein response (UPR): PERK, IRE1, and ATF627. Consistently, CALR-mutant MkPs showed upregulation of UPR genes (adjusted P-value 1.7 × 10−8) and ATF6-mediated activation of chaperone genes (adjusted",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:19"
    }
  },
  {
    "page_content": "activation of chaperone genes (adjusted P-value = 0.03, Fig. 3a, Supplementary Table 4), providing direct in vivo validation of in vitro studies that have shown increased UPR in CALR mutated cells28,29. UPR in this context may signal ER stress in response to misfolded proteins, as the CALR chaperone activity may be compromised by the mutation30,31. Notably, among 20 differentially expressed genes in mutant HSPCs, XBP1, an important regulator of UPR, was upregulated in mutant cells suggesting",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:20"
    }
  },
  {
    "page_content": "UPR, was upregulated in mutant cells suggesting that UPR activation by CALR mutations extends to uncommitted progenitors (Fig. 3b), further supported by upregulation of ATF6-target genes in mutant compared to wildtype HSPCs (Fig. 3c, Extended Data Fig. 7, Supplementary Table 2)32. UPR was previously demonstrated to be preferentially mediated in HSPCs through PERK resulting in enhanced apoptosis upon ER stress33, helping to eliminate ER stressed cells from the HSC pool. In contrast, committed",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:21"
    }
  },
  {
    "page_content": "cells from the HSC pool. In contrast, committed progenitors have a robust IRE1/XBP1 activity, promoting survival through ER stress challenge33. We observed that in the specific context of CALR mutation-induced ER stress, the PERK-branch of the UPR was not enhanced (Fig. 3c, Extended Data Fig. 7, Supplementary Table 2)33. In contrast, targets of XBP1 were upregulated in mutant MkPs (P-value = 5.3 × 10−10, linear mixed model), as well as in mutant HSPCs (P-value = 1.9 × 10−6, linear mixed model,",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:22"
    }
  },
  {
    "page_content": "HSPCs (P-value = 1.9 × 10−6, linear mixed model, Fig. 3c, Extended Data Fig. 7, Supplementary Table 2)34,35. As IRE1 catalyzes the unconventional splicing of XBP1 unspliced mRNA (XBP1u) into the active spliced form (XBP1s; Fig. 3d)36, we further validated that CALR mutations induce activation of the IRE1-branch of the UPR by repurposing GoT to probe for the spliced region of XBP1 in single cells. CALR mutations robustly augmented the amount of XBP1s in MkPs (Fig. 3e). Remarkably, CALR mutations",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:23"
    }
  },
  {
    "page_content": "in MkPs (Fig. 3e). Remarkably, CALR mutations also resulted in enhanced XBP1s/XBP1u ratio in HSPCs, indicating IRE1 activity (Fig. 3e). These data thus suggest that in CALR mutation-induced UPR, IRE1 is activated in both HSPCs and MkPs, skewing the ER stress-challenged stem and progenitor cells toward survival. Differential gene expression analysis in HSPCs also revealed upregulation of the NF-κB pathway (adjusted P-value = 0.03), including upregulation of CXCL2 and NFKBIA (Fig. 3b,",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:24"
    }
  },
  {
    "page_content": "upregulation of CXCL2 and NFKBIA (Fig. 3b, Supplementary Tables 3 and 4). Furthermore, NF-κB gene set upregulation in mutant vs. wildtype HSPCs was most notable in early uncommitted HSPCs (Fig. 3f, Supplementary Table 2). Mutant cells in this early HSPC subcluster also upregulated anti-apoptotic related genes (Fig. 3f, Supplementary Table 2). As NF-κB pathway activation has been previously associated with anti-apoptotic effects37 and HSC self-renewal38, our data thus points at another potential",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:25"
    }
  },
  {
    "page_content": "our data thus points at another potential mechanism linking CALR mutation and HSC outgrowth. ## IRE1-mediated UPR by mutant CALR is maintained through progression to myelofibrosis As a proportion of patients with CALR-mutated ET eventually progresses to post-ET myelofibrosis (MF) or present initially with MF, we examined whether CALR mutation imparted similar proliferative and survival advantage to progenitor cells from patients with CALR-mutated MF by examining 9,704 genotyped cells of total",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:26"
    }
  },
  {
    "page_content": "MF by examining 9,704 genotyped cells of total 11,093 cells (87.5% genotyping rate) across four MF samples (Fig. 4a,b, Extended Data Fig. 8a). In contrast to ET, we did not observe enrichment of mutated cells in differentiated progenitors compared to HSPCs (Fig. 4c, Extended Data Fig. 8b), consistent with previous reports39, suggesting that in the context of MF, CALR mutations impart a strong fitness advantage even to HSPCs. Indeed, mutant cells were highly enriched in cell cycle activity (Fig.",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:27"
    }
  },
  {
    "page_content": "were highly enriched in cell cycle activity (Fig. 4d, Extended Data Fig. 8c). As megakaryocytes have been demonstrated to play a principle role in the development of marrow fibrosis40, we performed differential expression analysis between mutant and wildtype MkPs, showing 92 differentially expressed genes (FDR adjusted P-value < 0.1, Fig. 4e, Supplementary Table 3). We identified upregulation of TGFB1, previously implicated in fibroblast stimulation by megakaryocytes41,42, thereby demonstrating",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:28"
    }
  },
  {
    "page_content": "by megakaryocytes41,42, thereby demonstrating that TGFβ production is dysregulated even in early progenitors. Indeed, TGFβ signaling upregulation in mutant MkPs correlated with the degree of fibrosis in the patient’s bone marrow (Extended Data Fig. 8d). As in CALR-mutated ET, we observed a robust upregulation of UPR genes in mutated MkPs (adjusted P-value = 4.7 × 10−7) and, specifically, IRE1 activation (adjusted P-value = 0.0017; Fig. 4e, Supplementary Table 4). Notably, comparison of cycling",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:29"
    }
  },
  {
    "page_content": "Table 4). Notably, comparison of cycling to non-cycling wildtype cells did not show UPR upregulation, affirming that UPR activation is not simply a byproduct of increased proliferation (Extended Data Fig. 8e, Supplementary Tables 3 and 4). These findings suggest that the enhanced survival of CALR-mutant progenitors through upregulation of the IRE1-mediated UPR is maintained through disease progression to myelofibrosis. ## Multiplexed GoT reveals subclonal transcriptomic identities Ongoing",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:30"
    }
  },
  {
    "page_content": "subclonal transcriptomic identities Ongoing clonal evolution results in multi-clonal malignant populations, requiring genotyping of multiple mutations in parallel. To test the ability of GoT to target multiple mutations, we targeted three mutations affecting CALR (VAF 43.5% by bulk exon sequencing), NFE2 (VAF 33%) and SF3B1 (VAF 47.5%) in 8,475 CD34+ cells from a patient with MF (Fig. 5a). The relative VAFs of these mutations suggest that this malignancy follows a nested (linear evolution)",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:31"
    }
  },
  {
    "page_content": "malignancy follows a nested (linear evolution) clonal structure, with a clonal SF3B1 mutation, a progeny subclone harboring a CALR mutation, which has an additional NFE2-mutated progeny (single-cell cloning validation in Extended Data Fig. 9a). GoT provided genotyping for CALR and NFE2 in 74% and 60% of cells, respectively, and showed mutant frequencies (64% and 56%, respectively) comparable to those of single cell cloning (85% and 71%, respectively, performed with unsorted peripheral blood",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:32"
    }
  },
  {
    "page_content": "performed with unsorted peripheral blood cells). In this context, GoT allows to compare the transcriptional outputs of the different mutations alone or in combination. For example, since SF3B1 mutations have been shown to block erythroid maturation43, we examined whether the addition of a CALR mutation would still confer increased proliferative status in megakaryocytic-erythroid progenitors. We found that SF3B1/CALR-double mutants exhibited increased proliferative advantage over SF3B1-single",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:33"
    }
  },
  {
    "page_content": "proliferative advantage over SF3B1-single mutants (Fig. 5b), while the addition of NFE2 mutation (triple-mutant) did not further increase cell cycle activation. Thus, multiplexed GoT demonstrated the ability to interrogate complex clonal structures, as well as the need to assess the combinatorial transcriptional output of mutations in the context of high-resolution cell identity mapping. ## Circularization GoT enables genotyping of mutations distant from transcript ends GoT amplicon recovery is",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:34"
    }
  },
  {
    "page_content": "from transcript ends GoT amplicon recovery is not only dependent on the expression level of the gene but also on the distance of the mutation locus from transcript ends (Extended Data Fig. 9b). Capture efficiency of a mutation distant from the 3’ end (>1.5 kb, e.g. SF3B1 genotyping of 9% of cells, Fig. 5a) was lower than for targets closer to the 3’ end. While driver mutations are often found within 1.5 kb of either transcript ends (Extended Data Fig. 9c), loci of interest may reside at larger",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:35"
    }
  },
  {
    "page_content": "Fig. 9c), loci of interest may reside at larger distances, and thus the dependency on relative proximity to transcript end is limiting. We reasoned that lower genotyping efficiency resulted, at least partially, from the inability of larger amplicon fragments to cluster efficiently on Illumina flow cells during sequencing. We further integrated our protocol with long-read sequencing with nanopore GridION X5 (Oxford Nanopore Technology), which demonstrated that SF3B1 transcripts were captured",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:36"
    }
  },
  {
    "page_content": "demonstrated that SF3B1 transcripts were captured accurately with our procedure (Extended Data Fig. 9d,e), and further confirmed low intra- and inter-transcript PCR recombination rate, even for these relatively large fragments (Extended Data Fig. 9f,g). To overcome this limitation, we applied sequential rounds of circularization and inverse PCR to remove the intervening sequence between the region of interest and the cell barcode (Fig. 5c). Circularization GoT showed high concordance with",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:37"
    }
  },
  {
    "page_content": "Circularization GoT showed high concordance with un-circularized (linear) GoT for CALR genotyping (Extended Data Fig. 9h,i). When applied to SF3B1 mutation capture, circularization GoT significantly increased the yield of genotyped cells from 750 to 2004 cells (9% to 24% of cells, Fig. 5d,e). These results demonstrate the ability of circularization GoT to extend our reach even to targets distant from gene ends. To further demonstrate the ability of circularization GoT to genotype despite",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:38"
    }
  },
  {
    "page_content": "of circularization GoT to genotype despite significant distance from the transcript end, we targeted JAK2V617F (~3 kb). We first validated circularization GoT for JAK2 via a mixing experiment with barcoded cDNA from TF1 cell line (wildtype JAK2) and from HEL cells (homozygous JAK2V617F), showing accurate genotype assignment (Fig. 5f). Next, we genotyped primary CD34+ cells from an individual with JAK2V617F ET, obtaining genotyping information for 7.3% of cells (Fig. 5g), even for this very",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:39"
    }
  },
  {
    "page_content": "for 7.3% of cells (Fig. 5g), even for this very lowly expressed gene. Mutant cell frequency was higher in MkPs compared to HSPCs, whereas the mutant cell frequency remained low in erythroid progenitors (Fig. 5h), concordant with the clinical phenotype of ET, rather than polycythemia vera (disease associated with the same JAK2 mutation, but with erythrocytosis as the leading abnormality). Consistent with this observation, we observed, albeit in a small number of genotyped HSPCs, a trend towards",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:40"
    }
  },
  {
    "page_content": "small number of genotyped HSPCs, a trend towards increased MkP-priming in mutant HSPCs (P-value = 0.04, Wilcoxon rank-sum; Fig. 5i, Supplementary Table 2). These data suggest skewing of differentiation toward megakaryopoiesis in HSPCs and may provide insights into the isolated megakaryocytic proliferation in JAK2-mutated ET. # Discussion Here, we present GoT, which co-captures somatic genotypes and transcriptomic identities in thousands of single cells from primary cancer specimens. Building on",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:41"
    }
  },
  {
    "page_content": "cells from primary cancer specimens. Building on previous experience for targeted amplification in droplet-based scRNA-seq44,45, GoT overcomes the unique set of challenges presented by somatic mutation genotyping, including lower expression levels and large distances from the end of the sequenced transcripts. Collectively, GoT allowed us to directly interrogate the transcriptional impact of CALR mutation in primary MPN samples, where wildtype cells in the sample provide an ideal comparison set,",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:42"
    }
  },
  {
    "page_content": "in the sample provide an ideal comparison set, controlling for patient-specific and technical confounders. We observed that mutant CALR provided a greater fitness advantage through differentiation in ET, associated with higher proliferation in committed myeloid progenitors compared with uncommitted HSPCs. GoT’s ability to fine-map mutant vs. wildtype transcriptional differences in HSPCs revealed upregulation of NF-κB pathway genes in the most undifferentiated mutant HSPCs, supporting a",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:43"
    }
  },
  {
    "page_content": "most undifferentiated mutant HSPCs, supporting a cell-intrinsic role for CALR mutation in NF-κB activation46. We further applied GoT to target the unconventional splice site of XBP1 to demonstrate that IRE1 activity was increased in the mutant cells, including HSPCs. Our data thus nominates the IRE1/XBP1 pathway as a potential therapeutic target for eradication of the mutant clone in the uncommitted HSPCs in patients with CALR-mutated MPNs. In conclusion, high-throughput linking of single-cell",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:44"
    }
  },
  {
    "page_content": "high-throughput linking of single-cell genotypic and transcriptomic data underscored the cell identity-dependency of somatic mutations in human hematopoiesis, allowing us to superimpose the native differentiation tree with a tree corrupted by somatic mutations. GoT further provides the means to gain insight into the integration of clonal diversification with lineage plasticity47 or differentiation topologies48 across cancer. Thus, GoT may pave the way to resolve central questions related to the",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:45"
    }
  },
  {
    "page_content": "way to resolve central questions related to the link between genetic mutations and cellular identities, and to unravel the underlying programs that enable clonal expansions and evolution in human neoplasms. # METHODS ## Species mixing experiment Previously published UT7 and Ba/F3 cell lines expressing human MPL and either human wildtype CALR or mutant CALR (type 1, 52 bp deletion), kindly provided by Dr. Mullally’s lab, were used for the species mixing study12. Briefly, human MPL expressing",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:46"
    }
  },
  {
    "page_content": "mixing study12. Briefly, human MPL expressing Ba/F3 and UT7 cell lines were generated by retroviral transduction, after which they were subjected to infection with CALR variant lentiviral supernatants. Wildtype UT7 cells and mutant Ba/F3 cells were mixed in equal proportions which underwent GoT, targeting ~1000 cells. While UT7 has been listed as a commonly misidentified cell line, it was used for the sole purpose of validating the CALR mutation status of the cells. All cell lines used in the",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:47"
    }
  },
  {
    "page_content": "status of the cells. All cell lines used in the study were tested for mycoplasma contamination. ## Patient samples The study was approved by the local ethics committee and by the Institutional Review Board (IRB) of Memorial Sloan-Kettering Cancer Center and Weill Cornell Medicine and conducted in accordance to the Declaration of Helsinki protocol. All patients provided informed consent. Cryopreserved bone marrow mononuclear (BMMCs) or peripheral blood mononuclear cells (PBMCs) from patients",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:48"
    }
  },
  {
    "page_content": "blood mononuclear cells (PBMCs) from patients with documented CALR mutations were retrieved after a database search. See Supplementary Table 1 for clinical information. Cryopreserved BMMCs or PBMCs were thawed and stained using standard procedures (10 min, 4°C) with the surface antibody CD34-PE-Vio770 (clone AC136, lot# 5180718070, dilution 1:50, Miltenyi Biotec) and DAPI (Sigma-Aldrich). Cells were then sorted for DAPI-negative, CD34+ and CD34-negative cells using BD Influx at the Weill",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:49"
    }
  },
  {
    "page_content": "CD34-negative cells using BD Influx at the Weill Cornell Medicine flow cytometry core. ## Targeted myeloid panel To determine the presence and location of recurrent somatic mutations and their VAF, targeted next-generation sequencing was performed on DNA samples extracted from unfractionated PBMCs (patients ET09, MF01, MF02, MF03, MF04), CD34-negative sorted BMMCs (patients ET02, ET03, ET04, ET05), CD34+ sorted BMMC (patient ET01) and CD34+ sorted PBMC (patient MF05), as previously described49.",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:50"
    }
  },
  {
    "page_content": "PBMC (patient MF05), as previously described49. Briefly, targeted enrichment of 45 genes (ABL1, ASXL1, BCOR, BRAF, CALR, CBL, CEBPA, DNMT3A, ETV6, EZH2, FAM5C, FLT3, GATA1, GATA2, HNRNPK, IDH1, IDH2, IKZF1, JAK1, JAK2, KDM6A, KIT, KRAS, MPL, NFE2, NOTCH1, NPM1, NRAS, PHF6, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SH2B3, SMC1A, SMC3, SRSF2, STAG2, SUZ12, TET2, TP53, U2AF1, ZRSR2) recurrently mutated in myeloid malignancies was performed using the Thunderstorm system (Raindance Technologies,",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:51"
    }
  },
  {
    "page_content": "the Thunderstorm system (Raindance Technologies, Billerica, MA) with a custom primer panel followed by sequencing using the Illumina MiSeq (v3 chemistry). ## Genotyping of Transcriptomes (GoT) Extending recent experience with targeted amplicon sequencing in scRNA-seq44,45, we developed GoT in order to simultaneously capture genotyping data and whole transcriptomic data in single cells by adapting the 10x Genomics platform (Pleasanton, CA). The standard 10x Genomics Chromium 3’ (v.2 or v.3",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:52"
    }
  },
  {
    "page_content": "The standard 10x Genomics Chromium 3’ (v.2 or v.3 chemistry) and 5’ libraries were carried out according to manufacturer’s recommendations until after emulsion breakage and recovery of first strand cDNA (Fig. 1a, step 1). For 3’ libraries, if the targeted gene of interest, e.g. SF3B1, was not robustly detected by the standard 10x procedure (i.e. if <60% of the expected cells showed expression) based on a priori knowledge in a similar dataset, a gene-specific primer was spiked into 10x primer",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:53"
    }
  },
  {
    "page_content": "a gene-specific primer was spiked into 10x primer mix at 1% of the concentration of the cDNA amplification primers for the initial cDNA PCR step (Fig. 1a, see Supplementary Table 5 for list of primers and Extended Data Fig. 1b,c for primer positions). For 5’ libraries, presence of 10X cell barcodes (CB) and UMI on 3’ side of the transcript enabled a gene-specific primer spike-in during the RT step (Guide RT primer: 0.12 μM final concentration, Supplementary Table 5) to increase capture and",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:54"
    }
  },
  {
    "page_content": "Supplementary Table 5) to increase capture and detection of the transcript of interest (e.g. JAK2). At cDNA amplification step, another spike-in primer (Additive primer) is added to increase yield of the same transcript. During the amplification step, for 3’ libraries v.2 chemistry only, the 10x cDNA library underwent an extra cycle of PCR beyond the manufacturer’s recommended number of cycles. (3’ v3 chemistry and 5’ libraries do not require extra cycles of PCR at amplification step.) After",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:55"
    }
  },
  {
    "page_content": "extra cycles of PCR at amplification step.) After cDNA amplification and cleanup with SPRIselect, a small portion of the cDNA library (3 μL for 3’ v.2 and 10 μl for 3’ v.3 chemistry and 5’ libraries) were aliquoted for targeted genotyping, and the remaining cDNA underwent the standard 10x protocol. In the case of 3’ v.2 chemistry, the cDNA set aside for GoT was amplified for 3 to 4 additional cycles using KAPA HiFi HotStart ReadyMix (KAPABiosystems) and 10x primer mix to provide sufficient",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:56"
    }
  },
  {
    "page_content": "and 10x primer mix to provide sufficient material for the enrichment step. After clean-up, locus-specific reverse primers and the generic forward SI-PCR were used to amplify the site of interest of the cDNA template (Extended Data Fig. 1b,c, Supplementary Table 5). Number of PCR cycles was determined experimentally and was dependent on the level of expression of targeted gene (for instance 10 cycles were used for CALR). The locus-specific reverse primers contain a partial Illumina read 2",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:57"
    }
  },
  {
    "page_content": "reverse primers contain a partial Illumina read 2 handle, a stagger to increase the complexity of the library for optimal sequencing and a gene specific region to allow specific priming. The SI-PCR oligo (10x Genomics) anneals to the partial Illumina read 1 sequence at either 3’ or 5’ end of the molecule when using 3’ or 5’ libraries, respectively, preserving the CB and UMI (Extended Data Fig. 1b,c). After the initial amplification and SPRI purification to remove unincorporated primers, a",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:58"
    }
  },
  {
    "page_content": "purification to remove unincorporated primers, a second PCR was performed with a generic forward PCR primer (P5_generic) to retain the CB and UMI together with an RPI-x primer (Illumina) to complete the P7 end of the library and add a sample index. The targeted amplicon library was subsequently spiked into the remainder of the 10x library to be sequenced together on a HiSeq 2500 or sequenced separately on MiSeq (Illumina). The cycle settings were as follows: 26 cycles for read 1, 98 or 130",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:59"
    }
  },
  {
    "page_content": "were as follows: 26 cycles for read 1, 98 or 130 cycles for read 2, and 8 cycles for sample index for 3’ v.2 chemistry and 5’ libraries, or 28 cycles for read 1, 98 or 130 cycles for read 2, and 8 cycles for sample index for 3’ v.3 chemistry. ## Circularization GoT For patient samples, we used the same starting material as for GoT (i.e. non-fragmented 10x cDNA fraction); for the JAK2 cDNA mixing study, we mixed barcoded cDNA from two cells lines (TF-1: JAK2 wildtype (ATCC CRL-2003), HEL:",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:60"
    }
  },
  {
    "page_content": "lines (TF-1: JAK2 wildtype (ATCC CRL-2003), HEL: Homozygote JAK2 V617F (ATCC TIB-180). With these cDNA libraries, we first performed a PCR to enrich for the amplicon, amplifying from ~50 bp upstream our region of interest to the 3’ end of the 10x library fragment, therefore retaining cell barcode (CB) and unique molecule identifier (UMI), using KAPA HiFi Uracil+ master mix (Kapa Biosystems) and the following PCR conditions: 98°C for 3’; 10 to 20 cycles of: 98°C for 20”, 65°C for 30”, 72°C for",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:61"
    }
  },
  {
    "page_content": "cycles of: 98°C for 20”, 65°C for 30”, 72°C for 2’, 72°C for 5’. Complementary U-overhang are added to the forward (Fw) and reverse (Rv) primers to allow circularization: Fw-primer#1: AGGUCAGTCU-[50bp-upstream-locus-specific], Rv-primer#1: AGACUGACCUCTACACGACGCTCTTCCGATCT (Extended Data Fig. 1b,c, Supplementary Table 5). For genes lowly represented in the cDNA library (such as SF3B1), we specifically pre-enriched the gene of interest by doing a PCR targeting ~100bp upstream our region of",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:62"
    }
  },
  {
    "page_content": "a PCR targeting ~100bp upstream our region of interest to the 3’ end of the 10x library fragment, using KAPA HiFi Ready mix (Kapa Biosystems) and the following PCR conditions: 95°C for 3’; 20 cycles of: 98°C for 20”, 65°C for 30”, 72°C for 2’, 72°C for 5’. PCR product resulting from the first single or double PCR was then cleaned-up and concentrated using 1.3X SPRI beads. Next, amplicon cohesive ends were created using 40U/mL USERII enzyme (M5508-NEB) digestion for 1 hour at 37°C in 1X CutSmart",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:63"
    }
  },
  {
    "page_content": "digestion for 1 hour at 37°C in 1X CutSmart buffer. Reaction was stopped by incubating for 10’ at 65°C. Relying on complementary overhang at both end of the amplicon, circularization was performed in a large volume (>1 mL) to favor intra-molecule ligation. The following reaction was set-up and incubated overnight at 16°C: USERII-digested amplicon, 2000 U/mL T4 ligase (NEB), 1X CutSmart Buffer (NEB), 1 mM ATP (Roche). Next, T4 DNA ligase was inactivated by incubating for 15’ at 70°C. Then,",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:64"
    }
  },
  {
    "page_content": "inactivated by incubating for 15’ at 70°C. Then, unwanted un-ligated products were removed by adding 6U of lambda exonuclease (NEB, M0262S) in the ligation mix and incubating for 30’ at 37°C. Exonuclease was inactivated for 20’ at 65°C. Ligated product was cleaned-up and concentrated using 1.3X SPRI beads. A second PCR was set-up to retain the locus of interest and barcodes on the same molecule while removing the unwanted 3’ downstream region of the targeted region. PCR reaction was set-up and",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:65"
    }
  },
  {
    "page_content": "the targeted region. PCR reaction was set-up and performed as previously described using the following primers: Fw-primer#2: AGGUCAGTCU[3’end-locus-specific], Rv-primer#2: AGACUGACCU[10bp-downstream-locus-specific]. After PCR#2, SPRI clean-up, USERII digestion, overnight T4 ligation, lambda exonuclease digestion were performed as previously described. After the second ligation, the ligated product was again cleaned-up and concentrated using 1.3X SPRI beads. To increase ligation efficiency",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:66"
    }
  },
  {
    "page_content": "1.3X SPRI beads. To increase ligation efficiency during the circularization step and also reduce protocol duration (3 days vs 1 day), we further improve ligation by using Gibson assembly molecular cloning approach. Instead of U-overhang handles, complementary Gibson handles are added to the forward (Fw) and reverse (Rv) primers to allow circularization post PCR#1 and PCR#2 (Supplementary Table 5, Extended Data Fig. 1b,c). PCR#1 and PCR#2 are performed as previously described for the U-overhang",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:67"
    }
  },
  {
    "page_content": "as previously described for the U-overhang version of this protocol but using KAPA HiFi Ready mix. Ligation is now perform during 1 hour at 50°C in a large volume (>1 mL, 1X CutSmart Buffer) and using 10 μl of Gibson master mix (NEB, E2611). Finally, to linearize the product of ligation, we performed a third PCR: Fw-primer#3: CCTTGGCACCCGAGAATTCCA[10bp-upstream-specific-locus], Rv-primer#3: SI-PCR (10x Genomics). We used KAPA HiFi master mix (Kapa Biosystems) and the following PCR conditions:",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:68"
    }
  },
  {
    "page_content": "Biosystems) and the following PCR conditions: 95°C for 3’; 10 cycles of: 98°C for 20”, 65°C for 30”, 72°C for 30”; 72°C for 5’. After SPRI purification, a last PCR was performed with a generic forward PCR primer (P5_generic) and an RPI-x primer (Illumina) to complete the P7 end of the library and add a sample index (95°C for 3’; 5 cycles of: 98°C for 20”, 67°C for 30”, 72°C for 30”; 72°C for 5’). Thus, this method generates amplicons that retain contiguity of the original molecules but are",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:69"
    }
  },
  {
    "page_content": "contiguity of the original molecules but are short enough to cluster effectively to be sequenced with standard parameters. The targeted amplicon library was subsequently sequenced using PE150 on MiSeq (Illumina). ## Single-cell RNA-seq data processing, alignment, cell type classification and clustering 10x data was processed using Cell Ranger 2.1.0 with default parameters. Reads were aligned to the human reference sequence GRCh38 or hg19 or to mouse reference mm10 (species mixing experiment).",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:70"
    }
  },
  {
    "page_content": "mouse reference mm10 (species mixing experiment). The genomic region of interest for genotyping was examined to determine how many UMIs with targeted sequence were present in the conventional 10x data (Fig. 1c, Extended Data Fig. 3a,b). The Seurat package (v. 3.0) was used to perform unbiased clustering of the CD34+ sorted cells from patient samples18,50. Briefly, for individual datasets, cells with UMI <200 or UMI >3 standard deviation from the mean UMI and mitochondrial gene percentage >10%",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:71"
    }
  },
  {
    "page_content": "mean UMI and mitochondrial gene percentage >10% were filtered. The data was log normalized using a scale factor of 10,000. Prior to clustering, the ET and MF datasets were integrated and underwent batch-correction which implements canonical correlation analysis (CCA) and principles of mutual nearest neighbor. Recommended settings were used for the integration (i.e., 30 canonical correlation vectors for CCA in the FindIntegrationAnchors function and 30 principle components for the anchor",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:72"
    }
  },
  {
    "page_content": "and 30 principle components for the anchor weighting procedure in IntegrateData function). For the datasets, potential confounders (e.g., number of UMI per cell and the proportion of mitochondrial genes) were regressed out of the data before principle component analysis (PCA) was performed using variable genes. JackStraw method was used to determine the statistically significant PCs to be used for graph-based clustering. t-SNE was used to visualize the clusters. Clusters were manually assigned",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:73"
    }
  },
  {
    "page_content": "the clusters. Clusters were manually assigned based on differentially expressed genes using the FindAllMarkers function using default settings (i.e. using all genes that are detected in a minimum of 25% of cells in either of the two comparison sets as input, and log(fold change) of 0.25 as the threshold). Wilcoxon rank-sum test is applied to rank genes, with the top ten differentially expressed genes per cluster presented in Extended Data Fig. 4b. We identified 19 distinct clusters in the",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:74"
    }
  },
  {
    "page_content": "4b. We identified 19 distinct clusters in the integrated data for ET01-ET05, which were annotated according to marker genes identified by Velten et al.26 (t-distributed stochastic neighbor embedding (t-SNE) in Fig. 1d, and clustering heatmap and t-SNE with representative marker genes in Extended Data Fig. 4b,c). Pseudotime analysis was performed using the Monocle R package (v.3.8) for individual datasets20 and the URD package (v.1.0.2) for the integrated datasets21. Linear mixed effects",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:75"
    }
  },
  {
    "page_content": "the integrated datasets21. Linear mixed effects analysis was performed using the lme4 package (v. 1.2–1). For mutant frequency analysis between HSPCs and MkPs (Fig. 1g), genotype status was defined as the fixed effect and, as random effects, we had intercepts for individual patients (i.e. subjects) and iterative downsampling. For integrated analysis of pseudotime comparison (Fig. 1i) and gene module expression (e.g. Fig. 3c), genotype status was entered as the fixed effect and subjects as",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:76"
    }
  },
  {
    "page_content": "was entered as the fixed effect and subjects as random effects. P-values were obtained by likelihood ratio tests of the full model with the fixed effect against the model without the fixed effect51. ## Deep Generative Model for Single Cell Analysis We applied the deep generative modeling approach of Lopez et al. (2018) for the single cell analysis of ET01-ET0519 (Extended Data Fig. 4d,e). Using the scVI package, we trained a variational autoencoder (VAE) that takes as input a feature vector for",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:77"
    }
  },
  {
    "page_content": "(VAE) that takes as input a feature vector for each cell consisting of transcript counts for the 256 genes with the highest standard deviation across all samples as well as an indicator for batch ID. Using 90% of cells for training and holding out 10% for validation, these features are provided to the VAE with 64-unit hidden layers in both the encoder and decoder modules and a four-dimensional internal latent vector of gaussian-distributed values that provide a more concise representation of",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:78"
    }
  },
  {
    "page_content": "that provide a more concise representation of biological variability between cells. t-SNE is applied to these vectors for visualization. ## IronThrone GoT: Targeted genotype amplicon sequence processing and mutation calling To ensure correct priming, targeted amplicon reads (read 2) were screened for the presence of the primer sequence and the expected intervening sequence between the primer and the start of the mutation site (‘shared sequence’, for circularization GoT, PCR #2Fw and PCR #2Rv",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:79"
    }
  },
  {
    "page_content": "for circularization GoT, PCR #2Fw and PCR #2Rv primer sequences; Extended Data Fig. 2a,b). 90.0% of the reads from the mixing study showed the expected primer and shared sequences. Subsequently, for reads that passed the priming step, the corresponding read 1 was screened for the presence of the 16 bp or 18 bp long CB that matched the CB in the whitelist provided by 10x Genomics (Extended Data Fig. 10). For CB reads that were 1-Hamming-distance away from the whitelisted CB, the probability that",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:80"
    }
  },
  {
    "page_content": "from the whitelisted CB, the probability that the observed barcode originated from the whitelisted CB was calculated taking into account the base quality (BQ) score at the differing base. The whitelisted CB with the highest probability was used to replace the observed CB, only if the probability exceeded 0.99. For the duplicate reads with the same CB and UMI, the genotype (wildtype vs. mutant) of the UMI was assigned based on majority rule in supporting reads or according to the read with the",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:81"
    }
  },
  {
    "page_content": "reads or according to the read with the highest BQ score in the rare case when only two supporting but discordant reads were available. The species-mixing study for CALR (type 1) mutation was used to further optimize to optimize the analytical assignment of genotypes to cells, to overcome technical sources of noise such as PCR errors, ambient mRNA and PCR recombination, which may accompany targeted amplification in scRNA-seq. A mean (± standard deviation) of 83.6 (± 95.3) CALR UMIs were",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:82"
    }
  },
  {
    "page_content": "deviation) of 83.6 (± 95.3) CALR UMIs were detected per cell in the amplicon data, with 52 (± 16.3) reads per UMI. We integrated targeted amplicon measures including BQ, number of base pair mismatches, and number of duplicate reads per UMI, and determined optimized parameters that maximize the number of genotyped cells while minimizing genotype mis-assignment (Extended Data Fig. 2c–g). Setting thresholds for the minimum number of duplicate reads and maximum frequency of mismatches contributed",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:83"
    }
  },
  {
    "page_content": "and maximum frequency of mismatches contributed significantly to filtering out mis-assigned reads likely due to technical errors (e.g. PCR recombinations). A combination of threshold of two or more duplicate reads for a given UMI and a threshold of allowing less than or equal to 0.2 mismatch ratio significantly improved correct assignment of cells, while maximizing the number of included cells for analysis, and was adopted in the analysis here (Extended Data Fig. 2c). Results of the precision",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:84"
    }
  },
  {
    "page_content": "(Extended Data Fig. 2c). Results of the precision and recall analyses also affirmed this combination of thresholds for minimum duplicate reads and maximum mismatch ratio (Extended Data Fig. 2d). Moreover, given the high number of CALR transcripts in the cell lines and thus higher potential impact of PCR recombination, cells were assigned as wildtype or mutant if >90% of CALR amplicon UMIs were wildtype or mutant, respectively. To further assess the impact of various parameters of the amplicon",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:85"
    }
  },
  {
    "page_content": "the impact of various parameters of the amplicon reads on the precision of mutation calling, we tested these parameters in a random forest classification using the mixing study, as implemented in the R randomForest package (v. ‎4.6–14)52 (Extended Data Fig. 2e–g). Mean decrease accuracy was determined as a measure of importance of each variable used for the calculation of splits in trees (Extended Data Fig. 2e). For each combination of mismatch ratio and duplicate thresholds, random forest was",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:86"
    }
  },
  {
    "page_content": "ratio and duplicate thresholds, random forest was run 100 times to find the optimal number of random variables used in each tree and the minimum out-of-bag error was selected (Extended Data Fig. 2f,g). This random forest analysis also showed a minimum duplicate read threshold of 2 and maximum mismatch ratio threshold of 0.2 to be optimal for minimizing mis-assignments, and the relatively low contribution of additional quality metrics. Moreover, the genotyping information is derived from",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:87"
    }
  },
  {
    "page_content": "the genotyping information is derived from transcribed molecules and may be affected by the capture of transcripts from wildtype vs. mutant alleles of heterozygous mutations in primary patient samples (in which median targeted amplicon UMI per cell was 5 [± 4.45, median absolute deviation]). This may be due to incomplete sampling of the transcript pool or due to transcriptional bursts53, which leads to skewed transcript pools. Consequently, as the number of UMIs per cell increases, the",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:88"
    }
  },
  {
    "page_content": "as the number of UMIs per cell increases, the likelihood of capturing a mutant transcript increases, resulting in an apparently higher frequency of mutated cells. Thus, the number of mutant reads may be underestimated in cells with lower amplicon UMI counts. Nonetheless, the frequency of mutant cells (e.g., 26% in patient sample ET01) as determined by GoT using all cells that harbor at least one UMI yielded values that were similar to that determined by bulk DNA exon sequencing of CALR from",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:89"
    }
  },
  {
    "page_content": "by bulk DNA exon sequencing of CALR from CD34+ cells (mutant cell fraction of 30% based on VAF of 0.15 in a diploid heterozygous mutation). While the bulk of the downstream analyses between CALR mutant and wildtype cells used a threshold of two or greater genotyping amplicon UMIs, we systematically applied three approaches to exclude the impact of this confounder (i.e., expression level of target gene) on the conclusions. First, to exclude the possibility that higher CALR expression in",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:90"
    }
  },
  {
    "page_content": "the possibility that higher CALR expression in committed progenitors can result in greater ability to detect mutant alleles and thereby result in higher mutated cell frequency, we down-sampled all cells to a single amplicon UMI prior to mutation calling and found that the increase in mutation frequencies in MkP compared with HSPC remained unchanged (Fig. 1f). Second, we explored the sensitivity of the difference between mutant and wildtype cells (e.g. pseudotime, mutant cell frequency) by",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:91"
    }
  },
  {
    "page_content": "cells (e.g. pseudotime, mutant cell frequency) by increasing the minimal amplicon UMI threshold allowed for mutation calling and demonstrated that this did not impact the central findings of this study (Extended Data Fig. 5a,b). Third, we explicitly modeled the impact of CALR amplicon UMI in multivariable models (generalized linear model using R Stats package v3.5.1, e.g., pseudotime analysis), in which the number of amplicon UMI was included in the model alongside the mutation status (Extended",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:92"
    }
  },
  {
    "page_content": "the model alongside the mutation status (Extended Data Fig. 5c). We further note that the GoT procedure did not result in significant loss of genes or UMIs per cell in comparison to published data of CD34+ selected cells from the standard 10x library (Extended Data Fig. 3d)54. For XBP1 splicing analyses, we required a cell to have at least one unspliced XBP1 for inclusion in the analyses. ## Mutant cell frequency analysis For integrated analysis of ET01-ET05 or MF01-MF04, an equal number of",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:93"
    }
  },
  {
    "page_content": "of ET01-ET05 or MF01-MF04, an equal number of cells from each sample (n = 900 for ET and n = 400 for MF) were subsampled randomly. Genotyping amplicon UMIs were downsampled (x100 iterations) to one per cell and mutant cell frequency was determined for each cluster for either the integrated dataset or individual samples. This frequency was then divided by the total mutant cell frequency across all progenitor subsets for each of the iterations (Figs. 1f,g, 4c, 5h, Extended Data Fig. 5d). ##",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:94"
    }
  },
  {
    "page_content": "(Figs. 1f,g, 4c, 5h, Extended Data Fig. 5d). ## Differential expression and gene set enrichment analysis For gene module analysis, the aggregate gene expression levels of modules of genes involved in biological processes of interest (see complete list of genes for each module in Supplementary Table 2) were calculated as log2 of the ratio of UMI in gene module per 10,000 UMIs per cell. The gene modules have been previously published (see references in main text and in Supplementary Table 2).",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:95"
    }
  },
  {
    "page_content": "in main text and in Supplementary Table 2). Differential gene expression analysis between mutant and wildtype cells for each of the progenitor cluster for each patient was performed via the ‘FindMarkers’ function within the Seurat Package using the logistic regression for differential gene expression55 with variable genes as input and requiring expression in at least 10% of cells in either group. UMI was included as a latent variable. The differentially expressed genes were examined",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:96"
    }
  },
  {
    "page_content": "The differentially expressed genes were examined individually for each patient; they were also examined in combination for each cluster across the patients by combining the P-values for the differentially expressed genes via Fisher’s method and performing a weighted average of the log2(fold change) (Supplementary Table 3). Genes that were differentially expressed with FDR < 0.1 and log2(fold change) >= 0.2 were included for gene set enrichment analysis. Hypergeometric test for gene set",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:97"
    }
  },
  {
    "page_content": "analysis. Hypergeometric test for gene set enrichment analysis was performed using the gProfileR package (v. 0.6.7)56. Multiple hypothesis testing correction was performed using the g:SCS algorithm developed by the authors of the gProfileR package. KEGG, Reactome, GO:MF, and GO:BP data sources were included in the analyses (Supplementary Table 4). ## Comparison of mutant allelic fraction in whole exome sequencing (WES) and RNA-seq We compared the mutant allelic fractions between gDNA and RNA,",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:98"
    }
  },
  {
    "page_content": "mutant allelic fractions between gDNA and RNA, estimated from WES and RNA-seq data, respectively, in five cancer cohorts (BRCA, breast invasive carcinoma; HNSC, head and neck squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; LUAD, lung adenocarcinoma; STAD, stomach adenocarcinoma). For this analysis, we thank Dr. Tae-Min Kim (Cancer Research Institute, College of Medicine, The Catholic University of Korea) for sharing the curated datasets based on his previous study57. In brief,",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:99"
    }
  },
  {
    "page_content": "datasets based on his previous study57. In brief, the datasets of each cancer cohorts were initially prepared with somatic mutation sets that are reported from The Cancer Genome Atlas (TCGA) portal (https://portal.gdc.cancer.gov/). Then, reference and alternative alleles for these mutations were counted in bam files of WES and RNA-seq using SAMtools mpileup58, and filtered for >10 coverage of reads. We then converted genomic coordinates of the datasets from hg19 to hg38 assembly. To identify",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:100"
    }
  },
  {
    "page_content": "datasets from hg19 to hg38 assembly. To identify the frequencies of somatic mutations in cancers, we used the CNT values from CosmicCodingMuts.vcf (v86) in the Catalogue of Somatic Mutations in Cancer (COSMIC) database59. Then, we further annotated the variants as oncogene or tumor suppressor gene (TSG) (Vogelstein et al. 201360), and as driver or passenger mutations (Bailey et al. 201861). ## Determination of targeted loci distance from 3’ or 5’ ends of transcripts To identify Ensembl",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:101"
    }
  },
  {
    "page_content": "3’ or 5’ ends of transcripts To identify Ensembl transcript ID (ENST) corresponding to each mutation in the datasets of five cancer cohorts described above, we matched them with COSMIC ID and annotated from the file of CosmicMutantExport.tsv (v86). We used the biomaRt R package62 with the GRCh38 version to annotate the transcript including the length of transcript and the position of cDNA start codon in the transcript. The positions of the 5’ untranslated region (UTR) ends were determined to",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:102"
    }
  },
  {
    "page_content": "untranslated region (UTR) ends were determined to calculate the distance from 5’ end to target site. ## Oxford Nanpore Technology (ONT) The cDNA amplicon samples were barcoded by ONT 1D native barcoding kit EXP-NBD104. The barcoded samples were fed into ONT SQK-LSK109 library preparation and sequencing workflow. FLO-MIN106 RevD flowcells and GridION X5 sequencer were used for sequencing. Data were basecalled by ONT Guppy 2.3.1. For analysis, the adaptor sequences were trimmed Porechop",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:103"
    }
  },
  {
    "page_content": "the adaptor sequences were trimmed Porechop (https://github.com/rrwick/Porechop). Then, the reads were assessed for correct priming as shown in Extended Data Fig. 9d. The correctly primed reads were aligned to the reference genome (Grch38) with minimap263 (v. 2.16) for variant calling. The cell barcodes underwent the same processing described above for IronThrone GoT (Extended Data Fig. 9d, 10). ## Droplet digital PCR Peripheral blood from three ET patients with mutations in CALR underwent",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:104"
    }
  },
  {
    "page_content": "ET patients with mutations in CALR underwent Ficoll density gradient separation, immunomagnetic selection for CD34+ cells (Miltenyi Biotech), and fluorescence-activated cell sorting (FACS) (Influx, Becton-Dickinson) using PeCy7-labeled CD34, clone 561 (lot# B257238, BioLegend), APC-labeled CD38, clone HIT2 (lot #B247250, BioLegend) and FITC-labeled CD10, clone HI10a (lot# B254556, BioLegend) antibodies were used to isolate CD34+CD38−, CD34+CD38+, and CD34+CD10+ cell compartments. DNA was",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:105"
    }
  },
  {
    "page_content": "and CD34+CD10+ cell compartments. DNA was extracted from sorted cells (Qiagen) and the VAF of CALR mutations was measured by droplet digital PCR (QX200 Droplet Digital PCR System, Bio-Rad) with primers that specifically detect CALR type 1 mutations (52-bp deletion (p.L367fs*46), CALR type 2 mutations (5-bp TTGTC insertion (p.K385fs*47) or wildtype alleles. ## Single cell colony genotyping assay Viably frozen mononuclear cells were thawed and plated in H4434 Methocultä media (StemCell",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:106"
    }
  },
  {
    "page_content": "and plated in H4434 Methocultä media (StemCell Technologies, Cambridge, MA) containing recombinant human SCF, GM-CSF, IL-3 and EPO according to the manufacturer’s specifications. Individual colonies (n = 94) were picked from the methylcellulose media after 14 days of culture at 37°C and sequenced by Sanger sequencing for SF3B1, CALR and NFE2 mutations using primers listed in Supplementary Table 5. # Extended Data # Supplementary Material",
    "metadata": {
      "source": "../data/plain/PMC6782071.plain.txt",
      "id": "../data/plain/PMC6782071.plain.txt:107"
    }
  }
]